<SEC-DOCUMENT>0001641489-26-000030.txt : 20260806
<SEC-HEADER>0001641489-26-000030.hdr.sgml : 20260806
<ACCEPTANCE-DATETIME>20260806162426
ACCESSION NUMBER:		0001641489-26-000030
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		54
CONFORMED PERIOD OF REPORT:	20260630
FILED AS OF DATE:		20260806
DATE AS OF CHANGE:		20260806

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			vTv Therapeutics Inc.
		CENTRAL INDEX KEY:			0001641489
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				473916571
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37524
		FILM NUMBER:		261249525

	BUSINESS ADDRESS:	
		STREET 1:		3980 PREMIER DR
		STREET 2:		SUITE 310
		CITY:			HIGH POINT
		STATE:			NC
		ZIP:			27265
		BUSINESS PHONE:		336-841-0300

	MAIL ADDRESS:	
		STREET 1:		3980 PREMIER DR
		STREET 2:		SUITE 310
		CITY:			HIGH POINT
		STATE:			NC
		ZIP:			27265

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	VTV Therapeutics Inc.
		DATE OF NAME CHANGE:	20150506
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>vtvt-20260630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019e6a7f-3a2c-7e30-acc1-d5ae4ae8f1fc,g:0d1f2584-f555-42ce-b27a-904151cd021c,d:9fadb18a1cc64d17ba910cfcf66d9538-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2026" xmlns:us-gaap="http://fasb.org/us-gaap/2026" xmlns:srt="http://fasb.org/srt/2026" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ecd="http://xbrl.sec.gov/ecd/2026" xmlns:vtvt="http://vtvtherapeutics.com/20260630" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>vtvt-20260630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-27">0001641489</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="f-28">12-31</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-29">2026</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-30">Q2</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-31">false</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="c-144" decimals="2" name="vtvt:EntityPublicFloatPercent" scale="0" id="f-424">0.33</ix:nonFraction><ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" scale="0" id="f-457">1</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-178" decimals="0" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="f-515">1</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="vtvt-20260630.xsd"/></ix:references><ix:resources><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="rate"><xbrli:measure>utr:Rate</xbrli:measure></xbrli:unit><xbrli:unit id="boardofdirectorsnumber"><xbrli:measure>vtvt:boardOfDirectorsNumber</xbrli:measure></xbrli:unit><xbrli:unit id="partner"><xbrli:measure>vtvt:partner</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>vtvt:Segment</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-08-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-08-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:VTvLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:NewsoaraBiopharmaCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-01-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-31</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:G42AgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-31</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:G42AgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:G42AgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:CognaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-31</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:G42AgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:G42AgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:G42AgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:G42AgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:G42AgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vtvt:IPLicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:CognaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vtvt:IPLicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:CognaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vtvt:IPLicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:CognaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vtvt:IPLicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:CognaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:CommercialSupplyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:CognaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:CommercialSupplyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:CognaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:CommercialSupplyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:CognaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:CommercialSupplyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:CognaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:CommercialSupplyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:CognaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:NewsoaraBiopharmaCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-30</xbrli:startDate><xbrli:endDate>2026-01-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:NewsoaraBiopharmaCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:NewsoaraBiopharmaCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-27</xbrli:startDate><xbrli:endDate>2024-02-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis"><us-gaap:QName.domain>us-gaap:ResearchAndDevelopmentExpense</us-gaap:QName.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis"><us-gaap:QName.domain>us-gaap:ResearchAndDevelopmentExpense</us-gaap:QName.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis"><us-gaap:QName.domain>us-gaap:ResearchAndDevelopmentExpense</us-gaap:QName.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis"><us-gaap:QName.domain>us-gaap:ResearchAndDevelopmentExpense</us-gaap:QName.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis"><us-gaap:QName.domain>us-gaap:GeneralAndAdministrativeExpense</us-gaap:QName.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis"><us-gaap:QName.domain>us-gaap:GeneralAndAdministrativeExpense</us-gaap:QName.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis"><us-gaap:QName.domain>us-gaap:GeneralAndAdministrativeExpense</us-gaap:QName.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis"><us-gaap:QName.domain>us-gaap:GeneralAndAdministrativeExpense</us-gaap:QName.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:NovoLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">vtvt:TypeOneDiabetesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vtvt:DevelopmentalAndRegulatoryMilestonePaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2007-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:NovoLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">vtvt:TypeTwoDiabetesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vtvt:DevelopmentalAndRegulatoryMilestonePaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2007-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:NovoLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">vtvt:OtherIndicationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vtvt:DevelopmentalAndRegulatoryMilestonePaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2007-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:NovoLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vtvt:SalesBasedMilestonesPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2007-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-08-01</xbrli:startDate><xbrli:endDate>2025-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:PrivatePlacementPreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-08-01</xbrli:startDate><xbrli:endDate>2025-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:CommonWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:CommonWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-08-01</xbrli:startDate><xbrli:endDate>2025-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-01</xbrli:startDate><xbrli:endDate>2024-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:PrivatePlacementPreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-01</xbrli:startDate><xbrli:endDate>2024-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:PrivatePlacementPreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtvt:StockWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtvt:StockWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtvt:StockWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:CommonWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtvt:TDCowenSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtvt:TDCowenSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-17</xbrli:startDate><xbrli:endDate>2024-09-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtvt:TDCowenSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtvt:TDCowenSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtvt:TDCowenSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtvt:TDCowenSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vtvt:MacAndrewsAndForbesIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vtvt:MacAndrewsAndForbesIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">vtvt:VTvTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-09-30</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vtvt:MacAndrewsAndForbesIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vtvt:MacAndrewsAndForbesIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">vtvt:ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vtvt:MacAndrewsAndForbesIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:MFTTPHoldingsTwoLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:PrivatePlacementInvestorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-02-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vtvt:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">vtvt:CadisegliatinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vtvt:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">vtvt:CadisegliatinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vtvt:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">vtvt:CadisegliatinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vtvt:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">vtvt:CadisegliatinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vtvt:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">vtvt:OtherProjectsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vtvt:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">vtvt:OtherProjectsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vtvt:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">vtvt:OtherProjectsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vtvt:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">vtvt:OtherProjectsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vtvt:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vtvt:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vtvt:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vtvt:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:MFTTPHoldingsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i9fadb18a1cc64d17ba910cfcf66d9538_1"></div><div style="min-height:14.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9fadb18a1cc64d17ba910cfcf66d9538_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.937%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:14pt;font-weight:700;line-height:100%">UNITED STATES</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:14pt;font-weight:700;line-height:100%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Washington, D.C. 20549</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">____________________________</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:14pt;font-weight:700;line-height:100%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-Q</ix:nonNumeric></span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">_____________________________</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(Mark One)</span></div><div style="margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.140%"><tr><td style="width:1.0%"/><td style="width:2.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.719%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="f-2">x</ix:nonNumeric></span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">For the quarterly period ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3">June 30, 2026</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Or</span></div><div style="margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.140%"><tr><td style="width:1.0%"/><td style="width:2.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.719%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-4">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number: <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-37524</ix:nonNumeric></span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-6">vTv Therapeutics Inc.</ix:nonNumeric></span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________</span></div><div style="margin-top:2pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.937%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-7">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-8">47-3916571</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-9">3980 Premier Dr</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-10">Suite 110</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-11">High Point</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-12">NC</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-13">27265</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Zip Code)</span></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-14">336</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-15">841-0300</ix:nonNumeric></span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(Former name, former address and former fiscal year, if changed since last report)</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.937%"><tr><td style="width:1.0%"/><td style="width:41.324%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:39.355%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-16">Class A common stock, par value $0.01 per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-17">VTVT</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" id="f-18">NASDAQ</ix:nonNumeric> Capital Market</span></div></td></tr></table></div><div style="margin-top:4pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-19">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">o</span></div><div style="margin-top:4pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-20">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">o</span></div><div style="margin-top:4pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:4pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.937%"><tr><td style="width:1.0%"/><td style="width:30.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.678%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.112%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.112%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.386%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Large accelerated filer</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accelerated filer</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-21">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Smaller reporting company</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="f-22">x</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-23">o</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:4pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">o</span></div><div style="margin-top:4pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-24">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></div><div style="margin-top:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.937%"><tr><td style="width:1.0%"/><td style="width:48.596%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Class of Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Shares Outstanding as of August&#160;6, 2026</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Class A common stock, par value $0.01 per share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-25">3,953,928</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Class B common stock, par value $0.01 per share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="f-26">92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.265%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="height:7.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div></div><div id="i9fadb18a1cc64d17ba910cfcf66d9538_7"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9fadb18a1cc64d17ba910cfcf66d9538_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">vTv THERAPEUTICS INC. AND SUBSIDIARIES</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO FORM 10-Q</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE QUARTER ENDED JUNE&#160;30, 2026</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:80.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.052%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">PAGE<br/>NUMBER</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fadb18a1cc64d17ba910cfcf66d9538_10">PART I &#8211; FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9fadb18a1cc64d17ba910cfcf66d9538_13">Item 1.</a></span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i9fadb18a1cc64d17ba910cfcf66d9538_13">Condensed Consolidated Balance Sheets as of </a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i9fadb18a1cc64d17ba910cfcf66d9538_13">June</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i9fadb18a1cc64d17ba910cfcf66d9538_13"> 3</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i9fadb18a1cc64d17ba910cfcf66d9538_13">0</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i9fadb18a1cc64d17ba910cfcf66d9538_13">, 2026 (Unaudited) and December 31, 2025</a></span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9fadb18a1cc64d17ba910cfcf66d9538_13">4</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i9fadb18a1cc64d17ba910cfcf66d9538_16">Unaudited Condensed Consolidated Statements of Operations for the three</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i9fadb18a1cc64d17ba910cfcf66d9538_16"> and six</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i9fadb18a1cc64d17ba910cfcf66d9538_16"> months ended </a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i9fadb18a1cc64d17ba910cfcf66d9538_16">June</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i9fadb18a1cc64d17ba910cfcf66d9538_16"> 3</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i9fadb18a1cc64d17ba910cfcf66d9538_16">0</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i9fadb18a1cc64d17ba910cfcf66d9538_16">, 2026 and 202</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">5</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9fadb18a1cc64d17ba910cfcf66d9538_16">5</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i9fadb18a1cc64d17ba910cfcf66d9538_22">Unaudited Condensed Consolidated Statement of Changes in Stockholders&#8217; Equity for the three </a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i9fadb18a1cc64d17ba910cfcf66d9538_22">and six </a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i9fadb18a1cc64d17ba910cfcf66d9538_22">months ended </a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i9fadb18a1cc64d17ba910cfcf66d9538_22">June</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i9fadb18a1cc64d17ba910cfcf66d9538_22"> 3</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i9fadb18a1cc64d17ba910cfcf66d9538_22">0</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i9fadb18a1cc64d17ba910cfcf66d9538_22">, 2026 and 2025</a></span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9fadb18a1cc64d17ba910cfcf66d9538_22">6</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i9fadb18a1cc64d17ba910cfcf66d9538_31">Unaudited Condensed Consolidated Statements of Cash Flows for the </a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i9fadb18a1cc64d17ba910cfcf66d9538_31">six</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i9fadb18a1cc64d17ba910cfcf66d9538_31"> months ended </a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i9fadb18a1cc64d17ba910cfcf66d9538_31">June</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i9fadb18a1cc64d17ba910cfcf66d9538_31"> 3</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i9fadb18a1cc64d17ba910cfcf66d9538_31">0</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i9fadb18a1cc64d17ba910cfcf66d9538_31">, 2026 and 2025</a></span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9fadb18a1cc64d17ba910cfcf66d9538_31">8</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.25pt;text-indent:-12.25pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i9fadb18a1cc64d17ba910cfcf66d9538_34">Notes to Unaudited Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9fadb18a1cc64d17ba910cfcf66d9538_34">9</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9fadb18a1cc64d17ba910cfcf66d9538_94">Item 2.</a></span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.25pt;text-indent:-12.25pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i9fadb18a1cc64d17ba910cfcf66d9538_94">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9fadb18a1cc64d17ba910cfcf66d9538_94">18</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9fadb18a1cc64d17ba910cfcf66d9538_133">Item 3.</a></span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.25pt;text-indent:-12.25pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i9fadb18a1cc64d17ba910cfcf66d9538_133">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9fadb18a1cc64d17ba910cfcf66d9538_133">27</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9fadb18a1cc64d17ba910cfcf66d9538_136">Item 4.</a></span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.25pt;text-indent:-12.25pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i9fadb18a1cc64d17ba910cfcf66d9538_136">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9fadb18a1cc64d17ba910cfcf66d9538_136">27</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fadb18a1cc64d17ba910cfcf66d9538_139">PART II &#8211; OTHER INFORMATION </a></span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9fadb18a1cc64d17ba910cfcf66d9538_142">Item 1.</a></span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.25pt;text-indent:-12.25pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i9fadb18a1cc64d17ba910cfcf66d9538_142">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9fadb18a1cc64d17ba910cfcf66d9538_142">28</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9fadb18a1cc64d17ba910cfcf66d9538_145">Item 1A.</a></span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.25pt;text-indent:-12.25pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i9fadb18a1cc64d17ba910cfcf66d9538_145">Risk Factors</a></span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9fadb18a1cc64d17ba910cfcf66d9538_145">28</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9fadb18a1cc64d17ba910cfcf66d9538_148">Item 2.</a></span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.25pt;text-indent:-12.25pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i9fadb18a1cc64d17ba910cfcf66d9538_148">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9fadb18a1cc64d17ba910cfcf66d9538_148">28</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9fadb18a1cc64d17ba910cfcf66d9538_151">Item 3.</a></span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.25pt;text-indent:-12.25pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i9fadb18a1cc64d17ba910cfcf66d9538_151">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9fadb18a1cc64d17ba910cfcf66d9538_151">28</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9fadb18a1cc64d17ba910cfcf66d9538_154">Item 4.</a></span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.25pt;text-indent:-12.25pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i9fadb18a1cc64d17ba910cfcf66d9538_154">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9fadb18a1cc64d17ba910cfcf66d9538_154">28</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9fadb18a1cc64d17ba910cfcf66d9538_157">Item 5.</a></span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.25pt;text-indent:-12.25pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i9fadb18a1cc64d17ba910cfcf66d9538_157">Other Information</a></span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9fadb18a1cc64d17ba910cfcf66d9538_157">28</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9fadb18a1cc64d17ba910cfcf66d9538_160">Item 6.</a></span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.25pt;text-indent:-12.25pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i9fadb18a1cc64d17ba910cfcf66d9538_160">Exhibits</a></span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9fadb18a1cc64d17ba910cfcf66d9538_160">28</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.25pt;text-indent:-12.25pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i9fadb18a1cc64d17ba910cfcf66d9538_163">Signatures</a></span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9fadb18a1cc64d17ba910cfcf66d9538_163">30</a></span></div></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i9fadb18a1cc64d17ba910cfcf66d9538_10"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9fadb18a1cc64d17ba910cfcf66d9538_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">PART I &#8211; FINANCIAL INFORMATION</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements and other disclosures contained in this report include those of vTv Therapeutics Inc. (&#8220;we&#8221;, the &#8220;Company&#8221; or the &#8220;Registrant&#8221;), which is the registrant, and those of vTv Therapeutics LLC (&#8220;vTv LLC&#8221;), which is the principal operating subsidiary of the Registrant. Unless the context suggests otherwise, references in this Quarterly Report on Form 10-Q to the &#8220;Company&#8221;, &#8220;we&#8221;, &#8220;us&#8221; and &#8220;our&#8221; refer to vTv Therapeutics Inc. and its consolidated subsidiaries.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i9fadb18a1cc64d17ba910cfcf66d9538_13"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9fadb18a1cc64d17ba910cfcf66d9538_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">vTv Therapeutics Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except number of shares and per share data)</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.363%"><tr><td style="width:1.0%"/><td style="width:71.971%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.061%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.063%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-32">86,643</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-33">88,932</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" scale="3" id="f-34">416</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" scale="3" id="f-35">743</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAssetsCurrent" scale="3" id="f-36">530</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherAssetsCurrent" scale="3" id="f-37">218</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-38">87,589</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-39">89,893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="f-40">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="f-41">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-42">87,593</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-43">89,899</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Stockholders&#8217; Equity </span></td><td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-44">6,992</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-45">6,557</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability, related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="vtvt:WarrantLiabilityCurrent" scale="3" id="f-46">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="vtvt:WarrantLiabilityCurrent" scale="3" id="f-47">84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-48">7,017</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-49">6,641</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-50">1,830</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-51">18,669</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability</span></td><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="vtvt:WarrantyLiability" scale="3" id="f-52">114</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="vtvt:WarrantyLiability" scale="3" id="f-53">152</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-54">8,961</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-55">25,462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-4" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-56"></ix:nonFraction></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-5" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-57"></ix:nonFraction></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Class A common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-10" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-58"><ix:nonFraction unitRef="usdPerShare" contextRef="c-11" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-59">0.01</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-60"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-61">200,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="c-11" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-62">3,938,803</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-63">3,938,654</ix:nonFraction> outstanding as of June&#160;30, 2026 and December&#160;31, 2025, respectively</span></div></td><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-64">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-65">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Class B common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-66"><ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-67">0.01</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-12" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-68"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-69">100,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="c-13" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="f-70">92</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-12" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="f-71">241</ix:nonFraction> outstanding as of June&#160;30, 2026 and December 31, 2025, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:fixed-zero" scale="3" id="f-72">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:fixed-zero" scale="3" id="f-73">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-74">394,205</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-75">391,090</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-76">315,612</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-77">326,692</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-78">78,632</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-79">64,437</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-80">87,593</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-81">89,899</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i9fadb18a1cc64d17ba910cfcf66d9538_16"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9fadb18a1cc64d17ba910cfcf66d9538_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">vTv Therapeutics Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations - Unaudited</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except number of shares and per share data)</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.251%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.251%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.251%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.253%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-82">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-83">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-84">36,839</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-85">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-86">8,770</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-87">4,103</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-88">17,748</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-89">6,933</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-90">5,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-91">3,618</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-92">9,758</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-93">7,291</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-94">13,930</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-95">7,721</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-96">27,506</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-97">14,224</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating (loss) income </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-98">13,930</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-99">7,721</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-100">9,333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-101">14,224</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-102">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-103">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-104">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-105">5</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other income &#8211; related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-106">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-107">54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-108">59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-109">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="f-110">812</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="f-111">275</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="f-112">1,650</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="f-113">606</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income before income taxes and noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-114">13,054</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-115">7,380</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-116">11,080</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-117">13,597</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision</span></td><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-118">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-119">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-120">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-121">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income before noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-122">13,054</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-123">7,380</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-124">11,080</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-125">13,597</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Less: net loss attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="f-126">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-127">1,334</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="f-128">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-129">2,459</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income attributable to vTv Therapeutics Inc.</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-130">13,054</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-131">6,046</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-132">11,080</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-133">11,138</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income attributable to vTv Therapeutics Inc. common shareholders</span></td><td colspan="2" style="background-color:#ebfeff;border-top:3pt double #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-134">13,054</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;border-top:3pt double #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-135">6,046</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;border-top:3pt double #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-136">11,080</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;border-top:3pt double #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-137">11,138</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 23.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Basic net (loss) income per share of vTv Therapeutics Inc. Class A common stock</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-25" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-138">1.05</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-26" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-139">0.92</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-27" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-140">0.89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-28" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-141">1.69</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 23.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted average number of vTv Therapeutics Inc. Class A common stock</span></td><td colspan="2" style="background-color:#ebfeff;border-top:3pt double #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-142">12,409,316</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;border-top:3pt double #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-26" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-143">6,587,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;border-top:3pt double #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-144">12,409,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;border-top:3pt double #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-28" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-145">6,584,969</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 23.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net (loss) income per share of vTv Therapeutics Inc. Class A common stock</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-25" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-146">1.05</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-26" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-147">0.92</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-27" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-148">0.76</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-28" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-149">1.69</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 23.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted average number of vTv Therapeutics Inc. Class A common stock</span></td><td colspan="2" style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-150">12,409,316</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-26" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-151">6,587,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-152">14,541,788</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-28" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-153">6,584,969</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i9fadb18a1cc64d17ba910cfcf66d9538_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9fadb18a1cc64d17ba910cfcf66d9538_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">vTv Therapeutics Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statement of Changes in Stockholders&#8217; Equity - Unaudited</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except number of shares)</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.229%"><tr><td style="width:1.0%"/><td style="width:40.045%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.224%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.004%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.224%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.004%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.224%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.004%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.224%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.004%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.224%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.641%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.224%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.641%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.224%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.889%"/><td style="width:0.1%"/></tr><tr><td colspan="45" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">For the three months ended June 30, 2026</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Class A Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Class B Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Total Stockholders&#8217;  <br/>Equity</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Balances at March 31, 2026</span></td><td colspan="3" style="background-color:#ebfeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-29" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-154">3,938,654</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-155">39</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-30" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="f-156">241</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="f-157">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-158">392,478</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-159">302,558</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-160">89,959</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Net loss attributable to vTv Therapeutics Inc.</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-161">13,054</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-162">13,054</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#ebfeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-163">1,727</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-164">1,727</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Conversion of Class B Common Stock to Class A Common Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-37" decimals="INF" sign="-" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" id="f-165">149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-38" decimals="INF" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" id="f-166">149</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Balances at June 30, 2026</span></td><td colspan="3" style="background-color:#ebfeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-39" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-167">3,938,803</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-168">39</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-40" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="f-169">92</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="f-170">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-171">394,205</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-172">315,612</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-173">78,632</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.375%"><tr><td style="width:1.0%"/><td style="width:28.983%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:5.189%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.219%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.189%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.219%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.219%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.219%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.189%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.219%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.132%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.219%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.744%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.219%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.219%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.294%"/><td style="width:0.1%"/></tr><tr><td colspan="54" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">For the three months ended June 30, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Class A Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Class B Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Total vTv Therapeutics Inc Stockholders&#8217; Equity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Noncontrolling<br/>Interest</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Total Stockholders&#8217; Equity</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Balances at March 31, 2025</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-44" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-174">2,612,257</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-175">26</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-45" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-176">577,349</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-177">6</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-178">312,698</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-179">304,810</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-180">7,920</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-181">977</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-182">8,897</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Net loss attributable to vTv Therapeutics Inc.</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-183">6,046</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-184">6,046</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-185">6,046</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of stock options</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-53" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="f-186">700</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-187">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-188">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-189">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Net shares withheld for tax withholding related to the settlement of equity awards.</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-53" decimals="INF" sign="-" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-190">4,258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-191">51</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-192">51</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-193">51</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-194">930</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-195">930</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-196">930</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Net loss attributable to noncontrolling interest</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-197">1,334</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-198">1,334</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Balances at June 30, 2025</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-56" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-199">2,617,215</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-200">26</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-57" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-201">577,349</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-202">6</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-203">313,586</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-204">310,856</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-205">2,762</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-206">357</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-207">2,405</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i9fadb18a1cc64d17ba910cfcf66d9538_28"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9fadb18a1cc64d17ba910cfcf66d9538_7">Table of Contents</a></span></div></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">vTv Therapeutics Inc.</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statement of Changes in Stockholders&#8217; Equity - Unaudited</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except number of shares)</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.551%"><tr><td style="width:1.0%"/><td style="width:40.045%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.224%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.004%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.224%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.004%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.224%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.004%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.224%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.004%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.224%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.641%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.224%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.641%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.224%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.889%"/><td style="width:0.1%"/></tr><tr><td colspan="45" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">For the six months ended June 30, 2026</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Class A Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Class B Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Shares </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Deficit </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Total Stockholders&#8217;  <br/>Equity</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Balances at December 31, 2025</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-63" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-208">3,938,654</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-209">39</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-64" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="f-210">241</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="f-211">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-212">391,090</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-213">326,692</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-214">64,437</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to vTv Therapeutics Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-215">11,080</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-216">11,080</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-217">3,115</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-218">3,115</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Conversion of Class B Common Stock to Class A Common Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-71" decimals="INF" sign="-" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" id="f-219">149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-72" decimals="INF" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" id="f-220">149</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Balances at June 30, 2026</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-39" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-221">3,938,803</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-222">39</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-40" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="f-223">92</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="f-224">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-225">394,205</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-226">315,612</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-227">78,632</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.742%"><tr><td style="width:1.0%"/><td style="width:28.952%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.218%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.182%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.218%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.182%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.218%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.182%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.218%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.182%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.218%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.182%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.218%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.334%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.218%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.627%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.218%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.858%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.218%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.557%"/><td style="width:0.1%"/></tr><tr><td colspan="57" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">For the six months ended June 30, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Class A Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Class B Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Deficit </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Total vTv Therapeutics Inc Stockholders&#8217; Equity </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Noncontrolling<br/>Interest</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Total Stockholders&#8217; <br/>Equity </span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Balances at December 31, 2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-73" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-228">2,612,257</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-229">26</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-74" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-230">577,349</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-231">6</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-232">311,885</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-233">299,718</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-234">12,199</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-235">2,102</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-236">14,301</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Net loss attributable to vTv Therapeutics Inc.</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-237">11,138</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-238">11,138</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-239">11,138</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of stock options</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-82" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="f-240">700</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-241">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="f-242">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-243">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-244">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Net shares withheld for tax withholding related to the settlement of equity awards.</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-82" decimals="INF" sign="-" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-245">4,258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-246">51</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-247">51</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="f-248">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-249">51</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-250">1,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-251">1,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-252">1,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Net loss attributable to noncontrolling interest</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-253">2,459</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-254">2,459</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Balances at June 30, 2025</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-56" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-255">2,617,215</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-256">26</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-57" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-257">577,349</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-258">6</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-259">313,586</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-260">310,856</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-261">2,762</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-262">357</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-263">2,405</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.</span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i9fadb18a1cc64d17ba910cfcf66d9538_31"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9fadb18a1cc64d17ba910cfcf66d9538_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">vTv Therapeutics Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows - Unaudited</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.542%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.783%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#c9fcff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#c9fcff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#c9fcff;padding:0 1pt"/><td colspan="3" style="background-color:#c9fcff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) before noncontrolling interest</span></td><td style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-264">11,080</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-265">13,597</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net income (loss) before noncontrolling interest to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Depreciation" scale="3" id="f-266">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:Depreciation" scale="3" id="f-267">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-268">3,115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-269">1,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrants, related party</span></td><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" sign="-" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="f-270">59</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" sign="-" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="f-271">26</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" sign="-" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="f-272">38</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="f-273">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 2.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Changes in assets and liabilities:</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses </span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-274">327</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-275">833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" scale="3" id="f-276">312</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" scale="3" id="f-277">82</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:fixed-zero" scale="3" id="f-278">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="f-279">67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="f-280">435</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="f-281">189</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-282">16,839</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:fixed-zero" scale="3" id="f-283">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:fixed-zero" scale="3" id="f-284">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" id="f-285">90</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-286">2,289</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-287">10,782</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#c9fcff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#c9fcff;padding:0 1pt"/><td colspan="3" style="background-color:#c9fcff;padding:0 1pt"/><td colspan="3" style="background-color:#c9fcff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the exercise of stock options</span></td><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="f-288">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="f-289">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Taxes paid related to net share settlement of equity awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="f-290">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-291">51</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-292">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="f-293">42</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net decrease in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-294">2,289</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-295">10,824</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents, beginning of period</span></td><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-296">88,932</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-297">36,746</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents, end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-298">86,643</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-299">25,922</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i9fadb18a1cc64d17ba910cfcf66d9538_34"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9fadb18a1cc64d17ba910cfcf66d9538_7">Table of Contents</a></span></div></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">vTv Therapeutics Inc.</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements &#8211; Unaudited</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(dollar amounts are in thousands, unless otherwise noted)</span></div><div id="i9fadb18a1cc64d17ba910cfcf66d9538_37"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Note 1:  <ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="f-300" continuedAt="f-300-1" escape="true">Description of Business and Basis of Presentation </ix:nonNumeric></span></div><ix:continuation id="f-300-1"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">vTv Therapeutics Inc. (the &#8220;Company,&#8221; the &#8220;Registrant,&#8221; &#8220;we&#8221; or &#8220;us&#8221;) was incorporated in the state of Delaware in April 2015. The Company is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. The Company&#8217;s clinical pipeline is led by </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, currently in a Phase 3 trial, a potential first-in-class oral liver-selective glucokinase activator being investigated as an adjunctive therapy to insulin for the treatment of type 1 diabetes. The Company and its development partners are investigating multiple molecules across different indications for chronic diseases. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">vTv Therapeutics Inc. is a holding company, and its principal asset is a controlling equity interest in vTv Therapeutics LLC (&#8220;vTv LLC&#8221;), the Company&#8217;s principal operating subsidiary.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has determined that vTv LLC is a variable-interest entity (&#8220;VIE&#8221;) for accounting purposes and that vTv Therapeutics Inc. is the primary beneficiary of vTv LLC because (through its managing member interest in vTv LLC and the fact that the senior management of vTv Therapeutics Inc. is also the senior management of vTv LLC) it has the power and benefits to direct all of the activities of vTv LLC, which include those that most significantly impact vTv LLC&#8217;s economic performance. vTv Therapeutics Inc. has therefore consolidated vTv LLC&#8217;s results pursuant to Accounting Standards Codification Topic 810, &#8220;Consolidation&#8221; in its Unaudited Condensed Consolidated Financial Statements. The assets and liabilities of vTv LLC represent substantially all of the Company&#8217;s consolidated assets and liabilities with the exception of the Warrants and $<ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="f-301">67.6</ix:nonFraction> million of cash and cash equivalents.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Various holders own non-voting interests in vTv LLC, representing a de minimis amount of economic interest. Effectively, vTv Therapeutics Inc.&#8217;s interest is approximately <ix:nonFraction unitRef="number" contextRef="c-86" decimals="1" name="vtvt:PercentageOfNonVotingEconomicInterestByParent" scale="-2" id="f-302">100.0</ix:nonFraction>% of vTv LLC&#8217;s economic results. vTv Therapeutics Inc. has provided financial and other support to vTv LLC in the form of its purchase of vTv Units with the net proceeds of the Company&#8217;s various debt and equity transactions in prior years and equity purchase agreements with various parties. v</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Tv Therapeutics Inc. will not be required to provide financial or other support for vTv LLC. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">However, vTv Therapeutics Inc. will control its business and other activities through its managing member interest in vTv LLC, and its management is the management of vTv LLC. Nevertheless, because vTv Therapeutics Inc. will have no material assets other than its interests in vTv LLC, any financial difficulties at vTv LLC could result in vTv Therapeutics Inc. recognizing a loss.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has not generated any product revenue and has not achieved profitable operations. The continuing development of our drug candidates will require additional financing. From its inception through June&#160;30, 2026, the Company has funded its operations primarily through a combination of private placements of common and preferred equity, research collaboration agreements, upfront and milestone payments for license agreements, debt and equity financings and the completion of its IPO in August 2015. As of June&#160;30, 2026, the Company had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="f-303">315.6</ix:nonFraction>&#160;million and has generated net losses in each year of its existence. As of June&#160;30, 2026, the Company&#8217;s liquidity sources included cash and cash equivalents of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="f-304">86.6</ix:nonFraction> million. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On January 30, 2026, the Company entered into a Second Amendment to License Agreement with Newsoara Biopharma Co., Ltd. (&#8220;Newsoara&#8221;) (the &#8220;Second Amendment&#8221;). Under the Second Amendment, Newsoara's rights in the Company's PDE4 inhibitor, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HPP737</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, will expand to include all countries of the world upon Newsoara's payment of the upfront fee of $<ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-5" name="vtvt:LicenseFeeReceived" scale="6" id="f-305">20.0</ix:nonFraction> million. See Note 3 for further details.</span></div></ix:continuation><div id="i9fadb18a1cc64d17ba910cfcf66d9538_43"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Note 2:  <ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-306" continuedAt="f-306-1" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="vtvt:UnauditedInterimFinancialInformationPolicyPolicyTextBlock" id="f-307" continuedAt="f-307-1" escape="true"><ix:continuation id="f-306-1" continuedAt="f-306-2"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Financial Information</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). The accompanying Condensed Consolidated Balance Sheet as of June&#160;30, 2026, Condensed Consolidated Statements of Operations for the three and six months ended June&#160;30, 2026 and 2025, Condensed Consolidated Statement of Changes in Stockholders&#8217; Equity for the three and six months ended June&#160;30, </span></div></ix:continuation></ix:nonNumeric><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9fadb18a1cc64d17ba910cfcf66d9538_7">Table of Contents</a></span></div></div><ix:continuation id="f-306-2"><ix:continuation id="f-307-1"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026 and 2025, and Condensed Consolidated Statements of Cash Flows for the six months ended June&#160;30, 2026 and 2025 are unaudited. These unaudited financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (&#8220;SEC&#8221;) for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. These financial statements should be read in conjunction with the audited financial statements and the accompanying notes for the year ended December&#160;31, 2025, contained in the Company&#8217;s Annual Report on Form 10-K. The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company&#8217;s financial position as of June&#160;30, 2026, the results of operations for the three and six months ended June&#160;30, 2026 and 2025, and cash flows for the six months ended June&#160;30, 2026 and 2025. The December&#160;31, 2025 Condensed Consolidated Balance Sheet included herein was derived from the audited financial statements but does not include all disclosures or notes required by GAAP for complete financial statements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The financial data and other information disclosed in these notes to the financial statements related to the three and six months ended June&#160;30, 2026 and 2025 are unaudited. Interim results are not necessarily indicative of results for an entire year.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not have any components of other comprehensive income recorded within its Condensed Consolidated Financial Statements, and, therefore, does not separately present a statement of comprehensive income in its Condensed Consolidated Financial Statements.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-308" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, the Company evaluates its estimates, including those related to the grant date fair value of equity awards, the fair value of warrants to purchase shares of its Class A common stock and the useful lives of property and equipment, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgments about the carrying value of assets and liabilities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There has been uncertainty and disruption in the global economy and financial markets due to a number of factors, including geopolitical instability, inflationary pressures, high interest rates, a recessionary environment, domestic and global monetary and fiscal policy, changes in trade policy, including tariffs or other trade restrictions or the threat of such actions, banking and other financial institution instability and other factors. Our business may also be impacted by changes or disruptions at the U.S. Food and Drug Administration (&#8220;FDA&#8221;) and other government agencies. The Company has taken into consideration any known impacts to its accounting estimates to date and is not aware of any additional specific events or circumstances that would require any additional updates to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of the filing date of this Quarterly Report on Form 10-Q.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to the Company&#8217;s significant accounting policies during the three and six months ended June&#160;30, 2026, as compared to those disclosed in Note 2 Summary of Significant Accounting Policies included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2025. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-309" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Disaggregation of Income Statement Expenses:</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> In November 2024, the FASB issued ASU No. 2024-03, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures: Disaggregation of Income Statement Expenses.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; This guidance requires disclosures about significant expense categories, including but not limited to, inventory purchases, employee compensation, depreciation, amortization, and selling expenses</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. This amendment is effective for our annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. We are currently assessing the impact of this guidance on our disclosures.</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="i9fadb18a1cc64d17ba910cfcf66d9538_46"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9fadb18a1cc64d17ba910cfcf66d9538_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Note 3:  <ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="f-310" continuedAt="f-310-1" escape="true">Collaboration Agreements</ix:nonNumeric></span></div><ix:continuation id="f-310-1" continuedAt="f-310-2"><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">G42 Agreements </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company and G42 Investments AI Holding RSC Ltd, a private limited company (&#8220;G42 Investments&#8221;), entered into a Common Stock Purchase Agreement (the &#8220;G42 Purchase Agreement&#8221;), on May 31, 2022, pursuant to which the Company sold to G42 Investments <ix:nonFraction unitRef="shares" contextRef="c-88" decimals="0" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-311">259,657</ix:nonFraction> shares of the Company&#8217;s Class A common stock, for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-5" name="vtvt:SaleOfStockConsiderationReceivedOnTransactionGross" scale="6" id="f-312">25.0</ix:nonFraction> million, which was paid (i) $<ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="f-313">12.5</ix:nonFraction> million in cash at the closing and (ii) $<ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-5" name="us-gaap:AccountsNotesAndLoansReceivableNetCurrent" scale="6" id="f-314">12.5</ix:nonFraction> million in the form of a promissory note of G42 Investments paid in 2023. G42 Investments agreed to certain transfer restrictions (including restrictions on short sales or similar transactions) and restrictions on further acquisitions of shares. The Company granted G42 Investments certain shelf and piggyback registration rights with respect to those shares, including the ability to conduct an underwritten offering to resell such shares under certain circumstances. The registration rights include customary cooperation, cut-back, expense reimbursement, and indemnification provisions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Contemporaneously with the G42 Purchase Agreement, in 2022, the Company entered into a collaboration and license agreement (the &#8220;Collaboration Agreement&#8221;) with Cogna Technology Solutions LLC, an affiliate of G42 Investments, with those rights transferring to G42 Healthcare Research Technology Projects LLC ("G42"), an affiliate of G42 Investments. The Collaboration Agreement requires G42 to work with the Company in performing clinical trials for </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TP399)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> as well as jointly creating a global development plan to develop, market, and commercialize </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">in certain countries in the Middle East, Africa, and Central Asia (the &#8220;Partner Territory&#8221;). Under the terms of the Collaboration Agreement, G42 obtained a license under certain intellectual property controlled by the Company to enable it to fulfill its obligations and exercise its rights under the Collaboration Agreement, including to develop and commercialize </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> in the Partner Territory. Specifically, the Company will share various protocols with G42 related to conducting the clinical trials and will provide the patient dosages and placebo of </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">needed to conduct the trials. Under the Collaboration Agreement, G42 has the right to develop and commercialize </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">in the Partner Territory at its own cost. The Company may supply at cost, or G42 may manufacture, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">for commercial sale under terms to be agreed upon by the parties at a later date. Separately, the Company will conduct its clinical trials for </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">outside of the Partner Territory at its own cost. The results of each party&#8217;s clinical trials may be combined by the Company to seek FDA approval in the United States for </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The G42 Purchase Agreement also provides for, following the receipt of the </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">FDA Approval, at the option of G42 Investments, either (a) the issuance of the Company&#8217;s Class A common stock (the &#8220;Milestone Shares&#8221;) having an aggregate value equal to $<ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-5" name="vtvt:CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue" scale="6" id="f-315">30.0</ix:nonFraction> million or (b) the payment by the Company of $<ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-5" name="vtvt:CollaborateArrangementContingentConsiderationTransferredCash" scale="6" id="f-316">30.0</ix:nonFraction> million in cash (the &#8220;Milestone Cash Payment&#8221;). The issuance of the Milestone Shares or the payment of the Milestone Cash Payment, as applicable, is conditioned upon receipt of the </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">FDA Approval and subject to certain limitations and conditions set forth in the G42 Purchase Agreement. There can be no assurance that the </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">FDA Approval will be granted or as to the timing thereof. Once commercialization takes place in the Partner Territory, the Company will receive royalties in the single digits from G42 Healthcare on the net sales of </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">for a period of at least <ix:nonNumeric contextRef="c-91" name="vtvt:CollaborativeArrangementRoyaltiesReceivablePeriod" format="ixt-sec:durwordsen" id="f-317">ten years</ix:nonNumeric> after the first commercial sale of </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">in the Partner Territory.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A premium was paid on the Class A common stock by G42 Investments of $<ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="f-318">18.7</ix:nonFraction> million, net of a note receivable discount of $<ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-5" name="vtvt:CollaborativeArrangementNoteReceivableDiscountPaid" scale="6" id="f-319">0.6</ix:nonFraction> million, which was deferred and recorded as a contract liability. This premium was determined to be the transaction price for all remaining obligations under the agreements and accounted for under ASC 808 or ASC 606 based on determination of the unit of account. As of December 31, 2025, $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ContractWithCustomerLiability" scale="6" id="f-320">18.7</ix:nonFraction> million was recorded in the Consolidated Balance Sheet.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that certain commitments under the agreements are in the scope of ASC 808 as both the Company and G42 are active participants in the clinical trials of </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, and both are exposed to significant risks and rewards based on the success of the clinical trials and subsequent FDA approval. G42 is determined to be a vendor of the Company during the clinical trial phase, working on the Company&#8217;s behalf to complete research and development activities, and not in a customer capacity. The Company accounted for the commitments related to the clinical trials, which includes transfer of trial protocols, supply of clinical trial dosages, and collaboration on the joint development committee as an ASC 808 unit of account, applying the recognition and measurement principles of ASC 606 by analogy. The Company will recognize collaboration revenue for its development activities under ASC 808 over time based on the estimated period of performance.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">By applying the principles in ASC 606 by analogy, the Company identified the performance obligation and considered the timing of satisfaction of the obligation to account for the pattern of revenue recognition. In order to recognize collaboration revenue, generally, the Company would begin satisfying its performance obligation and G42 would need to be able to use and benefit from delivery of the assets or services. The performance obligation under the agreements that fall </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9fadb18a1cc64d17ba910cfcf66d9538_7">Table of Contents</a></span></div></div><ix:continuation id="f-310-2"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">within the ASC 808 unit of account are concentrated in the clinical trials. As of June&#160;30, 2026, the clinical trials had not commenced. Accordingly, <ix:nonFraction unitRef="usd" contextRef="c-93" decimals="INF" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="0" id="f-321"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="INF" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="0" id="f-322"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="INF" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="0" id="f-323"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="INF" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="0" id="f-324">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> collaboration revenue was recognized for the ASC 808 unit of account during the three and six months ended June&#160;30, 2026 and 2025. $<ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="f-325">1.3</ix:nonFraction> million remains deferred and recorded in contract liabilities as of June&#160;30, 2026.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company identified certain commitments that are in the scope of ASC 606 as G42&#8217;s relationship is that of a customer for these commitments. The significant performance obligations that are in the scope of ASC 606 are (1) the development, commercialization and manufacturing license of the intellectual property (IP) once restrictions on the use of the IP have been lifted by the Company and (2) a potential material right to a commercial supply agreement. As a result, the Company recognizes revenue associated with the development, commercialization, and manufacturing license at a point in time upon the release of the IP restrictions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In March 2026, the Company lifted the contractual restrictions on the use of the IP. Accordingly, the Company determined that control of the license was transferred to G42 at that point in time, and the related performance obligation was satisfied. During the six months ended June&#160;30, 2026, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-326">16.9</ix:nonFraction>&#160;million license revenue associated with the transfer of the IP. <ix:nonFraction unitRef="usd" contextRef="c-98" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="f-327"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="f-328"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="f-329">No</ix:nonFraction></ix:nonFraction></ix:nonFraction> license revenue was recognized during the three months ended June&#160;30, 2026 or the three and six months ended June&#160;30, 2025. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company will recognize revenue from the material right related to G42&#8217;s ability to purchase the commercial supply at cost as G42 purchases the commercial supply from the Company, which will occur after the completion of the initial clinical trials (if G42 decides to purchase the clinical supply from the Company). <ix:nonFraction unitRef="usd" contextRef="c-101" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="f-330"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="f-331"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="f-332"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="f-333">No</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> revenue has been recognized related to the commercial supply agreement during the three and six months ended June&#160;30, 2026 and 2025, as G42 has not exercised its option to purchase commercial supply as of those dates. $<ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="f-334">0.5</ix:nonFraction> million remains deferred and recorded in contract liabilities as of June&#160;30, 2026.</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Newsoara License Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to a license agreement with Newsoara Biopharma Co., Ltd., (&#8220;Newsoara&#8221;) (the &#8220;Newsoara License Agreement&#8221;) under which Newsoara obtained an exclusive and sublicensable license to develop and commercialize the Company&#8217;s phosphodiesterase type 4 inhibitors (&#8220;PDE4&#8221;) program, including the compound </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HPP737</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, in China, Hong Kong, Macau, Taiwan and other pacific rim countries (collectively, the &#8220;Newsoara License Territory&#8221;). Additionally, under the Newsoara License Agreement, the Company obtained a non-exclusive, sublicensable, royalty-free license to develop and commercialize certain Newsoara patent rights and know-how related to the Company&#8217;s PDE4 program for therapeutic uses in humans outside of the Newsoara License Territory. In accordance with ASC 606, the Company identified all of the performance obligations at the inception of the Newsoara License Agreement. The significant obligations were determined to be the license and the technology transfer services. The Company determined that the license and technology transfer services represent a single performance obligation because they were not capable of being distinct on their own. The transaction price was fully allocated to this combined performance obligation and the related revenue was recognized during the year ended December 31, 2018.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Newsoara License Agreement was amended in 2020 to change certain future milestone payments and patent rights (the &#8220;First Newsoara Amendment&#8221;). On January 30, 2026, the Company entered into a new Second Amendment with Newsoara. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Although the Company had previously entered into an amendment with Newsoara to expand the Original Agreement, that amendment became null and void in June 2025. Under the new Second Amendment, Newsoara's rights in the Company's PDE4 inhibitor, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HPP737</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, will expand to include all countries of the world upon Newsoara's payment of the upfront fee of </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-5" name="vtvt:LicenseFeeReceived" scale="6" id="f-335">20.0</ix:nonFraction> million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The Second Amendment also requires Newsoara to pay vTv LLC up to approximately </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="f-336">50.0</ix:nonFraction> million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> in development milestones, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-5" name="vtvt:PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable" scale="6" id="f-337">65.0</ix:nonFraction> million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> in sales-related milestones and royalties in the mid single digits depending upon sales volumes.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> In February 2026, the Company received and recognized the $<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-5" name="vtvt:LicenseFeeReceived" scale="6" id="f-338">20.0</ix:nonFraction> million upfront payment from Newsoara as stipulated in the Second Amendment and recognized the related revenue due to satisfying the performance obligation.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2026, development milestones totaling $<ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-5" name="vtvt:PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable" scale="6" id="f-339">3.0</ix:nonFraction> million had been recognized in prior periods by the Company under the Second Amendment.</span></div></ix:continuation><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div id="i9fadb18a1cc64d17ba910cfcf66d9538_52"></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Note 4:  <ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-340" continuedAt="f-340-1" escape="true">Share-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="f-340-1" continuedAt="f-340-2"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has issued non-qualified stock option awards to management, other key employees, consultants, and non-employee directors and these options ratably vest over a <ix:nonNumeric contextRef="c-109" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-341">four-year</ix:nonNumeric> service period. In addition, we issued options in connection with the private placement on February 27, 2024, that vest ratably over a <ix:nonNumeric contextRef="c-110" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-342">three-year</ix:nonNumeric> period. The option awards expire after a term of <ix:nonNumeric contextRef="c-109" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="f-343">ten years</ix:nonNumeric> from the date of grant. As of June&#160;30, 2026, the Company had total unrecognized stock-based compensation expense for its outstanding stock option awards of approximately $<ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="f-344">13.5</ix:nonFraction> million, which is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="c-109" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-345">3.0</ix:nonNumeric> years. The weighted average grant date fair value of options granted during the six months ended June&#160;30, 2026 and 2025 was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-109" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-346">28.05</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-112" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-347">15.01</ix:nonFraction> per option, respectively. </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9fadb18a1cc64d17ba910cfcf66d9538_7">Table of Contents</a></span></div></div><ix:continuation id="f-340-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-348" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to the stock option awards for the six months ended June&#160;30, 2026:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.023%"><tr><td style="width:1.0%"/><td style="width:57.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.243%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.413%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.243%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.413%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.246%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Weighted <br/>Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value (in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Awards outstanding at December 31, 2025</span></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-349">1,017,620</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-350">25.18</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-351">564,719</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-352">36.52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or Expired</span></td><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-353">41,687</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-354">30.60</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Awards outstanding at June 30, 2026</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-355">1,540,652</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-356">29.19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-357">17,857</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable at June 30, 2026</span></td><td colspan="2" style="background-color:#ebfeff;border-top:3pt double #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-358">604,164</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-359">29.28</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="3" id="f-360">9,795</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining contractual term</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-361">7.1</ix:nonNumeric> Years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest at June 30, 2026</span></td><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-362">1,275,464</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="f-363">28.73</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining contractual term</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-364">8.1</ix:nonNumeric> Years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-365" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Compensation expense related to the grants of stock options is included in research and development and general and administrative expense as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.376%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.251%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.443%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-366">533</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-367">307</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-368">977</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-369">534</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-370">1,194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-371">623</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-372">2,138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-373">1,209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-374">1,727</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-375">930</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-376">3,115</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-377">1,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="i9fadb18a1cc64d17ba910cfcf66d9538_55"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Note 5:  <ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-378" continuedAt="f-378-1" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="f-378-1" continuedAt="f-378-2"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Matters</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is involved in various legal proceedings arising in the normal course of business. If a specific contingent liability is determined to be probable and can be reasonably estimated, the Company accrues and discloses the amount. The Company is not currently a party to any material legal proceedings.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Novo Nordisk</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><ix:continuation id="f-378-2" continuedAt="f-378-3"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In February 2007, the Company entered into an Agreement (the &#8220;Novo License Agreement&#8221;) Concerning Glucokinase Activator Project with Novo Nordisk A/S (the &#8220;Novo Nordisk&#8221;) whereby the Company obtained an exclusive, worldwide, sublicensable license under certain Novo Nordisk intellectual property rights to discover, develop, manufacture, have manufactured, use and commercialize products for the prevention, treatment, control, mitigation or palliation of human or animal diseases or conditions. As part of this license grant, the Company obtained certain worldwide rights to Novo Nordisk&#8217;s GKA program, including rights to preclinical and clinical compounds such as</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> cadisegliatin</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-378-3">. This agreement was amended in May 2019 to create milestone payments applicable to certain specific and non-specific areas of therapeutic use. Under the terms of the amended Novo License Agreement, the Company has potential developmental and regulatory milestone payment obligations totaling up to $<ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-5" name="vtvt:PotentialMilestonePayment" scale="6" id="f-379">6.0</ix:nonFraction> million for approval of a product for the treatment of type 1 diabetes, $<ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-5" name="vtvt:PotentialMilestonePayment" scale="6" id="f-380">50.5</ix:nonFraction> million for approval of a product for the treatment of type 2 diabetes, or $<ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-5" name="vtvt:PotentialMilestonePayment" scale="6" id="f-381">115.0</ix:nonFraction> million for approval of a product in any other indication. The Company may also be obligated to pay an additional $<ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-5" name="vtvt:PotentialMilestonePayment" scale="6" id="f-382">75.0</ix:nonFraction> million in potential sales-based milestones, as well as royalty payments, at mid-single digit royalty rates, based on tiered sales of commercialized licensed products. As of June&#160;30, 2026, the Company does not have any commercialized licensed products.</ix:continuation> </span></div><div id="i9fadb18a1cc64d17ba910cfcf66d9538_64"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Note 6:  <ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-383" continuedAt="f-383-1" escape="true">Stockholders&#8217; Equity </ix:nonNumeric></span></div><ix:continuation id="f-383-1" continuedAt="f-383-2"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock and Pre-funded Warrants</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In August 2025, the Company entered into a securities purchase agreement with certain Private Placement Investors pursuant to which the Company issued and sold an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-125" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-384">682,018</ix:nonFraction> shares of Class A common stock at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-126" decimals="3" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-385">15.265</ix:nonFraction> per share, Pre-funded Warrants to purchase </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-127" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-386">4,561,714</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> shares of Class A common stock at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-127" decimals="3" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-387">15.255</ix:nonFraction> per Pre-funded Warrant, and accompanying Common Warrants to purchase up to </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-127" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" format="ixt:num-dot-decimal" scale="0" id="f-388">5,243,732</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> shares of Class A common stock for aggregate gross proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="6" id="f-389">80.0</ix:nonFraction> million,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> before deducting offering costs payable by us</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The Pre-funded Warrants were immediately exercisable at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-129" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-390">0.01</ix:nonFraction> per share. The Common Warrants are </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9fadb18a1cc64d17ba910cfcf66d9538_7">Table of Contents</a></span></div></div><ix:continuation id="f-383-2"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">exercisable at </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-130" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-391">22.71</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> per share and expire upon the earlier of the fifth anniversary of issuance or </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-131" name="vtvt:WarrantsAndRightsImmediatelyExercisableTerm" format="ixt-sec:durday" id="f-392">90</ix:nonNumeric> days </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">following the announcement of positive top-line data from the Company&#8217;s ongoing CATT1 clinical trial.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In February 2024, the Company entered into a securities purchase agreement with certain Private Placement Investors pursuant to which the Company issued and sold an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-132" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-393">464,377</ix:nonFraction> shares of Class A common stock at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-133" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-394">11.81</ix:nonFraction> per share and Pre-funded Warrants to purchase <ix:nonFraction unitRef="shares" contextRef="c-134" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-395">3,853,997</ix:nonFraction> shares of Class A common stock at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-134" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-396">11.80</ix:nonFraction> per Pre-funded Warrant for aggregate gross proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="6" id="f-397">51.0</ix:nonFraction> million, b</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">efore deducting offering costs payable by us</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The Pre-funded Warrants were immediately exercisable at an exercise price of</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-136" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-398">0.01</ix:nonFraction> per share and contain customary beneficial ownership limitations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On March 5, 2024, the Company entered into a letter agreement with the Private Placement Investors pursuant to which the investors exchanged an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-137" decimals="INF" name="vtvt:CommonStockParOrStatedValueOfPrivatePlacementShares" format="ixt:num-dot-decimal" scale="0" id="f-399">116,493</ix:nonFraction> shares of Class A common stock for <ix:nonFraction unitRef="shares" contextRef="c-137" decimals="INF" name="vtvt:CommonStockParOrStatedValueOfPrivatePlacementPreFundedWarrantsShares" format="ixt:num-dot-decimal" scale="0" id="f-400">116,590</ix:nonFraction> Pre-funded Warrants.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Equity-Based Stock Warrants</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" id="f-401" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the equity-based stock warrant activity for the six months ended June&#160;30, 2026:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.703%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.329%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.025%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.563%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2025</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-138" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-402">13,714,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-138" decimals="INF" name="vtvt:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-403">8.69</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-139" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="f-404">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-139" decimals="INF" name="vtvt:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="f-405">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-139" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" format="ixt:fixed-zero" scale="0" id="f-406">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-139" decimals="INF" name="vtvt:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="f-407">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Expired or cancelled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-139" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" format="ixt:fixed-zero" scale="0" id="f-408">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2026*</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-140" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-409">13,714,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-140" decimals="INF" name="vtvt:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-410">8.69</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-140" decimals="INF" name="vtvt:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-411">13,714,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-140" decimals="INF" name="vtvt:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-412">8.69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">Amount includes <ix:nonFraction unitRef="shares" contextRef="c-141" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-413">8,470,624</ix:nonFraction> Pre-Funded Warrants and <ix:nonFraction unitRef="shares" contextRef="c-142" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-414">5,243,732</ix:nonFraction> Common Warrants.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Pre-Funded and Common Warrants were classified as a component of permanent equity in the Company&#8217;s Condensed Consolidated Balance Sheet as they are freestanding financial instruments that are immediately exercisable, do not embody an obligation for the Company to repurchase its own shares and permit the holders to receive a fixed number of shares of common stock upon exercise. All of the shares underlying the Pre-Funded Warrants have been included in the weighted-average number of shares of common stock used to calculate net loss per share attributable to common stockholders because the shares may be issued for little or no consideration, are fully vested and are exercisable after the original issuance date of the Pre-Funded Warrants.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ATM Offering</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On February 28, 2024, we entered into a sales agreement (the &#8220;TD Cowen Sales Agreement&#8221;) with Cowen and Company, LLC (&#8220;TD Cowen&#8221;), pursuant to which we may offer and sell, from time to time, through or to TD Cowen, as sales agent or principal, shares of our Class A common stock, having an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-5" name="vtvt:SaleOfStockAggregateOfferingPrice" scale="6" id="f-415">50.0</ix:nonFraction> million (the &#8220;TD Cowen ATM Offering&#8221;). Pursuant to General Instruction I.B.6 of Form S-3, at no time will we sell securities registered on the registration statement relating to the TD Cowen ATM Offering with an aggregate amount exceeding one-third of our public float in any 12-calendar month period, so long as our public float remains below $<ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-5" name="vtvt:EntityPublicFloatThreshold" scale="6" id="f-416">75.0</ix:nonFraction> million. Under the terms of the TD Cowen Sales Agreement, we will pay TD Cowen a commission of <ix:nonFraction unitRef="rate" contextRef="c-144" decimals="3" name="vtvt:SaleOfStockMaximumSecuritiesToBeSoldPercentOfPublicFloat" scale="-2" id="f-417">3.0</ix:nonFraction>% of the aggregate proceeds from the sale of shares and reimburse certain legal fees or other disbursements. On September 17, 2024, the Company sold <ix:nonFraction unitRef="shares" contextRef="c-145" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-418">179,400</ix:nonFraction> shares of Class A common stock under the TD Cowen ATM Offering for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="f-419">2.5</ix:nonFraction> million. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June&#160;30, 2026 and 2025, the Company did <ix:nonFraction unitRef="shares" contextRef="c-146" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:fixed-zero" scale="0" id="f-420"><ix:nonFraction unitRef="shares" contextRef="c-147" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:fixed-zero" scale="0" id="f-421"><ix:nonFraction unitRef="shares" contextRef="c-148" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:fixed-zero" scale="0" id="f-422"><ix:nonFraction unitRef="shares" contextRef="c-149" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:fixed-zero" scale="0" id="f-423">not</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> sell any shares of Class A common stock under the TD Cowen ATM Offering.</span></div></ix:continuation><div id="i9fadb18a1cc64d17ba910cfcf66d9538_70"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Note 7:  <ix:nonNumeric contextRef="c-1" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="f-425" continuedAt="f-425-1" escape="true">Related-Party Transactions</ix:nonNumeric></span></div><ix:continuation id="f-425-1" continuedAt="f-425-2"><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MacAndrews &amp; Forbes Incorporated</span></div><div style="margin-top:4pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On September 19, 2025, MacAndrews converted all <ix:nonFraction unitRef="shares" contextRef="c-150" decimals="INF" name="us-gaap:InvestmentOwnedBalanceShares" format="ixt:num-dot-decimal" scale="0" id="f-426">577,108</ix:nonFraction> outstanding shares of their Class B common stock (together with an equal number of vTv LLC units) into Class A common stock. As a result, vTv Therapeutics Inc. now owns approximately <ix:nonFraction unitRef="number" contextRef="c-151" decimals="INF" name="vtvt:OwnershipPercentageOfMajorityOwner" scale="-2" id="f-427">100</ix:nonFraction>% of vTv LLC, as of September 30, 2025. Further, as of June&#160;30, 2026, MacAndrews directly or indirectly holds <ix:nonFraction unitRef="shares" contextRef="c-152" decimals="INF" name="us-gaap:InvestmentOwnedBalanceShares" format="ixt:num-dot-decimal" scale="0" id="f-428">1,490,090</ix:nonFraction> shares of the Company&#8217;s Class A common stock. As a result, MacAndrews&#8217; holdings represent approximately <ix:nonFraction unitRef="number" contextRef="c-153" decimals="3" name="vtvt:OwnershipPercentageOfMajorityOwner" scale="-2" id="f-429">37.8</ix:nonFraction>% of the combined voting power of the Company&#8217;s outstanding common stock.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9fadb18a1cc64d17ba910cfcf66d9538_7">Table of Contents</a></span></div></div><ix:continuation id="f-425-2"><div style="margin-top:4pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into several agreements with MacAndrews or its affiliates as further detailed below:</span></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exchange Agreement</span></div><div style="margin-top:4pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the Exchange Agreement, but subject to the Amended and Restated LLC Agreement of vTv Therapeutics LLC, the vTv Units (along with a corresponding number of shares of the Class B common stock) are exchangeable for (i) shares of the Company&#8217;s Class A common stock on a <ix:nonFraction unitRef="number" contextRef="c-154" decimals="0" name="vtvt:RedeemableNonControllingInterestExchangeAgreementStockConversionRatio" format="ixt-sec:numwordsen" scale="0" id="f-430">one</ix:nonFraction>-for-one basis or (ii) cash (based on the fair market value of the Company&#8217;s Class A common stock as determined pursuant to the Exchange Agreement), at the Company&#8217;s option (as the managing member of vTv Therapeutics LLC), subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. Any decision to require an exchange for cash rather than shares of Class A common stock will ultimately be determined by the entire Board of Directors. On September 19, 2025, MacAndrews exchanged <ix:nonFraction unitRef="shares" contextRef="c-155" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-431">577,108</ix:nonFraction> shares under the provisions of the Exchange Agreement.</span></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tax Receivable Agreement</span></div><div style="margin-top:4pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company and MacAndrews are party to a tax receivable agreement (the &#8220;Tax Receivable Agreement&#8221;), which provides for the payment by the Company to M&amp;F TTP Holdings Two LLC (&#8220;M&amp;F&#8221;), as successor in interest to vTv Therapeutics Holdings, LLC (&#8220;vTv Therapeutics Holdings&#8221;), and M&amp;F TTP Holdings LLC (or certain of its transferees or other assignees) of <ix:nonFraction unitRef="number" contextRef="c-153" decimals="2" name="vtvt:PercentageOfAmountOfCashSavings" scale="-2" id="f-432">85</ix:nonFraction>% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that the Company actually realizes (or, in some circumstances, the Company is deemed to realize) as a result of (a) the exchange of Class B common stock, together with the corresponding number of vTv Units, for shares of the Company&#8217;s Class A common stock (or for cash), (b) tax benefits related to imputed interest deemed to be paid by the Company as a result of the Tax Receivable Agreement and (c) certain tax benefits attributable to payments under the Tax Receivable Agreement. MacAndrews exchanged <ix:nonFraction unitRef="shares" contextRef="c-155" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-433">577,108</ix:nonFraction> shares pursuant to the Exchange Agreement (discussed above), and the Company has not recognized any liability, nor has it made any payments pursuant to the Tax Receivable Agreement as of June&#160;30, 2026.</span></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investor Rights Agreement</span></div><div style="margin-top:4pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to an investor rights agreement with M&amp;F, as successor in interest to vTv Therapeutics Holdings (the &#8220;Investor Rights Agreement&#8221;). The Investor Rights Agreement provides M&amp;F with certain demand, shelf, and piggyback registration rights with respect to its shares of Class A common stock and also provides M&amp;F with certain governance rights, depending on the size of its holdings of Class A common stock. Under the Investor Rights Agreement, M&amp;F was initially entitled to nominate a majority of the members of the Board of Directors and designate the members of the committees of the Board of Directors. The Investor Rights Agreement was amended on February 27, 2024, to alter M&amp;F governance rights that now entitles M&amp;F the right to designate <ix:nonFraction unitRef="boardofdirectorsnumber" contextRef="c-156" decimals="0" name="vtvt:NumberOfBoardOfDirectorsRightToDesignateMembers" format="ixt-sec:numwordsen" scale="0" id="f-434">two</ix:nonFraction> members of our Board of Directors, and as part of the Private Placement, the Private Placement Investors have rights to designate <ix:nonFraction unitRef="boardofdirectorsnumber" contextRef="c-157" decimals="0" name="vtvt:NumberOfBoardOfDirectorsRightToDesignateMembers" format="ixt-sec:numwordsen" scale="0" id="f-435">three</ix:nonFraction> members of our Board of Directors, making it more difficult for a third party to acquire control of our Board. The agreement with the Private Placement Investors also provides that <ix:nonFraction unitRef="boardofdirectorsnumber" contextRef="c-158" decimals="0" name="vtvt:NumberOfBoardOfDirectorsToApproveCertainActions" format="ixt-sec:numwordsen" scale="0" id="f-436">five</ix:nonFraction> of our directors must approve certain actions including any acquisition by a third party, which makes it more difficult for our Board of Directors to approve such a transaction.</span></div></ix:continuation><div id="i9fadb18a1cc64d17ba910cfcf66d9538_73"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Note 8:  <ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingDisclosureTextBlock" id="f-437" continuedAt="f-437-1" escape="true">Segment Information</ix:nonNumeric></span></div><ix:continuation id="f-437-1" continuedAt="f-437-2"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our Chief Operating Decision Maker (&#8220;CODM&#8221;) is our President and Chief Executive Officer, Paul Sekhri. The CODM makes decisions on resource allocation, assesses performance of the business, and monitors budget versus actual results using net loss. Net (loss) income is also a measure that is considered in monitoring budget versus actual results. The measure of the segment assets is reported on the Condensed Consolidated Balance Sheet as total assets.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages its business activities on a consolidated basis and operates in a single reportable segment. Its operations primarily focus on the research and development of its lead product candidate, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin,</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and it has not yet generated any product revenue. All of the Company&#8217;s principal operations, assets, and decision-making functions are based in the U.S., and as a result, all of our financial information is derived from domestic sources except for collaboration and license revenue of $<ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-438">36.8</ix:nonFraction> million during the six months ended June&#160;30, 2026, which was derived from <ix:nonFraction unitRef="partner" contextRef="c-1" decimals="INF" name="vtvt:NumberOfForeignCollaborationPartners" format="ixt-sec:numwordsen" scale="0" id="f-439">two</ix:nonFraction> foreign collaboration partners located in China and United Arab Emirates. </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9fadb18a1cc64d17ba910cfcf66d9538_7">Table of Contents</a></span></div></div><ix:continuation id="f-437-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="f-440" escape="true"><div style="margin-top:4pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Significant segment expenses are included in the table below and represent direct and indirect research and development expenses by project for the three and six months ended June&#160;30, 2026, and 2025 were as follows (in thousands):</span></div><div style="margin-top:4pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:51.209%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.375%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.375%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.375%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.378%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Direct research and development expense:</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cadisegliatin</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-3" name="vtvt:DirectResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-441">5,488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-3" name="vtvt:DirectResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-442">1,992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-3" name="vtvt:DirectResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-443">11,995</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-3" name="vtvt:DirectResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-444">2,910</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other projects</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-3" name="vtvt:DirectResearchAndDevelopmentExpense" scale="3" id="f-445">240</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-3" name="vtvt:DirectResearchAndDevelopmentExpense" scale="3" id="f-446">136</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3" name="vtvt:DirectResearchAndDevelopmentExpense" scale="3" id="f-447">317</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-3" name="vtvt:DirectResearchAndDevelopmentExpense" scale="3" id="f-448">249</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Indirect research and development expense&#8224;</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-3" name="vtvt:IndirectResearchDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-449">3,042</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-3" name="vtvt:IndirectResearchDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-450">1,975</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-3" name="vtvt:IndirectResearchDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-451">5,436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-3" name="vtvt:IndirectResearchDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-452">3,774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expense</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-453">8,770</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-454">4,103</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-455">17,748</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-456">6,933</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:25.000%"><tr><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:89.972%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Includes HPP737 and azeliragon</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8224;</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Includes share-based compensation</span></div></td></tr></table></div></ix:nonNumeric><div style="margin-top:4pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Segment revenue is consistent with what is presented in the Company&#8217;s Condensed Consolidated Statements of Operations. Other segment items consist of (i) operating expenses, which include share-based compensation, (ii) interest and other expense and (iii) income tax expense, all of which are reflected in the Company&#8217;s Condensed Consolidated Statements of Operations.</span></div></ix:continuation><div id="i9fadb18a1cc64d17ba910cfcf66d9538_79"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Note 9:  <ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-458" continuedAt="f-458-1" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="f-458-1"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to U.S. federal income taxes as well as state taxes. The Company did not record an income tax provision for the three and six months ended June&#160;30, 2026 and 2025.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Management has evaluated the positive and negative evidence surrounding the realization of its deferred tax assets, including the Company&#8217;s history of losses, and under the applicable accounting standards determined that it is more-likely-than-not that the deferred tax assets will not be realized. The difference between the effective tax rate of the Company and the U.S. statutory tax rate of 21% on June&#160;30, 2026, is due to the valuation allowance against the Company&#8217;s expected net operating losses.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 7, the Company is party to a tax receivable agreement with a related party which provides for the payment by the Company to M&amp;F (or certain of its transferees or other assignees) of <ix:nonFraction unitRef="number" contextRef="c-171" decimals="2" name="vtvt:PercentageOfAmountOfCashSavings" scale="-2" id="f-459">85</ix:nonFraction>% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that the Company actually realizes (or, in some circumstances, the Company is deemed to realize) as a result of certain transactions. As no transactions have occurred which would trigger a liability under this agreement, the Company has not recognized any liability related to this agreement as of June&#160;30, 2026.</span></div></ix:continuation><div id="i9fadb18a1cc64d17ba910cfcf66d9538_82"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Note 10:  <ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-460" continuedAt="f-460-1" escape="true">Net (Loss) Income per Share</ix:nonNumeric></span></div><ix:continuation id="f-460-1" continuedAt="f-460-2"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Basic (loss) income per share is computed by dividing net (loss) income attributable to vTv Therapeutics Inc. by the weighted average number of shares of Class A common stock outstanding during the period. Diluted net (loss) income per share is computed by dividing net (loss) income by the weighted-average number of shares of common stock and potentially dilutive shares of common stock outstanding during the period.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For dilutive securities, all outstanding stock options, and Common Warrants, are considered potentially outstanding common stock. The dilutive effect, if any, of stock options, and Common Warrants is calculated using the treasury stock method. </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9fadb18a1cc64d17ba910cfcf66d9538_7">Table of Contents</a></span></div></div><ix:continuation id="f-460-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-461" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the numerator and denominator used in the calculation of basic and diluted net (loss) income per share of Class A common stock is as follows (amounts in thousands, except number of shares and per share amounts):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.321%"><tr><td style="width:1.0%"/><td style="width:56.392%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.144%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.411%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.074%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.329%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.144%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.329%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.077%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Basic net (loss) income per share:</span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income </span></td><td style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-462">13,054</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-463">7,380</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-464">11,080</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-465">13,597</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net loss attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="f-466">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-467">1,334</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="f-468">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-469">2,459</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income attributable to common shareholders of vTv Therapeutics Inc.</span></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-470">13,054</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-471">6,046</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-472"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="f-473">11,080</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-474"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="f-475">11,138</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average vTv Therapeutics Inc. Class A common stock </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-476">12,409,316</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-26" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-477">6,587,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-478">12,409,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-28" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-479"><ix:nonFraction unitRef="shares" contextRef="c-28" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-480">6,584,969</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Basic net (loss) income per share of vTv Therapeutics Inc. Class A common stock</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-25" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-481">1.05</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-26" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-482">0.92</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-27" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-483">0.89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-28" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-484"><ix:nonFraction unitRef="usdPerShare" contextRef="c-28" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-485">1.69</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net (loss) income per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income </span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-486">13,054</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-487">7,380</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-488">11,080</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-489">13,597</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net loss attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="f-490">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-491">1,334</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="f-492">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-493">2,459</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income attributable to common shareholders of vTv Therapeutics Inc</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="f-494">13,054</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="f-495">6,046</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="f-496">11,080</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="f-497">11,138</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average vTv Therapeutics Inc. Class A common stock </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-498">12,409,316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-26" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-499">6,587,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-500">14,541,788</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-28" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-501">6,584,969</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net (loss) income per share of vTv Therapeutics Inc. Class A common stock</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-25" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-502">1.05</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-26" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-503">0.92</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-27" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-504">0.76</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-28" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-505">1.69</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"/><td style="width:2.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:90.720%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">(1)</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">The shares underlying the pre-funded warrants to purchase shares of the Company&#8217;s common stock have been included in the calculation of the weighted average number of shares outstanding, basic and diluted, for the three and six months ended June&#160;30, 2026 and 2025.</span></div></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-506" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities not included in the calculation of dilutive net loss per share are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:72.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.865%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.867%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2025</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Class B common stock </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-172" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="f-507">92</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-173" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-508">577,349</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options granted under the Plan </span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-174" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-509">674,538</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-175" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-510">1,018,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Common stock warrants </span></td><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-176" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-511">19,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-177" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-512">70,639</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-513">693,790</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-514">1,666,238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">___________________________</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"/><td style="width:2.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:90.720%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">(1)</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Shares of Class B common stock do not share in the Company&#8217;s earnings and are not participating securities. Accordingly, separate presentation of loss per share of Class B common stock under the two-class method has not been provided. Each share of Class B common stock (together with a corresponding vTv Unit) is exchangeable for one share of Class A common stock.</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i9fadb18a1cc64d17ba910cfcf66d9538_91"></div><div style="margin-top:12pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Note 11:  <ix:nonNumeric contextRef="c-1" name="us-gaap:SubsequentEventsTextBlock" id="f-516" continuedAt="f-516-1" escape="true">Subsequent Events</ix:nonNumeric></span></div><ix:continuation id="f-516-1"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated subsequent events through August&#160;6, 2026, and determined that there have been no events that have occurred that would require adjustments to our disclosures or the Unaudited Condensed Consolidated Financial Statements.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><div id="i9fadb18a1cc64d17ba910cfcf66d9538_94"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9fadb18a1cc64d17ba910cfcf66d9538_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Cautionary Note Regarding Forward Looking Statements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In addition to historical financial information, this Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the federal securities laws regarding, among other things, our intentions, plans, estimates, assumptions, predictions and beliefs. Although we believe that these forward-looking statements are based upon reasonable assumptions that we have made in light of our experience in the industry, as well as our perceptions of historical trends, current conditions, expected future developments and other factors that we believe are appropriate under the circumstances, our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this report under &#8220;Part II, Other Information&#8212;Item 1A, Risk Factors&#8221; and under the heading &#8220;Risk Factors&#8221; under Item 1A of Part I in our Annual Report on Form 10-K. Forward-looking statements include information concerning our possible or assumed future results of operations, business strategies and operations, financing plans, potential growth opportunities, potential market opportunities, potential results of our drug development efforts or trials, and the effects of competition. Forward-looking statements include all statements that are not historical facts and can be identified by terms such as &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;could,&#8221; &#8220;seeks,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;potential,&#8221; &#8220;predicts,&#8221; &#8220;projects,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; or similar expressions and the negatives of those terms. Given the numerous uncertainties and factors to our operations and business environment, all of which are difficult to predict and many of which are beyond our control, you should not place undue reliance on these forward-looking statements and understand that these statements are not guarantees of performance or results. Also, forward-looking statements represent our management&#8217;s plans, estimates, assumptions and beliefs only as of the date of this report. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.</span></div><div id="i9fadb18a1cc64d17ba910cfcf66d9538_97"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Company Overview</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. The Company&#8217;s clinical pipeline is led by </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, currently in a Phase 3 trial, a potential first-in-class oral liver-selective glucokinase activator (&#8220;GKA&#8221;) being investigated as an adjunctive therapy to insulin for the treatment of type 1 diabetes (&#8220;T1D&#8221;). The Company and its development partners are investigating multiple molecules across different indications for chronic diseases. </span></div><div id="i9fadb18a1cc64d17ba910cfcf66d9538_100"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Recent Developments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material developments since our last reporting period.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9fadb18a1cc64d17ba910cfcf66d9538_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our current clinical development candidates and their respective stages of development:</span></div><div style="margin-top:6pt"><img src="vtvt-20260630_g1.jpg" alt="Pipeline image for 2025 10-K.jpg" style="height:395px;margin-bottom:5pt;vertical-align:text-bottom;width:672px" id="i-1"/></div><div style="text-align:justify"><span><br/></span></div><div id="i9fadb18a1cc64d17ba910cfcf66d9538_103"></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Our Type 1 Diabetes Program &#8211; </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cadisegliatin (TTP399)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Type 1 diabetes (&#8220;T1D&#8221;) is an autoimmune disease in which the body&#8217;s immune system destroys the insulin-producing beta cells of the pancreas. According to the T1D Index, an estimated 1.5 million individuals live with T1D in the United States as of 2026. Patients with T1D have difficulty achieving and maintaining glycemic control, defined as HbA1c &lt;7% as recommended by the American Diabetes Association (&#8220;ADA&#8221;), with approximately 75% of Americans living with T1D not achieving this target. Blood sugar management is a constant balancing act between reducing hyperglycemia while avoiding hypoglycemia, which the ADA Standard of Care 2026 identifies as often the major limiting factor in the glycemic management of T1D.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Given the lack of oral adjunctive treatments for T1D, several existing therapies developed for type 2 diabetes have been investigated in T1D with limited success, primarily due to safety risks including increased risk of diabetic ketoacidosis (&#8220;DKA&#8221;). Despite the FDA&#8217;s approval of teplizumab (to delay onset of Stage 3 T1D) and donislecel (an islet cell therapy restricted to patients with recurrent severe hypoglycemia), serious unmet medical need remains for a safe oral treatment option that reduces the incidence of hypoglycemia and improves glycemic control without the risk of DKA or other serious adverse effects.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> is a novel, small-molecule, liver-selective glucokinase activator (&#8220;GKA&#8221;) being evaluated as a potential first-in-class oral adjunctive therapy to insulin for the treatment of T1D. Glucokinase is a key regulator of glucose homeostasis that acts as a physiological glucose sensor; liver-selective activation of glucokinase could improve overall blood glucose control and reduce the frequency of hypoglycemic episodes through a mechanism of action distinct from currently marketed oral anti-diabetic drugs. The U.S. Food and Drug Administration (&#8220;FDA&#8221;) granted Breakthrough Therapy designation in 2021 for </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> as an adjunctive therapy to insulin for the treatment of T1D, supported by the positive results from the Phase 2 SimpliciT-1 study.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the Phase 2 SimpliciT-1 study, a multi-center, randomized, double-blind, adaptive trial, treatment with </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> resulted in a statistically significant improvement in HbA1c relative to placebo and a clinically meaningful decrease (40%) in the frequency of severe and symptomatic hypoglycemia. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> demonstrated a favorable safety profile, in which abnormal levels of serum or urine ketones were detected less frequently in patients taking </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> than those taking placebo. A Phase 1 mechanistic study further demonstrated no increased risk of ketoacidosis with </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> during acute </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9fadb18a1cc64d17ba910cfcf66d9538_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">insulin withdrawal in patients with T1D. We have completed eleven Phase 1 and three Phase 2 clinical trials of </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> totaling more than 500 patients with type 1 and type 2 diabetes.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In May of 2023, the FDA issued new draft guidance on &#8220;Diabetes Mellitus: Efficacy Endpoints for Clinical Trials Investigating Antidiabetic Drugs and Biological Products&#8221; which, for the first time, permitted the use of hypoglycemia as an endpoint to support a label claim. Consistent with this guidance and with input from the FDA, we initiated our CATT1 trial to assess the effect of </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> on reducing the frequency of Level 2 hypoglycemia (blood glucose levels are less than 54 mg/dL or 3 mmol/L, regardless of symptoms) and Level 3 hypoglycemia (&#8220;severe&#8221; hypoglycemia e.g., requiring assistance of another person) in 150 patients with type 1 diabetes on a 1:1:1 basis (i.e., 50 patients per study arm) to receive 800 mg </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> daily, 800 mg </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> twice daily, or placebo. A key secondary endpoint is reduction in glycated hemoglobin (HbA1c) to assess the potential of </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> to reduce hyperglycemia. The Company expects to complete enrollment of the CATT1 trial in the third quarter of 2026.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In 2025, the Company completed a food effect study in healthy volunteers that investigated the effect of fasting, low fat, and high fat meals on the absorption of </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The study showed significantly higher </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> exposure in the fed groups as compared to the fasted group. The results confirm the current recommendation in the CATT1 trial that </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> be taken with food to maximize its absorption.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During this reporting period, we also continued working on the design and execution of supportive trials for </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, including a thorough QT study. We expect to initiate a Phase 2 study in patients with T1D using hybrid closed loop insulin infusion systems in late 2026.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to work on the design for further registrational studies for </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> in type 1 diabetes, which we expect to start in 2027.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In December 2025, together with our partner, G42 Investments (&#8220;G42&#8221;), we initiated a double-blind, randomized, controlled Phase 2 trial in the Middle East region in insulin-using patients with type 2 diabetes (&#8220;T2D&#8221;). The study will randomize 300 patients to assess the potential of </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> as an adjunct therapy to insulin in patients with T2D, and is expected to start screening in 2026.</span></div><div id="i9fadb18a1cc64d17ba910cfcf66d9538_106"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Holding Company Structure</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">vTv Therapeutics Inc. is a holding company and its principal asset is a controlling equity interest in vTv Therapeutics LLC (&#8220;vTv LLC&#8221;), the principal operating subsidiary. We have determined that vTv LLC is a variable-interest entity (&#8220;VIE&#8221;) for accounting purposes and that vTv Therapeutics Inc. is the primary beneficiary of vTv LLC because (through its managing member interest in vTv LLC and the fact that the senior management of vTv Therapeutics Inc. is also the senior management of vTv LLC) it has the power to direct all of the activities of vTv LLC, which include those that most significantly impact vTv LLC&#8217;s economic performance. vTv Therapeutics Inc. has therefore consolidated vTv LLC&#8217;s results under the VIE accounting model in its consolidated financial statements.</span></div><div id="i9fadb18a1cc64d17ba910cfcf66d9538_109"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Financial Overview</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not generated any revenue from drug sales. Our revenue has been primarily derived from milestone payments, up-front proceeds and research fees under collaboration and license agreements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the future, we may generate revenue from a combination of product sales, license fees, milestone payments and royalties from the sales of products developed under licenses of our intellectual property. We expect that any revenue we generate will fluctuate from quarter to quarter as a result of the timing and amount of license fees, milestone and other payments, and the amount and timing of payments that we receive upon the sale of our products, to the extent any are successfully commercialized. If we fail to complete the development of our drug candidates in a timely manner or obtain regulatory approval for them, our ability to generate future revenue and our results of operations and financial position will be materially adversely affected.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have focused our resources on our research and development activities, including conducting preclinical studies and clinical trials, manufacturing development efforts and activities related to regulatory filings for our drug candidates. We recognize research and development expenses as they are incurred. Our direct research and development expenses consist primarily of external costs such as fees paid to investigators, consultants, central laboratories and clinical research organizations in connection with our clinical trials, and costs related to acquiring and manufacturing clinical trial </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9fadb18a1cc64d17ba910cfcf66d9538_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">materials. Our indirect research and development costs consist primarily of cash and share-based compensation costs, the cost of employee benefits and related overhead expenses for personnel in research and development functions. Since we typically use our employee and infrastructure resources across multiple research and development programs such costs are not allocated to the individual projects.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development expenses by project for the three and six months ended June&#160;30, 2026 and 2025 were as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.340%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.905%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.905%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.785%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Direct research and development expense:</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cadisegliatin</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,488&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,992&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11,995&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,910&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other projects*</span></td><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Indirect research and development expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,042&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,975&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,436&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,774&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expense</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8,770&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,103&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">17,748&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,933&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:14pt">Includes </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">HPP737</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">azeliragon</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We plan to continue to incur significant research and development expenses for the foreseeable future as we continue the development of </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and further advance the development of our other drug candidates, subject to the availability of additional funding.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The successful development of our clinical and preclinical drug candidates is highly uncertain. At this time, we cannot reasonably estimate the nature, timing or costs of the efforts that will be necessary to complete the remainder of the development of any of our clinical or preclinical drug candidates or the period, if any, in which material net cash inflows from these drug candidates may commence. This is due to the numerous risks and uncertainties associated with the development of our drug candidates, including:</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the scope, rate of progress and expense of our clinical trials as well as any additional, clinical trials and other research and development activities;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the potential benefits of our candidates over other therapies;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to market, commercialize and achieve market acceptance for any of our drug candidates that we are developing or may develop in the future;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">future clinical trial results;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to enroll patients in our clinical trials;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the timing and receipt of any regulatory approvals; </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to secure sufficient capital and cash resources, including access to available debt and equity financing and revenues from operations, to satisfy all of our short-term and longer-term cash requirements and other cash needs, at the times and in the amounts needed;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">legislation and regulatory actions and changes in laws or regulations; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the filing, prosecuting, defending and enforcing of patent claims and other intellectual property rights, and the expense of doing so.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A change in the outcome of any of these variables with respect to the development of a drug candidate could mean a significant change in the costs and timing associated with the development of that drug candidate. For example, if the FDA or another regulatory authority were to require us to conduct clinical trials beyond those that we currently anticipate will be required for the completion of clinical development of a drug candidate, or if we experience significant delays in enrollment in any of our clinical trials, we could be required to expend significant additional financial resources and time with respect to the development of that drug candidate.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9fadb18a1cc64d17ba910cfcf66d9538_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries, benefits and related costs for employees in executive, finance, corporate development, human resources and administrative support functions. Other significant general and administrative expenses include accounting and legal services, expenses associated with obtaining and maintaining patents, cost of various consultants, occupancy costs and information systems.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest income represents cash interest income from dividends and interest from our money market accounts, all of which are recognized in our Condensed Consolidated Statement of Operations. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income, net</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other income primarily consists of the recognition of changes in fair value of the warrants to purchase shares of our Class A common stock.</span></div><div id="i9fadb18a1cc64d17ba910cfcf66d9538_112"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the three months ended June&#160;30, 2026 and 2025</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth certain information concerning our results of operations for the periods shown:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.848%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(dollars in thousands)</span></td><td colspan="15" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Statement of operations data:</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Revenue </span></td><td style="background-color:#ebfeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000000;padding:2.62pt 7pt 1.5pt 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000000;padding:2.62pt 7pt 1.5pt 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000000;padding:2.62pt 7pt 1.5pt 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Research and development </span></td><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8,770</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,103</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,667</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative </span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,160</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,618</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,542</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses </span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000000;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13,930</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000000;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,721</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000000;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,209</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(13,930)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(7,721)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(6,209)</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">812</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">275</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">537</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">64</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">66</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net loss before income taxes and noncontrolling interest</span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000000;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(13,054)</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000000;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(7,380)</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000000;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(5,674)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net loss before noncontrolling interest</span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000000;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(13,054)</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000000;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(7,380)</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000000;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(5,674)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Less: net loss attributable to noncontrolling interest</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,334)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,334</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to vTv Therapeutics Inc.</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ebfeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 7pt 1.5pt 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(13,054)</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ebfeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 7pt 1.5pt 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(6,046)</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ebfeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 7pt 1.5pt 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(7,008)</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There was no revenue for the three months ended June&#160;30, 2026 and 2025. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $8.8 million and $4.1 million for the three months ended June&#160;30, 2026 and 2025, respectively. The increase in research and development expenses during this period of $4.7 million or 113.7%, was primarily driven by i) an increase in spending on </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> of $3.5 million due to increases in clinical studies and consulting related costs, ii) an increase in indirect research and development expense of $1.1 million primarily related to increases in payroll and share-based expenses and iii) an increase in other projects of $0.1 million.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expense</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">s</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $5.2 million and $3.6 million for the three months ended June&#160;30, 2026 and 2025, respectively. The increase in general and administrative expenses during this period of $1.5&#160;million, or 42.6%, was </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9fadb18a1cc64d17ba910cfcf66d9538_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">primarily driven by i) increases of $0.6 million in share-based expenses, ii) increases of $0.5 million in other operating costs, iii) increases of $0.2 million in payroll related costs and iv) increases of $0.2 million in legal expenses.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest income for the three months ended June&#160;30, 2026 and </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, of $0.8 million and </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$0.3 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, respectively, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">is related to dividend income from our money market accounts</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> Net</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other income for the three months ended June&#160;30, 2026 and 2025, was immaterial. </span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div id="i9fadb18a1cc64d17ba910cfcf66d9538_115"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the six months ended June&#160;30, 2026 and 2025</span></div><div style="margin-top:6pt;text-align:justify;text-indent:30.6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth certain information concerning our results of operations for the periods shown:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"/><td style="width:58.690%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.904%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.904%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.908%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(dollars in thousands)</span></td><td colspan="15" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Statement of operations data:</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Revenue </span></td><td style="background-color:#ebfeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000000;padding:2.62pt 7pt 1.5pt 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">36,839</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000000;padding:2.62pt 7pt 1.5pt 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000000;padding:2.62pt 7pt 1.5pt 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">36,839</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Research and development </span></td><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">17,748</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,933</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10,815</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative </span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9,758</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,291</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,467</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses </span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000000;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">27,506</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000000;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">14,224</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000000;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13,282</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating income/(loss)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9,333</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(14,224)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">23,557</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,650</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">606</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,044</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">97</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">21</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">76</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) before income taxes and noncontrolling interest</span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000000;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11,080</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000000;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(13,597)</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000000;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">24,677</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) before noncontrolling interest</span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000000;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11,080</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000000;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(13,597)</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000000;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">24,677</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Less: net loss attributable to noncontrolling interest</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2,459)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,459</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to vTv Therapeutics Inc.</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ebfeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 7pt 1.5pt 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11,080</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ebfeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 7pt 1.5pt 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(11,138)</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ebfeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 7pt 1.5pt 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">22,218</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of $36.8 million for the six months ended June&#160;30, 2026 was related to the Newsoara upfront fee received and recognizing the deferred revenue of G42 license agreement due to the transfer of the related IP and satisfaction of the performance obligation. There was no revenue for the six months ended June&#160;30, 2025. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $17.7 million and $6.9 million for the six months ended June&#160;30, 2026 and 2025, respectively. The increase in research and development expenses during the period of $10.8 million, or 156.0%, was primarily driven by i) an increase in spending on </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of $9.1 million due to increases in clinical studies and consulting related cost and ii) an increase in indirect research and development expense of $1.7 million primarily related to increases in payroll and share-based expenses.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expense</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">s</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $9.8 million and $7.3 million for the six months ended June&#160;30, 2026 and 2025, respectively. The increase of $2.5 million or 33.8%, was primarily driven by i) increases of $0.9 million in share-based expenses, ii) increases of $0.7 million in other operating costs, iii) increases of $0.5 million in payroll related costs and iv) increases of $0.4 million in legal expenses.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest income</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest income for the six months ended June&#160;30, 2026 and </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2025,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> of $1.7 million and $0.6 million respectively, is related to </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">dividend income from our money market accounts</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income, Net</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other income for the six months ended June&#160;30, 2026 and June&#160;30, 2025, was immaterial.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><div id="i9fadb18a1cc64d17ba910cfcf66d9538_118"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9fadb18a1cc64d17ba910cfcf66d9538_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2026, we had an accumulated deficit of $315.6 million. Since our inception, we have experienced a history of negative cash flows from operating activities. We anticipate that we will continue to incur losses and negative cash flow from operations for the foreseeable future as we continue our clinical trials. Further, we expect that we will need additional capital to continue to fund our operations. As of June&#160;30, 2026, we had cash and cash equivalents of $86.6 million. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On January 30, 2026, the Company entered into a Second Amendment to License Agreement with Newsoara Biopharma Co., Ltd. (&#8220;Newsoara&#8221;) (the &#8220;Second Amendment&#8221;). Under the Second Amendment, Newsoara's rights in the Company's PDE4 inhibitor, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HPP737</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, will expand to include all countries of the world upon Newsoara's payment of the upfront fee of $20.0 million. See Note 3 for further details.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On August 29, 2025, we entered into a securities purchase agreement (the &#8220;Securities Purchase Agreement&#8221;) with certain institutional accredited investors (the &#8220;Private Placement Investors&#8221;), pursuant to which we agreed to issue and sell 5,243,732 units (the &#8220;Units&#8221;) to the Private Placement Investors in a private placement (the &#8220;Private Placement&#8221;). Each Unit includes (i) either (A) one share (the &#8220;Shares&#8221;) of our Class A common stock at purchase price of $15.265 per share, (the &#8220;Common Stock&#8221;), or (B) a Pre-Funded Warrant (the &#8220;Pre-Funded Warrants&#8221;) to purchase one share of Common Stock (the &#8220;Pre-Funded Warrant Shares&#8221;) at a purchase price of $15.255 per share (representing per Private Placement Share purchase price less the exercise price of $0.01) and (ii) a warrant (the &#8220;Common Warrants&#8221;) to purchase one share of Common Stock (the &#8220;Warrant Shares&#8221;) (or a Pre-Funded warrant to purchase one share of Common Stock in lieu of a share of Common Stock (the &#8220;Replacement Warrants&#8221; and, together with the Pre-Funded Warrants and the Common Warrants, the &#8220;Warrants&#8221;). We received aggregate gross proceeds from the Private Placement of approximately $80.0&#160;million, before deducting offering costs payable by us. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Pre-Funded Warrants are exercisable for $0.01, at any time after their original issuance and will not expire. The common warrants are exercisable for (x) $22.71, if exercised for a Share, or (y) $22.70 if exercised for a Pre-Funded Warrant, after the original issuance through the termination date. The Common Warrants will expire upon the earlier to occur of (i) the fifth anniversary of the issuance of the Warrants and (ii) 90 days following the announcement of positive top-line data from the Company&#8217;s ongoing CATT1 clinical trial. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are evaluating several financing strategies to increase our cash reserves, including direct equity investments and the potential licensing and monetization of other Company programs. The timing and availability of such additional funding are not yet known and we can provide no assurance that these plans will be successful. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ATM Offering</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TD Cowen Sales Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On February 28, 2024, we entered into a sales agreement (the &#8220;TD Cowen Sales Agreement&#8221;) with Cowen and Company, LLC (&#8220;TD Cowen&#8221;), pursuant to which we may offer and sell, from time to time, through or to TD Cowen, as sales agent or principal, shares of our Class A common stock, having an aggregate offering price of up to $50.0 million (the &#8220;TD Cowen ATM Offering&#8221;). Pursuant to General Instruction I.B.6 of Form S-3, at no time will we sell securities registered on the registration statement relating to the TD Cowen ATM Offering with an aggregate amount exceeding one-third of our public float in any 12-calendar month period, so long as our public float remains below $75.0 million. Under the terms of the TD Cowen Sales Agreement, we will pay TD Cowen a commission of 3.0% of the aggregate proceeds from the sale of shares and reimburse certain legal fees or other disbursements. On September 17, 2024, the Company sold 179,400 shares of Class A common stock under the TD Cowen ATM Offering for net proceeds of $2.5 million, leaving $47.5 million available to be sold. The shares are offered and sold pursuant to the Company&#8217;s shelf registration statement on Form S-3. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in thousands)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2,289)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(10,782)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 22pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net decrease in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2,289)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(10,824)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9fadb18a1cc64d17ba910cfcf66d9538_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27.78pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2026, our net cash used in operating activities decreased by $8.5 million from the six months ended June 30, 2025. The significant contributor to the change was the $20.0 million received from the Newsoara upfront fee under the Second Amendment, partially offset by working capital changes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27.78pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There were no cash flows from investing activities for the six months ended June&#160;30, 2026, and 2025. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27.78pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There were no cash flows from financing activities for the six months ended June&#160;30, 2026. For the six months ended June&#160;30, 2025, our net cash used in financing activities was immaterial. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future Funding Requirements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not generated any revenue from drug product sales. We do not know when, or if, we will generate any revenue from drug product sales. We do not expect to generate revenue from drug sales unless and until we obtain regulatory approval of and commercialize any of our drug candidates. At the same time, we expect our expenses to continue or to increase in connection with our ongoing development activities, particularly as we continue the research, development and clinical trials of, and seek regulatory approval for, our drug candidates. In addition, subject to obtaining regulatory approval of any of our drug candidates, we expect to incur significant commercialization expenses for product sales, marketing, manufacturing and distribution. We anticipate that we will need substantial additional funding in connection with our continuing operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We plan to finance our operations through the use of our cash and cash equivalents, including cash received from future funding activities. We continue to evaluate financing strategies to fund future clinical trials of </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, including direct equity investments and the potential licensing and monetization of other Company programs. The timing of any such transactions is not certain, and we may not be able to complete such transactions on acceptable terms, or at all. Even if we are able to complete such transactions, they may contain restrictions on our operations or cause substantial dilution to our stockholders. We have based our estimates on assumptions that may prove to be wrong, and we may use our available capital resources sooner than we currently expect. Because of the numerous risks and uncertainties associated with the development and commercialization of our drug candidates, we are unable to estimate the amounts of increased capital outlays and operating expenditures necessary to complete the development of our drug candidates. Additionally, although we may sell shares of our Class A common stock pursuant to the TD Cowen ATM Offering, our ability to use this source of capital is dependent on a number of factors, including the prevailing market price of and the volume of trading in the Company&#8217;s Class A common stock</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our future capital requirements will depend on many factors, including:</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the progress, costs, results and timing of our trials to evaluate </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">as a potential adjunctive therapy for the treatment of type 1 diabetes;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the willingness of the FDA to rely upon our completed and planned clinical and preclinical studies and other work, as the basis for review and approval of our drug candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to maintain control over our costs in line with our budget for our lead product candidate, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the outcome, costs and timing of seeking and obtaining FDA and any other regulatory approvals;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the number and characteristics of drug candidates that we pursue, including our drug candidates in preclinical development;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the ability of our drug candidates to progress through clinical development successfully;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our need to expand our research and development activities;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the costs associated with securing, establishing and maintaining commercialization capabilities;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the costs of acquiring, licensing or investing in businesses, products, drug candidates and technologies;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to maintain, expand and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make, or that we may receive, in connection with the licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property rights;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9fadb18a1cc64d17ba910cfcf66d9538_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our need and ability to hire additional management, scientific, and medical personnel;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the effect of competing technological and market developments;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our need to implement additional internal systems and infrastructure, including financial and reporting systems;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the economic and other terms, timing and success of our existing licensing arrangements and any collaboration, licensing or other arrangements into which we may enter in the future; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the amount of any payments we are required to make to M&amp;F TTP Holdings Two LLC in the future under the Tax Receivable Agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate substantial revenue from drug sales, we expect to finance our cash needs through a combination of equity offerings, debt financings, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangement</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">s. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of our common stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants that will further limit or restrict our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may be required to relinquish valuable rights to our technologies, future revenue streams or drug candidates or grant licenses on terms that may not be favorable to us.</span></div><div id="i9fadb18a1cc64d17ba910cfcf66d9538_121"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2026, we did not have outstanding any off-balance sheet arrangements as defined under SEC rules. </span></div><div id="i9fadb18a1cc64d17ba910cfcf66d9538_124"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Discussion of Critical Accounting Policies and Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of our critical accounting policies and estimates, please refer to Part II, Item 7. &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in our Annual Report on Form 10-K for the year ended December&#160;31, 2025. There have been no material changes to our critical accounting policies and estimates in 2026.</span></div><div id="i9fadb18a1cc64d17ba910cfcf66d9538_127"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">This quarterly report includes certain forward-looking statements within the meaning of the federal securities laws regarding, among other things, our management&#8217;s intentions, plans, beliefs, expectations, or predictions of future events, which are considered forward-looking statements. You should not place undue reliance on those statements because they are subject to numerous uncertainties and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control. Forward-looking statements include information concerning our possible or assumed future results of operations, including descriptions of our business strategy. These statements often include words such as &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;could,&#8221; &#8220;seeks,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;potential,&#8221; &#8220;predicts,&#8221; &#8220;projects,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; or similar expressions and the negatives of those terms. These statements are based upon assumptions that we have made in light of our experience in the industry, as well as our perceptions of historical trends, current conditions, expected future developments and other factors that we believe are appropriate under the circumstances. As you read this quarterly report, you should understand that these statements are not guarantees of performance or results. They involve known and unknown risks, uncertainties, and assumptions, including those described under the heading &#8220;Risk Factors&#8221; under Item 1A of Part I in our Annual Report on Form 10-K and under Item 1A of Part II of this Quarterly Report on Form 10-Q. Although we believe that these forward-looking statements are based upon reasonable assumptions, you should be aware that many factors, including those described under the heading &#8220;Risk Factors&#8221; under Item 1A of Part I in our Annual Report on Form 10-K and under Item 1A of Part II of this Quarterly Report on Form 10-Q, could affect our actual financial results or results of operations and could cause actual results to differ materially from those in the forward-looking statements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our forward-looking statements made herein are made only as of the date of this quarterly report. We expressly disclaim any intent, obligation or undertaking to update or revise any forward-looking statements made herein to reflect any change in our expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based. All subsequent written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements contained in this quarterly report.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><div id="i9fadb18a1cc64d17ba910cfcf66d9538_130"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9fadb18a1cc64d17ba910cfcf66d9538_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Effect of Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">See discussion of recent accounting pronouncements in Note 2, &#8220;Summary of Significant Accounting Policies&#8221;, to the Unaudited Condensed Consolidated Financial Statements in this Form 10-Q.</span></div><div id="i9fadb18a1cc64d17ba910cfcf66d9538_133"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently have any material interest rate exposure.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Market Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our exposure to market risk is limited to our cash and cash equivalents, all of which have maturities of one year or less. The goals of our investment strategy are preservation of capital, fulfillment of liquidity needs and fiduciary control of cash and investments. We also seek to maximize income from our investments without assuming significant risk. To achieve our goals, we maintain cash and cash equivalents with multiple financial institutions that management believes to be of high credit quality. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Risk</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any material foreign currency exposure.</span></div><div id="i9fadb18a1cc64d17ba910cfcf66d9538_136"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the supervision and with the participation of our Chief Executive Officer (our Principal Executive Officer) and Chief Financial Officer (our Principal Financial Officer), management has evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) of the Securities Exchange Act of 1934) as of June&#160;30, 2026. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of June&#160;30, 2026, our disclosure controls and procedures were effective in causing material information relating to us (including our consolidated subsidiaries) to be recorded, processed, summarized, and reported by management on a timely basis and to ensure the quality and timeliness of our public disclosures pursuant to SEC disclosure obligations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, with the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error and mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of controls.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, a control may become inadequate because of changes in conditions or because the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and may not be detected.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Changes to Internal Control over Financial Reporting</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in our internal control over financial reporting during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Website Availability of Reports and other Corporate Governance Information</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a comprehensive corporate governance program, including Corporate Governance Guidelines for its Board of Directors, Board Guidelines for Assessing Director Independence, and charters for its Audit Committee, Nominating and Corporate Governance Committee and Compensation Committee. The Company maintains a corporate investor relations website, www.vtvtherapeutics.com, where stockholders and other interested persons may review, without charge, among other things, corporate governance materials and certain SEC filings, which are generally available on the </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9fadb18a1cc64d17ba910cfcf66d9538_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">same business day as the filing date with the SEC on the SEC&#8217;s website http://www.sec.gov. The contents of our website are not made a part of this Quarterly Report on Form 10-Q.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div id="i9fadb18a1cc64d17ba910cfcf66d9538_139"></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">PART II &#8211; OTHER INFORMATION</span></div><div><span><br/></span></div><div id="i9fadb18a1cc64d17ba910cfcf66d9538_142"></div><div style="padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are not currently a party to any material legal proceedings.</span></div><div id="i9fadb18a1cc64d17ba910cfcf66d9538_145"></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A.&#160;&#160;&#160;&#160;RISK FACTORS</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our risk factors are set forth under the heading &#8220;Risk Factors&#8221; under Item 1A of Part I in our Annual Report on Form 10-K for the year ended December&#160;31, 2025. </span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div id="i9fadb18a1cc64d17ba910cfcf66d9538_148"></div><div style="padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;&#160;&#160;UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div id="i9fadb18a1cc64d17ba910cfcf66d9538_151"></div><div style="padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160;DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i9fadb18a1cc64d17ba910cfcf66d9538_154"></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;&#160;&#160;MINE SAFETY DISCLOSURES</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i9fadb18a1cc64d17ba910cfcf66d9538_157"></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5.&#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div style="margin-top:4pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Rule 10b5-1 Trading Plans</span></div><div style="margin-top:4pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the second fiscal quarter ended June&#160;30, 2026, none of our directors or executive officers <ix:nonNumeric contextRef="c-14" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-517"><ix:nonNumeric contextRef="c-14" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-518">adopted</ix:nonNumeric></ix:nonNumeric> or <ix:nonNumeric contextRef="c-14" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-519"><ix:nonNumeric contextRef="c-14" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-520">terminated</ix:nonNumeric></ix:nonNumeric> any contract, instruction or written plan for the purchase or sale of our securities to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any &#8220;non-Rule 10b5-1 trading arrangement.&#8221;</span></div><div id="i9fadb18a1cc64d17ba910cfcf66d9538_160"></div><div style="-sec-extract:summary;margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6.&#160;&#160;&#160;&#160;EXHIBITS</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:86.173%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">31.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="vtvt-20260630xexx311.htm">Certification of President and Chief Executive Officer required by Rule 13a-14(a)/15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">31.2*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="vtvt-20260630xexx312.htm">Certification of Chief Financial Officer required by Rule 13a-14(a)/15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="vtvt-20260630xexx321.htm">Certification of President and Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">32.2*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="vtvt-20260630xexx322.htm">Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Document</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)</span></td></tr></table><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">___________________________</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="-sec-extract:summary;margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9fadb18a1cc64d17ba910cfcf66d9538_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Filed herewith</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><div id="i9fadb18a1cc64d17ba910cfcf66d9538_163"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9fadb18a1cc64d17ba910cfcf66d9538_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Date: August&#160;6, 2026</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"/><td style="width:58.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.265%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">VTV THERAPEUTICS INC.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Paul J. Sekhri</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Paul J. Sekhri</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">President, Chief Executive Officer and Executive Chairperson</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Michael Tung</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Michael Tung</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer</span></div></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>vtvt-20260630xexx311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i9a4e5ccbb31046c98667140c49814999_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">SECTION 302 CERTIFICATION</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">I, Paul J. Sekhri, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">I have reviewed this quarterly report on Form 10-Q of vTv Therapeutics Inc. (the &#8220;registrant&#8221;)&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Securities Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; August&#160;6, 2026</font></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.295%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">By&#58;</font></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; Paul J. Sekhri</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Paul J. Sekhri</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">President, Chief Executive Officer and Executive Chairperson</font></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>vtvt-20260630xexx312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="if313627bac61443183d74b1266d21727_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">SECTION 302 CERTIFICATION</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">I, Michael Tung, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">I have reviewed this quarterly report on Form 10-Q of vTv Therapeutics Inc. (the &#8220;registrant&#8221;)&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Securities Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; August&#160;6, 2026</font></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.295%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">By&#58;</font></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; Michael Tung</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"></td><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Michael Tung</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Executive Vice President and Chief Financial Officer</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>vtvt-20260630xexx321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="ie7e6191dae5549489d49aa62deb0dbf8_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">18 U.S.C. SECTION 1350</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of vTv Therapeutics Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended June&#160;30, 2026, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Paul J. Sekhri, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, in my capacity as an officer of the Company that, to my knowledge&#58;</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; August&#160;6, 2026</font></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.295%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">By&#58;</font></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; Paul J. Sekhri</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Paul J. Sekhri</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">President, Chief Executive Officer and Executive Chairperson</font></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>vtvt-20260630xexx322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i636a8cf44e064339a337e8464bd696e7_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">18 U.S.C. SECTION 1350</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of vTv Therapeutics Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended June&#160;30, 2026, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Michael Tung, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, in my capacity as an officer of the Company that, to my knowledge&#58;</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; August&#160;6, 2026</font></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.295%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Michael Tung</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Michael Tung</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>vtvt-20260630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019e6a7f-3a2c-7e30-acc1-d5ae4ae8f1fc,g:0d1f2584-f555-42ce-b27a-904151cd021c-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:vtvt="http://vtvtherapeutics.com/20260630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://vtvtherapeutics.com/20260630">
  <xs:import namespace="http://fasb.org/srt/2026" schemaLocation="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2026" schemaLocation="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2026" schemaLocation="https://xbrl.sec.gov/dei/2026/dei-2026.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2026" schemaLocation="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vtvt-20260630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vtvt-20260630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vtvt-20260630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vtvt-20260630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://vtvtherapeutics.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>9952151 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>9952152 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsUnaudited" roleURI="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited">
        <link:definition>9952153 - Statement - Condensed Consolidated Statements of Operations - Unaudited</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementofChangesinStockholdersEquityUnaudited" roleURI="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinStockholdersEquityUnaudited">
        <link:definition>9952154 - Statement - Condensed Consolidated Statement of Changes in Stockholders&#8217; Equity - Unaudited</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlowsUnaudited" roleURI="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited">
        <link:definition>9952155 - Statement - Condensed Consolidated Statements of Cash Flows - Unaudited</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessandBasisofPresentation" roleURI="http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentation">
        <link:definition>9952156 - Disclosure - Description of Business and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>9952157 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreements" roleURI="http://vtvtherapeutics.com/role/CollaborationAgreements">
        <link:definition>9952158 - Disclosure - Collaboration Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation" roleURI="http://vtvtherapeutics.com/role/ShareBasedCompensation">
        <link:definition>9952159 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://vtvtherapeutics.com/role/CommitmentsandContingencies">
        <link:definition>9952160 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://vtvtherapeutics.com/role/StockholdersEquity">
        <link:definition>9952161 - Disclosure - Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://vtvtherapeutics.com/role/RelatedPartyTransactions">
        <link:definition>9952162 - Disclosure - Related-Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformation" roleURI="http://vtvtherapeutics.com/role/SegmentInformation">
        <link:definition>9952163 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://vtvtherapeutics.com/role/IncomeTaxes">
        <link:definition>9952164 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossIncomeperShare" roleURI="http://vtvtherapeutics.com/role/NetLossIncomeperShare">
        <link:definition>9952165 - Disclosure - Net (Loss) Income per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://vtvtherapeutics.com/role/SubsequentEvents">
        <link:definition>9952166 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationTables" roleURI="http://vtvtherapeutics.com/role/ShareBasedCompensationTables">
        <link:definition>9955512 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://vtvtherapeutics.com/role/StockholdersEquityTables">
        <link:definition>9955513 - Disclosure - Stockholders&#8217; Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationTables" roleURI="http://vtvtherapeutics.com/role/SegmentInformationTables">
        <link:definition>9955514 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossIncomeperShareTables" roleURI="http://vtvtherapeutics.com/role/NetLossIncomeperShareTables">
        <link:definition>9955515 - Disclosure - Net (Loss) Income per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessandBasisofPresentationDetails" roleURI="http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetails">
        <link:definition>9955516 - Disclosure - Description of Business and Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsDetails" roleURI="http://vtvtherapeutics.com/role/CollaborationAgreementsDetails">
        <link:definition>9955517 - Disclosure - Collaboration Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationAdditionalInformationDetails" roleURI="http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails">
        <link:definition>9955518 - Disclosure - Share-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofStockAwardActivityforthePeriodDetails" roleURI="http://vtvtherapeutics.com/role/ShareBasedCompensationScheduleofStockAwardActivityforthePeriodDetails">
        <link:definition>9955519 - Disclosure - Share-Based Compensation - Schedule of Stock Award Activity for the Period (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofCompensationExpenseRelatedtoGrantsofStockOptionsDetails" roleURI="http://vtvtherapeutics.com/role/ShareBasedCompensationScheduleofCompensationExpenseRelatedtoGrantsofStockOptionsDetails">
        <link:definition>9955520 - Disclosure - Share-Based Compensation - Schedule of Compensation Expense Related to Grants of Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofCompensationExpenseRelatedtoGrantsofStockOptionsDetails_1" roleURI="http://vtvtherapeutics.com/role/ShareBasedCompensationScheduleofCompensationExpenseRelatedtoGrantsofStockOptionsDetails_1">
        <link:definition>9955520 - Disclosure - Share-Based Compensation - Schedule of Compensation Expense Related to Grants of Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://vtvtherapeutics.com/role/CommitmentsandContingenciesDetails">
        <link:definition>9955521 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityAdditionalInformationDetails" roleURI="http://vtvtherapeutics.com/role/StockholdersEquityAdditionalInformationDetails">
        <link:definition>9955522 - Disclosure - Stockholders&#8217; Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityScheduleofEquityBasedStockWarrantsDetails" roleURI="http://vtvtherapeutics.com/role/StockholdersEquityScheduleofEquityBasedStockWarrantsDetails">
        <link:definition>9955523 - Disclosure - Stockholders&#8217; Equity - Schedule of Equity-Based Stock Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://vtvtherapeutics.com/role/RelatedPartyTransactionsDetails">
        <link:definition>9955524 - Disclosure - Related-Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationAdditionalInformationDetails" roleURI="http://vtvtherapeutics.com/role/SegmentInformationAdditionalInformationDetails">
        <link:definition>9955525 - Disclosure - Segment Information - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails" roleURI="http://vtvtherapeutics.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails">
        <link:definition>9955526 - Disclosure - Segment Information - Schedule of Segment Reporting Information, by Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://vtvtherapeutics.com/role/IncomeTaxesDetails">
        <link:definition>9955527 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossIncomeperShareScheduleofReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetIncomeLossperShareofClassACommonStockDetails" roleURI="http://vtvtherapeutics.com/role/NetLossIncomeperShareScheduleofReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetIncomeLossperShareofClassACommonStockDetails">
        <link:definition>9955528 - Disclosure - Net (Loss) Income per Share - Schedule of Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Income (Loss) per Share of Class A Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossIncomeperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetails" roleURI="http://vtvtherapeutics.com/role/NetLossIncomeperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetails">
        <link:definition>9955529 - Disclosure - Net (Loss) Income per Share - Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="vtvt_WarrantLiabilityCurrent" abstract="false" name="WarrantLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_WarrantyLiability" abstract="false" name="WarrantyLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock" abstract="false" name="UnauditedInterimFinancialInformationPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" abstract="true" name="OrganizationConsolidationAndPresentationOfFinancialStatementsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="vtvt_VTvLLCMember" abstract="true" name="VTvLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtvt_NewsoaraBiopharmaCoLtdMember" abstract="true" name="NewsoaraBiopharmaCoLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" abstract="true" name="OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="vtvt_PercentageOfNonVotingEconomicInterestByParent" abstract="false" name="PercentageOfNonVotingEconomicInterestByParent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="vtvt_LicenseFeeReceived" abstract="false" name="LicenseFeeReceived" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_G42InvestmentsMember" abstract="true" name="G42InvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtvt_CognaMember" abstract="true" name="CognaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtvt_G42AgreementsMember" abstract="true" name="G42AgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtvt_CommercialSupplyAgreementMember" abstract="true" name="CommercialSupplyAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtvt_IPLicenseMember" abstract="true" name="IPLicenseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtvt_SaleOfStockConsiderationReceivedOnTransactionGross" abstract="false" name="SaleOfStockConsiderationReceivedOnTransactionGross" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue" abstract="false" name="CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_CollaborateArrangementContingentConsiderationTransferredCash" abstract="false" name="CollaborateArrangementContingentConsiderationTransferredCash" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod" abstract="false" name="CollaborativeArrangementRoyaltiesReceivablePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="vtvt_CollaborativeArrangementNoteReceivableDiscountPaid" abstract="false" name="CollaborativeArrangementNoteReceivableDiscountPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable" abstract="false" name="PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_CommitmentsAndContingenciesTable" abstract="true" name="CommitmentsAndContingenciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember" abstract="true" name="DevelopmentalAndRegulatoryMilestonePaymentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtvt_SalesBasedMilestonesPaymentMember" abstract="true" name="SalesBasedMilestonesPaymentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtvt_TypeOneDiabetesMember" abstract="true" name="TypeOneDiabetesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtvt_TypeTwoDiabetesMember" abstract="true" name="TypeTwoDiabetesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtvt_OtherIndicationMember" abstract="true" name="OtherIndicationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtvt_NovoLicenseAgreementMember" abstract="true" name="NovoLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtvt_CommitmentsAndContingenciesLineItems" abstract="true" name="CommitmentsAndContingenciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="vtvt_PotentialMilestonePayment" abstract="false" name="PotentialMilestonePayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_TDCowenSalesAgreementMember" abstract="true" name="TDCowenSalesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtvt_PrivatePlacementPreFundedWarrantsMember" abstract="true" name="PrivatePlacementPreFundedWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtvt_PreFundedWarrantsMember" abstract="true" name="PreFundedWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtvt_CommonWarrantsMember" abstract="true" name="CommonWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtvt_WarrantsAndRightsImmediatelyExercisableTerm" abstract="false" name="WarrantsAndRightsImmediatelyExercisableTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="vtvt_CommonStockParOrStatedValueOfPrivatePlacementShares" abstract="false" name="CommonStockParOrStatedValueOfPrivatePlacementShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="vtvt_CommonStockParOrStatedValueOfPrivatePlacementPreFundedWarrantsShares" abstract="false" name="CommonStockParOrStatedValueOfPrivatePlacementPreFundedWarrantsShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="vtvt_SaleOfStockAggregateOfferingPrice" abstract="false" name="SaleOfStockAggregateOfferingPrice" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_EntityPublicFloatPercent" abstract="false" name="EntityPublicFloatPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="vtvt_EntityPublicFloatThreshold" abstract="false" name="EntityPublicFloatThreshold" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_SaleOfStockMaximumSecuritiesToBeSoldPercentOfPublicFloat" abstract="false" name="SaleOfStockMaximumSecuritiesToBeSoldPercentOfPublicFloat" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="vtvt_StockWarrantMember" abstract="true" name="StockWarrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePriceAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePriceAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="vtvt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" abstract="false" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="vtvt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" abstract="false" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="vtvt_MacAndrewsAndForbesIncorporatedMember" abstract="true" name="MacAndrewsAndForbesIncorporatedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtvt_VTvTherapeuticsIncMember" abstract="true" name="VTvTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember" abstract="true" name="ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtvt_MFTTPHoldingsTwoLLCMember" abstract="true" name="MFTTPHoldingsTwoLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtvt_PrivatePlacementInvestorsMember" abstract="true" name="PrivatePlacementInvestorsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtvt_OwnershipPercentageOfMajorityOwner" abstract="false" name="OwnershipPercentageOfMajorityOwner" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio" abstract="false" name="RedeemableNonControllingInterestExchangeAgreementStockConversionRatio" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="vtvt_PercentageOfAmountOfCashSavings" abstract="false" name="PercentageOfAmountOfCashSavings" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="vtvt_NumberOfBoardOfDirectorsRightToDesignateMembers" abstract="false" name="NumberOfBoardOfDirectorsRightToDesignateMembers" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="vtvt_NumberOfBoardOfDirectorsToApproveCertainActions" abstract="false" name="NumberOfBoardOfDirectorsToApproveCertainActions" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="vtvt_ReportableSegmentMember" abstract="true" name="ReportableSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtvt_NumberOfForeignCollaborationPartners" abstract="false" name="NumberOfForeignCollaborationPartners" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="vtvt_CadisegliatinMember" abstract="true" name="CadisegliatinMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtvt_OtherProjectsMember" abstract="true" name="OtherProjectsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtvt_DirectResearchAndDevelopmentExpense" abstract="false" name="DirectResearchAndDevelopmentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_IndirectResearchDevelopmentExpense" abstract="false" name="IndirectResearchDevelopmentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_IncomeTaxesTable" abstract="true" name="IncomeTaxesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="vtvt_MFTTPHoldingsLLCMember" abstract="true" name="MFTTPHoldingsLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtvt_IncomeTaxesLineItems" abstract="true" name="IncomeTaxesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="vtvt_ScheduleOfEarningsPerShareTable" abstract="true" name="ScheduleOfEarningsPerShareTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="vtvt_ScheduleOfEarningsPerShareLineItems" abstract="true" name="ScheduleOfEarningsPerShareLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="vtvt_NetIncomeLossDilutedAbstract" abstract="true" name="NetIncomeLossDilutedAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="vtvt_WeightedAverageNumberOfDilutedSharesOutstandingAbstract" abstract="true" name="WeightedAverageNumberOfDilutedSharesOutstandingAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>vtvt-20260630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019e6a7f-3a2c-7e30-acc1-d5ae4ae8f1fc,g:0d1f2584-f555-42ce-b27a-904151cd021c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:type="simple" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item"/>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="vtvt-20260630.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_019e6a7f-3af5-741d-b425-e6ea65efac67" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_019e6a7f-3af5-7f54-bdab-bb2d2e873267" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_019e6a7f-3af5-741d-b425-e6ea65efac67" xlink:to="loc_us-gaap_AssetsCurrent_019e6a7f-3af5-7f54-bdab-bb2d2e873267" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_019e6a7f-3af5-7cd4-9b3f-1c727d961f1b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_019e6a7f-3af5-741d-b425-e6ea65efac67" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_019e6a7f-3af5-7cd4-9b3f-1c727d961f1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_019e6a7f-3af5-71ed-a880-c2326f16fca6" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_019e6a7f-3af5-7e58-a6f4-a17133ca0e2b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_019e6a7f-3af5-71ed-a880-c2326f16fca6" xlink:to="loc_us-gaap_LiabilitiesCurrent_019e6a7f-3af5-7e58-a6f4-a17133ca0e2b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_WarrantyLiability_019e6a7f-3af5-7e5d-8120-f6bd329253bd" xlink:href="vtvt-20260630.xsd#vtvt_WarrantyLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_019e6a7f-3af5-71ed-a880-c2326f16fca6" xlink:to="loc_vtvt_WarrantyLiability_019e6a7f-3af5-7e5d-8120-f6bd329253bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_019e6a7f-3af5-72d4-9d15-1f19a328b362" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_019e6a7f-3af5-71ed-a880-c2326f16fca6" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_019e6a7f-3af5-72d4-9d15-1f19a328b362" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_019e6a7f-3af5-7cfc-89f1-171c36091bd9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_019e6a7f-3af5-789e-b37f-3b9540d037a6" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_019e6a7f-3af5-7cfc-89f1-171c36091bd9" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_019e6a7f-3af5-789e-b37f-3b9540d037a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_WarrantLiabilityCurrent_019e6a7f-3af5-7a4d-b23a-6371e9f7b452" xlink:href="vtvt-20260630.xsd#vtvt_WarrantLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_019e6a7f-3af5-7cfc-89f1-171c36091bd9" xlink:to="loc_vtvt_WarrantLiabilityCurrent_019e6a7f-3af5-7a4d-b23a-6371e9f7b452" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019e6a7f-3af5-7c09-9160-d4f97ffd271a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_019e6a7f-3af5-7bd9-98b0-014b1c783c3b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_019e6a7f-3af5-7c09-9160-d4f97ffd271a" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_019e6a7f-3af5-7bd9-98b0-014b1c783c3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_019e6a7f-3af5-7a68-a53a-40f0259e15da" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_019e6a7f-3af5-7c09-9160-d4f97ffd271a" xlink:to="loc_us-gaap_CommonStockValue_019e6a7f-3af5-7a68-a53a-40f0259e15da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019e6a7f-3af5-70ab-9fb1-b1a38eeeb8af" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_019e6a7f-3af5-7c09-9160-d4f97ffd271a" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019e6a7f-3af5-70ab-9fb1-b1a38eeeb8af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_019e6a7f-3af5-711f-b7f9-7a94da57cc98" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_019e6a7f-3af5-7187-8098-b66ce9afaf4b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_019e6a7f-3af5-711f-b7f9-7a94da57cc98" xlink:to="loc_us-gaap_OtherAssetsCurrent_019e6a7f-3af5-7187-8098-b66ce9afaf4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_019e6a7f-3af5-7e6c-af08-c8e5ddfee113" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_019e6a7f-3af5-711f-b7f9-7a94da57cc98" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_019e6a7f-3af5-7e6c-af08-c8e5ddfee113" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019e6a7f-3af5-7335-bdcc-1e22bc7355ac" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_019e6a7f-3af5-711f-b7f9-7a94da57cc98" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019e6a7f-3af5-7335-bdcc-1e22bc7355ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_019e6a7f-3af5-72cf-a1f7-8c48643d9869" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_019e6a7f-3af5-74d7-90f7-a3258b39873b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_019e6a7f-3af5-72cf-a1f7-8c48643d9869" xlink:to="loc_us-gaap_Liabilities_019e6a7f-3af5-74d7-90f7-a3258b39873b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_019e6a7f-3af5-7c1a-bde4-c66b6b6c27a7" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_019e6a7f-3af5-72cf-a1f7-8c48643d9869" xlink:to="loc_us-gaap_CommitmentsAndContingencies_019e6a7f-3af5-7c1a-bde4-c66b6b6c27a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019e6a7f-3af5-7e90-a7e6-3190ab992019" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_019e6a7f-3af5-72cf-a1f7-8c48643d9869" xlink:to="loc_us-gaap_StockholdersEquity_019e6a7f-3af5-7e90-a7e6-3190ab992019" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="simple" xlink:href="vtvt-20260630.xsd#CondensedConsolidatedStatementsofOperationsUnaudited"/>
  <link:calculationLink xlink:role="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_019e6a7f-3af5-7e27-a629-09b795fa74c3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019e6a7f-3af5-7835-8bfb-cd2f31300199" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_019e6a7f-3af5-7e27-a629-09b795fa74c3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019e6a7f-3af5-7835-8bfb-cd2f31300199" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_019e6a7f-3af5-77ee-abd8-5e76009f0c84" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_019e6a7f-3af5-7e27-a629-09b795fa74c3" xlink:to="loc_us-gaap_OperatingExpenses_019e6a7f-3af5-77ee-abd8-5e76009f0c84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_019e6a7f-3af5-712d-b815-48d12bda4880" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_019e6a7f-3af5-7358-bf50-aec9bc1ff385" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_019e6a7f-3af5-712d-b815-48d12bda4880" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_019e6a7f-3af5-7358-bf50-aec9bc1ff385" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_019e6a7f-3af5-7577-98e6-4935e43d0d5e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_019e6a7f-3af5-712d-b815-48d12bda4880" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_019e6a7f-3af5-7577-98e6-4935e43d0d5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019e6a7f-3af5-7fb3-933b-279b9651c8b4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_019e6a7f-3af5-72fa-88ea-ae8f07a17286" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_019e6a7f-3af5-7fb3-933b-279b9651c8b4" xlink:to="loc_us-gaap_ProfitLoss_019e6a7f-3af5-72fa-88ea-ae8f07a17286" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_019e6a7f-3af5-7d97-9883-57a325da1b2d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_019e6a7f-3af5-7fb3-933b-279b9651c8b4" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_019e6a7f-3af5-7d97-9883-57a325da1b2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_019e6a7f-3af5-76e2-a278-7d8221cd01a0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019e6a7f-3af5-7205-9042-6deb51942aed" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_019e6a7f-3af5-76e2-a278-7d8221cd01a0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019e6a7f-3af5-7205-9042-6deb51942aed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_019e6a7f-3af5-715a-81eb-e861b7b43e75" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_019e6a7f-3af5-76e2-a278-7d8221cd01a0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_019e6a7f-3af5-715a-81eb-e861b7b43e75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019e6a7f-3af5-7116-ac0c-cf6554d54325" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_019e6a7f-3af5-7236-b946-66c78fbf3bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019e6a7f-3af5-7116-ac0c-cf6554d54325" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_019e6a7f-3af5-7236-b946-66c78fbf3bbd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_019e6a7f-3af5-708d-be24-091cea5881d5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019e6a7f-3af5-7116-ac0c-cf6554d54325" xlink:to="loc_us-gaap_InvestmentIncomeInterest_019e6a7f-3af5-708d-be24-091cea5881d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_019e6a7f-3af5-7c7f-8311-04092f6365b3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019e6a7f-3af5-7116-ac0c-cf6554d54325" xlink:to="loc_us-gaap_OperatingIncomeLoss_019e6a7f-3af5-7c7f-8311-04092f6365b3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="vtvt-20260630.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:calculationLink xlink:role="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019e6a7f-3af5-778a-8b53-1464a843b633" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_019e6a7f-3af5-7bf1-9ebf-ecc72ed586ec" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019e6a7f-3af5-778a-8b53-1464a843b633" xlink:to="loc_us-gaap_ProfitLoss_019e6a7f-3af5-7bf1-9ebf-ecc72ed586ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_019e6a7f-3af5-718e-9f39-02e97f45b19c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019e6a7f-3af5-778a-8b53-1464a843b633" xlink:to="loc_us-gaap_Depreciation_019e6a7f-3af5-718e-9f39-02e97f45b19c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_019e6a7f-3af5-7ab1-95aa-59e13fe9cf97" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019e6a7f-3af5-778a-8b53-1464a843b633" xlink:to="loc_us-gaap_ShareBasedCompensation_019e6a7f-3af5-7ab1-95aa-59e13fe9cf97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_019e6a7f-3af5-7731-a180-75295598724b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019e6a7f-3af5-778a-8b53-1464a843b633" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_019e6a7f-3af5-7731-a180-75295598724b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_019e6a7f-3af5-7453-8486-8b6b4ad755e8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019e6a7f-3af5-778a-8b53-1464a843b633" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_019e6a7f-3af5-7453-8486-8b6b4ad755e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_019e6a7f-3af5-7cf0-906f-8754ac010e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019e6a7f-3af5-778a-8b53-1464a843b633" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_019e6a7f-3af5-7cf0-906f-8754ac010e3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_019e6a7f-3af5-71b0-8e5d-d531d68c0959" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019e6a7f-3af5-778a-8b53-1464a843b633" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_019e6a7f-3af5-71b0-8e5d-d531d68c0959" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_019e6a7f-3af5-702f-85eb-078f9d69703e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019e6a7f-3af5-778a-8b53-1464a843b633" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_019e6a7f-3af5-702f-85eb-078f9d69703e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_019e6a7f-3af5-7443-82d2-6e6f4b5036b5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019e6a7f-3af5-778a-8b53-1464a843b633" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_019e6a7f-3af5-7443-82d2-6e6f4b5036b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_019e6a7f-3af5-743c-8370-b4d0aa52fc14" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019e6a7f-3af5-778a-8b53-1464a843b633" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_019e6a7f-3af5-743c-8370-b4d0aa52fc14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019e6a7f-3af5-7d92-9ffd-b57b97e3d915" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019fb194-6668-7562-9d19-8cf9fdad94ef" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019e6a7f-3af5-7d92-9ffd-b57b97e3d915" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019fb194-6668-7562-9d19-8cf9fdad94ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019e6a7f-3af5-70fc-a014-054101d556ad" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019e6a7f-3af5-7d92-9ffd-b57b97e3d915" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019e6a7f-3af5-70fc-a014-054101d556ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019f69c8-57f5-79dd-a1c5-dcb41b8e54d1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_019f69c8-57f5-7627-afd5-d2160b3fee75" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019f69c8-57f5-79dd-a1c5-dcb41b8e54d1" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_019f69c8-57f5-7627-afd5-d2160b3fee75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_019f69c8-57f5-70ea-8de3-cea90014a65d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019f69c8-57f5-79dd-a1c5-dcb41b8e54d1" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_019f69c8-57f5-70ea-8de3-cea90014a65d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails" xlink:type="simple" xlink:href="vtvt-20260630.xsd#SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"/>
  <link:calculationLink xlink:role="http://vtvtherapeutics.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_019e6a7f-3bcc-75d7-bd95-6459fbaa729f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_DirectResearchAndDevelopmentExpense_019e6a7f-3bcc-70e9-84ac-4e70e670aad8" xlink:href="vtvt-20260630.xsd#vtvt_DirectResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_019e6a7f-3bcc-75d7-bd95-6459fbaa729f" xlink:to="loc_vtvt_DirectResearchAndDevelopmentExpense_019e6a7f-3bcc-70e9-84ac-4e70e670aad8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_IndirectResearchDevelopmentExpense_019e6a7f-3bcc-7dc8-aaa0-451cd92e1d1a" xlink:href="vtvt-20260630.xsd#vtvt_IndirectResearchDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_019e6a7f-3bcc-75d7-bd95-6459fbaa729f" xlink:to="loc_vtvt_IndirectResearchDevelopmentExpense_019e6a7f-3bcc-7dc8-aaa0-451cd92e1d1a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/NetLossIncomeperShareScheduleofReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetIncomeLossperShareofClassACommonStockDetails" xlink:type="simple" xlink:href="vtvt-20260630.xsd#NetLossIncomeperShareScheduleofReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetIncomeLossperShareofClassACommonStockDetails"/>
  <link:calculationLink xlink:role="http://vtvtherapeutics.com/role/NetLossIncomeperShareScheduleofReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetIncomeLossperShareofClassACommonStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_019e6a7f-3bcc-7bae-a0d1-613d2cb982f9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_019e6a7f-3bcc-7d07-8a8d-ab9ad3560e50" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_019e6a7f-3bcc-7bae-a0d1-613d2cb982f9" xlink:to="loc_us-gaap_ProfitLoss_019e6a7f-3bcc-7d07-8a8d-ab9ad3560e50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_019e6a7f-3bcc-74b5-8195-fd1d58479293" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_019e6a7f-3bcc-7bae-a0d1-613d2cb982f9" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_019e6a7f-3bcc-74b5-8195-fd1d58479293" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_019e6a7f-3bcc-72d7-9098-95f1b8d5b36f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_019e6a7f-3bcc-7ec3-a2b9-bca0be65614e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_019e6a7f-3bcc-72d7-9098-95f1b8d5b36f" xlink:to="loc_us-gaap_ProfitLoss_019e6a7f-3bcc-7ec3-a2b9-bca0be65614e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_019e6a7f-3bcc-73b9-a312-bcc39df95abe" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_019e6a7f-3bcc-72d7-9098-95f1b8d5b36f" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_019e6a7f-3bcc-73b9-a312-bcc39df95abe" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>vtvt-20260630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019e6a7f-3a2c-7e30-acc1-d5ae4ae8f1fc,g:0d1f2584-f555-42ce-b27a-904151cd021c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/Cover" xlink:type="simple" xlink:href="vtvt-20260630.xsd#Cover"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_019e6a7f-3af5-7042-91e1-c51470aa60e6" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_019e6a7f-3af5-724c-93e4-1a83e2aae079" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_019e6a7f-3af5-7042-91e1-c51470aa60e6" xlink:to="loc_dei_DocumentInformationTable_019e6a7f-3af5-724c-93e4-1a83e2aae079" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_019e6a7f-3af5-7370-8628-7fb0409ba69a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_019e6a7f-3af5-724c-93e4-1a83e2aae079" xlink:to="loc_us-gaap_StatementClassOfStockAxis_019e6a7f-3af5-7370-8628-7fb0409ba69a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019e6a7f-3af5-7370-8628-7fb0409ba69a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019e6a7f-3af5-7370-8628-7fb0409ba69a" xlink:to="loc_us-gaap_ClassOfStockDomain_019e6a7f-3af5-7370-8628-7fb0409ba69a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019e6a7f-3af5-76ec-a1cd-6c3e8df4f27f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019e6a7f-3af5-7370-8628-7fb0409ba69a" xlink:to="loc_us-gaap_ClassOfStockDomain_019e6a7f-3af5-76ec-a1cd-6c3e8df4f27f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_019e6a7f-3af5-71fc-a665-52dbe815a896" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_019e6a7f-3af5-76ec-a1cd-6c3e8df4f27f" xlink:to="loc_us-gaap_CommonClassAMember_019e6a7f-3af5-71fc-a665-52dbe815a896" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_019e6a7f-3af5-7ec9-8ece-644b18d8bc4d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_019e6a7f-3af5-76ec-a1cd-6c3e8df4f27f" xlink:to="loc_us-gaap_CommonClassBMember_019e6a7f-3af5-7ec9-8ece-644b18d8bc4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_019e6a7f-3af5-7980-814b-98c1933a1e67" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019e6a7f-3af5-7042-91e1-c51470aa60e6" xlink:to="loc_dei_DocumentType_019e6a7f-3af5-7980-814b-98c1933a1e67" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_019e6a7f-3af5-7364-9d17-27329d533625" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentQuarterlyReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019e6a7f-3af5-7042-91e1-c51470aa60e6" xlink:to="loc_dei_DocumentQuarterlyReport_019e6a7f-3af5-7364-9d17-27329d533625" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_019e6a7f-3af5-736a-9a63-3111df183dbc" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019e6a7f-3af5-7042-91e1-c51470aa60e6" xlink:to="loc_dei_DocumentPeriodEndDate_019e6a7f-3af5-736a-9a63-3111df183dbc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_019e6a7f-3af5-7b35-9947-1a21e9942ce3" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019e6a7f-3af5-7042-91e1-c51470aa60e6" xlink:to="loc_dei_DocumentTransitionReport_019e6a7f-3af5-7b35-9947-1a21e9942ce3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_019e6a7f-3af5-7c1c-ba20-19a4310ba7ba" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019e6a7f-3af5-7042-91e1-c51470aa60e6" xlink:to="loc_dei_EntityFileNumber_019e6a7f-3af5-7c1c-ba20-19a4310ba7ba" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_019e6a7f-3af5-7b07-aea0-d384ce36453d" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019e6a7f-3af5-7042-91e1-c51470aa60e6" xlink:to="loc_dei_EntityRegistrantName_019e6a7f-3af5-7b07-aea0-d384ce36453d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_019e6a7f-3af5-75ff-8c5c-e0a482c9a74e" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019e6a7f-3af5-7042-91e1-c51470aa60e6" xlink:to="loc_dei_EntityIncorporationStateCountryCode_019e6a7f-3af5-75ff-8c5c-e0a482c9a74e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_019e6a7f-3af5-7c8d-a326-3fcfdaff41a6" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019e6a7f-3af5-7042-91e1-c51470aa60e6" xlink:to="loc_dei_EntityTaxIdentificationNumber_019e6a7f-3af5-7c8d-a326-3fcfdaff41a6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_019e6a7f-3af5-7773-827c-107a79c06a0a" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019e6a7f-3af5-7042-91e1-c51470aa60e6" xlink:to="loc_dei_EntityAddressAddressLine1_019e6a7f-3af5-7773-827c-107a79c06a0a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_019e6a7f-3af5-752e-88f3-5986cb49b3ee" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019e6a7f-3af5-7042-91e1-c51470aa60e6" xlink:to="loc_dei_EntityAddressAddressLine2_019e6a7f-3af5-752e-88f3-5986cb49b3ee" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_019e6a7f-3af5-78ed-a4aa-a98951cb07c7" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019e6a7f-3af5-7042-91e1-c51470aa60e6" xlink:to="loc_dei_EntityAddressCityOrTown_019e6a7f-3af5-78ed-a4aa-a98951cb07c7" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_019e6a7f-3af5-76ee-a52c-0d59a03b85ee" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019e6a7f-3af5-7042-91e1-c51470aa60e6" xlink:to="loc_dei_EntityAddressStateOrProvince_019e6a7f-3af5-76ee-a52c-0d59a03b85ee" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_019e6a7f-3af5-7bce-b291-0ff3f2dd2830" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019e6a7f-3af5-7042-91e1-c51470aa60e6" xlink:to="loc_dei_EntityAddressPostalZipCode_019e6a7f-3af5-7bce-b291-0ff3f2dd2830" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_019e6a7f-3af5-79fb-b0b0-770eea679c96" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019e6a7f-3af5-7042-91e1-c51470aa60e6" xlink:to="loc_dei_CityAreaCode_019e6a7f-3af5-79fb-b0b0-770eea679c96" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_019e6a7f-3af5-7b7e-b703-3d2ba9561559" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019e6a7f-3af5-7042-91e1-c51470aa60e6" xlink:to="loc_dei_LocalPhoneNumber_019e6a7f-3af5-7b7e-b703-3d2ba9561559" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_019e6a7f-3af5-780a-ac95-69012f715164" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019e6a7f-3af5-7042-91e1-c51470aa60e6" xlink:to="loc_dei_Security12bTitle_019e6a7f-3af5-780a-ac95-69012f715164" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_019e6a7f-3af5-7255-bfde-c90f039bdca1" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019e6a7f-3af5-7042-91e1-c51470aa60e6" xlink:to="loc_dei_TradingSymbol_019e6a7f-3af5-7255-bfde-c90f039bdca1" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_019e6a7f-3af5-7cf8-80fd-16f5c47287c2" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019e6a7f-3af5-7042-91e1-c51470aa60e6" xlink:to="loc_dei_SecurityExchangeName_019e6a7f-3af5-7cf8-80fd-16f5c47287c2" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_019e6a7f-3af5-75d7-a6e0-edf378323a0c" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019e6a7f-3af5-7042-91e1-c51470aa60e6" xlink:to="loc_dei_EntityCurrentReportingStatus_019e6a7f-3af5-75d7-a6e0-edf378323a0c" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_019e6a7f-3af5-76ac-acf2-560ab3efedda" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019e6a7f-3af5-7042-91e1-c51470aa60e6" xlink:to="loc_dei_EntityInteractiveDataCurrent_019e6a7f-3af5-76ac-acf2-560ab3efedda" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_019e6a7f-3af5-7da2-be19-d380be1ecde2" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019e6a7f-3af5-7042-91e1-c51470aa60e6" xlink:to="loc_dei_EntityFilerCategory_019e6a7f-3af5-7da2-be19-d380be1ecde2" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_019e6a7f-3af5-7a9c-ab03-555e0b6f9c6f" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntitySmallBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019e6a7f-3af5-7042-91e1-c51470aa60e6" xlink:to="loc_dei_EntitySmallBusiness_019e6a7f-3af5-7a9c-ab03-555e0b6f9c6f" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_019e6a7f-3af5-7ccd-b4d9-bed419e32dfe" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019e6a7f-3af5-7042-91e1-c51470aa60e6" xlink:to="loc_dei_EntityEmergingGrowthCompany_019e6a7f-3af5-7ccd-b4d9-bed419e32dfe" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_019e6a7f-3af5-7cfb-b4cc-53cdb0becf7d" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019e6a7f-3af5-7042-91e1-c51470aa60e6" xlink:to="loc_dei_EntityShellCompany_019e6a7f-3af5-7cfb-b4cc-53cdb0becf7d" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_019e6a7f-3af5-765e-bec6-1a96f0925c64" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019e6a7f-3af5-7042-91e1-c51470aa60e6" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_019e6a7f-3af5-765e-bec6-1a96f0925c64" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_019e6a7f-3af5-7a9e-9f46-13b6a1eec98b" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019e6a7f-3af5-7042-91e1-c51470aa60e6" xlink:to="loc_dei_EntityCentralIndexKey_019e6a7f-3af5-7a9e-9f46-13b6a1eec98b" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_019e6a7f-3af5-7ec3-b345-cca4e0d11927" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019e6a7f-3af5-7042-91e1-c51470aa60e6" xlink:to="loc_dei_CurrentFiscalYearEndDate_019e6a7f-3af5-7ec3-b345-cca4e0d11927" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_019e6a7f-3af5-791e-be85-78193b37026f" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019e6a7f-3af5-7042-91e1-c51470aa60e6" xlink:to="loc_dei_DocumentFiscalYearFocus_019e6a7f-3af5-791e-be85-78193b37026f" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_019e6a7f-3af5-7dc1-a7cc-9234df123358" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019e6a7f-3af5-7042-91e1-c51470aa60e6" xlink:to="loc_dei_DocumentFiscalPeriodFocus_019e6a7f-3af5-7dc1-a7cc-9234df123358" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_019e6a7f-3af5-74da-9fd1-c71846db1e5b" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019e6a7f-3af5-7042-91e1-c51470aa60e6" xlink:to="loc_dei_AmendmentFlag_019e6a7f-3af5-74da-9fd1-c71846db1e5b" xlink:type="arc" order="29"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="vtvt-20260630.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_019e6a7f-3af5-71c8-b632-7b4b5a2de8c7" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_019e6a7f-3af5-717a-8285-6922e0974804" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_019e6a7f-3af5-71c8-b632-7b4b5a2de8c7" xlink:to="loc_us-gaap_StatementTable_019e6a7f-3af5-717a-8285-6922e0974804" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_019e6a7f-3af5-7be7-ac97-848def498874" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_019e6a7f-3af5-717a-8285-6922e0974804" xlink:to="loc_us-gaap_StatementClassOfStockAxis_019e6a7f-3af5-7be7-ac97-848def498874" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019e6a7f-3af5-7be7-ac97-848def498874_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019e6a7f-3af5-7be7-ac97-848def498874" xlink:to="loc_us-gaap_ClassOfStockDomain_019e6a7f-3af5-7be7-ac97-848def498874_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019e6a7f-3af5-7b11-83fc-3244457db648" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019e6a7f-3af5-7be7-ac97-848def498874" xlink:to="loc_us-gaap_ClassOfStockDomain_019e6a7f-3af5-7b11-83fc-3244457db648" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_019e6a7f-3af5-75e2-beac-616d05f01ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_019e6a7f-3af5-7b11-83fc-3244457db648" xlink:to="loc_us-gaap_CommonClassAMember_019e6a7f-3af5-75e2-beac-616d05f01ea3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_019e6a7f-3af5-7603-a81c-0293df6fa80d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_019e6a7f-3af5-7b11-83fc-3244457db648" xlink:to="loc_us-gaap_CommonClassBMember_019e6a7f-3af5-7603-a81c-0293df6fa80d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e6a7f-3af5-7df2-81fb-15440b191d43" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_019e6a7f-3af5-717a-8285-6922e0974804" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e6a7f-3af5-7df2-81fb-15440b191d43" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019e6a7f-3af5-7df2-81fb-15440b191d43_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e6a7f-3af5-7df2-81fb-15440b191d43" xlink:to="loc_us-gaap_RelatedPartyDomain_019e6a7f-3af5-7df2-81fb-15440b191d43_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019e6a7f-3af5-73eb-b12a-d76b95e3fda6" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e6a7f-3af5-7df2-81fb-15440b191d43" xlink:to="loc_us-gaap_RelatedPartyDomain_019e6a7f-3af5-73eb-b12a-d76b95e3fda6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_019e6a7f-3af5-7e1e-81a1-8c97e9c3eb4b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_019e6a7f-3af5-73eb-b12a-d76b95e3fda6" xlink:to="loc_us-gaap_RelatedPartyMember_019e6a7f-3af5-7e1e-81a1-8c97e9c3eb4b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_019e6a7f-3af5-7d80-a689-e649cdd9e651" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_019e6a7f-3af5-73eb-b12a-d76b95e3fda6" xlink:to="loc_us-gaap_NonrelatedPartyMember_019e6a7f-3af5-7d80-a689-e649cdd9e651" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_019e6a7f-3af5-76c5-9274-e62d830be701" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019e6a7f-3af5-71c8-b632-7b4b5a2de8c7" xlink:to="loc_us-gaap_AssetsAbstract_019e6a7f-3af5-76c5-9274-e62d830be701" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_019e6a7f-3af5-78d9-8ac7-b2db5abe496a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_019e6a7f-3af5-76c5-9274-e62d830be701" xlink:to="loc_us-gaap_AssetsCurrentAbstract_019e6a7f-3af5-78d9-8ac7-b2db5abe496a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019e6a7f-3af5-72cb-8901-15e60d675110" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_019e6a7f-3af5-78d9-8ac7-b2db5abe496a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019e6a7f-3af5-72cb-8901-15e60d675110" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_019e6a7f-3af5-7f2e-b40d-762a9522af52" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_019e6a7f-3af5-78d9-8ac7-b2db5abe496a" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_019e6a7f-3af5-7f2e-b40d-762a9522af52" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_019e6a7f-3af5-78bc-aa09-8b4edb5dff18" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_019e6a7f-3af5-78d9-8ac7-b2db5abe496a" xlink:to="loc_us-gaap_OtherAssetsCurrent_019e6a7f-3af5-78bc-aa09-8b4edb5dff18" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_019e6a7f-3af5-71c7-b526-e1ed78eb84b5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_019e6a7f-3af5-78d9-8ac7-b2db5abe496a" xlink:to="loc_us-gaap_AssetsCurrent_019e6a7f-3af5-71c7-b526-e1ed78eb84b5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_019e6a7f-3af5-7b1d-ae79-4805e50766e0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_019e6a7f-3af5-76c5-9274-e62d830be701" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_019e6a7f-3af5-7b1d-ae79-4805e50766e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_019e6a7f-3af5-7599-a42e-146cbf1c05d8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_019e6a7f-3af5-76c5-9274-e62d830be701" xlink:to="loc_us-gaap_Assets_019e6a7f-3af5-7599-a42e-146cbf1c05d8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019e6a7f-3af5-712e-b1ac-cc3c8cea47f1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019e6a7f-3af5-71c8-b632-7b4b5a2de8c7" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019e6a7f-3af5-712e-b1ac-cc3c8cea47f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_019e6a7f-3af5-7cae-a2e7-f57d531d4328" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019e6a7f-3af5-712e-b1ac-cc3c8cea47f1" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_019e6a7f-3af5-7cae-a2e7-f57d531d4328" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_019e6a7f-3af5-7d97-b813-ad17c91e749c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_019e6a7f-3af5-7cae-a2e7-f57d531d4328" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_019e6a7f-3af5-7d97-b813-ad17c91e749c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_WarrantLiabilityCurrent_019e6a7f-3af5-7f13-86e4-106f9a0bdb61" xlink:href="vtvt-20260630.xsd#vtvt_WarrantLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_019e6a7f-3af5-7cae-a2e7-f57d531d4328" xlink:to="loc_vtvt_WarrantLiabilityCurrent_019e6a7f-3af5-7f13-86e4-106f9a0bdb61" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_019e6a7f-3af5-787d-856c-b6f4390f3753" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_019e6a7f-3af5-7cae-a2e7-f57d531d4328" xlink:to="loc_us-gaap_LiabilitiesCurrent_019e6a7f-3af5-787d-856c-b6f4390f3753" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_019e6a7f-3af5-77bd-98c8-fda5e46d27ed" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019e6a7f-3af5-712e-b1ac-cc3c8cea47f1" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_019e6a7f-3af5-77bd-98c8-fda5e46d27ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_WarrantyLiability_019e6a7f-3af5-713b-84cc-bcca88adbd34" xlink:href="vtvt-20260630.xsd#vtvt_WarrantyLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019e6a7f-3af5-712e-b1ac-cc3c8cea47f1" xlink:to="loc_vtvt_WarrantyLiability_019e6a7f-3af5-713b-84cc-bcca88adbd34" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_019e6a7f-3af5-7b65-a17a-d504c75ecbbc" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019e6a7f-3af5-712e-b1ac-cc3c8cea47f1" xlink:to="loc_us-gaap_Liabilities_019e6a7f-3af5-7b65-a17a-d504c75ecbbc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_019e6a7f-3af5-778f-ba1e-3d107ac44ec6" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019e6a7f-3af5-712e-b1ac-cc3c8cea47f1" xlink:to="loc_us-gaap_CommitmentsAndContingencies_019e6a7f-3af5-778f-ba1e-3d107ac44ec6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_019e6a7f-3af5-71a4-b53e-2f0185980782" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019e6a7f-3af5-712e-b1ac-cc3c8cea47f1" xlink:to="loc_us-gaap_StockholdersEquityAbstract_019e6a7f-3af5-71a4-b53e-2f0185980782" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_019e6a7f-3af5-718b-a745-6f120cedeb68" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_019e6a7f-3af5-71a4-b53e-2f0185980782" xlink:to="loc_us-gaap_CommonStockValue_019e6a7f-3af5-718b-a745-6f120cedeb68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_019e6a7f-3af5-797f-89d1-4f155acd6157" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_019e6a7f-3af5-71a4-b53e-2f0185980782" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_019e6a7f-3af5-797f-89d1-4f155acd6157" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019e6a7f-3af5-7f55-959e-9c8b8c5ff5ac" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_019e6a7f-3af5-71a4-b53e-2f0185980782" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019e6a7f-3af5-7f55-959e-9c8b8c5ff5ac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019e6a7f-3af5-78d0-94a1-d3a601d41187" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_019e6a7f-3af5-71a4-b53e-2f0185980782" xlink:to="loc_us-gaap_StockholdersEquity_019e6a7f-3af5-78d0-94a1-d3a601d41187" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_019e6a7f-3af5-7907-bb54-2bfb897aeb46" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019e6a7f-3af5-712e-b1ac-cc3c8cea47f1" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_019e6a7f-3af5-7907-bb54-2bfb897aeb46" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="vtvt-20260630.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_019e6a7f-3af5-796d-a5a6-5829c749cf54" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_019e6a7f-3af5-79b6-bb15-92b8b3e20fc4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_019e6a7f-3af5-796d-a5a6-5829c749cf54" xlink:to="loc_us-gaap_StatementTable_019e6a7f-3af5-79b6-bb15-92b8b3e20fc4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_019e6a7f-3af5-7e83-92c4-c9eeddb431c2" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_019e6a7f-3af5-79b6-bb15-92b8b3e20fc4" xlink:to="loc_us-gaap_StatementClassOfStockAxis_019e6a7f-3af5-7e83-92c4-c9eeddb431c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019e6a7f-3af5-7e83-92c4-c9eeddb431c2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019e6a7f-3af5-7e83-92c4-c9eeddb431c2" xlink:to="loc_us-gaap_ClassOfStockDomain_019e6a7f-3af5-7e83-92c4-c9eeddb431c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019e6a7f-3af5-7c9f-909c-cb5c5754adb2" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019e6a7f-3af5-7e83-92c4-c9eeddb431c2" xlink:to="loc_us-gaap_ClassOfStockDomain_019e6a7f-3af5-7c9f-909c-cb5c5754adb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_019e6a7f-3af5-7616-a563-33cabd120d83" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_019e6a7f-3af5-7c9f-909c-cb5c5754adb2" xlink:to="loc_us-gaap_CommonClassAMember_019e6a7f-3af5-7616-a563-33cabd120d83" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_019e6a7f-3af5-7ce0-8e2f-673e078a9216" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_019e6a7f-3af5-7c9f-909c-cb5c5754adb2" xlink:to="loc_us-gaap_CommonClassBMember_019e6a7f-3af5-7ce0-8e2f-673e078a9216" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_019e6a7f-3af5-753a-b2d5-e22b61928592" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019e6a7f-3af5-796d-a5a6-5829c749cf54" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_019e6a7f-3af5-753a-b2d5-e22b61928592" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_019e6a7f-3af5-7c5e-b8d5-c0ec4e287875" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019e6a7f-3af5-796d-a5a6-5829c749cf54" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_019e6a7f-3af5-7c5e-b8d5-c0ec4e287875" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_019e6a7f-3af5-7b5b-8918-5c65cc68c43d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019e6a7f-3af5-796d-a5a6-5829c749cf54" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_019e6a7f-3af5-7b5b-8918-5c65cc68c43d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="simple" xlink:href="vtvt-20260630.xsd#CondensedConsolidatedStatementsofOperationsUnaudited"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_019e6a7f-3af5-7938-8779-7a1c0d1a60d2" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_019e6a7f-3af5-70c4-a250-417d25f0a51e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_019e6a7f-3af5-7938-8779-7a1c0d1a60d2" xlink:to="loc_us-gaap_StatementTable_019e6a7f-3af5-70c4-a250-417d25f0a51e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_019e6a7f-3af5-78e1-a451-2d6cbac6b2a8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_019e6a7f-3af5-70c4-a250-417d25f0a51e" xlink:to="loc_us-gaap_StatementClassOfStockAxis_019e6a7f-3af5-78e1-a451-2d6cbac6b2a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019e6a7f-3af5-78e1-a451-2d6cbac6b2a8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019e6a7f-3af5-78e1-a451-2d6cbac6b2a8" xlink:to="loc_us-gaap_ClassOfStockDomain_019e6a7f-3af5-78e1-a451-2d6cbac6b2a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019e6a7f-3af5-7a1c-bbae-b2ad5f71113a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019e6a7f-3af5-78e1-a451-2d6cbac6b2a8" xlink:to="loc_us-gaap_ClassOfStockDomain_019e6a7f-3af5-7a1c-bbae-b2ad5f71113a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_019e6a7f-3af5-7427-af77-80a71c020fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_019e6a7f-3af5-7a1c-bbae-b2ad5f71113a" xlink:to="loc_us-gaap_CommonClassAMember_019e6a7f-3af5-7427-af77-80a71c020fb0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e6a7f-3af5-759c-bab0-2ef6b5c90ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_019e6a7f-3af5-70c4-a250-417d25f0a51e" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e6a7f-3af5-759c-bab0-2ef6b5c90ca9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019e6a7f-3af5-759c-bab0-2ef6b5c90ca9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e6a7f-3af5-759c-bab0-2ef6b5c90ca9" xlink:to="loc_us-gaap_RelatedPartyDomain_019e6a7f-3af5-759c-bab0-2ef6b5c90ca9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019e6a7f-3af5-7c0b-8c66-3bd826634d45" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e6a7f-3af5-759c-bab0-2ef6b5c90ca9" xlink:to="loc_us-gaap_RelatedPartyDomain_019e6a7f-3af5-7c0b-8c66-3bd826634d45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_019e6a7f-3af5-7478-b468-24bac58a5d68" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_019e6a7f-3af5-7c0b-8c66-3bd826634d45" xlink:to="loc_us-gaap_NonrelatedPartyMember_019e6a7f-3af5-7478-b468-24bac58a5d68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_019e6a7f-3af5-7bee-a394-f96c229cefb3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_019e6a7f-3af5-7c0b-8c66-3bd826634d45" xlink:to="loc_us-gaap_RelatedPartyMember_019e6a7f-3af5-7bee-a394-f96c229cefb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019e6a7f-3af5-76bd-aad6-965cf04931e9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019e6a7f-3af5-7938-8779-7a1c0d1a60d2" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019e6a7f-3af5-76bd-aad6-965cf04931e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_019e6a7f-3af5-7b1c-b315-2aa90a1eaf27" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019e6a7f-3af5-7938-8779-7a1c0d1a60d2" xlink:to="loc_us-gaap_OperatingExpensesAbstract_019e6a7f-3af5-7b1c-b315-2aa90a1eaf27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_019e6a7f-3af5-7754-8a71-04793603ee1a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019e6a7f-3af5-7b1c-b315-2aa90a1eaf27" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_019e6a7f-3af5-7754-8a71-04793603ee1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_019e6a7f-3af5-7366-8722-91c52772eb56" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019e6a7f-3af5-7b1c-b315-2aa90a1eaf27" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_019e6a7f-3af5-7366-8722-91c52772eb56" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_019e6a7f-3af5-7b24-903c-03d180e99883" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019e6a7f-3af5-7b1c-b315-2aa90a1eaf27" xlink:to="loc_us-gaap_OperatingExpenses_019e6a7f-3af5-7b24-903c-03d180e99883" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_019e6a7f-3af5-791b-a0fd-21574961ae61" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019e6a7f-3af5-7938-8779-7a1c0d1a60d2" xlink:to="loc_us-gaap_OperatingIncomeLoss_019e6a7f-3af5-791b-a0fd-21574961ae61" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_019e6a7f-3af5-72ff-a905-58e3180bda50" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019e6a7f-3af5-7938-8779-7a1c0d1a60d2" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_019e6a7f-3af5-72ff-a905-58e3180bda50" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_019e6a7f-3af5-71d8-b428-6491368f66e8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019e6a7f-3af5-7938-8779-7a1c0d1a60d2" xlink:to="loc_us-gaap_InvestmentIncomeInterest_019e6a7f-3af5-71d8-b428-6491368f66e8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019e6a7f-3af5-764d-aa05-b7c5e6e7ab51" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019e6a7f-3af5-7938-8779-7a1c0d1a60d2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019e6a7f-3af5-764d-aa05-b7c5e6e7ab51" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_019e6a7f-3af5-7439-bbbd-2065bbe7b516" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019e6a7f-3af5-7938-8779-7a1c0d1a60d2" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_019e6a7f-3af5-7439-bbbd-2065bbe7b516" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_019e6a7f-3af5-728e-b061-d388aea7a890" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019e6a7f-3af5-7938-8779-7a1c0d1a60d2" xlink:to="loc_us-gaap_ProfitLoss_019e6a7f-3af5-728e-b061-d388aea7a890" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_019e6a7f-3af5-7db8-aaba-5265cc3949d3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019e6a7f-3af5-7938-8779-7a1c0d1a60d2" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_019e6a7f-3af5-7db8-aaba-5265cc3949d3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019e6a7f-3af5-7c27-9832-16b433b58281" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019e6a7f-3af5-7938-8779-7a1c0d1a60d2" xlink:to="loc_us-gaap_NetIncomeLoss_019e6a7f-3af5-7c27-9832-16b433b58281" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_019e6a7f-3af5-7e9a-be1e-c715f208b265" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019e6a7f-3af5-7938-8779-7a1c0d1a60d2" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_019e6a7f-3af5-7e9a-be1e-c715f208b265" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_019e6a7f-3af5-73c2-a579-2912dc914a5f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019e6a7f-3af5-7938-8779-7a1c0d1a60d2" xlink:to="loc_us-gaap_EarningsPerShareBasic_019e6a7f-3af5-73c2-a579-2912dc914a5f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_019e6a7f-3af5-72f7-a69d-a6b396a339f0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019e6a7f-3af5-7938-8779-7a1c0d1a60d2" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_019e6a7f-3af5-72f7-a69d-a6b396a339f0" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_019e6a7f-3af5-7f81-89dd-6f216774cba3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019e6a7f-3af5-7938-8779-7a1c0d1a60d2" xlink:to="loc_us-gaap_EarningsPerShareDiluted_019e6a7f-3af5-7f81-89dd-6f216774cba3" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019e6a7f-3af5-7819-867a-b738a478e0d6" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019e6a7f-3af5-7938-8779-7a1c0d1a60d2" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019e6a7f-3af5-7819-867a-b738a478e0d6" xlink:type="arc" order="14"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinStockholdersEquityUnaudited" xlink:type="simple" xlink:href="vtvt-20260630.xsd#CondensedConsolidatedStatementofChangesinStockholdersEquityUnaudited"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinStockholdersEquityUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_019e6a7f-3af5-7df4-8312-f7f1ad6a1a9f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_019e6a7f-3af5-7cdb-b7de-17c81f2eceb3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_019e6a7f-3af5-7df4-8312-f7f1ad6a1a9f" xlink:to="loc_us-gaap_StatementTable_019e6a7f-3af5-7cdb-b7de-17c81f2eceb3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_019e6a7f-3af5-7bc1-a979-d38b38dd4925" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_019e6a7f-3af5-7cdb-b7de-17c81f2eceb3" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_019e6a7f-3af5-7bc1-a979-d38b38dd4925" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_019e6a7f-3af5-7bc1-a979-d38b38dd4925_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_019e6a7f-3af5-7bc1-a979-d38b38dd4925" xlink:to="loc_us-gaap_EquityComponentDomain_019e6a7f-3af5-7bc1-a979-d38b38dd4925_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_019e6a7f-3af5-7150-a52c-df0195464798" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_019e6a7f-3af5-7bc1-a979-d38b38dd4925" xlink:to="loc_us-gaap_EquityComponentDomain_019e6a7f-3af5-7150-a52c-df0195464798" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_019e6a7f-3af5-731c-bb92-17ac9a6083e8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_019e6a7f-3af5-7150-a52c-df0195464798" xlink:to="loc_us-gaap_ParentMember_019e6a7f-3af5-731c-bb92-17ac9a6083e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_019e6a7f-3af5-7562-8c96-e2a057c336b5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_019e6a7f-3af5-731c-bb92-17ac9a6083e8" xlink:to="loc_us-gaap_CommonStockMember_019e6a7f-3af5-7562-8c96-e2a057c336b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_019e6a7f-3af5-7a9f-831c-68eac5d4aae5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_019e6a7f-3af5-731c-bb92-17ac9a6083e8" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_019e6a7f-3af5-7a9f-831c-68eac5d4aae5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_019e6a7f-3af5-7f7d-ab33-5e9421371c29" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_019e6a7f-3af5-731c-bb92-17ac9a6083e8" xlink:to="loc_us-gaap_RetainedEarningsMember_019e6a7f-3af5-7f7d-ab33-5e9421371c29" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_019e6a7f-3af5-7c0f-b814-98c9171dbde7" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_019e6a7f-3af5-7150-a52c-df0195464798" xlink:to="loc_us-gaap_NoncontrollingInterestMember_019e6a7f-3af5-7c0f-b814-98c9171dbde7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_019e6a7f-3af5-7809-9ff9-718a3c156119" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_019e6a7f-3af5-7cdb-b7de-17c81f2eceb3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_019e6a7f-3af5-7809-9ff9-718a3c156119" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019e6a7f-3af5-7809-9ff9-718a3c156119_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019e6a7f-3af5-7809-9ff9-718a3c156119" xlink:to="loc_us-gaap_ClassOfStockDomain_019e6a7f-3af5-7809-9ff9-718a3c156119_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019e6a7f-3af5-7cd0-9369-9bde0fda2e07" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019e6a7f-3af5-7809-9ff9-718a3c156119" xlink:to="loc_us-gaap_ClassOfStockDomain_019e6a7f-3af5-7cd0-9369-9bde0fda2e07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_019e6a7f-3af5-703c-a389-9623d9f1ac7e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_019e6a7f-3af5-7cd0-9369-9bde0fda2e07" xlink:to="loc_us-gaap_CommonClassAMember_019e6a7f-3af5-703c-a389-9623d9f1ac7e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_019e6a7f-3af5-7ef5-8be4-7c939b8b42de" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_019e6a7f-3af5-7cd0-9369-9bde0fda2e07" xlink:to="loc_us-gaap_CommonClassBMember_019e6a7f-3af5-7ef5-8be4-7c939b8b42de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e6a7f-3af5-7386-b04e-ec8bd2a1ff02" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019e6a7f-3af5-7df4-8312-f7f1ad6a1a9f" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e6a7f-3af5-7386-b04e-ec8bd2a1ff02" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_019e6a7f-3af5-75df-8726-5e49e5c039f0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e6a7f-3af5-7386-b04e-ec8bd2a1ff02" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_019e6a7f-3af5-75df-8726-5e49e5c039f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_019e6a7f-3af5-7e76-a388-6ac2bffe46af" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e6a7f-3af5-7386-b04e-ec8bd2a1ff02" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_019e6a7f-3af5-7e76-a388-6ac2bffe46af" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019e6a7f-3af5-7f22-a553-b283d1af56bb" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e6a7f-3af5-7386-b04e-ec8bd2a1ff02" xlink:to="loc_us-gaap_NetIncomeLoss_019e6a7f-3af5-7f22-a553-b283d1af56bb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_019ea6c7-4ddb-7d4a-87fe-14baff62b0f2" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e6a7f-3af5-7386-b04e-ec8bd2a1ff02" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_019ea6c7-4ddb-7d4a-87fe-14baff62b0f2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_019ea6c6-ee7f-70c4-9308-7cf391c53b69" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e6a7f-3af5-7386-b04e-ec8bd2a1ff02" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_019ea6c6-ee7f-70c4-9308-7cf391c53b69" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_019ea6c9-9de0-7ac0-94f6-9e08e569a31d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e6a7f-3af5-7386-b04e-ec8bd2a1ff02" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_019ea6c9-9de0-7ac0-94f6-9e08e569a31d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_019ea6c9-e9a3-7755-a1b2-66ddd78a9506" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e6a7f-3af5-7386-b04e-ec8bd2a1ff02" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_019ea6c9-e9a3-7755-a1b2-66ddd78a9506" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_019e6a7f-3af5-7497-92be-e0b7b2cf8011" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e6a7f-3af5-7386-b04e-ec8bd2a1ff02" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_019e6a7f-3af5-7497-92be-e0b7b2cf8011" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_019f697f-4a91-7496-b498-39a613466fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e6a7f-3af5-7386-b04e-ec8bd2a1ff02" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_019f697f-4a91-7496-b498-39a613466fc3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_019e6a7f-3af5-7022-8067-8efb33b461ae" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e6a7f-3af5-7386-b04e-ec8bd2a1ff02" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_019e6a7f-3af5-7022-8067-8efb33b461ae" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_019e6a7f-3af5-76c8-8362-a38ae69cf508" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_019e6a7f-3af5-713a-ba0d-6b453e181478" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="vtvt-20260630.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_019e6a7f-3af5-7f5e-ad29-acfd208d2b81" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_019e6a7f-3af5-720f-8ae9-59036d2ed591" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_019e6a7f-3af5-7f5e-ad29-acfd208d2b81" xlink:to="loc_us-gaap_StatementTable_019e6a7f-3af5-720f-8ae9-59036d2ed591" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e6a7f-3af5-7508-bc43-f110a7a048e3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_019e6a7f-3af5-720f-8ae9-59036d2ed591" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e6a7f-3af5-7508-bc43-f110a7a048e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019e6a7f-3af5-7508-bc43-f110a7a048e3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e6a7f-3af5-7508-bc43-f110a7a048e3" xlink:to="loc_us-gaap_RelatedPartyDomain_019e6a7f-3af5-7508-bc43-f110a7a048e3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019e6a7f-3af5-7f44-9aba-b430e8518547" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e6a7f-3af5-7508-bc43-f110a7a048e3" xlink:to="loc_us-gaap_RelatedPartyDomain_019e6a7f-3af5-7f44-9aba-b430e8518547" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_019e6a7f-3af5-72f6-a51f-0b8ccc2131f5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_019e6a7f-3af5-7f44-9aba-b430e8518547" xlink:to="loc_us-gaap_RelatedPartyMember_019e6a7f-3af5-72f6-a51f-0b8ccc2131f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_019e6a7f-3af5-75d9-a099-003fb304cb27" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_019e6a7f-3af5-7f44-9aba-b430e8518547" xlink:to="loc_us-gaap_NonrelatedPartyMember_019e6a7f-3af5-75d9-a099-003fb304cb27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_019e6a7f-3af5-7794-abfc-23af8fd40b07" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019e6a7f-3af5-7f5e-ad29-acfd208d2b81" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_019e6a7f-3af5-7794-abfc-23af8fd40b07" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_019e6a7f-3af5-7e67-a41c-0475244c73d9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_019e6a7f-3af5-7794-abfc-23af8fd40b07" xlink:to="loc_us-gaap_ProfitLoss_019e6a7f-3af5-7e67-a41c-0475244c73d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019e6a7f-3af5-75cb-9c65-4eb80a0a24dc" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_019e6a7f-3af5-7794-abfc-23af8fd40b07" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019e6a7f-3af5-75cb-9c65-4eb80a0a24dc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_019e6a7f-3af5-7b81-aa2b-606875b4734b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019e6a7f-3af5-75cb-9c65-4eb80a0a24dc" xlink:to="loc_us-gaap_Depreciation_019e6a7f-3af5-7b81-aa2b-606875b4734b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_019e6a7f-3af5-73fe-be66-0f1f70145a80" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019e6a7f-3af5-75cb-9c65-4eb80a0a24dc" xlink:to="loc_us-gaap_ShareBasedCompensation_019e6a7f-3af5-73fe-be66-0f1f70145a80" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_019e6a7f-3af5-7ffe-a24a-9498002d7fdc" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019e6a7f-3af5-75cb-9c65-4eb80a0a24dc" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_019e6a7f-3af5-7ffe-a24a-9498002d7fdc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019e6a7f-3af5-77f7-a0a5-119fa05e75d9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019e6a7f-3af5-75cb-9c65-4eb80a0a24dc" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019e6a7f-3af5-77f7-a0a5-119fa05e75d9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_019e6a7f-3af5-7a67-9e6d-84fea6ed6307" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019e6a7f-3af5-77f7-a0a5-119fa05e75d9" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_019e6a7f-3af5-7a67-9e6d-84fea6ed6307" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_019e6a7f-3af5-7214-961a-55c7f5668626" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019e6a7f-3af5-77f7-a0a5-119fa05e75d9" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_019e6a7f-3af5-7214-961a-55c7f5668626" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_019e6a7f-3af5-7ab8-8085-5a78262af504" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019e6a7f-3af5-77f7-a0a5-119fa05e75d9" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_019e6a7f-3af5-7ab8-8085-5a78262af504" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_019e6a7f-3af5-7fea-a2ae-34c2fb2d80ea" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019e6a7f-3af5-77f7-a0a5-119fa05e75d9" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_019e6a7f-3af5-7fea-a2ae-34c2fb2d80ea" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_019e6a7f-3af5-7def-bee0-50f2dc15021c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019e6a7f-3af5-77f7-a0a5-119fa05e75d9" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_019e6a7f-3af5-7def-bee0-50f2dc15021c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_019e6a7f-3af5-7490-af82-c80634d62ce5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019e6a7f-3af5-77f7-a0a5-119fa05e75d9" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_019e6a7f-3af5-7490-af82-c80634d62ce5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019e6a7f-3af5-7d02-ac8e-1f5b0cca6166" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019e6a7f-3af5-75cb-9c65-4eb80a0a24dc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019e6a7f-3af5-7d02-ac8e-1f5b0cca6166" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019f69c2-4292-7fc6-a375-7d84f08b7ce5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019e6a7f-3af5-75cb-9c65-4eb80a0a24dc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019f69c2-4292-7fc6-a375-7d84f08b7ce5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_019f69c3-aceb-756b-ae38-e2dc299fb28b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019f69c2-4292-7fc6-a375-7d84f08b7ce5" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_019f69c3-aceb-756b-ae38-e2dc299fb28b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_019f69c3-aceb-736a-97f2-2765315d172d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019f69c2-4292-7fc6-a375-7d84f08b7ce5" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_019f69c3-aceb-736a-97f2-2765315d172d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019f69c3-aceb-74eb-9b74-8377bf2aae0b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019f69c2-4292-7fc6-a375-7d84f08b7ce5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019f69c3-aceb-74eb-9b74-8377bf2aae0b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019e6a7f-3af5-7a89-aad4-2ef63db4313d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019e6a7f-3af5-7f5e-ad29-acfd208d2b81" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019e6a7f-3af5-7a89-aad4-2ef63db4313d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019e6a7f-3af5-7d59-9ba8-66fe8ac480b8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019e6a7f-3af5-7f5e-ad29-acfd208d2b81" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019e6a7f-3af5-7d59-9ba8-66fe8ac480b8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019e6a7f-3af5-72f0-b92e-d4f712235f96" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetails" xlink:type="simple" xlink:href="vtvt-20260630.xsd#DescriptionofBusinessandBasisofPresentationDetails"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_019e6a7f-3af5-72c3-a1cb-98afc8cacf6d" xlink:href="vtvt-20260630.xsd#vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_019e6a7f-3af5-7e5d-accf-64597a5f353c" xlink:href="vtvt-20260630.xsd#vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_019e6a7f-3af5-72c3-a1cb-98afc8cacf6d" xlink:to="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_019e6a7f-3af5-7e5d-accf-64597a5f353c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_019e6a7f-3af5-75e3-b44d-69b7be1328ec" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_019e6a7f-3af5-7e5d-accf-64597a5f353c" xlink:to="loc_srt_ConsolidatedEntitiesAxis_019e6a7f-3af5-75e3-b44d-69b7be1328ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_019e6a7f-3af5-75e3-b44d-69b7be1328ec_default" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_019e6a7f-3af5-75e3-b44d-69b7be1328ec" xlink:to="loc_srt_ConsolidatedEntitiesDomain_019e6a7f-3af5-75e3-b44d-69b7be1328ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_019e6a7f-3af5-7bc0-a1ae-3853133c9b1d" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_019e6a7f-3af5-75e3-b44d-69b7be1328ec" xlink:to="loc_srt_ConsolidatedEntitiesDomain_019e6a7f-3af5-7bc0-a1ae-3853133c9b1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_019e6a7f-3af5-7375-9f66-08030d02d93f" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ParentCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_019e6a7f-3af5-7bc0-a1ae-3853133c9b1d" xlink:to="loc_srt_ParentCompanyMember_019e6a7f-3af5-7375-9f66-08030d02d93f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_019e6a7f-3af5-7d61-83e8-497265186b11" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_019e6a7f-3af5-7e5d-accf-64597a5f353c" xlink:to="loc_dei_LegalEntityAxis_019e6a7f-3af5-7d61-83e8-497265186b11" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_019e6a7f-3af5-7d61-83e8-497265186b11_default" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_019e6a7f-3af5-7d61-83e8-497265186b11" xlink:to="loc_dei_EntityDomain_019e6a7f-3af5-7d61-83e8-497265186b11_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_019e6a7f-3af5-78f6-b397-4227bb37e15e" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_019e6a7f-3af5-7d61-83e8-497265186b11" xlink:to="loc_dei_EntityDomain_019e6a7f-3af5-78f6-b397-4227bb37e15e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_VTvLLCMember_019e6a7f-3af5-7bd6-93e6-58cf987a0080" xlink:href="vtvt-20260630.xsd#vtvt_VTvLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_019e6a7f-3af5-78f6-b397-4227bb37e15e" xlink:to="loc_vtvt_VTvLLCMember_019e6a7f-3af5-7bd6-93e6-58cf987a0080" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_NewsoaraBiopharmaCoLtdMember_019e6a7f-3af5-7d2f-8ca5-25556fa2abd7" xlink:href="vtvt-20260630.xsd#vtvt_NewsoaraBiopharmaCoLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_019e6a7f-3af5-78f6-b397-4227bb37e15e" xlink:to="loc_vtvt_NewsoaraBiopharmaCoLtdMember_019e6a7f-3af5-7d2f-8ca5-25556fa2abd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_019e6a7f-3af5-779c-b146-6d7d3792fcdf" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_019e6a7f-3af5-7e5d-accf-64597a5f353c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_019e6a7f-3af5-779c-b146-6d7d3792fcdf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019e6a7f-3af5-779c-b146-6d7d3792fcdf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_019e6a7f-3af5-779c-b146-6d7d3792fcdf" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019e6a7f-3af5-779c-b146-6d7d3792fcdf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019e6a7f-3af5-706f-9559-56675ef02275" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_019e6a7f-3af5-779c-b146-6d7d3792fcdf" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019e6a7f-3af5-706f-9559-56675ef02275" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_019e6a7f-3af5-7b0c-b476-f9f1a7f1684e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019e6a7f-3af5-706f-9559-56675ef02275" xlink:to="loc_us-gaap_CollaborativeArrangementMember_019e6a7f-3af5-7b0c-b476-f9f1a7f1684e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019e6a7f-3af5-792d-b554-edfcc0a66ec4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_019e6a7f-3af5-72c3-a1cb-98afc8cacf6d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019e6a7f-3af5-792d-b554-edfcc0a66ec4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PercentageOfNonVotingEconomicInterestByParent_019e6a7f-3af5-7a3e-a8a1-ff58f5900629" xlink:href="vtvt-20260630.xsd#vtvt_PercentageOfNonVotingEconomicInterestByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_019e6a7f-3af5-72c3-a1cb-98afc8cacf6d" xlink:to="loc_vtvt_PercentageOfNonVotingEconomicInterestByParent_019e6a7f-3af5-7a3e-a8a1-ff58f5900629" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019e6a7f-3af5-72f8-8410-57d5424ed67d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_019e6a7f-3af5-72c3-a1cb-98afc8cacf6d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019e6a7f-3af5-72f8-8410-57d5424ed67d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LicenseFeeReceived_019e6a7f-3af5-7ec0-a0d3-19fe08cb03d9" xlink:href="vtvt-20260630.xsd#vtvt_LicenseFeeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_019e6a7f-3af5-72c3-a1cb-98afc8cacf6d" xlink:to="loc_vtvt_LicenseFeeReceived_019e6a7f-3af5-7ec0-a0d3-19fe08cb03d9" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CollaborationAgreementsDetails" xlink:type="simple" xlink:href="vtvt-20260630.xsd#CollaborationAgreementsDetails"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/CollaborationAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019e6a7f-3af5-7520-ac10-b923a46fe641" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019e6a7f-3af5-7da6-8d84-27b9f3549893" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019e6a7f-3af5-7520-ac10-b923a46fe641" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019e6a7f-3af5-7da6-8d84-27b9f3549893" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_019e6a7f-3af5-72b2-bd93-b96b6ba26eb1" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019e6a7f-3af5-7da6-8d84-27b9f3549893" xlink:to="loc_srt_CounterpartyNameAxis_019e6a7f-3af5-72b2-bd93-b96b6ba26eb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019e6a7f-3af5-72b2-bd93-b96b6ba26eb1_default" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_019e6a7f-3af5-72b2-bd93-b96b6ba26eb1" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019e6a7f-3af5-72b2-bd93-b96b6ba26eb1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019e6a7f-3af5-7925-ae15-0f8a48aedc8a" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_019e6a7f-3af5-72b2-bd93-b96b6ba26eb1" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019e6a7f-3af5-7925-ae15-0f8a48aedc8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_G42InvestmentsMember_019e6a7f-3af5-798e-bbcb-ff0ba4d23033" xlink:href="vtvt-20260630.xsd#vtvt_G42InvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019e6a7f-3af5-7925-ae15-0f8a48aedc8a" xlink:to="loc_vtvt_G42InvestmentsMember_019e6a7f-3af5-798e-bbcb-ff0ba4d23033" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CognaMember_019e6a7f-3af5-7049-88b2-ebc51a04e448" xlink:href="vtvt-20260630.xsd#vtvt_CognaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019e6a7f-3af5-7925-ae15-0f8a48aedc8a" xlink:to="loc_vtvt_CognaMember_019e6a7f-3af5-7049-88b2-ebc51a04e448" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_019e6a7f-3af5-7f5a-a631-540da0441d22" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019e6a7f-3af5-7da6-8d84-27b9f3549893" xlink:to="loc_us-gaap_TypeOfArrangementAxis_019e6a7f-3af5-7f5a-a631-540da0441d22" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019e6a7f-3af5-7f5a-a631-540da0441d22_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_019e6a7f-3af5-7f5a-a631-540da0441d22" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019e6a7f-3af5-7f5a-a631-540da0441d22_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019e6a7f-3af5-7d68-a6d3-86386fd3b9f0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_019e6a7f-3af5-7f5a-a631-540da0441d22" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019e6a7f-3af5-7d68-a6d3-86386fd3b9f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_G42AgreementsMember_019e6a7f-3af5-7aa8-bc82-419059ce6dd4" xlink:href="vtvt-20260630.xsd#vtvt_G42AgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019e6a7f-3af5-7d68-a6d3-86386fd3b9f0" xlink:to="loc_vtvt_G42AgreementsMember_019e6a7f-3af5-7aa8-bc82-419059ce6dd4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_019e6a7f-3af5-797a-8cfb-df143b559c05" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019e6a7f-3af5-7d68-a6d3-86386fd3b9f0" xlink:to="loc_us-gaap_CollaborativeArrangementMember_019e6a7f-3af5-797a-8cfb-df143b559c05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CommercialSupplyAgreementMember_019e6a7f-3af5-7ce1-8a61-6ff8e6119af1" xlink:href="vtvt-20260630.xsd#vtvt_CommercialSupplyAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019e6a7f-3af5-7d68-a6d3-86386fd3b9f0" xlink:to="loc_vtvt_CommercialSupplyAgreementMember_019e6a7f-3af5-7ce1-8a61-6ff8e6119af1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_019e6a7f-3af5-769f-8057-eb1894ce3333" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019e6a7f-3af5-7da6-8d84-27b9f3549893" xlink:to="loc_srt_ProductOrServiceAxis_019e6a7f-3af5-769f-8057-eb1894ce3333" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019e6a7f-3af5-769f-8057-eb1894ce3333_default" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_019e6a7f-3af5-769f-8057-eb1894ce3333" xlink:to="loc_srt_ProductsAndServicesDomain_019e6a7f-3af5-769f-8057-eb1894ce3333_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019e6a7f-3af5-79ba-8c60-3e90863e5712" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_019e6a7f-3af5-769f-8057-eb1894ce3333" xlink:to="loc_srt_ProductsAndServicesDomain_019e6a7f-3af5-79ba-8c60-3e90863e5712" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_IPLicenseMember_019e6a7f-3af5-7375-8595-10824cdd43c1" xlink:href="vtvt-20260630.xsd#vtvt_IPLicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_019e6a7f-3af5-79ba-8c60-3e90863e5712" xlink:to="loc_vtvt_IPLicenseMember_019e6a7f-3af5-7375-8595-10824cdd43c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_019e6a7f-3af5-7c38-bbd3-691d8d38817d" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019e6a7f-3af5-7da6-8d84-27b9f3549893" xlink:to="loc_dei_LegalEntityAxis_019e6a7f-3af5-7c38-bbd3-691d8d38817d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_019e6a7f-3af5-7c38-bbd3-691d8d38817d_default" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_019e6a7f-3af5-7c38-bbd3-691d8d38817d" xlink:to="loc_dei_EntityDomain_019e6a7f-3af5-7c38-bbd3-691d8d38817d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_019e6a7f-3af5-730f-becd-0d680af81187" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_019e6a7f-3af5-7c38-bbd3-691d8d38817d" xlink:to="loc_dei_EntityDomain_019e6a7f-3af5-730f-becd-0d680af81187" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_NewsoaraBiopharmaCoLtdMember_019e6a7f-3af5-7edf-918b-0a26ccda485b" xlink:href="vtvt-20260630.xsd#vtvt_NewsoaraBiopharmaCoLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_019e6a7f-3af5-730f-becd-0d680af81187" xlink:to="loc_vtvt_NewsoaraBiopharmaCoLtdMember_019e6a7f-3af5-7edf-918b-0a26ccda485b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_019e6a7f-3af5-7f2b-a2c5-f124e1ca163c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019e6a7f-3af5-7520-ac10-b923a46fe641" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_019e6a7f-3af5-7f2b-a2c5-f124e1ca163c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross_019e6a7f-3af5-73ce-b6dd-ecd922070484" xlink:href="vtvt-20260630.xsd#vtvt_SaleOfStockConsiderationReceivedOnTransactionGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019e6a7f-3af5-7520-ac10-b923a46fe641" xlink:to="loc_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross_019e6a7f-3af5-73ce-b6dd-ecd922070484" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_019e6a7f-3af5-717b-b18b-22461a217042" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019e6a7f-3af5-7520-ac10-b923a46fe641" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_019e6a7f-3af5-717b-b18b-22461a217042" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_019e6a7f-3af5-76dc-8893-66d709848011" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsNotesAndLoansReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019e6a7f-3af5-7520-ac10-b923a46fe641" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_019e6a7f-3af5-76dc-8893-66d709848011" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue_019e6a7f-3af5-704b-9e61-d9d2184c1430" xlink:href="vtvt-20260630.xsd#vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019e6a7f-3af5-7520-ac10-b923a46fe641" xlink:to="loc_vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue_019e6a7f-3af5-704b-9e61-d9d2184c1430" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CollaborateArrangementContingentConsiderationTransferredCash_019e6a7f-3af5-7172-aaa6-dd645d08f9f6" xlink:href="vtvt-20260630.xsd#vtvt_CollaborateArrangementContingentConsiderationTransferredCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019e6a7f-3af5-7520-ac10-b923a46fe641" xlink:to="loc_vtvt_CollaborateArrangementContingentConsiderationTransferredCash_019e6a7f-3af5-7172-aaa6-dd645d08f9f6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod_019e6a7f-3af5-7d07-80cc-63b1504d6a8b" xlink:href="vtvt-20260630.xsd#vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019e6a7f-3af5-7520-ac10-b923a46fe641" xlink:to="loc_vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod_019e6a7f-3af5-7d07-80cc-63b1504d6a8b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_019e6a7f-3af5-76bd-8cf4-f3dd1f764759" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019e6a7f-3af5-7520-ac10-b923a46fe641" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_019e6a7f-3af5-76bd-8cf4-f3dd1f764759" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CollaborativeArrangementNoteReceivableDiscountPaid_019e6a7f-3af5-7a66-b899-edcfbc614667" xlink:href="vtvt-20260630.xsd#vtvt_CollaborativeArrangementNoteReceivableDiscountPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019e6a7f-3af5-7520-ac10-b923a46fe641" xlink:to="loc_vtvt_CollaborativeArrangementNoteReceivableDiscountPaid_019e6a7f-3af5-7a66-b899-edcfbc614667" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_019e6a7f-3af5-7991-be95-ee312f311679" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019e6a7f-3af5-7520-ac10-b923a46fe641" xlink:to="loc_us-gaap_ContractWithCustomerLiability_019e6a7f-3af5-7991-be95-ee312f311679" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_019e6a7f-3af5-70aa-97b8-2039575f971e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019e6a7f-3af5-7520-ac10-b923a46fe641" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_019e6a7f-3af5-70aa-97b8-2039575f971e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019e6a7f-3af5-7545-9649-df844d526641" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019e6a7f-3af5-7520-ac10-b923a46fe641" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019e6a7f-3af5-7545-9649-df844d526641" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LicenseFeeReceived_019e6a7f-3af5-77d4-8276-8e9d63452a59" xlink:href="vtvt-20260630.xsd#vtvt_LicenseFeeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019e6a7f-3af5-7520-ac10-b923a46fe641" xlink:to="loc_vtvt_LicenseFeeReceived_019e6a7f-3af5-77d4-8276-8e9d63452a59" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_019e6a7f-3af5-719b-aab9-6091b7df95ff" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019e6a7f-3af5-7520-ac10-b923a46fe641" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_019e6a7f-3af5-719b-aab9-6091b7df95ff" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable_019e6a7f-3af5-7a61-a0cf-cbb9bd06569b" xlink:href="vtvt-20260630.xsd#vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019e6a7f-3af5-7520-ac10-b923a46fe641" xlink:to="loc_vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable_019e6a7f-3af5-7a61-a0cf-cbb9bd06569b" xlink:type="arc" order="14"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="vtvt-20260630.xsd#ShareBasedCompensationAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e6a7f-3af5-7b4e-b2d8-242fd0088aa6" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019e6a7f-3af5-73a2-ada8-12ee102c8c9f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e6a7f-3af5-7b4e-b2d8-242fd0088aa6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019e6a7f-3af5-73a2-ada8-12ee102c8c9f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019e6a7f-3af5-747c-a514-a89742d639a9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019e6a7f-3af5-73a2-ada8-12ee102c8c9f" xlink:to="loc_us-gaap_AwardTypeAxis_019e6a7f-3af5-747c-a514-a89742d639a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e6a7f-3af5-747c-a514-a89742d639a9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_019e6a7f-3af5-747c-a514-a89742d639a9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e6a7f-3af5-747c-a514-a89742d639a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e6a7f-3af5-7c47-9be2-9ea572238de6" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_019e6a7f-3af5-747c-a514-a89742d639a9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e6a7f-3af5-7c47-9be2-9ea572238de6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_019e6a7f-3af5-79a7-9f2a-4a88421d3d54" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e6a7f-3af5-7c47-9be2-9ea572238de6" xlink:to="loc_us-gaap_EmployeeStockOptionMember_019e6a7f-3af5-79a7-9f2a-4a88421d3d54" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_019e6a7f-3af5-7acd-9038-a77ea76afbaf" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e6a7f-3af5-7b4e-b2d8-242fd0088aa6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_019e6a7f-3af5-7acd-9038-a77ea76afbaf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_019e6a7f-3af5-7f7b-9f0a-37d2a3d22cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e6a7f-3af5-7b4e-b2d8-242fd0088aa6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_019e6a7f-3af5-7f7b-9f0a-37d2a3d22cd0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_019e6a7f-3af5-7193-b16c-40b3187cb1f3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e6a7f-3af5-7b4e-b2d8-242fd0088aa6" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_019e6a7f-3af5-7193-b16c-40b3187cb1f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_019e6a7f-3af5-702f-be93-0a031026ab39" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e6a7f-3af5-7b4e-b2d8-242fd0088aa6" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_019e6a7f-3af5-702f-be93-0a031026ab39" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019e6a7f-3af5-73cb-ab4d-2b98fa6cf549" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e6a7f-3af5-7b4e-b2d8-242fd0088aa6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019e6a7f-3af5-73cb-ab4d-2b98fa6cf549" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/ShareBasedCompensationScheduleofCompensationExpenseRelatedtoGrantsofStockOptionsDetails" xlink:type="simple" xlink:href="vtvt-20260630.xsd#ShareBasedCompensationScheduleofCompensationExpenseRelatedtoGrantsofStockOptionsDetails"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/ShareBasedCompensationScheduleofCompensationExpenseRelatedtoGrantsofStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019e6a7f-3af6-7f8e-9a54-28e18feadab4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_019e6a7f-3af6-7f8b-8820-815004181d09" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019e6a7f-3af6-7f8e-9a54-28e18feadab4" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_019e6a7f-3af6-7f8b-8820-815004181d09" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeLocationBalanceAxis_019e6a7f-3af6-79bb-a109-2f79d7498c6b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfIncomeLocationBalanceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_019e6a7f-3af6-7f8b-8820-815004181d09" xlink:to="loc_us-gaap_StatementOfIncomeLocationBalanceAxis_019e6a7f-3af6-79bb-a109-2f79d7498c6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_019e6a7f-3af6-721e-bdf6-aef50e63093c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019e6a7f-3af6-7f8e-9a54-28e18feadab4" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_019e6a7f-3af6-721e-bdf6-aef50e63093c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/ShareBasedCompensationScheduleofCompensationExpenseRelatedtoGrantsofStockOptionsDetails_1" xlink:type="simple" xlink:href="vtvt-20260630.xsd#ShareBasedCompensationScheduleofCompensationExpenseRelatedtoGrantsofStockOptionsDetails_1"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/ShareBasedCompensationScheduleofCompensationExpenseRelatedtoGrantsofStockOptionsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019e6a7f-3af6-7f8e-9a54-28e18feadab4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_019e6a7f-3af6-7f8b-8820-815004181d09" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019e6a7f-3af6-7f8e-9a54-28e18feadab4" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_019e6a7f-3af6-7f8b-8820-815004181d09" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_019e6a7f-3af6-721e-bdf6-aef50e63093c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019e6a7f-3af6-7f8e-9a54-28e18feadab4" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_019e6a7f-3af6-721e-bdf6-aef50e63093c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="vtvt-20260630.xsd#CommitmentsandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CommitmentsAndContingenciesLineItems_019e6a7f-3af6-73ba-aca1-5fcb8a49bef1" xlink:href="vtvt-20260630.xsd#vtvt_CommitmentsAndContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CommitmentsAndContingenciesTable_019e6a7f-3af6-7328-a66c-0aaf1e8ed5cd" xlink:href="vtvt-20260630.xsd#vtvt_CommitmentsAndContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_vtvt_CommitmentsAndContingenciesLineItems_019e6a7f-3af6-73ba-aca1-5fcb8a49bef1" xlink:to="loc_vtvt_CommitmentsAndContingenciesTable_019e6a7f-3af6-7328-a66c-0aaf1e8ed5cd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_019e6a7f-3af6-7e79-8649-db88a5deb496" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vtvt_CommitmentsAndContingenciesTable_019e6a7f-3af6-7328-a66c-0aaf1e8ed5cd" xlink:to="loc_srt_RangeAxis_019e6a7f-3af6-7e79-8649-db88a5deb496" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019e6a7f-3af6-7e79-8649-db88a5deb496_default" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_019e6a7f-3af6-7e79-8649-db88a5deb496" xlink:to="loc_srt_RangeMember_019e6a7f-3af6-7e79-8649-db88a5deb496_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019e6a7f-3af6-7050-89ef-b5cd940b1b36" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_019e6a7f-3af6-7e79-8649-db88a5deb496" xlink:to="loc_srt_RangeMember_019e6a7f-3af6-7050-89ef-b5cd940b1b36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_019e6a7f-3af6-7c48-b2d7-6c525b4af9a8" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_019e6a7f-3af6-7050-89ef-b5cd940b1b36" xlink:to="loc_srt_MaximumMember_019e6a7f-3af6-7c48-b2d7-6c525b4af9a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_019e6a7f-3af6-71b7-a7ec-35ab9a69a17d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vtvt_CommitmentsAndContingenciesTable_019e6a7f-3af6-7328-a66c-0aaf1e8ed5cd" xlink:to="loc_us-gaap_OtherCommitmentsAxis_019e6a7f-3af6-71b7-a7ec-35ab9a69a17d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_019e6a7f-3af6-71b7-a7ec-35ab9a69a17d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherCommitmentsAxis_019e6a7f-3af6-71b7-a7ec-35ab9a69a17d" xlink:to="loc_us-gaap_OtherCommitmentsDomain_019e6a7f-3af6-71b7-a7ec-35ab9a69a17d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_019e6a7f-3af6-746e-80b8-2780753020fb" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherCommitmentsAxis_019e6a7f-3af6-71b7-a7ec-35ab9a69a17d" xlink:to="loc_us-gaap_OtherCommitmentsDomain_019e6a7f-3af6-746e-80b8-2780753020fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember_019e6a7f-3af6-7a57-ad2e-5a69bfceed32" xlink:href="vtvt-20260630.xsd#vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_019e6a7f-3af6-746e-80b8-2780753020fb" xlink:to="loc_vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember_019e6a7f-3af6-7a57-ad2e-5a69bfceed32" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SalesBasedMilestonesPaymentMember_019e6a7f-3af6-7ce1-a2cd-739d9e21471f" xlink:href="vtvt-20260630.xsd#vtvt_SalesBasedMilestonesPaymentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_019e6a7f-3af6-746e-80b8-2780753020fb" xlink:to="loc_vtvt_SalesBasedMilestonesPaymentMember_019e6a7f-3af6-7ce1-a2cd-739d9e21471f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_019e6a7f-3af6-7ca8-b5d8-78d2f6523fad" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vtvt_CommitmentsAndContingenciesTable_019e6a7f-3af6-7328-a66c-0aaf1e8ed5cd" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_019e6a7f-3af6-7ca8-b5d8-78d2f6523fad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_019e6a7f-3af6-7ca8-b5d8-78d2f6523fad_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_019e6a7f-3af6-7ca8-b5d8-78d2f6523fad" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_019e6a7f-3af6-7ca8-b5d8-78d2f6523fad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_019e6a7f-3af6-779a-9265-8710aef74f68" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_019e6a7f-3af6-7ca8-b5d8-78d2f6523fad" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_019e6a7f-3af6-779a-9265-8710aef74f68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_TypeOneDiabetesMember_019e6a7f-3af6-782a-b66c-87af234d59a9" xlink:href="vtvt-20260630.xsd#vtvt_TypeOneDiabetesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_019e6a7f-3af6-779a-9265-8710aef74f68" xlink:to="loc_vtvt_TypeOneDiabetesMember_019e6a7f-3af6-782a-b66c-87af234d59a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_TypeTwoDiabetesMember_019e6a7f-3af6-7848-9ec0-c6987b8a6fb8" xlink:href="vtvt-20260630.xsd#vtvt_TypeTwoDiabetesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_019e6a7f-3af6-779a-9265-8710aef74f68" xlink:to="loc_vtvt_TypeTwoDiabetesMember_019e6a7f-3af6-7848-9ec0-c6987b8a6fb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_OtherIndicationMember_019e6a7f-3af6-78a0-bea3-7fd89252ec58" xlink:href="vtvt-20260630.xsd#vtvt_OtherIndicationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_019e6a7f-3af6-779a-9265-8710aef74f68" xlink:to="loc_vtvt_OtherIndicationMember_019e6a7f-3af6-78a0-bea3-7fd89252ec58" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_019e6a7f-3af6-7c52-a717-6e0b5d09d3ce" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vtvt_CommitmentsAndContingenciesTable_019e6a7f-3af6-7328-a66c-0aaf1e8ed5cd" xlink:to="loc_us-gaap_TypeOfArrangementAxis_019e6a7f-3af6-7c52-a717-6e0b5d09d3ce" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019e6a7f-3af6-7c52-a717-6e0b5d09d3ce_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_019e6a7f-3af6-7c52-a717-6e0b5d09d3ce" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019e6a7f-3af6-7c52-a717-6e0b5d09d3ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019e6a7f-3af6-77fc-8e11-df100dc5b506" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_019e6a7f-3af6-7c52-a717-6e0b5d09d3ce" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019e6a7f-3af6-77fc-8e11-df100dc5b506" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_NovoLicenseAgreementMember_019e6a7f-3af6-7751-a5f2-c821328f8b07" xlink:href="vtvt-20260630.xsd#vtvt_NovoLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019e6a7f-3af6-77fc-8e11-df100dc5b506" xlink:to="loc_vtvt_NovoLicenseAgreementMember_019e6a7f-3af6-7751-a5f2-c821328f8b07" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PotentialMilestonePayment_019e6a7f-3af6-764c-bf37-66a7df3bed6c" xlink:href="vtvt-20260630.xsd#vtvt_PotentialMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_CommitmentsAndContingenciesLineItems_019e6a7f-3af6-73ba-aca1-5fcb8a49bef1" xlink:to="loc_vtvt_PotentialMilestonePayment_019e6a7f-3af6-764c-bf37-66a7df3bed6c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/StockholdersEquityAdditionalInformationDetails" xlink:type="simple" xlink:href="vtvt-20260630.xsd#StockholdersEquityAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/StockholdersEquityAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_019e6a7f-3af6-7b35-b405-3f374736f25c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_019e6a7f-3af6-7145-be5c-39138f7e7db5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_019e6a7f-3af6-7b35-b405-3f374736f25c" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_019e6a7f-3af6-7145-be5c-39138f7e7db5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_019e6a7f-3af6-70cb-99b2-82412a396bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_019e6a7f-3af6-7145-be5c-39138f7e7db5" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_019e6a7f-3af6-70cb-99b2-82412a396bd4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019e6a7f-3af6-70cb-99b2-82412a396bd4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_019e6a7f-3af6-70cb-99b2-82412a396bd4" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019e6a7f-3af6-70cb-99b2-82412a396bd4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019e6a7f-3af6-7f87-881e-f2b136399a79" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_019e6a7f-3af6-70cb-99b2-82412a396bd4" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019e6a7f-3af6-7f87-881e-f2b136399a79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_019e6a7f-3af6-7724-b0e6-a76960959d3c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019e6a7f-3af6-7f87-881e-f2b136399a79" xlink:to="loc_us-gaap_PrivatePlacementMember_019e6a7f-3af6-7724-b0e6-a76960959d3c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_TDCowenSalesAgreementMember_019e6a7f-3af6-7fdc-88f2-7056326b58cc" xlink:href="vtvt-20260630.xsd#vtvt_TDCowenSalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019e6a7f-3af6-7f87-881e-f2b136399a79" xlink:to="loc_vtvt_TDCowenSalesAgreementMember_019e6a7f-3af6-7fdc-88f2-7056326b58cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_019e6a7f-3af6-7824-94d3-6805a6f9285b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_019e6a7f-3af6-7145-be5c-39138f7e7db5" xlink:to="loc_us-gaap_StatementClassOfStockAxis_019e6a7f-3af6-7824-94d3-6805a6f9285b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019e6a7f-3af6-7824-94d3-6805a6f9285b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019e6a7f-3af6-7824-94d3-6805a6f9285b" xlink:to="loc_us-gaap_ClassOfStockDomain_019e6a7f-3af6-7824-94d3-6805a6f9285b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019e6a7f-3af6-742f-a5bf-5bf9c323f723" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019e6a7f-3af6-7824-94d3-6805a6f9285b" xlink:to="loc_us-gaap_ClassOfStockDomain_019e6a7f-3af6-742f-a5bf-5bf9c323f723" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_019e6a7f-3af6-7dc9-ae53-ee5f40d9005e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_019e6a7f-3af6-742f-a5bf-5bf9c323f723" xlink:to="loc_us-gaap_CommonClassAMember_019e6a7f-3af6-7dc9-ae53-ee5f40d9005e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_019e6a7f-3af6-7555-b796-4ac72aa4b5e8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_019e6a7f-3af6-7145-be5c-39138f7e7db5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_019e6a7f-3af6-7555-b796-4ac72aa4b5e8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_019e6a7f-3af6-7555-b796-4ac72aa4b5e8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_019e6a7f-3af6-7555-b796-4ac72aa4b5e8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_019e6a7f-3af6-7555-b796-4ac72aa4b5e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_019e6a7f-3af6-7080-bc30-2ef83a5ba7b5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_019e6a7f-3af6-7555-b796-4ac72aa4b5e8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_019e6a7f-3af6-7080-bc30-2ef83a5ba7b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PrivatePlacementPreFundedWarrantsMember_019e6a7f-3af6-7a98-a4f3-3797bca8a2d0" xlink:href="vtvt-20260630.xsd#vtvt_PrivatePlacementPreFundedWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_019e6a7f-3af6-7080-bc30-2ef83a5ba7b5" xlink:to="loc_vtvt_PrivatePlacementPreFundedWarrantsMember_019e6a7f-3af6-7a98-a4f3-3797bca8a2d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PreFundedWarrantsMember_019e6a7f-3af6-747e-826b-c7597bf34ac0" xlink:href="vtvt-20260630.xsd#vtvt_PreFundedWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_019e6a7f-3af6-7080-bc30-2ef83a5ba7b5" xlink:to="loc_vtvt_PreFundedWarrantsMember_019e6a7f-3af6-747e-826b-c7597bf34ac0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CommonWarrantsMember_019e6a7f-3af6-7710-84fc-d222afbba257" xlink:href="vtvt-20260630.xsd#vtvt_CommonWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_019e6a7f-3af6-7080-bc30-2ef83a5ba7b5" xlink:to="loc_vtvt_CommonWarrantsMember_019e6a7f-3af6-7710-84fc-d222afbba257" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_019e6a7f-3af6-7181-8443-9ffc8cfaaa25" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019e6a7f-3af6-7b35-b405-3f374736f25c" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_019e6a7f-3af6-7181-8443-9ffc8cfaaa25" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_019e6a7f-3af6-7a28-9849-364547953b7f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019e6a7f-3af6-7b35-b405-3f374736f25c" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_019e6a7f-3af6-7a28-9849-364547953b7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_019e6a7f-3af6-7efa-82a2-449391ce140d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019e6a7f-3af6-7b35-b405-3f374736f25c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_019e6a7f-3af6-7efa-82a2-449391ce140d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_019e6a7f-3af6-7e23-8342-82d5fbaef801" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019e6a7f-3af6-7b35-b405-3f374736f25c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_019e6a7f-3af6-7e23-8342-82d5fbaef801" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_019e6a7f-3af6-72f6-8f7d-7e2ac8899ff3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019e6a7f-3af6-7b35-b405-3f374736f25c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_019e6a7f-3af6-72f6-8f7d-7e2ac8899ff3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_WarrantsAndRightsImmediatelyExercisableTerm_019e6a7f-3af6-7a0f-9203-371bdc867828" xlink:href="vtvt-20260630.xsd#vtvt_WarrantsAndRightsImmediatelyExercisableTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019e6a7f-3af6-7b35-b405-3f374736f25c" xlink:to="loc_vtvt_WarrantsAndRightsImmediatelyExercisableTerm_019e6a7f-3af6-7a0f-9203-371bdc867828" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_019e6a7f-3af6-7526-bcae-6c3787b1f964" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019e6a7f-3af6-7b35-b405-3f374736f25c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_019e6a7f-3af6-7526-bcae-6c3787b1f964" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CommonStockParOrStatedValueOfPrivatePlacementShares_019e6a7f-3af6-7323-a416-4b2bd25e6891" xlink:href="vtvt-20260630.xsd#vtvt_CommonStockParOrStatedValueOfPrivatePlacementShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019e6a7f-3af6-7b35-b405-3f374736f25c" xlink:to="loc_vtvt_CommonStockParOrStatedValueOfPrivatePlacementShares_019e6a7f-3af6-7323-a416-4b2bd25e6891" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CommonStockParOrStatedValueOfPrivatePlacementPreFundedWarrantsShares_019e6a7f-3bcb-784d-8d4d-0e254ccccc89" xlink:href="vtvt-20260630.xsd#vtvt_CommonStockParOrStatedValueOfPrivatePlacementPreFundedWarrantsShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019e6a7f-3af6-7b35-b405-3f374736f25c" xlink:to="loc_vtvt_CommonStockParOrStatedValueOfPrivatePlacementPreFundedWarrantsShares_019e6a7f-3bcb-784d-8d4d-0e254ccccc89" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SaleOfStockAggregateOfferingPrice_019e6a7f-3bcb-758f-9b07-ec70d6ce8d54" xlink:href="vtvt-20260630.xsd#vtvt_SaleOfStockAggregateOfferingPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019e6a7f-3af6-7b35-b405-3f374736f25c" xlink:to="loc_vtvt_SaleOfStockAggregateOfferingPrice_019e6a7f-3bcb-758f-9b07-ec70d6ce8d54" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_EntityPublicFloatPercent_019e6a7f-3bcb-70c4-83bf-03e75db8095b" xlink:href="vtvt-20260630.xsd#vtvt_EntityPublicFloatPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019e6a7f-3af6-7b35-b405-3f374736f25c" xlink:to="loc_vtvt_EntityPublicFloatPercent_019e6a7f-3bcb-70c4-83bf-03e75db8095b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_EntityPublicFloatThreshold_019e6a7f-3bcb-7a2b-80fd-04b627cf694e" xlink:href="vtvt-20260630.xsd#vtvt_EntityPublicFloatThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019e6a7f-3af6-7b35-b405-3f374736f25c" xlink:to="loc_vtvt_EntityPublicFloatThreshold_019e6a7f-3bcb-7a2b-80fd-04b627cf694e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SaleOfStockMaximumSecuritiesToBeSoldPercentOfPublicFloat_019e6a7f-3bcb-78af-9873-12ffd196ee53" xlink:href="vtvt-20260630.xsd#vtvt_SaleOfStockMaximumSecuritiesToBeSoldPercentOfPublicFloat"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019e6a7f-3af6-7b35-b405-3f374736f25c" xlink:to="loc_vtvt_SaleOfStockMaximumSecuritiesToBeSoldPercentOfPublicFloat_019e6a7f-3bcb-78af-9873-12ffd196ee53" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_019e6a7f-3bcb-7a55-b944-d391d1a6fc08" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019e6a7f-3af6-7b35-b405-3f374736f25c" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_019e6a7f-3bcb-7a55-b944-d391d1a6fc08" xlink:type="arc" order="13"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/StockholdersEquityScheduleofEquityBasedStockWarrantsDetails" xlink:type="simple" xlink:href="vtvt-20260630.xsd#StockholdersEquityScheduleofEquityBasedStockWarrantsDetails"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/StockholdersEquityScheduleofEquityBasedStockWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_019e6a7f-3bcb-7cef-a967-26b5b9b2198c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_019e6a7f-3bcb-7eaa-b465-dcea87fb761b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_019e6a7f-3bcb-7cef-a967-26b5b9b2198c" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_019e6a7f-3bcb-7eaa-b465-dcea87fb761b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019e6a7f-3bcb-7104-8948-2141a2451a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_019e6a7f-3bcb-7eaa-b465-dcea87fb761b" xlink:to="loc_us-gaap_AwardTypeAxis_019e6a7f-3bcb-7104-8948-2141a2451a3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e6a7f-3bcb-7104-8948-2141a2451a3a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_019e6a7f-3bcb-7104-8948-2141a2451a3a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e6a7f-3bcb-7104-8948-2141a2451a3a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e6a7f-3bcb-7e72-9856-c425c2e3f3cf" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_019e6a7f-3bcb-7104-8948-2141a2451a3a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e6a7f-3bcb-7e72-9856-c425c2e3f3cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_StockWarrantMember_019e6a7f-3bcb-7632-9cfc-0c6d8b4a7793" xlink:href="vtvt-20260630.xsd#vtvt_StockWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e6a7f-3bcb-7e72-9856-c425c2e3f3cf" xlink:to="loc_vtvt_StockWarrantMember_019e6a7f-3bcb-7632-9cfc-0c6d8b4a7793" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_019e6a7f-3bcb-7520-9530-f8d58b01f49e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_019e6a7f-3bcb-7eaa-b465-dcea87fb761b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_019e6a7f-3bcb-7520-9530-f8d58b01f49e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_019e6a7f-3bcb-7520-9530-f8d58b01f49e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_019e6a7f-3bcb-7520-9530-f8d58b01f49e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_019e6a7f-3bcb-7520-9530-f8d58b01f49e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_019e6a7f-3bcb-7b9c-9150-2688786fbf3a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_019e6a7f-3bcb-7520-9530-f8d58b01f49e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_019e6a7f-3bcb-7b9c-9150-2688786fbf3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PreFundedWarrantsMember_019e6a7f-3bcb-769e-b9b4-80c830d3871c" xlink:href="vtvt-20260630.xsd#vtvt_PreFundedWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_019e6a7f-3bcb-7b9c-9150-2688786fbf3a" xlink:to="loc_vtvt_PreFundedWarrantsMember_019e6a7f-3bcb-769e-b9b4-80c830d3871c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CommonWarrantsMember_019e6a7f-3bcb-7f1c-9c81-f2d96e6ceadd" xlink:href="vtvt-20260630.xsd#vtvt_CommonWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_019e6a7f-3bcb-7b9c-9150-2688786fbf3a" xlink:to="loc_vtvt_CommonWarrantsMember_019e6a7f-3bcb-7f1c-9c81-f2d96e6ceadd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_019e6a7f-3bcb-712f-a5b3-508ba72f0d28" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019e6a7f-3bcb-7cef-a967-26b5b9b2198c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_019e6a7f-3bcb-712f-a5b3-508ba72f0d28" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_019e6a7f-3bcb-7312-a6b2-49311663a180" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_019e6a7f-3bcb-712f-a5b3-508ba72f0d28" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_019e6a7f-3bcb-7312-a6b2-49311663a180" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_019e6a7f-3bcb-7b65-9c52-ab5eafba647a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_019e6a7f-3bcb-712f-a5b3-508ba72f0d28" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_019e6a7f-3bcb-7b65-9c52-ab5eafba647a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_019e6a7f-3bcb-7d3b-99b6-25172c7138c5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_019e6a7f-3bcb-712f-a5b3-508ba72f0d28" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_019e6a7f-3bcb-7d3b-99b6-25172c7138c5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_019e6a7f-3bcb-7e32-8e6e-81e6fbc1e576" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_019e6a7f-3bcb-712f-a5b3-508ba72f0d28" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_019e6a7f-3bcb-7e32-8e6e-81e6fbc1e576" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_019e6a7f-3bcb-703e-a0c4-4fab79c3f0e2" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_019e6a7f-3bcb-71c1-8190-f92c22453127" xlink:href="vtvt-20260630.xsd#vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_019e6a7f-3bcb-712f-a5b3-508ba72f0d28" xlink:to="loc_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_019e6a7f-3bcb-71c1-8190-f92c22453127" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePriceAbstract_019e6a7f-3bcb-73b2-acf9-a45182fa0878" xlink:href="vtvt-20260630.xsd#vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePriceAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019e6a7f-3bcb-7cef-a967-26b5b9b2198c" xlink:to="loc_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePriceAbstract_019e6a7f-3bcb-73b2-acf9-a45182fa0878" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_019e6a7f-3bcb-7a90-8b04-e2878d63d188" xlink:href="vtvt-20260630.xsd#vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePriceAbstract_019e6a7f-3bcb-73b2-acf9-a45182fa0878" xlink:to="loc_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_019e6a7f-3bcb-7a90-8b04-e2878d63d188" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_019e6a7f-3bcb-7ae0-b85a-13b3b84d2ba5" xlink:href="vtvt-20260630.xsd#vtvt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePriceAbstract_019e6a7f-3bcb-73b2-acf9-a45182fa0878" xlink:to="loc_vtvt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_019e6a7f-3bcb-7ae0-b85a-13b3b84d2ba5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_019e6a7f-3bcb-7f11-8775-4204e90425ee" xlink:href="vtvt-20260630.xsd#vtvt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePriceAbstract_019e6a7f-3bcb-73b2-acf9-a45182fa0878" xlink:to="loc_vtvt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_019e6a7f-3bcb-7f11-8775-4204e90425ee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_019e6a7f-3bcb-793d-99fa-00de49e694e8" xlink:href="vtvt-20260630.xsd#vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_019e6a7f-3bcb-79e6-b2e3-da1e049aa317" xlink:href="vtvt-20260630.xsd#vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePriceAbstract_019e6a7f-3bcb-73b2-acf9-a45182fa0878" xlink:to="loc_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_019e6a7f-3bcb-79e6-b2e3-da1e049aa317" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_019e6a7f-3bcb-7875-8301-f43a9ed7ed92" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019e6a7f-3bcb-7cef-a967-26b5b9b2198c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_019e6a7f-3bcb-7875-8301-f43a9ed7ed92" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="vtvt-20260630.xsd#RelatedPartyTransactionsDetails"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_019e6a7f-3bcb-7411-b0bc-ba339211d517" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019e6a7f-3bcb-75af-8a9d-7e6667b53dff" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019e6a7f-3bcb-7411-b0bc-ba339211d517" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019e6a7f-3bcb-75af-8a9d-7e6667b53dff" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_019e6a7f-3bcb-7261-b5a5-e72c24b63c67" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019e6a7f-3bcb-75af-8a9d-7e6667b53dff" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_019e6a7f-3bcb-7261-b5a5-e72c24b63c67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_019e6a7f-3bcb-7261-b5a5-e72c24b63c67_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_019e6a7f-3bcb-7261-b5a5-e72c24b63c67" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_019e6a7f-3bcb-7261-b5a5-e72c24b63c67_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_019e6a7f-3bcb-734d-aade-91407e8f0ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_019e6a7f-3bcb-7261-b5a5-e72c24b63c67" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_019e6a7f-3bcb-734d-aade-91407e8f0ea9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_MacAndrewsAndForbesIncorporatedMember_019e6a7f-3bcb-7ded-839c-74f2676dca35" xlink:href="vtvt-20260630.xsd#vtvt_MacAndrewsAndForbesIncorporatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_019e6a7f-3bcb-734d-aade-91407e8f0ea9" xlink:to="loc_vtvt_MacAndrewsAndForbesIncorporatedMember_019e6a7f-3bcb-7ded-839c-74f2676dca35" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e6a7f-3bcb-70c3-92b0-00c578298b2b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019e6a7f-3bcb-75af-8a9d-7e6667b53dff" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e6a7f-3bcb-70c3-92b0-00c578298b2b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019e6a7f-3bcb-70c3-92b0-00c578298b2b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e6a7f-3bcb-70c3-92b0-00c578298b2b" xlink:to="loc_us-gaap_RelatedPartyDomain_019e6a7f-3bcb-70c3-92b0-00c578298b2b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019e6a7f-3bcb-7638-ba84-c0df1c97e08f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e6a7f-3bcb-70c3-92b0-00c578298b2b" xlink:to="loc_us-gaap_RelatedPartyDomain_019e6a7f-3bcb-7638-ba84-c0df1c97e08f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_019e6a7f-3bcb-75ae-be2f-33944ed3c42f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_019e6a7f-3bcb-7638-ba84-c0df1c97e08f" xlink:to="loc_us-gaap_RelatedPartyMember_019e6a7f-3bcb-75ae-be2f-33944ed3c42f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_019e6a7f-3bcb-7692-a06c-82171a7e5112" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019e6a7f-3bcb-75af-8a9d-7e6667b53dff" xlink:to="loc_us-gaap_StatementClassOfStockAxis_019e6a7f-3bcb-7692-a06c-82171a7e5112" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019e6a7f-3bcb-7692-a06c-82171a7e5112_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019e6a7f-3bcb-7692-a06c-82171a7e5112" xlink:to="loc_us-gaap_ClassOfStockDomain_019e6a7f-3bcb-7692-a06c-82171a7e5112_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019e6a7f-3bcb-7438-98eb-3538d37a5c01" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019e6a7f-3bcb-7692-a06c-82171a7e5112" xlink:to="loc_us-gaap_ClassOfStockDomain_019e6a7f-3bcb-7438-98eb-3538d37a5c01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_019e6a7f-3bcb-7bc1-8b53-c8e24b2e5db8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_019e6a7f-3bcb-7438-98eb-3538d37a5c01" xlink:to="loc_us-gaap_CommonClassBMember_019e6a7f-3bcb-7bc1-8b53-c8e24b2e5db8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_019e6a7f-3bcb-7e7a-8086-c9e0968b9955" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_019e6a7f-3bcb-7438-98eb-3538d37a5c01" xlink:to="loc_us-gaap_CommonClassAMember_019e6a7f-3bcb-7e7a-8086-c9e0968b9955" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_019e6a7f-3bcb-7d9d-b4e6-a51814dfd1ff" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019e6a7f-3bcb-75af-8a9d-7e6667b53dff" xlink:to="loc_srt_OwnershipAxis_019e6a7f-3bcb-7d9d-b4e6-a51814dfd1ff" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_019e6a7f-3bcb-7d9d-b4e6-a51814dfd1ff_default" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_019e6a7f-3bcb-7d9d-b4e6-a51814dfd1ff" xlink:to="loc_srt_OwnershipDomain_019e6a7f-3bcb-7d9d-b4e6-a51814dfd1ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_019e6a7f-3bcb-7d33-9896-b7e8ba2f8672" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_019e6a7f-3bcb-7d9d-b4e6-a51814dfd1ff" xlink:to="loc_srt_OwnershipDomain_019e6a7f-3bcb-7d33-9896-b7e8ba2f8672" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_VTvTherapeuticsIncMember_019e6a7f-3bcb-7d04-91ce-e819da5921c9" xlink:href="vtvt-20260630.xsd#vtvt_VTvTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_019e6a7f-3bcb-7d33-9896-b7e8ba2f8672" xlink:to="loc_vtvt_VTvTherapeuticsIncMember_019e6a7f-3bcb-7d04-91ce-e819da5921c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_019e6a7f-3bcb-7ae0-a8a0-8071ec254156" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019e6a7f-3bcb-75af-8a9d-7e6667b53dff" xlink:to="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_019e6a7f-3bcb-7ae0-a8a0-8071ec254156" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_019e6a7f-3bcb-7ae0-a8a0-8071ec254156_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_019e6a7f-3bcb-7ae0-a8a0-8071ec254156" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_019e6a7f-3bcb-7ae0-a8a0-8071ec254156_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_019e6a7f-3bcb-761a-a973-ac0260fbb5c3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_019e6a7f-3bcb-7ae0-a8a0-8071ec254156" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_019e6a7f-3bcb-761a-a973-ac0260fbb5c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember_019e6a7f-3bcb-7efa-84f6-7a8b6aaa5e37" xlink:href="vtvt-20260630.xsd#vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_019e6a7f-3bcb-761a-a973-ac0260fbb5c3" xlink:to="loc_vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember_019e6a7f-3bcb-7efa-84f6-7a8b6aaa5e37" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_019e6a7f-3bcb-7de0-9dd3-bce6573e6480" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019e6a7f-3bcb-75af-8a9d-7e6667b53dff" xlink:to="loc_dei_LegalEntityAxis_019e6a7f-3bcb-7de0-9dd3-bce6573e6480" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_019e6a7f-3bcb-7de0-9dd3-bce6573e6480_default" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_019e6a7f-3bcb-7de0-9dd3-bce6573e6480" xlink:to="loc_dei_EntityDomain_019e6a7f-3bcb-7de0-9dd3-bce6573e6480_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_019e6a7f-3bcb-7d3f-940e-e5e1ec8bcbe7" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_019e6a7f-3bcb-7de0-9dd3-bce6573e6480" xlink:to="loc_dei_EntityDomain_019e6a7f-3bcb-7d3f-940e-e5e1ec8bcbe7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_MFTTPHoldingsTwoLLCMember_019e6a7f-3bcb-7fd3-b026-0a5d370dbed1" xlink:href="vtvt-20260630.xsd#vtvt_MFTTPHoldingsTwoLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_019e6a7f-3bcb-7d3f-940e-e5e1ec8bcbe7" xlink:to="loc_vtvt_MFTTPHoldingsTwoLLCMember_019e6a7f-3bcb-7fd3-b026-0a5d370dbed1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PrivatePlacementInvestorsMember_019e6a7f-3bcb-7f81-9021-9295c544a9cd" xlink:href="vtvt-20260630.xsd#vtvt_PrivatePlacementInvestorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_019e6a7f-3bcb-7d3f-940e-e5e1ec8bcbe7" xlink:to="loc_vtvt_PrivatePlacementInvestorsMember_019e6a7f-3bcb-7f81-9021-9295c544a9cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_019e6a7f-3bcb-7058-b9c9-765ec8d8979f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019e6a7f-3bcb-7411-b0bc-ba339211d517" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_019e6a7f-3bcb-7058-b9c9-765ec8d8979f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_OwnershipPercentageOfMajorityOwner_019e6a7f-3bcb-7cca-b26b-12a9fd9866ea" xlink:href="vtvt-20260630.xsd#vtvt_OwnershipPercentageOfMajorityOwner"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019e6a7f-3bcb-7411-b0bc-ba339211d517" xlink:to="loc_vtvt_OwnershipPercentageOfMajorityOwner_019e6a7f-3bcb-7cca-b26b-12a9fd9866ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio_019e6a7f-3bcb-7264-b4fe-8f0def86a035" xlink:href="vtvt-20260630.xsd#vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019e6a7f-3bcb-7411-b0bc-ba339211d517" xlink:to="loc_vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio_019e6a7f-3bcb-7264-b4fe-8f0def86a035" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_019e6a7f-3bcb-772b-a55a-3ac7888b40e9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019e6a7f-3bcb-7411-b0bc-ba339211d517" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_019e6a7f-3bcb-772b-a55a-3ac7888b40e9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PercentageOfAmountOfCashSavings_019e6a7f-3bcb-7ec3-9300-5b34cc7c15c6" xlink:href="vtvt-20260630.xsd#vtvt_PercentageOfAmountOfCashSavings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019e6a7f-3bcb-7411-b0bc-ba339211d517" xlink:to="loc_vtvt_PercentageOfAmountOfCashSavings_019e6a7f-3bcb-7ec3-9300-5b34cc7c15c6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_NumberOfBoardOfDirectorsRightToDesignateMembers_019e6a7f-3bcc-77a6-ad32-4f5519e2a90a" xlink:href="vtvt-20260630.xsd#vtvt_NumberOfBoardOfDirectorsRightToDesignateMembers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019e6a7f-3bcb-7411-b0bc-ba339211d517" xlink:to="loc_vtvt_NumberOfBoardOfDirectorsRightToDesignateMembers_019e6a7f-3bcc-77a6-ad32-4f5519e2a90a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_NumberOfBoardOfDirectorsToApproveCertainActions_019e6a7f-3bcc-7a56-bb76-d803ed30844a" xlink:href="vtvt-20260630.xsd#vtvt_NumberOfBoardOfDirectorsToApproveCertainActions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019e6a7f-3bcb-7411-b0bc-ba339211d517" xlink:to="loc_vtvt_NumberOfBoardOfDirectorsToApproveCertainActions_019e6a7f-3bcc-7a56-bb76-d803ed30844a" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/SegmentInformationAdditionalInformationDetails" xlink:type="simple" xlink:href="vtvt-20260630.xsd#SegmentInformationAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/SegmentInformationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_019e6a7f-3bcc-7bc2-b828-4aef3fc35c08" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019e6a7f-3bcc-79c7-b1a8-6e63beaa5dff" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e6a7f-3bcc-7bc2-b828-4aef3fc35c08" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019e6a7f-3bcc-79c7-b1a8-6e63beaa5dff" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_019e6a7f-3bcc-7fe8-a605-6259486ccd63" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019e6a7f-3bcc-79c7-b1a8-6e63beaa5dff" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_019e6a7f-3bcc-7fe8-a605-6259486ccd63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_019e6a7f-3bcc-7fe8-a605-6259486ccd63_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_019e6a7f-3bcc-7fe8-a605-6259486ccd63" xlink:to="loc_us-gaap_SegmentDomain_019e6a7f-3bcc-7fe8-a605-6259486ccd63_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_019e6a7f-3bcc-7ee4-ad7c-4ddeb092e344" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_019e6a7f-3bcc-7fe8-a605-6259486ccd63" xlink:to="loc_us-gaap_SegmentDomain_019e6a7f-3bcc-7ee4-ad7c-4ddeb092e344" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ReportableSegmentMember_019e6a7f-3bcc-7698-b4de-2b5a495f9aaa" xlink:href="vtvt-20260630.xsd#vtvt_ReportableSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_019e6a7f-3bcc-7ee4-ad7c-4ddeb092e344" xlink:to="loc_vtvt_ReportableSegmentMember_019e6a7f-3bcc-7698-b4de-2b5a495f9aaa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_019e6a7f-3bcc-7064-aebe-c88c6e991120" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e6a7f-3bcc-7bc2-b828-4aef3fc35c08" xlink:to="loc_us-gaap_NumberOfReportableSegments_019e6a7f-3bcc-7064-aebe-c88c6e991120" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019e6a7f-3bcc-788a-b7eb-f6beb9bda139" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e6a7f-3bcc-7bc2-b828-4aef3fc35c08" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019e6a7f-3bcc-788a-b7eb-f6beb9bda139" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_NumberOfForeignCollaborationPartners_019e6a7f-3bcc-7cd4-baac-548601feabb4" xlink:href="vtvt-20260630.xsd#vtvt_NumberOfForeignCollaborationPartners"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e6a7f-3bcc-7bc2-b828-4aef3fc35c08" xlink:to="loc_vtvt_NumberOfForeignCollaborationPartners_019e6a7f-3bcc-7cd4-baac-548601feabb4" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails" xlink:type="simple" xlink:href="vtvt-20260630.xsd#SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_019e6a7f-3bcc-7d64-a243-4e3a3f2a43c4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019e6a7f-3bcc-7e58-8382-16693402f39f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e6a7f-3bcc-7d64-a243-4e3a3f2a43c4" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019e6a7f-3bcc-7e58-8382-16693402f39f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_019e6a7f-3bcc-726f-ae0d-4d9bb5ec765e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019e6a7f-3bcc-7e58-8382-16693402f39f" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_019e6a7f-3bcc-726f-ae0d-4d9bb5ec765e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_019e6a7f-3bcc-726f-ae0d-4d9bb5ec765e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_019e6a7f-3bcc-726f-ae0d-4d9bb5ec765e" xlink:to="loc_us-gaap_SegmentDomain_019e6a7f-3bcc-726f-ae0d-4d9bb5ec765e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_019e6a7f-3bcc-7e46-a562-efff30674087" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_019e6a7f-3bcc-726f-ae0d-4d9bb5ec765e" xlink:to="loc_us-gaap_SegmentDomain_019e6a7f-3bcc-7e46-a562-efff30674087" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ReportableSegmentMember_019e6a7f-3bcc-773b-9813-31c40a1d7a32" xlink:href="vtvt-20260630.xsd#vtvt_ReportableSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_019e6a7f-3bcc-7e46-a562-efff30674087" xlink:to="loc_vtvt_ReportableSegmentMember_019e6a7f-3bcc-773b-9813-31c40a1d7a32" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_019e6a7f-3bcc-7488-8f1b-20765dbb98fe" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019e6a7f-3bcc-7e58-8382-16693402f39f" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_019e6a7f-3bcc-7488-8f1b-20765dbb98fe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_019e6a7f-3bcc-7488-8f1b-20765dbb98fe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_019e6a7f-3bcc-7488-8f1b-20765dbb98fe" xlink:to="loc_us-gaap_ProjectMember_019e6a7f-3bcc-7488-8f1b-20765dbb98fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_019e6a7f-3bcc-7a5b-9984-1c4813b30237" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_019e6a7f-3bcc-7488-8f1b-20765dbb98fe" xlink:to="loc_us-gaap_ProjectMember_019e6a7f-3bcc-7a5b-9984-1c4813b30237" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CadisegliatinMember_019e6a7f-3bcc-79bc-a163-5be4e34fb797" xlink:href="vtvt-20260630.xsd#vtvt_CadisegliatinMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_019e6a7f-3bcc-7a5b-9984-1c4813b30237" xlink:to="loc_vtvt_CadisegliatinMember_019e6a7f-3bcc-79bc-a163-5be4e34fb797" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_OtherProjectsMember_019e6a7f-3bcc-7a9f-9bfe-83e9dfae2d82" xlink:href="vtvt-20260630.xsd#vtvt_OtherProjectsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_019e6a7f-3bcc-7a5b-9984-1c4813b30237" xlink:to="loc_vtvt_OtherProjectsMember_019e6a7f-3bcc-7a9f-9bfe-83e9dfae2d82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_DirectResearchAndDevelopmentExpense_019e6a7f-3bcc-7576-a300-b00a41da5422" xlink:href="vtvt-20260630.xsd#vtvt_DirectResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e6a7f-3bcc-7d64-a243-4e3a3f2a43c4" xlink:to="loc_vtvt_DirectResearchAndDevelopmentExpense_019e6a7f-3bcc-7576-a300-b00a41da5422" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_IndirectResearchDevelopmentExpense_019e6a7f-3bcc-7832-8089-2c0e61fbcf44" xlink:href="vtvt-20260630.xsd#vtvt_IndirectResearchDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e6a7f-3bcc-7d64-a243-4e3a3f2a43c4" xlink:to="loc_vtvt_IndirectResearchDevelopmentExpense_019e6a7f-3bcc-7832-8089-2c0e61fbcf44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_019e6a7f-3bcc-7a15-a960-dcacfb701317" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e6a7f-3bcc-7d64-a243-4e3a3f2a43c4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_019e6a7f-3bcc-7a15-a960-dcacfb701317" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="vtvt-20260630.xsd#IncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_IncomeTaxesLineItems_019e6a7f-3bcc-75b8-b78f-105be5bb01b4" xlink:href="vtvt-20260630.xsd#vtvt_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_IncomeTaxesTable_019e6a7f-3bcc-72d2-8765-3b9de731b53e" xlink:href="vtvt-20260630.xsd#vtvt_IncomeTaxesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_vtvt_IncomeTaxesLineItems_019e6a7f-3bcc-75b8-b78f-105be5bb01b4" xlink:to="loc_vtvt_IncomeTaxesTable_019e6a7f-3bcc-72d2-8765-3b9de731b53e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_019e6a7f-3bcc-7551-bbc5-7c5f13110f72" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vtvt_IncomeTaxesTable_019e6a7f-3bcc-72d2-8765-3b9de731b53e" xlink:to="loc_dei_LegalEntityAxis_019e6a7f-3bcc-7551-bbc5-7c5f13110f72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_019e6a7f-3bcc-7551-bbc5-7c5f13110f72_default" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_019e6a7f-3bcc-7551-bbc5-7c5f13110f72" xlink:to="loc_dei_EntityDomain_019e6a7f-3bcc-7551-bbc5-7c5f13110f72_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_019e6a7f-3bcc-799d-ab0d-a52847c51e77" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_019e6a7f-3bcc-7551-bbc5-7c5f13110f72" xlink:to="loc_dei_EntityDomain_019e6a7f-3bcc-799d-ab0d-a52847c51e77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_MFTTPHoldingsLLCMember_019e6a7f-3bcc-7114-a86f-542da5c7e2e4" xlink:href="vtvt-20260630.xsd#vtvt_MFTTPHoldingsLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_019e6a7f-3bcc-799d-ab0d-a52847c51e77" xlink:to="loc_vtvt_MFTTPHoldingsLLCMember_019e6a7f-3bcc-7114-a86f-542da5c7e2e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PercentageOfAmountOfCashSavings_019e6a7f-3bcc-7d78-b4fb-3013758d6b10" xlink:href="vtvt-20260630.xsd#vtvt_PercentageOfAmountOfCashSavings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_IncomeTaxesLineItems_019e6a7f-3bcc-75b8-b78f-105be5bb01b4" xlink:to="loc_vtvt_PercentageOfAmountOfCashSavings_019e6a7f-3bcc-7d78-b4fb-3013758d6b10" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/NetLossIncomeperShareScheduleofReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetIncomeLossperShareofClassACommonStockDetails" xlink:type="simple" xlink:href="vtvt-20260630.xsd#NetLossIncomeperShareScheduleofReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetIncomeLossperShareofClassACommonStockDetails"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/NetLossIncomeperShareScheduleofReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetIncomeLossperShareofClassACommonStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ScheduleOfEarningsPerShareLineItems_019e6a7f-3bcc-7790-beed-98b60be774ea" xlink:href="vtvt-20260630.xsd#vtvt_ScheduleOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ScheduleOfEarningsPerShareTable_019e6a7f-3bcc-7b93-b3a9-83b191cfb387" xlink:href="vtvt-20260630.xsd#vtvt_ScheduleOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_vtvt_ScheduleOfEarningsPerShareLineItems_019e6a7f-3bcc-7790-beed-98b60be774ea" xlink:to="loc_vtvt_ScheduleOfEarningsPerShareTable_019e6a7f-3bcc-7b93-b3a9-83b191cfb387" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_019e6a7f-3bcc-71ff-a7ae-f3e0d8eae0b5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vtvt_ScheduleOfEarningsPerShareTable_019e6a7f-3bcc-7b93-b3a9-83b191cfb387" xlink:to="loc_us-gaap_StatementClassOfStockAxis_019e6a7f-3bcc-71ff-a7ae-f3e0d8eae0b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019e6a7f-3bcc-71ff-a7ae-f3e0d8eae0b5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019e6a7f-3bcc-71ff-a7ae-f3e0d8eae0b5" xlink:to="loc_us-gaap_ClassOfStockDomain_019e6a7f-3bcc-71ff-a7ae-f3e0d8eae0b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019e6a7f-3bcc-7721-b9dd-896c8af091e6" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019e6a7f-3bcc-71ff-a7ae-f3e0d8eae0b5" xlink:to="loc_us-gaap_ClassOfStockDomain_019e6a7f-3bcc-7721-b9dd-896c8af091e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_019e6a7f-3bcc-7300-b07d-77afd81571b2" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_019e6a7f-3bcc-7721-b9dd-896c8af091e6" xlink:to="loc_us-gaap_CommonClassAMember_019e6a7f-3bcc-7300-b07d-77afd81571b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_019e6a7f-3bcc-781f-85d2-0d1159cbb116" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_ScheduleOfEarningsPerShareLineItems_019e6a7f-3bcc-7790-beed-98b60be774ea" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_019e6a7f-3bcc-781f-85d2-0d1159cbb116" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_019e6a7f-3bcc-7b9f-a3a0-b95285a3cc68" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_019e6a7f-3bcc-781f-85d2-0d1159cbb116" xlink:to="loc_us-gaap_NetIncomeLossAbstract_019e6a7f-3bcc-7b9f-a3a0-b95285a3cc68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_019e6a7f-3bcc-78fb-a281-cfad2eabd077" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAbstract_019e6a7f-3bcc-7b9f-a3a0-b95285a3cc68" xlink:to="loc_us-gaap_ProfitLoss_019e6a7f-3bcc-78fb-a281-cfad2eabd077" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_019e6a7f-3bcc-7869-8aa1-ec9cbeccd598" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAbstract_019e6a7f-3bcc-7b9f-a3a0-b95285a3cc68" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_019e6a7f-3bcc-7869-8aa1-ec9cbeccd598" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_019e6a7f-3bcc-77d1-bee0-235ed69dbfac" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAbstract_019e6a7f-3bcc-7b9f-a3a0-b95285a3cc68" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_019e6a7f-3bcc-77d1-bee0-235ed69dbfac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_019e6a7f-3bcc-75ba-b1f3-78162fd3a173" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_019e6a7f-3bcc-781f-85d2-0d1159cbb116" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_019e6a7f-3bcc-75ba-b1f3-78162fd3a173" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_019e6a7f-3bcc-79d3-acf2-6494eac43312" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_019e6a7f-3bcc-75ba-b1f3-78162fd3a173" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_019e6a7f-3bcc-79d3-acf2-6494eac43312" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_019e6a7f-3bcc-7c39-89f2-351fb9de6632" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_019e6a7f-3bcc-75ba-b1f3-78162fd3a173" xlink:to="loc_us-gaap_EarningsPerShareBasic_019e6a7f-3bcc-7c39-89f2-351fb9de6632" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_019e6a7f-3bcc-7723-9768-4e0644fc2d08" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_ScheduleOfEarningsPerShareLineItems_019e6a7f-3bcc-7790-beed-98b60be774ea" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_019e6a7f-3bcc-7723-9768-4e0644fc2d08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_NetIncomeLossDilutedAbstract_019e6a7f-3bcc-7113-b230-5ecde7e7a736" xlink:href="vtvt-20260630.xsd#vtvt_NetIncomeLossDilutedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_019e6a7f-3bcc-7723-9768-4e0644fc2d08" xlink:to="loc_vtvt_NetIncomeLossDilutedAbstract_019e6a7f-3bcc-7113-b230-5ecde7e7a736" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_019e6a7f-3bcc-730a-b76f-e0cbbab3a935" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_019e6a7f-3bcc-7fa6-9f75-400e82834cfe" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_019e6a7f-3bcc-7666-a1d9-d0b560a104a5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_NetIncomeLossDilutedAbstract_019e6a7f-3bcc-7113-b230-5ecde7e7a736" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_019e6a7f-3bcc-7666-a1d9-d0b560a104a5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_WeightedAverageNumberOfDilutedSharesOutstandingAbstract_019e6a7f-3bcc-772a-a3db-96d90121c63e" xlink:href="vtvt-20260630.xsd#vtvt_WeightedAverageNumberOfDilutedSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_019e6a7f-3bcc-7723-9768-4e0644fc2d08" xlink:to="loc_vtvt_WeightedAverageNumberOfDilutedSharesOutstandingAbstract_019e6a7f-3bcc-772a-a3db-96d90121c63e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019e6a7f-3bcc-7348-ae76-5378dde1a253" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_WeightedAverageNumberOfDilutedSharesOutstandingAbstract_019e6a7f-3bcc-772a-a3db-96d90121c63e" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019e6a7f-3bcc-7348-ae76-5378dde1a253" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_019e6a7f-3bcc-7ccc-9f58-0899bee00de0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_WeightedAverageNumberOfDilutedSharesOutstandingAbstract_019e6a7f-3bcc-772a-a3db-96d90121c63e" xlink:to="loc_us-gaap_EarningsPerShareDiluted_019e6a7f-3bcc-7ccc-9f58-0899bee00de0" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/NetLossIncomeperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetails" xlink:type="simple" xlink:href="vtvt-20260630.xsd#NetLossIncomeperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetails"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/NetLossIncomeperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019e6a7f-3bcc-7045-99ba-6dc6a851f360" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019e6a7f-3bcc-7230-82f2-4f0a283ddb5c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019e6a7f-3bcc-7045-99ba-6dc6a851f360" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019e6a7f-3bcc-7230-82f2-4f0a283ddb5c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019e6a7f-3bcc-7ab9-b421-33e54cd059b5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019e6a7f-3bcc-7230-82f2-4f0a283ddb5c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019e6a7f-3bcc-7ab9-b421-33e54cd059b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019e6a7f-3bcc-7ab9-b421-33e54cd059b5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019e6a7f-3bcc-7ab9-b421-33e54cd059b5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019e6a7f-3bcc-7ab9-b421-33e54cd059b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019e6a7f-3bcc-75d9-9dbf-e36069a5d615" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019e6a7f-3bcc-7ab9-b421-33e54cd059b5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019e6a7f-3bcc-75d9-9dbf-e36069a5d615" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_019e6a7f-3bcc-731a-aaa3-4063044f416e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019e6a7f-3bcc-75d9-9dbf-e36069a5d615" xlink:to="loc_us-gaap_CommonClassBMember_019e6a7f-3bcc-731a-aaa3-4063044f416e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_019e6a7f-3bcc-75b0-b903-4a690426922b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019e6a7f-3bcc-75d9-9dbf-e36069a5d615" xlink:to="loc_us-gaap_EmployeeStockOptionMember_019e6a7f-3bcc-75b0-b903-4a690426922b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_019e6a7f-3bcc-76ea-8818-f36850b003bc" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019e6a7f-3bcc-75d9-9dbf-e36069a5d615" xlink:to="loc_us-gaap_WarrantMember_019e6a7f-3bcc-76ea-8818-f36850b003bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_019e6a7f-3bcc-7b79-958b-a6393257073b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019e6a7f-3bcc-75d9-9dbf-e36069a5d615" xlink:to="loc_us-gaap_CommonClassAMember_019e6a7f-3bcc-7b79-958b-a6393257073b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_019e6a7f-3bcc-73ee-adb9-89dd4b144da6" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019e6a7f-3bcc-7045-99ba-6dc6a851f360" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_019e6a7f-3bcc-73ee-adb9-89dd4b144da6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_019e6a7f-3bcc-7a28-a2a0-37b3d0bdc461" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019e6a7f-3bcc-7045-99ba-6dc6a851f360" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_019e6a7f-3bcc-7a28-a2a0-37b3d0bdc461" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>vtvt-20260630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019e6a7f-3a2c-7e30-acc1-d5ae4ae8f1fc,g:0d1f2584-f555-42ce-b27a-904151cd021c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_019e6a7f-3c96-7e8d-a91f-06352bd16e87_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_019e6a7f-3c97-7bb6-a143-d52fe6a7fa94_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_019e6a7f-3bcc-73f4-b948-aedd796b5543_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio_019e6a7f-3c96-7731-ba87-0e79073e5f95_terseLabel_en-US" xlink:label="lab_vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock conversion ratio</link:label>
    <link:label id="lab_vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio_label_en-US" xlink:label="lab_vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Redeemable Non Controlling Interest Exchange Agreement Stock Conversion Ratio</link:label>
    <link:label id="lab_vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio_documentation_en-US" xlink:label="lab_vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Redeemable non controlling interest exchange agreement stock conversion ratio.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio" xlink:href="vtvt-20260630.xsd#vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio" xlink:to="lab_vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_VTvLLCMember_019e6a7f-3bcd-75a7-98ad-70dac448b8a4_terseLabel_en-US" xlink:label="lab_vtvt_VTvLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">vTv Therapeutics LLC</link:label>
    <link:label id="lab_vtvt_VTvLLCMember_label_en-US" xlink:label="lab_vtvt_VTvLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">V Tv L L C [Member]</link:label>
    <link:label id="lab_vtvt_VTvLLCMember_documentation_en-US" xlink:label="lab_vtvt_VTvLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">vTv LLC.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_VTvLLCMember" xlink:href="vtvt-20260630.xsd#vtvt_VTvLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_VTvLLCMember" xlink:to="lab_vtvt_VTvLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_019e6a7f-3bcc-7b24-ad86-95c82b539e9c_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_019e6a7f-3c96-782d-9d60-00ea4f0c5669_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net (loss) income attributable to common shareholders of vTv Therapeutics Inc diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_019e6a7f-3bcc-7dc1-bfa8-d2f27dd04781_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_019e6a7f-3c96-7a19-b64a-a94606f79370_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock value</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_019e6a7f-3bcc-722b-b568-074fe1fea055_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Taxes paid related to net share settlement of equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_019e6a7f-3bcd-7fb6-9840-6946a1b3d17c_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue_019e6a7f-3c96-724c-a693-b1ae7c4617d0_terseLabel_en-US" xlink:label="lab_vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration transferred, aggregate share value</link:label>
    <link:label id="lab_vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue_label_en-US" xlink:label="lab_vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Contingent Consideration Transferred, Aggregate Share Value</link:label>
    <link:label id="lab_vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue_documentation_en-US" xlink:label="lab_vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Contingent Consideration Transferred, Aggregate Share Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue" xlink:href="vtvt-20260630.xsd#vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue" xlink:to="lab_vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_019e6a7f-3c96-7c37-be8d-d33c5f33c6d3_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of securities called by warrants or rights (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_019e6a7f-3c97-7aa4-912d-0670509547b2_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_019e6a7f-3bcc-784f-9cb3-c265233124c3_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_019e6a7f-3bcc-70d8-885c-141d0c1cc05e_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_019e6a7f-3bcd-72b1-8e57-48955e3d6e47_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Project [Axis]</link:label>
    <link:label id="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_label_en-US" xlink:label="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Project [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockSharesConverted1_019e6a7f-3bcc-7c2c-93f1-e1a1d12cf587_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Conversion of Class B common stock to Class A common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockSharesConverted1_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Shares Converted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesConverted1" xlink:to="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_019e6a7f-3c97-71fd-bbff-aeb1dc43fbc6_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_019e6a7f-3c97-75f6-ac97-e8beec8460d4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of warrants, related party</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_MacAndrewsAndForbesIncorporatedMember_019e6a7f-3bcd-7c97-aa47-ddeedab8dee6_terseLabel_en-US" xlink:label="lab_vtvt_MacAndrewsAndForbesIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MacAndrews &amp; Forbes Incorporated</link:label>
    <link:label id="lab_vtvt_MacAndrewsAndForbesIncorporatedMember_label_en-US" xlink:label="lab_vtvt_MacAndrewsAndForbesIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mac Andrews And Forbes Incorporated [Member]</link:label>
    <link:label id="lab_vtvt_MacAndrewsAndForbesIncorporatedMember_documentation_en-US" xlink:label="lab_vtvt_MacAndrewsAndForbesIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">MacAndrews and Forbes Incorporated.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_MacAndrewsAndForbesIncorporatedMember" xlink:href="vtvt-20260630.xsd#vtvt_MacAndrewsAndForbesIncorporatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_MacAndrewsAndForbesIncorporatedMember" xlink:to="lab_vtvt_MacAndrewsAndForbesIncorporatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_IndirectResearchDevelopmentExpense_019e6a7f-3c97-73a3-8e37-f7d5e00cb62f_terseLabel_en-US" xlink:label="lab_vtvt_IndirectResearchDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indirect research and development expense</link:label>
    <link:label id="lab_vtvt_IndirectResearchDevelopmentExpense_label_en-US" xlink:label="lab_vtvt_IndirectResearchDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indirect Research Development Expense</link:label>
    <link:label id="lab_vtvt_IndirectResearchDevelopmentExpense_documentation_en-US" xlink:label="lab_vtvt_IndirectResearchDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Indirect Research Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_IndirectResearchDevelopmentExpense" xlink:href="vtvt-20260630.xsd#vtvt_IndirectResearchDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_IndirectResearchDevelopmentExpense" xlink:to="lab_vtvt_IndirectResearchDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_TypeTwoDiabetesMember_019e6a7f-3c97-703c-84a4-e09abc5fc640_terseLabel_en-US" xlink:label="lab_vtvt_TypeTwoDiabetesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type 2 Diabetes</link:label>
    <link:label id="lab_vtvt_TypeTwoDiabetesMember_label_en-US" xlink:label="lab_vtvt_TypeTwoDiabetesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type Two Diabetes [Member]</link:label>
    <link:label id="lab_vtvt_TypeTwoDiabetesMember_documentation_en-US" xlink:label="lab_vtvt_TypeTwoDiabetesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Type 2 diabetes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_TypeTwoDiabetesMember" xlink:href="vtvt-20260630.xsd#vtvt_TypeTwoDiabetesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_TypeTwoDiabetesMember" xlink:to="lab_vtvt_TypeTwoDiabetesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_019e6a7f-3c96-78b7-bd27-7701a33c481b_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_019e6a7f-3bcd-7f2c-aa80-8d8f13d689de_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related-Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_019e6a7f-3bcc-7001-995c-2e64c9329a9d_terseLabel_en-US" xlink:label="lab_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization Consolidation And Presentation Of Financial Statements [Line Items]</link:label>
    <link:label id="lab_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_label_en-US" xlink:label="lab_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization Consolidation And Presentation Of Financial Statements [Line Items]</link:label>
    <link:label id="lab_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_documentation_en-US" xlink:label="lab_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Organization consolidation and presentation of financial statements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:href="vtvt-20260630.xsd#vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="lab_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_NumberOfBoardOfDirectorsRightToDesignateMembers_019e6a7f-3bcc-7315-8bff-3ef3ff0986bd_terseLabel_en-US" xlink:label="lab_vtvt_NumberOfBoardOfDirectorsRightToDesignateMembers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of board of directors right to designate members</link:label>
    <link:label id="lab_vtvt_NumberOfBoardOfDirectorsRightToDesignateMembers_label_en-US" xlink:label="lab_vtvt_NumberOfBoardOfDirectorsRightToDesignateMembers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Board Of Directors Right To Designate Members</link:label>
    <link:label id="lab_vtvt_NumberOfBoardOfDirectorsRightToDesignateMembers_documentation_en-US" xlink:label="lab_vtvt_NumberOfBoardOfDirectorsRightToDesignateMembers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Board Of Directors Right To Designate Members</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_NumberOfBoardOfDirectorsRightToDesignateMembers" xlink:href="vtvt-20260630.xsd#vtvt_NumberOfBoardOfDirectorsRightToDesignateMembers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_NumberOfBoardOfDirectorsRightToDesignateMembers" xlink:to="lab_vtvt_NumberOfBoardOfDirectorsRightToDesignateMembers" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_019e6a7f-3bcd-72ee-8673-aa228e9e2b7f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_019e6a7f-3c97-7cfd-8440-cbfdf773c03b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_019e6a7f-3c97-7d88-a957-168b93096356_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_019e6a7f-3bcc-75be-bd04-f15f6a606896_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic weighted average number of vTv Therapeutics Inc. Class A common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_019e6a7f-3bcc-748a-a7e2-69d4d6ce9259_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average vTv Therapeutics Inc. Class A common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019e6a7f-3c96-7bc1-a361-0cb6ebe9e96e_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_019e6a7f-3c96-7dab-bb16-870fe319c46b_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_019e6a7f-3c97-7f54-afac-4d7a6b1106ce_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_019e6a7f-3c96-7cb1-bb1a-f5aaf9fb98ba_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e6a7f-3c96-7391-b1f9-019f7f50897a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_019e6a7f-3c96-7476-94f9-1e3ba0b0bf18_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationLineItems_019e6a7f-3c96-7d28-a41e-146287ca0ab3_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_019e6a7f-3bcc-7946-a470-0e11e5764068_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_019e6a7f-3c96-79fc-aa5f-e0ca12ca2e57_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net (loss) income attributable to vTv Therapeutics Inc. common shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_019e6a7f-3c96-70a2-9722-51a83d14ca04_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net (loss) income attributable to common shareholders of vTv Therapeutics Inc., basic</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019e6a7f-3c96-7da9-8bca-97946db007af_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_NovoLicenseAgreementMember_019e6a7f-3bcc-7cef-b6e6-022f79bcfb74_terseLabel_en-US" xlink:label="lab_vtvt_NovoLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Novo License Agreement</link:label>
    <link:label id="lab_vtvt_NovoLicenseAgreementMember_label_en-US" xlink:label="lab_vtvt_NovoLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novo License Agreement [Member]</link:label>
    <link:label id="lab_vtvt_NovoLicenseAgreementMember_documentation_en-US" xlink:label="lab_vtvt_NovoLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Novo license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_NovoLicenseAgreementMember" xlink:href="vtvt-20260630.xsd#vtvt_NovoLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_NovoLicenseAgreementMember" xlink:to="lab_vtvt_NovoLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ParentCompanyMember_019e6a7f-3bcd-75db-9e20-9a6bfaf875fb_terseLabel_en-US" xlink:label="lab_srt_ParentCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Parent Company</link:label>
    <link:label id="lab_srt_ParentCompanyMember_label_en-US" xlink:label="lab_srt_ParentCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Parent Company [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ParentCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ParentCompanyMember" xlink:to="lab_srt_ParentCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_EntityPublicFloatPercent_019e6a7f-3c96-728a-9c02-4be592f62968_terseLabel_en-US" xlink:label="lab_vtvt_EntityPublicFloatPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity public float, percent</link:label>
    <link:label id="lab_vtvt_EntityPublicFloatPercent_label_en-US" xlink:label="lab_vtvt_EntityPublicFloatPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float, Percent</link:label>
    <link:label id="lab_vtvt_EntityPublicFloatPercent_documentation_en-US" xlink:label="lab_vtvt_EntityPublicFloatPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Entity Public Float, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_EntityPublicFloatPercent" xlink:href="vtvt-20260630.xsd#vtvt_EntityPublicFloatPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_EntityPublicFloatPercent" xlink:to="lab_vtvt_EntityPublicFloatPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_019e6a7f-3bcc-70a1-bc29-a8832273f9a3_terseLabel_en-US" xlink:label="lab_vtvt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in usd per share)</link:label>
    <link:label id="lab_vtvt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_vtvt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Non-Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:label id="lab_vtvt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_documentation_en-US" xlink:label="lab_vtvt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Non-Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="vtvt-20260630.xsd#vtvt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_vtvt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_019e6a7f-3c96-72e6-9bbb-39274d3eba44_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements Not Yet Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_019e6a7f-3c97-7b3c-a988-ad75a2ecc88e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_019e6a7f-3bcc-7d41-9838-06b2608966f3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_019e6a7f-3c97-748e-a315-141a5a254cba_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_019e6a7f-3bcc-7d04-901c-579ebae7819b_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e6a7f-3bcd-7804-8749-28b36112f7c6_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_019e6a7f-3bcc-7dad-96df-7e143f4abb6c_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise price of warrants or rights (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_019e6a7f-3bcd-74d4-8778-867aabb86ab8_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019e6a7f-3bcc-70ec-8570-c8f1737f70c3_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_019e6a7f-3bcd-7279-b15b-4cacf3cde115_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic net (loss) income per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockNameDomain_019e6a7f-3c97-7a29-980b-69894303a5b7_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Name</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockNameDomain_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockNameDomain" xlink:to="lab_us-gaap_ConversionOfStockNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_019e6a7f-3bcc-7a12-bdca-144750f2fa30_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_019e6a7f-3c97-7a0b-84ea-c130c9d0065b_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_019e6a7f-3bcd-743c-ae46-aa8b3ca62c83_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_PrivatePlacementInvestorsMember_019e6a7f-3bcc-7434-bba1-f906d85aa5f3_terseLabel_en-US" xlink:label="lab_vtvt_PrivatePlacementInvestorsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Private Placement Investors</link:label>
    <link:label id="lab_vtvt_PrivatePlacementInvestorsMember_label_en-US" xlink:label="lab_vtvt_PrivatePlacementInvestorsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement Investors [Member]</link:label>
    <link:label id="lab_vtvt_PrivatePlacementInvestorsMember_documentation_en-US" xlink:label="lab_vtvt_PrivatePlacementInvestorsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Private Placement Investors</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PrivatePlacementInvestorsMember" xlink:href="vtvt-20260630.xsd#vtvt_PrivatePlacementInvestorsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_PrivatePlacementInvestorsMember" xlink:to="lab_vtvt_PrivatePlacementInvestorsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_019e6a7f-3c96-753e-ba3e-abe93d72ab1c_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassBMember_019e6a7f-3c96-78d7-97bc-9419c4e269f2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class B Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonClassBMember_label_en-US" xlink:label="lab_us-gaap_CommonClassBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Class B [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonClassBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassBMember" xlink:to="lab_us-gaap_CommonClassBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_019e6a7f-3c96-74e3-86fa-522853576434_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net (Loss) Income per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_019e6a7f-3bcd-70a2-9db0-1b584d2ec128_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_019e6a7f-3bcc-7af1-bb88-b6c033bc0049_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_019e6a7f-3bcc-71ae-916c-abf269b3a96c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_019e6a7f-3bcd-7628-a728-f9efc2da435d_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_019e6a7f-3c97-764f-9941-67e85b1a87e1_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</link:label>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_label_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:to="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:to="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_019e6a7f-3bcc-72f7-8455-d6905b7cb8f6_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation cost related to non-vested share-based compensation arrangements</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross_019e6a7f-3bcd-718e-9c4d-5baf9a17b25c_terseLabel_en-US" xlink:label="lab_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, consideration received on transaction, gross</link:label>
    <link:label id="lab_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross_label_en-US" xlink:label="lab_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction, Gross</link:label>
    <link:label id="lab_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross_documentation_en-US" xlink:label="lab_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:href="vtvt-20260630.xsd#vtvt_SaleOfStockConsiderationReceivedOnTransactionGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:to="lab_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_019e6a7f-3c96-713e-9c5d-0784122b7de4_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_019e6a7f-3bcd-7e09-b2a8-0db3814b6ce8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_019e6a7f-3c97-78f7-97f4-b198e287abf6_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted net (loss) income per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_019e6a7f-3c96-7806-91c2-4c6401432abb_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_019e6a7f-3bcc-7a29-bf96-588daa23b108_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_019e6a7f-3bcc-7d90-b9bd-7dddb5c99461_verboseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019e6a7f-3c97-7547-99db-e7e66802f1e8_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted weighted average number of vTv Therapeutics Inc. Class A common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019e6a7f-3c97-735f-862d-cf64ec9c1d76_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average vTv Therapeutics Inc. Class A common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_019e6a7f-3c96-73bc-8073-50f36abce911_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_019e6a7f-3bcc-7139-95b7-8de3722541ff_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_019e6a7f-3c96-7264-9371-8637b4aa42f9_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_019e6a7f-3c96-70b5-b566-175940aee989_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_CommitmentsAndContingenciesLineItems_019e6a7f-3c97-7b31-a7ed-8c7f0ca53e32_terseLabel_en-US" xlink:label="lab_vtvt_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:label id="lab_vtvt_CommitmentsAndContingenciesLineItems_label_en-US" xlink:label="lab_vtvt_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:label id="lab_vtvt_CommitmentsAndContingenciesLineItems_documentation_en-US" xlink:label="lab_vtvt_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CommitmentsAndContingenciesLineItems" xlink:href="vtvt-20260630.xsd#vtvt_CommitmentsAndContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_CommitmentsAndContingenciesLineItems" xlink:to="lab_vtvt_CommitmentsAndContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019e6a7f-3c96-767a-a2ad-dde66dba851f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_019e6a7f-3bcc-77ac-8d95-ca558e2c5d9f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_SaleOfStockMaximumSecuritiesToBeSoldPercentOfPublicFloat_019e6a7f-3bcd-7218-9021-fbdd7bfe4694_terseLabel_en-US" xlink:label="lab_vtvt_SaleOfStockMaximumSecuritiesToBeSoldPercentOfPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percent of public float</link:label>
    <link:label id="lab_vtvt_SaleOfStockMaximumSecuritiesToBeSoldPercentOfPublicFloat_label_en-US" xlink:label="lab_vtvt_SaleOfStockMaximumSecuritiesToBeSoldPercentOfPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Maximum Securities To Be Sold, Percent Of Public Float</link:label>
    <link:label id="lab_vtvt_SaleOfStockMaximumSecuritiesToBeSoldPercentOfPublicFloat_documentation_en-US" xlink:label="lab_vtvt_SaleOfStockMaximumSecuritiesToBeSoldPercentOfPublicFloat" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale of Stock, Maximum Securities To Be Sold, Percent Of Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SaleOfStockMaximumSecuritiesToBeSoldPercentOfPublicFloat" xlink:href="vtvt-20260630.xsd#vtvt_SaleOfStockMaximumSecuritiesToBeSoldPercentOfPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_SaleOfStockMaximumSecuritiesToBeSoldPercentOfPublicFloat" xlink:to="lab_vtvt_SaleOfStockMaximumSecuritiesToBeSoldPercentOfPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_SaleOfStockAggregateOfferingPrice_019e6a7f-3bcd-7027-b596-36da80a5c13c_terseLabel_en-US" xlink:label="lab_vtvt_SaleOfStockAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate offering price</link:label>
    <link:label id="lab_vtvt_SaleOfStockAggregateOfferingPrice_label_en-US" xlink:label="lab_vtvt_SaleOfStockAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Aggregate Offering Price</link:label>
    <link:label id="lab_vtvt_SaleOfStockAggregateOfferingPrice_documentation_en-US" xlink:label="lab_vtvt_SaleOfStockAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Aggregate offering price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SaleOfStockAggregateOfferingPrice" xlink:href="vtvt-20260630.xsd#vtvt_SaleOfStockAggregateOfferingPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_SaleOfStockAggregateOfferingPrice" xlink:to="lab_vtvt_SaleOfStockAggregateOfferingPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_PercentageOfAmountOfCashSavings_019e6a7f-3bcd-79cc-a797-097c2e8fcdc8_terseLabel_en-US" xlink:label="lab_vtvt_PercentageOfAmountOfCashSavings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount of cash savings percentage</link:label>
    <link:label id="lab_vtvt_PercentageOfAmountOfCashSavings_label_en-US" xlink:label="lab_vtvt_PercentageOfAmountOfCashSavings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Amount Of Cash Savings</link:label>
    <link:label id="lab_vtvt_PercentageOfAmountOfCashSavings_documentation_en-US" xlink:label="lab_vtvt_PercentageOfAmountOfCashSavings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of amount of cash savings.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PercentageOfAmountOfCashSavings" xlink:href="vtvt-20260630.xsd#vtvt_PercentageOfAmountOfCashSavings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_PercentageOfAmountOfCashSavings" xlink:to="lab_vtvt_PercentageOfAmountOfCashSavings" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_CollaborateArrangementContingentConsiderationTransferredCash_019e6a7f-3c97-7636-9507-7896159161cb_terseLabel_en-US" xlink:label="lab_vtvt_CollaborateArrangementContingentConsiderationTransferredCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration transferred, cash</link:label>
    <link:label id="lab_vtvt_CollaborateArrangementContingentConsiderationTransferredCash_label_en-US" xlink:label="lab_vtvt_CollaborateArrangementContingentConsiderationTransferredCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborate Arrangement, Contingent Consideration Transferred, Cash</link:label>
    <link:label id="lab_vtvt_CollaborateArrangementContingentConsiderationTransferredCash_documentation_en-US" xlink:label="lab_vtvt_CollaborateArrangementContingentConsiderationTransferredCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborate Arrangement, Contingent Consideration Transferred, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CollaborateArrangementContingentConsiderationTransferredCash" xlink:href="vtvt-20260630.xsd#vtvt_CollaborateArrangementContingentConsiderationTransferredCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_CollaborateArrangementContingentConsiderationTransferredCash" xlink:to="lab_vtvt_CollaborateArrangementContingentConsiderationTransferredCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProjectMember_019e6a7f-3c97-7413-b10a-c0f6b1679b31_terseLabel_en-US" xlink:label="lab_us-gaap_ProjectMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Project [Domain]</link:label>
    <link:label id="lab_us-gaap_ProjectMember_label_en-US" xlink:label="lab_us-gaap_ProjectMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Project [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProjectMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProjectMember" xlink:to="lab_us-gaap_ProjectMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_019e6a7f-3c96-7aae-a43a-71eee00d9206_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_TypeOneDiabetesMember_019e6a7f-3c96-7b57-8382-1eed024787ae_terseLabel_en-US" xlink:label="lab_vtvt_TypeOneDiabetesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type 1 Diabetes</link:label>
    <link:label id="lab_vtvt_TypeOneDiabetesMember_label_en-US" xlink:label="lab_vtvt_TypeOneDiabetesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type One Diabetes [Member]</link:label>
    <link:label id="lab_vtvt_TypeOneDiabetesMember_documentation_en-US" xlink:label="lab_vtvt_TypeOneDiabetesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Type 1 diabetes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_TypeOneDiabetesMember" xlink:href="vtvt-20260630.xsd#vtvt_TypeOneDiabetesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_TypeOneDiabetesMember" xlink:to="lab_vtvt_TypeOneDiabetesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019e6a7f-3bcd-7cd6-9fee-901194b14b4a_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_G42InvestmentsMember_019e6a7f-3c97-76ab-88fd-5dfce58ffc1b_terseLabel_en-US" xlink:label="lab_vtvt_G42InvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">G42 Investments</link:label>
    <link:label id="lab_vtvt_G42InvestmentsMember_label_en-US" xlink:label="lab_vtvt_G42InvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">G42 Investments [Member]</link:label>
    <link:label id="lab_vtvt_G42InvestmentsMember_documentation_en-US" xlink:label="lab_vtvt_G42InvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">G42 Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_G42InvestmentsMember" xlink:href="vtvt-20260630.xsd#vtvt_G42InvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_G42InvestmentsMember" xlink:to="lab_vtvt_G42InvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_IncomeTaxesTable_019e6a7f-3c97-76b4-b5ef-564df99b6ba7_terseLabel_en-US" xlink:label="lab_vtvt_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_vtvt_IncomeTaxesTable_label_en-US" xlink:label="lab_vtvt_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_vtvt_IncomeTaxesTable_documentation_en-US" xlink:label="lab_vtvt_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income taxes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_IncomeTaxesTable" xlink:href="vtvt-20260630.xsd#vtvt_IncomeTaxesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_IncomeTaxesTable" xlink:to="lab_vtvt_IncomeTaxesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_ScheduleOfEarningsPerShareLineItems_019e6a7f-3bcd-7eef-8358-da7666332d47_terseLabel_en-US" xlink:label="lab_vtvt_ScheduleOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_vtvt_ScheduleOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_vtvt_ScheduleOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_vtvt_ScheduleOfEarningsPerShareLineItems_documentation_en-US" xlink:label="lab_vtvt_ScheduleOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ScheduleOfEarningsPerShareLineItems" xlink:href="vtvt-20260630.xsd#vtvt_ScheduleOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_ScheduleOfEarningsPerShareLineItems" xlink:to="lab_vtvt_ScheduleOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsSvcCstMember" xlink:to="lab_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_NetIncomeLossDilutedAbstract_019e6a7f-3c96-7dc6-929f-0ea3a01a2a23_verboseLabel_en-US" xlink:label="lab_vtvt_NetIncomeLossDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_vtvt_NetIncomeLossDilutedAbstract_label_en-US" xlink:label="lab_vtvt_NetIncomeLossDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income Loss Diluted [Abstract]</link:label>
    <link:label id="lab_vtvt_NetIncomeLossDilutedAbstract_documentation_en-US" xlink:label="lab_vtvt_NetIncomeLossDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net Income Loss Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_NetIncomeLossDilutedAbstract" xlink:href="vtvt-20260630.xsd#vtvt_NetIncomeLossDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_NetIncomeLossDilutedAbstract" xlink:to="lab_vtvt_NetIncomeLossDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_019e6a7f-3bcc-768b-a18b-8e33bb1f2b3a_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019e6a7f-3c96-78b2-8b17-bbb715979790_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_019e6a7f-3bcc-795f-9331-1e464fb22578_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_019e6a7f-3bcd-7e32-95b8-750ef6d20345_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Awards outstanding, beginning balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_019e6a7f-3bcd-799a-b1b8-c69c01872ba4_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Awards outstanding, ending balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePriceAbstract_019e6a7f-3c97-7e51-bd64-d375ad625095_terseLabel_en-US" xlink:label="lab_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePriceAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePriceAbstract_label_en-US" xlink:label="lab_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePriceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:label id="lab_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePriceAbstract_documentation_en-US" xlink:label="lab_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePriceAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePriceAbstract" xlink:href="vtvt-20260630.xsd#vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePriceAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePriceAbstract" xlink:to="lab_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePriceAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_019e6a7f-3bcd-78a5-a6b9-7a0c6d6afbac_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Income (Loss) per Share of Class A Common Stock</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_019e6a7f-3c97-70a7-8e90-f7e6dd1b5b45_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrExpirationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_ecd_TrdArrExpirationDate_label_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TrdArrExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrExpirationDate" xlink:to="lab_ecd_TrdArrExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_019e6a7f-3bcd-73cf-b8e2-75d2b0f35a41_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeLocationBalanceAxis_019e6a7f-3bcd-7082-a8fb-c388f1e5763a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeLocationBalanceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeLocationBalanceAxis_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeLocationBalanceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Location, Statement of Income, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeLocationBalanceAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfIncomeLocationBalanceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeLocationBalanceAxis" xlink:to="lab_us-gaap_StatementOfIncomeLocationBalanceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_019e6a7f-3c96-7847-98bc-196d093a50cb_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_019e6a7f-3c96-7dbe-9291-154dcb69b805_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonrelatedPartyMember_019e6a7f-3c97-71a1-acb3-a2c400c3ceec_terseLabel_en-US" xlink:label="lab_us-gaap_NonrelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nonrelated Party</link:label>
    <link:label id="lab_us-gaap_NonrelatedPartyMember_label_en-US" xlink:label="lab_us-gaap_NonrelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonrelated Party [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonrelatedPartyMember" xlink:to="lab_us-gaap_NonrelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_019e6a7f-3bcd-7f32-ba70-db91c8fa6117_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_019e6a7f-3bcd-7dc2-9fb5-f42ecc869c13_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019e6a7f-3c96-7dcf-936d-823cd2073111_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_019e6a7f-3bcd-7340-a563-6271b7c564b7_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares sold (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_WarrantsAndRightsImmediatelyExercisableTerm_019e6a7f-3c96-73fc-ac63-800401851c11_terseLabel_en-US" xlink:label="lab_vtvt_WarrantsAndRightsImmediatelyExercisableTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants and rights immediately exercisable term</link:label>
    <link:label id="lab_vtvt_WarrantsAndRightsImmediatelyExercisableTerm_label_en-US" xlink:label="lab_vtvt_WarrantsAndRightsImmediatelyExercisableTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants And Rights Immediately Exercisable Term</link:label>
    <link:label id="lab_vtvt_WarrantsAndRightsImmediatelyExercisableTerm_documentation_en-US" xlink:label="lab_vtvt_WarrantsAndRightsImmediatelyExercisableTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants And Rights Immediately Exercisable Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_WarrantsAndRightsImmediatelyExercisableTerm" xlink:href="vtvt-20260630.xsd#vtvt_WarrantsAndRightsImmediatelyExercisableTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_WarrantsAndRightsImmediatelyExercisableTerm" xlink:to="lab_vtvt_WarrantsAndRightsImmediatelyExercisableTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_019e6a7f-3bcc-72ea-ae2c-35f88ac6ddbc_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_019e6a7f-3bcd-74f1-94bb-f2bed832afd7_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_019e6a7f-3bcc-704f-aca8-646991032151_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_label_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:to="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_019e6a7f-3bcc-7a08-9b5b-d646ecc8a6c4_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019e6a7f-3bcc-7e4c-9813-1e43e55ec21d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_MFTTPHoldingsTwoLLCMember_019e6a7f-3bcd-778d-8f22-8cd518f45fbc_terseLabel_en-US" xlink:label="lab_vtvt_MFTTPHoldingsTwoLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">M&amp;F TTP Holdings Two LLC</link:label>
    <link:label id="lab_vtvt_MFTTPHoldingsTwoLLCMember_label_en-US" xlink:label="lab_vtvt_MFTTPHoldingsTwoLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">M&amp;F TTP Holdings Two LLC [Member]</link:label>
    <link:label id="lab_vtvt_MFTTPHoldingsTwoLLCMember_documentation_en-US" xlink:label="lab_vtvt_MFTTPHoldingsTwoLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">M&amp;F TTP Holdings Two LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_MFTTPHoldingsTwoLLCMember" xlink:href="vtvt-20260630.xsd#vtvt_MFTTPHoldingsTwoLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_MFTTPHoldingsTwoLLCMember" xlink:to="lab_vtvt_MFTTPHoldingsTwoLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_019e6a7f-3bcc-73a9-9f7a-d1885b48d0f9_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_019e6a7f-3bcc-7f32-9c83-4c6711c9b154_terseLabel_en-US" xlink:label="lab_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization Consolidation And Presentation Of Financial Statements [Table]</link:label>
    <link:label id="lab_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_label_en-US" xlink:label="lab_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization Consolidation And Presentation Of Financial Statements [Table]</link:label>
    <link:label id="lab_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_documentation_en-US" xlink:label="lab_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Organization Consolidation And Presentation Of Financial Statements [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:href="vtvt-20260630.xsd#vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="lab_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_NewsoaraBiopharmaCoLtdMember_019e6a7f-3c96-7d4d-9f3a-27ca0365e2a6_terseLabel_en-US" xlink:label="lab_vtvt_NewsoaraBiopharmaCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Newsoara Biopharma Co Ltd</link:label>
    <link:label id="lab_vtvt_NewsoaraBiopharmaCoLtdMember_label_en-US" xlink:label="lab_vtvt_NewsoaraBiopharmaCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Newsoara Biopharma Co Ltd [Member]</link:label>
    <link:label id="lab_vtvt_NewsoaraBiopharmaCoLtdMember_documentation_en-US" xlink:label="lab_vtvt_NewsoaraBiopharmaCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Newsoara Biopharma Co Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_NewsoaraBiopharmaCoLtdMember" xlink:href="vtvt-20260630.xsd#vtvt_NewsoaraBiopharmaCoLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_NewsoaraBiopharmaCoLtdMember" xlink:to="lab_vtvt_NewsoaraBiopharmaCoLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_019e6a7f-3bcd-7b54-9a91-b9e5796d9c6a_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate gross purchase price</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_PrivatePlacementPreFundedWarrantsMember_019e6a7f-3bcc-70ff-85f1-9e7a01d2482d_terseLabel_en-US" xlink:label="lab_vtvt_PrivatePlacementPreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Private Placement Pre-Funded Warrants</link:label>
    <link:label id="lab_vtvt_PrivatePlacementPreFundedWarrantsMember_label_en-US" xlink:label="lab_vtvt_PrivatePlacementPreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement Pre-Funded Warrants [Member]</link:label>
    <link:label id="lab_vtvt_PrivatePlacementPreFundedWarrantsMember_documentation_en-US" xlink:label="lab_vtvt_PrivatePlacementPreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Private Placement Pre-Funded Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PrivatePlacementPreFundedWarrantsMember" xlink:href="vtvt-20260630.xsd#vtvt_PrivatePlacementPreFundedWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_PrivatePlacementPreFundedWarrantsMember" xlink:to="lab_vtvt_PrivatePlacementPreFundedWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_019e6a7f-3bcc-7e41-bb74-ed11cd85b9dc_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_019e6a7f-3bcd-7ef2-8ed2-238887e726a4_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_CadisegliatinMember_019e6a7f-3c96-7486-b178-3a14288d7929_terseLabel_en-US" xlink:label="lab_vtvt_CadisegliatinMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cadisegliatin</link:label>
    <link:label id="lab_vtvt_CadisegliatinMember_label_en-US" xlink:label="lab_vtvt_CadisegliatinMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cadisegliatin [Member]</link:label>
    <link:label id="lab_vtvt_CadisegliatinMember_documentation_en-US" xlink:label="lab_vtvt_CadisegliatinMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cadisegliatin</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CadisegliatinMember" xlink:href="vtvt-20260630.xsd#vtvt_CadisegliatinMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_CadisegliatinMember" xlink:to="lab_vtvt_CadisegliatinMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_WarrantLiabilityCurrent_019e6a7f-3c96-7506-ae45-adb6b29add51_terseLabel_en-US" xlink:label="lab_vtvt_WarrantLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant liability, related party</link:label>
    <link:label id="lab_vtvt_WarrantLiabilityCurrent_label_en-US" xlink:label="lab_vtvt_WarrantLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant liability, Current</link:label>
    <link:label id="lab_vtvt_WarrantLiabilityCurrent_documentation_en-US" xlink:label="lab_vtvt_WarrantLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrant liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_WarrantLiabilityCurrent" xlink:href="vtvt-20260630.xsd#vtvt_WarrantLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_WarrantLiabilityCurrent" xlink:to="lab_vtvt_WarrantLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_019e6a7f-3bcc-7918-a44a-686e716fbc40_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_019e6a7f-3c96-793c-94c8-391eac6c9d8f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_NumberOfBoardOfDirectorsToApproveCertainActions_019e6a7f-3bcd-7b87-8f98-449a332ffa4d_terseLabel_en-US" xlink:label="lab_vtvt_NumberOfBoardOfDirectorsToApproveCertainActions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of board of directors to approve certain actions</link:label>
    <link:label id="lab_vtvt_NumberOfBoardOfDirectorsToApproveCertainActions_label_en-US" xlink:label="lab_vtvt_NumberOfBoardOfDirectorsToApproveCertainActions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Board Of Directors To Approve Certain Actions</link:label>
    <link:label id="lab_vtvt_NumberOfBoardOfDirectorsToApproveCertainActions_documentation_en-US" xlink:label="lab_vtvt_NumberOfBoardOfDirectorsToApproveCertainActions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Board Of Directors To Approve Certain Actions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_NumberOfBoardOfDirectorsToApproveCertainActions" xlink:href="vtvt-20260630.xsd#vtvt_NumberOfBoardOfDirectorsToApproveCertainActions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_NumberOfBoardOfDirectorsToApproveCertainActions" xlink:to="lab_vtvt_NumberOfBoardOfDirectorsToApproveCertainActions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019e6a7f-3bcd-7507-b85b-f97dcd1553cc_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Awards outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019e6a7f-3bcd-736a-8cb0-312b52a25e40_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Awards outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_VTvTherapeuticsIncMember_019e6a7f-3bcd-7190-9ffb-899baea39e74_terseLabel_en-US" xlink:label="lab_vtvt_VTvTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">vTv Therapeutics Inc</link:label>
    <link:label id="lab_vtvt_VTvTherapeuticsIncMember_label_en-US" xlink:label="lab_vtvt_VTvTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">vTv Therapeutics Inc [Member]</link:label>
    <link:label id="lab_vtvt_VTvTherapeuticsIncMember_documentation_en-US" xlink:label="lab_vtvt_VTvTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">vTv Therapeutics Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_VTvTherapeuticsIncMember" xlink:href="vtvt-20260630.xsd#vtvt_VTvTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_VTvTherapeuticsIncMember" xlink:to="lab_vtvt_VTvTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrivatePlacementMember_019e6a7f-3c97-7198-aedb-d2defe5e15ec_terseLabel_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Private Placement</link:label>
    <link:label id="lab_us-gaap_PrivatePlacementMember_label_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrivatePlacementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_019e6a7f-3bcc-7332-ae0c-f9342523d250_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_019e6a7f-3bcd-78c4-823b-47dc91b320de_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potentially dilutive securities not included in calculation of dilutive net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_019e6a7f-3bcd-7dce-a397-d7d98f628225_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_019e6a7f-3bcc-7042-a170-61d3b5de4eef_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_019e6a7f-3c96-761e-a9f9-79bfeccd5800_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_019e6a7f-3c96-70d8-8a38-58fa80a89d27_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of private placement</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Private Placement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_019e6a7f-3bcc-7351-b57d-1d8873db394d_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</link:label>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_label_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:to="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_019e6a7f-3c96-7b3e-aa5b-11824388a330_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_MFTTPHoldingsLLCMember_019e6a7f-3c97-70dd-b03c-2506dd4cfd5d_terseLabel_en-US" xlink:label="lab_vtvt_MFTTPHoldingsLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">M&amp;F TTP Holdings LLC</link:label>
    <link:label id="lab_vtvt_MFTTPHoldingsLLCMember_label_en-US" xlink:label="lab_vtvt_MFTTPHoldingsLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">M F T T P Holdings L L C [Member]</link:label>
    <link:label id="lab_vtvt_MFTTPHoldingsLLCMember_documentation_en-US" xlink:label="lab_vtvt_MFTTPHoldingsLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">M&amp;F TTP Holdings LLC.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_MFTTPHoldingsLLCMember" xlink:href="vtvt-20260630.xsd#vtvt_MFTTPHoldingsLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_MFTTPHoldingsLLCMember" xlink:to="lab_vtvt_MFTTPHoldingsLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_019e6a7f-3bcd-7ae9-ad62-efe2183fd9f1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_019e6a7f-3c97-79fd-8208-f23abace1a46_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_019e6a7f-3bcc-7b41-853a-3ec1fec42b41_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_019e6a7f-3c97-7df8-b3a0-11b6ea96a84f_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_019e6a7f-3c97-74f0-99de-d0f8f908da02_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_PotentialMilestonePayment_019e6a7f-3c97-721a-820b-50fffaf5ecbb_terseLabel_en-US" xlink:label="lab_vtvt_PotentialMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential milestone payment</link:label>
    <link:label id="lab_vtvt_PotentialMilestonePayment_label_en-US" xlink:label="lab_vtvt_PotentialMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential Milestone Payment</link:label>
    <link:label id="lab_vtvt_PotentialMilestonePayment_documentation_en-US" xlink:label="lab_vtvt_PotentialMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Potential milestone payment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PotentialMilestonePayment" xlink:href="vtvt-20260630.xsd#vtvt_PotentialMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_PotentialMilestonePayment" xlink:to="lab_vtvt_PotentialMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019e6a7f-3bcc-7cb2-956c-71eb2fded2c0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_019e6a7f-3c96-7cc9-9424-469cabdedcbd_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Commitments</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsDomain" xlink:to="lab_us-gaap_OtherCommitmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_019e6a7f-3c97-7ea2-be0a-3e0aa49e9ce1_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationTable_019e6a7f-3c97-744e-bae3-33bc585bc591_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_label_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_019e6a7f-3bcd-7742-bc76-bb1bacc25ed7_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_019e6a7f-3c97-72e1-b35a-c850fe12b0e0_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_019e6a7f-3bcc-7fa7-8403-08bb83507fb2_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average period to recognize unrecognized share-based compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_019e6a7f-3c96-7d52-a5ea-479d991afaf1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_019e6a7f-3bcc-7582-991f-e82df01e9cf4_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_019e6a7f-3c97-75b1-bdf7-bf92bac3fed2_terseLabel_en-US" xlink:label="lab_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_label_en-US" xlink:label="lab_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Options, Exercisable, Number</link:label>
    <link:label id="lab_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_documentation_en-US" xlink:label="lab_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" xlink:href="vtvt-20260630.xsd#vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" xlink:to="lab_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_019e6a7f-3c96-7a1f-8779-3007e6c4b570_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_019e6a7f-3c97-7298-8b31-24babaf4d24f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Equity-Based Stock Warrants</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Outstanding Award, Activity, Excluding Option [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable_019e6a7f-3bcd-700e-9371-55d3be16ba62_terseLabel_en-US" xlink:label="lab_vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential development and regulatory milestone payments receivable</link:label>
    <link:label id="lab_vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable_label_en-US" xlink:label="lab_vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential Development And Regulatory Milestone Payments Receivable</link:label>
    <link:label id="lab_vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable_documentation_en-US" xlink:label="lab_vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Potential development and regulatory milestone payments receivable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable" xlink:href="vtvt-20260630.xsd#vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable" xlink:to="lab_vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019e6a7f-3bcc-7831-9f64-fb4761149377_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant date fair value of options granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_019e6a7f-3c96-7e71-9e1c-839138d83504_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Compensation Expense Related to Grants of Stock Options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_019e6a7f-3bcc-7b50-a229-e207067dfbd2_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_019e6a7f-3bcd-720e-a061-8f9463a50f63_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_CollaborativeArrangementNoteReceivableDiscountPaid_019e6a7f-3bcc-7589-9653-263e512b9add_terseLabel_en-US" xlink:label="lab_vtvt_CollaborativeArrangementNoteReceivableDiscountPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Note receivable, discount paid</link:label>
    <link:label id="lab_vtvt_CollaborativeArrangementNoteReceivableDiscountPaid_label_en-US" xlink:label="lab_vtvt_CollaborativeArrangementNoteReceivableDiscountPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Note Receivable, Discount Paid</link:label>
    <link:label id="lab_vtvt_CollaborativeArrangementNoteReceivableDiscountPaid_documentation_en-US" xlink:label="lab_vtvt_CollaborativeArrangementNoteReceivableDiscountPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Note Receivable, Discount Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CollaborativeArrangementNoteReceivableDiscountPaid" xlink:href="vtvt-20260630.xsd#vtvt_CollaborativeArrangementNoteReceivableDiscountPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_CollaborativeArrangementNoteReceivableDiscountPaid" xlink:to="lab_vtvt_CollaborativeArrangementNoteReceivableDiscountPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_IncomeTaxesLineItems_019e6a7f-3bcd-703c-9618-788dc50c67fb_terseLabel_en-US" xlink:label="lab_vtvt_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_vtvt_IncomeTaxesLineItems_label_en-US" xlink:label="lab_vtvt_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_vtvt_IncomeTaxesLineItems_documentation_en-US" xlink:label="lab_vtvt_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income taxes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_IncomeTaxesLineItems" xlink:href="vtvt-20260630.xsd#vtvt_IncomeTaxesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_IncomeTaxesLineItems" xlink:to="lab_vtvt_IncomeTaxesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_019e6a7f-3bcc-70f0-9023-d76204adea8a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_019e6a7f-3bcd-789e-adb4-c75d1690618a_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Collaboration revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_019e6a7f-3c96-7dbc-934b-4df887f83c38_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_019e6a7f-3bcd-707e-abac-33193f399bf8_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_019f851e-f535-7cb2-ad73-8b2022100ada_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeited or Expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e6a7f-3bcc-7e9c-a5d5-d23660e61bfa_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_019e6a7f-3bcd-725e-967b-180693b41df9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_019e6a7f-3bcd-732e-a3d8-798748a48cf1_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance, shares (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_019e6a7f-3bcd-73b5-aedb-02d750755af3_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance, shares (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_019e6a7f-3bcd-7638-b8bc-586c7454ce31_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Diluted net (loss) income per share of vTv Therapeutics Inc. Class A common stock (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_019e6a7f-3bcd-735f-9f8c-64965151c70f_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted net (loss) income per share of vTv Therapeutics Inc. Class A common stock (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_019e6a7f-3bcd-71d7-86f9-9e0d82174165_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_019e6a7f-3bcc-7deb-9d79-a5cd1dde7817_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_019e6a7f-3c97-7a6a-8648-dace64a2e492_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net shares withheld for tax withholding related to the settlement of equity awards.</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_019e6a7f-3bcc-788a-8d81-c4be3024855e_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_WarrantyLiability_019e6a7f-3bcc-7712-84ea-eb00e4d92ba0_terseLabel_en-US" xlink:label="lab_vtvt_WarrantyLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant liability</link:label>
    <link:label id="lab_vtvt_WarrantyLiability_label_en-US" xlink:label="lab_vtvt_WarrantyLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warranty Liability</link:label>
    <link:label id="lab_vtvt_WarrantyLiability_documentation_en-US" xlink:label="lab_vtvt_WarrantyLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warranty Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_WarrantyLiability" xlink:href="vtvt-20260630.xsd#vtvt_WarrantyLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_WarrantyLiability" xlink:to="lab_vtvt_WarrantyLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_019e6a7f-3c97-7d57-a1c3-cb9bd321dd43_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_019e6a7f-3c97-7e3d-ba97-e7082601c624_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_019e6a7f-3c97-7629-bd13-91e2153530db_totalLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019e6a7f-3bcd-714c-bcae-20e121508fa8_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net income (loss) before noncontrolling interest to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019e6a7f-3c96-7fd3-98eb-c1e3a71cd93c_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019f69c2-4292-70d0-9ff8-b576e1acfb9d_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019e6a7f-3bcc-7c8a-8063-b45579fe6d00_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_019e6a7f-3bcd-7e9a-b53d-9c8a9ebc7782_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_019e6a7f-3bcd-7c97-9771-d494146cca45_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_019e6a7f-3bcc-7aca-91ea-04a364773b5b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_019e6a7f-3bcd-7521-99cc-7469f14478fc_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_PreFundedWarrantsMember_019e6a7f-3bcc-7d3b-982d-21eb3b3b9cbb_terseLabel_en-US" xlink:label="lab_vtvt_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-Funded Warrants</link:label>
    <link:label id="lab_vtvt_PreFundedWarrantsMember_label_en-US" xlink:label="lab_vtvt_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-Funded Warrants [Member]</link:label>
    <link:label id="lab_vtvt_PreFundedWarrantsMember_documentation_en-US" xlink:label="lab_vtvt_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pre-Funded Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PreFundedWarrantsMember" xlink:href="vtvt-20260630.xsd#vtvt_PreFundedWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_PreFundedWarrantsMember" xlink:to="lab_vtvt_PreFundedWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_019e6a7f-3c97-7dc5-92ac-d3e1257dceef_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited or Expired (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember_019e6a7f-3c97-776f-96cc-e62f33b68d8e_terseLabel_en-US" xlink:label="lab_vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Developmental and Regulatory Milestone Payment</link:label>
    <link:label id="lab_vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember_label_en-US" xlink:label="lab_vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Developmental And Regulatory Milestone Payment [Member]</link:label>
    <link:label id="lab_vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember_documentation_en-US" xlink:label="lab_vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Developmental and regulatory milestone payment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember" xlink:href="vtvt-20260630.xsd#vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember" xlink:to="lab_vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_019e6a7f-3bcc-71a5-b324-6988df277cc6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options vested and expected to vest (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019e6a7f-3c97-73e6-84d3-ea91720902ef_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019e6a7f-3c97-7702-b07f-30e161bad9f3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod_019e6a7f-3c96-78cd-b582-998cf1e2cd2f_terseLabel_en-US" xlink:label="lab_vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative arrangement, royalties receivable, period</link:label>
    <link:label id="lab_vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod_label_en-US" xlink:label="lab_vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Royalties Receivable, Period</link:label>
    <link:label id="lab_vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod_documentation_en-US" xlink:label="lab_vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Royalties Receivable, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod" xlink:href="vtvt-20260630.xsd#vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod" xlink:to="lab_vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_019e6a7f-3bcd-7ca7-88a5-967628d2c9ff_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_019e6a7f-3c97-7185-8f6a-ebf0412ec98c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019e6a7f-3bcc-78c7-bd75-f9fa559bad30_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_019e6a7f-3bcd-740d-92f3-bae46aa64ee2_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating (loss) income</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_019e6a7f-3bcd-78a5-a313-8f9649723a50_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_019e6a7f-3bcd-7c2a-9136-bb61f93003a6_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share held by related party (in shares)</link:label>
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_label_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Owned, Balance, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentOwnedBalanceShares" xlink:to="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_019e6a7f-3bcd-7f64-b8da-751cbc578c07_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_EntityPublicFloatThreshold_019e6a7f-3bcd-7556-a2a1-df78327976d9_terseLabel_en-US" xlink:label="lab_vtvt_EntityPublicFloatThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity public float, threshold</link:label>
    <link:label id="lab_vtvt_EntityPublicFloatThreshold_label_en-US" xlink:label="lab_vtvt_EntityPublicFloatThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float, Threshold</link:label>
    <link:label id="lab_vtvt_EntityPublicFloatThreshold_documentation_en-US" xlink:label="lab_vtvt_EntityPublicFloatThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Entity Public Float, Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_EntityPublicFloatThreshold" xlink:href="vtvt-20260630.xsd#vtvt_EntityPublicFloatThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_EntityPublicFloatThreshold" xlink:to="lab_vtvt_EntityPublicFloatThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</link:label>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:to="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_019e6a7f-3c97-7a41-89eb-6d0809f72f82_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_OtherIndicationMember_019e6a7f-3bcc-7a3a-ad65-0ed64deabe28_terseLabel_en-US" xlink:label="lab_vtvt_OtherIndicationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Indication</link:label>
    <link:label id="lab_vtvt_OtherIndicationMember_label_en-US" xlink:label="lab_vtvt_OtherIndicationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Indication [Member]</link:label>
    <link:label id="lab_vtvt_OtherIndicationMember_documentation_en-US" xlink:label="lab_vtvt_OtherIndicationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other indication.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_OtherIndicationMember" xlink:href="vtvt-20260630.xsd#vtvt_OtherIndicationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_OtherIndicationMember" xlink:to="lab_vtvt_OtherIndicationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_019e6a7f-3c96-7023-a060-2bc829133cf7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock Award Activity for the Period</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_019e6a7f-3bcc-736e-a114-8c96f1840b9e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019e6a7f-3bcd-7a30-b4da-064355afd18c_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_PercentageOfNonVotingEconomicInterestByParent_019e6a7f-3c96-7c4e-8ba6-516c6d1c005a_terseLabel_en-US" xlink:label="lab_vtvt_PercentageOfNonVotingEconomicInterestByParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of non-voting economic interest of vTv Therapeutics Inc in vTv LLC</link:label>
    <link:label id="lab_vtvt_PercentageOfNonVotingEconomicInterestByParent_label_en-US" xlink:label="lab_vtvt_PercentageOfNonVotingEconomicInterestByParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Non Voting Economic Interest By Parent</link:label>
    <link:label id="lab_vtvt_PercentageOfNonVotingEconomicInterestByParent_documentation_en-US" xlink:label="lab_vtvt_PercentageOfNonVotingEconomicInterestByParent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of non voting economic interest by parent.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PercentageOfNonVotingEconomicInterestByParent" xlink:href="vtvt-20260630.xsd#vtvt_PercentageOfNonVotingEconomicInterestByParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_PercentageOfNonVotingEconomicInterestByParent" xlink:to="lab_vtvt_PercentageOfNonVotingEconomicInterestByParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_019e6a7f-3c97-7c12-8519-3e9e843b1902_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Description of Business and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_019e6a7f-3bcc-7e16-a0e2-29ef32e99f31_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_019e6a7f-3c97-7d8b-bd15-9d9a8bfb3cf4_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyMember_019e6a7f-3c97-7774-b6bd-805d1d7adefc_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyMember_label_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyMember" xlink:to="lab_us-gaap_RelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_019e6a7f-3bcc-77e6-b39e-11967d2fb2d4_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class Of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis_019e6a7f-3c96-7ef9-b6e0-d7bb8ce17697_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Conversion Description</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Conversion Description [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassAMember_019e6a7f-3c96-78a6-bf36-9d4f2c005ec9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class A Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonClassAMember_label_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Class A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonClassAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_019e6a7f-3bcd-7ca9-bfa3-ef4254455d8c_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_019e6a7f-3c97-72e1-90a0-5236db384ecf_netLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Less: net loss attributable to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_019e6a7f-3c97-7735-83f7-f09df6837225_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss attributable to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_019e6a7f-3c97-702b-b913-39c45ecd0350_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Less: Net loss attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_OtherProjectsMember_019e6a7f-3bcc-7515-b091-d8e160357ae4_terseLabel_en-US" xlink:label="lab_vtvt_OtherProjectsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other projects</link:label>
    <link:label id="lab_vtvt_OtherProjectsMember_label_en-US" xlink:label="lab_vtvt_OtherProjectsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Projects [Member]</link:label>
    <link:label id="lab_vtvt_OtherProjectsMember_documentation_en-US" xlink:label="lab_vtvt_OtherProjectsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Projects</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_OtherProjectsMember" xlink:href="vtvt-20260630.xsd#vtvt_OtherProjectsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_OtherProjectsMember" xlink:to="lab_vtvt_OtherProjectsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_019e6a7f-3c97-718a-8ade-670ed799f658_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_019e6a7f-3c97-788a-b983-4e00659da892_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_019e6a7f-3bcd-74c6-9b63-8aae54ef679f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Commitments</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsAxis" xlink:to="lab_us-gaap_OtherCommitmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_019ea759-2cab-76a4-850c-b086239c338e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net shares withheld for tax withholding related to the settlement of equity awards (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_019e6a7f-3bcc-7f69-93b4-00ca7db21c4e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_019e6a7f-3c97-76ba-8adb-a63cc8b21911_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock split conversion ratio</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_019e6a7f-3bcd-7cbe-b7ae-a9e1b5399795_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-qualified stock option awards expiration term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_019e6a7f-3bcc-7c46-b173-2c567209d800_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_019e6a7f-3bcd-73f7-ba58-ebba1eaef734_verboseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember_019e6a7f-3c96-765a-a98f-f14b89a41214_terseLabel_en-US" xlink:label="lab_vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exchange of Redeemable Non controlling Interest to Class A Common Stock</link:label>
    <link:label id="lab_vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember_label_en-US" xlink:label="lab_vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exchange Of Redeemable Non Controlling Interest To Class A Common Stock [Member]</link:label>
    <link:label id="lab_vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember_documentation_en-US" xlink:label="lab_vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exchange of redeemable non controlling interest to class A common stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember" xlink:href="vtvt-20260630.xsd#vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember" xlink:to="lab_vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_019e6a7f-3c97-7262-8657-4e467cc0a56e_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_019e6a7f-3bcd-772a-91b2-3a2ea7f651a0_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_019e6a7f-3bcc-7415-99e9-e6de8e74455b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_019e6a7f-3bcd-78ea-a7a0-39389b945d43_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_019e6a7f-3bcd-7e8f-8077-5e1667cd851d_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_019e6a7f-3bcd-7933-abc1-0eb7c814aea6_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract liabilities, noncurrent</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_ScheduleOfEarningsPerShareTable_019e6a7f-3c96-7a51-ac07-50d19acb73bb_terseLabel_en-US" xlink:label="lab_vtvt_ScheduleOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Earnings Per Share [Table]</link:label>
    <link:label id="lab_vtvt_ScheduleOfEarningsPerShareTable_label_en-US" xlink:label="lab_vtvt_ScheduleOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Earnings Per Share [Table]</link:label>
    <link:label id="lab_vtvt_ScheduleOfEarningsPerShareTable_documentation_en-US" xlink:label="lab_vtvt_ScheduleOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ScheduleOfEarningsPerShareTable" xlink:href="vtvt-20260630.xsd#vtvt_ScheduleOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_ScheduleOfEarningsPerShareTable" xlink:to="lab_vtvt_ScheduleOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_019e6a7f-3c96-7a45-8751-2b17ab3662b5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_019e6a7f-3c96-7728-b72e-1f2729e88e3d_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_SalesBasedMilestonesPaymentMember_019e6a7f-3bcc-73f1-b214-28ebd62d525c_terseLabel_en-US" xlink:label="lab_vtvt_SalesBasedMilestonesPaymentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales-Based Milestones Payment</link:label>
    <link:label id="lab_vtvt_SalesBasedMilestonesPaymentMember_label_en-US" xlink:label="lab_vtvt_SalesBasedMilestonesPaymentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Based Milestones Payment [Member]</link:label>
    <link:label id="lab_vtvt_SalesBasedMilestonesPaymentMember_documentation_en-US" xlink:label="lab_vtvt_SalesBasedMilestonesPaymentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sales-based milestones payment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SalesBasedMilestonesPaymentMember" xlink:href="vtvt-20260630.xsd#vtvt_SalesBasedMilestonesPaymentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_SalesBasedMilestonesPaymentMember" xlink:to="lab_vtvt_SalesBasedMilestonesPaymentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019e6a7f-3bcc-77f1-816e-646c85f126ef_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net (loss) income before income taxes and noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_019e6a7f-3bcc-79b1-9546-14dcbf737325_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_019e6a7f-3c97-7951-b9e0-28555fdb111c_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_019e6a7f-3bcd-7520-a81b-8151c5ee0a1e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_019e6a7f-3bcc-7159-9a93-ac4fef624580_terseLabel_en-US" xlink:label="lab_vtvt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_vtvt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_vtvt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Non-Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:label id="lab_vtvt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_documentation_en-US" xlink:label="lab_vtvt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Non-Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="vtvt-20260630.xsd#vtvt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_vtvt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_LicenseFeeReceived_019e6a7f-3bcc-7522-92de-968139baf844_terseLabel_en-US" xlink:label="lab_vtvt_LicenseFeeReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License fee received</link:label>
    <link:label id="lab_vtvt_LicenseFeeReceived_label_en-US" xlink:label="lab_vtvt_LicenseFeeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Fee Received</link:label>
    <link:label id="lab_vtvt_LicenseFeeReceived_documentation_en-US" xlink:label="lab_vtvt_LicenseFeeReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Fee Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LicenseFeeReceived" xlink:href="vtvt-20260630.xsd#vtvt_LicenseFeeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_LicenseFeeReceived" xlink:to="lab_vtvt_LicenseFeeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_019e6a7f-3c97-761a-903a-c8975e1c8e10_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-qualified stock option awards vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_019e6a7f-3c96-759e-8cda-3e90e6f70991_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019e6a7f-3bcc-7fc5-94cb-ce4110a1a8c9_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_IPLicenseMember_019e6a7f-3c97-72a8-838a-9f2dcac87cff_terseLabel_en-US" xlink:label="lab_vtvt_IPLicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IP License</link:label>
    <link:label id="lab_vtvt_IPLicenseMember_label_en-US" xlink:label="lab_vtvt_IPLicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IP License [Member]</link:label>
    <link:label id="lab_vtvt_IPLicenseMember_documentation_en-US" xlink:label="lab_vtvt_IPLicenseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">IP License</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_IPLicenseMember" xlink:href="vtvt-20260630.xsd#vtvt_IPLicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_IPLicenseMember" xlink:to="lab_vtvt_IPLicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_019e6a7f-3bcd-7037-9bb4-4968c0b0e967_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options exercisable, weighted average remaining contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted-Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e6a7f-3bcd-7adc-bd12-58f9f8f6a9bd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_019e6a7f-3c96-7631-9ca8-41a91ab1e5eb_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options vested and expected to vest, weighted average remaining contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted-Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_019e6a7f-3c97-71f1-9264-24445bfad7df_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from collaborative arrangement</link:label>
    <link:label id="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_label_en-US" xlink:label="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:to="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_019e6a7f-3bcc-7063-809c-28a75e3825cd_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_019e6a7f-3bcd-7878-8327-c3bcffa00a78_terseLabel_en-US" xlink:label="lab_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable (in usd per share)</link:label>
    <link:label id="lab_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:label id="lab_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_documentation_en-US" xlink:label="lab_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:href="vtvt-20260630.xsd#vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_019e6a7f-3c96-7350-96bf-cded287513bb_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_019e6a7f-3bcc-7c61-a02d-8e6b571c9699_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock_019e6a7f-3bcc-7468-9d36-66dcd8a7ff12_terseLabel_en-US" xlink:label="lab_vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unaudited Interim Financial Information</link:label>
    <link:label id="lab_vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock_label_en-US" xlink:label="lab_vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unaudited Interim Financial Information Policy [Policy Text Block]</link:label>
    <link:label id="lab_vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unaudited interim financial information policy.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock" xlink:href="vtvt-20260630.xsd#vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock" xlink:to="lab_vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019e6a7f-3bcc-77b1-8e3d-eda034d847ca_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Total cash and cash equivalents, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019e6a7f-3bcc-7029-9f5f-ddc78b517c1c_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Total cash and cash equivalents, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019e6a7f-3bcc-77ea-9edb-52f39d815295_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_019e6a7f-3c96-77c1-b3ec-54aa14122555_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_NumberOfForeignCollaborationPartners_019e6a7f-3bcc-762b-a2d6-2ff0dc0f9c28_terseLabel_en-US" xlink:label="lab_vtvt_NumberOfForeignCollaborationPartners" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of foreign collaboration partners</link:label>
    <link:label id="lab_vtvt_NumberOfForeignCollaborationPartners_label_en-US" xlink:label="lab_vtvt_NumberOfForeignCollaborationPartners" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Foreign Collaboration Partners</link:label>
    <link:label id="lab_vtvt_NumberOfForeignCollaborationPartners_documentation_en-US" xlink:label="lab_vtvt_NumberOfForeignCollaborationPartners" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Foreign Collaboration Partners</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_NumberOfForeignCollaborationPartners" xlink:href="vtvt-20260630.xsd#vtvt_NumberOfForeignCollaborationPartners"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_NumberOfForeignCollaborationPartners" xlink:to="lab_vtvt_NumberOfForeignCollaborationPartners" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</link:label>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:to="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_019e6a7f-3c97-7096-894e-ed5df91f663c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_CommercialSupplyAgreementMember_019e6a7f-3bcd-78d1-be18-f12714c0fee2_terseLabel_en-US" xlink:label="lab_vtvt_CommercialSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial Supply Agreement</link:label>
    <link:label id="lab_vtvt_CommercialSupplyAgreementMember_label_en-US" xlink:label="lab_vtvt_CommercialSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Supply Agreement [Member]</link:label>
    <link:label id="lab_vtvt_CommercialSupplyAgreementMember_documentation_en-US" xlink:label="lab_vtvt_CommercialSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commercial Supply Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CommercialSupplyAgreementMember" xlink:href="vtvt-20260630.xsd#vtvt_CommercialSupplyAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_CommercialSupplyAgreementMember" xlink:to="lab_vtvt_CommercialSupplyAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_019e6a7f-3bcd-7ed1-aa1e-8e4204ec7ae9_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic net (loss) income per share of vTv Therapeutics Inc. Class A common stock (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_019e6a7f-3bcd-7b13-939c-58a5f3ae7d2c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic net (loss) income per share of vTv Therapeutics Inc. Class A common stock (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_019e6a7f-3c97-73c7-b18a-77302f821dcd_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_019e6a7f-3bcd-7b14-a5cd-6315845a5273_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_019e6a7f-3bcd-79fd-b1b5-2e8f9f5b863c_periodStartLabel_en-US" xlink:label="lab_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price beginning balance (in usd per share)</link:label>
    <link:label id="lab_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_019e6a7f-3bcd-7a12-aea9-7313b2a513d3_periodEndLabel_en-US" xlink:label="lab_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price ending balance ( in usd per share)</link:label>
    <link:label id="lab_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label id="lab_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_documentation_en-US" xlink:label="lab_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:href="vtvt-20260630.xsd#vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_ReportableSegmentMember_019e6a7f-3bcd-7643-bff3-c5a598a1630f_terseLabel_en-US" xlink:label="lab_vtvt_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reportable Segment</link:label>
    <link:label id="lab_vtvt_ReportableSegmentMember_label_en-US" xlink:label="lab_vtvt_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reportable Segment [Member]</link:label>
    <link:label id="lab_vtvt_ReportableSegmentMember_documentation_en-US" xlink:label="lab_vtvt_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reportable Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ReportableSegmentMember" xlink:href="vtvt-20260630.xsd#vtvt_ReportableSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_ReportableSegmentMember" xlink:to="lab_vtvt_ReportableSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_019e6a7f-3c96-7634-8ed2-acd58a46fe5f_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_019e6a7f-3c96-7cd2-ba75-6b3c7e99f266_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_019e6a7f-3c96-7b12-9f0c-a81a5b9223d6_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_019e6a7f-3bcc-7ba9-bab2-9a411e472ec3_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_019e6a7f-3bcd-74e7-a78f-f6c331a0bd18_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_CognaMember_019e6a7f-3c97-77b2-9cef-54bd3cbd9b2a_terseLabel_en-US" xlink:label="lab_vtvt_CognaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cogna</link:label>
    <link:label id="lab_vtvt_CognaMember_label_en-US" xlink:label="lab_vtvt_CognaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cogna [Member]</link:label>
    <link:label id="lab_vtvt_CognaMember_documentation_en-US" xlink:label="lab_vtvt_CognaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cogna</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CognaMember" xlink:href="vtvt-20260630.xsd#vtvt_CognaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_CognaMember" xlink:to="lab_vtvt_CognaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_019e6a7f-3bcc-7d39-8d1d-74d85f603067_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_TDCowenSalesAgreementMember_019e6a7f-3c97-7b3b-b652-52a67ebeede6_terseLabel_en-US" xlink:label="lab_vtvt_TDCowenSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TD Cowen Sales Agreement</link:label>
    <link:label id="lab_vtvt_TDCowenSalesAgreementMember_label_en-US" xlink:label="lab_vtvt_TDCowenSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TD Cowen Sales Agreement [Member]</link:label>
    <link:label id="lab_vtvt_TDCowenSalesAgreementMember_documentation_en-US" xlink:label="lab_vtvt_TDCowenSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">TD Cowen Sales Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_TDCowenSalesAgreementMember" xlink:href="vtvt-20260630.xsd#vtvt_TDCowenSalesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_TDCowenSalesAgreementMember" xlink:to="lab_vtvt_TDCowenSalesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="lab_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_019e6a7f-3bcc-7e22-ad71-d67361af6faa_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_019e6a7f-3c96-7031-a762-e1e18a798cd1_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_019e6a7f-3c97-7403-9018-bf9ab8f5c3df_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_019e6a7f-3c97-72d7-92d2-c190ca4d92c1_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock options granted under the Plan</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_019e6a7f-3c96-7cfb-b6e9-5cd30f249a4c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_019e6a7f-3c97-73ab-9b85-3cfe7b576f45_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_CommitmentsAndContingenciesTable_019e6a7f-3c96-74d3-94f9-f45d1f8d1617_terseLabel_en-US" xlink:label="lab_vtvt_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:label id="lab_vtvt_CommitmentsAndContingenciesTable_label_en-US" xlink:label="lab_vtvt_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:label id="lab_vtvt_CommitmentsAndContingenciesTable_documentation_en-US" xlink:label="lab_vtvt_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CommitmentsAndContingenciesTable" xlink:href="vtvt-20260630.xsd#vtvt_CommitmentsAndContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_CommitmentsAndContingenciesTable" xlink:to="lab_vtvt_CommitmentsAndContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_019e6a7f-3c97-7334-bdae-8b9830829a11_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_019e6a7f-3bcc-78cf-b9f2-07667d5d7037_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ParentMember_019e6a7f-3c97-74d8-b400-4cac4bdab277_verboseLabel_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total vTv Therapeutics Inc Stockholders&#8217; Equity (Deficit)</link:label>
    <link:label id="lab_us-gaap_ParentMember_label_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember" xlink:to="lab_us-gaap_ParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_StockWarrantMember_019e6a7f-3bcd-7727-9c4d-0150b8a851ea_terseLabel_en-US" xlink:label="lab_vtvt_StockWarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Warrant</link:label>
    <link:label id="lab_vtvt_StockWarrantMember_label_en-US" xlink:label="lab_vtvt_StockWarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Warrant [Member]</link:label>
    <link:label id="lab_vtvt_StockWarrantMember_documentation_en-US" xlink:label="lab_vtvt_StockWarrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Warrant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_StockWarrantMember" xlink:href="vtvt-20260630.xsd#vtvt_StockWarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_StockWarrantMember" xlink:to="lab_vtvt_StockWarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_terseLabel_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_label_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:to="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_019e6a7f-3bcc-7c88-ba64-0287ed5bb381_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_019e6a7f-3bcc-786b-b3ca-ba2872d9f1ec_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_019e6a7f-3bcd-746c-932d-f2e82513a8c1_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, price per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_019e6a7f-3bcd-7d51-973e-7cd1757056bf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Expired or cancelled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_019e6a7f-3bcd-71cf-ac33-7a5dbde838df_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_019e6a7f-3c97-79f9-936c-3c364a7c4333_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_G42AgreementsMember_019e6a7f-3c97-7fda-bcf9-4f94283158e2_terseLabel_en-US" xlink:label="lab_vtvt_G42AgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">G42 Agreements</link:label>
    <link:label id="lab_vtvt_G42AgreementsMember_label_en-US" xlink:label="lab_vtvt_G42AgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">G42 Agreements [Member]</link:label>
    <link:label id="lab_vtvt_G42AgreementsMember_documentation_en-US" xlink:label="lab_vtvt_G42AgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">G42 Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_G42AgreementsMember" xlink:href="vtvt-20260630.xsd#vtvt_G42AgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_G42AgreementsMember" xlink:to="lab_vtvt_G42AgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_019e6a7f-3c96-7b21-957a-2dbaefbec7ad_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_019e6a7f-3bcd-7b1b-9575-3aaab12fb9fa_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Current Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_WeightedAverageNumberOfDilutedSharesOutstandingAbstract_019e6a7f-3bcd-74b9-9f74-5028541e775a_verboseLabel_en-US" xlink:label="lab_vtvt_WeightedAverageNumberOfDilutedSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_vtvt_WeightedAverageNumberOfDilutedSharesOutstandingAbstract_label_en-US" xlink:label="lab_vtvt_WeightedAverageNumberOfDilutedSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number Of Diluted Shares Outstanding [Abstract]</link:label>
    <link:label id="lab_vtvt_WeightedAverageNumberOfDilutedSharesOutstandingAbstract_documentation_en-US" xlink:label="lab_vtvt_WeightedAverageNumberOfDilutedSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted Average Number Of Diluted Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_WeightedAverageNumberOfDilutedSharesOutstandingAbstract" xlink:href="vtvt-20260630.xsd#vtvt_WeightedAverageNumberOfDilutedSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_WeightedAverageNumberOfDilutedSharesOutstandingAbstract" xlink:to="lab_vtvt_WeightedAverageNumberOfDilutedSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_019e6a7f-3bcc-701b-b203-1b2cd4925216_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_019e6a7f-3bcc-713f-9ddd-c25c0f778588_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_019e6a7f-3bcd-7dc4-b893-a12d73fa8739_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_CommonWarrantsMember_019e6a7f-3c96-748a-80ab-ccbb187b5625_terseLabel_en-US" xlink:label="lab_vtvt_CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Warrants</link:label>
    <link:label id="lab_vtvt_CommonWarrantsMember_label_en-US" xlink:label="lab_vtvt_CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Warrants [Member]</link:label>
    <link:label id="lab_vtvt_CommonWarrantsMember_documentation_en-US" xlink:label="lab_vtvt_CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CommonWarrantsMember" xlink:href="vtvt-20260630.xsd#vtvt_CommonWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_CommonWarrantsMember" xlink:to="lab_vtvt_CommonWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_DirectResearchAndDevelopmentExpense_019e6a7f-3bcd-75a8-89ac-c862817b1a46_terseLabel_en-US" xlink:label="lab_vtvt_DirectResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Direct research and development expense</link:label>
    <link:label id="lab_vtvt_DirectResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_vtvt_DirectResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Direct Research and Development Expense</link:label>
    <link:label id="lab_vtvt_DirectResearchAndDevelopmentExpense_documentation_en-US" xlink:label="lab_vtvt_DirectResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Direct Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_DirectResearchAndDevelopmentExpense" xlink:href="vtvt-20260630.xsd#vtvt_DirectResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_DirectResearchAndDevelopmentExpense" xlink:to="lab_vtvt_DirectResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_019e6a7f-3c97-7558-ad23-33e19f7c79b2_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding number of beginning balance( in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_019e6a7f-3c97-778b-aacd-a70af928ae27_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding number of ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_019e6a7f-3bcc-72cc-9a72-686297290751_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_019e6a7f-3bcd-71d0-a777-9370c63f5de5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Stock By Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_019e6a7f-3bcc-7dd3-9461-c7afe9a5f0f2_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net (loss) income before noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_019e6a7f-3bcc-7614-a9f1-942e67df3cbb_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) before noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_019e6a7f-3bcc-782a-9389-d90aa0fe284b_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net (loss) income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_019e6a7f-3bcd-7631-a96a-8da2d3a752a0_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_019e6a7f-3bcc-762f-a111-4da9bfa21b65_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_CommonStockParOrStatedValueOfPrivatePlacementPreFundedWarrantsShares_019e6a7f-3c96-7369-adc0-f5043301563f_terseLabel_en-US" xlink:label="lab_vtvt_CommonStockParOrStatedValueOfPrivatePlacementPreFundedWarrantsShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Private placement pre-funded warrants, shares (in shares)</link:label>
    <link:label id="lab_vtvt_CommonStockParOrStatedValueOfPrivatePlacementPreFundedWarrantsShares_label_en-US" xlink:label="lab_vtvt_CommonStockParOrStatedValueOfPrivatePlacementPreFundedWarrantsShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value of Private Placement Pre-Funded Warrants, Shares</link:label>
    <link:label id="lab_vtvt_CommonStockParOrStatedValueOfPrivatePlacementPreFundedWarrantsShares_documentation_en-US" xlink:label="lab_vtvt_CommonStockParOrStatedValueOfPrivatePlacementPreFundedWarrantsShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value of Private Placement Pre-Funded Warrants, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CommonStockParOrStatedValueOfPrivatePlacementPreFundedWarrantsShares" xlink:href="vtvt-20260630.xsd#vtvt_CommonStockParOrStatedValueOfPrivatePlacementPreFundedWarrantsShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_CommonStockParOrStatedValueOfPrivatePlacementPreFundedWarrantsShares" xlink:to="lab_vtvt_CommonStockParOrStatedValueOfPrivatePlacementPreFundedWarrantsShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_019e6a7f-3bcd-78ef-af2a-23640f2e52ee_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax provision</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_CommonStockParOrStatedValueOfPrivatePlacementShares_019e6a7f-3c97-7b04-81e1-c0269fc2b031_negatedTerseLabel_en-US" xlink:label="lab_vtvt_CommonStockParOrStatedValueOfPrivatePlacementShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Private placement, shares (in shares)</link:label>
    <link:label id="lab_vtvt_CommonStockParOrStatedValueOfPrivatePlacementShares_label_en-US" xlink:label="lab_vtvt_CommonStockParOrStatedValueOfPrivatePlacementShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value of Private Placement, Shares</link:label>
    <link:label id="lab_vtvt_CommonStockParOrStatedValueOfPrivatePlacementShares_documentation_en-US" xlink:label="lab_vtvt_CommonStockParOrStatedValueOfPrivatePlacementShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value of Private Placement, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CommonStockParOrStatedValueOfPrivatePlacementShares" xlink:href="vtvt-20260630.xsd#vtvt_CommonStockParOrStatedValueOfPrivatePlacementShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_CommonStockParOrStatedValueOfPrivatePlacementShares" xlink:to="lab_vtvt_CommonStockParOrStatedValueOfPrivatePlacementShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_019e6a7f-3bcc-7e07-8b06-4092b0c1bf8b_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019e6a7f-3bcc-788b-9116-55e7c4cd13c3_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net decrease in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_019e6a7f-3bcc-7858-991b-1830fc94024d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts and financing receivable, after allowance for credit loss, current</link:label>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts and Financing Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsNotesAndLoansReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_019e6a7f-3c97-76ce-90d8-4099175e3f4f_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract" xlink:to="lab_us-gaap_NetIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_019e6a7f-3bcc-7bfe-a871-ee48c0e40134_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net (loss) income attributable to vTv Therapeutics Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_019e6a7f-3bcc-74d1-bd06-50c2a4c8da07_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) attributable to vTv Therapeutics Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_019e6a7f-3c96-7a3c-9550-193f9a7d857d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_019e6a7f-3bcd-72fb-a9f5-85a5aee421a1_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additionally number of securities called by warrants or rights (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_019e6a7f-3bcd-7bbb-8bc5-25391987a06d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from the exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_019e6a7f-3c97-7a68-949f-7ca7d1a5691a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_019e6a7f-3c96-7f7d-9da9-1e24c0da99f5_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_019e6a7f-3bcd-75fe-8d60-61c8398cb61d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options exercisable (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_OwnershipPercentageOfMajorityOwner_019e6a7f-3c97-7cda-9b0c-5ad28b9fa644_terseLabel_en-US" xlink:label="lab_vtvt_OwnershipPercentageOfMajorityOwner" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership percentage of majority owner</link:label>
    <link:label id="lab_vtvt_OwnershipPercentageOfMajorityOwner_label_en-US" xlink:label="lab_vtvt_OwnershipPercentageOfMajorityOwner" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership Percentage Of Majority Owner</link:label>
    <link:label id="lab_vtvt_OwnershipPercentageOfMajorityOwner_documentation_en-US" xlink:label="lab_vtvt_OwnershipPercentageOfMajorityOwner" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ownership percentage of majority owner.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_OwnershipPercentageOfMajorityOwner" xlink:href="vtvt-20260630.xsd#vtvt_OwnershipPercentageOfMajorityOwner"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_OwnershipPercentageOfMajorityOwner" xlink:to="lab_vtvt_OwnershipPercentageOfMajorityOwner" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:to="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>vtvt-20260630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019e6a7f-3a2c-7e30-acc1-d5ae4ae8f1fc,g:0d1f2584-f555-42ce-b27a-904151cd021c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/Cover" xlink:type="simple" xlink:href="vtvt-20260630.xsd#Cover"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_019e6a7f-3af5-7779-a9ab-9a2ea1851377" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_019e6a7f-3af5-724c-93e4-1a83e2aae079" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e6a7f-3af5-7779-a9ab-9a2ea1851377" xlink:to="loc_dei_DocumentInformationTable_019e6a7f-3af5-724c-93e4-1a83e2aae079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_019e6a7f-3af5-7370-8628-7fb0409ba69a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_019e6a7f-3af5-724c-93e4-1a83e2aae079" xlink:to="loc_us-gaap_StatementClassOfStockAxis_019e6a7f-3af5-7370-8628-7fb0409ba69a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019e6a7f-3af5-76ec-a1cd-6c3e8df4f27f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019e6a7f-3af5-7370-8628-7fb0409ba69a" xlink:to="loc_us-gaap_ClassOfStockDomain_019e6a7f-3af5-76ec-a1cd-6c3e8df4f27f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_019e6a7f-3af5-71fc-a665-52dbe815a896" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_019e6a7f-3af5-76ec-a1cd-6c3e8df4f27f" xlink:to="loc_us-gaap_CommonClassAMember_019e6a7f-3af5-71fc-a665-52dbe815a896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_019e6a7f-3af5-7ec9-8ece-644b18d8bc4d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_019e6a7f-3af5-76ec-a1cd-6c3e8df4f27f" xlink:to="loc_us-gaap_CommonClassBMember_019e6a7f-3af5-7ec9-8ece-644b18d8bc4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_019e6a7f-3af5-7042-91e1-c51470aa60e6" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_019e6a7f-3af5-724c-93e4-1a83e2aae079" xlink:to="loc_dei_DocumentInformationLineItems_019e6a7f-3af5-7042-91e1-c51470aa60e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_019e6a7f-3af5-7980-814b-98c1933a1e67" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019e6a7f-3af5-7042-91e1-c51470aa60e6" xlink:to="loc_dei_DocumentType_019e6a7f-3af5-7980-814b-98c1933a1e67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_019e6a7f-3af5-7364-9d17-27329d533625" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019e6a7f-3af5-7042-91e1-c51470aa60e6" xlink:to="loc_dei_DocumentQuarterlyReport_019e6a7f-3af5-7364-9d17-27329d533625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_019e6a7f-3af5-736a-9a63-3111df183dbc" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019e6a7f-3af5-7042-91e1-c51470aa60e6" xlink:to="loc_dei_DocumentPeriodEndDate_019e6a7f-3af5-736a-9a63-3111df183dbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_019e6a7f-3af5-7b35-9947-1a21e9942ce3" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019e6a7f-3af5-7042-91e1-c51470aa60e6" xlink:to="loc_dei_DocumentTransitionReport_019e6a7f-3af5-7b35-9947-1a21e9942ce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_019e6a7f-3af5-7c1c-ba20-19a4310ba7ba" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019e6a7f-3af5-7042-91e1-c51470aa60e6" xlink:to="loc_dei_EntityFileNumber_019e6a7f-3af5-7c1c-ba20-19a4310ba7ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_019e6a7f-3af5-7b07-aea0-d384ce36453d" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019e6a7f-3af5-7042-91e1-c51470aa60e6" xlink:to="loc_dei_EntityRegistrantName_019e6a7f-3af5-7b07-aea0-d384ce36453d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_019e6a7f-3af5-75ff-8c5c-e0a482c9a74e" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019e6a7f-3af5-7042-91e1-c51470aa60e6" xlink:to="loc_dei_EntityIncorporationStateCountryCode_019e6a7f-3af5-75ff-8c5c-e0a482c9a74e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_019e6a7f-3af5-7c8d-a326-3fcfdaff41a6" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019e6a7f-3af5-7042-91e1-c51470aa60e6" xlink:to="loc_dei_EntityTaxIdentificationNumber_019e6a7f-3af5-7c8d-a326-3fcfdaff41a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_019e6a7f-3af5-7773-827c-107a79c06a0a" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019e6a7f-3af5-7042-91e1-c51470aa60e6" xlink:to="loc_dei_EntityAddressAddressLine1_019e6a7f-3af5-7773-827c-107a79c06a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_019e6a7f-3af5-752e-88f3-5986cb49b3ee" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019e6a7f-3af5-7042-91e1-c51470aa60e6" xlink:to="loc_dei_EntityAddressAddressLine2_019e6a7f-3af5-752e-88f3-5986cb49b3ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_019e6a7f-3af5-78ed-a4aa-a98951cb07c7" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019e6a7f-3af5-7042-91e1-c51470aa60e6" xlink:to="loc_dei_EntityAddressCityOrTown_019e6a7f-3af5-78ed-a4aa-a98951cb07c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_019e6a7f-3af5-76ee-a52c-0d59a03b85ee" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019e6a7f-3af5-7042-91e1-c51470aa60e6" xlink:to="loc_dei_EntityAddressStateOrProvince_019e6a7f-3af5-76ee-a52c-0d59a03b85ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_019e6a7f-3af5-7bce-b291-0ff3f2dd2830" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019e6a7f-3af5-7042-91e1-c51470aa60e6" xlink:to="loc_dei_EntityAddressPostalZipCode_019e6a7f-3af5-7bce-b291-0ff3f2dd2830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_019e6a7f-3af5-79fb-b0b0-770eea679c96" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019e6a7f-3af5-7042-91e1-c51470aa60e6" xlink:to="loc_dei_CityAreaCode_019e6a7f-3af5-79fb-b0b0-770eea679c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_019e6a7f-3af5-7b7e-b703-3d2ba9561559" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019e6a7f-3af5-7042-91e1-c51470aa60e6" xlink:to="loc_dei_LocalPhoneNumber_019e6a7f-3af5-7b7e-b703-3d2ba9561559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_019e6a7f-3af5-780a-ac95-69012f715164" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019e6a7f-3af5-7042-91e1-c51470aa60e6" xlink:to="loc_dei_Security12bTitle_019e6a7f-3af5-780a-ac95-69012f715164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_019e6a7f-3af5-7255-bfde-c90f039bdca1" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019e6a7f-3af5-7042-91e1-c51470aa60e6" xlink:to="loc_dei_TradingSymbol_019e6a7f-3af5-7255-bfde-c90f039bdca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_019e6a7f-3af5-7cf8-80fd-16f5c47287c2" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019e6a7f-3af5-7042-91e1-c51470aa60e6" xlink:to="loc_dei_SecurityExchangeName_019e6a7f-3af5-7cf8-80fd-16f5c47287c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_019e6a7f-3af5-75d7-a6e0-edf378323a0c" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019e6a7f-3af5-7042-91e1-c51470aa60e6" xlink:to="loc_dei_EntityCurrentReportingStatus_019e6a7f-3af5-75d7-a6e0-edf378323a0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_019e6a7f-3af5-76ac-acf2-560ab3efedda" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019e6a7f-3af5-7042-91e1-c51470aa60e6" xlink:to="loc_dei_EntityInteractiveDataCurrent_019e6a7f-3af5-76ac-acf2-560ab3efedda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_019e6a7f-3af5-7da2-be19-d380be1ecde2" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019e6a7f-3af5-7042-91e1-c51470aa60e6" xlink:to="loc_dei_EntityFilerCategory_019e6a7f-3af5-7da2-be19-d380be1ecde2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_019e6a7f-3af5-7a9c-ab03-555e0b6f9c6f" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019e6a7f-3af5-7042-91e1-c51470aa60e6" xlink:to="loc_dei_EntitySmallBusiness_019e6a7f-3af5-7a9c-ab03-555e0b6f9c6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_019e6a7f-3af5-7ccd-b4d9-bed419e32dfe" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019e6a7f-3af5-7042-91e1-c51470aa60e6" xlink:to="loc_dei_EntityEmergingGrowthCompany_019e6a7f-3af5-7ccd-b4d9-bed419e32dfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_019e6a7f-3af5-7cfb-b4cc-53cdb0becf7d" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019e6a7f-3af5-7042-91e1-c51470aa60e6" xlink:to="loc_dei_EntityShellCompany_019e6a7f-3af5-7cfb-b4cc-53cdb0becf7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_019e6a7f-3af5-765e-bec6-1a96f0925c64" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019e6a7f-3af5-7042-91e1-c51470aa60e6" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_019e6a7f-3af5-765e-bec6-1a96f0925c64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_019e6a7f-3af5-7a9e-9f46-13b6a1eec98b" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019e6a7f-3af5-7042-91e1-c51470aa60e6" xlink:to="loc_dei_EntityCentralIndexKey_019e6a7f-3af5-7a9e-9f46-13b6a1eec98b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_019e6a7f-3af5-7ec3-b345-cca4e0d11927" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019e6a7f-3af5-7042-91e1-c51470aa60e6" xlink:to="loc_dei_CurrentFiscalYearEndDate_019e6a7f-3af5-7ec3-b345-cca4e0d11927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_019e6a7f-3af5-791e-be85-78193b37026f" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019e6a7f-3af5-7042-91e1-c51470aa60e6" xlink:to="loc_dei_DocumentFiscalYearFocus_019e6a7f-3af5-791e-be85-78193b37026f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_019e6a7f-3af5-7dc1-a7cc-9234df123358" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019e6a7f-3af5-7042-91e1-c51470aa60e6" xlink:to="loc_dei_DocumentFiscalPeriodFocus_019e6a7f-3af5-7dc1-a7cc-9234df123358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_019e6a7f-3af5-74da-9fd1-c71846db1e5b" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019e6a7f-3af5-7042-91e1-c51470aa60e6" xlink:to="loc_dei_AmendmentFlag_019e6a7f-3af5-74da-9fd1-c71846db1e5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="vtvt-20260630.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_019e6a7f-3af5-7b9a-ae37-0f826b6803ed" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_019e6a7f-3af5-717a-8285-6922e0974804" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019e6a7f-3af5-7b9a-ae37-0f826b6803ed" xlink:to="loc_us-gaap_StatementTable_019e6a7f-3af5-717a-8285-6922e0974804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_019e6a7f-3af5-7be7-ac97-848def498874" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_019e6a7f-3af5-717a-8285-6922e0974804" xlink:to="loc_us-gaap_StatementClassOfStockAxis_019e6a7f-3af5-7be7-ac97-848def498874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019e6a7f-3af5-7b11-83fc-3244457db648" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019e6a7f-3af5-7be7-ac97-848def498874" xlink:to="loc_us-gaap_ClassOfStockDomain_019e6a7f-3af5-7b11-83fc-3244457db648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_019e6a7f-3af5-75e2-beac-616d05f01ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_019e6a7f-3af5-7b11-83fc-3244457db648" xlink:to="loc_us-gaap_CommonClassAMember_019e6a7f-3af5-75e2-beac-616d05f01ea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_019e6a7f-3af5-7603-a81c-0293df6fa80d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_019e6a7f-3af5-7b11-83fc-3244457db648" xlink:to="loc_us-gaap_CommonClassBMember_019e6a7f-3af5-7603-a81c-0293df6fa80d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e6a7f-3af5-7df2-81fb-15440b191d43" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_019e6a7f-3af5-717a-8285-6922e0974804" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e6a7f-3af5-7df2-81fb-15440b191d43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019e6a7f-3af5-73eb-b12a-d76b95e3fda6" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e6a7f-3af5-7df2-81fb-15440b191d43" xlink:to="loc_us-gaap_RelatedPartyDomain_019e6a7f-3af5-73eb-b12a-d76b95e3fda6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_019e6a7f-3af5-7e1e-81a1-8c97e9c3eb4b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_019e6a7f-3af5-73eb-b12a-d76b95e3fda6" xlink:to="loc_us-gaap_RelatedPartyMember_019e6a7f-3af5-7e1e-81a1-8c97e9c3eb4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_019e6a7f-3af5-7d80-a689-e649cdd9e651" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_019e6a7f-3af5-73eb-b12a-d76b95e3fda6" xlink:to="loc_us-gaap_NonrelatedPartyMember_019e6a7f-3af5-7d80-a689-e649cdd9e651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_019e6a7f-3af5-71c8-b632-7b4b5a2de8c7" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_019e6a7f-3af5-717a-8285-6922e0974804" xlink:to="loc_us-gaap_StatementLineItems_019e6a7f-3af5-71c8-b632-7b4b5a2de8c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_019e6a7f-3af5-76c5-9274-e62d830be701" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019e6a7f-3af5-71c8-b632-7b4b5a2de8c7" xlink:to="loc_us-gaap_AssetsAbstract_019e6a7f-3af5-76c5-9274-e62d830be701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_019e6a7f-3af5-78d9-8ac7-b2db5abe496a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_019e6a7f-3af5-76c5-9274-e62d830be701" xlink:to="loc_us-gaap_AssetsCurrentAbstract_019e6a7f-3af5-78d9-8ac7-b2db5abe496a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019e6a7f-3af5-72cb-8901-15e60d675110" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_019e6a7f-3af5-78d9-8ac7-b2db5abe496a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019e6a7f-3af5-72cb-8901-15e60d675110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_019e6a7f-3af5-7f2e-b40d-762a9522af52" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_019e6a7f-3af5-78d9-8ac7-b2db5abe496a" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_019e6a7f-3af5-7f2e-b40d-762a9522af52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_019e6a7f-3af5-78bc-aa09-8b4edb5dff18" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_019e6a7f-3af5-78d9-8ac7-b2db5abe496a" xlink:to="loc_us-gaap_OtherAssetsCurrent_019e6a7f-3af5-78bc-aa09-8b4edb5dff18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_019e6a7f-3af5-71c7-b526-e1ed78eb84b5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_019e6a7f-3af5-78d9-8ac7-b2db5abe496a" xlink:to="loc_us-gaap_AssetsCurrent_019e6a7f-3af5-71c7-b526-e1ed78eb84b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_019e6a7f-3af5-7b1d-ae79-4805e50766e0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_019e6a7f-3af5-76c5-9274-e62d830be701" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_019e6a7f-3af5-7b1d-ae79-4805e50766e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_019e6a7f-3af5-7599-a42e-146cbf1c05d8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_019e6a7f-3af5-76c5-9274-e62d830be701" xlink:to="loc_us-gaap_Assets_019e6a7f-3af5-7599-a42e-146cbf1c05d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019e6a7f-3af5-712e-b1ac-cc3c8cea47f1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019e6a7f-3af5-71c8-b632-7b4b5a2de8c7" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019e6a7f-3af5-712e-b1ac-cc3c8cea47f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_019e6a7f-3af5-7cae-a2e7-f57d531d4328" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019e6a7f-3af5-712e-b1ac-cc3c8cea47f1" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_019e6a7f-3af5-7cae-a2e7-f57d531d4328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_019e6a7f-3af5-7d97-b813-ad17c91e749c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_019e6a7f-3af5-7cae-a2e7-f57d531d4328" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_019e6a7f-3af5-7d97-b813-ad17c91e749c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_WarrantLiabilityCurrent_019e6a7f-3af5-7f13-86e4-106f9a0bdb61" xlink:href="vtvt-20260630.xsd#vtvt_WarrantLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_019e6a7f-3af5-7cae-a2e7-f57d531d4328" xlink:to="loc_vtvt_WarrantLiabilityCurrent_019e6a7f-3af5-7f13-86e4-106f9a0bdb61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_019e6a7f-3af5-787d-856c-b6f4390f3753" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_019e6a7f-3af5-7cae-a2e7-f57d531d4328" xlink:to="loc_us-gaap_LiabilitiesCurrent_019e6a7f-3af5-787d-856c-b6f4390f3753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_019e6a7f-3af5-77bd-98c8-fda5e46d27ed" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019e6a7f-3af5-712e-b1ac-cc3c8cea47f1" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_019e6a7f-3af5-77bd-98c8-fda5e46d27ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_WarrantyLiability_019e6a7f-3af5-713b-84cc-bcca88adbd34" xlink:href="vtvt-20260630.xsd#vtvt_WarrantyLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019e6a7f-3af5-712e-b1ac-cc3c8cea47f1" xlink:to="loc_vtvt_WarrantyLiability_019e6a7f-3af5-713b-84cc-bcca88adbd34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_019e6a7f-3af5-7b65-a17a-d504c75ecbbc" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019e6a7f-3af5-712e-b1ac-cc3c8cea47f1" xlink:to="loc_us-gaap_Liabilities_019e6a7f-3af5-7b65-a17a-d504c75ecbbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_019e6a7f-3af5-778f-ba1e-3d107ac44ec6" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019e6a7f-3af5-712e-b1ac-cc3c8cea47f1" xlink:to="loc_us-gaap_CommitmentsAndContingencies_019e6a7f-3af5-778f-ba1e-3d107ac44ec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_019e6a7f-3af5-71a4-b53e-2f0185980782" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019e6a7f-3af5-712e-b1ac-cc3c8cea47f1" xlink:to="loc_us-gaap_StockholdersEquityAbstract_019e6a7f-3af5-71a4-b53e-2f0185980782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_019e6a7f-3af5-718b-a745-6f120cedeb68" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_019e6a7f-3af5-71a4-b53e-2f0185980782" xlink:to="loc_us-gaap_CommonStockValue_019e6a7f-3af5-718b-a745-6f120cedeb68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_019e6a7f-3af5-797f-89d1-4f155acd6157" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_019e6a7f-3af5-71a4-b53e-2f0185980782" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_019e6a7f-3af5-797f-89d1-4f155acd6157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019e6a7f-3af5-7f55-959e-9c8b8c5ff5ac" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_019e6a7f-3af5-71a4-b53e-2f0185980782" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019e6a7f-3af5-7f55-959e-9c8b8c5ff5ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019e6a7f-3af5-78d0-94a1-d3a601d41187" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_019e6a7f-3af5-71a4-b53e-2f0185980782" xlink:to="loc_us-gaap_StockholdersEquity_019e6a7f-3af5-78d0-94a1-d3a601d41187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_019e6a7f-3af5-7907-bb54-2bfb897aeb46" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019e6a7f-3af5-712e-b1ac-cc3c8cea47f1" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_019e6a7f-3af5-7907-bb54-2bfb897aeb46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="vtvt-20260630.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_019e6a7f-3af5-734b-988e-5a2499f2d9ed" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_019e6a7f-3af5-79b6-bb15-92b8b3e20fc4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019e6a7f-3af5-734b-988e-5a2499f2d9ed" xlink:to="loc_us-gaap_StatementTable_019e6a7f-3af5-79b6-bb15-92b8b3e20fc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_019e6a7f-3af5-7e83-92c4-c9eeddb431c2" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_019e6a7f-3af5-79b6-bb15-92b8b3e20fc4" xlink:to="loc_us-gaap_StatementClassOfStockAxis_019e6a7f-3af5-7e83-92c4-c9eeddb431c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019e6a7f-3af5-7c9f-909c-cb5c5754adb2" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019e6a7f-3af5-7e83-92c4-c9eeddb431c2" xlink:to="loc_us-gaap_ClassOfStockDomain_019e6a7f-3af5-7c9f-909c-cb5c5754adb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_019e6a7f-3af5-7616-a563-33cabd120d83" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_019e6a7f-3af5-7c9f-909c-cb5c5754adb2" xlink:to="loc_us-gaap_CommonClassAMember_019e6a7f-3af5-7616-a563-33cabd120d83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_019e6a7f-3af5-7ce0-8e2f-673e078a9216" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_019e6a7f-3af5-7c9f-909c-cb5c5754adb2" xlink:to="loc_us-gaap_CommonClassBMember_019e6a7f-3af5-7ce0-8e2f-673e078a9216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_019e6a7f-3af5-796d-a5a6-5829c749cf54" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_019e6a7f-3af5-79b6-bb15-92b8b3e20fc4" xlink:to="loc_us-gaap_StatementLineItems_019e6a7f-3af5-796d-a5a6-5829c749cf54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_019e6a7f-3af5-753a-b2d5-e22b61928592" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019e6a7f-3af5-796d-a5a6-5829c749cf54" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_019e6a7f-3af5-753a-b2d5-e22b61928592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_019e6a7f-3af5-7c5e-b8d5-c0ec4e287875" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019e6a7f-3af5-796d-a5a6-5829c749cf54" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_019e6a7f-3af5-7c5e-b8d5-c0ec4e287875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_019e6a7f-3af5-7b5b-8918-5c65cc68c43d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019e6a7f-3af5-796d-a5a6-5829c749cf54" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_019e6a7f-3af5-7b5b-8918-5c65cc68c43d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="simple" xlink:href="vtvt-20260630.xsd#CondensedConsolidatedStatementsofOperationsUnaudited"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_019e6a7f-3af5-78ff-8c45-d36c43792b38" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_019e6a7f-3af5-70c4-a250-417d25f0a51e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_019e6a7f-3af5-78ff-8c45-d36c43792b38" xlink:to="loc_us-gaap_StatementTable_019e6a7f-3af5-70c4-a250-417d25f0a51e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_019e6a7f-3af5-78e1-a451-2d6cbac6b2a8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_019e6a7f-3af5-70c4-a250-417d25f0a51e" xlink:to="loc_us-gaap_StatementClassOfStockAxis_019e6a7f-3af5-78e1-a451-2d6cbac6b2a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019e6a7f-3af5-7a1c-bbae-b2ad5f71113a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019e6a7f-3af5-78e1-a451-2d6cbac6b2a8" xlink:to="loc_us-gaap_ClassOfStockDomain_019e6a7f-3af5-7a1c-bbae-b2ad5f71113a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_019e6a7f-3af5-7427-af77-80a71c020fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_019e6a7f-3af5-7a1c-bbae-b2ad5f71113a" xlink:to="loc_us-gaap_CommonClassAMember_019e6a7f-3af5-7427-af77-80a71c020fb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e6a7f-3af5-759c-bab0-2ef6b5c90ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_019e6a7f-3af5-70c4-a250-417d25f0a51e" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e6a7f-3af5-759c-bab0-2ef6b5c90ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019e6a7f-3af5-7c0b-8c66-3bd826634d45" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e6a7f-3af5-759c-bab0-2ef6b5c90ca9" xlink:to="loc_us-gaap_RelatedPartyDomain_019e6a7f-3af5-7c0b-8c66-3bd826634d45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_019e6a7f-3af5-7478-b468-24bac58a5d68" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_019e6a7f-3af5-7c0b-8c66-3bd826634d45" xlink:to="loc_us-gaap_NonrelatedPartyMember_019e6a7f-3af5-7478-b468-24bac58a5d68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_019e6a7f-3af5-7bee-a394-f96c229cefb3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_019e6a7f-3af5-7c0b-8c66-3bd826634d45" xlink:to="loc_us-gaap_RelatedPartyMember_019e6a7f-3af5-7bee-a394-f96c229cefb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_019e6a7f-3af5-7938-8779-7a1c0d1a60d2" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_019e6a7f-3af5-70c4-a250-417d25f0a51e" xlink:to="loc_us-gaap_StatementLineItems_019e6a7f-3af5-7938-8779-7a1c0d1a60d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019e6a7f-3af5-76bd-aad6-965cf04931e9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019e6a7f-3af5-7938-8779-7a1c0d1a60d2" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019e6a7f-3af5-76bd-aad6-965cf04931e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_019e6a7f-3af5-7b1c-b315-2aa90a1eaf27" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019e6a7f-3af5-7938-8779-7a1c0d1a60d2" xlink:to="loc_us-gaap_OperatingExpensesAbstract_019e6a7f-3af5-7b1c-b315-2aa90a1eaf27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_019e6a7f-3af5-7754-8a71-04793603ee1a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019e6a7f-3af5-7b1c-b315-2aa90a1eaf27" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_019e6a7f-3af5-7754-8a71-04793603ee1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_019e6a7f-3af5-7366-8722-91c52772eb56" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019e6a7f-3af5-7b1c-b315-2aa90a1eaf27" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_019e6a7f-3af5-7366-8722-91c52772eb56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_019e6a7f-3af5-7b24-903c-03d180e99883" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019e6a7f-3af5-7b1c-b315-2aa90a1eaf27" xlink:to="loc_us-gaap_OperatingExpenses_019e6a7f-3af5-7b24-903c-03d180e99883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_019e6a7f-3af5-791b-a0fd-21574961ae61" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019e6a7f-3af5-7938-8779-7a1c0d1a60d2" xlink:to="loc_us-gaap_OperatingIncomeLoss_019e6a7f-3af5-791b-a0fd-21574961ae61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_019e6a7f-3af5-72ff-a905-58e3180bda50" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019e6a7f-3af5-7938-8779-7a1c0d1a60d2" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_019e6a7f-3af5-72ff-a905-58e3180bda50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_019e6a7f-3af5-71d8-b428-6491368f66e8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019e6a7f-3af5-7938-8779-7a1c0d1a60d2" xlink:to="loc_us-gaap_InvestmentIncomeInterest_019e6a7f-3af5-71d8-b428-6491368f66e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019e6a7f-3af5-764d-aa05-b7c5e6e7ab51" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019e6a7f-3af5-7938-8779-7a1c0d1a60d2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019e6a7f-3af5-764d-aa05-b7c5e6e7ab51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_019e6a7f-3af5-7439-bbbd-2065bbe7b516" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019e6a7f-3af5-7938-8779-7a1c0d1a60d2" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_019e6a7f-3af5-7439-bbbd-2065bbe7b516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_019e6a7f-3af5-728e-b061-d388aea7a890" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019e6a7f-3af5-7938-8779-7a1c0d1a60d2" xlink:to="loc_us-gaap_ProfitLoss_019e6a7f-3af5-728e-b061-d388aea7a890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_019e6a7f-3af5-7db8-aaba-5265cc3949d3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019e6a7f-3af5-7938-8779-7a1c0d1a60d2" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_019e6a7f-3af5-7db8-aaba-5265cc3949d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019e6a7f-3af5-7c27-9832-16b433b58281" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019e6a7f-3af5-7938-8779-7a1c0d1a60d2" xlink:to="loc_us-gaap_NetIncomeLoss_019e6a7f-3af5-7c27-9832-16b433b58281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_019e6a7f-3af5-7e9a-be1e-c715f208b265" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019e6a7f-3af5-7938-8779-7a1c0d1a60d2" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_019e6a7f-3af5-7e9a-be1e-c715f208b265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_019e6a7f-3af5-73c2-a579-2912dc914a5f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019e6a7f-3af5-7938-8779-7a1c0d1a60d2" xlink:to="loc_us-gaap_EarningsPerShareBasic_019e6a7f-3af5-73c2-a579-2912dc914a5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_019e6a7f-3af5-72f7-a69d-a6b396a339f0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019e6a7f-3af5-7938-8779-7a1c0d1a60d2" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_019e6a7f-3af5-72f7-a69d-a6b396a339f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_019e6a7f-3af5-7f81-89dd-6f216774cba3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019e6a7f-3af5-7938-8779-7a1c0d1a60d2" xlink:to="loc_us-gaap_EarningsPerShareDiluted_019e6a7f-3af5-7f81-89dd-6f216774cba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019e6a7f-3af5-7819-867a-b738a478e0d6" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019e6a7f-3af5-7938-8779-7a1c0d1a60d2" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019e6a7f-3af5-7819-867a-b738a478e0d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinStockholdersEquityUnaudited" xlink:type="simple" xlink:href="vtvt-20260630.xsd#CondensedConsolidatedStatementofChangesinStockholdersEquityUnaudited"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinStockholdersEquityUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_019e6a7f-3af5-7664-a9dd-d211f350d539" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_019e6a7f-3af5-7cdb-b7de-17c81f2eceb3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_019e6a7f-3af5-7664-a9dd-d211f350d539" xlink:to="loc_us-gaap_StatementTable_019e6a7f-3af5-7cdb-b7de-17c81f2eceb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_019e6a7f-3af5-7bc1-a979-d38b38dd4925" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_019e6a7f-3af5-7cdb-b7de-17c81f2eceb3" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_019e6a7f-3af5-7bc1-a979-d38b38dd4925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_019e6a7f-3af5-7150-a52c-df0195464798" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_019e6a7f-3af5-7bc1-a979-d38b38dd4925" xlink:to="loc_us-gaap_EquityComponentDomain_019e6a7f-3af5-7150-a52c-df0195464798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_019e6a7f-3af5-731c-bb92-17ac9a6083e8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_019e6a7f-3af5-7150-a52c-df0195464798" xlink:to="loc_us-gaap_ParentMember_019e6a7f-3af5-731c-bb92-17ac9a6083e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_019e6a7f-3af5-7562-8c96-e2a057c336b5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_019e6a7f-3af5-731c-bb92-17ac9a6083e8" xlink:to="loc_us-gaap_CommonStockMember_019e6a7f-3af5-7562-8c96-e2a057c336b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_019e6a7f-3af5-7a9f-831c-68eac5d4aae5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_019e6a7f-3af5-731c-bb92-17ac9a6083e8" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_019e6a7f-3af5-7a9f-831c-68eac5d4aae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_019e6a7f-3af5-7f7d-ab33-5e9421371c29" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_019e6a7f-3af5-731c-bb92-17ac9a6083e8" xlink:to="loc_us-gaap_RetainedEarningsMember_019e6a7f-3af5-7f7d-ab33-5e9421371c29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_019e6a7f-3af5-7c0f-b814-98c9171dbde7" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_019e6a7f-3af5-7150-a52c-df0195464798" xlink:to="loc_us-gaap_NoncontrollingInterestMember_019e6a7f-3af5-7c0f-b814-98c9171dbde7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_019e6a7f-3af5-7809-9ff9-718a3c156119" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_019e6a7f-3af5-7cdb-b7de-17c81f2eceb3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_019e6a7f-3af5-7809-9ff9-718a3c156119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019e6a7f-3af5-7cd0-9369-9bde0fda2e07" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019e6a7f-3af5-7809-9ff9-718a3c156119" xlink:to="loc_us-gaap_ClassOfStockDomain_019e6a7f-3af5-7cd0-9369-9bde0fda2e07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_019e6a7f-3af5-703c-a389-9623d9f1ac7e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_019e6a7f-3af5-7cd0-9369-9bde0fda2e07" xlink:to="loc_us-gaap_CommonClassAMember_019e6a7f-3af5-703c-a389-9623d9f1ac7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_019e6a7f-3af5-7ef5-8be4-7c939b8b42de" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_019e6a7f-3af5-7cd0-9369-9bde0fda2e07" xlink:to="loc_us-gaap_CommonClassBMember_019e6a7f-3af5-7ef5-8be4-7c939b8b42de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_019e6a7f-3af5-7df4-8312-f7f1ad6a1a9f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_019e6a7f-3af5-7cdb-b7de-17c81f2eceb3" xlink:to="loc_us-gaap_StatementLineItems_019e6a7f-3af5-7df4-8312-f7f1ad6a1a9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e6a7f-3af5-7386-b04e-ec8bd2a1ff02" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019e6a7f-3af5-7df4-8312-f7f1ad6a1a9f" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e6a7f-3af5-7386-b04e-ec8bd2a1ff02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_019e6a7f-3af5-75df-8726-5e49e5c039f0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e6a7f-3af5-7386-b04e-ec8bd2a1ff02" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_019e6a7f-3af5-75df-8726-5e49e5c039f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_019e6a7f-3af5-7e76-a388-6ac2bffe46af" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e6a7f-3af5-7386-b04e-ec8bd2a1ff02" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_019e6a7f-3af5-7e76-a388-6ac2bffe46af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019e6a7f-3af5-7f22-a553-b283d1af56bb" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e6a7f-3af5-7386-b04e-ec8bd2a1ff02" xlink:to="loc_us-gaap_NetIncomeLoss_019e6a7f-3af5-7f22-a553-b283d1af56bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_019ea6c7-4ddb-7d4a-87fe-14baff62b0f2" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e6a7f-3af5-7386-b04e-ec8bd2a1ff02" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_019ea6c7-4ddb-7d4a-87fe-14baff62b0f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_019ea6c6-ee7f-70c4-9308-7cf391c53b69" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e6a7f-3af5-7386-b04e-ec8bd2a1ff02" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_019ea6c6-ee7f-70c4-9308-7cf391c53b69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_019ea6c9-9de0-7ac0-94f6-9e08e569a31d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e6a7f-3af5-7386-b04e-ec8bd2a1ff02" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_019ea6c9-9de0-7ac0-94f6-9e08e569a31d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_019ea6c9-e9a3-7755-a1b2-66ddd78a9506" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e6a7f-3af5-7386-b04e-ec8bd2a1ff02" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_019ea6c9-e9a3-7755-a1b2-66ddd78a9506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_019e6a7f-3af5-7497-92be-e0b7b2cf8011" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e6a7f-3af5-7386-b04e-ec8bd2a1ff02" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_019e6a7f-3af5-7497-92be-e0b7b2cf8011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_019f697f-4a91-7496-b498-39a613466fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e6a7f-3af5-7386-b04e-ec8bd2a1ff02" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_019f697f-4a91-7496-b498-39a613466fc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_019e6a7f-3af5-7022-8067-8efb33b461ae" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e6a7f-3af5-7386-b04e-ec8bd2a1ff02" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_019e6a7f-3af5-7022-8067-8efb33b461ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_019e6a7f-3af5-76c8-8362-a38ae69cf508" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e6a7f-3af5-7386-b04e-ec8bd2a1ff02" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_019e6a7f-3af5-76c8-8362-a38ae69cf508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_019e6a7f-3af5-713a-ba0d-6b453e181478" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e6a7f-3af5-7386-b04e-ec8bd2a1ff02" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_019e6a7f-3af5-713a-ba0d-6b453e181478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="vtvt-20260630.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_019e6a7f-3af5-77a8-ac04-e221eec1adf3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_019e6a7f-3af5-720f-8ae9-59036d2ed591" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_019e6a7f-3af5-77a8-ac04-e221eec1adf3" xlink:to="loc_us-gaap_StatementTable_019e6a7f-3af5-720f-8ae9-59036d2ed591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e6a7f-3af5-7508-bc43-f110a7a048e3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_019e6a7f-3af5-720f-8ae9-59036d2ed591" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e6a7f-3af5-7508-bc43-f110a7a048e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019e6a7f-3af5-7f44-9aba-b430e8518547" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e6a7f-3af5-7508-bc43-f110a7a048e3" xlink:to="loc_us-gaap_RelatedPartyDomain_019e6a7f-3af5-7f44-9aba-b430e8518547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_019e6a7f-3af5-72f6-a51f-0b8ccc2131f5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_019e6a7f-3af5-7f44-9aba-b430e8518547" xlink:to="loc_us-gaap_RelatedPartyMember_019e6a7f-3af5-72f6-a51f-0b8ccc2131f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_019e6a7f-3af5-75d9-a099-003fb304cb27" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_019e6a7f-3af5-7f44-9aba-b430e8518547" xlink:to="loc_us-gaap_NonrelatedPartyMember_019e6a7f-3af5-75d9-a099-003fb304cb27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_019e6a7f-3af5-7f5e-ad29-acfd208d2b81" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_019e6a7f-3af5-720f-8ae9-59036d2ed591" xlink:to="loc_us-gaap_StatementLineItems_019e6a7f-3af5-7f5e-ad29-acfd208d2b81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_019e6a7f-3af5-7794-abfc-23af8fd40b07" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019e6a7f-3af5-7f5e-ad29-acfd208d2b81" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_019e6a7f-3af5-7794-abfc-23af8fd40b07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_019e6a7f-3af5-7e67-a41c-0475244c73d9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_019e6a7f-3af5-7794-abfc-23af8fd40b07" xlink:to="loc_us-gaap_ProfitLoss_019e6a7f-3af5-7e67-a41c-0475244c73d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019e6a7f-3af5-75cb-9c65-4eb80a0a24dc" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_019e6a7f-3af5-7794-abfc-23af8fd40b07" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019e6a7f-3af5-75cb-9c65-4eb80a0a24dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_019e6a7f-3af5-7b81-aa2b-606875b4734b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019e6a7f-3af5-75cb-9c65-4eb80a0a24dc" xlink:to="loc_us-gaap_Depreciation_019e6a7f-3af5-7b81-aa2b-606875b4734b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_019e6a7f-3af5-73fe-be66-0f1f70145a80" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019e6a7f-3af5-75cb-9c65-4eb80a0a24dc" xlink:to="loc_us-gaap_ShareBasedCompensation_019e6a7f-3af5-73fe-be66-0f1f70145a80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_019e6a7f-3af5-7ffe-a24a-9498002d7fdc" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019e6a7f-3af5-75cb-9c65-4eb80a0a24dc" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_019e6a7f-3af5-7ffe-a24a-9498002d7fdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019e6a7f-3af5-77f7-a0a5-119fa05e75d9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019e6a7f-3af5-75cb-9c65-4eb80a0a24dc" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019e6a7f-3af5-77f7-a0a5-119fa05e75d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_019e6a7f-3af5-7a67-9e6d-84fea6ed6307" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019e6a7f-3af5-77f7-a0a5-119fa05e75d9" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_019e6a7f-3af5-7a67-9e6d-84fea6ed6307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_019e6a7f-3af5-7214-961a-55c7f5668626" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019e6a7f-3af5-77f7-a0a5-119fa05e75d9" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_019e6a7f-3af5-7214-961a-55c7f5668626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_019e6a7f-3af5-7ab8-8085-5a78262af504" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019e6a7f-3af5-77f7-a0a5-119fa05e75d9" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_019e6a7f-3af5-7ab8-8085-5a78262af504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_019e6a7f-3af5-7fea-a2ae-34c2fb2d80ea" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019e6a7f-3af5-77f7-a0a5-119fa05e75d9" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_019e6a7f-3af5-7fea-a2ae-34c2fb2d80ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_019e6a7f-3af5-7def-bee0-50f2dc15021c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019e6a7f-3af5-77f7-a0a5-119fa05e75d9" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_019e6a7f-3af5-7def-bee0-50f2dc15021c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_019e6a7f-3af5-7490-af82-c80634d62ce5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019e6a7f-3af5-77f7-a0a5-119fa05e75d9" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_019e6a7f-3af5-7490-af82-c80634d62ce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019e6a7f-3af5-7d02-ac8e-1f5b0cca6166" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019e6a7f-3af5-75cb-9c65-4eb80a0a24dc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019e6a7f-3af5-7d02-ac8e-1f5b0cca6166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019f69c2-4292-7fc6-a375-7d84f08b7ce5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019e6a7f-3af5-75cb-9c65-4eb80a0a24dc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019f69c2-4292-7fc6-a375-7d84f08b7ce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_019f69c3-aceb-756b-ae38-e2dc299fb28b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019f69c2-4292-7fc6-a375-7d84f08b7ce5" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_019f69c3-aceb-756b-ae38-e2dc299fb28b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_019f69c3-aceb-736a-97f2-2765315d172d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019f69c2-4292-7fc6-a375-7d84f08b7ce5" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_019f69c3-aceb-736a-97f2-2765315d172d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019f69c3-aceb-74eb-9b74-8377bf2aae0b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019f69c2-4292-7fc6-a375-7d84f08b7ce5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019f69c3-aceb-74eb-9b74-8377bf2aae0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019e6a7f-3af5-7a89-aad4-2ef63db4313d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019e6a7f-3af5-7f5e-ad29-acfd208d2b81" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019e6a7f-3af5-7a89-aad4-2ef63db4313d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019e6a7f-3af5-7d59-9ba8-66fe8ac480b8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019e6a7f-3af5-7f5e-ad29-acfd208d2b81" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019e6a7f-3af5-7d59-9ba8-66fe8ac480b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019e6a7f-3af5-72f0-b92e-d4f712235f96" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019e6a7f-3af5-7f5e-ad29-acfd208d2b81" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019e6a7f-3af5-72f0-b92e-d4f712235f96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentation" xlink:type="simple" xlink:href="vtvt-20260630.xsd#DescriptionofBusinessandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_019e6a7f-3af5-7da9-b575-40ee8d1f0244" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_019e6a7f-3af5-7769-aced-8c29b806a78d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019e6a7f-3af5-7da9-b575-40ee8d1f0244" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_019e6a7f-3af5-7769-aced-8c29b806a78d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="vtvt-20260630.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_019e6a7f-3af5-76cc-bcd2-514b3ca431c1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_019e6a7f-3af5-7c50-8cc2-25c934cb7380" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019e6a7f-3af5-76cc-bcd2-514b3ca431c1" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_019e6a7f-3af5-7c50-8cc2-25c934cb7380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CollaborationAgreements" xlink:type="simple" xlink:href="vtvt-20260630.xsd#CollaborationAgreements"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/CollaborationAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019e6a7f-3af5-7545-a705-ead73a5e98b0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_019e6a7f-3af5-70c2-a569-62f7d2511ff2" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019e6a7f-3af5-7545-a705-ead73a5e98b0" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_019e6a7f-3af5-70c2-a569-62f7d2511ff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="vtvt-20260630.xsd#ShareBasedCompensation"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/ShareBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019e6a7f-3af5-7037-b5a7-ef2177140dbe" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_019e6a7f-3af5-796d-b294-ad024e23b4e5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019e6a7f-3af5-7037-b5a7-ef2177140dbe" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_019e6a7f-3af5-796d-b294-ad024e23b4e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="vtvt-20260630.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019e6a7f-3af6-7db4-84da-9d84ade31a02" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_019e6a7f-3af6-75b4-86f2-4ab071ae08fd" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019e6a7f-3af6-7db4-84da-9d84ade31a02" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_019e6a7f-3af6-75b4-86f2-4ab071ae08fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/StockholdersEquity" xlink:type="simple" xlink:href="vtvt-20260630.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_019e6a7f-3af6-799d-aa26-3dab4479b8de" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_019e6a7f-3af6-700f-8150-6ba037cefc54" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_019e6a7f-3af6-799d-aa26-3dab4479b8de" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_019e6a7f-3af6-700f-8150-6ba037cefc54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="vtvt-20260630.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_019e6a7f-3bcb-79a9-902c-feb2941c3833" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_019e6a7f-3bcb-73bb-8d50-ed8e2471f071" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_019e6a7f-3bcb-79a9-902c-feb2941c3833" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_019e6a7f-3bcb-73bb-8d50-ed8e2471f071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/SegmentInformation" xlink:type="simple" xlink:href="vtvt-20260630.xsd#SegmentInformation"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/SegmentInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_019e6a7f-3bcc-779a-a20e-f8fce1d53da7" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_019e6a7f-3bcc-7b2f-abc7-e730809cc525" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_019e6a7f-3bcc-779a-a20e-f8fce1d53da7" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_019e6a7f-3bcc-7b2f-abc7-e730809cc525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/IncomeTaxes" xlink:type="simple" xlink:href="vtvt-20260630.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_019e6a7f-3bcc-7d05-86f0-f86f324e387c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_019e6a7f-3bcc-7709-aa2a-62c2401ea080" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_019e6a7f-3bcc-7d05-86f0-f86f324e387c" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_019e6a7f-3bcc-7709-aa2a-62c2401ea080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/NetLossIncomeperShare" xlink:type="simple" xlink:href="vtvt-20260630.xsd#NetLossIncomeperShare"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/NetLossIncomeperShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_019e6a7f-3bcc-7880-bb93-6ee2e093cf93" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_019e6a7f-3bcc-7fc0-8fa4-0828f1bd76f3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_019e6a7f-3bcc-7880-bb93-6ee2e093cf93" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_019e6a7f-3bcc-7fc0-8fa4-0828f1bd76f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/SubsequentEvents" xlink:type="simple" xlink:href="vtvt-20260630.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_019e6a7f-3bcc-70e6-9989-b5173ff4d7c3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_019e6a7f-3bcc-7678-9c78-e357eaf9a525" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_019e6a7f-3bcc-70e6-9989-b5173ff4d7c3" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_019e6a7f-3bcc-7678-9c78-e357eaf9a525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="vtvt-20260630.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_019e6a7f-3af5-7900-a420-872549800430" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock_019e6a7f-3af5-72fb-bfa1-320198b54f08" xlink:href="vtvt-20260630.xsd#vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019e6a7f-3af5-7900-a420-872549800430" xlink:to="loc_vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock_019e6a7f-3af5-72fb-bfa1-320198b54f08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_019e6a7f-3af5-7679-ad23-d6f79a86d000" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019e6a7f-3af5-7900-a420-872549800430" xlink:to="loc_us-gaap_UseOfEstimates_019e6a7f-3af5-7679-ad23-d6f79a86d000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_019e6a7f-3af5-72dc-96da-23381b41dd75" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019e6a7f-3af5-7900-a420-872549800430" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_019e6a7f-3af5-72dc-96da-23381b41dd75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="vtvt-20260630.xsd#ShareBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/ShareBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019e6a7f-3af5-7590-b2b1-b3ee245139a4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_019e6a7f-3af5-7fb6-aa93-4abc392297ed" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019e6a7f-3af5-7590-b2b1-b3ee245139a4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_019e6a7f-3af5-7fb6-aa93-4abc392297ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_019e6a7f-3af5-714d-b98d-4616716e3f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019e6a7f-3af5-7590-b2b1-b3ee245139a4" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_019e6a7f-3af5-714d-b98d-4616716e3f9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="vtvt-20260630.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_019e6a7f-3af6-753a-8ae5-2ab719416aec" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_019e6a7f-3af6-7d83-a67c-eab4521220fe" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_019e6a7f-3af6-753a-8ae5-2ab719416aec" xlink:to="loc_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_019e6a7f-3af6-7d83-a67c-eab4521220fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/SegmentInformationTables" xlink:type="simple" xlink:href="vtvt-20260630.xsd#SegmentInformationTables"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/SegmentInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_019e6a7f-3bcc-7a7a-a337-734b603e72f3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_019e6a7f-3bcc-7e87-85d0-c5e51b632264" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_019e6a7f-3bcc-7a7a-a337-734b603e72f3" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_019e6a7f-3bcc-7e87-85d0-c5e51b632264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/NetLossIncomeperShareTables" xlink:type="simple" xlink:href="vtvt-20260630.xsd#NetLossIncomeperShareTables"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/NetLossIncomeperShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_019e6a7f-3bcc-7ddd-8fb9-173ad5802bc7" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_019e6a7f-3bcc-77a0-8838-94bd01a0bc84" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_019e6a7f-3bcc-7ddd-8fb9-173ad5802bc7" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_019e6a7f-3bcc-77a0-8838-94bd01a0bc84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_019e6a7f-3bcc-7d02-8586-558a960b211c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_019e6a7f-3bcc-7ddd-8fb9-173ad5802bc7" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_019e6a7f-3bcc-7d02-8586-558a960b211c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetails" xlink:type="simple" xlink:href="vtvt-20260630.xsd#DescriptionofBusinessandBasisofPresentationDetails"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_019e6a7f-3af5-7d64-9ca0-ec92a78b2501" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_019e6a7f-3af5-7e5d-accf-64597a5f353c" xlink:href="vtvt-20260630.xsd#vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019e6a7f-3af5-7d64-9ca0-ec92a78b2501" xlink:to="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_019e6a7f-3af5-7e5d-accf-64597a5f353c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_019e6a7f-3af5-75e3-b44d-69b7be1328ec" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_019e6a7f-3af5-7e5d-accf-64597a5f353c" xlink:to="loc_srt_ConsolidatedEntitiesAxis_019e6a7f-3af5-75e3-b44d-69b7be1328ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_019e6a7f-3af5-7bc0-a1ae-3853133c9b1d" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_019e6a7f-3af5-75e3-b44d-69b7be1328ec" xlink:to="loc_srt_ConsolidatedEntitiesDomain_019e6a7f-3af5-7bc0-a1ae-3853133c9b1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_019e6a7f-3af5-7375-9f66-08030d02d93f" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ParentCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_019e6a7f-3af5-7bc0-a1ae-3853133c9b1d" xlink:to="loc_srt_ParentCompanyMember_019e6a7f-3af5-7375-9f66-08030d02d93f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_019e6a7f-3af5-7d61-83e8-497265186b11" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_019e6a7f-3af5-7e5d-accf-64597a5f353c" xlink:to="loc_dei_LegalEntityAxis_019e6a7f-3af5-7d61-83e8-497265186b11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_019e6a7f-3af5-78f6-b397-4227bb37e15e" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_019e6a7f-3af5-7d61-83e8-497265186b11" xlink:to="loc_dei_EntityDomain_019e6a7f-3af5-78f6-b397-4227bb37e15e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_VTvLLCMember_019e6a7f-3af5-7bd6-93e6-58cf987a0080" xlink:href="vtvt-20260630.xsd#vtvt_VTvLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_019e6a7f-3af5-78f6-b397-4227bb37e15e" xlink:to="loc_vtvt_VTvLLCMember_019e6a7f-3af5-7bd6-93e6-58cf987a0080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_NewsoaraBiopharmaCoLtdMember_019e6a7f-3af5-7d2f-8ca5-25556fa2abd7" xlink:href="vtvt-20260630.xsd#vtvt_NewsoaraBiopharmaCoLtdMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_019e6a7f-3af5-78f6-b397-4227bb37e15e" xlink:to="loc_vtvt_NewsoaraBiopharmaCoLtdMember_019e6a7f-3af5-7d2f-8ca5-25556fa2abd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_019e6a7f-3af5-779c-b146-6d7d3792fcdf" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_019e6a7f-3af5-7e5d-accf-64597a5f353c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_019e6a7f-3af5-779c-b146-6d7d3792fcdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019e6a7f-3af5-706f-9559-56675ef02275" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_019e6a7f-3af5-779c-b146-6d7d3792fcdf" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019e6a7f-3af5-706f-9559-56675ef02275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_019e6a7f-3af5-7b0c-b476-f9f1a7f1684e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019e6a7f-3af5-706f-9559-56675ef02275" xlink:to="loc_us-gaap_CollaborativeArrangementMember_019e6a7f-3af5-7b0c-b476-f9f1a7f1684e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_019e6a7f-3af5-72c3-a1cb-98afc8cacf6d" xlink:href="vtvt-20260630.xsd#vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_019e6a7f-3af5-7e5d-accf-64597a5f353c" xlink:to="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_019e6a7f-3af5-72c3-a1cb-98afc8cacf6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019e6a7f-3af5-792d-b554-edfcc0a66ec4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_019e6a7f-3af5-72c3-a1cb-98afc8cacf6d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019e6a7f-3af5-792d-b554-edfcc0a66ec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PercentageOfNonVotingEconomicInterestByParent_019e6a7f-3af5-7a3e-a8a1-ff58f5900629" xlink:href="vtvt-20260630.xsd#vtvt_PercentageOfNonVotingEconomicInterestByParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_019e6a7f-3af5-72c3-a1cb-98afc8cacf6d" xlink:to="loc_vtvt_PercentageOfNonVotingEconomicInterestByParent_019e6a7f-3af5-7a3e-a8a1-ff58f5900629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019e6a7f-3af5-72f8-8410-57d5424ed67d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_019e6a7f-3af5-72c3-a1cb-98afc8cacf6d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019e6a7f-3af5-72f8-8410-57d5424ed67d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LicenseFeeReceived_019e6a7f-3af5-7ec0-a0d3-19fe08cb03d9" xlink:href="vtvt-20260630.xsd#vtvt_LicenseFeeReceived"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_019e6a7f-3af5-72c3-a1cb-98afc8cacf6d" xlink:to="loc_vtvt_LicenseFeeReceived_019e6a7f-3af5-7ec0-a0d3-19fe08cb03d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CollaborationAgreementsDetails" xlink:type="simple" xlink:href="vtvt-20260630.xsd#CollaborationAgreementsDetails"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/CollaborationAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019e6a7f-3af5-7207-80a6-bc368381e0e5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019e6a7f-3af5-7da6-8d84-27b9f3549893" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019e6a7f-3af5-7207-80a6-bc368381e0e5" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019e6a7f-3af5-7da6-8d84-27b9f3549893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_019e6a7f-3af5-72b2-bd93-b96b6ba26eb1" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019e6a7f-3af5-7da6-8d84-27b9f3549893" xlink:to="loc_srt_CounterpartyNameAxis_019e6a7f-3af5-72b2-bd93-b96b6ba26eb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019e6a7f-3af5-7925-ae15-0f8a48aedc8a" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_019e6a7f-3af5-72b2-bd93-b96b6ba26eb1" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019e6a7f-3af5-7925-ae15-0f8a48aedc8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_G42InvestmentsMember_019e6a7f-3af5-798e-bbcb-ff0ba4d23033" xlink:href="vtvt-20260630.xsd#vtvt_G42InvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019e6a7f-3af5-7925-ae15-0f8a48aedc8a" xlink:to="loc_vtvt_G42InvestmentsMember_019e6a7f-3af5-798e-bbcb-ff0ba4d23033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CognaMember_019e6a7f-3af5-7049-88b2-ebc51a04e448" xlink:href="vtvt-20260630.xsd#vtvt_CognaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019e6a7f-3af5-7925-ae15-0f8a48aedc8a" xlink:to="loc_vtvt_CognaMember_019e6a7f-3af5-7049-88b2-ebc51a04e448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_019e6a7f-3af5-7f5a-a631-540da0441d22" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019e6a7f-3af5-7da6-8d84-27b9f3549893" xlink:to="loc_us-gaap_TypeOfArrangementAxis_019e6a7f-3af5-7f5a-a631-540da0441d22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019e6a7f-3af5-7d68-a6d3-86386fd3b9f0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_019e6a7f-3af5-7f5a-a631-540da0441d22" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019e6a7f-3af5-7d68-a6d3-86386fd3b9f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_G42AgreementsMember_019e6a7f-3af5-7aa8-bc82-419059ce6dd4" xlink:href="vtvt-20260630.xsd#vtvt_G42AgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019e6a7f-3af5-7d68-a6d3-86386fd3b9f0" xlink:to="loc_vtvt_G42AgreementsMember_019e6a7f-3af5-7aa8-bc82-419059ce6dd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_019e6a7f-3af5-797a-8cfb-df143b559c05" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019e6a7f-3af5-7d68-a6d3-86386fd3b9f0" xlink:to="loc_us-gaap_CollaborativeArrangementMember_019e6a7f-3af5-797a-8cfb-df143b559c05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CommercialSupplyAgreementMember_019e6a7f-3af5-7ce1-8a61-6ff8e6119af1" xlink:href="vtvt-20260630.xsd#vtvt_CommercialSupplyAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019e6a7f-3af5-7d68-a6d3-86386fd3b9f0" xlink:to="loc_vtvt_CommercialSupplyAgreementMember_019e6a7f-3af5-7ce1-8a61-6ff8e6119af1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_019e6a7f-3af5-769f-8057-eb1894ce3333" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019e6a7f-3af5-7da6-8d84-27b9f3549893" xlink:to="loc_srt_ProductOrServiceAxis_019e6a7f-3af5-769f-8057-eb1894ce3333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019e6a7f-3af5-79ba-8c60-3e90863e5712" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_019e6a7f-3af5-769f-8057-eb1894ce3333" xlink:to="loc_srt_ProductsAndServicesDomain_019e6a7f-3af5-79ba-8c60-3e90863e5712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_IPLicenseMember_019e6a7f-3af5-7375-8595-10824cdd43c1" xlink:href="vtvt-20260630.xsd#vtvt_IPLicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_019e6a7f-3af5-79ba-8c60-3e90863e5712" xlink:to="loc_vtvt_IPLicenseMember_019e6a7f-3af5-7375-8595-10824cdd43c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_019e6a7f-3af5-7c38-bbd3-691d8d38817d" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019e6a7f-3af5-7da6-8d84-27b9f3549893" xlink:to="loc_dei_LegalEntityAxis_019e6a7f-3af5-7c38-bbd3-691d8d38817d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_019e6a7f-3af5-730f-becd-0d680af81187" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_019e6a7f-3af5-7c38-bbd3-691d8d38817d" xlink:to="loc_dei_EntityDomain_019e6a7f-3af5-730f-becd-0d680af81187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_NewsoaraBiopharmaCoLtdMember_019e6a7f-3af5-7edf-918b-0a26ccda485b" xlink:href="vtvt-20260630.xsd#vtvt_NewsoaraBiopharmaCoLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_019e6a7f-3af5-730f-becd-0d680af81187" xlink:to="loc_vtvt_NewsoaraBiopharmaCoLtdMember_019e6a7f-3af5-7edf-918b-0a26ccda485b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019e6a7f-3af5-7520-ac10-b923a46fe641" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019e6a7f-3af5-7da6-8d84-27b9f3549893" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019e6a7f-3af5-7520-ac10-b923a46fe641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_019e6a7f-3af5-7f2b-a2c5-f124e1ca163c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019e6a7f-3af5-7520-ac10-b923a46fe641" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_019e6a7f-3af5-7f2b-a2c5-f124e1ca163c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross_019e6a7f-3af5-73ce-b6dd-ecd922070484" xlink:href="vtvt-20260630.xsd#vtvt_SaleOfStockConsiderationReceivedOnTransactionGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019e6a7f-3af5-7520-ac10-b923a46fe641" xlink:to="loc_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross_019e6a7f-3af5-73ce-b6dd-ecd922070484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_019e6a7f-3af5-717b-b18b-22461a217042" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019e6a7f-3af5-7520-ac10-b923a46fe641" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_019e6a7f-3af5-717b-b18b-22461a217042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_019e6a7f-3af5-76dc-8893-66d709848011" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsNotesAndLoansReceivableNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019e6a7f-3af5-7520-ac10-b923a46fe641" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_019e6a7f-3af5-76dc-8893-66d709848011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue_019e6a7f-3af5-704b-9e61-d9d2184c1430" xlink:href="vtvt-20260630.xsd#vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019e6a7f-3af5-7520-ac10-b923a46fe641" xlink:to="loc_vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue_019e6a7f-3af5-704b-9e61-d9d2184c1430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CollaborateArrangementContingentConsiderationTransferredCash_019e6a7f-3af5-7172-aaa6-dd645d08f9f6" xlink:href="vtvt-20260630.xsd#vtvt_CollaborateArrangementContingentConsiderationTransferredCash"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019e6a7f-3af5-7520-ac10-b923a46fe641" xlink:to="loc_vtvt_CollaborateArrangementContingentConsiderationTransferredCash_019e6a7f-3af5-7172-aaa6-dd645d08f9f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod_019e6a7f-3af5-7d07-80cc-63b1504d6a8b" xlink:href="vtvt-20260630.xsd#vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019e6a7f-3af5-7520-ac10-b923a46fe641" xlink:to="loc_vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod_019e6a7f-3af5-7d07-80cc-63b1504d6a8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_019e6a7f-3af5-76bd-8cf4-f3dd1f764759" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019e6a7f-3af5-7520-ac10-b923a46fe641" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_019e6a7f-3af5-76bd-8cf4-f3dd1f764759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CollaborativeArrangementNoteReceivableDiscountPaid_019e6a7f-3af5-7a66-b899-edcfbc614667" xlink:href="vtvt-20260630.xsd#vtvt_CollaborativeArrangementNoteReceivableDiscountPaid"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019e6a7f-3af5-7520-ac10-b923a46fe641" xlink:to="loc_vtvt_CollaborativeArrangementNoteReceivableDiscountPaid_019e6a7f-3af5-7a66-b899-edcfbc614667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_019e6a7f-3af5-7991-be95-ee312f311679" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019e6a7f-3af5-7520-ac10-b923a46fe641" xlink:to="loc_us-gaap_ContractWithCustomerLiability_019e6a7f-3af5-7991-be95-ee312f311679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_019e6a7f-3af5-70aa-97b8-2039575f971e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019e6a7f-3af5-7520-ac10-b923a46fe641" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_019e6a7f-3af5-70aa-97b8-2039575f971e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019e6a7f-3af5-7545-9649-df844d526641" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019e6a7f-3af5-7520-ac10-b923a46fe641" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019e6a7f-3af5-7545-9649-df844d526641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LicenseFeeReceived_019e6a7f-3af5-77d4-8276-8e9d63452a59" xlink:href="vtvt-20260630.xsd#vtvt_LicenseFeeReceived"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019e6a7f-3af5-7520-ac10-b923a46fe641" xlink:to="loc_vtvt_LicenseFeeReceived_019e6a7f-3af5-77d4-8276-8e9d63452a59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_019e6a7f-3af5-719b-aab9-6091b7df95ff" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019e6a7f-3af5-7520-ac10-b923a46fe641" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_019e6a7f-3af5-719b-aab9-6091b7df95ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable_019e6a7f-3af5-7a61-a0cf-cbb9bd06569b" xlink:href="vtvt-20260630.xsd#vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019e6a7f-3af5-7520-ac10-b923a46fe641" xlink:to="loc_vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable_019e6a7f-3af5-7a61-a0cf-cbb9bd06569b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="vtvt-20260630.xsd#ShareBasedCompensationAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019e6a7f-3af5-728a-be23-07268713e40e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019e6a7f-3af5-73a2-ada8-12ee102c8c9f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019e6a7f-3af5-728a-be23-07268713e40e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019e6a7f-3af5-73a2-ada8-12ee102c8c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019e6a7f-3af5-747c-a514-a89742d639a9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019e6a7f-3af5-73a2-ada8-12ee102c8c9f" xlink:to="loc_us-gaap_AwardTypeAxis_019e6a7f-3af5-747c-a514-a89742d639a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e6a7f-3af5-7c47-9be2-9ea572238de6" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_019e6a7f-3af5-747c-a514-a89742d639a9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e6a7f-3af5-7c47-9be2-9ea572238de6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_019e6a7f-3af5-79a7-9f2a-4a88421d3d54" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e6a7f-3af5-7c47-9be2-9ea572238de6" xlink:to="loc_us-gaap_EmployeeStockOptionMember_019e6a7f-3af5-79a7-9f2a-4a88421d3d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e6a7f-3af5-7b4e-b2d8-242fd0088aa6" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019e6a7f-3af5-73a2-ada8-12ee102c8c9f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e6a7f-3af5-7b4e-b2d8-242fd0088aa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_019e6a7f-3af5-7acd-9038-a77ea76afbaf" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e6a7f-3af5-7b4e-b2d8-242fd0088aa6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_019e6a7f-3af5-7acd-9038-a77ea76afbaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_019e6a7f-3af5-7f7b-9f0a-37d2a3d22cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e6a7f-3af5-7b4e-b2d8-242fd0088aa6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_019e6a7f-3af5-7f7b-9f0a-37d2a3d22cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_019e6a7f-3af5-7193-b16c-40b3187cb1f3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e6a7f-3af5-7b4e-b2d8-242fd0088aa6" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_019e6a7f-3af5-7193-b16c-40b3187cb1f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_019e6a7f-3af5-702f-be93-0a031026ab39" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e6a7f-3af5-7b4e-b2d8-242fd0088aa6" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_019e6a7f-3af5-702f-be93-0a031026ab39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019e6a7f-3af5-73cb-ab4d-2b98fa6cf549" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e6a7f-3af5-7b4e-b2d8-242fd0088aa6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019e6a7f-3af5-73cb-ab4d-2b98fa6cf549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/ShareBasedCompensationScheduleofStockAwardActivityforthePeriodDetails" xlink:type="simple" xlink:href="vtvt-20260630.xsd#ShareBasedCompensationScheduleofStockAwardActivityforthePeriodDetails"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/ShareBasedCompensationScheduleofStockAwardActivityforthePeriodDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019e6a7f-3af5-76be-8867-05aa7cc5e09c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019e6a7f-3af5-70ce-8253-5c854fdb70ae" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019e6a7f-3af5-76be-8867-05aa7cc5e09c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019e6a7f-3af5-70ce-8253-5c854fdb70ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019e6a7f-3af5-7779-a8a2-1c83412aacb2" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019e6a7f-3af5-70ce-8253-5c854fdb70ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019e6a7f-3af5-7779-a8a2-1c83412aacb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_019e6a7f-3af5-77f2-9197-8c4e214080dd" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019e6a7f-3af5-70ce-8253-5c854fdb70ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_019e6a7f-3af5-77f2-9197-8c4e214080dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_019f851e-f535-7347-a39a-0cc2f040faf3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019e6a7f-3af5-70ce-8253-5c854fdb70ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_019f851e-f535-7347-a39a-0cc2f040faf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019e6a7f-3af5-7d71-922c-aa0e465a0ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019e6a7f-3af5-70ce-8253-5c854fdb70ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019e6a7f-3af5-7d71-922c-aa0e465a0ca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_019e6a7f-3af5-73e3-a9ff-d2e5f0d10bc4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019e6a7f-3af5-76be-8867-05aa7cc5e09c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_019e6a7f-3af5-73e3-a9ff-d2e5f0d10bc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_019e6a7f-3af5-70cb-8b42-66e596a5e5a4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019e6a7f-3af5-76be-8867-05aa7cc5e09c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_019e6a7f-3af5-70cb-8b42-66e596a5e5a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_019e6a7f-3af5-7d3c-87d5-aba2bbc12334" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019e6a7f-3af5-76be-8867-05aa7cc5e09c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_019e6a7f-3af5-7d3c-87d5-aba2bbc12334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_019e6a7f-3af5-79b8-85f6-3cb4812e3527" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019e6a7f-3af5-76be-8867-05aa7cc5e09c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_019e6a7f-3af5-79b8-85f6-3cb4812e3527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_019e6a7f-3af5-725b-a20b-c15a98ae563d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019e6a7f-3af5-76be-8867-05aa7cc5e09c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_019e6a7f-3af5-725b-a20b-c15a98ae563d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_019e6a7f-3af5-7101-8814-7fcb7de99a40" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_019e6a7f-3af5-725b-a20b-c15a98ae563d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_019e6a7f-3af5-7101-8814-7fcb7de99a40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_019e6a7f-3af5-737b-b6ac-6699c01c6077" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_019e6a7f-3af5-725b-a20b-c15a98ae563d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_019e6a7f-3af5-737b-b6ac-6699c01c6077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_019f8520-1ebb-7b7a-97e5-039711c30211" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_019e6a7f-3af5-725b-a20b-c15a98ae563d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_019f8520-1ebb-7b7a-97e5-039711c30211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_019e6a7f-3af5-7add-b1be-e5f93a92a45a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_019e6a7f-3af5-725b-a20b-c15a98ae563d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_019e6a7f-3af5-7add-b1be-e5f93a92a45a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_019e6a7f-3af5-71f7-a3ef-db3e460d6ee8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019e6a7f-3af5-76be-8867-05aa7cc5e09c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_019e6a7f-3af5-71f7-a3ef-db3e460d6ee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_019e6a7f-3af5-7160-a4af-2bdd57265118" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019e6a7f-3af5-76be-8867-05aa7cc5e09c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_019e6a7f-3af5-7160-a4af-2bdd57265118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_019e6a7f-3af5-746c-8b57-ab4fbd464eba" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019e6a7f-3af5-76be-8867-05aa7cc5e09c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_019e6a7f-3af5-746c-8b57-ab4fbd464eba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_019e6a7f-3af6-7a7f-b787-d3b861bb3a07" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019e6a7f-3af5-76be-8867-05aa7cc5e09c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_019e6a7f-3af6-7a7f-b787-d3b861bb3a07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/ShareBasedCompensationScheduleofCompensationExpenseRelatedtoGrantsofStockOptionsDetails" xlink:type="simple" xlink:href="vtvt-20260630.xsd#ShareBasedCompensationScheduleofCompensationExpenseRelatedtoGrantsofStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/ShareBasedCompensationScheduleofCompensationExpenseRelatedtoGrantsofStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019e6a7f-3af6-7dfd-9432-448926eb612d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_019e6a7f-3af6-7f8b-8820-815004181d09" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019e6a7f-3af6-7dfd-9432-448926eb612d" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_019e6a7f-3af6-7f8b-8820-815004181d09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeLocationBalanceAxis_019e6a7f-3af6-79bb-a109-2f79d7498c6b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfIncomeLocationBalanceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_019e6a7f-3af6-7f8b-8820-815004181d09" xlink:to="loc_us-gaap_StatementOfIncomeLocationBalanceAxis_019e6a7f-3af6-79bb-a109-2f79d7498c6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019e6a7f-3af6-7f8e-9a54-28e18feadab4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_019e6a7f-3af6-7f8b-8820-815004181d09" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019e6a7f-3af6-7f8e-9a54-28e18feadab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_019e6a7f-3af6-721e-bdf6-aef50e63093c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019e6a7f-3af6-7f8e-9a54-28e18feadab4" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_019e6a7f-3af6-721e-bdf6-aef50e63093c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="vtvt-20260630.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019e6a7f-3af6-7c05-ba98-da846985bc4a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CommitmentsAndContingenciesTable_019e6a7f-3af6-7328-a66c-0aaf1e8ed5cd" xlink:href="vtvt-20260630.xsd#vtvt_CommitmentsAndContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019e6a7f-3af6-7c05-ba98-da846985bc4a" xlink:to="loc_vtvt_CommitmentsAndContingenciesTable_019e6a7f-3af6-7328-a66c-0aaf1e8ed5cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_019e6a7f-3af6-7e79-8649-db88a5deb496" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_CommitmentsAndContingenciesTable_019e6a7f-3af6-7328-a66c-0aaf1e8ed5cd" xlink:to="loc_srt_RangeAxis_019e6a7f-3af6-7e79-8649-db88a5deb496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019e6a7f-3af6-7050-89ef-b5cd940b1b36" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_019e6a7f-3af6-7e79-8649-db88a5deb496" xlink:to="loc_srt_RangeMember_019e6a7f-3af6-7050-89ef-b5cd940b1b36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_019e6a7f-3af6-7c48-b2d7-6c525b4af9a8" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_019e6a7f-3af6-7050-89ef-b5cd940b1b36" xlink:to="loc_srt_MaximumMember_019e6a7f-3af6-7c48-b2d7-6c525b4af9a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_019e6a7f-3af6-71b7-a7ec-35ab9a69a17d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_CommitmentsAndContingenciesTable_019e6a7f-3af6-7328-a66c-0aaf1e8ed5cd" xlink:to="loc_us-gaap_OtherCommitmentsAxis_019e6a7f-3af6-71b7-a7ec-35ab9a69a17d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_019e6a7f-3af6-746e-80b8-2780753020fb" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsAxis_019e6a7f-3af6-71b7-a7ec-35ab9a69a17d" xlink:to="loc_us-gaap_OtherCommitmentsDomain_019e6a7f-3af6-746e-80b8-2780753020fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember_019e6a7f-3af6-7a57-ad2e-5a69bfceed32" xlink:href="vtvt-20260630.xsd#vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_019e6a7f-3af6-746e-80b8-2780753020fb" xlink:to="loc_vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember_019e6a7f-3af6-7a57-ad2e-5a69bfceed32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SalesBasedMilestonesPaymentMember_019e6a7f-3af6-7ce1-a2cd-739d9e21471f" xlink:href="vtvt-20260630.xsd#vtvt_SalesBasedMilestonesPaymentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_019e6a7f-3af6-746e-80b8-2780753020fb" xlink:to="loc_vtvt_SalesBasedMilestonesPaymentMember_019e6a7f-3af6-7ce1-a2cd-739d9e21471f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_019e6a7f-3af6-7ca8-b5d8-78d2f6523fad" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_CommitmentsAndContingenciesTable_019e6a7f-3af6-7328-a66c-0aaf1e8ed5cd" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_019e6a7f-3af6-7ca8-b5d8-78d2f6523fad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_019e6a7f-3af6-779a-9265-8710aef74f68" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_019e6a7f-3af6-7ca8-b5d8-78d2f6523fad" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_019e6a7f-3af6-779a-9265-8710aef74f68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_TypeOneDiabetesMember_019e6a7f-3af6-782a-b66c-87af234d59a9" xlink:href="vtvt-20260630.xsd#vtvt_TypeOneDiabetesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_019e6a7f-3af6-779a-9265-8710aef74f68" xlink:to="loc_vtvt_TypeOneDiabetesMember_019e6a7f-3af6-782a-b66c-87af234d59a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_TypeTwoDiabetesMember_019e6a7f-3af6-7848-9ec0-c6987b8a6fb8" xlink:href="vtvt-20260630.xsd#vtvt_TypeTwoDiabetesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_019e6a7f-3af6-779a-9265-8710aef74f68" xlink:to="loc_vtvt_TypeTwoDiabetesMember_019e6a7f-3af6-7848-9ec0-c6987b8a6fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_OtherIndicationMember_019e6a7f-3af6-78a0-bea3-7fd89252ec58" xlink:href="vtvt-20260630.xsd#vtvt_OtherIndicationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_019e6a7f-3af6-779a-9265-8710aef74f68" xlink:to="loc_vtvt_OtherIndicationMember_019e6a7f-3af6-78a0-bea3-7fd89252ec58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_019e6a7f-3af6-7c52-a717-6e0b5d09d3ce" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_CommitmentsAndContingenciesTable_019e6a7f-3af6-7328-a66c-0aaf1e8ed5cd" xlink:to="loc_us-gaap_TypeOfArrangementAxis_019e6a7f-3af6-7c52-a717-6e0b5d09d3ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019e6a7f-3af6-77fc-8e11-df100dc5b506" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_019e6a7f-3af6-7c52-a717-6e0b5d09d3ce" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019e6a7f-3af6-77fc-8e11-df100dc5b506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_NovoLicenseAgreementMember_019e6a7f-3af6-7751-a5f2-c821328f8b07" xlink:href="vtvt-20260630.xsd#vtvt_NovoLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019e6a7f-3af6-77fc-8e11-df100dc5b506" xlink:to="loc_vtvt_NovoLicenseAgreementMember_019e6a7f-3af6-7751-a5f2-c821328f8b07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CommitmentsAndContingenciesLineItems_019e6a7f-3af6-73ba-aca1-5fcb8a49bef1" xlink:href="vtvt-20260630.xsd#vtvt_CommitmentsAndContingenciesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_CommitmentsAndContingenciesTable_019e6a7f-3af6-7328-a66c-0aaf1e8ed5cd" xlink:to="loc_vtvt_CommitmentsAndContingenciesLineItems_019e6a7f-3af6-73ba-aca1-5fcb8a49bef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PotentialMilestonePayment_019e6a7f-3af6-764c-bf37-66a7df3bed6c" xlink:href="vtvt-20260630.xsd#vtvt_PotentialMilestonePayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_CommitmentsAndContingenciesLineItems_019e6a7f-3af6-73ba-aca1-5fcb8a49bef1" xlink:to="loc_vtvt_PotentialMilestonePayment_019e6a7f-3af6-764c-bf37-66a7df3bed6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/StockholdersEquityAdditionalInformationDetails" xlink:type="simple" xlink:href="vtvt-20260630.xsd#StockholdersEquityAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/StockholdersEquityAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_019e6a7f-3af6-70fc-88dd-1eedf635ffd8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_019e6a7f-3af6-7145-be5c-39138f7e7db5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_019e6a7f-3af6-70fc-88dd-1eedf635ffd8" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_019e6a7f-3af6-7145-be5c-39138f7e7db5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_019e6a7f-3af6-70cb-99b2-82412a396bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_019e6a7f-3af6-7145-be5c-39138f7e7db5" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_019e6a7f-3af6-70cb-99b2-82412a396bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019e6a7f-3af6-7f87-881e-f2b136399a79" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_019e6a7f-3af6-70cb-99b2-82412a396bd4" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019e6a7f-3af6-7f87-881e-f2b136399a79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_019e6a7f-3af6-7724-b0e6-a76960959d3c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019e6a7f-3af6-7f87-881e-f2b136399a79" xlink:to="loc_us-gaap_PrivatePlacementMember_019e6a7f-3af6-7724-b0e6-a76960959d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_TDCowenSalesAgreementMember_019e6a7f-3af6-7fdc-88f2-7056326b58cc" xlink:href="vtvt-20260630.xsd#vtvt_TDCowenSalesAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019e6a7f-3af6-7f87-881e-f2b136399a79" xlink:to="loc_vtvt_TDCowenSalesAgreementMember_019e6a7f-3af6-7fdc-88f2-7056326b58cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_019e6a7f-3af6-7824-94d3-6805a6f9285b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_019e6a7f-3af6-7145-be5c-39138f7e7db5" xlink:to="loc_us-gaap_StatementClassOfStockAxis_019e6a7f-3af6-7824-94d3-6805a6f9285b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019e6a7f-3af6-742f-a5bf-5bf9c323f723" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019e6a7f-3af6-7824-94d3-6805a6f9285b" xlink:to="loc_us-gaap_ClassOfStockDomain_019e6a7f-3af6-742f-a5bf-5bf9c323f723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_019e6a7f-3af6-7dc9-ae53-ee5f40d9005e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_019e6a7f-3af6-742f-a5bf-5bf9c323f723" xlink:to="loc_us-gaap_CommonClassAMember_019e6a7f-3af6-7dc9-ae53-ee5f40d9005e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_019e6a7f-3af6-7555-b796-4ac72aa4b5e8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_019e6a7f-3af6-7145-be5c-39138f7e7db5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_019e6a7f-3af6-7555-b796-4ac72aa4b5e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_019e6a7f-3af6-7080-bc30-2ef83a5ba7b5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_019e6a7f-3af6-7555-b796-4ac72aa4b5e8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_019e6a7f-3af6-7080-bc30-2ef83a5ba7b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PrivatePlacementPreFundedWarrantsMember_019e6a7f-3af6-7a98-a4f3-3797bca8a2d0" xlink:href="vtvt-20260630.xsd#vtvt_PrivatePlacementPreFundedWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_019e6a7f-3af6-7080-bc30-2ef83a5ba7b5" xlink:to="loc_vtvt_PrivatePlacementPreFundedWarrantsMember_019e6a7f-3af6-7a98-a4f3-3797bca8a2d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PreFundedWarrantsMember_019e6a7f-3af6-747e-826b-c7597bf34ac0" xlink:href="vtvt-20260630.xsd#vtvt_PreFundedWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_019e6a7f-3af6-7080-bc30-2ef83a5ba7b5" xlink:to="loc_vtvt_PreFundedWarrantsMember_019e6a7f-3af6-747e-826b-c7597bf34ac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CommonWarrantsMember_019e6a7f-3af6-7710-84fc-d222afbba257" xlink:href="vtvt-20260630.xsd#vtvt_CommonWarrantsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_019e6a7f-3af6-7080-bc30-2ef83a5ba7b5" xlink:to="loc_vtvt_CommonWarrantsMember_019e6a7f-3af6-7710-84fc-d222afbba257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_019e6a7f-3af6-7b35-b405-3f374736f25c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_019e6a7f-3af6-7145-be5c-39138f7e7db5" xlink:to="loc_us-gaap_ClassOfStockLineItems_019e6a7f-3af6-7b35-b405-3f374736f25c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_019e6a7f-3af6-7181-8443-9ffc8cfaaa25" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019e6a7f-3af6-7b35-b405-3f374736f25c" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_019e6a7f-3af6-7181-8443-9ffc8cfaaa25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_019e6a7f-3af6-7a28-9849-364547953b7f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019e6a7f-3af6-7b35-b405-3f374736f25c" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_019e6a7f-3af6-7a28-9849-364547953b7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_019e6a7f-3af6-7efa-82a2-449391ce140d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019e6a7f-3af6-7b35-b405-3f374736f25c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_019e6a7f-3af6-7efa-82a2-449391ce140d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_019e6a7f-3af6-7e23-8342-82d5fbaef801" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019e6a7f-3af6-7b35-b405-3f374736f25c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_019e6a7f-3af6-7e23-8342-82d5fbaef801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_019e6a7f-3af6-72f6-8f7d-7e2ac8899ff3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019e6a7f-3af6-7b35-b405-3f374736f25c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_019e6a7f-3af6-72f6-8f7d-7e2ac8899ff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_WarrantsAndRightsImmediatelyExercisableTerm_019e6a7f-3af6-7a0f-9203-371bdc867828" xlink:href="vtvt-20260630.xsd#vtvt_WarrantsAndRightsImmediatelyExercisableTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019e6a7f-3af6-7b35-b405-3f374736f25c" xlink:to="loc_vtvt_WarrantsAndRightsImmediatelyExercisableTerm_019e6a7f-3af6-7a0f-9203-371bdc867828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_019e6a7f-3af6-7526-bcae-6c3787b1f964" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019e6a7f-3af6-7b35-b405-3f374736f25c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_019e6a7f-3af6-7526-bcae-6c3787b1f964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CommonStockParOrStatedValueOfPrivatePlacementShares_019e6a7f-3af6-7323-a416-4b2bd25e6891" xlink:href="vtvt-20260630.xsd#vtvt_CommonStockParOrStatedValueOfPrivatePlacementShares"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019e6a7f-3af6-7b35-b405-3f374736f25c" xlink:to="loc_vtvt_CommonStockParOrStatedValueOfPrivatePlacementShares_019e6a7f-3af6-7323-a416-4b2bd25e6891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CommonStockParOrStatedValueOfPrivatePlacementPreFundedWarrantsShares_019e6a7f-3bcb-784d-8d4d-0e254ccccc89" xlink:href="vtvt-20260630.xsd#vtvt_CommonStockParOrStatedValueOfPrivatePlacementPreFundedWarrantsShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019e6a7f-3af6-7b35-b405-3f374736f25c" xlink:to="loc_vtvt_CommonStockParOrStatedValueOfPrivatePlacementPreFundedWarrantsShares_019e6a7f-3bcb-784d-8d4d-0e254ccccc89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SaleOfStockAggregateOfferingPrice_019e6a7f-3bcb-758f-9b07-ec70d6ce8d54" xlink:href="vtvt-20260630.xsd#vtvt_SaleOfStockAggregateOfferingPrice"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019e6a7f-3af6-7b35-b405-3f374736f25c" xlink:to="loc_vtvt_SaleOfStockAggregateOfferingPrice_019e6a7f-3bcb-758f-9b07-ec70d6ce8d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_EntityPublicFloatPercent_019e6a7f-3bcb-70c4-83bf-03e75db8095b" xlink:href="vtvt-20260630.xsd#vtvt_EntityPublicFloatPercent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019e6a7f-3af6-7b35-b405-3f374736f25c" xlink:to="loc_vtvt_EntityPublicFloatPercent_019e6a7f-3bcb-70c4-83bf-03e75db8095b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_EntityPublicFloatThreshold_019e6a7f-3bcb-7a2b-80fd-04b627cf694e" xlink:href="vtvt-20260630.xsd#vtvt_EntityPublicFloatThreshold"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019e6a7f-3af6-7b35-b405-3f374736f25c" xlink:to="loc_vtvt_EntityPublicFloatThreshold_019e6a7f-3bcb-7a2b-80fd-04b627cf694e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SaleOfStockMaximumSecuritiesToBeSoldPercentOfPublicFloat_019e6a7f-3bcb-78af-9873-12ffd196ee53" xlink:href="vtvt-20260630.xsd#vtvt_SaleOfStockMaximumSecuritiesToBeSoldPercentOfPublicFloat"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019e6a7f-3af6-7b35-b405-3f374736f25c" xlink:to="loc_vtvt_SaleOfStockMaximumSecuritiesToBeSoldPercentOfPublicFloat_019e6a7f-3bcb-78af-9873-12ffd196ee53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_019e6a7f-3bcb-7a55-b944-d391d1a6fc08" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019e6a7f-3af6-7b35-b405-3f374736f25c" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_019e6a7f-3bcb-7a55-b944-d391d1a6fc08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/StockholdersEquityScheduleofEquityBasedStockWarrantsDetails" xlink:type="simple" xlink:href="vtvt-20260630.xsd#StockholdersEquityScheduleofEquityBasedStockWarrantsDetails"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/StockholdersEquityScheduleofEquityBasedStockWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_019e6a7f-3bcb-74c5-955b-2a48d981b439" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_019e6a7f-3bcb-7eaa-b465-dcea87fb761b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_019e6a7f-3bcb-74c5-955b-2a48d981b439" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_019e6a7f-3bcb-7eaa-b465-dcea87fb761b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019e6a7f-3bcb-7104-8948-2141a2451a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_019e6a7f-3bcb-7eaa-b465-dcea87fb761b" xlink:to="loc_us-gaap_AwardTypeAxis_019e6a7f-3bcb-7104-8948-2141a2451a3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e6a7f-3bcb-7e72-9856-c425c2e3f3cf" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_019e6a7f-3bcb-7104-8948-2141a2451a3a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e6a7f-3bcb-7e72-9856-c425c2e3f3cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_StockWarrantMember_019e6a7f-3bcb-7632-9cfc-0c6d8b4a7793" xlink:href="vtvt-20260630.xsd#vtvt_StockWarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e6a7f-3bcb-7e72-9856-c425c2e3f3cf" xlink:to="loc_vtvt_StockWarrantMember_019e6a7f-3bcb-7632-9cfc-0c6d8b4a7793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_019e6a7f-3bcb-7520-9530-f8d58b01f49e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_019e6a7f-3bcb-7eaa-b465-dcea87fb761b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_019e6a7f-3bcb-7520-9530-f8d58b01f49e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_019e6a7f-3bcb-7b9c-9150-2688786fbf3a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_019e6a7f-3bcb-7520-9530-f8d58b01f49e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_019e6a7f-3bcb-7b9c-9150-2688786fbf3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PreFundedWarrantsMember_019e6a7f-3bcb-769e-b9b4-80c830d3871c" xlink:href="vtvt-20260630.xsd#vtvt_PreFundedWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_019e6a7f-3bcb-7b9c-9150-2688786fbf3a" xlink:to="loc_vtvt_PreFundedWarrantsMember_019e6a7f-3bcb-769e-b9b4-80c830d3871c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CommonWarrantsMember_019e6a7f-3bcb-7f1c-9c81-f2d96e6ceadd" xlink:href="vtvt-20260630.xsd#vtvt_CommonWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_019e6a7f-3bcb-7b9c-9150-2688786fbf3a" xlink:to="loc_vtvt_CommonWarrantsMember_019e6a7f-3bcb-7f1c-9c81-f2d96e6ceadd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_019e6a7f-3bcb-7cef-a967-26b5b9b2198c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_019e6a7f-3bcb-7eaa-b465-dcea87fb761b" xlink:to="loc_us-gaap_ClassOfStockLineItems_019e6a7f-3bcb-7cef-a967-26b5b9b2198c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_019e6a7f-3bcb-712f-a5b3-508ba72f0d28" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019e6a7f-3bcb-7cef-a967-26b5b9b2198c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_019e6a7f-3bcb-712f-a5b3-508ba72f0d28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_019e6a7f-3bcb-7312-a6b2-49311663a180" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_019e6a7f-3bcb-712f-a5b3-508ba72f0d28" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_019e6a7f-3bcb-7312-a6b2-49311663a180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_019e6a7f-3bcb-7b65-9c52-ab5eafba647a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_019e6a7f-3bcb-712f-a5b3-508ba72f0d28" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_019e6a7f-3bcb-7b65-9c52-ab5eafba647a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_019e6a7f-3bcb-7d3b-99b6-25172c7138c5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_019e6a7f-3bcb-712f-a5b3-508ba72f0d28" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_019e6a7f-3bcb-7d3b-99b6-25172c7138c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_019e6a7f-3bcb-7e32-8e6e-81e6fbc1e576" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_019e6a7f-3bcb-712f-a5b3-508ba72f0d28" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_019e6a7f-3bcb-7e32-8e6e-81e6fbc1e576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_019e6a7f-3bcb-703e-a0c4-4fab79c3f0e2" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_019e6a7f-3bcb-712f-a5b3-508ba72f0d28" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_019e6a7f-3bcb-703e-a0c4-4fab79c3f0e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_019e6a7f-3bcb-71c1-8190-f92c22453127" xlink:href="vtvt-20260630.xsd#vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_019e6a7f-3bcb-712f-a5b3-508ba72f0d28" xlink:to="loc_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_019e6a7f-3bcb-71c1-8190-f92c22453127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePriceAbstract_019e6a7f-3bcb-73b2-acf9-a45182fa0878" xlink:href="vtvt-20260630.xsd#vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePriceAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019e6a7f-3bcb-7cef-a967-26b5b9b2198c" xlink:to="loc_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePriceAbstract_019e6a7f-3bcb-73b2-acf9-a45182fa0878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_019e6a7f-3bcb-7a90-8b04-e2878d63d188" xlink:href="vtvt-20260630.xsd#vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePriceAbstract_019e6a7f-3bcb-73b2-acf9-a45182fa0878" xlink:to="loc_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_019e6a7f-3bcb-7a90-8b04-e2878d63d188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_019e6a7f-3bcb-7ae0-b85a-13b3b84d2ba5" xlink:href="vtvt-20260630.xsd#vtvt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePriceAbstract_019e6a7f-3bcb-73b2-acf9-a45182fa0878" xlink:to="loc_vtvt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_019e6a7f-3bcb-7ae0-b85a-13b3b84d2ba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_019e6a7f-3bcb-7f11-8775-4204e90425ee" xlink:href="vtvt-20260630.xsd#vtvt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePriceAbstract_019e6a7f-3bcb-73b2-acf9-a45182fa0878" xlink:to="loc_vtvt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_019e6a7f-3bcb-7f11-8775-4204e90425ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_019e6a7f-3bcb-793d-99fa-00de49e694e8" xlink:href="vtvt-20260630.xsd#vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePriceAbstract_019e6a7f-3bcb-73b2-acf9-a45182fa0878" xlink:to="loc_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_019e6a7f-3bcb-793d-99fa-00de49e694e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_019e6a7f-3bcb-79e6-b2e3-da1e049aa317" xlink:href="vtvt-20260630.xsd#vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePriceAbstract_019e6a7f-3bcb-73b2-acf9-a45182fa0878" xlink:to="loc_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_019e6a7f-3bcb-79e6-b2e3-da1e049aa317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_019e6a7f-3bcb-7875-8301-f43a9ed7ed92" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019e6a7f-3bcb-7cef-a967-26b5b9b2198c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_019e6a7f-3bcb-7875-8301-f43a9ed7ed92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="vtvt-20260630.xsd#RelatedPartyTransactionsDetails"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_019e6a7f-3bcb-77d1-a5b4-da37da3d163b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019e6a7f-3bcb-75af-8a9d-7e6667b53dff" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_019e6a7f-3bcb-77d1-a5b4-da37da3d163b" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019e6a7f-3bcb-75af-8a9d-7e6667b53dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_019e6a7f-3bcb-7261-b5a5-e72c24b63c67" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019e6a7f-3bcb-75af-8a9d-7e6667b53dff" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_019e6a7f-3bcb-7261-b5a5-e72c24b63c67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_019e6a7f-3bcb-734d-aade-91407e8f0ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_019e6a7f-3bcb-7261-b5a5-e72c24b63c67" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_019e6a7f-3bcb-734d-aade-91407e8f0ea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_MacAndrewsAndForbesIncorporatedMember_019e6a7f-3bcb-7ded-839c-74f2676dca35" xlink:href="vtvt-20260630.xsd#vtvt_MacAndrewsAndForbesIncorporatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_019e6a7f-3bcb-734d-aade-91407e8f0ea9" xlink:to="loc_vtvt_MacAndrewsAndForbesIncorporatedMember_019e6a7f-3bcb-7ded-839c-74f2676dca35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e6a7f-3bcb-70c3-92b0-00c578298b2b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019e6a7f-3bcb-75af-8a9d-7e6667b53dff" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e6a7f-3bcb-70c3-92b0-00c578298b2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019e6a7f-3bcb-7638-ba84-c0df1c97e08f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e6a7f-3bcb-70c3-92b0-00c578298b2b" xlink:to="loc_us-gaap_RelatedPartyDomain_019e6a7f-3bcb-7638-ba84-c0df1c97e08f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_019e6a7f-3bcb-75ae-be2f-33944ed3c42f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_019e6a7f-3bcb-7638-ba84-c0df1c97e08f" xlink:to="loc_us-gaap_RelatedPartyMember_019e6a7f-3bcb-75ae-be2f-33944ed3c42f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_019e6a7f-3bcb-7692-a06c-82171a7e5112" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019e6a7f-3bcb-75af-8a9d-7e6667b53dff" xlink:to="loc_us-gaap_StatementClassOfStockAxis_019e6a7f-3bcb-7692-a06c-82171a7e5112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019e6a7f-3bcb-7438-98eb-3538d37a5c01" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019e6a7f-3bcb-7692-a06c-82171a7e5112" xlink:to="loc_us-gaap_ClassOfStockDomain_019e6a7f-3bcb-7438-98eb-3538d37a5c01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_019e6a7f-3bcb-7bc1-8b53-c8e24b2e5db8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_019e6a7f-3bcb-7438-98eb-3538d37a5c01" xlink:to="loc_us-gaap_CommonClassBMember_019e6a7f-3bcb-7bc1-8b53-c8e24b2e5db8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_019e6a7f-3bcb-7e7a-8086-c9e0968b9955" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_019e6a7f-3bcb-7438-98eb-3538d37a5c01" xlink:to="loc_us-gaap_CommonClassAMember_019e6a7f-3bcb-7e7a-8086-c9e0968b9955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_019e6a7f-3bcb-7d9d-b4e6-a51814dfd1ff" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019e6a7f-3bcb-75af-8a9d-7e6667b53dff" xlink:to="loc_srt_OwnershipAxis_019e6a7f-3bcb-7d9d-b4e6-a51814dfd1ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_019e6a7f-3bcb-7d33-9896-b7e8ba2f8672" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_019e6a7f-3bcb-7d9d-b4e6-a51814dfd1ff" xlink:to="loc_srt_OwnershipDomain_019e6a7f-3bcb-7d33-9896-b7e8ba2f8672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_VTvTherapeuticsIncMember_019e6a7f-3bcb-7d04-91ce-e819da5921c9" xlink:href="vtvt-20260630.xsd#vtvt_VTvTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_019e6a7f-3bcb-7d33-9896-b7e8ba2f8672" xlink:to="loc_vtvt_VTvTherapeuticsIncMember_019e6a7f-3bcb-7d04-91ce-e819da5921c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_019e6a7f-3bcb-7ae0-a8a0-8071ec254156" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019e6a7f-3bcb-75af-8a9d-7e6667b53dff" xlink:to="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_019e6a7f-3bcb-7ae0-a8a0-8071ec254156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_019e6a7f-3bcb-761a-a973-ac0260fbb5c3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_019e6a7f-3bcb-7ae0-a8a0-8071ec254156" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_019e6a7f-3bcb-761a-a973-ac0260fbb5c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember_019e6a7f-3bcb-7efa-84f6-7a8b6aaa5e37" xlink:href="vtvt-20260630.xsd#vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_019e6a7f-3bcb-761a-a973-ac0260fbb5c3" xlink:to="loc_vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember_019e6a7f-3bcb-7efa-84f6-7a8b6aaa5e37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_019e6a7f-3bcb-7de0-9dd3-bce6573e6480" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019e6a7f-3bcb-75af-8a9d-7e6667b53dff" xlink:to="loc_dei_LegalEntityAxis_019e6a7f-3bcb-7de0-9dd3-bce6573e6480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_019e6a7f-3bcb-7d3f-940e-e5e1ec8bcbe7" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_019e6a7f-3bcb-7de0-9dd3-bce6573e6480" xlink:to="loc_dei_EntityDomain_019e6a7f-3bcb-7d3f-940e-e5e1ec8bcbe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_MFTTPHoldingsTwoLLCMember_019e6a7f-3bcb-7fd3-b026-0a5d370dbed1" xlink:href="vtvt-20260630.xsd#vtvt_MFTTPHoldingsTwoLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_019e6a7f-3bcb-7d3f-940e-e5e1ec8bcbe7" xlink:to="loc_vtvt_MFTTPHoldingsTwoLLCMember_019e6a7f-3bcb-7fd3-b026-0a5d370dbed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PrivatePlacementInvestorsMember_019e6a7f-3bcb-7f81-9021-9295c544a9cd" xlink:href="vtvt-20260630.xsd#vtvt_PrivatePlacementInvestorsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_019e6a7f-3bcb-7d3f-940e-e5e1ec8bcbe7" xlink:to="loc_vtvt_PrivatePlacementInvestorsMember_019e6a7f-3bcb-7f81-9021-9295c544a9cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_019e6a7f-3bcb-7411-b0bc-ba339211d517" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019e6a7f-3bcb-75af-8a9d-7e6667b53dff" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_019e6a7f-3bcb-7411-b0bc-ba339211d517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_019e6a7f-3bcb-7058-b9c9-765ec8d8979f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019e6a7f-3bcb-7411-b0bc-ba339211d517" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_019e6a7f-3bcb-7058-b9c9-765ec8d8979f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_OwnershipPercentageOfMajorityOwner_019e6a7f-3bcb-7cca-b26b-12a9fd9866ea" xlink:href="vtvt-20260630.xsd#vtvt_OwnershipPercentageOfMajorityOwner"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019e6a7f-3bcb-7411-b0bc-ba339211d517" xlink:to="loc_vtvt_OwnershipPercentageOfMajorityOwner_019e6a7f-3bcb-7cca-b26b-12a9fd9866ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio_019e6a7f-3bcb-7264-b4fe-8f0def86a035" xlink:href="vtvt-20260630.xsd#vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019e6a7f-3bcb-7411-b0bc-ba339211d517" xlink:to="loc_vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio_019e6a7f-3bcb-7264-b4fe-8f0def86a035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_019e6a7f-3bcb-772b-a55a-3ac7888b40e9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019e6a7f-3bcb-7411-b0bc-ba339211d517" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_019e6a7f-3bcb-772b-a55a-3ac7888b40e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PercentageOfAmountOfCashSavings_019e6a7f-3bcb-7ec3-9300-5b34cc7c15c6" xlink:href="vtvt-20260630.xsd#vtvt_PercentageOfAmountOfCashSavings"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019e6a7f-3bcb-7411-b0bc-ba339211d517" xlink:to="loc_vtvt_PercentageOfAmountOfCashSavings_019e6a7f-3bcb-7ec3-9300-5b34cc7c15c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_NumberOfBoardOfDirectorsRightToDesignateMembers_019e6a7f-3bcc-77a6-ad32-4f5519e2a90a" xlink:href="vtvt-20260630.xsd#vtvt_NumberOfBoardOfDirectorsRightToDesignateMembers"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019e6a7f-3bcb-7411-b0bc-ba339211d517" xlink:to="loc_vtvt_NumberOfBoardOfDirectorsRightToDesignateMembers_019e6a7f-3bcc-77a6-ad32-4f5519e2a90a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_NumberOfBoardOfDirectorsToApproveCertainActions_019e6a7f-3bcc-7a56-bb76-d803ed30844a" xlink:href="vtvt-20260630.xsd#vtvt_NumberOfBoardOfDirectorsToApproveCertainActions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019e6a7f-3bcb-7411-b0bc-ba339211d517" xlink:to="loc_vtvt_NumberOfBoardOfDirectorsToApproveCertainActions_019e6a7f-3bcc-7a56-bb76-d803ed30844a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/SegmentInformationAdditionalInformationDetails" xlink:type="simple" xlink:href="vtvt-20260630.xsd#SegmentInformationAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/SegmentInformationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_019e6a7f-3bcc-7603-8ae9-bd851ef76e5b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019e6a7f-3bcc-79c7-b1a8-6e63beaa5dff" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_019e6a7f-3bcc-7603-8ae9-bd851ef76e5b" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019e6a7f-3bcc-79c7-b1a8-6e63beaa5dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_019e6a7f-3bcc-7fe8-a605-6259486ccd63" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019e6a7f-3bcc-79c7-b1a8-6e63beaa5dff" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_019e6a7f-3bcc-7fe8-a605-6259486ccd63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_019e6a7f-3bcc-7ee4-ad7c-4ddeb092e344" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_019e6a7f-3bcc-7fe8-a605-6259486ccd63" xlink:to="loc_us-gaap_SegmentDomain_019e6a7f-3bcc-7ee4-ad7c-4ddeb092e344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ReportableSegmentMember_019e6a7f-3bcc-7698-b4de-2b5a495f9aaa" xlink:href="vtvt-20260630.xsd#vtvt_ReportableSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_019e6a7f-3bcc-7ee4-ad7c-4ddeb092e344" xlink:to="loc_vtvt_ReportableSegmentMember_019e6a7f-3bcc-7698-b4de-2b5a495f9aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_019e6a7f-3bcc-7bc2-b828-4aef3fc35c08" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019e6a7f-3bcc-79c7-b1a8-6e63beaa5dff" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_019e6a7f-3bcc-7bc2-b828-4aef3fc35c08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_019e6a7f-3bcc-7064-aebe-c88c6e991120" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e6a7f-3bcc-7bc2-b828-4aef3fc35c08" xlink:to="loc_us-gaap_NumberOfReportableSegments_019e6a7f-3bcc-7064-aebe-c88c6e991120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019e6a7f-3bcc-788a-b7eb-f6beb9bda139" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e6a7f-3bcc-7bc2-b828-4aef3fc35c08" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019e6a7f-3bcc-788a-b7eb-f6beb9bda139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_NumberOfForeignCollaborationPartners_019e6a7f-3bcc-7cd4-baac-548601feabb4" xlink:href="vtvt-20260630.xsd#vtvt_NumberOfForeignCollaborationPartners"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e6a7f-3bcc-7bc2-b828-4aef3fc35c08" xlink:to="loc_vtvt_NumberOfForeignCollaborationPartners_019e6a7f-3bcc-7cd4-baac-548601feabb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails" xlink:type="simple" xlink:href="vtvt-20260630.xsd#SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_019e6a7f-3bcc-7408-aa57-398480f5c343" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019e6a7f-3bcc-7e58-8382-16693402f39f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_019e6a7f-3bcc-7408-aa57-398480f5c343" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019e6a7f-3bcc-7e58-8382-16693402f39f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_019e6a7f-3bcc-726f-ae0d-4d9bb5ec765e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019e6a7f-3bcc-7e58-8382-16693402f39f" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_019e6a7f-3bcc-726f-ae0d-4d9bb5ec765e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_019e6a7f-3bcc-7e46-a562-efff30674087" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_019e6a7f-3bcc-726f-ae0d-4d9bb5ec765e" xlink:to="loc_us-gaap_SegmentDomain_019e6a7f-3bcc-7e46-a562-efff30674087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ReportableSegmentMember_019e6a7f-3bcc-773b-9813-31c40a1d7a32" xlink:href="vtvt-20260630.xsd#vtvt_ReportableSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_019e6a7f-3bcc-7e46-a562-efff30674087" xlink:to="loc_vtvt_ReportableSegmentMember_019e6a7f-3bcc-773b-9813-31c40a1d7a32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_019e6a7f-3bcc-7488-8f1b-20765dbb98fe" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019e6a7f-3bcc-7e58-8382-16693402f39f" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_019e6a7f-3bcc-7488-8f1b-20765dbb98fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_019e6a7f-3bcc-7a5b-9984-1c4813b30237" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_019e6a7f-3bcc-7488-8f1b-20765dbb98fe" xlink:to="loc_us-gaap_ProjectMember_019e6a7f-3bcc-7a5b-9984-1c4813b30237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CadisegliatinMember_019e6a7f-3bcc-79bc-a163-5be4e34fb797" xlink:href="vtvt-20260630.xsd#vtvt_CadisegliatinMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_019e6a7f-3bcc-7a5b-9984-1c4813b30237" xlink:to="loc_vtvt_CadisegliatinMember_019e6a7f-3bcc-79bc-a163-5be4e34fb797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_OtherProjectsMember_019e6a7f-3bcc-7a9f-9bfe-83e9dfae2d82" xlink:href="vtvt-20260630.xsd#vtvt_OtherProjectsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_019e6a7f-3bcc-7a5b-9984-1c4813b30237" xlink:to="loc_vtvt_OtherProjectsMember_019e6a7f-3bcc-7a9f-9bfe-83e9dfae2d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_019e6a7f-3bcc-7d64-a243-4e3a3f2a43c4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019e6a7f-3bcc-7e58-8382-16693402f39f" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_019e6a7f-3bcc-7d64-a243-4e3a3f2a43c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_DirectResearchAndDevelopmentExpense_019e6a7f-3bcc-7576-a300-b00a41da5422" xlink:href="vtvt-20260630.xsd#vtvt_DirectResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e6a7f-3bcc-7d64-a243-4e3a3f2a43c4" xlink:to="loc_vtvt_DirectResearchAndDevelopmentExpense_019e6a7f-3bcc-7576-a300-b00a41da5422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_IndirectResearchDevelopmentExpense_019e6a7f-3bcc-7832-8089-2c0e61fbcf44" xlink:href="vtvt-20260630.xsd#vtvt_IndirectResearchDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e6a7f-3bcc-7d64-a243-4e3a3f2a43c4" xlink:to="loc_vtvt_IndirectResearchDevelopmentExpense_019e6a7f-3bcc-7832-8089-2c0e61fbcf44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_019e6a7f-3bcc-7a15-a960-dcacfb701317" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e6a7f-3bcc-7d64-a243-4e3a3f2a43c4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_019e6a7f-3bcc-7a15-a960-dcacfb701317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="vtvt-20260630.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_019e6a7f-3bcc-7fa9-a452-cfdfae2fd1b7" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_IncomeTaxesTable_019e6a7f-3bcc-72d2-8765-3b9de731b53e" xlink:href="vtvt-20260630.xsd#vtvt_IncomeTaxesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_019e6a7f-3bcc-7fa9-a452-cfdfae2fd1b7" xlink:to="loc_vtvt_IncomeTaxesTable_019e6a7f-3bcc-72d2-8765-3b9de731b53e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_019e6a7f-3bcc-7551-bbc5-7c5f13110f72" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_IncomeTaxesTable_019e6a7f-3bcc-72d2-8765-3b9de731b53e" xlink:to="loc_dei_LegalEntityAxis_019e6a7f-3bcc-7551-bbc5-7c5f13110f72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_019e6a7f-3bcc-799d-ab0d-a52847c51e77" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_019e6a7f-3bcc-7551-bbc5-7c5f13110f72" xlink:to="loc_dei_EntityDomain_019e6a7f-3bcc-799d-ab0d-a52847c51e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_MFTTPHoldingsLLCMember_019e6a7f-3bcc-7114-a86f-542da5c7e2e4" xlink:href="vtvt-20260630.xsd#vtvt_MFTTPHoldingsLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_019e6a7f-3bcc-799d-ab0d-a52847c51e77" xlink:to="loc_vtvt_MFTTPHoldingsLLCMember_019e6a7f-3bcc-7114-a86f-542da5c7e2e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_IncomeTaxesLineItems_019e6a7f-3bcc-75b8-b78f-105be5bb01b4" xlink:href="vtvt-20260630.xsd#vtvt_IncomeTaxesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_IncomeTaxesTable_019e6a7f-3bcc-72d2-8765-3b9de731b53e" xlink:to="loc_vtvt_IncomeTaxesLineItems_019e6a7f-3bcc-75b8-b78f-105be5bb01b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PercentageOfAmountOfCashSavings_019e6a7f-3bcc-7d78-b4fb-3013758d6b10" xlink:href="vtvt-20260630.xsd#vtvt_PercentageOfAmountOfCashSavings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_IncomeTaxesLineItems_019e6a7f-3bcc-75b8-b78f-105be5bb01b4" xlink:to="loc_vtvt_PercentageOfAmountOfCashSavings_019e6a7f-3bcc-7d78-b4fb-3013758d6b10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/NetLossIncomeperShareScheduleofReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetIncomeLossperShareofClassACommonStockDetails" xlink:type="simple" xlink:href="vtvt-20260630.xsd#NetLossIncomeperShareScheduleofReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetIncomeLossperShareofClassACommonStockDetails"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/NetLossIncomeperShareScheduleofReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetIncomeLossperShareofClassACommonStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_019e6a7f-3bcc-7cf5-8953-672566104590" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ScheduleOfEarningsPerShareTable_019e6a7f-3bcc-7b93-b3a9-83b191cfb387" xlink:href="vtvt-20260630.xsd#vtvt_ScheduleOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_019e6a7f-3bcc-7cf5-8953-672566104590" xlink:to="loc_vtvt_ScheduleOfEarningsPerShareTable_019e6a7f-3bcc-7b93-b3a9-83b191cfb387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_019e6a7f-3bcc-71ff-a7ae-f3e0d8eae0b5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_ScheduleOfEarningsPerShareTable_019e6a7f-3bcc-7b93-b3a9-83b191cfb387" xlink:to="loc_us-gaap_StatementClassOfStockAxis_019e6a7f-3bcc-71ff-a7ae-f3e0d8eae0b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019e6a7f-3bcc-7721-b9dd-896c8af091e6" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019e6a7f-3bcc-71ff-a7ae-f3e0d8eae0b5" xlink:to="loc_us-gaap_ClassOfStockDomain_019e6a7f-3bcc-7721-b9dd-896c8af091e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_019e6a7f-3bcc-7300-b07d-77afd81571b2" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_019e6a7f-3bcc-7721-b9dd-896c8af091e6" xlink:to="loc_us-gaap_CommonClassAMember_019e6a7f-3bcc-7300-b07d-77afd81571b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ScheduleOfEarningsPerShareLineItems_019e6a7f-3bcc-7790-beed-98b60be774ea" xlink:href="vtvt-20260630.xsd#vtvt_ScheduleOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_ScheduleOfEarningsPerShareTable_019e6a7f-3bcc-7b93-b3a9-83b191cfb387" xlink:to="loc_vtvt_ScheduleOfEarningsPerShareLineItems_019e6a7f-3bcc-7790-beed-98b60be774ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_019e6a7f-3bcc-781f-85d2-0d1159cbb116" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_ScheduleOfEarningsPerShareLineItems_019e6a7f-3bcc-7790-beed-98b60be774ea" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_019e6a7f-3bcc-781f-85d2-0d1159cbb116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_019e6a7f-3bcc-7b9f-a3a0-b95285a3cc68" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_019e6a7f-3bcc-781f-85d2-0d1159cbb116" xlink:to="loc_us-gaap_NetIncomeLossAbstract_019e6a7f-3bcc-7b9f-a3a0-b95285a3cc68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_019e6a7f-3bcc-78fb-a281-cfad2eabd077" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_019e6a7f-3bcc-7b9f-a3a0-b95285a3cc68" xlink:to="loc_us-gaap_ProfitLoss_019e6a7f-3bcc-78fb-a281-cfad2eabd077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_019e6a7f-3bcc-7869-8aa1-ec9cbeccd598" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_019e6a7f-3bcc-7b9f-a3a0-b95285a3cc68" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_019e6a7f-3bcc-7869-8aa1-ec9cbeccd598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_019e6a7f-3bcc-77d1-bee0-235ed69dbfac" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_019e6a7f-3bcc-7b9f-a3a0-b95285a3cc68" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_019e6a7f-3bcc-77d1-bee0-235ed69dbfac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_019e6a7f-3bcc-75ba-b1f3-78162fd3a173" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_019e6a7f-3bcc-781f-85d2-0d1159cbb116" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_019e6a7f-3bcc-75ba-b1f3-78162fd3a173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_019e6a7f-3bcc-79d3-acf2-6494eac43312" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_019e6a7f-3bcc-75ba-b1f3-78162fd3a173" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_019e6a7f-3bcc-79d3-acf2-6494eac43312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_019e6a7f-3bcc-7c39-89f2-351fb9de6632" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_019e6a7f-3bcc-75ba-b1f3-78162fd3a173" xlink:to="loc_us-gaap_EarningsPerShareBasic_019e6a7f-3bcc-7c39-89f2-351fb9de6632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_019e6a7f-3bcc-7723-9768-4e0644fc2d08" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_ScheduleOfEarningsPerShareLineItems_019e6a7f-3bcc-7790-beed-98b60be774ea" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_019e6a7f-3bcc-7723-9768-4e0644fc2d08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_NetIncomeLossDilutedAbstract_019e6a7f-3bcc-7113-b230-5ecde7e7a736" xlink:href="vtvt-20260630.xsd#vtvt_NetIncomeLossDilutedAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_019e6a7f-3bcc-7723-9768-4e0644fc2d08" xlink:to="loc_vtvt_NetIncomeLossDilutedAbstract_019e6a7f-3bcc-7113-b230-5ecde7e7a736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_019e6a7f-3bcc-730a-b76f-e0cbbab3a935" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_NetIncomeLossDilutedAbstract_019e6a7f-3bcc-7113-b230-5ecde7e7a736" xlink:to="loc_us-gaap_ProfitLoss_019e6a7f-3bcc-730a-b76f-e0cbbab3a935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_019e6a7f-3bcc-7fa6-9f75-400e82834cfe" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_NetIncomeLossDilutedAbstract_019e6a7f-3bcc-7113-b230-5ecde7e7a736" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_019e6a7f-3bcc-7fa6-9f75-400e82834cfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_019e6a7f-3bcc-7666-a1d9-d0b560a104a5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_NetIncomeLossDilutedAbstract_019e6a7f-3bcc-7113-b230-5ecde7e7a736" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_019e6a7f-3bcc-7666-a1d9-d0b560a104a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_WeightedAverageNumberOfDilutedSharesOutstandingAbstract_019e6a7f-3bcc-772a-a3db-96d90121c63e" xlink:href="vtvt-20260630.xsd#vtvt_WeightedAverageNumberOfDilutedSharesOutstandingAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_019e6a7f-3bcc-7723-9768-4e0644fc2d08" xlink:to="loc_vtvt_WeightedAverageNumberOfDilutedSharesOutstandingAbstract_019e6a7f-3bcc-772a-a3db-96d90121c63e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019e6a7f-3bcc-7348-ae76-5378dde1a253" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_WeightedAverageNumberOfDilutedSharesOutstandingAbstract_019e6a7f-3bcc-772a-a3db-96d90121c63e" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019e6a7f-3bcc-7348-ae76-5378dde1a253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_019e6a7f-3bcc-7ccc-9f58-0899bee00de0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_WeightedAverageNumberOfDilutedSharesOutstandingAbstract_019e6a7f-3bcc-772a-a3db-96d90121c63e" xlink:to="loc_us-gaap_EarningsPerShareDiluted_019e6a7f-3bcc-7ccc-9f58-0899bee00de0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/NetLossIncomeperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetails" xlink:type="simple" xlink:href="vtvt-20260630.xsd#NetLossIncomeperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetails"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/NetLossIncomeperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_019e6a7f-3bcc-700e-9746-c3812df0f2ca" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019e6a7f-3bcc-7230-82f2-4f0a283ddb5c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_019e6a7f-3bcc-700e-9746-c3812df0f2ca" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019e6a7f-3bcc-7230-82f2-4f0a283ddb5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019e6a7f-3bcc-7ab9-b421-33e54cd059b5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019e6a7f-3bcc-7230-82f2-4f0a283ddb5c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019e6a7f-3bcc-7ab9-b421-33e54cd059b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019e6a7f-3bcc-75d9-9dbf-e36069a5d615" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019e6a7f-3bcc-7ab9-b421-33e54cd059b5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019e6a7f-3bcc-75d9-9dbf-e36069a5d615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_019e6a7f-3bcc-731a-aaa3-4063044f416e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019e6a7f-3bcc-75d9-9dbf-e36069a5d615" xlink:to="loc_us-gaap_CommonClassBMember_019e6a7f-3bcc-731a-aaa3-4063044f416e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_019e6a7f-3bcc-75b0-b903-4a690426922b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019e6a7f-3bcc-75d9-9dbf-e36069a5d615" xlink:to="loc_us-gaap_EmployeeStockOptionMember_019e6a7f-3bcc-75b0-b903-4a690426922b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_019e6a7f-3bcc-76ea-8818-f36850b003bc" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019e6a7f-3bcc-75d9-9dbf-e36069a5d615" xlink:to="loc_us-gaap_WarrantMember_019e6a7f-3bcc-76ea-8818-f36850b003bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_019e6a7f-3bcc-7b79-958b-a6393257073b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019e6a7f-3bcc-75d9-9dbf-e36069a5d615" xlink:to="loc_us-gaap_CommonClassAMember_019e6a7f-3bcc-7b79-958b-a6393257073b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019e6a7f-3bcc-7045-99ba-6dc6a851f360" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019e6a7f-3bcc-7230-82f2-4f0a283ddb5c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019e6a7f-3bcc-7045-99ba-6dc6a851f360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_019e6a7f-3bcc-73ee-adb9-89dd4b144da6" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019e6a7f-3bcc-7045-99ba-6dc6a851f360" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_019e6a7f-3bcc-73ee-adb9-89dd4b144da6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_019e6a7f-3bcc-7a28-a2a0-37b3d0bdc461" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019e6a7f-3bcc-7045-99ba-6dc6a851f360" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_019e6a7f-3bcc-7a28-a2a0-37b3d0bdc461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TrdArrExpirationDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>vtvt-20260630_g1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vtvt-20260630_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" Z/&,$# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M ()_\_VM?^"QO\:/^'E_P3_Y_M:_\%C?XU^0]%'^K6![R^]?Y!_;F*[+[O\
M@GZ\?\/+_@G_ ,_VM?\ @L;_ !H_X>7_  3_ .?[6O\ P6-_C7Y#T4?ZM8'O
M+[U_D']N8KLON_X)^O'_  \O^"?_ #_:U_X+&_QH_P"'E_P3_P"?[6O_  6-
M_C7Y#T4?ZM8'O+[U_D']N8KLON_X)^O'_#R_X)_\_P!K7_@L;_&C_AY?\$_^
M?[6O_!8W^-?D/11_JU@>\OO7^0?VYBNR^[_@GZ\?\/+_ ()_\_VM?^"QO\:/
M^'E_P3_Y_M:_\%C?XU^0]%'^K6![R^]?Y!_;F*[+[O\ @GZ\?\/+_@G_ ,_V
MM?\ @L;_ !H_X>7_  3_ .?[6O\ P6-_C7Y#T4?ZM8'O+[U_D']N8KLON_X)
M^O'_  \O^"?_ #_:U_X+&_QH_P"'E_P3_P"?[6O_  6-_C7Y#T4?ZM8'O+[U
M_D']N8KLON_X)^O'_#R_X)_\_P!K7_@L;_&C_AY?\$_^?[6O_!8W^-?D/11_
MJU@>\OO7^0?VYBNR^[_@GZ\?\/+_ ()_\_VM?^"QO\:/^'E_P3_Y_M:_\%C?
MXU^0]%'^K6![R^]?Y!_;F*[+[O\ @GZ\?\/+_@G_ ,_VM?\ @L;_ !H_X>7_
M  3_ .?[6O\ P6-_C7Y#T4?ZM8'O+[U_D']N8KLON_X)^O'_  \O^"?_ #_:
MU_X+&_QH_P"'E_P3_P"?[6O_  6-_C7Y#T4?ZM8'O+[U_D']N8KLON_X)^O'
M_#R_X)_\_P!K7_@L;_&C_AY?\$_^?[6O_!8W^-?D/11_JU@>\OO7^0?VYBNR
M^[_@GZ\?\/+_ ()_\_VM?^"QO\:/^'E_P3_Y_M:_\%C?XU^0]%'^K6![R^]?
MY!_;F*[+[O\ @GZ\?\/+_@G_ ,_VM?\ @L;_ !H_X>7_  3_ .?[6O\ P6-_
MC7Y#T4?ZM8'O+[U_D']N8KLON_X)^O'_  \O^"?_ #_:U_X+&_QH_P"'E_P3
M_P"?[6O_  6-_C7Y#T4?ZM8'O+[U_D']N8KLON_X)^O'_#R_X)_\_P!K7_@L
M;_&C_AY?\$_^?[6O_!8W^-?D/11_JU@>\OO7^0?VYBNR^[_@GZ\?\/+_ ()_
M\_VM?^"QO\:/^'E_P3_Y_M:_\%C?XU^0]%'^K6![R^]?Y!_;F*[+[O\ @GZ\
M?\/+_@G_ ,_VM?\ @L;_ !H_X>7_  3_ .?[6O\ P6-_C7Y#T4?ZM8'O+[U_
MD']N8KLON_X)^O'_  \O^"?_ #_:U_X+&_QH_P"'E_P3_P"?[6O_  6-_C7Y
M#T4?ZM8'O+[U_D']N8KLON_X)^O'_#R_X)_\_P!K7_@L;_&C_AY?\$_^?[6O
M_!8W^-?D/11_JU@>\OO7^0?VYBNR^[_@GZ\?\/+_ ()_\_VM?^"QO\:/^'E_
MP3_Y_M:_\%C?XU^0]%'^K6![R^]?Y!_;F*[+[O\ @GZ\?\/+_@G_ ,_VM?\
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MR^]?Y!_;F*[+[O\ @GZ\?\/+_@G_ ,_VM?\ @L;_ !H_X>7_  3_ .?[6O\
MP6-_C7Y#T4?ZM8'O+[U_D']N8KLON_X)^O'_  \O^"?_ #_:U_X+&_QH_P"'
ME_P3_P"?[6O_  6-_C7Y#T4?ZM8'O+[U_D']N8KLON_X)^O'_#R_X)_\_P!K
M7_@L;_&C_AY?\$_^?[6O_!8W^-?D/11_JU@>\OO7^0?VYBNR^[_@GZ\?\/+_
M ()_\_VM?^"QO\:/^'E_P3_Y_M:_\%C?XU^0]%'^K6![R^]?Y!_;F*[+[O\
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MP3_Y_M:_\%C?XU^0]%'^K6![R^]?Y!_;F*[+[O\ @GZ\?\/+_@G_ ,_VM?\
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MR^]?Y!_;F*[+[O\ @GZ\?\/+_@G_ ,_VM?\ @L;_ !H_X>7_  3_ .?[6O\
MP6-_C7Y#T4?ZM8'O+[U_D']N8KLON_X)^O'_  \O^"?_ #_:U_X+&_QH_P"'
ME_P3_P"?[6O_  6-_C7Y#T4?ZM8'O+[U_D']N8KLON_X)^O'_#R_X)_\_P!K
M7_@L;_&C_AY?\$_^?[6O_!8W^-?D/11_JU@>\OO7^0?VYBNR^[_@GZ\?\/+_
M ()_\_VM?^"QO\:/^'E_P3_Y_M:_\%C?XU^0]%'^K6![R^]?Y!_;F*[+[O\
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MP3_Y_M:_\%C?XU^0]%'^K6![R^]?Y!_;F*[+[O\ @GZ\?\/+_@G_ ,_VM?\
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MR^]?Y!_;F*[+[O\ @GZ\?\/+_@G_ ,_VM?\ @L;_ !H_X>7_  3_ .?[6O\
MP6-_C7Y#T4?ZM8'O+[U_D']N8KLON_X)^O'_  \O^"?_ #_:U_X+&_QH_P"'
ME_P3_P"?[6O_  6-_C7Y#T4?ZM8'O+[U_D']N8KLON_X)^O'_#R_X)_\_P!K
M7_@L;_&C_AY?\$_^?[6O_!8W^-?D/11_JU@>\OO7^0?VYBNR^[_@GZ\?\/+_
M ()_\_VM?^"QO\:/^'E_P3_Y_M:_\%C?XU^0]%'^K6![R^]?Y!_;F*[+[O\
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MP3_Y_M:_\%C?XU^0]%'^K6![R^]?Y!_;F*[+[O\ @GZ\?\/+_@G_ ,_VM?\
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MR^]?Y!_;F*[+[O\ @GZ\?\/+_@G_ ,_VM?\ @L;_ !H_X>7_  3_ .?[6O\
MP6-_C7Y#T4?ZM8'O+[U_D']N8KLON_X)^O'_  \O^"?_ #_:U_X+&_QH_P"'
ME_P3_P"?[6O_  6-_C7Y#T4?ZM8'O+[U_D']N8KLON_X)^O'_#R_X)_\_P!K
M7_@L;_&C_AY?\$_^?[6O_!8W^-?D/11_JU@>\OO7^0?VYBNR^[_@GZ\?\/+_
M ()_\_VM?^"QO\:/^'E_P3_Y_M:_\%C?XU^0]%'^K6![R^]?Y!_;F*[+[O\
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MP3_Y_M:_\%C?XU^0]%'^K6![R^]?Y!_;F*[+[O\ @GZ\?\/+_@G_ ,_VM?\
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MR^]?Y!_;F*[+[O\ @GZ\?\/+_@G_ ,_VM?\ @L;_ !H_X>7_  3_ .?[6O\
MP6-_C7Y#T4?ZM8'O+[U_D']N8KLON_X)^O'_  \O^"?_ #_:U_X+&_QH_P"'
ME_P3_P"?[6O_  6-_C7Y#T4?ZM8'O+[U_D']N8KLON_X)^O'_#R_X)_\_P!K
M7_@L;_&C_AY?\$_^?[6O_!8W^-?D/11_JU@>\OO7^0?VYBNR^[_@GZ\?\/+_
M ()_\_VM?^"QO\:/^'E_P3_Y_M:_\%C?XU^0]%'^K6![R^]?Y!_;F*[+[O\
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MP3_Y_M:_\%C?XU^0]%'^K6![R^]?Y!_;F*[+[O\ @GZ\?\/+_@G_ ,_VM?\
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MR^]?Y!_;F*[+[O\ @GZ\?\/+_@G_ ,_VM?\ @L;_ !H_X>7_  3_ .?[6O\
MP6-_C7Y#T4?ZM8'O+[U_D']N8KLON_X)^O'_  \O^"?_ #_:U_X+&_QH_P"'
ME_P3_P"?[6O_  6-_C7Y#T4?ZM8'O+[U_D']N8KLON_X)^O'_#R_X)_\_P!K
M7_@L;_&C_AY?\$_^?[6O_!8W^-?D/11_JU@>\OO7^0?VYBNR^[_@GZ\?\/+_
M ()_\_VM?^"QO\:/^'E_P3_Y_M:_\%C?XU^0]%'^K6![R^]?Y!_;F*[+[O\
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MP3_Y_M:_\%C?XU^0]%'^K6![R^]?Y!_;F*[+[O\ @GZ\?\/+_@G_ ,_VM?\
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M7_)KWQ'_ .P6W_H2UV8/_>:7^)?F<V)_@5/1_D?B'1117[B?E 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH _:O]A;_DT_X>_P#7K/\ ^E,M>\5X/^PM_P F
MG_#W_KUG_P#2F6O>*_$,=_O=7_%+\V?JN$_W>G_A7Y!1117"=84444 %%%%
M!1110 4444 %%%% !1110 5XQ^V5_P FO?$?_L%M_P"A+7L]>,?ME?\ )KWQ
M'_[!;?\ H2UV8/\ WFE_B7YG-B?X%3T?Y'XAT445^XGY0%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU<,VW V]ZBM6AAX.I4=HHJG3G6FH05VSQ>BON[_ATYXP_P"A[T3_ ,!IJ/\
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M"5L-9U8VN9]%%%=YR!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MN>*X*6/PU>JZ-.=Y+=:]#LJ82O2IJK.-HOKZGFM%%%=YQA1110 45]??"/\
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MYC GC"KN<^RFN"KC\-0JJC4G:3Z>NQV4\)7JTW5A&\5U]#X_HHHKO.,****
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M&[1\?T5]W?\ #ISQA_T/>B?^ TU'_#ISQA_T/>B?^ TU>?\ VWE__/U?<_\
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M[_UZS_\ I3+7O%>#_L+?\FG_  ]_Z]9__2F6O>*_$,=_O=7_ !2_-GZKA/\
M=Z?^%?D%%%%<)UA1110 4444 %%%% !1110 4444 %%%% !7C'[97_)KWQ'_
M .P6W_H2U[/7C'[97_)KWQ'_ .P6W_H2UV8/_>:7^)?F<V)_@5/1_D?B'111
M7[B?E 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3=FDCT3_ (>S>%?^A!UC_P #8O\ "C_A[-X5_P"A!UC_ ,#8O\*_,VBOK?\
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M /8.M_\ T6M?BQ^U]_R<[\2/^PS-_2OVG\#?\B5X?_[!UO\ ^BUK\6/VOO\
MDYWXD?\ 89F_I7YSPU_O=7T_4^VSW_=Z?K^AX_1117Z,?$A1110!^C?_  2/
M_P"0;\4/^NVF_P#H-S79?\%6O^2%^%_^QCC_ /26XKC?^"1__(-^*'_7;3?_
M $&YKLO^"K7_ "0OPO\ ]C''_P"DMQ7YQ5_Y*!>J_P#24?;4_P#D3?)_^E'Y
M94445^CGQ)T_PY^'/B#XL>,-/\,>&-/DU'5KU]J1KPJ+_$[MT5%'))Z5^N_[
M,G[&?@_]GC3+>^>"+7_&CH/M.MW"9\H]TMU/^K4=,_>;N<84<]^P+^S;!\&/
MA;;^(M4M5'C#Q) ES<.ZC?:VS8:*W!ZCC:[C^\0#]P5B?MW?MC3?!#3X_!W@
M^X0>-=0B\R:[P'_LR ]&P>/-?G:#G &XCE<_G>88ZOFF)^HX1^[L_/NWY+\?
MN/M,'A:. H?6\3\7Y>GF>S?&7]J;X;? <_9_%/B"--5*AETBQ0W%VP/0E%^X
M,<@N5!QP2>*^<=2_X*P^"8KV1;#P3K]S:#&R6YF@AD;@9RBLX'.1]X\<\=*_
M,[4-1NM6OKB]OKJ:]O+AS+-<7$ADDD<G)9F/))/))JM7KX?AO"0C^]O)^ME^
M'^9YM;/,3.7[NT5]Y^P/PU_X*,?![X@7T%C>:A?>#[R8A%_M^!8X"V!_RV1G
M15Y/S2%!\ISCC/O?C7P-X8^+?A";1?$.G6FOZ%?('"2893D?+)&XY5L'(=2"
M,\&OP#KZ\_88_;#U#X0>*+#P7XHOFN/ FI3"&.2X?/\ 94K' D4GI$21O7H,
MEA@[@WG8_AY48^WP4G=:V_R?<[<'G/M9>RQ25GU_S1QW[87[(^H_LU^)HKJP
MDFU3P3J<A%AJ$@&^!^3]GF(XW@#(; # $@ @@?.E?N%^U=)X!F^!_B/3_B+J
MEMI.BWMNT<,\HW2K< 9B:%!\SR*P# *.@.>,U^'[@*Q 8, <;AT->YD>/J8[
M#WJKWHZ7[_\ ![_\$\K-<)#"UK4WH];=OZZ'Z*>!?^"HGAGPEX)\/:'+X'U:
MXETO3K>R>5+N(*YCB5"P&. =N:W/^'LWA7_H0=8_\#8O\*_,VBG+(,!)N3@]
M?-_Y@LXQD592_!'Z9?\ #V;PK_T(.L?^!L7^%?9/PS\<P?$SX?>'O%=M;265
MOK-E%>I;RL&:,.H(4D<$C-?@)7[F?LH?\FU?#3_L VG_ *+%?+Y[EF&P-&$Z
M$;-ONWT/>RG'5\74E&J[I+L>4?'W_@H!H/P#^)NH>#+[PGJ.JW-G%#*UU;W,
M:(WF1JX !&>-V*\\_P"'LWA7_H0=8_\  V+_  KYH_X*.?\ )U_B3_KTL?\
MTF2OF2O9P61X&MAJ=2<-6DWJ^QYF*S7%TJ\X1EHFULC],O\ A[-X5_Z$'6/_
M  -B_P *^-OVM/CU8?M&?%.+Q7I^E7.CP+IT-D;>ZD5VW(TA+97C!WC\J\6H
MKV,+E.$P=3VM&-GMNSS,1F.(Q,/9U977H@HHHKV#S0HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*-97BW(^^G7GA\LA4INS21Z)_P /9O"O_0@ZQ_X&Q?X4?\/9O"O_ $(.L?\
M@;%_A7YFT5];_J_E_P#(_O?^9\Y_;.,_F_!'Z9?\/9O"O_0@ZQ_X&Q?X4?\
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M +"=S_Z-:N>KH?B%_P C]XE_["=S_P"C6KGJ^_I_ O0^/G\3"BBBM" HHHH
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MP**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!5_/[\/?^1^\-?\ 83MO_1JU_0%7Q7%/QT?1_H?4</\ PU/E^I\-Z[_P5/\
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MDGV_5GV&1NV&J-=_T/C/_A[-X5_Z$'6/_ V+_"C_ (>S>%?^A!UC_P #8O\
M"OS-HKZ3_5_+_P"1_>_\SP_[9QG\WX(_3+_A[-X5_P"A!UC_ ,#8O\*/^'LW
MA7_H0=8_\#8O\*_,VBC_ %?R_P#D?WO_ ##^V<9_-^"/MS]IW]O_ $'X^?!W
M5?!ECX3U+2KF\FMY5NKBXC=%\N57(( SR%(KXCHHKU\)@Z."I^SHJRO<\[$8
MFIBI\]5W>P4445V'*%%%% !15BRLKC4KR"TM();JZG<1Q00H7>1R<!54<DD]
MA7US\'O^"9_Q%\?00W_BN[M_ FFR#<(KF/[1?$=OW*L O_ W!&?NUQXG&4,)
M'FKS4?Z[;G30PU;$/EI1N?'U%?J9IW_!*;X9164:W_BCQ9<W8SOEMI[6&-N3
MC"&!R.,#[Q]>.E4?$W_!*#P)=6.WP_XR\1:;><_O=36"\C]OD1(C_P"/5XRX
MBP#=N9_<ST_[%QEKV7WGY@T5[=^T%^R)X^_9UE%SKEG%J?AZ1PD.N::2]N6/
M1) 0&C;V88/.TM@UXC7OT:U/$052E*Z?8\BI2G1DX5%9A1116QD%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX*G^&-"UO4=,?P+JTKV=S);M(MY$ Q1BN1Q[5]R5_/[\0O\ D?O$O_83N?\
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MO%_AVVO(?+O])U2U65-ZY2:&1 1D'J"K=#ZU\GB\/4R#%0K4&W!_TT_T_P"
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M:;^S)H>B:EJ6B7>MIJEP]LD=I*L9C*KNR=W7K7SU_P $F?\ D0/'W_83M_\
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MKYSB#_D7S]5^:/;R;_?(_/\ (/\ @K-_R('@'_L)W'_HH5^9M?IE_P %9O\
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MCT\TH4\5AUC:2UZ^G^:/@"I8()+N>.&&-YII&")'&I9F8G   ZDGM45?2O\
MP3U^'EO\0/VF=$>\B\ZUT&WEUID/0O&56(GZ2R1M_P !K[K$UUAJ,ZTOLIL^
M4H4G7JQIKJ['W)^QO^Q=HWP.\/6/B+Q)90:E\0;J,2O+* Z:8",^5%G@..C/
MUSD [>OI/QJ_:O\ AM\!)#:^)]<WZQL#KH^G1^?=D$9!*@@)D="Y7/:NA^/G
MQ);X1?!OQ;XOB1)+G2[%Y+=)/NF=B$B!]M[+GVK\+->UW4/%&M7VKZM>2ZAJ
M=],UQ<W4[;GED8Y9B?<FOSO+\#/.ZL\3BI.R=M/R79(^SQF+AE5.-##QU?\
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M1110 4444 %%%% '0_#W_D?O#7_83MO_ $:M?T!5_/[\/?\ D?O#7_83MO\
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MU&C_ /8.O/\ T4:_1_\ :^_Y-C^)/_8'F_D*_.#_ ()L_P#)U&C_ /8.O/\
MT4:_1_\ :^_Y-C^)/_8'F_D*_.,Z_P"1M2_[=_-GVV5_\BZI_P!O?D?AY7OO
M['G[2.G?LS^-]:UW4M&NM:BO].^Q+#:RK&R'S$?<2W;Y<?C7@5%?H%>A#$TW
M2J*\7N?'TJLZ$U4ANC],O^'LWA7_ *$'6/\ P-B_PH_X>S>%?^A!UC_P-B_P
MK\S:*\/_ %?R_P#D?WO_ #/5_MG&?S?@C]@_V<?VZ]$_:,^(4GA33_"VH:/<
M)927OVBYN$="$9 5PHSD[Q^5>U?&;XG6WP;^&6N^,[NREU&VTF))7M8'"/)N
MD5, G@?>S^%?F=_P2_\ ^3E;C_L W7_HR&OO#]N;_DU#XA_]>D/_ *4Q5\9C
M\#0H9E3P]-6B^6^KZO4^GP>+JUL#.O-^\K_@CP7_ (>S>%?^A!UC_P #8O\
M"C_A[-X5_P"A!UC_ ,#8O\*_,VBOL_\ 5_+_ .1_>_\ ,^8_MG&?S?@C] ?C
M!_P4L\.?$SX6^*O"EOX,U2QN-9TZ:R2XENHV6-G4@,0!D@9K\_J**]3!X&A@
M8N%!63UWN>?B<55Q<E*J[M'T/^QI^RU/^TGX[F.H/)9^#]'V2ZG<Q\/,23LM
MXS_>;!)/\*@GJ5!_7'3],\(?!7P+Y-K%IOA/PKI,.YB2L,$*C +.QZD\98DE
MB>22:\L_88^'EM\//V9O!Z1Q!+K6;<:U=/WD><!T/X1>4O\ P&OCS_@J#\9M
M2UKXE67PYM;EX=#T:WBO+N!6P)[N12REO4+&R[0>[L>XKX3$2JYYF+PRE:$;
M_<MWZOH?6T53RK!*NU><K?CT^1] ^.?^"GOPH\,W-S:Z+::WXJGC("3VENL%
MJYW8/SRL'Z9((C(/'KFN8TS_ (*P>!YKM5U'P5X@M;;!S):RP3N#V^5F0?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M /VZ_8Q_Y-<^'/\ V#!_Z&U?G=_P4L_Y.CU+_L&6?_H!K]$?V,?^37/AS_V#
M!_Z&U?G=_P %+/\ DZ/4O^P99_\ H!K\YR;_ )&]7_M[_P!*/M<S_P"1;3_[
M=_(^5J***_1CXH*_3O\ X)/7-P_PM\;6[$_9(]9CDC';>T"A_P!%2OS$K]E/
MV!/A3=?"K]G/1UU& VVJ:[,^LW$3+AT$@41*V><^4D9([%B*^6XDJ1A@N1[R
M:M^9]!DD)2Q7,MDF>._\%988CX \!2MCSUU2X5./X3$"W/U5:_,VOO/_ (*N
M^/H-2\:^"_!]O*&?2K.;4+H*<X:=E6-3Z$+"3CTD%?!E=60PE#+Z?-UN_P 6
M<^;R4L9.WE^1^NW_  3-_P"37[3_ +"UY_-:^=_^"L?_ "4CP)_V"9O_ $=7
MT1_P3-_Y-?M/^PM>?S6OG?\ X*Q_\E(\"?\ 8)F_]'5\Q@_^1]/UD>]B?^13
M'TC^A\(T445^C'Q(5]A_\$N+J>']HS48HF80R^'[D2J.A F@()_''YU\>5^C
M?_!*CX3W5G:>*OB->0M%#=J-'T]F&/,16$D[#U&Y8E!]58=J\/.JD:> J<W5
M6^;/5RN$IXN'+TU/I3]N&"&X_94^(:3@%!91N-Q_B6>)E_\ '@*_%"OUN_X*
M8^/HO"W[.<FA+,%O?$E_!:+$#\QBC83R,/8&.-3_ +X'>OR1KS>&82C@Y2>S
MD[?<D=V>R4L2DNB_S/4OV9/A:OQF^.GA+PK,I:PNKKSKW _Y=XE,DHSVRJ%0
M?5A7[@:KJ=CX8T*\U"[=+33=.MGGF<#"Q11J68X'8*#7YG?\$I/#<5]\6O%V
MMR*6?3]'6WC/93-,IS]<1$?B:^N?V_?&$G@_]EKQ<86VW&I^3IB'/:611(/Q
MC$@_&O%SQRQF8T\*ME9?-[O[K'J94EAL%/$/=W?W'Y0_&_XKZC\;?BCK_C#4
MF8-?SG[/ QX@@7Y8HP,G&% SCJ<GO7!T45^BTX1I04(*R6B/BYS<Y.4MV%%%
M%60%?KS_ ,$[?C?<?%?X)#1]5N3<ZYX6E6PDDD.7DMB,V[MZD ,F>_EYZDU^
M0U?8W_!+KQA)HGQ^U#0RW^C:WI$J;,_\M8F613^"B4?\"]J^>S[#+$8*3MK'
M5?K^![.4UW1Q45TEH_T_$]9_X*K?":.?1_"_Q&LX +BWE.CZ@ZKRT;!G@8_[
MK"1<G_GHHK\X*_;']MOPPGBK]EOX@6S1[WMK$7Z''*F"1921Z<(1]":_$ZN?
MARNZN"Y)?9;7RW_4WSNBJ>*YE]I7_0]D_8X_Y.@^&_\ V%H_Y-7[-?$O_DG'
MBO\ [!-W_P"B6K\9?V./^3H/AO\ ]A:/^35^S7Q+_P"2<>*_^P3=_P#HEJ\+
MB/\ WRCZ+\SULC_W:IZ_H?@#1117Z,?$A1110!]/?\$\_BW/\-?VA=+TJ6=D
MT?Q2!I5S$3\IF.3;OC^\),(/:5J_5#XT?#V#XK_"GQ5X2G16_M6PE@B+]$FQ
MNB?_ (#($;\*_"/PWK<_AKQ#I>KVQ*W.GW45W$0<$/&X8?J!7]!EO<)=V\<T
M3!XY%#JWJ",BOSGB2G[#$TL3#1O\XV_S_ ^UR.?M:%2A+9?DS^>6:%[>5XI4
M,<B,59&&""#@@U'7H?[0^A)X:^/'Q#TR-0L-OK]ZL2@8PAG<J/\ ODBO/*_0
MJ4U4@IKJKGQLX\DG%]#^@?P-_P B5X?_ .P=;_\ HM:_%C]K[_DYWXD?]AF;
M^E?M/X&_Y$KP_P#]@ZW_ /1:U^+'[7W_ "<[\2/^PS-_2OSWAK_>ZOI^I]GG
MO^[T_7]#Q^BBBOT8^)"BBB@#]&_^"1__ "#?BA_UVTW_ -!N:[+_ (*M?\D+
M\+_]C''_ .DMQ7&_\$C_ /D&_%#_ *[:;_Z#<UV7_!5K_DA?A?\ [&./_P!)
M;BOSBK_R4"]5_P"DH^VI_P#(F^3_ /2C\LJ]E_9!^%\7Q=_:%\(Z%=PK/ID=
MP;Z^1^5:"%3(48>C%53_ ('7C5?=O_!)[PY%=_$;QQKC(&EL-+AM$8_P^=*6
M./\ OP*^TS.N\/@ZE1;I?GI^I\Q@*2K8F$'M?\M3]'/&?BNQ\"^$=:\1:D^R
MPTFSEO9SWV1H6('N<8 ]37X,_$3QUJ?Q-\<ZYXJUB3S-1U:Z>ZEP>$R?E1?]
ME5PH'H!7ZS?\%%_%$OAO]EG7X87,<FJW5KI^X'!VF42,/Q6)A]":_':OF^%\
M.HT9XA[MV^2_X?\  ]O/JS=2-'HE?YL****^W/E0HHHH Z7QM\1_$_Q(N[*Y
M\3ZW=ZU-96R6=L;J3(AB0 *JCH.F2<9)R3DDFN:HHJ8QC!<L59%2DY.\G=A1
M115$A7[F?LH?\FU?#3_L VG_ *+%?AG7[F?LH?\ )M7PT_[ -I_Z+%?%<4_[
MO3]?T/J,@_C3]/U/S._X*.?\G7^)/^O2Q_\ 29*^9*^F_P#@HY_R=?XD_P"O
M2Q_])DKYDKZ/+?\ <J/^%?D>+CO]ZJ_XG^84445Z1PA1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M6=/_ /C]?=?VA@_^?T?_  )?YGR7U/$_\^I?<SYUHKZ*_P"'?7Q^_P"A"_\
M*SI__P ?KA_BO^S)\2_@?H]GJOC;PW_8MA=W'V6"7[?;7&^3:6VXBD8CA2<D
M8JX8W"U)*$*L6WT31,L+B()RE3:2\F>6T445VG*%%%% !1110 5]4_\ !.'X
M7Q?$#]H>UU6\A66P\,6K:H0_(,^0D(^H9BX]XZ^5J_3'_@DWX=BM_ 7CO7M@
M\^[U."QW]]L46_'YSUXF=5W0P-24=WI]^GY'JY725;%P3V6OW'U;^T'\4X_@
MM\&_%'C!MAN-/M#]DCDZ27+D)"I'<;V7/L#Z5^%>I:C<ZQJ-U?7LSW-Y=2O/
M/-(<M([$LS$^I))_&OT[_P""K'BB73OA%X4T*)RBZGK!GEP?O)#$WRGVW2J?
MJHK\NJ\OAK#JGA76ZR?X+3\[G?GE9SQ"I=(K\7_2"BBBOKSYL*L6-]<:9?6]
MY:3-;W5O(LL4R'#(ZG*L#V((!JO10U<-C>\;>.=?^(_B.ZU_Q-JUSK6KW1S+
M=73Y8@=% Z*HZ!0 !T K!HHJ8Q4$HQ5DAMN3N]SH?A[_ ,C]X:_["=M_Z-6O
MZ J_G]^'O_(_>&O^PG;?^C5K^@*OS[BGXZ/H_P!#[+A_X:GR_4_G]^(7_(_>
M)?\ L)W/_HUJYZNA^(7_ "/WB7_L)W/_ *-:N>K[^G\"]#X^?Q,****T("BB
MB@#ZI_X)I_\ )T>F_P#8,O/_ $ 5^B/[9W_)KGQ&_P"P8?\ T-:_.[_@FG_R
M='IO_8,O/_0!7Z(_MG?\FN?$;_L&'_T-:_.<Y_Y&]+_MW\S[;+/^1=4_[>_(
M_$6BBBOT8^)/TR_X),_\B!X^_P"PG;_^BC70_P#!2/Q]K?POL_A;XH\.W9LM
M7TW69YH9!RK?N0&1AW5@2I'<$BN>_P""3/\ R('C[_L)V_\ Z*-'_!6;_D0/
M /\ V$[C_P!%"OS>45//W&2NF_\ VT^W4G')U*+U2_\ ;CZG_9_^..B_M _#
M;3_%6CL(I7_<W]B6R]G<@#?&WJ.00>ZL#QG%?&?_  4?_92\I[GXM^%;3Y&(
M'B"SA3H>@NP!Z\!\>S=W-?-'[(7[2EY^SC\3(KV=I)_"NIE+;6+1.3Y>?EF0
M?WX\DCU!9>^1^S-K=:5XT\.1W$$EOJVB:I:AE<8DAN8)%_(JRG\C7/B*57(,
M:JM+6#_%=4_3_)FU&I3SC"NG4^-?GT9_/A17T+^V9^S#<_LY_$1O[/BEF\&:
MNS3:5=-EO*[M;N?[R9X)^\I!Z[L?/5?I.'KT\32C6INZ9\16I3H3=.:LT>R?
ML<?\G0?#?_L+1_R:OV:^)?\ R3CQ7_V";O\ ]$M7XR_L<?\ )T'PW_["T?\
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MA*&7T^;K=_BSGS>2EC)V\OR/UV_X)F_\FOVG_86O/YK7SO\ \%8_^2D>!/\
ML$S?^CJ^B/\ @F;_ ,FOVG_86O/YK7!_\%"OV:_B/\<O&OA._P#!/AS^V[2Q
MT^2"XD^W6UOL<R;@,2R*3QW&:^4P]6G1SR<ZDDE>6K=CZ&M"=3*H1@FW:.Q^
M8M%?17_#OKX_?]"%_P"5G3__ (_1_P .^OC]_P!"%_Y6=/\ _C]?=?VA@_\
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M^U D94W4F4A4_0>:X]XQ7R)7[$_\$]_A,WPQ_9VTJ\NH?+U7Q*YUB?(^81.
M(%^GEA6]C(:^>S[%?5L%))ZRT7Z_@>SE.']OBDWM'7_+\3%_X*4?%;_A ?@&
M?#UK,(]3\5W(L@ <,+9,/.P]C^[0^TM?GS^QY\53\(/VA/"FLRS>3IEU/_9N
MH%ON_9YL(2WLK%'_ . "NZ_X**_%;_A8W[0]_I5M,)-+\+Q#2H@I^4S@[KAO
MKO.P_P#7(5\N5GE6 C#+O95%\:;?S_X%B\PQ;EC?:0^P[+Y?\$_<?]JOX4_\
M+E^ OBSPY%$)=1^S&\T_ RWVF+]Y&!_O;2GT<U^'1!4D$$$=17[A?LG?%/\
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M^-W_  3;^'OQ-OKC5?#5S-X$UB=B\BV4(FLI&/4^02NP_P"XRKU^4U\B^/\
M_@FK\8/")DETBVTSQ?:H-^[3+L1RA0"3F.;9D\=%+$Y&,GI]=AL\P6)2]_E?
M9Z?CM^)\W7RK%4&_=YEW6OX;GRA173^-/ACXN^'-SY'BCPSJWA^3.U3J-G)"
MK\L 59AA@=K8()!VG'2N8KW8RC-<T7='E2BXNTE8****HDZ'X>_\C]X:_P"P
MG;?^C5K^@*OY_?A[_P C]X:_["=M_P"C5K^@*OSSBGXZ/H_T/L^'_AJ?+]3^
M?WXA?\C]XE_["=S_ .C6KGJ^H?&7[!/QVU7Q?KE[:^!O-M;F^GFB?^U[ ;D:
M1BIP9\C@CK61_P .^OC]_P!"%_Y6=/\ _C]?84\PP:@DZT?_  )?YGS4\'B>
M9_NI?<SYUHKZ*_X=]?'[_H0O_*SI_P#\?H_X=]?'[_H0O_*SI_\ \?J_[0P?
M_/Z/_@2_S)^IXG_GU+[F?.M%;_CGP-K?PU\5ZCX:\1V7]G:WI[A+FU\U)?+8
MJ& W(S*>&!X)ZU@5W1DII2B[IG(TXNSW"BBBJ$%%%% 'ZK_L _LFZ-X \$:1
M\1=>M8-1\7:Q;K=V3. ZZ=;N,H$[>8RD%FZC.T8^;=ZI^T1^V1X#_9U8:?JD
MTVL^)70.FB:<5,J*>C2L3MC!SD9RQ'(4CFOSQ_9I_;D\2?L_^"->\+R6QUO3
MY+:1]%$S9_L^[/0X/WH23N*>HXQN:OG+7M=U#Q1K5]J^K7DNH:G?3-<7-U.V
MYY9&.68GW)KXG^Q*N+QLZN-E>/2W5=O)+^NY]5_:M/#86%/"QM+KY?YW/MG7
MO^"L7C6YN"=%\$:#I\/F [+^::Z;R^Z[E,0W?[6,>U>A_"C_ (*I:/K6JQ6'
MC[PNV@02R!5U72YC<11 ]Y(B P [LI8_[/%?FG17KSR++YPY53MYIN_]>IYD
M<VQD9<SG?Y(_H+N+?1?'OA=HIDL]=T#5K7E6VS6]U!(OXAE93^M?C'^V!\ A
M^SU\9+[1+)9#X=O4%_I,DC;CY#$@QD]RC!EYY("D]:^]_P#@F'XPO?$G[.]S
MIM[*\HT/6)K.V+$G$+)'*%R?1I'X'08KSO\ X*T:-;/X>^'>K;0+N*ZN[7>!
MRR,D;8/T*<?4U\IE,JF7YG+!WO%MK[M4_P"NY]#F*AC, L3:S5G^C1^;M%%%
M?I1\.%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !70_#W_D?O#7_83MO_ $:M<]70_#W_ )'[PU_V$[;_ -&K
M6=3X'Z%P^)'] 5?S^_$+_D?O$O\ V$[G_P!&M7] 5?S^_$+_ )'[Q+_V$[G_
M -&M7P/"OQUO1?J?8<0?#3^?Z'/4445^A'Q@5^X?[(5S<7?[,GPV>Z),@T:&
M-=W]Q1M3_P ="U^*GA#PIJ7CKQ3I/A[1K<W6J:G<QVEM$,\N[ #/H!G)/8 G
MM7[V^!?"EMX$\%:!X;LR#:Z1806,;!<;ECC"9Q[[<_C7PW%-6/LZ=+K=OY'U
MF04Y<\ZG2UC\I/\ @I9#%%^U%J#1XWR:99M)QCYMA'X_*%KY5KVO]LOQ]!\2
M/VE?'.K6D@EL8KP:?;LIRK+;HL)93W#,C,#_ +5>*5]3E\)4\)2A+=17Y'S^
M,DIXFI*.UW^8X D@ $D] *_<C]EGX3CX+? KPKX:EC\O4EMA=ZAD8/VJ7YY
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MB+XM:CX[GB9=,\.VKP03$8#W<ZE-H]<1&0GTW)ZUY>:5(TL%5E+^5K[]$=^
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M8/WYXL\*Z/\ $'PIJ.@ZU:Q:EHNIV[03PMRLB,.H(Z$<$,.00".E?BW^V/\
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M*AC^Z=\8W#KCK7GU=E.I"K%3IM-/JM4<TX2IRY9JS\PK]NOV,?\ DUSX<_\
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MUSXC?]@P_P#H:U^=W_!-/_DZ/3?^P9>?^@"OTJ_::\&ZQ\0O@+XT\.>'[/\
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MT59O]/NM*NY+6]MIK.ZCQOAN(RCKD9&01D<$'\:K5ZZ=]3SK6"BBB@04444
M%%%% !1110 4444 %%%% !1110 4444 %%%% '[5_L+?\FG_  ]_Z]9__2F6
MO>*\'_86_P"33_A[_P!>L_\ Z4RU[Q7XACO][J_XI?FS]5PG^[T_\*_(****
MX3K"BBB@ HHHH **** "BBB@ HHHH **** "O&/VRO\ DU[XC_\ 8+;_ -"6
MO9Z\8_;*_P"37OB/_P!@MO\ T):[,'_O-+_$OS.;$_P*GH_R/Q#HHHK]Q/R@
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH _;K]C'_DUSX<_P#8,'_H;5\]
M_M=_L)>/OC[\9KOQ;X?U?PY9Z;+9P6ZQ:G<W"3;D7!)"0.,>G-?0G[&/_)KG
MPY_[!@_]#:N9^.'[=G@+X!>/9O"7B'2/$=YJ,,$=PTNF6UN\)5QE0"\Z'/KQ
M7Y'1J8JGF%66#5Y7EYZ7/T:K##SP=-8EVC9??8^./^'5'Q9_Z&+P9_X&W?\
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M!N'52?XV._/8..)4NC04445]:?.!1110 4444 %%%% !7[F?LH?\FU?#3_L
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MHUH2E>/=JWY&%?.*^(INE.*L^U_\PHHHKZ4\(**_H0\,_P#(MZ3_ ->D7_H
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M_M3Q_'GP(-"URZSXYT*%5NS(?FOH/NK<CU/17]&(/\8%,_;N_99'QX\"#7=
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M)_X>K_";_H7O&?\ X!6G_P E4?\ #U?X3?\ 0O>,_P#P"M/_ )*KW?KF??\
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M6>XE-KEC]S_S/V:_X>#? '_H??\ RC:A_P#&*/\ AX-\ ?\ H??_ "C:A_\
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M34]1M]'TV[O[N3RK2UB>>:3:6VHH+,< $G !X S7XE_L<?\ )T'PW_["T?\
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M??\ RC:A_P#&*^#O^"EG_)T>I?\ 8,L__0#7RM7/@^'L+B,/3K3E*\DGNO\
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M8?+LOG^]I>\EYW,SQOXW\-_"'P1>:[KMU;Z-H&EP#H J@ 82*-!U8\*J#J<
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_M(M?MM')H_CWPH&0P:QH&LV7!'S17-M*GZJRM^1K\TQ]*>2YA'%45[DM?\
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MAO\ ]A:/^35^S7Q+_P"2<>*_^P3=_P#HEJ^(XC_WRCZ+\SZO(_\ =JGK^A^
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M_P $Z/VK[?P-?#X8>+;T0:)?SE]&O)F^2UN'/S0,>R2$Y!Z!R<_?R/NWX_?
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M]+'_ -)DKYDKZ/+?]RH_X5^1XN._WJK_ (G^84445Z1PA1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 5^F7_!)G_D0/'W_83M_P#T4:_,VOTR_P""3/\ R('C
M[_L)V_\ Z*-?.<0?\B^?JOS1[>3?[Y'Y_D'_  5F_P"1 \ _]A.X_P#10K\S
M:_3+_@K-_P B!X!_["=Q_P"BA7YFT</_ /(OAZO\V&<_[Y+Y?D%%%%?1GB!1
M110 5]W?\$G/^2D>._\ L$P_^CJ^$:^[O^"3G_)2/'?_ &"8?_1U>)G?_(OJ
M^B_-'JY7_OE/U_1GT1_P4R_Y-?N_^PM9_P VK\B:_7;_ (*9?\FOW?\ V%K/
M^;5^1->?PU_N+_Q/]#LSS_>_DOU"OO\ _P""8O[0XTS4[OX4:W=!;6]9[W0W
MD/"38S- #_M ;U'3*OW85\ 5H:%KE]X9UJPU?2[F2RU*QG2YMKB(X:*1&#*P
M/L0#7MX_"1QV'E1EUV\GT9Y6$Q,L+6C5CTW\T?M+^UY\ H?V@_@[J&CP1H/$
M-AF^T>9N,3J#^[)_NR+E3VR5/\(K\4+JVELKF6WN(FAGB<QR1R##(P."".Q!
MK]S?V</C98?'[X2Z/XKM?+BO'7[/J-HAS]FND \Q/H<AE_V76O@/_@I9^SR/
M OCN#XC:-;;-$\22E-05!\L%_@L6^DJ@M_O+(>XKX[(,7+#5I9?7TUT]>J^?
M];GTN<8:->E'&4M>_IT?]?H?%%%%%?H)\<?KM_P3-_Y-?M/^PM>?S6OG?_@K
M'_R4CP)_V"9O_1U?1'_!,W_DU^T_["UY_-:^=_\ @K'_ ,E(\"?]@F;_ -'5
M^<X/_D?3]9'VV)_Y%,?2/Z'PC1117Z,?$A1110 4444 %%%% !1110 5ZI^S
M'\73\#OC=X:\5RECIT$QM]01!DM:R#9)QW*@[P.Y45Y71656G&M"5.>S5G\S
M2G.5*:G'=:G] _B#0])^(?@^_P!)O0E_HFLV3P2&-@RRPRH1E3R.0V0?H:_#
M/XV?"/5_@?\ $O6?"&L*QELI2;>YVE5NH#S',OLP^N"".H-?>?\ P3F_:NMM
M;T2T^%'BJ]$6K62[-!N9FXN8 "?LQ/\ ?0#Y1W7@?=&?H/\ :G_99T+]I?PB
MEO/(NE>)[ ,VF:P$W&//)BD Y:-O3JIY'<-^<8*O/(L9+#XCX'U_)_Y_\ ^V
MQ5&.;8:-:C\2_IK_ "_X)^)U%>@?%WX%>-_@;KC:;XOT*XT\%RL%ZJE[2Y]X
MI1\K<<X^\.X!KS^OTBG4A5BIP=T^J/B)PE3DXS5F%7-)TJ\U[5;/3=/MI+R_
MO)DM[>WB&7DD8A54#U)('XU>\)>#M=\>:W!HWAW2+S6]4F^Y:6,+2R$9Y8@#
MA1GECP.YK]/OV+/V%E^"]S#XT\<K!>>--I%G8QL)(=,!&"VX</*02,CY5&<$
MYS7FYAF5'+Z;E-^]T75_\#S.[!X*KC)I16G5]CX]^-_[ WQ*^#6C1:U#;)XK
MT<0I)=SZ0C-+9N5RXDBY8HIS\ZY&!D[<XKYIK]L?VN/VC=/_ &=OA?>7Z3QM
MXIU%'MM&LSAF:8C_ %S+_P \X\[B>A.U?XA7XIW%Q+=W$L\\C2S2L7>1SEF8
MG))/?DUQY+C<3C:+J8B/H]K]]#IS3"T,+54*+]5V-SX>_P#(_>&O^PG;?^C5
MK^@*OY_?A[_R/WAK_L)VW_HU:_H"KY[BGXZ/H_T/9X?^&I\OU/Y_?B%_R/WB
M7_L)W/\ Z-:N>KH?B%_R/WB7_L)W/_HUJYZOOZ?P+T/CY_$PHHHK0@**** /
MJG_@FG_R='IO_8,O/_0!7Z(_MG?\FN?$;_L&'_T-:_.[_@FG_P G1Z;_ -@R
M\_\ 0!7Z(_MG?\FN?$;_ +!A_P#0UK\YSG_D;TO^W?S/MLL_Y%U3_M[\C\1:
M***_1CXD_3+_ (),_P#(@>/O^PG;_P#HHT?\%9O^1 \ _P#83N/_ $4*/^"3
M/_(@>/O^PG;_ /HHT?\ !6;_ )$#P#_V$[C_ -%"OSG_ )J#Y_\ MI]M_P R
M;Y?^W'YFT445^C'Q)U7PQ^).N?"/QSI/BOP]<FVU/3Y1(N<[)4Z/&X'5&7*D
M>A['FOVY^!OQFT/X\?#G3?%NA/MBN!Y=S:.P,EI<+C?$_N"<@]U*GH:_!ROH
M#]C;]IBZ_9U^)4<E[-+)X.U8K;ZM:J"VP?P7"K_>0G\5+#KC'S.=Y8L=2]I3
M7[R.WFNW^7_!/=RK'_5:G)-^X_P??_,^U/BQ^RL/"W[6OP[^*?A6QVZ1J&M1
MC7;:%>+:Y;.VX [+(3AO1\'G?Q]5?$O_ ))QXK_[!-W_ .B6K;T[4+;5M/MK
MZRN([NSNHEF@N(6#)+&P!5E(X((((/O6)\2_^2<>*_\ L$W?_HEJ_.)XJIB)
M4HU=X:?*_P"A]M"A"BJDJ>TM?P/P!HHHK]M/RP_3+_@DS_R('C[_ +"=O_Z*
M-'_!6;_D0/ /_83N/_10H_X),_\ (@>/O^PG;_\ HHT?\%9O^1 \ _\ 83N/
M_10K\Y_YJ#Y_^VGVW_,F^7_MQ^9M6+&^GTR^M[RUE:"YMY%EBE7JCJ<J1[@@
M57HK]&:N?$['[P? +XM6?QO^$OA[Q?:%5DO;<+=P*?\ 47*?++'^# XSU4J>
M]?F;_P %#/V?9_A1\7;CQ3I]N1X8\4RO=QNBX6WNSS-$<<#)S(O3AB!]PU%^
MP;^U1'\!?&TV@>(KEH_!.NR+Y\AR18W.-JSX_ND85_8*?X,']2_B1\.?#7QI
M\!WOASQ!;)J6B:C$&62)AN0XRDT3\X8<$,./7()!_,GSY!F#E:].7Y?YK^MS
M[I<N<8.U_?C^?^3_ *V/P+HKZ"_:-_8P\=?L_P"HW5V;.;Q#X0!+0Z[90EE1
M/2=!DQ$>I^4]F/0?/M?HU#$4L3!5*4KIGQ=6C4H2<*BLPHJ6VMI;RXB@@B>:
M:5@B1QJ69V)P  .22>,"ON+]DG_@GEK/B?5;'Q5\4M.DT?P]"1-!H%R"EU>D
M=!,O6*/U5L,W3 !R<,7C:."INI6E;RZOT-</A:N*GR4E_DO4\O\ #W[ OQ)\
M7_!/3/B!HL4%Y/?*]PGA]_W5TUM_!*A8[6+ %@G!QM(W%L#YTU32;W0]1N-/
MU*SN-/O[=S'-:W4312Q,.JLK $'V-?OEXY\;Z#\*?!6H>(==NHM+T32X/,=L
M 8 &%C1>[$X55'4D 5^'_P <_BSJ'QO^*FO^,=04Q-J$_P#H]OG/D6ZC;%']
M0@&3W.3WKPLFS+$YA*HZD5R+9_IYZ?UJ>KF>"H8.,%"7O/=?KY'"11/-(D<:
M-)(Y"JBC))/0 >M?NE^S9\*H_@O\$O"OA0QA+VVM1+?$8RUU)^\FY[X=BH]E
M [5^6'["/PE/Q8_:*T!)X/.TC0R=9O2PRN(B/*4]CF4QC'<;O0U^NGQ0\>6?
MPP^'?B+Q9?X-MI%C+=E"<>8RK\B#W9MJCW85Y7$N(=2I3P=/?=^KT7Z_>>CD
M=%0A/$S]/ENSXJ_:A_X*(^*_A+\9M9\(>#=+\/:AIVDK'!/<ZI;SR2-<[=T@
M4I,@"KN"XQG<K<]*\G_X>K_%G_H7O!?_ (!7?_R57R#KVMWGB77-1U?49C<:
MAJ%S)=W$S=7ED8L[?B235"OHJ.2X*%.,9TTVEJ^[/%JYIBIS<HS:3>Q]F_\
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M7/AS_P!@P?\ H;5^=W_!2S_DZ/4O^P99_P#H!K\YR;_D;U?^WO\ TH^US/\
MY%M/_MW\CY6HHHK]&/B@HHHH **** /UV_X)F_\ )K]I_P!A:\_FM?.__!6/
M_DI'@3_L$S?^CJ^B/^"9O_)K]I_V%KS^:U\[_P#!6/\ Y*1X$_[!,W_HZOSG
M!_\ (^GZR/ML3_R*8^D?T/A&BBBOT8^)"BBB@#]<?^"9'_)L<7_89N__ &2O
M!/\ @K/_ ,CM\/O^P?=?^C$KWO\ X)D?\FQQ?]AF[_\ 9*\$_P""L_\ R.WP
M^_[!]U_Z,2OSG!_\CZ7K+\F?;8G_ )%$?2/YH^":?%$\TB1QHTDCD*J*,DD]
M !ZTROH;]A'X2GXL?M%: D\'G:1H9.LWI897$1'E*>QS*8QCN-WH:^^Q%:.'
MI2K2VBKGQ]&DZU2-..[=C]3_ -FSX51_!?X)>%?"AC"7MM:B6^(QEKJ3]Y-S
MWP[%1[*!VKY/_:A_X*(^*_A+\9M9\(>#=+\/:AIVDK'!/<ZI;SR2-<[=T@4I
M,@"KN"XQG<K<]*^U?BAX\L_AA\._$7BR_P &VTBQENRA./,95^1![LVU1[L*
M_!37M;O/$NN:CJ^HS&XU#4+F2[N)FZO+(Q9V_$DFOSW(\'',*U7$XE<R\^[U
M_#]3[+-<3+!TZ="@[/\ 1:?UZ'U]_P /5_BS_P!"]X+_ / *[_\ DJC_ (>K
M_%G_ *%[P7_X!7?_ ,E5\945]G_9& _Y](^9_M+%_P#/QGV;_P /5_BS_P!"
M]X+_ / *[_\ DJOT*_9Q^,$?QU^#?AWQ@4@AO;R(QWUO;Y"0W*,4D4 DD+D;
M@"2=K+R>M?A17Z _\$J?BRUIK/BCX<W<V(;M!K&GHQX$J[4G4>I9?*./^F;5
MX&=93AX81U</!)QUT[=?\SU\KS&M/$*G6E=2T^9Y_P#\%,_A-_PA/QN@\56D
M'EZ;XJMA,[*N%%U$ DH].5\I_<LU?'U?LC^W_P#"?_A:'[.>M3V\(EU7PZPU
MFU(7YBL8(F7/7!B9SCN56OQNKU,AQ7UG!13WAI_E^!P9OA_88IM;2U_S_$EB
MMY9XYGCB>1(4WR,JDA%W!<L>PRRC)[D#O45?JE_P3O\ V=-,T+X'7_B/Q%86
MVI7'C>(J]M<QB1!IX+*D; Y!WG<Y]04!Y6O,/VBO^"8U_;7EUKGPFN$N[1R7
M;PW?2A)8N^()F.&'8+(01C[S9I1SW"_69X>;M9V3Z/OZ:_()93B/81K05[ZV
MZ_\ !/S\HKH/&7@'Q+\/=3.G^)]!U'0+T%@(=0MGA+XQDKN ##D<C(Y!SS7/
MU]#&2FN:+NCQG%Q=FM0KZ1_X)Y^(K[0OVK/"EO:.XAU..ZL[J-"?WD7V>23!
M]@\:-_P&OG&.-I9%1%+NQ 55&23Z"OT7_P""=7[)?B#PIXD_X6=XRTZ;1VCM
MGAT;3[I"D[&1=KSNAY0;"RJ#R=['  !;R,WKTJ.#J*H]TTEW;/2RVE4JXF'(
MMFF_0^\O%PB;PIK0F ,1LI]X;IM\MLY_"OY\Z_;/]LSXLVOPA_9]\47[S*FI
M:G;/I.G1G[SSS*5R!G^!=[_\ _"OQ,KP>%J<HT:E1[-JWR_X<]?/YQ=2$%ND
M_P ?^&.A^'O_ "/WAK_L)VW_ *-6OZ J_G]^'O\ R/WAK_L)VW_HU:_H"KCX
MI^.CZ/\ 0Z>'_AJ?+]3^?WXA?\C]XE_["=S_ .C6KGJZ'XA?\C]XE_["=S_Z
M-:N>K[^G\"]#X^?Q,****T("BBB@ HHHH **** "BBB@#]\?@O\ \D=\"?\
M8!L/_2=*_(7]N;_DZ_XA?]?</_I-%7Z]?!?_ )([X$_[ -A_Z3I7Y"_MS?\
M)U_Q"_Z^X?\ TFBK\YX=_P!_J^C_ /2D?;9U_N=/U7Y,\(HHHK]&/B0HHHH
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M"#</,V$W# -MSC((SC@U^G7^A>(-)_Y97VG7L'L\<T3K^1!4_D:_GHK]B?\
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M\;+)-)C/3A$_[:?B/R0KAX9IRAA)3>TGI\CKSV<98B,5T1[)^QQ_R=!\-_\
ML+1_R:OV:^)?_)./%?\ V";O_P!$M7XR_L<?\G0?#?\ ["T?\FK]FOB7_P D
MX\5_]@F[_P#1+5Y'$?\ OE'T7YGI9'_NU3U_0_ &BBBOT8^)"BBB@ HHHH *
M*** "BBB@#U[]F3]G76/VD?B)%H5B[66DVH$^JZGMR+6'../5V((5?7)Z*37
M[*_#3X8>%O@MX+MO#_AG3X=*TFT3<[G&^5L?-+*_\3G'+'TP,  #R;]A'X00
M?";]GG07DM_+UKQ @U>_D*X<^8,Q(>X"Q;!C^\7/>O"O^"FO[1U]X?@M/A7H
M%TUL^H6PN];FB;#&!B1';Y[!MK,P[C:.C$'\TQM:MG6.^J4G:"?Y;M_I_P $
M^YPM*EE>$^LU%>37Y[+_ #&?M1_\%)HM'GO/#'PF>"]N5!BG\42*)(8V[BV0
MC$A'_/1LKZ*PPU?GEXD\3ZOXRUJZU?7=3NM7U2Y;=-=WLK2R.?=B<X]!VK*H
MK[G!9?0P$.6BM>KZL^4Q6,K8N7-4>G;H@HHHKTCA"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _;K]C
M'_DUSX<_]@P?^AM7YW?\%+/^3H]2_P"P99_^@&OT1_8Q_P"37/AS_P!@P?\
MH;5^=W_!2S_DZ/4O^P99_P#H!K\YR;_D;U?^WO\ TH^US/\ Y%M/_MW\CY6H
MHHK]&/B@HHHH **** /TR_X),_\ (@>/O^PG;_\ HHT?\%9O^1 \ _\ 83N/
M_10H_P""3/\ R('C[_L)V_\ Z*-'_!6;_D0/ /\ V$[C_P!%"OSG_FH/G_[:
M?;?\R;Y?^W'YFT445^C'Q(4444 ?I;_P27_Y$GXA?]A"U_\ 1;U=_P""L?\
MR2_P1_V&9/\ T0U4O^"2_P#R)/Q"_P"PA:_^BWJ[_P %8_\ DE_@C_L,R?\
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MH-A95!Y.]C@  MY&;UZ5'!U%4>Z:2[MGI9;2J5<3#D6S3?H?>7BX1-X4UH3
M&(V4^\-TV^6V<_A7\^=?MG^V9\6;7X0_L^^*+]YE34M3MGTG3HS]YYYE*Y S
M_ N]_P#@'X5^)E>#PM3E&C4J/9M6^7_#GKY_.+J0@MTG^/\ PQT/P]_Y'[PU
M_P!A.V_]&K7] 5?S^_#W_D?O#7_83MO_ $:M?T!5Q\4_'1]'^AT\/_#4^7ZG
M\_OQ"_Y'[Q+_ -A.Y_\ 1K5SU=#\0O\ D?O$O_83N?\ T:U<]7W]/X%Z'Q\_
MB84445H0%%%% !1110 4444 %%%% 'W-\"/^"D]G\)OAOX:\&7W@">]MM(M?
ML[:C;ZL \I!)!$1AP.N/OFOI_P"#_P#P4+^%?Q6U*VTJYN;OPAK$Y"1PZVJK
M!*YZ*DRL5YSQOV9/ '2OQZHKYO$Y!@L0Y22<9/6Z;W]'<]NAG&*HVBVFETM_
MD?N)\;_V6/A[\>M*NH]>T2WMM9D0B'7;&-8KR%NQ+@?O /[KY')Q@\U^/?QR
M^"^O? 3XB7_A/7E5YH<2VUW$"([N!L[)5]C@@CL01VK]'O\ @FS\>=1^*'PS
MU/PKKUW)>ZMX6>*."YF;+RV<@81@GJ2AC9<^A0?7$_X*H?#JVU?X5>'_ !E'
M&@U'1M0%G))CYFMYE/!/?#HF!_M-^/SV68BOEV._L^M*\6[>G9KU['LX^A1Q
MN$^N4E9[_P"=_0_+RBBBOT4^+"BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ KH?A[_P C]X:_["=M_P"C5KGJ
MZ'X>_P#(_>&O^PG;?^C5K.I\#]"X?$C^@*OY_?B%_P C]XE_["=S_P"C6K^@
M*OY_?B%_R/WB7_L)W/\ Z-:O@>%?CK>B_4^PX@^&G\_T.>HHHK]"/C HHHH
M*^Q_^"8_PE'C3XT7GBZ\@WZ=X6MO,B+#*F[F#)'UZX02M[$*?2OCBOV6_8(^
M$Q^%?[.NAO=6_D:OX@)UF[##Y@) /)4]^(A&<=BS5\YGV*^K8*44]9Z?Y_A^
M9[>48?V^*3>T=?\ +\3N?VFOC,/@)\&=>\7Q1P7&I6ZI!I]M<AC'-<R,%0,
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MS._X*.?\G7^)/^O2Q_\ 29*^9*^F_P#@HY_R=?XD_P"O2Q_])DKYDKZ/+?\
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M110!]>?\$O\ _DY6X_[ -U_Z,AK[P_;F_P"34/B'_P!>D/\ Z4Q5\'_\$O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MR[,H8*G*$HMW=S]F?^&</A-_T2_P9_X3]I_\;H_X9P^$W_1+_!G_ (3]I_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !7Z9?\$F?^1 \??]A.W_ /11K\S:Z?PE\3_&7@&W
MN(/#'BW7?#D%PP>:+2=2FM5D8# +"-@"0.YKR\RPDL=AI4(NS=OP9WX'$K"5
MU5DKVN?H7_P5F_Y$#P#_ -A.X_\ 10K\S:Z?Q;\3_&7CZWMX/$_BW7?$<%NQ
M>&+5M2FNEC8C!*B1B 2.XKF*,MPDL#AHT).[5_Q88[$K%UW5BK7L%%%%>H<
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MG$\/UZV)G7IU4N9M]>I]50SFE3H1HSIMV5NA^S/_  SA\)O^B7^#/_"?M/\
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M #__ ##^V<+_ ,^?R/V9_P"&</A-_P!$O\&?^$_:?_&Z_"K4%":A<JH"JLK
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MF_Y$#P#_ -A.X_\ 10K\]/"7Q/\ &7@&WN(/#'BW7?#D%PP>:+2=2FM5D8#
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MCC:UK)J$@@;@CF,$*3@D9QGFO/JTH<,N4N?%U>;T_P W_D15SVT>7#T[>O\
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M8G)))CR23SFOQB_X:.^+/_14?&?_ (4%W_\ '*/^&COBS_T5'QG_ .%!=_\
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MS,78LQ+,QR23DDTVOOEL?'A1113 **** "BBB@ HHHH **** "BBB@ HHHH
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M\\+9[DQLN??(J+3?CW\3M'T^VL+#XC>+;&QMHUA@MK?7+J.**-1A451( J@
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M&K7] 5?SPVUS+9W$4\$KPS1,'22-BK(P.001R"#SD5Z!_P -'?%G_HJ/C/\
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MBFP!@9D"[F.">223D^M8'QD_:6^'GP)L)9/%/B""._5=R:1:,)KZ7C( B!R
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M_14?&?\ X4%W_P#'*\;_ %>QG_/_ /,]/^V<-_SY_(_9G_AG#X3?]$O\&?\
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M?8S*GL'YD'N7 X6OFSPG\5/&O@*SFM/#/B_7O#MI-)YLL&DZG/:H[X W,L;
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MS^)M-CPB:W;8^W1KT'FJ<"8#^]D-W)<U]\?#']H+X>?&*WC?PGXKT[4[A_\
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M7O%?B&._WNK_ (I?FS]5PG^[T_\ "OR"BBBN$ZPHHHH **** "BBB@ HHHH
M**** "BBB@ KQC]LK_DU[XC_ /8+;_T):]GKQC]LK_DU[XC_ /8+;_T):[,'
M_O-+_$OS.;$_P*GH_P C\0Z***_<3\H"BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /K_\
M8_\ V\;[X'VT/A/QC%<ZWX+W8MIHCNN=-R>0@/WXN^S((Y*_W3^F7PY^,'@O
MXMZ8M_X0\2Z?KL)7>R6TN)HA_P!-(FP\9Y'#*#R*_ ZI[6[GL;B.XMII+>XB
M8,DL3%60CH01R#]*^7Q^04,9-U8/DD]^S^1[V#S>MAHJG)<T5]_WG[V:M\'_
M  )K]Q'/J?@GPYJ4\<AE22[TFWE97)R6!9"02><UMVFG:-X/TR<VMM8:)IZ$
MSS>3&EO$O R[8P.@')[ 5^%]A\?OB?I=I':V?Q'\6VEK$,1PP:Y=(B#T"B3
MKG_$OCWQ-XTE:3Q#XBU;79&979]3OI;@E@NT$EV/(7@'TXKQEPS6E[LZ^GHW
M^IZ?]NTEK"EKZ_\  /U&_:/_ ."B7@SX::;>:5X%NK?QCXK93&D]NV^PM&Y&
MYY <2$'HJ$@]V7O^6'B7Q+JGC+7[_7-;OI=2U:_F:>YNYSEY')Y)]/8#@  #
M@5E45]7@,LH9?%JEJWNWN?/XS'5<;*]39;+H%%%%>L><%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110!^U?["W_)I_P /?^O6?_TIEKWBO!_V%O\ DT_X
M>_\ 7K/_ .E,M>\5^(8[_>ZO^*7YL_5<)_N]/_"OR"BBBN$ZPHHHH **** "
MBBB@ HHHH **** "BBB@ KQC]LK_ )->^(__ &"V_P#0EKV>O&/VRO\ DU[X
MC_\ 8+;_ -"6NS!_[S2_Q+\SFQ/\"IZ/\C\0Z***_<3\H"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** /VK_86_Y-/^'O\ UZS_ /I3+7O%>#_L+?\ )I_P]_Z]9_\ TIEK
MWBOQ#'?[W5_Q2_-GZKA/]WI_X5^04445PG6%%%% !1110 4444 %%%% !111
M0 4444 %>,?ME?\ )KWQ'_[!;?\ H2U[/7C'[97_ ":]\1_^P6W_ *$M=F#_
M -YI?XE^9S8G^!4]'^1^(=%%%?N)^4!1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '[5_L+
M?\FG_#W_ *]9_P#TIEKWBO!_V%O^33_A[_UZS_\ I3+7O%?B&._WNK_BE^;/
MU7"?[O3_ ,*_(****X3K"BBB@ HHHH **** "BBB@ HHHH **** "O&/VRO^
M37OB/_V"V_\ 0EKV>O&/VRO^37OB/_V"V_\ 0EKLP?\ O-+_ !+\SFQ/\"IZ
M/\C\0Z***_<3\H"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** /VK_86_P"33_A[_P!>L_\
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M1110 4444 %%%% !1110!^U?["W_ ":?\/?^O6?_ -*9:]XKP?\ 86_Y-/\
MA[_UZS_^E,M>\5^(8[_>ZO\ BE^;/U7"?[O3_P *_(****X3K"BBB@ HHHH
M**** "BBB@ HHHH **** "O&/VRO^37OB/\ ]@MO_0EKV>O&/VRO^37OB/\
M]@MO_0EKLP?^\TO\2_,YL3_ J>C_ "/Q#HHHK]Q/R@**** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH _:O]A;_DT_X>_]>L__ *4RU[Q7@_["W_)I_P /?^O6?_TIEKWBOQ#'
M?[W5_P 4OS9^JX3_ '>G_A7Y!1117"=84444 %%%% !1110 4444 %%%% !1
M110 5XQ^V5_R:]\1_P#L%M_Z$M>SUXQ^V5_R:]\1_P#L%M_Z$M=F#_WFE_B7
MYG-B?X%3T?Y'XAT445^XGY0%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_$T?\(+X;_Z%[2O_  "C_P#B:VZ*.:7</K>(_P"?C^]F)_P@OAO_ *%[2O\
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M_$T?\(+X;_Z%[2O_  "C_P#B:VZ*.:7</K>(_P"?C^]F)_P@OAO_ *%[2O\
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M_$T?\(+X;_Z%[2O_  "C_P#B:VZ*.:7</K>(_P"?C^]F)_P@OAO_ *%[2O\
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M\,^_"[_HFWA#_P $5K_\;KOZ*/;5?YW]X<J[' ?\,^_"[_HFWA#_ ,$5K_\
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M_11[:K_._O#E78X#_AGWX7?]$V\(?^"*U_\ C='_  S[\+O^B;>$/_!%:_\
MQNN_HH]M5_G?WARKL<!_PS[\+O\ HFWA#_P16O\ \;H_X9]^%W_1-O"'_@BM
M?_C==_11[:K_ #O[PY5V. _X9]^%W_1-O"'_ ((K7_XW1_PS[\+O^B;>$/\
MP16O_P ;KOZ*/;5?YW]X<J[' ?\ #/OPN_Z)MX0_\$5K_P#&Z/\ AGWX7?\
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M4>VJ_P [^\.5=C@/^&??A=_T3;PA_P""*U_^-T?\,^_"[_HFWA#_ ,$5K_\
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M  S[\+O^B;>$/_!%:_\ QNN_HH]M5_G?WARKL<!_PS[\+O\ HFWA#_P16O\
M\;H_X9]^%W_1-O"'_@BM?_C==_11[:K_ #O[PY5V. _X9]^%W_1-O"'_ ((K
M7_XW1_PS[\+O^B;>$/\ P16O_P ;KOZ*/;5?YW]X<J[' ?\ #/OPN_Z)MX0_
M\$5K_P#&Z/\ AGWX7?\ 1-O"'_@BM?\ XW7?T4>VJ_SO[PY5V. _X9]^%W_1
M-O"'_@BM?_C='_#/OPN_Z)MX0_\ !%:__&Z[^BCVU7^=_>'*NQP'_#/OPN_Z
M)MX0_P#!%:__ !NC_AGWX7?]$V\(?^"*U_\ C==_11[:K_._O#E78X#_ (9]
M^%W_ $3;PA_X(K7_ .-T?\,^_"[_ *)MX0_\$5K_ /&Z[^BCVU7^=_>'*NQP
M'_#/OPN_Z)MX0_\ !%:__&Z/^&??A=_T3;PA_P""*U_^-UW]%'MJO\[^\.5=
MC@/^&??A=_T3;PA_X(K7_P"-T?\ #/OPN_Z)MX0_\$5K_P#&Z[^BCVU7^=_>
M'*NQP'_#/OPN_P"B;>$/_!%:_P#QNC_AGWX7?]$V\(?^"*U_^-UW]%'MJO\
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M,^_"[_HFWA#_ ,$5K_\ &Z[^BCVU7^=_>'*NQP'_  S[\+O^B;>$/_!%:_\
MQNC_ (9]^%W_ $3;PA_X(K7_ .-UW]%'MJO\[^\.5=C@/^&??A=_T3;PA_X(
MK7_XW1_PS[\+O^B;>$/_  16O_QNN_HH]M5_G?WARKL<!_PS[\+O^B;>$/\
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MPA_X(K7_ .-UZS=_\>TG^Z:Q:RI5ZMOC?WL[L="*FK(X#_AGWX7?]$V\(?\
M@BM?_C='_#/OPN_Z)MX0_P#!%:__ !NN_HK?VU7^=_>>;RKL<!_PS[\+O^B;
M>$/_  16O_QNC_AGWX7?]$V\(?\ @BM?_C==_11[:K_._O#E78X#_AGWX7?]
M$V\(?^"*U_\ C='_  S[\+O^B;>$/_!%:_\ QNN_HH]M5_G?WARKL<!_PS[\
M+O\ HFWA#_P16O\ \;H_X9]^%W_1-O"'_@BM?_C==_11[:K_ #O[PY5V. _X
M9]^%W_1-O"'_ ((K7_XW1_PS[\+O^B;>$/\ P16O_P ;KOZ*/;5?YW]X<J['
M ?\ #/OPN_Z)MX0_\$5K_P#&Z/\ AGWX7?\ 1-O"'_@BM?\ XW7?T4>VJ_SO
M[PY5V. _X9]^%W_1-O"'_@BM?_C='_#/OPN_Z)MX0_\ !%:__&Z[^BCVU7^=
M_>'*NQP'_#/OPN_Z)MX0_P#!%:__ !NC_AGWX7?]$V\(?^"*U_\ C==_11[:
MK_._O#E78X#_ (9]^%W_ $3;PA_X(K7_ .-T?\,^_"[_ *)MX0_\$5K_ /&Z
M[^BCVU7^=_>'*NQP'_#/OPN_Z)MX0_\ !%:__&Z/^&??A=_T3;PA_P""*U_^
M-UW]%'MJO\[^\.5=C@/^&??A=_T3;PA_X(K7_P"-T?\ #/OPN_Z)MX0_\$5K
M_P#&Z[^BCVU7^=_>'*NQP'_#/OPN_P"B;>$/_!%:_P#QNC_AGWX7?]$V\(?^
M"*U_^-UW]%'MJO\ ._O#E78X#_AGWX7?]$V\(?\ @BM?_C='_#/OPN_Z)MX0
M_P#!%:__ !NN_HH]M5_G?WARKL<!_P ,^_"[_HFWA#_P16O_ ,;H_P"&??A=
M_P!$V\(?^"*U_P#C==_11[:K_._O#E78X#_AGWX7?]$V\(?^"*U_^-T?\,^_
M"[_HFWA#_P $5K_\;KOZ*/;5?YW]X<J[' ?\,^_"[_HFWA#_ ,$5K_\ &Z/^
M&??A=_T3;PA_X(K7_P"-UW]%'MJO\[^\.5=C@/\ AGWX7?\ 1-O"'_@BM?\
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M_P#QNC_AGWX7?]$V\(?^"*U_^-UW]%'MJO\ ._O#E78X#_AGWX7?]$V\(?\
M@BM?_C='_#/OPN_Z)MX0_P#!%:__ !NN_HH]M5_G?WARKL<!_P ,^_"[_HFW
MA#_P16O_ ,;H_P"&??A=_P!$V\(?^"*U_P#C==_11[:K_._O#E78X#_AGWX7
M?]$V\(?^"*U_^-T?\,^_"[_HFWA#_P $5K_\;KOZ*/;5?YW]X<J[' ?\,^_"
M[_HFWA#_ ,$5K_\ &Z/^&??A=_T3;PA_X(K7_P"-UW]%'MJO\[^\.5=C@/\
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M&??A=_T3;PA_X(K7_P"-UW]%'MJO\[^\.5=C@/\ AGWX7?\ 1-O"'_@BM?\
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M_P#QNC_AGWX7?]$V\(?^"*U_^-UW]%'MJO\ ._O#E78X#_AGWX7?]$V\(?\
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M .-T?\,^_"[_ *)MX0_\$5K_ /&Z[^BCVU7^=_>'*NQP'_#/OPN_Z)MX0_\
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MC_AGWX7?]$V\(?\ @BM?_C==_11[:K_._O#E78X#_AGWX7?]$V\(?^"*U_\
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MX(K7_P"-UW]%'MJO\[^\.5=C@/\ AGWX7?\ 1-O"'_@BM?\ XW1_PS[\+O\
MHFWA#_P16O\ \;KOZ*/;5?YW]X<J[' ?\,^_"[_HFWA#_P $5K_\;H_X9]^%
MW_1-O"'_ ((K7_XW7?T4>VJ_SO[PY5V. _X9]^%W_1-O"'_@BM?_ (W1_P ,
M^_"[_HFWA#_P16O_ ,;KOZ*/;5?YW]X<J[' ?\,^_"[_ *)MX0_\$5K_ /&Z
M/^&??A=_T3;PA_X(K7_XW7?T4>VJ_P [^\.5=C@/^&??A=_T3;PA_P""*U_^
M-UI:=^SS\*Y(&+?#/P>QW=]!M3V'_3.NMK4TO_CW;_>/\A652O5Y?C?WG;@X
M1=75'G&I?L]_"Q)4"_#3P>HV]!H-J/\ VG5/_AGWX7?]$V\(?^"*U_\ C=>F
M:K_KD_W:I4X5JO*O??WLSQ,8JK))' ?\,^_"[_HFWA#_ ,$5K_\ &Z/^&??A
M=_T3;PA_X(K7_P"-UW]%:>VJ_P [^\YN5=C@/^&??A=_T3;PA_X(K7_XW1_P
MS[\+O^B;>$/_  16O_QNN_HH]M5_G?WARKL<!_PS[\+O^B;>$/\ P16O_P ;
MH_X9]^%W_1-O"'_@BM?_ (W7?T4>VJ_SO[PY5V. _P"&??A=_P!$V\(?^"*U
M_P#C='_#/OPN_P"B;>$/_!%:_P#QNN_HH]M5_G?WARKL<!_PS[\+O^B;>$/_
M  16O_QNC_AGWX7?]$V\(?\ @BM?_C==_11[:K_._O#E78X#_AGWX7?]$V\(
M?^"*U_\ C='_  S[\+O^B;>$/_!%:_\ QNN_HH]M5_G?WARKL<!_PS[\+O\
MHFWA#_P16O\ \;H_X9]^%W_1-O"'_@BM?_C==_11[:K_ #O[PY5V. _X9]^%
MW_1-O"'_ ((K7_XW1_PS[\+O^B;>$/\ P16O_P ;KOZ*/;5?YW]X<J[' ?\
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M[\+O^B;>$/\ P16O_P ;H_X9]^%W_1-O"'_@BM?_ (W7?T4>VJ_SO[PY5V.
M_P"&??A=_P!$V\(?^"*U_P#C='_#/OPN_P"B;>$/_!%:_P#QNN_HH]M5_G?W
MARKL<!_PS[\+O^B;>$/_  16O_QNC_AGWX7?]$V\(?\ @BM?_C==_11[:K_.
M_O#E78X#_AGWX7?]$V\(?^"*U_\ C='_  S[\+O^B;>$/_!%:_\ QNN_HH]M
M5_G?WARKL<!_PS[\+O\ HFWA#_P16O\ \;H_X9]^%W_1-O"'_@BM?_C==_11
M[:K_ #O[PY5V. _X9]^%W_1-O"'_ ((K7_XW1_PS[\+O^B;>$/\ P16O_P ;
MKOZ*/;5?YW]X<J[' ?\ #/OPN_Z)MX0_\$5K_P#&Z/\ AGWX7?\ 1-O"'_@B
MM?\ XW7?T4>VJ_SO[PY5V. _X9]^%W_1-O"'_@BM?_C='_#/OPN_Z)MX0_\
M!%:__&Z[^BCVU7^=_>'*NQP'_#/OPN_Z)MX0_P#!%:__ !NC_AGWX7?]$V\(
M?^"*U_\ C==_11[:K_._O#E78X#_ (9]^%W_ $3;PA_X(K7_ .-T?\,^_"[_
M *)MX0_\$5K_ /&Z[^BCVU7^=_>'*NQP'_#/OPN_Z)MX0_\ !%:__&Z/^&??
MA=_T3;PA_P""*U_^-UW]%'MJO\[^\.5=C@/^&??A=_T3;PA_X(K7_P"-T?\
M#/OPN_Z)MX0_\$5K_P#&Z[^BCVU7^=_>'*NQP'_#/OPN_P"B;>$/_!%:_P#Q
MNC_AGWX7?]$V\(?^"*U_^-UW]%'MJO\ ._O#E78X./\ 9]^%ID0'X:^$,9'_
M # K7_XW6VW[.OPH"G_BV/@W_P $%I_\;KHXO]:GU%;[?=/TKAQ%>JFK3?WL
M^DRJG"4)WBGKV/)_^&?/A;_T37PA_P""&U_^-T?\,^?"W_HFOA#_ ,$-K_\
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M .-UW]%'UBM_._O8>PI?RK[C@/\ AGSX6_\ 1-?"'_@AM?\ XW1_PSY\+?\
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MM_Z)KX0_\$-K_P#&Z[^BCZQ6_G?WL/84OY5]QP'_  SY\+?^B:^$/_!#:_\
MQNC_ (9\^%O_ $37PA_X(;7_ .-UW]%'UBM_._O8>PI?RK[C@/\ AGSX6_\
M1-?"'_@AM?\ XW1_PSY\+?\ HFOA#_P0VO\ \;KOZ*/K%;^=_>P]A2_E7W'
M?\,^?"W_ *)KX0_\$-K_ /&Z/^&?/A;_ -$U\(?^"&U_^-UW]%'UBM_._O8>
MPI?RK[C@/^&?/A;_ -$U\(?^"&U_^-T?\,^?"W_HFOA#_P $-K_\;KOZ*/K%
M;^=_>P]A2_E7W' ?\,^?"W_HFOA#_P $-K_\;H_X9\^%O_1-?"'_ ((;7_XW
M7?T4?6*W\[^]A["E_*ON. _X9\^%O_1-?"'_ ((;7_XW1_PSY\+?^B:^$/\
MP0VO_P ;KOZ*/K%;^=_>P]A2_E7W' ?\,^?"W_HFOA#_ ,$-K_\ &Z/^&?/A
M;_T37PA_X(;7_P"-UW]%'UBM_._O8>PI?RK[C@/^&?/A;_T37PA_X(;7_P"-
MT?\ #/GPM_Z)KX0_\$-K_P#&Z[^BCZQ6_G?WL/84OY5]QP'_  SY\+?^B:^$
M/_!#:_\ QNC_ (9\^%O_ $37PA_X(;7_ .-UW]%'UBM_._O8>PI?RK[C@/\
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M^B:^$/\ P0VO_P ;KOZ*/K%;^=_>P]A2_E7W' ?\,^?"W_HFOA#_ ,$-K_\
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M._O8>PI?RK[C@/\ AGSX6_\ 1-?"'_@AM?\ XW1_PSY\+?\ HFOA#_P0VO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !7VS\"?^23>'?^N3_P#H
MUZ^)J^V?@3_R2;P[_P!<G_\ 1KUXN:_P8^OZ,_2.!?\ D85?\#_]*B=[1117
MRY^X!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 5-9_\ 'U']:AJ:S_X^H_K4O9FE+XX^J-2[_P"/:3_=
M-8M;5W_Q[2?[IK%K&CLSOQ_QQ] HHHKH/,"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "K6F_\?0^AJK5K3?\ CZ'T-1/X6;T/XL?4NZC_
M ,>K?4?SK(K7U'_CU;ZC^=9%9TOA.G'?Q%Z!1116YYX4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% #X?]='_ +PK;D_U;?0UB0_ZZ/\ WA6W)_JV^AKFJ[H]?!?!(P:***Z3
MR HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *U-+_ ./=O]X_R%9=:FE_\>[?[Q_D*QJ_"=V"_BD&
MJ_ZY/]VJ57=5_P!<G^[5*JA\*,L3_&D%%%%:',%%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M Z+_ %J?45OM]T_2L"+_ %J?45OM]T_2N#$[H^FRCX)^IC4445QGT04444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %6M-_X^
MA]#56K6F_P#'T/H:B?PLWH?Q8^I=U'_CU;ZC^=9%:^H_\>K?4?SK(K.E\)TX
M[^(O0****W//"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH ?#_KH_P#>%;<G^K;Z&L2'_71_
M[PK;D_U;?0US5=T>O@O@D8-%%%=)Y 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %:FE_\>[?[Q_D
M*RZU-+_X]V_WC_(5C5^$[L%_%(-5_P!<G^[5*KNJ_P"N3_=JE50^%&6)_C2"
MBBBM#F"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !5K3?\ CZ'T-5:M:;_Q]#Z&HG\+-Z'\6/J7=1_X]6^H
M_G616OJ/_'JWU'\ZR*SI?"=.._B+T"BBBMSSPHHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** '
MP_ZZ/_>%;<G^K;Z&L2'_ %T?^\*VY/\ 5M]#7-5W1Z^"^"1@T445TGD!1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 5J:7_Q[M_O'^0K+K4TO_CW;_>/\A6-7X3NP7\4@U7_7)_NU
M2J[JO^N3_=JE50^%&6)_C2"BBBM#F"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4Z+_ %J?44VG1?ZU
M/J* .FHHHH("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KF_B3_R3WQ+
M_P!@VX_]%M725S?Q)_Y)[XE_[!MQ_P"BVK:C_$CZHX,P_P!SK?X9?DS\W:**
M*_5S^$0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ K[9^!/_))O#O_ %R?_P!&O7Q-7VS\"?\ DDWAW_KD_P#Z->O%
MS7^#'U_1GZ1P+_R,*O\ @?\ Z5$[VBBBOES]P"BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J:S_X^H_K
M4-36?_'U']:E[,TI?''U1J7?_'M)_NFL6MJ[_P"/:3_=-8M8T=F=^/\ CCZ!
M11170>8%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %6M-_
MX^A]#56K6F_\?0^AJ)_"S>A_%CZEW4?^/5OJ/YUD5KZC_P >K?4?SK(K.E\)
MTX[^(O0****W//"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ?#_ *Z/_>%;<G^K;Z&L2'_7
M1_[PK;D_U;?0US5=T>O@O@D8-%%%=)Y 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %:FE_\ 'NW^
M\?Y"LNM32_\ CW;_ 'C_ "%8U?A.[!?Q2#5?]<G^[5*KNJ_ZY/\ =JE50^%&
M6)_C2"BBBM#F"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4Z+_6I]13:=%_K4^HH
MZ:BBB@@**** "BBB@ HHHH **** "BBB@ HHHH **** "N;^)/\ R3WQ+_V#
M;C_T6U=)7-_$G_DGOB7_ +!MQ_Z+:MJ/\2/JC@S#_<ZW^&7Y,_-VBBBOU<_A
M$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *^V?@3_ ,DF\._]<G_]&O7Q-7VS\"?^23>'?^N3_P#HUZ\7-?X,?7]&
M?I' O_(PJ_X'_P"E1.]HHHKY<_< HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *FL_P#CZC^M0U-9_P#'
MU']:E[,TI?''U1J7?_'M)_NFL6MJ[_X]I/\ =-8M8T=F=^/^./H%%%%=!Y@4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** '1?ZU/J*WV^Z?I6!%_K4^HK?;[I^E<&)W1]-E'P
M3]3&HHHKC/H@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH ***YKXB^*5\(^%+N\5@+IQY-N/61AP?P&3^% CQ
M/XT>*SXA\5O:1/NL].S"F#P7_C;\QC_@-<WX,\-R>+/$EEIJ9"2/F5Q_!&.6
M/Y=/?%8A8LQ).2>23WKWKX">%18://K<Z8GO"8X21TB!Y/XL/_'102>IP01V
MT$<,2".*-0B*O10. !3Z**"PHHHH *CN;>.\MY8)D$D,JE'1NC*1@C\JDHH
M^2/&'AV3PKXCO=-D!VQ/F-C_ !QGE3^1'XYKI_@MXJ_X1_Q6EG,VVTU'$+<\
M"3/R'\R1_P "KN/CYX4^VZ5;ZY"N9K3$4V.\;'@_@Q_\>/I7A"LT;AE)5@<@
M@X(-!!]GT5SGP]\4+XN\*V=ZS W('E7 ':1>OY\'\:Z.@H****!A1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %.B_UJ?44V
MG1?ZU/J* .FHHHH("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KF_B3_
M ,D]\2_]@VX_]%M725S?Q)_Y)[XE_P"P;<?^BVK:C_$CZHX,P_W.M_AE^3/S
M=HHHK]7/X1"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "OMGX$_P#))O#O_7)__1KU\35]L_ G_DDWAW_KD_\ Z->O
M%S7^#'U_1GZ1P+_R,*O^!_\ I43O:***^7/W **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M $-.M?\ @PF_^*H_X61XN_Z&G6O_  83?_%5SM%'LX?RH/KF)_Y^2^]G1?\
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M9'B[_H:=:_\ !A-_\57.T4>SA_*@^N8G_GY+[V=%_P +(\7?]#3K7_@PF_\
MBJ/^%D>+O^AIUK_P83?_ !5<[11[.'\J#ZYB?^?DOO9T7_"R/%W_ $-.M?\
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M'B[_ *&G6O\ P83?_%5SM%'LX?RH/KF)_P"?DOO9T7_"R/%W_0TZU_X,)O\
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M[.'\J#ZYB?\ GY+[V=%_PLCQ=_T-.M?^#";_ .*H_P"%D>+O^AIUK_P83?\
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M3K7_ (,)O_BJYVBCV</Y4'US$_\ /R7WLZ+_ (61XN_Z&G6O_!A-_P#%4?\
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M3K7_ (,)O_BJYVBCV</Y4'US$_\ /R7WLZ+_ (61XN_Z&G6O_!A-_P#%4?\
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MG1?\+(\7?]#3K7_@PF_^*H_X61XN_P"AIUK_ ,&$W_Q5<[11[.'\J#ZYB?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M=%_K4^HK?;[I^E8$7^M3ZBM]ONGZ5P8G='TV4?!/U,:BBBN,^B"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "G1?ZU
M/J*;3HO]:GU% '34444$!1110 4444 %%%% !1110 4444 %%%% !1110 5S
M?Q)_Y)[XE_[!MQ_Z+:NDKF_B3_R3WQ+_ -@VX_\ 1;5M1_B1]4<&8?[G6_PR
M_)GYNT445^KG\(A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !7VS\"?^23>'?^N3_^C7KXFK[9^!/_ "2;P[_UR?\
M]&O7BYK_  8^OZ,_2.!?^1A5_P #_P#2HG>T445\N?N 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %36
M?_'U']:AJ:S_ ./J/ZU+V9I2^./JA_B__D4]9_Z\YO\ T U^<%?H_P"+_P#D
M4]9_Z\YO_0#7YP5[V1_!4]4?EGB9_'POI+\T%%%%?3'XL%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 5]L_ G_DDWAW_ *Y/_P"C7KXFK[9^!/\ R2;P[_UR?_T:]>+FO\&/
MK^C/TC@7_D85?\#_ /2HG>T445\N?N 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %36?_'U']:AJ:S_X
M^H_K4O9FE+XX^J'^+_\ D4]9_P"O.;_T U^<%?H_XO\ ^13UG_KSF_\ 0#7Y
MP5[V1_!4]4?EGB9_'POI+\T%%%%?3'XL%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M,<'_ 'ZE_P#B:/JN(_Y]R^YA_;V4_P#073_\#C_F=_17 ?\ "^? 7_0QP?\
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MT_\ !9-_\;H%<^_:*^.?@GX@^-%Y\4= A\31>*%T-I7%T;^PECAV^6V-S%
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MH **** "BBB@ HHHH *=%_K4^HIM.B_UJ?44 =-11100%%%% !1110 4444
M%%%% !1110 4444 %%%% !7-_$G_ ))[XE_[!MQ_Z+:NDKF_B3_R3WQ+_P!@
MVX_]%M6U'^)'U1P9A_N=;_#+\F?F[1117ZN?PB%%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?;/P)_P"23>'?^N3_
M /HUZ^)J^V?@3_R2;P[_ -<G_P#1KUXN:_P8^OZ,_2.!?^1A5_P/_P!*B=[1
M117RY^X!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 5-9_P#'U']:AJ:S_P"/J/ZU+V9I2^./JA_B_P#Y
M%/6?^O.;_P! -?G!7Z/^+_\ D4]9_P"O.;_T U^<%>]D?P5/5'Y9XF?Q\+Z2
M_-!1117TQ^+!1110 445Z7\#OA##\7M6U.RFU)]-%G LP=(1)NRV,8)&*RJU
M84(.I4=DCOP.!KYEB883#1O.6RNETON]#S2BOJW_ (8EL?\ H:[C_P  E_\
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MZ')-J]KIZ.ZZ-]F%%%%;GE!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5WOP)_Y*SX=_ZZO_ .BG
MK@J[WX$_\E9\._\ 75__ $4]88C^#/T?Y'J95_R,,/\ XX_^E(^V:***^$/Z
MD"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH =%_K4^HK?;[I^E8$7^M3ZBM]ONGZ
M5P8G='TV4?!/U,:BBBN,^B"BBB@ HHHH **** "BBB@ HHHH *1T61&1U#*P
MP589!'I2T4":N?"7Q<\$'P!XZU#3$4BS8^?:$]XFY4>^.5^JFM3X#>.AX'\?
MVC3R^7IU_P#Z)<Y/RJ&/R.?]UL<^A:O=/VG? A\1^#4UJVBW7ND$R/@<M ?O
MC_@)PWL WK7R-7Z+@ZL<PP?+4WM9_P"?ZG\B9_@ZO"7$'M<,K134X=K-_#Z+
M6+\O4_1ZBO/?@5X[/COP#:33OOU&R_T2ZR>690-K_P# EP?KGTKT*OS^K2E1
MJ2IRW1_5N QM+,<+3Q=!^[-)KY]/5;,****R.\**** "BBB@ HHJAK^MVOAO
M1;[5+UMEK9Q--(1UP!G ]ST ]::3DTEN9U*D:4'4F[)*[?9(^?/VK_'1:6Q\
M*6LORKB[O-I[_P#+-#^&6Q[J:^>K"QGU.^M[.UC,US/(L44:]69C@ ?B:M^)
MO$%SXJ\0:AJ]V<W%Y,TK#.0N3PH]@, >PKU[]EKP(=:\3S^(KE,VFEC9#D<-
M.P_]E4D_5EK]&@HY9@M>B^]O_@G\A8B=;C/B*T+VJ2LO[L%U^[7U?F?1_@/P
ME;^!O"6FZ-;X/V>("20#_62'EV_%B?PP.U?/'[57CO\ M37K7PQ;/FWTX":Y
MQT:9E^4?\!4_^/GTKZFKF;[X9>$]3O)KN[\/:=<7,SF22:6W5F=B>23CK7Q>
M#Q4*.(]O63D_U?4_HSB#),1F&5+*\OFJ<=$[W^&.R5O-+Y*W4^!Z*^\?^%2^
M#/\ H6-+_P# 9?\ "C_A4O@S_H6-+_\  9?\*^C_ +>H_P C_ _'_P#B%N8?
M]!$/NE_D?!U%?>/_  J7P9_T+&E_^ R_X4?\*E\&?]"QI?\ X#+_ (4?V]1_
MD?X!_P 0MS#_ *"(?=+_ "/@ZBO2_P!H;0M/\/?$>:STRSAL+46T3"&W0*N2
M#DX%<S\,[&WU/X@^';2[A2XMIKZ))(I!E74L,@CN*]Z%=3H*NEI:Y^78C*ZF
M'S*66RDG)3Y+]+WM?T.:HK[Q_P"%2^#/^A8TO_P&7_"C_A4O@S_H6-+_ / 9
M?\*\'^WJ/\C_  /U'_B%N8?]!$/NE_D?!U%?>/\ PJ7P9_T+&E_^ R_X4?\
M"I?!G_0L:7_X#+_A1_;U'^1_@'_$+<P_Z"(?=+_(\%_96\=C2O$%UX:NI2+?
M41YMMN/"S*.1_P "4?\ C@]:^A_'WA*#QSX1U/1IMH-S$?*=O^6<HY1OP8#Z
MC([U#8_#+PGIEY#=VGA[3K>YA<21S16ZJR,#P0<=:Z:OG,9BH5L0L113B]/O
M1^O\/Y'B,ORIY7F$U4CJE:_PRW3OZOY/R/SHO[&?3+ZXL[J,PW,$C12QMU5@
M<$'\17T-^RAXZ"O?>%+J7[V;NS#'O_RT0?HP'LQK!_:D\"#1/%,'B&V3%KJH
MVS8'"SJ!G_OI<'ZJQKR/PQXAN?"GB#3]7LS_ *19S+*H/1@.JGV(R#]:^TFH
MYG@KKJON:_X)_.F'G6X,XBM/:G*S_O0?7_P%I^I^A=%4=!UJV\1Z+8ZI9MOM
M;R%9HSW 89P?<=#[BKU?G+3BVGN?U[3J1JP52#NGJGW3"BBBD:!1110 4444
M %%%>=?'GQW_ ,(/X NVMY?+U*__ -$ML'Y@2/G<?[JYY]2M;4:4JU2-..[/
M/S#&TLMPM3%UG[L$V_ET]7LO,^:/CIXZ'CKQ]=S02;].LO\ 1+7!R&52=S_\
M";)^F*H_!_P.?'WCO3].DC+V,9^T79[")2,@_P"\<+_P*N+KZ\_9E\"_\(UX
M+.L7"8O=8(E&>JP#/EC\<EOH5]*^^QE6.7X/EAOLO\_U/Y4X>P57BSB#VV)5
MXMN<^UD_A]&[1]/0]A1 BA5 50,  8 I:**_.S^NDK!1110,**** "OS3_YN
M'_[FG_V[K]+*_-/_ )N'_P"YI_\ ;N@EGZ64444%!1110!X!^VU_R1R#_L*P
M?^@25SO[!W_(I>*?^OZ+_P!%UT7[;7_)'(/^PK!_Z!)7SK\!_P!HW_A26D:I
M8_\ "/?VU]NG6;S/MOD;,+C&/+;/Z4$GZ$T5\C_\-]?]2)_Y5_\ [11_PWU_
MU(G_ )5__M% [A^WU_S(G_;_ /\ MO7J'[('_)"=&_Z[W/\ Z.:OE/X_?'[_
M (7E_8/_ !(?[$_LOS_^7S[1YOF>7_TS3&/+]\Y]J^K/V0/^2$Z-_P!=[G_T
M<U CVBBBB@HIZQ_R"+[_ *X/_P"@FOSK_9C_ .2[>$O^N\G_ *)DK]%-8_Y!
M%]_UP?\ ]!-?F'\,?&W_  KCQWI/B3[%_:/V!V?[+YOE;\HRXW;6Q][/0]*"
M6?J117R/_P -]?\ 4B?^5?\ ^T4?\-]?]2)_Y5__ +10.Y]<45Y3\!/CK_PN
M^TUF?^P_[%_LYXDV_:_/\S>&.?N+C&WWZUZM0 4444#/S?\ VG/^2[>+?^N\
M?_HF.OT@K\W_ -IS_DNWBW_KO'_Z)CK](*"4%?,?[8WP=TFX\(3^-M-LXK/5
M;&5!>M"H47,3L$W,!U8,RG=UQG/08^G*\!_;(^(.GZ!\,;CPX)T;5]9:-4@4
MY=(4D5VD([ [=HSUR<=#@&SD/V$O%UQ<:?XD\-3.7@MFCO;<'G;ORL@^F50X
M]2?6OJVOD7]@WP]<"3Q5KCHRVI6&RC8CAWR7<?@-G_?5?75 (****!G+_$[Q
MO;_#GP)K/B&XVG[' 3%&W_+24_+&OXL0/ID]J^*OV8/AZWQ:^*UUJVN1C4-/
ML=]]?&896>>0G8K?5BS_ / #7;_MP_$C[9JFF>"K27,5H!?7P7O*P(B4_126
MQ_MKZ5[1^RW\.?\ A7_PIL&N(O+U/5L:A<Y'S ,!Y:'OPF..Q9J"3Y&#7G[-
MGQ_/^L>WTN]Z#K<6<@_(DQM^##VK]$K.[AU"S@NK:59[>=%EBD0Y5U89!'L0
M17R[^W%\.OMVCZ7XSM8\RV1%C>D#_EDS$QL?HY*_]M!Z5T_[&WQ(_P"$L^'3
MZ!=2[]0T%A$NX\M;MDQG_@.&7V"KZT!L?0%%%%!05\Z_MS_\DETG_L.0_P#H
MBXKZ*KYU_;G_ .22Z3_V'(?_ $1<4"93_83_ .2>>(/^PK_[1CKZ6KYI_83_
M .2>>(/^PK_[1CKZ6H$CG?'7P_T+XCZ%-I.NV,=Y;R*=DA \R%NSQMU5A_\
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MH&?#/[<__)6M)_[ </\ Z/N*^K/@7_R1OP9_V"K?_P! %?*?[<__ "5K2?\
ML!P_^C[BOJSX%_\ )&_!G_8*M_\ T 4$H[JBBB@H_-_XB?\ )R&L?]C&?_1X
MK](*_-_XB?\ )R&L?]C&?_1XK](*"4%%%%!05\I?MZ_\@GP;_P!=[K_T&.OJ
MVOE+]O7_ )!/@W_KO=?^@QT"9UW[$O\ R1R?_L*S_P#H$=>_UX!^Q+_R1R?_
M +"L_P#Z!'7O] D%%%%!05^;^C?\G/6/_8X1_P#I:*_2"OS?T;_DYZQ_['"/
M_P!+102S](****"@KY+_ &U_BU<6K6O@739VB26-;K4W0X+*3^[B^G&XCO\
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MP[X@T_Q5H=EJ^EW"W6GWD8EAF7^('V[$<@@]""#6C6FYR--.S"BBBF(****
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M!_&O-R['5,5*=.LDI1['U_%O#.%R6EAL7@)RG2JK>5GK9-;);I_@95>@Z!\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 5WOP)_Y*SX=_ZZO_Z*>N"KO?@3_P E9\._]=7_ /13UAB/X,_1
M_D>IE7_(PP_^./\ Z4C[9HHHKX0_J0**** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M!T7^M3ZBM]ONGZ5@1?ZU/J*WV^Z?I7!B=T?391\$_4QJ***XSZ(**** "BBB
M@ HHHH **** "BBB@ HHHH CN;:*[MI8)D$L,J%'1AD,I&"#^%?!?Q*\&R>
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MX_Z](?Y&N2^$O_)3?#'_ &$(?_0A7Z/A_P#D7Q_P_H?QWF?_ "5=3_K_ /\
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M3KY;_;@^(_\ 9VA:;X,M)<37Y%Y>@=1"K?NU/^\X)_[9T"/EX^+[;Q)\3/\
MA)?%4,MY9W.H?;+VV@PS2)NW>4N2!C "]>!7U>/V[/"0&!X?UD =@(?_ (NL
M;]F']G/PYXB^'0U_Q9HZ:C/J4Q>T661T\N!?E!PK#[S!CSVVUZ]_PS%\,/\
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M !1110 4444 %%%% !1110 5S?Q)_P"2>^)?^P;<?^BVKI*YOXD_\D]\2_\
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M^9]&^&_VZM2CF1=?\,VEQ$?O2:;,T17W"ONS_P!]"OHKX;?&;PK\5;4MH>H
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MLQ//?CC\7/\ A3'A.TUO^R?[8\^]2S\C[3Y&W='(^[=L;/\ J\8QWZ\5X?\
M\-Z_]2-_Y5__ +15G]K[XD>%O&'PTTVRT37]/U6[CU>*9H;6=794$,P+$#ME
M@/Q%?(5<%6K*,K19]+@L%2J4N:K'7YH_3#X.?$S_ (6UX)A\0_V;_97F320_
M9O/\[&TXSNVKU^E=Q7S3^RQ\4/"7A7X26MAK'B+3M-O5NYW-O<W"HX!;@X/K
M7O\ X;\7Z)XQM);G0]4M=5MXG\MY;24.JM@'!([X(KJA+FBKO4\7$T73J22C
M:*9\;_MN:+J%M\2M.U.97;3KK3TBMY<?*K(S;T^OS!O^!5\[5^FOQ+U3P*NG
M1Z5XXNM+CM+O+QP:DZKO*XRRYY!&1R.>:\FT3PI^SIH.II?6]]H<TR,'C6ZU
M-IHT/7[CN0?^! ]*Y:E*\KIGM87'<E%1E!NW9;G8?LJZ+J&A_!318M0C:%YF
MEN8HGZK$[DKQVR/F_P"!5ZY573=3L]5TZWOK&XCN;*>,213PG<CH1D$$=17(
M?\+S^'W_ $.6C?\ @6G^-=BM%)7/"GSUYRFH[L[FBN3T;XM>#/$.IP:=IGB?
M2[Z^G)$5O#<JSN0"3@9YX!-=95)I[&,HRCI)6"BBN,O/C/X$T^\GM;KQ;I$%
MS!(T4L3W2AD93@J1GJ""*&TMPC"4_A5SLZ*XRR^,W@74KR"TM?%FDW%U<2+%
M%#'=*S2.QPJ@=R20/QKLZ$T]@E"4/B5@HIDT\=M$\LLBQ1("SNYPJCN23T%>
M?ZG^T)\.=)N&@G\7:>T@X/V=FF7_ +Z0$?K2;2W'&G.?PJYZ'17+>%?BEX2\
M;R^5H?B&PU"?&?L\<P$N,==APV/?%7/$_CKP]X+^S?V]K-EI/VG=Y/VN81^9
MMQNQGKC<OYBBZM</9S4N6VINT5PW_"\_A]_T.6C?^!:?XUV&FZE:ZQI]O?6-
MQ'=V=P@DBGB;<DBGH0>XH33V82ISCK)6.;^*WCW_ (5CX U3Q-]A_M+[#Y7^
MB^=Y6_?*D?WMK8QOST/3%?/'_#>O_4C?^5?_ .T5VG[3OQ,\*:M\(/%&B67B
M'3[K5]\$?V**=6EW)=1EQMZY 5L_0U\+UQUJLHRM%GOX#!TJM)RK1UOYKHC]
M&O@3\:O^%U:1J=]_8W]C?8IU@\O[5Y^_*YSG8N/UKTZOD/\ 8Y^(/AKP;X7\
M00:YKECI,TUXCQI=S!"ZA,9&:^GO#/CWPYXS>=-"UJRU9[<!I5M)A(4!S@G'
M3.#^5=%.?-%7>IY>+H>RJR4(VBC>HHIDT\=M$\LLBQ1("SNYPJCN23T%;'"/
MHK@-6^/OP\T2=H;KQ=IID4X(MY#/@^YC#4:1\?/AYKEPL%KXMTWS6.U5GD,&
M3Z R!:CFCW-O8U;7Y7;T9W]%,AF2XC26)UEC<;E=#D,/4&GU9B%%5M2U*UT?
M3[B^OKB.TL[=#)+/*VU(U'4D]A7'_P#"\_A]_P!#EHW_ (%I_C4MI;LN,)3^
M%7.YHK!\,^/?#GC-YTT+6K+5GMP&E6TF$A0'."<=,X/Y5)XF\;:!X-@6;7=9
MLM*1_N?:IU1G_P!T$Y;\!3NK7#DE?EMJ;5%9OAWQ)IOBW1X-5TB[CO\ 3IRX
MBN(\[7VL4;&1V92/PK2HW)::=F%%%%,04444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %36?_'U']:AJ:S_ ./J/ZU+V9I2^./JA_B__D4]9_Z\
MYO\ T U^<%?H_P"+_P#D4]9_Z\YO_0#7YP5[V1_!4]4?EGB9_'POI+\T%%%%
M?3'XL%%%% !1110!;TG_ )"ME_UV3_T(5^B7Q5_Y)?XP_P"P/>?^B'K\[=)_
MY"ME_P!=D_\ 0A7Z)?%7_DE_C#_L#WG_ *(>OE<Z_C4/7]4?N?AU_P B_,O\
M,?\ TF9^<5%%%?5'X8?6W[&GC#[;X>U?PU,W[RQE%U!GO&_# ?1AG_@=<!^V
M!X2&C?$*UUF)-L.KVP+D#K+'A6_\=,?ZUQO[/WC#_A"_BKHUR\GEVEV_V&X)
M.!LDP 3[!]C?\!KZ;_:M\)CQ%\*Y[Z--USI$R72D=3&3L<?3#!O^ 5\I47U/
M-(S^S/\ 7_@V9^ZX27^L'!53#O6IAG=>D=5_Y(W%>AXA^R-X1_MWXD2ZM*@:
MWT>W,H)&1YKY1!^7F'_@(KM?VSO&>R'1?"T$G+DW]R >PRD8/X[S^ KM_P!E
M'PE_PCGPNCU"5-EQJ\S73$]1&/D0?3"EO^!U\I?%[QB?'GQ%UO5U<O;R3&*V
MYX$2?*F/J!G\36E)?7,SE4^S3T^?_#W9S8Z7]@<&T<(M*F*?,_\ "[/_ -)Y
M4_5F%X8_Y&72?^OR'_T,5^C?B[7E\+^%=7UAE#BPM);D(?XBJ$@?B0!^-?G)
MX8_Y&72?^OR'_P!#%?H1\5--FU?X:^*+.W4O/+ILX1!U9MA( ^O3\:RSI*5:
MBI;?\%'=X<3G3R_,)TOB237KRRL?G=JNIW.M:G=:A>S-<7ES(TTLKG)9F.2?
MUJK117UB22LC\'E*4Y.4G=L^Y_V7?&-QXM^%EO'>2&6YTN=K NQRS(JJR$_1
M6"_\!KYC_:/T1-"^,?B".)0D5PZ7:@#',B*S'_OHM7T%^QSI4UE\,[Z[E!5+
MS47>+CJJHBY_[Z##\*\,_:GO4O/C-JJ(P;[/#!$Q'KY:L?\ T*OE,"E#,ZT8
M;:_FC]TXEE*OP9@*N(^.\;/K;EE^:29]B?#O1QX9^'>@V$$19K;3X@8_NEI-
M@+=>A+$_G7Q_KG[/GQ5\1:S>ZI?>'C+=WDS32N;^VY9CDX_>=*^S_#^I"\\)
M:;J%NGG"6QCGC1#][,88 'WKP@_MJZ.#@^&KX'_KNG^%>9@*F+A4J2P\%)MZ
MW^?FC[/B?!Y#7PN$HYKB94H17N*.STBOY9;*UMMSQK_AF+XE_P#0M_\ D_;?
M_'*^NO@GI>OZ'\-=(TSQ);-:ZI9*T!1I4E)C#'R_F1B,!2!U[5Y5_P -K:-_
MT+5__P!_T_PH_P"&UM&_Z%J__P"_Z?X5UXN.8XR"A4I+1WT_X<\'(JW"/#V(
MEB<)CI-R7*U+56NGTIK73N?/?QFT:/0?BIXGLHD$<2WTDB(,857.\ >V&KC:
MZ7XE>+H_'GCG5]>BMVM8[V0.L+G)4!0O)_"N:KZV@I*E%3WLK^MC\&S.=*IC
M:\Z#]QSDX^EW;\ KN_@3_P E@\*?]?J_R-<)7=_ G_DL'A3_ *_5_D:G$_P)
M^C_(VR;_ )&6&_QP_P#2D?4G[6W_ "2"?_K]@_F:^(*^W_VMO^203_\ 7[!_
M,U\05X^1_P"ZOU?Z'WWB7_R.U_@C^<@HHHKZ _*3[?\ V2?^200?]?L_\Q7S
M/^T3_P EH\4?]=T_]%)7TQ^R3_R2"#_K]G_F*^9_VB?^2T>*/^NZ?^BDKY7
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH *=%_K4^HIM.B_UJ?44 =-11100%%%% !1110 4444 %%%% !1110
M4444 %%%% !7-_$G_DGOB7_L&W'_ *+:NDKF_B3_ ,D]\2_]@VX_]%M6U'^)
M'U1P9A_N=;_#+\F?F[1117ZN?PB%%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %?;/P)_Y)-X=_ZY/_ .C7KXFK[9^!
M/_))O#O_ %R?_P!&O7BYK_!CZ_HS](X%_P"1A5_P/_TJ)WM%%%?+G[@%%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 5WOP)_Y*SX=_ZZO_Z*>N"KO?@3_P E9\._]=7_ /13UAB/X,_1_D>IE7_(
MPP_^./\ Z4C[9HHHKX0_J0**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!T7^M3ZB
MM]ONGZ5@1?ZU/J*WV^Z?I7!B=T?391\$_4QJ***XSZ(**** "BBB@ HHHH *
M*** "BBB@ HHHH **** *6N:/:^(='O=,O4\RUNXFAD7O@C&1[CJ#[5\!^*O
M#USX3\1ZCH]V")[.9HB<8W#^%A[$$$>QK]":^<?VK_ N18^*[5.F+2\P/QC<
M_JI/^Z*^BR7%>RK.C+:7Y_\ !_R/R'Q&R7Z]EZQ])>_1W\X/?[GKY*YSO[+?
MCL:'XIG\/W4FVTU09AR>%G4<?]]+D?4+7UA7YT6%]/IE];WEK(8;F"198I%Z
MJRG((_$5]Z_#_P 80>._"&G:S 5#3Q@31J?]7*.'7\#G'M@UMGF%Y*BQ$=GH
M_7_AOR.#PTSKZQA9Y55?O4]8_P"%O5?)_GY'14445\N?MH5XM^U!XZ_X1_PA
M%H5M+MO=6)$@'58%^]]-QPON-U>SS31V\3RRNL<2*69V. H'))-?"/Q6\;M\
M0/'&H:J"?LN[R;53_#"O"_3/+$>K&O<RC#?6,1SO:.OSZ'YCQ_G7]EY4\/3=
MJE;W5Y1^T_NT^9R-?<'P0\"_\('X LK:9-NH7?\ I=UD<AV PG_ 5 'U!]:^
M:?@!X%_X37Q_:M/%YFFZ=BZN,]&(/R(?JV..X5J^U*]+/<3K'#Q]7^G]>A\?
MX8Y+95,WJK?W8?\ MS_)+YA1117R)^_!1110 4444 %%%% 'QU^T]_R56X_Z
M](?Y&N2^$O\ R4WPQ_V$(?\ T(5UO[3W_)5;C_KTA_D:Y+X2_P#)3?#'_80A
M_P#0A7Z/A_\ D7Q_P_H?QWF?_)5U/^O_ /[>C[RHHHK\X/[$"BBB@ HHHH *
M*** //?CIX$/COP#=PP1[]1LO]+M<#EF4?,@_P!Y<CZXKXCK]'J^)_CSX$'@
M?Q_=+;Q&/3K\?:[; ^50Q.Y!]&SQV!6OKLBQ/Q8:7JOU_KU/P#Q-R6_L\WI+
M^[/_ -M?YI_(]R_9A\='Q%X.?1+F3=>:00B9/+P-G9_WR05^FVO9J^$OA)XW
M/@#QUI^IN[+9LWD7:CO"W#?7'#?517W7%*D\221NLD;@,KJ<@@]"#W%>;F^%
M^KXASC\,M?GU/LN <Z_M3*E0J.]2C[K\U]E_=I\AU%%%>&?IH5\F?M1>.O[>
M\6PZ#;/FTTD?O<'AIV S_P!\C ^I:OI#XB>,8/ ?@_4=8E9?,AC*P1N?]9*>
M$7\^OL">U?!-Y=S7]W/=7$C37$[M))(W5V)R2?<DU]1D>%YYO$2V6B]?^&_,
M_$/$O.O88:&54G[U3WI?X4]%\WK\O,T?"/AJY\7^)-.T>T!,UW*(]V/N+U9C
M[!03^%??NCZ3;:%I-IIUG'Y5K:Q+#$GHJC _'WKY_P#V4/ NR&^\67*?,^;2
MS!].#(_YX4'V:OHNL<ZQ/M:WLH[1_,]+PYR7ZCESQ]5>_6V\HK;[]7YJP444
M5\Z?KH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MWLIFE?&!D]@.P P .P %<E6,(Z1W/>P=;$5KRJJR]"]\.O\ DH/AC_L*6O\
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M+V"VU0J%N=,ED FBD[@ \LI/1AU]CD56^+OQS\/?"O0KF26]@O-;*,+73(I
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!S[W:7W?\$]N^,W[0S^,K271/#ZRVFDOE;BYD^62Y']T#^%/U/?'(/B*J6(
M&2> !WJ>PL+G5+R*ULK>6ZN96VQPPH7=CZ #DU]._!/]GH^'+F'7O$\<<FHI
MA[:QR&6!O[[GH6'8#@=>3C'H3J8;*J/*ONZMGRN'PN<<<YC[2H[]'*WNP79?
MHMV]7U9V?P(^';_#[P3&EW'LU6_87-T#U3CY8_\ @(Z^Y:O1Z**_/ZU65>I*
MI/=G]89?@:.6X6G@\.K0@K+_ #?FWJ_,****Q/0"BBB@ HHHH **** /CK]I
M[_DJMQ_UZ0_R-<E\)?\ DIOAC_L(0_\ H0KK?VGO^2JW'_7I#_(UR7PE_P"2
MF^&/^PA#_P"A"OT?#_\ (OC_ (?T/X[S/_DJZG_7_P#]O1]Y4445^<']B!11
M10 4444 %%%% !7FWQ\^';^/O!+FTC\S5=.8W-L /FD&/GC'^\.1[JM>DT5M
M1JRH5(U(;H\[,<#1S/"5,'77NS5G_FO-/5>9^<+*4)!&"."#VKW+X,_M$'PE
M90:'XB62XTJ+Y;>[C&Z2W7LI'\2CMCD=.1@#KOC9^SP^O75QK_AB-5OY#ON=
M/R%68]W0] Q[@\'KUZ_,U]87.F74EK>6\MK<QG:\,R%'4^A!Y%?H$9X;-:-G
M]W5,_E"OA\XX&S'VD-.BE:\9Q[/]5NON9]X:7\4/".L6PFM?$>FLA_ADN5C<
M?56(8?B*SO$OQL\&>%[9I)]<MKR4#BWL'$\C'T^4X!_WB*^&:*\]9#14KN;M
M\CZJ?BEF$J7+##P4^^K7W7_4[WXL_%S4/B?JB&1#9Z3;D_9K(-G!_ON>['\A
MT'<GE_"OAF^\8>(++2-/3?<W4@0''"#^)S[ 9)^E3>$_!>L^-]16RT:PENY2
M0'=1B.(>KMT4?7\*^O\ X0?!VR^%^FO([I>:W<+BXNP,!1U\M,]%SWZDC)[
M=N*Q='+:/LZ>_1?J_P"M3Y_),BS+C#,'C,8W[-N\YOK_ '8^?332*^2?9^&]
M!M?"V@V&DV2[;:SB6)/4XZL?<G)/N:T:**_/9-R;D]V?UC3IPHPC3IJT4DDN
MR6P4444C4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ IT7^M3ZBFTZ+_6I]10!TU%%%
M! 4444 %%%% !1110 4444 %%%% !1110 4444 %<W\2?^2>^)?^P;<?^BVK
MI*YOXD_\D]\2_P#8-N/_ $6U;4?XD?5'!F'^YUO\,OR9^;M%%%?JY_"(4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M)V8LQ_,FOTX^(O@.R^)?A2Y\/ZC=WEG8W+(TK6+JDC!6#!<LK#&0.W:O'?\
MAAWP)_T%O$7_ ($P?_&:Y:T)3:L>U@,31PT9.>[/ /V5_AW:_$+XGHNI6D=[
MI.G6\ES<PS+NCD)&Q%(_WFW8_P!DU]F_\*,^'W_0FZ-_X")_A4'PE^"6@?!J
M'4DT2:]N7OV1II;Z1'?" [5&U% 'S'MWKT"KITU&-FM3GQ>+=:KS4VTCAO\
MA1GP^_Z$W1O_  $3_"OG']L3X1:/X1T[0=>\/Z5;:7:&1[.[CM(@BEB-\;$#
MO\KC/TK['KF_B'X!TSXF>%+OP_JYF2SN"C&2V95DC96# J2" >,=#P33G34H
MM)&>'Q4Z56,Y2;74_+NOT+_99\<?\)I\(=,263?>Z43IT^6R<(!Y9_[X*C/J
M#7*_\,.^!/\ H+>(O_ F#_XS7H?PE^!VB_!IM2&BZAJEU%?[/-BOY8W0%-V&
M7;&N#\Q!_#TK"E3G"5V>EC<70Q-+ECNMCAOVI?@--\2M,B\0:%"'\0Z?$4>
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MCWFFZ-<WUS!=3_:':_='8-M"X&U%&,*.U9TJ4H2NSKQF.HUZ+A#<^=OV\/\
MD,>#_P#KA<_^A1U\KU^D'Q:^ V@?&6YTV?6KS4K5[!'2(6$L:!@Y4G=N1O[H
MZ8K@/^&'? G_ $%O$7_@3!_\9I5*,I2;1>$Q]&C1C"=[K_,].^!G_)'?!O\
MV"X/_0!7<UE>%/#=MX/\-Z9HED\LMI80);Q/.0795& 6( &?H!6K79%621\_
M4DI3<EU9\V_MM^"/[5\$Z9XEA3,^DS^3,0/^6,N!D_1PF/\ ?-?%-?JEXK\,
MV7C/PUJ6AZB'-E?P-!*8R Z@C[RD@@$'!&0>0.*\._X8=\"?]!;Q%_X$P?\
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MS'*2Q_[KJ0P&>V<>HJZM+VFJW.?!8SZJVI*Z9^8%?5'[!_\ R&/&'_7"V_\
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ME<D5:/YG#?'/_DCOC+_L%S_^@&OS0K]4_%?ANU\8>&]3T2]>6*TU"![>5X"
MZJPP2I((S]0:\-_X8=\"?]!;Q%_X$P?_ !FIK4Y3::-L!BZ6'@XU.K.&_8/_
M .0QXP_ZX6W_ *%)7V!7F_PE^ V@?!NYU*;1;S4KI[]$247\L;@!22-NU%_O
M'KFO2*VI1<8V9P8RK&M6<X;/_(****U.(**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ J:S_ ./J/ZU#4UG_ ,?4?UJ7LS2E\<?5#_%_
M_(IZS_UYS?\ H!K\X*_2+Q/"]SX:U6&)2\LEK*BJ.I)0@"OA#_A3'C?_ *%J
M]_[Y'^->UDLX0A/F:6Q^:^(V%KXBOAG1IN5E+9-]5V.,HKL_^%,>-_\ H6KW
M_OD?XT?\*8\;_P#0M7O_ 'R/\:^D]M2_F7WH_'_[-QW_ #XG_P" O_(XRBNS
M_P"%,>-_^A:O?^^1_C1_PICQO_T+5[_WR/\ &CVU+^9?>@_LW'?\^)_^ O\
MR.,HKL_^%,>-_P#H6KW_ +Y'^-'_  ICQO\ ]"U>_P#?(_QH]M2_F7WH/[-Q
MW_/B?_@+_P CC**[/_A3'C?_ *%J]_[Y'^-'_"F/&_\ T+5[_P!\C_&CVU+^
M9?>@_LW'?\^)_P#@+_R.,HKL_P#A3'C?_H6KW_OD?XT?\*8\;_\ 0M7O_?(_
MQH]M2_F7WH/[-QW_ #XG_P" O_(XRBNS_P"%,>-_^A:O?^^1_C1_PICQO_T+
M5[_WR/\ &CVU+^9?>@_LW'?\^)_^ O\ R.,HKL_^%,>-_P#H6KW_ +Y'^-'_
M  ICQO\ ]"U>_P#?(_QH]M2_F7WH/[-QW_/B?_@+_P CC**[/_A3'C?_ *%J
M]_[Y'^-'_"F/&_\ T+5[_P!\C_&CVU+^9?>@_LW'?\^)_P#@+_R.,HKL_P#A
M3'C?_H6KW_OD?XT?\*8\;_\ 0M7O_?(_QH]M2_F7WH/[-QW_ #XG_P" O_(X
MRBNS_P"%,>-_^A:O?^^1_C1_PICQO_T+5[_WR/\ &CVU+^9?>@_LW'?\^)_^
M O\ R.,HKL_^%,>-_P#H6KW_ +Y'^-'_  ICQO\ ]"U>_P#?(_QH]M2_F7WH
M/[-QW_/B?_@+_P CC**[/_A3'C?_ *%J]_[Y'^-'_"F/&_\ T+5[_P!\C_&C
MVU+^9?>@_LW'?\^)_P#@+_R.,HKL_P#A3'C?_H6KW_OD?XT?\*8\;_\ 0M7O
M_?(_QH]M2_F7WH/[-QW_ #XG_P" O_(XRBNS_P"%,>-_^A:O?^^1_C1_PICQ
MO_T+5[_WR/\ &CVU+^9?>@_LW'?\^)_^ O\ R.,HKL_^%,>-_P#H6KW_ +Y'
M^-'_  ICQO\ ]"U>_P#?(_QH]M2_F7WH/[-QW_/B?_@+_P CC**[/_A3'C?_
M *%J]_[Y'^-'_"F/&_\ T+5[_P!\C_&CVU+^9?>@_LW'?\^)_P#@+_R.,HKL
M_P#A3'C?_H6KW_OD?XT?\*8\;_\ 0M7O_?(_QH]M2_F7WH/[-QW_ #XG_P"
MO_(XRBNS_P"%,>-_^A:O?^^1_C1_PICQO_T+5[_WR/\ &CVU+^9?>@_LW'?\
M^)_^ O\ R.,HKL_^%,>-_P#H6KW_ +Y'^-'_  ICQO\ ]"U>_P#?(_QH]M2_
MF7WH/[-QW_/B?_@+_P CC**[/_A3'C?_ *%J]_[Y'^-'_"F/&_\ T+5[_P!\
MC_&CVU+^9?>@_LW'?\^)_P#@+_R.,HKL_P#A3'C?_H6KW_OD?XT?\*8\;_\
M0M7O_?(_QH]M2_F7WH/[-QW_ #XG_P" O_(XRBNS_P"%,>-_^A:O?^^1_C1_
MPICQO_T+5[_WR/\ &CVU+^9?>@_LW'?\^)_^ O\ R.,HKL_^%,>-_P#H6KW_
M +Y'^-'_  ICQO\ ]"U>_P#?(_QH]M2_F7WH/[-QW_/B?_@+_P CC**[/_A3
M'C?_ *%J]_[Y'^-'_"F/&_\ T+5[_P!\C_&CVU+^9?>@_LW'?\^)_P#@+_R.
M,HKL_P#A3'C?_H6KW_OD?XT?\*8\;_\ 0M7O_?(_QH]M2_F7WH/[-QW_ #XG
M_P" O_(XRBNS_P"%,>-_^A:O?^^1_C1_PICQO_T+5[_WR/\ &CVU+^9?>@_L
MW'?\^)_^ O\ R.,HKL_^%,>-_P#H6KW_ +Y'^-'_  ICQO\ ]"U>_P#?(_QH
M]M2_F7WH/[-QW_/B?_@+_P CC**[/_A3'C?_ *%J]_[Y'^-'_"F/&_\ T+5[
M_P!\C_&CVU+^9?>@_LW'?\^)_P#@+_R.,HKL_P#A3'C?_H6KW_OD?XT?\*8\
M;_\ 0M7O_?(_QH]M2_F7WH/[-QW_ #XG_P" O_(XRBNS_P"%,>-_^A:O?^^1
M_C1_PICQO_T+5[_WR/\ &CVU+^9?>@_LW'?\^)_^ O\ R.,HKL_^%,>-_P#H
M6KW_ +Y'^-'_  ICQO\ ]"U>_P#?(_QH]M2_F7WH/[-QW_/B?_@+_P CC**[
M/_A3'C?_ *%J]_[Y'^-'_"F/&_\ T+5[_P!\C_&CVU+^9?>@_LW'?\^)_P#@
M+_R.,HKL_P#A3'C?_H6KW_OD?XT?\*8\;_\ 0M7O_?(_QH]M2_F7WH/[-QW_
M #XG_P" O_(XRBNS_P"%,>-_^A:O?^^1_C1_PICQO_T+5[_WR/\ &CVU+^9?
M>@_LW'?\^)_^ O\ R.,HKL_^%,>-_P#H6KW_ +Y'^-'_  ICQO\ ]"U>_P#?
M(_QH]M2_F7WH/[-QW_/B?_@+_P CC**[/_A3'C?_ *%J]_[Y'^-'_"F/&_\
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MWH/[-QW_ #XG_P" O_(XRBNS_P"%,>-_^A:O?^^1_C1_PICQO_T+5[_WR/\
M&CVU+^9?>@_LW'?\^)_^ O\ R.,HKL_^%,>-_P#H6KW_ +Y'^-'_  ICQO\
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M_D<9179_\*8\;_\ 0M7O_?(_QH_X4QXW_P"A:O?^^1_C1[:E_,OO0?V;CO\
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M"U>_]\C_ !H_X4QXW_Z%J]_[Y'^-'MJ7\R^]!_9N._Y\3_\  7_D<9179_\
M"F/&_P#T+5[_ -\C_&C_ (4QXW_Z%J]_[Y'^-'MJ7\R^]!_9N._Y\3_\!?\
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M_P#A3'C?_H6KW_OD?XT?\*8\;_\ 0M7O_?(_QH]M2_F7WH/[-QW_ #XG_P"
MO_(XRBNS_P"%,>-_^A:O?^^1_C1_PICQO_T+5[_WR/\ &CVU+^9?>@_LW'?\
M^)_^ O\ R.,HKL_^%,>-_P#H6KW_ +Y'^-'_  ICQO\ ]"U>_P#?(_QH]M2_
MF7WH/[-QW_/B?_@+_P CC**[/_A3'C?_ *%J]_[Y'^-'_"F/&_\ T+5[_P!\
MC_&CVU+^9?>@_LW'?\^)_P#@+_R.,HKL_P#A3'C?_H6KW_OD?XT?\*8\;_\
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M(_QH]M2_F7WH/[-QW_/B?_@+_P CC**[/_A3'C?_ *%J]_[Y'^-'_"F/&_\
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MWH/[-QW_ #XG_P" O_(XRBNS_P"%,>-_^A:O?^^1_C1_PICQO_T+5[_WR/\
M&CVU+^9?>@_LW'?\^)_^ O\ R.,HKL_^%,>-_P#H6KW_ +Y'^-'_  ICQO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IT7^M3
MZBFTZ+_6I]10!TU%%%! 4444 %%%% !1110 4444 %%%% !1110 4444 %<W
M\2?^2>^)?^P;<?\ HMJZ2N;^)/\ R3WQ+_V#;C_T6U;4?XD?5'!F'^YUO\,O
MR9^;M%%%?JY_"(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 5]L_ G_DDWAW_KD_\ Z->OB:OMGX$_\DF\._\ 7)__
M $:]>+FO\&/K^C/TC@7_ )&%7_ __2HG>T445\N?N 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %36?_
M !]1_6H:FL_^/J/ZU+V9I2^./JC4N_\ CVD_W36+6U=_\>TG^Z:Q:QH[,[\?
M\<?0****Z#S HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MJUIO_'T/H:JU:TW_ (^A]#43^%F]#^+'U+NH_P#'JWU'\ZR*U]1_X]6^H_G6
M16=+X3IQW\1>@4445N>>%%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 ^'_71_P"\*VY/]6WT
M-8D/^NC_ -X5MR?ZMOH:YJNZ/7P7P2,&BBBND\@**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "M32
M_P#CW;_>/\A676II?_'NW^\?Y"L:OPG=@OXI!JO^N3_=JE5W5?\ 7)_NU2JH
M?"C+$_QI!1116AS!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 .B_P!:GU%;[?=/TK B_P!:
MGU%;[?=/TK@Q.Z/ILH^"?J8U%%%<9]$%%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M(HP% X  ]*?117>?,A1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%07M_;:;;M/>7$5K O669PBC\30&Y/17*'XL^!UD,9\9>'Q(#M*G5(,@^F
M-]=%I^I6FK6ZW%E=07ENW26WD#J?Q!QZ4DT]BG"4=T6:***9(445'/<16D+S
M32I#$@RTDC!54>I)H DHKE9OBOX(MY6CE\8^'XI%X*/JD (^HW5NZ5K>G:Y
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MN58_+'(3B.7VP3@^S$]A7Z!UK2GSQN<.,PWU:IRK9[!1116QPA1110 4444
M%%%% !1110 4444 %%%% !1110 5-9_\?4?UJ&IK/_CZC^M2]F:4OCCZHU+O
M_CVD_P!TUBUM7?\ Q[2?[IK%K&CLSOQ_QQ] HHHKH/,"BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "K6F_\?0^AJK5K3?^/H?0U$_A9O0_
MBQ]2[J/_ !ZM]1_.LBM?4?\ CU;ZC^=9%9TOA.G'?Q%Z!1116YYX4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% #X?]='_O"MN3_5M]#6)#_KH_\ >%;<G^K;Z&N:KNCU\%\$
MC!HHHKI/("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ K4TO_ (]V_P!X_P A676II?\ Q[M_O'^0
MK&K\)W8+^*0:K_KD_P!VJ57=5_UR?[M4JJ'PHRQ/\:04445H<P4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% #HO]:GU%;[?=/TK B_UJ?45OM]T_2N#$[H^FRCX)^IC4445Q
MGT04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3HO]:G
MU%-IT7^M3ZB@#IJ***" HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YO
MXD_\D]\2_P#8-N/_ $6U=)7-_$G_ ))[XE_[!MQ_Z+:MJ/\ $CZHX,P_W.M_
MAE^3/S=HHHK]7/X1"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P ,B?#+_H#W/_@=-_\ %5ZSHFD6OA[1K#2[)#'96-O';0(S%BL:*%49/)X
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M^'_71_[PK;D_U;?0UB0_ZZ/_ 'A6W)_JV^AKFJ[H]?!?!(P:***Z3R HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 Z+
M_6I]16^WW3]*P(O]:GU%;[?=/TK@Q.Z/ILH^"?J8U%%%<9]$%%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M$0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=$_M/XQB\*@KIUA-<!B.C-MB'XXD/ZU]XU\F?L(:)\GBW5V!Y,%I&<_[[/\
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MC>:%?QMYEO=1M@$CO'(AP2/8\9K]/:Y;XF> ;#XE>#-1T*_B1O.C)@E8<PS
M'9(I[$'\QD=ZTEAU;W7J<=/-9N5JB5C\]OBC\5=4^*T^B76K$&[T^P6TD=0
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MS*-9MGU7LY5< H05W9?F?H%67XINX+#PQJ]S=,J6T-I+)*S] H0DY_"OFO\
MX;PT_P#Z$^Y_\#U_^(KRWXO_ +5/B#XH:3)HUK91Z!H\W^OBAE,LLX_NL^!\
MO'0 9[DCBNB5>"6C/*I9=B)37,K+Y'B-?J'\,X)[;X;^%(;G_CYCTFT27/\
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M +]1?_$T?V56_F7X_P"0?Z]9?_S[G]T?_DC[9HKXF_X7MX[_ .ABG_[]1?\
MQ-'_  O;QW_T,4__ 'ZB_P#B:/[*K?S+\?\ (/\ 7K+_ /GW/[H__)'VS17Q
M-_PO;QW_ -#%/_WZB_\ B:/^%[>._P#H8I_^_47_ ,31_95;^9?C_D'^O67_
M //N?W1_^2/MFBOB;_A>WCO_ *&*?_OU%_\ $T?\+V\=_P#0Q3_]^HO_ (FC
M^RJW\R_'_(/]>LO_ .?<_NC_ /)'VS17Q-_PO;QW_P!#%/\ ]^HO_B:/^%[>
M._\ H8I_^_47_P 31_95;^9?C_D'^O67_P#/N?W1_P#DC[9HKXF_X7MX[_Z&
M*?\ []1?_$T?\+V\=_\ 0Q3_ /?J+_XFC^RJW\R_'_(/]>LO_P"?<_NC_P#)
M'VS17Q-_PO;QW_T,4_\ WZB_^)H_X7MX[_Z&*?\ []1?_$T?V56_F7X_Y!_K
MUE__ #[G]T?_ )(^V:*^)O\ A>WCO_H8I_\ OU%_\31_PO;QW_T,4_\ WZB_
M^)H_LJM_,OQ_R#_7K+_^?<_NC_\ )'VS17Q-_P +V\=_]#%/_P!^HO\ XFC_
M (7MX[_Z&*?_ +]1?_$T?V56_F7X_P"0?Z]9?_S[G]T?_DC[9HKXF_X7MX[_
M .ABG_[]1?\ Q-'_  O;QW_T,4__ 'ZB_P#B:/[*K?S+\?\ (/\ 7K+_ /GW
M/[H__)'VS17Q-_PO;QW_ -#%/_WZB_\ B:/^%[>._P#H8I_^_47_ ,31_95;
M^9?C_D'^O67_ //N?W1_^2/MFBOB;_A>WCO_ *&*?_OU%_\ $T?\+V\=_P#0
MQ3_]^HO_ (FC^RJW\R_'_(/]>LO_ .?<_NC_ /)'VS17Q-_PO;QW_P!#%/\
M]^HO_B:/^%[>._\ H8I_^_47_P 31_95;^9?C_D'^O67_P#/N?W1_P#DC[9H
MKXF_X7MX[_Z&*?\ []1?_$T?\+V\=_\ 0Q3_ /?J+_XFC^RJW\R_'_(/]>LO
M_P"?<_NC_P#)'VS17Q-_PO;QW_T,4_\ WZB_^)H_X7MX[_Z&*?\ []1?_$T?
MV56_F7X_Y!_KUE__ #[G]T?_ )(^V:*^)O\ A>WCO_H8I_\ OU%_\31_PO;Q
MW_T,4_\ WZB_^)H_LJM_,OQ_R#_7K+_^?<_NC_\ )'VS17Q-_P +V\=_]#%/
M_P!^HO\ XFC_ (7MX[_Z&*?_ +]1?_$T?V56_F7X_P"0?Z]9?_S[G]T?_DC[
M9HKXF_X7MX[_ .ABG_[]1?\ Q-'_  O;QW_T,4__ 'ZB_P#B:/[*K?S+\?\
M(/\ 7K+_ /GW/[H__)'VS17Q-_PO;QW_ -#%/_WZB_\ B:/^%[>._P#H8I_^
M_47_ ,31_95;^9?C_D'^O67_ //N?W1_^2/MFBOB;_A>WCO_ *&*?_OU%_\
M$T?\+V\=_P#0Q3_]^HO_ (FC^RJW\R_'_(/]>LO_ .?<_NC_ /)'VS17Q-_P
MO;QW_P!#%/\ ]^HO_B:/^%[>._\ H8I_^_47_P 31_95;^9?C_D'^O67_P#/
MN?W1_P#DC[9HKXF_X7MX[_Z&*?\ []1?_$T?\+V\=_\ 0Q3_ /?J+_XFC^RJ
MW\R_'_(/]>LO_P"?<_NC_P#)'VS17Q-_PO;QW_T,4_\ WZB_^)H_X7MX[_Z&
M*?\ []1?_$T?V56_F7X_Y!_KUE__ #[G]T?_ )(^V:*^)O\ A>WCO_H8I_\
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M^)H_X7MX[_Z&*?\ []1?_$T?V56_F7X_Y!_KUE__ #[G]T?_ )(^V:*^)O\
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M +]1?_$T?V56_F7X_P"0?Z]9?_S[G]T?_DC[9HKXF_X7MX[_ .ABG_[]1?\
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M_P#B:/[*K?S+\?\ (/\ 7K+_ /GW/[H__)'VS17Q-_PO;QW_ -#%/_WZB_\
MB:/^%[>._P#H8I_^_47_ ,31_95;^9?C_D'^O67_ //N?W1_^2/MFBOB;_A>
MWCO_ *&*?_OU%_\ $T?\+V\=_P#0Q3_]^HO_ (FC^RJW\R_'_(/]>LO_ .?<
M_NC_ /)'VS17Q-_PO;QW_P!#%/\ ]^HO_B:/^%[>._\ H8I_^_47_P 31_95
M;^9?C_D'^O67_P#/N?W1_P#DC[9HKXF_X7MX[_Z&*?\ []1?_$T?\+V\=_\
M0Q3_ /?J+_XFC^RJW\R_'_(/]>LO_P"?<_NC_P#)'VS17Q-_PO;QW_T,4_\
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MY!_KUE__ #[G]T?_ )(^V:*^)O\ A>WCO_H8I_\ OU%_\31_PO;QW_T,4_\
MWZB_^)H_LJM_,OQ_R#_7K+_^?<_NC_\ )'VS17Q-_P +V\=_]#%/_P!^HO\
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M9HKXF_X7MX[_ .ABG_[]1?\ Q-'_  O;QW_T,4__ 'ZB_P#B:/[*K?S+\?\
M(/\ 7K+_ /GW/[H__)'VS17Q-_PO;QW_ -#%/_WZB_\ B:/^%[>._P#H8I_^
M_47_ ,31_95;^9?C_D'^O67_ //N?W1_^2/MFBOB;_A>WCO_ *&*?_OU%_\
M$T?\+V\=_P#0Q3_]^HO_ (FC^RJW\R_'_(/]>LO_ .?<_NC_ /)'VS17Q-_P
MO;QW_P!#%/\ ]^HO_B:/^%[>._\ H8I_^_47_P 31_95;^9?C_D'^O67_P#/
MN?W1_P#DC[9HKXF_X7MX[_Z&*?\ []1?_$T?\+V\=_\ 0Q3_ /?J+_XFC^RJ
MW\R_'_(/]>LO_P"?<_NC_P#)'VS17Q-_PO;QW_T,4_\ WZB_^)H_X7MX[_Z&
M*?\ []1?_$T?V56_F7X_Y!_KUE__ #[G]T?_ )(^V:*^)O\ A>WCO_H8I_\
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M^)H_X7MX[_Z&*?\ []1?_$T?V56_F7X_Y!_KUE__ #[G]T?_ )(^V:*^)O\
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M +]1?_$T?V56_F7X_P"0?Z]9?_S[G]T?_DC[9HKXF_X7MX[_ .ABG_[]1?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** '1?ZU/J*WV^Z
M?I6!%_K4^HK?;[I^E<&)W1]-E'P3]3&HHHKC/H@HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "G1?ZU/J*;3HO\ 6I]10!TU%%%! 444
M4 %%%% !1110 4444 %%%% !1110 4444 %<W\2?^2>^)?\ L&W'_HMJZ2N;
M^)/_ "3WQ+_V#;C_ -%M6U'^)'U1P9A_N=;_  R_)GYNT445^KG\(A1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MB6K\\J^@R3^%/U_0_)_$O_?,/_A?YA1117TA^-A1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %>K? SXV7?PTU:.QOI7G\-W,@$T
M)R3;D_\ +5!_,#J/?%>4T5E6I0KP=.:NF>A@,?B,LQ$<5AI6E'^K/NGU1^C]
M[/'=>1-"ZRQ21AT=#E64\@@]Q5:O)/V:/&$GB+P -.N'+W&D2?9U)Y)A;YD_
M+YE^BBO6Z^%J4G0FZ3Z']/87'PS.A#&05E-)V[/JOD] HHHJ#J"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH =%_K4^HK?;[I^E8$7^M3ZBM]ONGZ5P8G='TV4?!/U,:BBBN
M,^B"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH ***X3QM\>OAM\-KHVOBKQ[X;\/W@Y^R:AJD,4_;GRRV[N.U '=
MT5R/@;XP>!?B:&_X1'QEH/B9D7<\>E:E#<O&/]I48E>HZ@5UU !1110 4444
M %%%% !15?4=2L]'LY+N_NH+*TBP7GN)!'&N3@98G Y('XU5T;Q-H_B-93I.
MJV6J"' D-E<)-LSG&=I.,X/Y4 :5%%% !1110 45SOQ&\<6'PS\ >(_%VII+
M)I^AZ?/J,\<(!D=(HRY5<\;CMP,]S7R)^QM_P4B/[3WQ8O?!&K>#XO#<\MM+
M>:;/:WAN RQD%HI 57YMISN'!VD8&10(^W:***!A1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !116+J7C?PYH]ZUE?Z_I=C>)C=;W-[''(
MN1D94L#R"#^- &U1110 445X3^V3^U%;_LG?":/Q4=(.O:E>WJ:;86)E\J,R
MLCN7D;!(15C8X R3M'&<@$>[45\[?L3_ +6\7[7'P^U36)M$'A_6=(O!:7EI
M',9HFW+N21&(!P1D8/0J>3FOHF@ HHHH&%%%% !1110 445YK^T;\;K#]G7X
M-^(O'VH6,FJ1Z7'&(K&%PC7$TDBQQIN(.T;G&6P< $@'H01Z517R3^PO^W8?
MVN+GQ)I.J>&XO#FN:/''=*+6X,T-Q [%21N *LK8!'.=P(Z&OK:@ HHHH&%%
M%% !14=S<Q6=O+//*D,$2EY))&"JB@9))/  '>LW2/%^@^(;AX-*UO3M3G1=
M[16=W'*RKD#)"DX&2!GWH UJ**^7/A;_ ,%$_AO\6_CG;_"K1]$\4VWB&>ZO
M+1;F^M+9+0/;1RR2$LMPSX(A;'R=2,@<X!'U'1110,**** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH *=%_K4^HIM.B_UJ?44 =-11100%%%%
M !1110 4444 %%%% !1110 4444 %%%% !7-_$G_ ))[XE_[!MQ_Z+:NDKF_
MB3_R3WQ+_P!@VX_]%M6U'^)'U1P9A_N=;_#+\F?F[1117ZN?PB%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?;/P)
M_P"23>'?^N3_ /HUZ^)J^V?@3_R2;P[_ -<G_P#1KUXN:_P8^OZ,_2.!?^1A
M5_P/_P!*B=[1117RY^X!1110 4444 %%%% !1110 4444 <?\5/AEIGQ8\(W
M&B:EF)B?,MKI%!>WE'1QZCJ".X)''4?GM\2/A5XB^%NKO8ZY9/'&6(AO8P6@
MG'JC?T/([BOTYJMJ6EV>LV4EI?VD%]:2</!<QK)&P]U((-85*2J:]3TL)C9X
M;W;7B?FOX+^-?C;X?PI;Z)X@N;>T4\6LNV:$>P1P0OX8KI[[]K#XG7MNT0U^
M.W#=7@LH5;'UV<?4<U]7ZS^RI\--9E,O]@&QD/4V5S)&/^^=VT?@*JZ?^R-\
M,[*4.^CW%X0<A;B]EQ^2L,_C7.J55:)GI/'8.7O2IZ^B/A:XO/$/Q#U]#-+J
M'B'6+@[4#%[B9_8#DX]AP*^G/@9^R$]O<0:YX\B0E")(-%#;AGJ#,1Q_P 9]
MSU%?3'AKP7H/@ZW,.AZ/9:5&?O?98%0O_O$#+?C6U6L*"3O+4Y:^92G'DI+E
M7X_\ 1$"*%4!548  P *;/#'<PR12HLD3J5=&&0P/!!'I3Z*ZCQ3\Z/CW\%+
M_P"$GBJ<QP22>'+N0M87F"5 //E.>SKTYZ@9]0.=^'OQ9\4_"^YDE\/:F]K'
M,09K:11)#+[E&XSVR,''>OTOU/2K+6[&:QU"T@OK.8;9+>XC#HX]"IX->/ZU
M^R#\.-7N6FBL+S2RQR4LKI@GX!]V/H/3BN*5!IW@SZ*EF5.4.3$1O^-SYSU'
M]LGXC7UH\,4VFV+MP)[:TRZ_3>6'Z5R.E> ?%OQ0L=<\8ZK/=/IEC;2W-SJ]
M^6?SBBDB*//WB2 N!PN><< _9/AO]E?X<>&[A+@:(=2F3&&U&9IE_%.$/XBO
M1M=\+:7XD\/7&A:A:"72KB,126T;M$"@(.T%""!P.A'I3]C*7QLAX^A2=J$+
M=V?E?;V[W4\<,2EY9&"(H[DG %?JOH>F)HFBZ?IT>/+L[>.W7'HBA1_*O.K#
M]E_X9:9?6]Y;>&0EQ;R++&QOKE@&4@@X,A!Y X(Q7J=71ING>YS8[&0Q/*H)
MJW<YCXE^ [/XE>"=3\/WA\M;J/\ =38R891RCCZ$#([C([U^;/C3P7K'P_\
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M<_\ )$[3_K]N/_0JZCQ-^SQ\/O&.NW>LZOX?^UZE=L&FF^VW";B %'RK( .
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%!!'D>X1,C.UF)X8T%7/U;\&_M]?L_\ CW68]*TGXEZ:+V5@D:ZC!<6".QX
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M520@=R%P.,]:^&_@9_P29TWXA^"K/Q=\7?%_B+_A*->C&HS6FDSQ*\)E^?\
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M@ HHHH *=%_K4^HIM.B_UJ?44 =-11100%%%% !1110 4444 %%%% !1110
M4444 %%%% !7-_$G_DGOB7_L&W'_ *+:NDKF_B3_ ,D]\2_]@VX_]%M6U'^)
M'U1P9A_N=;_#+\F?F[1117ZN?PB%%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %?;/P)_Y)-X=_ZY/_ .C7KXFK[9^!
M/_))O#O_ %R?_P!&O7BYK_!CZ_HS](X%_P"1A5_P/_TJ)WM%%%?+G[@%%%%
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M\9P/.J^BI585H*I!W3/R'&X*OEV(GA<3'EG%V:_KH]T^P4445J<045]0Z/\
ML:V.J:38WA\47$9N($F*"S4[=R@XSO\ >KG_  Q+8_\ 0UW'_@$O_P 77CO-
M\&G9S_!_Y'Z#'@+B"<5*-!6?]^'_ ,D?*5%?26O?L6:I;PN^C^([:]D R(KN
MW:#/MN!?G\!7A?C'P'KW@'4OL6NZ;+83')1FP4D [HXR&_ _6NRAC,/B7:E.
M[_'\3P<RX=S7*%SXV@XQ[Z-?>FU^)@U8TW3;O6+Z&RL;:6[NYFV1P0(7=SZ
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\$V!9BQ@CC@R3D_+$GO[UG574^EX4QDGSX26VZ_4[&BBBN<_20HHHH ****
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MT^+?AU?^-OB_XBO]0CUDQ'0].O8(H6CM@"6N"$13^\+#:#_"F[&&!H ^ /\
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M:_*K_@C;_P G.^)_^Q/NO_2VRH&SWK_@M#_R2OX=_P#8:G_]$5[M_P $R_\
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M ?FOSD_91_X*6^*/A/XU\0:)\=[S7]?LIW2 3RQ W6DSQ,ZNK1':=K;L,/O
MH.#S0!#X2_X*2?M!_L[^)(-!^,'AJ77($P)+?6[ Z;J'ECC='*JA7'^TR/N_
MO<YK]2_@[\7/#?QS^'>D>-/"EVUUH^I1DJ)%VRPNI*O%(O\ "ZL"".1W!(()
M_,?_ (*&_MY?#']H/X4V7@OP78WNKWOV^.];5[ZT^SI:*@8$1AOG+-G!X QW
M/2OKG_@E_P##[6_A]^R;HRZY ]I-K-]<:O;V\H(=+>38L9([;@F\>SCO0"/K
M*O"?VZ/^31/BI_V!9/\ T):]VKPG]NC_ )-$^*G_ &!9/_0EH&SXU_X(F?\
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MOS\--*>5[N/[)!%!=W#*?+M8B(]Q"E@[8/"J 3EA0!^EU%%%!04444 %%%%
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M\2_]\P_^%_F%%%%?2'XV%%%% !73^ OB3KWPVO+JZT&Y2VFN8Q'(7A63*@Y
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M)(9F &/K7T=^VGX9C:R\/>(43$JR/82OC[RD%T&?;;)^9KSO]DS_ )+#:_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110![S^R3_P C'K__ %ZI_P"AU].U\Q?LD_\ (QZ__P!>J?\ H=?3M?(9
ME_O,OE^1_0G"'_(HI^LOS84445YA]H%%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 Z+_ %J?
M45OM]T_2L"+_ %J?45OM]T_2N#$[H^FRCX)^IC4445QGT04444 %%%% !111
M0 4444 %%%% !1110 4444 4M<U>WT#1-0U2Z;9:V5O)<RM@G"(I9CP">@/0
M5^-W[3WQ1G^*OQF\3:GYN_3DOI(K)=H&(T"Q@YVJ>1$I^89'2OM7_@HI\9QX
M5\(VO@W3[A4U74-DT\>_!-I)'<Q-P'#?> ZJ5_E7YID[B2>M>AAX67,SX7/<
M7SS6'CLM7ZB5T7@7P'K/Q&\00:+H=K]LOYMVR+S$3.U&<\NRCHI/7M6-IUA/
MJM_;65M&TUQ<2K%'&BDEF8@  #DDDBOUA_8G^ D/P?\ AHM_>PJVM:X(+Z1Y
M$!DA0P+B/)164@O)E><9Z\FMZM3V:OU/'R_!/&U>7:*W9TW[,W[.VG_ 3P1%
M8%OMFLO++)<WN&3?N88&SS'485$'![?6O9J**\EMR=V?IE*E"C!4Z:LD%%%%
M(V"BBB@ KR3]H;]G70OC]X<%K?\ ^BZM;KLL]0_>/Y ,B,X\L2(K;@F/FZ9R
M*];HIIN+NC*K2A6@X5%=,^&_V._V.M2\"^-;_P 1>+8=KV+>1:P[U.9 ;>9)
M=T<QZ'>NT@CC)["ON3 08Z "BO%/VA?'4NFPVVBV-P8WGC,DSQ.0RX==HR&X
M.5;J*T<I59:GCU94,DPDII:+[VSSGXS^-!XK\62&UDWV$44:1_+C)P23RH/5
MC7 4A))R3D^IK6\,^'+OQ1JD=C9H7E?/)!(&%)YP#Z&NE)11^,UJM7'8AU&K
MRF_SZ([3X*_#Y_%>MQW\ZXL+20.6S]YU9#MP&!'!ZTWX]0);^-(88QMC2U"J
MN<X DDQ7TAX/\,6_A#08-,MA\D99BW&6+,3DX SU Z=J^<_V@/\ D>E_Z]O_
M &K)6,9<TS[3,<MCEV4QC]MM-OS[?(\TKWC]E[IXB^MO_*6O!Z]X_9>Z>(OK
M;_REK2I\+/"X>_Y&E'_M[_TEGO%%%%<9^V!1110!7U*\33M/N;J4XC@B:5C[
M*"3_ "KXN\8WR:EXKUBZC.8YKR:13[&1B/YU[-^T)X^1;>'0K&<^:'9KDQOU
M4QC"\-T(<Y!'.*\"ZG-=-*-E<_*.)\PCB*RPL-H;OS_X J#YUQZBOJ[X'6S6
MW@=-PQOE#CZ&*.OE_P /Z:^K:W96B*6,TR1X SU8#W]:^S?"^F#1_#VG6@4*
M8K>-& &.0@![>U%5Z6-.$\/*5>=?HE8U****YC]3"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!LT*7$3Q2HL
MD3J59'&0P/!!'<5\Y^.O^">'[/\ \0-3?4+[X?6FG7DC;G?1KF:Q1NN?W43K
M'R3G(7/'6OHZB@1X+\-/V$_@7\)K^'4-#^'VGS:E$V^.\U9Y+^1&!R&3SF94
M(XP5 /'KS7O5%% !7AOQE_8E^#7QVU275O%7@VW;6Y?]9JNG2O:7$AQC+M&0
M)#TY<-T'I7N5% 'S;\-O^"=OP&^%^LP:M8>"DU74K=@\,VMW,EXL; Y!$3GR
M\@XP2N1@$&OI( *    . !110!XE\6OV+?@U\<_%[^*/&_@[^V]=>%+=KO\
MM2]M\QIG:-D4R+QD\XS7MM%% !7@/CG]@CX!?$;7I]8USX;V#ZC.S22RV%U<
MV(D8G)9DMY44DGG)&>M>_44 <O\ #+X9>&O@[X'TWP?X0TW^R/#NG>;]ELO/
MEG\OS)7E?YY69SEY'/)/7 XP*Y_XR_LY_#C]H#3XK3QYX5L]=,"E8+IBT5S
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5]L_ G_DDWAW_KD__HUZ^)J^V?@3_P DF\._]<G_ /1KUXN:_P &/K^C/TC@
M7_D85?\  _\ TJ)WM%%%?+G[@%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@#WG]DG_D8]?_Z]4_\ 0Z^G:^8O
MV2?^1CU__KU3_P!#KZ=KY#,O]YE\OR/Z$X0_Y%%/UE^;"BBBO,/M HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** '1?ZU/J*WV^Z?I6!%_K4^HK?;[I^E<&)W1]-E'P3]3&HH
MHKC/H@HHHH **** "BBB@ HHHH **** "BBB@ HHJOJ%R+2TDE) "XY/U H$
MW8_)#]N;Q8/%W[1>N3IQ#;VUI;QCT'D*Y[ ]7:O *WO'.OOXH\4WNIR'<\^S
M)S_=15]3Z>M8->W%<L4C\BQ%3VM:=3NVSZK_ ."?GPB?QU\4SKM[%C2M)B^T
M13;NMS%/;.$VAPWW6)R05^M?J4JA%"C@ 8%?,'_!.C18]-_9SMKI8PLE]J=W
M.YP 205C]/2,>O2OJ"O+K2YIOR/T3*:"HX6+6\M?O"BBBL#V@HHHH **** "
MBBH+^_M]-M7N;J:.W@3&Z25@JC) &2>.I%!+:BKO8Y7XG^-HO!GAR>7/^DS*
MT4(P>&*/M/W2.J]Z^2-3OY=4U"YNYCF6>1I6/'5B2>GUKH/B1XPD\:^)YK\E
MEAV)'&AXV@#GC)QR6/7O7+UV0CRH_%<[S-YCB&H_!'1>?G\PK9\->,=6\)-*
MVEW/V=I<%SY:-G&0/O ^IK&HJWJ>#3J3I24Z;::ZH[G_ (77XO\ ^@I_Y+P_
M_$5R^O\ B*^\3WPN]0F\^X"[-^U5XR3T4 =2:SJ*+);&]7%XBO'EJU')>;;"
MMOPQXVU?PA]H_LJZ^S?:-OF?NT?.W./O*?[QK$HIVN84ZDZ4E.G)IKJMSN/^
M%U>+_P#H*#_P'A_^(JUIGQ8\:ZQ>QVEMJ6Z:3.T>1 .@)/51V!KSQ5+,  23
MT KZ6_9_\$_V-HDVJ7EL!=73(\#21_,L?EY!4E01G>0<'!Q64N6*O8^CRMX_
M,L0J*KR2ZN[V^\].T6VN;3388KR;[1<C.^38%W<DC@<=,#\*Y7XJ_$"/P-HF
M4;_B83C,"8/.'0-SM(Z,>M=1KNM6WA[2KF_NI%CBAC9_F8 L0I;:,D9)P>*^
M1/B'XPG\:>(Y[R1CY",Z6ZY/$>]BO&2,X/...*QA'F=V?=YWF:RW#>RI/WVK
M+NO/^NISEQ</=2M+(VYSU.,=L4RBO0O@_P##@>.-3DEN@XTZV;;*R\$DHV ,
MJ1U SGUKJ;45=GY/AL/4QE:-&GK*1VG[.W@AUFN==NDQ&T0CM^?O'S#D\-V,
M8X(YS7O5,@MXK6)8H8TAC7HB*% _ 4^N*4N9W/W#+L##+\/&A#6V[[L****D
M]0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BOPJD_;A^+OP]_:"N;VZ\>^(=5T#2/$<IFT:>^>2&>U2X8-#
ML8XP4!4>G![5^XWA_7;'Q3H.FZSIEPMWINHVT5W:W"'*RQ2('1A[%2#^- B_
M117YQ_\ !5;]K/Q+\,-8\)> O ?B2^\/:P8VU;5;O3)C%*(SF."+<O.#B5BO
M'2,T ?HY7A/Q<_;<^#_P/^(5IX*\6^)C9:[*L;SI#:R31V:O@H9W4$)D'=CD
MA<$@ @GRO_@E;\3?%GQ6_9[\0ZMXQ\0ZCXEU.'Q1<6L=WJ=PTTB1"TM&" GH
MH9W./5C7$?M5_P#!,#4/V@/V@+SQ[I'C*TT73=9\@ZI;7=N\LT+QQI$6AP<,
M&6-3M8K@YYQ@ $??\,R7$22Q.LD3J&5T.0P/((/<4ZJ'A_1+?PUH.FZ1:&0V
MEA;16D)E;<Y2- JY/<X YJ_04%<=XS^-'P^^'.IQ:;XL\=^&O#&HRPBXCL]9
MUBWM)GB+,HD"2.I*DHPSC&5([&NQK\;_ /@LE_R<[X8_[$^U_P#2V]H$?L=#
M,EQ$DL3K)$ZAE=#D,#R"#W%.K)\)_P#(JZ-_UY0_^@"M:@85QWC/XT?#[X<Z
MG%IOBSQWX:\,:C+"+B.SUG6+>TF>(LRB0)(ZDJ2C#.,94CL:[&OQO_X+)?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5]L_ G_DDWAW_KD__HUZ^)J^V?@3_P DF\._]<G_
M /1KUXN:_P &/K^C/TC@7_D85?\  _\ TJ)WM%%%?+G[@%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!^QK*U[_ (GO\5YQ3GQ#_:.75%+EY&FMKQ2_IGZ+?$CP#IWQ6\&3:3<2J$F
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M 5F5]+@Z'U:A&D^G_#GXYQ!F:SG,ZV.BK*;T7DDDK^=DK^84445UGSX4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M 'U)_P#%T?\ "@O"_P#SZK_WU)_\77$_\-P_"[_H)O\ ]_[7_P"/4']N+X7
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M?$__ &)]U_Z6V5 V?H#^W-^UG#^RC\+(M0L88+_Q?K,C6NCV=P28PR@&2>0
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MJ]._X(W?"<ZU\0/&?Q(O8S)'I%JNEV<DASFXG.^5A[K&@!SVF_+N_P#@LO\
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MM4$ K\S]<+^B7QE\'^&_V?/V6?BQ)X \/:=X64:%?W0BTN!8%\\VQ02D*.6
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M* "BBB@ HHHH **** "BBB@ HHHH *=%_K4^HIM.B_UJ?44 =-11100%%%%
M!1110 4444 %%%% !1110 4444 %%%% !7-_$G_DGOB7_L&W'_HMJZ2N;^)/
M_)/?$O\ V#;C_P!%M6U'^)'U1P9A_N=;_#+\F?F[1117ZN?PB%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?;/P)_
MY)-X=_ZY/_Z->OB:OMGX$_\ ))O#O_7)_P#T:]>+FO\ !CZ_HS](X%_Y&%7_
M  /_ -*B=[1117RY^X!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MT+P@K9/3]9?^E,****\T^S"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'G8[$RPU%SA&\NA\D?%SXIZU\8_&]UXEURXEFNY8XX561P1$B* %7"J ,Y;
M Y8GJ2:XW)]37JG_  S!\2_^A1U?_P %MS_\:H_X9@^)?_0HZO\ ^"VY_P#C
M5>LI12LF?FLJ.(G)RE%MOR/*\GU-&3ZFO5!^R_\ $PG'_"(ZP2>,?V9<_P#Q
MJO/O$?AR_P#"FJRZ;J4+6U["666%T96C8,5*L& ((*D$$52DGLS&5*I!7E%H
MS,GU-:WA;P_/XIURVTRV.)I]VWIV4MW([#UK(KZB_P""?WPZ_P"$N^,4.L21
M&2VT<L'RN5_>VUPHS\I'4#N/QI3ERQ;-,-1>(K1I+JS]1M"T>#0-*@L+9%CA
MBW;548 RQ)_4FOF?]H'_ )'I?^O;_P!JR5]35\Z_&OP7K&N>,%N+*PN+B$0;
M=\<+L,^9(>H!]1^=>33?O:GUW$M*4\"HTU?5;'C->]?LN_ZOQ+];;_VK7EO_
M  K/Q)_T";O_ ,!I/_B:]E_9W\-ZCX=77QJ%I-:>:8"AFB9-V/,SC<!GJ/SK
M:HURL^+R##5H9E2E.#2UZ?W6>A^.?%</@[P[<7\I_>;76%>?FDV,5'0X^[U/
M%?(OBGQ->^+-7FO[V9Y69F\M7.?+0L6"C@<#/I7J7Q@@\3>.-;$,&E7@TRU.
MZ ?9Y<L61=Q.,J<$'&/4UY__ ,*S\2?] F[_ / :3_XFE322N=>?XG$XZNZ5
M*#]G'R>K[_Y'+T5U'_"L_$G_ $";O_P&D_\ B:/^%9^)/^@3=_\ @-)_\36M
MT?*?5,1_S[?W'+T5U'_"L_$G_0)N_P#P&D_^)H_X5GXD_P"@3=_^ TG_ ,31
M=!]3Q'_/M_<<O7N_[,'37_\ >@_E)7F'_"L_$G_0)N__  &D_P#B:]C_ &>O
M#&I>'AK7]H6DUKYK0[/-C9-V ^<9 ]16=1KE9]!D&&K4\QI2G!I:]/)GLM%%
M%<A^QA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!^)/[$G_*3'2?^PUK_ /Z27M?4/_!8?X&GQ!X \.?%+3[?
M=>:!+_9FILJC)M)FS$['T28[1_U\&N[^"/\ P36_X4Y^TS:?%S_A8W]K_9[V
M_O/['_L/R-WVF&>/;YWVAL;?/SG9SMQ@9X^M/B;X TSXJ_#WQ%X/UA-^FZU8
MRV4QV@E ZD!U_P!I3A@>Q4&@D_%+PQK_ (J_X*%_M*_"[P]XA\R2UL-/M-.O
MGC?_ )=;==]W<$]%>4A^?5D'8"OT)_X*K6L-E^QM?V]O$D,$.J:?'''&,*BA
MR  .P XK9_8O_8"TW]D7Q#XBUZ3Q5_PF&KZI:QV4%P=,%E]EA#;Y% \V0MO9
M8R3D8\L<'->G_M8?L\_\-/\ P?NO O\ ;_\ PC7GW<%U]O\ L7VO;Y;9V^7Y
MD?7UW<4 ?./_  1M_P"38O$__8X77_I%95\=?\%9O^3N[S_L"V/_ *"U?I[^
MQM^RW_PR1\,=4\'_ /"3?\)7]MUB75OMGV#['LWPP1>7L\V3./(SNS_%C'&3
MX[^UG_P36_X:C^+TWCG_ (6-_P (SYEE!9_8/[#^UX\L$;O,^T1]<]-O'K0!
M[]^UI\(Y_CI^SIXY\%V:JVI7]CYEB&.T-<PNLT*Y[!GC52?0FORW_P"";/[6
M6E_LS>/_ !!X0\>-+I/AO7Y(UDNYXV']FWL191YJXW*K!BK''RE$) &XC]I*
M^/?VK/\ @FKX'_:.U^Y\4Z5J4G@CQ?<C-U=VULL]K>-_?EAW+\YZ%U89ZD,:
M L>\>)_VEOA3X/\ ";^)=3^(7AV/1EC\U+B#48IS,/2)(RS2'_90$^U?A?\
MM>?']_VE?COK_C..&2UTI]MGI=M* 'CM(AB/=C.&8EG(R<%R 2 *^U_!/_!%
MN5-;BD\7?$F.72$;,EOHNGE9YE]!)(Q6/Z['^E>G?';_ ()-^&/B=JWAIO"'
MBV/X?Z)H>BQZ1'IJZ.;YIF6>>9KAY3<1EG8SX.0?N]<8  /H3]HCX1S_ !T_
M9*U_P79JK:E?Z+!)8JQVAKF'RYH5SV#/&JD^A-?F9_P39_:RTO\ 9F\?^(/"
M'CQI=)\-Z_)&LEW/&P_LV]B+*/-7&Y58,58X^4HA( W$?LUI-A_9>E65EO\
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M;^SY)8+65QP^H71+S.I]4B8@_P#7<4 ?J]11104%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3HO]:GU%-IT
M7^M3ZB@#IJ***" HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YOXD_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117:?"KX8:A\4/$L5A
M;!X;&,A[R\V_+#'GG![L>P_H":B<XTHN<W9(ZL+A:V-K1P]"/-.3LD>[?LK^
M%Y-*\'7VL2H4;5)P(L_Q1QY /_?3./PKVRE32;30K"RTZQA$%G:P+#%&/X5'
M I*^%JUOK%1U>Y_3^ R]97A:>#3OR+7S>[?WMA11161WA1110 4444 %%%%
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M,.KWDR[&5Y$VK)+--DD%WX X51Z&ON+1=>T[Q'81WNEWUMJ%I( 5FM9EE0Y
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MUHHHJ3<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OMG
MX$_\DF\._P#7)_\ T:]?$U?;/P)_Y)-X=_ZY/_Z->O%S7^#'U_1GZ1P+_P C
M"K_@?_I43O:***^7/W **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M [_X4?\ "-ZO_P! N]_\!W_PK]!**/[6E_)^(?ZA4O\ H(?_ (#_ ,$_/O\
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M [_X4?\ "-ZO_P! N]_\!W_PK]!**/[6E_)^(?ZA4O\ H(?_ (#_ ,$_/O\
MX1O5_P#H%WO_ (#O_A1_PC>K_P#0+O?_  '?_"OT$HH_M:7\GXA_J%2_Z"'_
M . _\$_/O_A&]7_Z!=[_ . [_P"%'_"-ZO\ ] N]_P# =_\ "OT$HH_M:7\G
MXA_J%2_Z"'_X#_P3\^_^$;U?_H%WO_@._P#A1_PC>K_] N]_\!W_ ,*_02BC
M^UI?R?B'^H5+_H(?_@/_  3\^_\ A&]7_P"@7>_^ [_X4?\ "-ZO_P! N]_\
M!W_PK]!**/[6E_)^(?ZA4O\ H(?_ (#_ ,$_/O\ X1O5_P#H%WO_ (#O_A1_
MPC>K_P#0+O?_  '?_"OT$HH_M:7\GXA_J%2_Z"'_ . _\$_/O_A&]7_Z!=[_
M . [_P"%'_"-ZO\ ] N]_P# =_\ "OT$HH_M:7\GXA_J%2_Z"'_X#_P3\^_^
M$;U?_H%WO_@._P#A1_PC>K_] N]_\!W_ ,*_02BC^UI?R?B'^H5+_H(?_@/_
M  3\^_\ A&]7_P"@7>_^ [_X4?\ "-ZO_P! N]_\!W_PK]!**/[6E_)^(?ZA
M4O\ H(?_ (#_ ,$_/O\ X1O5_P#H%WO_ (#O_A1_PC>K_P#0+O?_  '?_"OT
M$HH_M:7\GXA_J%2_Z"'_ . _\$_/O_A&]7_Z!=[_ . [_P"%'_"-ZO\ ] N]
M_P# =_\ "OT$HH_M:7\GXA_J%2_Z"'_X#_P3\^_^$;U?_H%WO_@._P#A1_PC
M>K_] N]_\!W_ ,*_02BC^UI?R?B'^H5+_H(?_@/_  3\^_\ A&]7_P"@7>_^
M [_X4?\ "-ZO_P! N]_\!W_PK]!**/[6E_)^(?ZA4O\ H(?_ (#_ ,$_/O\
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M [_X4?\ "-ZO_P! N]_\!W_PK]!**/[6E_)^(?ZA4O\ H(?_ (#_ ,$_/O\
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M [_X4?\ "-ZO_P! N]_\!W_PK]!**/[6E_)^(?ZA4O\ H(?_ (#_ ,$_/O\
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M2_D_$/\ 4*E_T$/_ ,!_X)^??_"-ZO\ ] N]_P# =_\ "C_A&]7_ .@7>_\
M@._^%?H)11_:TOY/Q#_4*E_T$/\ \!_X)^??_"-ZO_T"[W_P'?\ PH_X1O5_
M^@7>_P#@._\ A7Z"44?VM+^3\0_U"I?]!#_\!_X)^??_  C>K_\ 0+O?_ =_
M\*/^$;U?_H%WO_@._P#A7Z"44?VM+^3\0_U"I?\ 00__  '_ ()^??\ PC>K
M_P#0+O?_  '?_"C_ (1O5_\ H%WO_@._^%?H)11_:TOY/Q#_ %"I?]!#_P#
M?^"?GW_PC>K_ /0+O?\ P'?_  H_X1O5_P#H%WO_ (#O_A7Z"44?VM+^3\0_
MU"I?]!#_ / ?^"?GW_PC>K_] N]_\!W_ ,*/^$;U?_H%WO\ X#O_ (5^@E%'
M]K2_D_$/]0J7_00__ ?^"?GW_P (WJ__ $"[W_P'?_"C_A&]7_Z!=[_X#O\
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M_ =_\*/^$;U?_H%WO_@._P#A7Z"44?VM+^3\0_U"I?\ 00__  '_ ()^??\
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M .@7>_\ @._^%?H)11_:TOY/Q#_4*E_T$/\ \!_X)^??_"-ZO_T"[W_P'?\
MPH_X1O5_^@7>_P#@._\ A7Z"44?VM+^3\0_U"I?]!#_\!_X)^??_  C>K_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 .B_UJ?45OM]T_2L"+
M_6I]16^WW3]*X,3NCZ;*/@GZF-1117&?1!1110 4444 %%%% !1110 4444
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M5YM[ZL^]C%02C%62"OS4_P""FUS-%\:_#:)*Z(?#T9*JQ _X^;BOTKK\S_\
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M!(;]$?P5MMBPS)_:O0<9X^S9]:^L/@)\>=$^/?A:?5=(_=2VCI#=6_SGRG9
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MWS+&V.=HY ^]GM7RYJ7_  4_>*]=;3P7YUN&.V3^U=N1DXX-MGTKZQ^.VB^
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MO\,OR9^;M%%%?JY_"(4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5]L_ G_DDWAW_KD_\ Z->OB:OMGX$_\DF\._\
M7)__ $:]>+FO\&/K^C/TC@7_ )&%7_ __2HG>T445\N?N 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M36?_ !]1_6H:FL_^/J/ZU+V9I2^./JC4N_\ CVD_W36+6U=_\>TG^Z:Q:QH[
M,[\?\<?0****Z#S HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ JUIO_'T/H:JU:TW_ (^A]#43^%F]#^+'U+NH_P#'JWU'\ZR*U]1_X]6^
MH_G616=+X3IQW\1>@4445N>>%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 ^'_71_P"\*VY/
M]6WT-8D/^NC_ -X5MR?ZMOH:YJNZ/7P7P2,&BBBND\@**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MD&))GFBD,ORWH'^K^484(/\ )KV;_@F]M'P0U': #_;$F>._V:UKZLGMHKE
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M-NC:)>^+OACJEU%9ZCJL\>JZ2)"!]I=4V3Q _P!X*L; =2 Y_AK]420H))
MY)-!2/P2_P""A'P+TGX _M+:QHOA^U^P^']3MHM8L+0#"P)*65XT_P!@21R!
M?08':OW7\)_\BKHW_7E#_P"@"OPV_P""C_QKTGXW_M0:O?:#<I?:+HEI%H=M
M>1L&2X\IG>1T(X*^;+( 1D, ".#7[D^$_P#D5=&_Z\H?_0!0)&M7XQ_\%@[B
MZD_:ETF.<OY$?ABT%N&7 V&XN22/7YMW/MCM7[.5^;?_  6)^!%[K_A[PO\
M%32K9K@:,C:3J_EKEDMW??!*?15D:13[S+[T S]!OA_;VUKX#\-PV846<>FV
MR0!/NA!$H7'MC%;U?'O_  3A_:MT3XT_!S0_!U_J$4'CKPS9I83V4S@27=M$
MH6*XC'5QL"*_<,"3PP)^PJ!A45[=Q:?9SW4Q*PP1M(Y SA0,GCZ"OC']J_\
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M6 8,I#+ ""&52"#U H)/O;_@F?\ %S_A:G[*/ARWN)Q+JGAAWT&Y!;+;(@#
M<'D#R7B7TRI],#C?^"LWPE\0_$C]G[3-6\/VDVH_\(SJ1U"^M8 6<6QB='E"
MCKL)4GT4L>@-?+7_  2&^*4W@?X\>(OAYJ9DM8O$EDS1VT^59+VUW-MVGD'R
MC/GO\@!'''Z3?M!_M0^!_P!F.PT6]\;RW]O:ZM)+#;2V5HTXWH%)#8Z9#<>N
M#Z4#/S__ &!?^"BWP_\ @M\)=*^&OCO3KS18].FG>#7K& W$,RRS-*3.B_O
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7VS\"?\
MDDWAW_KD_P#Z->OB:OMGX$_\DF\._P#7)_\ T:]>+FO\&/K^C/TC@7_D85?\
M#_\ 2HG>T445\N?N 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %36?\ Q]1_6H:FL_\ CZC^M2]F:4OC
MCZHU+O\ X]I/]TUBUM7?_'M)_NFL6L:.S._'_''T"BBBN@\P**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *M:;_P ?0^AJK5K3?^/H?0U$
M_A9O0_BQ]2[J/_'JWU'\ZR*U]1_X]6^H_G616=+X3IQW\1>@4445N>>%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 ^'_71_[PK;D_U;?0UB0_ZZ/_>%;<G^K;Z&N:KNCU\%
M\$C!HHHKI/("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ K4TO_CW;_>/\A676II?_'NW^\?Y"L:O
MPG=@OXI!JO\ KD_W:I5=U7_7)_NU2JH?"C+$_P :04445H<P4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY:^:DGE2I& R[D)5L'NI(]Z],HH"Q^6_[+?[%GQE^'/[<NG_ !!\1>#O[/\
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M&..N2*_2RBB@#Y2_;F_88TS]J[1K75])N8-$^(.F0^3:7\X/D7<.2WD3X!(
M)8JX!*EFX(/'P-X2_9\_;7^!;S^&/"%IXFTW3G=ML>DZK!+8DDY+IF0I&3US
MA6]>:_::B@+'Y'7W_!+OXL>(?A7XT\:>,KZ3Q5\7+];<Z5HHU1))-YN8?.EN
M;J5PC,(1* H8KWW$X ^K?^"9?P"\>?L^?"CQ5HWC_0O[ U*]UK[7;P_;+>YW
MQ>1&F[=#(X'S*PP3GCI7V)10%C\M_P#@H9^Q;\9?CG^T9=>*/!'@[^V]"?3+
M6W6Z_M2RM\R(&W#9+,C<9'.,5^I%%% !7Y\_\%-_V?OC7^T;XI\':5X"\(/K
M/A71;26XENO[4L[827DK;679+,C'8D:8.,?O& [U^@U% 'F_[-_PIC^"'P+\
M%>"515GTK3HTNRF,-=-^\G88]97<]^O4UZ1110!^5GQ2_8D^-'@/]MBY^)OP
MN\&C6O#4>O0Z];O#J=E;;MY62Y@\N69& +-*G0#:PP1V^]?VHOV;]"_:D^%-
MWX0UJ5]/N5D%WIVIQH'>RN5!"OMS\RD,RLN1D$X(."/7J* L?C58?LJ?MB_L
MLZG?V'P]EU.XTBZ<DW'AG4(IK6X/3>;>0AE?&/F,8/8$XK?^%_\ P3I^-_[0
MOQ-M_%GQVO;K3-+,B/>2ZI?K<ZA>1*?]1$D;-Y*D9&6*[<Y"FOUVHH"QSOBS
MP^9OAWK.B:1:HI?2IK*SM8\(HS"R1H,X '0>@K\]?^":/['_ ,7/V?OCMKOB
M+Q]X2_L'1[GPW/817/\ :5I<[IVNK5U3;#,[#*Q.<D8XZY(K]+** /!?VP?V
M2?#_ .UE\/H]*O9AI7B332\VCZR$W&W=@-T;C^*)]J[AU!52.1@_FAHO[*7[
M8G[->N7EAX&MM;AM+B3FX\-:G')971Z!VC9A@XXS(BD8]*_:FB@+'Y->'O\
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M5+%8:EB'BFN>*=N5:72?\Q^9G_",:S_T";__ ,!G_P *9)X<U:&-I)-+O41
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M_P!?Z_\ HL5PXW$O"4752O8^GX;R>.>YC# RGR*2;O:^ROM='RO_ ,(QK/\
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MPBQ/+>Z6GJ?F&6<.QS#/9Y.ZME&4US6O\%^E^MNY\K_\(QK/_0)O_P#P&?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *FL_P#CZC^M
M0U-9_P#'U']:E[,TI?''U1J7?_'M)_NFL6MJ[_X]I/\ =-8M8T=F=^/^./H%
M%%%=!Y@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5:TW_
M (^A]#56K6F_\?0^AJ)_"S>A_%CZEW4?^/5OJ/YUD5KZC_QZM]1_.LBLZ7PG
M3COXB] HHHK<\\**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@!\/^NC_WA6W)_JV^AK$A_P!=
M'_O"MN3_ %;?0US5=T>O@O@D8-%%%=)Y 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %:FE_\>[?[
MQ_D*RZU-+_X]V_WC_(5C5^$[L%_%(-5_UR?[M4JNZK_KD_W:I54/A1EB?XT@
MHHHK0Y@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** '1?ZU/J*WV^Z?I6!%_K4^HK?;[I^E<&
M)W1]-E'P3]3&HHHKC/H@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_+FOU&K\N:X>'_\ E[\OU/I?%;_F"_[B?^V!1117UQ^ FWX'\,3>,_%^D:)
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M>=CZ2_X:0\"?]!.?_P !)?\ XFC_ (:0\"?]!.?_ ,!)?_B:^??^&>OB!_T
M/_)VW_\ CE'_  SU\0/^@!_Y.V__ ,<KR_J>"_Y^?BC[;_6#B7_H#_\ *<_\
MSZ"_X:0\"?\ 03G_ / 27_XFC_AI#P)_T$Y__ 27_P")KY]_X9Z^('_0 _\
M)VW_ /CE'_#/7Q _Z '_ ).V_P#\<H^IX+_GY^*#_6#B7_H#_P#*<_\ ,^@O
M^&D/ G_03G_\!)?_ (FC_AI#P)_T$Y__  $E_P#B:^??^&>OB!_T /\ R=M_
M_CE'_#/7Q _Z '_D[;__ !RCZG@O^?GXH/\ 6#B7_H#_ /*<_P#,^@O^&D/
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ME_\ B:/^&D/ G_03G_\  27_ .)KY]_X9Z^('_0 _P#)VW_^.4?\,]?$#_H
M?^3MO_\ '*/J>"_Y^?B@_P!8.)?^@/\ \IS_ ,SZ"_X:0\"?]!.?_P !)?\
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MB@_U@XE_Z __ "G/_,^@O^&D/ G_ $$Y_P#P$E_^)H_X:0\"?]!.?_P$E_\
MB:^??^&>OB!_T /_ "=M_P#XY1_PSU\0/^@!_P"3MO\ _'*/J>"_Y^?B@_U@
MXE_Z _\ RG/_ #/H+_AI#P)_T$Y__ 27_P")H_X:0\"?]!.?_P !)?\ XFOG
MW_AGKX@?] #_ ,G;?_XY1_PSU\0/^@!_Y.V__P <H^IX+_GY^*#_ %@XE_Z
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M0\"?]!.?_P !)?\ XFC_ (:0\"?]!.?_ ,!)?_B:^??^&>OB!_T /_)VW_\
MCE'_  SU\0/^@!_Y.V__ ,<H^IX+_GY^*#_6#B7_ * __*<_\SZ"_P"&D/ G
M_03G_P# 27_XFC_AI#P)_P!!.?\ \!)?_B:^??\ AGKX@?\ 0 _\G;?_ ..4
M?\,]?$#_ * '_D[;_P#QRCZG@O\ GY^*#_6#B7_H#_\ *<_\SZ"_X:0\"?\
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M:0\"?]!.?_P$E_\ B:^??^&>OB!_T /_ "=M_P#XY1_PSU\0/^@!_P"3MO\
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M@?\ 0 _\G;?_ ..4?\,]?$#_ * '_D[;_P#QRCZG@O\ GY^*#_6#B7_H#_\
M*<_\SZ"_X:0\"?\ 03G_ / 27_XFC_AI#P)_T$Y__ 27_P")KY]_X9Z^('_0
M _\ )VW_ /CE'_#/7Q _Z '_ ).V_P#\<H^IX+_GY^*#_6#B7_H#_P#*<_\
M,^@O^&D/ G_03G_\!)?_ (FC_AI#P)_T$Y__  $E_P#B:^??^&>OB!_T /\
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M_P#B:/\ AI#P)_T$Y_\ P$E_^)KY]_X9Z^('_0 _\G;?_P".4?\ #/7Q _Z
M'_D[;_\ QRCZG@O^?GXH/]8.)?\ H#_\IS_S/H+_ (:0\"?]!.?_ ,!)?_B:
M/^&D/ G_ $$Y_P#P$E_^)KY]_P"&>OB!_P! #_R=M_\ XY1_PSU\0/\ H ?^
M3MO_ /'*/J>"_P"?GXH/]8.)?^@/_P IS_S/H+_AI#P)_P!!.?\ \!)?_B:/
M^&D/ G_03G_\!)?_ (FOGW_AGKX@?] #_P G;?\ ^.4?\,]?$#_H ?\ D[;_
M /QRCZG@O^?GXH/]8.)?^@/_ ,IS_P SZ"_X:0\"?]!.?_P$E_\ B:/^&D/
MG_03G_\  27_ .)KY]_X9Z^('_0 _P#)VW_^.4?\,]?$#_H ?^3MO_\ '*/J
M>"_Y^?B@_P!8.)?^@/\ \IS_ ,SZ"_X:0\"?]!.?_P !)?\ XFC_ (:0\"?]
M!.?_ ,!)?_B:^??^&>OB!_T /_)VW_\ CE'_  SU\0/^@!_Y.V__ ,<H^IX+
M_GY^*#_6#B7_ * __*<_\SZ"_P"&D/ G_03G_P# 27_XFC_AI#P)_P!!.?\
M\!)?_B:^??\ AGKX@?\ 0 _\G;?_ ..4?\,]?$#_ * '_D[;_P#QRCZG@O\
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M\"?]!.?_ ,!)?_B:/^&D/ G_ $$Y_P#P$E_^)KY]_P"&>OB!_P! #_R=M_\
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M ,<J'_AGKX@?] #_ ,G;?_XY4PP6 2]VK_Y,C>OQ'Q3-IU,%;_N'/_,^@O\
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M?_B:/^&D/ G_ $$Y_P#P$E_^)KY]_P"&>OB!_P! #_R=M_\ XY1_PSU\0/\
MH ?^3MO_ /'*/J>"_P"?GXH/]8.)?^@/_P IS_S/H+_AI#P)_P!!.?\ \!)?
M_B:/^&D/ G_03G_\!)?_ (FOGW_AGKX@?] #_P G;?\ ^.4?\,]?$#_H ?\
MD[;_ /QRCZG@O^?GXH/]8.)?^@/_ ,IS_P SZ"_X:0\"?]!.?_P$E_\ B:/^
M&D/ G_03G_\  27_ .)KY]_X9Z^('_0 _P#)VW_^.4?\,]?$#_H ?^3MO_\
M'*/J>"_Y^?B@_P!8.)?^@/\ \IS_ ,SZ"_X:0\"?]!.?_P !)?\ XFC_ (:0
M\"?]!.?_ ,!)?_B:^??^&>OB!_T /_)VW_\ CE'_  SU\0/^@!_Y.V__ ,<H
M^IX+_GY^*#_6#B7_ * __*<_\SZ"_P"&D/ G_03G_P# 27_XFC_AI#P)_P!!
M.?\ \!)?_B:^??\ AGKX@?\ 0 _\G;?_ ..4?\,]?$#_ * '_D[;_P#QRCZG
M@O\ GY^*#_6#B7_H#_\ *<_\SZ"_X:0\"?\ 03G_ / 27_XFC_AI#P)_T$Y_
M_ 27_P")KY]_X9Z^('_0 _\ )VW_ /CE'_#/7Q _Z '_ ).V_P#\<H^IX+_G
MY^*#_6#B7_H#_P#*<_\ ,^@O^&D/ G_03G_\!)?_ (FC_AI#P)_T$Y__  $E
M_P#B:^??^&>OB!_T /\ R=M__CE'_#/7Q _Z '_D[;__ !RCZG@O^?GXH/\
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MOB!_T /_ "=M_P#XY1_PSU\0/^@!_P"3MO\ _'*/J>"_Y^?B@_U@XE_Z _\
MRG/_ #/H+_AI#P)_T$Y__ 27_P")H_X:0\"?]!.?_P !)?\ XFOGW_AGKX@?
M] #_ ,G;?_XY1_PSU\0/^@!_Y.V__P <H^IX+_GY^*#_ %@XE_Z _P#RG/\
MS/H+_AI#P)_T$Y__  $E_P#B:/\ AI#P)_T$Y_\ P$E_^)KY]_X9Z^('_0 _
M\G;?_P".4?\ #/7Q _Z '_D[;_\ QRCZG@O^?GXH/]8.)?\ H#_\IS_S/H+_
M (:0\"?]!.?_ ,!)?_B:/^&D/ G_ $$Y_P#P$E_^)KY]_P"&>OB!_P! #_R=
MM_\ XY1_PSU\0/\ H ?^3MO_ /'*/J>"_P"?GXH/]8.)?^@/_P IS_S/H+_A
MI#P)_P!!.?\ \!)?_B:/^&D/ G_03G_\!)?_ (FOGW_AGKX@?] #_P G;?\
M^.4?\,]?$#_H ?\ D[;_ /QRCZG@O^?GXH/]8.)?^@/_ ,IS_P SZ"_X:0\"
M?]!.?_P$E_\ B:/^&D/ G_03G_\  27_ .)KY]_X9Z^('_0 _P#)VW_^.4?\
M,]?$#_H ?^3MO_\ '*/J>"_Y^?B@_P!8.)?^@/\ \IS_ ,SZ"_X:0\"?]!.?
M_P !)?\ XFC_ (:0\"?]!.?_ ,!)?_B:^??^&>OB!_T /_)VW_\ CE'_  SU
M\0/^@!_Y.V__ ,<H^IX+_GY^*#_6#B7_ * __*<_\SZ"_P"&D/ G_03G_P#
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M*/J>"_Y^?B@_U@XE_P"@/_RG/_,^@O\ AI#P)_T$Y_\ P$E_^)H_X:0\"?\
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M ,SZ"_X:0\"?]!.?_P !)?\ XFC_ (:0\"?]!.?_ ,!)?_B:^??^&>OB!_T
M/_)VW_\ CE'_  SU\0/^@!_Y.V__ ,<H^IX+_GY^*#_6#B7_ * __*<_\SZ"
M_P"&D/ G_03G_P# 27_XFC_AI#P)_P!!.?\ \!)?_B:^??\ AGKX@?\ 0 _\
MG;?_ ..4?\,]?$#_ * '_D[;_P#QRCZG@O\ GY^*#_6#B7_H#_\ *<_\SZ"_
MX:0\"?\ 03G_ / 27_XFC_AI#P)_T$Y__ 27_P")KY]_X9Z^('_0 _\ )VW_
M /CE'_#/7Q _Z '_ ).V_P#\<H^IX+_GY^*#_6#B7_H#_P#*<_\ ,^@O^&D/
M G_03G_\!)?_ (FC_AI#P)_T$Y__  $E_P#B:^??^&>OB!_T /\ R=M__CE'
M_#/7Q _Z '_D[;__ !RCZG@O^?GXH/\ 6#B7_H#_ /*<_P#,^@O^&D/ G_03
MG_\  27_ .)H_P"&D/ G_03G_P# 27_XFOGW_AGKX@?] #_R=M__ (Y1_P ,
M]?$#_H ?^3MO_P#'*/J>"_Y^?B@_U@XE_P"@/_RG/_,^@O\ AI#P)_T$Y_\
MP$E_^)H_X:0\"?\ 03G_ / 27_XFOGW_ (9Z^('_ $ /_)VW_P#CE'_#/7Q
M_P"@!_Y.V_\ \<H^IX+_ )^?B@_U@XE_Z __ "G/_,^@O^&D/ G_ $$Y_P#P
M$E_^)H_X:0\"?]!.?_P$E_\ B:^??^&>OB!_T /_ "=M_P#XY1_PSU\0/^@!
M_P"3MO\ _'*/J>"_Y^?B@_U@XE_Z _\ RG/_ #/H+_AI#P)_T$Y__ 27_P")
MH_X:0\"?]!.?_P !)?\ XFOGW_AGKX@?] #_ ,G;?_XY1_PSU\0/^@!_Y.V_
M_P <H^IX+_GY^*#_ %@XE_Z _P#RG/\ S/H+_AI#P)_T$Y__  $E_P#B:/\
MAI#P)_T$Y_\ P$E_^)KY]_X9Z^('_0 _\G;?_P".4?\ #/7Q _Z '_D[;_\
MQRCZG@O^?GXH/]8.)?\ H#_\IS_S/H+_ (:0\"?]!.?_ ,!)?_B:/^&D/ G_
M $$Y_P#P$E_^)KY]_P"&>OB!_P! #_R=M_\ XY1_PSU\0/\ H ?^3MO_ /'*
M/J>"_P"?GXH/]8.)?^@/_P IS_S/H+_AI#P)_P!!.?\ \!)?_B:/^&D/ G_0
M3G_\!)?_ (FOGW_AGKX@?] #_P G;?\ ^.4?\,]?$#_H ?\ D[;_ /QRCZG@
MO^?GXH/]8.)?^@/_ ,IS_P SZ"_X:0\"?]!.?_P$E_\ B:/^&D/ G_03G_\
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M$Y__  $E_P#B:/\ AI#P)_T$Y_\ P$E_^)KY]_X9Z^('_0 _\G;?_P".4?\
M#/7Q _Z '_D[;_\ QRCZG@O^?GXH/]8.)?\ H#_\IS_S/H+_ (:0\"?]!.?_
M ,!)?_B:/^&D/ G_ $$Y_P#P$E_^)KY]_P"&>OB!_P! #_R=M_\ XY1_PSU\
M0/\ H ?^3MO_ /'*/J>"_P"?GXH/]8.)?^@/_P IS_S/H+_AI#P)_P!!.?\
M\!)?_B:/^&D/ G_03G_\!)?_ (FOGW_AGKX@?] #_P G;?\ ^.4?\,]?$#_H
M ?\ D[;_ /QRCZG@O^?GXH/]8.)?^@/_ ,IS_P SZ"_X:0\"?]!.?_P$E_\
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M?_B:/^&D/ G_ $$Y_P#P$E_^)KY]_P"&>OB!_P! #_R=M_\ XY1_PSU\0/\
MH ?^3MO_ /'*/J>"_P"?GXH/]8.)?^@/_P IS_S/H+_AI#P)_P!!.?\ \!)?
M_B:/^&D/ G_03G_\!)?_ (FOGW_AGKX@?] #_P G;?\ ^.4?\,]?$#_H ?\
MD[;_ /QRCZG@O^?GXH/]8.)?^@/_ ,IS_P SZ"_X:0\"?]!.?_P$E_\ B:/^
M&D/ G_03G_\  27_ .)KY]_X9Z^('_0 _P#)VW_^.4?\,]?$#_H ?^3MO_\
M'*/J>"_Y^?B@_P!8.)?^@/\ \IS_ ,SZ"_X:0\"?]!.?_P !)?\ XFC_ (:0
M\"?]!.?_ ,!)?_B:^??^&>OB!_T /_)VW_\ CE'_  SU\0/^@!_Y.V__ ,<H
M^IX+_GY^*#_6#B7_ * __*<_\SZ"_P"&D/ G_03G_P# 27_XFC_AI#P)_P!!
M.?\ \!)?_B:^??\ AGKX@?\ 0 _\G;?_ ..4?\,]?$#_ * '_D[;_P#QRCZG
M@O\ GY^*#_6#B7_H#_\ *<_\SZ"_X:0\"?\ 03G_ / 27_XFC_AI#P)_T$Y_
M_ 27_P")KY]_X9Z^('_0 _\ )VW_ /CE'_#/7Q _Z '_ ).V_P#\<H^IX+_G
MY^*#_6#B7_H#_P#*<_\ ,^@O^&D/ G_03G_\!)?_ (FC_AI#P)_T$Y__  $E
M_P#B:^??^&>OB!_T /\ R=M__CE'_#/7Q _Z '_D[;__ !RCZG@O^?GXH/\
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MOB!_T /_ "=M_P#XY1_PSU\0/^@!_P"3MO\ _'*/J>"_Y^?B@_U@XE_Z _\
MRG/_ #/H+_AI#P)_T$Y__ 27_P")H_X:0\"?]!.?_P !)?\ XFOGW_AGKX@?
M] #_ ,G;?_XY1_PSU\0/^@!_Y.V__P <H^IX+_GY^*#_ %@XE_Z _P#RG/\
MS/H+_AI#P)_T$Y__  $E_P#B:/\ AI#P)_T$Y_\ P$E_^)KY]_X9Z^('_0 _
M\G;?_P".4?\ #/7Q _Z '_D[;_\ QRCZG@O^?GXH/]8.)?\ H#_\IS_S/H+_
M (:0\"?]!.?_ ,!)?_B:/^&D/ G_ $$Y_P#P$E_^)KY]_P"&>OB!_P! #_R=
MM_\ XY1_PSU\0/\ H ?^3MO_ /'*/J>"_P"?GXH/]8.)?^@/_P IS_S/H+_A
MI#P)_P!!.?\ \!)?_B:/^&D/ G_03G_\!)?_ (FOGW_AGKX@?] #_P G;?\
M^.4?\,]?$#_H ?\ D[;_ /QRCZG@O^?GXH/]8.)?^@/_ ,IS_P SZ"_X:0\"
M?]!.?_P$E_\ B:/^&D/ G_03G_\  27_ .)KY]_X9Z^('_0 _P#)VW_^.4?\
M,]?$#_H ?^3MO_\ '*/J>"_Y^?B@_P!8.)?^@/\ \IS_ ,SZ"_X:0\"?]!.?
M_P !)?\ XFC_ (:0\"?]!.?_ ,!)?_B:^??^&>OB!_T /_)VW_\ CE'_  SU
M\0/^@!_Y.V__ ,<H^IX+_GY^*#_6#B7_ * __*<_\SZ"_P"&D/ G_03G_P#
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M*/J>"_Y^?B@_U@XE_P"@/_RG/_,^@O\ AI#P)_T$Y_\ P$E_^)H_X:0\"?\
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M ,SZ"_X:0\"?]!.?_P !)?\ XFC_ (:0\"?]!.?_ ,!)?_B:^??^&>OB!_T
M/_)VW_\ CE'_  SU\0/^@!_Y.V__ ,<H^IX+_GY^*#_6#B7_ * __*<_\SZ"
M_P"&D/ G_03G_P# 27_XFC_AI#P)_P!!.?\ \!)?_B:^??\ AGKX@?\ 0 _\
MG;?_ ..4?\,]?$#_ * '_D[;_P#QRCZG@O\ GY^*#_6#B7_H#_\ *<_\SZ"_
MX:0\"?\ 03G_ / 27_XFC_AI#P)_T$Y__ 27_P")KY]_X9Z^('_0 _\ )VW_
M /CE'_#/7Q _Z '_ ).V_P#\<H^IX+_GY^*#_6#B7_H#_P#*<_\ ,^@O^&D/
M G_03G_\!)?_ (FC_AI#P)_T$Y__  $E_P#B:^??^&>OB!_T /\ R=M__CE'
M_#/7Q _Z '_D[;__ !RCZG@O^?GXH/\ 6#B7_H#_ /*<_P#,^@O^&D/ G_03
MG_\  27_ .)H_P"&D/ G_03G_P# 27_XFOGW_AGKX@?] #_R=M__ (Y1_P ,
M]?$#_H ?^3MO_P#'*/J>"_Y^?B@_U@XE_P"@/_RG/_,^@O\ AI#P)_T$Y_\
MP$E_^)H_X:0\"?\ 03G_ / 27_XFOGW_ (9Z^('_ $ /_)VW_P#CE'_#/7Q
M_P"@!_Y.V_\ \<H^IX+_ )^?B@_U@XE_Z __ "G/_,^@O^&D/ G_ $$Y_P#P
M$E_^)H_X:0\"?]!.?_P$E_\ B:^??^&>OB!_T /_ "=M_P#XY1_PSU\0/^@!
M_P"3MO\ _'*/J>"_Y^?B@_U@XE_Z _\ RG/_ #/H+_AI#P)_T$Y__ 27_P")
MH_X:0\"?]!.?_P !)?\ XFOGW_AGKX@?] #_ ,G;?_XY1_PSU\0/^@!_Y.V_
M_P <H^IX+_GY^*#_ %@XE_Z _P#RG/\ S/H+_AI#P)_T$Y__  $E_P#B:/\
MAI#P)_T$Y_\ P$E_^)KY]_X9Z^('_0 _\G;?_P".4?\ #/7Q _Z '_D[;_\
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ME_\ B:/^&D/ G_03G_\  27_ .)KY]_X9Z^('_0 _P#)VW_^.4?\,]?$#_H
M?^3MO_\ '*/J>"_Y^?B@_P!8.)?^@/\ \IS_ ,SZ"_X:0\"?]!.?_P !)?\
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MB@_U@XE_Z __ "G/_,^@O^&D/ G_ $$Y_P#P$E_^)H_X:0\"?]!.?_P$E_\
MB:^??^&>OB!_T /_ "=M_P#XY1_PSU\0/^@!_P"3MO\ _'*/J>"_Y^?B@_U@
MXE_Z _\ RG/_ #/H+_AI#P)_T$Y__ 27_P")H_X:0\"?]!.?_P !)?\ XFOG
MW_AGKX@?] #_ ,G;?_XY1_PSU\0/^@!_Y.V__P <H^IX+_GY^*#_ %@XE_Z
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M0\"?]!.?_P !)?\ XFC_ (:0\"?]!.?_ ,!)?_B:^??^&>OB!_T /_)VW_\
MCE'_  SU\0/^@!_Y.V__ ,<H^IX+_GY^*#_6#B7_ * __*<_\SZ"_P"&D/ G
M_03G_P# 27_XFC_AI#P)_P!!.?\ \!)?_B:^??\ AGKX@?\ 0 _\G;?_ ..4
M?\,]?$#_ * '_D[;_P#QRCZG@O\ GY^*#_6#B7_H#_\ *<_\SZ"_X:0\"?\
M03G_ / 27_XFC_AI#P)_T$Y__ 27_P")KY]_X9Z^('_0 _\ )VW_ /CE'_#/
M7Q _Z '_ ).V_P#\<H^IX+_GY^*#_6#B7_H#_P#*<_\ ,^@O^&D/ G_03G_\
M!)?_ (FC_AI#P)_T$Y__  $E_P#B:^??^&>OB!_T /\ R=M__CE'_#/7Q _Z
M '_D[;__ !RCZG@O^?GXH/\ 6#B7_H#_ /*<_P#,^@O^&D/ G_03G_\  27_
M .)H_P"&D/ G_03G_P# 27_XFOGW_AGKX@?] #_R=M__ (Y1_P ,]?$#_H ?
M^3MO_P#'*/J>"_Y^?B@_U@XE_P"@/_RG/_,^@O\ AI#P)_T$Y_\ P$E_^)H_
MX:0\"?\ 03G_ / 27_XFOGW_ (9Z^('_ $ /_)VW_P#CE'_#/7Q _P"@!_Y.
MV_\ \<H^IX+_ )^?B@_U@XE_Z __ "G/_,^@O^&D/ G_ $$Y_P#P$E_^)H_X
M:0\"?]!.?_P$E_\ B:^??^&>OB!_T /_ "=M_P#XY1_PSU\0/^@!_P"3MO\
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MO^&D/ G_ $$Y_P#P$E_^)KY_E_9S^(<#8?P]@GG_ (_;?_XY3?\ AGKX@?\
M0 _\G;?_ ..4XX/ I653\415XAXGE-N6#U_Z]S_S/H+_ (:0\"?]!.?_ ,!)
M?_B:/^&D/ G_ $$Y_P#P$E_^)KY]_P"&>OB!_P! #_R=M_\ XY1_PSU\0/\
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M * __*<_\SZ"_P"&D/ G_03G_P# 27_XFC_AI#P)_P!!.?\ \!)?_B:^??\
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M=M__ (Y1_P ,]?$#_H ?^3MO_P#'*/J>"_Y^?B@_U@XE_P"@/_RG/_,^@O\
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M?_B:/^&D/ G_ $$Y_P#P$E_^)KY]_P"&>OB!_P! #_R=M_\ XY1_PSU\0/\
MH ?^3MO_ /'*/J>"_P"?GXH/]8.)?^@/_P IS_S/H+_AI#P)_P!!.?\ \!)?
M_B:/^&D/ G_03G_\!)?_ (FOGW_AGKX@?] #_P G;?\ ^.4?\,]?$#_H ?\
MD[;_ /QRCZG@O^?GXH/]8.)?^@/_ ,IS_P SZ"_X:0\"?]!.?_P$E_\ B:/^
M&D/ G_03G_\  27_ .)KY]_X9Z^('_0 _P#)VW_^.4?\,]?$#_H ?^3MO_\
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M_P#B:^??^&>OB!_T /\ R=M__CE'_#/7Q _Z '_D[;__ !RCZG@O^?GXH/\
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MOB!_T /_ "=M_P#XY1_PSU\0/^@!_P"3MO\ _'*/J>"_Y^?B@_U@XE_Z _\
MRG/_ #/H+_AI#P)_T$Y__ 27_P")H_X:0\"?]!.?_P !)?\ XFOGW_AGKX@?
M] #_ ,G;?_XY1_PSU\0/^@!_Y.V__P <H^IX+_GY^*#_ %@XE_Z _P#RG/\
MS/H+_AI#P)_T$Y__  $E_P#B:/\ AI#P)_T$Y_\ P$E_^)KY]_X9Z^('_0 _
M\G;?_P".4?\ #/7Q _Z '_D[;_\ QRCZG@O^?GXH/]8.)?\ H#_\IS_S/H+_
M (:0\"?]!.?_ ,!)?_B:/^&D/ G_ $$Y_P#P$E_^)KY]_P"&>OB!_P! #_R=
MM_\ XY1_PSU\0/\ H ?^3MO_ /'*/J>"_P"?GXH/]8.)?^@/_P IS_S/H+_A
MI#P)_P!!.?\ \!)?_B:/^&D/ G_03G_\!)?_ (FOGW_AGKX@?] #_P G;?\
M^.4?\,]?$#_H ?\ D[;_ /QRCZG@O^?GXH/]8.)?^@/_ ,IS_P SZ"_X:0\"
M?]!.?_P$E_\ B:/^&D/ G_03G_\  27_ .)KY]_X9Z^('_0 _P#)VW_^.4?\
M,]?$#_H ?^3MO_\ '*/J>"_Y^?B@_P!8.)?^@/\ \IS_ ,SZ"_X:0\"?]!.?
M_P !)?\ XFC_ (:0\"?]!.?_ ,!)?_B:^??^&>OB!_T /_)VW_\ CE'_  SU
M\0/^@!_Y.V__ ,<H^IX+_GY^*#_6#B7_ * __*<_\SZ"_P"&D/ G_03G_P#
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M*/J>"_Y^?B@_U@XE_P"@/_RG/_,^@O\ AI#P)_T$Y_\ P$E_^)H_X:0\"?\
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M_P -*> O^@I/_P" DO\ \37SS_PSK\0O^A?_ /)VW_\ CE'_  SK\0O^A?\
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M$+_H7_\ R=M__CE']GY9_P _O_)HA_K9QG_T+W_X)J?YGT-_PTIX"_Z"D_\
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M_H*3_P#@)+_\31_PTIX"_P"@I/\ ^ DO_P 37SS_ ,,Z_$+_ *%__P G;?\
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MPTIX"_Z"D_\ X"2__$T?\-*> O\ H*3_ /@)+_\ $U\\_P##.OQ"_P"A?_\
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M^9]#?\-*> O^@I/_ . DO_Q-'_#2G@+_ *"D_P#X"2__ !-?//\ PSK\0O\
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M]"]_^":G^9]#?\-*> O^@I/_ . DO_Q-'_#2G@+_ *"D_P#X"2__ !-?//\
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MA_K9QG_T+W_X)J?YGT-_PTIX"_Z"D_\ X"2__$T?\-*> O\ H*3_ /@)+_\
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M+_\ $U\\_P##.OQ"_P"A?_\ )VW_ /CE'_#.OQ"_Z%__ ,G;?_XY1_9^6?\
M/[_R:(?ZV<9_]"]_^":G^9]#?\-*> O^@I/_ . DO_Q-'_#2G@+_ *"D_P#X
M"2__ !-?//\ PSK\0O\ H7__ "=M_P#XY1_PSK\0O^A?_P#)VW_^.4?V?EG_
M #^_\FB'^MG&?_0O?_@FI_F?0W_#2G@+_H*3_P#@)+_\31_PTIX"_P"@I/\
M^ DO_P 37SS_ ,,Z_$+_ *%__P G;?\ ^.4?\,Z_$+_H7_\ R=M__CE']GY9
M_P _O_)HA_K9QG_T+W_X)J?YGT-_PTIX"_Z"D_\ X"2__$T?\-*> O\ H*3_
M /@)+_\ $U\\_P##.OQ"_P"A?_\ )VW_ /CE'_#.OQ"_Z%__ ,G;?_XY1_9^
M6?\ /[_R:(?ZV<9_]"]_^":G^9]#?\-*> O^@I/_ . DO_Q-'_#2G@+_ *"D
M_P#X"2__ !-?//\ PSK\0O\ H7__ "=M_P#XY1_PSK\0O^A?_P#)VW_^.4?V
M?EG_ #^_\FB'^MG&?_0O?_@FI_F?0W_#2G@+_H*3_P#@)+_\31_PTIX"_P"@
MI/\ ^ DO_P 37SS_ ,,Z_$+_ *%__P G;?\ ^.4?\,Z_$+_H7_\ R=M__CE'
M]GY9_P _O_)HA_K9QG_T+W_X)J?YGT-_PTIX"_Z"D_\ X"2__$T?\-*> O\
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MTIX"_P"@I/\ ^ DO_P 37SS_ ,,Z_$+_ *%__P G;?\ ^.4?\,Z_$+_H7_\
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M$+_H7_\ R=M__CE']GY9_P _O_)HA_K9QG_T+W_X)J?YGT-_PTIX"_Z"D_\
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M_H*3_P#@)+_\31_PTIX"_P"@I/\ ^ DO_P 37SS_ ,,Z_$+_ *%__P G;?\
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MPTIX"_Z"D_\ X"2__$T?\-*> O\ H*3_ /@)+_\ $U\\_P##.OQ"_P"A?_\
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M^9]#?\-*> O^@I/_ . DO_Q-'_#2G@+_ *"D_P#X"2__ !-?//\ PSK\0O\
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M]"]_^":G^9]#?\-*> O^@I/_ . DO_Q-'_#2G@+_ *"D_P#X"2__ !-?//\
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MA_K9QG_T+W_X)J?YGT-_PTIX"_Z"D_\ X"2__$T?\-*> O\ H*3_ /@)+_\
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M+_\ $U\\_P##.OQ"_P"A?_\ )VW_ /CE'_#.OQ"_Z%__ ,G;?_XY1_9^6?\
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MXLQ&-HT<3@7&G*45)^RJ*T6TF[MV5EU>B/L>BBBOE3]Q"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ KF_B3_ ,D]\2_]@VX_]%M725S?Q)_Y)[XE_P"P
M;<?^BVK:C_$CZHX,P_W.M_AE^3/S=HHHK]7/X1"BBB@ HHHH **** "BBB@
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MM+>[[GS;1117T9^.A7J_[+G_ "6S0O\ <N?_ $1)7E%>K_LN?\ELT+_<N?\
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M_P#"C_A&-9_Z!-__ . S_P"%?IG17L_V_+_GW^/_  #\\_XA71_Z"W_X O\
MY(_,B;P]JMM$\LNF7D42#+.]NX 'J215"OT-^./_ "2+Q7_UX25^>5>[E^->
M-IN;C:SL?F/%G#D>&\33P\:O/S1O>UNK7=]CN/@?K,6@?%GPO>3.(XOMBPLY
MZ 2 QY/M\]?H=7Y<JQ5@0<$<@BON+X!_'6P^(FC6VE:G<K;^);:,(Z2L!]K
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4UG_Q]1_6
MH:FL_P#CZC^M2]F:4OCCZHU+O_CVD_W36+6U=_\ 'M)_NFL6L:.S._'_ !Q]
M HHHKH/,"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "K6F
M_P#'T/H:JU:TW_CZ'T-1/X6;T/XL?4NZC_QZM]1_.LBM?4?^/5OJ/YUD5G2^
M$Z<=_$7H%%%%;GGA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 /A_P!='_O"MN3_ %;?0UB0
M_P"NC_WA6W)_JV^AKFJ[H]?!?!(P:***Z3R HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *U-+_X]
MV_WC_(5EUJ:7_P >[?[Q_D*QJ_"=V"_BD&J_ZY/]VJ57=5_UR?[M4JJ'PHRQ
M/\:04445H<P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% #HO]:GU%;[?=/TK B_UJ?45OM]T
M_2N#$[H^FRCX)^IC4445QGT04444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MN]A@?A7Z$T5\I@<<\$Y2C&[9^Y\2<-0XDA2IU:SA&%W9).[=M[]NGJS\X?\
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M);>0J2/0^H]CQ7VW^SU\89OBMX=NDU&-$UK32B7+1KA)58';(!V)VMD#C([
MX'RV.RJ>$C[2+O'\4?M_#''.'SZLL'6I^SK-::W4K:NW5.VMGTZGH/BSPKIW
MC7P_>:/JL GL[I-K#^)3V93V8'D'VK\ZO&?A>X\%>*M4T.[.Z>QG:(OC =1]
MU@/1E(/XU^EM?$'[6]E':_%Z65  US8P2O[D;D_D@KJR*M*-65'HU?YH\7Q-
MRZE4P-+'I>_"2C?O%IZ?)K3U9XQ1117VQ_-84444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 5]L_ G_DDWAW_KD__HUZ^)J^V?@3_P D
MF\._]<G_ /1KUXN:_P &/K^C/TC@7_D85?\  _\ TJ)WM%%%?+G[@%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !4UG_Q]1_6H:FL_P#CZC^M2]F:4OCCZHU+O_CVD_W36+6U=_\ 'M)_
MNFL6L:.S._'_ !Q] HHHKH/,"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "K6F_P#'T/H:JU:TW_CZ'T-1/X6;T/XL?4NZC_QZM]1_.LBM
M?4?^/5OJ/YUD5G2^$Z<=_$7H%%%%;GGA1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 /A_P!=
M'_O"MN3_ %;?0UB0_P"NC_WA6W)_JV^AKFJ[H]?!?!(P:***Z3R HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *U-+_X]V_WC_(5EUJ:7_P >[?[Q_D*QJ_"=V"_BD&J_ZY/]VJ57
M=5_UR?[M4JJ'PHRQ/\:04445H<P4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #HO]:GU%;[?
M=/TK B_UJ?45OM]T_2N#$[H^FRCX)^IC4445QGT04444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4455U'5+/2+<SWUU#9PC^.9P@^G/?VH M45P]Y\9_"=FY4:@]PPZ^3 Y'YD
M46?QG\)WCA3J#V['IYT#@?F 10*YW%%5M.U2SU:W$]E=0W<)_P"6D,@<?F*L
MT#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MEM=>2V7>[>U@K[D_9/\ ^2-V/_7U/_Z'7PW7W)^R?_R1NQ_Z^I__ $.C//\
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OMGX$_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 5:TW_CZ'T-5:M:;_ ,?0^AJ)
M_"S>A_%CZEW4?^/5OJ/YUD5KZC_QZM]1_.LBLZ7PG3COXB] HHHK<\\****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@!\/^NC_ -X5MR?ZMOH:Q(?]='_O"MN3_5M]#7-5W1Z^
M"^"1@T445TGD!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 5J:7_Q[M_O'^0K+K4TO_CW;_>/\A6-
M7X3NP7\4@U7_ %R?[M4JNZK_ *Y/]VJ55#X498G^-(****T.8**** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MK_\ X#P?_'J/^&S/!7_0+U__ ,!X/_CU?&=%>;_8N$[/[SZ__B(V??S1_P#
M4?9G_#9G@K_H%Z__ . \'_QZC_ALSP5_T"]?_P# >#_X]7QG11_8N$[/[P_X
MB-GW\T?_  %'U1XA_;4MUCD30O#<CR$G9-J,X4#D8)1,YSSQN&/4UX%X_P#B
MCXC^)=ZMQKE^9HXR3#:Q#9!#G^Z@[^YR?>N4HKNP^ P^&=Z<=>^[/FLTXHS;
M.(^SQ=9N'\JLE\TK7^=PHHHKO/E3[ TK]L+P;8Z79VTFF:ZSPPI&Q6WAP2%
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M8BHZM:3E)ZMMW;]6%%%%48A1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !7VS\"?^23>'?^N3_^C7KXFK[9^!/_ "2;P[_UR?\ ]&O7
MBYK_  8^OZ,_2.!?^1A5_P #_P#2HG>T445\N?N 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[1]3Q'\C#_6+*?\ H(B>TT5XM_PU?X1_Z!VM?]^(?_CM'_#5_A'_ *!VM?\
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M[1]3Q'\C#_6+*?\ H(B>TT5XM_PU?X1_Z!VM?]^(?_CM'_#5_A'_ *!VM?\
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M[1]3Q'\C#_6+*?\ H(B>TT5XM_PU?X1_Z!VM?]^(?_CM'_#5_A'_ *!VM?\
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M[1]3Q'\C#_6+*?\ H(B>TT5XM_PU?X1_Z!VM?]^(?_CM'_#5_A'_ *!VM?\
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M[1]3Q'\C#_6+*?\ H(B>TT5XM_PU?X1_Z!VM?]^(?_CM'_#5_A'_ *!VM?\
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M *!VM?\ ?B'_ ..T?\-7^$?^@=K7_?B'_P".T?4\1_(P_P!8LI_Z"(GMD/\
MKH_]X5MR?ZMOH:^>H_VL/"*NK'3M:P#G_40__':T6_;!\&LA']F:[R,?\>\/
M_P =K"I@<2VK09ZF$XFR>$9*6)BCU:BO%O\ AJ_PC_T#M:_[\0__ !VC_AJ_
MPC_T#M:_[\0__':W^IXC^1GE_P"L64_]!$3VFBO%O^&K_"/_ $#M:_[\0_\
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MZQ93_P!!$3VFBO%O^&K_  C_ - [6O\ OQ#_ /':/^&K_"/_ $#M:_[\0_\
MQVCZGB/Y&'^L64_]!$3VFBO%O^&K_"/_ $#M:_[\0_\ QVC_ (:O\(_] [6O
M^_$/_P =H^IXC^1A_K%E/_01$]IHKQ;_ (:O\(_] [6O^_$/_P =H_X:O\(_
M] [6O^_$/_QVCZGB/Y&'^L64_P#01$]IHKQ;_AJ_PC_T#M:_[\0__':/^&K_
M  C_ - [6O\ OQ#_ /':/J>(_D8?ZQ93_P!!$3VFBO%O^&K_  C_ - [6O\
MOQ#_ /':/^&K_"/_ $#M:_[\0_\ QVCZGB/Y&'^L64_]!$3VFBO)M,_:<\%:
M@ZK-)?:=G^*YML@?]\%J]&T'Q-I7BBT^TZ3J%OJ$/=H) VWV8=0?8XK&I1JT
MOCBT>CALRP>-=L/5C)]DU?[MS3K4TO\ X]V_WC_(5EUJ:7_Q[M_O'^0KCJ_"
M?08+^*0:K_KD_P!VJ57=5_UR?[M4JJ'PHRQ/\:04445H<P4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% #HO]:GU%;[?=/TK B_UJ?45OM]T_2N#$[H^FRCX)^IC4445QGT04
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !7@'QX\5_VIKL6CP-F"P&Z3'1I6']!@?4FO:/%OB&+PMX=O
M=2E(_<QGRU/\3GA5_$D5\EW=U+>W4UQ.YDFE<R.YZLQ.2?SH)99T'1Y_$&LV
M>G6PS-<2!!_LCN3[ 9/X5]<:3IEOHNF6UC:H([>W01H/8=S[GK7D/P \*_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IT7^
MM3ZBFTZ+_6I]10!TU%%%! 4444 %%%% !1110 4444 %%%% !1110 4444 %
M<W\2?^2>^)?^P;<?^BVKI*YOXD_\D]\2_P#8-N/_ $6U;4?XD?5'!F'^YUO\
M,OR9^;M%%%?JY_"(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5]L_ G_DDWAW_KD__HUZ^)J^V?@3_P DF\._]<G_
M /1KUXN:_P &/K^C/TC@7_D85?\  _\ TJ)WM%%%?+G[@%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "OMGX$_P#))O#O_7)__1KU\35]L_ G_DDWAW_KD_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "G1?ZU/J*;3HO]:GU% '34444$!1110
M4444 %%%% !1110 4444 %%%% !1110 5S?Q)_Y)[XE_[!MQ_P"BVKI*YOXD
M_P#)/?$O_8-N/_1;5M1_B1]4<&8?[G6_PR_)GYNT445^KG\(A1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M,_GYB_115X>5I.+.;-:7/355=/R9[[7GO[0?_)%O%_\ UXM_,5Z%7GO[0?\
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M"EM:6T:PPPQC"QHH 50.P  'X5W4J3IMML^:QN,AB8I1C:Q/11172>2%%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "G1?ZU/J*;3HO\ 6I]1
M0!TU%%%! 4444 %%%% !1110 4444 %%%% !1110 4444 %<W\2?^2>^)?\
ML&W'_HMJZ2N;^)/_ "3WQ+_V#;C_ -%M6U'^)'U1P9A_N=;_  R_)GYNT445
M^KG\(A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !7VS\"?^23>'?\ KD__ *->OB:OMGX$_P#))O#O_7)__1KUXN:_
MP8^OZ,_2.!?^1A5_P/\ ]*B=[1117RY^X!1110 4444 %%%% !1110 4444
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M/C:9;.W F9>C2L2TA'MN9L>V*C#I\S9TYK-*DH=6SYA_;L_Y&GPM_P!>4O\
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M[B0=&*J6<CZMG ]Q7E9ZTZ<*:^)O^OT/NO#"G4AB\3BI.U*,+-]+W37W),^
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M3WROI71A<;B*.(6%QF[V9Y.=<.Y3C\KEG7#[:C#XX.^G?>[36[5VFM5Y^8_
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M^F_V+>OC+_MS_P#:]?,E?3?[%O7QE_VY_P#M>O*S7_<Y_+\T?<\$?\E!A_\
MM_\ ](D?1&J_ZY/]VJ57=5_UR?[M4J^.A\*/Z(Q/\:04445H<P4444 %%%%
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M**^9OBI^V!>?#GQ_K'AR/PQ!?)82*@N&O&0OE%;.W8<?>QU[5RG_  WK?_\
M0G6W_@>W_P ;H%<^Q**^0;;]O>X64?:/!<3Q_P#3+4BI'OS$<_2O4_AS^UIX
M)\>W<5A<23>'M1D.U(M1VB)V]%D!QG_>VY[4!<]KHHHH&%%%% !117A'QY_:
M?C^#WB2ST2RTF+6;M[?S[G?<&,0@G"+PIY(!/;@KZT"/=Z*\N^ ?QO@^-FA:
MA<FR33-1L9Q'-:)+YF$891P<#@X<=/X37J- !1110,***\V^/?Q<F^#'@^SU
MN'3$U5KB_2S,,DQB #1R/NR ?^>>,>] CTFBOCO_ (;UO_\ H3K;_P #V_\
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M[?\ QNC_ (;UO_\ H3K;_P #V_\ C= 7/L2BOCO_ (;UO_\ H3K;_P #V_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQG#22T.K,*F'KVG2EKZ,\C_;8\;_ -C> K#PY!(%N-8N-\R@\^1%AC^;E/\
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MF7B>7=V<[V\R>CHQ5A^8-?JY7SK\4?V/[;XA^.-2\16WB7^QQ?,LDEI_9_G
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M4(5& NH0I,PX_OD;S^)KZU^(G[,'@?XA3RW;63Z+J4AW-=:81'O/JR$%3[G
M)]:\>U/]A"Z68G3O%T,D1/"W5D591]5<Y[=A7%[*I!^Z?0K'82NOWJ^]7/+/
M$?[4WQ(\1VS6[:[_ &="PPPT^%(6/_ P-P_ BO*W>:^NBS&2XN)GR226=V)_
M,DDU]5:3^PA,95.I^+D6(=4M+(EC_P "9QC\C7M_PW_9Z\&?#"1+K3=/:\U-
M>FH7["69?]W@*GU4 ^]"I5)OWA/'86A']RK^BL>4_LN?LX7/ABZB\7^*K7R=
M1"YT_3Y!\T&1S)(.SX. O\/)/.,?4%%%=T(*"LCYRO7GB)\\SXV_;L_Y&GPM
M_P!>4O\ Z&*^?/ _BVX\"^+-,U^TABN+FPE\U(IL[&.",'!![U]S_';]G?\
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M'@GQ7@<LS&@O>FU"5NG-N_2,E+[SUV>2V^#7P?)&TIHFFA1Z23!<#_OJ0_\
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M<#O7WA\3O$EO\//AGJ]^A$(M;,P6J?\ 30C9$!^)'X FO$SN7M)4L/'XF_\
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MZ?"5%%%?3GXF%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7TW^Q;U\9?]N?_ +7KYDKZ;_8MZ^,O^W/_ -KUY6:_[G/Y?FC[G@C_
M )*##_\ ;_\ Z1(^B-5_UR?[M4JNZK_KD_W:I5\=#X4?T1B?XT@HHHK0Y@HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\1BGY]]?^ ?ON>Y9CJ.1QRO)(:V4;W2M%;N[:U>S]6SY=_X3CQ'_ -!_5/\
MP-D_^*H_X3CQ'_T']4_\#9/_ (JOH7_AD/2/^A@OO^_*4?\ #(>D?]#!??\
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M2O+_ +5P/?\ !_Y'VW^HW$_\G_DZ_P SYQ_X235_^@K??^!#_P"-'_"2:O\
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MBC_AIWX8?]#9;?\ ?B;_ .(H V8_@=\/HG5T\':,KJ00PLTR"/PKN*XKP?\
M&?P7X^U8Z9H&NQ:E?")IC"D4BG8" 3EE [BNUH&@HHHH&?#/[<__ "5K2?\
ML!P_^C[BOJSX%_\ )&_!G_8*M_\ T 5\I_MS_P#)6M)_[ </_H^XKZL^!?\
MR1OP9_V"K?\ ] %!*.ZHHHH*/S?^(G_)R&L?]C&?_1XK](*_-_XB?\G(:Q_V
M,9_]'BOT@H)05GZ]X>TSQ1IDFG:O8P:E8R$%[>Y0.C$'()!]" :T**"CA?\
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MXDU16\J3K]EA'#2X_O$\+[Y/\.#[A7YT?M,Z[<^+_CIKT08RBUF33K>/^Z$
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M$W[/WP]\5P/'=^%=/@=A_KK"(6T@/KF/&3]<UR'@S]L/P!XFAC74;F?PY>$
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MY)_!GZ_H?D?B5_OU#_!^K"BBBOHS\?"BBB@ HHHH ^K?V)?^05XK_P"NUO\
M^@R5QG[9O_)4-+_[ \7_ *.GKA?A=\;=<^$EOJ$.D6FGW*WK(\AO8W8@J"!C
M:Z_WCZUF?$WXF:I\5=>@U;5H+.WN8;9;55LD9$*!G8$AF8YRY[]A7A0P=6.8
M2Q+^%_Y(_4,3Q!@JO"=+*(M^VB[O33XI/?T9R5%%%>Z?EYZU^R_XP/A;XJV-
MO(^VTU938R#/&YN8S]=X4?\  C7W-]FB^T_:/+7S]GE^;CYMN<XSZ9K\X?AU
MX?NO%'CO0M+LW>*>XNXP)8_O1J#N9Q_NJ"WX5]V?&?QE_P ()\-=;U1)/+NO
M),%L0<'S7^52/IG=_P !-?&9S14\334/BEI^.G]>1_1GAYF#H9-BIXE?NJ+<
MD_\ MV\DO2U_^WCXP^._C/\ X3CXH:S?1R;[2"3[';>GEQ_+D>Q;<W_ JX"B
MBOKZ5-4H1IQV2L?S_C<74QV)J8JK\4VV_F[GV_\ LD_\D@@_Z_9_YBNK\<^#
MO#'QFTR^T2\E66ZTV;898"!/9RE01U[$$<="/<<<I^R3_P D@@_Z_9_YBO _
MBSXWUKP%\?O$NHZ'?265P)HPX7E)%\I/E=3PP^M?$QPT\3CJRIRY9*[3^9_2
M53-\/E'#& >,I>TI5%&$EY.+=UYIK_@IG9C]BC4#?[3XHMOL6[_6?96\S;_N
M[L9_&OH#X??#S0_A-X9:PT[]W$,S75Y<,-TK <NYZ  #IT _$U\XV/[:/B"*
MV"7>@:=<3A<>;&[Q@GU*Y/\ ,5P'Q&_:!\6_$BW>SN[F/3],;[UE8*41Q_MD
MDLWT)Q[5V3P>98QJGB))1^7Z?J?/8;B#A#((RQ65TI2K-:)\UUY7EHEW:N_4
MM?M$_%"/XE^.";&0R:-IRFWM&[2'.7D_X$0,>RK6-\%_B.WPQ\=V>JR;VT^0
M&WO8TY+0MC) [E2 P^F.]<+17TD<-3C0^KV]VUC\>J9SBZF9/-7+][S<U^EU
MLO1+2W;0_0[QSX&\/_&KP=##-,)[:4"XLM0M6!:,D<,IZ$$<$'^8!'SZ_P"Q
M9KHO"J>(]/:USQ*8I ^/7;TS[;J\K^'GQF\4_#(M'H]Z&LF.YK&Z7S("?4#(
M*GW4C/>O55_;4UOR I\.:>9N/F$SA>G/'U]Z^>CA,PP=X8:2<?E^I^MUL_X3
MXA4<3G%)PK)6=N;7YQW7:Z36Q[_\.?AWHGP9\)S6T$XV@&>]U&XPID('WCSA
M5 Z#M[DDGXX^/'Q,'Q/\>3WML6&E6B_9;(,,%D!)+D>K$D^N, ]*C^(OQT\6
M?$R(VNI7B6NFD@_8+)3'$2.A;DLW8_,2,C( KSZN[ 8"=&;Q&(=YO\#Y?BCB
MK#YAAJ>5953]GAH?)NVVFNG775O5A1117NGY@>T?LO\ PRTKXA>*[VYUA3<6
MFE)',+,CY)G8G&__ &1MSCOQGC(/VM<PR-:216T@MI"A6.39N$9Q@';WQZ5^
M=?@+XG^(/AI->2Z!=1VKW:JLQDA63(7)'W@<=379?\-4_$7_ *"UO_X!1?\
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M8]?$<29!DN7UL'P_"3G55G)WTT:O[VNB;LDK7U]<.BBBOJ#\0"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KZ;_8MZ^,O^W/_P!K
MU\R5]-_L6]?&7_;G_P"UZ\K-?]SG\OS1]SP1_P E!A_^W_\ TB1]$:K_ *Y/
M]VJ57=5_UR?[M4J^.A\*/Z(Q/\:04445H<P4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:RDV^G#S;G:>&F8<#_@*G_Q\^E?1OC7Q1;^#/"VI:U<X*6D)=4)QO?HB_BQ
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M &8_^2[>$O\ KO)_Z)DH)9[G_P ,%6'_ $.5S_X +_\ '*/^&"K#_H<KG_P
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M."!N^KU8,H*G(/((H **"<<G@#GFO+Y?VD/ Z?$6#P@NJ+)=2 H;Y"#:I-G
MA+Y^\>>>@.!G/% 'J%%%% PKD?'_ ,)_"OQ.M5B\0Z3%>2(,1W*DQSQ_[KK@
MX]NGM70ZWK%IX>T>]U2_E$%E9PO/-(?X44$D_D*P_A_\3?#GQ/TA-0T#48[I
M=H,MLQ"SP'^ZZ=0??H>Q(H$?/7BG]@^RE9Y/#GB>:V':WU. 2#_OXFW'_?)K
MQ?QK^S[\1/@\3K'D.]M;?/\ VKHL[,(?]HXVN@_VB />OT6JKJU[9:?IEU<Z
MC+#!811,\\EP0(U3'S%L\8Q0%CY<_9@_:9U7Q/KT'A#Q;.+VXN%(L-28!9&=
M1GRY,<'(!PW7(P<[ACZMK\V/A);KJ_[0'AW^Q(VBM3KB3P1XY6W63>0?I&IK
M])Z!(****"@HHHH **** "BBB@ HHHH *=%_K4^HIM.B_P!:GU% '34444$!
M1110 4444 %%%% !1110 4444 %%%% !1110 5S?Q)_Y)[XE_P"P;<?^BVKI
M*YOXD_\ )/?$O_8-N/\ T6U;4?XD?5'!F'^YUO\ #+\F?F[1117ZN?PB%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%?;/P)_Y)-X=_P"N3_\ HUZ^)J^V?@3_ ,DF\._]<G_]&O7BYK_!CZ_HS](X
M%_Y&%7_ _P#TJ)WM%%%?+G[@%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OIO]BW
MKXR_[<__ &O7S)7TW^Q;U\9?]N?_ +7KRLU_W.?R_-'W/!'_ "4&'_[?_P#2
M)'T1JO\ KD_W:I5=U7_7)_NU2KXZ'PH_HC$_QI!1116AS!1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MHHH ^.OVGO\ DJMQ_P!>D/\ (UR7PE_Y*;X8_P"PA#_Z$*ZW]I[_ )*K<?\
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MV%>U_LJ^!#J.N7?B>YCS;6 ,%MN'WIF'S$?[JG_Q\>E?HBY<LP7FE][?_!_
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M6_6=7GBU'Q+-&8PT0/E6J'JJ9Y9CCEL#C@#&2?<J**!A1110,**** "BBB@
MHHHH **** "G1?ZU/J*;3HO]:GU% '34444$!1110 4444 %%%% !1110 44
M44 %%%% !1110 5S?Q)_Y)[XE_[!MQ_Z+:NDKF_B3_R3WQ+_ -@VX_\ 1;5M
M1_B1]4<&8?[G6_PR_)GYNT445^KG\(A1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !7VS\"?^23>'?^N3_^C7KXFK[9
M^!/_ "2;P[_UR?\ ]&O7BYK_  8^OZ,_2.!?^1A5_P #_P#2HG>T445\N?N
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M\CCD\K:S1N' .$S@D5Z[\1_ MI\2O!FH^&[ZXFM;6]\O?-;XWKLD608R".J
M=*ZHJIROFW/'K/"^UA[)>[UW[GS?_P -Z_\ 4C?^5?\ ^T4?\-Z_]2-_Y5__
M +170_\ ##'A3_H/ZS_Y"_\ B*\H_:)_9VT7X.>&=-U+3=2O[V6ZO/L[)=;-
MH&QFR-JCGY:PDZT5=L]*G'+ZLE",=7Z_YG;?\-Z_]2-_Y5__ +11_P -Z_\
M4C?^5?\ ^T5X=\"/AM8_%;Q_'H.H75Q9V[6TLWFVVW?E0,#Y@1CFOI+_ (88
M\*?]!_6?_(7_ ,12C*M-73*K4\!0ER3CK\_\SN?@)\>_^%W_ -N_\2+^Q?[,
M\C_E[\_S/,\S_IFN,>7[YS[5UOQ6\>_\*Q\ :IXF^P_VE]A\K_1?.\K?OE2/
M[VUL8WYZ'IBL+X-_ S2?@M_:_P#9>H7E]_:?D^9]KV?)Y>_&-H'7S#^0K/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *FL_P#CZC^M0U-9_P#'U']:E[,TI?''U1C_ !D_Y)5XK_[!
MTW_H)K\^Z_03XR?\DJ\5_P#8.F_]!-?GW7T.2?P9^OZ'Y'XE?[]0_P 'ZL**
M**^C/Q\**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[_X$G_"C^U*'F'^I&:=X?>_\CY!HKZ^_X9D\$?\ /"]_\"3_ (4?\,R>"/\
MGA>_^!)_PH_M2AYA_J1FG>'WO_(^0:*^OO\ AF3P1_SPO?\ P)/^%'_#,G@C
M_GA>_P#@2?\ "C^U*'F'^I&:=X?>_P#(^0:*^OO^&9/!'_/"]_\  D_X4?\
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M$?\ /"]_\"3_ (4?\,R>"/\ GA>_^!)_PH_M2AYA_J1FG>'WO_(^0:*^OO\
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M1_PS)X(_YX7O_@2?\*/[4H>8?ZD9IWA][_R/D&BOK[_AF3P1_P \+W_P)/\
MA1_PS)X(_P">%[_X$G_"C^U*'F'^I&:=X?>_\CY!HKZ^_P"&9/!'_/"]_P#
MD_X4?\,R>"/^>%[_ .!)_P */[4H>8?ZD9IWA][_ ,CY!HKZ^_X9D\$?\\+W
M_P "3_A1_P ,R>"/^>%[_P"!)_PH_M2AYA_J1FG>'WO_ "/D&BOK[_AF3P1_
MSPO?_ D_X4?\,R>"/^>%[_X$G_"C^U*'F'^I&:=X?>_\CY!HKZ^_X9D\$?\
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M$?\ /"]_\"3_ (4?\,R>"/\ GA>_^!)_PH_M2AYA_J1FG>'WO_(^0:*^OO\
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M1_PS)X(_YX7O_@2?\*/[4H>8?ZD9IWA][_R/D&BOK[_AF3P1_P \+W_P)/\
MA1_PS)X(_P">%[_X$G_"C^U*'F'^I&:=X?>_\CY!HKZ^_P"&9/!'_/"]_P#
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IT7^M3ZBFTZ+
M_6I]10!TU%%%! 4444 %%%% !1110 4444 %%%% !1110 4444 %<W\2?^2>
M^)?^P;<?^BVKI*YOXD_\D]\2_P#8-N/_ $6U;4?XD?5'!F'^YUO\,OR9^;M%
M%%?JY_"(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ J:S_ ./J/ZU#4UG_ ,?4?UJ7
MLS2E\<?5&I=_\>TG^Z:Q:VKO_CVD_P!TUBUC1V9WX_XX^@4445T'F!1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5K3?\ CZ'T-5:M:;_Q
M]#Z&HG\+-Z'\6/J7=1_X]6^H_G616OJ/_'JWU'\ZR*SI?"=.._B+T"BBBMSS
MPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** 'P_ZZ/_>%;<G^K;Z&L2'_ %T?^\*VY/\ 5M]#
M7-5W1Z^"^"1@T445TGD!1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 5J:7_Q[M_O'^0K+K4TO_CW;
M_>/\A6-7X3NP7\4@U7_7)_NU2J[JO^N3_=JE50^%&6)_C2"BBBM#F"BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %.B_UJ?44VG1?ZU/J* .FHHHH("BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ KF_B3_R3WQ+_ -@VX_\ 1;5TE<W\2?\
MDGOB7_L&W'_HMJVH_P 2/JC@S#_<ZW^&7Y,_-VBBBOU<_A$**** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %6M-_X^A]#56K6F_P#'T/H:B?PLWH?Q8^I=U'_CU;ZC^=9%
M:^H_\>K?4?SK(K.E\)TX[^(O0****W//"BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ?#_KH
M_P#>%;<G^K;Z&L2'_71_[PK;D_U;?0US5=T>O@O@D8-%%%=)Y 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %:FE_\>[?[Q_D*RZU-+_X]V_WC_(5C5^$[L%_%(-5_P!<G^[5*KNJ
M_P"N3_=JE50^%&6)_C2"BBBM#F"BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH =%_K4^HK?;[
MI^E8$7^M3ZBM]ONGZ5P8G='TV4?!/U,:BBBN,^B"BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH *=%_K4^HIM.B_UJ?44 =-11100%%%%
M !1110 4444 %%%% !1110 4444 %%%% !7-_$G_ ))[XE_[!MQ_Z+:NDKF_
MB3_R3WQ+_P!@VX_]%M6U'^)'U1P9A_N=;_#+\F?F[1117ZN?PB%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?;/P)
M_P"23>'?^N3_ /HUZ^)J^V?@3_R2;P[_ -<G_P#1KUXN:_P8^OZ,_2.!?^1A
M5_P/_P!*B=[1117RY^X!1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 5-9_P#'U']:AJ:S_P"/J/ZU+V9I
M2^./JC4N_P#CVD_W36+6U=_\>TG^Z:Q:QH[,[\?\<?0****Z#S HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JUIO_ !]#Z&JM6M-_X^A]
M#43^%F]#^+'U+NH_\>K?4?SK(K7U'_CU;ZC^=9%9TOA.G'?Q%Z!1116YYX44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 .B_UJ?45OM]T_2L"+_6I]16^WW3]*X,3NCZ;*/@GZF-1117
M&?1!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %.B_UJ
M?44VG1?ZU/J* .FHHHH("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KF
M_B3_ ,D]\2_]@VX_]%M725S?Q)_Y)[XE_P"P;<?^BVK:C_$CZHX,P_W.M_AE
M^3/S=HHHK]7/X1"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "OMGX$_P#))O#O_7)__1KU\35]L_ G_DDWAW_KD_\
MZ->O%S7^#'U_1GZ1P+_R,*O^!_\ I43O:***^7/W **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "IK/\
MX^H_K4-36?\ Q]1_6I>S-*7QQ]4:EW_Q[2?[IK%K:N_^/:3_ '36+6-'9G?C
M_CCZ!11170>8%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M8G^-(****T.8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@!T7^M3ZBM]ONGZ5@1?ZU/J*WV^
MZ?I7!B=T?391\$_4QJ***XSZ(**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ IT7^M3ZBFTZ+_6I]10!TU%%%! 4444 %%%% !1110 44
M44 %%%% !1110 4444 %<W\2?^2>^)?^P;<?^BVKI*YOXD_\D]\2_P#8-N/_
M $6U;4?XD?5'!F'^YUO\,OR9^;M%%%?JY_"(4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5Z]X+_:.U+P9X8L-%AT>
MUN8K16599)&#-EBW('UKR&O>OA[^SCIOC/P;IFM3:Q=6TMVC,T4<:E5P[+P3
M]*XL6Z"@O;[7/I,AAF53$265NT^77;:Z[^=A/^&M=7_Z %E_W^>C_AK75_\
MH 67_?YZZ/\ X9*TC_H/WO\ WZ2C_ADK2/\ H/WO_?I*\OGR[M^9]Q]6XO\
MY_Q@<Y_PUKJ__0 LO^_ST?\ #6NK_P#0 LO^_P ]='_PR5I'_0?O?^_24?\
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M&2M(_P"@_>_]^DHY\N[?F'U;B_\ G_&!SG_#6NK_ /0 LO\ O\]'_#6NK_\
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M?_#)6D?]!^]_[])1_P ,E:1_T'[W_OTE'/EW;\P^K<7_ ,_XP.<_X:UU?_H
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M .&2M(_Z#][_ -^DH_X9*TC_ *#][_WZ2CGR[M^8?5N+_P"?\8'.?\-:ZO\
M] "R_P"_ST?\-:ZO_P! "R_[_/71_P##)6D?]!^]_P"_24?\,E:1_P!!^]_[
M])1SY=V_,/JW%_\ /^,#G/\ AK75_P#H 67_ '^>C_AK75_^@!9?]_GKH_\
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M\_XP.<_X:UU?_H 67_?YZ/\ AK75_P#H 67_ '^>NC_X9*TC_H/WO_?I*/\
MADK2/^@_>_\ ?I*.?+NWYA]6XO\ Y_Q@<Y_PUKJ__0 LO^_ST?\ #6NK_P#0
M LO^_P ]='_PR5I'_0?O?^_24?\ #)6D?]!^]_[])1SY=V_,/JW%_P#/^,#G
M/^&M=7_Z %E_W^>C_AK75_\ H 67_?YZZ/\ X9*TC_H/WO\ WZ2C_ADK2/\
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M7_?YZZ/_ (9*TC_H/WO_ 'Z2C_ADK2/^@_>_]^DHY\N[?F'U;B_^?\8'.?\
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M_P! "R_[_/71_P##)6D?]!^]_P"_24?\,E:1_P!!^]_[])1SY=V_,/JW%_\
M/^,#G/\ AK75_P#H 67_ '^>C_AK75_^@!9?]_GKH_\ ADK2/^@_>_\ ?I*/
M^&2M(_Z#][_WZ2CGR[M^8?5N+_Y_Q@<Y_P -:ZO_ - "R_[_ #T?\-:ZO_T
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M?JW%_P#/^,#G/^&M=7_Z %E_W^>C_AK75_\ H 67_?YZZ/\ X9*TC_H/WO\
MWZ2C_ADK2/\ H/WO_?I*.?+NWYA]6XO_ )_Q@<Y_PUKJ_P#T ++_ +_/1_PU
MKJ__ $ ++_O\]='_ ,,E:1_T'[W_ +])1_PR5I'_ $'[W_OTE'/EW;\P^K<7
M_P _XP.<_P"&M=7_ .@!9?\ ?YZ/^&M=7_Z %E_W^>NC_P"&2M(_Z#][_P!^
MDH_X9*TC_H/WO_?I*.?+NWYA]6XO_G_&!SG_  UKJ_\ T ++_O\ /1_PUKJ_
M_0 LO^_SUT?_  R5I'_0?O?^_24?\,E:1_T'[W_OTE'/EW;\P^K<7_S_ (P.
M<_X:UU?_ * %E_W^>C_AK75_^@!9?]_GKH_^&2M(_P"@_>_]^DH_X9*TC_H/
MWO\ WZ2CGR[M^8?5N+_Y_P 8'.?\-:ZO_P! "R_[_/1_PUKJ_P#T ++_ +_/
M71_\,E:1_P!!^]_[])1_PR5I'_0?O?\ OTE'/EW;\P^K<7_S_C YS_AK75_^
M@!9?]_GH_P"&M=7_ .@!9?\ ?YZZ/_ADK2/^@_>_]^DH_P"&2M(_Z#][_P!^
MDHY\N[?F'U;B_P#G_&!SG_#6NK_] "R_[_/1_P -:ZO_ - "R_[_ #UT?_#)
M6D?]!^]_[])1_P ,E:1_T'[W_OTE'/EW;\P^K<7_ ,_XP.<_X:UU?_H 67_?
MYZ/^&M=7_P"@!9?]_GKH_P#ADK2/^@_>_P#?I*/^&2M(_P"@_>_]^DHY\N[?
MF'U;B_\ G_&!SG_#6NK_ /0 LO\ O\]'_#6NK_\ 0 LO^_SUT?\ PR5I'_0?
MO?\ OTE'_#)6D?\ 0?O?^_24<^7=OS#ZMQ?_ #_C YS_ (:UU?\ Z %E_P!_
MGH_X:UU?_H 67_?YZZ/_ (9*TC_H/WO_ 'Z2C_ADK2/^@_>_]^DHY\N[?F'U
M;B_^?\8'.?\ #6NK_P#0 LO^_P ]'_#6NK_] "R_[_/71_\ #)6D?]!^]_[]
M)1_PR5I'_0?O?^_24<^7=OS#ZMQ?_/\ C YS_AK75_\ H 67_?YZ/^&M=7_Z
M %E_W^>NC_X9*TC_ *#][_WZ2C_ADK2/^@_>_P#?I*.?+NWYA]6XO_G_ !@<
MY_PUKJ__ $ ++_O\]'_#6NK_ /0 LO\ O\]='_PR5I'_ $'[W_OTE'_#)6D?
M]!^]_P"_24<^7=OS#ZMQ?_/^,#G/^&M=7_Z %E_W^>C_ (:UU?\ Z %E_P!_
MGKH_^&2M(_Z#][_WZ2C_ (9*TC_H/WO_ 'Z2CGR[M^8?5N+_ .?\8'.?\-:Z
MO_T ++_O\]'_  UKJ_\ T ++_O\ /71_\,E:1_T'[W_OTE'_  R5I'_0?O?^
M_24<^7=OS#ZMQ?\ S_C YS_AK75_^@!9?]_GH_X:UU?_ * %E_W^>NC_ .&2
MM(_Z#][_ -^DH_X9*TC_ *#][_WZ2CGR[M^8?5N+_P"?\8'.?\-:ZO\ ] "R
M_P"_ST?\-:ZO_P! "R_[_/71_P##)6D?]!^]_P"_24?\,E:1_P!!^]_[])1S
MY=V_,/JW%_\ /^,#G/\ AK75_P#H 67_ '^>C_AK75_^@!9?]_GKH_\ ADK2
M/^@_>_\ ?I*/^&2M(_Z#][_WZ2CGR[M^8?5N+_Y_Q@<Y_P -:ZO_ - "R_[_
M #T?\-:ZO_T ++_O\]='_P ,E:1_T'[W_OTE'_#)6D?]!^]_[])1SY=V_,/J
MW%_\_P",#G/^&M=7_P"@!9?]_GH_X:UU?_H 67_?YZZ/_ADK2/\ H/WO_?I*
M/^&2M(_Z#][_ -^DHY\N[?F'U;B_^?\ &!SG_#6NK_\ 0 LO^_ST?\-:ZO\
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M6NK_ /0 LO\ O\]'_#6NK_\ 0 LO^_SUT?\ PR5I'_0?O?\ OTE'_#)6D?\
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MJ_\ T ++_O\ /71_\,E:1_T'[W_OTE'_  R5I'_0?O?^_24<^7=OS#ZMQ?\
MS_C YS_AK75_^@!9?]_GH_X:UU?_ * %E_W^>NC_ .&2M(_Z#][_ -^DH_X9
M*TC_ *#][_WZ2CGR[M^8?5N+_P"?\8'.?\-:ZO\ ] "R_P"_ST?\-:ZO_P!
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M_P! "R_[_/1_PUKJ_P#T ++_ +_/71_\,E:1_P!!^]_[])1_PR5I'_0?O?\
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M^@_>_P#?I*/^&2M(_P"@_>_]^DHY\N[?F'U;B_\ G_&!SG_#6NK_ /0 LO\
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MDK2/^@_>_P#?I*.?+NWYA]6XO_G_ !@<Y_PUKJ__ $ ++_O\]'_#6NK_ /0
MLO\ O\]='_PR5I'_ $'[W_OTE'_#)6D?]!^]_P"_24<^7=OS#ZMQ?_/^,#G/
M^&M=7_Z %E_W^>C_ (:UU?\ Z %E_P!_GKH_^&2M(_Z#][_WZ2C_ (9*TC_H
M/WO_ 'Z2CGR[M^8?5N+_ .?\8'.?\-:ZO_T ++_O\]'_  UKJ_\ T ++_O\
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M_P"&2M(_Z#][_P!^DH_X9*TC_H/WO_?I*.?+NWYA]6XO_G_&!SG_  UKJ_\
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M1_\ #)6D?]!^]_[])1_PR5I'_0?O?^_24<^7=OS#ZMQ?_/\ C YS_AK75_\
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M'_0?O?\ OTE'/EW;\P^K<7_S_C YS_AK75_^@!9?]_GH_P"&M=7_ .@!9?\
M?YZZ/_ADK2/^@_>_]^DH_P"&2M(_Z#][_P!^DHY\N[?F'U;B_P#G_&!SG_#6
MNK_] "R_[_/1_P -:ZO_ - "R_[_ #UT?_#)6D?]!^]_[])1_P ,E:1_T'[W
M_OTE'/EW;\P^K<7_ ,_XP.<_X:UU?_H 67_?YZ/^&M=7_P"@!9?]_GKH_P#A
MDK2/^@_>_P#?I*/^&2M(_P"@_>_]^DHY\N[?F'U;B_\ G_&!SG_#6NK_ /0
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M_P#H 67_ '^>NC_X9*TC_H/WO_?I*/\ ADK2/^@_>_\ ?I*.?+NWYA]6XO\
MY_Q@<Y_PUKJ__0 LO^_ST?\ #6NK_P#0 LO^_P ]='_PR5I'_0?O?^_24?\
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M&2M(_P"@_>_]^DHY\N[?F'U;B_\ G_&!SG_#6NK_ /0 LO\ O\]'_#6NK_\
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MEEO>7YG10PW&3G^[GKZP.7N/VO\ 6+EPQ\/V((&/]:]0_P##6NK_ /0 LO\
MO\]=5=_L@Z/;2!1X@OFR,\PI4'_#)6D?]!^]_P"_24XSRVVB_,BKAN,5-\\]
M?6!SG_#6NK_] "R_[_/1_P -:ZO_ - "R_[_ #UT?_#)6D?]!^]_[])1_P ,
ME:1_T'[W_OTE5SY=V_,R^K<7_P _XP.<_P"&M=7_ .@!9?\ ?YZ/^&M=7_Z
M%E_W^>NC_P"&2M(_Z#][_P!^DH_X9*TC_H/WO_?I*.?+NWYA]6XO_G_&!SG_
M  UKJ_\ T ++_O\ /1_PUKJ__0 LO^_SUT?_  R5I'_0?O?^_24?\,E:1_T'
M[W_OTE'/EW;\P^K<7_S_ (P.<_X:UU?_ * %E_W^>C_AK75_^@!9?]_GKH_^
M&2M(_P"@_>_]^DH_X9*TC_H/WO\ WZ2CGR[M^8?5N+_Y_P 8'.?\-:ZO_P!
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M'_PR5I'_ $'[W_OTE'_#)6D?]!^]_P"_24<^7=OS#ZMQ?_/^,#G/^&M=7_Z
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M'_#)6D?]!^]_[])1SY=V_,/JW%_\_P",#G/^&M=7_P"@!9?]_GH_X:UU?_H
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MZ#][_P!^DH_X9*TC_H/WO_?I*.?+NWYA]6XO_G_&!SG_  UKJ_\ T ++_O\
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M^DHY\N[?F'U;B_\ G_&!SG_#6NK_ /0 LO\ O\]'_#6NK_\ 0 LO^_SUT?\
MPR5I'_0?O?\ OTE'_#)6D?\ 0?O?^_24<^7=OS#ZMQ?_ #_C YS_ (:UU?\
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ME'_#)6D?]!^]_P"_24<^7=OS#ZMQ?_/^,#G/^&M=7_Z %E_W^>C_ (:UU?\
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MI1[7)_Y?PD'U/Q!_Y^?C3.<_X:[UC_H 6/\ W^>C_AKO6/\ H 6/_?YZZ/\
MX9#TC_H8+[_ORE'_  R'I'_0P7W_ 'Y2CVN3_P OX2#ZGX@_\_/QIG.?\-=Z
MQ_T +'_O\]'_  UWK'_0 L?^_P ]='_PR'I'_0P7W_?E*/\ AD/2/^A@OO\
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M>UR?^7\)!]3\0?\ GY^-,YS_ (:[UC_H 6/_ '^>C_AKO6/^@!8_]_GKH_\
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MOO\ ORE'M<G_ )?PD'U/Q!_Y^?C3.<_X:[UC_H 6/_?YZ/\ AKO6/^@!8_\
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MKH_^&0](_P"A@OO^_*4?\,AZ1_T,%]_WY2CVN3_R_A(/J?B#_P _/QIG.?\
M#7>L?] "Q_[_ #T?\-=ZQ_T +'_O\]='_P ,AZ1_T,%]_P!^4H_X9#TC_H8+
M[_ORE'M<G_E_"0?4_$'_ )^?C3.<_P"&N]8_Z %C_P!_GH_X:[UC_H 6/_?Y
MZZ/_ (9#TC_H8+[_ +\I1_PR'I'_ $,%]_WY2CVN3_R_A(/J?B#_ ,_/QIG.
M?\-=ZQ_T +'_ +_/1_PUWK'_ $ +'_O\]='_ ,,AZ1_T,%]_WY2C_AD/2/\
MH8+[_ORE'M<G_E_"0?4_$'_GY^-,YS_AKO6/^@!8_P#?YZ/^&N]8_P"@!8_]
M_GKH_P#AD/2/^A@OO^_*4?\ #(>D?]#!??\ ?E*/:Y/_ "_A(/J?B#_S\_&F
M<Y_PUWK'_0 L?^_ST?\ #7>L?] "Q_[_ #UT?_#(>D?]#!??]^4H_P"&0](_
MZ&"^_P"_*4>UR?\ E_"0?4_$'_GY^-,YS_AKO6/^@!8_]_GH_P"&N]8_Z %C
M_P!_GKH_^&0](_Z&"^_[\I1_PR'I'_0P7W_?E*/:Y/\ R_A(/J?B#_S\_&F<
MY_PUWK'_ $ +'_O\]'_#7>L?] "Q_P"_SUT?_#(>D?\ 0P7W_?E*/^&0](_Z
M&"^_[\I1[7)_Y?PD'U/Q!_Y^?C3.<_X:[UC_ * %C_W^>C_AKO6/^@!8_P#?
MYZZ/_AD/2/\ H8+[_ORE'_#(>D?]#!??]^4H]KD_\OX2#ZGX@_\ /S\:9SG_
M  UWK'_0 L?^_P ]'_#7>L?] "Q_[_/71_\ #(>D?]#!??\ ?E*/^&0](_Z&
M"^_[\I1[7)_Y?PD'U/Q!_P"?GXTSG/\ AKO6/^@!8_\ ?YZ/^&N]8_Z %C_W
M^>NC_P"&0](_Z&"^_P"_*4?\,AZ1_P!#!??]^4H]KD_\OX2#ZGX@_P#/S\:9
MSG_#7>L?] "Q_P"_ST?\-=ZQ_P! "Q_[_/71_P##(>D?]#!??]^4H_X9#TC_
M *&"^_[\I1[7)_Y?PD'U/Q!_Y^?C3.<_X:[UC_H 6/\ W^>C_AKO6/\ H 6/
M_?YZZ/\ X9#TC_H8+[_ORE'_  R'I'_0P7W_ 'Y2CVN3_P OX2#ZGX@_\_/Q
MIG.?\-=ZQ_T +'_O\]'_  UWK'_0 L?^_P ]='_PR'I'_0P7W_?E*/\ AD/2
M/^A@OO\ ORE'M<G_ )?PD'U/Q!_Y^?C3.<_X:[UC_H 6/_?YZ/\ AKO6/^@!
M8_\ ?YZZ/_AD/2/^A@OO^_*4?\,AZ1_T,%]_WY2CVN3_ ,OX2#ZGX@_\_/QI
MG.?\-=ZQ_P! "Q_[_/1_PUWK'_0 L?\ O\]='_PR'I'_ $,%]_WY2C_AD/2/
M^A@OO^_*4>UR?^7\)!]3\0?^?GXTSG/^&N]8_P"@!8_]_GH_X:[UC_H 6/\
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M(_Z&"^_[\I1[7)_Y?PD'U/Q!_P"?GXTSG/\ AKO6/^@!8_\ ?YZ/^&N]8_Z
M%C_W^>NC_P"&0](_Z&"^_P"_*4?\,AZ1_P!#!??]^4H]KD_\OX2#ZGX@_P#/
MS\:9SG_#7>L?] "Q_P"_ST?\-=ZQ_P! "Q_[_/71_P##(>D?]#!??]^4H_X9
M#TC_ *&"^_[\I1[7)_Y?PD'U/Q!_Y^?C3.<_X:[UC_H 6/\ W^>C_AKO6/\
MH 6/_?YZZ/\ X9#TC_H8+[_ORE'_  R'I'_0P7W_ 'Y2CVN3_P OX2#ZGX@_
M\_/QIG.?\-=ZQ_T +'_O\]'_  UWK'_0 L?^_P ]='_PR'I'_0P7W_?E*/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !7VS\"?^23>'?^N3_^C7KXFK[9^!/_ "2;P[_U
MR?\ ]&O7BYK_  8^OZ,_2.!?^1A5_P #_P#2HG>T445\N?N 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %36?_'U']:AJ:S_ ./J/ZU+V9I2^./JC4N_^/:3_=-8M;5W_P >TG^Z:Q:Q
MH[,[\?\ ''T"BBBN@\P**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *M:;_ ,?0^AJK5K3?^/H?0U$_A9O0_BQ]2[J/_'JWU'\ZR*U]1_X]
M6^H_G616=+X3IQW\1>@4445N>>%%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 ^'_ %T?^\*V
MY/\ 5M]#6)#_ *Z/_>%;<G^K;Z&N:KNCU\%\$C!HHHKI/("BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ K4TO_CW;_>/\A676II?_ ![M_O'^0K&K\)W8+^*0:K_KD_W:I5=U7_7)
M_NU2JH?"C+$_QI!1116AS!1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 .B_UJ?45OM]T_2L"
M+_6I]16^WW3]*X,3NCZ;*/@GZF-1117&?1!1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^V?@3_R
M2;P[_P!<G_\ 1KU\35]L_ G_ ))-X=_ZY/\ ^C7KQ<U_@Q]?T9^D<"_\C"K_
M ('_ .E1.]HHHKY<_< HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *FL_^/J/ZU#4UG_Q]1_6I>S-*7QQ
M]4:EW_Q[2?[IK%K:N_\ CVD_W36+6-'9G?C_ (X^@4445T'F!1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !5K3?^/H?0U5JUIO_'T/H:B?
MPLWH?Q8^I=U'_CU;ZC^=9%:^H_\ 'JWU'\ZR*SI?"=.._B+T"BBBMSSPHHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** 'P_P"NC_WA6W)_JV^AK$A_UT?^\*VY/]6WT-<U7='K
MX+X)&#11172>0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !6II?_ ![M_O'^0K+K4TO_ (]V_P!X
M_P A6-7X3NP7\4@U7_7)_NU2J[JO^N3_ ':I54/A1EB?XT@HHHK0Y@HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** '1?ZU/J*WV^Z?I6!%_K4^HK?;[I^E<&)W1]-E'P3]3&H
MHHKC/H@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M);:?%*)7:7& SLN5 &<@ G) ].?JZBBI*/O!F$J,JMZ/SML%%%%=!Y@4444
M%%%>9_M)S/!\$/%4D3M'(L$>&0X(_?)WJ6[)LNG#VDU#NSTRBORC_MG4/^?Z
MY_[_ #?XU^DOP0D:7X0>#WD9G=M,@)9CDD[1UK&G5]H[6/0Q>!>%BI<U[^1V
M]%%%=!Y@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %36?_'U']:AJ:S_ ./J/ZU+V9I2^./JC4N_^/:3_=-8M;5W_P >TG^Z
M:Q:QH[,[\?\ ''T"BBBN@\P**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *M:;_ ,?0^AJK5K3?^/H?0U$_A9O0_BQ]2[J/_'JWU'\ZR*U]
M1_X]6^H_G616=+X3IQW\1>@4445N>>%%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 ^'_ %T?
M^\*VY/\ 5M]#6)#_ *Z/_>%;<G^K;Z&N:KNCU\%\$C!HHHKI/("BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ K4TO_CW;_>/\A676II?_ ![M_O'^0K&K\)W8+^*0:K_KD_W:I5=U
M7_7)_NU2JH?"C+$_QI!1116AS!1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 .B_UJ?45OM]T
M_2L"+_6I]16^WW3]*X,3NCZ;*/@GZF-1117&?1!1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "G1?ZU/J*;3HO]:GU% '34444$!1110 4444 %%%% !1110 4444 %%%
M% !1110 5S?Q)_Y)[XE_[!MQ_P"BVKI*YOXD_P#)/?$O_8-N/_1;5M1_B1]4
M<&8?[G6_PR_)GYNT445^KG\(A1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !7VS\"?^23>'?^N3_P#HUZ^)J^V?@3_R
M2;P[_P!<G_\ 1KUXN:_P8^OZ,_2.!?\ D85?\#_]*B=[1117RY^X!1110 44
M44 %%%% !1110 4444 ?&W[=G_(T^%O^O*7_ -#%>.? C3;36/B]X6L[^UAO
M;.:["RV]S&)(W&T\,I&"/K7L?[=G_(T^%O\ KRE_]#%>2_L[_P#);/"/_7Z/
M_06KS)_Q3Z_#Z8&_D_U/O;_A4/@3_H2O#O\ X*H/_B*XOXF?LQ>#?&NA74>F
M:/9Z!K"H3;76GQ"% X' =%PI4\ \9[@U[#6)XS\7Z9X$\-WNMZM<+;V=JA8[
MC@NV/E1?5B> *]!QC;5'S%.M64ER2=S\M)8VAE:-UVNI*L#V(ZU]Q_L5^+)]
M<^&5YI5Q)YC:1>&.(DY(B<;U'KPWF?A@=J^(M0O9-2O[F\E_UMQ*TKX]6))_
MG7V?^P[X?FL/ &M:M*A1-0O@D1/\21KC</;<S#ZJ:\^A\>A]/F5GAGS;Z'TC
M116#X\\5P^!O!NLZ]/M*6%L\P5NCN!\B_P# F('XUZ3=M3Y&,7)I(^'OVM_&
MW_"6_%V\M(GW6FC1K8)@\%Q\TA^NYBO_   5Y;I7A74=8T'6M8MH?,L=(6)K
MM_[GF/L3]<UG7MY-J-[<7=PYEN)Y&ED<]69CDG\S7VU^SE\);>Y_9ZU"TO4"
MS>*HYG=FZHA!2(_AC>/]ZO,C%U9L^SJU(X&A%>B_S/C+PQX@N?"GB/3-9LSB
MZL+B.XCYZE6!P?8XP?8U^H^AZQ;>(=%L-4LW\RTO8$N(6]4=0P_0U^5NHV$^
ME:A<V5U&8KFVE:&5#U5U)!'Y@U]S?L;^-_\ A)/A<VD32;[O0YS!@]?)?+QG
M\]Z_1*TP\K-Q./-:7-3C573\F>]56U34K;1M-NK^\E6"TM8GGFE;HJ*"6/Y
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MBJ^B?ML>.+"[5]0L]+U.V/WHO):)L?[+*W!^H->;_"WX,^)?BY?2PZ);HEI
M0)[^Y8I#$3VS@DMCG !/X5[-=?L)ZTEHS6WBJQFN@N1');.B$^FX$G]*Y4ZT
MM4>U4C@:+]G-*YZ]HO[3NB>+_AWX@UG1T6WU[2;&2[?2+X\G:,Y!4C>F<#(P
M?4#(KQ3_ (;G\5_] #1O_(O_ ,77B7C/P1XB^%VOR:9K-K+IUV48*Z-\DT;
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5-9_\?4?UJ&IK/_CZC^M2]F:4OCCZHE\4
MZU;^'/#NHZI=[S;6D#32",9;:!DX'K7BG_#4G@W_ )Y:I_X#K_\ %UZ=\9/^
M25>*_P#L'3?^@FOS[KU,KPE/$4Y2GT9\-QMG^,RC%TJ>&M:4;ZJ_5GUM_P -
M2>#?^>6J?^ Z_P#Q='_#4G@W_GEJG_@.O_Q=?)-%>W_9F'\_O/SC_77-?[OW
M?\$^MO\ AJ3P;_SRU3_P'7_XNC_AJ3P;_P \M4_\!U_^+KY)HH_LS#^?WA_K
MKFO]W[O^"?6W_#4G@W_GEJG_ (#K_P#%T?\ #4G@W_GEJG_@.O\ \77R311_
M9F'\_O#_ %US7^[]W_!/K;_AJ3P;_P \M4_\!U_^+H_X:D\&_P#/+5/_  '7
M_P"+KY)HH_LS#^?WA_KKFO\ =^[_ ()];?\ #4G@W_GEJG_@.O\ \71_PU)X
M-_YY:I_X#K_\77R311_9F'\_O#_77-?[OW?\$^MO^&I/!O\ SRU3_P !U_\
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MS#^?WA_KKFO]W[O^"?6W_#4G@W_GEJG_ (#K_P#%T?\ #4G@W_GEJG_@.O\
M\77R311_9F'\_O#_ %US7^[]W_!/K;_AJ3P;_P \M4_\!U_^+H_X:D\&_P#/
M+5/_  '7_P"+KY)HH_LS#^?WA_KKFO\ =^[_ ()];?\ #4G@W_GEJG_@.O\
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MM4_\!U_^+KY)HH_LS#^?WA_KKFO]W[O^"?6W_#4G@W_GEJG_ (#K_P#%T?\
M#4G@W_GEJG_@.O\ \77R311_9F'\_O#_ %US7^[]W_!/K;_AJ3P;_P \M4_\
M!U_^+H_X:D\&_P#/+5/_  '7_P"+KY)HH_LS#^?WA_KKFO\ =^[_ ()];?\
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M_LS#^?WA_KKFO]W[O^"?6W_#4G@W_GEJG_@.O_Q='_#4G@W_ )Y:I_X#K_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!\/^NC_P!X5MR?ZMOH
M:Q(?]='_ +PK;D_U;?0US5=T>O@O@D8-%%%=)Y 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %:FE
M_P#'NW^\?Y"LNM32_P#CW;_>/\A6-7X3NP7\4@U7_7)_NU2J[JO^N3_=JE50
M^%&6)_C2"BBBM#F"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH =%_K4^HK?;[I^E8$7^M3ZB
MM]ONGZ5P8G='TV4?!/U,:BBBN,^B"BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ IT7^M3ZBFTZ+_6I]10!TU%%%! 4444 %%%% !1110 4444 %%%%
M!1110 4444 %<W\2?^2>^)?^P;<?^BVKI*YOXD_\D]\2_P#8-N/_ $6U;4?X
MD?5'!F'^YUO\,OR9^;M%%%?JY_"(4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5]L_ G_DDWAW_KD__HUZ^)J^V?@3
M_P DF\._]<G_ /1KUXN:_P &/K^C/TC@7_D85?\  _\ TJ)WM%%%?+G[@%%%
M% !1110 4444 %%%% !1110!\;?MV?\ (T^%O^O*7_T,5\UZ3JU[H6HP7^GW
M4ME>V[;XKB%MKH?4'M7TI^W9_P C3X6_Z\I?_0Q7C'P0T:Q\0_%CPSIVI6R7
MEC<7026"495QM)P:\NHKU6D?98.2CA(R>R3_ %%_X7G\0?\ H<M9_P# M_\
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M\1**IK1?F<5^USX,_P"$5^+UW>11[;368EOD(Z!S\L@^NY2W_ Q4G[(?C?\
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M7G=?'7B*$-^[?30Y7U(E4 _^/'\Z\W_:8_Y+GXL_Z[Q_^B4KT7]AC_DH.O\
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M-CV/##OAA6/^TQ_R0SQ9_P!<(_\ T<E=C:<&UV/#I1E'$1C/=-?F?G+7Z7_
MS_DCO@W_ +!<'_H K\T*_2_X&?\ )'?!O_8+@_\ 0!7'AOB9[N;?PX^IW-%%
M%>@?+A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 5-9_\?4?UJ&IK/_CZC^M2]F:4OCCZHQ_C)_R2KQ7_ -@Z;_T$U^?=?H)\
M9/\ DE7BO_L'3?\ H)K\^Z^AR3^#/U_0_(_$K_?J'^#]6%%%%?1GX^%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 ;7@OQ9>^"/$EGK%BY$
ML#_/'G"RH?O(WL1^7!ZBOOKPMJUOKME9:C:-OMKJ!9HV_P!E@"/QYK\ZZ^RO
MV5]6?4_AO;PNV[[%<36P]0.' _\ (E?/YQ23I*JMUH?K'A_CYQQLL%)^[+WE
MY-6O]Z_(]CU'_CU;ZC^=9%:^H_\ 'JWU'\ZR*^6I?"?N&._B+T"BBBMSSPHH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** 'P_ZZ/\ WA6W)_JV^AK$A_UT?^\*VY/]6WT-<U7=
M'KX+X)&#11172>0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !6II?_'NW^\?Y"LNM32_^/=O]X_R
M%8U?A.[!?Q2#5?\ 7)_NU2J[JO\ KD_W:I54/A1EB?XT@HHHK0Y@HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&@HHHH&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4Z+_6I]13:=%_K4^HH Z:BBB@@**** "BBB@ HHHH **** "BBB@ H
MHHH **** "N;^)/_ "3WQ+_V#;C_ -%M725S?Q)_Y)[XE_[!MQ_Z+:MJ/\2/
MJC@S#_<ZW^&7Y,_-VBBBOU<_A$**** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH *^V?@3_P DF\._]<G_ /1KU\35]L_
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MA/8.<*X^NT_7K7-4HRB^:!ZN&Q].K#V5??SV9W/A3]N#PU?6Z)X@T>_TNZP
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M?'?_ $)7B+_P53__ !%<,)SI[(^EQ-"ABFG.>W9H^X?^&K?A9_T-/_E/NO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %?7'['_\ R(FH?]A27_T3#7R/7UQ^Q_\ \B)J'_84E_\ 1,->1FO^ZL_0
M.!?^1W3]&>ZZC_QZM]1_.LBM?4?^/5OJ/YUD5\;2^$_HC'?Q%Z!1116YYX44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %.B_UJ?44VG1?ZU/J* .FHHHH("BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ KF_B3_P D]\2_]@VX_P#1;5TE<W\2?^2>^)?^P;<?^BVK:C_$CZHX
M,P_W.M_AE^3/S=HHHK]7/X1"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "OMGX$_\ ))O#O_7)_P#T:]?$U?;/P)_Y
M)-X=_P"N3_\ HUZ\7-?X,?7]&?I' O\ R,*O^!_^E1.]HHHKY<_< HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X#XQ_%VV^#FA66JWFF7.H
MVUS<_9O]'=5*,5+#.?4*?RKOZY#XL?#V#XH> ]3\/S.L,LZA[>=AD13*<HWT
MSP?8FIE>SY=S6CR>T7M/AZGBD/[='AUY45_#FI1H6 9S+&=H]<5]):=J%MJ]
MA;WME.ES:7$:RQ31G*NI&00?3%?EGXF\,:GX.URZTC6+22RO[9MDD4@_(@]"
M#U!'!'2NM^'?QY\9_#"W^R:-J>[3LEOL-V@EA4DY)4'E?^ D9KBA7:=IGT-?
M+(3BGA]/U/TGKY&_;E\:6MQ+H'A:"19+JW9KZZ4'_5Y&V,'W(+G'I@]ZX;6O
MVS?B'JUFT$']E:2S#'GV5JQ<?3S'< _A7B.HZC=ZM>S7E]<RW=W.Q>6>=R[N
MQ[DGDFBK64H\L18/+YTJBJ5'L;'P^T27Q)XZ\/Z7$I=[J_AB('8%QD_@,G\*
M_4BOD?\ 8Y^"US%??\)WK%NT$:(T>EQ2##.6&UYL>F"57URQ[ GZXK7#Q<8W
M?4XLSK1J55"/V?S"BBBNH\<**** "BBB@ HHHH **** "BBB@ HHHH ****
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MO%T55:MN>KQ+DT,AS&6!A-S22=VK;JX4445WGRP4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 /A_UT?\ O"MN3_5M]#6)#_KH_P#>
M%;<G^K;Z&N:KNCU\%\$C!HHHKI/("BBB@ HHHH **** "BBB@ HHHH ****
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M@P^7Y9(PP^\<@X'IW]:ZF@84444#"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ IT7^M3ZBFTZ+_6I]10!TU%%%! 4444 %%%% !1
M110 4444 %%%% !1110 4444 %<W\2?^2>^)?^P;<?\ HMJZ2N;^)/\ R3WQ
M+_V#;C_T6U;4?XD?5'!F'^YUO\,OR9^;M%%%?JY_"(4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5]L_ G_DDWAW_K
MD_\ Z->OB:OMGX$_\DF\._\ 7)__ $:]>+FO\&/K^C/TC@7_ )&%7_ __2HG
M>T445\N?N 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M'(?$/X4>&/BC8I;^(--2YDC!$-U&=D\.?[KCG'L<CVKY]U_]A*-IF?1/%;1Q
M$_+#J%J&8?5T89_[Y%?6-%9RIQGNCKI8NM15H2T/CB/]A+6#(HD\5V*IW9;5
MR1^&1_.O4/AY^Q[X/\'7<=[JLDOB>]CY5;M ENI]?*&<_P# BP]J]WHJ51@M
M;&D\?B*BLY?H(B!%"J JJ,  8 %+116QP!1110 4444 %%%% !1110 4444
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MP<TI4:JLN;72?P[]IJU^QS/[1'@R'P1\4]2M;2W2UT^Z5+RVBB0(BHXY"@<
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M\**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@!\/\ KH_]X5MR?ZMOH:Q(?]='_O"MN3_5M]#7
M-5W1Z^"^"1@T445TGD!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 5J:7_P >[?[Q_D*RZU-+_P"/
M=O\ >/\ (5C5^$[L%_%(-5_UR?[M4JNZK_KD_P!VJ55#X498G^-(****T.8*
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@!T7^M3ZBM]ONGZ5@1?ZU/J*WV^Z?I7!B=T?391\
M$_4QJ***XSZ(**** "BBB@ HHHH **** "BBB@ K&\8^(F\)>&K[6!92Z@MG
M'YKP0L Q0'YB,^@R?H#6S39HDGB>*5%DC=2K(PR"#P0:J+2DG)71A7C.=*4:
M4N633L][/H[/>QX'_P ->:1_T+]]_P!_DKT[X8_$VP^*&C7%]90R6KV\WE2V
M\Q!9>,@\=B/Y&OCOXH>"G\ >-M1T@Y-LK>9;.?XH6Y7\1]T^ZFNC_9Z\=_\
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M3<*^2?V@_B[\4_"7Q1U+3?"]U>Q:-%'"T2PZ7%.N3&I;YVB8GDGO7UM10(^
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M_&?[17Q#TGXV:EH%KX@\K2(=:-HEO]BMSB+S0NW<8RW3C.<^]?;%?F_\1/\
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M0[CX[6OAV3Q!NT=_$B6#6WV*W&8#=",IN\O=]WC.<^]?;%?F_HW_ "<]8_\
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M9A_N=;_#+\F?F[1117ZN?PB%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M.K8>E3JPA&=T]WIH;7_"WO G_0Z^'?\ P:P?_%T?\+>\"?\ 0Z^'?_!K!_\
M%U\)?\,S_$W_ *%.Y_[_ $/_ ,77/^,OA+XM^'UC!>>(=%ETRVGD\F.221&#
M/@G'RL>P/Y5BZTUO$[UE^'D[1JW?R/T-_P"%O>!/^AU\._\ @U@_^+H_X6]X
M$_Z'7P[_ .#6#_XNOS<\*>#]8\<:N-+T*Q?4+\HT@A1E4[1U.6(%=M_PS/\
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M_OBN>G6YY6:/5Q67*A2]I%WL?2U%%%=9X@4444 %%%% !1110 4444 %%%%
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M@))OH#(?_'*^%IUWE_UC#OY?E^33^1_3F*RV/%CRG-HJZ_Y>?+WFO3FBX_\
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M'FV9R$!/RK^ P/PKY?+F\5C:N*7P[+^O1'[;Q<EDO#F"R6;_ 'FDFNUKM_\
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MFZF4;8HP-L<2^B*.!_,]R:H>&/\ D9=)_P"OR'_T,5F5I^&/^1ETG_K\A_\
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MGEU&%:-.I7?-T5KG@8?BW,,3@*V*P>615))J4E)):+7HKVN<K\"?^2P>%/\
MK]7^1KZD_:V_Y)!/_P!?L'\S7RW\"?\ DL'A3_K]7^1KZD_:V_Y)!/\ ]?L'
M\S71C_\ D8T/E^9Y'"W_ "2.9_\ ;W_I"/B"N]^ SM'\8?"K*2I^V <>A!!_
M0UP5=W\"?^2P>%/^OU?Y&OH,3_ GZ/\ (_*<F_Y&>&_QP_\ 2D?3?[8'_))H
MO^PE#_Z#)7QII/\ R%;+_KLG_H0K[+_; _Y)-%_V$H?_ $&2OC32?^0K9?\
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MSX<Z9:ZUX\T"PO8A/:7-[%%+$Q(#*6 (XYKM_P!I[_DJMQ_UZ0_R-<E\)?\
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M^A7U'_O_ !T?\-XZ#_T*^H_]_P".O1?^&3OA5_T*W_E1N_\ X[1_PR=\*O\
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M**"@KY2_;U_Y!/@W_KO=?^@QU]6U\I?MZ_\ ()\&_P#7>Z_]!CH$SKOV)?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M87"T\)3]G3_X<_+<ZSK%9[BWB\4]=DELEV7]:A11176>"?1O[%?_ "-?B/\
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M117T%&C3P\%3IJR1^4YAF.)S3$2Q6+GS3?\ 5DNB78^W_P!DG_DD$'_7[/\
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MYME:UO7K?S['I8;B3ZOD-;)/8W]I*_-S;:Q?PVU^'OU"BBBO3/B@KZX_8_\
M^1$U#_L*2_\ HF&OD>OKC]C_ /Y$34/^PI+_ .B8:\C-?]U9^@<"_P#([I^C
M/==1_P"/5OJ/YUD5KZC_ ,>K?4?SK(KXVE\)_1&._B+T"BBBMSSPHHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** 'P_P"NC_WA6W)_JV^AK$A_UT?^\*VY/]6WT-<U7='KX+X)
M&#11172>0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !6II?_ ![M_O'^0K+K4TO_ (]V_P!X_P A
M6-7X3NP7\4@U7_7)_NU2J[JO^N3_ ':I54/A1EB?XT@HHHK0Y@HHHH ****
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M48'\JM5\5BJ[Q-:55]?RZ'](9'E<,FR^E@H?96K[R>K?W_@%%%%<I[P4444
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MY_T%O#G_ ($S_P#QBC_AACQY_P!!;PY_X$S_ /QB@#[/_P"$PT'_ *#>G?\
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M$_\ ))O#O_7)_P#T:]?$U?;/P)_Y)-X=_P"N3_\ HUZ\7-?X,?7]&?I' O\
MR,*O^!_^E1.]HHHKY<_< HHHH **** "BBB@ HHHH **** "J>L_\@>^_P"N
M$G_H)JY5/6?^0/??]<)/_032''<_*.OU3\)_\BMHW_7E#_Z *_*ROU3\)_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "OKC]C_ /Y$34/^PI+_ .B8:^1Z^R/V4]+?3OAQ#,R[?MMU-<+]
M.(__ &G7CYL[89^I^A\!P<LZBUT3_1'LNH_\>K?4?SK(K7U'_CU;ZC^=9%?'
M4OA/Z%QW\1>@4445N>>%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 ^'_71_[PK;D_U;?0UB
M0_ZZ/_>%;<G^K;Z&N:KNCU\%\$C!HHHKI/("BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K4TO_CW
M;_>/\A676II?_'NW^\?Y"L:OPG=@OXI!JO\ KD_W:I5=U7_7)_NU2JH?"C+$
M_P :04445H<P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M'_80A_\ 0A76_M/?\E5N/^O2'^1KDOA+_P E-\,?]A"'_P!"%?H^'_Y%\?\
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M-?49UB?9450CO+\C\2\.,F>-Q\LRK*\:6WG-_P"2U]6F7Z***^&/Z<"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *=%_K4^HIM.B_UJ?44 =-11100%%%% !1110 44
M44 %%%% !1110 4444 %%%% !7-_$G_DGOB7_L&W'_HMJZ2N;^)/_)/?$O\
MV#;C_P!%M6U'^)'U1P9A_N=;_#+\F?F[1117ZN?PB%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ^S^3!YB1[MMQ&[?,Y &%4GD]JUGK%HX<.TJT&^Z_,^%/@9_R6+P;_V%(/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "IK/_CZC^M0U-9_\?4?UJ7LS2E\<?5&/\9/^25>*_P#L'3?^@FOS[K]!
M/C)_R2KQ7_V#IO\ T$U^?=?0Y)_!GZ_H?D?B5_OU#_!^K"BBBOHS\?"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 ^'_71_[PK;D_U;?0UB0_ZZ/_>%;<G^K;Z&
MN:KNCU\%\$C!HHHKI/("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ K4TO_CW;_>/\A676II?_'NW
M^\?Y"L:OPG=@OXI!JO\ KD_W:I5=U7_7)_NU2JH?"C+$_P :04445H<P4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>!FN*^LXA\K]V.B_5GZKP-DCR?*HNK&U6K[TNZ_E7R7W-L****\<_0PHHHH
M**** "BBB@#XZ_:>_P"2JW'_ %Z0_P C7)?"7_DIOAC_ +"$/_H0KK?VGO\
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MR&:ZN9&FED;JS,<D_F:] ^,GQDNOBA?QP01O9Z';.6@MF/S.W3S'QQG&0 .
M">N2:X?P]H%[XHUNSTK3XC-=W4@C1>PSU)] !DD]@#7W>68/ZE1<ZNDGOY+^
MMS^7N-.(%Q'CX8?!7E3AI'^])[M+[DO^">]_LH>!"TU]XKN4^5 ;2SW#N<&1
MQ^&%!]V%?2=9/A+PU:^#_#>GZ-9C]Q:1",-C!=NK,?<DD_C6M7QN-Q+Q5>53
MIT]#^BN&\HCDF64L']I*\O.3W_R7DD%%%%<)],%%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4Z+_6I]13:=%_K4^HH Z:BBB@@**** "BBB@ HHHH **** "BBB@ HH
MHH **** "N;^)/\ R3WQ+_V#;C_T6U=)7-_$G_DGOB7_ +!MQ_Z+:MJ/\2/J
MC@S#_<ZW^&7Y,_-VBBBOU<_A$**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P#QJC_AE#PC_P!!'6O^_P##_P#&J]IHH^N8C^=A_J[E/_0/$\6_X90\(_\
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M^&4/"/\ T$=:_P"_\/\ \:KVFBCZYB/YV'^KN4_] \3Q;_AE#PC_ -!'6O\
MO_#_ /&J/^&4/"/_ $$=:_[_ ,/_ ,:KVFBCZYB/YV'^KN4_] \3Q;_AE#PC
M_P!!'6O^_P##_P#&J/\ AE#PC_T$=:_[_P /_P :KVFBCZYB/YV'^KN4_P#0
M/$\6_P"&4/"/_01UK_O_  __ !JC_AE#PC_T$=:_[_P__&J]IHH^N8C^=A_J
M[E/_ $#Q/%O^&4/"/_01UK_O_#_\:H_X90\(_P#01UK_ +_P_P#QJO::*/KF
M(_G8?ZNY3_T#Q/%O^&4/"/\ T$=:_P"_\/\ \:H_X90\(_\ 01UK_O\ P_\
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M(_\ 01UK_O\ P_\ QJC_ (90\(_]!'6O^_\ #_\ &J]IHH^N8C^=A_J[E/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M+$_QI!1116AS!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "G1?ZU/J*;3HO]:GU% '34444$!1110 4444 %%%% !1110 4444 %%%%
M!1110 5S?Q)_Y)[XE_[!MQ_Z+:NDKF_B3_R3WQ+_ -@VX_\ 1;5M1_B1]4<&
M8?[G6_PR_)GYNT445^KG\(A1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !7VS\"?^23>'?^N3_^C7KXFK[9^!/_ "2;
MP[_UR?\ ]&O7BYK_  8^OZ,_2.!?^1A5_P #_P#2HG>T445\N?N 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %36?_'U']:AJ:S_ ./J/ZU+V9I2^./JC4N_^/:3_=-8M;5W_P >TG^Z
M:Q:QH[,[\?\ ''T"BBBN@\P**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *M:;_ ,?0^AJK5K3?^/H?0U$_A9O0_BQ]2[J/_'JWU'\ZR*U]
M1_X]6^H_G616=+X3IQW\1>@4445N>>%%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 ^'_ %T?
M^\*VY/\ 5M]#6)#_ *Z/_>%;<G^K;Z&N:KNCU\%\$C!HHHKI/("BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ K4TO_CW;_>/\A676II?_ ![M_O'^0K&K\)W8+^*0:K_KD_W:I5=U
M7_7)_NU2JH?"C+$_QI!1116AS!1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 .B_UJ?45OM]T
M_2L"+_6I]16^WW3]*X,3NCZ;*/@GZF-1117&?1!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %.B_P!:GU%-IT7^M3ZB@#IJ***" HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH *YOXD_\D]\2_\ 8-N/_1;5TE<W
M\2?^2>^)?^P;<?\ HMJVH_Q(^J.#,/\ <ZW^&7Y,_-VBBBOU<_A$**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^V?
M@3_R2;P[_P!<G_\ 1KU\35]L_ G_ ))-X=_ZY/\ ^C7KQ<U_@Q]?T9^D<"_\
MC"K_ ('_ .E1.]HHHKY<_< HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *FL_^/J/ZU#4UG_Q]1_6I>S-
M*7QQ]4:EW_Q[2?[IK%K:N_\ CVD_W36+6-'9G?C_ (X^@4445T'F!1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7='KX+X)&#11172>0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !6II?_ ![M_O'^0K+K4TO_ (]V
M_P!X_P A6-7X3NP7\4@U7_7)_NU2J[JO^N3_ ':I54/A1EB?XT@HHHK0Y@HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** '1?ZU/J*WV^Z?I6!%_K4^HK?;[I^E<&)W1]-E'P3
M]3&HHHKC/H@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "G1?ZU/J*;3HO\ 6I]10!TU%%%! 4444 %%%% !1110 4444 %%%% !1110
M 4444 %<W\2?^2>^)?\ L&W'_HMJZ2N;^)/_ "3WQ+_V#;C_ -%M6U'^)'U1
MP9A_N=;_  R_)GYNT445^KG\(A1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !7VS\"?^23>'?\ KD__ *->OB:OMGX$
M_P#))O#O_7)__1KUXN:_P8^OZ,_2.!?^1A5_P/\ ]*B=[1117RY^X!1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 5-9_\?4?UJ&IK/_CZC^M2]F:4OCCZHU+O_CVD_P!TUBUM7?\ Q[2?
M[IK%K&CLSOQ_QQ] HHHKH/,"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "K6F_\?0^AJK5K3?^/H?0U$_A9O0_BQ]2[J/_ !ZM]1_.LBM?
M4?\ CU;ZC^=9%9TOA.G'?Q%Z!1116YYX4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #X?]='
M_O"MN3_5M]#6)#_KH_\ >%;<G^K;Z&N:KNCU\%\$C!HHHKI/("BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ K4TO_ (]V_P!X_P A676II?\ Q[M_O'^0K&K\)W8+^*0:K_KD_P!V
MJ57=5_UR?[M4JJ'PHRQ/\:04445H<P4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #HO]:GU%
M;[?=/TK B_UJ?45OM]T_2N#$[H^FRCX)^IC4445QGT04444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !3HO]:GU%-IT7^M3ZB@#IJ***"
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *\Y_:*\7?\ "!_ [QKKOV3[
M=]DTR4_9_,\O?N&S[V#C&[/3M7HU>5?M2^''\6_L]>/-*CF%N\^FN1(R[@-I
M#],CKMQ^-=&&Y57AS[75_O.7%0]IAZD.Z:_ _*#_ (:6_P"I<_\ )[_[71_P
MTM_U+G_D]_\ :ZYC_A3,_P#T%4_[\G_&C_A3,_\ T%4_[\G_ !K]9^N9?_-^
M9^'_ .IN!_Z!_P#R:7_R1T__  TM_P!2Y_Y/?_:Z/^&EO^I<_P#)[_[77,?\
M*9G_ .@JG_?D_P"-'_"F9_\ H*I_WY/^-'US+_YOS#_4W _] _\ Y-+_ .2.
MG_X:6_ZES_R>_P#M='_#2W_4N?\ D]_]KKF/^%,S_P#053_OR?\ &C_A3,__
M $%4_P"_)_QH^N9?_-^8?ZFX'_H'_P#)I?\ R1T__#2W_4N?^3W_ -KH_P"&
MEO\ J7/_ ">_^UUS'_"F9_\ H*I_WY/^-'_"F9_^@JG_ 'Y/^-'US+_YOS#_
M %-P/_0/_P"32_\ DCI_^&EO^I<_\GO_ +71_P -+?\ 4N?^3W_VNN8_X4S/
M_P!!5/\ OR?\:/\ A3,__053_OR?\:/KF7_S?F'^IN!_Z!__ ":7_P D=/\
M\-+?]2Y_Y/?_ &NC_AI;_J7/_)[_ .UUS'_"F9_^@JG_ 'Y/^-'_  IF?_H*
MI_WY/^-'US+_ .;\P_U-P/\ T#_^32_^2.G_ .&EO^I<_P#)[_[71_PTM_U+
MG_D]_P#:ZYC_ (4S/_T%4_[\G_&C_A3,_P#T%4_[\G_&CZYE_P#-^8?ZFX'_
M *!__)I?_)'3_P##2W_4N?\ D]_]KH_X:6_ZES_R>_\ M=<Q_P *9G_Z"J?]
M^3_C1_PIF?\ Z"J?]^3_ (T?7,O_ )OS#_4W _\ 0/\ ^32_^2.G_P"&EO\
MJ7/_ ">_^UT?\-+?]2Y_Y/?_ &NN8_X4S/\ ]!5/^_)_QH_X4S/_ -!5/^_)
M_P :/KF7_P WYA_J;@?^@?\ \FE_\D=/_P -+?\ 4N?^3W_VNC_AI;_J7/\
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MUT?\-+?]2Y_Y/?\ VNN8_P"%,S_]!5/^_)_QH_X4S/\ ]!5/^_)_QH^N9?\
MS?F'^IN!_P"@?_R:7_R1T_\ PTM_U+G_ )/?_:Z/^&EO^I<_\GO_ +77,?\
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M_P"UUS'_  IF?_H*I_WY/^-'_"F9_P#H*I_WY/\ C1]<R_\ F_,/]3<#_P!
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M_P"%,S_]!5/^_)_QH^N9?_-^8?ZFX'_H'_\ )I?_ "1T_P#PTM_U+G_D]_\
M:Z/^&EO^I<_\GO\ [77,?\*9G_Z"J?\ ?D_XT?\ "F9_^@JG_?D_XT?7,O\
MYOS#_4W _P#0/_Y-+_Y(Z?\ X:6_ZES_ ,GO_M='_#2W_4N?^3W_ -KKF/\
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M_P"_)_QH^N9?_-^8?ZFX'_H'_P#)I?\ R1T__#2W_4N?^3W_ -KH_P"&EO\
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M.%M_X -_\<KCMDG]<Y[_ -4QW\OY'J'_  ]3_P"J8?\ EP?_ '+1_P /4_\
MJF'_ )<'_P!RUY?_ ,,'W_\ T.%M_P" #?\ QRC_ (8/O_\ H<+;_P  &_\
MCE%LD_KG#ZICOY?R/4/^'J?_ %3#_P N#_[EH_X>I_\ 5,/_ "X/_N6O+_\
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M\<H_X8/O_P#H<+;_ , &_P#CE%LD_KG#ZICOY?R/4/\ AZG_ -4P_P#+@_\
MN6C_ (>I_P#5,/\ RX/_ +EKR_\ X8/O_P#H<+;_ , &_P#CE'_#!]__ -#A
M;?\ @ W_ ,<HMDG]<X?5,=_+^1ZA_P /4_\ JF'_ )<'_P!RT?\ #U/_ *IA
M_P"7!_\ <M>7_P##!]__ -#A;?\ @ W_ ,<H_P"&#[__ *'"V_\  !O_ (Y1
M;)/ZYP^J8[^7\CU#_AZG_P!4P_\ +@_^Y:/^'J?_ %3#_P N#_[EKR__ (8/
MO_\ H<+;_P  &_\ CE'_  P??_\ 0X6W_@ W_P <HMDG]<X?5,=_+^1ZA_P]
M3_ZIA_Y<'_W+1_P]3_ZIA_Y<'_W+7E__  P??_\ 0X6W_@ W_P <H_X8/O\
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M ( -_P#'*+9)_7.'U3'?R_D>H?\ #U/_ *IA_P"7!_\ <M'_  ]3_P"J8?\
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M@^__ .APMO\ P ;_ ..46R3^N</JF._E_(]0_P"'J?\ U3#_ ,N#_P"Y:/\
MAZG_ -4P_P#+@_\ N6O+_P#A@^__ .APMO\ P ;_ ..4?\,'W_\ T.%M_P"
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M ;_XY1;)/ZYP^J8[^7\CU#_AZG_U3#_RX/\ [EH_X>I_]4P_\N#_ .Y:\O\
M^&#[_P#Z'"V_\ &_^.4?\,'W_P#T.%M_X -_\<HMDG]<X?5,=_+^1ZA_P]3_
M .J8?^7!_P#<M'_#U/\ ZIA_Y<'_ -RUY?\ \,'W_P#T.%M_X -_\<H_X8/O
M_P#H<+;_ , &_P#CE%LD_KG#ZICOY?R/4/\ AZG_ -4P_P#+@_\ N6C_ (>I
M_P#5,/\ RX/_ +EKR_\ X8/O_P#H<+;_ , &_P#CE'_#!]__ -#A;?\ @ W_
M ,<HMDG]<X?5,=_+^1ZA_P /4_\ JF'_ )<'_P!RT?\ #U/_ *IA_P"7!_\
M<M>7_P##!]__ -#A;?\ @ W_ ,<H_P"&#[__ *'"V_\  !O_ (Y1;)/ZYP^J
M8[^7\CU#_AZG_P!4P_\ +@_^Y:/^'J?_ %3#_P N#_[EKR__ (8/O_\ H<+;
M_P  &_\ CE'_  P??_\ 0X6W_@ W_P <HMDG]<X?5,=_+^1ZA_P]3_ZIA_Y<
M'_W+1_P]3_ZIA_Y<'_W+7E__  P??_\ 0X6W_@ W_P <H_X8/O\ _H<+;_P
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MF'_EP?\ W+1_P]3_ .J8?^7!_P#<M>7_ /#!]_\ ]#A;?^ #?_'*/^&#[_\
MZ'"V_P# !O\ XY1;)/ZYP^J8[^7\CU#_ (>I_P#5,/\ RX/_ +EH_P"'J?\
MU3#_ ,N#_P"Y:\O_ .&#[_\ Z'"V_P# !O\ XY1_PP??_P#0X6W_ ( -_P#'
M*+9)_7.'U3'?R_D>H?\ #U/_ *IA_P"7!_\ <M'_  ]3_P"J8?\ EP?_ '+7
ME_\ PP??_P#0X6W_ ( -_P#'*/\ A@^__P"APMO_   ;_P".46R3^N</JF._
ME_(]0_X>I_\ 5,/_ "X/_N6C_AZG_P!4P_\ +@_^Y:\O_P"&#[__ *'"V_\
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M , &_P#CE%LD_KG#ZICOY?R/4/\ AZG_ -4P_P#+@_\ N6C_ (>I_P#5,/\
MRX/_ +EKR_\ X8/O_P#H<+;_ , &_P#CE'_#!]__ -#A;?\ @ W_ ,<HMDG]
M<X?5,=_+^1ZA_P /4_\ JF'_ )<'_P!RT?\ #U/_ *IA_P"7!_\ <M>7_P##
M!]__ -#A;?\ @ W_ ,<H_P"&#[__ *'"V_\  !O_ (Y1;)/ZYP^J8[^7\CU#
M_AZG_P!4P_\ +@_^Y:/^'J?_ %3#_P N#_[EKR__ (8/O_\ H<+;_P  &_\
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MO_ !O_CE'_#!]_\ ]#A;?^ #?_'*+9)_7.'U3'?R_D>H?\/4_P#JF'_EP?\
MW+1_P]3_ .J8?^7!_P#<M>7_ /#!]_\ ]#A;?^ #?_'*/^&#[_\ Z'"V_P#
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M  ]3_P"J8?\ EP?_ '+1_P /4_\ JF'_ )<'_P!RUY?_ ,,'W_\ T.%M_P"
M#?\ QRC_ (8/O_\ H<+;_P  &_\ CE%LD_KG#ZICOY?R/4/^'J?_ %3#_P N
M#_[EH_X>I_\ 5,/_ "X/_N6O+_\ A@^__P"APMO_   ;_P".4?\ #!]__P!#
MA;?^ #?_ !RBV2?USA]4QW\OY'J'_#U/_JF'_EP?_<M'_#U/_JF'_EP?_<M>
M7_\ #!]__P!#A;?^ #?_ !RC_A@^_P#^APMO_ !O_CE%LD_KG#ZICOY?R/4/
M^'J?_5,/_+@_^Y:/^'J?_5,/_+@_^Y:\O_X8/O\ _H<+;_P ;_XY1_PP??\
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M]4P_\N#_ .Y:/^'J?_5,/_+@_P#N6O+_ /A@^_\ ^APMO_ !O_CE'_#!]_\
M]#A;?^ #?_'*+9)_7.'U3'?R_D>H?\/4_P#JF'_EP?\ W+1_P]3_ .J8?^7!
M_P#<M>7_ /#!]_\ ]#A;?^ #?_'*/^&#[_\ Z'"V_P# !O\ XY1;)/ZYP^J8
M[^7\CU#_ (>I_P#5,/\ RX/_ +EH_P"'J?\ U3#_ ,N#_P"Y:\O_ .&#[_\
MZ'"V_P# !O\ XY1_PP??_P#0X6W_ ( -_P#'*+9)_7.'U3'?R_D>H?\ #U/_
M *IA_P"7!_\ <M'_  ]3_P"J8?\ EP?_ '+7E_\ PP??_P#0X6W_ ( -_P#'
M*/\ A@^__P"APMO_   ;_P".46R3^N</JF._E_(]0_X>I_\ 5,/_ "X/_N6C
M_AZG_P!4P_\ +@_^Y:\O_P"&#[__ *'"V_\  !O_ (Y1_P ,'W__ $.%M_X
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M6W_@ W_QRBV2?USA]4QW\OY'J'_#U/\ ZIA_Y<'_ -RT?\/4_P#JF'_EP?\
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M_+@_^Y:/^'J?_5,/_+@_^Y:\O_X8/O\ _H<+;_P ;_XY1_PP??\ _0X6W_@
MW_QRBV2?USA]4QW\OY'J'_#U/_JF'_EP?_<M'_#U/_JF'_EP?_<M>7_\,'W_
M /T.%M_X -_\<H_X8/O_ /H<+;_P ;_XY1;)/ZYP^J8[^7\CU#_AZG_U3#_R
MX/\ [EH_X>I_]4P_\N#_ .Y:\O\ ^&#[_P#Z'"V_\ &_^.4?\,'W_P#T.%M_
MX -_\<HMDG]<X?5,=_+^1ZA_P]3_ .J8?^7!_P#<M'_#U/\ ZIA_Y<'_ -RU
MY?\ \,'W_P#T.%M_X -_\<H_X8/O_P#H<+;_ , &_P#CE%LD_KG#ZICOY?R/
M4/\ AZG_ -4P_P#+@_\ N6C_ (>I_P#5,/\ RX/_ +EKR_\ X8/O_P#H<+;_
M , &_P#CE'_#!]__ -#A;?\ @ W_ ,<HMDG]<X?5,=_+^1ZA_P /4_\ JF'_
M )<'_P!RT?\ #U/_ *IA_P"7!_\ <M>7_P##!]__ -#A;?\ @ W_ ,<H_P"&
M#[__ *'"V_\  !O_ (Y1;)/ZYP^J8[^7\CU#_AZG_P!4P_\ +@_^Y:/^'J?_
M %3#_P N#_[EKR__ (8/O_\ H<+;_P  &_\ CE'_  P??_\ 0X6W_@ W_P <
MHMDG]<X?5,=_+^1ZA_P]3_ZIA_Y<'_W+1_P]3_ZIA_Y<'_W+7E__  P??_\
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M (>I_P#5,/\ RX/_ +EH_P"'J?\ U3#_ ,N#_P"Y:\O_ .&#[_\ Z'"V_P#
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M '+1_P /4_\ JF'_ )<'_P!RUY?_ ,,'W_\ T.%M_P" #?\ QRC_ (8/O_\
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MZF'S&;O..OR/4/\ AZG_ -4P_P#+@_\ N6C_ (>I_P#5,/\ RX/_ +EKR_\
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M\/4_^J8?^7!_]RT?\/4_^J8?^7!_]RUY?_PP??\ _0X6W_@ W_QRC_A@^_\
M^APMO_ !O_CE%LD_KG#ZICOY?R/4/^'J?_5,/_+@_P#N6C_AZG_U3#_RX/\
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M (>I_P#5,/\ RX/_ +EKR_\ X8/O_P#H<+;_ , &_P#CE'_#!]__ -#A;?\
M@ W_ ,<HMDG]<X?5,=_+^1ZA_P /4_\ JF'_ )<'_P!RT?\ #U/_ *IA_P"7
M!_\ <M>7_P##!]__ -#A;?\ @ W_ ,<H_P"&#[__ *'"V_\  !O_ (Y1;)/Z
MYP^J8[^7\CU#_AZG_P!4P_\ +@_^Y:/^'J?_ %3#_P N#_[EKR__ (8/O_\
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M8/O_ /H<+;_P ;_XY1_PP??_ /0X6W_@ W_QRBV2?USA]4QW\OY'J'_#U/\
MZIA_Y<'_ -RT?\/4_P#JF'_EP?\ W+7E_P#PP??_ /0X6W_@ W_QRC_A@^__
M .APMO\ P ;_ ..46R3^N</JF._E_(]0_P"'J?\ U3#_ ,N#_P"Y:/\ AZG_
M -4P_P#+@_\ N6O+_P#A@^__ .APMO\ P ;_ ..4?\,'W_\ T.%M_P" #?\
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M!]__ -#A;?\ @ W_ ,<HMDG]<X?5,=_+^1ZA_P /4_\ JF'_ )<'_P!RT?\
M#U/_ *IA_P"7!_\ <M>7_P##!]__ -#A;?\ @ W_ ,<H_P"&#[__ *'"V_\
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M?^ #?_'*/^&#[_\ Z'"V_P# !O\ XY1;)/ZYP^J8[^7\CU#_ (>I_P#5,/\
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M_P"Y:/\ AZG_ -4P_P#+@_\ N6O+_P#A@^__ .APMO\ P ;_ ..4?\,'W_\
MT.%M_P" #?\ QRBV2?USA]4QW\OY'J'_  ]3_P"J8?\ EP?_ '+1_P /4_\
MJF'_ )<'_P!RUY?_ ,,'W_\ T.%M_P" #?\ QRC_ (8/O_\ H<+;_P  &_\
MCE%LD_KG#ZICOY?R/4/^'J?_ %3#_P N#_[EH_X>I_\ 5,/_ "X/_N6O+_\
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M\<H_X8/O_P#H<+;_ , &_P#CE%LD_KG#ZICOY?R/4/\ AZG_ -4P_P#+@_\
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M3_ZIA_Y<'_W+1_P]3_ZIA_Y<'_W+7E__  P??_\ 0X6W_@ W_P <H_X8/O\
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M ( -_P#'*+9)_7.'U3'?R_D>H?\ #U/_ *IA_P"7!_\ <M'_  ]3_P"J8?\
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M\/4_^J8?^7!_]RT?\/4_^J8?^7!_]RUY?_PP??\ _0X6W_@ W_QRC_A@^_\
M^APMO_ !O_CE%LD_KG#ZICOY?R/4/^'J?_5,/_+@_P#N6C_AZG_U3#_RX/\
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M (>I_P#5,/\ RX/_ +EKR_\ X8/O_P#H<+;_ , &_P#CE'_#!]__ -#A;?\
M@ W_ ,<HMDG]<X?5,=_+^1ZA_P /4_\ JF'_ )<'_P!RT?\ #U/_ *IA_P"7
M!_\ <M>7_P##!]__ -#A;?\ @ W_ ,<H_P"&#[__ *'"V_\  !O_ (Y1;)/Z
MYP^J8[^7\CU#_AZG_P!4P_\ +@_^Y:/^'J?_ %3#_P N#_[EKR__ (8/O_\
MH<+;_P  &_\ CE'_  P??_\ 0X6W_@ W_P <HMDG]<X?5,=_+^1ZA_P]3_ZI
MA_Y<'_W+1_P]3_ZIA_Y<'_W+7E__  P??_\ 0X6W_@ W_P <H_X8/O\ _H<+
M;_P ;_XY1;)/ZYP^J8[^7\CU#_AZG_U3#_RX/_N6C_AZG_U3#_RX/_N6O+_^
M&#[_ /Z'"V_\ &_^.4?\,'W_ /T.%M_X -_\<HMDG]<X?5,=_+^1ZA_P]3_Z
MIA_Y<'_W+1_P]3_ZIA_Y<'_W+7E__#!]_P#]#A;?^ #?_'*/^&#[_P#Z'"V_
M\ &_^.46R3^N</JF._E_(]0_X>I_]4P_\N#_ .Y:/^'J?_5,/_+@_P#N6O+_
M /A@^_\ ^APMO_ !O_CE'_#!]_\ ]#A;?^ #?_'*+9)_7.'U3'?R_D>H?\/4
M_P#JF'_EP?\ W+1_P]3_ .J8?^7!_P#<M>7_ /#!]_\ ]#A;?^ #?_'*/^&#
M[_\ Z'"V_P# !O\ XY1;)/ZYP^J8[^7\CU#_ (>I_P#5,/\ RX/_ +EH_P"'
MJ?\ U3#_ ,N#_P"Y:\O_ .&#[_\ Z'"V_P# !O\ XY1_PP??_P#0X6W_ ( -
M_P#'*+9)_7.'U3'?R_D>H?\ #U/_ *IA_P"7!_\ <M'_  ]3_P"J8?\ EP?_
M '+7E_\ PP??_P#0X6W_ ( -_P#'*/\ A@^__P"APMO_   ;_P".46R3^N</
MJF._E_(]0_X>I_\ 5,/_ "X/_N6C_AZG_P!4P_\ +@_^Y:\O_P"&#[__ *'"
MV_\  !O_ (Y1_P ,'W__ $.%M_X -_\ '*+9)_7.'U3'?R_D>H?\/4_^J8?^
M7!_]RT?\/4_^J8?^7!_]RUY?_P ,'W__ $.%M_X -_\ '*/^&#[_ /Z'"V_\
M &_^.46R3^N</JF._E_(]0_X>I_]4P_\N#_[EH_X>I_]4P_\N#_[EKR__A@^
M_P#^APMO_ !O_CE'_#!]_P#]#A;?^ #?_'*+9)_7.'U3'?R_D>H?\/4_^J8?
M^7!_]RT?\/4_^J8?^7!_]RUY?_PP??\ _0X6W_@ W_QRC_A@^_\ ^APMO_ !
MO_CE%LD_KG#ZICOY?R/4/^'J?_5,/_+@_P#N6C_AZG_U3#_RX/\ [EKR_P#X
M8/O_ /H<+;_P ;_XY1_PP??_ /0X6W_@ W_QRBV2?USA]4QW\OY'J'_#U/\
MZIA_Y<'_ -RT?\/4_P#JF'_EP?\ W+7E_P#PP??_ /0X6W_@ W_QRC_A@^__
M .APMO\ P ;_ ..46R3^N</JF._E_(]23_@JIL<'_A5^<'./^$@_^Y:OG_@K
M3D$?\*J_\N+_ .Y:\FT_]@2_U#4+:U'C.V0SRK'N_L]CC<<9_P!9[UZ2?^"3
MFK 9_P"%CV?_ (*7_P#CM85(Y!?W_P#V\[*%/-:2:I*W_@/ZDG_#UC_JEW_E
MP?\ W+1_P]8_ZI=_Y<'_ -RUG_\ #J[5/^BB6?\ X*G_ /CM'_#J[5/^BB6?
M_@J?_P".UCR\._USG5?._P"N0T/^'K'_ %2[_P N#_[EH_X>L?\ 5+O_ "X/
M_N6L_P#X=7:I_P!%$L__  5/_P#':/\ AU=JG_11+/\ \%3_ /QVCEX=_KG"
M^=_UR&A_P]8_ZI=_Y<'_ -RT?\/6/^J7?^7!_P#<M9__  ZNU3_HHEG_ ."I
M_P#X[1_PZNU3_HHEG_X*G_\ CM'+P[_7.%\[_KD-#_AZQ_U2[_RX/_N6C_AZ
MQ_U2[_RX/_N6L_\ X=7:I_T42S_\%3__ !VC_AU=JG_11+/_ ,%3_P#QVCEX
M=_KG"^=_UR&A_P /6/\ JEW_ )<'_P!RT?\ #UC_ *I=_P"7!_\ <M9__#J[
M5/\ HHEG_P""I_\ X[1_PZNU3_HHEG_X*G_^.T<O#O\ 7.%\[_KD-#_AZQ_U
M2[_RX/\ [EH_X>L?]4N_\N#_ .Y:S_\ AU=JG_11+/\ \%3_ /QVC_AU=JG_
M $42S_\ !4__ ,=HY>'?ZYPOG?\ 7(:'_#UC_JEW_EP?_<M'_#UC_JEW_EP?
M_<M9_P#PZNU3_HHEG_X*G_\ CM'_  ZNU3_HHEG_ ."I_P#X[1R\._USA?._
MZY#0_P"'K'_5+O\ RX/_ +EH_P"'K'_5+O\ RX/_ +EK/_X=7:I_T42S_P#!
M4_\ \=H_X=7:I_T42S_\%3__ !VCEX=_KG"^=_UR&A_P]8_ZI=_Y<'_W+1_P
M]8_ZI=_Y<'_W+6?_ ,.KM4_Z*)9_^"I__CM'_#J[5/\ HHEG_P""I_\ X[1R
M\._USA?._P"N0T/^'K'_ %2[_P N#_[EH_X>L?\ 5+O_ "X/_N6L_P#X=7:I
M_P!%$L__  5/_P#':/\ AU=JG_11+/\ \%3_ /QVCEX=_KG"^=_UR&A_P]8_
MZI=_Y<'_ -RT?\/6/^J7?^7!_P#<M9__  ZNU3_HHEG_ ."I_P#X[1_PZNU3
M_HHEG_X*G_\ CM'+P[_7.%\[_KD-#_AZQ_U2[_RX/_N6C_AZQ_U2[_RX/_N6
ML_\ X=7:I_T42S_\%3__ !VC_AU=JG_11+/_ ,%3_P#QVCEX=_KG"^=_UR&A
M_P /6/\ JEW_ )<'_P!RT?\ #UC_ *I=_P"7!_\ <M9__#J[5/\ HHEG_P""
MI_\ X[1_PZNU3_HHEG_X*G_^.T<O#O\ 7.%\[_KD-#_AZQ_U2[_RX/\ [EH_
MX>L?]4N_\N#_ .Y:S_\ AU=JG_11+/\ \%3_ /QVC_AU=JG_ $42S_\ !4__
M ,=HY>'?ZYPOG?\ 7(:'_#UC_JEW_EP?_<M'_#UC_JEW_EP?_<M9_P#PZNU3
M_HHEG_X*G_\ CM'_  ZNU3_HHEG_ ."I_P#X[1R\._USA?._ZY#0_P"'K'_5
M+O\ RX/_ +EH_P"'K'_5+O\ RX/_ +EK/_X=7:I_T42S_P#!4_\ \=H_X=7:
MI_T42S_\%3__ !VCEX=_KG"^=_UR&A_P]8_ZI=_Y<'_W+1_P]8_ZI=_Y<'_W
M+6?_ ,.KM4_Z*)9_^"I__CM'_#J[5/\ HHEG_P""I_\ X[1R\._USA?._P"N
M0T/^'K'_ %2[_P N#_[EH_X>L?\ 5+O_ "X/_N6L_P#X=7:I_P!%$L__  5/
M_P#':/\ AU=JG_11+/\ \%3_ /QVCEX=_KG"^=_UR&A_P]8_ZI=_Y<'_ -RT
M?\/6/^J7?^7!_P#<M9__  ZNU3_HHEG_ ."I_P#X[1_PZNU3_HHEG_X*G_\
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MG?\ 7(:'_#UC_JEW_EP?_<M'_#UC_JEW_EP?_<M9_P#PZNU3_HHEG_X*G_\
MCM'_  ZNU3_HHEG_ ."I_P#X[1R\._USA?._ZY#0_P"'K'_5+O\ RX/_ +EH
M_P"'K'_5+O\ RX/_ +EK/_X=7:I_T42S_P#!4_\ \=H_X=7:I_T42S_\%3__
M !VCEX=_KG"^=_UR&A_P]8_ZI=_Y<'_W+1_P]8_ZI=_Y<'_W+6?_ ,.KM4_Z
M*)9_^"I__CM'_#J[5/\ HHEG_P""I_\ X[1R\._USA?._P"N0T/^'K'_ %2[
M_P N#_[EH_X>L?\ 5+O_ "X/_N6L_P#X=7:I_P!%$L__  5/_P#':/\ AU=J
MG_11+/\ \%3_ /QVCEX=_KG"^=_UR&A_P]8_ZI=_Y<'_ -RT?\/6/^J7?^7!
M_P#<M9__  ZNU3_HHEG_ ."I_P#X[1_PZNU3_HHEG_X*G_\ CM'+P[_7.%\[
M_KD-#_AZQ_U2[_RX/_N6C_AZQ_U2[_RX/_N6L_\ X=7:I_T42S_\%3__ !VC
M_AU=JG_11+/_ ,%3_P#QVCEX=_KG"^=_UR&A_P /6/\ JEW_ )<'_P!RT?\
M#UC_ *I=_P"7!_\ <M9__#J[5/\ HHEG_P""I_\ X[1_PZNU3_HHEG_X*G_^
M.T<O#O\ 7.%\[_KD-#_AZQ_U2[_RX/\ [EH_X>L?]4N_\N#_ .Y:S_\ AU=J
MG_11+/\ \%3_ /QVC_AU=JG_ $42S_\ !4__ ,=HY>'?ZYPOG?\ 7(:'_#UC
M_JEW_EP?_<M'_#UC_JEW_EP?_<M9_P#PZNU3_HHEG_X*G_\ CM'_  ZNU3_H
MHEG_ ."I_P#X[1R\._USA?._ZY#0_P"'K'_5+O\ RX/_ +EH_P"'K'_5+O\
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M?\/6/^J7?^7!_P#<M9__  ZNU3_HHEG_ ."I_P#X[1_PZNU3_HHEG_X*G_\
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MG?\ 7(:'_#UC_JEW_EP?_<M'_#UC_JEW_EP?_<M9_P#PZNU3_HHEG_X*G_\
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M_AU=JG_11+/_ ,%3_P#QVCEX=_KG"^=_UR&A_P /6/\ JEW_ )<'_P!RT?\
M#UC_ *I=_P"7!_\ <M9__#J[5/\ HHEG_P""I_\ X[1_PZNU3_HHEG_X*G_^
M.T<O#O\ 7.%\[_KD-#_AZQ_U2[_RX/\ [EH_X>L?]4N_\N#_ .Y:S_\ AU=J
MG_11+/\ \%3_ /QVC_AU=JG_ $42S_\ !4__ ,=HY>'?ZYPOG?\ 7(:'_#UC
M_JEW_EP?_<M'_#UC_JEW_EP?_<M9_P#PZNU3_HHEG_X*G_\ CM'_  ZNU3_H
MHEG_ ."I_P#X[1R\._USA?._ZY#0_P"'K'_5+O\ RX/_ +EH_P"'K'_5+O\
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M /QVC_AU=JG_ $42S_\ !4__ ,=HY>'?ZYPOG?\ 7(;&G_\ !4W[=J%M;?\
M"L=GG2K'N_M_.W)QG'V7WK[WB_UJ?45^?.G?\$N-4L-0M;D_$*S<0RK(5_LM
MQG!!Q_K?:OT&B_UJ?45\]FJR].'U#SO\7E;?YGMY<\:U+ZYY6V^>QTU%%%>
M>L%%%% !1110 4444 %%%% !1110 4444 %%%% !7$?&W_DD7B__ +!D_P#Z
M":[>N(^-O_)(O%__ &#)_P#T$U</B1$_A9^5U%%%?2GS04444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5]0?"?_ ))Y
MHW_7-O\ T-J^7Z^H/A/_ ,D\T;_KFW_H;5C5V.BA\3.MHHHK [0HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *U_"7_(R:?\ ]=/Z5D5K^$O^1DT__KI_2I>S*6Z/3O$W_(OZC_UP?^5>
M-5[+XF_Y%_4?^N#_ ,J\:K*ELRZFX4445N9!1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !73?#S_D9$_ZY/_*N9KIOAY_R,B?]<G_E43^%
ME1W1V/C_ /Y%>X_WD_\ 0A7E%>K^/_\ D5[C_>3_ -"%>45%+X2ZFX4445L9
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 6]'_Y"UE_UW3_ -"%>S7W_'C<_P#7)OY5XSH_
M_(6LO^NZ?^A"O9K[_CQN?^N3?RKFJ[HVI[,\.HHHKI,0HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% &CX<_P"1ATO_ *^HO_0Q7TVWW3]*^9/#G_(PZ7_U]1?^ABOIMONGZ5P8
MG='71V9C4445QG6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4Z+_6I]13:=%_K4^HH Z:BBB@@**** "BBB@ HHHH **** "BBB@ H
MHHH **** "N(^-O_ "2+Q?\ ]@R?_P!!-=O7$?&W_DD7B_\ [!D__H)JX?$B
M)_"S\KJ***^E/F@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ KZ@^$_P#R3S1O^N;?^AM7R_7U!\)_^2>:-_US;_T-
MJQJ['10^)G6T445@=H4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %:_A+_D9-/_ZZ?TK(K7\)?\C)I_\
MUT_I4O9E+='IWB;_ )%_4?\ K@_\J\:KV7Q-_P B_J/_ %P?^5>-5E2V9=3<
M****W,@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KIOAY
M_P C(G_7)_Y5S-=-\//^1D3_ *Y/_*HG\+*CNCL?'_\ R*]Q_O)_Z$*\HKU?
MQ_\ \BO<?[R?^A"O**BE\)=3<****V,@HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** +>C_\
M(6LO^NZ?^A"O9K[_ (\;G_KDW\J\9T?_ )"UE_UW3_T(5[-??\>-S_UR;^5<
MU7=&U/9GAU%%%=)B%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !7IGPR_Y 5Q_P!?+?\ H*5YG7IG
MPR_Y 5Q_U\M_Z"E95/A-*>YB?$[_ )"UI_UP_P#9C7'5V/Q._P"0M:?]</\
MV8UQU.G\*)E\3"BBBM"0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** -'PY_R,.E_]?47_H8K
MZ;;[I^E?,GAS_D8=+_Z^HO\ T,5]-M]T_2N#$[HZZ.S,:BBBN,ZPHHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "G1?ZU/J*;3HO]:GU%
M '34444$!1110 4444 %%%% !1110 4444 %%%% !1110 5Q'QM_Y)%XO_[!
MD_\ Z":[>N(^-O\ R2+Q?_V#)_\ T$U</B1$_A9^5U%%%?2GS04444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5]0?"?
M_DGFC?\ 7-O_ $-J^7Z^H/A/_P D\T;_ *YM_P"AM6-78Z*'Q,ZVBBBL#M"B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 5TWP\_Y&1/^N3_ ,JYFNF^'G_(
MR)_UR?\ E43^%E1W1V/C_P#Y%>X_WD_]"%>45ZOX_P#^17N/]Y/_ $(5Y144
MOA+J;A1116QD%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!;T?\ Y"UE_P!=T_\ 0A7LU]_Q
MXW/_ %R;^5>,Z/\ \A:R_P"NZ?\ H0KV:^_X\;G_ *Y-_*N:KNC:GLSPZBBB
MNDQ"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ KTSX9?\@*X_Z^6_]!2O,Z],^&7_ " KC_KY;_T%
M*RJ?":4]S$^)W_(6M/\ KA_[,:XZNQ^)W_(6M/\ KA_[,:XZG3^%$R^)A111
M6A(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% &CX<_Y&'2_^OJ+_ -#%?3;?=/TKYD\.?\C#
MI?\ U]1?^ABOIMONGZ5P8G='71V9C4445QG6%%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4Z+_6I]13:=%_K4^HH Z:BBB@@**** "B
MBB@ HHHH **** "BBB@ HHHH **** "N(^-O_)(O%_\ V#)__037;UQ'QM_Y
M)%XO_P"P9/\ ^@FKA\2(G\+/RNHHHKZ4^:"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "OJ#X3_P#)/-&_ZYM_Z&U?
M+]?4'PG_ .2>:-_US;_T-JQJ['10^)G6T445@=H4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P#Q%'_"XO&'_08_\EH?_B*/9L/;Q['TU17S+_PN+QA_T&/_ "6A_P#B*/\
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M .(H_P"%Q>,/^@Q_Y+0__$4>S8>WCV/IJBOF7_A<7C#_ *#'_DM#_P#$4?\
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M+B\8?]!C_P EH?\ XBCV;#V\>Q]-45\R_P#"XO&'_08_\EH?_B*/^%Q>,/\
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MMS]"O _*O5/!WQ1T;QBRP12&SOR/^/6X(!;_ '3T;^?M4.#1I&I&6AW>C_\
M(6LO^NZ?^A"O9K[_ (\;G_KDW\J\9T?_ )"UE_UW3_T(5[-??\>-S_UR;^5<
ME7='53V9X=111728A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 5Z9\,O^0%<?]?+?^@I7F=>F?#+
M_D!7'_7RW_H*5E4^$TI[F)\3O^0M:?\ 7#_V8UQU=C\3O^0M:?\ 7#_V8UQU
M.G\*)E\3"BBBM"0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** -'PY_R,.E_]?47_ *&*^FV^
MZ?I7S)X<_P"1ATO_ *^HO_0Q7TVWW3]*X,3NCKH[,QJ***XSK"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *=%_K4^HIM.B_P!:GU%
M'34444$!1110 4444 %%%% !1110 4444 %%%% !1110 5Q'QM_Y)%XO_P"P
M9/\ ^@FNWKB/C;_R2+Q?_P!@R?\ ]!-7#XD1/X6?E=1117TI\T%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?4'PG
M_P"2>:-_US;_ -#:OE^OJ#X3_P#)/-&_ZYM_Z&U8U=CHH?$SK:***P.T****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "M?PE_R,FG_ /73^E9%:_A+_D9-/_ZZ?TJ7LRENCJ_C9_R23Q;_
M -@Z7^5?GA7Z'_&S_DDGBW_L'2_RK\\*O"_"SFQ7Q(****[#A"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** -'PY_R,.E_]?47_H8KZ;;[I^E?,GAS_D8=
M+_Z^HO\ T,5]-M]T_2N#$[HZZ.S,:BBBN,ZPHHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "G1?ZU/J*;3HO]:GU% '34444$!1110 44
M44 %%%% !1110 4444 %%%% !1110 5Q'QM_Y)%XO_[!D_\ Z":[>N(^-O\
MR2+Q?_V#)_\ T$U</B1$_A9^5U%%%?2GS04444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5]0?"?_DGFC?\ 7-O_ $-J
M^7Z^H/A/_P D\T;_ *YM_P"AM6-78Z*'Q,ZVBBBL#M"BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K7\)
M?\C)I_\ UT_I616OX2_Y&33_ /KI_2I>S*6Z.K^-G_))/%O_ &#I?Y5^>%?H
M?\;/^22>+?\ L'2_RK\\*O"_"SFQ7Q(****[#A"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!H^'/^1ATO_KZB_P#0
MQ7TVWW3]*^9/#G_(PZ7_ -?47_H8KZ;;[I^E<&)W1UT=F8U%%%<9UA1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %.B_UJ?44VG1?ZU/
MJ* .FHHHH("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KB/C;_R2+Q?_
M -@R?_T$UV]<1\;?^21>+_\ L&3_ /H)JX?$B)_"S\KJ***^E/F@HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KZ@^
M$_\ R3S1O^N;?^AM7R_7U!\)_P#DGFC?]<V_]#:L:NQT4/B9UM%%%8':%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M85---70FFG9A1113$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!H^'/^1ATO_KZ
MB_\ 0Q7TVWW3]*^9/#G_ ",.E_\ 7U%_Z&*^FV^Z?I7!B=T=='9F-1117&=8
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJ65P+=DN8V8L2H;(Q]:]Q_X*"_\ (%\%_P#7Q=?^@QUH?L ?\B+XG_["*?\
MHH5V^VG[#VE]?^"<7L8>WY.AP_\ P[^\1?\ 0U:7_P!^)*/^'?WB+_H:M+_[
M\25]OT5Q?6JO<[?JM+L?$'_#O[Q%_P!#5I?_ 'XDH_X=_>(O^AJTO_OQ)7V_
M11]:J]P^JTNQ\0?\._O$7_0U:7_WXDH_X=_>(O\ H:M+_P"_$E?;]%'UJKW#
MZK2['YY?%7]D/6?A5X&U#Q->:_8WT%F8U,$$3AFWR*@Y/'&[->"5^C_[8O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *U_"7_(R:?_ -=/Z5D5K^$O
M^1DT_P#ZZ?TJ7LRENCJ_C9_R23Q;_P!@Z7^5?GA7Z'_&S_DDGBW_ +!TO\J_
M/"KPOPLYL5\2"BBBNPX0HHHH **** /3OV<?AQI/Q4^)MOH&M-<+8R6TTI-K
M($?<HR.2#_*OK/\ X88^''_/;6__  ,3_P"-U\[?L3_\EULO^O&Y_P#0:^B/
MVU/&>N^"? >A76@:M=Z1<S:EY4DMG*8V9?*<[21VR!^5>96E4=90B[7/2HQ@
MJ+G)7L-F_84^',D;*MUKL3'HZ7<>1^<9%>;^/?V"+VSMI+GPAKPU!U!(L=30
M1NWLLJ_*3[%5'O7AEK^T1\2[.0/'XTU9F!!_>S^8./9LBO=O@E^VSJ,FKVNC
M^/O)GM;AA&FLPQB)X6. #*HPI7U*@8]#V;AB*?O*5P4\/4T<;'RMXA\.ZGX3
MU>YTK6+&;3M1MVVRV\Z[67_$'L1P1R*SZ_1_]ICX&VGQ=\%S7EC;I_PE&GQ&
M6QN$'S3*.3 Q[AN=OHQ'8G/YW:!HS^(->T_2DN(+.6]N$MEGNF*Q1LS!07(!
M( )Y.#731K*K&_5'+6HNE*W1E&BO?O%'[%'COPKX<U/69[_0KN#3[>2ZDAM;
MB9I61%+-M#0@$X!XR*\!K:$XSUB[F4H2AI)6"BBO>/!O[&7CGQMX5TO7K2_T
M.TM=1@6XABO)YEE"-RI8+$PY&",$\$43G&&LF$(2F[11X/15K6--.C:O>V#3
MPW36L[P&>W),<A5BNY20"0<<9 ^E>D?"K]FOQK\6X%O=-LX]/T@G U+46,<3
M\\[  6?OR!C(P2*'.,5=L(PE)V2U/+:*^JYO^"?VO+:AHO%FG/<\YC>VD5/;
MYLD^G:O"_BA\&/%?PAOHX/$-AY<$Q(@OK=O,MYB.RMV/LP![XJ(5J<W:++E1
MG!7DCB*_3S]FO_DA7@W_ *\1_P"A-7YAU^GG[-?_ "0KP;_UXC_T)JY<;\"]
M3JP7QOT/SF^)?_)1O%7_ &%;O_T<]?='[(7Q \/7_P &-*TF._M;74=)\V.[
MM99%1US*SB3!/*L&^]ZY':OA?XE_\E&\5?\ 85N__1SUZ!\+?V5_%GQ<\*)X
M@T?4-&MK-IG@"7T\J2;EQGA8F&.?6M:T8SII2=C.C*4*C<5<A_:L\8:1XV^-
M&JWNBS1W5G%%%;&ZAY29T7#,ISR ?EST.WCU/D5;WC[P3??#GQ?J7AS4I;>:
M^L'5)9+5F:,DJ&&TLJGHPZ@5T'P?^"FM_&O4]0L=#NM/M9K*%9Y&U"1T4J6V
M\;$;G/TK:+C3@M=$824JDWIJ<#17IOQ._9X\5?"S6M$TF]:SU?4-8WBT@T<R
MS.Q4J",-&IR=PQC/>O1_"?["7C+6;**YUG5-/T$R '[,=UQ,G^\%PN?HQI.M
M32YFQJC4;Y4CYKHKZ%\<_L1^.?"]C+>Z5/9^)8HP2T%IN2XQZA&&&^@8GT!K
MY[FADMI7BE1HI8V*NCC#*1P01V-5"I&:O%W)G3E#22L=)\+]?LO"OQ'\,:QJ
M*[["QU&"XGPNXA%<$L!W(QG\*_1WXG?%'PII'PMUC5I]7L+RQNK&1+=8IED^
MU,Z$*B 'YLY_ 9)P 37YB:;8R:IJ-K9PE5EN95A0N2 "Q &?;FO<_%_[&'C;
MP7X7U37K[5- EL].MWN94M[B<R,JC)"@P@$_4BN:O3A*47*5CIH5)QC)15SP
M6BBM?PGX/UGQUK<&D:#ITVI:A-]V&$=!W9B>%4=R2 *[&TM6<:5]$9%%?4&B
M?L#>*KRT635/$.EZ;,RY\B%'G*GT)^4?EG\:XOXE?LB>.OAY8RZA%#!X@TR)
M=TDVF%FDC'<M&0&P/5=P Y-8JO3;LI&SH5$KM'UU^R'_ ,F[^$_^WO\ ]*YJ
M^%OC[_R6SQM_V%KC_P!#-?=/[(?_ ";OX3_[>_\ TKFKX6^/O_);/&W_ &%K
MC_T,UR8?^//Y_F=>(_@P_KH<%117N'PZ_8]\>^/;"'4)X;;P]I\PWQOJ;,LK
MKV(C4%AG_:V_RKOE.,%>3L<$82F[11X?17U/J7[ /B2&VWV'BC2[J?;GRYX9
M(5SZ;AN_/%> ?$'X8^)?A;JPT[Q'IDEA*X+12Y#Q3*.Z..#VXZC(R!40JPF[
M19<Z4X:R1R]%%>Q_"W]E?Q9\7/"B>(-'U#1K:S:9X E]/*DFY<9X6)ACGUJY
M3C!7DR(PE-VBCQRBO6-,_9@\<ZSX\U;PO86MM=2Z5*D5YJ2RLMG&60,/G90Q
M.&' 4GVQ7J1_X)_^(19;AXJTPW?_ #R,$GE]/[_7K_L_X5FZ]..[-(T*DMD?
M*M%=O\4/@QXK^$-]'!XAL/+@F)$%];MYEO,1V5NQ]F /?%/^%WP2\6?%^[DB
M\/V -K"0LU_=-Y=O$?0M@DGV4$^U:<\>7FOH9\DN;EMJ<+17U4W_  3_ /$(
ML@R^*]--WWB-O((^G]_KU_V:\,^)_P %_%?PAO8X?$.G^7;S$K!?6[>9;S$=
ME?L>^U@#WQBHC6IS=HLN5&<%>2.(K[<_86\=Z#!X%U/PY->6]GK$5^]WY4SJ
MAGC9$ 9<_>P4(/I\OK7Q'7J'P?\ V=O$GQKT[4+S0[W2[6*QE6&0:A+*C$L,
MC;LC;CZXJ:\8RA:3L50E*,[Q5SN_VW_&NB^*OB+I=II-S#?2Z79F&ZN(&#*'
M9RWE[@<$J.N.A8CKD#YTKL?BO\*]6^#WBA=!UFXL[F\:W2Y#V+N\>UBP RRJ
M<_*>U<=5TDHP2B[HBK)RFW)6845[!\*_V5_&WQ3L8M2A@AT;1Y.4O=1)7S1Z
MQH 68>Y ![&O1M3_ & O$L%F7L?$^EW=R$SY,T4D2EO0,-WYD"I=>G%V;*5"
MI)72/EFBO1;'X ^+Y_B;8^!+VRCT;6KT2-!)?L1;NJ1LY82(&W#"$94'G@XY
MK:^*W[+OBKX/>%UU[6=0T>YLVN$M@EC-*\FY@Q!PT2C'RGO5^TA=*^Y'LYV;
MML>04445H9A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !7Z!?!7_DB'AW_ +!Q_P#9J_/VOT"^"O\ R1#P[_V#C_[-7'B?A7J=N%^)
M^AQ5%%%(Z HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *],^&7_("N/\ KY;_ -!2O,Z],^&7_("N
M/^OEO_04K*I\)I3W,3XG?\A:T_ZX?^S&N.KL?B=_R%K3_KA_[,:XZG3^%$R^
M)A1116A(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4 %%%% !1110 4444 %%%% !1110 4Z+_6I]13:=%_K4^HH Z:BBB@@****
M"BBB@ HHHH **** "BBB@ HHHH **** "N(^-O\ R2+Q?_V#)_\ T$UV]<1\
M;?\ DD7B_P#[!D__ *":N'Q(B?PL_*ZBBBOI3YH**** "BBB@ HHHH ****
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M,<!0,DFO7HW]G&_8\BM;VDK=SZ4_8P^"L?C7Q-+XNU>W$NCZ/(%MHI!E9[K
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MDD'H2YW@?[K ^]?;_P "/V@-'^-VDR>2G]G:[:(&O--=\D \>9&?XDSQZ@D
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M/X:]3QZBBBO9/&"BBB@ K]=/"W_(L:1_UYP_^@"OR+K]=/"W_(L:1_UYP_\
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M\D,M_P#L(7/\Q3Q7\%"PO\9GR1^U-_R7WQA_UWC_ /1,=>J?\$_O^1T\5?\
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M_DAEO_V$+G^8KYH_;4TF/3?CM?S1J%^W6=O<MCUV^7_[3KZ7_8C_ .2&6_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !7Z!?!7_DB'AW_ +!Q_P#9J_/VOT"^"O\ R1#P[_V#C_[-7'B?
MA7J=N%^)^AQ5%%%(Z HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *],^&7_("N/\ KY;_ -!2O,Z]
M,^&7_("N/^OEO_04K*I\)I3W,3XG?\A:T_ZX?^S&N.KL?B=_R%K3_KA_[,:X
MZG3^%$R^)A1116A(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% &CX<_Y&'2_^OJ+_P!#%?3;
M?=/TKYD\.?\ (PZ7_P!?47_H8KZ;;[I^E<&)W1UT=F8U%%%<9UA1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M? EE+^\N-2AOM0VGH@)\J,_5@6(_V4/>O=J_-WX=>-KSXB_M3:%XBOB?.O\
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MRK#)DA03@?E7W167XI_Y%C5_^O.;_P! -4L55ON2\+2['Y%T445[AX84444
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M9V[M3N5![\QQ?^U?S%>%#]_6NSW)_N:-D?)&E:G<:+JEGJ%H_EW5I,EQ"_\
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M_P#7G!_Z&U?/GQ@9'^+?C9H\>6=<OBN.F/M#XKZ#_P""?G_(S>+_ /KS@_\
M0VKUJ[O0;/)H*U9(^V*_-C]K[_DXCQ;_ -NG_I)#7Z3U^;'[7W_)Q'BW_MT_
M])(:X<%_$?I_D=V,_AKU/'J***]D\8**** "OUT\+?\ (L:1_P!></\ Z *_
M(NOUT\+?\BQI'_7G#_Z *\S&[1/3P6\CS']KS_DW?Q9_VZ?^E<-?FS7Z3?M>
M?\F[^+/^W3_TKAK\V:TP7\-^O^1GC?XB]/\ ,_3+]EK1ET3X#>$HE7:TT#W3
M$]6,DC.#^3 ?0"O0O$^KCP_X:U;5#C%C:2W)W=/D0MS^5<I\ IHY_@IX):,
M*-)MU./4( ?U!J[\9HWF^$/C>./.]M$O0 !G/[A^/QZ5Y<O>J._<]./NTU;L
M?E9<W$EW<2SS.99I6+N[=68G))_&F445]&?.A1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 5]0?"?_DGFC?\ 7-O_ $-J^7Z^H/A/_P D\T;_ *YM
M_P"AM6-78Z*'Q,ZVBBBL#M"BBB@ HHHH **** "BBB@ HHHH \/_ &A-7O\
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M&?\ @5>4_P#"5:W_ -!B_P#_  *?_&E\5ZX_B7Q)J.IOG_29F=0W4)T4?@H
MJC+8SP6EO<R1E8)RPB<]&VD!L?0FO)G)RDVCT(Q44D?2'P,\42^(/"+V]U,\
M]Y8RF-GD8LS(WS*23_P(?\!KT:OF;X%>(O[%\;QVLC;8-10P'/3?U0_F,?\
M J^F:[Z,N:!R5(\L@K@?C?>W%AX"FFM;B6VE$\0#Q.4;&>>17?5YW\>O^2>S
M_P#7Q%_.KJ? R8?$CYZ_X2K6_P#H,7__ (%/_C1_PE6M_P#08O\ _P "G_QK
M+KZ<TOX->#[G3+2632-TDD*,S?:9ADE03_'7G0A*ILSLE*,-T?/4/C+7[:0/
M%K>HHWJ+I_\ &NW\*?'K7-'F2/5B-6L\X8L LRCU##K^/YBO3=2^!/A.]M6C
MM[2;3Y2#MEAG=B#]')!KYX\4^'KCPIK]YI5R5>6W?&]>C*0"K#Z@@U4HU*6M
MR4X5-+'UUH6N67B32X-0T^83VTPR&Z$'N".Q%7Z\!_9U\0RV^MWVC.Q-M<1>
M>BG^&12 <?53S_NBO?J[J<^>-SEG'E=@HHHK4@**** "BBB@#EOB7XP/@GPK
M/?Q*KW3L(8%?IO.>3] "?PKY\\.^&M?^+6MW#M=F9XP&GN[IR5C!S@ #UP<
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M3V<^Q[E17)VOQ+TC5/"U_K6G2?:A9PF66U8[)5P,X(YQG'7D5PG_  TG:_\
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M3YC7PE\5_&TGQ%^(FO>(79BE[=,T(;.5A'RQKSZ(%%?>'[4WC"#X9_ N]L+
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M5BOX*%A?XS/DC]J;_DOOC#_KO'_Z)CKU3_@G]_R.GBK_ +!\?_HRO*_VIO\
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MR12;_L+7'_H$=?*7[4W_ "7WQA_UWC_]$QUQ4?\ >)G;6_W>!Y77Z _L,?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?H%\%?^2(>'?^P<
M?_9J_/VOT"^"O_)$/#O_ &#C_P"S5QXGX5ZG;A?B?H<51112.@**** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "O3/AE_R KC_KY;_T%*\SKTSX9?\ ("N/^OEO_04K*I\)I3W,3XG?
M\A:T_P"N'_LQKCJ['XG?\A:T_P"N'_LQKCJ=/X43+XF%%%%:$A1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 :/AS_D8=+_Z^HO\ T,5]-M]T_2OF3PY_R,.E_P#7U%_Z&*^F
MV^Z?I7!B=T=='9F-1117&=84444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3HO]:GU%-IT7^M3ZB@
M#IJ***" HHHH **** "BBB@ HHHH **** "BBB@ HHHH *XCXV_\DB\7_P#8
M,G_]!-=O7$?&W_DD7B__ +!D_P#Z":N'Q(B?PL_*ZBBBOI3YH**** "BBB@
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MEW8@*JC))]!6ID%%?97A?]A^QUKX2Z?_ &K<3:-XUFW7+S#+QQAL;()(\XX
M&2N"&9N6  KYE^)?PC\4?";5A9>(=.:!7)\B\B^>WN .Z/CGZ'##N!6$*T)M
MI/4WG1G!)M''T445N8!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5]0?"?\ Y)YHW_7-
MO_0VKY?KZ@^$_P#R3S1O^N;?^AM6-78Z*'Q,ZVBBBL#M"BBB@ HHHH ****
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MBL)T:=1WDC>%:I35HL^P)O\ @H5(T;"+P&J2=F?5RP'X" ?SKSKQU^VEX_\
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M)! [8KQ&BJG",U:2)A.4'>+/MK_AX#H7V;=_PB6H_:/^>?VF/9T_O8SU]O\
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M_:/GYVAAMV^4O7=USVKY_HJ_8PNI6V(]M.S5]PHHHK8Q"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M10 4444 %%%% !7$?&W_ ))%XO\ ^P9/_P"@FNWKB/C;_P DB\7_ /8,G_\
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M]XPN(LQ6<8T^U8CCS'PTA'N%"CZ25]K5XN,GS3Y>Q[6$ARPYNY\_?MK>.?\
MA%_A"^DQ2;;S7;A;4 =1$IWR$?DJG_?K\^*^@OVVO'7_  D_Q:&CPR;[30K<
M6^ <CSGP\A_(HI_W*^?:]##0Y*:\SS\3/GJ/R"BBBNHY3]0?V>O'(^(7P@\.
MZH\GF7B6XM+HGKYT7R,3_O8#?\"KJO''A6W\<>#]9T"Z($.HVDEN6Q]PLN%8
M>ZG!'TKY0_8$\<^7=^(O"$\F!*JZE:J3_$,)+CZCRC_P$U]F5\]6C[.HTCZ"
MC+VE--GX_P"J:=<:-J=W87<9BNK69X)HSU5U)5A^!!KW;]B#_DN*?]@VX_\
M9:B_;/\  ?\ PB/Q@GU*&,I9:[$+U3V$H^64?7(#'_?J7]B#_DN*?]@VX_\
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MV?ORW/.Q-?VGNQV"OK#_ ()^?\C-XO\ ^O.#_P!#:OD^OK#_ ()^?\C-XO\
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MC#$XA).$2G1117KGD!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5]0?"?_DGFC?]<V_]
M#:OE^OJ#X3_\D\T;_KFW_H;5C5V.BA\3.MHHHK [0HHHH **** "BBB@ HHH
MH **** / _VD?^0UHW_7N_\ Z%7G7@C1K?Q#XLTS3KHN+>XEV/Y9PV,'H:]%
M_:1_Y#6C?]>[_P#H5<1\+/\ DH6A?]? _D:\RIK5.V&E,]G_ .&??"_]^_\
M^_Z__$U;L?@3X3LY%=[:XN\'.V><X/\ WSBO0:*[O9P['+SR[E73=*L]&M%M
MK&UBM(%Z1PH%'UX[^]6J**T(/'_VD/\ D!:/_P!?+?\ H->%Z7;I>:G:6\F=
MDLR(VWK@L :]T_:0_P"0%H__ %\M_P"@UXAH'_(=T[_KYC_]"%>;6_B';2^
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ K7\)?\C)I_P#UT_I616OX2_Y&33_^NG]*
ME[,I;HZOXV?\DD\6_P#8.E_E7YX5^A_QL_Y))XM_[!TO\J_/"KPOPLYL5\2"
MBBBNPX0HHHH **** "BBB@ HHHH **** /0?@#-X=LOBMH>H^*M0BT[1].D^
MV/)*C,'D3F-<*"?O[3TZ U](_M2_M(^%?$GPNGT'PGK<>IWFI3I%<>3&Z>7
MIWMRRCJ55>.Q-?%M%82HQG-3?0WC6<(."6X4445N8!1110 4444 %%%% !11
M10 5]$?L8?$#P[\/_%/B*Y\1:M;Z3!<621Q/.3AV#Y(&!Z5\[T5G4@JD7%FD
M)NG)21])_MI_$3PW\0M4\*R^'-8M]6CMH;A9FMR3L+-&0#D#K@U\V4444X*G
M%105)NI)R84445H9A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% $^G:?/JVH6UE:Q^;<W,JPQ(/XG8X _,B
MOTETG1(_#7@VSTF(YBL;!+92.X2/;G\<9KY#_9[^'DBZYI_B+48=JB9/L<;C
MDY(_>8],=/S]*^SK[_CQN?\ KDW\J\_$RNTCT\-"R<F>'4445904444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %>F?#+_D!7'_ %\M_P"@I7F=>F?#+_D!7'_7RW_H*5E4^$TI[F)\
M3O\ D+6G_7#_ -F-<=78_$[_ )"UI_UP_P#9C7'4Z?PHF7Q,****T)"BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU%1[*G_*ON+]K4_F?WGL/_#7WQ:_Z&W_ ,IMI_\ &J/^&OOBU_T-O_E-M/\
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M1MO!7A^'3;<^8P.^:;&#)(>K?H /8"MX    8 [45O3I*GKU,YS<PKPGXO\
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MM/(/8>9\>_V)J/\ T#[K_ORW^%']B:C_ - ^Z_[\M_A7V%11[3R#V'F?'O\
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MM/(/8>9\>_V)J/\ T#[K_ORW^%']B:C_ - ^Z_[\M_A7V%11[3R#V'F?'O\
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MM/(/8>9\>_V)J/\ T#[K_ORW^%']B:C_ - ^Z_[\M_A7V%11[3R#V'F?'O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "O3/AE_R KC_ *^6_P#04KS.O3/AE_R KC_KY;_T%*RJ?":4]S$^
M)W_(6M/^N'_LQKCJ['XG?\A:T_ZX?^S&N.IT_A1,OB84445H2%%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY%_4?^N#_P J\:K*ELRZFX4445N9!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !73?#S_D9$_ZY/\ RKF:Z;X>?\C(G_7)_P"51/X65'='
M8^/_ /D5[C_>3_T(5Y17J_C_ /Y%>X_WD_\ 0A7E%12^$NIN%%%%;&04444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MM4NC:3>^ZM=NZZG7T5\\_P##7]G_ -"Q/_X&+_\ $4?\-?V?_0L3_P#@8O\
M\179_96-_P"??XK_ #/ _P!>N'?^@I?^ S_^1/H:BOGG_AK^S_Z%B?\ \#%_
M^(H_X:_L_P#H6)__  ,7_P"(H_LK&_\ /O\ %?YA_KUP[_T%+_P&?_R)]#45
M\\_\-?V?_0L3_P#@8O\ \11_PU_9_P#0L3_^!B__ !%']E8W_GW^*_S#_7KA
MW_H*7_@,_P#Y$^AJ*^>?^&O[/_H6)_\ P,7_ .(H_P"&O[/_ *%B?_P,7_XB
MC^RL;_S[_%?YA_KUP[_T%+_P&?\ \B?0U%?//_#7]G_T+$__ (&+_P#$4?\
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MT'_H-Z=_X%Q_XT?\)AH/_0;T[_P+C_QKXP_X88\>?]!;PY_X$S__ !BO#O\
MA%+O_A,_^$9\R#[?]O\ [-\S<?*\SS/+SG&=N?;..U C]0/^$PT'_H-Z=_X%
MQ_XU/9^(])U"=8+75+*YF;)$<-PCL<=> :^*?^&&/'G_ $%O#G_@3/\ _&*]
M ^!'[+'BOX7_ !*T_P 0ZKJ&C7%E;QS(\=G-*TA+QLHP&B4=3ZT ?4U%%%!1
M7OM0M=,@\Z\N8;2(G;YD\@1<^F33;#5;+54=[*\M[Q4.&:WE60 ^^#7A7[;7
M_)'(/^PK!_Z!)7._L'?\BEXI_P"OZ+_T70*Y]0T444#*FH:Q8:3Y?VV^MK/S
M,[/M$RQ[L8SC)YQD?G4MG?6^HVZSVMQ%<PMD"2%PZG'7D<5\F_M]?\R)_P!O
M_P#[;UZA^R!_R0G1O^N]S_Z.:@5SVBBBB@8,P4$DX Y)-9'_  F&@_\ 0;T[
M_P "X_\ &K>L?\@B^_ZX/_Z":_+GP)X,O?B%XLT[P]ITL$-[?.R1/=,RQ@A2
MQR5!/13T!H$S]._^$PT'_H-Z=_X%Q_XT?\)AH/\ T&]._P# N/\ QKXP_P"&
M&/'G_06\.?\ @3/_ /&*/^&&/'G_ $%O#G_@3/\ _&*!'VI:^)M'O9T@MM6L
M;B9^%CBN$9F^@!R:TJ^2_@[^R5XO^'WQ*T/Q#J.I:)-96,CO(EK/,TA!C91M
M#1 =6'4BOK2@:"BBB@9FW7B;1[&=X+G5K&WF3AHY;A%9?J"<BHO^$PT'_H-Z
M=_X%Q_XU^>W[3G_)=O%O_7>/_P!$QUW7_##'CS_H+>'/_ F?_P",4$GVE%XK
MT2>0)'K&GR.W15ND)/X9K4KX2O?V(/B!:6[217FA7CCI%!=2AC_WW$H_6N3T
MGQQ\2_V<_$<>G7,EYIXCP[:5?GS;69/51DK@\C<A'(QGC% 7/T9HKD/A3\3-
M-^+'@VUU[3E:'>3%<6KG+6\PQN0GOU!![@@\=*Z^@84444#"JFH:SI^E%!?7
MUM9F3.W[1,L>['7&3SU%6Z_//]H_QQ<_%KXQ7%GI0DOK2Q?^S;"&'YO,*D[V
M4#KN?//]T+Z4"/T%LK^VU* 36ES#=0YQYD+AUR.V14]?&/[#_P 2/[-U_4O!
MEW+B#4 ;NR#'CSD7YU'^\@S_ -L_>OLZ@ HHHH&%5[_4K32X1+>W4%I$S;0\
M\@12?3)/7@U8KYU_;G_Y)+I/_8<A_P#1%Q0(]S_X3#0?^@WIW_@7'_C1_P )
MAH/_ $&]._\  N/_ !K\^/A/^SMXD^,>C7FIZ+>Z7:P6MQ]F=;^61&+;0V1M
MC88PP[UW'_##'CS_ *"WAS_P)G_^,4"/N"TO;;4(1-:W$5S$>!)"X=3^(J:O
MSI\3?!?XF?!!O[;6.YM((NNJ:-=%E3_>*X91VRP YQ7T!^S)^TU=>/;Y/"OB
MJ2-M:*%K._4!/M6T9*.HX#@9((P" >,CD"Y]+4444%!6;<>)]&LYWAGU:Q@F
M0X:.2Y164^X)XK2K\V/V@(&NOCKXKA0@-)J&P%NF2%% F?HA_P )AH/_ $&]
M._\  N/_ !H_X3#0?^@WIW_@7'_C7QA_PPQX\_Z"WAS_ ,"9_P#XQ1_PPQX\
M_P"@MX<_\"9__C% C[07Q?H3$ :UIQ)X %W'D_K6M7Q!8?L/>.K6^MYGU;PZ
M5CD5R!<SYP#G_GC7V_0-!1110,HWVO:9I<RQ7NHVEI*R[@D\ZHQ'K@GIP?RJ
MW!/%=0I-#(DT3@,DD;!E8>H(ZU\.?MS_ /)6M)_[ </_ */N*^K/@7_R1OP9
M_P!@JW_] % KG=4444#,V7Q-H\-RUO)JMDEP&V&)KE X;IC&<YK2K\W_ (B?
M\G(:Q_V,9_\ 1XK](*!!4-Y?6^G6[3W5Q%;0K@&29PBC/3D\5-7G_P =_A]J
M/Q0^&NH>'M*FM;>]N)(722\=EC 20,<E58]!Z4 =3_PF&@_]!O3O_ N/_&C_
M (3#0?\ H-Z=_P"!<?\ C7QA_P ,,>//^@MX<_\  F?_ .,5Y]\7/@)X@^#%
MMIDVMWFFW2:@\B1"PED<@H%)W;XU_O#IF@1^B'_"8:#_ -!O3O\ P+C_ ,:/
M^$PT'_H-Z=_X%Q_XU\ ?"W]F?Q1\7/#+ZYH]_I%M:+<-;%+Z:5)-RA23A8V&
M/F'>NP_X88\>?]!;PY_X$S__ !B@#[C@GBNH4FAD2:)P&22-@RL/4$=:?7-_
M#;PW<^#O 'A_0[V2&6[T^RBMI7@),;,J@$J2 <?4"NDH*"LU?$VCM="V&K61
MN2_EB$7";]V<;<9SG/&*TJ_-_1O^3GK'_L<(_P#TM% F?I!1110,***PO&_C
M32OA[X9O==UB?R+*U7) QOD;^%$'=B> * -VL#5OB%X6T"<P:GXET?3IAP8[
MN_BB;\F8&OA?XD?M$>./C+K7]E:.;O3]-N)/+MM(TO<99AV$C+\TA/I]WCIW
MK4\-?L6>/M;M%N+Z33=## $0W<[/+^(C5@/H3GVH)N?:>D_$+PMK]P(-,\2Z
M/J,QX$=I?Q2M^2L:Z"O@_P 2?L4>.]&M7N-/GTS6PF3Y%O,T<I'L'4+_ ./5
M!\'_ (Y_$#X8^+K;PQ?VNH:Y TXMGT.\#&YC8G&(BW*D?W3\I]LY %S[WHI$
M8LJD@J2,[3U%+04%%17=W#86DUS<2+#;PHTDDC' 10,DGV %?G]\4?C;XO\
MCSXM_L/0C=QZ1/*8;+2+,E6G']Z7'WB0,D'Y5'T)((^X;_XG>#M*G:"]\6:'
M9SKP8KC4848?@6JSH_COPUXAF$6E>(M)U.4G 2SO8I6S]%8U\>Z%^PQXMOK-
M)=3UG3-+E< ^0N^=D]F( 7/T)'O5/Q'^Q+XXT>!KC2[W3=:*<B&*5H92?;>
MO_CU C[JHKYH_9%3XAV^H^(-.\4W&HQ:1I:)!'8ZFA+K.QR-CM\VT(.@.WYU
M(KZ7H&%%%% PHHHH **** "BBB@ HHHH *=%_K4^HIM.B_UJ?44 =-11100%
M%%% !1110 4444 %%%% !1110 4444 %%%% !7$?&W_DD7B__L&3_P#H)KMZ
MXCXV_P#)(O%__8,G_P#035P^)$3^%GY74445]*?-!1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7U!\)_^2>:-_P!<
MV_\ 0VKY?KZ@^$__ "3S1O\ KFW_ *&U8U=CHH?$SK:***P.T**** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?44Z[GAE7MJU?\#\2Q>60P^<2RQ2;BJG)?K;FM<K_P#"M?%__0JZW_X+IO\
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MXZ_L#Q=+H5S+MLM6 $88\+.OW?IN&5]SMKJ?VK_ @:*Q\5VL?S*1:7FT=O\
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M_B)_R<AK'_8QG_T>*_2"OS?^(G_)R&L?]C&?_1XK](*"4%%%%!05\I?MZ_\
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MF:I_WZ'^-=O^Q!_R7%/^P;<?^RU^A59U\1*E/E2+H8>-6',V?E]_PSC\3?\
MH3-4_P"_0_QH_P"&<?B;_P!"9JG_ 'Z'^-?J#17/]=GV1T?4H=V?EW)^SI\2
MXHW=O!>JD*"Q"P[CQZ ')^@KB-9T'4_#MZUGJVG7>EW:C)M[R!H9 /=6 -?K
MW6#XQ\#Z%X_T:72_$&F0:G9N"-LR_,A/\2,.4;W4@U<<:[^\B98)6]UGY*T5
M[-^T9^SK>?!;58[RSDDO_#%[(5MKIQ\\+]?*DQQG&<-QN / P17C->E":FN:
M)YDXN#Y9!117I?P)^!FJ_&SQ*UK;L;+1[7#7VH%<B,'HBCN[8.!VY)]W*2@K
ML48N;LCSBTM)[^XC@MH9+B>0X2*)"S,?8#DUZ1HG[,_Q/\0)NM?!NH1#:6_T
MW9:'&<=)67GVZ]^E?H3\./A%X5^%.FK:>'M+BMY2NV6]D >YG_WY,9([X&%'
M8"NSKS)8UW]Q'IPP2M[[/S.U#]E+XK:9!YTWA"=T)VXM[JWF;_OE)"?QQ7GO
MB'PAKGA&Y%OKFCW^D3'.U+ZW>(M[C<!D>XK]<ZJ:GI5EK=C+9:C9V]_9RC;)
M;W42R1N/1E8$&ICC9?:14L%'[+/R"HK[H^+?[$.@^((IK_P5*- U+!;[!,Q>
MTE/H#RT9^F1["OB/6]&N_#NLWVE7R+'>V4[V\Z(ZN%D5BK#<I(."#T->C3K0
MJKW3SJE&5)^\4Z***V,0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^H/A/_ ,D\T;_K
MFW_H;5\OU]0?"?\ Y)YHW_7-O_0VK&KL=%#XF=;1116!VA1110 4444 %%%%
M !1110 4444 %?&WBK4?[6\3:M> [EGNI)%/^R6./TQ7UOXEU#^R?#NIWNXJ
M;>UDE!!YR%)&/QKXTKAQ+V1TT5NSVK]F_6MMQJ^DLW#*MU&ON/E;^:?E7N=?
M*'PFUK^Q/'VDRLVV*:3[,^>F'&T?J0?PKZOK6A*\+=B*JM(***1W$:EF(55&
M22< "NDQ.:^(GC*+P3X:N+XE3=/^ZMHS_%(1QQZ#J?I[U\F7-S+>7$L\\C2S
M2L7=V.2S$Y)-=A\5_'!\:^)9&A<G3;3,5L,\$?Q/_P "(_("N+KRZU3GEIL=
MU./*CZC^">G?V?\ #K3B1A[AI)R,>K$#] *[JLSPOIW]D>&]*LL;3;VL<9'N
M% /ZYK3KT8JT4CCD[ML**X'QK\9M%\)2O:PYU34%X:&!@$0^C/T!]@"?6O,[
MS]HGQ#-+FWM+"WC[*49S^)W?T%1*M"+M<J-.4M3Z*HKP'1?VC-3AG5=5TVVN
M8,\M:YC<#UY)!^G'UKT'Q'\6;"Q\$IX@TDQWP>98!#*2I5B"2K#J" "?_K4*
MK"2NF#IR3L=[17CO@[XXZCXJ\3:?I7]E6\2W,FUG61B54 DG'T!KU#Q-J<^B
M^']1U"WB6>:U@:81N2 VT9(X]@:J,XR5T)Q<79FE17@?_#2.H_\ 0&M?^_K5
M[Q;7"W=M%.A^25 Z_0C(HA4C/X0E%QW)***HZYK%OX?T>[U&Z;;!;1F1O?'0
M#W)P!]:O8@O45X*O[1^I2,%71+9F8X $C$G]*]OTF:[N-,MI;^)(+QT#2Q1D
ME4)_AR?3I40J1G\)<HN.Y;HJCK>NV'AVP>\U*Z2TMEX+N>I] .I/L*\B\0_M
M')'*\>BZ8)4' N+QB ?^ #M^-$IQANPC&4MCVNBOF\_M">)RY/E:>!G.T0MC
MZ?>KIO#7[1<<T\<6NZ>+=6X-S:$E5^J')Q]"?I6:KP93I21[514%C?6^IV<5
MU:3)<6TJ[DDC.585/6YD%%!(5220 .237F7C'X[Z/X?EDM=-C.KW2<,R-MA4
M_P"]SN_ 8]ZF4E%7923EL>FT5\Y7/[0WB264M%;:?"G9/*9OS):MOP[^T;,)
M4CUO38S&3@SV1(*^^QB<_F*R5>#+=*1WWQCU'^SOAUJS#[\RK O_  )@#^F:
M^;O!NG?VMXLT>TQE9;N-6XS\NX;OTS7K_P =_%%IJW@K1CI]REQ;7MP95=/X
ME12"/;!89!YS7#_ S3A?_$2S<C*VT4DY_P"^=H_5A7/5]^JD;4_=@V?3U%%5
M]0U&UTFSEN[R>.VMHAEY9&"J!7><A8HKQWQ)^T59VLKPZ+I[7I!Q]HN6V(?<
M*.2/KBN2D_:%\3NY*PZ>@[*(6P/S:L'7@NIJJ4F?1]%>&^'OVC9O.2/6],C,
M1.#/9$@K[[&)S^8KV;1]9LM?T^*]T^X2ZM9!E9$/Z'T/L>:TA.,]F3*+CN7*
M\E_:,U'R/#.FV0;!N+K>1ZJBG^K+7K5?/W[1VH>;XBTJR#$B"U,N,\ NQ'\D
M'Z5%9V@RJ:O-&'\"M/\ MWQ$M)""1:Q23G_OG:/U85].UX3^S;IV^_UN^(_U
M<<<"GUW$L?\ T$5[K(ZQHSL=JJ"23V%305H#JN\A:*\%;]I&_#G;HUL5SP3*
MV<5Z)JWQ4TSPUX>T^[U4@:E=6Z3?V?;'<X+*#SGH.>I].,U:JP?4EPDNAVU%
M?/FJ?M&:Q/*?[/TZSM(>WG;I7_,%1^E1Z=^T5KT$P-Y8V5U%GE4#1M^!R1^A
MJ?;P*]E(^AZ*Y?P/\1=*\=6S&S=H;N,9EM)>'4>H]1[C\<5U%;IJ2NC)IK1A
M117'>-?BIHG@G,,\AO+_ !Q:6Y!9?]X]%_'GVI-J*NP2;T1V-%?/.H_M%ZY/
M)_H=A96D6<@2!I&_/('Z4[3/VB];@F'VZPL[N'/(B#1/^!R1^E8^W@:^RD?0
ME%<-_P +8TN^\$ZAKVGD22V: R6DYVNCD@*#CL2>"*X;2_VA-3U34[2S31K8
M/<3)"I$C'EF _K5.K!=25"3Z'N5%%<#\4_B7+\/CIJ6]I%>277F%ED8C:%VX
M/'KN/Y5I*2BKLA)MV1WU%>7_  Z^+]SXRU.\BO;*VT^RM;9KB2X\TX7! P2>
M .2?PK'\5_M$1VUP]OH%DETJG'VNZR$;Z(,''N2/I6?M86O<OV<KVL>T45SG
MP\UN_P#$?A"PU+41&MS<AV(B7:H7<0O&3V /XUT=:IW5R&K:!1113$8OC37/
M^$;\*:IJ0.'@@)C_ -\\+_X\17R)96LVJ:A!;1Y>>XE6-<\Y9C@?J:^A/VAM
M2-KX,MK5<YNKI0W^ZH)_GMKRSX*Z6-4^(>GEAE+8/<$>ZK\O_CQ%<%;WJBB=
M5+W8.1],:+I4.AZ19Z? /W-M$L2G'7 QG\>OXU<HHKN.4*^(J^W:^(JXL3T.
MJCU/LGPK_P BOH__ %YP_P#H K4K+\*_\BOH_P#UYP_^@"M2NQ;(YGN%?-'Q
M\_Y*#+_U[1?R-?2]?-'Q\_Y*#+_U[1?R-88CX#:E\1V_[-__ " M8_Z^5_\
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M"/\ KG7E]?:UA_QXVW_7-?Y"N&C3C.]SJJS<;6/GS_AG3Q)_S^Z5_P!_9/\
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M7:P['KW(XZU]65Q'QH\C_A6^J^?C_EGY>>N_S%QC]?UISHP46T*-27-J>7_
M7QI/INOKH4\A>QO<F)6/$<H&<CV8 C'KBOH>ODCX90O/X_T%4&6%TC8'H.3^
M@-?6]/#MN.H55:05YM\>_#PU?P7]N1-T^G2"4$==C?*X_P#03_P&O2:J:SIJ
M:QI%[8R8V7,+PG/;<I']:WG'FBT91=FF?*_POUT^'O'.E7&[;%)*+>7T*O\
M+S]"0?PKZSKXE=7MIBIS'(C8/8J0:^S-!U'^U]#T^^R#]IMXYLC_ &E!_K7+
MAGHXF]9;,O4445VG,%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %:_A+_D9-/_ .NG]*R*U_"7_(R:?_UT_I4O9E+='IWB;_D7]1_ZX/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MW&C:E:W]I(8KJVE6:)Q_"RG(/Z5]]^"O%%OXS\+:;K5M@)=PAV0'.Q^CK^#
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M->F5XN:8KZSB';:.B_4_2N",E_L?*8>T5JE7WI?/9?)?BV%%%%>.?H(4444
M%%%% !7YI_\ -P__ '-/_MW7Z65^:?\ S</_ -S3_P"W=!+/TLHHHH*"BBB@
M#P#]MK_DCD'_ &%8/_0)*YW]@[_D4O%/_7]%_P"BZZ+]MK_DCD'_ &%8/_0)
M*YW]@[_D4O%/_7]%_P"BZ"3ZAHHHH*/D?]OK_F1/^W__ -MZ]0_9 _Y(3HW_
M %WN?_1S5Y?^WU_S(G_;_P#^V]>H?L@?\D)T;_KO<_\ HYJ"3VBBBB@HIZQ_
MR"+[_K@__H)K\Z_V8_\ DNWA+_KO)_Z)DK]%-8_Y!%]_UP?_ -!-?F;\'?&5
ME\/OB5H?B'48KB:RL9'>1+55:0@QLHP&('5AU(H)9^GU%?.O_#<_@/\ Z!/B
M/_P&@_\ C]'_  W/X#_Z!/B/_P !H/\ X_0.Y]%45X%HG[:7@C7M:L-,M]+U
M])[VXCMHVEMX H9V"@G$Q.,GTKWV@ HHHH&?F_\ M.?\EV\6_P#7>/\ ]$QU
MT?\ PQG\2?\ GUT[_P #5_PKG/VG/^2[>+?^N\?_ *)CK](*"3\Z/&7[+_CS
MP-X:O-<U&SMI+*T :86MQYKJI."VT#H.,GMG/0'&E^RY\-_!WQ*\7SV7B6[G
M-W @GM=,4B..[4??!?.3CKM&#C)SP:_0&YMXKRWE@GC2:&52CQR#*NI&"".X
M(K\^?C=\-M2_9\^)UKJ>A22V^FRS?;-*NAR8R#EHB>Y7..>JD9ZF@#]!;2T@
ML+2&VMH8[>VA01QPQ*%1% P  .  .U2UP_P<^*5C\7/!5KK5MMBNQ^ZO;0')
M@F &X?[IZ@^A]0:[B@85R/Q9\>P_#3X?ZQX@E*M+;PE;>-O^6DS?+&OTW$9]
M@3VKKJ^,/VW_ (D?VEX@T[P;:3;K?3E%W>A3P9W'R*?]U#G_ +:>U ,^??#?
MB#5=.\66_B."W&J:E;70O";B)I5:7.X,X&,G=SUZBO:O^&POBC_T"]._\%\O
M_P 77T/^RQ\.?^%?_"FQDN(]FIZOC4+G(Y4,!Y:?@F#CL6:O8*!6/A*]_:V^
M)>HV<]I=:/IDUM/&T4L;Z=*0ZL,$'Y^A!(KR7X>^,+WX8^/-(UZ.*1)+*8/)
M 05,D1X=.?521^M?J/7RK^W'\.?M>E:7XTM(LRVA%C?%1_RS8DQ,?HQ*Y_VU
MH ^H=,U*VUG3;6_LY5N+2ZB6:&5>CHP!4CZ@BK-?.O[%WQ(_X23P)<>&;N;?
M?:(P\D,>6MG)*X]=K;E]@5%?15 PKYU_;G_Y)+I/_8<A_P#1%Q7T57SK^W/_
M ,DETG_L.0_^B+B@&?+OPU^ WBOXL:5=:CH$-K);6TWV>0SW C._:&X!]B*Z
M_P#X8S^)/_/KIW_@:O\ A7L_["?_ "3SQ!_V%?\ VC'7TM0(^)O#'[#'B>]G
M1M=UK3M,MLC<MKNN)<=Q@A5'IU-?4WPP^$GAWX2:,UCH=L1)+@W%[.0T\Y'0
MLV.@R<   9Z5V=% [!1110,*_-_XX_\ )P?B+_L*K_[+7Z05^;?QYG6U^/?B
MB9P2L>I!R!UP-IH)9^DE%?.O_#<_@/\ Z!/B/_P&@_\ C]'_  W/X#_Z!/B/
M_P !H/\ X_0.Y]%45\Z_\-S^ _\ H$^(_P#P&@_^/U[[HFK0Z_HUAJ=NKI!>
MV\=S&L@ 8*ZA@" 2,X/J: +M%%% SXG_ &[M*DA\?>'=3(/DW.F&V4]MT<KL
M?_1JU]!?LN>((?$/P0\.&.0/+9(]E,N[)1D8@ _\!*'Z$4_]HSX1M\7/ $EI
M9A!K5@YNK$L0-[8PT1)Z!AQ]0I/ KXV^$GQE\1_L_P#B2]M9;)YK-WV7^CW>
M8F#CC<"02CCIG!!'4=,!)^CE([K&A=V"JHR68X 'K7SS9?MP^!)[4/<:?K=M
M/CYHA;QOS[$2<CZXKRCXT?MAW7CK1+K0O#&GS:/IUTACN+RY<?:)$/5 JDA
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M*^"?V]O^2PZ/_P!@&'_THN*\C#0C.I:2/7Q$I0IWBS7_ .'@'B+_ *%72_\
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MG)W'[*L9/NGR']5KYU^+6F'2OB%K,>,+++]H4COO 8_J3^5>R_L_ZA]K\!F
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M[;<_\]Y?^^S45% 7)?MMS_SWE_[[-'VVY_Y[R_\ ?9J*B@+DOVVY_P">\O\
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MS_SWE_[[-'VVY_Y[R_\ ?9J*B@+DOVVY_P">\O\ WV:/MMS_ ,]Y?^^S45%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>F?#+_D!7'_7RW_H
M*5YG7IGPR_Y 5Q_U\M_Z"E95/A-*>YB?$[_D+6G_ %P_]F-<=78_$[_D+6G_
M %P_]F-<=3I_"B9?$PHHHK0D**** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#1\.?\C#I?_7U%
M_P"ABOIMONGZ5\R>'/\ D8=+_P"OJ+_T,5]-M]T_2N#$[HZZ.S,:BBBN,ZPH
MHHH **** "BBB@ HHHH **** "BBB@ H(# @C(/4&BB@1\,_&?P+_P (#X]O
M[&&,II\Y^TVAQQY;?PC_ '3E?P%2_!+QU_P@?CZRNIY-FG77^BW?/ 1CPQ_W
M6 /T!]:^A/VEO A\4^!SJELFZ^T<M/P.6A(_>#\  W_ 3ZU\?5^B8*K',,)R
MU-[6?^?ZG\C<1X*KPKG_ +;"JT;JI#M:_P /HG=6[6[GZ/<$9%%>:?L_^.SX
MU\ 6Z7$F_4=-(M+C)^9@!\CGZKQGN5:O2Z^!K4I4*DJ<MT?U1EV.I9EA*>,H
M_#-)_P# ]4]&%%%%8GI!1169XH\06WA3P]J&KWA/V>SA:5@#RQ'11[DX ^M5
M&+DU%;LRJU8482JU':,4VWV2W/G?]J[QU]IU"R\*VLN8[8"ZO IZR$?(I^BD
MG'^T/2O!M)TNYUO5+33[.,RW5U*L,2#NS' _G4FO:U<^(]:OM4O&WW5Y,TTA
M[ L<X'L.@'H*]M_94\"?VEK=WXGN8LV]B#!:EAP9F'S$?[JG_P ?'I7Z*N7+
M,%YI?>W_ ,'\#^0Y.MQGQ%I>U27_ (#!?Y17SD_,^BO!OABV\&>&-.T:U ,5
MI$$+XQO?JS'ZL2?QK9HHK\ZE)SDY2W9_7=&C##TXT:2M&*22[):)!1114FP4
M444 %%%% 'QU^T]_R56X_P"O2'^1KDOA+_R4WPQ_V$(?_0A76_M/?\E5N/\
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M-M%%%>V>&%?H/^Q+XKD\0_!E;">0O+H][+:+N.3Y9 D7\/G8#_=K\^*^T_\
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MW=E<QM%-!,H9)$(P5(/4$5\F_$G]@R&[N)KSP3K*62N=PTW5-QC3V6506 ]
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MFD8?[1^C>9IVDZJJ\Q2-;.1Z,-R_D5;\ZP/V==:^R>)+_368A+N#>H[;T/\
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MC7TO7S1\?/\ DH,O_7M%_(UAB/@-J7Q';_LW_P#("UC_ *^5_P#0:]@KQ_\
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MBG1K.W\^;5K**'&=[7"8/TYYKP'XR?$R#QC<0Z;IA9M,MG+F4@CSI.1D#^Z
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!-I]]/IE_;WEM(8KFWD6:*1>J
MLIR#^8K])M'UN/Q+X,L]7B 6.^L$N0HYV[X]V/PS7YIU^@?P89G^"/ATL2Q_
MLW&2<\#<!7%B5HF=^%>K1Q-%%%!L%%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "G1?ZU/J*;3HO]:GU% '34444$!1110 44
M44 %%%% !1110 4444 %%%% !1110 5Q'QM_Y)%XO_[!D_\ Z":[>N(^-O\
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M&%NK99_H[ 8]DST-<^(FH4VSHP\'.HCZIKX]_P""@NK*(/!>F*V7+75RZ^@
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MX?\ B*ZO;>&30M3B2214:1K.0!03@DDK@8]:^NZ*MT(NUB55:$C18T5%&U5
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MVV[LS/$?ARQ\5Z1-IVH1>;!)R".&1NS*>Q%?/OBKX%:_HL\CZ=&-7L\_*T1
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7Z!
M?!7_ )(AX=_[!Q_]FK\_:_0+X*_\D0\._P#8./\ [-7'B?A7J=N%^)^AQ5%%
M%(Z HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *],^&7_ " KC_KY;_T%*\SKTSX9?\@*X_Z^6_\
M04K*I\)I3W,3XG?\A:T_ZX?^S&N.KL?B=_R%K3_KA_[,:XZG3^%$R^)A1116
MA(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'<RIMWE.6[7:*>_96]U?@;/PY\$V_P /O"-CHT!$CQKOGF _ULIY9OIG@>P
MKI:**^!G.523G)W;/ZHPV'I82C##T5:,4DEV2"BBBH.D**** "BBB@ HHHH
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M0-,X+/<K^^8>BQ]0?=L?CTKZJ\(>#M*\#:-%IFD6PM[=.68\O*V.6<]R<?\
MZJY\=F=+#4_98=WEMILCU>&N#,=G&*6.S6+C2O=\U^:;^>MGU;W6W=:UM;16
M=M%;P1K%!$@CCC48"J!@ >P%2445\*?T\DHJR"BBB@H**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MY\'?]?A_]%M7Z>5^8?[,O_)>?!W_ %^'_P!%M7Z>5YF-^->AZ>"^!^I\=?\
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M&2**VC(<:+:R[VD/I+(IP![(3G^\*^R+>WBM((X((TAAB4(D<:A510,  #@
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M)*YI/!PEK%V/Q[M+.>_N%@M8)+F=\[8H4+,V!DX ]@37VC^QA\"=>\':I?\
MB_Q'8RZ5)-:FSLK*Y4I,59E9Y'4\K]T  \G+' XS]9T4JN*=2/*E8=+"JG+F
M;N%?!O[>7B6/4_B;I.D1-N_LO3P9<'[LDK%L?]\JA_&OK[XL?%71?A#X3GUG
M5Y07P4M;-3^\N9<<(H_F>@'/U_,'Q=XIO_&WB?4]=U.3S;Z_G:>4CH">BCT
M& /8"KP=-N7.]D1C*B4>3J9-%%%>N>0%%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7U!
M\)_^2>:-_P!<V_\ 0VKY?KZ@^$__ "3S1O\ KFW_ *&U8U=CHH?$SK:***P.
MT**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#E_B?J']F> -<F#;2UN801ZN0G_LU?+&@Z?\ VMKN
MG66,_:;B.' _VF _K7U?XY\)#QKH#Z6UVUFCR*[2*FXD*<XQD=\?E7&>&/@/
M:^&]?LM3_M:2Z-J_F")H H8XXYW>O-<E6G*<E;8WIS48L]3[4445UF 4444
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MM-=2>7#$\SXSMC4L?R%27&FW=HF^>UFA3.-TD949^IKW']B?_DNME_UXW/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4Z+_ %J?44VG1?ZU/J*
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M6=/X6?8?_#PO_J0/_*S_ /:*/^'A?_4@?^5G_P"T5\>45E]5H]OS-?K5;O\
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M_P"AM6-78Z*'Q,ZVBBBL#M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M9,27.HS.+:QM7.!),03EN^U0"QQZ 9&:_.?Q1\5?%_C+5'U#5_$6H7-PS%E
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ K] O@K_R1#P[_ -@X_P#LU?G[7Z!?!7_DB'AW_L''_P!FKCQ/PKU.W"_$
M_0XJBBBD= 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %>F?#+_D!7'_7RW_H*5YG7IGPR_Y 5Q_U
M\M_Z"E95/A-*>YB?$[_D+6G_ %P_]F-<=78_$[_D+6G_ %P_]F-<=3I_"B9?
M$PHHHK0D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@#1\.?\C#I?_7U%_P"ABOIMONGZ5\R>
M'/\ D8=+_P"OJ+_T,5]-M]T_2N#$[HZZ.S,:BBBN,ZPHHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "G1?ZU/J*;3HO\ 6I]10!TU%%%!
M 4444 %%%% !1110 4444 %%%% !1110 4444 %<1\;?^21>+_\ L&3_ /H)
MKMZXCXV_\DB\7_\ 8,G_ /035P^)$3^%GY74445]*?-!1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7U!\)_\ DGFC
M?]<V_P#0VKY?KZ@^$_\ R3S1O^N;?^AM6-78Z*'Q,ZVBBBL#M"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ K7\)?\C)I_P#UT_I616OX2_Y&33_^NG]*E[,I;HZOXV?\DD\6_P#8.E_E
M7YX5^A_QL_Y))XM_[!TO\J_/"KPOPLYL5\2"BBBNPX0HHHH **** />/V)_^
M2ZV7_7C<_P#H->W_ +?G_).?#O\ V%O_ &B]>(?L3_\ )=;+_KQN?_0:]O\
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M^OBZ_P#08ZY+]@GPA=W?C;7/$K1NNGV=D;)9",!YI&5L ]\*A)'^TOKSUO\
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M/X#]37R'7WU^VU\,[OQG\/['7=.@>XO- D>26*-<L;=P/,8 ==I1#[#<>U?
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ K] O@K_R1#P[_ -@X_P#LU?G[
M7Z!?!7_DB'AW_L''_P!FKCQ/PKU.W"_$_0XJBBBD= 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M>F?#+_D!7'_7RW_H*5YG7IGPR_Y 5Q_U\M_Z"E95/A-*>YB?$[_D+6G_ %P_
M]F-<=78_$[_D+6G_ %P_]F-<=3I_"B9?$PHHHK0D**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@#1\.?\C#I?_7U%_P"ABOIMONGZ5\R>'/\ D8=+_P"OJ+_T,5]-M]T_2N#$
M[HZZ.S,:BBBN,ZPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "G1?ZU/J*;3HO\ 6I]10!TU%%%! 4444 %%%% !1110 4444 %%%% !
M1110 4444 %<1\;?^21>+_\ L&3_ /H)KMZXCXV_\DB\7_\ 8,G_ /035P^)
M$3^%GY74445]*?-!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !7U!\)_\ DGFC?]<V_P#0VKY?KZ@^$_\ R3S1O^N;
M?^AM6-78Z*'Q,ZVBBBL#M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ K7\)?\C)I_P#UT_I616OX2_Y&
M33_^NG]*E[,I;HZOXV?\DD\6_P#8.E_E7YX5^A_QL_Y))XM_[!TO\J_/"KPO
MPLYL5\2"BBBNPX0HHHH **** />/V)_^2ZV7_7C<_P#H->W_ +?G_).?#O\
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M*>SOO&.OWEG.ACEM[C5)WCD4]592Q!!]#5UJ+J2BT]B:-94XRBUN<O5S0_\
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MBQ_#FJ%=U./)!1.&I/GFY!1116AF%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% &CX<_Y&'2_^OJ+_ -#%?3;?=/TKYD\.?\C#I?\
MU]1?^ABOIMONGZ5P8G='71V9C4445QG6%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4Z+_6I]13:=%_K4^HH Z:BBB@@**** "BBB@
MHHHH **** "BBB@ HHHH **** "N(^-O_)(O%_\ V#)__037;UQ'QM_Y)%XO
M_P"P9/\ ^@FKA\2(G\+/RNHHHKZ4^:"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "OJ#X3_P#)/-&_ZYM_Z&U?+]?4
M'PG_ .2>:-_US;_T-JQJ['10^)G6T445@=H4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %:_A+_D9-/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^@W
MP=MWM?@GX<2088Z6K@>S*6'Z$5\%^&/#]QXI\0Z=H]K_ *^\G6%2>BY/+'V
MR3]*_2--.@TCP\MA;+LMK6U$$2^B*FT#\@*XL2]D=^$CJY'B]%%%!L%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !7IGPR_Y 5Q_U\M_Z"E>9UZ9\,O\ D!7'_7RW_H*5E4^$TI[F
M)\3O^0M:?]</_9C7'5V/Q._Y"UI_UP_]F-<=3I_"B9?$PHHHK0D**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@#1\.?\ (PZ7_P!?47_H8KZ;;[I^E?,GAS_D8=+_ .OJ+_T,
M5]-M]T_2N#$[HZZ.S,:BBBN,ZPHHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "G1?ZU/J*;3HO]:GU% '34444$!1110 4444 %%%% !1
M110 4444 %%%% !1110 5Q'QM_Y)%XO_ .P9/_Z":[>N(^-O_)(O%_\ V#)_
M_035P^)$3^%GY74445]*?-!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !7U!\)_P#DGFC?]<V_]#:OE^OJ#X3_ /)/
M-&_ZYM_Z&U8U=CHH?$SK:***P.T**** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_%__ $"/_)F'_P"+H_X4WXO_ .@1_P"3,/\ \71S+N')+L<;179?\*;\7_\
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MF8?_ (NC_A3?B_\ Z!'_ ),P_P#Q=',NX<DNQQM%=E_PIOQ?_P! C_R9A_\
MBZ/^%-^+_P#H$?\ DS#_ /%T<R[AR2['&T5V7_"F_%__ $"/_)F'_P"+H_X4
MWXO_ .@1_P"3,/\ \71S+N')+L<;179?\*;\7_\ 0(_\F8?_ (NC_A3?B_\
MZ!'_ ),P_P#Q=',NX<DNQQM%=E_PIOQ?_P! C_R9A_\ BZ/^%-^+_P#H$?\
MDS#_ /%T<R[AR2['&T5V7_"F_%__ $"/_)F'_P"+H_X4WXO_ .@1_P"3,/\
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M7_\ 0(_\F8?_ (NC_A3?B_\ Z!'_ ),P_P#Q=',NX<DNQQM%=E_PIOQ?_P!
MC_R9A_\ BZ/^%-^+_P#H$?\ DS#_ /%T<R[AR2['&T5V7_"F_%__ $"/_)F'
M_P"+H_X4WXO_ .@1_P"3,/\ \71S+N')+L<;179?\*;\7_\ 0(_\F8?_ (NC
M_A3?B_\ Z!'_ ),P_P#Q=',NX<DNQQM%=E_PIOQ?_P! C_R9A_\ BZ/^%-^+
M_P#H$?\ DS#_ /%T<R[AR2['&T5V7_"F_%__ $"/_)F'_P"+H_X4WXO_ .@1
M_P"3,/\ \71S+N')+L<;179?\*;\7_\ 0(_\F8?_ (NC_A3?B_\ Z!'_ ),P
M_P#Q=',NX<DNQQM%=E_PIOQ?_P! C_R9A_\ BZ/^%-^+_P#H$?\ DS#_ /%T
M<R[AR2['&T5V7_"F_%__ $"/_)F'_P"+H_X4WXO_ .@1_P"3,/\ \71S+N')
M+L<;179?\*;\7_\ 0(_\F8?_ (NC_A3?B_\ Z!'_ ),P_P#Q=',NX<DNQQM%
M=E_PIOQ?_P! C_R9A_\ BZ/^%-^+_P#H$?\ DS#_ /%T<R[AR2['&T5V7_"F
M_%__ $"/_)F'_P"+H_X4WXO_ .@1_P"3,/\ \71S+N')+L<;179?\*;\7_\
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MUP_]F-<=3I_"B9?$PHHHK0D**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#1\.?\ (PZ7_P!?
M47_H8KZ;;[I^E?,GAS_D8=+_ .OJ+_T,5]-M]T_2N#$[HZZ.S,:BBBN,ZPHH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "G1?ZU/J*;3H
MO]:GU% '34444$!1110 4444 %%%% !1110 4444 %%%% !1110 5Q'QM_Y)
M%XO_ .P9/_Z":[>N(^-O_)(O%_\ V#)__035P^)$3^%GY74445]*?-!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
MU!\)_P#DGFC?]<V_]#:OE^OJ#X3_ /)/-&_ZYM_Z&U8U=CHH?$SK:***P.T*
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "M?PE_R,FG_]=/Z5D5K^$O\ D9-/_P"NG]*E[,I;H].\3?\
M(OZC_P!<'_E7C5>R^)O^1?U'_K@_\J\:K*ELRZFX4445N9!1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !73?#S_D9$_P"N3_RKF:Z;X>?\
MC(G_ %R?^51/X65'='8^/_\ D5[C_>3_ -"%>45ZOX__ .17N/\ >3_T(5Y1
M44OA+J;A1116QD%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110!;T?_D+67_7=/_0A7LU]_P >
M-S_UR;^5>,Z/_P A:R_Z[I_Z$*]FOO\ CQN?^N3?RKFJ[HVI[,\.HHHKI,0H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KZ@^$__)/-&_ZYM_Z&
MU?+]?4'PG_Y)YHW_ %S;_P!#:L:NQT4/B9UM%%%8':%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6OX2
M_P"1DT__ *Z?TK(K7\)?\C)I_P#UT_I4O9E+='IWB;_D7]1_ZX/_ "KQJO9?
M$W_(OZC_ -<'_E7C594MF74W"BBBMS(**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH MZ/_ ,A:R_Z[I_Z$*]FOO^/&Y_ZY-_*O&='_ .0M
M9?\ 7=/_ $(5[-??\>-S_P!<F_E7-5W1M3V9X=111728A1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 5Z9\,O^0%<?]?+?^@I7F=>F?#+_D!7'_7RW_H*5E4^$TI[F)\3O^0M:?\
M7#_V8UQU=C\3O^0M:?\ 7#_V8UQU.G\*)E\3"BBBM"0HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** -'PY_R,.E_]?47_ *&*^FV^Z?I7S)X<_P"1ATO_ *^HO_0Q7TVWW3]*
MX,3NCKH[,QJ***XSK"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *=%_K4^HIM.B_P!:GU% '34444$!1110 4444 %%%% !1110 444
M4 %%%% !1110 5Q'QM_Y)%XO_P"P9/\ ^@FNWKB/C;_R2+Q?_P!@R?\ ]!-7
M#XD1/X6?E=1117TI\T%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %?4'PG_P"2>:-_US;_ -#:OE^OJ#X3_P#)/-&_
MZYM_Z&U8U=CHH?$SK:***P.T**** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "M?PE_R,FG_ /73^E9%:_A+
M_D9-/_ZZ?TJ7LRENCT[Q-_R+^H_]<'_E7C5>R^)O^1?U'_K@_P#*O&JRI;,N
MIN%%%%;F04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5TW
MP\_Y&1/^N3_RKF:Z;X>?\C(G_7)_Y5$_A94=T=CX_P#^17N/]Y/_ $(5Y17J
M_C__ )%>X_WD_P#0A7E%12^$NIN%%%%;&04444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %O1_
M^0M9?]=T_P#0A7LU]_QXW/\ UR;^5>,Z/_R%K+_KNG_H0KV:^_X\;G_KDW\J
MYJNZ-J>S/#J***Z3$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "O3/AE_P @*X_Z^6_]!2O,Z],^
M&7_("N/^OEO_ $%*RJ?":4]S$^)W_(6M/^N'_LQKCJ['XG?\A:T_ZX?^S&N.
MIT_A1,OB84445H2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!H^'/\ D8=+_P"OJ+_T,5]-
MM]T_2OF3PY_R,.E_]?47_H8KZ;;[I^E<&)W1UT=F8U%%%<9UA1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[_P)?_&C_A)]:_Z"U]_X$O\ XT?V)4_G0?VE#^5GT/17SQ_PD^M?]!:^_P#
ME_\ &C_A)]:_Z"U]_P"!+_XT?V)4_G0?VE#^5GT/17SQ_P )/K7_ $%K[_P)
M?_&C_A)]:_Z"U]_X$O\ XT?V)4_G0?VE#^5GT/17SQ_PD^M?]!:^_P# E_\
M&C_A)]:_Z"U]_P"!+_XT?V)4_G0?VE#^5GT/17SQ_P )/K7_ $%K[_P)?_&C
M_A)]:_Z"U]_X$O\ XT?V)4_G0?VE#^5GT/17SQ_PD^M?]!:^_P# E_\ &C_A
M)]:_Z"U]_P"!+_XT?V)4_G0?VE#^5GT/17SQ_P )/K7_ $%K[_P)?_&C_A)]
M:_Z"U]_X$O\ XT?V)4_G0?VE#^5GT/17SQ_PD^M?]!:^_P# E_\ &C_A)]:_
MZ"U]_P"!+_XT?V)4_G0?VE#^5GT/17SQ_P )/K7_ $%K[_P)?_&C_A)]:_Z"
MU]_X$O\ XT?V)4_G0?VE#^5GT/17SQ_PD^M?]!:^_P# E_\ &C_A)]:_Z"U]
M_P"!+_XT?V)4_G0?VE#^5GT/17SQ_P )/K7_ $%K[_P)?_&C_A)]:_Z"U]_X
M$O\ XT?V)4_G0?VE#^5GT/17SQ_PD^M?]!:^_P# E_\ &C_A)]:_Z"U]_P"!
M+_XT?V)4_G0?VE#^5GT/17SQ_P )/K7_ $%K[_P)?_&C_A)]:_Z"U]_X$O\
MXT?V)4_G0?VE#^5GT/17SQ_PD^M?]!:^_P# E_\ &C_A)]:_Z"U]_P"!+_XT
M?V)4_G0?VE#^5GT/17SQ_P )/K7_ $%K[_P)?_&C_A)]:_Z"U]_X$O\ XT?V
M)4_G0?VE#^5GT/17SQ_PD^M?]!:^_P# E_\ &C_A)]:_Z"U]_P"!+_XT?V)4
M_G0?VE#^5GT/17SQ_P )/K7_ $%K[_P)?_&C_A)]:_Z"U]_X$O\ XT?V)4_G
M0?VE#^5GT/17SQ_PD^M?]!:^_P# E_\ &C_A)]:_Z"U]_P"!+_XT?V)4_G0?
MVE#^5GT/17SQ_P )/K7_ $%K[_P)?_&C_A)]:_Z"U]_X$O\ XT?V)4_G0?VE
M#^5GT/17SQ_PD^M?]!:^_P# E_\ &C_A)]:_Z"U]_P"!+_XT?V)4_G0?VE#^
M5GT/17SQ_P )/K7_ $%K[_P)?_&C_A)]:_Z"U]_X$O\ XT?V)4_G0?VE#^5G
MT/17SQ_PD^M?]!:^_P# E_\ &C_A)]:_Z"U]_P"!+_XT?V)4_G0?VE#^5GT/
M17SQ_P )/K7_ $%K[_P)?_&C_A)]:_Z"U]_X$O\ XT?V)4_G0?VE#^5GT/17
MSQ_PD^M?]!:^_P# E_\ &C_A)]:_Z"U]_P"!+_XT?V)4_G0?VE#^5GT/17SQ
M_P )/K7_ $%K[_P)?_&C_A)]:_Z"U]_X$O\ XT?V)4_G0?VE#^5GT/17SQ_P
MD^M?]!:^_P# E_\ &C_A)]:_Z"U]_P"!+_XT?V)4_G0?VE#^5GT/17SQ_P )
M/K7_ $%K[_P)?_&C_A)]:_Z"U]_X$O\ XT?V)4_G0?VE#^5GT/17SQ_PD^M?
M]!:^_P# E_\ &C_A)]:_Z"U]_P"!+_XT?V)4_G0?VE#^5GT/17SQ_P )/K7_
M $%K[_P)?_&C_A)]:_Z"U]_X$O\ XT?V)4_G0?VE#^5GT/17SQ_PD^M?]!:^
M_P# E_\ &C_A)]:_Z"U]_P"!+_XT?V)4_G0?VE#^5GT/17SQ_P )/K7_ $%K
M[_P)?_&C_A)]:_Z"U]_X$O\ XT?V)4_G0?VE#^5GT/17SQ_PD^M?]!:^_P#
ME_\ &C_A)]:_Z"U]_P"!+_XT?V)4_G0?VE#^5GT/17SQ_P )/K7_ $%K[_P)
M?_&C_A)]:_Z"U]_X$O\ XT?V)4_G0?VE#^5GT/17SQ_PD^M?]!:^_P# E_\
M&C_A)]:_Z"U]_P"!+_XT?V)4_G0?VE#^5GT/17SQ_P )/K7_ $%K[_P)?_&C
M_A)]:_Z"U]_X$O\ XT?V)4_G0?VE#^5GT/17SQ_PD^M?]!:^_P# E_\ &C_A
M)]:_Z"U]_P"!+_XT?V)4_G0?VE#^5GT/17SQ_P )/K7_ $%K[_P)?_&C_A)]
M:_Z"U]_X$O\ XT?V)4_G0?VE#^5GT/17SQ_PD^M?]!:^_P# E_\ &C_A)]:_
MZ"U]_P"!+_XT?V)4_G0?VE#^5GT/17SQ_P )/K7_ $%K[_P)?_&C_A)]:_Z"
MU]_X$O\ XT?V)4_G0?VE#^5GT/17SQ_PD^M?]!:^_P# E_\ &C_A)]:_Z"U]
M_P"!+_XT?V)4_G0?VE#^5GT/17SQ_P )/K7_ $%K[_P)?_&C_A)]:_Z"U]_X
M$O\ XT?V)4_G0?VE#^5GT/7U!\)_^2>:-_US;_T-J_-C_A)]:_Z"U]_X$O\
MXUJVGQ1\9Z?;I;VOB[7K:W3A(H=2F55^@#8%1/(JDE;G7XFM/-80=^5GZ?T5
M^8G_  M[QU_T.OB+_P &L_\ \71_PM[QU_T.OB+_ ,&L_P#\76?^K]7_ )^+
M[F;_ -LT_P"1GZ=T5^8G_"WO'7_0Z^(O_!K/_P#%T?\ "WO'7_0Z^(O_  :S
M_P#Q='^K]7_GXON8?VS3_D9^G=%?F)_PM[QU_P!#KXB_\&L__P 71_PM[QU_
MT.OB+_P:S_\ Q='^K]7_ )^+[F']LT_Y&?IW17YB?\+>\=?]#KXB_P#!K/\
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M[F']LT_Y&?IW17YB?\+>\=?]#KXB_P#!K/\ _%T?\+>\=?\ 0Z^(O_!K/_\
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MXON8?VS3_D9^G=%?F)_PM[QU_P!#KXB_\&L__P 71_PM[QU_T.OB+_P:S_\
MQ='^K]7_ )^+[F']LT_Y&?IW17YB?\+>\=?]#KXB_P#!K/\ _%T?\+>\=?\
M0Z^(O_!K/_\ %T?ZOU?^?B^YA_;-/^1GZ=T5^8G_  M[QU_T.OB+_P &L_\
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M ,&L_P#\71_J_5_Y^+[F']LT_P"1GZ=T5^8G_"WO'7_0Z^(O_!K/_P#%T?\
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MT.OB+_P:S_\ Q='^K]7_ )^+[F']LT_Y&?IW17YB?\+>\=?]#KXB_P#!K/\
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M[F']LT_Y&?IW17YB?\+>\=?]#KXB_P#!K/\ _%T?\+>\=?\ 0Z^(O_!K/_\
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MXON8?VS3_D9^G=%?F)_PM[QU_P!#KXB_\&L__P 71_PM[QU_T.OB+_P:S_\
MQ='^K]7_ )^+[F']LT_Y&?IW17YB?\+>\=?]#KXB_P#!K/\ _%T?\+>\=?\
M0Z^(O_!K/_\ %T?ZOU?^?B^YA_;-/^1GZ=T5^8G_  M[QU_T.OB+_P &L_\
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M ,&L_P#\71_J_5_Y^+[F']LT_P"1GZ=T5^8G_"WO'7_0Z^(O_!K/_P#%T?\
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MT.OB+_P:S_\ Q='^K]7_ )^+[F']LT_Y&?IW17YB?\+>\=?]#KXB_P#!K/\
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M/T[HK\Q/^%O>.O\ H=?$7_@UG_\ BZ/^%O>.O^AU\1?^#6?_ .+H_P!7ZO\
MS\7W,/[9I_R,_3NBOS$_X6]XZ_Z'7Q%_X-9__BZ/^%O>.O\ H=?$7_@UG_\
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M>.O^AU\1?^#6?_XNC_5^K_S\7W,/[9I_R,_3NBOS$_X6]XZ_Z'7Q%_X-9_\
MXNC_ (6]XZ_Z'7Q%_P"#6?\ ^+H_U?J_\_%]S#^V:?\ (S].Z*_,3_A;WCK_
M *'7Q%_X-9__ (NC_A;WCK_H=?$7_@UG_P#BZ/\ 5^K_ ,_%]S#^V:?\C/T[
MHK\Q/^%O>.O^AU\1?^#6?_XNC_A;WCK_ *'7Q%_X-9__ (NC_5^K_P _%]S#
M^V:?\C/T[HK\Q/\ A;WCK_H=?$7_ (-9_P#XNC_A;WCK_H=?$7_@UG_^+H_U
M?J_\_%]S#^V:?\C/T[HK\Q/^%O>.O^AU\1?^#6?_ .+H_P"%O>.O^AU\1?\
M@UG_ /BZ/]7ZO_/Q?<P_MFG_ ",_3NBOS$_X6]XZ_P"AU\1?^#6?_P"+H_X6
M]XZ_Z'7Q%_X-9_\ XNC_ %?J_P#/Q?<P_MFG_(S].Z*_,3_A;WCK_H=?$7_@
MUG_^+H_X6]XZ_P"AU\1?^#6?_P"+H_U?J_\ /Q?<P_MFG_(S].Z*_,3_ (6]
MXZ_Z'7Q%_P"#6?\ ^+H_X6]XZ_Z'7Q%_X-9__BZ/]7ZO_/Q?<P_MFG_(S].Z
M*_,3_A;WCK_H=?$7_@UG_P#BZ/\ A;WCK_H=?$7_ (-9_P#XNC_5^K_S\7W,
M/[9I_P C/U&T?_D+67_7=/\ T(5[-??\>-S_ -<F_E7XK)\8/'L;JZ>-O$:.
MIR&75IP0?7[]7&^/?Q-92K?$7Q8RD8(.N76"/^^ZQGPY5DU^\7W,TCG=.*MR
M,_2RBOS$_P"%O>.O^AU\1?\ @UG_ /BZ/^%O>.O^AU\1?^#6?_XNMO\ 5^K_
M ,_%]S,_[9I_R,_3NBOS$_X6]XZ_Z'7Q%_X-9_\ XNC_ (6]XZ_Z'7Q%_P"#
M6?\ ^+H_U?J_\_%]S#^V:?\ (S].Z*_,3_A;WCK_ *'7Q%_X-9__ (NC_A;W
MCK_H=?$7_@UG_P#BZ/\ 5^K_ ,_%]S#^V:?\C/T[HK\Q/^%O>.O^AU\1?^#6
M?_XNC_A;WCK_ *'7Q%_X-9__ (NC_5^K_P _%]S#^V:?\C/T[HK\Q/\ A;WC
MK_H=?$7_ (-9_P#XNC_A;WCK_H=?$7_@UG_^+H_U?J_\_%]S#^V:?\C/T[HK
M\Q/^%O>.O^AU\1?^#6?_ .+H_P"%O>.O^AU\1?\ @UG_ /BZ/]7ZO_/Q?<P_
MMFG_ ",_3NBOS$_X6]XZ_P"AU\1?^#6?_P"+H_X6]XZ_Z'7Q%_X-9_\ XNC_
M %?J_P#/Q?<P_MFG_(S].Z*_,3_A;WCK_H=?$7_@UG_^+H_X6]XZ_P"AU\1?
M^#6?_P"+H_U?J_\ /Q?<P_MFG_(S].Z*_,3_ (6]XZ_Z'7Q%_P"#6?\ ^+H_
MX6]XZ_Z'7Q%_X-9__BZ/]7ZO_/Q?<P_MFG_(S].Z*_,3_A;WCK_H=?$7_@UG
M_P#BZ/\ A;WCK_H=?$7_ (-9_P#XNC_5^K_S\7W,/[9I_P C/T[HK\Q/^%O>
M.O\ H=?$7_@UG_\ BZ/^%O>.O^AU\1?^#6?_ .+H_P!7ZO\ S\7W,/[9I_R,
M_3NBOS$_X6]XZ_Z'7Q%_X-9__BZ/^%O>.O\ H=?$7_@UG_\ BZ/]7ZO_ #\7
MW,/[9I_R,_3NBOS$_P"%O>.O^AU\1?\ @UG_ /BZ/^%O>.O^AU\1?^#6?_XN
MC_5^K_S\7W,/[9I_R,_3NBOS$_X6]XZ_Z'7Q%_X-9_\ XNC_ (6]XZ_Z'7Q%
M_P"#6?\ ^+H_U?J_\_%]S#^V:?\ (S].Z*_,3_A;WCK_ *'7Q%_X-9__ (NC
M_A;WCK_H=?$7_@UG_P#BZ/\ 5^K_ ,_%]S#^V:?\C/T[HK\Q/^%O>.O^AU\1
M?^#6?_XNC_A;WCK_ *'7Q%_X-9__ (NC_5^K_P _%]S#^V:?\C/T[HK\Q/\
MA;WCK_H=?$7_ (-9_P#XNC_A;WCK_H=?$7_@UG_^+H_U?J_\_%]S#^V:?\C/
MT[HK\Q/^%O>.O^AU\1?^#6?_ .+H_P"%O>.O^AU\1?\ @UG_ /BZ/]7ZO_/Q
M?<P_MFG_ ",_3NBOS$_X6]XZ_P"AU\1?^#6?_P"+H_X6]XZ_Z'7Q%_X-9_\
MXNC_ %?J_P#/Q?<P_MFG_(S].Z*_,3_A;WCK_H=?$7_@UG_^+H_X6]XZ_P"A
MU\1?^#6?_P"+H_U?J_\ /Q?<P_MFG_(S].Z*_,3_ (6]XZ_Z'7Q%_P"#6?\
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M .+H_P!7ZO\ S\7W,/[9I_R,_3NBOS$_X6]XZ_Z'7Q%_X-9__BZ/^%O>.O\
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M.O\ H=?$7_@UG_\ BZ/]7ZO_ #\7W,/[9I_R,_3NBOS$_P"%O>.O^AU\1?\
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M_P"BE>,/_!]=?_'*/^&@_BG_ -%*\8?^#ZZ_^.4?ZK5O^?J^YA_K!2_Y]O\
M _;NBOQ$_P"&@_BG_P!%*\8?^#ZZ_P#CE'_#0?Q3_P"BE>,/_!]=?_'*/]5J
MW_/U?<P_U@I?\^W^!^W=%?B)_P -!_%/_HI7C#_P?77_ ,<H_P"&@_BG_P!%
M*\8?^#ZZ_P#CE'^JU;_GZON8?ZP4O^?;_ _;NBOQ$_X:#^*?_12O&'_@^NO_
M (Y1_P -!_%/_HI7C#_P?77_ ,<H_P!5JW_/U?<P_P!8*7_/M_@?MW17XB?\
M-!_%/_HI7C#_ ,'UU_\ '*/^&@_BG_T4KQA_X/KK_P".4?ZK5O\ GZON8?ZP
M4O\ GV_P/V[HK\1/^&@_BG_T4KQA_P"#ZZ_^.4?\-!_%/_HI7C#_ ,'UU_\
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MMW17XB?\-!_%/_HI7C#_ ,'UU_\ '*/^&@_BG_T4KQA_X/KK_P".4?ZK5O\
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M?77_ ,<H_P!5JW_/U?<P_P!8*7_/M_@?MW17XB?\-!_%/_HI7C#_ ,'UU_\
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M_#E6A2G5=1-13>SZ*YM1SRG6J1IJ#U:7WGZXT445\@?1A1110 4444 %%%%
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M?_S_ )_^!2_S#^R,N_Z!X?\ @$?\CDO^%2>"_P#H5]+_ / 9?\*/^%2>"_\
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M?^ 1_P CDO\ A4G@O_H5]+_\!E_PH_X5)X+_ .A7TO\ \!E_PKK:*/[4Q_\
MS_G_ .!2_P P_LC+O^@>'_@$?\CDO^%2>"_^A7TO_P !E_PH_P"%2>"_^A7T
MO_P&7_"NMHH_M3'_ //^?_@4O\P_LC+O^@>'_@$?\CDO^%2>"_\ H5]+_P#
M9?\ "C_A4G@O_H5]+_\  9?\*ZVBC^U,?_S_ )_^!2_S#^R,N_Z!X?\ @$?\
MCDO^%2>"_P#H5]+_ / 9?\*/^%2>"_\ H5]+_P# 9?\ "NMHH_M3'_\ /^?_
M (%+_,/[(R[_ *!X?^ 1_P CDO\ A4G@O_H5]+_\!E_PH_X5)X+_ .A7TO\
M\!E_PKK:*/[4Q_\ S_G_ .!2_P P_LC+O^@>'_@$?\CDO^%2>"_^A7TO_P !
ME_PH_P"%2>"_^A7TO_P&7_"NMHH_M3'_ //^?_@4O\P_LC+O^@>'_@$?\CDO
M^%2>"_\ H5]+_P# 9?\ "C_A4G@O_H5]+_\  9?\*ZVBC^U,?_S_ )_^!2_S
M#^R,N_Z!X?\ @$?\CDO^%2>"_P#H5]+_ / 9?\*/^%2>"_\ H5]+_P# 9?\
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M"_\ H5]+_P# 9?\ "NMHH_M3'_\ /^?_ (%+_,/[(R[_ *!X?^ 1_P CDO\
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M_P# 9?\ "C_A4G@O_H5]+_\  9?\*ZVBC^U,?_S_ )_^!2_S#^R,N_Z!X?\
M@$?\CDO^%2>"_P#H5]+_ / 9?\*/^%2>"_\ H5]+_P# 9?\ "NMHH_M3'_\
M/^?_ (%+_,/[(R[_ *!X?^ 1_P CDO\ A4G@O_H5]+_\!E_PH_X5)X+_ .A7
MTO\ \!E_PKK:*/[4Q_\ S_G_ .!2_P P_LC+O^@>'_@$?\CDO^%2>"_^A7TO
M_P !E_PH_P"%2>"_^A7TO_P&7_"NMHH_M3'_ //^?_@4O\P_LC+O^@>'_@$?
M\CDO^%2>"_\ H5]+_P# 9?\ "C_A4G@O_H5]+_\  9?\*ZVBC^U,?_S_ )_^
M!2_S#^R,N_Z!X?\ @$?\CDO^%2>"_P#H5]+_ / 9?\*/^%2>"_\ H5]+_P#
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M2>"_^A7TO_P&7_"NMHH_M3'_ //^?_@4O\P_LC+O^@>'_@$?\CDO^%2>"_\
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M?_@4O\P_LC+O^@>'_@$?\CDO^%2>"_\ H5]+_P# 9?\ "C_A4G@O_H5]+_\
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M[_P C_PKTBBOJ_KV*_Y^R_\  G_F?G?U+"_\^H_<O\CS?_AF[X6?]$_\/?\
M@!'_ (4?\,W?"S_HG_A[_P  (_\ "O2**/KV*_Y^R_\  G_F'U+"_P#/J/W+
M_(\W_P"&;OA9_P!$_P##W_@!'_A1_P ,W?"S_HG_ (>_\ (_\*](HH^O8K_G
M[+_P)_YA]2PO_/J/W+_(\W_X9N^%G_1/_#W_ ( 1_P"%'_#-WPL_Z)_X>_\
M "/_  KTBBCZ]BO^?LO_  )_YA]2PO\ SZC]R_R/-_\ AF[X6?\ 1/\ P]_X
M 1_X4?\ #-WPL_Z)_P"'O_ "/_"O2**/KV*_Y^R_\"?^8?4L+_SZC]R_R/-_
M^&;OA9_T3_P]_P" $?\ A1_PS=\+/^B?^'O_   C_P *](HH^O8K_G[+_P "
M?^8?4L+_ ,^H_<O\CS?_ (9N^%G_ $3_ ,/?^ $?^%'_  S=\+/^B?\ A[_P
M C_PKTBBCZ]BO^?LO_ G_F'U+"_\^H_<O\CS?_AF[X6?]$_\/?\ @!'_ (4?
M\,W?"S_HG_A[_P  (_\ "O2**/KV*_Y^R_\  G_F'U+"_P#/J/W+_(\W_P"&
M;OA9_P!$_P##W_@!'_A1_P ,W?"S_HG_ (>_\ (_\*](HH^O8K_G[+_P)_YA
M]2PO_/J/W+_(\W_X9N^%G_1/_#W_ ( 1_P"%'_#-WPL_Z)_X>_\  "/_  KT
MBBCZ]BO^?LO_  )_YA]2PO\ SZC]R_R/-_\ AF[X6?\ 1/\ P]_X 1_X4?\
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M_P"'O_ "/_"O2**/KV*_Y^R_\"?^8?4L+_SZC]R_R/-_^&;OA9_T3_P]_P"
M$?\ A1_PS=\+/^B?^'O_   C_P *](HH^O8K_G[+_P "?^8?4L+_ ,^H_<O\
MCS?_ (9N^%G_ $3_ ,/?^ $?^%'_  S=\+/^B?\ A[_P C_PKTBBCZ]BO^?L
MO_ G_F'U+"_\^H_<O\CS?_AF[X6?]$_\/?\ @!'_ (4?\,W?"S_HG_A[_P
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M_#W_ ( 1_P"%'_#-WPL_Z)_X>_\  "/_  KTBBCZ]BO^?LO_  )_YA]2PO\
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M>_\  "/_  KTBBCZ]BO^?LO_  )_YA]2PO\ SZC]R_R/-_\ AF[X6?\ 1/\
MP]_X 1_X4?\ #-WPL_Z)_P"'O_ "/_"O2**/KV*_Y^R_\"?^8?4L+_SZC]R_
MR/-_^&;OA9_T3_P]_P" $?\ A1_PS=\+/^B?^'O_   C_P *](HH^O8K_G[+
M_P "?^8?4L+_ ,^H_<O\CS?_ (9N^%G_ $3_ ,/?^ $?^%'_  S=\+/^B?\
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MO_ "/_"O2**/KV*_Y^R_\"?^8?4L+_SZC]R_R/-_^&;OA9_T3_P]_P" $?\
MA1_PS=\+/^B?^'O_   C_P *](HH^O8K_G[+_P "?^8?4L+_ ,^H_<O\CS?_
M (9N^%G_ $3_ ,/?^ $?^%'_  S=\+/^B?\ A[_P C_PKTBBCZ]BO^?LO_ G
M_F'U+"_\^H_<O\CS?_AF[X6?]$_\/?\ @!'_ (4?\,W?"S_HG_A[_P  (_\
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M?^!/_,/J6%_Y]1^Y?Y'F_P#PS=\+/^B?^'O_   C_P */^&;OA9_T3_P]_X
M1_X5Z111]>Q7_/V7_@3_ ,P^I87_ )]1^Y?Y'F__  S=\+/^B?\ A[_P C_P
MH_X9N^%G_1/_  ]_X 1_X5Z111]>Q7_/V7_@3_S#ZEA?^?4?N7^1YO\ \,W?
M"S_HG_A[_P  (_\ "C_AF[X6?]$_\/?^ $?^%>D44?7L5_S]E_X$_P#,/J6%
M_P"?4?N7^1YO_P ,W?"S_HG_ (>_\ (_\*/^&;OA9_T3_P /?^ $?^%>D44?
M7L5_S]E_X$_\P^I87_GU'[E_D>;_ /#-WPL_Z)_X>_\  "/_  H_X9N^%G_1
M/_#W_@!'_A7I%%'U[%?\_9?^!/\ S#ZEA?\ GU'[E_D>;_\ #-WPL_Z)_P"'
MO_ "/_"C_AF[X6?]$_\ #W_@!'_A7I%%'U[%?\_9?^!/_,/J6%_Y]1^Y?Y'F
M_P#PS=\+/^B?^'O_   C_P */^&;OA9_T3_P]_X 1_X5Z111]>Q7_/V7_@3_
M ,P^I87_ )]1^Y?Y'F__  S=\+/^B?\ A[_P C_PH_X9N^%G_1/_  ]_X 1_
MX5Z111]>Q7_/V7_@3_S#ZEA?^?4?N7^1YO\ \,W?"S_HG_A[_P  (_\ "C_A
MF[X6?]$_\/?^ $?^%>D44?7L5_S]E_X$_P#,/J6%_P"?4?N7^1YO_P ,W?"S
M_HG_ (>_\ (_\*/^&;OA9_T3_P /?^ $?^%>D44?7L5_S]E_X$_\P^I87_GU
M'[E_D>;_ /#-WPL_Z)_X>_\  "/_  H_X9N^%G_1/_#W_@!'_A7I%%'U[%?\
M_9?^!/\ S#ZEA?\ GU'[E_D>;_\ #-WPL_Z)_P"'O_ "/_"C_AF[X6?]$_\
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M?^!/_,/J6%_Y]1^Y?Y'F_P#PS=\+/^B?^'O_   C_P */^&;OA9_T3_P]_X
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M_9?^!/\ S#ZEA?\ GU'[E_D>;_\ #-WPL_Z)_P"'O_ "/_"C_AF[X6?]$_\
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M?^!/_,/J6%_Y]1^Y?Y'F_P#PS=\+/^B?^'O_   C_P */^&;OA9_T3_P]_X
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M_9?^!/\ S#ZEA?\ GU'[E_D>;_\ #-WPL_Z)_P"'O_ "/_"C_AF[X6?]$_\
M#W_@!'_A7I%%'U[%?\_9?^!/_,/J6%_Y]1^Y?Y'F_P#PS=\+/^B?^'O_   C
M_P */^&;OA9_T3_P]_X 1_X5Z111]>Q7_/V7_@3_ ,P^I87_ )]1^Y?Y'F__
M  S=\+/^B?\ A[_P C_PJ]HW[-'PIFO0LGP]\.NNT\'3X_\ "NZK1T'_ )"
M_P!TUI3QN*<U^]E][_S,:N#PRIRM2C]R.&U?]F'X2PV$C)\.O#B,",$:?'Z_
M2N?_ .&;OA9_T3_P]_X 1_X5[?K?_(.D^H_G7,5K7QN)4]*LOO9AA,'AG!WI
MQW[(\W_X9N^%G_1/_#W_ ( 1_P"%'_#-WPL_Z)_X>_\  "/_  KTBBN;Z]BO
M^?LO_ G_ )G;]2PO_/J/W+_(\W_X9N^%G_1/_#W_ ( 1_P"%'_#-WPL_Z)_X
M>_\  "/_  KTBBCZ]BO^?LO_  )_YA]2PO\ SZC]R_R/-_\ AF[X6?\ 1/\
MP]_X 1_X4?\ #-WPL_Z)_P"'O_ "/_"O2**/KV*_Y^R_\"?^8?4L+_SZC]R_
MR/-_^&;OA9_T3_P]_P" $?\ A1_PS=\+/^B?^'O_   C_P *](HH^O8K_G[+
M_P "?^8?4L+_ ,^H_<O\CS?_ (9N^%G_ $3_ ,/?^ $?^%'_  S=\+/^B?\
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MO_ "/_"O2**/KV*_Y^R_\"?^8?4L+_SZC]R_R/-_^&;OA9_T3_P]_P" $?\
MA1_PS=\+/^B?^'O_   C_P *](HH^O8K_G[+_P "?^8?4L+_ ,^H_<O\CS?_
M (9N^%G_ $3_ ,/?^ $?^%'_  S=\+/^B?\ A[_P C_PKTBBCZ]BO^?LO_ G
M_F'U+"_\^H_<O\CS?_AF[X6?]$_\/?\ @!'_ (4?\,W?"S_HG_A[_P  (_\
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M?_AF[X6?]$_\/?\ @!'_ (4?\,W?"S_HG_A[_P  (_\ "O2**/KV*_Y^R_\
M G_F'U+"_P#/J/W+_(\W_P"&;OA9_P!$_P##W_@!'_A1_P ,W?"S_HG_ (>_
M\ (_\*](HH^O8K_G[+_P)_YA]2PO_/J/W+_(\W_X9N^%G_1/_#W_ ( 1_P"%
M'_#-WPL_Z)_X>_\  "/_  KTBBCZ]BO^?LO_  )_YA]2PO\ SZC]R_R/-_\
MAF[X6?\ 1/\ P]_X 1_X4?\ #-WPL_Z)_P"'O_ "/_"O2**/KV*_Y^R_\"?^
M8?4L+_SZC]R_R/.[;]FSX5M<1 _#[P\07 (^P1\\_2NFF_9>^$:PN1\./#8(
M4_\ ,.C_ ,*Z.U_X^H?]\?SKK9_]1)_NG^5=M#&8EIWJR^]GFXK"8=2C:G'[
MD>"_\,W?"S_HG_A[_P  (_\ "C_AF[X6?]$_\/?^ $?^%>D45Q?7L5_S]E_X
M$_\ ,]+ZEA?^?4?N7^1YO_PS=\+/^B?^'O\ P C_ ,*/^&;OA9_T3_P]_P"
M$?\ A7I%%'U[%?\ /V7_ ($_\P^I87_GU'[E_D>;_P##-WPL_P"B?^'O_ "/
M_"C_ (9N^%G_ $3_ ,/?^ $?^%>D44?7L5_S]E_X$_\ ,/J6%_Y]1^Y?Y'F_
M_#-WPL_Z)_X>_P# "/\ PH_X9N^%G_1/_#W_ ( 1_P"%>D44?7L5_P _9?\
M@3_S#ZEA?^?4?N7^1YO_ ,,W?"S_ *)_X>_\ (_\*/\ AF[X6?\ 1/\ P]_X
M 1_X5Z111]>Q7_/V7_@3_P P^I87_GU'[E_D>;_\,W?"S_HG_A[_ , (_P#"
MC_AF[X6?]$_\/?\ @!'_ (5Z111]>Q7_ #]E_P"!/_,/J6%_Y]1^Y?Y'F_\
MPS=\+/\ HG_A[_P C_PH_P"&;OA9_P!$_P##W_@!'_A7I%%'U[%?\_9?^!/_
M ##ZEA?^?4?N7^1YO_PS=\+/^B?^'O\ P C_ ,*/^&;OA9_T3_P]_P" $?\
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M]$_\/?\ @!'_ (5Z111]>Q7_ #]E_P"!/_,/J6%_Y]1^Y?Y'F_\ PS=\+/\
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M7^1YO_PS=\+/^B?^'O\ P C_ ,*/^&;OA9_T3_P]_P" $?\ A7I%%'U[%?\
M/V7_ ($_\P^I87_GU'[E_D>;_P##-WPL_P"B?^'O_ "/_"C_ (9N^%G_ $3_
M ,/?^ $?^%>D44?7L5_S]E_X$_\ ,/J6%_Y]1^Y?Y'F__#-WPL_Z)_X>_P#
M"/\ PH_X9N^%G_1/_#W_ ( 1_P"%>D44?7L5_P _9?\ @3_S#ZEA?^?4?N7^
M1YO_ ,,W?"S_ *)_X>_\ (_\*/\ AF[X6?\ 1/\ P]_X 1_X5Z111]>Q7_/V
M7_@3_P P^I87_GU'[E_D>;_\,W?"S_HG_A[_ , (_P#"C_AF[X6?]$_\/?\
M@!'_ (5Z111]>Q7_ #]E_P"!/_,/J6%_Y]1^Y?Y'F_\ PS=\+/\ HG_A[_P
MC_PH_P"&;OA9_P!$_P##W_@!'_A7I%%'U[%?\_9?^!/_ ##ZEA?^?4?N7^1Y
MO_PS=\+/^B?^'O\ P C_ ,*/^&;OA9_T3_P]_P" $?\ A7I%%'U[%?\ /V7_
M ($_\P^I87_GU'[E_D>;_P##-WPL_P"B?^'O_ "/_"C_ (9N^%G_ $3_ ,/?
M^ $?^%>D44?7L5_S]E_X$_\ ,/J6%_Y]1^Y?Y'F__#-WPL_Z)_X>_P# "/\
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M_#W_ ( 1_P"%'_#-WPL_Z)_X>_\  "/_  KTBBCZ]BO^?LO_  )_YA]2PO\
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M>_\  "/_  KTBBCZ]BO^?LO_  )_YA]2PO\ SZC]R_R/-_\ AF[X6?\ 1/\
MP]_X 1_X4?\ #-WPL_Z)_P"'O_ "/_"O2**/KV*_Y^R_\"?^8?4L+_SZC]R_
MR/-_^&;OA9_T3_P]_P" $?\ A1_PS=\+/^B?^'O_   C_P *](HH^O8K_G[+
M_P "?^8?4L+_ ,^H_<O\CS?_ (9N^%G_ $3_ ,/?^ $?^%'_  S=\+/^B?\
MA[_P C_PKTBBCZ]BO^?LO_ G_F'U+"_\^H_<O\CS?_AF[X6?]$_\/?\ @!'_
M (4?\,W?"S_HG_A[_P  (_\ "O2**/KV*_Y^R_\  G_F'U+"_P#/J/W+_(\W
M_P"&;OA9_P!$_P##W_@!'_A1_P ,W?"S_HG_ (>_\ (_\*](HH^O8K_G[+_P
M)_YA]2PO_/J/W+_(\W_X9N^%G_1/_#W_ ( 1_P"%'_#-WPL_Z)_X>_\  "/_
M  KTBBCZ]BO^?LO_  )_YA]2PO\ SZC]R_R/-_\ AF[X6?\ 1/\ P]_X 1_X
M4?\ #-WPL_Z)_P"'O_ "/_"O2**/KV*_Y^R_\"?^8?4L+_SZC]R_R/-_^&;O
MA9_T3_P]_P" $?\ A1_PS=\+/^B?^'O_   C_P *](HH^O8K_G[+_P "?^8?
M4L+_ ,^H_<O\CS?_ (9N^%G_ $3_ ,/?^ $?^%'_  S=\+/^B?\ A[_P C_P
MKTBBCZ]BO^?LO_ G_F'U+"_\^H_<O\CS?_AF[X6?]$_\/?\ @!'_ (4?\,W?
M"S_HG_A[_P  (_\ "O2**/KV*_Y^R_\  G_F'U+"_P#/J/W+_(\W_P"&;OA9
M_P!$_P##W_@!'_A1_P ,W?"S_HG_ (>_\ (_\*](HH^O8K_G[+_P)_YA]2PO
M_/J/W+_(\W_X9N^%G_1/_#W_ ( 1_P"%'_#-WPL_Z)_X>_\  "/_  KTBBCZ
M]BO^?LO_  )_YA]2PO\ SZC]R_R/-_\ AF[X6?\ 1/\ P]_X 1_X4?\ #-WP
ML_Z)_P"'O_ "/_"O2**/KV*_Y^R_\"?^8?4L+_SZC]R_R/-_^&;OA9_T3_P]
M_P" $?\ A1_PS=\+/^B?^'O_   C_P *](HH^O8K_G[+_P "?^8?4L+_ ,^H
M_<O\CS?_ (9N^%G_ $3_ ,/?^ $?^%'_  S=\+/^B?\ A[_P C_PKTBBCZ]B
MO^?LO_ G_F'U+"_\^H_<O\CS?_AF[X6?]$_\/?\ @!'_ (4?\,W?"S_HG_A[
M_P  (_\ "O2**/KV*_Y^R_\  G_F'U+"_P#/J/W+_(\[M?V;/A6]U"K?#[P\
M074$?8(_7Z5VS?LL?!\*?^+;>&NG_0.C_P *U++_ (_(/^NB_P Z[YONGZ5Z
MF#QF)<7>I+[V>#F6%H1E'EII?)'B_P#PS!\)/^B<^&__  71_P"%'_#,'PD_
MZ)SX;_\ !='_ (5Z?17H_6L1_P _'][/(^KT?Y%]R/,/^&8/A)_T3GPW_P""
MZ/\ PH_X9@^$G_1.?#?_ (+H_P#"O3Z*/K6(_P"?C^]A]7H_R+[D>8?\,P?"
M3_HG/AO_ ,%T?^%'_#,'PD_Z)SX;_P#!='_A7I]%'UK$?\_'][#ZO1_D7W(\
MP_X9@^$G_1.?#?\ X+H_\*/^&8/A)_T3GPW_ ."Z/_"O3Z*/K6(_Y^/[V'U>
MC_(ON1YA_P ,P?"3_HG/AO\ \%T?^%'_  S!\)/^B<^&_P#P71_X5Z?11]:Q
M'_/Q_>P^KT?Y%]R/,/\ AF#X2?\ 1.?#?_@NC_PH_P"&8/A)_P!$Y\-_^"Z/
M_"O3Z*/K6(_Y^/[V'U>C_(ON1YA_PS!\)/\ HG/AO_P71_X4?\,P?"3_ *)S
MX;_\%T?^%>GT4?6L1_S\?WL/J]'^1?<CS#_AF#X2?]$Y\-_^"Z/_  H_X9@^
M$G_1.?#?_@NC_P *]/HH^M8C_GX_O8?5Z/\ (ON1YA_PS!\)/^B<^&__  71
M_P"%'_#,'PD_Z)SX;_\ !='_ (5Z?11]:Q'_ #\?WL/J]'^1?<CS#_AF#X2?
M]$Y\-_\ @NC_ ,*/^&8/A)_T3GPW_P""Z/\ PKT^BCZUB/\ GX_O8?5Z/\B^
MY'F'_#,'PD_Z)SX;_P#!='_A1_PS!\)/^B<^&_\ P71_X5Z?11]:Q'_/Q_>P
M^KT?Y%]R/,/^&8/A)_T3GPW_ ."Z/_"C_AF#X2?]$Y\-_P#@NC_PKT^BCZUB
M/^?C^]A]7H_R+[D>8?\ #,'PD_Z)SX;_ /!='_A1_P ,P?"3_HG/AO\ \%T?
M^%>GT4?6L1_S\?WL/J]'^1?<CS#_ (9@^$G_ $3GPW_X+H_\*/\ AF#X2?\
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MG/AO_P %T?\ A7I]%'UK$?\ /Q_>P^KT?Y%]R/,/^&8/A)_T3GPW_P""Z/\
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MC_PH_P"&8/A)_P!$Y\-_^"Z/_"O3Z*/K6(_Y^/[V'U>C_(ON1YA_PS!\)/\
MHG/AO_P71_X5K>%/@/\ #OP9X@L]9T+P7HFDZK;,WDWEG9)'+'N4HV& R,JS
M#Z$UW-.B_P!:GU%2\37DK.;MZL:H4HNZBON1TU%%%<YJ%%%% !1110 4444
M%%%% !1110 4444 %%%% !7/_$'_ )$;7O\ KRE_]!-=!7/_ !!_Y$;7O^O*
M7_T$UAB/X,_1_D=>#_WFG_B7YGP_1117XB?U4%%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %?0_P -?^1'TK_<;_T-
MJ^>*^A_AK_R(^E?[C?\ H;5[V3?QY>GZH^/XG_W6'^+]&=-1117UY^:A1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 5:TO_D(0?[U5:M:7_R$(/\ >JX?$C.?P/T.CU'_ (\9_P#<-<E7
M6ZC_ ,>,_P#N&N2KHQ/Q(X\'\+"BBBN0] **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *T=!_Y" _W36=6CH/_ "$!_NFM:7QHQK?PY>AK
M:W_R#I/J/YUS%=/K?_(.D^H_G7,5KB/C.?!_PWZA1117*=P4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% $MK_P ?4/\ OC^==;/_ *B3_=/\JY*U_P"/J'_?'\ZZV?\ U$G^
MZ?Y5W8?X6>9B_BB<;1117">F%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !70^'?^/)_^NA_D*YZN
MA\._\>3_ /70_P A710^,X\5_#*GB+_CZB_W/ZFLFM;Q%_Q]1?[G]3634UOC
M9IA_X40HHHK$Z HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** )K+_ (_(/^NB_P Z[YONGZ5P
M-E_Q^0?]=%_G7?-]T_2O6P7PR/GLS^*)C4445Z1Y 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !3HO]:GU%-IT7^M3ZB@#IJ***" HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *Y_X@_P#(C:]_UY2_^@FN@KG_
M (@_\B-KW_7E+_Z":PQ'\&?H_P CKP?^\T_\2_,^'Z***_$3^J@HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ JUI?\ R$(/]ZJM6M+_ .0A!_O5</B1G/X'Z'1ZC_QXS_[AKDJZ
MW4?^/&?_ '#7)5T8GXD<>#^%A1117(>@%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** );7_CZA_WQ_.NMG_U$G^Z?Y5R5K_Q]0_[X_G76S_ZB3_=/\J[L
M/\+/,Q?Q1.-HHHKA/3"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ KH?#O_'D_P#UT/\ (5SU=#X=
M_P"/)_\ KH?Y"NBA\9QXK^&5/$7_ !]1?[G]3636MXB_X^HO]S^IK)J:WQLT
MP_\ "B%%%%8G0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!-9?\?D'_ %T7^==\WW3]*X&R
M_P"/R#_KHO\ .N^;[I^E>M@OAD?/9G\43&HHHKTCR HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "M'0?\ D(#_ '36=6CH/_(0'^Z:UI?&C&M_#EZ&MK?_
M "#I/J/YUS%=/K?_ "#I/J/YUS%:XCXSGP?\-^H4445RG<%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110!+:_\?4/^^/YUUL_^HD_W3_*N2M?^/J'_?'\ZZV?_42?[I_E7=A_
MA9YF+^*)QM%%%<)Z84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %=#X=_X\G_ .NA_D*YZNA\._\
M'D__ %T/\A710^,X\5_#*GB+_CZB_P!S^IK)K6\1?\?47^Y_4UDU-;XV:8?^
M%$****Q.@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MRE_]!-88C^#/T?Y'7@_]YI_XE^9\/T445^(G]5!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:3[%S_A/O$__ $,>K?\ @=+_ /%4^'XB>*[>59(O$VL1R+T9;^4$?^/5]O\
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M3H5(*\D*GBJ-5VC+4[RO&_VL_P#DCUU_U]P?^A5[)7C?[6?_ "1ZZ_Z^X/\
MT*E1_B1]2L3_  9^C/AZOTR\+_\ (M:3_P!>D/\ Z *_,VON[Q/\=/#/PN\-
MZ3;W\SWNJFRA9=/M &D *#!8DX4?4Y] :]+%Q<N511XV73C3YY2=EH>KT5\H
M7G[:]^\[&T\+6T4/837;.WYA173^#?VQ]$U:ZCMO$&E3:)N./M4,GGQ ^K#
M8#Z!JX7AJJ5['J1QM"3MS'T17%_&C_DDWBW_ +!LW_H)KK;*]M]2M(;JTGCN
M;:9!)'-$P9'4C(((ZBGS01W,3Q2QK+$XPR. 01Z$&N>+Y6F=<ESQ:[GY?45]
M\_&_P]I=K\)?%$L.FV<4B6;%72!%93D="!7P-7O4:OMDW:Q\EB<.\/)1;O<^
M_P#]G;_DB_A?_K@__HUZ]&KSG]G;_DB_A?\ ZX/_ .C7KT:O$J_'+U9]30_A
M1]%^04445D;GQK^U+XJUK2/BO-;V&L7]E;_8X6\JWNGC7)!R< @5Y38?$KQ5
MIU_;7<?B#4WD@D655EO)&0E2" P+<CCD5Z%^UM_R5^?_ *\H/Y&O&*^@HQ3I
MQTZ'R&)G)5I6?4_2[PCXDMO&'AG3-:LS_H][ LRKG.TD<J?<'(/TK7KYK_8W
M\=?;-)U/PG<R9EM&^V6@8]8V.)%'L&(/_ S7TI7BU8>SFXGT^'J^VIJ853UC
M5K;0=)O-2O'\NUM(7GE;T502?T%7*\!_:^\=_P!B>#+7PY;2;;K5Y-TP4\K
MA!/TW-M'N PI4X>TFHCK5%2IN;Z'S-XC^*OB?7]>U#41KFI6JW4[RK!#=NB1
MJ3PH (& ,#\*[G]G'Q=KNJ?&?P]:WFM:C=VS_:-\,]U(Z-BWE(RI.#R ?PKQ
MBO4?V8_^2X^&O^WG_P!)I:]RI%*G*RZ'RU&<I5HW?5?F?>E%%,DD2&-I)&"(
M@+,S'  '4D]J^>/L!]%>'^.?VL_"OA>XDM=*AF\1W49(9K=Q';@^GF$'/U52
M/>O.Y/VUM6+DQ^&;)4[!KER1^.!_*NF.&JR5TCBGC*$'9R/K2BOG'PK^V=H]
M].D6O:)<:6K'!N+647"#W*X5@/INKWW0?$&F^*-,BU'2;V'4+*7[LT#[A]#Z
M'V/(K.=*=/XD;4J].M\#N:-%%%9&X45Y=\2_VB/"WPVN);&21]5U=.&L;/!\
ML_\ 31SPOTY/M7C]S^VOJ;3,;?PO:1Q=EENF=A]2%'\JZ(X>I-72..IBZ--\
MLI:GUC7RC^VS_P A;PI_UPN/_0HZZOP5^V'H.LW$=MK^G3:$[D*+F-_/@!]6
MX#+^1^M<=^V9>0:A=^#[FUFCN+>6VG>.:)@R.I,>""."*WH4Y4ZR4D<N*K4Z
MV&DX.^WYGD/P7_Y*SX2_["4/_H0K]$J_.WX+_P#)6?"7_82A_P#0A7Z)56-^
M)$99_#EZA17AOQ)_:BM/AUXUU'P]+X?FOGL_+S.ET$#[XU?IM.,;L=>U:7P@
M_:'MOBWXEN='AT2736AM&NS*]P) 0'1=N H_OYS[5R^QJ*//;0[UB:3G[-2U
M/8****P.H**^;+K]M&QM;J:$^%;AC&Y3(O5YP<?W*]1^#GQ>A^+VF:A>0Z8^
MF+9S+"5DF$A8E<YX Q6\J%2"YI+0Y88FE4ER0E=G7^*/^1:U;_KTF_\ 0#7Y
MFU^F7BC_ )%K5O\ KTF_] -?F;7=@MI'E9IO#YGW#^R9_P D>M?^ON?_ -"K
MV2O&_P!DS_DCUK_U]S_^A5[)7!6_B2]3UL-_!AZ(**X#XE_&[PS\+D\K4KA[
MG4V7<FG6@#2D=BV2 H]R?H#7B-_^VO?-<M]B\+V\< Z">Z9F/N<* /I50H5)
MJ\434Q5&D^64M3ZMHKYL\)_MG:=>720>(=#DTZ-CC[79R^<J^Y0@$#Z$_2O1
M_B-\=-*\"^$=+\164 \06&HS>3$]M.$'W2V<D'TQC&12="I%J+0XXJC.+DI:
M(],HKYLM?VT;&ZNH81X5N%,CA,F]7C)Q_<KZ3J9TYT_B1=*M3K7]F[V/(?VH
M?$FJ>%OAK'>Z1?W&FW9OXHS-;.4;:5?(R.W _*ODO_A='CO_ *&W5O\ P*;_
M !KO_C-^T=;?%7P@NBPZ'+ISK=)<><]P)!A0PQ@*/[U>&UZ^'I<L+36I\[B\
M1SU;TY:'Z=Z9(TNFVCNQ9VA0ECU)P,FK5?,-G^VC8VMG!"?"MPQC14W?;5YP
M,?W*]X^&WC:/XB^"M.\116C6*7GF8@=]Y79(R=<#.=N>G>O*J49PUDK'OTL1
M2JOE@[LZ:BBO(?B%^TYX2\"W,ME \FNZE&=KPV1'EH>X:0\9]AG'>LX0E-VB
MC:=2%)7F['KU%?)UQ^VMJ;2DP>%[2.+LLETSG\PH_E6QX=_;3LYYTCUSPY+:
MQD@&XL9Q+CWV,%_]"-;O"U5K8Y%CL.W;F_,^F:*P_"'C71/'>EKJ&AZA%?V_
M ;8</&?[KJ>5/L16Y7,TT[,[4U)7045Q_P 5/B''\,/"4FNRV+:@B2I$84D\
ML_,<9S@UXO\ \-LV/_0J7'_@:O\ \16L*,YJ\485,32I/EG*S/IBBO/O''QM
M\._#W0;*_P!5E8WEY LT&FVY#S,&&<]L+VW''0XR>*X7X7_M-W'Q,^(5KH,>
M@QZ=9S)*XE:X,DGRH6'\('./UH5&;BY):()8BE&:@WJSWNBBBL3I"BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "K6E_P#(0@_WJJU:TO\
MY"$'^]5P^)&<_@?H='J/_'C/_N&N2K9\;ZA-I7A#6+RW($T-L[H6&1D#CBOF
M_P#X7!XB_P">MO\ ]^16&8XVEA9QC4OJCLR7*L1F%*<Z-K)VU?EZ'N]%>$?\
M+@\1?\];?_OR*/\ A<'B+_GK;_\ ?D5Y']KX?S^[_@GT7^K>-[Q^_P#X![O1
M7A'_  N#Q%_SUM_^_(H_X7!XB_YZV_\ WY%']KX?S^[_ ((?ZMXWO'[_ /@'
MN]%>$?\ "X/$7_/6W_[\BC_A<'B+_GK;_P#?D4?VOA_/[O\ @A_JWC>\?O\
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MZMXWO'[_ /@'N]%>$?\ "X/$7_/6W_[\BC_A<'B+_GK;_P#?D4?VOA_/[O\
M@A_JWC>\?O\ ^ >[T5X1_P +@\1?\];?_OR*/^%P>(O^>MO_ -^11_:^'\_N
M_P""'^K>-[Q^_P#X![O17A'_  N#Q%_SUM_^_(H_X7!XB_YZV_\ WY%']KX?
MS^[_ ((?ZMXWO'[_ /@'N]%>$?\ "X/$7_/6W_[\BC_A<'B+_GK;_P#?D4?V
MOA_/[O\ @A_JWC>\?O\ ^ >[T5X1_P +@\1?\];?_OR*/^%P>(O^>MO_ -^1
M1_:^'\_N_P""'^K>-[Q^_P#X![O17A'_  N#Q%_SUM_^_(H_X7!XB_YZV_\
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MQ%_SUM_^_(H_X7!XB_YZV_\ WY%']KX?S^[_ ((?ZMXWO'[_ /@'N]%>$?\
M"X/$7_/6W_[\BC_A<'B+_GK;_P#?D4?VOA_/[O\ @A_JWC>\?O\ ^ >[T5X1
M_P +@\1?\];?_OR*/^%P>(O^>MO_ -^11_:^'\_N_P""'^K>-[Q^_P#X![O1
M7A'_  N#Q%_SUM_^_(H_X7!XB_YZV_\ WY%']KX?S^[_ ((?ZMXWO'[_ /@'
MN]%>$?\ "X/$7_/6W_[\BC_A<'B+_GK;_P#?D4?VOA_/[O\ @A_JWC>\?O\
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MZMXWO'[_ /@'N]%>$?\ "X/$7_/6W_[\BC_A<'B+_GK;_P#?D4?VOA_/[O\
M@A_JWC>\?O\ ^ >[T5X1_P +@\1?\];?_OR*/^%P>(O^>MO_ -^11_:^'\_N
M_P""'^K>-[Q^_P#X![O17A'_  N#Q%_SUM_^_(H_X7!XB_YZV_\ WY%']KX?
MS^[_ ((?ZMXWO'[_ /@'N]%>$?\ "X/$7_/6W_[\BC_A<'B+_GK;_P#?D4?V
MOA_/[O\ @A_JWC>\?O\ ^ >[T5X1_P +@\1?\];?_OR*/^%P>(O^>MO_ -^1
M1_:^'\_N_P""'^K>-[Q^_P#X![O17A'_  N#Q%_SUM_^_(H_X7!XB_YZV_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!-9?\?D
M'_71?YUWS?=/TK@;+_C\@_ZZ+_.N^;[I^E>M@OAD?/9G\43&HHHKTCR HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "5^?_KR@_D:\FTK1;K6!>_94\QK2V:ZD4=?+4C<1] <_0&O6?VMO^2OS_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !4EO<2VDZ302-%*AW*Z'
M!!]0:CHHVU0FDU9GOOPM\>?\)3Y=K>%5U.%E+$# E7/W@/7U'O\ E[%/_J)/
M]T_RKXR\.:Y-X;UVRU*#[]O('*Y^\O=?Q&17V0ES'>:>+B%M\4L7F(P[@C(-
M?H>2XMXBE*$_BC^*/QCBC+HX+$0J4E:$[_)]5_D<E11174>:%%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !70^'?^/)_^NA_D*YZNA\._\>3_ /70_P A710^,X\5_#*GB+_CZB_W
M/ZFLFM;Q%_Q]1?[G]3634UOC9IA_X40HHHK$Z HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&O?/V)K:0WGBVXVGRA';1[O5B9#C]/Y5\QU]V?LT_#^;P)\-X&O8S%J.J/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7T/\-?^1'TK_<;_ -#:OGBOH?X:_P#(CZ5_N-_Z&U>]DW\>7I^J/C^)_P#=
M8?XOT9TU%%%?7GYJ%%%% !1110 4444 %%%% !1110 5^9_BW_D:]:_Z_9O_
M $8U?IA1730K>Q;TO<X<5AOK*2O:Q\Y?L5_\BIXC_P"OU/\ T77T;11652?M
M).1O1I^QIJ%[V(KB"*[MY()HUEAD4H\;C*LI&"".X(KX$^.7PLE^%OC.6VB5
MCH]WF:PF;GY,\H3ZJ3CZ8/>OT HK2C6=%WZ&6)PT<3%)NS74_-?P#_R/7AS_
M +"5M_Z-6OTHHHIUZWMFG:UB<+AOJR:O>Y\D_MJ_\C+X:_Z])?\ T,5Y=\!/
M^2P^%?\ K['_ *":_0>BM8XGEI^SL8SP//6]KS=;[?\ !"BBBN$]0^<OVU/^
M14\.?]?K_P#HNOE+2/\ D+67_7=/_0A7Z=45W4L5[.')RGE5\#[:I[3FM\O^
M"%>1_M1:9>:M\)[FWL;2>]N#=0$16\;2.0&Y. ":]<HKDA+DDI=CT:D/:0<.
MY^:__" ^)_\ H7-6_P# &7_XFC_A ?$__0N:M_X R_\ Q-?I117?]=?\IY']
MF1_F/S7_ .$!\3_]"YJW_@#+_P#$T?\ " ^)_P#H7-6_\ 9?_B:_2BBCZZ_Y
M0_LR/\Q\P_L=>'M5T34_$[:CIEY8+)# $-U \88AGSC<!FO?O'_B >%?!&NZ
MODAK2SEE3'=PIVC_ +ZP*Z"O$_VM_$/]D?"IK%7*RZG=Q0;1UV+F1C],HH_&
MN?F]O53:W.WE6%P[2>USXF)R<GDU]Z?LU>'_ /A'O@]H@9=LUZ'O7XQG>WRG
M_O@)7PEI]C-J>H6UG;KNGN)5AC4]V8@ ?F:_3+1],BT32;'3K<8@M($MXQC'
MRHH4?H*[<;*T5$\O+(7G*?8N4445Y!]$?.7[:G_(J>'/^OU__1=?(]?J+17=
M2Q7LH<O+<\K$8'V]1SYK?+_@GY=4J1M*ZHBEW8X"J,DFOU$HK;Z]_=_'_@'-
M_9?]_P##_@GYY^#/@GXQ\<W,:6&BW$%LW6]O$,,"CUW,/F^BY/M7V;\'?A'I
M_P )?#S6D#_:]2N2'O+PC'F,.BJ.RC)P/<GO7?T5RU<1*KILCOP^#A0?-NPK
MYE^/O[,]QJ^H7'B/PA LEQ.QDN],!"[F[R1YXR>I7UY'I7TU165.I*E+FB=%
M:C"O'EF?F%J.FW>D7DEK?6LUG=1G#PSQE'4^X/-1VUK->W"06\,D\SG"1Q*6
M9CZ #DU^FNH:/8:L@2^L;:]3IMN(ED'Z@TW3=!TS1\_8-.M+'(P?LT"QY_("
MO0^NZ?">1_9>OQZ>A\9Z#^SEJ=CX!\0>*?%$+Z>+2PFEL]/;B5G"G#R#^$#J
M%ZD]< <^*5^HM%9QQDE?F5S6>6QDDHRM8\Y_9V_Y(OX7_P"N#_\ HUZ[Z_L+
M?5+*>SNX4N+6X1HI8I!E74C!!'N*L45PRES2<CU80Y(*'9'Q?\7?V7M:\*WD
M^H>&+>76=%=BPMX@7N;<?W2O5P.Q&3ZCN?#9H9+>5XI8VBE0X9'4@J?0@U^H
M54-1T#3-8_X_].M+WM_I,"R?S!KNIXR25I*YY57+8R=Z;L?F7%$\\BQQHTDC
M'"JHR2?0"O;?A%^S'KGC*\@OO$-O-HFA ABDPVW%P/[JJ>5!_O'\ :^QM.\/
M:7I!!L=-L[(C(!MX$CQ^0%:%$\8VK15@I9;&+O4=RMING6NCV%O8V4"6UI;Q
MK%%#&,*B@8 %>2?M9_\ )'KK_K[@_P#0J]DHKBA/EDI'J5*?M(.&US\NJ_3+
MPO\ \BUI/_7I#_Z *TZ*WK5_;6TM8Y,+A/JS;YKW"OE']MG_ )"WA3_KA<?^
MA1U]745C2J>RFI6.BO2]O3=.]KGYV_!?_DK/A+_L)0_^A"OT2HHJZ];VS3M8
MRPN'^K1<;WN<'\=O^20>*_\ KR;^8K\]J_46BM*.(]BFK7,L3@_K,E+FM;R/
M.?V=O^2+^%_^N#_^C7KT:BBN64N:3?<[X1Y(J/8****DL^(?VMO^2OS_ /7E
M!_(T?LD_\E?@_P"O*?\ D*^WJ*[OK/[OV=NAY?U']][;FZWM;_@A7P_^U3X&
M_P"$4^)<NHPIMLM:4W:XZ"4<2CZYPW_ Z^X**PHU71ES'5B:"Q$.5NQ\$_LY
M>!_^$V^*.FK-%YEAIW^GW&1P0A&Q3]7*\>F:^]J**=:LZTKVL+#8=8:'*G<^
M-/VS/^2H:7_V!XO_ $?/7+?LQ_\ )<?#7_;S_P"DTM?>E%;+%6I^SMTL<TL#
M>M[;FZWM;_@A7FGQJ^">G_%O2XF\Q;'6[52+6\VY!!Y\M_5<\^H))'4@^ET5
MQQDX/FB>A.$:D7&2T/SC\:_##Q-\/[IXM:TF>WC!PMTB[X)/=9!Q^'!YY KE
MJ_4-E#J58!E(P0>AK(?P;X?DG$SZ%IKS#D2-:1EOSQ7I1QNGO(\:>6*_N2T/
MSJ\-^$-;\7W@M=%TNZU*8G!%O&6"_P"\W11[DBOK3X$?LVIX#N8M?\1-'=:Z
MHS!;1D-%:Y'7/\3^XX';/6O=K>VBM(5B@B2&)>%2-0JCZ 5)6-7%2FN5*R.F
MA@(47S2=V%9/BKPOIWC/0+S1M5@^T6-TFQUS@CN&4]B" 0?45K45Q)V=T>FT
MFK,^"_BG^SYXD^'%W/-%;2ZOH8),=_;(6VK_ --%'*'WZ>_:O+J_46LBZ\(Z
M%?S^=<Z+IUQ-G/F2VL;-^9%>E#&M*TD>+4RR+=X2L?G;X3\$:[XXU!;/0],G
MU"4D!FC7Y(\]W<\*/<D5VOQH^$D?PETSPO:R3BZU2\CGFO)DSLW H B?[*Y/
M)Y))/H!]WVUM#9Q+%!$D,2](XU"J/H!4M2\9+F3MH4LMBH-.6KZGYV_!?_DK
M/A+_ +"4/_H0K]$J**YJ];VS3M8[,+A_JT7&][G%_%CX9V/Q4\*2Z3=,+>Y0
M^;:707)AD X/NIZ$?U KX:\=?"WQ+\.KUX=9TV6*$-A+R,%X)!ZJXX[C@X//
M(K]&::Z+(C*RAE88*L,@CTJZ.(E2TW1.(P<,1[U[,_+RO3_A7\ /$7Q'U""2
M6UFTK0]P,M_<(5W+Z1*>7)]>@[GM7W-#X>TNWE66+3;..53D.D"!@?KBM"MY
MXQM>ZK''3RR*=YRNC\P+^%;:^N(DSLCD9!GK@$BOK+]BO_D5/$?_ %^I_P"B
MZ^C:*SJXKVD.6QM0P/L*BJ<U_E_P3,\4?\BUJW_7I-_Z :_,VOU%HJ*%?V*>
ME[FN*PGUEI\UK'C?[)G_ "1ZU_Z^Y_\ T*O6]2TZUUC3[BQO8$NK2XC:*6&0
M95U(P0:LT5A.?-)R.NG3]G!0WL?$OQ>_9HUSP3?7%]H-M-K.@$EU,(WSVX_N
MNHY(']X#IUQ7BK*48JP*L#@@]0:_42LS4/#&C:M)YE]I-C>2==]Q;)(?S(KM
MAC&E:2N>55RV,G>F['YO^'_#.J^*K];+2-/N-1NF('EV\9;'N?0>YXXKTOXE
M_ V3X5_#;2]1U259=>OKX1R1Q-F.WC\MSL!_B;.,GIQ@>I^X;.QMM/B\JUMX
MK:+KLA0(OY"IZ)8R3::6@XY;!1:<KO\ (_,72/\ D+67_7=/_0A7Z=445A7K
M^VMI:QUX7"_5K^]>YC>,?"UIXU\,:EH=\#]FO83$S 9*'JK#W5@"/<5\'^/_
M ()^*_A]J,T5UID]Y8JQ\O4+2(O#(O8DC.T^S?KUK]":*5&O*CHM@Q&%AB+-
MNS1^71!4D$8(X(-?>G[,?_)#O#7_ &\_^E,M>HT5I6Q/MH\MK&6&P?U>;GS7
MT['&?%/X6Z5\5O#O]FZAF"XB8R6MY&H+P/CGZJ>A7O@=P"/B?X@?!;Q7\.;F
M4:AILD]@I.S4+53) P[$D?=/LV#Q7Z%T5%+$2I:;HTQ&#AB-7HS\NJO:-H.I
M>(KQ;32["YU&Y;I%;1-(WUP!T]Z_2"Z\'Z#?2^;<Z)IUQ)UWRVD;'\R*T+2Q
MM["+R[:WBMH\YV0H%&?H*ZWC=-(G LK=]9_@?-GP/_9<ETJ^MM?\8HGGPD26
M^E*0X5AT:4]#C@A1WZGM7TU117GU*DJKO(]>C1A0CRP1XW^UG_R1ZZ_Z^X/_
M $*OAZOU%HKHHXGV4>6USCQ."^L3Y^:WR_X)F>%_^1:TG_KTA_\ 0!6G117&
MW<])*RL%%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 5:TO_D(0?[U5:M:7_R$(/\ >JX?$C.?P/T)_B3_ ,B#K_\ UYR?RKY!KZ^^
M)/\ R(.O_P#7G)_*OD&OFN(OX\/3]3[O@O\ W6K_ (OT04445\H?H84444 %
M%%% !117K_P__9WU+Q+;Q7^M3MI%C( R0A<SR+ZX/"#ZY/M75AL+6Q<^2C&[
M/.QV8X;+:?M<5/E7XOT6[/(**^L;7]G3P9;PA'M;JY8?\M);E@Q_[YP/TK)\
M0_LRZ!?0L=)N[G3+@#Y1(WG1'Z@\_CG\*]R7#V-C&ZL_*^OY6_$^4AQIE<Y\
MKYDN[6GX-O\  ^9**Z+QIX#UCP'J/V35+?:K\Q7$?S12CU4_T."/2N=KYRI3
MG2DX5%9H^VHUJ>(IJK2DI1>S04445!L%%%% '2>#?AYKGCR6==(M?-2#'F32
M.$12>@R>I]A6?XD\,ZEX2U:73M5MC:W2 ':2"&4]&!'!!]?ZBO?/V:/$VF1^
M&;W2)+B*WU!+II_+D8*9$*J,C/7&T@^G'K7%?M(>(].UOQ;906,T=R]G;F.:
M6(Y7<6)VY[X_KCZ?0U<!AX9='%1G[[Z?I\CXK#YOC*N=5,OG2M32>MG?;1WV
MLSR2BBBOGC[4*D@MY;J58H8WFD;HB*6)[]!4=>@? 3_DK.A?]M__ $1)6^'I
M>WK0I7MS-+[W8XL;B'A<-4Q"5^2+=N]E<XFXTN]LX_,N+2>"/.-\D3*,^F2*
MJU]4?M+_ /).8_\ K^B_]!>OE>NW,L$L!7]BI7T3/,R/-'F^$^LRARZM6O?;
M[@HHHKRSZ **** "BBO4/@U\*-.^)-KJDM]=W5J;1XU46^WYMP8G.0?2NG#8
M>IBJJHTEJSAQV-HY?0EB:[M%6\]W8\OHKL_BSX'M?A_XI72[.>:YA-LDV^?&
M[)+#' 'I7&5G6I2H5)4I[HUPV)IXNC&O2^&2NCK?"'PK\1^-[*6[TNS5K6-M
MGG32"-6;N%SU_E7.:II5WHFHSV-] UM=P-LDB?JI_P \Y[U]2? 7Q5I-U\/+
M&Q2ZA@N['>L\+NJD9=F#8]"#U]<^E>'?'#7[#Q%\1+ZYTZ1)[=$2$S1\K(RC
M!(/<=L^WXU[F+P&'H8&EB*<[RE:ZT[:_=L?)Y=F^,Q>:U\%5I6A"]G9WT=E=
M[/F6IP5%%%?/'VH4444 %%%% !1110 4444 %%%% !17TO9_L\>%9_#T%ZSZ
MAYSVJS'$ZXW%,_W>F:^:*]'&8"M@E%U;>]M;^O,\3+<XPV:NHL/?W+)W5M[_
M .04445YQ[84444 %.1&D=412[L<!5&23Z"FU[5^S+X3M]4US4=9N8EE_L]4
M2W#C($CYRP]P%_\ 'J[,'AI8RO&A%VO_ $SR\SQT,MPD\5-7Y>G=O1+[SE]&
M^ WC+6;=)O[-6RC?I]LE$;8]UY8?B*X":(P3/&V-R,5./45]<_$SXQZ?\-[F
M"S:TDU'4)H_.$*.$54R0"S8/4@] >GTS\CW,OVBXEEQMWN6QG.,FO2S7"83!
MRC2H2<I+XK_*W0\/A_,,PS*$\1BZ:C!VY+==[[MOMV\BT-"U(J&&GW14\@B%
ML?RJC7W-IG_(FVG_ %X)_P"BQ7PS49GEJR]4VI7YK]/3_,TR+.Y9PZRE3Y>1
MI;WO>_DNP4445XA]8%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%>Q_";X*:7\0/"S:I>7]Y;3"X>'9!LVX 4YY!
M]:Z\+A:N,J>RHJ[/-S#,*&64?;XEVC>VU]SQRBN@^('AR#PCXPU+2+:62:"U
M=55Y<;CE ><<=ZY^N>I"5*;IRW3M]QV4:T<12C5AM))KT>H4445!L%%%% !1
M110 4444 %%%% !1110 4444 %%%?2]G^SQX5G\/07K/J'G/:K,<3KC<4S_=
MZ9KT<'@*V.<E1M[N]SQ,SSC#92H/$7][165]O^'/FBBBBO./;"BBB@ HHHH
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MFA2PU+F4WKH]==E;9GQ=1117SQ]J%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 5]:_#+_DFVB_]>G^-?)5?6OPR_P"2;:+_ ->G^-?4\/?QY_X?U1\!QE_N
ME+_%^C*]%%%?2'P@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %=#X=_X\G_ZZ'^0KGJZ'P[_ ,>3
M_P#70_R%=%#XSCQ7\,J>(O\ CZB_W/ZFLFM;Q%_Q]1?[G]3634UOC9IA_P"%
M$****Q.@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@":R_X_(/\ KHO\Z[YONGZ5P-E_Q^0?
M]=%_G7?-]T_2O6P7PR/GLS^*)C4445Z1Y 4444 %%%% !1110 4444 %%%%
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MNTLFVRN_]'GST )^5OP..?3-!)]/4444%A1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %.B_UJ?44VG1?ZU/J* .FHHHH("B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ KG_B#_R(VO?]>4O_ *":Z"N?
M^(/_ "(VO?\ 7E+_ .@FL,1_!GZ/\CKP?^\T_P#$OS/A^BBBOQ$_JH**** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^
MA_AK_P B/I7^XW_H;5\\5]#_  U_Y$?2O]QO_0VKWLF_CR]/U1\?Q/\ [K#_
M !?HSIJ***^O/S4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *^=/VI_ OB[Q_JVA6VA:--J%A
M9022/+&Z*/,=@"/F8'("#_OJOHNBM*=1TY<R,:U)5H.#>A\9_!OX!>+]-^)F
M@WVN:'+8Z;9S_:9)I)(V 9 63@,3]\+7V91155:KJN[,Z&'CAXN,0HHHK$Z@
MHHHH **** "BBB@ HHHH **** "BBJ^H7L6F6%S>3MM@MXFED/HJC)_04;BV
M+%%?,_\ PVS8_P#0J7'_ (&K_P#$5](:?<O>6%M<20FWDEB5VB)R4) )7/?&
M<5K.E.G\2,*5>G6O[-WL6****R.@**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ JUI?_ "$(/]ZJM6M+_P"0A!_O5</B1G/X'Z$_
MQ)_Y$'7_ /KSD_E7R#7U]\2?^1!U_P#Z\Y/Y5\@U\UQ%_'AZ?J?=\%_[K5_Q
M?H@HHHKY0_0PHHHH **** /:/V>/AM%K]])XAU*$2V5G)LMHG&1)*.2Q'<+D
M?C]*]-^+GQB@^'L265G&EYK4R[EC<_)"O9GQR<]AQZY'?H?AKH\?AOX?Z):\
M)LM5EE/;<XWN?S8U\@>+?$$OBGQ+J6JS,6:ZF9U!_A3HJ_@H _"ON\15>39?
M3IT=*D]6_P _\D?D.#H+B;.*U?$ZTJ6B73>R^^S;^[8V]0^,/C'4K@S2:_=1
M$G(2W(B4>V% KI?!?[0WB#0[R./69/[8T\MAPZ@3(.Y5AC/T;/ID5Y117R=/
M,,53G[2-1W];GZ+6R;+Z]+V,Z$;>22MZ-:H^V-:TC1OBGX-\HR+<6%[&)8+A
M!\T;=G'H0>"/J#WKXWUW1+GP[K5YI=X EQ:RF)\=#@]1[$8(]C7O7[+OB.2X
MT[5M$E9F6W=;B$'G ;(8#TY /XFN7_:<T5++QC8Z@B@?;K7#X[NAQG_ODH/P
MKZ;-%#'X"GF$5:2T?Y?GMZGPF02J91FU;)Y2O!ZQ^Z_XQW\T5K3]FOQ)J%E#
M=VVIZ-/;S1B6-TFEPZD9!'[KN#7EEW:3:?=S6UQ&T-Q"YCDC<8*L#@@_0U]$
M_LV^/?[0TV;PS=R9GM 9;0L?O1$_,O\ P$G/T/M7/?M)> O[.U.+Q+9Q8M[P
MB*Z"CA90/E;_ ($!^8]ZX<3E]">!CC,)?^\M_P"K/\-3U<!G.+I9M/+,P:U^
M!VM?JOO7XJQYIX%\!:G\0=5DL-,,*/'&99);ABL:C(') )R2>!BM#Q_\+-2^
M',5HVIWVGS27+$1PVLCL^ .6(9 ,<@=>]?07P6\(0^ ? GVV^"V]W>)]LNY)
M./+C )53Z;5R3[L:^<_B5XUE\>>+;O4V+"V!\JVC;^"(=/Q/+'W)K/$X&A@L
M#"=6_M9[>2_X;\6;X#-<5F>:U:=!KZO3T;MN]M'YN[]%YESP!\)M7^(UI=W&
MFW-E ELXC<7;NI)(SQM1JR_''@B^\ :T-,U"6WFN#$LVZV9F7!) Y90<\'M7
MMO[*_P#R M=_Z^4_]!KB/VE_^2C1_P#7C%_Z$].M@*,,KABE\;?ZL6&S;%5<
M^JY?)KV<5=::[)[_ #/**[_P3\$O$GC6V2\BBCT^P?E;B[)7S!ZJH!)^O ]Z
MN_ GX>Q>-O$SW-]&)-+TX+)(C#B5R?D0^W!)^F.]?17CWX@:7\.M(6ZOB7DD
M)2WM(L;Y2/3T XR>W'<@5IEF54JU%XO%RM37X_UMYF.>\08C#8F.79=#FJO?
MK:_2W>VKOHE^'BE[^RYK,5L7M=8LKF8+GRW1HP3Z \_KBLGX4^%=5\(_&G1+
M+5K.2TG_ 'Y7=RKCR).58<$?2MY/VJ+_ .VAGT&V-IG_ %:SMYF/][&/TKV+
MPEXFT/XD6%EK-FBR3V;L0DH'FVTA4JP/U4GV/X<>GAL)EF)KPE@IVE%IV=]4
MGKO_ %Y'@8W,<]P.%J0S2FI0J1E&ZMHVFEMI]Z]&<E^TO_R3F/\ Z_HO_07K
MY7KZH_:7_P"2<Q_]?T7_ *"]?,.EZ9<:SJ=K86J>9<W,JPQKZLQP,_G7E\0)
MRQUEV1]!P;)0RERD[)2E^AH>%O!VK^--0^QZ19O<R#EVZ)&/5F/ _KVKU.V_
M9:U=[?=<:U9PSX'[N.-W7/INX_E7MWA+PQIGPY\*I9Q,D,%O&9;FZDPN]@,M
M(Q_S@ #M7D_B7]J!;>_>'0]*2XMD.!<W;E?,]P@Z#TR<^PKT%EF R^E&6/E>
M3Z:_A;73OL>*\^S?.,1*&3P2A'JTOQ;T5^RU/-_'/P:\1>!86N;B%+W3UZW=
MH2RI_O @%?KC'O6QHW[.?B37-(L=1@O=*2&\@CN(UDED#!74, <1D9P?6O5_
MAS\<M,\?W!TC4K1-.OYE*K&[!X;CCE1D<$\_*<Y]:]-L+*#3+&VL[:,16UO&
ML,48YVHH  _("NG#9-@,4W6I2<H/IU3_ *[G%CN)\WP$5AL134*JZVNFOOMO
MU6GI8^#OLK?;/LV5\SS/+SVSG%?5WP5^&NJ?#BUU6+4I[2=KMXV0VKLP 4-G
M.Y5]17RO=3&WU>:4 $I.6P?9J^K_ (/_ !-N_B5;:G+=6<-F;1XU40L3NW!C
MSGZ5Y?#ZPZQ3Y_C^S]SN>_QC+%O +V27LOM]]X\MOF<U\7?@MK?C_P 5IJ>G
MW5A# +9(=MU(ZMD%B>%0C'([UX;X[\":A\/-8AT[49K:>>6 7"M:LS*%+,N#
MN53G*GMZ5[Y\5?C;?_#[Q.NEVVFV]W&;=)O,E=@<DL,<?2O"/B+X^N/B-K<&
MI7-K%:216ZVX2)B00&9L\_[YHSE8#FJ.FW[6^N]O,.&99O[.DJR7U?ETVOY>
M9L>"O@EKOCS0UU73[O3X;=I&CVW,CJ^5Z\*A'ZURGB?PW<^$_$%WI%Y+"]Q;
M,%=X22G(!X) /?TKZ9_9P_Y)I%_U]2_S%>#_ !L_Y*EK_P#UU3_T6M<^-P%&
MAE]'$0^*5K_<V=N69MBL7G&)P55KDA>VFNDDOU.AE_9K\3I8O=1WVDW$8C,J
MB*:4EQC(V_N\9/:O)Z^P/@;XD_X23X=:<7?=<66;.7_@&-O_ (X5KYG^)WAW
M_A%_'>LZ>J;(5G,D([>6_P RC\ <?A1F> HT</2Q.'ORRWZ[JZ_4619OBL3C
M<1@,:US0VLK:)V?Z,Y>O2?"GP$\1>+] M=7M;G3[>VN03&ES)(KX#$9("$<X
M]:\\LK274+R"U@7?-/(L2+ZLQP!^9K[6OI[;X=^ 9'0#R-*L=J#'WRJX4?4G
M'YU.3X"EC'4J8CX(K^OP1IQ+F^(RY4:.#M[2H^JOIM^+:/C+7]'D\/:U>Z9-
M-#/-:2F&22W8LA8<'!(!X.1THT30K_Q'J,=AIEI)>7<GW8XQV]2>@'N>*JRR
MS7UT\CEIIYG+$XR68G^I-?8/PM\!6GPY\*()A&FH2H)KZY;'!QDKG^ZO3TZG
MO7/EV7_VC7DE[L%J_3HO4Z\ZSG^Q<+%R7-5EHET;ZOT\O.QY!I7[+^NW,2O?
MZG96+'K&@:5E^O0?D35'Q#^S;XFTBW>>QEMM651DQ0DI+^"MP?SS[5U'BG]I
MYK?4I(-!TR*XM8R5%S=LW[SW"C&!]3^ K>^''[0=KXLU.'2M6M%TV^G;9#-&
M^8I&[+SRI/0<G->['#Y)5G]7A)\VU[O?\CY.>-XIH4_K=2"<-W&RT7HGS?C<
M^8YX)+:9X9HWBEC8J\;J592.H(/0TROI+]HWX>17^D?\)/9Q!+RTPMUM&/-B
M/ 8^I4X_ ^PKYMKYG'X*> KNE+7JGW1]YD^:4\WPJQ--6>S79_UJ@HHHKSCV
MS[FTS_D3;3_KP3_T6*^&:^YM,_Y$VT_Z\$_]%BOAFOM.(_AH>C_0_+N"/BQ?
MK'_VX]-\-_L_>(O%&AV>JVEYID=O=)YB+-+(' SCD",CMZUF^&/@OXD\5:A=
M06T,4-K:SO;R7TS%82RD@[>,MT/0?7%?2GP>_P"29>'O^O8?S-<]\3/C3I_P
MXG72K&R6^U(+O>(-LCA!Y&[ Y)SG ]<YK>64X"EAZ>(K2<8V3?FVMD<<.(LW
MKXRM@L+!3E=J.FR3:N_PWT//KG]EK5TM]T&M64L^#\DD;HN?3=S_ "KRSQ5X
M.U?P7J'V/5[1K:5AN1L[DD'JK#@_T[U[7X5_:=6\U**WUW3([2VE8+]JMG)$
M>3U93U'J0>W2O3?B3X.MO'_@^ZLPJ27/E^=9S#G;(!E<'T/0^QK*668#'4)3
MR]^]'IK^NNO1[&]//<VRG%0I9Q%.$^NFGFFM-.J>I\9VELU[=P6Z%0\SK&I;
MH"3@9KZR^"_PXU+X<Z;J5OJ4]I.]S,LB&U=F  &.=RK7R=97#6%]!<!=S0R*
M^T\9(.<?I7UQ\(?B3<_$G3M0N+JSALVM95C"Q,2"",\YKEX=5#ZQ[_Q]/N=S
MT.-'B_J:5)+V7VMKWNN6QR/Q9^"6O>//%\FJV-YI\5L88XE2YED## .> A&,
MGUKYWU*PDTO4;JRE*M+;2O"Y0DJ64D'&>W%?27Q/^.=_X"\5R:3;Z9;74:1)
M)YDKL"=PSVKYNU6_;5M5O+UD$;7,SS%%.0I9B<?K7/G:PGMG[!OGN^8[.%GF
M/U:*Q27LN5<EK7MY_(^W-,_Y$VT_Z\$_]%BOAFON;3/^1-M/^O!/_18KX9KT
M.(_AH>C_ $/(X(^+%^L?_;BQI^GW.JWD5I9P275S*VU(HE+,Q]@*];T7]F/7
M[Z!)=0O[33&;_ED,S.OUQ@?D37H_P#^'D/A?PS#J]S$#JNI1B3<PYBB/*J/3
M(P3^ [5!\1OV@;'PAJ4NF:9:#5;Z$[9G:3;%$W=<CEF'<<8]<Y%3ALJPF&PZ
MQ.82M?9?\-JW^0\;Q!F&-QLL#DT+\N\M.F^^B7KOT/,?$_[.?B70K1[FS>#6
M(T!+1VV5E ]0IZ_0$GVK'\#?!G7/'^E3W]A<6-O%#<-;/'=NZN'"JQX"'CYA
MW[&O3/"/[3D-]?Q6NOZ<EE%(P7[9;.2B'_:4\X]P3]*]JTZQL[47$]E'&JWL
MOVF1XC\LCE5&_P!.0J\CKUKJP^59=C9^TP\FXK==5V\S@QO$&=973]CC::4W
MK&5E9]UII^375:GQ/XR\)7G@C7YM(OI();F)59FMV9D(8 C!(!Z'TJ]X!^'6
MI?$:\NK;39[6"2VC$CFZ=E!!..-JM6_^T+_R5+4?^N4/_HM:Z?\ 98_Y&'6_
M^O5/_0Z^?I8.E/,WA7\/,U]US['$9CB*>1+'Q:]IR1>VEW:^GS.-\1?!7Q)X
M?UC3M+"6^IWM\KO$EB[,%"XR6+*H Y'/2NMT[]EW6I[8/>:M9VDQ7/E(K28/
MH3Q^F?QKW;QEXJTOP1I$VLZEP$'E($4&21CR$7ZXSZ<9[5XD_P"U1J'VPLN@
MVWV3/^K,[;\?[V,?I7O5\!E6!J-8F3UV6NB^1\EA<WXAS:@I8*"7+O+35^5]
M-K?J]3B_&_P3\1>"+9[R6.+4-/3EKFT).P>K*0"/KR/>N1T#P]J/B?4H[#2[
M5[RZ?HB#H/4GH![FOLKP1XUTWXAZ +^S'R$F*>VEP6C;NK#N"#U[BL)-.\-?
M [P_JNJ!"D=Q<%]J@&1R<[(4]ASC\2:BKD6'E*->E4M1:N_)>7_!V+P_%F,I
MQGA,11OB$[125KOS7EY;^6YY7I_[+FM36V^\U>SM9B,B*-&D /H3Q^F:Y3QO
M\$O$?@BV>\ECCU#3TY:YM"6V#U92 0/?D#UKM'_:HU#[8670;;[)G_5F=M^/
M][&/TKV?P1XUTWXB:!]NLP=I)BGMI0"T;8Y5O4$'KW'XBJI8'*<<G1PTFIKU
M_)[_ "(Q&;<192UB,=!.FWJM-/*ZU7DW=>I\2UN^"_!M[X[UU-*L)8(;AT:0
M-<LRIA1SR 3^E;?QC\&Q>"?'-W:6R>78W"BYME[*K9ROT#!@/8"M?]G+_DIM
MO_U[3?RKYBCA+8V.%K?S6?WGWN)S#FRN>/PS^PY*_I?7]2CXM^!_B+PC'8&9
MK34);V<6T,%@SNY?!/0H., UT>B_LQ:]?6R2ZCJ%IIK-SY(!E=?KC _(FOHG
M7]5L/#^F3:KJ++';V:ES*RY*YXPON>GXUX1J/[4]W]N/V'0X19@\"XE)D8>O
M' _6OJ<1EV58"I?$2>NRU^_34_/\%G6?YM1M@H*\=Y:;]$KZ;>OR.6\6_L_>
M)?#%F]Y"(=6M8UW/]D)\Q1W)0C)'TS7G>G:==:O>PV=E;R75U,VV.*)<LQK[
M#^&OQ.T_XD:=++;QFTO8,">T=@Q7/1@>-R^^!TZ4V/PMX<^'%YK_ (L=5MO/
M7S)6V\1#C*H/5FYQW) J*N1X>OR5\+.U-[WZ+NORUV-:'%>-PCJ83'TKUEI%
M);M]';[TUN>-:+^S#KU[;K+J&HVFFLW/DJ#*Z^QQ@?D36/XM_9^\2^&;1[N
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MVN^NNOE;R/%/%7@[5_!>H?8]7M&MI6&Y&SN20>JL.#_3O6+7VE\2?!UMX_\
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MSC.*TXY1!*G'J[:_?IKV2NNIR_BK]GOQ1X<MGN8%AU>W09869/F*/781D_\
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M0Y5#V^84U*F^JY;QOM\/ZZ=+G@OBCX!>(?"6@7>K7EYILEM:J&=8)9"YR0.
M8P._K7-^ OA]J/Q$U*XLM-FM898(O.8W3LJD9 XVJ>>:^H?C9_R2W7_^N2?^
MC%KYD^''Q$N?AQJEU>VUI%>//#Y)65B !N!SQ]*X\PP6$P6-ITY75-J[_$]3
M)LTS'-,KK5H6=92M'1);)_JSZ^TO2Y;+PS::<[(9X;-+=F4G:6"!21QG&?:O
MG3_AE[Q5_P!!#1_^_P!+_P#&J^C=,U5K[PY:ZDT:K)-:)<% > 2@;'ZUX#_P
MU/JW_0$LO^_CU])FBR]QI?6V]G:U_+_@'P^0/.5*O_9R3=US7MOK:UWZGBUI
M;->W<%NA4/,ZQJ6Z DX&:]*U[]GGQ'X=T6]U.YO=+>"TB:9UBED+$ 9. 8P,
M_C7GN@?\AW3O^OF/_P!"%?9/Q1_Y)UXD_P"O&7_T$U\ME> HXNA6J5=XK3[G
M_D?H&?YMB<NQ>&HT&K5'9W5^J7ZGQ14MK:S7UQ';VT3SSR,%2*-2S,3T  ZU
M%7U#^S_\.(= T"+7[R -JM^F^(N.883TQ[L.2?0@>M>=E^!GCZWLHNRW;[(]
MO.LVIY/A?;S5V]$N[_R[GG/A_P#9K\2ZK;I-?3VNDJP!$4I,D@^H7@?G5K5_
MV8->M(6DL-2LM09>D3[HF;Z9R,_4BNZ^(7[0]EX6U2;3-*LUU2[@;9-,TFV)
M&'51CEB._0#WK+\(?M-V]_?Q6VO:<MA'(0HN[=RR(?5E/('N"?I7TKPV20G]
M7E-\VU[O?UV_0^$6.XIJT_KD*:Y-^6RV]+\WXW/ M9T2_P##VH26.I6DEG=Q
M_>BE7!QZCU'N.*HU]C_%/X>6?Q$\-N$1/[3@0R65RN,YQG:3W5NGY'M7QU)&
MT,C(ZE'4E64C!!':OG\SRZ67U5&]XO9GV60YW#.:#G;EG'22_)KR?]=STOPW
M^S]XB\4:'9ZK:7FF1V]TGF(LTL@<#..0(R.WK6;X8^"_B3Q5J%U!;0Q0VMK.
M]O)?3,5A+*2#MXRW0]!]<5]*?![_ ))EX>_Z]A_,USWQ,^-.G_#B==*L;);[
M4@N]X@VR.$'D;L#DG.<#USFOHY93@*6'IXBM)QC9-^;:V1\3#B+-Z^,K8+"P
M4Y7:CILDVKO\-]#SZY_9:U=+?=!K5E+/@_))&Z+GTW<_RKRSQ5X.U?P7J'V/
M5[1K:5AN1L[DD'JK#@_T[U[7X5_:=6\U**WUW3([2VE8+]JMG)$>3U93U'J0
M>W2O3?B3X.MO'_@^ZLPJ27/E^=9S#G;(!E<'T/0^QK*668#'4)3R]^]'IK^N
MNO1[&]//<VRG%0I9Q%.$^NFGFFM-.J>I\6UI^'?#6I^*]12QTJSDO+EN=J#A
M1ZL3PH]S6:05)!&".U?6WP$\+V_A_P"']E=+&/M>I#[3-)CD@D[!] N/Q)]:
M\#*\!_:%?V;=DE=GV.?9O_8^$]M&-Y-V2Z7[OR1YGIW[+FLS0JU[J]G:R$9V
M1HTN#Z$_+6#XM_9^\2^&+-[R$0ZM:QKN?[(3YBCN2A&2/IFNR\5_M,7>GZY=
MV>DZ5;26MO(T7G7+,6D(.-P (P./>O1OA5\48/B5IEPQM_L>H6I43P!MRD'.
MUE/H<'CM7T=/!9/BIO#49-3[Z]/70^(JYIQ)@*2QN)BG3TNK+1/TU7X^9\=4
M5Z5\?O"5OX7\=/)9QB*UU"(70C485')(<#\1G_@5>:U\;B*$L-6E1GO%V/T_
M!8N&.PT,33VDK_\  ^6P4445SG:%%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %?6OPR_Y)MHO_ %Z?XU\E5]:_#+_DFVB_]>G^-?4\
M/?QY_P"']4? <9?[I2_Q?HRO1117TA\(%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !70^'?^/)_^
MNA_D*YZNA\._\>3_ /70_P A710^,X\5_#*GB+_CZB_W/ZFLFM;Q%_Q]1?[G
M]3634UOC9IA_X40HHHK$Z HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** )K+_ (_(/^NB_P Z
M[YONGZ5P-E_Q^0?]=%_G7?-]T_2O6P7PR/GLS^*)C4445Z1Y 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5QGQ9\5
MGPMX2G,,FR]N_P#1X,'D9'S,/H,\^N*[.JU]I5EJ>S[99V]ULSM\^)7VYZXR
M..@H$?'%?17P/\*?V)X9.HS)BZU$B09'(B'W!^.2WXCTKLO^$6T7_H$6'_@,
MG^%:<<:Q1JB*$11A548 'H* L+1110,**** "BBB@ HHHH **** /-OCEX5_
MMGPTNIP)NNM.)=L#DQ'[WY<-] ?6OGBOL]T66-D=0Z,,,K#((]#69_PBVB_]
M BP_\!D_PH%8POA3XJ_X2KPE;O*VZ\M?]'GSU) X;\1@_7-=C5:RTNRTP/\
M8[2"UWXW>1$J;L=,X'/4_G5F@ HHHH&%%%% !1110 4444 %%%% !1110 44
M44 %%%% !117+:]\5/!_A?4Y-.U?Q+INFWT84O;W-RJ.H(R,@GN"#0(ZFBN%
M_P"%Z?#W_H<]%_\  Q/\:/\ A>GP]_Z'/1?_  ,3_&@+G=45PO\ PO3X>_\
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MUJ?44VG1?ZU/J* .FHHHH("BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MKG_B#_R(VO?]>4O_ *":Z"N?^(/_ "(VO?\ 7E+_ .@FL,1_!GZ/\CKP?^\T
M_P#$OS/A^BBBOQ$_JH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *^A_AK_P B/I7^XW_H;5\\5]#_  U_Y$?2O]QO
M_0VKWLF_CR]/U1\?Q/\ [K#_ !?HSIJ***^O/S4**** "BBB@ HHHH ****
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M\/:4R[HKB]C$@QG,8.Y__'0:_1VOC#]CWP]_:?Q)NM3=<QZ99.RMZ22$(/\
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MTFOU/RO@^2PN+Q>!J:23_)M/\T<U1117Q1^J'M/[+:$^+-7?'RBR )]S(O\
M@:U?VK'4OX84$%@+HD=\?NO\*W/V:?"DFD^&KS69TV/J3@1 CGRDR,_BQ/X
M&O._VD/$*:OX\6QA</'IT B;'_/1CN;]"H^H-?;5$\/D2A/>;7YW_)'Y50DL
M9Q9*I2U5-._RCRO\78\\\->(+KPMKUCJMFV)[60.!G 8=U/L1D'ZU]H6-QI?
MC_PQ:W)B2[TZ]1)O+<9&0P.#[JRX/N*^)-.T^?5;^WLK6(S7-Q(L<<:]68G
M%?:G@GPW:^ _"VFZ.LJ[D&UG+8\V9LLV,^IS@>@HX;=1NI!K]WU]?^"M_D+C
MB-&*H58NU:^EM^5:W^3V^9YI^TCX^_LW2XO#-G)_I-X!)=%3]R('A?JQ'Y#W
MKYNKZ(_:5\!FYM;?Q/:1YDA @O HY*9^1_P)P3[KZ5\[UY.>NL\;+VNW3T_K
M?S/H^$EAUE<'A][OF[\W7\+6\K'T=^RO_P @+7?^OE/_ $&N(_:7_P"2C1_]
M>,7_ *$]=O\ LK_\@+7?^OE/_0:XC]I?_DHT?_7C%_Z$]>KB?^1'2]?U9X&"
M_P"2LK^C_*)ZC^S9IRV?P[-P%P]W=R2%NY"X4?\ H)_.O'/C[KTNL_$B_B9R
M8+$+;1+V& "W_CQ/Z5[/^S??K=?#=(006M;J6(CTSA__ &:O$OCKH\ND_$S5
M2ZD1W12YB8_Q*RC/Y,&'X4\PNLGH<FVE_N?ZD9,D^)<6ZOQ>];[U^GX' 5ZI
M^SCKLVF_$)-/5CY&HPO&Z=BR*74_4;6'_ C7E=>F_L[:5+?_ !+M+E%/EV,$
MLTC8X&Y#&!^;_I7S>6.2QM+DWYE]W7\#[C/53>5XA5-N5_?;3\;'K?[2_P#R
M3F/_ *_HO_07KR#]GO3EU#XFV+NNX6L,L^#V.W:#^;"O7_VE_P#DG,?_ %_1
M?^@O7D?[.U\MG\3;6-B!]I@EA&>YV[O_ &6OI<PM_;-+F_N_F?"Y-S+AC$<F
M]I_EK^!ZQ^TIKTNE^!8;*%RC:A<K'(1WC4%B/S"_K7RW7T_^TWH\M[X*L[V-
M2PLKL&3'9'!7/_?6T?C7S!7F\0N7UY\VUE;T_P"'N>[P8J:RI<F_,[^O_#6)
M;2ZFL;J&Y@D:*>%Q)'(O56!R"/H17W3X<U,ZUX?TS42-IN[6*<CTWH&_K7PF
MB-(ZHBEW8X"J,DGT%?=/A;37T?PSI&GR?ZRTLX8&^JH%/\J]+AARYZJZ67WZ
MGA\=JG[/#O[5Y?=I_P  ^'-1_P"0A=?]=6_F:^@/V5/^0?XB_P"NL'\GKY_U
M'_D(77_75OYFOH#]E3_D'^(O^NL'\GKR<D_Y&,/G^3/HN*O^1+4_[=_]*1QW
M[2__ "4:/_KQB_\ 0GKRBO5_VE_^2C1_]>,7_H3UY17%FG^^U?5GJY!_R*\/
M_A1]7_LX?\DTB_Z^I?YBO!_C9_R5+7_^NJ?^BUKWC]G#_DFD7_7U+_,5X/\
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M/@BTLHG*_;;M1)C^)%4MC_OK:?PKY@KZ9_:@TY[CPAIMX@RMM>;7QV#(>?S
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M/_\ (@:;_P!@R+_T4*^'ZUXB^##^C_0Y^"_XF,_Q+_VXO:!_R'=._P"OF/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MWCG_ *%J]_[Y'^-'_"EO'/\ T+5[_P!\C_&OJ/JF6?W?O_X)^+?V[QGWJ_\
M@O\ ^U/2/^&N]8_Z %C_ -_GH_X:[UC_ * %C_W^>O-_^%+>.?\ H6KW_OD?
MXT?\*6\<_P#0M7O_ 'R/\:/JF6?W?O\ ^"']N\9]ZO\ X+_^U/2/^&N]8_Z
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M+AT<>H(X(J:@=CYH_9&^'WCGP1JGB.W\2M?Z=IELJ00:=/('@DE8[C)'U&
M!E3@[N<XX^EZ** "BBB@84444 %%%% !1110 4444 %.B_UJ?44VG1?ZU/J*
M .FHHHH("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KG_B#_ ,B-KW_7
ME+_Z":Z"N?\ B#_R(VO?]>4O_H)K#$?P9^C_ ".O!_[S3_Q+\SX?HHHK\1/Z
MJ"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "OH?X:_\B/I7^XW_H;5\\5]#_#7_D1]*_W&_P#0VKWLF_CR]/U1\?Q/
M_NL/\7Z,Z:BBBOKS\U"BBB@ HHHH **** "BBB@ HHHH *_.+XJ_\E0\8?\
M88O/_1[U^CM?G%\5?^2H>,/^PQ>?^CWKT<%\3/%S/X(^I]K_ +.W_)%_"_\
MUP?_ -&O7HU><_L[?\D7\+_]<'_]&O7HU<=7XY>K/3H?PH^B_(*^2?VU?^1E
M\-?]>DO_ *&*^MJ^2?VU?^1E\-?]>DO_ *&*VPO\5'+C_P#=W\OS#]BK_D9?
M$O\ UZ1?^AFOK:ODG]BK_D9?$O\ UZ1?^AFOK:C%?Q6& _W=?/\ ,_.+XJ_\
ME0\8?]AB\_\ 1[UG67@[7M2M8[FTT34KJWD&4FAM)'1N<<$#!K1^*O\ R5#Q
MA_V&+S_T>]?:_P"SM_R1?PO_ -<'_P#1KUZ52JZ5--(\6CAUB*THMVW_ #/A
MJ7P=XCT\":31-4M@G(D:TD3&.<YQ6[X/^-/C+P1<1OI^MW,D"G)M+MS- P]-
MK'C_ (#@^]?H=7S?^UM\,M+/AE?%ME:Q6FHV\Z1W;Q*%\]'. 6 ZL&(YZX)S
MT%80Q,:LN2<=SKJX*5"+J4Y['I?P9^,NG_%S19)4C%EJ]K@7=D6SC/1T/=3C
M\#P>Q/HM? /[//B6;PS\7- >-RL5[,+&9.SK+\H!^C%3]0*^_JX\125*=ELS
MT<'7=>G>6Z/SB^*O_)4/&'_88O/_ $>]9UEX.U[4K6.YM-$U*ZMY!E)H;21T
M;G'! P:T?BK_ ,E0\8?]AB\_]'O7VO\ L[?\D7\+_P#7!_\ T:]>G4JNE332
M/#HX=8BM*+=M_P SX:E\'>(]/ FDT35+8)R)&M)$QCG.<5N^#_C3XR\$7$;Z
M?K=S) IR;2[<S0,/3:QX_P" X/O7Z'5\W_M;?#+2SX97Q;96L5IJ-O.D=V\2
MA?/1S@%@.K!B.>N"<]!6$,3&K+DG'<ZZN"E0BZE.>QZ7\&?C+I_Q<T625(Q9
M:O:X%W9%LXST=#W4X_ \'L3Z+7P#^SSXEF\,_%S0'C<K%>S"QF3LZR_* ?HQ
M4_4"OOZN/$4E2G9;,]'!UW7IWENCXW_:J^+%QX@\3R^%+"9H])TQ@MR$.!//
MWS[)G&/4$^E<9\(O@1K?Q9:6X@D33-(A;8]_,A8,W]U%XW$=^0!GK7 ZUJ+Z
MQK%]?R$F2ZGDG8MURS%C_.OT0^%VA0^&?AUX=TZ% @BL8B^T=790SG\6)/XU
MWU)?5Z:C'<\FA#Z[7E.IM_5CQ.Y_8HTQK4BW\3W:7..'DM59,_[H8']:^?OB
M5\+]:^%>N+I^K(K)*"]O=P$F.90>2#U!'&0>1QV()_1:O%_VM-$AU+X1W%XZ
M!IM.NH9HW[KN;RR/H=_Z#TKGHXF;FHR=[G;BL%25-R@K-#OV8?BA<>/_  ;+
MI^I3>=JVD%87E8Y::(C]VY]3P03[ GDU[-7Q%^R5KK:5\6H;/?B/4K2: KV)
M4>8/_0#^=?;M88F"A4=NITX*JZM%-[K0^,+_ /9&\<W-]<3)+I6R21G&;ELX
M))_N5!_PR!X[_P">ND_^!3?_ !%?:U%7];J&?]G4?,^*?^&0/'?_ #UTG_P*
M;_XBN.^)/P5U[X66-G<ZW/8$7<ACBCMIB[M@98X*C@9 _P"!"OT'KX0_:5\>
M_P#";_$R\C@DWZ?I0^Q08/#,I_>-^+9'T45TT*]2K.SV.'%X6C0IW5[O8N?L
MHZ#=:I\7[&^A7_1],@FGG<] &C:)1]27''H#Z5]/?'KP/JGQ#^'L^CZ0D3WK
MW$4@$S[%PIR>:YK]E/P)_P (K\.5U6>,+?:TPN22.1",B(?B,M_P.O:JYJ]7
M]]S+H=^%H)8?DE]K]3\]_B%\$_$OPQTVVOM;2U2WN)O(0P3ASNP3R,>@-;_[
M*W_):-*_ZX7'_HIJ]D_;1_Y$70_^PE_[2>O&_P!E;_DM&E?]<+C_ -%-7<JC
MJ4'*7F>5*E&CBXPCM='W31117B'TX5\,_M5>(?[;^+U];J^Z+38(K1<=,[=[
M?^/.1^%?<4\\=K!)-*X2*-2[NW0 #)-?FEXIUM_$GB;5=6DR7OKJ6X.>HW.6
MQ^&<5Z."C>3EV/&S.=J<8=W^1]8_L;>'OL'@/5-6=-LFHWNQ6_O1Q+@?^/-)
M7T!7&?!SPZ?"WPO\-Z<RA)$LTED7'1Y/WC#\V-=G7)6ESU&ST</#V=*,?(\%
M_;,_Y)?I?_88B_\ 1$]>(?LK?\EHTK_KA<?^BFKV_P#;,_Y)?I?_ &&(O_1$
M]>(?LK?\EHTK_KA<?^BFKT*/^[2^9X^(_P!]C\C[IHHHKR3Z S/%'_(M:M_U
MZ3?^@&OS-K],O%'_ "+6K?\ 7I-_Z :_,VO5P6TCP,TWA\S],O"__(M:3_UZ
M0_\ H KQC]LS_DE^E_\ 88B_]$3U[/X7_P"1:TG_ *](?_0!7C'[9G_)+]+_
M .PQ%_Z(GKCH_P 5>IZ6)_W>7H?'FGZ;=ZM=+;65K->7# E8K>,NY &3P.:U
M?^$!\3_]"YJW_@#+_P#$UW_[*W_):-*_ZX7'_HIJ^Z:]&OB'2ERI'C87!K$0
MYW*VI^:<5WXA\&W*&.74M#N,[EVM);MQW'2O<?A#^U9J>FW]OIGC&7^T--D8
M(-2*XF@SW?'WU]?XAUR>E?5.O^'=,\4Z7-IVK64-_93 AHIER/J.X([$<CM7
MYX?$CPH/!'CK6]#1S)%9W#)&QZF,_,F??:1GWI0G#%)QDM2JM*K@6IPE='Z/
M12I/$DD;K)&X#*ZG(8'H0>]?+_[;O_,E_P#;[_[0KT?]EOQ--XC^$=BEPYDE
MTZ:2QWD\[5PR _174?0"O./VW?\ F2_^WW_VA7)0CR5U'M<]'%353".:ZV_-
M'S3IFBZAK<SQ:=8W-_*B[F2UA:1@/4A0>*T3X"\3#D^'-6 '_3C+_P#$U[1^
MQ=_R/6N?]@W_ -JI7V!776Q+I3Y4CS<-@57IJ;E8_->PU_Q)X*O%%I?ZEHMP
MF"$21X3CW7C(_"OHSX'_ +4=QJNI6N@>,7C,D["*WU50$RYX"R@<<]-PQVR.
M]>]^./ FC_$'0I]+U>TCGCD4B.8J/,@;LZ-U!'Z]#Q7YS:OITFBZO>V$K S6
MD[P.R]"RL5)'Y40<,4FFK,=2-7 23C*Z9^G5>"_M6?%:Z\&Z#:^'])G:WU+5
M%9IIXSAXK<<'![%CD9[!6]0:]&^#7B6;Q=\+_#FJ7#^9<2VHCED/\3QL8V8^
MY*$_C7+?%/\ 9UT_XJ^)EUF]UF\LY$MTMDAA16554L>_NQ->?2485/WG0]BL
MYU:/[G=GQUX!^'^L?$GQ!'I&C0K).5+R2R$K'"@ZLYP<#D>IR0!7T%:?L31F
MU'VGQ8PN2.?*L04!_&3)_2O7?A%\&-,^$5OJ*V5U-?S7K(7GG10P50<*,=LD
MG\:]#K>KBI.7[MZ''A\!!0O55V? 7Q<^!>M_"5X;BYECU'29W\N*^@4J V,[
M74_=) )')!P>:[;]DWXFW6B>+4\*74S2:5J>XP(YXAG +9'H& ((]=I]<^Z_
MM,_9?^%+:_\ :MN?W/E9Z^9YR8Q[]?PS7R)\#K>2Z^+GA1(E+,+^-R!_=7YF
M_0&NF$O;T7SG'4IK"XJ*I];'Z&UYY\=?B7_PK#P'<W]NR_VK<L+:R5AG]X1R
M^.X503Z9P#UKT.OCO]LKQ&]]XYTO1E8^1I]GYI';S)&.?_'53\S7G8>"J5$F
M>QBZKHT7);GA\$&J>+M>6*)9]4U:_FX'+R32,>23W/O7N&C?L:>*+RT674-6
MT[3IF&?(7=*R^S$ #/T)^M;?[&/@Z">?6_$\\8>6 K96S$?<)&Z0CWP4'T)]
M:^J:[:^)E"7)#H>9A,%"I#VE36Y^?WQ-^!'B?X6P)=ZA'#>:8[!!>V;%D5CT
M# @%?Q&/>MK]F[XK3^ ?&=OIEU.QT'595AFC9OEAD; 24>G. 3Z?05]L:[HM
MIXCT:]TN_B$UG=Q-#*A[J1CCT/I7YL:[I4OA_7=1TR4_OK*YDMG.,?,C%3^H
MK2C4^L0<9F.(H_4ZD:E-Z'Z;5Q?Q?\?K\-? 6HZT%5[M0(;2-NCS-PN?4#EC
M[*:N?##Q$_BWX>^']6E;?/<V<9F;.<R ;7/_ 'T#6;\6OA7;_%K1;/3+O4)]
M/@M[C[3F!0Q9@I49SZ!C^=>7%*,[3V/>G*4J3=/=K0^!YIM5\:>(2\C3ZIK&
MHS@9/S22R,< ?R&.U?0?AO\ 8MO;JP2;7/$,=C=,,FVM+?S0GL7+#)^@Q[FO
M2?AO^S'HOPZ\66VO1:G=:C/;JXBBN(U"JS#;NX[@$_G7LU=M;%/14MCR\/@%
M9RKJ[]3XM^)W[*FL^!]&N=7TO4$UVPME,D\8A,4T:#JP7+!@!R3D'OBO//A5
M\1K[X9>,+35;61S:EA'>6P/$\)/S CU'4'L17Z(7/D_9I?/V^1L/F>9]W;CG
M/MBOS$NO*^U3>1_J=YV9_NYX_2M\/4=:+C/4Y<91CA9QG2T_X!^GD$\=U!'-
M$X>*10Z.O0@C(->7?M%_%";X:>!BUA)Y>L:DYM[5^IB&,O)^ P![LI[5WG@N
MWDM/!^A03*5FBL($=3U#"-01^=<;\7O@A9_%ZYTR2]U6YL$L$D6..!%8$N5R
M>?\ ='Y5YM/E4US['N5?:2I/V?Q,^'/#_A_5?'/B.#3=/BDO]4O9#C<V2QZL
M[,>PY))]Z^B=(_8H=K-&U3Q2(KH@;HK2TWHI[@,S M]<"O4?A-^S[I'PGUF[
MU.UO[C4;J>#R%:X11Y:Y!.,>N!^5>J5U5L5*]J;T//P^ BHWK*[/A?XM?LWZ
MW\+].;58KN/6=&1@LEQ%&8Y(23@%TR< D@9!/)YQ5?\ 9T^)MUX"\>V5H\S'
M1M5E6VNH6/RJS':DGL5)&3Z9'I7V/\4_LO\ PK7Q3]MV_9O[,N-V[_KFV/QS
MC'OBOSS\/6\EWK^F00J6FENHD11U+%P *Z:,W7IM3./$TEA:T94C]-:***\4
M^E"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M"V68O+I8AXJ'+S-6U3O;F[-]S[/^#W_),O#W_7L/YFOD?QC_ ,C=KG_7]/\
M^C&KU#P?^T9_PB?AG3](_P"$>^U?9(_+\[[;LW\GG'EG'7UKR/6=0_M;5[Z^
M\OROM4[S>7G.W<Q.,]\9HS3&T,3A:%.E*[BM='V7="R#+,7@L?BZ^(A:,WH[
MIW]YOH_/J5*^R/@G_P DMT#_ *Y/_P"C&KXWKV3P5^T1_P (=X6T_1O^$?\
MM?V1"OG?;=F_+$_=\LXZ^M99'BZ.#Q$IUY635MF^J['3Q7EV*S+"0I82'-)2
MONEI9KJUW/,O&/\ R-VN?]?T_P#Z,:O=_P!E?_D!:[_U\I_Z#7SYK.H?VMJ]
M]?>7Y7VJ=YO+SG;N8G&>^,UWGPK^,/\ PK.QOK;^R/[2^U2K)N^T^5MP,8QL
M;-8Y9B:6'QRK57:.NNO6YT9[@<1C,I>%H1O/W=+I;-7U;L6/VC?^2FW'_7M#
M_*O,*Z?XC>-O^$_\32:O]B^P;XTC\GS?,QM&,YVC^5<Q7!CJD:V*J5(.Z;;1
M[&4T*F&P-&C55I1BDUYI>1]S:9_R)MI_UX)_Z+%?#->YVW[3GV?1HK#_ (1O
M=LMQ!YGV_&<+MSCRZ\,KVL[QM#%JE["5^5.^C7;NCY?A;+,7ETL0\5#EYFK:
MIWMS=F^Y]<_ [QW%XO\ !]O;22C^T].1;>>,GYF4#"/]"."?4&N.^)?[.TNK
MZI/JGAN6&%IV,DMC,=BACU,; <9/.#T['M7A/A_Q#J'A;58=1TRY:UNXNCKR
M".X(Z$'T->W:)^U*HMT75]$9IP/FELI?E;WVMT_,UW4,QP6.PT</F&CCL_UN
MMGWZ'D8O)<SRK&RQF3ZQGO'3[K.UUVMJOSRO"7[,^K7&HH_B"X@M+%&RT5O)
MOED'H#C"CWZ^U?1.G):6MN+*R\M(;/;!Y4?2+"@A?^^2I_$5\^>*/VGKV]M6
M@T/3%TZ1A@W5PXD9?]U<8!]SGZ5A_#KX[S>!=)O;6XTM]8N+J\>\DNI+S8Q9
ME52"-C9^[G.>]=6$Q^5Y?/V=!Z/>3O\ );7_  L<&891GV<4O;XI+FC\,$TM
M]WO;[VWZ%+]H7_DJ6H_]<H?_ $6M=/\ LL?\C#K?_7JG_H=>:?$+QC_PGGBF
MYUG[)]A\Y$7R?-\S&U0/O8'7'I6G\+/B7_PK34;ZZ_LW^TOM,0BV>?Y6W!SG
M.ULU\_1Q5&.:/$N7N<S=]=G?IN?98G 8FID"P48_O.2*M=;JU];VZ=ST#]JO
M_D(>'?\ KE/_ #2O"*[SXJ_%'_A9MQITO]F?V;]D5UQ]H\W?N(_V5QT]ZX.N
M3-*]/$XR=6D[Q=OR7<]'(,+6P66TL/B(VG&]UH^K?30]H_9;_P"1NU;_ *\?
M_:BU?_:K_P"0AX=_ZY3_ ,TKSSX6_$?_ (5KJ]W??V?_ &C]H@\GR_/\K;\P
M.<[6STJQ\5?BC_PLVXTZ7^S/[-^R*ZX^T>;OW$?[*XZ>]>DL9064/"\WOWVL
M^]][6/#EEF+?$<<>H?NDK7NOY6MKWW\C@Z]H_9;_ .1NU;_KQ_\ :BUXO7:?
M"WXC_P#"M=7N[[^S_P"T?M$'D^7Y_E;?F!SG:V>E>7EM:&'Q=.K4=HIZGT&>
M8:KB\NK4*"O*2T6BZKOH>A_M5_\ (0\._P#7*?\ FE<O^SE_R4VW_P"O:;^5
M9GQ5^*/_  LVXTZ7^S/[-^R*ZX^T>;OW$?[*XZ>]97PY\;?\(!XFCU?[%]OV
M1O'Y/F^7G<,9SM/\J[ZV+HSS58E2]SF3O9]$NFYXV%R_%4^'W@90_>\LE:ZW
M;=M;VZ]SW#]J3_D4=)_Z_O\ VFU?-%>E_%+XS_\ "RM(M+'^Q_[.^SS^=YGV
MKS=WRD8QL7'6O-*PS?$4L5BY5:+O&R[_ *G;PU@J^ RZ-#$QY9)O2Z>[\FT>
MD?L]?\E2T[_KE-_Z+:O3_P!J3_D4=)_Z_O\ VFU>&?#WQC_P@?BFVUG[)]N\
ME'7R?-\O.Y2/O8/3/I73_%+XS_\ "RM(M+'^Q_[.^SS^=YGVKS=WRD8QL7'6
MNS#8RA3RNKAI2]]O16?EY6Z'EX[+,76S^AC:<+TXI)NZ_O=+WZKH>:5Z1^SU
M_P E2T[_ *Y3?^BVKS>ND^'OC'_A _%-MK/V3[=Y*.OD^;Y>=RD?>P>F?2O%
MP52-+$TZDW9)IO[SZC-*,\1@:U&DKRE&22\VCW/]J3_D4=)_Z_O_ &FU>$_#
M_P 6/X)\7:?JZ@O'"^V9%ZM&PPP^N#D>X%=5\4OC/_PLK2+2Q_L?^SOL\_G>
M9]J\W=\I&,;%QUKS2O1S3&0JX[ZQAY7M:S\UZGB9#EE2AE7U+&PLWS)JZ>C]
M&S[AUK1])^(OA5K:5EN]-O8P\<\1Y'=74]B/_K'N*^>]8_9I\36E\Z:?-::A
M:DG9*9/+;';<I'!^A-<W\//B]K7P]S;P;+[3&;<UG.3@'N4;^$_F/:O5!^U/
MIOD9.@W0F_N"==O3UQG]*]ZIB\KS2$9XM\DUZ_G9W7XGR-'+L^R&I*GEZ52D
MWI>WXJZ:?>VAK?"WX,6WPY:37-;NH9]1BC8AE.(;9<?,<G&3C/.!@9^M>B^,
M?^11US_KQG_]%M7RS\0_C5K7CZ)K/:NF:62";2%BQ?TWOQN^F /:NQUG]IW^
MUM(OK'_A&O*^TP20>9]OSMW*1G'EC.,UOA\URZA3GAZ7NQ2T=G[S=[]/3<Y<
M9P_G6+K4L97]^;>J3244K66K2[[7];L\,KZ<_9AU&*X\%7]F"//M[UG9?]ET
M7:?S5A^%?,=;W@WQMJG@35A?Z7*$<C9)%(,QRKZ,/Z]:^2RS&1P.)C5FM-G\
MS]%S_+9YK@98>F[2T:OM='M'Q3^ ^L^*?&%WK&DSVA@NPK/'<2,K(P4*>BD$
M'&?QKP_Q5X:O/!^O76D7YB-W;[-YA8LOS(&&#@=F%>RV_P"U7*L2B?PTDDO=
MH[THI_ QG^=>2>/?%G_";^++_6_LOV+[5Y?[CS/,V[8U3[V!G.W/3O7=FKRZ
MHO:X63<Y.[6O6]]UW\SR<@CG5"2P^802I1C9.\6[JR6S?2_0^EO@;X^A\7^$
MH+.:4?VIIR+#+&3\SH!A9![$8!]Q[BN(^(G[.-S>:K-?^&98%AG;>]C.VSRV
M/78<8Q['&*\/T/7;_P -ZG#J&FW+VEY$?ED3]01T(/H:]LT#]J22.V6/6=%$
MTP&#/9R[0W_ &''Y_@*]"CF&#QV'CA\PT<=G_77OT/&Q639GE.,GC,GLXSWC
MI^3M==K.ZV]:?@_]F?4IK])?$5Q#;62,"UO;/ODE'IGHH]^37LGCWQC8?#;P
MF]SB-'2/R;*T'&]P,*H']T<9] *\NU?]J=/(9=+T)O..=LEY-\H]"57K^8KQ
M;Q5XNU7QGJ9OM6NFN9L;47HD:_W54< ?Y-7+,,#EM&5/ >].77_A_P $M#*&
M3YMGF)A6SBT:<?LJVOHDWOU;=^QE7-S)>7,L\SF2:5R[N>I8G)/YU]E_![_D
MF7A[_KV'\S7QA7L_@_\ :,_X1/PSI^D?\(]]J^R1^7YWVW9OY/./+..OK7FY
M'C*.$KSGB)637F^J[7/>XJRS%9CA*=+"0YFI7M=+2S75H\O\8_\ (W:Y_P!?
MT_\ Z,:LBK>LZA_:VKWU]Y?E?:IWF\O.=NYB<9[XS52OGZC4IR:[GV5"+A2C
M&6Z2"OLWX9Z['XX^'.GS7.)F> VMTI_B91L;/U'/_ J^,J^E_P!E^TO(O">J
M32L?L4MV/(0C^(* [?0_*/\ @)KZ7AVK*.+=.UU)._R_JWS/A>-:$)Y?&NW:
M4)*WST:_7Y'0_&OQ!%X.^&EQ;6Q$,ETJV%N@/12,-CZ(",^XKY'KV#]I;Q1_
M:GBZVTB)\P:;%EP#QYKX)_)=GZUX_7-GF)]OC'&.T-%^OX_D=W">">$RV,Y_
M%4]Y_/;\-?F%%%%?/GV05]S:9_R)MI_UX)_Z+%?#->YVW[3GV?1HK#_A&]VR
MW$'F?;\9PNW./+KZ?(\;0P;J>WE:Z5M&^_9'P7%>68O,HT%A8<W*W?5+MW:/
M#*^S_@]_R3+P]_U[#^9KXPKV?P?^T9_PB?AG3](_X1[[5]DC\OSOMNS?R><>
M6<=?6L\CQ=#!UY3KRLFK;-]5V-N+,NQ6986G3PD.9J5WJEI9]VCR_P 8_P#(
MW:Y_U_3_ /HQJR*MZSJ']K:O?7WE^5]JG>;R\YV[F)QGOC-5*\"HU*<FNY]C
M0BX4HQENDC[(^"?_ "2W0/\ KD__ *,:OD[QC_R-VN?]?T__ *,:O3?!7[1'
M_"'>%M/T;_A'_M?V1"OG?;=F_+$_=\LXZ^M>3:SJ']K:O?7WE^5]JG>;R\YV
M[F)QGOC-?19GC*&(PE"E2E>45KH]-%Y'Q.0Y9B\%F&+KUX6C-MQ=T[^\WT;M
MOU/H[]G'QW%JOAX^';F4+?6&6@#'F2$G/'NI)'T(J;XL_ @>,;]]7T6:*TU.
M0?OX)LB*8@?>R <-VZ8/MR3\T:=J-UI-]!>64[VUU"V^.6,X937M_AO]J&XM
M[5(M;TD7<JC!N;1PA;W*$8S]"![5V8/,<)B<*L)C^FS_ "VV:/,S+),PP./E
MF.3Z\V\=.N^^C3>O=/8Q]"_9H\17E^BZI/:Z?9@@NZ2>8Y'HH QGZG\Z^B_#
MNE:=X;T^#1=."QQ6<2GRMV6 8G#-[L0QSZ@UXGKO[4K/;/'H^BF*<Y"S7DN0
MOOL4<_G7'> OCC?>$M3UO4-1LWUR\U1HF>1[CRMNS?P!L(Q\_ & ,5UX;&97
MEU51H-N^\G?1?=WMLO4\['99G^=4'/%I+EMRP32N[I-[VT5]WY):FW^U)_R-
MVD_]>/\ [4:L;]G+_DIMO_U[3?RK$^*7Q'_X65J]I??V?_9WV>#R?+\_S=WS
M$YSM7'6J7PY\;?\ " >)H]7^Q?;]D;Q^3YOEYW#&<[3_ "KP:F*HRS3ZRI>Y
MS)WUVTZ;GU]' 8F.0/!./[SD:M=;N_6]OQ/</VI/^11TG_K^_P#:;5\\>'M:
MG\.:Y8:I;8,UI,LRJ3@-@]#[$<?C7=_%+XS_ /"RM(M+'^Q_[.^SS^=YGVKS
M=WRD8QL7'6O-*SS;%4\1C'7H2NM+/5;>IKP]E];"98L+BX6=Y75T]&_)M'VR
MCZ-\4_!3 -]HTS48L,%.&C;K^#*P_,5\^ZU^S=XIL;^2/3Q;ZE:YRDPE6-L=
MMRMT/TR/>N3\!_$K6?A[=M)ITJR6TA!EM)LF-_?V/N/QR*]?LOVI[!H ;O0;
MA)MO(AG5E)_$ @5[DL9EV:4XO&/DFNJ_X9Z>NQ\G#+<ZR"K..6)5*4G>SMIZ
MJZ=^EUH^IM?!KX+2^!;J35M6EBFU1XS''%"=R0J>ISW8]..!SUS7*?M+^.H;
MN2T\,V<PD,+_ &B\V'@-C")]0"21[BJ'BS]IG4]3M9+;1+!=*#C:;J1_,E _
MV1@!3[\UXO+*\\KR2.TDCDLSN<EB>I)[FN7'9CAJ6%^I8#X7N_Z[]?+0]'*L
MFQV(Q_\ :F;?$OACIIVVT271;WU?GW/P8\<)X'\:0SW+[-.NU^S7+'HBDC#_
M ($#/L37TYX[\#:=\1O#_P!ANGV'(EMKN(!FC;'!'J".H[_D:^**]*^'OQTU
MGP/;1V$T2ZMI:<)!*Y5XAZ*_/'L0?;%995F=*C3EA,6KTW^'_ ]-F='$.18C
M$UX9AE\K5H_*]MFGM?IKHU^-V[_9J\60WABA:QN(<X$XF*C'J01D?K^->P_"
M[X5V/POM'N[RZCN=5N=L+W.-J)N8!8TSSRQ'/4G' KDY?VI]-$&8M!NGFP?D
M>=57VYP?Y5YKK_QJUKQ+XDTK4;U46PTZ[BNX]-@8HC%&#<MR23C&3G&3@5W1
MK91E\U6H-SETWLO/;_-GD5,-Q'G%-X?%I4Z?6UKRMTT;Z^B/H;XV?\DMU_\
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M&1\]F?Q1,:BBBO2/("BBB@ HHHH **** "BBB@ HHHH **** .(^,G@8>/O
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MBD4JR-X80A@1@@C[/TKR30+[7_A!X]TG5+K3KO2]3L)DN?LM[ T#O&<A@58
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MHFC@96]O(H7]D+#<?P7)_"OI[]L_Q%]D\*:'HJ/AKV[:X=1U*1KC!]LR _\
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M^&'C*"-Y)?"6NQQH"S.^FS *!U).WBN9KKH4E23L[GGXJO*NTY1M8_3+PO\
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M%HQGZAVKIHJCK[4XL4\0K>P_3]3RSXG?&?Q)\8;NWMKF-8+*-\V^FV88@N>
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M^W"D$K>3A@.QR#_(BO9JYZ_\27J=N&_@P] K\]OCQ:BT^,'BI NP&\:3'^\
MV?QSG\:_0FOS\_:#E$WQE\4, 1BY5>?:-1_2NG!?&_0X<S_A1]3ZH_99NS<_
M!;1T+;O(EN(OH/-9L?\ CU>MUX[^RA$8_@W8L<8DNKAACTWX_I7L5<M;^)+U
M._#?P8>B"O"?&7[66B^$/$6I:,VAW]U<V,[V[N'1$9E...2<?A7NU?.7CO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "NA\._\>3_]=#_(5SU=#X=_X\G_ .NA_D*Z*'QG
M'BOX94\1?\?47^Y_4UDUK>(O^/J+_<_J:R:FM\;-,/\ PHA1116)T!1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M )(Y/_V%9_\ T".O?ZQ/!_@G1/ .DG3- L$TVQ,K3&%&9AO( )RQ)[#\JVZ
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MH&%%%% !1110 4444 %%%% !3HO]:GU%-IT7^M3ZB@#IJ***" HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *Y_X@_P#(C:]_UY2_^@FN@KG_ (@_\B-K
MW_7E+_Z":PQ'\&?H_P CKP?^\T_\2_,^'Z***_$3^J@HHHH **** "BBB@ H
MHHH *W?!W@O4_'>IRV&E)&]Q'"9V$CA!M#*IY^K"L*O8/V7O^1_U#_L&2?\
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MJ]@KZ[ Y'A<3AH59MW:[_P# /SC-N*\PP..JX:DH\L7973O^9\G?\,Y>,_\
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M???V%A?JGM[N_+??K:_8_'5Q9F#S%86T>7GY=G>W-;ON?&%%%%? G[$%%%%
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M(S_P%=WXLIK[%KKQ<[R4%T.#+J5H.J]V%%%%><>P?/7[:/\ R(NA_P#82_\
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MN.C_ !5ZGI8G_=Y>AX/^S+IMIJWQ>TRVO;6&\MVAG)AN(PZ$B)B,@\5]J?\
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M:\I[Z'OQO97"BBBI*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)\"#QAX!FNX(R^HZ3FZAVCEDQ^\7_OD9^J"OC.OT>(# @C(/4&OACXR>!F\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>UB6)!Z@#J?<]?QK0K]EP&%6#P\**Z;^O4_F3-L?+,L;4Q+V;T\DMOP_$*^
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MC_S-/_;K_P"UJ^@*^?\ ]E'_ )FG_MU_]K5] 5^A9'_R+Z?S_P#2F?C7%?\
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M0**** "NG^''@F?Q[XJM=,CW+;_ZVYE7_EG$"-Q^IR /<BN8ZU]=_!+X??\
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MP*/LD'_/&/\ [X%']BO_ )^?A_P0_P!:8_\ /G_R;_@'RO17U1]D@_YXQ_\
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M^?GX?\$/]:8_\^?_ ";_ (!\KT5]4?9(/^>,?_? H^R0?\\8_P#O@4?V*_\
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M;_@'RO17U1]D@_YXQ_\ ? H^R0?\\8_^^!1_8K_Y^?A_P0_UIC_SY_\ )O\
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MP*/LD'_/&/\ [X%']BO_ )^?A_P0_P!:8_\ /G_R;_@'RO17U1]D@_YXQ_\
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M^?GX?\$/]:8_\^?_ ";_ (!\KT5]4?9(/^>,?_? H^R0?\\8_P#O@4?V*_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %.B_P!:GU%-IT7^M3ZB@#IJ***" HHHH **** "BBB@ HHHH **** "BBB@
M HHHH *Y_P"(/_(C:]_UY2_^@FN@KG_B#_R(VO?]>4O_ *":PQ'\&?H_R.O!
M_P"\T_\ $OS/A^BBBOQ$_JH**** "BBB@ HHHH **** "O8/V7O^1_U#_L&2
M?^C8J\?KV#]E[_D?]0_[!DG_ *-BKULI_P!^I>I\[Q%_R*L1_A_R/J"OD/\
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MRR?B1O\ R%=;^S=XA_M7P(U@[9FTZ=HP"?\ EFWS*?S+#\*ZKXK>&O\ A*O
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M]QXC^T;X._L+Q<FK0)MM-47>V!PLRX##\1AO<DUP'@GPQ-XQ\4Z?I$.1]HD
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MU*,\M4WO&2_&Z/1?%VE+K?A;5[!EW?:+62,#W*G!_ XKX7K] *^ IP%GD &
M&('YUW\3P2E2GUU7Y?YGD<!5&X8BGT7*_OO_ )(]]_91_P"9I_[=?_:U?0%?
M/_[*/_,T_P#;K_[6KZ KZ#(_^1?3^?\ Z4SX[BO_ )'-?_MW_P!(B<'X%^(T
M?B#Q)XA\/W;*FH:=>3+#V\V .0"/=> ?;!]:[ROC+Q9KEWX:^+.M:G82^5=V
MVISNC=1]]L@CN",@_6OJWP/XPL_'/ARVU6S.T2#;+"3DQ2#[RG_'N"#WK+*\
MQ^LRGAZC]^+?S5_T-L_R5X&%+&45^[FE?RE;\GNOFNQX)^T)\-/[!U,^(M/B
M T^]?%Q&@XAF/?Z-R?KGU%>-5]Y:SI%KK^EW6G7L0FM+A#'(A[@^GH>X/:OC
M#Q_X+NO 7B6YTNYR\8^>WF(XEB/W6_0@^X-?+Y]EWU:I]8IKW9;^3_X)]]PE
MG?UVA]2KO]Y!:><?\UMZ6\SZP^$O_)-O#O\ UZ)4?QA_Y)EXA_Z]C_,5)\)?
M^2;>'?\ KT2H_C#_ ,DR\0_]>Q_F*^U?_(N_[<_]M/R^/_(Z7_7W_P!O/C"B
MBBOQ\_I0***O:)HUUXAU:TTVRC,MU<R".-?<]SZ =2?04XQ<FHQ6K(G.-.+G
M)V2/2?V??A]_PE'B(ZO>1;M,TU@P##Y99NJCW"\,?^ ^M?5-8?@[PM:^#/#E
MGI-H,I GSR8P9'/+,?J?Z#M6-\5_'B> /"<]VA4ZA/F&T0]Y"/O$>BCG\AWK
M]8P.'IY3@[U-UK)^?]:(_GC-<;6XAS)1HJZ;Y8+R[_/=_P# /'_VCOB#_:NJ
M)X:LI<VMDV^Z93P\V.%^B@_F?:O%*?+*]Q*\LKM)([%F=CDL3R233*_,L9BI
MXRO*M/K^"Z(_=LLP%/+,+##4^F[[OJPHHHKC/4"BBB@ HHHH *^A_AK_ ,B/
MI7^XW_H;5\\5]#_#7_D1]*_W&_\ 0VKWLF_CR]/U1\?Q/_NL/\7Z,Z:BBBOK
MS\U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M KQ#X^? S7?BWKNF7-AJ5C9V5E;&,1W)?<9&8ECPI&,!!^%>WT5I";IOFB95
M:<:L>26QXW^S_P# R\^$=QK-UJ5[:WUU>+''$UMNPB*6+9W =25_*O9***4Y
MNH^:6X4Z<:45"&P4445!J%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %6M+_Y"$'^]56K6E_\ (0@_WJN'Q(SG\#]#H]1_
MX\9_]PUR5=;J/_'C/_N&N2KHQ/Q(X\'\+"BBBN0] **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *T=!_Y" _W36=6CH/\ R$!_NFM:7QHQ
MK?PY>AK:W_R#I/J/YUS%=/K?_(.D^H_G7,5KB/C.?!_PWZA1117*=P4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% $MK_ ,?4/^^/YUUL_P#J)/\ =/\ *N2M?^/J'_?'\ZZV
M?_42?[I_E7=A_A9YF+^*)QM%%%<)Z84444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %=#X=_P"/)_\
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M6U[KT>O_  #^A<AQO]H9=2K-ZVL_5:/[]_F?0'[*/_,T_P#;K_[6KZ KY_\
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MUIU$_=4HI>B:_/<_=,/EW]F</5:+7O.G-R]7%_EHOD?8%?,?[4?_ ".VF?\
M8.7_ -&R5].5\Q_M1_\ ([:9_P!@Y?\ T;)7UO$'^XOU1^=\'?\ (VC_ (9?
MD>-UZ)\!O#/_  D7Q$LI'3=;Z>#>29'&5^Y_X\5/X&O.Z^G/V9O#7]F^$KO6
M)%Q+J,VV,X_Y9QY _P#'B_Y"OA\GPWUG&0B]EJ_E_P &Q^K<2XWZCEE22?O2
M]U?/_@79[)7A7Q0^"?B?Q[XPNM5AO-,BM"B101S32!U11WQ&1R=QZ]Z]UHK]
M/Q>#I8VG[.K>U[Z'X-EV95\KK.OA[<S5M5?^MCY?_P"&7O%7_00T?_O]+_\
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M_@)'9P/A94L'4Q$E\;T](_\ !;^X^@/V4?\ F:?^W7_VM7T!7S_^RC_S-/\
MVZ_^UJ^@*^JR/_D7T_G_ .E,^ XK_P"1S7_[=_\ 2(GQ'\2O^2A>)/\ L(S_
M /HPUM_!SXCOX \1@7#,=(O"([I!_!_=D'NN>?49]JQ/B5_R4+Q)_P!A&?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *M:7_ ,A"#_>JK5K2_P#D(0?[U7#XD9S^!^AT>H_\>,_^X:Y*
MNMU'_CQG_P!PUR5=&)^)''@_A84445R'H!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !6CH/\ R$!_NFLZM'0?^0@/]TUK2^-&-;^'+T-;
M6_\ D'2?4?SKF*Z?6_\ D'2?4?SKF*UQ'QG/@_X;]0HHHKE.X**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@"6U_X^H?]\?SKK9_]1)_NG^5<E:_\?4/^^/YUUL_^HD_W3_*N
M[#_"SS,7\43C:***X3TPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *Z'P[_QY/\ ]=#_ "%<]70^
M'?\ CR?_ *Z'^0KHH?&<>*_AE3Q%_P ?47^Y_4UDUK>(O^/J+_<_J:R:FM\;
M-,/_  HA1116)T!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 367_'Y!_P!=%_G7?-]T_2N!
MLO\ C\@_ZZ+_ #KOF^Z?I7K8+X9'SV9_%$QJ***](\@**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ IT7^M3ZBFTZ+_6I]10!TU%%%!
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M,\IS_%9-"<,/&+4G=W3_ $:/C_\ X4)X[_Z 7_DY!_\ '*/^%">._P#H!?\
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M\V![ DC_ (#7I\2X;2&(7H_S7ZG@\"XVSJX*3_O+\G^AZ?\ LH_\S3_VZ_\
MM:OH"OG_ /91_P"9I_[=?_:U?0%>[D?_ "+Z?S_]*9\IQ7_R.:__ &[_ .D1
M/B/XE?\ )0O$G_81G_\ 1AKF^E=)\2O^2A>)/^PC/_Z,-<W7Y?B/X\_5_F?O
M>"_W6E_AC^1]1>"/C[X;;PKIRZ[JC6NJQQB.=6MY7W%> ^54CD 'ZDUY+\<?
MB';^//$D"Z=.9M)LHML+[67>[8+MA@".PY'\->;T5Z6)S?$XK#K#U+6TUUN[
M=]?GL>%@N&L#@,8\;2OS.]D[65^VE_):O0*^H/V7O^1 U#_L)R?^BHJ^7Z^H
M/V7O^1 U#_L)R?\ HJ*NKA[_ 'Y>C.'C+_D52_Q1/8*^ [G_ (^9?]\_SK[\
MKX#N?^/F7_?/\Z]?BC:C_P!O?H?-<![XG_MS_P!N-SX>?\C_ .&?^PG;?^C5
MK[@KX?\ AY_R/_AG_L)VW_HU:^X*WX9_@U/5?D<W'?\ O-#_  O\SP/]JS_C
MV\-?[]Q_*.OGNOH3]JS_ (]O#7^_<?RCKY[KYO/?^1A4^7Y(^WX2_P"1-1_[
M>_\ 2F>M? ;XH6/@BXU"PUFY:WTNX FCDV,XCE'!X4$_,._^R*[7XK?''0=0
M\%WEAX?U$W=[>?N'Q!)'LC.=YRRCJ/E_X%7SA144LWQ-'#/"QMRZJ^M]?G^A
MKB.&\#B<<LPG?FNG;3E;7=6OZZA7H'P$_P"2LZ%_VW_]$25Y_7H'P$_Y*SH7
M_;?_ -$25Q8#_?*/^*/YH]/./^1;B?\ !/\ ])9]@5\Q_M1_\CMIG_8.7_T;
M)7TY7S'^U'_R.VF?]@Y?_1LE?H?$'^XOU1^,<'?\C:/^&7Y'D-E:2ZA>06L"
M[YYY%BC0?Q,3@#\S7W/X<T6+P[H&GZ9#CR[2!(<C^(@8)_$Y/XU\O?L^>&O[
M>^(,%RZ9M]-C-TQ/3?\ =0?7)S_P&OK2O/X:PW+2GB']IV7HO^#^1Z_'&-]I
MB*>#B](J[]7M]R_,\\^.WB/_ (1WX<Z@$;;<7V+./W#??_\ ' WZ5\A5[5^T
M[XC-YXCT_18VS'90^=(!_P ]'Z _10/^^J\5KY_/L1[?&.*VCI_G^)]EPC@O
MJF61FUK4?-\ME^"O\PJ>PO9=-OK:\MVV3V\BRQMZ,I!!_,5!17SR;3NC[245
M)6>Q]XZ'JL6NZ-8ZC <PW4*3+[!AG%<-\>_#/_"0_#R[EC0-<Z>PNT/?:.'_
M /'23^ K-_9N\1_VOX&?3G;=-ILQC SSY;Y93^>\?A7JES;QW=O+!,@DBE4H
MZ'HRD8(K]@@XYE@5?[<?Q_X#/YJJJ>29J^7>G/3S5]/O1\"T5J^*]"D\,>)=
M2TJ7.ZTG:,$_Q+GY3^(P?QK*K\AE%PDXRW1_25.I&K!5(.Z:NO1GLG[+G_([
M:G_V#F_]&QU].5\Q_LN?\CMJ?_8.;_T;'7TY7Z?P_P#[BO5GX+QC_P C:7^&
M/Y'Q_P#'O_DK.N_]L/\ T1'7G]>@?'O_ )*SKO\ VP_]$1UY_7YYC_\ ?*W^
M*7YL_9\G_P"1;AO\$/\ TE!1117">N?H!7D?[3G_ "3VU_[",?\ Z+DKURO(
M_P!IS_DGMK_V$8__ $7)7[!FO^Y5?0_FKA__ )&N'_Q(^6ZZGX:>-I? 7BRU
MU(;GMC^ZN8UZO$2,X]Q@$>X%<M17Y'2J2HS52#LUJ?T;B*%/%4I4:JO&2L_F
M?>]A?V^J64%W:3+/;3H)(Y4/#*>016)XX\"Z7X^T@V.I1G*G=#<1X$D+>JGW
M[CH?P%?.7PC^,UQX#D73M0#W>ANV=HY>W)ZLGJ/5?Q'.<_4.BZ[I_B.PCO=,
MNXKVU?I)$V>?0CJ#['FOU;!8[#YI1Y96O;6+_K;S/YZS/*L9D&)52#?*G[LU
M_6C[K]#YF\0?LW^*M-N7&FBWUBWS\CQRK$Y'NKD 'Z$U%H?[.7BW4K@+?16^
MDPY^:2:99#CV"$Y_$BOJZBN/_5W!<_-K;M?3\K_B>HN-,T5/D]V_>VOYV_ Y
M7P#\/-+^'FE&UL%,D\F#/=R ;Y6_H!V';W.371W=W!86LUU<2+#;PH9))'.
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 2VO_ !]0_P"^/YUUL_\ J)/]T_RKDK7_ (^H?]\?SKK9_P#42?[I
M_E7=A_A9YF+^*)QM%%%<)Z84444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %=#X=_X\G_ZZ'^0KGJZ'
MP[_QY/\ ]=#_ "%=%#XSCQ7\,J>(O^/J+_<_J:R:UO$7_'U%_N?U-9-36^-F
MF'_A1"BBBL3H"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH FLO\ C\@_ZZ+_ #KOF^Z?I7 V
M7_'Y!_UT7^==\WW3]*];!?#(^>S/XHF-1117I'D!1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %.B_UJ?44VG1?ZU/J* .FHHHH("BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ KG_B#_ ,B-KW_7E+_Z":Z"N?\
MB#_R(VO?]>4O_H)K#$?P9^C_ ".O!_[S3_Q+\SX?HHHK\1/ZJ"BBB@ HHHH
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M$%3IU&DNA%?)<OQ51UJU%2D]VS2\2>(+KQ5KMYJM[L^U73[W$8(5>, #))P
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %6M+_Y"$'^]
M56K6E_\ (0@_WJN'Q(SG\#]#H]1_X\9_]PUR5=;J/_'C/_N&N2KHQ/Q(X\'\
M+"BBBN0] **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *T=
M!_Y" _W36=6CH/\ R$!_NFM:7QHQK?PY>AK:W_R#I/J/YUS%=/K?_(.D^H_G
M7,5KB/C.?!_PWZA1117*=P4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $MK_ ,?4/^^/YUUL
M_P#J)/\ =/\ *N2M?^/J'_?'\ZZV?_42?[I_E7=A_A9YF+^*)QM%%%<)Z844
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %.B_P!:GU%-IT7^M3ZB@#IJ***" HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *Y_P"(/_(C:]_UY2_^@FN@KG_B#_R(VO?]>4O_ *":PQ'\&?H_
MR.O!_P"\T_\ $OS/A^BBBOQ$_JH**** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MF'_Y\?E_D?-G]K7W_/[<?]_6_P :/[6OO^?VX_[^M_C7TG_PCNE?] RS_P#
M=/\ "C_A'=*_Z!EG_P" Z?X4?V15_P"?@?ZR8?\ Y\?E_D?-G]K7W_/[<?\
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M .?'Y?Y'S9_:U]_S^W'_ '];_&C^UK[_ )_;C_OZW^-?2?\ PCNE?] RS_\
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MK[_G]N/^_K?XU])_\([I7_0,L_\ P'3_  H_X1W2O^@99_\ @.G^%']D5?\
MGX'^LF'_ .?'Y?Y'S9_:U]_S^W'_ '];_&C^UK[_ )_;C_OZW^-?2?\ PCNE
M?] RS_\  =/\*/\ A'=*_P"@99_^ Z?X4?V15_Y^!_K)A_\ GQ^7^1\V?VM?
M?\_MQ_W];_&C^UK[_G]N/^_K?XU])_\ ".Z5_P! RS_\!T_PH_X1W2O^@99_
M^ Z?X4?V15_Y^!_K)A_^?'Y?Y'S9_:U]_P _MQ_W];_&C^UK[_G]N/\ OZW^
M-?2?_".Z5_T#+/\ \!T_PH_X1W2O^@99_P#@.G^%']D5?^?@?ZR8?_GQ^7^1
M\V?VM??\_MQ_W];_ !H_M:^_Y_;C_OZW^-?2?_".Z5_T#+/_ ,!T_P */^$=
MTK_H&6?_ (#I_A1_9%7_ )^!_K)A_P#GQ^7^1\V?VM??\_MQ_P!_6_QH_M:^
M_P"?VX_[^M_C7TG_ ,([I7_0,L__  '3_"C_ (1W2O\ H&6?_@.G^%']D5?^
M?@?ZR8?_ )\?E_D?-G]K7W_/[<?]_6_QH_M:^_Y_;C_OZW^-?2?_  CNE?\
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M'3_"C_A'=*_Z!EG_ . Z?X4?V15_Y^!_K)A_^?'Y?Y'S9_:U]_S^W'_?UO\
M&C^UK[_G]N/^_K?XU])_\([I7_0,L_\ P'3_  H_X1W2O^@99_\ @.G^%']D
M5?\ GX'^LF'_ .?'Y?Y'S9_:U]_S^W'_ '];_&C^UK[_ )_;C_OZW^-?2?\
MPCNE?] RS_\  =/\*/\ A'=*_P"@99_^ Z?X4?V15_Y^!_K)A_\ GQ^7^1\V
M?VM??\_MQ_W];_&C^UK[_G]N/^_K?XU])_\ ".Z5_P! RS_\!T_PH_X1W2O^
M@99_^ Z?X4?V15_Y^!_K)A_^?'Y?Y'S9_:U]_P _MQ_W];_&C^UK[_G]N/\
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ME?\ 0,L__ =/\*/^$=TK_H&6?_@.G^%']D5?^?@?ZR8?_GQ^7^1\V?VM??\
M/[<?]_6_QH_M:^_Y_;C_ +^M_C7TG_PCNE?] RS_ / =/\*/^$=TK_H&6?\
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MM_C7TG_PCNE?] RS_P# =/\ "C_A'=*_Z!EG_P" Z?X4?V15_P"?@?ZR8?\
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MW'_?UO\ &C^UK[_G]N/^_K?XU])_\([I7_0,L_\ P'3_  H_X1W2O^@99_\
M@.G^%']D5?\ GX'^LF'_ .?'Y?Y'S9_:U]_S^W'_ '];_&C^UK[_ )_;C_OZ
MW^-?2?\ PCNE?] RS_\  =/\*/\ A'=*_P"@99_^ Z?X4?V15_Y^!_K)A_\
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MZ!EG_P" Z?X4?V15_P"?@?ZR8?\ Y\?E_D?-G]K7W_/[<?\ ?UO\:/[6OO\
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MS9_:U]_S^W'_ '];_&C^UK[_ )_;C_OZW^-?2?\ PCNE?] RS_\  =/\*/\
MA'=*_P"@99_^ Z?X4?V15_Y^!_K)A_\ GQ^7^1\V?VM??\_MQ_W];_&C^UK[
M_G]N/^_K?XU])_\ ".Z5_P! RS_\!T_PH_X1W2O^@99_^ Z?X4?V15_Y^!_K
M)A_^?'Y?Y'S9_:U]_P _MQ_W];_&C^UK[_G]N/\ OZW^-?2?_".Z5_T#+/\
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M\?E_D?-G]K7W_/[<?]_6_P :/[6OO^?VX_[^M_C7TG_PCNE?] RS_P# =/\
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MF'_Y\?E_D?-G]K7W_/[<?]_6_P :/[6OO^?VX_[^M_C7TG_PCNE?] RS_P#
M=/\ "C_A'=*_Z!EG_P" Z?X4?V15_P"?@?ZR8?\ Y\?E_D?-G]K7W_/[<?\
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M .?'Y?Y'S9_:U]_S^W'_ '];_&C^UK[_ )_;C_OZW^-?2?\ PCNE?] RS_\
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M;_&OI/\ X1W2O^@99_\ @.G^%'_".Z5_T#+/_P !T_PH_LBK_P _ _UDP_\
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M^W'_ '];_&OI/_A'=*_Z!EG_ . Z?X4?\([I7_0,L_\ P'3_  H_LBK_ ,_
M_P!9,/\ \^/R_P CYL_M:^_Y_;C_ +^M_C1_:U]_S^W'_?UO\:^D_P#A'=*_
MZ!EG_P" Z?X4?\([I7_0,L__  '3_"C^R*O_ #\#_63#_P#/C\O\CYL_M:^_
MY_;C_OZW^-']K7W_ #^W'_?UO\:^D_\ A'=*_P"@99_^ Z?X4?\ ".Z5_P!
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M //C\O\ (^;/[6OO^?VX_P"_K?XT?VM??\_MQ_W];_&OI/\ X1W2O^@99_\
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MM)X>]_-?Y'Q__:U]_P _MQ_W];_&C^UK[_G]N/\ OZW^-?2?_".Z5_T#+/\
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M4?V15_Y^!_K)A_\ GQ^7^1\V?VM??\_MQ_W];_&C^UK[_G]N/^_K?XU])_\
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M?]_6_P :/[6OO^?VX_[^M_C7TG_PCNE?] RS_P# =/\ "C_A'=*_Z!EG_P"
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MK)A_^?'Y?Y'S9_:U]_S^W'_?UO\ &C^UK[_G]N/^_K?XU])_\([I7_0,L_\
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M\?E_D?-G]K7W_/[<?]_6_P :/[6OO^?VX_[^M_C7TG_PCNE?] RS_P# =/\
M"C_A'=*_Z!EG_P" Z?X4?V15_P"?@?ZR8?\ Y\?E_D?-G]K7W_/[<?\ ?UO\
M:/[6OO\ G]N/^_K?XU])_P#".Z5_T#+/_P !T_PH_P"$=TK_ *!EG_X#I_A1
M_9%7_GX'^LF'_P"?'Y?Y'S9_:U]_S^W'_?UO\:/[6OO^?VX_[^M_C7TG_P (
M[I7_ $#+/_P'3_"C_A'=*_Z!EG_X#I_A1_9%7_GX'^LF'_Y\?E_D?-G]K7W_
M #^W'_?UO\:/[6OO^?VX_P"_K?XU])_\([I7_0,L_P#P'3_"C_A'=*_Z!EG_
M . Z?X4?V15_Y^!_K)A_^?'Y?Y'S9_:U]_S^W'_?UO\ &C^UK[_G]N/^_K?X
MU])_\([I7_0,L_\ P'3_  H_X1W2O^@99_\ @.G^%']D5?\ GX'^LF'_ .?'
MY?Y'S9_:U]_S^W'_ '];_&C^UK[_ )_;C_OZW^-?2?\ PCNE?] RS_\  =/\
M*/\ A'=*_P"@99_^ Z?X4?V15_Y^!_K)A_\ GQ^7^1\V?VM??\_MQ_W];_&C
M^UK[_G]N/^_K?XU])_\ ".Z5_P! RS_\!T_PH_X1W2O^@99_^ Z?X4?V15_Y
M^!_K)A_^?'Y?Y'S9_:U]_P _MQ_W];_&C^UK[_G]N/\ OZW^-?2?_".Z5_T#
M+/\ \!T_PH_X1W2O^@99_P#@.G^%']D5?^?@?ZR8?_GQ^7^1\V?VM??\_MQ_
MW];_ !H_M:^_Y_;C_OZW^-?2?_".Z5_T#+/_ ,!T_P */^$=TK_H&6?_ (#I
M_A1_9%7_ )^!_K)A_P#GQ^7^1\V?VM??\_MQ_P!_6_QH_M:^_P"?VX_[^M_C
M7TG_ ,([I7_0,L__  '3_"C_ (1W2O\ H&6?_@.G^%']D5?^?@?ZR8?_ )\?
ME_D?-G]K7W_/[<?]_6_QH_M:^_Y_;C_OZW^-?2?_  CNE?\ 0,L__ =/\*/^
M$=TK_H&6?_@.G^%']D5?^?@?ZR8?_GQ^7^1\V?VM??\ /[<?]_6_QH_M:^_Y
M_;C_ +^M_C7TG_PCNE?] RS_ / =/\*/^$=TK_H&6?\ X#I_A1_9%7_GX'^L
MF'_Y\?E_D?-G]K7W_/[<?]_6_P :/[6OO^?VX_[^M_C7TG_PCNE?] RS_P#
M=/\ "C_A'=*_Z!EG_P" Z?X4?V15_P"?@?ZR8?\ Y\?E_D?-G]K7W_/[<?\
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M .?'Y?Y'S9_:U]_S^W'_ '];_&C^UK[_ )_;C_OZW^-?2?\ PCNE?] RS_\
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MR8?_ )\?E_D?-HU>^!R+VX!'_35O\:D_M_5/^@E=_P#?]O\ &OI.T\.:2UW
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M_P"$5T3_ * ]A_X"I_A1_P (KHG_ $![#_P%3_"C_5RO_P _OS_S#_77"?\
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M_P"$5T3_ * ]A_X"I_A1_P (KHG_ $![#_P%3_"C_5RO_P _OS_S#_77"?\
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M_P"$5T3_ * ]A_X"I_A1_P (KHG_ $![#_P%3_"C_5RO_P _OS_S#_77"?\
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M_P"$5T3_ * ]A_X"I_A1_P (KHG_ $![#_P%3_"C_5RO_P _OS_S#_77"?\
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M_P"$5T3_ * ]A_X"I_A1_P (KHG_ $![#_P%3_"C_5RO_P _OS_S#_77"?\
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MR;^/+T_5'Q_$_P#NL/\ %^C.FHHHKZ\_-0HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *M:7_ ,A"#_>J
MK5K2_P#D(0?[U7#XD9S^!^AT>H_\>,_^X:Y*NMU'_CQG_P!PUR5=&)^)''@_
MA84445R'H!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6C
MH/\ R$!_NFLZM'0?^0@/]TUK2^-&-;^'+T-;6_\ D'2?4?SKF*Z?6_\ D'2?
M4?SKF*UQ'QG/@_X;]0HHHKE.X**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"6U_X^H?]\?SK
MK9_]1)_NG^5<E:_\?4/^^/YUUL_^HD_W3_*N[#_"SS,7\43C:***X3TPHHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *Z'P[_QY/\ ]=#_ "%<]70^'?\ CR?_ *Z'^0KHH?&<>*_A
ME3Q%_P ?47^Y_4UDUK>(O^/J+_<_J:R:FM\;-,/_  HA1116)T!1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 367_'Y!_P!=%_G7?-]T_2N!LO\ C\@_ZZ+_ #KOF^Z?I7K8
M+X9'SV9_%$QJ***](\@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=8_$QL?U&?\ =KW\?D#PE"5:$^:W2W3[SX_*>+UF.+CA:M)0YMG>^O1;+?\
M,^?Z***^1/T@***MZ/I5QK>J6FGVB;[FZE6&-?=CCGV]Z:3DTEN3*2A%RD[)
M!!I%_=1++#97$T;='2)F![=0*?\ V!J?_0.N_P#OPW^%?;WAO0K?PQH-AI5J
M,06D2Q@_WCW8^Y.3^-:E?=0X83BG*K9^G_!/R6IQW*,Y*G0O&^CYNGW'Y_\
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M45\F?HP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%?0_PU_Y$?2O]QO_ $-J^>*^A_AK_P B/I7^XW_H;5[V3?QY>GZH^/XG_P!U
MA_B_1G34445]>?FH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %6M+_Y"$'^]56K6E_\ (0@_WJN'Q(SG
M\#]#H]1_X\9_]PUR5=;J/_'C/_N&N2KHQ/Q(X\'\+"BBBN0] **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *T=!_Y" _W36=6CH/\ R$!_
MNFM:7QHQK?PY>AK:W_R#I/J/YUS%=/K?_(.D^H_G7,5KB/C.?!_PWZA1117*
M=P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% $MK_ ,?4/^^/YUUL_P#J)/\ =/\ *N2M?^/J
M'_?'\ZZV?_42?[I_E7=A_A9YF+^*)QM%%%<)Z84444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %=#X=
M_P"/)_\ KH?Y"N>KH?#O_'D__70_R%=%#XSCQ7\,J>(O^/J+_<_J:R:UO$7_
M !]1?[G]3634UOC9IA_X40HHHK$Z HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** )K+_C\@_Z
MZ+_.N^;[I^E<#9?\?D'_ %T7^==\WW3]*];!?#(^>S/XHF-1117I'D!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %6M+_ .0A!_O55JUI?_(0@_WJ
MN'Q(SG\#]#H]1_X\9_\ <-<E76ZC_P >,_\ N&N2KHQ/Q(X\'\+"BBBN0] *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *T=!_Y" _W36=
M6CH/_(0'^Z:UI?&C&M_#EZ&MK?\ R#I/J/YUS%=/K?\ R#I/J/YUS%:XCXSG
MP?\ #?J%%%%<IW!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 2VO_'U#_OC^==;/_J)/]T_R
MKDK7_CZA_P!\?SKK9_\ 42?[I_E7=A_A9YF+^*)QM%%%<)Z84444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %=#X=_X\G_ZZ'^0KGJZ'P[_ ,>3_P#70_R%=%#XSCQ7\,J>(O\ CZB_
MW/ZFLFM;Q%_Q]1?[G]3634UOC9IA_P"%$****Q.@**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@":R_X_(/\ KHO\Z[YONGZ5P-E_Q^0?]=%_G7?-]T_2O6P7PR/GLS^*)C44
M45Z1Y 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3HO
M]:GU%-IT7^M3ZB@#IJ***" HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*Y_X@_\ (C:]_P!>4O\ Z":Z"N?^(/\ R(VO?]>4O_H)K#$?P9^C_(Z\'_O-
M/_$OS/A^BBBOQ$_JH**** "BBB@ HHHH **** "O8/V7O^1_U#_L&2?^C8J\
M?KV#]E[_ )'_ %#_ +!DG_HV*O6RG_?J7J?.\1?\BK$?X?\ (^H*^0_V@/\
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M7_?/\ZW/AY_R/_AG_L)VW_HU:P[G_CYE_P!\_P ZW/AY_P C_P"&?^PG;?\
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M_4^3OVC?^2FW'_7M#_*L/X.:*NO?$G1+=UW11RFX<'IB,%QG\0!^-;G[1O\
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MWE^T8^5!_P!\@5]H^(9FM] U.5#ATMI64^X0FOA"O7XGJNU*DMM7^5OU/G>
MZ$7*O7>ZLE\[M_D@HHHKX,_70KZ5_9A\0M>^&]2T>1]QL9A+$">B29R!]&5C
M_P "KYJKV7]ER=E\9:I",[7T\N?J)$ _]"->YDE5TL=3MUNOP_S/DN*J$:^4
MU;[QLU\G_E='TT1D8-?#GCC1E\/>,-9TY!MCM[J1(Q_L9ROZ$5]R5\?_ !ZA
M6'XJZUM& WDL1[F%,U]3Q-33P\*G52M]Z_X!\!P-6<<;5H]'&_W-?YL]W_9^
MT9=*^&EC+MQ+>R27+\>K;5_\=5:[S6-1CT?2KR_E_P!5:PO,^?15)/\ *L/X
M7PB'X=^'%7H;&%OS4$_SJM\7I6A^&GB%E.";4KD>A(!_0U[E'_9L!%Q^S"_W
M(^4Q/^W9O.,W\=2WR<K?D?'6I:A-JVHW5[<N7GN)6ED8]V8Y/\ZK445^/MMN
M[/Z5C%02C'9!174^ ?AWJ7Q%OKJUTV>UADMXQ*YNG9003CC:K5V__#+WBK_H
M(:/_ -_I?_C5=U' 8K$0]I2IMKN>1B<XP&#J.C7JJ,ET9Y 6+').3ZFDKV#_
M (9>\5?]!#1_^_TO_P :KG/'7P9UOX?Z-'J6HW5A- \P@"VLCLVXAB/O(!CY
M3WJZF6XNE!SG3:2,Z.>9;7J*E2K)R>R."KU/]GOQH/#7C+^SKA]MEJN(>3PL
MH^X?QR5_X$/2O+*<CM&ZNC%'4Y#*<$'U%<V%Q$L+6C6ANF=N/P<,?AIX:IM)
M6].S^3U/OZOD_P#:#\'_ /"-^-WOH(]MGJH-PN!P)?\ EH/S(;_@=?0?PO\
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MZ'^&O_(CZ5_N-_Z&U>]DW\>7I^J/C^)_]UA_B_1G34445]>?FH4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M9_\ PD6E?]!.S_\  A/\:/\ A(M*_P"@G9_^!"?XT>TAW0>QJ?RO[C0HK/\
M^$BTK_H)V?\ X$)_C1_PD6E?]!.S_P# A/\ &CVD.Z#V-3^5_<:%%9__  D6
ME?\ 03L__ A/\:/^$BTK_H)V?_@0G^-'M(=T'L:G\K^XT**S_P#A(M*_Z"=G
M_P"!"?XT?\)%I7_03L__  (3_&CVD.Z#V-3^5_<:%%9__"1:5_T$[/\ \"$_
MQH_X2+2O^@G9_P#@0G^-'M(=T'L:G\K^XT**S_\ A(M*_P"@G9_^!"?XT?\
M"1:5_P!!.S_\"$_QH]I#N@]C4_E?W&A16?\ \)%I7_03L_\ P(3_ !H_X2+2
MO^@G9_\ @0G^-'M(=T'L:G\K^XT**S_^$BTK_H)V?_@0G^-'_"1:5_T$[/\
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MZ"=G_P"!"?XT?\)%I7_03L__  (3_&CVD.Z#V-3^5_<:%%9__"1:5_T$[/\
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MG9_^!"?XT?\ "1:5_P!!.S_\"$_QH]I#N@]C4_E?W&A16?\ \)%I7_03L_\
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M^+-$,,@&LZ>25/\ R])Z?6NVA4@D_>1YN+H57*-H/[F85%9__"1:5_T$[/\
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MC0HK/_X2+2O^@G9_^!"?XT?\)%I7_03L_P#P(3_&CVD.Z#V-3^5_<:%%9_\
MPD6E?]!.S_\  A/\:/\ A(M*_P"@G9_^!"?XT>TAW0>QJ?RO[C0HK/\ ^$BT
MK_H)V?\ X$)_C1_PD6E?]!.S_P# A/\ &CVD.Z#V-3^5_<:%%9__  D6E?\
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M@G9_^!"?XT>TAW0>QJ?RO[C0HK/_ .$BTK_H)V?_ ($)_C1_PD6E?]!.S_\
M A/\:/:0[H/8U/Y7]QH45G_\)%I7_03L_P#P(3_&C_A(M*_Z"=G_ .!"?XT>
MTAW0>QJ?RO[C0HK/_P"$BTK_ *"=G_X$)_C1_P )%I7_ $$[/_P(3_&CVD.Z
M#V-3^5_<:%%9_P#PD6E?]!.S_P# A/\ &C_A(M*_Z"=G_P"!"?XT>TAW0>QJ
M?RO[C0HK/_X2+2O^@G9_^!"?XT?\)%I7_03L_P#P(3_&CVD.Z#V-3^5_<:%%
M9_\ PD6E?]!.S_\  A/\:/\ A(M*_P"@G9_^!"?XT>TAW0>QJ?RO[C0HK/\
M^$BTK_H)V?\ X$)_C1_PD6E?]!.S_P# A/\ &CVD.Z#V-3^5_<:%%9__  D6
ME?\ 03L__ A/\:/^$BTK_H)V?_@0G^-'M(=T'L:G\K^XT**S_P#A(M*_Z"=G
M_P"!"?XT?\)%I7_03L__  (3_&CVD.Z#V-3^5_<:%=#X=_X\G_ZZ'^0KCO\
MA(M*_P"@G9_^!"?XUO:#XIT:*S</J]@I\PG#7*#L/>NBA4AS_$CDQ5&JZ?PO
M[F6/$7_'U%_N?U-9-/U_Q-H\MS&4U:Q<;.HN4/?ZUF?\)%I7_03L_P#P(3_&
MHJU(.;]Y&E"C5]E'W7]QH45G_P#"1:5_T$[/_P "$_QH_P"$BTK_ *"=G_X$
M)_C67M(=T;^QJ?RO[C0HK/\ ^$BTK_H)V?\ X$)_C1_PD6E?]!.S_P# A/\
M&CVD.Z#V-3^5_<:%%9__  D6E?\ 03L__ A/\:/^$BTK_H)V?_@0G^-'M(=T
M'L:G\K^XT**S_P#A(M*_Z"=G_P"!"?XT?\)%I7_03L__  (3_&CVD.Z#V-3^
M5_<:%%9__"1:5_T$[/\ \"$_QH_X2+2O^@G9_P#@0G^-'M(=T'L:G\K^XT**
MS_\ A(M*_P"@G9_^!"?XT?\ "1:5_P!!.S_\"$_QH]I#N@]C4_E?W&A16?\
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MT$[/_P "$_QH]I#N@]C4_E?W&A16?_PD6E?]!.S_ / A/\:/^$BTK_H)V?\
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M)_C1_P )%I7_ $$[/_P(3_&CVD.Z#V-3^5_<:%%9_P#PD6E?]!.S_P# A/\
M&C_A(M*_Z"=G_P"!"?XT>TAW0>QJ?RO[C0HK/_X2+2O^@G9_^!"?XT?\)%I7
M_03L_P#P(3_&CVD.Z#V-3^5_<:%%9_\ PD6E?]!.S_\  A/\:/\ A(M*_P"@
MG9_^!"?XT>TAW0>QJ?RO[C0HK/\ ^$BTK_H)V?\ X$)_C1_PD6E?]!.S_P#
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MTU6N2E#VE2,>[/2Q57V-&4^R9P/B?]I.UT5Y81ID4C R)N&H!3D<9^Y7*?\
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M.TM\VH ]\?W!7'ZI^S[86MLTB6UJ&",P/VF8\@5Y7XE\,77AB]D6VDAB4,J
M*2W5<G[PK".782K&Z7XLVIYOBX_#+\$?;6C>);+68R8[BWW[BHC296)P ?\
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MUJ?44VG1?ZU/J* .FHHHH("BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MKG_B#_R(VO?]>4O_ *":Z"N?^(/_ "(VO?\ 7E+_ .@FL,1_!GZ/\CKP?^\T
M_P#$OS/A^BBBOQ$_JH**** "BBB@ HHHH **** "O8/V7O\ D?\ 4/\ L&2?
M^C8J\?KV#]E[_D?]0_[!DG_HV*O6RG_?J7J?.\1?\BK$?X?\CZ@KY#_: _Y*
MKJ_^Y!_Z)2OKROD/]H#_ )*KJ_\ N0?^B4K[3B3_ './^)?DS\NX'_Y&4_\
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ME5L<J57V?+?YGZ/4445PGJ!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %6M+_Y"$'^]56K6E_\ (0@_WJN'Q(SG
M\#]"?XD_\B#K_P#UYR?RKY!KZ^^)/_(@Z_\ ]><G\J^0:^:XB_CP]/U/N^"_
M]UJ_XOT04445\H?H84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!MZ'XSUCP\Z_9+U_
M*'_+"0[XS^!Z?ABO8_!/Q%L_%@%O(HM-1 R82<A\=2I_IU^O6O :DM[B2TGC
MGA=HY8V#(ZG!!'0UZ6%Q]7#22O>/;_(\+,,HP^.BW;EGW7Z]SZOLO^/R#_KH
MO\Z[YONGZ5X_\-_%(\6:=:7+86ZCD6.=1_>&.1[$<_F.U>P-]T_2OT[+IQJT
M^>.S/P?.:4Z%94JBLU=&-1117JGA!1110 4444 %%%% !1110 4444 %%%%
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MONX&.P_PJY7QM>?M*CD?I^ H?5\/&#5GU/GO]H/57;3KN+"82*\4<'T%>+?
M>VBN_$USYS,@^Q.?E]?,2OJ#XQ> &\2:'<RVR1AH[:Y9\1KDEE!Y)(]#7R?;
M+?\ PYUF>00,WR>3^[E$?WMK=L^E?4X*<:E)1B?G^<T:E.I)/J?=NGVD2#*,
MQY[_ $K0KY5\._M)3/(JRV<X!8\F^8_P_P"Y7KFE?''2[I/WD10[B.7=NW^Y
M7!B<NQ-1W@KH]'*,RPN$I<M?W7WU?Y7/3J*YO2O'^D:H!MGV,=N!L<]?^ UT
M,%Q'<Q+)&VY#T.,5XE2C4I.TXV/L\/C</BU>A-2_/[MQ]))((U+,< =Z6J&N
MRF#2IY!G(V]#C^(5G%<TDC:M-TZ<IKHFSP[XX>.X/L-]9121M)Y=W#M,;YSC
M&,]*\!^'GA:[\2Z[.3"Q4V[.#&ZCHRCN:T/B%KDNI>.[NS+R%6U*>+#.2.9<
M=*]N^!7@Z*U9;B2.)]UM(O,2_P#/4>_M7VJI^RH>T70_$:;G/&N#^TSU/P=X
M#M_#<)(>XWB1G D=3U4#L*ZT#%%4M5U-=*M7F9=RJ >N.IQZ5\?.I4KSN]6?
ML]*A2PL++1%UOF&#65K7A^#6(%CF>50'#?NR!S@CN/>J^G^,;&]9PS>45P,8
M8YS^%:/]L6<G FS_ ,!;_"M*<*L)K1HXL76PLZ,KM/YGQ_\ %7X=76@0O.L,
MNU(4.7E0]9".U;_P(\>)ILT<<S1)FYE;_5N>/*'I]*]<^,6EVVH^'[M0L>\Q
MQ $Q@GB4&OE'1IY-"UFW19& (9_D)7JI';Z5]+?V\/>1^8X>,L/733V=S[XL
M+H7UC;W"D%9HUD! (!!&:GKE_AQJO]I^%-+R""EE;Y);.<H/\*ZBODZD>2;B
MS]@PU55J4:B=[A7%_%?7%TCPE?ME0P6)OF4GK*H[5V;L$4DG '>OG+X[?$.W
MU72+FUM6<,\$6 KL.1-GNH]*[,#3YZT7;1,\C.<2J.'=-/WI:?+J>2:E<MXH
MULJ #BX8'9\OWF]_I7JWA_P$D7A2RD;SPQ9P1O7'WF]JY/X%>!KGQ-J=W<2*
MHCBFMI"7"OPS.3U/M7U19>&K6TTR&S,<+B,D[O) SDD]/QK[/&YK2H4XTX?%
MU/S;"9%B,PFY+2*Z]SX?^&NL'2/&NG%]BJ/,)+ GK&P[5]U:7JD.J0-)$X<!
MBN0I'8'O]:^0/B7\-)OAQ=+>^:KB*!7RD8C/S.4ZACZUZS\#/B1!K&GN)9I-
MQNY%VN[MD"-3Z5Q9G06+I*M#4]S 8O\ LNMR5=$]&>YT5S%]XZ@L\[(?.QG^
M(KT_X#6OH>K#6=.BNA%Y0DS\N[=C#$=<#TKXZ=.=/XD?H%#&4,3_  I7^\T*
M^6?CXA@TJX9A@""+_P!'5]35\O?M$'S=&N@!C_1X?_1U?19')J<[>7ZGPW%R
MN\/_ -O?^VE+]E^".^O]1?<V8I;,C''>3_"OJT+M&*^5/V3_ -S>:P&Y+268
M'YR5]65QYM*3KV9ZW#E&$<,Y+=L.M4-7TJ+4K*6&1G57QDH0#P0?2K_?UJMJ
M-U'9VDDLC;47&3C/?%>1!R4ERGTN(C3=.3J;69\4_%OP_P#V5XDOY(@[*MW<
ML"[ \!^.E=C^S=KLO]KR(RQ@"QE/ /\ SU3WKG_C)KEM>:WJ$4)WL;BZ4<$<
MEL#J*U/V<-,N?[:E?R_E-C)CYA_SU3WK[6M9X?7L?F^%G^]?)W/KJBBBOAC]
M3"O)/C#XWATTM8&2,213H2IC<GF,GJ..]>F:YJ46EZ;<RR.4*PNRXSSA<]NE
M?%_QB\93:IXTU%8WE9=T3#]Z?^>2CN*^AR>@I5?:36A\9Q%B(NBL/%^]>[^Y
ME?X1^%YM0\::<\R.L8:52R.O_/)JW/CMX(>TUF*:!975;-,EW7J9''M7KWP?
M\ ?9IH[UXXL13R+_ *M<\Q@>OO78?$GX?P^)-/FFC6$3+&D:H8%).'SU)'J:
M];'8NDL0J:>A\9@LJKXBE+&);=/QN>(_!'QLFGWUCI\K1*?,M;<@HQ/!VGD<
M5]413+/&'0[E/0XKX.A-QX3^(XB8LJPZL%.Q]HPDV.@S7V+\._%,.NZ3;Q*2
M90CN2Q). Y'<>XKR\PP5105:*T/JLEQ].G5>&D[-[>O8Z^BBBOG#[P**** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IT7^M3ZBFTZ+_6I]10!
MTU%%%! 4444 %%%% !1110 4444 %%%% !1110 4444 %<_\0?\ D1M>_P"O
M*7_T$UT%<_\ $'_D1M>_Z\I?_036&(_@S]'^1UX/_>:?^)?F?#]%%%?B)_50
M4444 %%%% !1110 4444 %>P?LO?\C_J'_8,D_\ 1L5>/U[!^R]_R/\ J'_8
M,D_]&Q5ZV4_[]2]3YWB+_D58C_#_ )'U!7R'^T!_R575_P#<@_\ 1*5]>5\A
M_M ?\E5U?_<@_P#1*5]IQ)_N<?\ $OR9^7<#_P#(RG_@?_I43SNON#X>?\B!
MX9_[!EM_Z*6OA^ON#X>?\B!X9_[!EM_Z*6O(X9_C5/1?F?2<=_[M0_Q/\C#^
M.?\ R2K7O]R+_P!')7QW7V)\<_\ DE6O?[D7_HY*^.ZQXE_WN'^%?FSJX&_Y
M%]3_ !O_ -)B>C_ ;QE_PBGCB&WF<)8ZEBVER<!6)_=M^?'T8U]7ZC?P:587
M-[<OY=O;QM+(Y[*HR3^0KX)HKFR_.IX"BZ/)S=M;6_ [,YX6I9OBEB54Y'9)
MZ7O;YJSMIUZ&OXM\13^+/$FH:M<9\RZE+A2?N+T5?P4 ?A61117SLYRG)SD[
MMGVM*G&C"-."LDK+T1^@%>1_M.?\D]M?^PC'_P"BY*]<KR/]IS_DGMK_ -A&
M/_T7)7Z]FO\ N57T/YNX?_Y&N'_Q(^6Z^@/V4?\ F:?^W7_VM7S_ %] ?LH_
M\S3_ -NO_M:OSS(_^1A3^?\ Z2S]HXL_Y$U?_MW_ -+B?0%?$?Q*_P"2A>)/
M^PC/_P"C#7VY7Q'\2O\ DH7B3_L(S_\ HPU]+Q-_ I^OZ'PG G^]5O\ "OS,
M"TNI;"[AN;=S'/"ZR1NO56!R"/Q%?;G@?Q/%XR\*Z?JT6T&>,>:BG[D@X=?P
M(/X8KX>HKY?+,SEETI/EYD^E[?/9GWV>Y#3SN$$Y\DHO>U]'NMUY'MW[3/C+
M[=J]GX=@DS#9@3W !X,K#Y0?HI_\?KQ&BBN'&8J6,KRK2TOT[+L>MEF AEF$
MAA:;OR]>[ZL^H/V7O^1 U#_L)R?^BHJ]@KQ_]E[_ )$#4/\ L)R?^BHJ]@K]
M3RG_ '&EZ'X!Q%_R-<1_B/@.Y_X^9?\ ?/\ .HZDN?\ CYE_WS_.HZ_('NS^
MD8['U)^SEXO36_![:1+(/MFF-M"D\M$QRI_ Y7VP/6O6642 JP#*1@@]"*^(
M? _C&]\"^(K;5;,[BGRRPDX$L9^\A_Q['![5]B^$?%^F>-M'BU'3)Q+$W#QD
M_/$W=6'8_P ^HXK]-R/,(XF@J$W[\=/5=/\ @GX1Q7D]3!8N6+IK]W-W])/=
M/U>J^[H?/?Q6^!6H:'J$^I>'[22^TJ4ES;P+NDMSW&T<E?0CIWZ9/D;VTT<_
MDO$ZS9V^6RD-GTQ7WY16&)X<HUJCG2GRWZ6NOEJCLP/&N)PU%4L1351KK>S^
M>CO^!\D_#CX(ZSXPO8IM0MYM+T=2&>:9"CR#T13SSZ]![]*^K;"PM],LH+2T
MB6"V@01QQ(,!5 P *LUGZUKECX=TV;4-1N8[2TB&6DD/Y >I/8#K7KX'+Z&6
M4WRO7JW_ %HCYK-<XQ>>5HJ:LE\,5Y_FW_PQR/QI\8)X1\"7K*^V]O5-I;@'
MG+ [F_!<G/KCUKX]KLOBE\1)_B+XB:ZPT.GP QVD#=53NQ_VFQD_0#M7&U^?
M9QCECL1>'PQT7^?S/V;AK*7E6"4:B_>3UEY=E\OSN%?H!7Y_U^@%>]PO_P O
MO^W?_;CY'C[_ )A?^W__ &T\C_:<_P"2>VO_ &$8_P#T7)7RW7U)^TY_R3VU
M_P"PC'_Z+DKY;KRN(?\ ??DCZ#@S_D5+_%+] KZ"_9U^)F]%\*:C+\RY:PD<
M]1U,7X<D?B.PKY]J6UNI;&YBN()&AGB</'(AP58'((^AKR<#C)X&NJT/FNZ/
MH<VRVEFN%EAJF^Z?9]'_ )^1]]T5Q/PH^(47Q!\,QW#,JZE;XCO(E&,/V8#T
M;K^8[5VU?L%&M#$4XU:;NF?S9B<-5PE:5"LK2B[,^3OVC?\ DIMQ_P!>T/\
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M!_Z%7*_L7^(9+SPQK^C2/N6RN8YXU)Z+*I! ]LQY_P"!>]=5^UG_ ,D>NO\
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MMMYH^[:^(?VMO^2OS_\ 7E!_(U]O5\0_M;?\E?G_ .O*#^1KEP?\3Y'=F/\
M!^93_9@U:ST+XFMJ&H7,=I96^GW$DLTIPJJ .37H?C;]LR<74D'A32(C IP+
MS4MQ+^XC4C'MDGW%?,D$,EQ,D,*-++(P18T!+,2>  .IS7T)X5_8UUO5M-BN
M=:UN#1)I%W"UCMS<.GLYW* ?H37=5C24N>H>5AZF(</9T$8EO^UWX\AF#O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'H_P "M3:U\7_8BW[N
MZ0''^TK C]"U?53?=/TKY$^#/_)1-,_X'_Z":^NV^Z?I7Z3PW)O"R3Z,_#>-
MH*.80:ZQ3_%K]#&HHHKZP_/PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** /C_P#:Y9A\6]' SC^QX^G_ %VGKT3X/1AKJ+&"?.DX _Z9UYY^
MUP<?%O1Q_P!0>/\ ]'3UZ7\%;<KJ$!XP)Y/_ $57Z/2JN.4I=HO]3\-QD%7S
MZ5)]9I?>T>D^+?!%GXETEEF@@>1() N^V$ARR]L]^*^0/BGX#O/#/B&[^RP3
MQ1AXT'DVQC',8)Z>]?=0X&*\[^)O@2#7XOM!CC,CS(2SR.,X0CM7RV7XM^TY
M*CT9]OF^4PIT%5P\=5O_ )GB7P1^+4\>M6MK=74CQ/-*Q26^.T_NN,@^XKI_
MCOJ*:U,980N!:QI\C;^1*Q[?6O!3H=SX'U>"[\R,"-"_[DEC\P*_Q"NENOB&
M->MW#F=LX7YXT'0Y[&OM*.!IU*GUC9I'PRS&OAZ?U=.\&[_UU,KX?1,OC>US
MD?\ $QAZC_IK7W#X:&-&MO\ @7_H1KXL^'VV?QC:R ?\O\+<_P#72OM3P[_R
M![?_ (%_Z$:^-S5-/YGV?#M3VE>3_N_JC2KC_B@O_%)WY_V8_P#T:M=A7*_$
MZ,'P9J+8Y C_ /1JUX^'=JL?5'V&81YL-->3_(^)O&UNTVL$#)S/+T&?XA7<
M_#OPA=7VE6[10S-E'/R0%OXR*Y7Q/M_MY<\_Z2__ *$*^E/@-8P2^'K-C'DF
M&7G)_P">QK[_ /M"6"I<R1^0/!/&5XT8NS;/,H_AKKCRKBRU KZ_8Y,5)-\+
M=:8?\>-^3_UY/7U.D:QC"C S3J^=J9Y5F[\J/NZ7#-&"5YNY\X?#[X?ZSI?B
M2SFGM+^.)+N!R9+5U7 ?)Y/:OH^BBO$Q&(EB)<TD?2X/!QP<'"+O<****Y3T
M#PG]I#P:VJV=E/%$9"D=V[%(-^,A#R?PKYU\.:O-X8U26UWR1>7$1M\PQ]2K
M=.W6ONCQ5I,&JZ)>I*@=A;RA"6(P2I]/PKX6^*6G'1/'6IQKM4+Y2_*2>L2'
MO7U>66KPY.J/@<VI?5J[FMF?;T7B-?[*FN' 0(X'S2_3O^-?'7Q1NFUGQ/:E
M"7'V55.T[^C.:]6U_P")'V/PE?*#.&+J01&A_B7WKS;P=HY\8:E!,VQL,T7[
MPE>B%OX?K7K4,O6'IR<E9GQ=3,ZN+KQE4=TM.A]-_!C0ETSP?ILI0;I["U;F
M/:<B//X]:D^+'AD:_HL*"/S&%TKX$.\\(P_K73^%+(6'AK2;< #RK.&/@DCA
M .]:-Q;I<H%==P!SUQ7QOMW#$^TET9^I5<$J^7>PANUIZO\ X<^%9IY/">N6
M\2EX<QF3 )BZ[AT_#K7V;9ZTEKHEQ=2L#Y<F,-)CKM'7\:^1/C;IOV'Q/:LF
MT 62'@D_\M''>O4-<^)HA\*7L2FX!+J?]6F/O+[^U?6U,'+'./+MU/S7 8F>
M72NMY'GGQXUQM;UVW6-BRBYN1A9-_!9?\*]8_9T\.Q-X<LII8D+-!,#OB&?]
M>>_X5X.A;Q5K:LQW8N,_O/E^\WM]*^LO@]H0TGPC8'"#Y)5^5B?^6K'O3S.G
M]2PZ4';H>Y@L-''8F/.KK=G>T445\$?IPRX@2YMY87 9)%*,&&001CD5PFO_
M  BTC67:1K:R!9@>;%&Z#%=]1711KSH.\&>;B\!1QJ2JK5'SAXB^!QM(V-C9
M;FV@C[/IV#G=ST]J\EU?P/XQT]ML=IKD?R@_+;3+WQ7W352[TJUOFW3Q;SC'
MWB./P->W#.JEN62/GJO#L.1^SEKYGP0NM>+?#5U%]HDUJ%0XSYLDT8PIYZU[
MC\*/C9Y4$<6H77FLL+DK<ZAR#YG'##TKK?BS\+K35+"2:VAAC9([AR9)I.I
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ IT7^M3ZBFTZ+_6I]10!TU%%%! 4444 %%%% !1110 44
M44 %%%% !1110 4444 %<_\ $'_D1M>_Z\I?_03705S_ ,0?^1&U[_KRE_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M=M\&?^2B:9_P/_T$U]=M]T_2OD3X,_\ )1-,_P"!_P#H)KZ[;[I^E?I'#7^Z
MR_Q?HC\0XX_W^G_A_5F-1117UI^>!1110 4444 %%%% !1110 4444 %%%%
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MMO\ \"_]"-?+/PY_9^\5:)X@M[BXMBD$5U!(Y\R+A5?)X$A[5]6Z3:-8Z?%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/W:];#22I:L^>QT9/$-I=C]$Z^(?VMO^2OS_ /7E!_(U]O5\>?M/^!?$FO\
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MBTO0-0NRW\8@98Q]7;"C\37U/\"_V:8O =U#KWB)X[W7$Y@MXSNAM21][/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\*07C27-^Z[DL[8 L!V+$D!1]>?05RN@?M+^']4OEM[^SN=*5SA9W(DC'/\
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MB>+,70QM?"1I*;BVH))W;OUU=]+Z)*_D?)GC/X>ZQX"-FNKI#$]TK,BQR!R
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MZ"WB?Q+IFE*Q3[7.L3..JJ3\Q_ 9-?8FJ:EHWPN\'^<8OLVF62*B0PKEF).
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 =M\&?^2B:9_P/_P!!-?7;?=/TKY$^#/\ R433/^!_^@FOKMONGZ5^D<-?
M[K+_ !?HC\0XX_W^G_A_5F-1117UI^>!1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 12V<%PX>6".1@,!G0$@5(J!1A0 /0#%+13N]B%"*=T
M@HHHI%A0RAA@@$>AHHH%N-6)(\[452>N!UIU%% )6V"BBB@8UXTE&'16'3##
M-0G3+1CDVL)/J8Q_A5BBFFULR'",MT5QIUHO2VA'_;,4UM*LG.6L[=CZF)?\
M*M44^:7<GV<.R(5L;:,#;;Q+CIA *F"A1A0 !V%%%)N^Y2BEL@HHHI%A1QT[
M444"(UM88V#+%&K>H4 U)111>XDE'8****"@J"2PMI6#/;PNP&,L@)Q4]%--
MK8B48STDKC8XTB "*$ XPHQ3J**1226B"BBB@84F,TM% BI)HUA*?GL;9_\
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MPRL"\,;D<@LH.*>D:QC"J% [ 8I:*+LA12U2"@@'@\CWHHH*  #H,?2BBB@
MHHHH&%%%% B 6%L/^7>+_O@5/113;;W)C",?A5@HHHI%A1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-TMSJURAAE>%MRVZ'ALD?Q8R,=1U..,_/-[XRU_4H3%=ZYJ5U$>#'-=R.I_
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %.B_P!:GU%-IT7^M3ZB@#IJ***" HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *Y_P"(/_(C:]_UY2_^@FN@KG_B#_R(VO?]>4O_
M *":PQ'\&?H_R.O!_P"\T_\ $OS/A^BBBOQ$_JH**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^A_AK_R(^E?[C?\
MH;5\\5]#_#7_ )$?2O\ <;_T-J][)OX\O3]4?'\3_P"ZP_Q?HSIJ***^O/S4
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "K6E_\ (0@_WJJU:TO_ )"$'^]5P^)&<_@?H3_$G_D0=?\
M^O.3^5?(-?7WQ)_Y$'7_ /KSD_E7R#7S7$7\>'I^I]WP7_NM7_%^B"BBBOE#
M]#"BBB@ HHHH ^K_ -G#_DFD7_7U+_,5X/\ &S_DJ6O_ /75/_1:UVOPF^-N
MA>!/"*:5J%IJ$MP)GDW6T:,F&QCDN#^E>:_$3Q';>+?&>IZO9I+';73JR).
M' " <@$CJ/6OJL?BJ-7+*%&$KR5KKY,_/,HP&*H9YBL35IM0ES6?1^\F<[11
M17RI^AFAX=O;?3=?TZZNX$N;2&XCDFAD0,KH&!92#P<C-?6OB+X7>&O%'A:Z
MM]-TO2[*6ZA#6U[;6D:E3PRL&49P>,X[$U\=5ZE\,?CK?>![5--OX#J>DK_J
MU#8EA]E)X(]C^!KZ+*,9AZ'/1Q2]V76VW_#GQ7$>68W%*GB<!)JI3Z7M?KZ7
M3[[G/7OP?\8V5Z]LV@W<K*V!)"N^-O<,.,?Y-?2'P4\&:AX(\%K9:F0MW/.U
MRT(;=Y(95&S(X_AR<<9)K+A_:/\ !TL6]I+V%N/W;VWS?H2/UKB/'?[2C7]E
M-9>&[66U\U2K7US@2*#UV*"<'W)_"O;PZRO*YO$0J\SMHM_R_4^4QLL^SZ$<
M%5P_)&Z;=FEIZO;TNSSOXQ:G!J_Q+UZXMBK1><L0*]"4148_FIKW7]GGQM%K
M_A!-(ED'V_2QLVGJT)/R,/I]WVP/6OEDDL22<D]ZOZ!K]_X8U6#4=-N&MKN$
MY5UZ$=P1W![BOG,'F4L-C)8EK23=UZN_X'VN9Y'#'99' Q=G!+E?FE;7U7^9
M[1\7/@-J-QK-SK/AR$74-RQEFLE8*\;D\E,X!!/..H_EQ7A[X$>+M<OEAGT\
MZ7;Y^>XNR %'LH.2?\Y%>G>&/VG=+N;9(]>L)[.Z ^:6T DB;WP3N7Z<_6M;
M4?VD_"=I"S6RWM]*/NHD.P$X[EB,?D:]^>&R;$3^L>ULGJU>WX6O_6A\A2QW
M$V#I+!_5^9K12M?TU3L_G\SMM(TS2OAIX-2#S!!IVGPEY9Y.K'JS'U)/\P!7
MQYXR\22^+_%&HZO*"INI2RH3G:@X5?P4 ?A70_$GXNZM\19%AD5;'2XVW1V<
M3$Y/9G;^(_@ /2N$KR,VS*&+Y:&'5J<=O/\ X"Z'T?#F25<OY\7C'>M4WZV6
M^_5M[]#ZO_9P_P"2:1?]?4O\Q7@_QL_Y*EK_ /UU3_T6M=K\)OC;H7@3PBFE
M:A::A+<"9Y-UM&C)AL8Y+@_I7FOQ$\1VWBWQGJ>KV:2QVUTZLB3@!P @'(!(
MZCUKHQ^*HU<LH482O)6NODSCRC 8JAGF*Q-6FU"7-9]'[R9SM?1W[*__ " M
M=_Z^4_\ 0:^<:]9^"_Q9TCX<Z;J5OJ5M>SO<S+(AM41@ !CG<ZUY^35J>'QD
M:E5V6NOR/:XFPU;&99.C0CS2;6B\FAO[2_\ R4:/_KQB_P#0GK3_ &:?&<>E
MZS=Z!=2;(]0Q+;ECQYJCE?JR_JH'>N,^+OC>Q\?^*UU/3XKB&W%LD.VZ55;(
M+$\!B,<^M<5%*\$J21NT<B$,KH<%2.A![&JJ8WV&92Q5)W5W\T94<K^MY)#
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MA6 Y!'3T->B_L]_#;7/#&IWVL:M ]A'-;_9X[:0_.^65MY';&W'//)K8TO\
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MR?E^@]JTZ^<G'DDXGW]"K[:FI]PHHHJ#H"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IT7^M3ZBFTZ+_
M %J?44 =-11100%%%% !1110 4444 %%%% !1110 4444 %%%% !7/\ Q!_Y
M$;7O^O*7_P!!-=!7/_$'_D1M>_Z\I?\ T$UAB/X,_1_D=>#_ -YI_P")?F?#
M]%%%?B)_504444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MFOO^AKM__ )O_BZ/^&)K[_H:[?\ \ F_^+KJMA>_YG#S8_M^1T/_  VIH?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5:TO_D(0?[U5:M:7_P A"#_>JX?$C.?P/T)_B3_R(.O_
M /7G)_*OD&OK[XD_\B#K_P#UYR?RKY!KYKB+^/#T_4^[X+_W6K_B_1!1117R
MA^AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110!VWP9_Y*)IG_  /_ -!-?7;?
M=/TKY$^#/_)1-,_X'_Z":^NV^Z?I7Z1PU_NLO\7Z(_$../\ ?Z?^']68U%%%
M?6GYX%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 ,2!P,FOE+QOHDNK:C&)$89A5?D8#HS'O7U;7
ME7Q+T^RM=7B\N"&'_1U.U(@/XVYX%>KE\DJG*^I\WGE&4Z"G'I^IYM%\,8K?
M0A<DW&X6WF<R)C[N?2N;M;!HKIXT!.%[D>U>S75I/<^'"L.<&T(X..J<5Q6A
M:+]DU&5[Q5(,>/G4-SD?7M7W&%DE%O<_':M.I=W,2YT"<V[R&-N./O+ZUH_
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5M[ ?W/:NY/PBT95PEE&/K/+_C5<_!K2'/SV<1'I]HE_QKTZN*I5(<MSYF.
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *=%_K4^HIM.B_P!:GU% '34444$!
M1110 4444 %%%% !1110 4444 %%%% !1110 5S_ ,0?^1&U[_KRE_\ 0370
M5S_Q!_Y$;7O^O*7_ -!-88C^#/T?Y'7@_P#>:?\ B7YGP_1117XB?U4%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M /B:/[/Q7\C#^V<!_P _5^)YS17HW_"D-5_Y_P"S_P#'_P#XFC_A2&J_\_\
M9_\ C_\ \31_9^*_D8?VS@/^?J_$\YHKT;_A2&J_\_\ 9_\ C_\ \31_PI#5
M?^?^S_\ '_\ XFC^S\5_(P_MG ?\_5^)YS17HW_"D-5_Y_[/_P ?_P#B:/\
MA2&J_P#/_9_^/_\ Q-']GXK^1A_;. _Y^K\3SFBO1O\ A2&J_P#/_9_^/_\
MQ-'_  I#5?\ G_L__'__ (FC^S\5_(P_MG ?\_5^)YS17HW_  I#5?\ G_L_
M_'__ (FC_A2&J_\ /_9_^/\ _P 31_9^*_D8?VS@/^?J_$\YHKT;_A2&J_\
M/_9_^/\ _P 31_PI#5?^?^S_ /'_ /XFC^S\5_(P_MG ?\_5^)YS17HW_"D-
M5_Y_[/\ \?\ _B:/^%(:K_S_ -G_ ./_ /Q-']GXK^1A_;. _P"?J_$\YHKT
M;_A2&J_\_P#9_P#C_P#\31_PI#5?^?\ L_\ Q_\ ^)H_L_%?R,/[9P'_ #]7
MXGG-%>C?\*0U7_G_ +/_ ,?_ /B:/^%(:K_S_P!G_P"/_P#Q-']GXK^1A_;.
M _Y^K\3SFBO1O^%(:K_S_P!G_P"/_P#Q-'_"D-5_Y_[/_P ?_P#B:/[/Q7\C
M#^V<!_S]7XGG-%>C?\*0U7_G_L__ !__ .)H_P"%(:K_ ,_]G_X__P#$T?V?
MBOY&']LX#_GZOQ/.:*]&_P"%(:K_ ,_]G_X__P#$T?\ "D-5_P"?^S_\?_\
MB:/[/Q7\C#^V<!_S]7XGG-%>C?\ "D-5_P"?^S_\?_\ B:/^%(:K_P _]G_X
M_P#_ !-']GXK^1A_;. _Y^K\3SFBO1O^%(:K_P _]G_X_P#_ !-'_"D-5_Y_
M[/\ \?\ _B:/[/Q7\C#^V<!_S]7XGG-%>C?\*0U7_G_L_P#Q_P#^)H_X4AJO
M_/\ V?\ X_\ _$T?V?BOY&']LX#_ )^K\3SFBO1O^%(:K_S_ -G_ ./_ /Q-
M'_"D-5_Y_P"S_P#'_P#XFC^S\5_(P_MG ?\ /U?B><T5Z-_PI#5?^?\ L_\
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M/[/Q7\C#^V<!_P _5^)YS17HW_"D-5_Y_P"S_P#'_P#XFC_A2&J_\_\ 9_\
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M !-']GXK^1A_;. _Y^K\3SFBO1O^%(:K_P _]G_X_P#_ !-'_"D-5_Y_[/\
M\?\ _B:/[/Q7\C#^V<!_S]7XGG-%>C?\*0U7_G_L_P#Q_P#^)H_X4AJO_/\
MV?\ X_\ _$T?V?BOY&']LX#_ )^K\3SFBO1O^%(:K_S_ -G_ ./_ /Q-'_"D
M-5_Y_P"S_P#'_P#XFC^S\5_(P_MG ?\ /U?B><T5Z-_PI#5?^?\ L_\ Q_\
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M7\C#^V<!_P _5^)YS17HW_"D-5_Y_P"S_P#'_P#XFC_A2&J_\_\ 9_\ C_\
M\31_9^*_D8?VS@/^?J_$\YHKT;_A2&J_\_\ 9_\ C_\ \31_PI#5?^?^S_\
M'_\ XFC^S\5_(P_MG ?\_5^)YS17HW_"D-5_Y_[/_P ?_P#B:/\ A2&J_P#/
M_9_^/_\ Q-']GXK^1A_;. _Y^K\3SFBO1O\ A2&J_P#/_9_^/_\ Q-'_  I#
M5?\ G_L__'__ (FC^S\5_(P_MG ?\_5^)YS17HW_  I#5?\ G_L__'__ (FC
M_A2&J_\ /_9_^/\ _P 31_9^*_D8?VS@/^?J_$\YHKT;_A2&J_\ /_9_^/\
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M^S\5_(P_MG ?\_5^)YS17HW_  I#5?\ G_L__'__ (FC_A2&J_\ /_9_^/\
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M_P#XFC_A2&J_\_\ 9_\ C_\ \31_9^*_D8?VS@/^?J_$\YHKT;_A2&J_\_\
M9_\ C_\ \31_PI#5?^?^S_\ '_\ XFC^S\5_(P_MG ?\_5^)YS17HW_"D-5_
MY_[/_P ?_P#B:/\ A2&J_P#/_9_^/_\ Q-']GXK^1A_;. _Y^K\3SFBO1O\
MA2&J_P#/_9_^/_\ Q-'_  I#5?\ G_L__'__ (FC^S\5_(P_MG ?\_5^)YS1
M7HW_  I#5?\ G_L__'__ (FC_A2&J_\ /_9_^/\ _P 31_9^*_D8?VS@/^?J
M_$\YHKT;_A2&J_\ /_9_^/\ _P 31_PI#5?^?^S_ /'_ /XFC^S\5_(P_MG
M?\_5^)YS17HW_"D-5_Y_[/\ \?\ _B:/^%(:K_S_ -G_ ./_ /Q-']GXK^1A
M_;. _P"?J_$\YHKT;_A2&J_\_P#9_P#C_P#\31_PI#5?^?\ L_\ Q_\ ^)H_
ML_%?R,/[9P'_ #]7XGG-%>C?\*0U7_G_ +/_ ,?_ /B:/^%(:K_S_P!G_P"/
M_P#Q-']GXK^1A_;. _Y^K\3SFBO1O^%(:K_S_P!G_P"/_P#Q-'_"D-5_Y_[/
M_P ?_P#B:/[/Q7\C#^V<!_S]7XGG-%>C?\*0U7_G_L__ !__ .)H_P"%(:K_
M ,_]G_X__P#$T?V?BOY&']LX#_GZOQ/.:*]&_P"%(:K_ ,_]G_X__P#$T?\
M"D-5_P"?^S_\?_\ B:/[/Q7\C#^V<!_S]7XGG-%>C?\ "D-5_P"?^S_\?_\
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M%?R,/[9P'_/U?B><T5Z-_P *0U7_ )_[/_Q__P")H_X4AJO_ #_V?_C_ /\
M$T?V?BOY&']LX#_GZOQ/.:*]&_X4AJO_ #_V?_C_ /\ $T?\*0U7_G_L_P#Q
M_P#^)H_L_%?R,/[9P'_/U?B><T5Z-_PI#5?^?^S_ /'_ /XFC_A2&J_\_P#9
M_P#C_P#\31_9^*_D8?VS@/\ GZOQ/.:*]&_X4AJO_/\ V?\ X_\ _$T?\*0U
M7_G_ +/_ ,?_ /B:/[/Q7\C#^V<!_P _5^)YS17HW_"D-5_Y_P"S_P#'_P#X
MFC_A2&J_\_\ 9_\ C_\ \31_9^*_D8?VS@/^?J_$\YHKT;_A2&J_\_\ 9_\
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M^)YS17HW_"D-5_Y_[/\ \?\ _B:/^%(:K_S_ -G_ ./_ /Q-']GXK^1A_;.
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MC_A2&J_\_P#9_P#C_P#\31_9^*_D8?VS@/\ GZOQ/.:*]&_X4AJO_/\ V?\
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M']GXK^1A_;. _P"?J_$\YHKT;_A2&J_\_P#9_P#C_P#\31_PI#5?^?\ L_\
MQ_\ ^)H_L_%?R,/[9P'_ #]7XGG-%>C?\*0U7_G_ +/_ ,?_ /B:/^%(:K_S
M_P!G_P"/_P#Q-']GXK^1A_;. _Y^K\3SFBO1O^%(:K_S_P!G_P"/_P#Q-'_"
MD-5_Y_[/_P ?_P#B:/[/Q7\C#^V<!_S]7XGG-%>C?\*0U7_G_L__ !__ .)H
M_P"%(:K_ ,_]G_X__P#$T?V?BOY&']LX#_GZOQ/.:*]&_P"%(:K_ ,_]G_X_
M_P#$T?\ "D-5_P"?^S_\?_\ B:/[/Q7\C#^V<!_S]7XGG-%>C?\ "D-5_P"?
M^S_\?_\ B:/^%(:K_P _]G_X_P#_ !-']GXK^1A_;. _Y^K\3SFBO1O^%(:K
M_P _]G_X_P#_ !-'_"D-5_Y_[/\ \?\ _B:/[/Q7\C#^V<!_S]7XGG-%>C?\
M*0U7_G_L_P#Q_P#^)H_X4AJO_/\ V?\ X_\ _$T?V?BOY&']LX#_ )^K\3SF
MBO1O^%(:K_S_ -G_ ./_ /Q-'_"D-5_Y_P"S_P#'_P#XFC^S\5_(P_MG ?\
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M&J_\_P#9_P#C_P#\31_9^*_D8?VS@/\ GZOQ/.:*]&_X4AJO_/\ V?\ X_\
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MS^^XC_[Y'7\2:[=$6-%15"JHP%48 %>MA<I:DIXC[O\ ,^=S#B.+BZ>#6O\
M,_T7^9)I5O%:2VD$*".*-D5$48"@$8%>A-]T_2N!LO\ C\@_ZZ+_ #KOF^Z?
MI7WN"TBS\AS1MSBV8U%%%>D>.%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4Z+_ %J?44VG1?ZU/J* .FHHHH("BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ KG_ (@_\B-KW_7E+_Z":Z"N?^(/_(C:]_UY2_\
MH)K#$?P9^C_(Z\'_ +S3_P 2_,^'Z***_$3^J@HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MV>AC(N5"2BKO3\SSG]B[_D>M<_[!O_M5*^P*^;OV8_A'XL^'GBS5;SQ!I/\
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MI,-BHNKM5/!E8?(I_P!U"3_P.G_L;^!/MFLZEXLN8\Q6:FSM"1P96&78>X7
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MXJJI-1CLCS\OH2@G.:LV%%%%>>>N%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 5:TO_ )"$'^]56K6E_P#(
M0@_WJN'Q(SG\#]#H]1_X\9_]PUR5=;J/_'C/_N&N2KHQ/Q(X\'\+"BBBN0]
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *T=!_P"0@/\
M=-9U:.@_\A ?[IK6E\:,:W\.7H:VM_\ (.D^H_G7,5T^M_\ (.D^H_G7,5KB
M/C.?!_PWZA1117*=P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% $MK_Q]0_[X_G76S_ZB3_=
M/\JY*U_X^H?]\?SKK9_]1)_NG^5=V'^%GF8OXHG&T445PGIA1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 5T/AW_CR?\ ZZ'^0KGJZ'P[_P >3_\ 70_R%=%#XSCQ7\,J>(O^/J+_
M '/ZFLFM;Q%_Q]1?[G]3634UOC9IA_X40HHHK$Z HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4 %.B_UJ?44VG1?ZU/J* .FHHHH("BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ KG_B#_ ,B-KW_7E+_Z":Z"N?\ B#_R(VO?]>4O_H)K#$?P9^C_ ".O
M!_[S3_Q+\SX?HHHK\1/ZJ"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "OH?X:_\B/I7^XW_H;5\\5]#_#7_D1]*_W&
M_P#0VKWLF_CR]/U1\?Q/_NL/\7Z,Z:BBBOKS\U"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JUI?_(0@
M_P!ZJM6M+_Y"$'^]5P^)&<_@?H='J/\ QXS_ .X:Y*NMU'_CQG_W#7)5T8GX
MD<>#^%A1117(>@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %:.@_\A ?[IK.K1T'_ )" _P!TUK2^-&-;^'+T-;6_^0=)]1_.N8KI];_Y
M!TGU'\ZYBM<1\9SX/^&_4****Y3N"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH EM?\ CZA_
MWQ_.NMG_ -1)_NG^5<E:_P#'U#_OC^==;/\ ZB3_ '3_ "KNP_PL\S%_%$XV
MBBBN$],**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "NA\._\ 'D__ %T/\A7/5T/AW_CR?_KH?Y"N
MBA\9QXK^&5/$7_'U%_N?U-9-:WB+_CZB_P!S^IK)J:WQLTP_\*(4445B= 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% $UE_Q^0?]=%_G7?-]T_2N!LO^/R#_KHO\Z[YONGZ
M5ZV"^&1\]F?Q1,:BBBO2/("BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JEKFLVGA
MW1=0U6^D\JRL;>2ZGDQ]V-%+,?P -7:\V_:8L[O4?V<?BG:V.XWDWA75(X50
M99F-I* ![GI0(_./]ASP3+^VO^UEXV^,WCN :AI6B7"75MIUR/,B$\A86D.#
MP4ACC)Q_>"$]3G]9:_/'_@C!<6S?![Q_"I7[8FO1O(!UV&W0)GVRK_K7Z'4
MCE/BG\,?#_QD\ ZSX/\ $]BE_H^J0&&1'4%HV_AD0_PNC896[$"L#]GS]G_P
MO^S9\.K;P?X4%V]FDAN+BYO9S))<SL 'E(^ZI(51A HX'&<D_(/QP_;#_:L\
M$_%OQ7H/@[X(_P!O^%]/OG@T[4_^$3U:Y^TPC[K^;%,$?/JH KN?V ?VROB!
M^U#XF\>:1XYT/0]$F\.QV^R'2[2XMY5D=Y5D642S2<@Q@8P"#G- CPCXT?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "G1?ZU/J*;3HO]:GU% '34444$!111
M0 4444 %%%% !1110 4444 %%%% !1110 5S_P 0?^1&U[_KRE_]!-=!7/\
MQ!_Y$;7O^O*7_P!!-88C^#/T?Y'7@_\ >:?^)?F?#]%%%?B)_504444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5]#_#
M7_D1]*_W&_\ 0VKYXKZ'^&O_ "(^E?[C?^AM7O9-_'EZ?JCX_B?_ '6'^+]&
M=-1117UY^:A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 5:TO_D(0?[U5:M:7_P A"#_>JX?$C.?P/T.C
MU'_CQG_W#7)5UNH_\>,_^X:Y*NC$_$CCP?PL****Y#T HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ K1T'_D(#_=-9U:.@_P#(0'^Z:UI?
M&C&M_#EZ&MK?_(.D^H_G7,5T^M_\@Z3ZC^=<Q6N(^,Y\'_#?J%%%%<IW!111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 2VO\ Q]0_[X_G76S_ .HD_P!T_P JY*U_X^H?]\?S
MKK9_]1)_NG^5=V'^%GF8OXHG&T445PGIA1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5T/AW_ (\G
M_P"NA_D*YZNA\._\>3_]=#_(5T4/C./%?PRIXB_X^HO]S^IK)K6\1?\ 'U%_
MN?U-9-36^-FF'_A1"BBBL3H"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH FLO^/R#_KHO\Z[
MYONGZ5P-E_Q^0?\ 71?YUWS?=/TKUL%\,CY[,_BB8U%%%>D>0%%%% !1110
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M*/AFXLO#PEU/7+\+_:.NWJ@3W..B*!Q'&"3A!GW+'FO/?V_?V2O%_P"U39>
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *=%_K4^HIM.B_P!:GU% '34444$!1110 4444 %%
M%% !1110 4444 %%%% !1110 5S_ ,0?^1&U[_KRE_\ 03705S_Q!_Y$;7O^
MO*7_ -!-88C^#/T?Y'7@_P#>:?\ B7YGP_1117XB?U4%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?0_PU_Y$?2O]
MQO\ T-J^>*^A_AK_ ,B/I7^XW_H;5[V3?QY>GZH^/XG_ -UA_B_1G34445]>
M?FH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %6M+_P"0A!_O55JUI?\ R$(/]ZKA\2,Y_ _0Z/4?^/&?
M_<-<E76ZC_QXS_[AKDJZ,3\2./!_"PHHHKD/0"BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "M'0?\ D(#_ '36=6CH/_(0'^Z:UI?&C&M_
M#EZ&MK?_ "#I/J/YUS%=/K?_ "#I/J/YUS%:XCXSGP?\-^H4445RG<%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110!+:_\?4/^^/YUUL_^HD_W3_*N2M?^/J'_?'\ZZV?_42?
M[I_E7=A_A9YF+^*)QM%%%<)Z84444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %=#X=_X\G_ .NA_D*Y
MZNA\._\ 'D__ %T/\A710^,X\5_#*GB+_CZB_P!S^IK)K6\1?\?47^Y_4UDU
M-;XV:8?^%$****Q.@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@":R_X_(/^NB_SKOF^Z?I7
M V7_ !^0?]=%_G7?-]T_2O6P7PR/GLS^*)C4445Z1Y 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7@_]YI_XE^9\/T445^(G]5!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !7T/\ #7_D1]*_W&_]#:OGBOH?X:_\B/I7
M^XW_ *&U>]DW\>7I^J/C^)_]UA_B_1G34445]>?FH4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %6M+_Y
M"$'^]56K6E_\A"#_ 'JN'Q(SG\#]#H]1_P"/&?\ W#7)5UNH_P#'C/\ [AKD
MJZ,3\2./!_"PHHHKD/0"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "M'0?^0@/]TUG5HZ#_P A ?[IK6E\:,:W\.7H:VM_\@Z3ZC^=<Q73
MZW_R#I/J/YUS%:XCXSGP?\-^H4445RG<%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!+:_\
M'U#_ +X_G76S_P"HD_W3_*N2M?\ CZA_WQ_.NMG_ -1)_NG^5=V'^%GF8OXH
MG&T445PGIA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5T/AW_CR?_KH?Y"N>KH?#O_'D_P#UT/\
M(5T4/C./%?PRIXB_X^HO]S^IK)K6\1?\?47^Y_4UDU-;XV:8?^%$****Q.@*
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@":R_P"/R#_KHO\ .N^;[I^E<#9?\?D'_71?YUWS
M?=/TKUL%\,CY[,_BB8U%%%>D>0%%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4Z+_6I]13:=%_K4^HH Z:BBB@@**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "N?^(/\ R(VO?]>4O_H)KH*Y_P"(/_(C:]_UY2_^
M@FL,1_!GZ/\ (Z\'_O-/_$OS/A^BBBOQ$_JH**** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^A_AK_R(^E?[C?^AM7S
MQ7T/\-?^1'TK_<;_ -#:O>R;^/+T_5'Q_$_^ZP_Q?HSIJ***^O/S4**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "K6E_\A"#_ 'JJU:TO_D(0?[U7#XD9S^!^AT>H_P#'C/\ [AKDJZW4
M?^/&?_<-<E71B?B1QX/X6%%%%<AZ 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 5HZ#_R$!_NFLZM'0?\ D(#_ '36M+XT8UOX<O0UM;_Y
M!TGU'\ZYBNGUO_D'2?4?SKF*UQ'QG/@_X;]0HHHKE.X**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@"6U_P"/J'_?'\ZZV?\ U$G^Z?Y5R5K_ ,?4/^^/YUUL_P#J)/\ =/\
M*N[#_"SS,7\43C:***X3TPHHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Z'P[_P >3_\ 70_R%<]7
M0^'?^/)_^NA_D*Z*'QG'BOX94\1?\?47^Y_4UDUK>(O^/J+_ '/ZFLFIK?&S
M3#_PHA1116)T!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 367_'Y!_UT7^==\WW3]*X&R_X
M_(/^NB_SKOF^Z?I7K8+X9'SV9_%$QJ***](\@**** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MFC_A?G@'_H8X/^_,O_Q-?+O_  H#XB?]"EJ'_?"_XT?\* ^(G_0I:A_WPO\
MC1_Q#[(O^@J7_@4/_D0_XBCGO_0+#_P&?_R1]1?\+\\ _P#0QP?]^9?_ (FC
M_A?G@'_H8X/^_,O_ ,37R[_PH#XB?]"EJ'_?"_XT?\* ^(G_ $*6H?\ ?"_X
MT?\ $/LB_P"@J7_@4/\ Y$/^(HY[_P! L/\ P&?_ ,D?47_"_/ /_0QP?]^9
M?_B:/^%^> ?^AC@_[\R__$U\N_\ "@/B)_T*6H?]\+_C1_PH#XB?]"EJ'_?"
M_P"-'_$/LB_Z"I?^!0_^1#_B*.>_] L/_ 9__)'U%_POSP#_ -#'!_WYE_\
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M_P */^%U^!O^AFL?^^C_ (5\D_\ "D_'W_0GZS_X"/\ X4?\*3\??]"?K/\
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M_P */^%U^!O^AFL?^^C_ (5\D_\ "D_'W_0GZS_X"/\ X4?\*3\??]"?K/\
MX"/_ (4?\0[R;_H*E]\/\@_XBGG/_0+#[I_YGUPOQJ\#,P4>)K')..7('YXJ
MQ_PMOP7_ -#1I?\ X$K_ (U\?/\ !;Q[&A8^#]:( S\ME(3^0%5O^%2^./\
MH3?$'_@KG_\ B*E^'.4OX<7+[X_Y#7BGFR^+"0_\F_S/LK_A;?@O_H:-+_\
M E?\:/\ A;?@O_H:-+_\"5_QKXU_X5+XX_Z$WQ!_X*Y__B*/^%2^./\ H3?$
M'_@KG_\ B*7_ !#C*_\ H+E_Y*5_Q%3-?^@2/_DW^9]E?\+;\%_]#1I?_@2O
M^-'_  MOP7_T-&E_^!*_XU\:_P#"I?''_0F^(/\ P5S_ /Q%'_"I?''_ $)O
MB#_P5S__ !%'_$.,K_Z"Y?\ DH?\14S7_H$C_P"3?YGV5_PMOP7_ -#1I?\
MX$K_ (T?\+;\%_\ 0T:7_P"!*_XU\:_\*E\<?]";X@_\%<__ ,11_P *E\<?
M]";X@_\ !7/_ /$4?\0XRO\ Z"Y?^2A_Q%3-?^@2/_DW^9]E?\+;\%_]#1I?
M_@2O^-'_  MOP7_T-&E_^!*_XU\:_P#"I?''_0F^(/\ P5S_ /Q%'_"I?''_
M $)OB#_P5S__ !%'_$.,K_Z"Y?\ DH?\14S7_H$C_P"3?YGV5_PMOP7_ -#1
MI?\ X$K_ (T?\+;\%_\ 0T:7_P"!*_XU\:_\*E\<?]";X@_\%<__ ,11_P *
ME\<?]";X@_\ !7/_ /$4?\0XRO\ Z"Y?^2A_Q%3-?^@2/_DW^9]E?\+;\%_]
M#1I?_@2O^-'_  MOP7_T-&E_^!*_XU\:_P#"I?''_0F^(/\ P5S_ /Q%'_"I
M?''_ $)OB#_P5S__ !%'_$.,K_Z"Y?\ DH?\14S7_H$C_P"3?YGV5_PMOP7_
M -#1I?\ X$K_ (T?\+;\%_\ 0T:7_P"!*_XU\:_\*E\<?]";X@_\%<__ ,11
M_P *E\<?]";X@_\ !7/_ /$4?\0XRO\ Z"Y?^2A_Q%3-?^@2/_DW^9]E?\+;
M\%_]#1I?_@2O^-'_  MOP7_T-&E_^!*_XU\:_P#"I?''_0F^(/\ P5S_ /Q%
M'_"I?''_ $)OB#_P5S__ !%'_$.,K_Z"Y?\ DH?\14S7_H$C_P"3?YGV5_PM
MOP7_ -#1I?\ X$K_ (T?\+;\%_\ 0T:7_P"!*_XU\:_\*E\<?]";X@_\%<__
M ,11_P *E\<?]";X@_\ !7/_ /$4?\0XRO\ Z"Y?^2A_Q%3-?^@2/_DW^9]E
M?\+;\%_]#1I?_@2O^-'_  MOP7_T-&E_^!*_XU\:_P#"I?''_0F^(/\ P5S_
M /Q%'_"I?''_ $)OB#_P5S__ !%'_$.,K_Z"Y?\ DH?\14S7_H$C_P"3?YGV
M5_PMOP7_ -#1I?\ X$K_ (T?\+;\%_\ 0T:7_P"!*_XU\:_\*E\<?]";X@_\
M%<__ ,11_P *E\<?]";X@_\ !7/_ /$4?\0XRO\ Z"Y?^2A_Q%3-?^@2/_DW
M^9]F1_%?P9*X5?%.D@G^]=HH_,FIO^%F>$/^AKT3_P &,/\ \57Q5-\+/&EN
MA>7PAKT:#JSZ9, /_':K_P#"O/%7_0LZQ_X+Y?\ XFE_Q#;+7\.+E_Y*->*N
M9+XL)'[Y'V[_ ,+,\(?]#7HG_@QA_P#BJ/\ A9GA#_H:]$_\&,/_ ,57Q%_P
MKSQ5_P!"SK'_ (+Y?_B:/^%>>*O^A9UC_P %\O\ \32_XAKE_P#T%R_\E'_Q
M%;,/^@2/WR/MW_A9GA#_ *&O1/\ P8P__%4?\+,\(?\ 0UZ)_P"#&'_XJOB+
M_A7GBK_H6=8_\%\O_P 31_PKSQ5_T+.L?^"^7_XFC_B&N7_]!<O_ "4/^(K9
MA_T"1^^1]N_\+,\(?]#7HG_@QA_^*H_X69X0_P"AKT3_ ,&,/_Q5?$7_  KS
MQ5_T+.L?^"^7_P")H_X5YXJ_Z%G6/_!?+_\ $T?\0UR__H+E_P"2A_Q%;,/^
M@2/WR/MW_A9GA#_H:]$_\&,/_P 51_PLSPA_T->B?^#&'_XJOB+_ (5YXJ_Z
M%G6/_!?+_P#$T?\ "O/%7_0LZQ_X+Y?_ (FC_B&N7_\ 07+_ ,E#_B*V8?\
M0)'[Y'V[_P +,\(?]#7HG_@QA_\ BJ/^%F>$/^AKT3_P8P__ !5?$7_"O/%7
M_0LZQ_X+Y?\ XFC_ (5YXJ_Z%G6/_!?+_P#$T?\ $-<O_P"@N7_DH?\ $5LP
M_P"@2/WR/MW_ (69X0_Z&O1/_!C#_P#%4?\ "S/"'_0UZ)_X,8?_ (JOB+_A
M7GBK_H6=8_\ !?+_ /$T?\*\\5?]"SK'_@OE_P#B:/\ B&N7_P#07+_R4/\
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MC_\ BJ^#O^$3US_H#:A_X"O_ (4?\(GKG_0&U#_P%?\ PH_XAG@_^@M_<O\
M,/\ B+.,_P"@./\ X$_\C[Q_X3GPW_T,&E?^!L?_ ,51_P )SX;_ .A@TK_P
M-C_^*KX._P"$3US_ * VH?\ @*_^%'_")ZY_T!M0_P# 5_\ "C_B&>#_ .@M
M_<O\P_XBSC/^@./_ ($_\C[Q_P"$Y\-_]#!I7_@;'_\ %4?\)SX;_P"A@TK_
M ,#8_P#XJO@[_A$]<_Z VH?^ K_X4?\ ")ZY_P! ;4/_  %?_"C_ (AG@_\
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M]PO[>TS_ *"-I_W_ %_QH_M[3/\ H(VG_?\ 7_&OP]HH_P!2(_\ 01_Y+_\
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MZ1_Z!_\ R;_[4_<&BOP^_MW4_P#H(W?_ '_;_&C^W=3_ .@C=_\ ?]O\:/\
M4B7_ $$?^2__ &P?ZZ1_Z!__ ";_ .U/W!HK\/O[=U/_ *"-W_W_ &_QH_MW
M4_\ H(W?_?\ ;_&C_4B7_01_Y+_]L'^ND?\ H'_\F_\ M3]P:*_#[^W=3_Z"
M-W_W_;_&C^W=3_Z"-W_W_;_&C_4B7_01_P"2_P#VP?ZZ1_Z!_P#R;_[4_<&B
MOP^_MW4_^@C=_P#?]O\ &C^W=3_Z"-W_ -_V_P :/]2)?]!'_DO_ -L'^ND?
M^@?_ ,F_^U/W!HK\2T\<>(XD5(_$&J(B@!56]D  '0#YJ=_PG?B;_H8=6_\
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M^)O^AAU;_P #I?\ XJC_ %(J?\_U_P" _P#!#_7.G_SX?_@7_ /VRHK\3?\
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M\_U]S_S#_7.C_P ^7]Z_R/VDHK\6_P#A;?CG_H=/$/\ X-)__BZ/^%M^.?\
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M\_U]S_S#_7.C_P ^7]Z_R/VDHK\6_P#A;?CG_H=/$/\ X-)__BZ/^%M^.?\
MH=/$/_@TG_\ BZ/]2:W_ #_7W/\ S#_7.C_SY?WK_(_:2BOQ;_X6WXY_Z'3Q
M#_X-)_\ XNC_ (6WXY_Z'3Q#_P"#2?\ ^+H_U)K?\_U]S_S#_7.C_P ^7]Z_
MR/VDHK\6_P#A;?CG_H=/$/\ X-)__BZ/^%M^.?\ H=/$/_@TG_\ BZ/]2:W_
M #_7W/\ S#_7.C_SY?WK_(_:2BOQ;_X6WXY_Z'3Q#_X-)_\ XNE7XN>.E8,O
MC3Q"&!R"-5GR/_'Z7^I-;_G^ON?^8?ZYT?\ GR_O7^1^T=%?C5_PO?XF?]%$
M\5_^#NY_^+H_X7O\3/\ HHGBO_P=W/\ \74_ZDXC_G]'[F5_KGA_^?+^]'[*
MT5^-7_"]_B9_T43Q7_X.[G_XNC_A>_Q,_P"BB>*__!W<_P#Q='^I.(_Y_1^Y
MA_KGA_\ GR_O1^RM%?C5_P +W^)G_11/%?\ X.[G_P"+H_X7O\3/^BB>*_\
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M_P#SY?WH_96BOQJ_X7O\3/\ HHGBO_P=W/\ \71_PO?XF?\ 11/%?_@[N?\
MXNC_ %)Q'_/Z/W,/]<\/_P ^7]Z/V5HK\:O^%[_$S_HHGBO_ ,'=S_\ %TZ+
MX^?$V&177XA^*BRG(#:S<,/Q!?!H_P!2<1_S^C]S#_7+#_\ /E_>C]DZ*_'C
M_AI'XI_]% \0?^#"3_&C_AI'XI_]% \0?^#"3_&H_P!2L5_S]C^)7^N6&_Y]
M2_ _8>BOQX_X:1^*?_10/$'_ (,)/\:/^&D?BG_T4#Q!_P"#"3_&C_4K%?\
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M:L^+?_0^:M_WVO\ \31_J5C/^?L?Q_R#_7'"?\^Y?A_F?KS17Y#?\-6?%O\
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MXQ_]#Q=_^ UO_P#&Z/\ AL;XQ_\ 0\7?_@-;_P#QNC_4O'?\_(?>_P#Y$/\
M7'!?\^Y_<O\ ,_6JBOR5_P"&QOC'_P!#Q=_^ UO_ /&Z/^&QOC'_ -#Q=_\
M@-;_ /QNC_4O'?\ /R'WO_Y$/]<<%_S[G]R_S/UJHK\E?^&QOC'_ -#Q=_\
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MJ7F'\\/OE_\ (A_KC@/Y)_='_P"2/U;HK\I/^&WOC7_T.O\ Y2K'_P",T?\
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MQ?E_\L_N7_R1^H=%?F!_P\!^+G_/YI/_ (+U_P :/^'@/Q<_Y_-)_P#!>O\
MC2_U.S'O'[W_ )#_ -;\O_EE]R_S/T_HK\P/^'@/Q<_Y_-)_\%Z_XT?\/ ?B
MY_S^:3_X+U_QH_U.S'O'[W_D'^M^7_RR^Y?YGZ?T5^8'_#P'XN?\_FD_^"]?
M\:/^'@/Q<_Y_-)_\%Z_XT?ZG9CWC][_R#_6_+_Y9?<O\S]/Z*_,#_AX#\7/^
M?S2?_!>O^-'_  \!^+G_ #^:3_X+U_QH_P!3LQ[Q^]_Y!_K?E_\ ++[E_F?I
M_17Y@?\ #P'XN?\ /YI/_@O7_&C_ (> _%S_ )_-)_\ !>O^-'^IV8]X_>_\
M@_UOR_\ EE]R_P S]/Z*_,#_ (> _%S_ )_-)_\ !>O^-'_#P'XN?\_FD_\
M@O7_ !H_U.S'O'[W_D'^M^7_ ,LON7^9^G]%?F!_P\!^+G_/YI/_ (+U_P :
M/^'@/Q<_Y_-)_P#!>O\ C1_J=F/>/WO_ "#_ %OR_P#EE]R_S/T_HK\P/^'@
M/Q<_Y_-)_P#!>O\ C1_P\!^+G_/YI/\ X+U_QH_U.S'O'[W_ )!_K?E_\LON
M7^9^G]%?F!_P\!^+G_/YI/\ X+U_QH_X> _%S_G\TG_P7K_C1_J=F/>/WO\
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MI^9?W?O_ . '^MV7=I?<O\S],**_,_\ X>)?%/\ Y]_#_P#X R?_ !VKJ?\
M!2#XF*B@Z+X5<@8+&SN<GWXN*3X0S)?R_?\ \ %Q;EW:7W?\$_2.BOS=_P"'
MD?Q+_P"@'X4_\!+G_P"2*/\ AY'\2_\ H!^%/_ 2Y_\ DBE_JAF?]W[_ /@#
M_P!;<N_O?=_P3](J*_-W_AY'\2_^@'X4_P# 2Y_^2*/^'D?Q+_Z ?A3_ ,!+
MG_Y(H_U0S/\ N_?_ , /];<N_O?=_P $_2*BOS=_X>1_$O\ Z ?A3_P$N?\
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MN_O?=_P3](J*_-W_ (>1_$O_ * ?A3_P$N?_ )(J_P#\/)_'/_0L>'ORG_\
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MA_K9EO>7W?\ !/T3HK\[/^'D_CG_ *%CP]^4_P#\<H_X>3^.?^A8\/?E/_\
M'*/]4<S[1^\/];,M[R^[_@GZ)T5^=G_#R?QS_P!"QX>_*?\ ^.4?\/)_'/\
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M ($2T?\ #R[Q/_T)NE?^!$M'^J6:?RK_ ,"0?ZUY;W?W'Z"T5^?7_#R[Q/\
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M9I_(O_ D'^M66?S/[F?>]%?!'_#S74_^A"M/_!FW_P ;H_X>:ZG_ -"%:?\
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M^!+_ ##_ %IRS^=_<S[IHKX6_P"'G1_Z)N/_  >__<U'_#SH_P#1-Q_X/?\
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M ,:H_P"'FFG?]"#=_P#@S7_XU1_JMFO_ #[_ !7^8?ZT99_._N9]M45\2_\
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M/+_#?_0FZK_X$Q4?ZL9I_P ^_P 4'^L^6_SO[C[,HKXS_P"'E_AO_H3=5_\
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M?X'!_:F#_P"?B/LZBOC'_AZ+X!_Z%3Q)^5O_ /'*/^'HO@'_ *%3Q)^5O_\
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MXFX'\JD_X>??"S_H ^+_ /P#M?\ Y)I?V1C_ /GTRO[3P?\ S\1]?45\@_\
M#S[X6?\ 0!\7_P#@':__ "31_P //OA9_P! 'Q?_ . =K_\ )-+^R,?_ ,^F
M']I83_GXCZ^HKY!_X>??"S_H ^+_ /P#M?\ Y)H_X>??"S_H ^+_ /P#M?\
MY)H_LC'_ //IA_:6$_Y^(^OJ*^0?^'GWPL_Z /B__P  [7_Y)H_X>??"S_H
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M+_\ P#M?_DFC^R,?_P ^F']I83_GXCZ^HKY!_P"'GWPL_P"@#XO_ / .U_\
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M+_\ ^,4?V?C/^?,O_ 7_ )!]=PO_ #]C]Z/?Z*\ _P"&]/@5_P!#S_Y2+_\
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MO]%> ?\ #>GP*_Z'G_RD7_\ \8H_X;T^!7_0\_\ E(O_ /XQ1_9^,_Y\R_\
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MP2_Z'VS_ / 6X_\ C='U'%_\^I?^ O\ R#ZWA_\ GY'[T>WT5XA_PVQ\$O\
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MW1]1Q?\ SZE_X"_\@^MX?_GY'[T>WTZ+_6I]17AW_#;'P2_Z'VS_ / 6X_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% %6XTJRNY/,GL[>:3&-\D2L?S(J+^
MP=,_Z!UI_P!^%_PJ_13YGW)LNQ0_L'3/^@=:?]^%_P */[!TS_H'6G_?A?\
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M_P#@#%_\36[11[2?\S#DCV,+_A _#/\ T+ND_P#@#%_\31_P@?AG_H7=)_\
M &+_ .)K=HH]I/\ F8<D>QA?\('X9_Z%W2?_  !B_P#B:/\ A _#/_0NZ3_X
M Q?_ !-;M%'M)_S,.2/8PO\ A _#/_0NZ3_X Q?_ !-'_"!^&?\ H7=)_P#
M&+_XFMVBCVD_YF')'L87_"!^&?\ H7=)_P# &+_XFC_A _#/_0NZ3_X Q?\
MQ-;M%'M)_P S#DCV,+_A _#/_0NZ3_X Q?\ Q-'_  @?AG_H7=)_\ 8O_B:W
M:*/:3_F8<D>QRK_"CP1(S,W@[0&9CDLVEP$D_P#?%-_X5+X&_P"A,\/?^"N#
M_P"(KK**?MJG\S^\GV</Y5]QR?\ PJ7P-_T)GA[_ ,%<'_Q%'_"I? W_ $)G
MA[_P5P?_ !%=911[:I_,_O#V4/Y5]QR?_"I? W_0F>'O_!7!_P#$4?\ "I?
MW_0F>'O_  5P?_$5UE%'MJG\S^\/90_E7W')_P#"I? W_0F>'O\ P5P?_$4?
M\*E\#?\ 0F>'O_!7!_\ $5UE%'MJG\S^\/90_E7W')_\*E\#?]"9X>_\%<'_
M ,11_P *E\#?]"9X>_\ !7!_\17644>VJ?S/[P]E#^5?<<G_ ,*E\#?]"9X>
M_P#!7!_\11_PJ7P-_P!"9X>_\%<'_P 17644>VJ?S/[P]E#^5?<<G_PJ7P-_
MT)GA[_P5P?\ Q%'_  J7P-_T)GA[_P %<'_Q%=911[:I_,_O#V4/Y5]QR?\
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M)?0J_P /O#S*6Y!L(^?TKOZM:5_R$(/]ZCZU7_Y^/[V/V%'^1?<CEM0_9?\
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M'_\ P C_ ,*/^&;OA9_T('A__P  (_\ "O2**/K5?_GX_O8>PH_R+[D>;_\
M#-WPL_Z$#P__ . $?^%'_#-WPL_Z$#P__P" $?\ A7I%%'UJO_S\?WL/84?Y
M%]R/-_\ AF[X6?\ 0@>'_P#P C_PH_X9N^%G_0@>'_\ P C_ ,*](HH^M5_^
M?C^]A["C_(ON1YO_ ,,W?"S_ *$#P_\ ^ $?^%,F_9I^%<\31MX!T$*W4I9J
MI_,8(KTNBCZUB/\ GX_O8?5Z/\B^Y'E/_#*WPE_Z$32O^^&_QH_X96^$O_0B
M:5_WPW^->K457US$_P#/V7WL7U:A_(ON1Y3_ ,,K?"7_ *$32O\ OAO\:/\
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M\"Z:%SG,9D0_FK UZW13^N8G_G[+[V'U:A_(ON1XU_PQY\'?^A'M/_ FX_\
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M/:?^!-Q_\<H_X8\^#O\ T(]I_P"!-Q_\<KV6BCZ]BO\ G[+_ ,"?^8?5,/\
M\^U]R/&O^&//@[_T(]I_X$W'_P <H_X8\^#O_0CVG_@3<?\ QRO9:*/KV*_Y
M^R_\"?\ F'U3#_\ /M?<CQK_ (8\^#O_ $(]I_X$W'_QRC_ACSX._P#0CVG_
M ($W'_QRO9:*/KV*_P"?LO\ P)_YA]4P_P#S[7W(\:_X8\^#O_0CVG_@3<?_
M !RC_ACSX._]"/:?^!-Q_P#'*]EHH^O8K_G[+_P)_P"8?5,/_P ^U]R/&O\
MACSX._\ 0CVG_@3<?_'*/^&//@[_ -"/:?\ @3<?_'*]EHH^O8K_ )^R_P#
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M]H8S_G]+_P "?^8OJ>&_Y]Q^Y'AG_#$?P5_Z$O\ \JM[_P#'J/\ AB/X*_\
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MCY^_X82^#O\ T+]W_P"#*X_^+H_X82^#O_0OW?\ X,KC_P"+KZ!HH_M+&?\
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M5?\ P8-_A7T?11_:>-_Y_2^]A]1PO_/M?<?.'_# /PE_Y\]5_P#!@W^%'_#
M/PE_Y\]5_P#!@W^%?1]%']IXW_G]+[V'U'"_\^U]Q\X?\, _"7_GSU7_ ,&#
M?X4?\, _"7_GSU7_ ,&#?X5]'T4?VGC?^?TOO8?4<+_S[7W'SA_PP#\)?^?/
M5?\ P8-_A1_PP#\)?^?/5?\ P8-_A7T?11_:>-_Y_2^]A]1PO_/M?<?.'_#
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MIZBC^U<=_P _7]X?V?A?^?:^X^8?^'>'PL_Y^/$'_@;'_P#&J/\ AWA\+/\
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M ,$N/ ,<3L/%GB3*@D<V_P#\;KZ@M?\ CZA_WQ_.NON/^/>3_=/\J7]L8_\
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MS_H?KO\ \%B__':/^'9NF?\ 0_7?_@L7_P".U]KT4?VYF'_/W\%_D']EX/\
MY]_B_P#,^*/^'9NF?]#]=_\ @L7_ ..T?\.S=,_Z'Z[_ /!8O_QVOM>BC^W,
MP_Y^_@O\@_LO!_\ /O\ %_YGQ1_P[-TS_H?KO_P6+_\ ':/^'9NF?]#]=_\
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M_P#GW^+_ ,SXEG_X)F6+1$0_$"XCD[,^DJP'X"8?SJI_P['_ .JD_P#E"_\
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MH_X=C_\ 52?_ "A?_=-?<M%']NYC_P _?PC_ )!_9."_D_%_YGPU_P .Q_\
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M7_0^VG_@L;_X[1_P[-U+_H?;3_P6-_\ ':^]**/[>S#_ )^?@O\ (/[(P?\
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MP]^<_P#\;H_X=M>./^AG\/?G/_\ &Z_1"BC_ %AQ_P#,ON0?V/A.S^\_._\
MX=M>./\ H9_#WYS_ /QNC_AVUXX_Z&?P]^<__P ;K]$**/\ 6''_ ,R^Y!_8
M^$[/[S\[_P#AVUXX_P"AG\/?G/\ _&Z/^';7CC_H9_#WYS__ !NOT0HH_P!8
M<?\ S+[D']CX3L_O/SO_ .';7CC_ *&?P]^<_P#\;H_X=M>./^AG\/?G/_\
M&Z_1"BC_ %AQ_P#,ON0?V/A.S^\_._\ X=M>./\ H9_#WYS_ /QNC_AVUXX_
MZ&?P]^<__P ;K]$**/\ 6''_ ,R^Y!_8^$[/[S\[_P#AVUXX_P"AG\/?G/\
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MBO\ A1_P[G^,G_/EH_\ X,5_PK]7**/]9<;VC]W_  0_L+"=W]__  #\H_\
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M_P#!I;__ !=?K911_K-C?Y8_<_\ ,/[!PO>7WK_(_)/_ (=]_&W_ *%RS_\
M!I;_ /Q='_#OOXV_]"Y9_P#@TM__ (NOULHH_P!9L;_+'[G_ )A_8.%[R^]?
MY'Y)_P##OOXV_P#0N6?_ (-+?_XNC_AWW\;?^A<L_P#P:6__ ,77ZV44?ZS8
MW^6/W/\ S#^P<+WE]Z_R/R3_ .'??QM_Z%RS_P#!I;__ !='_#OOXV_]"Y9_
M^#2W_P#BZ_6RBC_6;&_RQ^Y_YA_8.%[R^]?Y'Y)_\.^_C;_T+EG_ .#2W_\
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MCHTIQJ*;T:?3H=-1117R1]"%%%% !1110 4444 %%%% !1110 4444 %%%%
M!6'XW_Y%#6/^O5_Y5N5A^-_^10UC_KU?^5-;B>S/E"BBBNH\T**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *]:\'?\
MBU8_[I_]"->2UZUX._Y%JQ_W3_Z$:B6QK3W-FBBBLCI"BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JUI
M7_(0@_WJJU:TK_D(0?[U '3:E_QXW/\ N&N/KL-2_P"/&Y_W#7'TD#"BBBF
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5HZ!_P A%?\
M=-9U:.@?\A%?]TT :^N_\@V3ZC^=<O74:[_R#9/J/YUR]) PHHHI@%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!+:_\?4/^^/YUU]Q_Q[R?[I_E7(6O_'U#_OC^==?<?\>\
MG^Z?Y4F!Q=%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *Z/PW_QXR?\ 70_R%<Y71^&_^/&3
M_KH?Y"DP12\2?\?<7^Y_4UDUK>)/^/N+_<_J:R: "BBBF 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% $UC_ ,?MO_UT7^=>AM]T_2O/+'_C]M_^NB_SKT-ONGZ5++B8U%%%
M(U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *=%_K4^
MHIM.B_UJ?44 =-11100%%%% !1110 4444 %%%% !1110 4444 %%%% !6'X
MW_Y%#6/^O5_Y5N5A^-_^10UC_KU?^5-;B>S/E"BBBNH\T**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *]:\'?\BU8_
M[I_]"->2UZUX._Y%JQ_W3_Z$:B6QK3W-FBBBLCI"BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JUI7_(0
M@_WJJU:TK_D(0?[U '3:E_QXW/\ N&N/KL-2_P"/&Y_W#7'TD#"BBBF 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5HZ!_P A%?\ =-9U
M:.@?\A%?]TT :^N_\@V3ZC^=<O74:[_R#9/J/YUR]) PHHHI@%%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% $UC_ ,?MO_UT7^=>AM]T_2O/+'_C]M_^NB_SKT-ONGZ5++B8U%%%(U"B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *=%_K4^HIM.
MB_UJ?44 =-11100%%%% !1110 4444 %%%% !1110 4444 %%%% !6'XW_Y%
M#6/^O5_Y5N5A^-_^10UC_KU?^5-;B>S/E"BBBNH\T**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *]:\'?\BU8_[I_]
M"->2UZUX._Y%JQ_W3_Z$:B6QK3W-FBBBLCI"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JUI7_(0@_WJ
MJU:TK_D(0?[U '3:E_QXW/\ N&N/KL-2_P"/&Y_W#7'TD#"BBBF 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5HZ!_P A%?\ =-9U:.@?
M\A%?]TT :^N_\@V3ZC^=<O74:[_R#9/J/YUR]) PHHHI@%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110!+:_\?4/^^/YUU]Q_Q[R?[I_E7(6O_'U#_OC^==?<?\>\G^Z?Y4F!
MQ=%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *Z/PW_QXR?\ 70_R%<Y71^&_^/&3_KH?Y"DP
M12\2?\?<7^Y_4UDUK>)/^/N+_<_J:R: "BBBF 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M$UC_ ,?MO_UT7^=>AM]T_2O/+'_C]M_^NB_SKT-ONGZ5++B8U%%%(U"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *=%_K4^HIM.B_UJ
M?44 =-11100%%%% !1110 4444 %%%% !1110 4444 %%%% !6'XW_Y%#6/^
MO5_Y5N5A^-_^10UC_KU?^5-;B>S/E"BBBNH\T**** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *]:\'?\BU8_[I_]"->2
MUZUX._Y%JQ_W3_Z$:B6QK3W-FBBBLCI"BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JUI7_(0@_WJJU:T
MK_D(0?[U &SXKNY+#PWJ5S%C?% S+N&1G%>(?\+$U7^[;_\ ?!_QKVCQS_R*
M&K_]>S_RKYPJX)-&-1M/0Z?_ (6)JO\ =M_^^#_C1_PL35?[MO\ ]\'_ !KF
M**NR,>9]SI_^%B:K_=M_^^#_ (T?\+$U7^[;_P#?!_QKF**+(.9]SI_^%B:K
M_=M_^^#_ (T?\+$U7^[;_P#?!_QKF**+(.9]SI_^%B:K_=M_^^#_ (T?\+$U
M7^[;_P#?!_QKF**+(.9]SI_^%B:K_=M_^^#_ (T?\+$U7^[;_P#?!_QKF**+
M(.9]SI_^%B:K_=M_^^#_ (T?\+$U7^[;_P#?!_QKF**+(.9]SI_^%B:K_=M_
M^^#_ (T?\+$U7^[;_P#?!_QKF**+(.9]SI_^%B:K_=M_^^#_ (T?\+$U7^[;
M_P#?!_QKF**+(.9]SI_^%B:K_=M_^^#_ (T?\+$U7^[;_P#?!_QKF**+(.9]
MSI_^%B:K_=M_^^#_ (T?\+$U7^[;_P#?!_QKF**+(.9]SI_^%B:K_=M_^^#_
M (T?\+$U7^[;_P#?!_QKF**+(.9]SI_^%B:K_=M_^^#_ (T?\+$U7^[;_P#?
M!_QKF**+(.9]SI_^%B:K_=M_^^#_ (T?\+$U7^[;_P#?!_QKF**+(.9]SI_^
M%B:K_=M_^^#_ (T?\+$U7^[;_P#?!_QKF**+(.9]SI_^%B:K_=M_^^#_ (T?
M\+$U7^[;_P#?!_QKF**+(.9]SI_^%B:K_=M_^^#_ (T?\+$U7^[;_P#?!_QK
MF**+(.9]SI_^%B:K_=M_^^#_ (T?\+$U7^[;_P#?!_QKF**+(.9]SI_^%B:K
M_=M_^^#_ (T?\+$U7^[;_P#?!_QKF**+(.9]SI_^%B:K_=M_^^#_ (T?\+$U
M7^[;_P#?!_QKF**+(.9]SI_^%B:K_=M_^^#_ (T?\+$U7^[;_P#?!_QKF**+
M(.9]SI_^%B:K_=M_^^#_ (T?\+$U7^[;_P#?!_QKF**+(.9]SI_^%B:K_=M_
M^^#_ (T?\+$U7^[;_P#?!_QKF**+(.9]SI_^%B:K_=M_^^#_ (T?\+$U7^[;
M_P#?!_QKF**+(.9]SI_^%B:K_=M_^^#_ (T?\+$U7^[;_P#?!_QKF**+(.9]
MSI_^%B:K_=M_^^#_ (T?\+$U7^[;_P#?!_QKF**+(.9]SI_^%B:K_=M_^^#_
M (T?\+$U7^[;_P#?!_QKF**+(.9]SI_^%B:K_=M_^^#_ (T?\+$U7^[;_P#?
M!_QKF**+(.9]SI_^%B:K_=M_^^#_ (T?\+$U7^[;_P#?!_QKF**+(.9]SI_^
M%B:K_=M_^^#_ (T?\+$U7^[;_P#?!_QKF**+(.9]SI_^%B:K_=M_^^#_ (T?
M\+$U7^[;_P#?!_QKF**+(.9]SI_^%B:K_=M_^^#_ (T?\+$U7^[;_P#?!_QK
MF**+(.9]SI_^%B:K_=M_^^#_ (T?\+$U7^[;_P#?!_QKF**+(.9]SI_^%B:K
M_=M_^^#_ (T?\+$U7^[;_P#?!_QKF**+(.9]SI_^%B:K_=M_^^#_ (T?\+$U
M7^[;_P#?!_QKF**+(.9]SI_^%B:K_=M_^^#_ (T?\+$U7^[;_P#?!_QKF**+
M(.9]SI_^%B:K_=M_^^#_ (T?\+$U7^[;_P#?!_QKF**+(.9]SI_^%B:K_=M_
M^^#_ (T?\+$U7^[;_P#?!_QKF**+(.9]SI_^%B:K_=M_^^#_ (T?\+$U7^[;
M_P#?!_QKF**+(.9]SI_^%B:K_=M_^^#_ (T?\+$U7^[;_P#?!_QKF**+(.9]
MSI_^%B:K_=M_^^#_ (T?\+$U7^[;_P#?!_QKF**+(.9]SI_^%B:K_=M_^^#_
M (T?\+$U7^[;_P#?!_QKF**+(.9]SI_^%B:K_=M_^^#_ (T?\+$U7^[;_P#?
M!_QKF**+(.9]SI_^%B:K_=M_^^#_ (T?\+$U7^[;_P#?!_QKF**+(.9]SI_^
M%B:K_=M_^^#_ (T?\+$U7^[;_P#?!_QKF**+(.9]SI_^%B:K_=M_^^#_ (T?
M\+$U7^[;_P#?!_QKF**+(.9]SI_^%B:K_=M_^^#_ (T?\+$U7^[;_P#?!_QK
MF**+(.9]SI_^%B:K_=M_^^#_ (T?\+$U7^[;_P#?!_QKF**+(.9]SI_^%B:K
M_=M_^^#_ (T?\+$U7^[;_P#?!_QKF**+(.9]SI_^%B:K_=M_^^#_ (T?\+$U
M7^[;_P#?!_QKF**+(.9]SI_^%B:K_=M_^^#_ (T?\+$U7^[;_P#?!_QKF**+
M(.9]SI_^%B:K_=M_^^#_ (T?\+$U7^[;_P#?!_QKF**+(.9]SI_^%B:K_=M_
M^^#_ (T?\+$U7^[;_P#?!_QKF**+(.9]SI_^%B:K_=M_^^#_ (T?\+$U7^[;
M_P#?!_QKF**+(.9]SI_^%B:K_=M_^^#_ (T?\+$U7^[;_P#?!_QKF**+(.9]
MSI_^%B:K_=M_^^#_ (T?\+$U7^[;_P#?!_QKF**+(.9]SI_^%B:K_=M_^^#_
M (U-:?$[6+.82QK;;L8^:,_XUR5%'*@YI=SMKOXN:Y>0F*1+0*?[L1S_ .A5
M0_X6)JO]VW_[X/\ C7,44<J#FEW.G_X6)JO]VW_[X/\ C1_PL35?[MO_ -\'
M_&N8HHL@YGW.G_X6)JO]VW_[X/\ C1_PL35?[MO_ -\'_&N8HHL@YGW.G_X6
M)JO]VW_[X/\ C1_PL35?[MO_ -\'_&N8HHL@YGW.G_X6)JO]VW_[X/\ C1_P
ML35?[MO_ -\'_&N8HHL@YGW.G_X6)JO]VW_[X/\ C1_PL35?[MO_ -\'_&N8
MHHL@YGW.G_X6)JO]VW_[X/\ C1_PL35?[MO_ -\'_&N8HHL@YGW.G_X6)JO]
MVW_[X/\ C1_PL35?[MO_ -\'_&N8HHL@YGW.G_X6)JO]VW_[X/\ C1_PL35?
M[MO_ -\'_&N8HHL@YGW.G_X6)JO]VW_[X/\ C1_PL35?[MO_ -\'_&N8HHL@
MYGW.G_X6)JO]VW_[X/\ C1_PL35?[MO_ -\'_&N8HHL@YGW.G_X6)JO]VW_[
MX/\ C1_PL35?[MO_ -\'_&N8HHL@YGW.G_X6)JO]VW_[X/\ C1_PL35?[MO_
M -\'_&N8HHL@YGW.G_X6)JO]VW_[X/\ C1_PL35?[MO_ -\'_&N8HHL@YGW.
MG_X6)JO]VW_[X/\ C1_PL35?[MO_ -\'_&N8HHL@YGW.G_X6)JO]VW_[X/\
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MG_X6)JO]VW_[X/\ C1_PL35?[MO_ -\'_&N8HHL@YGW.G_X6)JO]VW_[X/\
MC1_PL35?[MO_ -\'_&N8HHL@YGW.G_X6)JO]VW_[X/\ C1_PL35?[MO_ -\'
M_&N8HHL@YGW.G_X6)JO]VW_[X/\ C1_PL35?[MO_ -\'_&N8HHL@YGW.G_X6
M)JO]VW_[X/\ C1_PL35?[MO_ -\'_&N8HHL@YGW.G_X6)JO]VW_[X/\ C1_P
ML35?[MO_ -\'_&N8HHL@YGW.G_X6)JO]VW_[X/\ C1_PL35?[MO_ -\'_&N8
MHHL@YGW.G_X6)JO]VW_[X/\ C1_PL35?[MO_ -\'_&N8HHL@YGW.G_X6)JO]
MVW_[X/\ C1_PL35?[MO_ -\'_&N8HHL@YGW.G_X6)JO]VW_[X/\ C1_PL35?
M[MO_ -\'_&N8HHL@YGW.G_X6)JO]VW_[X/\ C1_PL35?[MO_ -\'_&N8HHL@
MYGW.IC^(VK12*X6WRIR,QG_&M%_C'KSHRE+/!&/]4?\ XJN%HHY4'-+N=/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@":Q_X_;?\ ZZ+_ #KT
M-ONGZ5YY8_\ '[;_ /71?YUZ&WW3]*EEQ,:BBBD:A1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %.B_UJ?44VG1?ZU/J* .FHHHH("BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ K#\;_ /(H:Q_UZO\ RK<K#\;_
M /(H:Q_UZO\ RIK<3V9\H4445U'FA1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !7K7@[_D6K'_ '3_ .A&O):]:\'?
M\BU8_P"Z?_0C42V-:>YLT445D=(4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %6M*_P"0A!_O55JUI7_(
M0@_WJ -+QS_R*&K_ /7L_P#*OG"OH_QS_P BAJ__ %[/_*OG"M(;&%7=!111
M6A@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% "JQ1@RG# Y!':O8/#VI_VMH]M<L?WA7:
M_P#O#@_XUX]7HWPWD+:-<(>BSG'XJ*B6QK3>MCK:***R.D**** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ KH_#?\ QXR?]=#_ "%<Y71^&_\ CQD_ZZ'^0I,$4O$G_'W%_N?U-9-:
MWB3_ (^XO]S^IK)H ****8!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 36/_'[;_P#71?YU
MZ&WW3]*\\L?^/VW_ .NB_P Z]#;[I^E2RXF-1112-0HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "G1?ZU/J*;3HO]:GU% '34444$!1
M110 4444 %%%% !1110 4444 %%%% !1110 5A^-_P#D4-8_Z]7_ )5N5A^-
M_P#D4-8_Z]7_ )4UN)[,^4****ZCS0HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ KUKP=_R+5C_NG_ -"->2UZUX._
MY%JQ_P!T_P#H1J);&M/<V:***R.D**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 5Z)\-?\ D%77_7;_ -E%>=UZ)\-?^05=?]=O_9142V-*?Q'7
MT445D=04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4Z+_ %J?44VG
M1?ZU/J* .FHHHH("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K#\;_\
M(H:Q_P!>K_RK<K#\;_\ (H:Q_P!>K_RIK<3V9\H4445U'FA1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7K7@[_D6K
M'_=/_H1KR6O6O!W_ "+5C_NG_P!"-1+8UI[FS11161TA1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5:T
MK_D(0?[U5:M:5_R$(/\ >H TO'/_ "*&K_\ 7L_\J^<*^C_'/_(H:O\ ]>S_
M ,J^<*TAL85=T%%%%:& 4444 %%%% #HXVF=412[L=JJHR23T %>Q>#/@6DD
M$=WX@D=68;A90G&/]]OZ#\Z3X%^#$E$GB&[C#%6,=HK#H1]Y_P"@^AK?^*/Q
M1;PH_P#9FF;7U-E#22.,K #TX[L>N#TX]:RDVW9'1&*2YI'26_PW\,6T01-$
MM"!WD3>?S;)K/UCX0^&=6B(6Q^P2GI+:L5(_X#]W]*^?K[Q5K.I3&6YU2[F<
M^LS8'T&<#\*Z+PC\6-:\.7<8NKJ74K G]Y#.V]@.Y5CR#[=*7+)=1JI!Z-%7
MQW\.K_P1.&D/VK3Y&Q'=(,#/HP['^=<E7UM/#I_C#P\4<"YT^^A!!]5(R"/0
MC]"*^6O$.C2^'=;O=-G.9+>0IN_O#J&_$8/XU497W(J0Y=5L>]? [_D1(_\
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MZ::>A+BTKLSZ***HD**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "O1/AK_P @JZ_Z[?\ LHKSNO1/AK_R"KK_ *[?^RBHEL:4_B.OHHHK(Z@H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "NC\-_\>,G_ %T/\A7.5T?AO_CQD_ZZ'^0I,$4O$G_'
MW%_N?U-9-:WB3_C[B_W/ZFLF@ HHHI@%%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!-8_P#'
M[;_]=%_G7H;?=/TKSRQ_X_;?_KHO\Z]#;[I^E2RXF-1112-0HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "G1?ZU/J*;3HO]:GU% '34
M444$!1110 4444 %%%% !1110 4444 %%%% !1110 5A^-_^10UC_KU?^5;E
M8?C?_D4-8_Z]7_E36XGLSY0HHHKJ/-"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "O6O!W_(M6/^Z?_0C7DM>M>#O^
M1:L?]T_^A&HEL:T]S9HHHK(Z0HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *M:5_R$(/]ZJM6M*_Y"$'^
M]0!I>.?^10U?_KV?^5?.%?1_CG_D4-7_ .O9_P"5?.%:0V,*NZ"BBBM# ***
M* "BBB@#ZN\(V,6A^$-,AX5(;57<^Y7<Q_,DU\O:SJ<NM:K=WT[$RW$K2'/;
M)Z?@./PKZI .H>&,1<F>S^3_ ($G'\Z^2:RAU.BKLD%%>K_!/Q1I7AVTU9=2
MOHK1I7C*"3/S !L_S%>F_P#"S/"__0:MOS/^%-R:>Q,8)J[9\MT5]<:+XDTS
MQ$DK:;>1W:Q$!S'GY2>E>-?M!?\ (RZ;_P!>G_L[4*5W8<J?*KW.X^!W_(B1
M_P#7Q)_,5Y!\5O\ DH.L_P#71?\ T!:]?^!W_(B1_P#7Q)_,5Y!\5O\ DH.L
M_P#71?\ T!:4?B8Y_P -'6?L]_\ (:U;_KW7_P!"J?\ :'_X_=$_ZYR_S6H/
MV>_^0UJW_7NO_H53_M#_ /'[HG_7.7^:T?;!?PCC?AEX2'B[Q/#!.I:R@'G7
M'NHZ+^)P/IFO>/&GC"R\!:*D[Q"21OW=M:Q_+N('3V4#^E<1^SU:*NG:Q=;?
MF>5(]WLH)Q_X]7-?'G4'N/%\-L2?*MK9<+_M,22?Y?E2?O2L.+Y*=T0R_'3Q
M*]T9$^R1QYXA$.5Q]2<_K7J?PZ^)$'CBWDBDC6UU*$;I(0V59>FY?;/4=N*^
M::ZKX7ZA)IWCO2&C) EE\EAZJPQ_4'\*J458B%25]6=%\;/!L6AZK#JMG$([
M6])$B*,!)1R?IN'/U!JE\#_^1]A_ZX2?RKU#XUV:W/@"[D8#-O+%*N?4L$_D
MYKR_X'_\C[#_ -<)/Y4D[Q*DK5$?0&HSVEC;M?7A2.*U5I#*X^X,<D?AQ7B/
MB'X\:K<WCKI$45G:*<(TJ;Y''J<\#Z8X]378_'?4)+3P=#!&2HNKE4?'=0"V
M/S _*OGVE"*>K'5FT[(]N\ _&J35=0BT[7(XHFF(2*ZB!4;CT#CW]1^7>NB^
M+OA%/$GAB:YCC!O[%3-&P'+*/O+^7/U KYP!(.1P:^L?"]XVL^%=+N)_G:XM
M(S+N_B)4;OS.:)+E=T.#YTXL^3:^M['_ )%BW_Z\U_\ 0*^3[VW%K>3PYSY4
MC)GZ'%?6%C_R+%O_ ->:_P#H%.?05'J?)%>^_!'PA'IFA_VS,@-[>Y$9(Y2(
M'C'U(S],5X%7UKIRIHOABV"J-EI9K\J_[*?_ %J<WI8FDKNYPOQ&^+__  C=
MZ^F:3%'<7L?^NFER4B/]T =3^.![\XX_2/COKEK=JU_';WUL3\RJFQP/]DCC
M\P:\YN;F2\N9;B9B\LKF1V/=B<D_G45-11+J2;O<^N=$U.RU^QAU2Q*R17"
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M_P"@TFN66A47[2#3/F/1O^0Q8_\ 7>/_ -"%?7LCK&C,Y"JHR2>@%?(6C?\
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M?3_Q"0/X'UL,,@6KG\0,BAKE:L$6YQ:9\LPQ//*D4:EY'8*JCN3P!7U1X/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Z)\-?^05
M=?\ 7;_V45YW7HGPU_Y!5U_UV_\ 9142V-*?Q'7T445D=04444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MV^Z?I7GEC_Q^V_\ UT7^=>AM]T_2I9<3&HHHI&H4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !3HO]:GU%-IT7^M3ZB@#IJ***" HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *P_&_\ R*&L?]>K_P JW*P_&_\
MR*&L?]>K_P J:W$]F?*%%%%=1YH4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5ZUX._P"1:L?]T_\ H1KR6O6O!W_(
MM6/^Z?\ T(U$MC6GN;-%%%9'2%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M$HDM+9]T\J'Y7D'  ]0.?Q^E*_-+0:7LX.^[/.=&_P"0Q8_]=X__ $(5]/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "O1/AK_P @JZ_Z[?\ LHKSNO1/AK_R"KK_ *[?^RBHEL:4_B.OHHHK
M(Z@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "NC\-_\>,G_ %T/\A7.5T?AO_CQD_ZZ'^0I,$4O
M$G_'W%_N?U-9-:WB3_C[B_W/ZFLF@ HHHI@%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!-8
M_P#'[;_]=%_G7H;?=/TKSRQ_X_;?_KHO\Z]#;[I^E2RXF-1112-0HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "G1?ZU/J*;3HO]:GU%
M '34444$!1110 4444 %%%% !1110 4444 %%%% !1110 5A^-_^10UC_KU?
M^5;E8?C?_D4-8_Z]7_E36XGLSY0HHHKJ/-"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "O6O!W_(M6/^Z?_0C7DM>M
M>#O^1:L?]T_^A&HEL:T]S9HHHK(Z0HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *M:5_R$(/]ZJM6M*_Y
M"$'^]0!I>.?^10U?_KV?^5?.%?1_CG_D4-7_ .O9_P"5?.%:0V,*NZ"BBBM#
M **** "BBB@ K7\/^+-6\+3F33;V2W!.6CZH_P!5/!_G6112'L>HVW[0&LQQ
MA9["RF8#&]=RY^O)K*UOXT>(]8A:**6'3HV&#]E4AS_P(DD?ABN#HI<J*YY=
MQSNTKL[L6=CDL3DDTVBBJ(.T\*_%;5_"&DKIUG;V4L(=GW3HY;)Z]& _2N;\
M0:W/XDUBYU*Y2-)[@AF6($*, #C))[>M9]%*RW*;;5F=#X.\;7W@BZN)[&*W
ME>= C"X5F  .>,,*=XR\=W_CB6UDOXK>(VRLJ?9U9<YQG.6/I7.4465[A=VL
M%=%X6\>ZSX/8BPN<V['+6TPW1D^N.WU!%<[11:XDVMCUA?VA-1$6#I-J9/[P
MD8#\O_KUR/BGXF:[XMC,%U<+!:'K;6P*(?KR2?Q-<K12Y4BG.3T;"MCPMXGN
MO".K+J-G'#+.J,@6=25P?H1_.L>BGN3MJCKO%OQ.U7QE:6]O=PVL @E$R/:J
MZL&P1U+'UK7T/XXZ]I=LL%TD&IJHP))LK)^)'7\1GWKSJBERK8KGE>]STO5_
MCQK=] T5G;V^G[O^6B@R./H3Q^E><W-U->W$D]Q*\\TAW/)(VYF/J2:BHII)
M;"<G+<*]$B^.6NPV"6BVFG>6D0B!,<F< 8_OUYW10TGN";6P4Z.1HG5T8HZG
M*LIP01W%-HIDGHNA_'+7=*MUANDAU-5&!),"LGXD=?Q&?>I-9^.VN:A;M#:0
M6^G!N#*@+R#Z$\#\LUYM14\J+YY6M<ZGPG\1]5\(37\ULL%W+>E6F>\#.Q*[
MN<AA_>.<U5\8>-+WQM>P75]%;Q211^6HMU901DGG)//-8%%.RO<7,[6'([1.
MKHQ5U.0P."#7H6B?'#7]+@6&Y6#4D48#S@B3\6!Y_$5YW10TGN"DX['J.H?'
M[6+B)DM+&UM&(XD;,A7Z9P/S%><ZGJMWK5[)=WUP]S<2?>DD.3_]8>PJI122
M2V!R<MV%=-X6^(NM^$(C#8W"O:D[OL\Z[TS[=Q^!KF:*=KB3:U1Z%J?QNUW5
MM-N[&:TT]8KF%X7*1R!@K @XRYYP:\]HHH22V&VWN;/AOQ;JOA.Y,VFW30AO
MOQ'YHW^J]/QZUWT/[0>IK%B72[1Y<?>1V49^G/\ .O***3BF-2E'9G:^)OBY
MK_B2%[<RI86K\-%:@J6'H6)S_(>U<51132ML2VWN2VT[6EQ%,@!>-PX#=,@Y
MKN]8^-6N:WI=U83VNGK#<QF)VCC<, 1@XRY_E7G]%#28TVM@I\4AAE210"5(
M8 ^U,HIDGH&L?&K7-;TNZL)[73UAN8S$[1QN& (P<9<_RKS^BBDDEL4VWN/B
MD,,J2* 2I# 'VKO=8^-6N:WI=U83VNGK#<QF)VCC<, 1@XRY_E7G]%#28)M;
M!5S2M7O-#OH[RPN'M;A.CH?T/J/8U3HH)/4K'X_ZO# $N=/M;F0#'F*63/N1
MS^F*P_%'Q<UWQ/;O;;X["T<8:*UR"X]&8G/X# KB:*7*BW.35KG<^&_B_K/A
M?1;;3+6VL9+>#=M::-RQW,6.2' ZD]JY+6-4EUO5;J_G5$FN9#*ZQ@A02<G&
M2>/QJG13LD)MM684444R0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH *]$^&O_(*NO^NW_LHKSNO1/AK_ ,@JZ_Z[?^RBHEL:4_B.OHHHK(Z@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "NC\-_\>,G_70_R%<Y71^&_P#CQD_ZZ'^0I,$4O$G_
M !]Q?[G]3636MXD_X^XO]S^IK)H ****8!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 36/_
M !^V_P#UT7^=>AM]T_2O/+'_ (_;?_KHO\Z]#;[I^E2RXF-1112-0HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "G1?ZU/J*;3HO]:GU
M% '34444$!1110 4444 %%%% !1110 4444 %%%% !1110 5A^-_^10UC_KU
M?^5;E8?C?_D4-8_Z]7_E36XGLSY0HHHKJ/-"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "O6O!W_(M6/\ NG_T(UY+
M7K7@[_D6K'_=/_H1J);&M/<V:***R.D**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "K6E?\A"#_>JK5K2
MO^0A!_O4 :7CG_D4-7_Z]G_E7SA7T?XY_P"10U?_ *]G_E7SA6D-C"KN@HHH
MK0P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ KT3X;?\@JZ_Z[_^RBO.Z]3\#V+67AZ$
ML,-.QEQ['@?H!42V-:?Q'04445D=(4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !71^&_P#CQD_Z
MZ'^0KG*Z/PW_ ,>,G_70_P A28(I>)/^/N+_ '/ZFLFM;Q)_Q]Q?[G]3630
M4444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH FL?^/VW_ .NB_P Z]#;[I^E>>6/_ !^V
M_P#UT7^=>AM]T_2I9<3&HHHI&H4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !3HO]:GU%-IT7^M3ZB@#IJ***" HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *P_&_P#R*&L?]>K_ ,JW*P_&_P#R*&L?]>K_ ,J:
MW$]F?*%%%%=1YH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 5ZUX._Y%JQ_P!T_P#H1KR6O6O!W_(M6/\ NG_T(U$M
MC6GN;-%%%9'2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !5K2O\ D(0?[U5:M:5_R$(/]Z@#2\<_\BAJ
M_P#U[/\ RKYPKZ/\<_\ (H:O_P!>S_RKYPK2&QA5W04445H8!1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !14MO:SW;[((7F8_PQJ6/Z5TVC> +N[=7O3]DA[KP7;_  _'\J3:
M123>QF^&/#\FO7ZJ01:H097]O0>YKUA%6-550%51@ =A4-C80:9;+;VT8CB7
ML._N3W-6*Q;N=,8\J"BBBD6%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5T?AO_ (\9/^NA_D*Y
MRNC\-_\ 'C)_UT/\A28(I>)/^/N+_<_J:R:UO$G_ !]Q?[G]3630 4444P"B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH FL?^/VW_P"NB_SKT-ONGZ5YY8_\?MO_ -=%_G7H
M;?=/TJ67$QJ***1J%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4Z+_6I]13:=%_K4^HH Z:BBB@@**** "BBB@ HHHH **** "BBB@
MHHHH **** "L/QO_ ,BAK'_7J_\ *MRL/QO_ ,BAK'_7J_\ *FMQ/9GRA111
M74>:%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %>M>#O\ D6K'_=/_ *$:\EKUKP=_R+5C_NG_ -"-1+8UI[FS1116
M1TA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MG_?(J2B@"/[/%_SS3_OD4?9XO^>:?]\BI** (_L\7_/-/^^11]GB_P">:?\
M?(J2B@"/[/%_SS3_ +Y%'V>+_GFG_?(J2B@"/[/%_P \T_[Y%'V>+_GFG_?(
MJ2B@"/[/%_SS3_OD4?9XO^>:?]\BI** (_L\7_/-/^^11]GB_P">:?\ ?(J2
MB@"/[/%_SS3_ +Y%'V>+_GFG_?(J2B@"/[/%_P \T_[Y%'V>+_GFG_?(J2B@
M"/[/%_SS3_OD4?9XO^>:?]\BI** (_L\7_/-/^^11]GB_P">:?\ ?(J2B@"/
M[/%_SS3_ +Y%'V>+_GFG_?(J2B@"/[/%_P \T_[Y%'V>+_GFG_?(J2B@"/[/
M%_SS3_OD4?9XO^>:?]\BI** (_L\7_/-/^^11]GB_P">:?\ ?(J2B@"/[/%_
MSS3_ +Y%'V>+_GFG_?(J2B@"/[/%_P \T_[Y%'V>+_GFG_?(J2B@"/[/%_SS
M3_OD4?9XO^>:?]\BI** (_L\7_/-/^^11]GB_P">:?\ ?(J2B@"/[/%_SS3_
M +Y%'V>+_GFG_?(J2B@"/[/%_P \T_[Y%'V>+_GFG_?(J2B@"/[/%_SS3_OD
M4?9XO^>:?]\BI** (_L\7_/-/^^11]GB_P">:?\ ?(J2B@"/[/%_SS3_ +Y%
M'V>+_GFG_?(J2B@"/[/%_P \T_[Y%'V>+_GFG_?(J2B@"/[/%_SS3_OD4?9X
MO^>:?]\BI** (_L\7_/-/^^11]GB_P">:?\ ?(J2B@"/[/%_SS3_ +Y%'V>+
M_GFG_?(J2B@"/[/%_P \T_[Y%'V>+_GFG_?(J2B@"/[/%_SS3_OD4?9XO^>:
M?]\BI** (_L\7_/-/^^11]GB_P">:?\ ?(J2B@"/[/%_SS3_ +Y%'V>+_GFG
M_?(J2B@"/[/%_P \T_[Y%:.@VT1U%<Q(?E/515*M'0/^0BO^Z:!FEKMK"-.D
MQ#&.1T4>M<Q]GB_YYI_WR*ZS7?\ D&R?4?SKEZ2!D?V>+_GFG_?(H^SQ?\\T
M_P"^14E%,1']GB_YYI_WR*/L\7_/-/\ OD5)10!']GB_YYI_WR*/L\7_ #S3
M_OD5)10!']GB_P">:?\ ?(H^SQ?\\T_[Y%244 1_9XO^>:?]\BC[/%_SS3_O
MD5)10!']GB_YYI_WR*/L\7_/-/\ OD5)10!']GB_YYI_WR*/L\7_ #S3_OD5
M)10!']GB_P">:?\ ?(H^SQ?\\T_[Y%244 1_9XO^>:?]\BC[/%_SS3_OD5)1
M0!']GB_YYI_WR*/L\7_/-/\ OD5)10!']GB_YYI_WR*/L\7_ #S3_OD5)10!
M']GB_P">:?\ ?(H^SQ?\\T_[Y%244 1_9XO^>:?]\BC[/%_SS3_OD5)10!']
MGB_YYI_WR*/L\7_/-/\ OD5)10!']GB_YYI_WR*/L\7_ #S3_OD5)10!']GB
M_P">:?\ ?(H^SQ?\\T_[Y%244 1_9XO^>:?]\BC[/%_SS3_OD5)10!']GB_Y
MYI_WR*/L\7_/-/\ OD5)10!']GB_YYI_WR*/L\7_ #S3_OD5)10!']GB_P">
M:?\ ?(H^SQ?\\T_[Y%244 1_9XO^>:?]\BC[/%_SS3_OD5)10!']GB_YYI_W
MR*/L\7_/-/\ OD5)10!']GB_YYI_WR*/L\7_ #S3_OD5)10!']GB_P">:?\
M?(H^SQ?\\T_[Y%244 1_9XO^>:?]\BC[/%_SS3_OD5)10!']GB_YYI_WR*/L
M\7_/-/\ OD5)10!']GB_YYI_WR*/L\7_ #S3_OD5)10!']GB_P">:?\ ?(H^
MSQ?\\T_[Y%244 1_9XO^>:?]\BC[/%_SS3_OD5)10!']GB_YYI_WR*/L\7_/
M-/\ OD5)10!']GB_YYI_WR*/L\7_ #S3_OD5)10!']GB_P">:?\ ?(H^SQ?\
M\T_[Y%244 1_9XO^>:?]\BC[/%_SS3_OD5)10!']GB_YYI_WR*/L\7_/-/\
MOD5)10!']GB_YYI_WR*/L\7_ #S3_OD5)10!']GB_P">:?\ ?(H^SQ?\\T_[
MY%244 1_9XO^>:?]\BC[/%_SS3_OD5)10!']GB_YYI_WR*/L\7_/-/\ OD5)
M10!']GB_YYI_WR*/L\7_ #S3_OD5)10 MK;Q&ZA_=I]]?X1ZUU]Q:0>1)^YC
M^Z?X1Z5REK_Q]0_[X_G77W'_ ![R?[I_E28SA_L\7_/-/^^11]GB_P">:?\
M?(J2BF(C^SQ?\\T_[Y%'V>+_ )YI_P!\BI** (_L\7_/-/\ OD4?9XO^>:?]
M\BI** (_L\7_ #S3_OD4?9XO^>:?]\BI** (_L\7_/-/^^11]GB_YYI_WR*D
MHH C^SQ?\\T_[Y%'V>+_ )YI_P!\BI** (_L\7_/-/\ OD4?9XO^>:?]\BI*
M* (_L\7_ #S3_OD4?9XO^>:?]\BI** (_L\7_/-/^^11]GB_YYI_WR*DHH 1
M5"C"@ #L*6BB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %='X;_P"/&3_KH?Y"
MN<KH_#?_ !XR?]=#_(4F"*7B3_C[B_W/ZFLFM;Q)_P ?<7^Y_4UDT %%%%,
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** )K'_C]M_\ KHO\Z]#;[I^E>>6/_'[;_P#71?YU
MZ&WW3]*EEQ,:BBBD:A1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %.B_UJ?44VG1?ZU/J* .FHHHH("BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ K#\;_P#(H:Q_UZO_ "K<K#\;_P#(H:Q_UZO_ "IK<3V9\H44
M45U'FA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !7K7@[_ )%JQ_W3_P"A&O):]:\'?\BU8_[I_P#0C42V-:>YLT44
M5D=(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %6M*_Y"$'^]56K6E?\ (0@_WJ .FU+_ (\;G_<-<?78
M:E_QXW/^X:X^D@84444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "M'0/^0BO^Z:SJT= _Y"*_[IH U]=_Y!LGU'\ZY>NHUW_D&R?4?S
MKEZ2!A1113 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@"6U_P"/J'_?'\ZZ^X_X]Y/]T_RK
MD+7_ (^H?]\?SKK[C_CWD_W3_*DP.+HHHI@%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !71^&_\
MCQD_ZZ'^0KG*Z/PW_P >,G_70_R%)@BEXD_X^XO]S^IK)K6\2?\ 'W%_N?U-
M9- !1113 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@":Q_X_;?_ *Z+_.O0V^Z?I7GEC_Q^
MV_\ UT7^=>AM]T_2I9<3&HHHI&H4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 44N*3!]#0*X44A8 ]14?V
MF'_GJG_?0IV9/,NY+1437<"#+3QCZN*9]OM?^?F'_OL4^5]@YH]RQ142W<#C
M*S1GZ.*47,1X$J?]]"EROL',NY)12!@QX(/TIV*0[IB448HH&%%%% PHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *=%_
MK4^HIM.B_P!:GU% '34444$!1110 4444 %%%% !1110 4444 %%%% !1110
M 5A^-_\ D4-8_P"O5_Y5N5A^-_\ D4-8_P"O5_Y4UN)[,^4****ZCS0HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
MUKP=_P BU8_[I_\ 0C7DM>M>#O\ D6K'_=/_ *$:B6QK3W-FBBBLCI"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ JUI7_(0@_P!ZJM6M*_Y"$'^]0!TVI?\ 'C<_[AKCZ[#4O^/&Y_W#
M7'TD#"BBBF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
MHZ!_R$5_W36=6CH'_(17_=- &OKO_(-D^H_G7+UU&N_\@V3ZC^=<O20,****
M8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 2VO_ !]0_P"^/YUU]Q_Q[R?[I_E7(6O_ !]0
M_P"^/YUU]Q_Q[R?[I_E28'%T444P"BBB@ HHHH **** "BBB@ HHHH ****
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MQ/:>SF&/R0BO@#'%)L'H/RKCGPO@9?"Y+YK]4=T.+,PCNHOY?Y-'Z5Z5\9/
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MT445@=04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !3HO]:GU%-IT7^M3ZB@#IJ***" HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *P_&_\ R*&L?]>K_P JW*P_&_\ R*&L
M?]>K_P J:W$]F?*%%%%=1YH4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5ZUX._P"1:L?]T_\ H1KR6O6O!W_(M6/^
MZ?\ T(U$MC6GN;-%%%9'2%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !5K2O^0A!_O55JUI7_ "$(/]Z@
M#IM2_P"/&Y_W#7'UV&I?\>-S_N&N/I(&%%%%, HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ K1T#_D(K_NFLZM'0/^0BO^Z: -?7?^0;)]
M1_.N7KJ-=_Y!LGU'\ZY>D@84444P"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH EM?\ CZA_
MWQ_.NON/^/>3_=/\JY"U_P"/J'_?'\ZZ^X_X]Y/]T_RI,#BZ***8!1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MB_SKT-ONGZ5YY8_\?MO_ -=%_G7H;?=/TJ67$QJ***1J%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444%@H))  Y)-
M @HKS7QG^T5X"\$QR"XUR'4;I"5-II9%Q)D'!!*G:I'HS#I7BWBW]N*=P8_#
M/AQ(^?\ CXU5RV1_US0C!Z\[C7KX;*<;BDI4Z;MW>B_$\7%9U@,&W&K55^RU
M?X'UG7+^*?BAX3\%*W]M>(+&QD SY+2AI?\ OVN6_2O@KQU\=O&OQ%C>#5M8
MD2P?K868\F C@X8+RXR!]\FN VCK@?E7U&&X5E*TL14MY+_/_@'R6*XOBKQP
MM._F_P#+_@GV]XD_;1\$Z7#*-)MM0UNX'^KQ&((F/'5G.X=_X#7E7B3]MCQ5
MJ221Z-I.GZ,C#Y9)-UQ*GT)PI_%37SN !VH Q7T5#A[+Z.KAS/S=_P#)?@?,
M5^),RKZ*?*O)6_S?XG>ZW\>OB%K[-]J\6:@BMU2T<6ZX],1[:X.662XE,LLK
MR2,22[MDD^I/K245[E/#T:.E."CZ*WY'@5<16K.]6;?JV_S$ Q2T45T6.<**
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!I7..]2VMS<6%PD]
MK<2VTR'<DD3E64^H(Z&F45#@FK-712<HNZ>IZ%H?[0GQ%\/@+;>*[V9!@;;S
M;<\#M^\#5ZAX=_;@\06,2QZUH%CJI4 >;;2M;,WJ3D.,_0"OFVBO,K93@L0O
MWE)?)6?WH];#YOC\,[TZK^;NON>A]T>&_P!L?P#K$*?VB]]H<^!O6XMS*@;'
M(5H]Q(]R!]*]2\-_$/PQXO2,Z-KUAJ#.,B**=?,_%"=P_$5^8FT>E(44 _*#
M^%?/U^%L-)7HS<7YZK]&?1X?B[%P_CP4EY:/]5^!^KM%?G=X)_:,\=^ H8[>
MSU=K^Q3&+34E\] /12?F4>RL!7L_A3]N.$QI'XF\.2(X^]<:4^Y3_P!LW((_
M[Z-?,8GAW&T-8)27E_D_TN?687BC 5[*;<'YZK[U^MCZJHK@O!GQV\#^.Q F
MFZ_;1W<Q5%LKQO(F+GHH5L;C_NDUWQ%?.5:52C+EJ1:?F?44J].O'GI24EY"
M4445D;A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4Z+_ %J?44VG1?ZU/J* .FHHHH("BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ K#\;_\ (H:Q_P!>K_RK<K#\;_\ (H:Q_P!>K_RIK<3V9\H4445U
M'FA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !7K7@[_D6K'_=/_H1KR6O6O!W_ "+5C_NG_P!"-1+8UI[FS11161TA
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 5:TK_D(0?[U5:M:5_R$(/\ >H VO%-ZVG>'-1N44.\4+, W
M0X%>+_\ "RK[_GUM_P#Q[_&O8/'/_(H:O_U[/_*OG"K@DT95&T]#K_\ A95]
M_P ^MO\ ^/?XT?\ "RK[_GUM_P#Q[_&N0HJ^5&//+N=?_P +*OO^?6W_ /'O
M\:/^%E7W_/K;_P#CW^-<A11RH.>7<Z__ (65??\ /K;_ /CW^-'_  LJ^_Y]
M;?\ \>_QKD**.5!SR[G7_P#"RK[_ )];?_Q[_&C_ (65??\ /K;_ /CW^-<A
M11RH.>7<Z_\ X65??\^MO_X]_C1_PLJ^_P"?6W_\>_QKD**.5!SR[G7_ /"R
MK[_GUM__ ![_ !H_X65??\^MO_X]_C7(44<J#GEW.O\ ^%E7W_/K;_\ CW^-
M'_"RK[_GUM__ ![_ !KD**.5!SR[G7_\+*OO^?6W_P#'O\:/^%E7W_/K;_\
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M /A95]_SZV__ (]_C1_PLJ^_Y];?_P >_P :Y"BCE0<\NYU__"RK[_GUM_\
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M"BCE0<\NYU__  LJ^_Y];?\ \>_QH_X65??\^MO_ ./?XUR%%'*@YY=SK_\
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MY=SO[SXR:G>V[1/96B@X.5W9_G6?_P +*OO^?6W_ /'O\:Y"BCE0<\NYU_\
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M^-'_  LJ^_Y];?\ \>_QKD**.5!SR[G7_P#"RK[_ )];?_Q[_&C_ (65??\
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M95]_SZV__CW^-'_"RK[_ )];?_Q[_&N0HHY4'/+N=?\ \+*OO^?6W_\ 'O\
M&C_A95]_SZV__CW^-<A11RH.>7<Z_P#X65??\^MO_P"/?XT?\+*OO^?6W_\
M'O\ &N0HHY4'/+N=?_PLJ^_Y];?_ ,>_QH_X65??\^MO_P"/?XUR%%'*@YY=
MSK_^%E7W_/K;_P#CW^-'_"RK[_GUM_\ Q[_&N0HHY4'/+N=?_P +*OO^?6W_
M /'O\:/^%E7W_/K;_P#CW^-<A11RH.>7<[&+XFW\4BN+6V)4@X.[_&M-_C9J
MKHRFQL\$8_C_ ,:\[HHY4'/+N=?_ ,+*OO\ GUM__'O\:/\ A95]_P ^MO\
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M6QO7S/\ \LY3_'['W]^_UKL:S:L=":DKH****104444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "G1?ZU/J*;3HO\ 6I]10!TU%%%! 4444 %%%% !1110 4444 %%%% !
M1110 4444 %8?C?_ )%#6/\ KU?^5;E8?C?_ )%#6/\ KU?^5-;B>S/E"BBB
MNH\T**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *]:\'?\ (M6/^Z?_ $(UY+7K7@[_ )%JQ_W3_P"A&HEL:T]S9HHH
MK(Z0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *M:5_R$(/\ >JK5K2O^0A!_O4 :7CG_ )%#5_\ KV?^
M5?.%?1_CG_D4-7_Z]G_E7SA6D-C"KN@HHHK0P"BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@!T<C12*Z,5=3N!'4$5[%H>I#5M*M[K@,Z_,!V8<']:\;KT?X<2E]%G0]$G
M./H0*B2T-:;UL=911161TA1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %='X;_X\9/\ KH?Y"N<K
MH_#?_'C)_P!=#_(4F"*7B3_C[B_W/ZFLFM;Q)_Q]Q?[G]3630 4444P"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH FL?^/VW_ZZ+_.O0V^Z?I7GEC_Q^V__ %T7^=>AM]T_
M2I9<3&HHHI&H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ML?J669[A<Q2A%\L^S_1]?S\CO****\(^D"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "G1?ZU/J*;3HO\ 6I]10!TU%%%! 4444 %%%% !1110 4444 %%
M%% !1110 4444 %8?C?_ )%#6/\ KU?^5;E8?C?_ )%#6/\ KU?^5-;B>S/E
M"BBBNH\T**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *]:\'?\ (M6/^Z?_ $(UY+7K7@[_ )%JQ_W3_P"A&HEL:T]S
M9HHHK(Z0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *M:5_R$(/\ >JK5K2O^0A!_O4 :7CG_ )%#5_\
MKV?^5?.%?1_CG_D4-7_Z]G_E7SA6D-C"KN@HHHK0P"BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **U?#GAC4?%5\;73;<S2*NYF)VJ@]23T
MIWB7PIJ?A*[2WU*W\EI%W1NK!E<=\$?RI7'9VN9%%%%,04444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 5Z)\-?^05=?]=O_ &45YW7HGPU_Y!5U_P!=O_9142V-*?Q'
M7T445D=04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !71^&_^/&3_KH?Y"N<KH_#?_'C)_UT/\A2
M8(I>)/\ C[B_W/ZFLFM;Q)_Q]Q?[G]3630 4444P"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M71>@4445Z!YH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1113
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M<RC*$G&2LT?J,)QJ14X.Z84445)H%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3HO]:G
MU%-IT7^M3ZB@#IJ***" HHHH **** "BBB@ HHHH **** "BBB@ HHHH *P_
M&_\ R*&L?]>K_P JW*P_&_\ R*&L?]>K_P J:W$]F?*%%%%=1YH4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5ZUX.
M_P"1:L?]T_\ H1KR6O6O!W_(M6/^Z?\ T(U$MC6GN;-%%%9'2%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ KH_#?_'C)_UT/\A7.5T?AO\ X\9/^NA_D*3!%+Q)_P ?
M<7^Y_4UDUK>)/^/N+_<_J:R: "BBBF 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG0,4M%?KE.G&E!0@K)'XQ4J3JS=2H[MA1116AF%%%% !1110 4444 %(2<X
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MNX6YL+R,2Q2+W![$=B#D$=B"*T:_)I1<6XR5FC]GC)32E%W3"BBBI*"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "G1?ZU/J*;3HO]:GU% '34444$!1110 4444 %%%% !111
M0 4444 %%%% !1110 5A^-_^10UC_KU?^5;E8?C?_D4-8_Z]7_E36XGLSY0H
MHHKJ/-"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "O6O!W_(M6/^Z?_0C7DM>M>#O^1:L?]T_^A&HEL:T]S9HHHK(Z
M0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH *M:5_R$(/]ZJM6M*_Y"$'^]0!I>.?^10U?_KV?^5?.%?1_
MCG_D4-7_ .O9_P"5?.%:0V,*NZ"BBBM# **** "BBB@#Z+^!W_(B1_\ 7Q)_
M,5Y!\5O^2@ZS_P!=%_\ 0%KU_P"!W_(B1_\ 7Q)_,5T.H>!- U6]EN[O2X)[
MF4Y>1@<DXQZ^U87M)G6XN<$D?*T,+W,J11(TDKL%5$&2Q/0 >M?5_AFR;0O"
MNG6UTP1[6U193V4A?F_+FH;3PYX<\+$W4-E8Z>P!_?N%4@=_F;I7G/Q1^+-I
M=:?/H^BR^?YPV3W:_<"]U7USW/3'KV;?/HA12I*[9Y0L$NOZYY5JFZ6\N,1H
M?5FXS^=?3_AO0+#P1X>2UC9(X84,D]P_&\XRSL?\X%>%_!:R6\\>VCLNX6\<
MDN/?;M!_\>KTGXZZO)I_A&.UC8J;V<(^.Z*"Q'YA:<M6D*G:,7,Q->^/XANW
MBTG3UG@0X\^Y8C?[A1T'U/X"M_P1\6K#QE/_ &;?6RV5Y("JHS;XYO4#(Z^Q
M_.OGBI+>XDM+B*>%S'-$P=''56!R"*?(B/:RO=GV!9VD-A:06T""."%%CC0<
M[5 P!^0KY"OO^/VX_P"NC?SKZVT2_P#[5T:PO2,&YMXYL8Z;E!_K7R3??\?M
MQ_UT;^=3#J76V1]"? [_ )$2/_KXD_F*N^._B'8> 8D00"YO[C,BVZ':,=-[
M''MCWQ5+X'?\B)'_ -?$G\Q7DWQ=NI+GX@:IO.1&4C0>@"+_ %)/XTDKR93D
MXP31U^E_M!3&[4:AI48MF."UNYWJ/7!X/Z5ZCJ5AI_C7PX\+%;BRO(MT<BC.
M,CY6'N#S7R;7T9\$+M[GP)"CDD03R1KGTSN_]F-.44M4*G-R=I'SYJ5C+I>H
M7-G,,36\K1.!ZJ<'^5>F_!#P5%JEW+KE[$)(;9]ENC#AI.I;_@.1CW/M7)?$
M^%8/'VM*O0S!OQ*@G^=>[?"RQ6P\!:0H7:9(S,?<LQ.?U%5)Z$4XIS]"E\0?
MBA:^"2EK%"+W49%W>3NVK&O8L?Z?RKC-*_:!N3>(-2TR'[*>&:U8AU]\$D'Z
M<5YUXSU-]7\5ZM=.Q;?<N%SV4'"C\  *Q:%!6%*I*^A]6:[HVG>/?#9A<K+;
MW$8D@N%&2A(^5Q_GU%?+5]9RZ=>W%K,NV:"1HG'HP.#_ "K2LO&6NZ;:QVUK
MJUW!;QC"1QRD*HZ\"LR[O)K^YDN+F5IIY#N>1SDL?4FG%-"G)3/I[X9_\B%H
MO_7 ?S-5?$GCW0/A\J6<@=ISF3[+:J"PW$DLQ) &22?7GI5KX9_\B%HO_7 ?
MS-?.WC:]DU'Q?K$\IRQNI%&3G #%5'X  5FE=LWE+EBK%[XC>++?QGX@6_M8
M98(Q"L6V7&<@DYX)]:]%^!_@F*&R_P"$@NXPT\I*6H8?<4'!?ZDY'T'O7B-?
M6WAZR_LSPWIUK$H5H;5$ ;ID*.N/>JGHK(SIKFDY,XOQ]\88/"U^^G6%NM]>
MQ_ZUG;$<9]..2?RQ6#H?[0#/=K'JVGQQV['!FM2<I[E3G/YUEW/P(\2WEQ+/
M-?Z;)+*Y=W,LF2Q.2?\ 5^M1_P#"@/$/_/YIG_?V3_XW2M&PVZE[GJOC?PK:
M>/?#)6(QR3[/.L[A<'DC(Y_NMP#^?:OF"2-H9&1U*NIVLIZ@BOJ?P%HE]X;\
M,6FFZA+%-/;E@'A8LI4L2!R >,X_"O _&FDK_P ++O[%1A9[X#"_]-"#_P"S
M40?0*JNE(]:^#O@J+0-!CU*>,'4;Y ^YAS'&>54>F1@G\!VJ+QO\9[3PU?26
M%A;C4;N,[97+[8XSW7CDD=_3USQ78>*=2/A_PMJ-W" C6ULQC&. V,+^N*^3
MW=G<LQ+,3DDG))HBN9W8YR]FE&)[7X:^/<=W>1V^L62VD;G'VF!B53_>4\X]
MP?PKU.QM+6W\Z6U1%%U)Y[M'T=BH&[\0HKX_KZ.^"VKRZKX'A25B[6<K6P8_
MW0 RC\ P'X43BEJ@IS<G9GE7QI_Y*#??]<XO_0!76?!_X@W-S<Z;X:-I$+>.
M.3$X8[CC<W3I7)_&G_DH-]_USB_] %'P6_Y*#8_]<Y?_ $ U5KQ(3:J:'L7Q
M)\:S^!]*M;N"VCN6FF\HK(2 !M)SQ]*\;\;_ !2N_&^E16,]E#;)'.)P\;$D
MD*PQS_O5Z#^T%_R+6F_]??\ [(U>#TH)6N.K)WL>L?L]_P#(:U;_ *]U_P#0
MJG_:'_X_=$_ZYR_S6H/V>_\ D-:M_P!>Z_\ H53_ +0__'[HG_7.7^:T?;!?
MPCB/AUX1/C'Q+#:2 BSC'FW#+Q\@[?4D@?F>U?0/B?Q-IO@'0EGE0)&H$5O:
MQ  L0.% [ >O;]*X/]GNQ5;'5[PK\SR)$&]@"2/_ !X5SWQ[U)[GQ7;6>X^5
M;6P(7MN8DD_D%_*D_>E8<?<AS+<N#]H34OM&?[*M?(S]S>V['INZ9_"O4_#7
MB/3O'N@&XBC#PR9BGMI@"5/=6'?@_K7RI6CI7B+5-#61=/O[BS60@N(9"H;'
M3/YU3@NA$:K3]XU?B+X5'A#Q3<64>?LK@309_N'/'X$$?A7,U>U76]0UR5)-
M0O)KQT&U6F<L0/2J-6O,R=KZ!7O/P"TE;;PY>WY \VYN-@/^P@X_5FKP:OH[
MX*,I\ VH7JLTH;CON/\ 3%1/8UI+WCS7XX:V^H^,39!LP6,:H%'3<P#,?U _
M"O.ZZ?XFJR>/=:#=?/SSZ$#'Z5S%4MB).\F%7]/U[4])1TL=1N[)'.YEMYVC
M!/J0"*H44R"[J.LZAJYC-_?7-Z8\[#<3-)MSUQDG'05M?#OPE_PF7B:&S?<+
M2,&6X8==@[#W)('XY[5S%>V_L]V*K8ZO>%?F>1(@WL 21_X\*F6B-(+FDDST
M36];TSP3H?VBXVV]I"!'%#$HRQQPBCUX_2O*[C]H6[-UF#2(1;9^[)*2Y'U
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MOCSQ%/&\<FM7KQN"K*TQ((/457+9W1"J734C*TZPFU6_M[.W7?//(L:+ZDG
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@1R/UN+88"G/=EZ'VVGG)K\XXCRE17UVBO\ $OU_S/TGAK-W/_8J[_PO]/\
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MMA[RX(Y9B.>OS,>@'3L*_//Q)XDU'QAKM[K.JW+W>H7DADEE<D_0#T    [
M 5YV%I2S[&?6JR_<P?NKO_6[^X]+%58\/X/ZK0=ZTU[S[?UT^\H3W$]W/+/<
M323SRL7DDD8LSL3DL3W)))_&F445]^DD? -W"BBB@04444 %%%% !1110 44
M44!L>\_LH?&0^"/$H\-:G.%T/5I0(W8']Q<G"JV?1L!3GIA3D '/W%7Y1D8[
M5^@_[-OQ.;XE?#JW:[D+ZOIA%G=L[;FD(4;)3W^8=2>K*U?F_$V7*$EC*:WT
MEZ]_T/T_A7,W)?4*KVUCZ=5\MU\SU6BBBO@C]'"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "G
M1?ZU/J*;3HO]:GU% '34444$!1110 4444 %%%% !1110 4444 %%%% !111
M0 5A^-_^10UC_KU?^5;E8?C?_D4-8_Z]7_E36XGLSY0HHHKJ/-"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O6O!W
M_(M6/^Z?_0C7DM>M>#O^1:L?]T_^A&HEL:T]S9HHHK(Z0HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *M
M:5_R$(/]ZJM6M*_Y"$'^]0!I>.?^10U?_KV?^5?.%?1_CG_D4-7_ .O9_P"5
M?.%:0V,*NZ"BBBM# **** "BBB@#Z+^!W_(B1_\ 7Q)_,5Y!\5O^2@ZS_P!=
M%_\ 0%KU_P"!W_(B1_\ 7Q)_,5Y!\5O^2@ZS_P!=%_\ 0%K*/Q,Z)_PT<G11
M16ISG>_!*\6U\>VZ,0//ADB&?7&[_P!EKT'X]Z9)=>%;6[C!86MP"^.RL",_
MGM'XUX;I&IS:-JEI?P']];RK*N>AP<X/L:^IK"]T[QOX<6556XL;R+:\;=1D
M<J?0@UE+1IG13]Z+B?)M.56D<*H+,QP% R2:]/U[X#:K;WC'2IX;RT8_*)GV
M2*/0\8/U'Y"NB^'WP:;0[^+4]:ECFGA(>&VB.51NS,3U(]!Q[U7.C-4Y-VL>
MD>'[%M+T#3;.3[]O;10M]50#^E?)=]_Q^W'_ %T;^=?7\$\=S#'-$XDBD4,C
MJ<@@C((KY OO^/VX_P"NC?SJ(=36MLCZ$^!W_(B1_P#7Q)_,5Y!\5O\ DH.L
M_P#71?\ T!:]?^!W_(B1_P#7Q)_,5Y!\5O\ DH.L_P#71?\ T!:<?B8I_P -
M')U]"_ C_D2'_P"ON3_T%:^>J^A?@1_R)#_]?<G_ *"M.>Q-+XCR;XK?\E!U
MG_KHO_H"U[M\,;M;WP'HSJ0=L'EG'JI*_P!*\)^*W_)0=9_ZZ+_Z M=M\"?&
M$4 FT"ZD",[F:U+'[Q(^9/TR/QI25XHJ#M-GF7BJR?3O$VJVT@(:.YD'/<;C
M@_B,&LJOH#XF_"AO%=U_:>F21Q:@5"RQR'"S8Z'/9L<>AXZ5PFE? SQ#=WB)
M>""QM_XY3('./8+U/UQ5*2L1*G).R1Y^EK/(H9(9'4]"JD@TQT:-BK JPZ@C
M!KZLGGTWP#X7!8^58V,(503\SD=![L3^IKY<U74I=8U.ZOISF:XD:5O8DYQ1
M&5Q3AR6U/IGX9_\ (A:+_P!<!_,U\W>)_P#D9=6_Z^YO_0S7TC\,_P#D0M%_
MZX#^9KYN\3_\C+JW_7W-_P"AFICNS2I\,3,KZYT:\-]X>L;J':S2VJ2(#T)*
M BOD:O>O@?XPCU'1O[$N) +NTR8@>KQ$YX^A./IBB:TN*D[.QSS_ +0.IQNR
M-I%LK*<%2[9!I/\ AH34?^@3:_\ ?QJU?B'\&9]6U.;4]$>)9)VWS6LAV@L>
MK*>G/4@^_/:N>T'X%:U=WT8U0Q6-F#^\*R!W8>B@9'XFCW+#?M4[%S_AH34?
M^@3:_P#?QJX2]\3/JWC%=;G18G:YCF9%Y"[2/\*^@O$TFA>"/#<ES)86FV&,
M101-&I,C8PJ^I]SZ FOF.>9KB:25R"[L6; QR>M.-GLB:EU9-GU9XRTY]9\(
MZK:P_/)+;/Y87^)L9 _$@5\H=/K7TE\)O%T?B;PS!;R2#[?9*(94)Y*CA7_$
M?J#7,^._@F^I:A-J&AR11-,Q>2TE.U=QZE"!W]#^?:IB^71FDUSI21XG7T3\
M#M.DL? ZR2 C[5<O.H/IA4_]DKB_#?P'U&:]1]9FBMK-#EHX'W2./0'& /?]
M*]LL4MK>$6MKL6*V A\M#Q'A00OMP1^=$Y7T04H-.[/G?XT_\E!OO^N<7_H
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "O1/AK_P @JZ_Z[?\ LHKSNO1/AK_R"KK_ *[?^RBH
MEL:4_B.OHHHK(Z@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "NC\-_\>,G_ %T/\A7.5T?AO_CQ
MD_ZZ'^0I,$4O$G_'W%_N?U-9-:WB3_C[B_W/ZFLF@ HHHI@%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZ1\B_M^7S"'P=99.PM<S$>I'E@?S/YU\>U]>?M_6K^;X-N/^6>+J//O^Z/\
M2OD.OJN'TO[.IV\_S/E>(F_[2J7\OR04445]$?-!2$9.>]+10 8X Z#T%%%%
M !1110 5ZK^S+\/%^(GQ;TFVN4+:?8?\3"Y _B6,C:I]BQ4'VS7E)Z<5][?L
M>_#.3P#\.I_$.HHL5_K>VY7(^:.U5?DR??+/QV*]Q7S^>8U8/!R:?O2T7K_P
M#Z#(\$\;C()KW8ZOT_X.QS'[=GQ!:QT72/!]N0#?,+V[YY\M&(C7Z%@3_P
M%?-_P*^(1^&7Q/T;6&.+0R?9KL9QF!SAC^'#?514_P 9=:UOXF_$G6M>_LK4
MS:33;+1)+60%($^6,8QQD?,1ZDUQ7_",ZSD?\2F_X_Z=9/\ XFL<OPM"AEZP
MU1J\E[WJ_P#+]#;,<77KYD\533M%^[H]E_F?K7N\Q,XR",XZU^:_[2_PZ;X;
M_%G5+:*!8=,OS]NLMG3RW)RN.VUPXQZ 'O7V9^R_XVO/%WPITZ#48+F'4M*
MT^?[3&R,X4#8_P PYRN!GU!KD?VU_APOB;X?6WB.UA+7^AN6<IU-NY ?(]B%
M;/8!O>OB<EKO+<Q="H]&^5]O)GW6=4%F>6+$4UJES+]5]WY'P=12#..>32U^
MN'X^%%%% !1W'UHH[CZT!U/T)T/_ ),YC_[%:3_T4U?"?@3QOJOP[\4V.O:-
M.8+RU;)!Y65/XHV]58#!_,<@&ONS0O\ DSB+_L5I/_135^>@%?%9%3C56)A-
M73F_U/ML_G*D\+.F[-01^J/PN^)&F?%/P?9Z]IC!5E&R>W9@6@E'WD/T['N"
M#WKRG]JS]GU?B/HA\1:) H\3:=$=T:\?;(1DE3_M+R5_+TQ\K?L__&V\^#/B
MP2MYEQH%Z0E_9J>W02+_ +2YS[C(]*_1[2-7L]>TFUU*PN8KRQNHA+#/$V4=
M",@@U\KC<-7R+&JK1^'H_+L_R/K<#BJ&?X)T*_Q6U76_22^>J/R0!R 0.*<O
MWU^HKZH_:U_9UETNYO/'7AJV!TZ3,NJ6B$9A<GF91_</\0['GH3CY64_O%'&
M<CBOTS!8ZEC\.JM+YKL^Q^78W U<OKNC57H^Z[GZ$?M4_P#)ME[_ +MG_P"C
M(Z_/>OT(_:I_Y-LO?]VS_P#1D=?GO7A<+_[G+_$SZ'BG_?(?X4%%%%?8'Q@4
M444 %%%% 'V%_P $_O\ 4^-_]ZS_ /:U>]?M#_\ )$/&O_8,E_E7@O\ P3^_
MU/C?_>L__:U>]?M#_P#)$/&O_8,E_E7Y'F?_ ".G_BC^43]BRG_D1_\ ;L_U
M/S#_ (F^M%'\3?6BOUU=3\="BBBD 4444 %7=$_Y#-C_ -=T_P#0A5*KNB?\
MABQ_Z[I_Z$*SJ? RX?''U/UR0_*OTKY%_:,_9J\:_$SXGWFMZ)'I[6,T,4:&
MXNO+?*K@\;3Z5]<I]U?I7RU\>_VJO$OPH^(UWX?TW2M+NK6&&*02W:RER67)
M'RL!7XUD[Q?UI_4TN:SW[:'[;G2PGU5?7;\MUMW/*=-_8=^(5W<QK=W&C6,&
M?FD-R\C*/953G\Q7T-XS^'-I\*?V5?$GARSF:Y6VTV9I+AQ@RR,=S-CMDG@=
M@ *\>T;]OO68IE_M;PI97,6.?L<[Q'Z_,&_*O;/B-XZTWXE?LP>)?$6E%OLE
MYI4IV2##1L#AD;W!!'IQ7MXZ>:2KT5C5[G,K6M:]_O/ P$,I5"L\"[SY97OO
M:WW'YU#J:6D'4TM?IJV/R\****8@HHHH *V/!OBW4/ ?BC3M>TN01WMC*)4W
M?=8=&1O]EAD'V-8](>N.]14A&<7"2NF7"<J<E*+LT?JK\-?'UA\3_!FF^(-.
M8K%=)\\9^]%(#AT/T8$9[]:DUG_A'_ RZ]XMNX+>QD%L)+^_6/YWBB!VAL<G
M ) 'T%>,_L8?#S7?!G@6[U+5;B:&VUADN+73)!Q&H'$Q]"X(X] OK7T)=6L%
M_;36]S$EQ!*A22*50RNI&""#U!'%?A>+ITL/BITZ;O!.VG;L?O6#J5<3A(5:
ML;3:OKW_ *U/S&^-GQ;O_C%XSGU6YW06$68K&SW96&+/?_:;JWN<= *X$#BO
M4OVA_@W-\'O'$D$*N^@W^Z?3IV' 7/S1$]RF0/<%3W->7"OV?+W0EAH/#_!9
M6/Q''QKQQ518GX[N_P#7;L%%%%>@< 4444 %%%% !1110 4444 %%%% !7L_
M[)_CT^$/BG;V$TKK8:THLI$!.WS2?W+$=SNRH/82&O&*MZ-J<VB:S8ZC;MLN
M+29)XVQT96!'Z@5Q8VA'%8>=&2W7X]#NP6)EA,33KQ>S_P"'7S/U0HJIH^J0
M:YI-EJ-JV^VNX$N(F]4=0P/Y$5;K\(::=F?T,FI*Z"BBBD4%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4Z+_6I]13:=%_K4^HH Z:BBB@@**** "BBB@ HHHH **** "BBB@ HHHH
M**** "L/QO\ \BAK'_7J_P#*MRL/QO\ \BAK'_7J_P#*FMQ/9GRA11174>:%
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %>M>#O^1:L?\ =/\ Z$:\EKUKP=_R+5C_ +I_]"-1+8UI[FS11161TA11
M10 4444 %%%% !1110 4444 %%03WMO:L!-/'$3R!(X7/YU'_:UC_P _MO\
M]_5_QH MT54_M:Q_Y_;?_OZO^-30W$-RA:&5)5!P2C C/IQ0!+1110 4444
M%%-=UB0N[!$49+,< 56_M:Q_Y_;?_OZO^- %NBHH+J&Z!,,J2@<$QL&Q^52T
M %%%% !1110 45D:KXOT+0V*ZEK6G:>PZBZNXXB/^^B/45!8>/?#.JN$LO$6
MDWCDX"P7T3G/IPU &]12 Y&1R*6@ HHJ*>ZAM0#-*D0/ ,C!<_G0!+153^UK
M'_G]M_\ OZO^-']K6/\ S^V__?U?\: +=%5/[6L?^?VW_P"_J_XU+!>071(A
MGCF(ZB-PV/RH FHHHH **** "BBH)[ZVMGV2W$43XSM=P#C\: )Z*JKJMDQ
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU+ZA]7C\>]_/_+H:0XBK?VC]8?\ #VY>EO\ /J?I1\:/A39?%KP/=Z-=!$O
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MA'Z8KT^OP;&I1Q55+^9_FS^A\ W+"49/K&/Y(****XSO"BBB@ HHHH ****
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MF\TRV2+4;12PCB0+YR=2N!W[C\N]?/G3ZTT[BE%Q=F%%%%40%%7-(4-JUD"
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MZ.-IX*G@U/4T6QQ53V5]<Z=.)[2XEM9ATDA<HP_$<U^B/_"K/!?_ $*&@_\
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M6U"UM[.:&^>U"6V[:5$<;9^8DYRYKTBJ("BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ JUI7_ "$(/]ZJM6M*_P"0A!_O4 :7
MCG_D4-7_ .O9_P"5?.%?1_CG_D4-7_Z]G_E7SA6D-C"KN@HHHK0P"BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ KT3X:_\@JZ_P"NW_LHKSNO4? EF;7P]&S#!F=I<'\
M/T J);&M/XCHJ***R.D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MI4LN)C4444C4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%N1_S(T7_@U/_P 9H_X>"W)Z^!HO_!J?_C-?3_7<]_Y\1_K_ +>/E?J60?\
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M3V5E/J-Y#:VT;2SS.$1%ZDDX KZ:\ >!+7P3I*QJ%EOY0#<7&.6/]T?[(_\
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M(DY9C]Z1N[,>Y-:%Q<16L+S32)#"@RSNP55'J2>E/9@BEF(  R2>U?./Q/\
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M*,+ZLJ=3E=D?0=K\>/#=Q,$DCO[9?^>DL*E?_'6)_2NXTC7+#7K07.GW4=W
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M7CZA?7%U)_K)Y&E;ZDDG^=?7'[&^A2V7@?5]3D0HM]>A(\_Q+&N-P]MS,/\
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MYGX.^$H?''Q*T'1[E=]I+.9)U[-&BEV4^F0I'XU^A<4201I'&BQQH JHHP%
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M^O9_Y5\X5I#8PJ[H****T, HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HIRHTC!5!9CT &2:Z
M'1O ]_J3J\Z&SM^[2#YB/9?\<4KV&DWL4/#NARZ[J"0J"(5YED'\*_XFO7(H
MEAC2-%"H@"JHZ #H*K:7I=OH]HMO;)M0<DGJQ]2:N5DW<Z81Y4%%%%2:!111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %='X;_P"/&3_KH?Y"N<KH_#?_ !XR?]=#_(4F"*7B3_C[
MB_W/ZFLFM;Q)_P ?<7^Y_4UDT %%%%, HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** )K'_C]
MM_\ KHO\Z]#;[I^E>>6/_'[;_P#71?YUZ&WW3]*EEQ,:BBBD:A1110 4444
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M***!60449HS0,****86"BBBD 44446 **,T9I@%%%% 6"BBBD 4444 %%%%
M!1110 4444 !KZ&_8T^'[:[XWN_$US KV.D1%(7<'FY<8&.,':F\GT+(>]>
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MY,P__%T72W!)O9'(&>1H5A:1C$K%EC+':"<9('J<#\JCKL_^%/>+_P#H$?\
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M-XG_ .NR?^BDKO?V,O\ D>M<_P"P;_[52IZEO8^OJ^&?VIO^2S:K_P!<;?\
M]%+7W-7Q#^UA8RVGQ?NI9%(2ZM()8SZJ%V']4--DQW+?[(?_ "5>7_L&S?\
MH4=?:=? 'P,^(EG\,O'L.K:A!+-9/ ]M*80"Z!B"& /7!4<>A-?5VB_M)^!-
M?U2QTZTU&X:\O9H[>&-K209=V"J"<8')'/2A#9R/[9=@\W@'1[M5++!J(1B.
MP:-^?S4?G7R#;SM;3QRIC?&P<9Z9!S7Z'_%CP4/B#X U?15V_:9HM]LQXQ,A
MW)SV!(P3Z$U^>-S;2V=S+;SQM#/$YCDC<89&!P01V(-)CB?I=H>KV_B#1K'4
M[1@]M>0)/&0<_*P!'\ZO5\7_  ,_:.E^'5FNB:Y#-?Z&&)@DAP9;7)R0 2-R
MY.<9R.<9Z5[I<_M3_#N"R\]-4N;B7&?LT5E*)/IEE"_^/4[DV-G]H#6(=%^$
M/B229@IGM_LL:GJS2$* /S)_ U\!5Z=\:OC???%N]@A6 Z?HMJQ:"TW;F9^G
MF.>YQP!T&3ZDUYC29:5C[Z_9X_Y(SX8_ZXO_ .C7KYU_:_L'M?BE;SE2$N=.
MB<-V)#NI'Z#]*^BOV>/^2,^&/^N+_P#HUZXS]K;X?R^(O!]KK]G$9+G1V8SJ
MHY-NV-Q]]I /T+'M3Z$+<^?OV>=>A\/?%_P]<7#*D$TCVK,QQ@R(R+_X\5K[
MZK\P$=HV5E)5E.00<$&OJ?X6_M:V*:5!I_C-)TO(5"#4X(_,68#H74<AO< Y
MZ\4D-H^F*^;/VT=8A31/#FE;@;B2XDNBHZA57:"?J7/Y'TKJO$O[67@C2;)W
MTN:YUVZQ\D,4#PKG_::11@?0'Z5\E>/_ !WJ7Q&\3W.M:HR^=)A(XD^Y#&/N
MHOL,GZDD]Z;!(Q])_P"0K9?]=D_]"%?IM7YDZ3_R%;+_ *[)_P"A"OTVI()'
MYR?$VQETWXB^)[>52'34KC\09&(/X@@_C7NW[%>K1I<^*=,9@)G2"YC'<JI=
M6/X%D_.L3]KCX=3:/XJB\56T).GZF%BN&4<1W"K@9_WE (]U:O'_  'XVU#X
M>^)[/6]-9?/@)#1O]R5#PR-[$?EP>U&P]T?I!17C/AO]J_P+JU@DFIW-QH=W
MCYX)K>249_V6C5LCZ@?2N3^)_P"UMIB:5<6/@Y9KF^F4H-1GC,<<(/\ $BGY
MF;TR !UYQBF39GB?[06K0ZU\8_$]S P:-9UM\C^]%&D;?JAKL_V/+&6X^)E]
M<J/W5OILFYO=I(P!_,_A7A<DC2NSNQ=V.69CDD^IK[4_99^&TW@SP7+JM_"8
M=2UDK+Y;C#1P+GRP?0G);\5STI%/1%C]K#_DC]U_U]P?^A5\15]N_M8?\D?N
MO^ON#_T*OB*AA'8_2WPQ_P BUI/_ %Z0_P#H K3K,\,?\BUI/_7I#_Z *TZH
M@^5/VU?^0KX4_P"N-Q_Z%'7CGP9_Y*OX3_["4/\ Z$*]C_;5_P"0KX4_ZXW'
M_H4=>.?!G_DJ_A/_ +"4/_H0J>I:V/T.KXD_:S_Y*]-_UY0?R-?;=?$G[6?_
M "5Z;_KR@_D:;)CN'[)G_)7H?^O*?^0K[;KXD_9,_P"2O0_]>4_\A7V=K-G-
MJ&CWUK;SM:W$\$D4<Z$AHV92 P(Y!!(/X4();F5XU\ :%\0M,%CKM@EY$IS&
M^2LD1]58<C^1QSFO O%/[&"L[R>'/$&U3]VWU././^VB#_V2O&=1^*WQ"TG4
M+FRN_$^L075M(T,L37395E."#SZBO;?@'^TC9+ICZ-XTU65+U9&>#4KMBZR*
M?X';J"#G!/&/3'(.S1XOXS^!'C7P-%)<7VD/<648RUW8GSHP/4X^91[L!7)^
M&O$^J>$-8@U/2+R2RO83E9(SU'<,.A![@\5]X>(/CCX%\/Z9+=R^)-.O=JDK
M;V-PEQ)(>RA4)Y/O@>IKX#U&Y2\O[FXCA6WCEE:185Z("20H^G2D-:[GZ#_"
M;X@1_$OP/8ZV(Q!<OF*YA7HDR\-CV/!'LPK*_:'_ .2,^)_^N*?^C4KE?V0-
M/GLOA3/-*A6.[U.::$G^) D<9/\ WTC#\*[+X\V,NH_!_P 4Q0J6<6GFD#^Z
MC*[?HIID]3\_:_0WX,_\DH\)_P#8-A_]!%?GE7UE\)/VF/".B^!-(TC6GNM/
MO=/@6W8K TB2!> P*Y/(QU YS214CZ.HKG? WC[1?B+I,VI:%</<VD4YMV9X
MFC(<*K$88#LX_.NBJB HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M #Y6_P#WZ7_"C^R;'_GRM_\ OTO^%6Z*+A9%3^R;'_GRM_\ OTO^%']DV/\
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M_"C^R;'_ )\K?_OTO^%6Z*+A9%3^R;'_ )\K?_OTO^%']DV/_/E;_P#?I?\
M"K=%%PLBI_9-C_SY6_\ WZ7_  H_LFQ_Y\K?_OTO^%6Z*+A9%3^R;'_GRM_^
M_2_X4?V38_\ /E;_ /?I?\*MT47"R*G]DV/_ #Y6_P#WZ7_"C^R;'_GRM_\
MOTO^%6Z*+A9%3^R;'_GRM_\ OTO^%']DV/\ SY6__?I?\*MT47"R*G]DV/\
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M #Y6_P#WZ7_"C^R;'_GRM_\ OTO^%6Z*+A9%3^R;'_GRM_\ OTO^%']DV/\
MSY6__?I?\*MT47"R*G]DV/\ SY6__?I?\*/[)L?^?*W_ ._2_P"%6Z*+A9%3
M^R;'_GRM_P#OTO\ A1_9-C_SY6__ 'Z7_"K=%%PLBI_9-C_SY6__ 'Z7_"C^
MR;'_ )\K?_OTO^%6Z*+A9%3^R;'_ )\K?_OTO^%']DV/_/E;_P#?I?\ "K=%
M%PLBI_9-C_SY6_\ WZ7_  H_LFQ_Y\K?_OTO^%6Z*+A9%3^R;'_GRM_^_2_X
M4?V38_\ /E;_ /?I?\*MT47"R*G]DV/_ #Y6_P#WZ7_"C^R;'_GRM_\ OTO^
M%6Z*+A9%3^R;'_GRM_\ OTO^%']DV/\ SY6__?I?\*MT47"R*G]DV/\ SY6_
M_?I?\*/[)L?^?*W_ ._2_P"%6Z*+A9%3^R;'_GRM_P#OTO\ A1_9-C_SY6__
M 'Z7_"K=%%PLBI_9-C_SY6__ 'Z7_"C^R;'_ )\K?_OTO^%6Z*+A9%3^R;'_
M )\K?_OTO^%']DV/_/E;_P#?I?\ "K=%%PLBI_9-C_SY6_\ WZ7_  H_LFQ_
MY\K?_OTO^%6Z*+A9%3^R;'_GRM_^_2_X4?V38_\ /E;_ /?I?\*MT47"R*G]
MDV/_ #Y6_P#WZ7_"C^R;'_GRM_\ OTO^%6Z*+A9$%KH]@US"#96Q!<?\LE]?
MI763^'M*$$A&F68.T\^0GI]*Y^U_X^H?]\?SKK[C_CWD_P!T_P J38[(X#^R
M;'_GRM_^_2_X4?V38_\ /E;_ /?I?\*MT4[BLBI_9-C_ ,^5O_WZ7_"C^R;'
M_GRM_P#OTO\ A5NBBX614_LFQ_Y\K?\ []+_ (4?V38_\^5O_P!^E_PJW11<
M+(J?V38_\^5O_P!^E_PH_LFQ_P"?*W_[]+_A5NBBX614_LFQ_P"?*W_[]+_A
M1_9-C_SY6_\ WZ7_  JW11<+(J?V38_\^5O_ -^E_P */[)L?^?*W_[]+_A5
MNBBX614_LFQ_Y\K?_OTO^%']DV/_ #Y6_P#WZ7_"K=%%PLBI_9-C_P ^5O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4 %%%% !1110 4444 %%%% !1110 4Z+_6I]13:=%_K4^HH Z:BBB@@****
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MX)]@< ?0  5,%=FE65E8R****W.,**** "BBB@ HHHH **** "BBB@ HHHH
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M.TX#V,1N%/N#'FM#X;?#;Q=8_$7PM<W/A;6K>VAU6UDEFET^94C43*2S$K@
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ME(M/T*[6)B ;JYC,,*^Y=L _09/M7H/QD^"UA\)?AAI!\T7VM7>H+]JO-N
M(G(1!V4'\2>3T 'V97RU^V7XNMIY=$\-PR+)<0,UY<J#_J\C;&#[D%S],>M%
M@O=GS=I/_(5LO^NR?^A"OTVK\V_ NCR>(/&FAZ=$I9KF]ACP.P+C)_ 9/X5^
MDE""1G>(?#^G^*M&NM*U2V2[L;E-DL3]QU!![$$ @CH0#7R-\2?V4O$'AZZF
MNO#2G7=+)RL((%S$/0KP'^J\^PK[*HIB3L?FIJ'A/6]*E,=[H]_:2 X*SVSH
M<_B*T="^&7BSQ+,L6F^'M1N"W\?V=DC'IEVPH_$U^C5%*P^8^<?@_P#LJ)H=
MW!K'C!H;NZB(DATR([HD8<@R-_$1_=''J3TKZ.HHID[GE'[3.C:AKWPKN;33
M+&YU&Z-U"P@M(6E<@-R=J@G%?'W_  JSQI_T*&O?^"R;_P")K]&**+#3L9WA
MV)X?#^F1R(T<B6L2LC#!4A!D$5HT44Q'S3^UWX3USQ+J7AIM(T;4-56&&<2-
M96KS!"2F,[0<9P?RKRGX3?#GQ9IOQ,\,75WX7UFUMH;^%Y)IM/F1$4,,DL5P
M![FONRBE8=]+!7Q_^T[X&\2:_P#%*:[TSP_JNI6IM(5$]I922H2 <C<JD9K[
M HH$G8^0/V8O WB30/BE#=ZGX?U73;46DRF>[LI(D!(&!N90,U]?T44 W<\3
M^.'[.=M\1YVUG1I8M.U_;B42 B*ZQP-Q'W6 &-V#G@'U'RSXC^$GC#PI<-%J
M/AZ_0*<>=#"98C]'3(_6OT2HHL-.Q^:-GX9U?4)/+M=*OKF3ILAMW<_D!7K'
MPW_9;\3>*KR*?7H)/#^D@@N9@/M$@_NJG53[MC'H>E?:U%%A\Q2T71[/P_I-
MIIMA"+>SM8UBBC7^%0.*M2PI<1/%(@DC=2K*PR&!Z@T^BF2?''Q0_96U[1-4
MGNO"L!U?2)&+);AP)X ?X2#C<!V(R?4=Z\PD^%'C6-RI\(ZX2.ZZ=,P_,+BO
MT6HI6*YCQ;]D_0-4\.?#K4;;5M-N]+N7U6218;V!H7*F&$!@& .,@C/L:]IH
MHIDA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 5:TK_D(0?[U5:M:5_R$(/\ >H Z;4O^/&Y_W#7'UV&I?\>-S_N&N/I(&%%%
M%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K1T#_ )"*
M_P"Z:SJT= _Y"*_[IH U]=_Y!LGU'\ZY>NHUW_D&R?4?SKEZ2!A1113 ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@"6U_X^H?\ ?'\ZZ^X_X]Y/]T_RKD+7_CZA_P!\?SKK
M[C_CWD_W3_*DP.+HHHI@%%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !71^&_^/&3_ *Z'^0KG*Z/P
MW_QXR?\ 70_R%)@BEXD_X^XO]S^IK)K6\2?\?<7^Y_4UDT %%%%, HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** )K'_C]M_^NB_SKT-ONGZ5YY8_\?MO_P!=%_G7H;?=/TJ6
M7$QJ***1J%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5B^,?!VE>//#UUHNLVPN
MK&X7!'1D;LZGLPZ@_P!*VJ*J,G"2E%V:(G",XN,E=,_.CXS?!75_@_K7EW0-
MWH\[G[)J2*0C#DA']' '(_$<=/.@<YK]3/$'A[3O%.CW.EZM9Q7UA<ILE@E'
M!'\P1U!&"#R*^+OCK^R[J7@66YUKPS'+J?AWF22%07FLAWW=W0?WAT ^;IN/
MZ=E&?PQ"5#%.T]D^C_X)^39UPY/"MXC"*\-VNJ_S1X+1117VNY\*%%%% !11
M10 4444 (W2OK[]H/QQHFH_LW>$M/TW7;&XU&(V(EMK6[1IDQ;L&RH.1@XKY
M"(R,4@4#.*\S%X)8JK2JN5O9N_J>GA,=+"4JM.,;^T5O3S%9GD8LYW,>22<F
MBBBO32LK'F;Z@1Q7U-\+?%^A6/[(OB[2+C6;"#5)OM?EV4ERBS/D+C"$Y.?I
M7RP1D4C("<GJ*\[&X18R,8N5N62EWV/1P6,>"G*:C?FBX_>?6?[,?C'0=!^!
MOC:RU+6M/L+R=KCRH+FY2-WS!@;5)!//I7R8O8]L"C8#3NIS2PN"6&K5JRE?
MG:?I8,3C7B:-&BXV]FFO6^H5[1^R7!H=O\5X=9U_5;'2K72K>2>%[ZX2)7F8
M;% W$9P&8_A7B]-(S_2M\70>*H3HJ5N96N887$?5:\*_+S<KO8^NH/VQ(W^+
MOE-H&BQZ/_:1L_[:.3/]FW[!+OZ8V_-Z8XKAOVRI/#^I^/\ 3-;T'5-/U,7]
MGY=T;&Y2;$L9P"VTG!*LH&>NROGXJ"".QXQ0$"]*\G#Y-1PN(A7H.UE9KN>K
MB,YKXNA/#UUS7=T^WD.IIX(^E.I*^A9X'4^IOC%XPTB\_96\!:?8:U:2ZM:&
MR,MM;72F>(K;R DJIW+@X_'%3?M4>+]$\8_!_P #2V&M6&IZC"\3SI#<)).@
M: YW '(^8#.>XKY2" '(XH"*O0<BOG:63QI3IRC/6,I2VWYNGR/H:N<SJPJ0
M</BC&/\ X#U%'3WI:!17T1\ZCZA^$OBK1+#]DSQSI%UJ]C!JER+T0V,MPBS2
MYA0#:A.3D^@KTP_'K0W_ &:/[2@UJRB\4C1/L8MOM""Z6?'DDA,[OOC?TZ8-
M?"!0%@>]&P>E?+U\BIUZDJDI[SYO\U_P3ZBAGU6C35.,=%#D_%Z_F?3GQ4\4
MZ+?_ +)7@C2;75[&XU2WGMS-9Q7"--& DN=R Y'4=1WKYEIH09SSFG5[&"PB
MP<)Q3OS2<OO/(QN,>,E&35N6*C]W7Y@1FOJ3]E+Q5X?^&7PU\:^)K_4=/BU=
M@1;64]PJSS+%&6553.XAG<#IV]J^6Z0J.OI4X_"+'4?8N5E=7\TM0P&,> KJ
MM&-VDTO5Z7^1]F? C]JFV\4>+KG2M>TOP_X7T^YMGF-U PA5Y 1PY8@'(+\]
M:^6/B5H^G:#X^UZPTBYBN]+ANY!:2PRB53"3N3YP2#A2 ?>N9* YSSGK2]/_
M -5<V$RNE@:\JM#2+27+Y][G3B\TK8ZA"C75W%MI];/I86M;PCK[>%?%>C:T
MD?FMIUY#=B,'&_8X;;^.,?C632$9ZU[,XJ<7&6S/(C)Q:E'='W-XX\%^#/CI
MXZ\*>.[/Q9H[Z98I&FHV%ZZ-YD2.9 C(W0G>P97&,8_'YO\ VE=7\):O\2G'
M@RUTVWTBVM8X"^DP)%#+*"Q9AL #?>4;N^VO)S$K')'-.KP,%E+P=2,G5<HQ
M3235K7_,]W'9M'&4W%4E%R:<GO>RM\A:0]*6D(S7T+V/ V/MGQ%:^&/BM^SS
MX/\ #/\ PG>@Z'>VUO9S2?:[J,E2D)4H5W@@_-^E?+GQ1^'-C\.=1L[:Q\4Z
M9XJ6XB,C3Z8P98R#C:<,W)ZUQ!C4GU- 0*>*\' Y=5P4WRU;P;;M9=?/<]O'
M9C3QT5S4K322O=[+RV'4AXQ]:6@BO>W1XA]DZ7>>&/CO^S;H/@Z#Q1I^B:_I
MEO;QF"_E"'?"-F2O5E91D%<XR.X(K*^*>O>'/A/^S>/AK;:[:>(/$%R563["
MX98LS"5G8 G:.-H!Y).>F:^264.,$?I0J!>E?,0R7DJ)^U?(I<ZC9;^I]-//
M'.F_W24W#D<KO;T' 8HHHKZ?9'S)U'PJNX-/^*/@^ZN9H[>VAUBRDEFE8*D:
M"="68G@  'GVKU;]M+Q'I7B?XFZ7<Z1J5IJENFE1QM+9SK*H;S9>"5)YY'YU
MX!MSGZ8H"@'CC\*\VI@U/%0Q7-\*:MWOYGH0QKIX.>$MI)IW[6\A:***](\\
M^A?V+/$ND^%_'VM7&L:G9Z7 ^G;$EO)UB5F\Q3@%B,GVKQWXDW,-[\1/%%Q;
MRI/!+JER\<L;!E=3*Q!!'4$'K7-%0PYI<#.<5YU/!JGBYXGF^))6]#T*F,=3
M"4\+;2+;OZBU>T'5GT#7--U2-0\EC<Q7*HQP"4<, ?RJC0>17H2BI)Q>S.&+
M<7S(^Y?B!X=\'_M%ZOX,\4V'BS28;736!U"RNY%WM$61S&4/1N&&&&.?S^>/
MVG]5\':C\0XH/!5KI=OIEG:)%+)I,*1PRS;F+$%  V 5&?4'FO'C$K8R,XIV
M,8KY_!93+!U(2]JY1A?E5MK_ )GNX[-EC:<H^R492:<G>][=NWHA: "3@<D\
M44'D5]"M$>"?9?C+XS:+\$?A'X-\,:)_87C"]6$1WL7GK<01LJ[I&(4GDR,<
M9]#3-8^*6@_'']F?6;6_N](\/Z]:;C%I@F6(;X2)$$2,02&3"C'&21[5\:A0
MO2C8-V[J>G-?*QR"E%1DI/VBES<VNNM[6N?3O/ZTG*+C^[<>7E[:6O>PHZ_6
ME/2BBOJCY<^HOV&_%>A^%9_&G]M:Q8Z3YZ60B-[<I")-IGW;=Q&<9'3U'K7*
M?$_X%^'].MO$7B:T^)N@:I-YDMVFFVS(TLFYR0@(D.3SZ>O%>#% 3SS2",*V
M<<UX,LMJ+&2Q=*KR\UKJR>VA[:S*G+!PPE6DI*-[.[6^O3U'TA&012T'D5[Q
MXA]!? ;P7\,_B+X#U?1]:FM-,\;DRK97MY<R1@*47RW1=X5]K9R,$],\$5Z?
MXHUS3?A/^S=J_@[7_&5CXGUZZAEALX8;CS7"N0% !);:O)!. ,8'0"OBPH",
M'GZT! .G3VKYJMD[KUO:2JODYE*UKZKL^A]'0SA8>A[.-)<_*XWUV?==7YL4
M4M%%?2H^<UZA1110 4444 %%%% !2;@.O%+C) ! )..:^EO@7^R?=ZU);ZYX
MVA:STSAXM(;*S3Y&09"""B\_=^\<'H.O!C<=0P%/VE:5O+J_)?UZGHX' 8C,
M*JI4(W[OHO-_UZ'!? ;X ZC\6]16\NA+8>&8'Q/>$#=,P()BC]R#RV,#W/!^
M]-"T+3_#.CVFE:7:I9Z?:1B*&"/HJCW/)/<DY)))/-3V-A;:79PVEG;Q6EI"
MH2*"! B(H[!1P!4]?D699I6S*I>6D5LOZW9^S93E%'*Z=HZS>[_K9!1117C'
MOA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MR?\ "*XCO/\ A-=5@:&-5:/38Y!@N6&&EQZ8)4>N2?3/U)354(H50% & !T
MIU,AZA1113 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "K6E?\A"#_>JK5K2O^0A!_O4 =-J7_'C<_[AKCZ[#4O^/&Y_
MW#7'TD#"BBBF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 5HZ!_R$5_W36=6CH'_(17_=- &OKO\ R#9/J/YUR]=1KO\ R#9/J/YUR])
MPHHHI@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110!+:_\?4/^^/YUU]Q_P >\G^Z?Y5R%K_Q
M]0_[X_G77W'_ ![R?[I_E28'%T444P"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KH_#?_'C)_UT
M/\A7.5T?AO\ X\9/^NA_D*3!%+Q)_P ?<7^Y_4UDUK>)/^/N+_<_J:R: "BB
MBF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MBBBN4[ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M54D[<$_[.#^-<=^T/\5KKX7>$H'TQ5_M;49&A@D<;EA4#+/CN1D  \<Y/3!
M/5:*^#/!'QT\;:;XRL+J;7K_ %.*:X1)K.YE:2.1"P!54/"G!X*@<U]YT#:L
M%%%%,04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %6M*_Y"$'^]56K6E?
M\A"#_>H Z;4O^/&Y_P!PUQ]=AJ7_ !XW/^X:X^D@84444P"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "M'0/^0BO^Z:SJT= _Y"*_[IH
MU]=_Y!LGU'\ZY>NHUW_D&R?4?SKEZ2!A1113 **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"
M6U_X^H?]\?SKK[C_ (]Y/]T_RKD+7_CZA_WQ_.NON/\ CWD_W3_*DP.+HHHI
M@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !71^&_^/&3_KH?Y"N<KH_#?_'C)_UT/\A28(I>)/\
MC[B_W/ZFLFM;Q)_Q]Q?[G]3630 4444P"BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH FL?\
MC]M_^NB_SKT-ONGZ5YY8_P#'[;_]=%_G7H;?=/TJ67$QJ***1J%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 5Y_\1_@5X0^*&Z;5]-$>H[2
MJ:A:-Y<R_7'#_P# @?:O0**UI5:E&2G3DT_(PK4*>(A[.K%27F?#'Q&_9"\6
M>$!]IT(_\)58@%F^S(([A,#O&6.[VV%CQT%>'7$,MI/)!/%)#/&Q1XY%*LK#
MJ"#T-?JQ7)>._A3X6^)%MY>O:3#<RC_5W:#RYXS@@8<<XYZ'(X&0:^TP7%%6
MG[N*CS+NM']VWY'PF/X2I5/>P<N5]GJOOW_,_-$'-%?3?CS]B?4[$7%UX3U>
M/48ERR6%\!'-CLHD'RL?J$%?.NO>&=8\+7OV36-,NM,NNHBNH6C+#.,C(Y&>
MXS7W6$S'"XU7HSOY=3\^QF6XO .U>%O/HS.HH'2BO2/,"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBMKPOX)U_QM>BVT+2;O4Y-P5C;Q$K'D\;F
MZ*/<D#@UG.I&FG*;LC2$)U)<L%=LQ21^'K4^GZ==ZO?16=C:3WMU*VV.&",N
MS-Z #DU]1^ ?V)9&>&Z\8:PJQ\,VGZ9U_P!UI3T]]H/L>]?2'@_X?>'/ -D+
M70-(MM.3&&DC3,LG?YY#EFZ]R?2ODL9Q-AJ'NT%SO[E]_P#E]Y]C@>%L7B/>
MQ#]FOO?W?YGR;\-_V-]?U\Q77BJ<:!8ALFU0K)=2+QZ':F1ZDD'JM?47@#X0
M^%/AE 5T'2HX+AAB2\E/F3O[%SR![# ]J[&BO@L;FN*QVE67N]EHO^#\S]%P
M.38/+]:4+R[O5_\  ^04445Y![@4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %.B_UJ?44VG1?ZU/J* .FHHHH("BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ K#\;_P#(H:Q_UZO_ "K<K#\;_P#(H:Q_UZO_ "IK<3V9\H44
M45U'FA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !7K7@[_ )%JQ_W3_P"A&O):]:\'?\BU8_[I_P#0C42V-:>YLT44
M5D=(4444 %%%% !1110 4444 %%%% !1110!R7Q3\=P_#CP1J.MR;7FC3R[:
M)O\ EI,W"#Z9Y/L#7YY7MY-J-Y/=W,K37,\C2RR-U=V.23[DDFO:OVJ_B/\
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MOVP;>QN);/PCIZ7^W*_VA>[EC)_V8Q@D>Y(^E K7/I2BO@V__:5^(E_.9/\
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MGVB7_GH__?1H^T2_\]'_ .^C4=% $GVB7_GH_P#WT:/M$O\ ST?_ +Z-1T4
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MZ-1T4 2?:)?^>C_]]&C[1+_ST?\ [Z-1T4 2?:)?^>C_ /?1H^T2_P#/1_\
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M]HE_YZ/_ -]&HZ* )/M$O_/1_P#OHT?:)?\ GH__ 'T:CHH D^T2_P#/1_\
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M_P!]&C[1+_ST?_OHU'10!)]HE_YZ/_WT:/M$O_/1_P#OHU'10!)]HE_YZ/\
M]]&C[1+_ ,]'_P"^C4=% $GVB7_GH_\ WT:/M$O_ #T?_OHU'10!)]HE_P">
MC_\ ?1H^T2_\]'_[Z-1T4 2?:)?^>C_]]&C[1+_ST?\ [Z-1T4 2?:)?^>C_
M /?1H^T2_P#/1_\ OHU'10!)]HE_YZ/_ -]&C[1+_P ]'_[Z-1T4 2?:)?\
MGH__ 'T:/M$O_/1_^^C4=% %RVUB^LV!AO)H\=@YQ^5=/H_Q#FB=8]1031]/
M.C&&'N1T/Z5QE%*R92DUL>VVMW#>P)-!(LL3#(93Q4U>5>$_$;Z'?*DC$V<I
MQ(O]T_WA_GI7J@(8 @@@\@CO6+5CIC+F0M%%%(L**** "BBB@ HHHH ****
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M* "BBB@ HHHH **** "G1?ZU/J*;3HO]:GU% '34444$!1110 4444 %%%%
M!1110 4444 %%%% !1110 5A^-_^10UC_KU?^5;E8?C?_D4-8_Z]7_E36XGL
MSY0HHHKJ/-"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "O6O!W_(M6/^Z?_0C7DM>M>#O^1:L?]T_^A&HEL:T]S9HH
MHK(Z0HHHH **** "BBB@ HHHH **** "N#^-/Q$3X:^ K[4D8?VA*/LUDA[S
M,#AL>B@%C],=Z[ROAW]ICXD?\)SX]EL;28OI.D;K:( _*\N?WC_F-H/HH/>D
M-*YY_P"#?#%[X_\ &&GZ/;LSW5_/AYFRQ4=7D;UP 2?I7W!\2?!MI;_!'6]
MT^$+:V>EL((SR?W2[U^I)0<]S7FO[(?PY_LW1[OQ;>P[;F^S!9[QRL(/S./]
MYACZ+[U]#W5LE[:S6\HS'*AC8>H(P?YT(;>I^9NEW[Z5J=G>Q<R6TR3)SCE6
M!'\J_3*VN8[RVBGB.Z*5 Z'U!&17YFZI82:5J5W92_ZVVF>%^,?,K$'^5?H%
M\%]8.O?"GPO=EM[?88X68=VC'ED_7*&D@D=K7->+OASX<\>/:MK^EIJ1M0PA
M\QW79NQNQM(Z[1^5=+15$GG/_#/'P[_Z%BW_ ._TO_Q=>,_M#:5\.?AQIG]D
M:/X=M&\27:9#>;(PM(S_ !D;_O'^$'ZGT/M/QG^+ME\*?#;392XUFY!2RM"?
MO'N[?[*_J<#OD?$%G9ZY\3/%XBC$NJ:WJ<^6=NK,>K$]E _  >@I,I%GX<_#
M[4_B7XF@TC3$P6^>>X8?)!&#R[?T'<X%?H#X0\+67@KPUIVB:>&%I91"-"YR
MS')+,?<DDGZU@?"7X6V'PJ\,)I]MMGOI<27EYC!FD]O11T _'J34OQA\5MX+
M^&FOZK$_EW,=N8H&SR)'(12/H6!_"@3=SYB_:9^,DOC+7YO#FF3E="T^4I*4
M.!<S*<$GU53P!Z@GTQ%\"_V=IOB1"-:UJ66QT -B)8L"6Z(.#M)^ZH(P3CGH
M/4>*KM:1=Y8*3\Q R<=Z^K]'_:X\'Z%I5GIUEX?U6*TM(EAB0"+A5&!_%[4B
MGHM#U&P^ _@#3[401^%[&10NW?.IE<^^YB3FO)OCE^S/I%GX=O?$'A2%K&>R
MC:>XT_>7CDC'+%,DE6 R<9P<8 !K4_X;-\,_] /5O_(7_P 75;4OVP_#5[IU
MW;#0]4S-$\8W^7CE2.?FZ<T]!:GS%X0\3W?@SQ-IVM6+E;FRF$@&<!Q_$I]F
M&0?8U^D5C>1ZC96]U"<PSQK*A/=6&1^AK\QJ_27P3"]OX,T"*0;9(]/MT8>A
M$:@TD$CQG]LK6#:^!M&TY6VF[O\ S&'JL:'C\W4UXY^RQH_]J_&+3I2I9+&"
M:Z([?<V G\9!^E=5^V=K'VCQCH.F!B1:V+3D9X!D<C\\1C]*O?L6:/YFK^)M
M5*C]S!#:JQZ_.S,P'_?M?THZAT/JRO@3]H76/[:^,7B24,"D,RVJ@=O+14(_
M,'\Z^^7=8D9W(5%!))Z 5^:'B#5&US7M2U%R2]Y<R7#%N22[EN?SH81/L?\
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M;)/'ME%KWB&26RT63FWMXCMEN0#][)^ZG4>I[8X)^C;3X%> ;&U%O'X6T]T
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/L[9;]:ZVBBO$G4G4?--MOS/>ITH4H\M.*2\E8****@U"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "G1?ZU/J
M*;3HO]:GU% '34444$!1110 4444 %%%% !1110 4444 %%%% !1110 5A^-
M_P#D4-8_Z]7_ )5N5A^-_P#D4-8_Z]7_ )4UN)[,^4****ZCS0HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M81_Y#KY>^!&CG7/B]X7M]NX)=BY/_;(&3_V2A@MC[^MK:.SMHH(AMBB0(@]
M!@5X3^V+K'V/X>:;IZD!KV_4MD]41&)_4I7O=?)O[:.L>=XC\.:6'.+>UDN2
MG;,C[0?_ "$?\FFQ+<X;]F+1_P"UOC'H[,,QV:373#'I&0O_ (\RU]UU\F?L
M7:/YWB7Q'JA7BWM([8-_UT?=_P"TJ^LZ$#W"OS,UN1Y=:U!Y"3(UQ(S$CJ=Q
MS7Z9U^?OQT\&S^"?B;K-L\92VNIFO;5NS12,6&/H<K_P&ACB?7_[/T\%S\'/
M##6Y&Q;<HV.S!V#?J#7H=?%W[/7Q\B^&XDT/7%D?09Y/-2>-2S6KGJ=O4J<
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %6M*_Y"$'^]56K6E?\A"#_>H TO'/_(H:O_U[/_*O
MG"OH_P <_P#(H:O_ ->S_P J^<*TAL85=T%%%%:& 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %>B?#7_D%77_7;_P!E%>=UZ)\-?^05=?\ 7;_V45$MC2G\1U]%%%9'
M4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5T?AO_CQD_ZZ'^0KG*Z/PW_QXR?]=#_(4F"*7B3_
M (^XO]S^IK)K6\2?\?<7^Y_4UDT %%%%, HHHH **** "BBB@ HHHH ****
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M)?@?FW_PI+Q__P!"?K'_ (!O_A2?\*1\?_\ 0GZQ_P" C_X5^DM%5_K7B/\
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M;9W4\'AJ/\.G%>B2&QHL2[44(O8*,"G445S'6E8****!A1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %.B_UJ?44VG1?ZU/J* .FHHHH("BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ K#\;_ /(H:Q_UZO\ RK<K#\;_ /(H:Q_UZO\
MRIK<3V9\H4445U'FA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*3*Q48PC$CY=_/\ C7T]118+Z6"OE3X_?!SQWX_^)5[J6E:&;K35AB@@F-Y
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M/*;N!\*C!ONJY)R0!P.]?9M%(=[!1113$%%%% !1110 4444 %%%% !1110
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M=@E3 D9+@C@Y';%*X[,J45>U?1+[0;H6^H6SVLY0.(WQG:<X/Z&J-,04444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5Z)\-?^05=?\ 7;_V45YW7HGP
MU_Y!5U_UV_\ 9142V-*?Q'7T445D=04444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !71^&_\ CQD_
MZZ'^0KG*Z/PW_P >,G_70_R%)@BEXD_X^XO]S^IK)K6\2?\ 'W%_N?U-9- !
M1113 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@":Q_X_;?_ *Z+_.O0V^Z?I7GEC_Q^V_\
MUT7^=>AM]T_2I9<3&HHHI&H4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !3HO]:GU%-IT7^M3ZB@#IJ***" HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *P_&_\ R*&L?]>K_P JW*P_&_\ R*&L?]>K_P J:W$]
MF?*%%%%=1YH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8^S3DSP[6;M+_5[ZYC^Y-.\BY]"Q(_G7O_P._P"1$C_Z^)/YBOG2OHOX'?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *]$^&O\ R"KK_KM_[**\[KT3X:_\@JZ_
MZ[?^RBHEL:4_B.OHHHK(Z@HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "NC\-_\ 'C)_UT/\A7.5
MT?AO_CQD_P"NA_D*3!%+Q)_Q]Q?[G]3636MXD_X^XO\ <_J:R: "BBBF 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% $UC_Q^V__ %T7^=>AM]T_2O/+'_C]M_\ KHO\Z]#;
M[I^E2RXF-1112-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "G1?ZU/J*;3HO\ 6I]10!TU%%%! 4444 %%%% !1110 4444 %%%% !
M1110 4444 %8?C?_ )%#6/\ KU?^5;E8?C?_ )%#6/\ KU?^5-;B>S/E"BBB
MNH\T**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *]:\'?\ (M6/^Z?_ $(UY+7K7@[_ )%JQ_W3_P"A&HEL:T]S9HHH
MK(Z0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *M:5_R$(/\ >JK5K2O^0A!_O4 :7CG_ )%#5_\ KV?^
M5?.%?1_CG_D4-7_Z]G_E7SA6D-C"KN@HHHK0P"BBB@ HHHH ^B_@=_R(D?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MRBBB@84444 %%?F]_P $M?BMXV^(/Q<^+-GXI\8:_P");2RAC-K;ZQJD]W'
M3<2 [%D8A> !QV%?I#0(****!A1110 445^<?_!,KXJ^-?'WQW^,&G^)O&&O
M^(["Q3-I:ZMJ<]U%;_Z4Z_NUD8A> !P!P,4"/T<HHHH&%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %.B_UJ?44VG1?ZU/J* .
MFHHHH("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K#\;_P#(H:Q_UZO_
M "K<K#\;_P#(H:Q_UZO_ "IK<3V9\H4445U'FA1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7K7@[_ )%JQ_W3_P"A
M&O):]:\'?\BU8_[I_P#0C42V-:>YLT445D=(4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %6M*_Y"$'^]
M56K6E?\ (0@_WJ -+QS_ ,BAJ_\ U[/_ "KYPKZ/\<_\BAJ__7L_\J^<*TAL
M85=T%%%%:& 4444 %%%% 'M'PJ^(7A_PWX32RU&_^SW(F=BGDR-P<8Y52*[#
M_A</A#_H+_\ DM-_\17S/16;@F;*K)*Q]*R?&/PDB%EU1I"/X5MI<G\UQ7 >
M._C6VL6<NGZ)%+:P2 K)=2<2,O<*!TSZYS]*\IHIJ"0.K)JP5[1\*OB%X?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "O1/AK_P @JZ_Z[?\ LHKS
MNO1/AK_R"KK_ *[?^RBHEL:4_B.OHHHK(Z@HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "NC\-_\
M>,G_ %T/\A7.5T?AO_CQD_ZZ'^0I,$4O$G_'W%_N?U-9-:WB3_C[B_W/ZFLF
M@ HHHI@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!-8_P#'[;_]=%_G7H;?=/TKSRQ_X_;?
M_KHO\Z]#;[I^E2RXF-1112-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MW>+SKCD@-UP0#C(H ^Q_V^_^3._BC_V#!_Z.CKSG_@D__P F@:7_ -A:^_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *]:\'?\BU8_[I_]"->2UZUX._Y%JQ_W3_Z$:B6QK3W-FBBB
MLCI"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ JUI7_(0@_WJJU:TK_D(0?[U &EXY_Y%#5_^O9_Y5\X5
M]'^.?^10U?\ Z]G_ )5\X5I#8PJ[H****T, HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *]&^&Z,NCW#'HTY _!5KSH#/ Y)KUWPSIITG1;:!QB7&]_9CSC\.GX5$MC6
MFM35HHHK(Z0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "NC\-_\>,G_ %T/\A7.5T?AO_CQD_ZZ
M'^0I,$4O$G_'W%_N?U-9-:WB3_C[B_W/ZFLF@ HHHI@%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MK7>_M5_LK^&/VKOA_%X?UZ:73-0LI3<:9K%L@>6SE(PWRG&]& &Y,C.U3D$
M@ ]#^'/@;PG\/?"6GZ3X+TG3M(T!(E-O%IJ*(W4CA]P^^2.=Y)+9R2<YK\X_
M^"R?B#P2]MX-T2S;2Y/'D=Y)=WPMXD-W':F$*OG.!N 8[-JL>0F<8 IWAO\
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M0 4444 %%%% !1110 4Z+_6I]13:=%_K4^HH Z:BBB@@**** "BBB@ HHHH
M**** "BBB@ HHHH **** "L/QO\ \BAK'_7J_P#*MRL/QO\ \BAK'_7J_P#*
MFMQ/9GRA11174>:%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %>M>#O^1:L?\ =/\ Z$:\EKUKP=_R+5C_ +I_]"-1
M+8UI[FS11161TA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5:TK_ )"$'^]56K6E?\A"#_>H TO'/_(H
M:O\ ]>S_ ,J^<*^E?%UK)>^&-3@A :62!E49QDXKPK_A!-9_Y]T_[^K_ (U<
M'H8U4VU8Y^BN@_X036?^?=/^_J_XT?\ "":S_P ^Z?\ ?U?\:TNC'E?8Y^BN
M@_X036?^?=/^_J_XT?\ "":S_P ^Z?\ ?U?\:+H.5]CGZ*Z#_A!-9_Y]T_[^
MK_C1_P ()K/_ #[I_P!_5_QHN@Y7V.?HKH/^$$UG_GW3_OZO^-'_  @FL_\
M/NG_ ']7_&BZ#E?8Y^BN@_X036?^?=/^_J_XT?\ "":S_P ^Z?\ ?U?\:+H.
M5]CGZ*Z#_A!-9_Y]T_[^K_C1_P ()K/_ #[I_P!_5_QHN@Y7V.?HKH/^$$UG
M_GW3_OZO^-'_  @FL_\ /NG_ ']7_&BZ#E?8Y^BN@_X036?^?=/^_J_XT?\
M"":S_P ^Z?\ ?U?\:+H.5]CGZ*Z#_A!-9_Y]T_[^K_C1_P ()K/_ #[I_P!_
M5_QHN@Y7V.?HKH/^$$UG_GW3_OZO^-'_  @FL_\ /NG_ ']7_&BZ#E?8Y^BN
M@_X036?^?=/^_J_XT?\ "":S_P ^Z?\ ?U?\:+H.5]CGZ*Z#_A!-9_Y]T_[^
MK_C1_P ()K/_ #[I_P!_5_QHN@Y7V.?HKH/^$$UG_GW3_OZO^-'_  @FL_\
M/NG_ ']7_&BZ#E?8Y^BN@_X036?^?=/^_J_XT?\ "":S_P ^Z?\ ?U?\:+H.
M5]CGZ*Z#_A!-9_Y]T_[^K_C1_P ()K/_ #[I_P!_5_QHN@Y7V.?HKH/^$$UG
M_GW3_OZO^-'_  @FL_\ /NG_ ']7_&BZ#E?8Y^BN@_X036?^?=/^_J_XT?\
M"":S_P ^Z?\ ?U?\:+H.5]CGZ*Z#_A!-9_Y]T_[^K_C1_P ()K/_ #[I_P!_
M5_QHN@Y7V.?HKH/^$$UG_GW3_OZO^-'_  @FL_\ /NG_ ']7_&BZ#E?8Y^BN
M@_X036?^?=/^_J_XT?\ "":S_P ^Z?\ ?U?\:+H.5]CGZ*Z#_A!-9_Y]T_[^
MK_C1_P ()K/_ #[I_P!_5_QHN@Y7V.?HKH/^$$UG_GW3_OZO^-'_  @FL_\
M/NG_ ']7_&BZ#E?8Y^BN@_X036?^?=/^_J_XT?\ "":S_P ^Z?\ ?U?\:+H.
M5]CGZ*Z#_A!-9_Y]T_[^K_C1_P ()K/_ #[I_P!_5_QHN@Y7V.?HKH/^$$UG
M_GW3_OZO^-'_  @FL_\ /NG_ ']7_&BZ#E?8Y^BN@_X036?^?=/^_J_XT?\
M"":S_P ^Z?\ ?U?\:+H.5]CGZ*Z#_A!-9_Y]T_[^K_C1_P ()K/_ #[I_P!_
M5_QHN@Y7V.?HKH/^$$UG_GW3_OZO^-'_  @FL_\ /NG_ ']7_&BZ#E?8Y^BN
M@_X036?^?=/^_J_XT?\ "":S_P ^Z?\ ?U?\:+H.5]CGZ*Z#_A!-9_Y]T_[^
MK_C1_P ()K/_ #[I_P!_5_QHN@Y7V.?HKH/^$$UG_GW3_OZO^-'_  @FL_\
M/NG_ ']7_&BZ#E?8Y^BN@_X036?^?=/^_J_XT?\ "":S_P ^Z?\ ?U?\:+H.
M5]CGZ*Z#_A!-9_Y]T_[^K_C1_P ()K/_ #[I_P!_5_QHN@Y7V.?HKH/^$$UG
M_GW3_OZO^-'_  @FL_\ /NG_ ']7_&BZ#E?8Y^BN@_X036?^?=/^_J_XT?\
M"":S_P ^Z?\ ?U?\:+H.5]CGZ*Z#_A!-9_Y]T_[^K_C1_P ()K/_ #[I_P!_
M5_QHN@Y7V.?HKH/^$$UG_GW3_OZO^-'_  @FL_\ /NG_ ']7_&BZ#E?8Y^BN
M@_X036?^?=/^_J_XT?\ "":S_P ^Z?\ ?U?\:+H.5]CGZ*Z#_A!-9_Y]T_[^
MK_C1_P ()K/_ #[I_P!_5_QHN@Y7V.?HKH/^$$UG_GW3_OZO^-'_  @FL_\
M/NG_ ']7_&BZ#E?8Y^BN@_X036?^?=/^_J_XT?\ "":S_P ^Z?\ ?U?\:+H.
M5]CGZ*Z#_A!-9_Y]T_[^K_C1_P ()K/_ #[I_P!_5_QHN@Y7V.?HKH/^$$UG
M_GW3_OZO^-'_  @FL_\ /NG_ ']7_&BZ#E?8Y^BN@_X036?^?=/^_J_XT?\
M"":S_P ^Z?\ ?U?\:+H.5]CGZ*Z#_A!-9_Y]T_[^K_C1_P ()K/_ #[I_P!_
M5_QHN@Y7V.?HKH/^$$UG_GW3_OZO^-'_  @FL_\ /NG_ ']7_&BZ#E?8Y^BN
M@_X036?^?=/^_J_XT?\ "":S_P ^Z?\ ?U?\:+H.5]CGZ*Z#_A!-9_Y]T_[^
MK_C1_P ()K/_ #[I_P!_5_QHN@Y7V.?HKH/^$$UG_GW3_OZO^-'_  @FL_\
M/NG_ ']7_&BZ#E?8Y^BN@_X036?^?=/^_J_XT?\ "":S_P ^Z?\ ?U?\:+H.
M5]CGZ*Z#_A!-9_Y]T_[^K_C1_P ()K/_ #[I_P!_5_QHN@Y7V.?HKH/^$$UG
M_GW3_OZO^-'_  @FL_\ /NG_ ']7_&BZ#E?8Y^BN@_X036?^?=/^_J_XT?\
M"":S_P ^Z?\ ?U?\:+H.5]CGZ*Z#_A!-9_Y]T_[^K_C1_P ()K/_ #[I_P!_
M5_QHN@Y7V.?HKH/^$$UG_GW3_OZO^-'_  @FL_\ /NG_ ']7_&BZ#E?8Y^BN
M@_X036?^?=/^_J_XU+;?#O7+N7RXK9"V,X,JC^M%T'*^QS5%=9<?"[Q#:Q&2
M2TC"#OYR'^M4_P#A!-9_Y]T_[^K_ (TKH.5]CGZ*Z#_A!-9_Y]T_[^K_ (T?
M\()K/_/NG_?U?\:=T'*^QS]%=!_P@FL_\^Z?]_5_QH_X036?^?=/^_J_XT70
M<K['/T5T'_"":S_S[I_W]7_&C_A!-9_Y]T_[^K_C1=!ROL<_170?\()K/_/N
MG_?U?\:/^$$UG_GW3_OZO^-%T'*^QS]%=!_P@FL_\^Z?]_5_QH_X036?^?=/
M^_J_XT70<K['/T5T'_"":S_S[I_W]7_&C_A!-9_Y]T_[^K_C1=!ROL<_170?
M\()K/_/NG_?U?\:/^$$UG_GW3_OZO^-%T'*^QS]%=!_P@FL_\^Z?]_5_QH_X
M036?^?=/^_J_XT70<K['/T5T'_"":S_S[I_W]7_&C_A!-9_Y]T_[^K_C1=!R
MOL<_170?\()K/_/NG_?U?\:/^$$UG_GW3_OZO^-%T'*^QS]%=!_P@FL_\^Z?
M]_5_QH_X036?^?=/^_J_XT70<K['/T5T'_"":S_S[I_W]7_&C_A!-9_Y]T_[
M^K_C1=!ROL<_170?\()K/_/NG_?U?\:/^$$UG_GW3_OZO^-%T'*^QS]%=!_P
M@FL_\^Z?]_5_QH_X036?^?=/^_J_XT70<K['/T5T'_"":S_S[I_W]7_&C_A!
M-9_Y]T_[^K_C1=!ROL<_170?\()K/_/NG_?U?\:/^$$UG_GW3_OZO^-%T'*^
MQS]%=!_P@FL_\^Z?]_5_QH_X036?^?=/^_J_XT70<K['/T5T'_"":S_S[I_W
M]7_&C_A!-9_Y]T_[^K_C1=!ROL<_170?\()K/_/NG_?U?\:/^$$UG_GW3_OZ
MO^-%T'*^QS]%=!_P@FL_\^Z?]_5_QH_X036?^?=/^_J_XT70<K['/T5T'_""
M:S_S[I_W]7_&C_A!-9_Y]T_[^K_C1=!ROL<_170?\()K/_/NG_?U?\:/^$$U
MG_GW3_OZO^-%T'*^QS]%=!_P@FL_\^Z?]_5_QH_X036?^?=/^_J_XT70<K['
M/T5T'_"":S_S[I_W]7_&C_A!-9_Y]T_[^K_C1=!ROL<_170?\()K/_/NG_?U
M?\:/^$$UG_GW3_OZO^-%T'*^QS]%=!_P@FL_\^Z?]_5_QH_X036?^?=/^_J_
MXT70<K['/T5T'_"":S_S[I_W]7_&C_A!-9_Y]T_[^K_C1=!ROL<_170?\()K
M/_/NG_?U?\:/^$$UG_GW3_OZO^-%T'*^QS]%=!_P@FL_\^Z?]_5_QH_X036?
M^?=/^_J_XT70<K['/T5T'_"":S_S[I_W]7_&C_A!-9_Y]T_[^K_C1=!ROL<_
M170?\()K/_/NG_?U?\:/^$$UG_GW3_OZO^-%T'*^QS]%=!_P@FL_\^Z?]_5_
MQH_X036?^?=/^_J_XT70<K['/T5T'_"":S_S[I_W]7_&C_A!-9_Y]T_[^K_C
M1=!ROL<_170?\()K/_/NG_?U?\:/^$$UG_GW3_OZO^-%T'*^QS]%=!_P@FL_
M\^Z?]_5_QH_X036?^?=/^_J_XT70<K['/T5T'_"":S_S[I_W]7_&C_A!-9_Y
M]T_[^K_C1=!ROL<_170?\()K/_/NG_?U?\:/^$$UG_GW3_OZO^-%T'*^QS]%
M=!_P@FL_\^Z?]_5_QH_X036?^?=/^_J_XT70<K['/T5T'_"":S_S[I_W]7_&
MC_A!-9_Y]T_[^K_C1=!ROL<_171)X"UEW55MTRQP/WJ_XU=;X4>)%4L;./ &
M3^_3_&BZ#E?8Y"BN@_X036?^?=/^_J_XT?\ "":S_P ^Z?\ ?U?\:+H.5]CG
MZ*Z#_A!-9_Y]T_[^K_C1_P ()K/_ #[I_P!_5_QHN@Y7V.?HKH/^$$UG_GW3
M_OZO^-'_  @FL_\ /NG_ ']7_&BZ#E?8Y^BN@_X036?^?=/^_J_XT?\ "":S
M_P ^Z?\ ?U?\:+H.5]CGZ*Z#_A!-9_Y]T_[^K_C1_P ()K/_ #[I_P!_5_QH
MN@Y7V.?HKH/^$$UG_GW3_OZO^-'_  @FL_\ /NG_ ']7_&BZ#E?8Y^BN@_X0
M36?^?=/^_J_XT?\ "":S_P ^Z?\ ?U?\:+H.5]CGZ*Z#_A!-9_Y]T_[^K_C1
M_P ()K/_ #[I_P!_5_QHN@Y7V.?HKH/^$$UG_GW3_OZO^-'_  @FL_\ /NG_
M ']7_&BZ#E?8Y^BNHMOAYJ<Q'FF&!>^Y\G]*Z?1_ MCIC++-F\F'(,@PH/LO
M^.:GF0U"3,3P5X3>66/4;Q-L2_-%&PY8]F/MZ>O\^_HHK-NYTQBHJP4444B@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "NC\-_\>,G_70_R%<Y71^&_P#CQD_ZZ'^0I,$4O$G_
M !]Q?[G]3636MXD_X^XO]S^IK)H ****8!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 36/_
M !^V_P#UT7^=>AM]T_2O/+'_ (_;?_KHO\Z]#;[I^E2RXF-1112-0HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "G1?ZU/J*;3HO]:GU
M% '34444$!1110 4444 %%%% !1110 4444 %%%% !1110 5A^-_^10UC_KU
M?^5;E8?C?_D4-8_Z]7_E36XGLSY0HHHKJ/-"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "O6O!W_(M6/\ NG_T(UY+
M7K7@[_D6K'_=/_H1J);&M/<V:***R.D**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "K6E?\A"#_>JK5K2
MO^0A!_O4 =-J7_'C<_[AKCZ[#4O^/&Y_W#7'TD#"BBBF 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 5HZ!_R$5_W36=6CH'_(17_=- &O
MKO\ R#9/J/YUR]=1KO\ R#9/J/YUR]) PHHHI@%%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M!+:_\?4/^^/YUU]Q_P >\G^Z?Y5R%K_Q]0_[X_G77W'_ ![R?[I_E28'%T44
M4P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ KH_#?_'C)_UT/\A7.5T?AO\ X\9/^NA_D*3!%+Q)
M_P ?<7^Y_4UDUK>)/^/N+_<_J:R: "BBBF 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $UC
M_P ?MO\ ]=%_G7H;?=/TKSRQ_P"/VW_ZZ+_.O0V^Z?I4LN)C4444C4**** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IT7^M3ZBFTZ+_6I
M]10!TU%%%! 4444 %%%% !1110 4444 %%%% !1110 4444 %8?C?_D4-8_Z
M]7_E6Y6'XW_Y%#6/^O5_Y4UN)[,^4****ZCS0HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KUKP=_R+5C_ +I_]"->
M2UZUX._Y%JQ_W3_Z$:B6QK3W-FBBBLCI"BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JUI7_(0@_WJJU:
MTK_D(0?[U '3:E_QXW/^X:X^NPU+_CQN?]PUQ]) PHHHI@%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %:.@?\A%?]TUG5HZ!_R$5_W30!
MKZ[_ ,@V3ZC^=<O74:[_ ,@V3ZC^=<O20,****8!1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 2VO_'U#_OC^==?<?\ 'O)_NG^5<A:_\?4/^^/YUU]Q_P >\G^Z?Y4F!Q=%
M%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *Z/PW_QXR?]=#_(5SE='X;_ ./&3_KH?Y"DP12\
M2?\ 'W%_N?U-9-:WB3_C[B_W/ZFLF@ HHHI@%%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!-
M8_\ '[;_ /71?YUZ&WW3]*\\L?\ C]M_^NB_SKT-ONGZ5++B8U%%%(U"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *=%_K4^HIM.B_U
MJ?44 =-11100%%%% !1110 4444 %%%% !1110 4444 %%%% !6'XW_Y%#6/
M^O5_Y5N5A^-_^10UC_KU?^5-;B>S/E"BBBNH\T**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *]:\'?\BU8_P"Z?_0C
M7DM>M>#O^1:L?]T_^A&HEL:T]S9HHHK(Z0HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *M:5_R$(/]ZJM
M6M*_Y"$'^]0!TVI?\>-S_N&N/KL-2_X\;G_<-<?20,****8!1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !6CH'_(17_=-9U:.@?\A%?]TT
M :^N_P#(-D^H_G7+UU&N_P#(-D^H_G7+TD#"BBBF 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% $MK_Q]0_[X_G77W'_ ![R?[I_E7(6O_'U#_OC^==?<?\ 'O)_NG^5)@<7
M1113 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "NC\-_\>,G_70_R%<Y71^&_P#CQD_ZZ'^0I,$4
MO$G_ !]Q?[G]3636MXD_X^XO]S^IK)H ****8!1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M36/_ !^V_P#UT7^=>AM]T_2O/+'_ (_;?_KHO\Z]#;[I^E2RXF-1112-0HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "G1?ZU/J*;3HO
M]:GU% '34444$!1110 4444 %%%% !1110 4444 %%%% !1110 5A^-_^10U
MC_KU?^5;E8?C?_D4-8_Z]7_E36XGLSY0HHHKJ/-"BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O6O!W_(M6/\ NG_T
M(UY+7K7@[_D6K'_=/_H1J);&M/<V:***R.D**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/^%E6/\ SZW'_CO^-'*PYX]SKZ*Y#_A95C_SZW'_ ([_ (T?\+*L?^?6X_\
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MK'_GUN/_ !W_ !HY6'/'N=?17(?\+*L?^?6X_P#'?\:/^%E6/_/K<?\ CO\
MC1RL.>/<Z^BN0_X658_\^MQ_X[_C1_PLJQ_Y];C_ ,=_QHY6'/'N=?17(?\
M"RK'_GUN/_'?\:/^%E6/_/K<?^._XT<K#GCW.OHKD/\ A95C_P ^MQ_X[_C1
M_P +*L?^?6X_\=_QHY6'/'N=?17(?\+*L?\ GUN/_'?\:/\ A95C_P ^MQ_X
M[_C1RL.>/<Z^BN0_X658_P#/K<?^._XT?\+*L?\ GUN/_'?\:.5ASQ[G7T5R
M'_"RK'_GUN/_ !W_ !H_X658_P#/K<?^._XT<K#GCW.OHKD/^%E6/_/K<?\
MCO\ C1_PLJQ_Y];C_P =_P :.5ASQ[G7T5R'_"RK'_GUN/\ QW_&C_A95C_S
MZW'_ ([_ (T<K#GCW.OHKD/^%E6/_/K<?^._XT?\+*L?^?6X_P#'?\:.5ASQ
M[G7T5R'_  LJQ_Y];C_QW_&C_A95C_SZW'_CO^-'*PYX]SKZ*Y#_ (658_\
M/K<?^._XT?\ "RK'_GUN/_'?\:.5ASQ[G7T5R'_"RK'_ )];C_QW_&C_ (65
M8_\ /K<?^._XT<K#GCW.OHKD/^%E6/\ SZW'_CO^-'_"RK'_ )];C_QW_&CE
M8<\>YU]%<A_PLJQ_Y];C_P =_P :/^%E6/\ SZW'_CO^-'*PYX]SKZ*Y#_A9
M5C_SZW'_ ([_ (T?\+*L?^?6X_\ '?\ &CE8<\>YU]%<A_PLJQ_Y];C_ ,=_
MQH_X658_\^MQ_P"._P"-'*PYX]SKZ*Y#_A95C_SZW'_CO^-'_"RK'_GUN/\
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MK'_GUN/_ !W_ !HY6'/'N=?17(?\+*L?^?6X_P#'?\:/^%E6/_/K<?\ CO\
MC1RL.>/<Z^BN0_X658_\^MQ_X[_C1_PLJQ_Y];C_ ,=_QHY6'/'N=?17(?\
M"RK'_GUN/_'?\:/^%E6/_/K<?^._XT<K#GCW.OHKD/\ A95C_P ^MQ_X[_C1
M_P +*L?^?6X_\=_QHY6'/'N=?17(?\+*L?\ GUN/_'?\:/\ A95C_P ^MQ_X
M[_C1RL.>/<Z^BN0_X658_P#/K<?^._XT?\+*L?\ GUN/_'?\:.5ASQ[G7T5R
M'_"RK'_GUN/_ !W_ !H_X658_P#/K<?^._XT<K#GCW.OHKD/^%E6/_/K<?\
MCO\ C1_PLJQ_Y];C_P =_P :.5ASQ[G7T5R'_"RK'_GUN/\ QW_&C_A95C_S
MZW'_ ([_ (T<K#GCW.OHKD/^%E6/_/K<?^._XT?\+*L?^?6X_P#'?\:.5ASQ
M[G7T5R'_  LJQ_Y];C_QW_&C_A95C_SZW'_CO^-'*PYX]SKZ*Y#_ (658_\
M/K<?^._XT?\ "RK'_GUN/_'?\:.5ASQ[G7T5R'_"RK'_ )];C_QW_&C_ (65
M8_\ /K<?^._XT<K#GCW.OHKD/^%E6/\ SZW'_CO^-'_"RK'_ )];C_QW_&CE
M8<\>YU]%<A_PLJQ_Y];C_P =_P :/^%E6/\ SZW'_CO^-'*PYX]SKZ*Y#_A9
M5C_SZW'_ ([_ (T?\+*L?^?6X_\ '?\ &CE8<\>YU]%<A_PLJQ_Y];C_ ,=_
MQH_X658_\^MQ_P"._P"-'*PYX]SKZ*Y#_A95C_SZW'_CO^-'_"RK'_GUN/\
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M'_"RK'_GUN/_ !W_ !HY6'/'N=?17(?\+*L?^?6X_P#'?\:/^%E6/_/K<?\
MCO\ C1RL.>/<Z^BN0_X658_\^MQ_X[_C1_PLJQ_Y];C_ ,=_QHY6'/'N=?17
M(?\ "RK'_GUN/_'?\:/^%E6/_/K<?^._XT<K#GCW.OHKD/\ A95C_P ^MQ_X
M[_C1_P +*L?^?6X_\=_QHY6'/'N=?17(?\+*L?\ GUN/_'?\:/\ A95C_P ^
MMQ_X[_C1RL.>/<Z^BN0_X658_P#/K<?^._XT?\+*L?\ GUN/_'?\:.5ASQ[G
M7T5R'_"RK'_GUN/_ !W_ !H_X658_P#/K<?^._XT<K#GCW.OHKD/^%E6/_/K
M<?\ CO\ C1_PLJQ_Y];C_P =_P :.5ASQ[G7T5R'_"RK'_GUN/\ QW_&C_A9
M5C_SZW'_ ([_ (T<K#GCW.OHKD/^%E6/_/K<?^._XT?\+*L?^?6X_P#'?\:.
M5ASQ[G7T5R'_  LJQ_Y];C_QW_&C_A95C_SZW'_CO^-'*PYX]SKZ*Y#_ (65
M8_\ /K<?^._XT?\ "RK'_GUN/_'?\:.5ASQ[G7T5R'_"RK'_ )];C_QW_&C_
M (658_\ /K<?^._XT<K#GCW.OHKD/^%E6/\ SZW'_CO^-'_"RK'_ )];C_QW
M_&CE8<\>YU]%<A_PLJQ_Y];C_P =_P :/^%E6/\ SZW'_CO^-'*PYX]SKZ*Y
M#_A95C_SZW'_ ([_ (T?\+*L?^?6X_\ '?\ &CE8<\>YU]%<A_PLJQ_Y];C_
M ,=_QH_X658_\^MQ_P"._P"-'*PYX]SKZ*Y#_A95C_SZW'_CO^-'_"RK'_GU
MN/\ QW_&CE8<\>YU]%<A_P +*L?^?6X_\=_QH_X658_\^MQ_X[_C1RL.>/<Z
M^BN0_P"%E6/_ #ZW'_CO^-'_  LJQ_Y];C_QW_&CE8<\>YU]%<A_PLJQ_P"?
M6X_\=_QH_P"%E6/_ #ZW'_CO^-'*PYX]SKZ*Y#_A95C_ ,^MQ_X[_C1_PLJQ
M_P"?6X_\=_QHY6'/'N=?17(?\+*L?^?6X_\ '?\ &C_A95C_ ,^MQ_X[_C1R
ML.>/<Z^BN0_X658_\^MQ_P"._P"-'_"RK'_GUN/_ !W_ !HY6'/'N=?17(?\
M+*L?^?6X_P#'?\:/^%E6/_/K<?\ CO\ C1RL.>/<Z^BN0_X658_\^MQ_X[_C
M1_PLJQ_Y];C_ ,=_QHY6'/'N=?17(?\ "RK'_GUN/_'?\:/^%E6/_/K<?^._
MXT<K#GCW.OHKD/\ A95C_P ^MQ_X[_C1_P +*L?^?6X_\=_QHY6'/'N=?17(
M?\+*L?\ GUN/_'?\:/\ A95C_P ^MQ_X[_C1RL.>/<Z^BN0_X658_P#/K<?^
M._XT?\+*L?\ GUN/_'?\:.5ASQ[G7T5R'_"RK'_GUN/_ !W_ !H_X658_P#/
MK<?^._XT<K#GCW.OHKD/^%E6/_/K<?\ CO\ C1_PLJQ_Y];C_P =_P :.5AS
MQ[G7T5R'_"RK'_GUN/\ QW_&C_A95C_SZW'_ ([_ (T<K#GCW.OHKD/^%E6/
M_/K<?^._XT?\+*L?^?6X_P#'?\:.5ASQ[G7T5R'_  LJQ_Y];C_QW_&C_A95
MC_SZW'_CO^-'*PYX]SKZZ/PW_P >,G_70_R%>6_\+*L?^?6X_P#'?\:U=)^,
M&FV%LT;V5TQ+EOEVXZ#W]J'%@IQ[G8>)/^/N+_<_J:R:Y[5OBQIU_.CI9W2@
M+C#;?7ZU1_X658_\^MQ_X[_C1RL.>/<Z^BN0_P"%E6/_ #ZW'_CO^-'_  LJ
MQ_Y];C_QW_&CE8<\>YU]%<A_PLJQ_P"?6X_\=_QH_P"%E6/_ #ZW'_CO^-'*
MPYX]SKZ*Y#_A95C_ ,^MQ_X[_C1_PLJQ_P"?6X_\=_QHY6'/'N=?17(?\+*L
M?^?6X_\ '?\ &C_A95C_ ,^MQ_X[_C1RL.>/<Z^BN0_X658_\^MQ_P"._P"-
M'_"RK'_GUN/_ !W_ !HY6'/'N=?17(?\+*L?^?6X_P#'?\:/^%E6/_/K<?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "G1?ZU/J*;3HO]:GU% '3444
M4$!1110 4444 %%%% !1110 4444 %%%% !1110 5A^-_P#D4-8_Z]7_ )5N
M5A^-_P#D4-8_Z]7_ )4UN)[,^4****ZCS0HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KUKP=_R+5C_NG_ -"->2UZ
MUX._Y%JQ_P!T_P#H1J);&M/<V:***R.D**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "K6E?\ (0@_WJJU
M:TK_ )"$'^]0!I>.?^10U?\ Z]G_ )5\X5]'^.?^10U?_KV?^5?.%:0V,*NZ
M"BBBM# **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4Z+_6I]13:
M=%_K4^HH Z:BBB@@**** "BBB@ HHHH **** "BBB@ HHHH **** "L/QO\
M\BAK'_7J_P#*MRL/QO\ \BAK'_7J_P#*FMQ/9GRA11174>:%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>M>#O^1:
ML?\ =/\ Z$:\EKUKP=_R+5C_ +I_]"-1+8UI[FS11161TA1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
M:TK_ )"$'^]56K6E?\A"#_>H TO'/_(H:O\ ]>S_ ,J^<*^C_'/_ "*&K_\
M7L_\J^<*TAL85=T%%%%:& 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 5O>![@P>)+8 G$@9&]_E)_F!6#6SX._P"1EL?]X_\ H)I/
M8I;H]:HHHK [ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** )K'_C]M_^NB_SKT-O
MNGZ5YY8_\?MO_P!=%_G7H;?=/TJ67$QJ***1J%%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4Z+_ %J?44VG1?ZU/J* .FHHHH("BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ K#\;_\ (H:Q_P!>K_RK<K#\;_\
M(H:Q_P!>K_RIK<3V9\H4445U'FA1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !7K7@[_D6K'_=/_H1KR6O6O!W_ "+5
MC_NG_P!"-1+8UI[FS11161TA1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 5:TK_D(0?[U5:M:5_R$(/\
M>H TO'/_ "*&K_\ 7L_\J^<*^C_'/_(H:O\ ]>S_ ,J^<*TAL85=T%%%%:&
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %;/@[_D9;'_ 'C_
M .@FL:MGP=_R,MC_ +Q_]!-)[#6Z/6J***P.T**** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@":Q_X_;?_ *Z+_.O0V^Z?I7GEC_Q^V_\ UT7^=>AM]T_2I9<3&HHH
MI&H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3HO]:G
MU%-IT7^M3ZB@#IJ***" HHHH **** "BBB@ HHHH **** "BBB@ HHHH *P_
M&_\ R*&L?]>K_P JW*P_&_\ R*&L?]>K_P J:W$]F?*%%%%=1YH4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5ZUX.
M_P"1:L?]T_\ H1KR6O6O!W_(M6/^Z?\ T(U$MC6GN;-%%%9'2%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MON/_ -!:OGJKB[JYG./*[!1115&84444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %;/@[_D9;'_ 'C_ .@FL:MGP=_R,MC_ +Q_]!-)[#6Z/6J***P.T**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@":Q_X_;?_ *Z+_.O0V^Z?I7GEC_Q^V_\ UT7^
M=>AM]T_2I9<3&HHHI&H4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !3HO]:GU%-IT7^M3ZB@#IJ***" HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *P_&_\ R*&L?]>K_P JW*P_&_\ R*&L?]>K_P J:W$]F?*%
M%%%=1YH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5ZUX._P"1:L?]T_\ H1KR6O6O!W_(M6/^Z?\ T(U$MC6GN;-%
M%%9'2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ K9\'?\C+8_[Q_P#036-6SX._Y&6Q_P!X_P#H)I/8:W1ZU1116!VA
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 36/_'[;_\ 71?YUZ&WW3]*\\L?^/VW
M_P"NB_SKT-ONGZ5++B8U%%%(U"BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *=%_K4^HIM.B_P!:GU% '34444$!1110 4444 %%%% !
M1110 4444 %%%% !1110 5A^-_\ D4-8_P"O5_Y5N5A^-_\ D4-8_P"O5_Y4
MUN)[,^4****ZCS0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ KUKP=_P BU8_[I_\ 0C7DM>M>#O\ D6K'_=/_ *$:
MB6QK3W-FBBBLCI"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ JUI7_(0@_P!ZJM6M*_Y"$'^]0!I>.?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !6SX._Y&6Q_WC_Z":QJV?!W_(RV/^\?_032>PUN
MCUJBBBL#M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH FL?^/VW_ .NB_P Z]#;[
MI^E>>6/_ !^V_P#UT7^=>AM]T_2I9<3&HHHI&H4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !3HO]:GU%-IT7^M3ZB@#IJ***" HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *P_&_P#R*&L?]>K_ ,JW*P_&_P#R
M*&L?]>K_ ,J:W$]F?*%%%%=1YH4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 5ZUX._Y%JQ_P!T_P#H1KR6O6O!W_(M
M6/\ NG_T(U$MC6GN;-%%%9'2%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !5K2O\ D(0?[U5:M:5_R$(/
M]Z@#2\<_\BAJ_P#U[/\ RKYPKZ/\<_\ (H:O_P!>S_RKYPK2&QA5W04445H8
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6SX._Y&
M6Q_WC_Z":QJV?!W_ ",MC_O'_P!!-)[#6Z/6J***P.T**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@":Q_P"/VW_ZZ+_.O0V^Z?I7GEC_ ,?MO_UT7^=>AM]T_2I9
M<3&HHHI&H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M3HO]:GU%-IT7^M3ZB@#IJ***" HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *P_&__(H:Q_UZO_*MRL/QO_R*&L?]>K_RIK<3V9\H4445U'FA1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7K7@
M[_D6K'_=/_H1KR6O6O!W_(M6/^Z?_0C42V-:>YLT445D=(4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M6M*_Y"$'^]56K6E?\A"#_>H TO'/_(H:O_U[/_*OG"OH_P <_P#(H:O_ ->S
M_P J^<*TAL85=T%%%%:& 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 5T/@2U-QXCA?&5A5G/Y8'ZD5SU>F^!M";2].:XF7;<7&#M/
M55'0?U_*ID[(N"O(Z:BBBL3K"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH FL?\
MC]M_^NB_SKT-ONGZ5YY8_P#'[;_]=%_G7H;?=/TJ67$QJ***1J%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4Z+_6I]13:=%_K4^HH
MZ:BBB@@**** "BBB@ HHHH **** "BBB@ HHHH **** "L/QO_R*&L?]>K_R
MK<K#\;_\BAK'_7J_\J:W$]F?*%%%%=1YH4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 5ZUX._Y%JQ_W3_Z$:\EKUKP
M=_R+5C_NG_T(U$MC6GN;-%%%9'2%%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !5K2O^0A!_O55JUI7_(0
M@_WJ -+QS_R*&K_]>S_RKYPKZ>UVUCO=&O()06BDB96&<9&*\S_X031O^?=_
M^_K?XU479&52+D]#RVBO4O\ A!-&_P"?=_\ OZW^-'_"":-_S[O_ -_6_P :
MOF1G[.1Y;17J7_"":-_S[O\ ]_6_QH_X031O^?=_^_K?XT<R#V<CRVBO4O\
MA!-&_P"?=_\ OZW^-'_"":-_S[O_ -_6_P :.9![.1Y;17J7_"":-_S[O_W]
M;_&C_A!-&_Y]W_[^M_C1S(/9R/+:*]2_X031O^?=_P#OZW^-'_"":-_S[O\
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MC1_P@FC?\^[_ /?UO\:.9![.1Y;17J7_  @FC?\ /N__ '];_&C_ (031O\
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MX031O^?=_P#OZW^-'_"":-_S[O\ ]_6_QHYD'LY'EM%>I?\ "":-_P ^[_\
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MMHKU+_A!-&_Y]W_[^M_C1_P@FC?\^[_]_6_QHYD'LY'EM%>I?\()HW_/N_\
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MMHKU+_A!-&_Y]W_[^M_C1_P@FC?\^[_]_6_QHYD'LY'EM%>I?\()HW_/N_\
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M;_GW?_OZW^-',@]G(\MHKU+_ (031O\ GW?_ +^M_C1_P@FC?\^[_P#?UO\
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MS(/9R/+:*]2_X031O^?=_P#OZW^-'_"":-_S[O\ ]_6_QHYD'LY'EM%>I?\
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M:.9![.1Y;17J7_"":-_S[O\ ]_6_QH_X031O^?=_^_K?XT<R#V<CRVBO4O\
MA!-&_P"?=_\ OZW^-'_"":-_S[O_ -_6_P :.9![.1Y;17J7_"":-_S[O_W]
M;_&C_A!-&_Y]W_[^M_C1S(/9R/+:*]2_X031O^?=_P#OZW^-'_"":-_S[O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*=%_K4^HIM.B_P!:GU% '34444$!1110 4444 %%%% !1110 4444 %%%% !
M1110 5A^-_\ D4-8_P"O5_Y5N5A^-_\ D4-8_P"O5_Y4UN)[,^4****ZCS0H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ KUKP=_P BU8_[I_\ 0C7DM>M>#O\ D6K'_=/_ *$:B6QK3W-FBBBLCI"B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ JUI7_(0@_P!ZJM6M*_Y"$'^]0!TVI?\ 'C<_[AKCZ[#4O^/&
MY_W#7'TD#"BBBF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 5HZ!_R$5_W36=6CH'_(17_=- &OKO_(-D^H_G7+UU&N_\@V3ZC^=<O20,
M****8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 2VO_ !]0_P"^/YUU]Q_Q[R?[I_E7(6O_
M !]0_P"^/YUU]Q_Q[R?[I_E28'%T444P"BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KH_#?_ !XR
M?]=#_(5SE='X;_X\9/\ KH?Y"DP12\2?\?<7^Y_4UDUK>)/^/N+_ '/ZFLF@
M HHHI@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110!-8_\?MO_P!=%_G7H;?=/TKSRQ_X_;?_
M *Z+_.O0V^Z?I4LN)C4444C4**** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ IT7^M3ZBFTZ+_ %J?44 =-11100%%%% !1110 4444 %%
M%% !1110 4444 %%%% !6'XW_P"10UC_ *]7_E6Y6'XW_P"10UC_ *]7_E36
MXGLSY0HHHKJ/-"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "O6O!W_ "+5C_NG_P!"->2UZUX._P"1:L?]T_\ H1J)
M;&M/<V:***R.D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "K6E?\A"#_ 'JJU:TK_D(0?[U '3:E_P >
M-S_N&N/KL-2_X\;G_<-<?20,****8!1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !6CH'_(17_=-9U:.@?\A%?]TT :^N_\@V3ZC^=<O74:
M[_R#9/J/YUR]) PHHHI@%%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!+:_\ 'U#_ +X_G77W
M'_'O)_NG^5<A:_\ 'U#_ +X_G77W'_'O)_NG^5)@<71113 **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "NC\-_\ 'C)_UT/\A7.5T?AO_CQD_P"NA_D*3!%+Q)_Q]Q?[G]3636MX
MD_X^XO\ <_J:R: "BBBF 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $UC_Q^V__ %T7^=>A
MM]T_2O/+'_C]M_\ KHO\Z]#;[I^E2RXF-1112-0HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M ._$W_Q%'_#2?PU_Z&JW_P"_$W_Q%'U+%?\ /J7W/_(/K-#^=?>CTNBO-/\
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M*_Y]2^Y_Y!]9H?SK[T>ET5YI_P -)_#7_H:K?_OQ-_\ $4?\-)_#7_H:K?\
M[\3?_$4?4L5_SZE]S_R#ZS0_G7WH]+HKS3_AI/X:_P#0U6__ 'XF_P#B*/\
MAI/X:_\ 0U6__?B;_P"(H^I8K_GU+[G_ )!]9H?SK[T>ET5YI_PTG\-?^AJM
M_P#OQ-_\11_PTG\-?^AJM_\ OQ-_\11]2Q7_ #ZE]S_R#ZS0_G7WH]+HKS3_
M (:3^&O_ $-5O_WXF_\ B*/^&D_AK_T-5O\ ]^)O_B*/J6*_Y]2^Y_Y!]9H?
MSK[T>ET5YI_PTG\-?^AJM_\ OQ-_\11_PTG\-?\ H:K?_OQ-_P#$4?4L5_SZ
ME]S_ ,@^LT/YU]Z/2Z*\T_X:3^&O_0U6_P#WXF_^(H_X:3^&O_0U6_\ WXF_
M^(H^I8K_ )]2^Y_Y!]9H?SK[T>ET5YI_PTG\-?\ H:K?_OQ-_P#$4?\ #2?P
MU_Z&JW_[\3?_ !%'U+%?\^I?<_\ (/K-#^=?>CTNBO-/^&D_AK_T-5O_ -^)
MO_B*/^&D_AK_ -#5;_\ ?B;_ .(H^I8K_GU+[G_D'UFA_.OO1Z717FG_  TG
M\-?^AJM_^_$W_P 11_PTG\-?^AJM_P#OQ-_\11]2Q7_/J7W/_(/K-#^=?>CT
MNBO-/^&D_AK_ -#5;_\ ?B;_ .(H_P"&D_AK_P!#5;_]^)O_ (BCZEBO^?4O
MN?\ D'UFA_.OO1Z717FG_#2?PU_Z&JW_ ._$W_Q%'_#2?PU_Z&JW_P"_$W_Q
M%'U+%?\ /J7W/_(/K-#^=?>CTNBO-/\ AI/X:_\ 0U6__?B;_P"(H_X:3^&O
M_0U6_P#WXF_^(H^I8K_GU+[G_D'UFA_.OO1Z717FG_#2?PU_Z&JW_P"_$W_Q
M%'_#2?PU_P"AJM_^_$W_ ,11]2Q7_/J7W/\ R#ZS0_G7WH]+HKS3_AI/X:_]
M#5;_ /?B;_XBC_AI/X:_]#5;_P#?B;_XBCZEBO\ GU+[G_D'UFA_.OO1Z717
MFG_#2?PU_P"AJM_^_$W_ ,11_P -)_#7_H:K?_OQ-_\ $4?4L5_SZE]S_P @
M^LT/YU]Z/2Z*\T_X:3^&O_0U6_\ WXF_^(H_X:3^&O\ T-5O_P!^)O\ XBCZ
MEBO^?4ON?^0?6:'\Z^]'I=%>:?\ #2?PU_Z&JW_[\3?_ !%'_#2?PU_Z&JW_
M ._$W_Q%'U+%?\^I?<_\@^LT/YU]Z/2Z*\T_X:3^&O\ T-5O_P!^)O\ XBC_
M (:3^&O_ $-5O_WXF_\ B*/J6*_Y]2^Y_P"0?6:'\Z^]'I=%>:?\-)_#7_H:
MK?\ [\3?_$4?\-)_#7_H:K?_ +\3?_$4?4L5_P ^I?<_\@^LT/YU]Z/2Z*\T
M_P"&D_AK_P!#5;_]^)O_ (BC_AI/X:_]#5;_ /?B;_XBCZEBO^?4ON?^0?6:
M'\Z^]'I=%>:?\-)_#7_H:K?_ +\3?_$4?\-)_#7_ *&JW_[\3?\ Q%'U+%?\
M^I?<_P#(/K-#^=?>CTNBO-/^&D_AK_T-5O\ ]^)O_B*/^&D_AK_T-5O_ -^)
MO_B*/J6*_P"?4ON?^0?6:'\Z^]'I=%>:?\-)_#7_ *&JW_[\3?\ Q%'_  TG
M\-?^AJM_^_$W_P 11]2Q7_/J7W/_ "#ZS0_G7WH]+HKS3_AI/X:_]#5;_P#?
MB;_XBC_AI/X:_P#0U6__ 'XF_P#B*/J6*_Y]2^Y_Y!]9H?SK[T>ET5YI_P -
M)_#7_H:K?_OQ-_\ $4?\-)_#7_H:K?\ [\3?_$4?4L5_SZE]S_R#ZS0_G7WH
M]+HKS3_AI/X:_P#0U6__ 'XF_P#B*/\ AI/X:_\ 0U6__?B;_P"(H^I8K_GU
M+[G_ )!]9H?SK[T>ET5YI_PTG\-?^AJM_P#OQ-_\11_PTG\-?^AJM_\ OQ-_
M\11]2Q7_ #ZE]S_R#ZS0_G7WH]+HKS3_ (:3^&O_ $-5O_WXF_\ B*/^&D_A
MK_T-5O\ ]^)O_B*/J6*_Y]2^Y_Y!]9H?SK[T>ET5YI_PTG\-?^AJM_\ OQ-_
M\11_PTG\-?\ H:K?_OQ-_P#$4?4L5_SZE]S_ ,@^LT/YU]Z/2Z*\T_X:3^&O
M_0U6_P#WXF_^(H_X:3^&O_0U6_\ WXF_^(H^I8K_ )]2^Y_Y!]9H?SK[T>ET
M5YI_PTG\-?\ H:K?_OQ-_P#$4?\ #2?PU_Z&JW_[\3?_ !%'U+%?\^I?<_\
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M)_#7_H:K?_OQ-_\ $4?4L5_SZE]S_P @^LT/YU]Z/2Z*\T_X:3^&O_0U6_\
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M3_P&N/\ XW1]1Q7_ #ZE_P" O_(/K6'_ .?D?O1[+17C7_#8?P=_Z'BT_P#
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M"_\ (/K6'_Y^1^]'LM%>-?\ #8?P=_Z'BT_\!KC_ .-T?\-A_!W_ *'BT_\
M :X_^-T?4<5_SZE_X"_\@^M8?_GY'[T>RT5XU_PV'\'?^AXM/_ :X_\ C='_
M  V'\'?^AXM/_ :X_P#C='U'%?\ /J7_ ("_\@^M8?\ Y^1^]'LM%>-?\-A_
M!W_H>+3_ ,!KC_XW1_PV'\'?^AXM/_ :X_\ C='U'%?\^I?^ O\ R#ZUA_\
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M_P#(/K6'_P"?D?O1[+17C7_#8?P=_P"AXM/_  &N/_C='_#8?P=_Z'BT_P#
M:X_^-T?4<5_SZE_X"_\ (/K6'_Y^1^]'LM%>-?\ #8?P=_Z'BT_\!KC_ .-T
M?\-A_!W_ *'BT_\  :X_^-T?4<5_SZE_X"_\@^M8?_GY'[T>RT5XU_PV'\'?
M^AXM/_ :X_\ C='_  V'\'?^AXM/_ :X_P#C='U'%?\ /J7_ ("_\@^M8?\
MY^1^]'LM%>-?\-A_!W_H>+3_ ,!KC_XW1_PV'\'?^AXM/_ :X_\ C='U'%?\
M^I?^ O\ R#ZUA_\ GY'[T>RT5XU_PV'\'?\ H>+3_P !KC_XW1_PV'\'?^AX
MM/\ P&N/_C='U'%?\^I?^ O_ "#ZUA_^?D?O1[+17C7_  V'\'?^AXM/_ :X
M_P#C='_#8?P=_P"AXM/_  &N/_C='U'%?\^I?^ O_(/K6'_Y^1^]'LM%>-?\
M-A_!W_H>+3_P&N/_ (W1_P -A_!W_H>+3_P&N/\ XW1]1Q7_ #ZE_P" O_(/
MK6'_ .?D?O1[+17C7_#8?P=_Z'BT_P# :X_^-T?\-A_!W_H>+3_P&N/_ (W1
M]1Q7_/J7_@+_ ,@^M8?_ )^1^]'LM%>-?\-A_!W_ *'BT_\  :X_^-T?\-A_
M!W_H>+3_ ,!KC_XW1]1Q7_/J7_@+_P @^M8?_GY'[T>RT5XU_P -A_!W_H>+
M3_P&N/\ XW1_PV'\'?\ H>+3_P !KC_XW1]1Q7_/J7_@+_R#ZUA_^?D?O1[+
M17C7_#8?P=_Z'BT_\!KC_P"-T?\ #8?P=_Z'BT_\!KC_ .-T?4<5_P ^I?\
M@+_R#ZUA_P#GY'[T>RT5XU_PV'\'?^AXM/\ P&N/_C='_#8?P=_Z'BT_\!KC
M_P"-T?4<5_SZE_X"_P#(/K6'_P"?D?O1[+17C7_#8?P=_P"AXM/_  &N/_C=
M'_#8?P=_Z'BT_P# :X_^-T?4<5_SZE_X"_\ (/K6'_Y^1^]'LM%>-?\ #8?P
M=_Z'BT_\!KC_ .-T?\-A_!W_ *'BT_\  :X_^-T?4<5_SZE_X"_\@^M8?_GY
M'[T>RT5XU_PV'\'?^AXM/_ :X_\ C='_  V'\'?^AXM/_ :X_P#C='U'%?\
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MKC_XW1]1Q7_/J7_@+_R#ZUA_^?D?O1[+17C7_#8?P=_Z'BT_\!KC_P"-T?\
M#8?P=_Z'BT_\!KC_ .-T?4<5_P ^I?\ @+_R#ZUA_P#GY'[T>RT5XU_PV'\'
M?^AXM/\ P&N/_C='_#8?P=_Z'BT_\!KC_P"-T?4<5_SZE_X"_P#(/K6'_P"?
MD?O1[+17C7_#8?P=_P"AXM/_  &N/_C='_#8?P=_Z'BT_P# :X_^-T?4<5_S
MZE_X"_\ (/K6'_Y^1^]'LM%>-?\ #8?P=_Z'BT_\!KC_ .-T?\-A_!W_ *'B
MT_\  :X_^-T?4<5_SZE_X"_\@^M8?_GY'[T>RT5XU_PV'\'?^AXM/_ :X_\
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M_(/K6'_Y^1^]'LM%>-?\-A_!W_H>+3_P&N/_ (W1_P -A_!W_H>+3_P&N/\
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M%>-?\-A_!W_H>+3_ ,!KC_XW1_PV'\'?^AXM/_ :X_\ C='U'%?\^I?^ O\
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M ,!KC_XW1]1Q7_/J7_@+_P @^M8?_GY'[T>RT5XU_P -A_!W_H>+3_P&N/\
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M\@^M8?\ Y^1^]'LM%>-?\-A_!W_H>+3_ ,!KC_XW1_PV'\'?^AXM/_ :X_\
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M'\'?^AXM/_ :X_\ C='U'%?\^I?^ O\ R#ZUA_\ GY'[T>RT5XU_PV'\'?\
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M@[_T/%I_X#7'_P ;H^HXK_GU+_P%_P"0?6L/_P _(_>CV6BO&O\ AL/X._\
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M3]FN/7_KG72S?MM?!%HG \?69)4@#[+<>G_7.D\#B_\ GU+_ ,!?^0?6L/\
M\_%]Z.[HKQK_ (;#^#O_ $/%I_X#7'_QNC_AL/X._P#0\6G_ (#7'_QNG]1Q
M7_/J7_@+_P @^M8?_GY'[T>RT5XU_P -A_!W_H>+3_P&N/\ XW1_PV'\'?\
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M O\ R#ZUA_\ GY'[T>RT5XU_PV'\'?\ H>+3_P !KC_XW1_PV'\'?^AXM/\
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M+3_P&N/_ (W1]1Q7_/J7_@+_ ,@^M8?_ )^1^]'LM%>-?\-A_!W_ *'BT_\
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M3_P&N/\ XW1]1Q7_ #ZE_P" O_(/K6'_ .?D?O1[+17C7_#8?P=_Z'BT_P#
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M UQ_\;H^HXK_ )]2_P# 7_D'UK#_ //R/WH]EHKQK_AL/X._]#Q:?^ UQ_\
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M )!]:P__ #\C]Z/9:*\:_P"&P_@[_P!#Q:?^ UQ_\;H_X;#^#O\ T/%I_P"
MUQ_\;H^HXK_GU+_P%_Y!]:P__/R/WH]EHKQK_AL/X._]#Q:?^ UQ_P#&Z/\
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MO&O^&P_@[_T/%I_X#7'_ ,;H_P"&P_@[_P!#Q:?^ UQ_\;H^HXK_ )]2_P#
M7_D'UK#_ //R/WH]EHKQK_AL/X._]#Q:?^ UQ_\ &Z/^&P_@[_T/%I_X#7'_
M ,;H^HXK_GU+_P !?^0?6L/_ ,_(_>CV6BO&O^&P_@[_ -#Q:?\ @-<?_&Z/
M^&P_@[_T/%I_X#7'_P ;H^HXK_GU+_P%_P"0?6L/_P _(_>CV6BO&O\ AL/X
M._\ 0\6G_@-<?_&Z/^&P_@[_ -#Q:?\ @-<?_&Z/J.*_Y]2_\!?^0?6L/_S\
MC]Z/9:*\:_X;#^#O_0\6G_@-<?\ QNC_ (;#^#O_ $/%I_X#7'_QNCZCBO\
MGU+_ ,!?^0?6L/\ \_(_>CV6BO&O^&P_@[_T/%I_X#7'_P ;H_X;#^#O_0\6
MG_@-<?\ QNCZCBO^?4O_  %_Y!]:P_\ S\C]Z/9:*\:_X;#^#O\ T/%I_P"
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M"_\ (/K>'_Y^1^]'M]%>(?\ #;'P2_Z'VS_\!;C_ .-T?\-L?!+_ *'VS_\
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M ,!;C_XW1]1Q?_/J7_@+_P @^MX?_GY'[T>WT5XA_P -L?!+_H?;/_P%N/\
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M[T>WT5XA_P -L?!+_H?;/_P%N/\ XW1_PVQ\$O\ H?;/_P !;C_XW1]1Q?\
MSZE_X"_\@^MX?_GY'[T>WT5XA_PVQ\$O^A]L_P#P%N/_ (W1_P -L?!+_H?;
M/_P%N/\ XW1]1Q?_ #ZE_P" O_(/K>'_ .?D?O1[?17B'_#;'P2_Z'VS_P#
M6X_^-T?\-L?!+_H?;/\ \!;C_P"-T?4<7_SZE_X"_P#(/K>'_P"?D?O1[?17
MB'_#;'P2_P"A]L__  %N/_C='_#;'P2_Z'VS_P# 6X_^-T?4<7_SZE_X"_\
M(/K>'_Y^1^]'M]%>(?\ #;'P2_Z'VS_\!;C_ .-T?\-L?!+_ *'VS_\  6X_
M^-T?4<7_ ,^I?^ O_(/K>'_Y^1^]'M]%>(?\-L?!+_H?;/\ \!;C_P"-T?\
M#;'P2_Z'VS_\!;C_ .-T?4<7_P ^I?\ @+_R#ZWA_P#GY'[T>WT5XA_PVQ\$
MO^A]L_\ P%N/_C='_#;'P2_Z'VS_ / 6X_\ C='U'%_\^I?^ O\ R#ZWA_\
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M>(?\-L?!+_H?;/\ \!;C_P"-T?\ #;'P2_Z'VS_\!;C_ .-T?4<7_P ^I?\
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M  %N/_C='U'%_P#/J7_@+_R#ZWA_^?D?O1[?17B'_#;'P2_Z'VS_ / 6X_\
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M#ZWA_P#GY'[T>WT5XA_PVQ\$O^A]L_\ P%N/_C='_#;'P2_Z'VS_ / 6X_\
MC='U'%_\^I?^ O\ R#ZWA_\ GY'[T>WT5XA_PVQ\$O\ H?;/_P !;C_XW1_P
MVQ\$O^A]L_\ P%N/_C='U'%_\^I?^ O_ "#ZWA_^?D?O1[?17B'_  VQ\$O^
MA]L__ 6X_P#C='_#;'P2_P"A]L__  %N/_C='U'%_P#/J7_@+_R#ZWA_^?D?
MO1[?17B'_#;'P2_Z'VS_ / 6X_\ C='_  VQ\$O^A]L__ 6X_P#C='U'%_\
M/J7_ ("_\@^MX?\ Y^1^]'M]%>(?\-L?!+_H?;/_ ,!;C_XW1_PVQ\$O^A]L
M_P#P%N/_ (W1]1Q?_/J7_@+_ ,@^MX?_ )^1^]'M]%>(?\-L?!+_ *'VS_\
M 6X_^-T?\-L?!+_H?;/_ ,!;C_XW1]1Q?_/J7_@+_P @^MX?_GY'[T>WT5XA
M_P -L?!+_H?;/_P%N/\ XW1_PVQ\$O\ H?;/_P !;C_XW1]1Q?\ SZE_X"_\
M@^MX?_GY'[T>WT5XA_PVQ\$O^A]L_P#P%N/_ (W1_P -L?!+_H?;/_P%N/\
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MVS_\!;C_ .-T?4<7_P ^I?\ @+_R#ZWA_P#GY'[T>WT5XA_PVQ\$O^A]L_\
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M4!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %?0/[ __ "=KX$_WK[_TAN*^?J^B/^"?B!_VO/ 0
M89'^G]?^O"XKS\Q_W.M_AE^3.S!?[S2_Q+\T?LW1117XD?J@4444 %%%% !1
M110 4444 %%%% !1110 4444 %>0_M;:7>ZU^S;\0+'3K2>_O9]-98K:VB:2
M21MR\*J@DGZ5Z]16M&I[*I&HELT_N,ZD/:0E#NK'X(_\*5^(?_0A^)__  3W
M'_Q%'_"E?B'_ -"'XG_\$]Q_\17[W45]G_K35_Y]+[V?+_ZOT_\ GX_N/P1_
MX4K\0_\ H0_$_P#X)[C_ .(H_P"%*_$/_H0_$_\ X)[C_P"(K][J*/\ 6FK_
M ,^E][#_ %?I_P#/Q_<?@C_PI7XA_P#0A^)__!/<?_$4?\*5^(?_ $(?B?\
M\$]Q_P#$5^]U%'^M-7_GTOO8?ZOT_P#GX_N/P1_X4K\0_P#H0_$__@GN/_B*
M/^%*_$/_ *$/Q/\ ^">X_P#B*_>ZBC_6FK_SZ7WL/]7Z?_/Q_<?@C_PI7XA_
M]"'XG_\ !/<?_$4?\*5^(?\ T(?B?_P3W'_Q%?O=11_K35_Y]+[V'^K]/_GX
M_N/P1_X4K\0_^A#\3_\ @GN/_B*/^%*_$/\ Z$/Q/_X)[C_XBOWNHH_UIJ_\
M^E][#_5^G_S\?W'X(_\ "E?B'_T(?B?_ ,$]Q_\ $4?\*5^(?_0A^)__  3W
M'_Q%?O=11_K35_Y]+[V'^K]/_GX_N/P1_P"%*_$/_H0_$_\ X)[C_P"(H_X4
MK\0_^A#\3_\ @GN/_B*_>ZBC_6FK_P ^E][#_5^G_P _']Q^"/\ PI7XA_\
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M?_0A^)__  3W'_Q%?O=11_K35_Y]+[V'^K]/_GX_N/P1_P"%*_$/_H0_$_\
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M%?O=11_K35_Y]+[V'^K]/_GX_N/P1_X4K\0_^A#\3_\ @GN/_B*/^%*_$/\
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M*_>ZBC_6FK_SZ7WL/]7Z?_/Q_<?@C_PI7XA_]"'XG_\ !/<?_$4?\*5^(?\
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M5_Y]+[V'^K]/_GX_N/P1_P"%*_$/_H0_$_\ X)[C_P"(H_X4K\0_^A#\3_\
M@GN/_B*_>ZBC_6FK_P ^E][#_5^G_P _']Q^"/\ PI7XA_\ 0A^)_P#P3W'_
M ,11_P *5^(?_0A^)_\ P3W'_P 17[W44?ZTU?\ GTOO8?ZOT_\ GX_N/P1_
MX4K\0_\ H0_$_P#X)[C_ .(H_P"%*_$/_H0_$_\ X)[C_P"(K][J*/\ 6FK_
M ,^E][#_ %?I_P#/Q_<?@C_PI7XA_P#0A^)__!/<?_$4?\*5^(?_ $(?B?\
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MK\0_^A#\3_\ @GN/_B*_>ZBC_6FK_P ^E][#_5^G_P _']Q^"/\ PI7XA_\
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M?_0A^)__  3W'_Q%?O=11_K35_Y]+[V'^K]/_GX_N/P1_P"%*_$/_H0_$_\
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M%?O=11_K35_Y]+[V'^K]/_GX_N/P1_X4K\0_^A#\3_\ @GN/_B*/^%*_$/\
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M*_>ZBC_6FK_SZ7WL/]7Z?_/Q_<?@C_PI7XA_]"'XG_\ !/<?_$4?\*5^(?\
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M5_Y]+[V'^K]/_GX_N/P1_P"%*_$/_H0_$_\ X)[C_P"(H_X4K\0_^A#\3_\
M@GN/_B*_>ZBC_6FK_P ^E][#_5^G_P _']Q^"/\ PI7XA_\ 0A^)_P#P3W'_
M ,11_P *5^(?_0A^)_\ P3W'_P 17[W44?ZTU?\ GTOO8?ZOT_\ GX_N/P1_
MX4K\0_\ H0_$_P#X)[C_ .(H_P"%*_$/_H0_$_\ X)[C_P"(K][J*/\ 6FK_
M ,^E][#_ %?I_P#/Q_<?@C_PI7XA_P#0A^)__!/<?_$4?\*5^(?_ $(?B?\
M\$]Q_P#$5^]U%'^M-7_GTOO8?ZOT_P#GX_N/P1_X4K\0_P#H0_$__@GN/_B*
M/^%*_$/_ *$/Q/\ ^">X_P#B*_>ZBC_6FK_SZ7WL/]7Z?_/Q_<?@C_PI7XA_
M]"'XG_\ !/<?_$4?\*5^(?\ T(?B?_P3W'_Q%?O=11_K35_Y]+[V'^K]/_GX
M_N/P1_X4K\0_^A#\3_\ @GN/_B*/^%*_$/\ Z$/Q/_X)[C_XBOWNHH_UIJ_\
M^E][#_5^G_S\?W'X(_\ "E?B'_T(?B?_ ,$]Q_\ $4?\*5^(?_0A^)__  3W
M'_Q%?O=11_K35_Y]+[V'^K]/_GX_N/P1_P"%*_$/_H0_$_\ X)[C_P"(H_X4
MK\0_^A#\3_\ @GN/_B*_>ZBC_6FK_P ^E][#_5^G_P _']Q^"/\ PI7XA_\
M0A^)_P#P3W'_ ,11_P *5^(?_0A^)_\ P3W'_P 17[W44?ZTU?\ GTOO8?ZO
MT_\ GX_N/P1_X4K\0_\ H0_$_P#X)[C_ .(H_P"%*_$/_H0_$_\ X)[C_P"(
MK][J*/\ 6FK_ ,^E][#_ %?I_P#/Q_<?@C_PI7XA_P#0A^)__!/<?_$4?\*5
M^(?_ $(?B?\ \$]Q_P#$5^]U%'^M-7_GTOO8?ZOT_P#GX_N/P1_X4K\0_P#H
M0_$__@GN/_B*/^%*_$/_ *$/Q/\ ^">X_P#B*_>ZBC_6FK_SZ7WL/]7Z?_/Q
M_<?@C_PI7XA_]"'XG_\ !/<?_$4?\*5^(?\ T(?B?_P3W'_Q%?O=11_K35_Y
M]+[V'^K]/_GX_N/P1_X4K\0_^A#\3_\ @GN/_B*/^%*_$/\ Z$/Q/_X)[C_X
MBOWNHH_UIJ_\^E][#_5^G_S\?W'X(_\ "E?B'_T(?B?_ ,$]Q_\ $4?\*5^(
M?_0A^)__  3W'_Q%?O=11_K35_Y]+[V'^K]/_GX_N/P1_P"%*_$/_H0_$_\
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M%?O=11_K35_Y]+[V'^K]/_GX_N/P1_X4K\0_^A#\3_\ @GN/_B*/^%*_$/\
MZ$/Q/_X)[C_XBOWNHH_UIJ_\^E][#_5^G_S\?W'X(_\ "E?B'_T(?B?_ ,$]
MQ_\ $4?\*5^(?_0A^)__  3W'_Q%?O=11_K35_Y]+[V'^K]/_GX_N/P1_P"%
M*_$/_H0_$_\ X)[C_P"(H_X4K\0_^A#\3_\ @GN/_B*_>ZBC_6FK_P ^E][#
M_5^G_P _']Q^"/\ PI7XA_\ 0A^)_P#P3W'_ ,11_P *5^(?_0A^)_\ P3W'
M_P 17[W44?ZTU?\ GTOO8?ZOT_\ GX_N/P1_X4K\0_\ H0_$_P#X)[C_ .(H
M_P"%*_$/_H0_$_\ X)[C_P"(K][J*/\ 6FK_ ,^E][#_ %?I_P#/Q_<?@C_P
MI7XA_P#0A^)__!/<?_$4?\*5^(?_ $(?B?\ \$]Q_P#$5^]U%'^M-7_GTOO8
M?ZOT_P#GX_N/P1_X4K\0_P#H0_$__@GN/_B*/^%*_$/_ *$/Q/\ ^">X_P#B
M*_>ZBC_6FK_SZ7WL/]7Z?_/Q_<?@C_PI7XA_]"'XG_\ !/<?_$4?\*5^(?\
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M5_Y]+[V'^K]/_GX_N/P1_P"%*_$/_H0_$_\ X)[C_P"(H_X4K\0_^A#\3_\
M@GN/_B*_>ZBC_6FK_P ^E][#_5^G_P _']Q^"/\ PI7XA_\ 0A^)_P#P3W'_
M ,11_P *5^(?_0A^)_\ P3W'_P 17[W44?ZTU?\ GTOO8?ZOT_\ GX_N/P1_
MX4K\0_\ H0_$_P#X)[C_ .(H_P"%*_$/_H0_$_\ X)[C_P"(K][J*/\ 6FK_
M ,^E][#_ %?I_P#/Q_<?@C_PI7XA_P#0A^)__!/<?_$4?\*5^(?_ $(?B?\
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MK\0_^A#\3_\ @GN/_B*_>ZBC_6FK_P ^E][#_5^G_P _']Q^"/\ PI7XA_\
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M?_0A^)__  3W'_Q%?O=11_K35_Y]+[V'^K]/_GX_N/P1_P"%*_$/_H0_$_\
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M%?O=11_K35_Y]+[V'^K]/_GX_N/P1_X4K\0_^A#\3_\ @GN/_B*/^%*_$/\
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M*_>ZBC_6FK_SZ7WL/]7Z?_/Q_<?@C_PI7XA_]"'XG_\ !/<?_$4?\*5^(?\
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M5_Y]+[V'^K]/_GX_N/P1_P"%*_$/_H0_$_\ X)[C_P"(H_X4K\0_^A#\3_\
M@GN/_B*_>ZBC_6FK_P ^E][#_5^G_P _']Q^"/\ PI7XA_\ 0A^)_P#P3W'_
M ,11_P *5^(?_0A^)_\ P3W'_P 17[W44?ZTU?\ GTOO8?ZOT_\ GX_N/P1_
MX4K\0_\ H0_$_P#X)[C_ .(H_P"%*_$/_H0_$_\ X)[C_P"(K][J*/\ 6FK_
M ,^E][#_ %?I_P#/Q_<?@C_PI7XA_P#0A^)__!/<?_$4?\*5^(?_ $(?B?\
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MK\0_^A#\3_\ @GN/_B*_>ZBC_6FK_P ^E][#_5^G_P _']Q^"/\ PI7XA_\
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M?_0A^)__  3W'_Q%?O=11_K35_Y]+[V'^K]/_GX_N/P1_P"%*_$/_H0_$_\
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M%?O=11_K35_Y]+[V'^K]/_GX_N/P1_X4K\0_^A#\3_\ @GN/_B*/^%*_$/\
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M*_>ZBC_6FK_SZ7WL/]7Z?_/Q_<?@C_PI7XA_]"'XG_\ !/<?_$4?\*5^(?\
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M5_Y]+[V'^K]/_GX_N/P1_P"%*_$/_H0_$_\ X)[C_P"(H_X4K\0_^A#\3_\
M@GN/_B*_>ZBC_6FK_P ^E][#_5^G_P _']Q^"/\ PI7XA_\ 0A^)_P#P3W'_
M ,11_P *5^(?_0A^)_\ P3W'_P 17[W44?ZTU?\ GTOO8?ZOT_\ GX_N/P1_
MX4K\0_\ H0_$_P#X)[C_ .(H_P"%*_$/_H0_$_\ X)[C_P"(K][J*/\ 6FK_
M ,^E][#_ %?I_P#/Q_<?@C_PI7XA_P#0A^)__!/<?_$4?\*5^(?_ $(?B?\
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MK\0_^A#\3_\ @GN/_B*_>ZBC_6FK_P ^E][#_5^G_P _']Q^"/\ PI7XA_\
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M?_0A^)__  3W'_Q%?O=11_K35_Y]+[V'^K]/_GX_N/P1_P"%*_$/_H0_$_\
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M%?O=11_K35_Y]+[V'^K]/_GX_N/P1_X4K\0_^A#\3_\ @GN/_B*/^%*_$/\
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M*_>ZBC_6FK_SZ7WL/]7Z?_/Q_<?@C_PI7XA_]"'XG_\ !/<?_$4?\*5^(?\
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M5_Y]+[V'^K]/_GX_N/P1_P"%*_$/_H0_$_\ X)[C_P"(H_X4K\0_^A#\3_\
M@GN/_B*_>ZBC_6FK_P ^E][#_5^G_P _']Q^"/\ PI7XA_\ 0A^)_P#P3W'_
M ,11_P *5^(?_0A^)_\ P3W'_P 17[W44?ZTU?\ GTOO8?ZOT_\ GX_N/P1_
MX4K\0_\ H0_$_P#X)[C_ .(H_P"%*_$/_H0_$_\ X)[C_P"(K][J*/\ 6FK_
M ,^E][#_ %?I_P#/Q_<?@C_PI7XA_P#0A^)__!/<?_$4?\*5^(?_ $(?B?\
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MK\0_^A#\3_\ @GN/_B*_>ZBC_6FK_P ^E][#_5^G_P _']Q^"/\ PI7XA_\
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M?_0A^)__  3W'_Q%?O=11_K35_Y]+[V'^K]/_GX_N/P1_P"%*_$/_H0_$_\
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M%?O=11_K35_Y]+[V'^K]/_GX_N/P1_X4K\0_^A#\3_\ @GN/_B*/^%*_$/\
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M*_>ZBC_6FK_SZ7WL/]7Z?_/Q_<?@C_PI7XA_]"'XG_\ !/<?_$4?\*5^(?\
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M5_Y]+[V'^K]/_GX_N/P1_P"%*_$/_H0_$_\ X)[C_P"(H_X4K\0_^A#\3_\
M@GN/_B*_>ZBC_6FK_P ^E][#_5^G_P _']Q^"/\ PI7XA_\ 0A^)_P#P3W'_
M ,11_P *5^(?_0A^)_\ P3W'_P 17[W44?ZTU?\ GTOO8?ZOT_\ GX_N/P1_
MX4K\0_\ H0_$_P#X)[C_ .(H_P"%*_$/_H0_$_\ X)[C_P"(K][J*/\ 6FK_
M ,^E][#_ %?I_P#/Q_<?@C_PI7XA_P#0A^)__!/<?_$4?\*5^(?_ $(?B?\
M\$]Q_P#$5^]U%'^M-7_GTOO8?ZOT_P#GX_N/P1_X4K\0_P#H0_$__@GN/_B*
M/^%*_$/_ *$/Q/\ ^">X_P#B*_>ZBC_6FK_SZ7WL/]7Z?_/Q_<?@C_PI7XA_
M]"'XG_\ !/<?_$4?\*5^(?\ T(?B?_P3W'_Q%?O=11_K35_Y]+[V'^K]/_GX
M_N/P1_X4K\0_^A#\3_\ @GN/_B*/^%*_$/\ Z$/Q/_X)[C_XBOWNHH_UIJ_\
M^E][#_5^G_S\?W'X(_\ "E?B'_T(?B?_ ,$]Q_\ $4?\*5^(?_0A^)__  3W
M'_Q%?O=11_K35_Y]+[V'^K]/_GX_N/P1_P"%*_$/_H0_$_\ X)[C_P"(H_X4
MK\0_^A#\3_\ @GN/_B*_>ZBC_6FK_P ^E][#_5^G_P _']Q^"/\ PI7XA_\
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M?_0A^)__  3W'_Q%?O=11_K35_Y]+[V'^K]/_GX_N/P1_P"%*_$/_H0_$_\
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M%?O=11_K35_Y]+[V'^K]/_GX_N/P1_X4K\0_^A#\3_\ @GN/_B*/^%*_$/\
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M*_>ZBC_6FK_SZ7WL/]7Z?_/Q_<?@C_PI7XA_]"'XG_\ !/<?_$4?\*5^(?\
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M5_Y]+[V'^K]/_GX_N/P1_P"%*_$/_H0_$_\ X)[C_P"(H_X4K\0_^A#\3_\
M@GN/_B*_>ZBC_6FK_P ^E][#_5^G_P _']Q^"/\ PI7XA_\ 0A^)_P#P3W'_
M ,11_P *5^(?_0A^)_\ P3W'_P 17[W44?ZTU?\ GTOO8?ZOT_\ GX_N/P1_
MX4K\0_\ H0_$_P#X)[C_ .(H_P"%*_$/_H0_$_\ X)[C_P"(K][J*/\ 6FK_
M ,^E][#_ %?I_P#/Q_<?@C_PI7XA_P#0A^)__!/<?_$4?\*5^(?_ $(?B?\
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MK\0_^A#\3_\ @GN/_B*_>ZBC_6FK_P ^E][#_5^G_P _']Q^"/\ PI7XA_\
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M?_0A^)__  3W'_Q%?O=11_K35_Y]+[V'^K]/_GX_N/P1_P"%*_$/_H0_$_\
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M%?O=11_K35_Y]+[V'^K]/_GX_N/P1_X4K\0_^A#\3_\ @GN/_B*/^%*_$/\
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M*_>ZBC_6FK_SZ7WL/]7Z?_/Q_<?@C_PI7XA_]"'XG_\ !/<?_$4?\*5^(?\
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M5_Y]+[V'^K]/_GX_N/P1_P"%*_$/_H0_$_\ X)[C_P"(H_X4K\0_^A#\3_\
M@GN/_B*_>ZBC_6FK_P ^E][#_5^G_P _']Q^"/\ PI7XA_\ 0A^)_P#P3W'_
M ,11_P *5^(?_0A^)_\ P3W'_P 17[W44?ZTU?\ GTOO8?ZOT_\ GX_N/P1_
MX4K\0_\ H0_$_P#X)[C_ .(H_P"%*_$/_H0_$_\ X)[C_P"(K][J*/\ 6FK_
M ,^E][#_ %?I_P#/Q_<?@C_PI7XA_P#0A^)__!/<?_$4?\*5^(?_ $(?B?\
M\$]Q_P#$5^]U%'^M-7_GTOO8?ZOT_P#GX_N/P1_X4K\0_P#H0_$__@GN/_B*
M/^%*_$/_ *$/Q/\ ^">X_P#B*_>ZBC_6FK_SZ7WL/]7Z?_/Q_<?@C_PI7XA_
M]"'XG_\ !/<?_$4?\*5^(?\ T(?B?_P3W'_Q%?O=11_K35_Y]+[V'^K]/_GX
M_N/P1_X4K\0_^A#\3_\ @GN/_B*/^%*_$/\ Z$/Q/_X)[C_XBOWNHH_UIJ_\
M^E][#_5^G_S\?W'X(_\ "E?B'_T(?B?_ ,$]Q_\ $4?\*5^(?_0A^)__  3W
M'_Q%?O=11_K35_Y]+[V'^K]/_GX_N/P1_P"%*_$/_H0_$_\ X)[C_P"(H_X4
MK\0_^A#\3_\ @GN/_B*_>ZBC_6FK_P ^E][#_5^G_P _']Q^"/\ PI7XA_\
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M?_0A^)__  3W'_Q%?O=11_K35_Y]+[V'^K]/_GX_N/P1_P"%*_$/_H0_$_\
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M%?O=11_K35_Y]+[V'^K]/_GX_N/P1_X4K\0_^A#\3_\ @GN/_B*/^%*_$/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%.GZ?J5L0)K:9R'0E0PSQZ$'\:[A&$B!E.589!]J_,C]KC_DXCQA_P!=+?\
M])HJ_3*Q_P"/*W_ZYK_*@">BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MI;VEQ]F==0C1'+;0V0$=AC##O7?U\L?\$^?^2;>)/^PM_P"T8Z^IZ "BBB@
MKR'XP_M.>%_@GXAM-'URPU>ZN;FU%VCZ?#$Z!"[)@EY%.<H>WIS7KU? W_!0
M/_DJ^@_]@1/_ $?-0!]N>"/%UGX^\)Z7XAT^*>&RU&$3Q1W*JLBJ?[P4D9X[
M$U9\4>(+?PEX:U?7+Q)9+33+2:]F2  R,D:%V"@D G"G&2.>]<1^S7_R0CP5
M_P!@]/YFNJ^(7A^X\6^ ?$VAV;Q1W>IZ9<V4+SDB-7DB9%+$ D#+#. ?I0!Y
MW\)?VJ/"?QD\5-H&BZ?K-K>+;O<[[^")(]JE01E)6.?F':O9:^5OV:?V5_%G
MP:^(LFOZUJ&C75FUC+;!+">9Y-S,A!PT2C'RGO7U30 4444 %%%% '"_&#XP
M:-\%/#5MKFN6U]=6EQ=K9*FGQH\@=D=P2'=1C$9[^G%1?!WXT:)\;=$O=4T*
MUU"TM[2X^S.NH1HCEMH;(".PQAAWKR7_ (* ?\D;T;_L/P_^D]S5'_@GS_R3
M;Q)_V%O_ &C'0!]3T444 %%%% !1110 4444 %%%% !1110!3UC4XM%TF^U&
M=7>"T@>XD6, L512Q R0,X'K7COPO_:W\'_%GQC:^&](TW6[:^N4DD22]@A6
M(!%+')65CT'I7I_Q _Y$/Q)_V#;G_P!%-7Y\_L5_\G!:)_U[W7_HEJ /TEHH
MHH **** .<\>?$/P_P##+0UUCQ+J']FZ<9E@$WDR2_.P) VQJQ_A/;M7GG_#
M8GPA_P"AN_\ *;>?_&:ZGXT?"2S^-'@]/#]]?SZ= MTEUYUNBLV5# #GC^+]
M*\+_ .'>OAO_ *&O5?\ OQ'0!Z7_ ,-B?"'_ *&[_P IMY_\9H_X;$^$/_0W
M?^4V\_\ C->)_$/]AO0/!G@3Q#K\'B74KB;3+">\2*2&,*Y1"P!(['%>"?L]
M_"FS^,OQ"7P[?7T^GP&UEN/.MU#-E<8&#QWH ^Y_^&Q/A#_T-W_E-O/_ (S5
MO2/VK_A7KVK66F6/BGS[V]G2V@B_L^Z7?([!5&3$ ,DCDD"O*?\ AWKX;_Z&
MO5?^_$=:?A?]A+P_X7\3:1K,7B?4IY=.NX;Q(WAC"NT;AP#CL=M 'N_Q*^(&
MG?"WP5J/B?58;FXL+'R_-CLU5I3OD6,;0S*.K@G)'&:Y3X,_M$>'/CC=:I!H
M5EJMH^G)&\IU&*- P<L!MV2/G[IZXK+_ &Q/^3<O%W_;G_Z605X7_P $[_\
MD-^-O^O>U_\ 0I* /MJBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@#A?C!\8-&^"GAJVUS7+:^NK2XNULE33XT>0.R.X)#NHQB,]_3
MBHO@[\:-$^-NB7NJ:%:ZA:6]I<?9G74(T1RVT-D!'88PP[USW[4'P?UGXU^
M-/T/0[FQM;NWU..]9]0D=(RBQ2H0"B,<YD';L>:K?LN?!;6_@EX2U;2]<NM/
MN[B[OOM2-I\CN@7RU7!+HISE3VH ]IHHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MD53_ '@I(SQV)K=KS3]FO_DA'@K_ +!Z?S->ET %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !7C_ ,8/VH/"OP4\2VVAZYI^L75W
M<6BWJOI\,3H$9W0 EY5.<QGMZ<U[!7R_^U!^R_XJ^-?C_3]<T/4-'M;2WTR.
MR9-0FE20NLLKD@)$PQB0=_7B@#Z'\'>*;3QMX5TK7[&.:*SU*W2YB2X4+(JL
M,@, 2 ?H36S7+?"[PO=^"?AUX<T"^DAEO--L8K:5[=BT;,J@$J2 2/J!74T
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M *604 :GP9_:(\.?'&ZU2#0K+5;1].2-Y3J,4:!@Y8#;LD?/W3UQ7J5?$O\
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M^%7CW5/"UWX>O[ZYL/*W7$$J*C[XDD& >> X'X5]"U^9O[8G_)QOB[_MS_\
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M),6%>/\  !R@]DH ]_KBOB9\8O"?PCT]+GQ)JB6LDHS!9QCS+B;_ '4'./\
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M:C87"[XKBV<.CCV(_EVJ_7YU_!'XDZ_^S)\7+GPIXE+PZ-+="VU*U+;HXF.
MES'[8*DD?>0],@8_1,$$9'(H 6BBB@ KQWXK_M4>!OA/=S:?=74NKZU%D/I^
MFJ':)O21R0J>XR6'I7+?MB?'BZ^%WAFVT#0IS!XAUA&/VE#A[2W!P77T9CE0
M>V&/! KYV_9L_9<N?C09?$.OW,]AX9CE*!H_]??2 _,%)Z*.[\\\#G) !Z7/
M_P %$XUGD$/@%I(0Q"-)K 5F7/!($!P<=LGZFO2_AI^VCX$\?:A%IU^;CPOJ
M$I"Q_P!HE3!(Q_A$H. ?]X*/?/%=%:_LH?"FUTLV'_"(6\L;##2RSS-,??S-
M^X=.Q'M7S9^T3^QM+X-M4UWP'%?:MI[2+%/I 0SW$)8X5H]HW.I) (P2,@\C
M. #[OJ&ZNX+&VEN+F:.WMXE+R2RL%1%'4DG@#WKQ']DVW^(FD>!GTCQUI<]I
M;VFT:7<74J-.8N08W4,64+@;=P!P<= *ZC]H+X0R_&CP"VA6VI-IEVEQ'/'(
MSOY+8/S+(BGYA@DC(X8#IS0!P?CW]N#P#X3NGM-*%WXHN5)#/8J$MP1_TT;&
M?JH(Z\UY[#_P44C,R"7P R1%@'9-8#,%SR0# ,GVR/K7J/P]_8R^'G@NVC;4
MK)O%.I8&^XU(_NL]]L(.T#V;<?>N\U+X"?#?5+1[:;P-H"1N,%K;3XH''T=
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M+LIKUXD(#.L<;.5&>YVXKY7_ ."=_P#R!/&W_7Q:_P#H,E?1GQJ_Y(WX\_[
M%_\ ^D\E 'GOP7_:OTCXT>,&\/V.A7VG3+:O=>=<2HRX4J,8'?YOTKW6OSR_
M8/\ ^2WS?]@FX_\ 0XZ_0/4]2MM&TV[U"]F6WL[2%YYIGZ(BJ69C[  F@#%\
M>?$3P]\,]#?5O$>IPZ;: [4W\O*V,[40<LWL![]*^:=>_P""ANDVMZR:/X-O
M-1M02!->7RVS'_@*I)_.OG#XD^._$7[1_P 5E-O'-<-=W'V32=-W?+!$6PH]
M 2/F9O7)Z 8^N?A;^Q'X-\+:;;S>*HO^$GUH@-)OD=+6-O[J(I&X#IE\YZX'
M2@!/AO\ MR^#?&-_!8:Y9W'A2ZF.U9KB59K4'L#* I7MR5 ]2*Y;_@H2ZR^%
M/!CHP=&NYRK*<@CRUY%=W\0_V*_A]XNL)CHUF_A;52,QW-F[-"6Q@!XF)&WC
M^':>^:^.OB_=>,?!^DV/PT\7H9#H-RT^GW)8L&MW7: C'[T?RY7NOS*>F  ?
M7'[!_P#R1";_ +"UQ_Z!'7T4S! 68@ #))[5\Z_L'_\ )$)O^PM<?^@1UZY\
M6_ 3?$SX=ZWX<2\DL)KV I%/'(RA7'*A]I^9"1AEYR">* /.OB-^V/\ #[P!
M<RV=O=3>)-1C;:T.E -&A[[I20O_ 'SN.>U>4R_\%%$$C"/P S1Y.UFUC!([
M9'D''YUWOPT_8@\$^$[>*?Q)YGBO5-N6\XF*U1O]F-3D]QER<]<"O59O@7\.
M9[9H&\"^'0A7:2FF0J^/]X*"#[YS0!P?PN_;#\#?$G48=+E:X\/:K,VR*'4=
MHCE;/"I(#C)]&VY/ S7NM?GY^UU^S;IOPH%EXE\,AX="O9_LTUB[%_LTI4LN
MQCDE&"MP<X(Z\@#Z0_8^^*%W\2?A/''J<[7.JZ-,;"::0Y>5 H:-R>YVG;GJ
M2A)ZT 0_'#]JO2/@YXI;PW>Z'>ZA/+9K<":"1%4!RP P>?X?UKX6^"WCZW^%
M_P 3=$\3W=K+>V^GM*SP0L [;HG08)XZL#^%?HS\1_@#X"^).I2:WXCT+^T=
M32W\E9_MEQ%A%R5&U)%'!)[=Z_/?]G7PCI/COXS>&]"URT^W:5>/,)[?S'CW
MA8)&'S(0PY4'@B@#Z^\!?MMZ%X]\9:/X=MO#>HVL^I7"VZ32S1E4)[D#FOI.
MO*O#G[+OPQ\):[8ZSI/AG[)J5E*)K>?[?=/L<=#M:4@_B#7IU[>0:=9W%W=2
MK!;01M++*YPJ(HRS'V !- %#Q/XJT?P7HT^K:YJ-OI>G0CY[BX?:N>P'<D]@
M,D]A7S5XM_X*!>&-,N7B\/\ AV_UU$('GW,RVD;]<E?E=L=.JCOTQSX#\0O'
M'B?]K'XOVFD:7O%@\[0Z78NQ$5O".6FD_P!HJ"S'D_PC. *^O/AI^R+\/_ 6
MG0B^TB#Q/JN/WUYJL0E1CC!"Q'**O)QP3TR3@4 >8:)_P4.TFXNMNK^#+RPM
M^/WEE?)<M[_*R1_SKZ1^'GQ1\,?%/2/[1\-:K%J$2X$L7*30L>SH>5[\]#C@
MFN:\6?LS_#3Q?IS6L_A+3M-;'R7&DP+:2H?4&, '_@0(]J^*O''@_P 5_L??
M%BQU#2;YYK.3,EE=D82\A!'F02J.,C@$>ZL,'& #]):P?&OCK0OAWH$VL^(=
M1BTW3XCCS),EG8]%11RS'!X )X)[&H_A]XVL?B-X,TGQ)IN1::A )0C'+1MT
M=#[JP*GZ5\&?MC>,M1\<_'*?P[',QL=):*RM(&.$\UU4NY]RS8SZ** /7_$?
M_!0K0[.[:/0_"5]JEN&(\Z\NUM=PXY"A9.ISUQQCZ \._P#!0K0[RZ5-;\)7
MVEPEL>;97:76T8ZD,L??'3/&?H?5_A[^RO\ #SP+H\%O-X>L=?U#RPMQ?:M
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M0UZUX8_9N^&GA73UM+?P=I5[A0&GU2V6[E<C/):0'!.3TP/;@5RWQ0_8_P#
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M],D<K0!=O?\ @HE;1W3K:> Y9[<8VR3ZJ(W/'.5$+ <Y[G^E>T?!+]IGPO\
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M4$P6<(\RXFQUVH.W^T<#WK\\/%GBIO _[2_B/Q L N9--\3WETD). [+<R$
M^V<9KUSX0?LXZ[^T5J4WQ!^(FIW4>G:A(9(HHSMGNP#@8R"(HAC: !D@<8&"
M0#JM6_X*(:=#>%=+\$75Y:XXDN]16W?J?X5C<=,'[W<CMD^D_!?]KOPO\7-7
MBT6>TG\.Z[,/W-M<R"2*<XR5CD &6X/#*N>V3P-B?]DKX4S:*=-'A2&),';<
M1W$WGJ3GYO,+DG!/0Y';&.*^!_B_\/;WX&_%.[T>"[E9K*6.[T^]'RNR'#1O
MQ_$",$CNIQ0!^J]?-R?ML:';>/1X5U3PWJ&EW2:C_9UQ<2S(8X'\S86/<J#S
M]*]Q^'_B<>-/ WA_7MH1M2L(;ID'16= 67\"2/PKX<_;J^'@\,?$ZU\26L7E
MVFO0;Y"HP!<Q85_IE3&?<[C0!^@=%>>? 'Q]_P +*^$GAW6I)/,O&MQ;W9SS
MY\?R.3]2-WT85Z'0!QGQ<^)^G_"#P3=>)-2ADNHHI(XDMH2 \KNP  )XX&3]
M%-<]\"_CQ;_'2UU6[L-#N]+LK!TB,]U*K>;(P)*J%]!@G/\ >'X?.O\ P4!\
M?_;-<T#P=;RYBLXSJ%TH/'FOE8P?<*'/TDKZ/_9M^'A^&GP>T'2YHA'J$\?V
MZ\&.?.EPQ!]U7:G_  "@#T^O"OB;^V+X"^'=[+IT$T_B/4XFVR0Z7M:*,YY#
M2DA<CGA=QSP<=O/OVV/C[>>&43P'X?NFMKN[A$NJ7438>.)ONP@]BPY;_9P.
MC&L7]FK]CK3M9T*Q\5^.X9+A;M!/9Z-O*+Y9Y5Y2,$DC!"@@8(SG.  3+_P4
M4C,RAO +"+=RPU@%@,]<>1U]L_C7L/PI_:R\"_%.\CTZ.XFT+6)#MCLM3"IY
MQ](Y 2K'V)#'L#77M\"?ARUG]F_X07P]Y>SR]PTV$28QC[^W=GWSGWKY=_:8
M_8_LO"FA77BWP,DL=I: RWVDLYD\N,<F6)B=V%ZE23QD@\8H ^W*0D 9/ KY
MJ_8R^/%U\1M N?"^O7#7.NZ1&)(;J0Y>YMLA<L>[(2 3W#+U.36I^VSX]O?!
MGPA%GI\SV]SK5VMD\B<$0;6:0 ]LX5?HQH C^)'[;7@?P1?SZ?I<5SXIOH69
M':R94ME8=O-/WN<#*AAUYXP?/;;_ (*)PO/&+CP%)% 3\[Q:N'91ZA3" ?S%
M9'['/[.?AGQYX9N_%OBFT_M4?:FM;2QD<B)0JJ6D< C<26P >!C.#D8^I;OX
M%?#F^MWAD\"^'51L9,.F0Q-P<\,J@C\#0!S/PJ_:G\"_%:Y@L+2\DTC69<*N
MG:F!&\C>D; E7]AG<?2O0_''BJ'P-X/UCQ!<0/<PZ;:O=/#&0&<*,D GO7S9
M\0_V#-'U#5K&\\&ZG)H5N;A!=6=R[2K'%GYGA<Y;<!T5B<_WAW^E;WPAINJ>
M$7\-:@DVH:7+:"RF6XG<R31[=IW2 ABQ'5LYS0!^>7[3?[0.G?'B?P[)I^E7
M6F#3%N%<7+JV_P PQXQM]-A_.NY^!G[8>B_";X9:5X8O/#]_?7%FTS-/!*BH
MV^5W& >> V*R?VSOA!X1^$]UX23PKI/]E+?)=&X'VF:;>4,6W_6.V,;FZ8ZU
MZ;^S-^S?\.OB%\&=#UW7_#OV_5;E[@2W'VVYCW!9W5?E20*,*H' [4 >_?!K
MXKVGQE\&CQ%96,VG0&XDMQ#.P9LKC)R..]8'QX_:%TWX#?V'_:&DW6J?VKY^
MS[,ZKL\KR\YW>OF#\J[?P+\/]!^&NA#1O#=A_9VFB5IO)\Z27YVQD[G9CV'>
MOE7_ (**_P#-/O\ N(?^VU 'TS\(_B7:_%SP/9^)K.SFL+>YDDC$$[!G&QRI
MR1QSBNSKPO\ 8K_Y-]T3_KXNO_1S5>_:G^,\GP=^'9DTYPOB#57:UL2>?*XS
M)-@]=H(Q_M,O49H L_%S]I_P5\(+A["^N9=5UI1DZ;IP5WC/;S&)"IVX)W8Y
MP:\4/_!1.'[3M'@*3[/OQO\ [7&_;GKM\C&<=L_CWKQ']G_X!ZK^T!XFO;B[
MO)K31K9_,U#4W^>661CG8A/WG;DDG..ISD _:^C_ +)?PKT?3#9_\(M%>[UV
MR7%Y-))*W&,[MWRG_=V^M $_P?\ VE_!OQDE^Q:;/+IVM!-YTR_ 21@.IC()
M5P.>ASCD@5S7Q,_:ZT?X9_$:Z\(76@7U[=0-"OVF&5 C>8BN.#SQOQ^%>9_&
MS]C(>&+5_%7PRN+RUN]//VDZ5YK/(-IW;K>3.[<N/NDDGL<\'YE\6>/[_P")
MWQ$M/$.J*@U&<VD4[1C D>-$C+X[;MFX@< DXXH _6.N8\>?$KPS\,]+^W^)
M=7M]+@;/EK(2TDI'9$&68_05T]?.?Q2_8_M?BK\6Y/$VH^(+JWT::",36<9+
MS^8N05C9\K&A&#C!P2V ,YH YCQ)_P %"- LKEH]#\*7^JQ*^WS;RZ6T##^\
M %D/7UQQZ=*B\/?\%"]&N[P)K?@^]TVV) \ZRO5NB.N259(_;H3U/IS[9X;_
M &;/AEX7M%M[;P;I=WA0K2ZE +MV/J3+NP3[8'IQ6+\2/V4/A]X\T:>"TT.S
M\-ZGL/V>^TJ!8!&W;=&N%<>H(SZ$'F@#T/P)\0O#_P 2M"CUCPYJ46HV3':Q
M3(>)O[KJ>5;V(]^E3>./%4/@;P?K'B"X@>YATVU>Z>&,@,X49(!/>OSO^ WC
M'5O@1\>8])O9#%;/?G1M6@!S&P\PQ[_?8WS ^F1T8U^CGB#0+#Q3HE]H^J0?
M:M.OH6@N(=[)O1A@C*D$?4$4 ?G1^TW^T#IWQXG\.R:?I5UI@TQ;A7%RZMO\
MPQXQM]-A_.NY^!G[8>B_";X9:5X8O/#]_?7%FTS-/!*BHV^5W& >> V*R?VS
MOA!X1^$]UX23PKI/]E+?)=&X'VF:;>4,6W_6.V,;FZ8ZUZ;^S-^S?\.OB%\&
M=#UW7_#OV_5;E[@2W'VVYCW!9W5?E20*,*H' [4 >_?!KXKVGQE\&CQ%96,V
MG0&XDMQ#.P9LKC)R..]8'QX_:%TWX#?V'_:&DW6J?VKY^S[,ZKL\KR\YW>OF
M#\J[?P+\/]!^&NA#1O#=A_9VFB5IO)\Z27YVQD[G9CV'>OE7_@HK_P T^_[B
M'_MM0!],_"/XEVOQ<\#V?B:SLYK"WN9)(Q!.P9QL<J<D<<XKLZ\+_8K_ .3?
M=$_Z^+K_ -'-6U^TK\:!\%_A[)?6A1]>OW^RZ=&XR%?&6E([A!S[DJ#UH T?
MBK^T)X+^#P$6NZ@TVI,H==,L5$MR5/0E<@*/0L1GM7@5[_P42MH[IUM/ <L]
MN,;9)]5$;GCG*B%@.<]S_2O$?@C\$=?_ &C_ !??WU]J$T6G1R^;J>L3_O)'
M=N=BY/S.W/)X4<GL#]IZ#^R5\+-"TW[)_P (Q'J+,NU[F_FDEE?WSD!3S_"%
MH Y+X??MR^!_%ES#::W!=>%;J3 \RZ(EMLXZ>:N".<\LH'?([?14$\=U!'-#
M(DT,BATDC8,K*1D$$=01WKXV^/G[$MCINB7FO_#\3H]JAEFT25S+O0<DPNV6
MW <[6)SC@YP#SG[%GQ\N] \1VW@+6;EIM&U%RFG/*V?LLYR0@_V9#QCLQ&.I
MH ^\*\ M?VOM&N_BVW@)?#]\+T:N^D?:S*GE[UE,9?'7&1G%>_U^7/BSQ4W@
M?]I?Q'X@6 7,FF^)[RZ2$G =EN9" ?;.,T ?H?\ $[XR^$_A%IZ7/B34UMY9
M03!9PCS+B;'7:@[?[1P/>OG;5O\ @HAIT-X5TOP1=7EKCB2[U%;=^I_A6-QT
MP?O=R.V3ROP@_9QUW]HK4IOB#\1-3NH].U"0R111G;/=@' QD$11#&T #) X
MP,$_1<_[)7PIFT4Z:/"D,28.VXCN)O/4G/S>87).">AR.V,<4 8_P7_:[\+_
M !<U>+19[2?P[KLP_<VUS()(ISC)6.0 9;@\,JY[9/ ]WK\J/B_\/;WX&_%.
M[T>"[E9K*6.[T^]'RNR'#1OQ_$",$CNIQ7Z;_#_Q./&G@;P_KVT(VI6$-TR#
MHK.@++^!)'X4 =!1110 4444 %>0?$_]JCP#\+IY[*ZU!]7U>+AM/TM1*Z-Z
M.Q(1?<$Y]J]-\2:(GB7P_J.E23SVJ7MN\!GMI&CDCW C<K @@C.:^</AC^PC
MX8\/!+KQA=R>);T'(M82T%JOIG!#N>AZ@=B#0!S-W_P43@2X=;;P%)- #\CR
MZL(V(]U$+ ?F:[OX=?MQ>"/&-Y!8ZS;W/A6\F(427;++:[B.AE&".<C+*!T.
M1V]3A^!?PY@ME@7P+X=*!=H+Z9"SX_WBI)/OG-?+_P"UI^RWH?@_PQ-XT\(V
MYTZ"U=%O]-5BT6UV"B2/))7#, 5Z8.1C!R ?:\<BRHKHP=&&593D$>HIU?+/
M["'Q0N_$WA'5/">HSM/-HA22S=SD_9GR-F?1&7CV< <"OJ:@#Y_^$?[7VC?%
MSQS9^&;+0+ZPGN4D<3SRHRJ$0L>!SSBNU^*_[0O@OX.XAUR_:;4V7>FF6*B6
MX*]B1D! >Q8C/;-?G!\+OB+>?"OQ3_PD&G(LFHQ6L\-N9!E4>1"@<COMW9QW
M( Z5]+_!+]CV?QY$OC+XFWEY-)J1^U)IHE*S3!N=\\GWANSG:N#TR1RM %V]
M_P""B5M'=.MIX#EGMQC;)/JHC<\<Y40L!SGN?Z5[1\$OVF?"_P ;));&R2?2
M=<B0R/IUX02Z#JT;#AP,C/0CTQS5;Q#^R'\+]<T%M.@\.II,JQ[(;ZSFD$T9
MQPQ+,=__  //Y\U\$*-6^ OQC4,Y.H^'=2&YH_E$R*W./]ET/3T:@#]7JJZG
MJ=GHNGW%]?W4-E96Z&2:XN'"1QJ.I9CP!4T$R74$<T3!XI%#JP[@C(-? O[:
MOQNN?%GC*;P5IETR:%H[[+M8VP+FZ'WMWJ(S\H']X,?3 !Z[XX_;X\)Z#>2V
MWA[1KSQ*8VVFX>46D#^ZDJS'\5%9WA;_ (*#Z!J%\L6O>%KW1K=F %Q:72W8
M7W92D9P/;)]JP/V??V*K'6-#L_$7C[SI!>1K-;Z+#(T6V,\@S.,-DCG:I&.Y
MSP/;O$/[(WPLU_3?L@\-+IDBH5CNM/G>*5.G/)*L>/XPW?UH 9\>_$^E>,?V
M:?%>K:+?PZEIUQ8AH[B!LJ?WBY'J".X/([U\Y_\ !/G_ )*3XD_[!/\ [6CK
M"^*?@7Q=^S#8:_X>2Z?6/ GBB$P1S,"JK*"&4LO1)0%P<<.N?3Y=W_@GS_R4
MGQ)_V"?_ &M'0!]Y4444 07ER+.SGN&!98D:0J.^!FOSZ_:3_:BTGXX>#M.T
M:PT6\TV6UOUO&EN9$9641NF!CO\ ./RK]")X$N8)(9%W1R*49<XR",&OB7]L
M+X#^!OA9\/M(U/POH?\ 9E[/JBVTDOVN>;=&8I6(Q([ <JISC/% '(_LV?M1
M:3\#_!VHZ-?Z+>:E+=7[7BRVTB*JJ8T3!SW^0_G7UW\"OCQI_P ==.U6[T_2
M[G3$T^5(F6Y=6+E@3D;?I7SE^Q[\"/ WQ3^'VK:GXHT/^T[V#5'MHY?M<\.V
M,11,%Q&Z@\LQSC/-?5_P\^$_A7X4VMY;>%M*_LN&\=9)U^T2S;V4$ YD=B."
M>F* /%?^"@'_ "1O1O\ L/P_^D]S6?\ \$_I$A^&7B:21E2--5+,[' 4"&/)
M)K0_X* ?\D;T;_L/P_\ I/<U\L?"S5/%OC3PP?A5X31HWUK46O+Z?<54PB-%
MVNP^[&-K,W7/R@>A /K#XB_MR^"O"-Y+9:';7'BRZCX,MLXAM<^@E();ZJI'
MH37*:!_P4,TF[U%(]9\&W6FV;8!N+2_6Y9>>I0QIQ]#^%=[\._V+?A_X0T^+
M^V;-O%.J[1YMS>LRQ XY"1*< ?[VX\=:\O\ VJ?V4O#_ (9\'77B_P &VCZ:
MUDXDOM/61GB:)FP73<25*DCY0=NW. ,<@'UOX4\5Z3XWT"TUK0[V/4-,NUW1
M3Q]#V((/(((((/((P:UZ^(?^"?OCJXA\0^(/"$LI:SGMO[2@0]$D1E1\?[RN
MI_X!7VO>WD&G6=Q=W4JP6T$;2RRN<*B*,LQ]@ 30!0\3^*M'\%Z-/JVN:C;Z
M7IT(^>XN'VKGL!W)/8#)/85\U>+?^"@7AC3+EXO#_AV_UU$('GW,RVD;]<E?
ME=L=.JCOTQSX#\0O''B?]K'XOVFD:7O%@\[0Z78NQ$5O".6FD_VBH+,>3_",
MX KZ\^&G[(OP_P# 6G0B^TB#Q/JN/WUYJL0E1CC!"Q'**O)QP3TR3@4 >8:)
M_P %#M)N+K;J_@R\L+?C]Y97R7+>_P K)'_.OI'X>?%'PQ\4](_M'PUJL6H1
M+@2Q<I-"Q[.AY7OST..":YKQ9^S/\-/%^G-:S^$M.TUL?)<:3 MI*A]08P ?
M^! CVKXJ\<>#_%?['WQ8L=0TF^>:SDS)979&$O(01YD$JCC(X!'NK#!Q@ _2
M6BN=^'WC:Q^(W@S2?$FFY%IJ$ E",<M&W1T/NK J?I714 %(2 ,G@4M?/O[;
M/CV]\&?"$6>GS/;W.M7:V3R)P1!M9I #VSA5^C&@"/XD?MM>!_!%_/I^EQ7/
MBF^A9D=K)E2V5AV\T_>YP,J&'7GC!\]MO^"B<+SQBX\!210$_.\6KAV4>H4P
M@'\Q61^QS^SGX9\>>&;OQ;XIM/[5'VIK6TL9'(B4*JEI' (W$EL '@8S@Y&/
MJ6[^!7PYOK=X9/ OAU4;&3#ID,3<'/#*H(_ T <S\*OVI_ OQ6N8+"TO)-(U
MF7"KIVI@1O(WI&P)5_89W'TKV"OD_P"(?[!FCZAJUC>>#=3DT*W-P@NK.Y=I
M5CBS\SPN<MN Z*Q.?[P[_4VEV":5IMI91RS3I;1)"LMQ(9)'"@#+,>68XY)Z
MF@#"\>?$KPS\,]+^W^)=7M]+@;/EK(2TDI'9$&68_05\Y^)/^"A&@65RT>A^
M%+_58E?;YMY=+:!A_> "R'KZXX].E=/\4OV/[7XJ_%N3Q-J/B"ZM]&F@C$UG
M&2\_F+D%8V?*QH1@XP<$M@#.:] \-_LV?#+PO:+;VW@W2[O"A6EU* 7;L?4F
M7=@GVP/3B@#Q/P]_P4+T:[O FM^#[W3;8D#SK*]6Z(ZY)5DC]NA/4^G/TKX$
M^(7A_P")6A1ZQX<U*+4;)CM8ID/$W]UU/*M[$>_2O//B1^RA\/O'FC3P6FAV
M?AO4]A^SWVE0+ (V[;HUPKCU!&?0@\U\<? ;QCJWP(^/,>DWLABMGOSHVK0
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M+Z<_,R*QS@ $;F]P!Z@ ]/OO^"B5K'<L+/P)-/;X&))]5$3GCG*B%@/SKL?
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MVVFX>46D#^ZDJS'\5%?/'PSL/%WQY\/^'OA=H<AT[0-+:6\U*Z?)CW/*S!W
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M9VGFT0I)9NYR?LSY&S/HC+Q[. .!7T!\3/%3>!_A[XCU^-0TVG6$UQ$I&09
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M_P#Z3R5^:?PN^)VM?#;^W5\.^8FL:S:+IT-Q$"9(0TBDE .=YVA1CIG(Y H
M^_\ XL?M3>!_A-=RZ==W4NKZU&/GT[30':,]A(Q(5/IDM[5XPW_!1. 7;*O@
M.0VWF8$AU8!RF>NWR<9QVW>V>]7_ (-?L-Z8FGQ:M\1GFU'4KA=YTF"=DCAS
MS^\D4AG?UVD '/WNM>@?$?\ 8[\ >+/#MS!HVD1>'=96,_9;VT=PH<=!(F2K
M*3U.-WH: .R^#?QW\-?&W2IKC19);:^M@/M6G78"S0YZ-P2&4D'# _4 \5Z-
M7Y=_L]>)KWX9?'CP_P";NMV:_&E7T1.!LD?RG#>NUB&^J"OU$H CFFCMX7EE
M=8HHU+.[D*J@#)))Z 5\[_$+]N/P-X1NIK/1H;GQ5=QY'F6A$=KG!X\ULD\X
MY56&"3DXP?(_VU?CY=ZOK]QX T2Z:'2;+ U.2)L&YGZ^42/X$XR.[9S]T5J?
ML^?L56>M:+:>(O'_ )Y2Z19;;187,1\L\AIG!W D?PJ01W.>  7K+_@HE;O<
MHMWX#EAMSG?)#JPD<<<84PJ#SCN*][^%/[0_@OXP_N-$U!X-4"EVTR^417
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M &POC&1<7'DJX,CL<M!IMH#]U1WZ@#NS')ZD@ ]Y\1?\%"M#M+LIH?A&^U2
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MHQ1110 445\D_ML?'V\\,HG@/P_=-;7=W")=4NHFP\<3?=A![%ARW^S@=&-
M'H/Q-_;%\!?#N]ETZ":?Q'J<3;9(=+VM%&<\AI20N1SPNXYX..WE2_\ !12,
MS*&\ L(MW+#6 6 SUQY'7VS^-0_LU?L=:=K.A6/BOQW#)<+=H)[/1MY1?+/*
MO*1@DD8(4$#!&<YP/I9O@3\.6L_LW_""^'O+V>7N&FPB3&,??V[L^^<^] '(
M?"G]K+P+\4[R/3H[B;0M8D.V.RU,*GG'TCD!*L?8D,>P->TU\1_M,?L?V7A3
M0KKQ;X&26.TM 9;[26<R>7&.3+$Q.["]2I)XR0>,5Z-^QE\>+KXC:!<^%]>N
M&N==TB,20W4AR]S;9"Y8]V0D GN&7J<F@#Z6KQ'XK?M<^!_A;J4VE%[C7M9A
M;9+:Z<%*0G/(>0D*".>!D@\$"MW]I?QW=_#KX,>(=6T^5H-19$M;:5.L;R.$
M+ ]B%+$>X%?)/['GP)T7XN:IK>L^)T>^T[3&C1+,2%1/*^XDN00< *.,\EN>
M 00#O1_P440R 'P PCS]X:QSCZ>1_6O5/AM^V1X ^(%W'8W,\_AK49&VI%J@
M58I#G@+*"5]/O;>>!FN]_P"%%?#G[)]F_P"$$\.^7Y?E[O[,AWXQC._;NS_M
M9SWS7BOQ;_88\.^(K>6]\$RCP[J>[<;.9V>TDR><9RT9ZXQE>V .0 ?3EY<B
MSLY[A@66)&D*CO@9K\^OVD_VHM)^.'@[3M&L-%O--EM;];QI;F1&5E$;I@8[
M_./RK[H\#>"H?!?@73/#)N[C4H;.U%LUQ=2%GEXYYSD#DX /RC '2OD7]L+X
M#^!OA9\/M(U/POH?]F7L^J+;22_:YYMT9BE8C$CL!RJG.,\4 <C^S9^U%I/P
M/\':CHU_HMYJ4MU?M>++;2(JJIC1,'/?Y#^=?7?P*^/&G_'73M5N]/TNYTQ-
M/E2)EN75BY8$Y&WZ5\Y?L>_ CP-\4_A]JVI^*-#_ +3O8-4>VCE^USP[8Q%$
MP7$;J#RS'.,\U]7_  \^$_A7X4VMY;>%M*_LN&\=9)U^T2S;V4$ YD=B.">F
M* .AUG6]/\.Z;/J.J7L&GV$"[I;FYD"(@]R:^=/&W[>7@K0+B6WT'3K[Q-(@
M/[]<6UNQ] S M^.S'3&:[3]HW]G^3X[66@PP:TVD/87):7?ODB:)EPQ$8(!D
M! P>."PS3? O[(WPU\$VT8DT-/$%X,%[O6/W^X_]<_\ 5@=?X<^I- 'D%E_P
M42MWN46[\!RPVYSODAU82...,*85!YQW%>_?";]H#P=\9(W30KYXM1C7?)IM
MZHCN%7^\ "0P]U)QWQFG:_\ L[_#7Q'I\EI<>"M&MD8$>;86B6LJ^X>,*:^"
MOBYX"U3]F7XPVZZ-J,O[C9J.EWIX<QEB-KXX)!5E8=&'8!L4 ?IW7S-_P4 _
MY(WHW_8?A_\ 2>YKWGP!XLA\=^"=#\0P+Y<>I6D=R8\_<9E!9?P.1^%>#?\
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M#/IL4S]>[NI8_B30!YAX _;B\">++J.SU>*[\+7+D!9+S$EL3CIYB\KSGEE
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MWOP[_8M^'_A#3XO[9LV\4ZKM'FW-ZS+$#CD)$IP!_O;CQUKR_P#:I_92\/\
MAGP==>+_  ;:/IK63B2^T]9&>)HF;!=-Q)4J2/E!V[<X QR ?6_A3Q7I/C?0
M+36M#O8]0TR[7=%/'T/8@@\@@@@@\@C!K7KXA_X)^^.KB'Q#X@\(2REK.>V_
MM*!#T21&5'Q_O*ZG_@%?:][>0:=9W%W=2K!;01M++*YPJ(HRS'V !- %#Q/X
MJT?P7HT^K:YJ-OI>G0CY[BX?:N>P'<D]@,D]A7S5XM_X*!>&-,N7B\/^';_7
M40@>?<S+:1OUR5^5VQTZJ._3'/@/Q"\<>)_VL?B_::1I>\6#SM#I=B[$16\(
MY::3_:*@LQY/\(S@"OKSX:?LB_#_ ,!:="+[2(/$^JX_?7FJQ"5&.,$+$<HJ
M\G'!/3).!0!YAHG_  4.TFXNMNK^#+RPM^/WEE?)<M[_ "LD?\Z^D?AY\4?#
M'Q3TC^T?#6JQ:A$N!+%RDT+'LZ'E>_/0XX)KFO%G[,_PT\7Z<UK/X2T[36Q\
MEQI,"VDJ'U!C !_X$"/:OBKQQX/\5_L??%BQU#2;YYK.3,EE=D82\A!'F02J
M.,C@$>ZL,'& #]):9)(D,;22,J1H"S,QP% ZDFL#X?>-K'XC>#-)\2:;D6FH
M0"4(QRT;='0^ZL"I^E?*W[<WQNNK6YB^'NC730*T2SZN\389@PS' 3V&/G8=
MPR=L@@'>?$;]N3P5X/O9K'0[6X\674609;:18K4GT$I!+?55(]":Y+1/^"AV
ME7%ZJ:OX+N["T/6:SOUN7'/]QHXQ_P"/5PG[-7[(:?$;28/%/BZ6:UT*8DVE
MA =DMT <;V;^%,@@ <GKD#&?IJ]_9.^%-[I0L/\ A$H($4?)-#<3+,IP0#YF
M_+=>C$CID'% &W)\0O#_ ,2_A+X@UCP[J,>H6;:;<JVWAXF\EB4=3RK>Q^HX
MKX<_8K_Y."T3_KWNO_1+5VWQ&^$WB;]DW4KSQ!X7O)]8\%:I"]A?0S'YHUD4
MJJS;1@D%LI( ,'@@9PW$_L5_\G!:)_U[W7_HEJ /TEHHHH **** "BBB@#A?
MCM_R1;QU_P!@2\_]$M7Q+^PO_P EU3_L&W'_ +)7VU\=O^2+>.O^P)>?^B6K
MXE_87_Y+JG_8-N/_ &2@#]%**** /&?VQ/\ DW+Q=_VY_P#I9!7A?_!._P#Y
M#?C;_KWM?_0I*]T_;$_Y-R\7?]N?_I9!7PE\)O&7B32;/6_"GA**5M;\5-;V
M22P'$BQ@N753_"6W %NRANG4 'VW\4_VQO!'PXOYM,M3-XEU6%BDL.GE1%$P
MX*O*>,YXPH;'?%>::;_P41LY;R-;_P "SVUH?ORVVIK,X^B&) ?^^A77?"C]
MB#PCX7TVWN?%T?\ PDVM%0TD9D9+2%NN%52"^.F7R#_=%9_[07['_A6[\%ZI
MK?@[3?[&URQA-S]FMY&,-RB+\R;&)"MM!(*XR>H.<@ ]]^'7Q)\/_%/PY'K7
MAV]%W:,WER*PVR0R  E'7^%AD?7(()!S745^=W[#WCFX\-_&*+0_-(L-=@DA
MDC/W?-C1I(V^ORLO_ Z_1&@"IJFJV6AZ=<7^HW<-C8VZ%YKBYD"1QKZLQX K
MYM\;_MZ^#=!N9;;P_I=]XEDCR//W"UMV.1]UF!8]^=GIUSQX;^TO\8]9^./Q
M(3P=X=:2XT.VO!9V=K;MQ?7&[;YK=B,Y"YX YXR:^B/A!^QGX/\ !&EV]SXE
MLH?%&OL%>5KH%K6)N"42,\,,]W!SZ '% '":;_P41LI;I5U#P-<6MMCF2VU-
M9G'_  %HD'_CU?0GPM^./A#XP6;2^'M2#W<:[IM.N5\NYA'NF>1_M*67WJ#7
MOV>/AKXAT][.X\%:+;HP_P!986:6LJ^X>(*WZU\6_'7X):U^S)XPTSQ-X7U*
MY_LAY\V-_D>;:R@$^3)CALKG!QAAN!'!R ?HO7DWQX_:%TWX#?V'_:&DW6J?
MVKY^S[,ZKL\KR\YW>OF#\JV/@5\5H/C'\.=/U]$6"]R;>^MUZ17"XW >QR&'
MLP[U\Z?\%%?^:??]Q#_VVH ^EO WQ7TGQA\,;/QS<8T/29XI)G-[*H$*I(R$
MLW3JOZ@5XSK?[>_@NSU<V>E:1JFL0!M@O,+ CG/50QW8_P!X ^U?/7@N/Q?^
MT'X<\)?##PZ&L]#T.%Y]1N921#YCSR/YCD=<*X54ZD[CTY'TOX-_8:^'OAZ"
M!M7^W^([U/F>2:=K>(GMM2,@@=\%C]<<4 ?15<WX[^(OAWX::*VJ>)-4ATRU
MY""0Y>5O[J(/F8^P'OTJUXR\5V'@7PKJFOZF_EV.GP-/)CJV.BCW)P![D5^=
M6G6WB_\ ;"^,9%Q<>2K@R.QRT&FV@/W5'?J .[,<GJ2 #WGQ%_P4*T.TNRFA
M^$;[5( Q'G7MVEJ2..0JK)WSUQQCUP)/#'_!0?P_?72QZ[X5OM(B9MOG6ERM
MV%'JP*QG\L_CTKUCP-^RU\-O!&FQVX\-6>MW.S;+>:S"MT\AXR=K@JO3^$#]
M3F+Q[^RI\./'.G20KX?M= O-I$5YHT2VQC/8E% 1OQ'XB@#T3PAXUT/Q]HL6
MK>'M3@U73Y.!+ ?NG^ZRG!5O9@#[5MU^;6DZGXK_ &.?C0]I<N]S8$J;B&/B
M+4;,D[74$\,/FQ_=8$9(SG]&=(U6UUW2K/4K&43V5Y"EQ!*O1T90RG\010!<
MHHHH \\^-_QDLO@?X4M-=O\ 3[C4H;B]2R$5LZJP9HY'W<]L1D?C4/P-^-EA
M\<O#^H:M8:;<:;':77V5H[EU8L=BMD8[?-7E_P#P4 _Y(WHW_8?A_P#2>YJC
M_P $^?\ DFWB3_L+?^T8Z /J8D 9/ KYZ^)'[;7@?P1?SZ?I<5SXIOH69':R
M94ME8=O-/WN<#*AAUYXP9/VV?'M[X,^$(L]/F>WN=:NULGD3@B#:S2 'MG"K
M]&->1?L<_LY^&?'GAF[\6^*;3^U1]J:UM+&1R(E"JI:1P"-Q); !X&,X.1@
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M-XT2'#.([MVVCZXQ^- 'Z$?%;XW>$_@WIT=QXBOF6XF!-OI]JOF7,^.I5<@
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M!)K?[+/QXDBCN&FFTBY59#&-JWEHX5L$9Q\R$<9.&]QF@#]0:\F^/'[0NF_
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MT.UI2#^(->JT %07ER+.SGN&!98D:0J.^!FIZCG@2Y@DAD7='(I1ESC((P:
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MW.3QR0 ?27C;]OSPMHM]);>'="O/$:QOM-U+,+2%QSRF5=B.G55[^G-3PO\
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M!($!P<=LGZFO+?V;_P!F*]^-T\NNZU=36'AF*8H\R8,]Y)U94)S@#/+D'G@
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M[YC_ +P-?(OQ+_9;\;_"[XAV,7@^WU/7K>4_:=/U&PB;S8"A'$K+PC*2/FR
M<C'.0 #[]\<>*H? W@_6/$%Q ]S#IMJ]T\,9 9PHR0">]?GI^TW^T#IWQXG\
M.R:?I5UI@TQ;A7%RZMO\PQXQM]-A_.OO#PGI>K^-_A7!I?Q%TE(-3O+5K75+
M.*<%91RI(>)N-PP3M/!) KXR_;.^$'A'X3W7A)/"ND_V4M\ET;@?:9IMY0Q;
M?]8[8QN;ICK0!K? S]L/1?A-\,M*\,7GA^_OKBS:9FG@E14;?*[C // ;%?6
MOP:^*]I\9?!H\165C-IT!N)+<0SL&;*XR<CCO7@/[,W[-_PZ^(7P9T/7=?\
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M *4Q5\]_\$\_^1N\7?\ 7C#_ .C#0!]R5\#?\% _^2KZ#_V!$_\ 1\U??-?
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M8,Z[)7C.2..2A/XU\E_\%#?^1H\'?]><_P#Z&M>]_L=_\FY>$?\ M\_]+)Z
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M)]AM&(Y\F,YD(]F? _[95ZA^T;^S_)\=K+088-:;2'L+DM+OWR1-$RX8B,$
MR @8/'!89H XOQM^WEX*T"XEM]!TZ^\32(#^_7%M;L?0,P+?CLQTQFN2LO\
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M &'X?_2>YH S/^">]K"G@#Q1<K&HGDU-8WD Y95B4J#[ NW_ 'T:^K*^2?\
M@GOKED_A+Q1HXG4:C'?+=F \$Q-&J!AZC*$'TR/45];4 %?GW^WCX2M]#^+%
MCJ]LJQ_VQ8+),JC&98V*%OQ79^(-?H)7YZ_MU^,;?Q#\7K?2K6194T6R6WE*
MG.)G)=AGV4H/8Y% 'U?^SAXJDU']G/POJ]T6F:VT^6-LGEE@=XQS](Q7Y[_#
M[QGI^E_%G2_%7BF&XU"TBU ZC=I;(K2229+@A690?GP3DCC-?H;^SGX5.E?L
M\^%-)N@R?:=.:9P>H6X9Y?Y25^>O@K0-+T7XQ:=H/C*V$VF0:K_9^HQ-(\0
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M(]8GC$EWIUE'';EA]PRLP9A[X3'T8U]$?MB?\FY>+O\ MS_]+(*\+_X)W_\
M(;\;?]>]K_Z%)0!]M4UE#J58 @C!![TZB@#\NO@ BZ?^T3X4BB'R1ZMY2AN>
M,LO\J_1'XT:Y+X;^$OC#4H#MN(-+N#$W]URA"G\"0:_/#X&_\G'^&?\ L-_^
MSFOT5^+OAV7Q;\+O%>D6ZE[F[TRXCA5>K2;"4'_?0% 'P/\ L9>%+?Q1\=M+
MDN4$L6EP2ZB$(X+IA4/X,ZL/=17Z35^:'[(/C2V\%?'+26O9/(MM2CDTUY&.
M K28*9^KJ@_'-?I?0 5\X_MX:=;77P6@NI85>XM=3A,,A'S)N5PP!]".WL/2
MOHZOG+]N^_M[;X*16\LJI/<:I (HR?F?"N3@>P'7Z>HH XW_ ()W_P#($\;?
M]?%K_P"@R5]&?&K_ )(WX\_[ %__ .D\E?.?_!.__D">-O\ KXM?_09*^C/C
M5_R1OQY_V +_ /\ 2>2@#XE_8/\ ^2WS?]@FX_\ 0XZ^IOVO]<ET/X >)# =
MLEWY-IN]%>50_P":[A^-?+/[!_\ R6^;_L$W'_H<=?5G[6WAR;Q)\ _$\=NC
M23VB1WJJO]V.16<_@@<_A0!\V?L ^%;?5/B'KNNS())-)LEC@R/N/,Q&X>^U
M''T8U]Z5\!_L%>-+;0?B5JNA74@B.MV@$!)P&FB)8+]2C2'\,=Z^_* "OC[_
M (*&Z=;'2?!M_P"2HO!/<0>:!\Q3:C;3ZC//XGUK[!KY _X*'7UN-%\&6?FK
M]J:XN)A$#\VP*@W>PR?Y^AH [/\ 8/\ ^2(3?]A:X_\ 0(Z]^UO6[#PWI%UJ
MFJ7<5CI]K&99KB=MJHH[D_T[]*\!_8/_ .2(3?\ 86N/_0(Z\[_X*">.+R.Z
M\-^$896BLWA;4;E%)'FMN*1Y]AM<_4CTH U?&G[?=N-3-AX*\,2ZMF3RX[N^
M=D\T]!LA4;CDXQE@<=@3QFVO[47QYV17<WPM$UAM$K/%H5^H:/&<ARY &.^"
M*]5_9%^$^B>#?A;HNO1VD4VO:Q;B[GOW0&14?)6-"?NJ%(R!U.2>V/>* /S^
M^-_[5<GQ2^&]YX2UGPI/H&M"XAF#>:63Y3N^9&563*GCK^M=[_P3ND8Z=XZC
M)^19;-@/<B;/\A^5=]^W+96TOP/GN9((GN8KZW$4SH"Z98YVGJ,CTKS_ /X)
MV?\ 'EX\_P"NEE_*>@#Z_OO^/*X_ZYM_*OS-_9'_ .3B/!__ %TN/_2:6OTR
MOO\ CRN/^N;?RK\S?V1_^3B/!_\ UTN/_2:6@#].:\:_:]U^;P_\ /$K6[%9
M;L0V>X=EDE4/^:;A^->RUY!^UEX;E\3_  #\40VZEI[2-+Y0!GY8G5W_ /'
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MKX<W5QKV@C4->L+UX;B3[;<1$HP#1MM20*!@LO3^ T =[_P\ ^'G_0&\3?\
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M0_%]D+W2]062W2-II(0)]I,?S(RGDC;C/5A0!]7_ /#P#X>?] ;Q-_X"V_\
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M22QN5/TV9_H*^MOVO=?F\/\ P \2M;L5ENQ#9[AV6250_P":;A^-?(W[$?\
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M^/\ DBVG_P#8;@_]$SU])U\V?M\?\D6T_P#[#<'_ *)GH P?^">O_(D^*_\
ML(1_^BZ^L:^3O^">O_(D^*_^PA'_ .BZ^L: /@']OK7YK_XKZ5I98_9M/TM&
M5?\ II([EC^(6,?\!KL/@U^V#\/?A?\ #/0?#<FCZ^US9P?Z3);6T!1YF8M(
MP)F!(W,<$@<8KEOV_O#<NG_$S1=:VG[-J.FB$,1_RTB=MP_[YDC_ #KT?]G;
M]G_X3_$_X1Z'K=[X;%WJA5X+YQJ%TA\Y&(.564 9&UL =&% &O\ \/ /AY_T
M!O$W_@+;_P#Q^C_AX!\//^@-XF_\!;?_ ./UV?\ PQW\(?\ H4?_ "I7G_QZ
MC_ACOX0_]"C_ .5*\_\ CU 'PK\<OB)HWCSXLWOBWPM!>Z;#<F&?;>(B2+.B
M@%@%9AR5!Z]<U^H&@:E_;.A:=J&,?:[:.? [;E#?UKRG_ACOX0_]"C_Y4KS_
M ./5Z]8V4&F65O:6T8BMK>-8HHP2=J*, <^@% 'YG?M<?\G$>,/^NEO_ .DT
M5?IE8_\ 'E;_ /7-?Y5^9O[7'_)Q'C#_ *Z6_P#Z315^F5C_ ,>5O_US7^5
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M*5'4A03C]*_,7XL?\G+^(/\ L8V_]'"OT[O[--1L;BUDSY<\;1-CKA@0?YT
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M._\ !/;PY9KX=\4Z]Y8;4)+I+$2'JL2H'P/J6&?]T5]=U\L?\$^?^2;>)/\
ML+?^T8Z^IZ .4^+%M'>_"WQC!*-T<FCWBL/8PO7P?^Q!*4^/=BHQA[&Y4_\
M?&?Z5]Z_$[_DFWBS_L$W?_HEZ^!_V(_^2^Z;_P!>=S_Z+- 'UU^UYX@F\/?
M'Q*UNS)+>"*RW*>BR2*''XIN'XU\X_L >%+?5/B!K^NSQK))I-DL<&[^!YF(
M+#WVHZ_1C7TC^UKX<F\2_ /Q/%;H7GM$CO54?W8I%9_R0.?PKYK_ &!/%]MH
M_P 0];T&XD6-]8LU> L0-\D))V#WVNY_X": /O6BBB@#Y)_X*#^%;:;PGX9\
M2!%6\M[XZ<SCJZ21O( ?H8CC_>/K6S^P)K\^H_"S5],F8O'IVIMY)/\ "DB*
MQ7_OH,?^!5SW_!0?QC;)H7AGPHDBO=R7)U.6,=414:-"?]XO)C_=-=+^P/X=
MGTSX3:EJDRE%U/4G:'/1HXT5-W_?>\?\!H ^F:*** /C7_@H=KDJQ^"]&1R(
M&-S=RIV9AL1#^ ,GYUW_ .PMX6@T;X,?VLJ#[5K%[+*\G?9&?*5?H"KG_@1K
MB/\ @H7X:EETOPAK\:$PV\L]E,V.A<*\?_HN2NI_80\=VFM_"ZY\,EPNH:+<
MNWE$\M#*Q=7'_ BX/IQZT ?3-%%% 'YL_MH:?;6'Q^UDV\2P^?!;S2;>-SF,
M9;ZG _G7Z ?#'_DFWA/_ +!-I_Z)2OS\_;-U.UU/X_:W]EF686T-O;RE.0LB
MQC<OU&<'WR*_0/X8_P#)-O"?_8)M/_1*4 ?(G_!0W_D:/!W_ %YS_P#H:U[W
M^QW_ ,FY>$?^WS_TLGKP;_@H;&P\2>#)"/D-I<*#ZD.F?YC\Z]S_ &-+N*X_
M9W\-1QMEK>2[CD'HWVF5L?DP_.@#VRO)OVK/^3??&7_7O'_Z.CKUFO%?VPO$
M-CHGP$\007<PCFU$Q6EM'_%)(9%; ^BHQ/L* /G[_@GM_P CYXI_[!J?^C17
MW77PI_P3V_Y'SQ3_ -@U/_1HKZ!_:^\<7G@;X):G+82M;WFI31Z<DR$AD#Y+
MX/8E$<9]Z .7^+?[;GAGP'J-SI/A^R;Q1J4!:.6=)A%:1OTQOP2^#UVC';=Z
M>?6G[6/QO\0(;S1/AI%=Z<Y_=R1:-?7 Q@$?.C@'@@\ =153]A'X3Z)XD_MG
MQ=J]I%J-Q87"VEE#.@9(GV[FDVG@M\R@'M@GKC'V]0!\9ZA^VOKMAI][H_C?
MX?7.DR7=O);^;%YD+!MFUOW4J\X+#C=Q[YKR']C&1D_:&\.JIP'BNU8>H^SR
M'^8%?H5X^LK;4/!&O07D$-S;FQG+1SH'4XC8\@\5^>?[&?\ R<1X:_ZYW?\
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M ?>?PGD:;X6^#9'.YWT:S9CZDP)7R]_P45_YI]_W$/\ VVKZ?^$?_)*/!?\
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M8)[V"%(U&&5P2LK'D-TQU KZ/_X8[^$/_0H_^5*\_P#CU'_#'?PA_P"A1_\
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M(OPGT3P;\+=%UZ.TBFU[6+<7<]^Z R*CY*QH3]U0I&0.IR3VQ[Q0!^?WQO\
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MY)1KW_8;?_T1#0!]05\S?\% /^2-Z-_V'X?_ $GN:^F:^9O^"@'_ "1O1O\
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MW_\ ' ]?'G[(7@CP7\1O'NHZ!XPTP:B9;(S6(-S+#^\1AO4>6ZY)4D\YX0T
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M,Q_"OU,1UD565@RL,A@<@B@!U%%% !7Q9_P43_X_? ?_ %SO?YP5]IU\6?\
M!1/_ (_? ?\ USO?YP4 >S?L9_\ )N_AK_KI=_\ I3+7MM>)?L9_\F[^&O\
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M/^PM_P"T8ZO?\% /^2-Z-_V'X?\ TGN:H_\ !/G_ ))MXD_["W_M&.@#T?\
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MGP(MU/2/4;E1],J?ZFN"_P""B'_($\$_]?%U_P"@QUW7["__ "0I/^PE<?\
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M-K$C;<)GHQ8,2PYQ@>N?JN@#X8^(O[8=[XI\!>(?"7B?P3<:'?ZC:-'#,LC
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M_';4-!U"WTB;1[BQMY(9H9)1*I)8$%7 !(Z]5%?;'[)<C2_L\^#V<[B(IU_
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M6N,8ZGK0!S'[%?\ R;[HG_7Q=?\ HYJYK_@H!_R1O1O^P_#_ .D]S7MOPO\
MAMIGPF\'6OAO2)[NYL;9Y'22]=6E)=BQR551U/I7B7_!0#_DC>C?]A^'_P!)
M[F@#Y9^%>B^,?"?A:3XI^#I7>;1+][2^@1"X$!C1MSJ/OQG<0P_APK#&,K]5
M> _V[/ VN6$*^)8[KPUJ &)3Y+7%N3CJK1@MCCH5XR.3UK+_ ."?B+)\-/$J
MLH96U8@@C((\F.NL^(/[%GP^\;W\U_9QW?AJ]E.YQIC*(&8GDF)@0/HA4=Z
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MABYCNM2-_P"))D.?*OI0D&03CY$ )[9#,0<=.U 'S%\:?%'C3X]:)=_$/4;
M:5X/TN5;/3[<DE2TC8;:2!YC?*-S\#@ #T]H_8 ^(5I+HNL^"#;3"_BFDU=;
M@8,31$0Q%3SD,#@],$'J,<_3GB7P#H'BWPA/X7U'38'T.6(1?9(E\M8PI!79
MMQM*D C'3%<+\(OV9_"OP6\1WVM:#=ZK/<W=NUJT=]/&\:(75_E"QJ<Y4#))
MXH J?MB?\FY>+O\ MS_]+(*\+_X)W_\ (;\;?]>]K_Z%)7UG\2OA_IWQ2\%:
MCX8U6:YM["^\OS9+-E64;)%D&TLK#J@!R#QFN4^#/[._AOX'76J3Z#>ZK=OJ
M*1I*-1EC<*$+$;=D:8^\>N: /4J*** /R\^!O_)Q_AG_ +#?_LYK]0Z\%\*_
ML:>"O!_C:Q\466J:]+J%G=?:XXY[B Q%\DX($(..?7\:]ZH _.W]K;X!7OPV
M\7W7B?2;9F\+ZG.9A)$.+.=CEHVQ]U2<E3TYQVY]!^"W[=,.G:3;Z1X_M;F>
M2W01QZS9J)&D Z><A(.<#[RYSW'4U]DWUA;:I9S6E[;0W=I,I26"= Z2*>H9
M3P1[&OGKQE^PM\/_ !'>27>ES:CX<DD;<T%I()(/?"N"1^#8'84 6O$O[<7P
MTT>P,NFW5]K]T4RMO;6CQ8;T9I0H'N1G\:^7O'>K^-_VFK7Q#XXU&(:?X9\-
MVK&"% ?(C)91Y2$_?D.0S-Z*,X^45]'>%OV"_ >C7JW&JW^J:\JG(MI9%AB8
M?[6P!C^#"O?5\':&GA9_#<>E6L6@O UL=/CC"Q&,C!7 ]<GGKWZT ?%_[ WQ
M!L]&\3ZQX2GMIWN]:V3V\\>#&GDI(7#Y((R",8!YZXKZV^-7_)&_'G_8 O\
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M9L=2A59]/U.T2=5;Y@T<B X/KP:\5\,_L0_#+P_<I-<VVI:ZR/O5=3N_DXZ
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M!CT/:JOCC]L7X;>$M,FELM8'B'4-FZ&RTZ-FWDYQND("*,CGDG!R :Y+7/V
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MQAIWB2PO=:OKVP9GABOYX7BW%2H8A8E.1G(YZ@4 >M^!_"EKX&\'Z/X?L_\
MCWTZUCMU;'WRHP6/N3DGW-;E%% 'RY^V;^S[>>/+&'QEX<M6NM:T^'RKRSB7
M+W, R0R#NZ9/'5@>.5 /EG[-W[7@^&VE0^%?%\%Q=:);DK:7L W36HS_ *ME
M)^9 <XQRO3!& /O:O(_B7^RW\/OBA=2WU_IDFF:I*VZ34-*D$,KG/)8$%&)[
MDJ3[T 3G]J7X5BP^V?\ "9V7D[=^WRY?-Q_USV;\^V,U\T_M#?MBMX]TU_#'
M@6*\M+*=U6?4FS'//@@A(E!RH)')/)Z8'.>^C_X)[^%A.AD\4:NT(8%D6.(,
M5SR V" <=\'Z5ZW\,?V:_ 7PHN$O-)THW>J( %U+4G\^=>.J\!4/7E%!Y].*
M ,[]F#PKXV\/> 1<^.M9U'4-4OB)(K+4IC))91#.%8MEM[;LD$\ *O!!%<E^
MUK\;?&OPDN?#I\-:<T6GES/=:G/ );>5N5%LW]W(^8\J3QM/!KZ0JO?Z?:ZK
M936=[;0WEI,I26WN(P\<BGJ&4\$>QH ^</A[^W9X*\06L<?BB"Y\+Z@  [^6
MUS;,?560%QSV*\9')Y->BWG[3_PLL;9YY/&FGLB8R(0\K]<<*BEC^ KE?&/[
M%'PT\4S/<6MI>^'9VY/]EW&(R>?X) X Y'"[>@Z<YXV'_@GOX769#+XIU=X@
MPWJD42L5[@$@X/O@_2@#PK]ISXWQ_'_QEH]GX>L;IM,T\/!9(\?[^ZEE90S!
M!DC.U J]>.Q.!]Q_ 3P%<?#/X1^'/#]YC[=;P-)<@'.V61VD9<_[)?;^%9WP
MM_9M\"_"2X%YH^FO=:J!M&I:B_G3J,?P\!4[\JH)SCIQ7J- 'QO_ ,%$-*N7
MMO!&I+$S6<3W=O)*!PKL(F0'ZA'_ .^36'^S%^UEX<^&G@*/PKXGMKV%;262
M2UO+2,2HR.Q<JPR""&)P1D$'G&.?L[Q1X5TCQIHESH^N:?!J>FW Q);SKD'T
M([@CL1@CL:\&NOV"_AO<:@;A+O7[:$L&^R17D9B &.,M$7P?][//!% '3_!?
M]J#0OC=XNU31=*TV[T];2T6ZADOG023C=M<;%)"[=R<[CG<>!CGQO_@HK_S3
M[_N(?^VU?1OPX^!/@CX5,9O#VAPV]\05:^G9IK@@]0'8DJ#@<+@>U4?C1^S_
M .'OCI_8_P#;UYJ=I_97G>3_ &=+&F[S=F[=OC?/^K7&,=3UH YC]BO_ )-]
MT3_KXNO_ $<U=1^T%\'8/C3\/[C2 Z0:K;M]IT^Y?HDP!&UO]E@2I^H/:N@^
M%_PVTSX3>#K7PWI$]W<V-L\CI)>NK2DNQ8Y*JHZGTKJ)IX[6)I9I$BB499W8
M*!]2: /RW\">/_&?[-7CV[$=N]E>1L(=0TJ]4^7<*#P#^9*NI[\$@D'ZS\/_
M +?'@/4+#S-5TW6-)O5CW/ L23QLW]U'# GZLJU[/\1/A!X1^*MHL/B718+^
M1%*Q70S'/$.ORR+A@,\XS@]P:\?_ .&"/AP+_P"T?;O$!BW[_LOVN+R\9^[G
MRMV.WWL^] 'G7CK]K#Q-\;KQ/!7PPT2\L)-2_<O>3,/M10\-C:2L*@=7W' Z
M%>M?-WBCP@W@'XHS^'7N!=2:;?QV[S@8#L"NX@=AG./:OTZ^'GPH\*_"O3C9
M^&M'@T\.,2S\O/-_OR-ECSVS@9X K\X/B)J$?C/]H?6)]./G1WOB QV[+R)!
MYP12,=0< _C0!^G^N:3#KVBZAIESG[/>V\EM+CKM=2I_0FOS)\-:KK_[+GQM
M62^LC)=:7,\-Q;M\JW=NX(+(WHRD,I]0,CJ*_42N%^*/P6\)_&"QC@\1Z=YL
M\((@OH&\NXA!Y(5_3V8$>V: .:\.?M8_"_Q%ID=V?$T.F2,!OM-11HI8SZ'@
M@_521[UYU\4?VX=#LX'TOX?6T_B/6[@B&"[>!T@1VX&U" \C9. N ">YZ&!O
M^"?'A0W>X>)]9%KOSY92(OMSTW;<9QWV_A7KOPP_9Q\"_"65;K1M+-QJBC']
MI:@_G3CC^$X"I_P%1UH _.?XF>%?$/@CQ>%\4G=KUY&FIW*NVYP\I+X<_P![
MUQT)QVK]/_AIX]L_B?X&TKQ/86\]I:Z@C,L-SC>A5V1@<$C[RG!],=.E<I\7
MOV<?!WQJNK:]UR*[M=2@C\E;[3Y5CE,><A6W*RD D]1D9/-==\._ FG_  S\
M&Z;X:TJ6XFL+!76*2[96E;<[.2Q4 =6/0"@#Y;_X*(:5<O;>"-26)FLXGN[>
M24#A781,@/U"/_WR:P_V8OVLO#GPT\!1^%?$]M>PK:2R26MY:1B5&1V+E6&0
M00Q.",@@\XQS]G>*/"ND>--$N='US3X-3TVX&)+>=<@^A'<$=B,$=C7@UU^P
M7\-[C4#<)=Z_;0E@WV2*\C,0 QQEHB^#_O9YX(H Z?X+_M0:%\;O%VJ:+I6F
MW>GK:6BW4,E\Z"2<;MKC8I(7;N3G<<[CP,<^-_\ !17_ )I]_P!Q#_VVKZ-^
M''P)\$?"IC-X>T.&WOB"K7T[--<$'J [$E0<#A<#VJC\:/V?_#WQT_L?^WKS
M4[3^RO.\G^SI8TW>;LW;M\;Y_P!6N,8ZGK0!S'[%?_)ONB?]?%U_Z.:NF_:%
M^#L/QI^'MQI"LD&K6[?:M/N'Z+, 1M8_W6!*GTR#SC%=%\+_ (;:9\)O!UKX
M;TB>[N;&V>1TDO75I278L<E54=3Z5UE 'YB?"KXL>+/V9/'5_:76GR>7O\G4
M]$NCLWE>C*W.UAGAAD$'N"*^O=$_;>^%^IZ8US>7]]I%RJ;C9W-E([LW/RJT
M89>W4D=1TYQZ1\2/@UX0^+%ND?B31XKR:-=L5VA,<\8SG"R+@X]CD>U>%7G_
M  3X\*/<.UKXGUF& XVI,D4C#CG+!5!YSV% ' _'[]M4^,=&NO#O@BWN=/L;
MD&*YU2XPDTL9X*QJ"=@/.6)S@XP*N_L6_L]WL^LVWQ!\06CVUE; MI-O,N&G
M<@CSB#_"H/RGN3D?=&?:?A]^QO\ #OP'=07LMI<>(K^(AUEU9U>-6P.1$H"X
MR"1N#$9ZU[BJA%"J  !@ =!0 ZOR_P!<_P"3K=0_['63_P!+C7Z@5X-=_L;^
M"[SX@S>,'U/7AJ<NJ-JS1+<0^2)3+YNT#R<[=W&,YQW[T >\T444 ?!O_!0;
M_DI/AO\ [!/_ +6DKZ@_9?\ ^2!>"_\ KS/_ *,>JWQB_9G\,?&W6[+5-=O]
M7M;BTM_LR+I\T2(5W%LD/&QSECWKO/ ?@RR^'GA#3/#FG2W$UCI\7E1273*T
MC#)/S%0!GGL!0!XW^US\:O$OP:TWPU/X<DMHWOY9TF^TPB0$*J%<<\?>->G_
M  :\4W_C?X7>&]>U-D;4+^T6:8Q)M4L2>@[5\C_MY^-+G7/'FB^#XK ;=-B^
MT)*C%Y)WGP H7'&-@'<DFOK+X&^'K[PK\(?"6E:G";:_MM/C6:%NL;$9VGW&
M<'W!H [JBBB@#YX_;8^&-]X\^&5OJ>EP/=7V@SM<M!&,L\#+B7:.Y&$;Z*:\
M+_9._:@TOX5Z;/X6\5"6+199S<6VH0QF3[,S ;U=1\Q0X!!4$@YX(/'WW7@W
MQ(_8S\ ^/]1GU*WCNO#FH3'=(VF,HAD8G)9HF! )_P!G;Z^N0#H=4_:H^%FE
M6#W;^+[2X4#*Q6J22R,<< *JY&?4X [D5\X_$[XS^)OVJIKOPGX)TJ;3_"MH
MAN]0N[K[TB1Y93*1D(N5^5 268#GT]'T+]@+P3878FU/6=8U6-2"+<-'"C=<
MAB%+'MT(Z5]!>$O ^@>!=%72-!TFVTS3QUAA3[YZ$N3DN?=B30!^?/[&OQ!M
M/ ?QBMX;RVGN%UR$:1$T&,Q2R31E&8$CY<K@XYYX!QBOTCKPS3_V.? &C>/+
M#Q5IK:II]Q97:7L-C!<(;4.K[@,,A;;G' :O<Z /R_\ V4_^3@O!O_7Q)_Z)
MDK]0*\'^'W[&_@OX;^,=,\2:9J>O3WVGNSQ1W=Q"T3$J5.X+"IZ,>A%>\4 %
M?FU^VI_R<%K?_7O:_P#HE:_26O$?BA^R1X/^+/C&Z\2:OJ6MV]]<I&CQV4\*
MQ (H48#1,>@]: /3_A__ ,B'X;_[!MM_Z*6OC_\ ;5^ %Y9ZS<?$'0K5I]/N
M0#JT40R8)  /.Q_=8 ;CV()/WN/M/1],BT72;'3H&=X+2!+>-I""Q5%"@G
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MV7<8C)Y_@D#@#D<+MZ#ISGC8?^">_A=9D,OBG5WB##>J11*Q7N 2#@^^#]*
M/"OVG/C?'\?_ !EH]GX>L;IM,T\/!9(\?[^ZEE90S!!DC.U J]>.Q.!]K?!_
MX6MX2^!.F>"]5_UTMA-%>JISM:<NTB@]/E\PK^%1_"W]FWP+\)+@7FCZ:]UJ
MH&T:EJ+^=.HQ_#P%3ORJ@G..G%>HT ?EWX:U77_V7/C:LE]9&2ZTN9X;BW;Y
M5N[=P061O1E(93Z@9'45]R^'/VL?A?XBTR.[/B:'3)& WVFHHT4L9]#P0?JI
M(]ZZ7XH_!;PG\8+&.#Q'IWFSP@B"^@;R[B$'DA7]/9@1[9KPYO\ @GQX4-WN
M'B?61:[\^64B+[<]-VW&<=]OX4 3_%']N'0[.!]+^'UM/XCUNX(A@NW@=($=
MN!M0@/(V3@+@ GN>A^/?B9X5\0^"/%X7Q2=VO7D::G<J[;G#RDOAS_>]<="<
M=J_1CX8?LX^!?A+*MUHVEFXU11C^TM0?SIQQ_"<!4_X"HZU'\7OV<?!WQJNK
M:]UR*[M=2@C\E;[3Y5CE,><A6W*RD D]1D9/- '5_#3Q[9_$_P #:5XGL+>>
MTM=01F6&YQO0J[(P."1]Y3@^F.G2O$_V^/\ DBVG_P#8;@_]$SU[?\._ FG_
M  S\&Z;X:TJ6XFL+!76*2[96E;<[.2Q4 =6/0"LOXN_"/1_C1X8AT+6[F^M;
M2*Z2[5["1$DWJK* 2Z,,8<]O3F@#P;_@GK_R)/BO_L(1_P#HNOK&O//@W\$-
M"^!^EZA8:%=ZC=PWTRSR-J,D;L&"[1MV(O&/K7H= 'F/[0OP=A^-/P]N-(5D
M@U:W;[5I]P_19@"-K'^ZP)4^F0><8KXB^#7QC\2_LP>-=1TK6-+G-C)((]2T
MB;Y)$8=)8STW8[_=88YZ$?I77$_$?X->#_BO;I'XET:*]FC7;%=H3'/$/19%
MP<9YP<CVH Y;P]^UC\+?$&GI=#Q1#ISG[]MJ$;0RH?0Y&#]5)'O7FWQ?_;E\
M.:/I=U8^!O,UO5I%*)?RPM';0'^\ P#.1V& O?)'!;>_\$^/"4ERS6GB;68(
M/X4F6*1A_P ""K_*NQ\"?L7?#CP9=PWEU:W7B2[CPP.K2*\(; R?*554CKP^
M[KWXH \[_8LT/XB:W=S>)]=\0:R/"@#?9;*\N'=+V4[LNJL3A%+$DKC<V.NT
MU]>TR.)(8TCC18XT 5548"@= !3Z /S2_;(TJYTW]H/Q')/$R1WB6UQ Q'$B
M>0B9'_ D9?JIKZ(\+?MY>#$\'6CZUI^K1:W!"D<UK:PI(LK@ %HW+@;>_P V
M".1SU/N'Q*^#WA/XMV,-MXETM;QH.8+E&,<\.>H5QS@]P>/;BO)=-_8+^&]A
M="6>ZU[48P,>1<WD80^_[N)6_7O0!Z=\$?C!9?&SP;)KUE9MI_EW<MK):R2B
M1D*X*DD =496QVR1DXS7H-<]X+^'_AWX=:5_9WAO2+;2;0X++ OS2$# +N<L
MYQW8DUT- 'YY?M@>#;GX7_'*W\4:7FVBU5TU6VE48"74;#S,>^X(_P#VTK,_
MM*?]JW]I?2WD@>/3KIX5> _\L;6% THSVW$28]W'TKWO_@H!>Z3'\.-"M;E-
M^L2ZCOLBIP414/FD^H^9!CU*GM7/?\$_OA[Y5KX@\:7,6&E(TRS8C^$8>4CZ
MGRQG_984 ?8B(L:JJJ%51@*!@ 4ZBB@ HHHH _,;XF>&];_9S^/#7MO#L6UO
M_P"TM+ED7,=Q 7W!<]^"48>Q]C7V7X'_ &P?AOXNTB.XO-97P[?!1YUCJ*LI
M0_[+@;7&<X(.<=0.E>C?$'X:>'/BCHATOQ)ID>H6P):)R2LD+$8W(XY4_H>X
M(KY]OO\ @GSX2ENG>T\2ZQ;6Y.5BE6*1E_X%M&?RH V_B9^W!X*\*V<T/ADR
M>*=5P53RD:*U1N>6=@"P'7Y <],BOCGXR:'XP75++Q5XV4Q:KXF1[U89%V2)
M&I"KE/X!C "]0H&:^\_AM^RC\/?AG>Q7]KITNKZG$=T=YJ\@F:,^JJ%5 1V.
MW(QUKH_BW\$/"_QITZVM?$-O,);4L;:\M)!'-#N W $@@@X'!!' H Q_V8?B
M#:?$/X.Z)-:VTUJVE0QZ1.LV,-+##&"RD$Y4@@\X/48XR?E?_@H!_P EDT;_
M + $/_I1<U]D?"/X2:/\&/"\N@Z)<7MS:27+W;27\B/)O954\JJC&$':N6^,
M'[+_ (5^-?B6VUS7-0UBUN[>T6R5-/FB1"BN[@D/$QSF0]_3B@#?_9]_Y(AX
M'_[!-O\ ^@"O0:QO!WA:T\$>%=*T"QDFEL]-MTM8I+A@TC*HP"Q  )^@%;-
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MZ]I(&I;=HU*S;R;D # RPX;'8,& KQB?_@GMX6:=S!XHU>.(GY$DCB=@/0D
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MU[X!KW=$6-555"JHP% P * '4444 <9\:O\ DC?CS_L 7_\ Z3R5\2_L'_\
M);YO^P3<?^AQU]\^*/#]OXM\-:OH=X\L=IJ=I-93/ 0)%21"C%200#ACC(//
M:O+OA+^ROX3^#?BIM?T74-9NKQK=[;9?SQ/'M8J2<)$IS\H[T >RT444 ?EY
M\6/^3E_$'_8QM_Z.%?J'7@OB']C3P5XE\<WGBJYU37H]0NKTWSQ17$ B#EMV
M #"3MS[Y]Z]ZH ^*?VU?V?;P:I/\0_#]JUQ;2J/[7MXERT3*,"< =5( #>A&
MX\$D9?P!_;5;P9HUIX<\;6USJ-A;*(K;5+;#S11C@)(A(WJ!T8'( QAJ^Z2
M1@\BO#OB'^QS\._'MS+>16<_AW4)"6:;2'6.-VP>6B8%<9.3M"DXZT 4]:_;
M=^%^FZ8+FSU"^U:Y:/<+.WLI$=6X^5FD"KWZ@D<'VS\A?%?XM^*_VF?'-C:6
MMA*8=YBTS1+0F383U9CQN8@<L0  .P!KZ0L_^"?'A1+A&NO$^LS0#.Y(4BC8
M\<88JP'..QKW/X;?!?P?\)X)$\-Z/':3RC$MY(3+/(/0NV3CV&![4 8G[.GP
M:C^"WP]ATR5DFUF\;[5J,Z<@RD !%/=4 P/4Y/&<5TGQ?TJYUSX4>,=/LXFG
MN[G2+N*&)1DNYB8*H]R<"NOHH _+/]GGXN0_!?XD0:_=V<M]820/:744!'FB
M-BIW)D@$@JIP2,],CK7UIJW[>G@:"ZLH-,T[5+_SI8EFGG1;>*!&8!V))9B5
M&3@+@]-W<=5\0?V/OAU\0M5FU.6TO-$OIW\R>31YEB$K<Y)1U9023DD $D9[
MG,7A#]C+X8^$[B*XDTRYU^>,DJVL3^:N?>-0J-]"I'X\T >XJP=0RD$$9!'0
MTZHX88[>%(HD6**-0J(@"JH P  .@%24 %?FO^U=8C4_VHO$-F7\L7$UA%OQ
MG;NM8!G'XU^E%>)^.?V3/"'Q ^(EQXSU'4=;AU2>6"5H;6>%808D1%P&B+8(
MC&?FZD]* /G[X>?'GQ3^ROKMQX!\<Z9/JFBVDA^SR0G$L49)(> M@21MU"DC
M!)Y&"M>ZO^VQ\*DTP70U:]><_P#+D-/E\W\R-G_CW>O3/B)\+/"_Q5TD:?XE
MTJ+4(TR89LE)H">Z.N&';C.#@9!KP&^_X)\^$I;IWM/$NL6UN3E8I5BD9?\
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M1O>:B\+11[$8.$0. Q.Y5R2 ,#C.>.\_80^&U_X5\$ZOXCU&%[9M>DB^RQ2
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ML6VGCZ#/N* /,_'OQG\6?M;^);7P)X0TZ72_#TTJR3^8<NZ*1^]N&'"HO!"
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MG:I90:A87"[);:YC#QN/<'BOGSQ;^PC\/]=NGN-*N=3\/,QR8+>42P#KG"R
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M -A:W_\ 0)*^C*XKXM?"C2/C+X670-:N+VULUN$N?,L'1)-RA@!EU88^8]J
M/GS_ ()Y?\BOXQ_Z_(/_ $!J;^WO\,;[6-,T;QG80-<1Z;&UI?A!DQQ,VZ.3
M_=#%@3_M+[U[I\&O@7H/P/L-2M-"N]1NX[^5)93J,D;E2H(&W8B<<]\UZ%/!
M'=020S1I-#(I1XY%#*RD8((/4$=J /C']ES]K30?"_A*R\'^,I7TY;+*66J"
M-GB:,G(20*"5()(#8QC&<8R?<O$7[6?PN\/6#7)\3Q:E)CY+;3HWFD<^@X"C
MZL0*Y3QM^PSX!\3W\EYIDU_X;DD;<UO9.KV_OM1P2O/HV!V'I5\+?L&> M&N
MUN-5OM5U[:V1;RRK#"1QPP0!CWZ,.O2@#PWXO_$GQ?\ M0:9J^HZ;I;:1X#\
M,1M=N)6SYDH&!N;&&D(;A!PH)R3U.O\ L$?$*TT'QGJWA2>VF>YU]8Y+>>/&
MR,P)*[!\G."IX(SR.G.1]JP^"M!MO"TGAN'2;2#09(&MWT^*()$8V&&! ]<G
M)Z]^M>8?#[]DSP5\,_'EOXKT6XU=;RW$@AM9[A'MT#H4/'E[SPQQEC0![-<1
M&:WEC!P74KGTR*_)_P"'7BR[^#7Q4TW6;FQ:2ZT6\>.YLV.QCPT<B9['!8?6
MOUDKR3XH?LO> _BQJ$FI:G8SZ?JTH DO],D$4LF,<L"K(QP,9*DX[\# !Y_K
MG[?7@6STI9M+TK6-3OW0LMK+&D"HW99'W-C/JH?I7T5X=URV\3Z!INL6;;[2
M_MH[J(YS\CJ&'Z&O$?#/[$/PR\/W*37-MJ6NLC[U74[OY..@*Q*@(XZ'.>^1
MQ7NFEZ59:'IUO8:=:0V-C;H$AM[:,)'&OHJC@"@"W1110!\U?M\:5<WWP<T^
MZ@B:2*RU>&6<J.$1HY4#'VW,@_X$*\-_90_:5T;X-:?JNA^(K6Z;3KVX%W%=
MV:"0Q2;0K!U)!VD*O(R<CISD??NJ:79ZUI]Q8:A:Q7ME<H8YK>= Z2*>H(/!
M%?/^M_L)?#;5]0>YMY=;T>-O^7:QNT,8.2>/,C=N^.O84 :7PY_:]\,?$_XE
M6GA32-.OH8[F*9H[Z^*1[Y$&X*J MD%0YR2"-H&.>.>_X* ?\D;T;_L/P_\
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M2H=,T;3[;3-/A&$M[6,(@]3@=2>Y/)[UI4 %%%% 'S-_P4 _Y(WHW_8?A_\
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MP<;TE=F&?I(M?3/PP_9K\#?"35%U30[*Y?55B,'VV[NGD?:0-WRC"<X_N_3
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MREKIZ,$)[;I6 4#Z;B/2OGCX2>(/BI^T'\9;C5[#7=3T'2WF5]1FL)G2TMH
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MQMX>\ BY\=:SJ.H:I?$2166I3&22RB&<*Q;+;VW9()X 5>""*]CHHH ****
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MCF"GV)4''3KD^]=9X _8R^'?@>[AO+BUN?$E[&0ROJSJ\2MQR(E4*1[-NZT
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M( R>!0!^6'@KXRWW@_X3^-/!D._RM>,)B=3Q#R!-_P!]QA5_"OKW]A;X>_\
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M)-=2GA6DV_>;GY5'3/<\U]6?LE? :;X0^$Y]2UJ()XFU<*T\7!^RQ#)2+/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#FO&OQ'\-_#J&RE\2:K%I$-Y*88)9U;8SA2Q!8 A> >N/3K7PA^V!\=
M[#XL^)[#2O#]R;GP[I*L1<!2JW,[?>8 @':H 4$C^\1P17U]^T'\"E^/'A[3
M-,.M'0VL;HW F^R_: ^5*E=N]<=<YSVZ5P7PO_8=\*^!]9M]5US4I_%5W;.)
M(8)8%@M@P.0S1Y8MCC@MCKD'/ !VO[*WPZ/PY^#6CV\\1CU'4A_:5V&&&#R
M;5/H50("/4&O7J** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 ?,W_!0#_DC>C?]A^'_P!)[FJ/_!/G
M_DFWB3_L+?\ M&.O=_B?\*] ^+V@0:/XBBGELH+E;M%MY3&WF*KH#D=L.W%1
M_"[X2>'O@_I-WIOAR*>&UNI_M$@N)C(2^T+P3[ 4 =I1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MA)X>^#^DW>F^'(IX;6ZG^T2"XF,A+[0O!/L!0!VE%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45B^,?&.C^
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MW;P^?+']DGAVIN"YS(B@\D=*[V@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M17#?##XT^$OB]9S3>&]3%Q-!S/9S(8YXAG@E#U!_O#([9SQ7<T %%>8?$_\
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M?SK9HEV!E7()]V'%>FT %%</\1/C3X,^%<8_X2/7(+.X9=R6<>9;AQVQ&H)
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M?<ZG-K&HP\2VNCQB<QG(!4N65 PYR-V1M.0#@'G- _;H^&FM7JV]S_;&BJ2
M)]0M%,>3Z^4[D?4CO0!]#T52T?6+'Q!IEOJ.F7D-_87*;X;FW<.DB^H(X-7:
M /S3_;,_Y.(\2_\ 7.T_])HJ_13P=_R*.A_]>,'_ *+6OSK_ &S/^3B/$O\
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MM9_#C6O%MEX=TW5;C4+Z\NDLX9(;1Q$TCL%'S,!QD]>GIF@#V.BBB@ K\O\
M_FZ[_N=?_;ZOOSXI_'?PI\'+G3H/$D]U#)?H[P_9[<RY"D YQT^\*_.C_A,=
M-_X7Q_PE6^3^R/\ A)?[3W[/G\C[5YF=OKM[4 ?JW17@]E^VK\,K^\@MH;S4
M6FFD6- ;%AEB<#^=>\4 ?E_KG_)UNH?]CK)_Z7&OU K\O]<_Y.MU#_L=9/\
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M^27=?Z;N/1@/WT8^H <#_9<]Z^TZ_,[XEV4_[/?[2]S=Z;'Y4%AJ*:E:1*0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_I1<U]/_ +)GBF?Q7\!O#4MRQ>XLT>P9CW6)RJ?^.;!^%?,'_!0#_DLFC?\
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MWINT5P?]E0FW'U!_&O8/A)X)MOAY\-_#^@VJ!!:VB>:P&-\S#=(Y^K%C77T
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M .P?<_R6ONKXN?\ )*/&G_8$O?\ T0]?"O[#?_)=[?\ [!]S_): /T7KP_\
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M'7^ZVTJ1V93@\ U^E'A/Q):^,/#.E:Y8DFTU&UCNHL]0KJ& /N,X/N*_//\
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MG[K*?O#^( ]P"/TCKX(_;X\#VV@_$'1O$-K$L7]N6SK.%&-TT)4%_J4>,?\
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MX^?LJZI\$XT\7>#]2O+O1[60.[;MMW8-GY7W)C<N<#<,$9''>OHO]E+X^/\
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M6C>8?LNIZ<[&//!EB964_@ID'XT ;7_!0K76F\7^$]&W_);6,MYL]Y9-F?\
MR#_.OI3]F/P\GAKX$>#K=4"-<62WKGJ6,Q,N3^#C\@.U?*O_  4"MW7XMZ%.
M1^[?0XT4^ZW$Y/\ Z$*^R/@O=)>_"#P1-$JJC:)9C:@PJD0("!]""/PH [.O
MS?\ CIXMUKX_?'__ (1JUNO]!AU(Z1ID))\J/#[&F(_VB"Q/7: .U?I!7YJ?
M%_PEXE_9_P#CK+XACM&-J-5;4],O)(RT$ZES)Y9/J 2K#(/<8R#0!]5^%?V(
M?AGHFFI#JMC=^(KS:-]U=7<L/S=]J1,H /H=QX'/KE>.OV$? VNVLC>&YKSP
MS>@'RU$K7-N3@<,LA+]1U#]SUX 7P1^W=X#UV"-/$$%]X9N]H\QFA-S!G!SM
M:,%SR.Z#J/?'N'A7XD>%?'"YT#Q#INK.!EHK6Y1Y%Z_>3.X=#U% 'C7[)WP7
M\;?",^(+?Q)JA&EF;RK/3(91+!(>";E3U3(XQP3SN' KZ)HHH ^'_P#@H7X>
M6W\3>$=<5.;NTFLW<#_GDZLN?^_S8^A]*^C?V7M<?Q#\ _!MU(Q=X[0VN6ZX
MAD>(?H@KP[_@HC=(NG^!K?/[UI;R0#V A!_F*]7_ &-;)[3]GGPVSY!GDNI0
MI&"!]HD _/&?QH ]MHHHH \9_;$_Y-R\7?\ ;G_Z605\/?!CXJ:Y\/=.\2:3
MX7MIIO$OB,6UC9R0+N>+E]Q0#DN=RA?3)/;G[A_;$_Y-R\7?]N?_ *605\Y_
ML ^%=/U;Q[KVM740FO-*M(Q:%ND;2E@SCWVJ5'LQH [3X:_L'6MQ;)J?Q"U>
MZNM3G)EDL+"4!58\D22D$NW)SMQSW;J;?Q%_8%T*\T^:X\&:M=Z=J*J62SU%
MQ-;R$#A0P 9,GG<=WT%?6=% 'Y<_"WXE>)?V<?B3(MQ#<6Z03_9]7T>0X$J@
MX88SC>!DJWZE2<_ISH^KVFOZ39:G83+<6-Y"EQ!*O1T90RG\B*^+?^"@7@:W
ML->\.>*[:,)+J$<EG=L/XFCVF-C[E68?1!7L7[$?B2;7_@5:6\SF1M*O9[!6
M/7;\LH'X"4#Z 4 9?[7W[1%S\+M+@\,^'9_*\2:E$9)+I?O6<!)&Y?1V((![
M $]=IKQ7]GS]D6Z^*MC'XL\87MU9:-=,98((S_I-[SS(SMG:I.><$MR1C@GR
M[XP^)(/''Q^U^]U>Z:#3'U@VKSX9C%:QR>4&  )X1<X /.<5]OV7[6_P:TVS
MM[2U\4K!;01K%%$FF7@5$4851^YZ  "@ /[&?PE-GY(\-2B39M^TC4;GS,X^
M]CS-N>_3'M7S7\?/V5=4^"<:>+O!^I7EWH]K('=MVV[L&S\K[DQN7.!N&",C
MCO7TW_PV)\(?^AN_\IMY_P#&:J:K^UC\%];TR[TZ]\4+<6=W"\$T3Z9=D.C
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M^A?CI\7+3X+^ +K79HUN;UF%O8VC' FG8'&>^T %C[#'4BM/X1^!(OAG\-]
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M0U:_U'0K[5KN>]@%O(NHS1.H4,&R-D:\Y'J:\%_X)V?\?OCS_KG9?SGK[3H
M\9_;$_Y-R\7?]N?_ *605X7_ ,$[_P#D-^-O^O>U_P#0I*]T_;$_Y-R\7?\
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M  4 _P"2R:-_V (?_2BYH ^OOV??^2(>!_\ L$V__H KT&O/OV??^2(>!_\
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M+2(I5PS[AA[@>@VY53WW,?0G[/H _+_]E/\ Y."\&_\ 7Q)_Z)DK]0*_+_\
M93_Y."\&_P#7Q)_Z)DK]0* "OR\\>_\ )S^M?]C7)_Z55^H=?EYX]_Y.?UK_
M +&N3_TJH _4.BBB@#\VOVU/^3@M;_Z][7_T2M?H-\/_ /D0_#?_ &#;;_T4
MM?GS^VI_R<%K?_7O:_\ HE:_0;X?_P#(A^&_^P;;?^BEH ^'_P#@H!_R631O
M^P!#_P"E%S7U]^S[_P D0\#_ /8)M_\ T 5\@_\ !0#_ )+)HW_8 A_]*+FO
MK[]GW_DB'@?_ +!-O_Z * /0:^.?^"B?_'EX#_ZZ7O\ *"OL:OCG_@HG_P >
M7@/_ *Z7O\H* /2/V'_^2"V7_7]<_P#H5>_5X#^P_P#\D%LO^OZY_P#0J]^H
M ^<_V\/^2(0_]A:W_P#0)*Y/_@GE_P BOXQ_Z_(/_0&KK/V\/^2(0_\ 86M_
M_0)*Y/\ X)Y?\BOXQ_Z_(/\ T!J ,G_@H=H<Q?P9K"KFW N;1S_=;Y&7\P'_
M .^:YS]FK]F#P1\:OAZ^LZGJFM6^J6]Y):W$%E<0K&N K*0&B8\JPYSU!KZR
M^.?PM@^,'PWU+P\[)%>-BXLIW'$5PF=A/H#DJ3Z,:^$/@K\6M<_9C^(NHV&M
M:?<BR=_LVJZ6WRR*5/RR)G@L,DCLRMUY! !]*_\ #O\ ^'G_ $&?$W_@5;__
M !BC_AW_ /#S_H,^)O\ P*M__C%>Q>#_ (U^!O'6GK=Z1XGTZ5< M!-.L,T?
M^]&^&'UQCT-<Y\3/VGO 7PTL9VDUFWUG5%4B/3-,E6:1G[*[+D1CU+'..@/2
M@#@/^'?_ ,//^@SXF_\  JW_ /C%>]^!/!MC\/?".E^'=-DGEL=/B\F)[E@T
MC#).6( &<D] *^3/V<OC)\6_C!\5+GR]21?"RSFZOXIK5'BM8BP*PQ/@-N(&
MU1N/&YB#BOM&@#\O]<_Y.MU#_L=9/_2XU^H%?E_KG_)UNH?]CK)_Z7&OU H
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M!)9((RRR>2LS2 D#"D*<\XS@]^#]%?M76DM[^SYXQCA0NZV\4I _NI/&['\
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M_0(M ^-GB/3-6,D5G'K4OG/$0'\AI2VY<@\E&!'!K]"OV7_^2!>"_P#KS/\
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MT:21ZWXE>-P&5EN[8A@>A!\BN3_;C^!MU?3+\0]%MFG"1+#J\42Y95482?W
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M*_\ -/O^XA_[;4 >L?L5_P#)ONB?]?%U_P"CFKW2O"_V*_\ DWW1/^OBZ_\
M1S5[I0!Y-^U9_P F^^,O^O>/_P!'1U\V_P#!/;_D?/%/_8-3_P!&BOI+]JS_
M )-]\9?]>\?_ *.CKYM_X)[?\CYXI_[!J?\ HT4 ?==?GK^VOX'E\#?&*#Q)
M8*UO!K4:WD<J<;+F,A9,'U_U;_5S7Z%5X;^V+\/#XZ^#&H7-O'OU#0V_M*+
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MT/P[]J^W?V9:1VOVGR_+\W:,;MN3C/IDUT-%% 'CG[1/[//_  OR'08_[?\
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M;MWKUW=<]JR?V>?@%_PH72]8L_[=_MW^T9HY=_V/[/Y>U2,8\Q\YS[5ZY10
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M/-=?17GGQ#^./A/P#X-U+7&UO3KZ2W5T@M;>Z21YYP2HB 4YSN&#_=P2>AH
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M9_VE_9TC2?9?[+\KS,HRXW^<V/O9Z'I7U!110 5\V?&K]CC_ (7!\0;WQ/\
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MCT^BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ KF_'OP[\/_$W07T?Q'IL>H69.Y-W#Q/C
M=&'*M[CZ'()%=)10!\;>)_\ @GG&]VTGA[Q>T5L6XM]2M=[*.?\ EHA ;M_
M*R;7_@GEK#7""Y\96,4!^\\5D[L/HI90?S%?;]% 'B7PD_9*\$_"J\AU,QRZ
M_KD1W1WNH8*PMZQQCY5/3D[F!Z$5[;110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5XW\8_
MV6?!WQ@N7U&>.31=>8#=J5@ #+C@>:AX?COPW &<#%>R44 ?$%U_P3RUA+AU
MMO&5C+!_"\MDZ,?JH8@?F:U?#7_!/-%NED\0>,&>W#<P:9:;78<?\M')"GK_
M  '^E?95% ')?#GX6^&?A3HQTWPUID=C$Y#32DEYIV'\3N>3WP.@SP!76T44
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
24444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Aug. 06, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">vTv Therapeutics Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-3916571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3980 Premier Dr<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">High Point<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">27265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">841-0300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Class A common stock, par value $0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">VTVT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001641489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,953,928<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 86,643<span></span>
</td>
<td class="nump">$ 88,932<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">416<span></span>
</td>
<td class="nump">743<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">530<span></span>
</td>
<td class="nump">218<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">87,589<span></span>
</td>
<td class="nump">89,893<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">87,593<span></span>
</td>
<td class="nump">89,899<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">6,992<span></span>
</td>
<td class="nump">6,557<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">7,017<span></span>
</td>
<td class="nump">6,641<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Contract liabilities</a></td>
<td class="nump">1,830<span></span>
</td>
<td class="nump">18,669<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">8,961<span></span>
</td>
<td class="nump">25,462<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">394,205<span></span>
</td>
<td class="nump">391,090<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(315,612)<span></span>
</td>
<td class="num">(326,692)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">78,632<span></span>
</td>
<td class="nump">64,437<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">87,593<span></span>
</td>
<td class="nump">89,899<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_WarrantLiabilityCurrent', window );">Warrant liability, related party</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">84<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember', window );">Nonrelated Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_WarrantyLiability', window );">Warrant liability</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">152<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock value</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 27: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 860<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481420/860-30-50-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_WarrantLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant liability, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_WarrantLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_WarrantyLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warranty Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_WarrantyLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in usd per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">3,938,803<span></span>
</td>
<td class="nump">3,938,654<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in usd per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">92<span></span>
</td>
<td class="nump">241<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - Unaudited - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 36,839<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">8,770<span></span>
</td>
<td class="nump">4,103<span></span>
</td>
<td class="nump">17,748<span></span>
</td>
<td class="nump">6,933<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">5,160<span></span>
</td>
<td class="nump">3,618<span></span>
</td>
<td class="nump">9,758<span></span>
</td>
<td class="nump">7,291<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">13,930<span></span>
</td>
<td class="nump">7,721<span></span>
</td>
<td class="nump">27,506<span></span>
</td>
<td class="nump">14,224<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating (loss) income</a></td>
<td class="num">(13,930)<span></span>
</td>
<td class="num">(7,721)<span></span>
</td>
<td class="nump">9,333<span></span>
</td>
<td class="num">(14,224)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">812<span></span>
</td>
<td class="nump">275<span></span>
</td>
<td class="nump">1,650<span></span>
</td>
<td class="nump">606<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net (loss) income before income taxes and noncontrolling interest</a></td>
<td class="num">(13,054)<span></span>
</td>
<td class="num">(7,380)<span></span>
</td>
<td class="nump">11,080<span></span>
</td>
<td class="num">(13,597)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss) income before noncontrolling interest</a></td>
<td class="num">(13,054)<span></span>
</td>
<td class="num">(7,380)<span></span>
</td>
<td class="nump">11,080<span></span>
</td>
<td class="num">(13,597)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: net loss attributable to noncontrolling interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,334)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,459)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income attributable to vTv Therapeutics Inc.</a></td>
<td class="num">(13,054)<span></span>
</td>
<td class="num">(6,046)<span></span>
</td>
<td class="nump">11,080<span></span>
</td>
<td class="num">(11,138)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net (loss) income attributable to vTv Therapeutics Inc. common shareholders</a></td>
<td class="num">(13,054)<span></span>
</td>
<td class="num">(6,046)<span></span>
</td>
<td class="nump">11,080<span></span>
</td>
<td class="num">(11,138)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember', window );">Nonrelated Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">$ 54<span></span>
</td>
<td class="nump">$ 59<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net (loss) income per share of vTv Therapeutics Inc. Class A common stock (in usd per share)</a></td>
<td class="num">$ (1.05)<span></span>
</td>
<td class="num">$ (0.92)<span></span>
</td>
<td class="nump">$ 0.89<span></span>
</td>
<td class="num">$ (1.69)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted average number of vTv Therapeutics Inc. Class A common stock (in shares)</a></td>
<td class="nump">12,409,316<span></span>
</td>
<td class="nump">6,587,070<span></span>
</td>
<td class="nump">12,409,297<span></span>
</td>
<td class="nump">6,584,969<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net (loss) income per share of vTv Therapeutics Inc. Class A common stock (in usd per share)</a></td>
<td class="num">$ (1.05)<span></span>
</td>
<td class="num">$ (0.92)<span></span>
</td>
<td class="nump">$ 0.76<span></span>
</td>
<td class="num">$ (1.69)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted average number of vTv Therapeutics Inc. Class A common stock (in shares)</a></td>
<td class="nump">12,409,316<span></span>
</td>
<td class="nump">6,587,070<span></span>
</td>
<td class="nump">14,541,788<span></span>
</td>
<td class="nump">6,584,969<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3A<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3A<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 44: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Changes in Stockholders&#8217; Equity - Unaudited - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Class A Common Stock</div></th>
<th class="th"><div>Class B Common Stock</div></th>
<th class="th"><div>Total vTv Therapeutics Inc Stockholders&#8217; Equity (Deficit)</div></th>
<th class="th">
<div>Common Stock </div>
<div>Class A Common Stock</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Class B Common Stock</div>
</th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Noncontrolling Interest</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares (in shares) at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,612,257<span></span>
</td>
<td class="nump">577,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2024</a></td>
<td class="nump">$ 14,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,199<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 311,885<span></span>
</td>
<td class="num">$ (299,718)<span></span>
</td>
<td class="nump">$ 2,102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to vTv Therapeutics Inc.</a></td>
<td class="num">(11,138)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,138)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,138)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Net shares withheld for tax withholding related to the settlement of equity awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Net shares withheld for tax withholding related to the settlement of equity awards.</a></td>
<td class="num">(51)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(51)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(51)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">1,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to noncontrolling interest</a></td>
<td class="num">(2,459)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,459)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares (in shares) at Jun. 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,617,215<span></span>
</td>
<td class="nump">577,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2025</a></td>
<td class="nump">2,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,762<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">313,586<span></span>
</td>
<td class="num">(310,856)<span></span>
</td>
<td class="num">(357)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares (in shares) at Mar. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,612,257<span></span>
</td>
<td class="nump">577,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Mar. 31, 2025</a></td>
<td class="nump">8,897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,920<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">312,698<span></span>
</td>
<td class="num">(304,810)<span></span>
</td>
<td class="nump">977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to vTv Therapeutics Inc.</a></td>
<td class="num">(6,046)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,046)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,046)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Net shares withheld for tax withholding related to the settlement of equity awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Net shares withheld for tax withholding related to the settlement of equity awards.</a></td>
<td class="num">(51)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(51)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(51)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to noncontrolling interest</a></td>
<td class="num">(1,334)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,334)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares (in shares) at Jun. 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,617,215<span></span>
</td>
<td class="nump">577,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2025</a></td>
<td class="nump">2,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,762<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">313,586<span></span>
</td>
<td class="num">(310,856)<span></span>
</td>
<td class="num">$ (357)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares (in shares) at Dec. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,938,654<span></span>
</td>
<td class="nump">241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,938,654<span></span>
</td>
<td class="nump">241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,437<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">391,090<span></span>
</td>
<td class="num">(326,692)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to vTv Therapeutics Inc.</a></td>
<td class="nump">11,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of Class B common stock to Class A common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149<span></span>
</td>
<td class="num">(149)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to noncontrolling interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares (in shares) at Jun. 30, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,938,803<span></span>
</td>
<td class="nump">92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,938,803<span></span>
</td>
<td class="nump">92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,632<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">394,205<span></span>
</td>
<td class="num">(315,612)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares (in shares) at Mar. 31, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,938,654<span></span>
</td>
<td class="nump">241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Mar. 31, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,959<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">392,478<span></span>
</td>
<td class="num">(302,558)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to vTv Therapeutics Inc.</a></td>
<td class="num">(13,054)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,054)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,054)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of Class B common stock to Class A common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149<span></span>
</td>
<td class="num">(149)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to noncontrolling interest</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares (in shares) at Jun. 30, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,938,803<span></span>
</td>
<td class="nump">92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,938,803<span></span>
</td>
<td class="nump">92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,632<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 394,205<span></span>
</td>
<td class="num">$ (315,612)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480339/815-10-65-8<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480339/815-10-65-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480339/815-10-65-8<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481229/860-50-50-5<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 35: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 36: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 67: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 69: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 70: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 71: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 72: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 73: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 74: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 75: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - Unaudited - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss) before noncontrolling interest</a></td>
<td class="nump">$ 11,080<span></span>
</td>
<td class="num">$ (13,597)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) before noncontrolling interest to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">3,115<span></span>
</td>
<td class="nump">1,743<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses</a></td>
<td class="nump">327<span></span>
</td>
<td class="nump">833<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other current assets</a></td>
<td class="num">(312)<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">67<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">435<span></span>
</td>
<td class="nump">189<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="num">(16,839)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(90)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(2,289)<span></span>
</td>
<td class="num">(10,782)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of equity awards</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(51)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(42)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents</a></td>
<td class="num">(2,289)<span></span>
</td>
<td class="num">(10,824)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash and cash equivalents, beginning of period</a></td>
<td class="nump">88,932<span></span>
</td>
<td class="nump">36,746<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash and cash equivalents, end of period</a></td>
<td class="nump">86,643<span></span>
</td>
<td class="nump">25,922<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) before noncontrolling interest to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrants, related party</a></td>
<td class="num">(59)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember', window );">Nonrelated Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) before noncontrolling interest to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrants, related party</a></td>
<td class="num">$ (38)<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 44: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Description of Business and Basis of Presentation</a></td>
<td class="text">Description of Business and Basis of Presentation <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">vTv Therapeutics Inc. (the &#8220;Company,&#8221; the &#8220;Registrant,&#8221; &#8220;we&#8221; or &#8220;us&#8221;) was incorporated in the state of Delaware in April 2015. The Company is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. The Company&#8217;s clinical pipeline is led by </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, currently in a Phase 3 trial, a potential first-in-class oral liver-selective glucokinase activator being investigated as an adjunctive therapy to insulin for the treatment of type 1 diabetes. The Company and its development partners are investigating multiple molecules across different indications for chronic diseases. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">vTv Therapeutics Inc. is a holding company, and its principal asset is a controlling equity interest in vTv Therapeutics LLC (&#8220;vTv LLC&#8221;), the Company&#8217;s principal operating subsidiary.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has determined that vTv LLC is a variable-interest entity (&#8220;VIE&#8221;) for accounting purposes and that vTv Therapeutics Inc. is the primary beneficiary of vTv LLC because (through its managing member interest in vTv LLC and the fact that the senior management of vTv Therapeutics Inc. is also the senior management of vTv LLC) it has the power and benefits to direct all of the activities of vTv LLC, which include those that most significantly impact vTv LLC&#8217;s economic performance. vTv Therapeutics Inc. has therefore consolidated vTv LLC&#8217;s results pursuant to Accounting Standards Codification Topic 810, &#8220;Consolidation&#8221; in its Unaudited Condensed Consolidated Financial Statements. The assets and liabilities of vTv LLC represent substantially all of the Company&#8217;s consolidated assets and liabilities with the exception of the Warrants and $67.6 million of cash and cash equivalents.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Various holders own non-voting interests in vTv LLC, representing a de minimis amount of economic interest. Effectively, vTv Therapeutics Inc.&#8217;s interest is approximately 100.0% of vTv LLC&#8217;s economic results. vTv Therapeutics Inc. has provided financial and other support to vTv LLC in the form of its purchase of vTv Units with the net proceeds of the Company&#8217;s various debt and equity transactions in prior years and equity purchase agreements with various parties. v</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Tv Therapeutics Inc. will not be required to provide financial or other support for vTv LLC. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">However, vTv Therapeutics Inc. will control its business and other activities through its managing member interest in vTv LLC, and its management is the management of vTv LLC. Nevertheless, because vTv Therapeutics Inc. will have no material assets other than its interests in vTv LLC, any financial difficulties at vTv LLC could result in vTv Therapeutics Inc. recognizing a loss.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has not generated any product revenue and has not achieved profitable operations. The continuing development of our drug candidates will require additional financing. From its inception through June&#160;30, 2026, the Company has funded its operations primarily through a combination of private placements of common and preferred equity, research collaboration agreements, upfront and milestone payments for license agreements, debt and equity financings and the completion of its IPO in August 2015. As of June&#160;30, 2026, the Company had an accumulated deficit of $315.6&#160;million and has generated net losses in each year of its existence. As of June&#160;30, 2026, the Company&#8217;s liquidity sources included cash and cash equivalents of $86.6 million. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On January 30, 2026, the Company entered into a Second Amendment to License Agreement with Newsoara Biopharma Co., Ltd. (&#8220;Newsoara&#8221;) (the &#8220;Second Amendment&#8221;). Under the Second Amendment, Newsoara's rights in the Company's PDE4 inhibitor, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HPP737</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, will expand to include all countries of the world upon Newsoara's payment of the upfront fee of $20.0 million. See Note 3 for further details.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Financial Information</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). The accompanying Condensed Consolidated Balance Sheet as of June&#160;30, 2026, Condensed Consolidated Statements of Operations for the three and six months ended June&#160;30, 2026 and 2025, Condensed Consolidated Statement of Changes in Stockholders&#8217; Equity for the three and six months ended June&#160;30, </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026 and 2025, and Condensed Consolidated Statements of Cash Flows for the six months ended June&#160;30, 2026 and 2025 are unaudited. These unaudited financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (&#8220;SEC&#8221;) for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. These financial statements should be read in conjunction with the audited financial statements and the accompanying notes for the year ended December&#160;31, 2025, contained in the Company&#8217;s Annual Report on Form 10-K. The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company&#8217;s financial position as of June&#160;30, 2026, the results of operations for the three and six months ended June&#160;30, 2026 and 2025, and cash flows for the six months ended June&#160;30, 2026 and 2025. The December&#160;31, 2025 Condensed Consolidated Balance Sheet included herein was derived from the audited financial statements but does not include all disclosures or notes required by GAAP for complete financial statements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The financial data and other information disclosed in these notes to the financial statements related to the three and six months ended June&#160;30, 2026 and 2025 are unaudited. Interim results are not necessarily indicative of results for an entire year.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not have any components of other comprehensive income recorded within its Condensed Consolidated Financial Statements, and, therefore, does not separately present a statement of comprehensive income in its Condensed Consolidated Financial Statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, the Company evaluates its estimates, including those related to the grant date fair value of equity awards, the fair value of warrants to purchase shares of its Class A common stock and the useful lives of property and equipment, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgments about the carrying value of assets and liabilities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There has been uncertainty and disruption in the global economy and financial markets due to a number of factors, including geopolitical instability, inflationary pressures, high interest rates, a recessionary environment, domestic and global monetary and fiscal policy, changes in trade policy, including tariffs or other trade restrictions or the threat of such actions, banking and other financial institution instability and other factors. Our business may also be impacted by changes or disruptions at the U.S. Food and Drug Administration (&#8220;FDA&#8221;) and other government agencies. The Company has taken into consideration any known impacts to its accounting estimates to date and is not aware of any additional specific events or circumstances that would require any additional updates to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of the filing date of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to the Company&#8217;s significant accounting policies during the three and six months ended June&#160;30, 2026, as compared to those disclosed in Note 2 Summary of Significant Accounting Policies included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2025. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Disaggregation of Income Statement Expenses:</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> In November 2024, the FASB issued ASU No. 2024-03, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures: Disaggregation of Income Statement Expenses.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; This guidance requires disclosures about significant expense categories, including but not limited to, inventory purchases, employee compensation, depreciation, amortization, and selling expenses</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. This amendment is effective for our annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. We are currently assessing the impact of this guidance on our disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration Agreements</a></td>
<td class="text">Collaboration Agreements<div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">G42 Agreements </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company and G42 Investments AI Holding RSC Ltd, a private limited company (&#8220;G42 Investments&#8221;), entered into a Common Stock Purchase Agreement (the &#8220;G42 Purchase Agreement&#8221;), on May 31, 2022, pursuant to which the Company sold to G42 Investments 259,657 shares of the Company&#8217;s Class A common stock, for an aggregate purchase price of $25.0 million, which was paid (i) $12.5 million in cash at the closing and (ii) $12.5 million in the form of a promissory note of G42 Investments paid in 2023. G42 Investments agreed to certain transfer restrictions (including restrictions on short sales or similar transactions) and restrictions on further acquisitions of shares. The Company granted G42 Investments certain shelf and piggyback registration rights with respect to those shares, including the ability to conduct an underwritten offering to resell such shares under certain circumstances. The registration rights include customary cooperation, cut-back, expense reimbursement, and indemnification provisions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Contemporaneously with the G42 Purchase Agreement, in 2022, the Company entered into a collaboration and license agreement (the &#8220;Collaboration Agreement&#8221;) with Cogna Technology Solutions LLC, an affiliate of G42 Investments, with those rights transferring to G42 Healthcare Research Technology Projects LLC ("G42"), an affiliate of G42 Investments. The Collaboration Agreement requires G42 to work with the Company in performing clinical trials for </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TP399)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> as well as jointly creating a global development plan to develop, market, and commercialize </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">in certain countries in the Middle East, Africa, and Central Asia (the &#8220;Partner Territory&#8221;). Under the terms of the Collaboration Agreement, G42 obtained a license under certain intellectual property controlled by the Company to enable it to fulfill its obligations and exercise its rights under the Collaboration Agreement, including to develop and commercialize </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> in the Partner Territory. Specifically, the Company will share various protocols with G42 related to conducting the clinical trials and will provide the patient dosages and placebo of </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">needed to conduct the trials. Under the Collaboration Agreement, G42 has the right to develop and commercialize </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">in the Partner Territory at its own cost. The Company may supply at cost, or G42 may manufacture, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">for commercial sale under terms to be agreed upon by the parties at a later date. Separately, the Company will conduct its clinical trials for </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">outside of the Partner Territory at its own cost. The results of each party&#8217;s clinical trials may be combined by the Company to seek FDA approval in the United States for </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The G42 Purchase Agreement also provides for, following the receipt of the </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">FDA Approval, at the option of G42 Investments, either (a) the issuance of the Company&#8217;s Class A common stock (the &#8220;Milestone Shares&#8221;) having an aggregate value equal to $30.0 million or (b) the payment by the Company of $30.0 million in cash (the &#8220;Milestone Cash Payment&#8221;). The issuance of the Milestone Shares or the payment of the Milestone Cash Payment, as applicable, is conditioned upon receipt of the </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">FDA Approval and subject to certain limitations and conditions set forth in the G42 Purchase Agreement. There can be no assurance that the </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">FDA Approval will be granted or as to the timing thereof. Once commercialization takes place in the Partner Territory, the Company will receive royalties in the single digits from G42 Healthcare on the net sales of </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">for a period of at least ten years after the first commercial sale of </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">in the Partner Territory.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A premium was paid on the Class A common stock by G42 Investments of $18.7 million, net of a note receivable discount of $0.6 million, which was deferred and recorded as a contract liability. This premium was determined to be the transaction price for all remaining obligations under the agreements and accounted for under ASC 808 or ASC 606 based on determination of the unit of account. As of December 31, 2025, $18.7 million was recorded in the Consolidated Balance Sheet.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that certain commitments under the agreements are in the scope of ASC 808 as both the Company and G42 are active participants in the clinical trials of </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, and both are exposed to significant risks and rewards based on the success of the clinical trials and subsequent FDA approval. G42 is determined to be a vendor of the Company during the clinical trial phase, working on the Company&#8217;s behalf to complete research and development activities, and not in a customer capacity. The Company accounted for the commitments related to the clinical trials, which includes transfer of trial protocols, supply of clinical trial dosages, and collaboration on the joint development committee as an ASC 808 unit of account, applying the recognition and measurement principles of ASC 606 by analogy. The Company will recognize collaboration revenue for its development activities under ASC 808 over time based on the estimated period of performance.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">By applying the principles in ASC 606 by analogy, the Company identified the performance obligation and considered the timing of satisfaction of the obligation to account for the pattern of revenue recognition. In order to recognize collaboration revenue, generally, the Company would begin satisfying its performance obligation and G42 would need to be able to use and benefit from delivery of the assets or services. The performance obligation under the agreements that fall </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">within the ASC 808 unit of account are concentrated in the clinical trials. As of June&#160;30, 2026, the clinical trials had not commenced. Accordingly, no collaboration revenue was recognized for the ASC 808 unit of account during the three and six months ended June&#160;30, 2026 and 2025. $1.3 million remains deferred and recorded in contract liabilities as of June&#160;30, 2026.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company identified certain commitments that are in the scope of ASC 606 as G42&#8217;s relationship is that of a customer for these commitments. The significant performance obligations that are in the scope of ASC 606 are (1) the development, commercialization and manufacturing license of the intellectual property (IP) once restrictions on the use of the IP have been lifted by the Company and (2) a potential material right to a commercial supply agreement. As a result, the Company recognizes revenue associated with the development, commercialization, and manufacturing license at a point in time upon the release of the IP restrictions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In March 2026, the Company lifted the contractual restrictions on the use of the IP. Accordingly, the Company determined that control of the license was transferred to G42 at that point in time, and the related performance obligation was satisfied. During the six months ended June&#160;30, 2026, the Company recognized $16.9&#160;million license revenue associated with the transfer of the IP. No license revenue was recognized during the three months ended June&#160;30, 2026 or the three and six months ended June&#160;30, 2025. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company will recognize revenue from the material right related to G42&#8217;s ability to purchase the commercial supply at cost as G42 purchases the commercial supply from the Company, which will occur after the completion of the initial clinical trials (if G42 decides to purchase the clinical supply from the Company). No revenue has been recognized related to the commercial supply agreement during the three and six months ended June&#160;30, 2026 and 2025, as G42 has not exercised its option to purchase commercial supply as of those dates. $0.5 million remains deferred and recorded in contract liabilities as of June&#160;30, 2026.</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Newsoara License Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to a license agreement with Newsoara Biopharma Co., Ltd., (&#8220;Newsoara&#8221;) (the &#8220;Newsoara License Agreement&#8221;) under which Newsoara obtained an exclusive and sublicensable license to develop and commercialize the Company&#8217;s phosphodiesterase type 4 inhibitors (&#8220;PDE4&#8221;) program, including the compound </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HPP737</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, in China, Hong Kong, Macau, Taiwan and other pacific rim countries (collectively, the &#8220;Newsoara License Territory&#8221;). Additionally, under the Newsoara License Agreement, the Company obtained a non-exclusive, sublicensable, royalty-free license to develop and commercialize certain Newsoara patent rights and know-how related to the Company&#8217;s PDE4 program for therapeutic uses in humans outside of the Newsoara License Territory. In accordance with ASC 606, the Company identified all of the performance obligations at the inception of the Newsoara License Agreement. The significant obligations were determined to be the license and the technology transfer services. The Company determined that the license and technology transfer services represent a single performance obligation because they were not capable of being distinct on their own. The transaction price was fully allocated to this combined performance obligation and the related revenue was recognized during the year ended December 31, 2018.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Newsoara License Agreement was amended in 2020 to change certain future milestone payments and patent rights (the &#8220;First Newsoara Amendment&#8221;). On January 30, 2026, the Company entered into a new Second Amendment with Newsoara. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Although the Company had previously entered into an amendment with Newsoara to expand the Original Agreement, that amendment became null and void in June 2025. Under the new Second Amendment, Newsoara's rights in the Company's PDE4 inhibitor, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HPP737</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, will expand to include all countries of the world upon Newsoara's payment of the upfront fee of </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$20.0 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The Second Amendment also requires Newsoara to pay vTv LLC up to approximately </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$50.0 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> in development milestones, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$65.0 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> in sales-related milestones and royalties in the mid single digits depending upon sales volumes.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> In February 2026, the Company received and recognized the $20.0 million upfront payment from Newsoara as stipulated in the Second Amendment and recognized the related revenue due to satisfying the performance obligation.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2026, development milestones totaling $3.0 million had been recognized in prior periods by the Company under the Second Amendment.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text">Share-Based Compensation<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has issued non-qualified stock option awards to management, other key employees, consultants, and non-employee directors and these options ratably vest over a four-year service period. In addition, we issued options in connection with the private placement on February 27, 2024, that vest ratably over a three-year period. The option awards expire after a term of ten years from the date of grant. As of June&#160;30, 2026, the Company had total unrecognized stock-based compensation expense for its outstanding stock option awards of approximately $13.5 million, which is expected to be recognized over a weighted average period of 3.0 years. The weighted average grant date fair value of options granted during the six months ended June&#160;30, 2026 and 2025 was $28.05 and $15.01 per option, respectively. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to the stock option awards for the six months ended June&#160;30, 2026:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.023%"><tr><td style="width:1.0%"></td><td style="width:57.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.243%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.243%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.246%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Weighted <br/>Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value (in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Awards outstanding at December 31, 2025</span></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,017,620&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">25.18&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">564,719&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">36.52&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or Expired</span></td><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(41,687)</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">30.60&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Awards outstanding at June 30, 2026</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,540,652&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">29.19&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">17,857&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable at June 30, 2026</span></td><td colspan="2" style="background-color:#ebfeff;border-top:3pt double #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">604,164&#160;</span></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">29.28&#160;</span></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9,795&#160;</span></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining contractual term</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7.1 Years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest at June 30, 2026</span></td><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,275,464&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">28.73&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining contractual term</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8.1 Years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Compensation expense related to the grants of stock options is included in research and development and general and administrative expense as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.376%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.251%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.443%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">307&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">977&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">534&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,194&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">623&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,138&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,209&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,727&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">930&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,115&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,743&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Matters</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is involved in various legal proceedings arising in the normal course of business. If a specific contingent liability is determined to be probable and can be reasonably estimated, the Company accrues and discloses the amount. The Company is not currently a party to any material legal proceedings.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Novo Nordisk</span></div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In February 2007, the Company entered into an Agreement (the &#8220;Novo License Agreement&#8221;) Concerning Glucokinase Activator Project with Novo Nordisk A/S (the &#8220;Novo Nordisk&#8221;) whereby the Company obtained an exclusive, worldwide, sublicensable license under certain Novo Nordisk intellectual property rights to discover, develop, manufacture, have manufactured, use and commercialize products for the prevention, treatment, control, mitigation or palliation of human or animal diseases or conditions. As part of this license grant, the Company obtained certain worldwide rights to Novo Nordisk&#8217;s GKA program, including rights to preclinical and clinical compounds such as</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> cadisegliatin</span>. This agreement was amended in May 2019 to create milestone payments applicable to certain specific and non-specific areas of therapeutic use. Under the terms of the amended Novo License Agreement, the Company has potential developmental and regulatory milestone payment obligations totaling up to $6.0 million for approval of a product for the treatment of type 1 diabetes, $50.5 million for approval of a product for the treatment of type 2 diabetes, or $115.0 million for approval of a product in any other indication. The Company may also be obligated to pay an additional $75.0 million in potential sales-based milestones, as well as royalty payments, at mid-single digit royalty rates, based on tiered sales of commercialized licensed products. As of June&#160;30, 2026, the Company does not have any commercialized licensed products.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders&#8217; Equity</a></td>
<td class="text">Stockholders&#8217; Equity <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock and Pre-funded Warrants</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In August 2025, the Company entered into a securities purchase agreement with certain Private Placement Investors pursuant to which the Company issued and sold an aggregate of 682,018 shares of Class A common stock at a purchase price of $15.265 per share, Pre-funded Warrants to purchase </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,561,714</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> shares of Class A common stock at a purchase price of $15.255 per Pre-funded Warrant, and accompanying Common Warrants to purchase up to </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5,243,732</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> shares of Class A common stock for aggregate gross proceeds of approximately $80.0 million,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> before deducting offering costs payable by us</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The Pre-funded Warrants were immediately exercisable at an exercise price of $0.01 per share. The Common Warrants are </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">exercisable at </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$22.71</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> per share and expire upon the earlier of the fifth anniversary of issuance or </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">90 days </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">following the announcement of positive top-line data from the Company&#8217;s ongoing CATT1 clinical trial.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In February 2024, the Company entered into a securities purchase agreement with certain Private Placement Investors pursuant to which the Company issued and sold an aggregate of 464,377 shares of Class A common stock at a purchase price of $11.81 per share and Pre-funded Warrants to purchase 3,853,997 shares of Class A common stock at a purchase price of $11.80 per Pre-funded Warrant for aggregate gross proceeds of approximately $51.0 million, b</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">efore deducting offering costs payable by us</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The Pre-funded Warrants were immediately exercisable at an exercise price of</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$0.01 per share and contain customary beneficial ownership limitations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On March 5, 2024, the Company entered into a letter agreement with the Private Placement Investors pursuant to which the investors exchanged an aggregate of 116,493 shares of Class A common stock for 116,590 Pre-funded Warrants.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Equity-Based Stock Warrants</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the equity-based stock warrant activity for the six months ended June&#160;30, 2026:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.703%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.025%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.563%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2025</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13,714,356&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8.69</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Expired or cancelled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2026*</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13,714,356&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8.69&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13,714,356&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8.69&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">Amount includes 8,470,624 Pre-Funded Warrants and 5,243,732 Common Warrants.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Pre-Funded and Common Warrants were classified as a component of permanent equity in the Company&#8217;s Condensed Consolidated Balance Sheet as they are freestanding financial instruments that are immediately exercisable, do not embody an obligation for the Company to repurchase its own shares and permit the holders to receive a fixed number of shares of common stock upon exercise. All of the shares underlying the Pre-Funded Warrants have been included in the weighted-average number of shares of common stock used to calculate net loss per share attributable to common stockholders because the shares may be issued for little or no consideration, are fully vested and are exercisable after the original issuance date of the Pre-Funded Warrants.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ATM Offering</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On February 28, 2024, we entered into a sales agreement (the &#8220;TD Cowen Sales Agreement&#8221;) with Cowen and Company, LLC (&#8220;TD Cowen&#8221;), pursuant to which we may offer and sell, from time to time, through or to TD Cowen, as sales agent or principal, shares of our Class A common stock, having an aggregate offering price of up to $50.0 million (the &#8220;TD Cowen ATM Offering&#8221;). Pursuant to General Instruction I.B.6 of Form S-3, at no time will we sell securities registered on the registration statement relating to the TD Cowen ATM Offering with an aggregate amount exceeding one-third of our public float in any 12-calendar month period, so long as our public float remains below $75.0 million. Under the terms of the TD Cowen Sales Agreement, we will pay TD Cowen a commission of 3.0% of the aggregate proceeds from the sale of shares and reimburse certain legal fees or other disbursements. On September 17, 2024, the Company sold 179,400 shares of Class A common stock under the TD Cowen ATM Offering for net proceeds of $2.5 million. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June&#160;30, 2026 and 2025, the Company did not sell any shares of Class A common stock under the TD Cowen ATM Offering.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479951/505-20-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479982/505-20-S25-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479951/505-20-S50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479982/505-20-S25-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 1.D.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479921/505-20-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479951/505-20-S50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 1.B.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480148/855-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S25<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479982/505-20-S25-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-5<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related-Party Transactions</a></td>
<td class="text">Related-Party Transactions<div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MacAndrews &amp; Forbes Incorporated</span></div><div style="margin-top:4pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On September 19, 2025, MacAndrews converted all 577,108 outstanding shares of their Class B common stock (together with an equal number of vTv LLC units) into Class A common stock. As a result, vTv Therapeutics Inc. now owns approximately 100% of vTv LLC, as of September 30, 2025. Further, as of June&#160;30, 2026, MacAndrews directly or indirectly holds 1,490,090 shares of the Company&#8217;s Class A common stock. As a result, MacAndrews&#8217; holdings represent approximately 37.8% of the combined voting power of the Company&#8217;s outstanding common stock.</span></div><div style="margin-top:4pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into several agreements with MacAndrews or its affiliates as further detailed below:</span></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exchange Agreement</span></div><div style="margin-top:4pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the Exchange Agreement, but subject to the Amended and Restated LLC Agreement of vTv Therapeutics LLC, the vTv Units (along with a corresponding number of shares of the Class B common stock) are exchangeable for (i) shares of the Company&#8217;s Class A common stock on a one-for-one basis or (ii) cash (based on the fair market value of the Company&#8217;s Class A common stock as determined pursuant to the Exchange Agreement), at the Company&#8217;s option (as the managing member of vTv Therapeutics LLC), subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. Any decision to require an exchange for cash rather than shares of Class A common stock will ultimately be determined by the entire Board of Directors. On September 19, 2025, MacAndrews exchanged 577,108 shares under the provisions of the Exchange Agreement.</span></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tax Receivable Agreement</span></div><div style="margin-top:4pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company and MacAndrews are party to a tax receivable agreement (the &#8220;Tax Receivable Agreement&#8221;), which provides for the payment by the Company to M&amp;F TTP Holdings Two LLC (&#8220;M&amp;F&#8221;), as successor in interest to vTv Therapeutics Holdings, LLC (&#8220;vTv Therapeutics Holdings&#8221;), and M&amp;F TTP Holdings LLC (or certain of its transferees or other assignees) of 85% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that the Company actually realizes (or, in some circumstances, the Company is deemed to realize) as a result of (a) the exchange of Class B common stock, together with the corresponding number of vTv Units, for shares of the Company&#8217;s Class A common stock (or for cash), (b) tax benefits related to imputed interest deemed to be paid by the Company as a result of the Tax Receivable Agreement and (c) certain tax benefits attributable to payments under the Tax Receivable Agreement. MacAndrews exchanged 577,108 shares pursuant to the Exchange Agreement (discussed above), and the Company has not recognized any liability, nor has it made any payments pursuant to the Tax Receivable Agreement as of June&#160;30, 2026.</span></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investor Rights Agreement</span></div><div style="margin-top:4pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to an investor rights agreement with M&amp;F, as successor in interest to vTv Therapeutics Holdings (the &#8220;Investor Rights Agreement&#8221;). The Investor Rights Agreement provides M&amp;F with certain demand, shelf, and piggyback registration rights with respect to its shares of Class A common stock and also provides M&amp;F with certain governance rights, depending on the size of its holdings of Class A common stock. Under the Investor Rights Agreement, M&amp;F was initially entitled to nominate a majority of the members of the Board of Directors and designate the members of the committees of the Board of Directors. The Investor Rights Agreement was amended on February 27, 2024, to alter M&amp;F governance rights that now entitles M&amp;F the right to designate two members of our Board of Directors, and as part of the Private Placement, the Private Placement Investors have rights to designate three members of our Board of Directors, making it more difficult for a third party to acquire control of our Board. The agreement with the Private Placement Investors also provides that five of our directors must approve certain actions including any acquisition by a third party, which makes it more difficult for our Board of Directors to approve such a transaction.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(7)(e)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text">Segment Information<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our Chief Operating Decision Maker (&#8220;CODM&#8221;) is our President and Chief Executive Officer, Paul Sekhri. The CODM makes decisions on resource allocation, assesses performance of the business, and monitors budget versus actual results using net loss. Net (loss) income is also a measure that is considered in monitoring budget versus actual results. The measure of the segment assets is reported on the Condensed Consolidated Balance Sheet as total assets.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages its business activities on a consolidated basis and operates in a single reportable segment. Its operations primarily focus on the research and development of its lead product candidate, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin,</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and it has not yet generated any product revenue. All of the Company&#8217;s principal operations, assets, and decision-making functions are based in the U.S., and as a result, all of our financial information is derived from domestic sources except for collaboration and license revenue of $36.8 million during the six months ended June&#160;30, 2026, which was derived from two foreign collaboration partners located in China and United Arab Emirates. </span></div><div style="margin-top:4pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Significant segment expenses are included in the table below and represent direct and indirect research and development expenses by project for the three and six months ended June&#160;30, 2026, and 2025 were as follows (in thousands):</span></div><div style="margin-top:4pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:51.209%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.375%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.375%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.375%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.378%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Direct research and development expense:</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cadisegliatin</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,488&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,992&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11,995&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,910&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other projects</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Indirect research and development expense&#8224;</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,042&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,975&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,436&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,774&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expense</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8,770&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,103&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">17,748&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,933&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:25.000%"><tr><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.972%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Includes HPP737 and azeliragon</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8224;</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Includes share-based compensation</span></div></td></tr></table></div><div style="margin-top:4pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Segment revenue is consistent with what is presented in the Company&#8217;s Condensed Consolidated Statements of Operations. Other segment items consist of (i) operating expenses, which include share-based compensation, (ii) interest and other expense and (iii) income tax expense, all of which are reflected in the Company&#8217;s Condensed Consolidated Statements of Operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 22: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to U.S. federal income taxes as well as state taxes. The Company did not record an income tax provision for the three and six months ended June&#160;30, 2026 and 2025.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Management has evaluated the positive and negative evidence surrounding the realization of its deferred tax assets, including the Company&#8217;s history of losses, and under the applicable accounting standards determined that it is more-likely-than-not that the deferred tax assets will not be realized. The difference between the effective tax rate of the Company and the U.S. statutory tax rate of 21% on June&#160;30, 2026, is due to the valuation allowance against the Company&#8217;s expected net operating losses.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 7, the Company is party to a tax receivable agreement with a related party which provides for the payment by the Company to M&amp;F (or certain of its transferees or other assignees) of 85% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that the Company actually realizes (or, in some circumstances, the Company is deemed to realize) as a result of certain transactions. As no transactions have occurred which would trigger a liability under this agreement, the Company has not recognized any liability related to this agreement as of June&#160;30, 2026.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net (Loss) Income per Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net (Loss) Income per Share</a></td>
<td class="text">Net (Loss) Income per Share<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Basic (loss) income per share is computed by dividing net (loss) income attributable to vTv Therapeutics Inc. by the weighted average number of shares of Class A common stock outstanding during the period. Diluted net (loss) income per share is computed by dividing net (loss) income by the weighted-average number of shares of common stock and potentially dilutive shares of common stock outstanding during the period.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For dilutive securities, all outstanding stock options, and Common Warrants, are considered potentially outstanding common stock. The dilutive effect, if any, of stock options, and Common Warrants is calculated using the treasury stock method. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the numerator and denominator used in the calculation of basic and diluted net (loss) income per share of Class A common stock is as follows (amounts in thousands, except number of shares and per share amounts):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.321%"><tr><td style="width:1.0%"></td><td style="width:56.392%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.144%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.411%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.144%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.077%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Basic net (loss) income per share:</span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income </span></td><td style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(13,054)</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(7,380)</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11,080&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(13,597)</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net loss attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,334)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2,459)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income attributable to common shareholders of vTv Therapeutics Inc.</span></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(13,054)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(6,046)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11,080&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(11,138)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average vTv Therapeutics Inc. Class A common stock </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">12,409,316&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,587,070&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">12,409,297&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,584,969&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Basic net (loss) income per share of vTv Therapeutics Inc. Class A common stock</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1.05)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(0.92)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">0.89&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1.69)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net (loss) income per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income </span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(13,054)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(7,380)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11,080&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(13,597)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net loss attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,334)</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2,459)</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income attributable to common shareholders of vTv Therapeutics Inc</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(13,054)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(6,046)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11,080&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(11,138)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average vTv Therapeutics Inc. Class A common stock </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">12,409,316&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,587,070&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">14,541,788&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,584,969&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net (loss) income per share of vTv Therapeutics Inc. Class A common stock</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1.05)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(0.92)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">0.76&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1.69)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.720%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">(1)</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">The shares underlying the pre-funded warrants to purchase shares of the Company&#8217;s common stock have been included in the calculation of the weighted average number of shares outstanding, basic and diluted, for the three and six months ended June&#160;30, 2026 and 2025.</span></div></td></tr></table></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities not included in the calculation of dilutive net loss per share are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:72.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.865%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.867%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2025</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Class B common stock </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">577,349&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options granted under the Plan </span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">674,538&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,018,250&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Common stock warrants </span></td><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">19,160&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">70,639&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">693,790&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,666,238&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">___________________________</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.720%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">(1)</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Shares of Class B common stock do not share in the Company&#8217;s earnings and are not participating securities. Accordingly, separate presentation of loss per share of Class B common stock under the two-class method has not been provided. Each share of Class B common stock (together with a corresponding vTv Unit) is exchangeable for one share of Class A common stock.</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481468/505-20-05-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent Events<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated subsequent events through August&#160;6, 2026, and determined that there have been no events that have occurred that would require adjustments to our disclosures or the Unaudited Condensed Consolidated Financial Statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock', window );">Unaudited Interim Financial Information</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Financial Information</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). The accompanying Condensed Consolidated Balance Sheet as of June&#160;30, 2026, Condensed Consolidated Statements of Operations for the three and six months ended June&#160;30, 2026 and 2025, Condensed Consolidated Statement of Changes in Stockholders&#8217; Equity for the three and six months ended June&#160;30, </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026 and 2025, and Condensed Consolidated Statements of Cash Flows for the six months ended June&#160;30, 2026 and 2025 are unaudited. These unaudited financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (&#8220;SEC&#8221;) for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. These financial statements should be read in conjunction with the audited financial statements and the accompanying notes for the year ended December&#160;31, 2025, contained in the Company&#8217;s Annual Report on Form 10-K. The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company&#8217;s financial position as of June&#160;30, 2026, the results of operations for the three and six months ended June&#160;30, 2026 and 2025, and cash flows for the six months ended June&#160;30, 2026 and 2025. The December&#160;31, 2025 Condensed Consolidated Balance Sheet included herein was derived from the audited financial statements but does not include all disclosures or notes required by GAAP for complete financial statements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The financial data and other information disclosed in these notes to the financial statements related to the three and six months ended June&#160;30, 2026 and 2025 are unaudited. Interim results are not necessarily indicative of results for an entire year.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not have any components of other comprehensive income recorded within its Condensed Consolidated Financial Statements, and, therefore, does not separately present a statement of comprehensive income in its Condensed Consolidated Financial Statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, the Company evaluates its estimates, including those related to the grant date fair value of equity awards, the fair value of warrants to purchase shares of its Class A common stock and the useful lives of property and equipment, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgments about the carrying value of assets and liabilities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There has been uncertainty and disruption in the global economy and financial markets due to a number of factors, including geopolitical instability, inflationary pressures, high interest rates, a recessionary environment, domestic and global monetary and fiscal policy, changes in trade policy, including tariffs or other trade restrictions or the threat of such actions, banking and other financial institution instability and other factors. Our business may also be impacted by changes or disruptions at the U.S. Food and Drug Administration (&#8220;FDA&#8221;) and other government agencies. The Company has taken into consideration any known impacts to its accounting estimates to date and is not aware of any additional specific events or circumstances that would require any additional updates to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of the filing date of this Quarterly Report on Form 10-Q.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Disaggregation of Income Statement Expenses:</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> In November 2024, the FASB issued ASU No. 2024-03, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures: Disaggregation of Income Statement Expenses.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; This guidance requires disclosures about significant expense categories, including but not limited to, inventory purchases, employee compensation, depreciation, amortization, and selling expenses</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. This amendment is effective for our annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. We are currently assessing the impact of this guidance on our disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unaudited interim financial information policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Award Activity for the Period</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to the stock option awards for the six months ended June&#160;30, 2026:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.023%"><tr><td style="width:1.0%"></td><td style="width:57.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.243%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.243%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.246%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Weighted <br/>Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value (in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Awards outstanding at December 31, 2025</span></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,017,620&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">25.18&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">564,719&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">36.52&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or Expired</span></td><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(41,687)</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">30.60&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Awards outstanding at June 30, 2026</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,540,652&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">29.19&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">17,857&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable at June 30, 2026</span></td><td colspan="2" style="background-color:#ebfeff;border-top:3pt double #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">604,164&#160;</span></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">29.28&#160;</span></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9,795&#160;</span></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining contractual term</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7.1 Years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest at June 30, 2026</span></td><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,275,464&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">28.73&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining contractual term</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8.1 Years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Compensation Expense Related to Grants of Stock Options</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Compensation expense related to the grants of stock options is included in research and development and general and administrative expense as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.376%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.251%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.443%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">307&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">977&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">534&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,194&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">623&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,138&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,209&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,727&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">930&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,115&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,743&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock', window );">Schedule of Equity-Based Stock Warrants</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the equity-based stock warrant activity for the six months ended June&#160;30, 2026:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.703%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.025%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.563%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2025</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13,714,356&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8.69</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Expired or cancelled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2026*</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13,714,356&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8.69&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13,714,356&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8.69&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">Amount includes 8,470,624 Pre-Funded Warrants and 5,243,732 Common Warrants.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for outstanding award under share-based payment arrangement excluding share and unit options and nonvested award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Reporting Information, by Segment</a></td>
<td class="text"><div style="margin-top:4pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Significant segment expenses are included in the table below and represent direct and indirect research and development expenses by project for the three and six months ended June&#160;30, 2026, and 2025 were as follows (in thousands):</span></div><div style="margin-top:4pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:51.209%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.375%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.375%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.375%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.378%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Direct research and development expense:</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cadisegliatin</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,488&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,992&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11,995&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,910&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other projects</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Indirect research and development expense&#8224;</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,042&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,975&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,436&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,774&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expense</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8,770&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,103&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">17,748&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,933&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:25.000%"><tr><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.972%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Includes HPP737 and azeliragon</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8224;</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Includes share-based compensation</span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of segment reporting. Includes, but is not limited to, reconciliation of reportable segment amount to corresponding consolidated total.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26A<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net (Loss) Income per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Income (Loss) per Share of Class A Common Stock</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the numerator and denominator used in the calculation of basic and diluted net (loss) income per share of Class A common stock is as follows (amounts in thousands, except number of shares and per share amounts):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.321%"><tr><td style="width:1.0%"></td><td style="width:56.392%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.144%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.411%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.144%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.077%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Basic net (loss) income per share:</span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income </span></td><td style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(13,054)</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(7,380)</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11,080&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(13,597)</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net loss attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,334)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2,459)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income attributable to common shareholders of vTv Therapeutics Inc.</span></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(13,054)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(6,046)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11,080&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(11,138)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average vTv Therapeutics Inc. Class A common stock </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">12,409,316&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,587,070&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">12,409,297&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,584,969&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Basic net (loss) income per share of vTv Therapeutics Inc. Class A common stock</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1.05)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(0.92)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">0.89&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1.69)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net (loss) income per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income </span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(13,054)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(7,380)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11,080&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(13,597)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net loss attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,334)</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2,459)</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income attributable to common shareholders of vTv Therapeutics Inc</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(13,054)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(6,046)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11,080&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(11,138)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average vTv Therapeutics Inc. Class A common stock </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">12,409,316&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,587,070&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">14,541,788&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,584,969&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net (loss) income per share of vTv Therapeutics Inc. Class A common stock</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1.05)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(0.92)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">0.76&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1.69)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.720%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">(1)</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">The shares underlying the pre-funded warrants to purchase shares of the Company&#8217;s common stock have been included in the calculation of the weighted average number of shares outstanding, basic and diluted, for the three and six months ended June&#160;30, 2026 and 2025.</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss per Share</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities not included in the calculation of dilutive net loss per share are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:72.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.865%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.867%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2025</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Class B common stock </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">577,349&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options granted under the Plan </span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">674,538&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,018,250&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Common stock warrants </span></td><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">19,160&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">70,639&#160;</span></td><td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">693,790&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,666,238&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">___________________________</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.720%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">(1)</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Shares of Class B common stock do not share in the Company&#8217;s earnings and are not participating securities. Accordingly, separate presentation of loss per share of Class B common stock under the two-class method has not been provided. Each share of Class B common stock (together with a corresponding vTv Unit) is exchangeable for one share of Class A common stock.</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Basis of Presentation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Feb. 28, 2026</div></th>
<th class="th"><div>Jan. 30, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 86,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88,932<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 315,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 326,692<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=vtvt_VTvLLCMember', window );">vTv Therapeutics LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_PercentageOfNonVotingEconomicInterestByParent', window );">Percentage of non-voting economic interest of vTv Therapeutics Inc in vTv LLC</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=vtvt_NewsoaraBiopharmaCoLtdMember', window );">Newsoara Biopharma Co Ltd | Collaborative Arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_LicenseFeeReceived', window );">License fee received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">Parent Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 67,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 860<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481420/860-30-50-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_LicenseFeeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Fee Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_LicenseFeeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Organization consolidation and presentation of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_PercentageOfNonVotingEconomicInterestByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of non voting economic interest by parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_PercentageOfNonVotingEconomicInterestByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=vtvt_VTvLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=vtvt_VTvLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=vtvt_NewsoaraBiopharmaCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=vtvt_NewsoaraBiopharmaCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 30, 2026</div></th>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Feb. 28, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Contract liabilities, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,830,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,830,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,669,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">36,839,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangements | Newsoara Biopharma Co Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_LicenseFeeReceived', window );">License fee received</a></td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Collaboration revenue recognized</a></td>
<td class="nump">50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable', window );">Potential development and regulatory milestone payments receivable</a></td>
<td class="nump">$ 65,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=vtvt_G42InvestmentsMember', window );">G42 Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">259,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Aggregate gross purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=vtvt_G42InvestmentsMember', window );">G42 Investments | G42 Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross', window );">Sale of stock, consideration received on transaction, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableNetCurrent', window );">Accounts and financing receivable, after allowance for credit loss, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue', window );">Contingent consideration transferred, aggregate share value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_CollaborateArrangementContingentConsiderationTransferredCash', window );">Contingent consideration transferred, cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Contract liabilities, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_CollaborativeArrangementNoteReceivableDiscountPaid', window );">Note receivable, discount paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue from collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=vtvt_CognaMember', window );">Cogna | G42 Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod', window );">Collaborative arrangement, royalties receivable, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=vtvt_CognaMember', window );">Cogna | Collaborative Arrangements | IP License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,900,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=vtvt_CognaMember', window );">Cogna | Commercial Supply Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of accounts and financing receivables, classified as current. Includes, but is not limited to, notes and loan receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479428/808-10-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_CollaborateArrangementContingentConsiderationTransferredCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborate Arrangement, Contingent Consideration Transferred, Cash</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_CollaborateArrangementContingentConsiderationTransferredCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Contingent Consideration Transferred, Aggregate Share Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_CollaborativeArrangementNoteReceivableDiscountPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Note Receivable, Discount Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_CollaborativeArrangementNoteReceivableDiscountPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Royalties Receivable, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_LicenseFeeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Fee Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_LicenseFeeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential development and regulatory milestone payments receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Consideration Received on Transaction, Gross</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_SaleOfStockConsiderationReceivedOnTransactionGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=vtvt_NewsoaraBiopharmaCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=vtvt_NewsoaraBiopharmaCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vtvt_G42InvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vtvt_G42InvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vtvt_G42AgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vtvt_G42AgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vtvt_CognaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vtvt_CognaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vtvt_IPLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vtvt_IPLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vtvt_CommercialSupplyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vtvt_CommercialSupplyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Additional Information (Details) - Stock Option - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 27, 2024</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Non-qualified stock option awards vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Non-qualified stock option awards expiration term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost related to non-vested share-based compensation arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period to recognize unrecognized share-based compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of options granted (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28.05<span></span>
</td>
<td class="nump">$ 15.01<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant to expiration date of share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Schedule of Stock Award Activity for the Period (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2026 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Awards outstanding, beginning balance (in shares) | shares</a></td>
<td class="nump">1,017,620<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">564,719<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited or Expired (in shares) | shares</a></td>
<td class="num">(41,687)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Awards outstanding, ending balance (in shares) | shares</a></td>
<td class="nump">1,540,652<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">604,164<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable, weighted average remaining contractual term</a></td>
<td class="text">7 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Options vested and expected to vest (in shares) | shares</a></td>
<td class="nump">1,275,464<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Options vested and expected to vest, weighted average remaining contractual term</a></td>
<td class="text">8 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Awards outstanding, beginning balance (in usd per share) | $ / shares</a></td>
<td class="nump">$ 25.18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="nump">36.52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited or Expired (in usd per share) | $ / shares</a></td>
<td class="nump">30.60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Awards outstanding, ending balance (in usd per share) | $ / shares</a></td>
<td class="nump">29.19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable (in usd per share) | $ / shares</a></td>
<td class="nump">29.28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Options vested and expected to vest (in usd per share) | $ / shares</a></td>
<td class="nump">$ 28.73<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value outstanding | $</a></td>
<td class="nump">$ 17,857<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value exercisable | $</a></td>
<td class="nump">$ 9,795<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average contractual term remaining for vested portion of option outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average contractual term remaining for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested option for which requisite service period has not been rendered but that is expected to vest based on achievement of performance condition, if forfeiture is recognized when it occurs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Schedule of Compensation Expense Related to Grants of Stock Options (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 1,727<span></span>
</td>
<td class="nump">$ 930<span></span>
</td>
<td class="nump">$ 3,115<span></span>
</td>
<td class="nump">$ 1,743<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeLocationBalanceAxis=us-gaap_GeneralAndAdministrativeExpense', window );">Income Statement Location: us-gaap:GeneralAndAdministrativeExpense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">1,194<span></span>
</td>
<td class="nump">623<span></span>
</td>
<td class="nump">2,138<span></span>
</td>
<td class="nump">1,209<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeLocationBalanceAxis=us-gaap_ResearchAndDevelopmentExpense', window );">Income Statement Location: us-gaap:ResearchAndDevelopmentExpense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 533<span></span>
</td>
<td class="nump">$ 307<span></span>
</td>
<td class="nump">$ 977<span></span>
</td>
<td class="nump">$ 534<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeLocationBalanceAxis=us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeLocationBalanceAxis=us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeLocationBalanceAxis=us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeLocationBalanceAxis=us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - Novo License Agreement<br> $ in Millions</strong></div></th>
<th class="th">
<div>Feb. 28, 2007 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=vtvt_SalesBasedMilestonesPaymentMember', window );">Sales-Based Milestones Payment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_PotentialMilestonePayment', window );">Potential milestone payment</a></td>
<td class="nump">$ 75.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Developmental and Regulatory Milestone Payment | Type 1 Diabetes</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_PotentialMilestonePayment', window );">Potential milestone payment</a></td>
<td class="nump">6.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Developmental and Regulatory Milestone Payment | Type 2 Diabetes</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_PotentialMilestonePayment', window );">Potential milestone payment</a></td>
<td class="nump">50.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Developmental and Regulatory Milestone Payment | Other Indication</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_PotentialMilestonePayment', window );">Potential milestone payment</a></td>
<td class="nump">$ 115.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments and Contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_PotentialMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_PotentialMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=vtvt_SalesBasedMilestonesPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=vtvt_SalesBasedMilestonesPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vtvt_NovoLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vtvt_NovoLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vtvt_TypeOneDiabetesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vtvt_TypeOneDiabetesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vtvt_TypeTwoDiabetesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vtvt_TypeTwoDiabetesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vtvt_OtherIndicationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vtvt_OtherIndicationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 17, 2024</div></th>
<th class="th"><div>Aug. 31, 2025</div></th>
<th class="th"><div>Feb. 29, 2024</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 05, 2024</div></th>
<th class="th"><div>Feb. 28, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=vtvt_PreFundedWarrantsMember', window );">Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities called by warrants or rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,470,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,470,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=vtvt_CommonWarrantsMember', window );">Common Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities called by warrants or rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,243,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,243,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_WarrantsAndRightsImmediatelyExercisableTerm', window );">Warrants and rights immediately exercisable term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold (in shares)</a></td>
<td class="nump">179,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Aggregate gross purchase price</a></td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80.0<span></span>
</td>
<td class="nump">$ 51.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_CommonStockParOrStatedValueOfPrivatePlacementShares', window );">Private placement, shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(116,493)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_CommonStockParOrStatedValueOfPrivatePlacementPreFundedWarrantsShares', window );">Private placement pre-funded warrants, shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Private Placement Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants or rights (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">682,018<span></span>
</td>
<td class="nump">464,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.265<span></span>
</td>
<td class="nump">$ 11.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Class A Common Stock | Private Placement Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.255<span></span>
</td>
<td class="nump">$ 11.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities called by warrants or rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,561,714<span></span>
</td>
<td class="nump">3,853,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Additionally number of securities called by warrants or rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,243,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vtvt_TDCowenSalesAgreementMember', window );">TD Cowen Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_EntityPublicFloatPercent', window );">Entity public float, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_EntityPublicFloatThreshold', window );">Entity public float, threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_SaleOfStockMaximumSecuritiesToBeSoldPercentOfPublicFloat', window );">Percent of public float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vtvt_TDCowenSalesAgreementMember', window );">TD Cowen Sales Agreement | Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_SaleOfStockAggregateOfferingPrice', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-5<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-13<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_CommonStockParOrStatedValueOfPrivatePlacementPreFundedWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Par or Stated Value of Private Placement Pre-Funded Warrants, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_CommonStockParOrStatedValueOfPrivatePlacementPreFundedWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_CommonStockParOrStatedValueOfPrivatePlacementShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Par or Stated Value of Private Placement, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_CommonStockParOrStatedValueOfPrivatePlacementShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_EntityPublicFloatPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity Public Float, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_EntityPublicFloatPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_EntityPublicFloatThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity Public Float, Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_EntityPublicFloatThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_SaleOfStockAggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate offering price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_SaleOfStockAggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_SaleOfStockMaximumSecuritiesToBeSoldPercentOfPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Maximum Securities To Be Sold, Percent Of Public Float</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_SaleOfStockMaximumSecuritiesToBeSoldPercentOfPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_WarrantsAndRightsImmediatelyExercisableTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants And Rights Immediately Exercisable Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_WarrantsAndRightsImmediatelyExercisableTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=vtvt_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=vtvt_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=vtvt_CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=vtvt_CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=vtvt_PrivatePlacementPreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=vtvt_PrivatePlacementPreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=vtvt_TDCowenSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=vtvt_TDCowenSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity - Schedule of Equity-Based Stock Warrants (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2026 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=vtvt_PreFundedWarrantsMember', window );">Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePriceAbstract', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities called by warrants or rights (in shares)</a></td>
<td class="nump">8,470,624<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=vtvt_CommonWarrantsMember', window );">Common Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePriceAbstract', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities called by warrants or rights (in shares)</a></td>
<td class="nump">5,243,732<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=vtvt_StockWarrantMember', window );">Stock Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Outstanding number of beginning balance( in shares)</a></td>
<td class="nump">13,714,356<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations', window );">Expired or cancelled (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Outstanding number of ending balance (in shares)</a></td>
<td class="nump">13,714,356<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="nump">13,714,356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePriceAbstract', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price beginning balance (in usd per share) | $ / shares</a></td>
<td class="nump">$ 8.69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in usd per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price ending balance ( in usd per share) | $ / shares</a></td>
<td class="nump">8.69<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in usd per share) | $ / shares</a></td>
<td class="nump">$ 8.69<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were either cancelled or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Options, Exercisable, Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Options, Exercisable, Weighted Average Exercise Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Options, Outstanding, Weighted Average Exercise Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePriceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Options, Outstanding, Weighted Average Exercise Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePriceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangements by Share-Based Payment Award, Non-Options, Exercises in Period, Weighted Average Exercise Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangements by Share-Based Payment Award, Non-Options, Grants in Period, Weighted Average Exercise Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=vtvt_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=vtvt_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=vtvt_CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=vtvt_CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vtvt_StockWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vtvt_StockWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th">
<div>Jun. 30, 2026 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 19, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 27, 2024 </div>
<div>boardOfDirectorsNumber</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_NumberOfBoardOfDirectorsToApproveCertainActions', window );">Number of board of directors to approve certain actions | boardOfDirectorsNumber</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=vtvt_MFTTPHoldingsTwoLLCMember', window );">M&amp;F TTP Holdings Two LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_NumberOfBoardOfDirectorsRightToDesignateMembers', window );">Number of board of directors right to designate members | boardOfDirectorsNumber</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=vtvt_PrivatePlacementInvestorsMember', window );">Private Placement Investors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_NumberOfBoardOfDirectorsRightToDesignateMembers', window );">Number of board of directors right to designate members | boardOfDirectorsNumber</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92<span></span>
</td>
<td class="nump">241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,938,803<span></span>
</td>
<td class="nump">3,938,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock | Exchange of Redeemable Non controlling Interest to Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio', window );">Stock conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=vtvt_MacAndrewsAndForbesIncorporatedMember', window );">MacAndrews &amp; Forbes Incorporated | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_OwnershipPercentageOfMajorityOwner', window );">Ownership percentage of majority owner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_PercentageOfAmountOfCashSavings', window );">Amount of cash savings percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=vtvt_MacAndrewsAndForbesIncorporatedMember', window );">MacAndrews &amp; Forbes Incorporated | Related Party | Class B Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Share held by related party (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">577,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">577,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=vtvt_MacAndrewsAndForbesIncorporatedMember', window );">MacAndrews &amp; Forbes Incorporated | Related Party | Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Share held by related party (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,490,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=vtvt_MacAndrewsAndForbesIncorporatedMember', window );">MacAndrews &amp; Forbes Incorporated | Related Party | Class A Common Stock | vTv Therapeutics Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_OwnershipPercentageOfMajorityOwner', window );">Ownership percentage of majority owner</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of investment owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(7)(e)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 970<br> -SubTopic 810<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477383/970-810-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_NumberOfBoardOfDirectorsRightToDesignateMembers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Board Of Directors Right To Designate Members</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_NumberOfBoardOfDirectorsRightToDesignateMembers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_NumberOfBoardOfDirectorsToApproveCertainActions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Board Of Directors To Approve Certain Actions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_NumberOfBoardOfDirectorsToApproveCertainActions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_OwnershipPercentageOfMajorityOwner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ownership percentage of majority owner.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_OwnershipPercentageOfMajorityOwner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_PercentageOfAmountOfCashSavings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of amount of cash savings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_PercentageOfAmountOfCashSavings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Redeemable non controlling interest exchange agreement stock conversion ratio.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=vtvt_MFTTPHoldingsTwoLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=vtvt_MFTTPHoldingsTwoLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=vtvt_PrivatePlacementInvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=vtvt_PrivatePlacementInvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=vtvt_MacAndrewsAndForbesIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=vtvt_MacAndrewsAndForbesIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=vtvt_VTvTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=vtvt_VTvTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2026 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2026 </div>
<div>USD ($) </div>
<div>Segment </div>
<div>partner</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 36,839<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_NumberOfForeignCollaborationPartners', window );">Number of foreign collaboration partners | partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=vtvt_ReportableSegmentMember', window );">Reportable Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (j)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_NumberOfForeignCollaborationPartners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Foreign Collaboration Partners</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_NumberOfForeignCollaborationPartners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=vtvt_ReportableSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=vtvt_ReportableSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Schedule of Segment Reporting Information, by Segment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expense</a></td>
<td class="nump">$ 8,770<span></span>
</td>
<td class="nump">$ 4,103<span></span>
</td>
<td class="nump">$ 17,748<span></span>
</td>
<td class="nump">$ 6,933<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=vtvt_ReportableSegmentMember', window );">Reportable Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_IndirectResearchDevelopmentExpense', window );">Indirect research and development expense</a></td>
<td class="nump">3,042<span></span>
</td>
<td class="nump">1,975<span></span>
</td>
<td class="nump">5,436<span></span>
</td>
<td class="nump">3,774<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expense</a></td>
<td class="nump">8,770<span></span>
</td>
<td class="nump">4,103<span></span>
</td>
<td class="nump">17,748<span></span>
</td>
<td class="nump">6,933<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=vtvt_ReportableSegmentMember', window );">Reportable Segment | Cadisegliatin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_DirectResearchAndDevelopmentExpense', window );">Direct research and development expense</a></td>
<td class="nump">5,488<span></span>
</td>
<td class="nump">1,992<span></span>
</td>
<td class="nump">11,995<span></span>
</td>
<td class="nump">2,910<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=vtvt_ReportableSegmentMember', window );">Reportable Segment | Other projects</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_DirectResearchAndDevelopmentExpense', window );">Direct research and development expense</a></td>
<td class="nump">$ 240<span></span>
</td>
<td class="nump">$ 136<span></span>
</td>
<td class="nump">$ 317<span></span>
</td>
<td class="nump">$ 249<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (j)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_DirectResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Direct Research and Development Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_DirectResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_IndirectResearchDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indirect Research Development Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_IndirectResearchDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=vtvt_ReportableSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=vtvt_ReportableSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=vtvt_CadisegliatinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=vtvt_CadisegliatinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=vtvt_OtherProjectsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=vtvt_OtherProjectsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=vtvt_MFTTPHoldingsLLCMember', window );">M&amp;F TTP Holdings LLC</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_PercentageOfAmountOfCashSavings', window );">Amount of cash savings percentage</a></td>
<td class="nump">85.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_PercentageOfAmountOfCashSavings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of amount of cash savings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_PercentageOfAmountOfCashSavings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=vtvt_MFTTPHoldingsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=vtvt_MFTTPHoldingsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net (Loss) Income per Share - Schedule of Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Income (Loss) per Share of Class A Common Stock (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss) income</a></td>
<td class="num">$ (13,054)<span></span>
</td>
<td class="num">$ (7,380)<span></span>
</td>
<td class="nump">$ 11,080<span></span>
</td>
<td class="num">$ (13,597)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: Net loss attributable to noncontrolling interests</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,334)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,459)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net (loss) income attributable to common shareholders of vTv Therapeutics Inc., basic</a></td>
<td class="num">(13,054)<span></span>
</td>
<td class="num">(6,046)<span></span>
</td>
<td class="nump">11,080<span></span>
</td>
<td class="num">(11,138)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_NetIncomeLossDilutedAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss) income</a></td>
<td class="num">(13,054)<span></span>
</td>
<td class="num">(7,380)<span></span>
</td>
<td class="nump">11,080<span></span>
</td>
<td class="num">(13,597)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: Net loss attributable to noncontrolling interests</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,334)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,459)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net (loss) income attributable to common shareholders of vTv Therapeutics Inc diluted</a></td>
<td class="num">$ (13,054)<span></span>
</td>
<td class="num">$ (6,046)<span></span>
</td>
<td class="nump">$ 11,080<span></span>
</td>
<td class="num">$ (11,138)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average vTv Therapeutics Inc. Class A common stock (in shares)</a></td>
<td class="nump">12,409,316<span></span>
</td>
<td class="nump">6,587,070<span></span>
</td>
<td class="nump">12,409,297<span></span>
</td>
<td class="nump">6,584,969<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net (loss) income per share of vTv Therapeutics Inc. Class A common stock (in usd per share)</a></td>
<td class="num">$ (1.05)<span></span>
</td>
<td class="num">$ (0.92)<span></span>
</td>
<td class="nump">$ 0.89<span></span>
</td>
<td class="num">$ (1.69)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_WeightedAverageNumberOfDilutedSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average vTv Therapeutics Inc. Class A common stock (in shares)</a></td>
<td class="nump">12,409,316<span></span>
</td>
<td class="nump">6,587,070<span></span>
</td>
<td class="nump">14,541,788<span></span>
</td>
<td class="nump">6,584,969<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net (loss) income per share of vTv Therapeutics Inc. Class A common stock (in usd per share)</a></td>
<td class="num">$ (1.05)<span></span>
</td>
<td class="num">$ (0.92)<span></span>
</td>
<td class="nump">$ 0.76<span></span>
</td>
<td class="num">$ (1.69)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 44: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_NetIncomeLossDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Income Loss Diluted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_NetIncomeLossDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_WeightedAverageNumberOfDilutedSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Number Of Diluted Shares Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_WeightedAverageNumberOfDilutedSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net (Loss) Income per Share - Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss per Share (Details)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2026 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities not included in calculation of dilutive net loss per share (in shares)</a></td>
<td class="nump">693,790<span></span>
</td>
<td class="nump">1,666,238<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_CommonClassBMember', window );">Class B Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities not included in calculation of dilutive net loss per share (in shares)</a></td>
<td class="nump">92<span></span>
</td>
<td class="nump">577,349<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Common stock options granted under the Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities not included in calculation of dilutive net loss per share (in shares)</a></td>
<td class="nump">674,538<span></span>
</td>
<td class="nump">1,018,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities not included in calculation of dilutive net loss per share (in shares)</a></td>
<td class="nump">19,160<span></span>
</td>
<td class="nump">70,639<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split conversion ratio</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479951/505-20-S50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479982/505-20-S25-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>178</ContextCount>
  <ElementCount>183</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>46</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="vtvt-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="vtvt-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>9952151 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="vtvt-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952152 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="vtvt-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952153 - Statement - Condensed Consolidated Statements of Operations - Unaudited</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Operations - Unaudited</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="vtvt-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952154 - Statement - Condensed Consolidated Statement of Changes in Stockholders’ Equity - Unaudited</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinStockholdersEquityUnaudited</Role>
      <ShortName>Condensed Consolidated Statement of Changes in Stockholders’ Equity - Unaudited</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="vtvt-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952155 - Statement - Condensed Consolidated Statements of Cash Flows - Unaudited</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows - Unaudited</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="vtvt-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952156 - Disclosure - Description of Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentation</Role>
      <ShortName>Description of Business and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="vtvt-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952157 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="vtvt-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - Collaboration Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/CollaborationAgreements</Role>
      <ShortName>Collaboration Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="vtvt-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/ShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="vtvt-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="vtvt-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - Stockholders’ Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders’ Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="vtvt-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - Related-Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related-Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="vtvt-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="vtvt-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="vtvt-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - Net (Loss) Income per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/NetLossIncomeperShare</Role>
      <ShortName>Net (Loss) Income per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="vtvt-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952166 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="vtvt-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="vtvt-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="vtvt-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9955512 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/ShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://vtvtherapeutics.com/role/ShareBasedCompensation</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="vtvt-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9955513 - Disclosure - Stockholders’ Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders’ Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://vtvtherapeutics.com/role/StockholdersEquity</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="vtvt-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9955514 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://vtvtherapeutics.com/role/SegmentInformation</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="vtvt-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9955515 - Disclosure - Net (Loss) Income per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/NetLossIncomeperShareTables</Role>
      <ShortName>Net (Loss) Income per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://vtvtherapeutics.com/role/NetLossIncomeperShare</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="vtvt-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9955516 - Disclosure - Description of Business and Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetails</Role>
      <ShortName>Description of Business and Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentation</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="vtvt-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9955517 - Disclosure - Collaboration Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/CollaborationAgreementsDetails</Role>
      <ShortName>Collaboration Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://vtvtherapeutics.com/role/CollaborationAgreements</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="vtvt-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9955518 - Disclosure - Share-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Share-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="vtvt-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9955519 - Disclosure - Share-Based Compensation - Schedule of Stock Award Activity for the Period (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/ShareBasedCompensationScheduleofStockAwardActivityforthePeriodDetails</Role>
      <ShortName>Share-Based Compensation - Schedule of Stock Award Activity for the Period (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="vtvt-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9955520 - Disclosure - Share-Based Compensation - Schedule of Compensation Expense Related to Grants of Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/ShareBasedCompensationScheduleofCompensationExpenseRelatedtoGrantsofStockOptionsDetails</Role>
      <ShortName>Share-Based Compensation - Schedule of Compensation Expense Related to Grants of Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="vtvt-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9955521 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://vtvtherapeutics.com/role/CommitmentsandContingencies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="vtvt-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9955522 - Disclosure - Stockholders’ Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/StockholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Stockholders’ Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="vtvt-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9955523 - Disclosure - Stockholders’ Equity - Schedule of Equity-Based Stock Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/StockholdersEquityScheduleofEquityBasedStockWarrantsDetails</Role>
      <ShortName>Stockholders’ Equity - Schedule of Equity-Based Stock Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="vtvt-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9955524 - Disclosure - Related-Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related-Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://vtvtherapeutics.com/role/RelatedPartyTransactions</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="vtvt-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9955525 - Disclosure - Segment Information - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/SegmentInformationAdditionalInformationDetails</Role>
      <ShortName>Segment Information - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="vtvt-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9955526 - Disclosure - Segment Information - Schedule of Segment Reporting Information, by Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails</Role>
      <ShortName>Segment Information - Schedule of Segment Reporting Information, by Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="vtvt-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9955527 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://vtvtherapeutics.com/role/IncomeTaxes</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="vtvt-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9955528 - Disclosure - Net (Loss) Income per Share - Schedule of Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Income (Loss) per Share of Class A Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/NetLossIncomeperShareScheduleofReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetIncomeLossperShareofClassACommonStockDetails</Role>
      <ShortName>Net (Loss) Income per Share - Schedule of Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Income (Loss) per Share of Class A Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://vtvtherapeutics.com/role/NetLossIncomeperShareTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="vtvt-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9955529 - Disclosure - Net (Loss) Income per Share - Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/NetLossIncomeperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetails</Role>
      <ShortName>Net (Loss) Income per Share - Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://vtvtherapeutics.com/role/NetLossIncomeperShareTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="vtvt-20260630.htm">vtvt-20260630.htm</File>
    <File>vtvt-20260630.xsd</File>
    <File>vtvt-20260630_cal.xml</File>
    <File>vtvt-20260630_def.xml</File>
    <File>vtvt-20260630_lab.xml</File>
    <File>vtvt-20260630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>vtvt-20260630_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="431">http://fasb.org/us-gaap/2026</BaseTaxonomy>
    <BaseTaxonomy items="31">http://xbrl.sec.gov/dei/2026</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2026</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>56
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "vtvt-20260630.htm": {
   "nsprefix": "vtvt",
   "nsuri": "http://vtvtherapeutics.com/20260630",
   "dts": {
    "inline": {
     "local": [
      "vtvt-20260630.htm"
     ]
    },
    "schema": {
     "local": [
      "vtvt-20260630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd",
      "https://xbrl.fasb.org/srt/2026/elts/srt-roles-2026.xsd",
      "https://xbrl.fasb.org/srt/2026/elts/srt-types-2026.xsd",
      "https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd",
      "https://xbrl.fasb.org/us-gaap/2026/elts/us-roles-2026.xsd",
      "https://xbrl.fasb.org/us-gaap/2026/elts/us-types-2026.xsd",
      "https://xbrl.sec.gov/country/2026/country-2026.xsd",
      "https://xbrl.sec.gov/dei/2026/dei-2026.xsd",
      "https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd",
      "https://xbrl.sec.gov/stpr/2026/stpr-2026.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "vtvt-20260630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "vtvt-20260630_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "vtvt-20260630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "vtvt-20260630_pre.xml"
     ]
    }
   },
   "keyStandard": 151,
   "keyCustom": 32,
   "axisStandard": 21,
   "axisCustom": 0,
   "memberStandard": 16,
   "memberCustom": 27,
   "hidden": {
    "total": 8,
    "http://xbrl.sec.gov/dei/2026": 5,
    "http://fasb.org/us-gaap/2026": 2,
    "http://vtvtherapeutics.com/20260630": 1
   },
   "contextCount": 178,
   "entityCount": 1,
   "segmentCount": 46,
   "elementCount": 429,
   "unitCount": 8,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2026": 431,
    "http://xbrl.sec.gov/dei/2026": 31,
    "http://xbrl.sec.gov/ecd/2026": 4
   },
   "report": {
    "R1": {
     "role": "http://vtvtherapeutics.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets",
     "longName": "9952151 - Statement - Condensed Consolidated Balance Sheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "longName": "9952152 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-11",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-11",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
     "longName": "9952153 - Statement - Condensed Consolidated Statements of Operations - Unaudited",
     "shortName": "Condensed Consolidated Statements of Operations - Unaudited",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinStockholdersEquityUnaudited",
     "longName": "9952154 - Statement - Condensed Consolidated Statement of Changes in Stockholders\u2019 Equity - Unaudited",
     "shortName": "Condensed Consolidated Statement of Changes in Stockholders\u2019 Equity - Unaudited",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-73",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-73",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
     "longName": "9952155 - Statement - Condensed Consolidated Statements of Cash Flows - Unaudited",
     "shortName": "Condensed Consolidated Statements of Cash Flows - Unaudited",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentation",
     "longName": "9952156 - Disclosure - Description of Business and Basis of Presentation",
     "shortName": "Description of Business and Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "9952157 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://vtvtherapeutics.com/role/CollaborationAgreements",
     "longName": "9952158 - Disclosure - Collaboration Agreements",
     "shortName": "Collaboration Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://vtvtherapeutics.com/role/ShareBasedCompensation",
     "longName": "9952159 - Disclosure - Share-Based Compensation",
     "shortName": "Share-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://vtvtherapeutics.com/role/CommitmentsandContingencies",
     "longName": "9952160 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://vtvtherapeutics.com/role/StockholdersEquity",
     "longName": "9952161 - Disclosure - Stockholders\u2019 Equity",
     "shortName": "Stockholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://vtvtherapeutics.com/role/RelatedPartyTransactions",
     "longName": "9952162 - Disclosure - Related-Party Transactions",
     "shortName": "Related-Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://vtvtherapeutics.com/role/SegmentInformation",
     "longName": "9952163 - Disclosure - Segment Information",
     "shortName": "Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://vtvtherapeutics.com/role/IncomeTaxes",
     "longName": "9952164 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://vtvtherapeutics.com/role/NetLossIncomeperShare",
     "longName": "9952165 - Disclosure - Net (Loss) Income per Share",
     "shortName": "Net (Loss) Income per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://vtvtherapeutics.com/role/SubsequentEvents",
     "longName": "9952166 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-14",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "longName": "9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "vtvt:UnauditedInterimFinancialInformationPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "vtvt:UnauditedInterimFinancialInformationPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://vtvtherapeutics.com/role/ShareBasedCompensationTables",
     "longName": "9955512 - Disclosure - Share-Based Compensation (Tables)",
     "shortName": "Share-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://vtvtherapeutics.com/role/StockholdersEquityTables",
     "longName": "9955513 - Disclosure - Stockholders\u2019 Equity (Tables)",
     "shortName": "Stockholders\u2019 Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://vtvtherapeutics.com/role/SegmentInformationTables",
     "longName": "9955514 - Disclosure - Segment Information (Tables)",
     "shortName": "Segment Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://vtvtherapeutics.com/role/NetLossIncomeperShareTables",
     "longName": "9955515 - Disclosure - Net (Loss) Income per Share (Tables)",
     "shortName": "Net (Loss) Income per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetails",
     "longName": "9955516 - Disclosure - Description of Business and Basis of Presentation (Details)",
     "shortName": "Description of Business and Basis of Presentation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-86",
      "name": "vtvt:PercentageOfNonVotingEconomicInterestByParent",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "1",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "unique": true
     }
    },
    "R25": {
     "role": "http://vtvtherapeutics.com/role/CollaborationAgreementsDetails",
     "longName": "9955517 - Disclosure - Collaboration Agreements (Details)",
     "shortName": "Collaboration Agreements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:ContractWithCustomerLiabilityNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ContractWithCustomerLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "unique": true
     }
    },
    "R26": {
     "role": "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails",
     "longName": "9955518 - Disclosure - Share-Based Compensation - Additional Information (Details)",
     "shortName": "Share-Based Compensation - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-110",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-110",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://vtvtherapeutics.com/role/ShareBasedCompensationScheduleofStockAwardActivityforthePeriodDetails",
     "longName": "9955519 - Disclosure - Share-Based Compensation - Schedule of Stock Award Activity for the Period (Details)",
     "shortName": "Share-Based Compensation - Schedule of Stock Award Activity for the Period (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://vtvtherapeutics.com/role/ShareBasedCompensationScheduleofCompensationExpenseRelatedtoGrantsofStockOptionsDetails",
     "longName": "9955520 - Disclosure - Share-Based Compensation - Schedule of Compensation Expense Related to Grants of Stock Options (Details)",
     "shortName": "Share-Based Compensation - Schedule of Compensation Expense Related to Grants of Stock Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://vtvtherapeutics.com/role/CommitmentsandContingenciesDetails",
     "longName": "9955521 - Disclosure - Commitments and Contingencies (Details)",
     "shortName": "Commitments and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-124",
      "name": "vtvt:PotentialMilestonePayment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-124",
      "name": "vtvt:PotentialMilestonePayment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://vtvtherapeutics.com/role/StockholdersEquityAdditionalInformationDetails",
     "longName": "9955522 - Disclosure - Stockholders\u2019 Equity - Additional Information (Details)",
     "shortName": "Stockholders\u2019 Equity - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-129",
      "name": "us-gaap:SaleOfStockPricePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-129",
      "name": "us-gaap:SaleOfStockPricePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://vtvtherapeutics.com/role/StockholdersEquityScheduleofEquityBasedStockWarrantsDetails",
     "longName": "9955523 - Disclosure - Stockholders\u2019 Equity - Schedule of Equity-Based Stock Warrants (Details)",
     "shortName": "Stockholders\u2019 Equity - Schedule of Equity-Based Stock Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-141",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-138",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "unique": true
     }
    },
    "R32": {
     "role": "http://vtvtherapeutics.com/role/RelatedPartyTransactionsDetails",
     "longName": "9955524 - Disclosure - Related-Party Transactions (Details)",
     "shortName": "Related-Party Transactions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-158",
      "name": "vtvt:NumberOfBoardOfDirectorsToApproveCertainActions",
      "unitRef": "boardofdirectorsnumber",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-158",
      "name": "vtvt:NumberOfBoardOfDirectorsToApproveCertainActions",
      "unitRef": "boardofdirectorsnumber",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://vtvtherapeutics.com/role/SegmentInformationAdditionalInformationDetails",
     "longName": "9955525 - Disclosure - Segment Information - Additional Information (Details)",
     "shortName": "Segment Information - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "vtvt:NumberOfForeignCollaborationPartners",
      "unitRef": "partner",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "unique": true
     }
    },
    "R34": {
     "role": "http://vtvtherapeutics.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails",
     "longName": "9955526 - Disclosure - Segment Information - Schedule of Segment Reporting Information, by Segment (Details)",
     "shortName": "Segment Information - Schedule of Segment Reporting Information, by Segment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-168",
      "name": "vtvt:IndirectResearchDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://vtvtherapeutics.com/role/IncomeTaxesDetails",
     "longName": "9955527 - Disclosure - Income Taxes (Details)",
     "shortName": "Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-171",
      "name": "vtvt:PercentageOfAmountOfCashSavings",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-171",
      "name": "vtvt:PercentageOfAmountOfCashSavings",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://vtvtherapeutics.com/role/NetLossIncomeperShareScheduleofReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetIncomeLossperShareofClassACommonStockDetails",
     "longName": "9955528 - Disclosure - Net (Loss) Income per Share - Schedule of Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Income (Loss) per Share of Class A Common Stock (Details)",
     "shortName": "Net (Loss) Income per Share - Schedule of Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Income (Loss) per Share of Class A Common Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://vtvtherapeutics.com/role/NetLossIncomeperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetails",
     "longName": "9955529 - Disclosure - Net (Loss) Income per Share - Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss per Share (Details)",
     "shortName": "Net (Loss) Income per Share - Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20260630.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsNotesAndLoansReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccountsNotesAndLoansReceivableNetCurrent",
     "crdr": "debit",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts and financing receivable, after allowance for credit loss, current",
        "label": "Accounts and Financing Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of accounts and financing receivables, classified as current. Includes, but is not limited to, notes and loan receivable."
       }
      }
     },
     "auth_ref": [
      "r623",
      "r873"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued expenses",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r729"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r787",
      "r892"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-in Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r463",
      "r521",
      "r851",
      "r852",
      "r853",
      "r854",
      "r938",
      "r996"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Net shares withheld for tax withholding related to the settlement of equity awards.",
        "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r300"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net income (loss) before noncontrolling interest to net cash used in operating activities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table",
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r701",
      "r711",
      "r721",
      "r753"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r704",
      "r714",
      "r724",
      "r756"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Pension Adjustments Service Cost",
        "label": "Aggregate Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r705",
      "r715",
      "r725",
      "r749",
      "r757",
      "r761",
      "r769"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationScheduleofCompensationExpenseRelatedtoGrantsofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total share-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r330",
      "r336",
      "r337"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://vtvtherapeutics.com/role/NetLossIncomeperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potentially dilutive securities not included in calculation of dilutive net loss per share (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://vtvtherapeutics.com/role/NetLossIncomeperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://vtvtherapeutics.com/role/NetLossIncomeperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://vtvtherapeutics.com/role/NetLossIncomeperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsDetails",
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesDetails",
      "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r367"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48",
      "r59",
      "r93",
      "r95",
      "r96",
      "r141",
      "r153",
      "r171",
      "r175",
      "r183",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r266",
      "r369",
      "r374",
      "r403",
      "r444",
      "r445",
      "r446",
      "r459",
      "r460",
      "r466",
      "r558",
      "r643",
      "r644",
      "r650",
      "r673",
      "r679",
      "r680",
      "r692",
      "r882",
      "r883",
      "r942"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48",
      "r77",
      "r93",
      "r95",
      "r96",
      "r183",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r266",
      "r369",
      "r374",
      "r403",
      "r673",
      "r783",
      "r882",
      "r883",
      "r942"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://vtvtherapeutics.com/role/StockholdersEquityScheduleofEquityBasedStockWarrantsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r763"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of Business and Basis of Presentation",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r780",
      "r844"
     ]
    },
    "vtvt_CadisegliatinMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20260630",
     "localname": "CadisegliatinMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cadisegliatin",
        "label": "Cadisegliatin [Member]",
        "documentation": "Cadisegliatin"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis",
     "presentation": [
      "http://vtvtherapeutics.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Project [Axis]",
        "label": "Project [Axis]",
        "documentation": "Information by project."
       }
      }
     },
     "auth_ref": [
      "r442",
      "r443",
      "r948"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets",
      "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalent",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r89",
      "r90",
      "r622",
      "r944"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Total cash and cash equivalents, beginning of period",
        "periodEndLabel": "Total cash and cash equivalents, end of period",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r89",
      "r90"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net decrease in cash and cash equivalents",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation",
        "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r19"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year",
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested",
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "CityAreaCode",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinStockholdersEquityUnaudited",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://vtvtherapeutics.com/role/Cover",
      "http://vtvtherapeutics.com/role/NetLossIncomeperShareScheduleofReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetIncomeLossperShareofClassACommonStockDetails",
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsDetails",
      "http://vtvtherapeutics.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock",
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r52",
      "r53",
      "r65",
      "r66",
      "r67",
      "r68",
      "r69",
      "r70",
      "r93",
      "r96",
      "r125",
      "r126",
      "r133",
      "r135",
      "r143",
      "r144",
      "r183",
      "r216",
      "r218",
      "r219",
      "r220",
      "r223",
      "r224",
      "r228",
      "r229",
      "r231",
      "r232",
      "r234",
      "r236",
      "r239",
      "r240",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r249",
      "r252",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r261",
      "r262",
      "r265",
      "r266",
      "r267",
      "r403",
      "r444",
      "r445",
      "r451",
      "r452",
      "r453",
      "r463",
      "r510",
      "r511",
      "r512",
      "r513",
      "r521",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r546",
      "r566",
      "r588",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r779",
      "r846",
      "r847",
      "r855",
      "r894",
      "r900"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://vtvtherapeutics.com/role/StockholdersEquityScheduleofEquityBasedStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class Of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r53",
      "r65",
      "r69",
      "r70",
      "r143",
      "r231",
      "r240",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r249",
      "r252",
      "r255",
      "r256",
      "r258",
      "r259",
      "r261",
      "r262",
      "r265",
      "r267",
      "r380",
      "r444",
      "r445",
      "r452",
      "r453",
      "r510",
      "r511",
      "r512",
      "r513",
      "r779",
      "r845",
      "r846",
      "r894"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://vtvtherapeutics.com/role/StockholdersEquityScheduleofEquityBasedStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Axis]",
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://vtvtherapeutics.com/role/StockholdersEquityScheduleofEquityBasedStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Domain]",
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price of warrants or rights (in usd per share)",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r98",
      "r256"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additionally number of securities called by warrants or rights (in shares)",
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares."
       }
      }
     },
     "auth_ref": [
      "r256"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://vtvtherapeutics.com/role/StockholdersEquityScheduleofEquityBasedStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of securities called by warrants or rights (in shares)",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "vtvt_CognaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20260630",
     "localname": "CognaMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cogna",
        "label": "Cogna [Member]",
        "documentation": "Cogna"
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_CollaborateArrangementContingentConsiderationTransferredCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vtvtherapeutics.com/20260630",
     "localname": "CollaborateArrangementContingentConsiderationTransferredCash",
     "crdr": "credit",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration transferred, cash",
        "label": "Collaborate Arrangement, Contingent Consideration Transferred, Cash",
        "documentation": "Collaborate Arrangement, Contingent Consideration Transferred, Cash"
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vtvtherapeutics.com/20260630",
     "localname": "CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue",
     "crdr": "credit",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration transferred, aggregate share value",
        "label": "Collaborative Arrangement, Contingent Consideration Transferred, Aggregate Share Value",
        "documentation": "Collaborative Arrangement, Contingent Consideration Transferred, Aggregate Share Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration Agreements",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r365",
      "r366"
     ]
    },
    "us-gaap_CollaborativeArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CollaborativeArrangementMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsDetails",
      "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangements",
        "label": "Collaborative Arrangement [Member]",
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity."
       }
      }
     },
     "auth_ref": [
      "r367"
     ]
    },
    "vtvt_CollaborativeArrangementNoteReceivableDiscountPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vtvtherapeutics.com/20260630",
     "localname": "CollaborativeArrangementNoteReceivableDiscountPaid",
     "crdr": "credit",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Note receivable, discount paid",
        "label": "Collaborative Arrangement, Note Receivable, Discount Paid",
        "documentation": "Collaborative Arrangement, Note Receivable, Discount Paid"
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://vtvtherapeutics.com/20260630",
     "localname": "CollaborativeArrangementRoyaltiesReceivablePeriod",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative arrangement, royalties receivable, period",
        "label": "Collaborative Arrangement, Royalties Receivable, Period",
        "documentation": "Collaborative Arrangement, Royalties Receivable, Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r367"
     ]
    },
    "vtvt_CommercialSupplyAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20260630",
     "localname": "CommercialSupplyAgreementMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial Supply Agreement",
        "label": "Commercial Supply Agreement [Member]",
        "documentation": "Commercial Supply Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r444",
      "r445",
      "r450",
      "r468",
      "r545"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]",
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r211",
      "r615",
      "r875",
      "r877",
      "r878"
     ]
    },
    "vtvt_CommitmentsAndContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://vtvtherapeutics.com/20260630",
     "localname": "CommitmentsAndContingenciesLineItems",
     "presentation": [
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments And Contingencies [Line Items]",
        "label": "Commitments And Contingencies [Line Items]",
        "documentation": "Commitments and Contingencies."
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_CommitmentsAndContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://vtvtherapeutics.com/20260630",
     "localname": "CommitmentsAndContingenciesTable",
     "presentation": [
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments And Contingencies [Table]",
        "label": "Commitments And Contingencies [Table]",
        "documentation": "Commitments And Contingencies [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonClassAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommonClassAMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinStockholdersEquityUnaudited",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://vtvtherapeutics.com/role/Cover",
      "http://vtvtherapeutics.com/role/NetLossIncomeperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetails",
      "http://vtvtherapeutics.com/role/NetLossIncomeperShareScheduleofReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetIncomeLossperShareofClassACommonStockDetails",
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsDetails",
      "http://vtvtherapeutics.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class A Common Stock",
        "label": "Common Class A [Member]",
        "documentation": "Classification of common stock representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r786",
      "r889",
      "r891",
      "r949",
      "r950",
      "r952",
      "r996"
     ]
    },
    "us-gaap_CommonClassBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommonClassBMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinStockholdersEquityUnaudited",
      "http://vtvtherapeutics.com/role/Cover",
      "http://vtvtherapeutics.com/role/NetLossIncomeperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetails",
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class B Common Stock",
        "label": "Common Class B [Member]",
        "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r786",
      "r889",
      "r891",
      "r949",
      "r950",
      "r952",
      "r996"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommonStockMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r262",
      "r444",
      "r445",
      "r453",
      "r682",
      "r683",
      "r684",
      "r686",
      "r687",
      "r688",
      "r689",
      "r851",
      "r852",
      "r854",
      "r938",
      "r994",
      "r996"
     ]
    },
    "vtvt_CommonStockParOrStatedValueOfPrivatePlacementPreFundedWarrantsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://vtvtherapeutics.com/20260630",
     "localname": "CommonStockParOrStatedValueOfPrivatePlacementPreFundedWarrantsShares",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private placement pre-funded warrants, shares (in shares)",
        "label": "Common Stock, Par or Stated Value of Private Placement Pre-Funded Warrants, Shares",
        "documentation": "Common Stock, Par or Stated Value of Private Placement Pre-Funded Warrants, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_CommonStockParOrStatedValueOfPrivatePlacementShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://vtvtherapeutics.com/20260630",
     "localname": "CommonStockParOrStatedValueOfPrivatePlacementShares",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Private placement, shares (in shares)",
        "label": "Common Stock, Par or Stated Value of Private Placement, Shares",
        "documentation": "Common Stock, Par or Stated Value of Private Placement, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock par value (in usd per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r786",
      "r891",
      "r949",
      "r950",
      "r952"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r262",
      "r444",
      "r445",
      "r453",
      "r546"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinStockholdersEquityUnaudited",
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "periodStartLabel": "Beginning balance, shares (in shares)",
        "periodEndLabel": "Ending balance, shares (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r262",
      "r444",
      "r445",
      "r453",
      "r546",
      "r564",
      "r888",
      "r996",
      "r997"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock value",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r229",
      "r235",
      "r262",
      "r444",
      "r445",
      "r453",
      "r469",
      "r673"
     ]
    },
    "vtvt_CommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20260630",
     "localname": "CommonWarrantsMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://vtvtherapeutics.com/role/StockholdersEquityScheduleofEquityBasedStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Warrants",
        "label": "Common Warrants [Member]",
        "documentation": "Common Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "srt_ConsolidatedEntitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "ConsolidatedEntitiesAxis",
     "presentation": [
      "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated Entities [Axis]",
        "label": "Consolidated Entities [Axis]"
       }
      }
     },
     "auth_ref": [
      "r94",
      "r103",
      "r369",
      "r370",
      "r373",
      "r374",
      "r375",
      "r423",
      "r462",
      "r616",
      "r881",
      "r884",
      "r885",
      "r895"
     ]
    },
    "srt_ConsolidatedEntitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "ConsolidatedEntitiesDomain",
     "presentation": [
      "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated Entities [Domain]",
        "label": "Consolidated Entities [Domain]"
       }
      }
     },
     "auth_ref": [
      "r94",
      "r103",
      "r369",
      "r370",
      "r373",
      "r374",
      "r375",
      "r423",
      "r462",
      "r616",
      "r881",
      "r884",
      "r885",
      "r895"
     ]
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract liabilities",
        "label": "Contract with Customer, Liability",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r281",
      "r282",
      "r283",
      "r287"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsDetails",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Contract liabilities",
        "terseLabel": "Contract liabilities, noncurrent",
        "label": "Contract with Customer, Liability, Noncurrent",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r281",
      "r282",
      "r283",
      "r287"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Collaboration revenue recognized",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due."
       }
      }
     },
     "auth_ref": [
      "r288"
     ]
    },
    "us-gaap_ConversionOfStockByUniqueDescriptionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ConversionOfStockByUniqueDescriptionAxis",
     "presentation": [
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Conversion Description",
        "label": "Stock Conversion Description [Axis]",
        "documentation": "Information by description of stock conversions."
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "us-gaap_ConversionOfStockNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ConversionOfStockNameDomain",
     "presentation": [
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of Stock, Name",
        "label": "Conversion of Stock, Name [Domain]",
        "documentation": "The unique name of a noncash or part noncash stock conversion."
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ConversionOfStockSharesConverted1",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Conversion of Class B common stock to Class A common stock (in shares)",
        "label": "Conversion of Stock, Shares Converted",
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r93",
      "r101",
      "r102",
      "r225",
      "r246",
      "r421",
      "r427",
      "r437",
      "r465",
      "r625",
      "r626",
      "r627",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r934",
      "r935",
      "r936",
      "r937",
      "r945",
      "r946"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expense",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r85",
      "r201",
      "r628",
      "r629",
      "r631",
      "r633"
     ]
    },
    "vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20260630",
     "localname": "DevelopmentalAndRegulatoryMilestonePaymentMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Developmental and Regulatory Milestone Payment",
        "label": "Developmental And Regulatory Milestone Payment [Member]",
        "documentation": "Developmental and regulatory milestone payment."
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_DirectResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vtvtherapeutics.com/20260630",
     "localname": "DirectResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Direct research and development expense",
        "label": "Direct Research and Development Expense",
        "documentation": "Direct Research and Development Expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r298",
      "r302",
      "r331",
      "r332",
      "r334",
      "r654"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement [Abstract]",
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Information [Line Items]",
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Information [Table]",
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Quarterly Report",
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r696"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r728"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentType",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year",
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share [Abstract]",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://vtvtherapeutics.com/role/NetLossIncomeperShareScheduleofReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetIncomeLossperShareofClassACommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basic net (loss) income per share of vTv Therapeutics Inc. Class A common stock (in usd per share)",
        "terseLabel": "Basic net (loss) income per share of vTv Therapeutics Inc. Class A common stock (in usd per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r83",
      "r107",
      "r109",
      "r110",
      "r111",
      "r112",
      "r113",
      "r114",
      "r115",
      "r116",
      "r122",
      "r125",
      "r133",
      "r134",
      "r135",
      "r140",
      "r199",
      "r227",
      "r291",
      "r335",
      "r359",
      "r364",
      "r397",
      "r398",
      "r458",
      "r478",
      "r635"
     ]
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EarningsPerShareBasicAbstract",
     "presentation": [
      "http://vtvtherapeutics.com/role/NetLossIncomeperShareScheduleofReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetIncomeLossperShareofClassACommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic net (loss) income per share:",
        "label": "Earnings Per Share, Basic [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://vtvtherapeutics.com/role/NetLossIncomeperShareScheduleofReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetIncomeLossperShareofClassACommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Diluted net (loss) income per share of vTv Therapeutics Inc. Class A common stock (in usd per share)",
        "terseLabel": "Diluted net (loss) income per share of vTv Therapeutics Inc. Class A common stock (in usd per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r83",
      "r107",
      "r109",
      "r110",
      "r111",
      "r112",
      "r113",
      "r114",
      "r115",
      "r116",
      "r125",
      "r133",
      "r134",
      "r135",
      "r140",
      "r199",
      "r227",
      "r291",
      "r335",
      "r359",
      "r364",
      "r397",
      "r398",
      "r458",
      "r478",
      "r635"
     ]
    },
    "us-gaap_EarningsPerShareDilutedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EarningsPerShareDilutedAbstract",
     "presentation": [
      "http://vtvtherapeutics.com/role/NetLossIncomeperShareScheduleofReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetIncomeLossperShareofClassACommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted net (loss) income per share:",
        "label": "Earnings Per Share, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/NetLossIncomeperShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net (Loss) Income per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r136",
      "r137",
      "r138",
      "r139",
      "r271"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationScheduleofCompensationExpenseRelatedtoGrantsofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r927"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average period to recognize unrecognized share-based compensation cost",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation cost related to non-vested share-based compensation arrangements",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r928"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/NetLossIncomeperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetails",
      "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Option",
        "verboseLabel": "Common stock options granted under the Plan",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r694"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityDomain",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsDetails",
      "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetails",
      "http://vtvtherapeutics.com/role/IncomeTaxesDetails",
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity",
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r694"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r694"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "vtvt_EntityPublicFloatPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://vtvtherapeutics.com/20260630",
     "localname": "EntityPublicFloatPercent",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity public float, percent",
        "label": "Entity Public Float, Percent",
        "documentation": "Entity Public Float, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_EntityPublicFloatThreshold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vtvtherapeutics.com/20260630",
     "localname": "EntityPublicFloatThreshold",
     "crdr": "credit",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity public float, threshold",
        "label": "Entity Public Float, Threshold",
        "documentation": "Entity Public Float, Threshold"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r694"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r694"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r694"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r694"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Footnote",
        "label": "Equity Awards Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r733"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r774"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments",
        "label": "Equity Awards Adjustments [Member]"
       }
      }
     },
     "auth_ref": [
      "r774"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table",
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r774"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity [Abstract]",
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r44",
      "r52",
      "r69",
      "r70",
      "r80",
      "r81",
      "r82",
      "r104",
      "r105",
      "r106",
      "r108",
      "r115",
      "r117",
      "r119",
      "r142",
      "r184",
      "r185",
      "r198",
      "r199",
      "r200",
      "r226",
      "r255",
      "r260",
      "r261",
      "r262",
      "r265",
      "r267",
      "r270",
      "r289",
      "r290",
      "r292",
      "r293",
      "r335",
      "r349",
      "r350",
      "r356",
      "r357",
      "r358",
      "r360",
      "r363",
      "r364",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r396",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r438",
      "r444",
      "r445",
      "r452",
      "r453",
      "r463",
      "r477",
      "r502",
      "r503",
      "r504",
      "r521",
      "r588",
      "r900"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r743"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r701",
      "r711",
      "r721",
      "r753"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r698",
      "r708",
      "r718",
      "r750"
     ]
    },
    "vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20260630",
     "localname": "ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange of Redeemable Non controlling Interest to Class A Common Stock",
        "label": "Exchange Of Redeemable Non Controlling Interest To Class A Common Stock [Member]",
        "documentation": "Exchange of redeemable non controlling interest to class A common stock."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of warrants, related party",
        "label": "Fair Value Adjustment of Warrants",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r705",
      "r715",
      "r725",
      "r757"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r705",
      "r715",
      "r725",
      "r757"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r705",
      "r715",
      "r725",
      "r757"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r705",
      "r715",
      "r725",
      "r757"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r705",
      "r715",
      "r725",
      "r757"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year",
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r738"
     ]
    },
    "vtvt_G42AgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20260630",
     "localname": "G42AgreementsMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "G42 Agreements",
        "label": "G42 Agreements [Member]",
        "documentation": "G42 Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_G42InvestmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20260630",
     "localname": "G42InvestmentsMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "G42 Investments",
        "label": "G42 Investments [Member]",
        "documentation": "G42 Investments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r568"
     ]
    },
    "vtvt_IPLicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20260630",
     "localname": "IPLicenseMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IP License",
        "label": "IP License [Member]",
        "documentation": "IP License"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net (loss) income before income taxes and noncontrolling interest",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r30",
      "r459",
      "r461",
      "r473",
      "r621",
      "r630",
      "r632",
      "r634",
      "r638",
      "r643",
      "r858",
      "r861",
      "r867",
      "r870",
      "r871"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Abstract]",
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r97",
      "r341",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r351",
      "r353",
      "r354",
      "r355",
      "r464",
      "r508",
      "r515",
      "r656"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax provision",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r40",
      "r93",
      "r118",
      "r119",
      "r141",
      "r161",
      "r175",
      "r342",
      "r343",
      "r352",
      "r479",
      "r621",
      "r630",
      "r632",
      "r634",
      "r656"
     ]
    },
    "vtvt_IncomeTaxesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://vtvtherapeutics.com/20260630",
     "localname": "IncomeTaxesLineItems",
     "presentation": [
      "http://vtvtherapeutics.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes [Line Items]",
        "label": "Income Taxes [Line Items]",
        "documentation": "Income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_IncomeTaxesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://vtvtherapeutics.com/20260630",
     "localname": "IncomeTaxesTable",
     "presentation": [
      "http://vtvtherapeutics.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes [Table]",
        "label": "Income Taxes [Table]",
        "documentation": "Income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued expenses",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract liabilities",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r440",
      "r842"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in assets and liabilities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncreaseDecreaseInOtherCurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other current assets",
        "label": "Increase (Decrease) in Other Current Assets",
        "documentation": "Amount of increase (decrease) in current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other assets",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other liabilities",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_IndirectResearchDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vtvtherapeutics.com/20260630",
     "localname": "IndirectResearchDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indirect research and development expense",
        "label": "Indirect Research Development Expense",
        "documentation": "Indirect Research Development Expense"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r705",
      "r715",
      "r725",
      "r749",
      "r757",
      "r761",
      "r769"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r697",
      "r773"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r697",
      "r773"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r697",
      "r773"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Investment Income, Interest",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r156",
      "r175",
      "r643",
      "r799"
     ]
    },
    "us-gaap_InvestmentOwnedBalanceShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "InvestmentOwnedBalanceShares",
     "presentation": [
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share held by related party (in shares)",
        "label": "Investment Owned, Balance, Shares",
        "documentation": "Number of shares of investment owned."
       }
      }
     },
     "auth_ref": [
      "r534",
      "r535",
      "r597",
      "r601",
      "r603",
      "r684"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsDetails",
      "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetails",
      "http://vtvtherapeutics.com/role/IncomeTaxesDetails",
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal Entity",
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48",
      "r93",
      "r95",
      "r96",
      "r183",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r266",
      "r370",
      "r374",
      "r375",
      "r403",
      "r544",
      "r637",
      "r650",
      "r692",
      "r788",
      "r882",
      "r942",
      "r943"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r444",
      "r445",
      "r455",
      "r471",
      "r673",
      "r679",
      "r680",
      "r845",
      "r848",
      "r874",
      "r940"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities and Stockholders\u2019 Equity",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48",
      "r51",
      "r61",
      "r93",
      "r95",
      "r96",
      "r183",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r266",
      "r370",
      "r374",
      "r375",
      "r403",
      "r673",
      "r882",
      "r942",
      "r943"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_LicenseFeeReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vtvtherapeutics.com/20260630",
     "localname": "LicenseFeeReceived",
     "crdr": "debit",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsDetails",
      "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License fee received",
        "label": "License Fee Received",
        "documentation": "License Fee Received"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_MFTTPHoldingsLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20260630",
     "localname": "MFTTPHoldingsLLCMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "M&amp;F TTP Holdings LLC",
        "label": "M F T T P Holdings L L C [Member]",
        "documentation": "M&amp;F TTP Holdings LLC."
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_MFTTPHoldingsTwoLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20260630",
     "localname": "MFTTPHoldingsTwoLLCMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "M&amp;F TTP Holdings Two LLC",
        "label": "M&amp;F TTP Holdings Two LLC [Member]",
        "documentation": "M&amp;F TTP Holdings Two LLC"
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_MacAndrewsAndForbesIncorporatedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20260630",
     "localname": "MacAndrewsAndForbesIncorporatedMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MacAndrews &amp; Forbes Incorporated",
        "label": "Mac Andrews And Forbes Incorporated [Member]",
        "documentation": "MacAndrews and Forbes Incorporated."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "MaximumMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r49",
      "r50",
      "r148",
      "r212",
      "r213",
      "r214",
      "r215",
      "r297",
      "r326",
      "r327",
      "r328",
      "r338",
      "r399",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r439",
      "r498",
      "r500",
      "r507",
      "r536",
      "r537",
      "r596",
      "r598",
      "r599",
      "r600",
      "r602",
      "r611",
      "r612",
      "r613",
      "r614",
      "r617",
      "r618",
      "r648",
      "r653",
      "r657",
      "r659",
      "r660",
      "r667",
      "r668",
      "r669",
      "r670",
      "r675",
      "r886",
      "r887"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in financing activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities:",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r21"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities:",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinStockholdersEquityUnaudited",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net (loss) income attributable to vTv Therapeutics Inc.",
        "terseLabel": "Net income (loss) attributable to vTv Therapeutics Inc.",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r21",
      "r31",
      "r44",
      "r47",
      "r48",
      "r78",
      "r79",
      "r82",
      "r93",
      "r95",
      "r96",
      "r100",
      "r107",
      "r111",
      "r112",
      "r113",
      "r114",
      "r115",
      "r118",
      "r119",
      "r131",
      "r183",
      "r199",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r227",
      "r230",
      "r233",
      "r237",
      "r266",
      "r291",
      "r335",
      "r359",
      "r364",
      "r398",
      "r403",
      "r476",
      "r565",
      "r586",
      "r587",
      "r630",
      "r632",
      "r634",
      "r690",
      "r882"
     ]
    },
    "us-gaap_NetIncomeLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NetIncomeLossAbstract",
     "presentation": [
      "http://vtvtherapeutics.com/role/NetLossIncomeperShareScheduleofReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetIncomeLossperShareofClassACommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Numerator:",
        "label": "Net Income (Loss) Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://vtvtherapeutics.com/role/NetLossIncomeperShareScheduleofReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetIncomeLossperShareofClassACommonStockDetails": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinStockholdersEquityUnaudited",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://vtvtherapeutics.com/role/NetLossIncomeperShareScheduleofReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetIncomeLossperShareofClassACommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Less: net loss attributable to noncontrolling interest",
        "terseLabel": "Net loss attributable to noncontrolling interest",
        "verboseLabel": "Less: Net loss attributable to noncontrolling interests",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r29",
      "r47",
      "r48",
      "r78",
      "r79",
      "r115",
      "r118",
      "r119",
      "r183",
      "r475",
      "r798"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/NetLossIncomeperShareScheduleofReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetIncomeLossperShareofClassACommonStockDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://vtvtherapeutics.com/role/NetLossIncomeperShareScheduleofReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetIncomeLossperShareofClassACommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net (loss) income attributable to vTv Therapeutics Inc. common shareholders",
        "totalLabel": "Net (loss) income attributable to common shareholders of vTv Therapeutics Inc., basic",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r84",
      "r111",
      "r112",
      "r113",
      "r114",
      "r122",
      "r123",
      "r132",
      "r135",
      "r230",
      "r233",
      "r237",
      "r364"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/NetLossIncomeperShareScheduleofReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetIncomeLossperShareofClassACommonStockDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/NetLossIncomeperShareScheduleofReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetIncomeLossperShareofClassACommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net (loss) income attributable to common shareholders of vTv Therapeutics Inc diluted",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r124",
      "r127",
      "r128",
      "r129",
      "r130",
      "r132",
      "r135"
     ]
    },
    "vtvt_NetIncomeLossDilutedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://vtvtherapeutics.com/20260630",
     "localname": "NetIncomeLossDilutedAbstract",
     "presentation": [
      "http://vtvtherapeutics.com/role/NetLossIncomeperShareScheduleofReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetIncomeLossperShareofClassACommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Numerator:",
        "label": "Net Income Loss Diluted [Abstract]",
        "documentation": "Net Income Loss Diluted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Pronouncements Not Yet Adopted",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "vtvt_NewsoaraBiopharmaCoLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20260630",
     "localname": "NewsoaraBiopharmaCoLtdMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsDetails",
      "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Newsoara Biopharma Co Ltd",
        "label": "Newsoara Biopharma Co Ltd [Member]",
        "documentation": "Newsoara Biopharma Co Ltd."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r705",
      "r715",
      "r725",
      "r749",
      "r757"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r732"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r731"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "us-gaap_NoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NoncontrollingInterestMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling Interest",
        "label": "Noncontrolling Interest [Member]",
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r265",
      "r267",
      "r851",
      "r852",
      "r853",
      "r854",
      "r996"
     ]
    },
    "us-gaap_NonrelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NonrelatedPartyMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nonrelated Party",
        "label": "Nonrelated Party [Member]",
        "documentation": "Party not related to reporting entity."
       }
      }
     },
     "auth_ref": [
      "r845",
      "r849",
      "r850"
     ]
    },
    "vtvt_NovoLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20260630",
     "localname": "NovoLicenseAgreementMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Novo License Agreement",
        "label": "Novo License Agreement [Member]",
        "documentation": "Novo license agreement."
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_NumberOfBoardOfDirectorsRightToDesignateMembers": {
     "xbrltype": "integerItemType",
     "nsuri": "http://vtvtherapeutics.com/20260630",
     "localname": "NumberOfBoardOfDirectorsRightToDesignateMembers",
     "presentation": [
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of board of directors right to designate members",
        "label": "Number of Board Of Directors Right To Designate Members",
        "documentation": "Number of Board Of Directors Right To Designate Members"
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_NumberOfBoardOfDirectorsToApproveCertainActions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://vtvtherapeutics.com/20260630",
     "localname": "NumberOfBoardOfDirectorsToApproveCertainActions",
     "presentation": [
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of board of directors to approve certain actions",
        "label": "Number of Board Of Directors To Approve Certain Actions",
        "documentation": "Number of Board Of Directors To Approve Certain Actions"
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_NumberOfForeignCollaborationPartners": {
     "xbrltype": "integerItemType",
     "nsuri": "http://vtvtherapeutics.com/20260630",
     "localname": "NumberOfForeignCollaborationPartners",
     "presentation": [
      "http://vtvtherapeutics.com/role/SegmentInformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of foreign collaboration partners",
        "label": "Number Of Foreign Collaboration Partners",
        "documentation": "Number Of Foreign Collaboration Partners"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://vtvtherapeutics.com/role/SegmentInformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r639",
      "r647",
      "r860"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r634",
      "r781",
      "r782",
      "r874"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating (loss) income",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r630",
      "r634",
      "r638",
      "r781",
      "r782",
      "r858",
      "r861",
      "r867",
      "r870",
      "r871",
      "r874"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://vtvtherapeutics.com/20260630",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems",
     "presentation": [
      "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization Consolidation And Presentation Of Financial Statements [Line Items]",
        "label": "Organization Consolidation And Presentation Of Financial Statements [Line Items]",
        "documentation": "Organization consolidation and presentation of financial statements."
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://vtvtherapeutics.com/20260630",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsTable",
     "presentation": [
      "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization Consolidation And Presentation Of Financial Statements [Table]",
        "label": "Organization Consolidation And Presentation Of Financial Statements [Table]",
        "documentation": "Organization Consolidation And Presentation Of Financial Statements [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets",
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r673"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r58"
     ]
    },
    "us-gaap_OtherCommitmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OtherCommitmentsAxis",
     "presentation": [
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commitments",
        "label": "Other Commitments [Axis]",
        "documentation": "Information by type of other commitment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OtherCommitmentsDomain",
     "presentation": [
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commitments",
        "label": "Other Commitments [Domain]",
        "documentation": "Other future obligation."
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_OtherIndicationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20260630",
     "localname": "OtherIndicationMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Indication",
        "label": "Other Indication [Member]",
        "documentation": "Other indication."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense), net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r663"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "vtvt_OtherProjectsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20260630",
     "localname": "OtherProjectsMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other projects",
        "label": "Other Projects [Member]",
        "documentation": "Other Projects"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r703",
      "r713",
      "r723",
      "r755"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r706",
      "r716",
      "r726",
      "r758"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r706",
      "r716",
      "r726",
      "r758"
     ]
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership [Axis]",
        "label": "Ownership [Axis]"
       }
      }
     },
     "auth_ref": [
      "r265",
      "r267"
     ]
    },
    "srt_OwnershipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "OwnershipDomain",
     "presentation": [
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership [Domain]",
        "label": "Ownership [Domain]"
       }
      }
     },
     "auth_ref": [
      "r265",
      "r267"
     ]
    },
    "vtvt_OwnershipPercentageOfMajorityOwner": {
     "xbrltype": "percentItemType",
     "nsuri": "http://vtvtherapeutics.com/20260630",
     "localname": "OwnershipPercentageOfMajorityOwner",
     "presentation": [
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership percentage of majority owner",
        "label": "Ownership Percentage Of Majority Owner",
        "documentation": "Ownership percentage of majority owner."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ParentCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "ParentCompanyMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Parent Company",
        "label": "Parent Company [Member]"
       }
      }
     },
     "auth_ref": [
      "r94",
      "r103",
      "r462"
     ]
    },
    "us-gaap_ParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ParentMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total vTv Therapeutics Inc Stockholders\u2019 Equity (Deficit)",
        "label": "Parent [Member]",
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r730"
     ]
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Taxes paid related to net share settlement of equity awards",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r732"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r731"
     ]
    },
    "vtvt_PercentageOfAmountOfCashSavings": {
     "xbrltype": "percentItemType",
     "nsuri": "http://vtvtherapeutics.com/20260630",
     "localname": "PercentageOfAmountOfCashSavings",
     "presentation": [
      "http://vtvtherapeutics.com/role/IncomeTaxesDetails",
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount of cash savings percentage",
        "label": "Percentage Of Amount Of Cash Savings",
        "documentation": "Percentage of amount of cash savings."
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_PercentageOfNonVotingEconomicInterestByParent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://vtvtherapeutics.com/20260630",
     "localname": "PercentageOfNonVotingEconomicInterestByParent",
     "presentation": [
      "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of non-voting economic interest of vTv Therapeutics Inc in vTv LLC",
        "label": "Percentage Of Non Voting Economic Interest By Parent",
        "documentation": "Percentage of non voting economic interest by parent."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Prior Service Cost",
        "label": "Pension Adjustments Prior Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r733"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Service Cost",
        "label": "Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Benefits Adjustments, Footnote",
        "label": "Pension Benefits Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r732"
     ]
    },
    "vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vtvtherapeutics.com/20260630",
     "localname": "PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable",
     "crdr": "debit",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potential development and regulatory milestone payments receivable",
        "label": "Potential Development And Regulatory Milestone Payments Receivable",
        "documentation": "Potential development and regulatory milestone payments receivable."
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_PotentialMilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vtvtherapeutics.com/20260630",
     "localname": "PotentialMilestonePayment",
     "crdr": "credit",
     "presentation": [
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potential milestone payment",
        "label": "Potential Milestone Payment",
        "documentation": "Potential milestone payment."
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20260630",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://vtvtherapeutics.com/role/StockholdersEquityScheduleofEquityBasedStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-Funded Warrants",
        "label": "Pre-Funded Warrants [Member]",
        "documentation": "Pre-Funded Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses",
        "label": "Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r186",
      "r187",
      "r624"
     ]
    },
    "vtvt_PrivatePlacementInvestorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20260630",
     "localname": "PrivatePlacementInvestorsMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Placement Investors",
        "label": "Private Placement Investors [Member]",
        "documentation": "Private Placement Investors"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Placement",
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_PrivatePlacementPreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20260630",
     "localname": "PrivatePlacementPreFundedWarrantsMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Placement Pre-Funded Warrants",
        "label": "Private Placement Pre-Funded Warrants [Member]",
        "documentation": "Private Placement Pre-Funded Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of private placement",
        "label": "Proceeds from Issuance of Private Placement",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the exercise of stock options",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r8"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r178",
      "r441",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r620",
      "r629",
      "r632",
      "r634",
      "r651",
      "r652",
      "r674",
      "r675",
      "r676",
      "r678",
      "r681",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r879",
      "r880",
      "r953",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r178",
      "r441",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r620",
      "r629",
      "r632",
      "r634",
      "r651",
      "r652",
      "r674",
      "r675",
      "r676",
      "r678",
      "r681",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r879",
      "r880",
      "r953",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://vtvtherapeutics.com/role/NetLossIncomeperShareScheduleofReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetIncomeLossperShareofClassACommonStockDetails": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://vtvtherapeutics.com/role/NetLossIncomeperShareScheduleofReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetIncomeLossperShareofClassACommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net (loss) income before noncontrolling interest",
        "terseLabel": "Net income (loss) before noncontrolling interest",
        "verboseLabel": "Net (loss) income",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r47",
      "r48",
      "r78",
      "r79",
      "r88",
      "r93",
      "r95",
      "r96",
      "r100",
      "r107",
      "r115",
      "r118",
      "r119",
      "r183",
      "r199",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r227",
      "r266",
      "r291",
      "r335",
      "r359",
      "r364",
      "r368",
      "r371",
      "r372",
      "r398",
      "r403",
      "r459",
      "r461",
      "r474",
      "r520",
      "r565",
      "r586",
      "r587",
      "r621",
      "r661",
      "r662",
      "r691",
      "r798",
      "r882"
     ]
    },
    "us-gaap_ProjectMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ProjectMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Project [Domain]",
        "label": "Project [Domain]",
        "documentation": "Planned program of work."
       }
      }
     },
     "auth_ref": [
      "r442",
      "r443",
      "r948"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r730"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r730"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "RangeAxis",
     "presentation": [
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r49",
      "r50",
      "r148",
      "r212",
      "r213",
      "r214",
      "r215",
      "r294",
      "r297",
      "r326",
      "r327",
      "r328",
      "r334",
      "r338",
      "r399",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r439",
      "r498",
      "r500",
      "r507",
      "r536",
      "r537",
      "r596",
      "r598",
      "r599",
      "r600",
      "r602",
      "r611",
      "r612",
      "r613",
      "r614",
      "r617",
      "r618",
      "r648",
      "r653",
      "r657",
      "r659",
      "r660",
      "r667",
      "r668",
      "r669",
      "r670",
      "r675",
      "r684",
      "r876",
      "r886",
      "r887",
      "r939"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "RangeMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r49",
      "r50",
      "r148",
      "r212",
      "r213",
      "r214",
      "r215",
      "r294",
      "r297",
      "r326",
      "r327",
      "r328",
      "r334",
      "r338",
      "r399",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r439",
      "r498",
      "r500",
      "r507",
      "r536",
      "r537",
      "r596",
      "r598",
      "r599",
      "r600",
      "r602",
      "r611",
      "r612",
      "r613",
      "r614",
      "r617",
      "r618",
      "r648",
      "r653",
      "r657",
      "r659",
      "r660",
      "r667",
      "r668",
      "r669",
      "r670",
      "r675",
      "r684",
      "r876",
      "r886",
      "r887",
      "r939"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r698",
      "r708",
      "r718",
      "r750"
     ]
    },
    "vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://vtvtherapeutics.com/20260630",
     "localname": "RedeemableNonControllingInterestExchangeAgreementStockConversionRatio",
     "presentation": [
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock conversion ratio",
        "label": "Redeemable Non Controlling Interest Exchange Agreement Stock Conversion Ratio",
        "documentation": "Redeemable non controlling interest exchange agreement stock conversion ratio."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r56",
      "r60",
      "r62",
      "r63",
      "r93",
      "r99",
      "r100",
      "r182",
      "r295",
      "r296",
      "r418",
      "r419",
      "r444",
      "r445",
      "r447",
      "r448",
      "r449",
      "r456",
      "r467",
      "r472",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r563",
      "r595",
      "r623",
      "r995",
      "r998"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r56",
      "r60",
      "r62",
      "r63",
      "r93",
      "r99",
      "r100",
      "r418",
      "r419",
      "r420",
      "r421",
      "r444",
      "r445",
      "r449",
      "r467",
      "r472",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r563",
      "r595"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Axis]",
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r99",
      "r100",
      "r418",
      "r419",
      "r941"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Domain]",
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r99",
      "r100",
      "r941"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Line Items]",
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r99",
      "r100",
      "r182",
      "r418",
      "r419",
      "r421",
      "r444",
      "r445",
      "r447",
      "r448",
      "r449",
      "r456",
      "r569",
      "r570",
      "r573",
      "r998"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transactions [Abstract]",
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r56",
      "r60",
      "r62",
      "r63",
      "r93",
      "r99",
      "r100",
      "r182",
      "r295",
      "r296",
      "r418",
      "r419",
      "r444",
      "r445",
      "r447",
      "r448",
      "r449",
      "r456",
      "r467",
      "r472",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r563",
      "r595",
      "r623",
      "r941",
      "r995",
      "r998"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related-Party Transactions",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r415",
      "r416",
      "r417",
      "r419",
      "r422",
      "r444",
      "r445",
      "r457",
      "r516",
      "r517",
      "r518",
      "r571",
      "r572",
      "r573",
      "r592",
      "r594"
     ]
    },
    "vtvt_ReportableSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20260630",
     "localname": "ReportableSegmentMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/SegmentInformationAdditionalInformationDetails",
      "http://vtvtherapeutics.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reportable Segment",
        "label": "Reportable Segment [Member]",
        "documentation": "Reportable Segment"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r93",
      "r101",
      "r102",
      "r225",
      "r246",
      "r421",
      "r427",
      "r437",
      "r465",
      "r625",
      "r626",
      "r627",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r934",
      "r935",
      "r936",
      "r937",
      "r945",
      "r946"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "presentation": [
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "documentation": "Information by form of arrangement related to research and development."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r930"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "presentation": [
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r930"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      },
      "http://vtvtherapeutics.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://vtvtherapeutics.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "totalLabel": "Total research and development expense",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r619",
      "r630",
      "r631",
      "r643",
      "r947"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r699",
      "r709",
      "r719",
      "r751"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r700",
      "r710",
      "r720",
      "r752"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r707",
      "r717",
      "r727",
      "r759"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets",
      "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r72",
      "r263",
      "r444",
      "r445",
      "r454",
      "r470",
      "r505",
      "r506",
      "r514",
      "r547",
      "r673"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r44",
      "r104",
      "r105",
      "r106",
      "r108",
      "r115",
      "r117",
      "r119",
      "r184",
      "r185",
      "r198",
      "r199",
      "r200",
      "r226",
      "r260",
      "r270",
      "r289",
      "r290",
      "r292",
      "r293",
      "r335",
      "r349",
      "r350",
      "r356",
      "r357",
      "r358",
      "r360",
      "r363",
      "r364",
      "r381",
      "r382",
      "r383",
      "r384",
      "r386",
      "r387",
      "r389",
      "r396",
      "r413",
      "r438",
      "r463",
      "r502",
      "r504",
      "r521",
      "r893",
      "r896",
      "r996"
     ]
    },
    "us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
     "crdr": "credit",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from collaborative arrangement",
        "label": "Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer",
        "documentation": "Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r933"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsDetails",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://vtvtherapeutics.com/role/SegmentInformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r154",
      "r155",
      "r169",
      "r175",
      "r178",
      "r180",
      "r181",
      "r284",
      "r285",
      "r286",
      "r441",
      "r630",
      "r634"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "vtvt_SaleOfStockAggregateOfferingPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vtvtherapeutics.com/20260630",
     "localname": "SaleOfStockAggregateOfferingPrice",
     "crdr": "credit",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate offering price",
        "label": "Sale Of Stock, Aggregate Offering Price",
        "documentation": "Aggregate offering price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsDetails",
      "http://vtvtherapeutics.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate gross purchase price",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_SaleOfStockConsiderationReceivedOnTransactionGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vtvtherapeutics.com/20260630",
     "localname": "SaleOfStockConsiderationReceivedOnTransactionGross",
     "crdr": "debit",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, consideration received on transaction, gross",
        "label": "Sale of Stock, Consideration Received on Transaction, Gross",
        "documentation": "Sale of Stock, Consideration Received on Transaction, Gross"
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_SaleOfStockMaximumSecuritiesToBeSoldPercentOfPublicFloat": {
     "xbrltype": "percentItemType",
     "nsuri": "http://vtvtherapeutics.com/20260630",
     "localname": "SaleOfStockMaximumSecuritiesToBeSoldPercentOfPublicFloat",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percent of public float",
        "label": "Sale of Stock, Maximum Securities To Be Sold, Percent Of Public Float",
        "documentation": "Sale of Stock, Maximum Securities To Be Sold, Percent Of Public Float"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsDetails",
      "http://vtvtherapeutics.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares sold (in shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, price per share (in usd per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_SalesBasedMilestonesPaymentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20260630",
     "localname": "SalesBasedMilestonesPaymentMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales-Based Milestones Payment",
        "label": "Sales Based Milestones Payment [Member]",
        "documentation": "Sales-based milestones payment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://vtvtherapeutics.com/role/NetLossIncomeperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/NetLossIncomeperShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss per Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r367"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/NetLossIncomeperShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Income (Loss) per Share of Class A Common Stock",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "vtvt_ScheduleOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://vtvtherapeutics.com/20260630",
     "localname": "ScheduleOfEarningsPerShareLineItems",
     "presentation": [
      "http://vtvtherapeutics.com/role/NetLossIncomeperShareScheduleofReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetIncomeLossperShareofClassACommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Earnings Per Share [Line Items]",
        "label": "Schedule Of Earnings Per Share [Line Items]",
        "documentation": "Schedule Of Earnings Per Share [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_ScheduleOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://vtvtherapeutics.com/20260630",
     "localname": "ScheduleOfEarningsPerShareTable",
     "presentation": [
      "http://vtvtherapeutics.com/role/NetLossIncomeperShareScheduleofReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetIncomeLossperShareofClassACommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Earnings Per Share [Table]",
        "label": "Schedule Of Earnings Per Share [Table]",
        "documentation": "Schedule Of Earnings Per Share [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationScheduleofCompensationExpenseRelatedtoGrantsofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Compensation Expense Related to Grants of Stock Options",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfOtherShareBasedCompensationActivityTableTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Equity-Based Stock Warrants",
        "label": "Share-Based Payment Arrangement, Outstanding Award, Activity, Excluding Option [Table Text Block]",
        "documentation": "Tabular disclosure of activity for outstanding award under share-based payment arrangement excluding share and unit options and nonvested award."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]",
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r99",
      "r100",
      "r418",
      "r419",
      "r421",
      "r444",
      "r445",
      "r447",
      "r448",
      "r449",
      "r456",
      "r569",
      "r570",
      "r573",
      "r998"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://vtvtherapeutics.com/role/SegmentInformationAdditionalInformationDetails",
      "http://vtvtherapeutics.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting [Table]",
        "label": "Segment Reporting [Table]",
        "documentation": "Disclosure of information about segment reporting. Includes, but is not limited to, reconciliation of reportable segment amount to corresponding consolidated total."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r175",
      "r176",
      "r177"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/SegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information, by Segment",
        "label": "Segment Reporting [Table Text Block]",
        "documentation": "Tabular disclosure of segment reporting. Includes, but is not limited to, reconciliation of reportable segment amount to corresponding consolidated total."
       }
      }
     },
     "auth_ref": [
      "r859",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r868",
      "r869",
      "r872"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r299",
      "r301",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r334"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock Award Activity for the Period",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r7",
      "r23"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://vtvtherapeutics.com/role/StockholdersEquityScheduleofEquityBasedStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Stock By Class [Table]",
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r33",
      "r34",
      "r35",
      "r52",
      "r69",
      "r70",
      "r143",
      "r239",
      "r240",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r249",
      "r252",
      "r255",
      "r256",
      "r258",
      "r259",
      "r261",
      "r262",
      "r265",
      "r267",
      "r380",
      "r444",
      "r445",
      "r452",
      "r453",
      "r510",
      "r511",
      "r512",
      "r513",
      "r779",
      "r845",
      "r846",
      "r894"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "Security12bTitle",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r693"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r695"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SegmentDomain",
     "presentation": [
      "http://vtvtherapeutics.com/role/SegmentInformationAdditionalInformationDetails",
      "http://vtvtherapeutics.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Domain]",
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r141",
      "r150",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r175",
      "r176",
      "r177",
      "r181",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r202",
      "r204",
      "r207",
      "r209",
      "r361",
      "r362",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r640",
      "r643",
      "r644",
      "r649",
      "r677",
      "r953",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r992",
      "r993"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/SegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Information",
        "label": "Segment Reporting [Text Block]",
        "documentation": "The entire disclosure for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r165",
      "r167",
      "r168",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r181",
      "r639",
      "r641",
      "r642",
      "r643",
      "r645",
      "r646",
      "r647"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://vtvtherapeutics.com/role/SegmentInformationAdditionalInformationDetails",
      "http://vtvtherapeutics.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting [Line Items]",
        "label": "Segment Reporting [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r175",
      "r176",
      "r177"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-qualified stock option awards vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r654"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r299",
      "r301",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r334"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersEquityScheduleofEquityBasedStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised",
        "documentation": "Number of non-option equity instruments exercised by participants."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersEquityScheduleofEquityBasedStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Expired or cancelled (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations",
        "documentation": "Number of shares under non-option equity instrument agreements that were either cancelled or expired."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersEquityScheduleofEquityBasedStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted",
        "documentation": "Net number of non-option equity instruments granted to participants."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersEquityScheduleofEquityBasedStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding number of beginning balance( in shares)",
        "periodEndLabel": "Outstanding number of ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r25"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersEquityScheduleofEquityBasedStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://vtvtherapeutics.com/20260630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersEquityScheduleofEquityBasedStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Options, Exercisable, Number",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Options, Exercisable, Number"
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://vtvtherapeutics.com/20260630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersEquityScheduleofEquityBasedStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Options, Exercisable, Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://vtvtherapeutics.com/20260630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersEquityScheduleofEquityBasedStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average exercise price beginning balance (in usd per share)",
        "periodEndLabel": "Weighted average exercise price ending balance ( in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Options, Outstanding, Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePriceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://vtvtherapeutics.com/20260630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePriceAbstract",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersEquityScheduleofEquityBasedStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Options, Outstanding, Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationScheduleofStockAwardActivityforthePeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercisable (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r308"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationScheduleofStockAwardActivityforthePeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercisable (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r308"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationScheduleofStockAwardActivityforthePeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Forfeited or Expired (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r312",
      "r784",
      "r785",
      "r786",
      "r890",
      "r891"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationScheduleofStockAwardActivityforthePeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r310",
      "r784",
      "r785",
      "r786",
      "r890",
      "r891"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average grant date fair value of options granted (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r320"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationScheduleofStockAwardActivityforthePeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationScheduleofStockAwardActivityforthePeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Awards outstanding, beginning balance (in shares)",
        "periodEndLabel": "Awards outstanding, ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r307"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationScheduleofStockAwardActivityforthePeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationScheduleofStockAwardActivityforthePeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Awards outstanding, beginning balance (in usd per share)",
        "periodEndLabel": "Awards outstanding, ending balance (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r307"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationScheduleofStockAwardActivityforthePeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationScheduleofStockAwardActivityforthePeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options vested and expected to vest (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r323"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationScheduleofStockAwardActivityforthePeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options vested and expected to vest (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r323"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://vtvtherapeutics.com/role/StockholdersEquityScheduleofEquityBasedStockWarrantsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329"
     ]
    },
    "vtvt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://vtvtherapeutics.com/20260630",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersEquityScheduleofEquityBasedStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (in usd per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Non-Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Share-Based Compensation Arrangements by Share-Based Payment Award, Non-Options, Exercises in Period, Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://vtvtherapeutics.com/20260630",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersEquityScheduleofEquityBasedStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in usd per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Non-Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Share-Based Compensation Arrangements by Share-Based Payment Award, Non-Options, Grants in Period, Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationScheduleofStockAwardActivityforthePeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited or Expired (in usd per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationScheduleofStockAwardActivityforthePeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in usd per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r310"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-qualified stock option awards expiration term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant to expiration date of share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationScheduleofStockAwardActivityforthePeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationScheduleofStockAwardActivityforthePeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercisable, weighted average remaining contractual term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted-Average Remaining Contractual Term",
        "documentation": "Weighted-average contractual term remaining for vested portion of option outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationScheduleofStockAwardActivityforthePeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options vested and expected to vest, weighted average remaining contractual term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted-Average Remaining Contractual Term",
        "documentation": "Weighted-average contractual term remaining for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested option for which requisite service period has not been rendered but that is expected to vest based on achievement of performance condition, if forfeiture is recognized when it occurs."
       }
      }
     },
     "auth_ref": [
      "r323"
     ]
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Net shares withheld for tax withholding related to the settlement of equity awards (in shares)",
        "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation",
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r92"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://vtvtherapeutics.com/role/SegmentInformationAdditionalInformationDetails",
      "http://vtvtherapeutics.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Axis]",
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r141",
      "r150",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r175",
      "r176",
      "r177",
      "r181",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r202",
      "r204",
      "r207",
      "r209",
      "r361",
      "r362",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r640",
      "r643",
      "r644",
      "r649",
      "r677",
      "r953",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r992",
      "r993"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinStockholdersEquityUnaudited",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://vtvtherapeutics.com/role/Cover",
      "http://vtvtherapeutics.com/role/NetLossIncomeperShareScheduleofReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetIncomeLossperShareofClassACommonStockDetails",
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsDetails",
      "http://vtvtherapeutics.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock",
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r52",
      "r53",
      "r65",
      "r66",
      "r67",
      "r68",
      "r69",
      "r70",
      "r93",
      "r96",
      "r125",
      "r126",
      "r133",
      "r135",
      "r143",
      "r144",
      "r183",
      "r216",
      "r218",
      "r219",
      "r220",
      "r223",
      "r224",
      "r228",
      "r229",
      "r231",
      "r232",
      "r234",
      "r236",
      "r239",
      "r240",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r249",
      "r252",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r261",
      "r262",
      "r265",
      "r266",
      "r267",
      "r403",
      "r444",
      "r445",
      "r451",
      "r452",
      "r453",
      "r463",
      "r510",
      "r511",
      "r512",
      "r513",
      "r521",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r546",
      "r566",
      "r588",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r779",
      "r846",
      "r847",
      "r855",
      "r894",
      "r900"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r44",
      "r52",
      "r69",
      "r70",
      "r80",
      "r81",
      "r82",
      "r104",
      "r105",
      "r106",
      "r108",
      "r115",
      "r117",
      "r119",
      "r142",
      "r184",
      "r185",
      "r198",
      "r199",
      "r200",
      "r226",
      "r255",
      "r260",
      "r261",
      "r262",
      "r265",
      "r267",
      "r270",
      "r289",
      "r290",
      "r292",
      "r293",
      "r335",
      "r349",
      "r350",
      "r356",
      "r357",
      "r358",
      "r360",
      "r363",
      "r364",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r396",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r438",
      "r444",
      "r445",
      "r452",
      "r453",
      "r463",
      "r477",
      "r502",
      "r503",
      "r504",
      "r521",
      "r588",
      "r900"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StatementLineItems",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinStockholdersEquityUnaudited",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r53",
      "r55",
      "r56",
      "r60",
      "r62",
      "r63",
      "r65",
      "r68",
      "r69",
      "r70",
      "r72",
      "r104",
      "r105",
      "r106",
      "r142",
      "r228",
      "r229",
      "r231",
      "r234",
      "r239",
      "r255",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r267",
      "r269",
      "r270",
      "r280",
      "r413",
      "r441",
      "r444",
      "r445",
      "r451",
      "r452",
      "r453",
      "r509",
      "r522",
      "r533",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r546",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r567",
      "r568",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r588",
      "r623",
      "r632",
      "r634",
      "r685",
      "r995"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeLocationBalanceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StatementOfIncomeLocationBalanceAxis",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationScheduleofCompensationExpenseRelatedtoGrantsofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location",
        "label": "Location, Statement of Income, Balance [Axis]",
        "documentation": "Information by location in statement of income line item where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r205",
      "r206",
      "r208",
      "r376",
      "r377",
      "r378",
      "r379",
      "r400",
      "r401",
      "r402",
      "r404",
      "r405",
      "r406",
      "r499",
      "r501",
      "r573",
      "r619",
      "r657",
      "r658",
      "r664",
      "r665",
      "r666",
      "r671",
      "r672",
      "r931",
      "r932",
      "r954"
     ]
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StatementTable",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinStockholdersEquityUnaudited",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r52",
      "r53",
      "r55",
      "r56",
      "r60",
      "r62",
      "r63",
      "r65",
      "r68",
      "r69",
      "r70",
      "r72",
      "r104",
      "r105",
      "r106",
      "r142",
      "r182",
      "r228",
      "r229",
      "r231",
      "r234",
      "r239",
      "r255",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r267",
      "r269",
      "r270",
      "r280",
      "r413",
      "r441",
      "r444",
      "r445",
      "r451",
      "r452",
      "r453",
      "r463",
      "r509",
      "r522",
      "r533",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r546",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r567",
      "r568",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r588",
      "r623",
      "r632",
      "r634",
      "r685",
      "r995"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r702",
      "r712",
      "r722",
      "r754"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": [
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon exercise of stock options (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r311",
      "r784",
      "r785",
      "r786",
      "r888",
      "r890",
      "r891",
      "r893",
      "r896",
      "r949",
      "r950",
      "r951",
      "r952"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon exercise of stock options",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r784",
      "r785",
      "r786",
      "r888",
      "r890",
      "r891",
      "r893",
      "r896",
      "r949",
      "r950",
      "r951",
      "r952"
     ]
    },
    "vtvt_StockWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20260630",
     "localname": "StockWarrantMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersEquityScheduleofEquityBasedStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Warrant",
        "label": "Stock Warrant [Member]",
        "documentation": "Stock Warrant"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r548",
      "r564",
      "r589",
      "r590",
      "r673",
      "r692",
      "r788",
      "r845",
      "r847",
      "r848",
      "r874",
      "r940",
      "r996"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r12",
      "r13",
      "r43",
      "r44",
      "r70",
      "r81",
      "r104",
      "r105",
      "r106",
      "r108",
      "r115",
      "r117",
      "r184",
      "r185",
      "r198",
      "r199",
      "r200",
      "r226",
      "r255",
      "r261",
      "r262",
      "r265",
      "r267",
      "r289",
      "r290",
      "r292",
      "r293",
      "r335",
      "r349",
      "r350",
      "r356",
      "r357",
      "r358",
      "r360",
      "r363",
      "r364",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r396",
      "r407",
      "r408",
      "r412",
      "r414",
      "r438",
      "r444",
      "r445",
      "r452",
      "r453",
      "r503",
      "r504",
      "r519",
      "r548",
      "r564",
      "r589",
      "r590",
      "r609",
      "r679",
      "r680",
      "r691",
      "r784",
      "r785",
      "r845",
      "r847",
      "r848",
      "r874",
      "r940",
      "r996"
     ]
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r69",
      "r70",
      "r73",
      "r238",
      "r241",
      "r243",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r256",
      "r261",
      "r262",
      "r265",
      "r267",
      "r268",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r380",
      "r394",
      "r395",
      "r426",
      "r591",
      "r593",
      "r610"
     ]
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "presentation": [
      "http://vtvtherapeutics.com/role/NetLossIncomeperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock split conversion ratio",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one."
       }
      }
     },
     "auth_ref": [
      "r897",
      "r898",
      "r899"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events [Abstract]",
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r424",
      "r425"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_TDCowenSalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20260630",
     "localname": "TDCowenSalesAgreementMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TD Cowen Sales Agreement",
        "label": "TD Cowen Sales Agreement [Member]",
        "documentation": "TD Cowen Sales Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "TradingSymbol",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r770"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r771"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trading Arrangement Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r771"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r772"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r770"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsDetails",
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesDetails",
      "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r367"
     ]
    },
    "vtvt_TypeOneDiabetesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20260630",
     "localname": "TypeOneDiabetesMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Type 1 Diabetes",
        "label": "Type One Diabetes [Member]",
        "documentation": "Type 1 diabetes."
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_TypeTwoDiabetesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20260630",
     "localname": "TypeTwoDiabetesMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Type 2 Diabetes",
        "label": "Type Two Diabetes [Member]",
        "documentation": "Type 2 diabetes."
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://vtvtherapeutics.com/20260630",
     "localname": "UnauditedInterimFinancialInformationPolicyPolicyTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unaudited Interim Financial Information",
        "label": "Unaudited Interim Financial Information Policy [Policy Text Block]",
        "documentation": "Unaudited interim financial information policy."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r39",
      "r145",
      "r146",
      "r147",
      "r148",
      "r459",
      "r461",
      "r636"
     ]
    },
    "vtvt_VTvLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20260630",
     "localname": "VTvLLCMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "vTv Therapeutics LLC",
        "label": "V Tv L L C [Member]",
        "documentation": "vTv LLC."
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_VTvTherapeuticsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20260630",
     "localname": "VTvTherapeuticsIncMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "vTv Therapeutics Inc",
        "label": "vTv Therapeutics Inc [Member]",
        "documentation": "vTv Therapeutics Inc"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year",
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "vtvt_WarrantLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vtvtherapeutics.com/20260630",
     "localname": "WarrantLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant liability, related party",
        "label": "Warrant liability, Current",
        "documentation": "Warrant liability, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "WarrantMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/NetLossIncomeperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock warrants",
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r682",
      "r683",
      "r686",
      "r687",
      "r688",
      "r689"
     ]
    },
    "vtvt_WarrantsAndRightsImmediatelyExercisableTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://vtvtherapeutics.com/20260630",
     "localname": "WarrantsAndRightsImmediatelyExercisableTerm",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants and rights immediately exercisable term",
        "label": "Warrants And Rights Immediately Exercisable Term",
        "documentation": "Warrants And Rights Immediately Exercisable Term"
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_WarrantyLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vtvtherapeutics.com/20260630",
     "localname": "WarrantyLiability",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant liability",
        "label": "Warranty Liability",
        "documentation": "Warranty Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://vtvtherapeutics.com/role/NetLossIncomeperShareScheduleofReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetIncomeLossperShareofClassACommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted weighted average number of vTv Therapeutics Inc. Class A common stock (in shares)",
        "verboseLabel": "Weighted average vTv Therapeutics Inc. Class A common stock (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r135"
     ]
    },
    "vtvt_WeightedAverageNumberOfDilutedSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://vtvtherapeutics.com/20260630",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstandingAbstract",
     "presentation": [
      "http://vtvtherapeutics.com/role/NetLossIncomeperShareScheduleofReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetIncomeLossperShareofClassACommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Denominator:",
        "label": "Weighted Average Number Of Diluted Shares Outstanding [Abstract]",
        "documentation": "Weighted Average Number Of Diluted Shares Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://vtvtherapeutics.com/role/NetLossIncomeperShareScheduleofReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetIncomeLossperShareofClassACommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Denominator:",
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://vtvtherapeutics.com/role/NetLossIncomeperShareScheduleofReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetIncomeLossperShareofClassACommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic weighted average number of vTv Therapeutics Inc. Class A common stock (in shares)",
        "verboseLabel": "Weighted average vTv Therapeutics Inc. Class A common stock (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r135"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested",
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r36": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r37": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479428/808-10-45-3"
  },
  "r38": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r39": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r40": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r41": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/808/tableOfContent"
  },
  "r42": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r43": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r44": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r45": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-10"
  },
  "r46": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r47": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5A"
  },
  "r48": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r49": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480868/205-20-S45-2"
  },
  "r50": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.Z.5.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480781/205-20-S99-2"
  },
  "r51": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r52": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-11"
  },
  "r53": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-13"
  },
  "r54": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-7"
  },
  "r55": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-8"
  },
  "r56": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-9"
  },
  "r57": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-12"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482705/350-40-65-4"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482705/350-40-65-4"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-11"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480125/505-10-S35-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-2"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-3"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-4"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-8"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480070/505-10-S50-1"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480070/505-10-S50-6"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 4.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-5"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SAB Topic 5.Q.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-7"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481468/505-20-05-5"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479982/505-20-S25-1"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479982/505-20-S25-2"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S25",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479982/505-20-S25-3"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479951/505-20-S50-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479951/505-20-S50-2"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479951/505-20-S50-3"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 1.D.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479921/505-20-S99-1"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-2"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-11"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-7"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-2"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-2"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-2"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-3"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-3"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2AG",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-2AG"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480339/815-10-65-8"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480339/815-10-65-8"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480339/815-10-65-8"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481435/852-10-45-14"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 1.B.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480148/855-10-S99-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480088/860-10-S50-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-5"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-10(c)(7)(ii)(B)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479664/932-10-S99-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477385/932-360-S50-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477657/942-210-S45-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478478/942-210-S50-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(7)(e)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(7)(e)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.9-06)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "405",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477787/942-405-45-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3A"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-24"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "184",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5A"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-11"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-12"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(r)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(s)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(t)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(u)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-30"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-31"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-32"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-33"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-2"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-3"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-4"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480070/505-10-S50-1"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480070/505-10-S50-2"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480070/505-10-S50-6"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479982/505-20-S25-2"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479951/505-20-S50-2"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-4"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-8"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-8"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-1B"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477657/942-210-S45-1"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478478/942-210-S50-1"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "810",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477383/970-810-45-1"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>57
<FILENAME>0001641489-26-000030-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001641489-26-000030-xbrl.zip
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M]]X?4=?[,IW'8A@$&'1L^M4D ^K3@P]XQ$MD;\,\LAF>Y5AXX\*2&<L\TI?
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M^V5+01X.7S3X=>D%;13MA7$;>!"T4?2!RP:W$1-!&T4?M6YR&[UYI!;LRGC
M#J+/X,IZ1,<## MH^IWH?=MPZ9L'__GFN /JX=E.=X(][^*CEJ=.'W[)Z[4;
M]N]]F2[^LKR.Q5^.768$)F\^F8HFM]&MDI+@P7(2CS3=O]G4]4;F9'GD_?.(
MNF1" ]_4<:?G2^RKBKN;LLGLRJ6'"6=N8Y"7RAG\TNN1HK)-;J.RW) @?[3
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ME\ *LVI/M6?I Q:&M3])JJ;6HRO\D<G*22983G)LB1 N>,;HU/N8G8T7((.
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MDO[[AISM25L7M3T>=41#:W9<X+05NF&U",@8UG::#W?EU"<GTD&*M8KUI/O
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M[UMT3&T?0U>4%:1*Y(VXAB>J_KB/76TZ%<CNQV:3WQSWF;S_?8Y_^(+]^H4
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M"V(\H;;'3L076898/H;:3V?N(AN.*V<$B@2*!(H$B@2*N$-1%N.NO:-[:M_
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M$^I,X&K+?,4GO9G^2#),,J#,!,:H>MC\?>0Z-C VF/^82_>6UL\40/N3)^F
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MCRK<( F2$D$)[WEW6Q()5&7E79F_7/_A.F9Y5<'XXJHS;A74N$0U'JC)J)R
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M-\O,K1]B=OFG\-R"/IENY^*JTC;Z]=Q&M^(V!O7<1J_B-H;UW$;_XLIQ<WF
M/7Y1XN^J1 +Y/'% 4:8>]H6H2: (/U^^KRBS,@#SW>J5)U8X*566"V/PR70F
M+,9^RF_[O%W]NV+'O2CGPA"8)3D6# @,:H-(3+F6H._WUHJ'=AHRMQK%OI(5
M_51TR\YM,G=0[.CNLB+XVYL.7]$GHCV]X.Z,XLZHS \%0-5:1_#P1476;VZ^
MOM5<!A!)MW0%C,6HOG[S-0$H95OS(%\J16UXW;=X7>2B?\(8?1)W*BH$-5(W
M,;)F,;Z%O?8)XPPKN-+12Z0!_'@^I>^[B#8BH81W().^@4Y4R+>BE ">!X;,
M=#G/$3Y>>B6)D237>8O0#78+8^XG/Q1/GC.G;UBG2'#5S:R2'UQ0GAUU>?:N
M_*XZ#-3Y05P#HCJDZ!X>_BMU3'H"0]96.8VBR!(?RH&OA=[=Q]A0[(1@5LB-
M%<>Y3TJ&O16:\+S=B,SW-:&^B-F=\:/(A S!A Q;DRVC,16Q-\E3*O<F#[?2
MAL=5G)9==[R[<S*JZ&--3KO<<;7E0A!^VO5.$-1C'U<ORWL9)R_GQ&USWO88
M/I&#]CLSQ;TA<1REBM7(BHP=3B3@DRY/HDTZ CQ0N?N,Q>8N ^DSQ=!@)1^/
MUB'7&UWIXK)=TT14K:A>(SW-F'T7B[R);,C^QN)R492 F?#SZU:?+UG&VVJZ
MK-/NG%3:>NVJVJ%[VO563#=TVI72)L=?;\6\0J==*3]R_/7V]M2^>76L%$:$
MS9W0Q=G;NG+W_?#86U<:1<V=5_V;:HR[ND")Y+Q@.?(:E@!F">._FH_6:0^.
M&]'W^EC@L@$,Y$01?0GN5-U IJ(!V[D!W"_&?&.5$G8I<8"<1ZS8.FA<WVW2
M>#DIHX_S]1N;Y^CC<0NW Q()2HO05655 R^7+B?4RC<V?!;5)*Q 6N$_,^!K
M< /(?J]70DM,+_>C'>)4\VBY*\]=>,8R"_A"PXA@*_4I=3GQR'-0(A_N+<?0
MM;_BW(S_@O_2(>XWC5#7[@SKT7 20/M8T8& ]HA2&N,)O,'T+&.AJJB^C*T*
MD .N([1[_')\R5O.DNF(.X$B #KT,N)"/<V"NBP#7U_.T?[LQ) J6Q@M964$
MA(["< 'X!1P<<'GO/F:-89:/D3<53ZKTH&>L1(AC(4*?*Q#N0SA+4-[I[L9R
M(M+U?W9&I<P1EM8N)"9#EN4?95<#2(Y8)=WM\B/)YS:3SWO$!HK""LM(H\E$
M31"CVD0)AG1Q0%F^*/>T#4]"A-UX#!@W Y2DAJ8")(&CAC7O@ZX"C96Z<YT*
MFI= $QC-0&:]+ ];3WG!^2)2#&GG(4UWLFW7C-F&6H!DN^F&RHMD1FM[F%P
M9"]+13OC\TY0WFUD22()(38+!8[6IMHVGL&J9'L>8O<[>ERR24MV;TDPB)3
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MQ+'L1N!ZVE?/_8<P ^W1"NZUY/EHUS_?YM\D_Q@]__$>UCA=IQ;N3@.#1,K
MA+=I@TP^@, _NIX]>[1F\$\?G 1:,HF:+5</_H7P-%@N?CV]%J"!L&W!6 $@
M$"N!\D(.@H]B@T+G@J>@J\X"':3(">?8M.[!"^^-!Y'\#<AOZ$LA!QN$'?#
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MN:)LP \SBR$QTF[;$N025DENHN19=AM7^ =XPHP5.CR\(@WZQZ(!!#FCC22
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MUK$O\P19(FK@3"5%CM'%5:^ &C]%@T4B7HFP12*T)E05"7/-LT.LY93F>RE
M(AZ+-1<\2(>'-LPLGSY$SE%+ R5[*U8!]TQU1D5]^X1(5-FW/R%\=[\SOKCJ
MC"8ZV)7*G?-AQ('%@HSN";H^2;B7B@*U!> E09D/2=?G&_N0LR]ITN3%;')Q
MU=TPNZ15,-#AC-R"CZ&GG%XPI8*1-G;HS*;/Y;'R9]8>S#U\,N;>6*C3;>^1
M;M^&]OQ4:^WLL=:MS81/M-;N'FO=6NSU1&OM75Q!M%K0+%;Y%^SSD(H_2"<6
M9$+VG24[:K^XD3&CRB-COJ%'B?EL+U@GF&33(-D^CLO(C&Z!W^6'QLAG7]+#
MM>33]YD9(U]1\.)R(-M^;2/GWPWSVIEYXM'7_L58KMYCP#"%=]TXINNM$!PX
M44*[@4>+=U@#TYEV]B:Z-(>)?<-)XB4"9E5 -535B8-MM5B,XX2NYY='1\QD
M7F\_<* N1!.#T4COM MFM+B)6KU8N8$&LU3T_$M:Q;T)W(4@!UE%:N*?.$(S
M3HP]W#U05@")X+_EY$.1MJ397 9XXWYH0X""7[N+)PD2-[4@^GS$Q*&?00HL
M);@C+[*S!"^[.*!@Y8M"&),1B;$ @_2[\0\7XI4U_;$H+.GB%(T"Q_FG!!$H
M6P$_QMPDO:Q!2_L<>DA']9&B$64)AIM9GC!QM*_+\^3D3QA!5K]'&6R[4#@J
M_V&0H?<G;;U=!$^5XKI\HGL[X\1$4L.]D"@TW-D3*_@4)A\.9)]>>:2[)_-
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M&OD^EGR7;_'52W9UTKP0F2Z+1)]&I@<XS5(?]0^N!SWNF3;B?'*F;<3Y2;,
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M_6R3LIJ%_XU<G+M</#W,UGAT.,Q6(Q:-6-2G)>H 61@?"V:KD8A&(FK9S72
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M''!8K^$#*Z%^2;Q9^@/2?5@:,PI6;#P1) #N0OR :,(2CAG%,2 4P#'>&O<
MW[5M_%_\*'S0%/+!\.W$Z06><&:P3_)"P-<Q,220>\<7F.A!S,, / [P;QZ$
M[:[D+H 83-FY8<+3XA4K:E!E^PKBE)5G84 41S:FY9GA$CLD3"&/!)X1PG+
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ME6NIO.H'Q8-WS(,WJ?(:AL&0(3Y&\GP_^DN<X?A*EQ]!5+9.OET\(8'R,UH
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M R-<X9-SXTA.GPI\A0E6<1X>Q!UUR/%<W_VN?9':?=M.9 X:-U.SO96H]H_
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M"UTN<WX_YR!Y7&!DPQ&3#VF$0"4.57&!,,&YJO+'3BE6,"G]S4+5R4T\)?5
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M882DLPI)Q*JI>9$TLSV"Y(&-,#S<>'CLH/+TD24VPG"8&1DA$Y+BLD?VO_'
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MABH%E!22(1.,#S/,#=8R\+GQO*=(&]PF@[QC+S M[8E/U555WD]FIF9.<.>
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MQM0C=@T#$A<TH,%6$!C.O# UV2\1C,]R8K_P (%F>*57:!Z#"=I "2N!4*8
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MK$6^X+1@,K%)UQ/:*U2UG.35=:S(LFI%(_3Y97@[F2]MTRLUJ;T2BG.@A93
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MZA1["Z$02J5N.CT<=;JR@%NQS-O -(9:$X6!LDH A)U#$!MA9.K-.QGXL8H
MCJRE[:7_QB3[T!7_OL<[+.&'+S?%(]/" ,40!4K(@N)@'4N5VB7X L#ADRQ&
MU8'-V).]N<@1/[>W()ZG,;-74S5K+Y34.*=,I5]RS.<P]6$&J,GFTG<L')^H
M_AI: *D=!M(I5F!,A'6C6T-'H[=;RM"<EMIV4IM!7=^%\TSYX-PRSO73;9Q0
M2]4,%8!YK !50E",++$L=4^75C#CG\ /SW69@Z@<B3O[FM'+/_[IYC&V:Q5P
M@VI> V.!A$0 511.%5QYK9*?6Q+B/T(]S7R(.13YN119;Y^+WIS+NV^WDU5(
M8G/<F"]T>".A J2P6!&+L;&I"\(E _\Z57ATVG-NY:LB#,UB_:5<5NYUJQ=P
M_J5<J.GZ[R_+>0PL^M]N\7Q_L+;EU$2-8F%HQ V@4!,D"J.13]UG8I2)O3J]
M/SYUR9 7E6V2JU?^?5D]?A2_5]O!((Z9V6'*4$&"@EHK35+[L<:=X8^WY'@4
M*$/KZKV%_?BZ_RU\<3'_\+@A_N8FUU^C5.Y=I:[=\I=OU<*]5Y.J,4N(& V4
MIA9@+857W'A&4[\O(T_QU;TPQZQ"K8EFXUPS/WG[2[_^:3 C8Z309[=LC+@H
M5P(H_?HVFOPN>CB4G!?6B065Z%:[UU9P,5T^:!([*VXN]G$;:(G+X.&X(!R0
MBE& A4/".V6#'A_"6.@_A73WW6F U:_"EG+50 @,@4 ,0HH$LC#YII)C(F/=
M@Q]2K]LOQ0^E$<=R0?Z]&^LG_V$6UDOW\7&F;]14S1K*8_)88#%L?@A*@'TA
M;4&E,%RG5O4>N Y_G7XP[=G4Y]0LYFAWL1)#.+@W2NEQV]U$B5$P"FWX23G/
MH OFADQ><ZL?LO%-[&-:,3.PU^I;/Q$S^7=T1(;R[^BX3>5-8?TPEG\8RS^,
MY9-8^@^O$<=B+/\P87Z8,(<Q86+SF<FJ$:J:V>^5BLS$#7':]7AJ&J-B5_@#
MK8/O_7H>Q[S8&+-5GXA60!F% /-&"T6E=COT1=HVVN .3RT#-"ZH!,?&1MP
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M;0@$V'E!PAJIBN3W%:,KQA8+X>!ZT2GTU,$-F]Z*J\J]OXM7?H](6R[YE11
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MJ\<9L,8I47A=<)0\]>CX:R!LYWN_&@C;97PL-1 N_E"5;2AWNYP!@L'\EE0
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M77=TZ#_>F*QO3#XU2N@"// ^*HD%4GH%(+2.AE])NMFAXL@,L(-Z)'82K>-
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MSIWJ]<9O'^M,6,\AV=2[];:SW=,I\.*Z<LO%[*DK^N.!\W,L2U!/>:% 4^^
M\#"P)[B"/=,^DL Y)_49GY\<+>F>'0.KM6ZMBL8FM@)KH!A3@"A3""%TV')3
MYY-UX3D3Y4DN^M0UA]:7PXN;\BYLB?Y2S;_^JNZC(5QS'<40=@(A8)I08PJ#
MF.']#,SN@<Z$[^0R31CQL<3V5!KD3:DJ^\F_G53.1)MX60[D2_G6S2?7LR"7
ME8W\$JL)NJDX4)9@0#UCX5=A:X3]S(T=!SXG?<@I\X27BIU8OY07M[=5>>\N
M7;4(XKQ8.3$WL2K&@=8%!U9 XBR!(IRC!NE'R\"O03]2R+S5NYNZ9L^OJV(:
M'V:^K&Y61;*L73Y83=<^'%#"9\<1TE3T&3*M1 5^'B%\=K=EM5C:G-^';58^
M$R.$,= ""T"5\\0;P@Q,WC:P!ZYTA7XZ1GOS\/C+^B5*$(4T!=!("< =)]HI
MQ7*6^>D-<ZPB/\FUI[W03QZ*CJ7,S_>\CC=W\R"X^?QQ1O/:?4&8D7<"* X9
MX)A)*K@QEJ>.GN@$=/A[STS:T)89-YB5'*T 5U@:'-EM8#(%9+T <N"<N.%$
M;:K 8"F/3;US-%CTA0'46J>AQ(Y0>GJ4]TV$&Y?Q3N&F]]O&U2VN8H^8&NZ6
M3$SU$T!3ZP#63%')O%2JW[&H98 #]!O:7^9E8H%E",]^.H+5X-44%?(P51<V
M0R.$X4Y*A'#J%L7M: [&>S[[,9'HLU1:NG>S._<^R&3I\@\'_M\FBZ^7=_-%
M>>.J=]_,]"XZ<"_F\["Z.?M%?=N$+(2*.0L:>*Z=EMHJ1-*79=L9YAFJ46ZR
M4N\<3VK_OJS<Y'IV64[#-\I5Y\3H8YHU> *-I4 K90 +.R1$WBFM::]MI,]H
M9Z04>20\6OWKNM/IZ5A5=AVK]-.Q*JF3;;^A<WG?$@CB@&XY&W<P3 F@CBCB
ML:+$9#+\C]TMYY@ @@@,$.>24(@]21[2=&9NN4[MR>"6ZZ3H)-URF/M@04(;
MSBE2:^9,#.KZX99+H U#W'*=K(SMFVD$\\,MUX.H79PTO:0\NEN.QN( ' /G
MO2>0%Q2*U-7Y3\PMEX[Q3N$>R"U7$ VD0 009"A4R!:*X%[GJ1-QRW7*? ^W
M7*? <E1-4+>3A9I._A7;;\T7\T_^'[-E1(2]JLJP_<761JN3O;/QY']Q$S>U
M?SWN9H_?>?A4A9_^TYE%DX93$;8UCW0@.>BVU5H*G]HDR#"-UV)('%H#,H3A
M/D)I?L,:P60R/UX .5!AAD/36Z;F)H/1T@E*L; D2T%!6)%%;.T+\6:._2DH
MRK;*#*>D)YV4I#9U+I6=A*/T=!+F.FO&([4!"G$"F';4$>IU(?N586AX^/@F
MS@!9EPD%E3S7*[H\'^?6E)(8)R<]D#HFB! GK5<.6]'//FUX^,D2-U10J=^X
M57SN9S=WX9E?+V;VK;MWT_(V&CSOOL4>L363AQ7!$(\A_AI"19%5C.)^1/88
M[#3N;7HY+[/(-_6+^V%F7R#<#D\0'(NX2H -=!QY;?QFO$\+_=O'.C?V$TLW
M2Q^,'313(1:;^4)@C3)A/X&HUOX[00# ZU@=TA,PVHUN;"-VX[ZH;VY($^.&
MIZ2Y9]T&;^"5Z>.+_7V,5C5@6@!=" \0#"88TQJBG@$.34\?N,I_?V"C%P/;
ML.J$@T+XJ[2N($@SLI7 QB?GOG),(_V-17J < Y]<[BMW$^4!$- :\- 89@/
M"P:"OK- \M&7)4O 6L]R8]ND-U:)JC8<9UYN;*OX^]2JZBN[$;F4T@*E8?B#
M84$#*.2*,RTWEHK"3I%E+3?67#LK0$(HF'F">Q#.9^&09@J'7;_]O?GY1U*6
M:JNP6PN-[2>IY%7&=BA8$(WU(@;G>PU(,*8+)BS7"/9B\6B*0&2PB5(*L97@
MU.>27]SB8SF?KR01[(AE<9+G&,O/+MA>9K+TF9:STH>'_')W$QX4E$G%T]>L
MO)G,XM_^$<RVP,%7=ZFFYF[Z^/TW:CXQ\8N3Z=W"V3#::J0XYM-HI:^5K1UP
M1#KN":4YK1WW'),?')^OG-^I:A;?I:M'%*UO;2$AT,Y9((7F4(>EF/:LBM9C
ML$%+;?OS&TUR+0G01$D@B$82&:_)9DC2SA,9[]"9FKD7ZVU*21[Z2%J+S>KL
M'1C- ^^!*I0#GCAHA5,.ZM3]UHZF[VIZNO=JK[I-[.,WUFQ#]*.]:A^Z=NNP
MV5?6!]&" H?SHK06",F-4!Y*Y))W"3JE]JKIR>\4<=[VJDVM(0.BU7UG86.%
M,&\%8@72J7MOGT#/S:W<[-9S<YM@,T2Y;FYH2P/\0L^72:RUVT[D@6 6 V@1
M8M)HC5#J5[T3T,B']%PV9'KAYRA+L'[V:@.E95CHB ISE@P+IH@Q/'6MKT8@
MXR\%"<G:K$(P6-)Y C_]9'G6K\W-:Z"P0,!X9;%3VL).=_B>49^/HX]/= (Z
MZA&;^\@R ZLOY[985!-]MTR]^%+^4LY,O;AT#3 /QQJE$' F:+4SQC*9]X7O
M ?(<="0O,QE2"5X"OE>3Z0KMFEON:SD-8\V7*V5MH[0H;I008,*<Y=)JKTQ6
M1=H*\?S4*"TK">M_/\']S<4ZQ,Y>W+M*7;NGLAFU.N5MLF%: 8T\B3LNQ]X2
MA8K4M0YWQ7A.IDE6?C(L2GWQ-BJ_M+$GHL> 4QFL=D,)0:D/M3L!'%^3\O*]
MIW+M3E8&RZGQ':N5\"%A#Y8!%&'(QT FSC>3>O,<D,]<4X8+/\-:LPGJ\<ZR
M;<(%)D 67 #J(*?4&VR3E\7> NG,W2=#"$A>8FW=#ML"#"$"-"80,&>L*URA
M"M*OL4G7*(<W0P;Q4>80YJA^$@)C23_N@8/!R%+Q1G"S!58V/\D!/ -><2!]
MP0"%T DL"#7)BQD,] SD/.0^JF6MF"SG0"$K@86:<:@0I"JU$NP,<N1](-WK
MN_=A=Q]V4K>[:K&8'J'U-IP*K( B5@/)K80((\-[)G_L">",-I(Q*!CO5-L&
MN[8140&4*SA@I!#6.J0P&\E)T@9QY!5H%-[[G6Z3D#;"^;9EQ33A#^F9 %!(
M&3V%T+K4)<A;H+P"G4E!PFAYI5M"@:_*A9LM)FHZ?5A.8W+O?G7FKIK$>BFS
M,N[<RY(ID]F+".#GR-_UF-]\4=E98(X2:YU?P(FJ%5\$E+:&<+UD3C#8;H,A
M'P'NX"R E(&@_PIP:[@2#'G"4Z]%J;"GJWH\$%%S]F4PN 7VL<TC5.'H9JUF
MJ2_CTLY@K%K)!]'=]GK*HY-_+-'I R?^YJ'Y 4W!FTI+H"E&@!#'J+&0R>3Q
M[1FG<_CJC.,K:7F<RI+!3&]&]HNZ<<WAJ8WX,L7H;\-VF(C]HU&&7DHZD,DC
MT#AF)8AQ(\"%'8U+Q2Q'XRR?N35M2W; N2A:)X%YLPW>M 3%HW"&5HH &D]U
ME'J*>/(ZR344X_L]TS+5GGNPCYASY!Z$XWOYX-S24?_I-LJV&1C3,?@-!F"*
M2T@QEQCKU$ZG-C!GI@9IA)YA&?A-595J[<GH%! ""1".28)!#6'X/+4+>QW
MF;&^OW S7&=LSX+219@;$QHH3B3!K( %2?W"'T-ZV5@+_CYBSA#M.]!"6E4V
MJ>U:S@%E=8S]LI9J1*E5J9/2D@ _%O4:V7DU/ND93)7U6()W_WTW63S\4BY6
M>^BOM]/)XK*<W8=?A1E\CO- -8,="Z"P@H 4FEBHK:$<I7:P[HCQE>IC5BI;
M[:*6R[?'C^,?6LW=?_S;_P]02P,$%     @ ":,&7;>=3(<4_ P O<07 !0
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M= "]=<&_.+B,,8U-8W+6T=-N]"3^VT@CJO?K6WS^64H-)"7)BH!!TX[2FND
M7S7'4+O?!&27>?(1<?;-E)16=Z>0T*A%P2,G.+7,9:&&*0FG4[CV;-CUZE''
MX@/,.8\$3R<)P?NMFFS3@E?#]_PZ-R<Z06^)&3W6=RI1F$1Q26LZT,-V)MU,
M][F@!H ZLR$Z@7[HI,:/T.BGB'NZ\ZU]CG C1IF?SS0Z7_519:*2 GI'2'2
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MJ<..-J2K!4OFU[W\-S,6#FJ'V<KE\>Z+^W1[%7)5[UKH#_XPTE4>Y-M6_/7
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M&!<'<E:+GS8*Z_H[)R^#_J-CJZU-M)2G^6'K*!U_VSY+_VU&07Z:4+FD-3)
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MBQHI;?"F [_.93*U:.VL6A9\T!<)]RQ;*6+H#(;.^+]!9_S_6&_\DIMO(HZ
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M<SP#]B:>0GZK'!_,S-XD2%DY:YD _@L.7U*#4Y_!TA5DM5QZZWI?+9K(^,2
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M/,BH.XJER"VNT?A1# /D2^BRDA0CQ)$V!5__([2<0 NMAE/=R.'_J@4*Y+-
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M[6>'_/SF470!=OE6AM]APA8JI,K@_OY,XO[%<[)MTH<3;XM#;EA.J,[C!M1
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M1AP *69;=*%-/1I?&\,(L<:HZT=VY*Y+8F]A)S["UYUVD-M'BQC.\&CE.<(
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M8QD%Y' =?T"B'J:0Z$S0)0&&Q5,FB '5HVDL3>_0#\#)ECU,$(GN/[ =Q,5
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M<XUTVIZ6(IJYFY> TD$#<VHJM,A% "_Q%)/M<C0M'.#Z(]CH]9+?R^OY^"F
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M;=_B=(@?\3@&:WC[.9>;> >N+\O5<(+Q*'(8,VE,DX<_KSY#F#%A]P 7B71
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M/7\ &/DV6P<X%TTPE/WZ@)ZRY657$\_%;<.NZZWV<C2 [$:R4*#Q&]:H)X1
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M% 8(6LE97"M$@V\9&#)"4H'&ES%51A.#@G#!>0^X%Q&RY4=_8PDZVAJ<$EQ
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M=JZKXLU1YCX/[8.C?=\F^N.;NHJ9*LO3TPPO=77"7K*7.R1XD:EM_:O;0=O
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M[?/F./O*U8V<^" 15#7S:+X!I:.=(9EJ:W9+T=?&QL^*(9![;K6F^U:R4W_
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MQTU"F]G*PG.-T/X0Q SZYRJ7SB\UTW?;(W_'+3[$/W"+&J3?<D.0/+TP[\7
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M0#6N3'+8IPA>YDJV=AF\9K:(24P+UNZLBWU5=D1;>V"KS1 =6+>JI2PA(YU
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M/@:$?(-,9K@%?0^6N!R"63%4E]BM_Q@QN$K( "XR7D>_6Z^"4;ZOP;.HK32
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M=\LH354X1J[4.:5L>L?CTO;1Z^9S$D/4(W_("7LP_9L;0U2IT=A 8=9.1;Q
M0*1YMV>DOV6.^T).OWHY#\A^Z'FBBLA'4?-)19[)\96YVU$BA_(^O%TKFWM%
M#&K\7J/;DF((A&I2%^T5.7,CC6I+*:M7%H $T@T81=F# R4+GP("YS@^Y;P_
M/BRMESD5=V /0>,<AR><!R7GHSF:')JW3A28 V)TA6G#MWZM!QO.F<,*(I^M
M"T3.;=D]BI=KLM%"N:-K)&$3I"H@^-TM:6(F#I@#6,H4O:6, :-_= /@[T.R
MU]8B,C]:NH5/I:QE<6";GD>%..I S#(.W,I(EL=G3OF)_T3:M9&&O=)T38IX
M0TH^1GE 6K8$49GC6YI(%&Q;R O<P[]/Z @X[]$Q\Y$[\BG\GNF2!I6;93-Q
M*RIMC?F*IXU/N_7M@)0 F."OD_3'MK/_R<:4R>4(_&@RGD>1P#VW'040RZ!O
MAUN;\T5NRYX-VN\MO:>A@+]F/?<7V@?70\#(-V6#_82Q 9E&O_O49!:]71Q.
M*RJ1O,V7):)\<EPD1C+SY_"8'2.K86R6F?G^-&DE:7B:BE'[-_.<Z T+ )"B
M9]![2[ZJFXX9Z,&.4?/97U\2TI*1UOTZ\N1-Y7B:$HAP^+E M?*&+R,7R4W3
MU\W5)(65J!UNEQ9I=\YI.':C0NFB)YM(X.]1PI?VQ1H;,O*J?,<)(;#]ZW!N
MG[T#C=/&W5_C5Q>?GV_GR#_HFW;]RW'-DIA1[<[Z&*GV>H<+2:?0-[*WK(K]
M+%'+!42=_4_3P'DF5LT(XEW9 >Q&8M<.R!$2FJS\S8"G*4(VS:<XX-QSB]L/
MGDIAX1*<AX7I9R[8PB,J<#F^6)>RBM1W'IO>FPD:[?4K0L7Q:L<=H!/Q:(%N
M2ED,_1)%I-X;N-CP=<1;A'DYK*JB EFJ)AD3D5;X$?28YRG</='^>6N6HG_S
M$H <)I 9MK%)2LX#798GL=GH/Z]__,/_ZU]M6/+?=#,:RZBW8U@8<YALV$]*
MC#$9U#"JG[B"P!S%+_"AUQ2Q]19D%3AC().*O^(//&,*:7:[B BS/?RLE)&+
M@ZA''1.,?,$ZG"=FO!T'SR?RO?>/?6:C'*%(%)GQ;LF9,Z@<-1\3KX$(8.NP
MD4P.BO0S:0&''-<'%]Q2KS_WQ5!)+HR)BM)0XZ*4$7NN00)_=-]'>]M F(@-
MG*NACD>O3!]EN /*&HXK4=?0"W#?PE)95YNU/.%'JB!>Y,TFU$ER^USAT"SO
MZNT+MJV^;C>5.Y\<A(:4#S"XY$WTC/LQ_&<^EZ:2;'IHIY#'NZ!0ND,)D+3/
MEAS64+*\L"1@+7]%-^C4!,A:R*XO@F(QQQ1 &E-@M>!C36.P@W/HW1D3=:E'
M&SX9M2IU'(52LM#/N7+GLE3EHWF=SR_0VYWTCN;PWS2/\-N&I*/_ZU$$X.;5
MU:!@Z+\A)1B E/X7=^\9UN2VM0M' 9&B2%.0$A44 1%!>HNH@( 2D1*I41$1
M$ $!:2%1$!"D" I(D4@3$"'2I49Z4SH$04I"[PDUD'8>UMK[^\Y>:^^]]OM>
MWSGG.M^/YT^N)T^;<]YCW&..<0]8_S@1BAYV)<!:N,)LQ7JK70CPY3P.38GE
MFSI;' ^5]&=UJXKYG*"<NFPMBD1RBI9'<(947\'G*F6ZWL#-_/A[4E(WTU>H
M"3NIQRANR%;D85H20A/OS !Q.EE.4X>S^KNO5Y806S_EA#>X)O#<F5J/=9Y2
MHP%T(K $U?J&N$VO/P;?E9%>-ZA-.)UOPAT8;%"PYHV;Z>)5R&)7R;V<5-2W
MII4+G+TG2M SC]WBK 86) L2X]/5; EI&.=PTA+#K6K593CV^.)@6B9MTQ\O
M=?:S1(M['L">1?W;+J13%X>="AR,4LJ<I%<?[6JD/T[=[V'U<7PB"O57&SHU
M7?_OCHXO_/^3]!NWVN/T00:(C2[K\Q%\B&S8A!H>_MY3G;N77738[,#ME=C3
MMJPULGMMTL^TD"3HW]91)^$I8.(-](Y:))A>AT/OGL7-,4#_>()LQ+>^CO7C
MIHY*N,K-S;5KV\2AW,D+9E*F^IKFJ:'X:3YC>!XZ];?M5%M4G2R <-./ ?[H
MQ0!EG,140QZ[[BARO41MSG/1WS;!60'R]!>GI#S KJEF+7)]ISRJHNO$_=;7
MU60OP.CQ6^(<1Z4N)@!/,\+=ZI.5Z-ODL#AZ^WQ^IEP;;]#K]H;7>J4!6"*<
MSAY# '-I.W^DZG;C&LL*\4*P/H,&W_(J!0?NUJ$-.4KJ)O$]?T/X-SRI<!HC
M1'>>\<*3S+X4;&2YMM(*R-X4%\1Q<NR7+'3$LD+RO KEZ-=#;\-_?K/IO:<D
M\47O<0:6?WDPX;73T4+KX2Z1'R6?1%73W%H7_([H,?OCUEMLX,^14N06?!QN
M6$.2$&!RZ8FA_)"-AGNKT<6:?<.CK#?]N+3W$E9]-!^:EK_!D>!3 8>$Z<X&
MW=@TROM);/ 8-_G]G7/5%O@:98 25&PMVL=,;NN)/1&%2FE/[>+JX25H*N]Y
M=2&AKB.(TTF.B"SY-GQRV_6(2\LNDE.O(8&7]6</I4BVD+D9(!9M7$D'Q>8B
M(2["LOF]V L7#Z,75SQ &JX^;YEC]&X=D612.?0-TS/.10X"&&KHW<_SQV*<
MCMML2+N[>#'9GXX,,0O%VS+1>UH_26.]5U_1:Z]O'>LO?J@N@YS!8K[2$2LN
M6<5?X]D(/@_"PC6>2)KKLC(?\646O> D10$&(8#XH*L.SE."$IIW.W=T[&R4
M3DV4W#/94R.5UY^.166/QK1-X9KX=Q]P\ O;'\1%P^?1'.%IYQ0=;R5< L:[
M9/HW-8I_<4"< (OONJ, K!;LYB*$_K;#EF3+1>% M67O[6-@ !:R\=%R.YQZ
M180.,-=;U)^[!;RT,309MM?RW.W]W7_5(\M6CF*/:L,@]M2RK%!SAK9=?_S%
MYAUD.PE.@"?^"*.S0/5VP"\]C760!.3-_]/5\O\G#\#:_OLFH'/1?]U'R^,-
MJG4,0ZMA@++ SHD MI6A:54[8.F]MF)R).V_]R1=+/^W]<!7_[**HY.+KM>W
M&;,UA-[A:^F%I!$C?^M$RH-LH-=!2E3(H\1PD8MFE>L("WRIH?3H[.S74($0
M%")'JJ5@2IR&MS4#5I8R+16"/TF<QC1I'OTE<D5?IW20FU5^.+[QR82W[B->
MVJ!(;.TI6B)=Q98.F-)C"M%\E^Z_,1K=LC$:5&I!/YQRM?:6?K9([Y5!CNB=
MB9X<9S]PY4#A!V<E:^YU'0\7*>2G]O$8S ^YC>S8&>XF8]NI4@9(D0XG<E74
M]4<Y!GE*07Q1^@Q0(G77V+:8 J4>JJ2AD;(+= %W\20K<.D\3-XKJ:=M2'^E
M_8H8>/6DYD',&4Q/KEFPGU.F2-\ F/]62NZ->F=3+Q1[=8 WL9P "=6PN,\!
MS83K>4U'[SQ\7NNY*[\";\;Z:&@6.-JJ$_-#,-EMHFD93H-A[AP7.(L:3@7*
M:];5L?Z"K<_#/Z"(1ES#1>.Z:[6\/I^(5UP4/N^R3*V^T+.++Q7?^-58A"JQ
M\,_!O"6<8R[DBS^5M)V&S:9RK6L%G6Z64A01K#F]L]<4U9KV"<D\AMS[6ILN
MH+H3/1)/JWK/W^8I&BX\K;NRA':OP0&O <;\P@Q?V0*\IN63@#];&OAHD^.!
M8\FHN<+HZ91&.Y7))TJ@^ZVM3&F@Z%;7R/%B[R@Z:%%^V"=#+\Z3 ;J055OH
M]-%0.F;H\[L)]$J9@!_,%IILTMQGNJ!N"H].HADA.LZG'GWL9CM)U4B<[C>V
M5.,*+87R+0SNVD9FVS@-QS4\"NEM/QIOP97^*?!&@)B3U!*)Q^4G7UJ(8=BM
MLS%9\;KL+Y_%WS,",55@AN%#51.&U -DL8_SE2].0;B=(FE9G_9K/9SV$KH+
MV?RQ/W>YRE?$N1%U;W5(D"Z\H*2E3H[DE">'"QMF/WP6QE-',904/'26?D2>
MM\#0SK4;6\JZ+)1![P0?+E!,_AB^:%MYZ/";K&($[J+=ZA%5[H_><I,1H"?U
M6/5.#ZYE]IAO>,WI )<!!BAVE:[W<_H=)+?^]F>CI( .ZD\2C,HO/<EG>X)4
M%DQ<A[Z_7][=/>XD)"2V?*M [,I*S#H#Y%*3AS?H)1U[J0@^ZCP<4IIGHQ^0
M.]ZYK:PLGU(2JWHZC'KC 6[DCEL>:V@P2]_Z J),]@C)+,MLD_I?[V3U V$(
M/*4[ 4MA'F6 YN(Q+PF0[7:M5^M:&#$&Z&GNXB[XF0* L1&(:\8FP\/0 '>1
MFA)Y:VN#NEMGWQ:K:H*88I%QF[BE$0:(>9D4W9AO@#,G3>=W!5'/?GT:Z#Z]
M<,PNJ%1,3(YI-&6_NN2""DFE4N6:QV!<PNQ<5)* T]?$)[<B.V?I; '$HP0&
MJ!'& /$K&@8D!83KW\T4/,!9_*6Q%U.4)IDZ/>1E K="#H./WB-?H6CZH&]:
MO/#[F,W6ZTF*^?I#/N[7Q5%>_VU*W,*P>=P'J@HQ0DG)V/*AEDC/\M/T^WJ'
M2LY6B!?.@9CC)?K?P%^/EW4M*Z$>HL,X1./$7TTL\P;4O@N5W@J1V$XXE_T:
M#@+Y247MDX&GXC-,-+X'5"=4""%B?R( %Y$BM2)HSO%3A]*U[H]-V &K[L&C
M.S%T$0[ (N$<4H:6BL6#8V_BQ@1KX_O35%U/W7H0&5UFJP/>[*PNI[-CB$G^
M>:X<"+WB%VW\G]Z#C>W![H8*K^6V?O7F:GVN+5UW6-*F:+<0.2:%>9UB=Y#'
M!GL\:<;1U[0?M4"H^RH9H**N<?[=G4G(P8=HWNICN61_B_+H6]V;_G:<K4(G
M>T*N2!]^(2S_96Y/;MPY\E;[1;,PP]$WV'&2K"W6?5O%UKI%=NL0I:=O961W
M$X(>EAYC@!RCAQB@9G!Q;;F[0GSQHBV7]YD^V_*((JE8MS?/Z?F[7CM0XIM6
M439X6C<&RLMRZVU!(LG+T2CBEY2T K_XA39W*1T>A:+6.N,C/-_UOX&\%<H&
M>\>L=9BY-?H,ZGA4^HO5>9^!A&.A OR[(I3#]'K+U!C,;<15<ERVXHOX1Q*]
MGAQQC?7&@6\ZL74E:X7H9#?F29#R>7410R;]_AS:,7//NVZE<EY\)VK@=HM[
MO0T,J8)D+CR$T[I9K#^]C'*#O'+>_HP^W^ZR3+'62^GU9#J[!8D'(HCLD<T8
M;A<O(8Z^,#]4,HW8^EX$SEGGAE;"YO66F4@8?3(+$6M&LOW8NMX8(LVA]$BH
MZB-KQTOO9MW;4>&?_6%XS$O%D54^Y^&HXMQ.G%]\FL?IT>^K@_HVKRZ"<\5Q
M+<1--H(<O]R !GT;.[J+UD\9"#Y^H?Y*QXH5RE8WP!-[J-K=G]C7,@8FF:<P
MV<P?*[0]Q?O\A#ESVM;=.*U&G*). #4]^YC@HZ[7$2F6L:/@;HF@:E@60I?X
M.(YP2$JGJE?1_VK%RZ^L3]1FG;F,8P\N:?.3>RC6U/U[QN:"DZ7!90:(&#5>
M;#NWS8S(?]Q"LT75"*IS]1@=P-L"Y)!YCI:W3#V$T!+P*=O03H=WPG6K$VL-
MK4(A"IS^XB^F1)^W=8VW4LHGM[_!#R.[Z?N_$F>P@B%F9ZP.&9P^X"Q):L#D
M: KZ7=A0$5LWN)BJ'16GAFY(F.[9+<C^9?;"(^)4BI;BSB9<*Q2OP[^(%6&
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M[YZ\WK]"YW/VUG9QM5CU5'Y-?&-W\1(7Y9*K<9\4;0CVC3\MS3EA3'#PLV+
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MV-?GZ]4QOL$7WP0BWU(:/$>FRSS(L/59>!FJS*$I&?X"4KP:+CMF?\/0I"Q
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M#%9L*KBH8.UU K2XDLE5 X]'<R#%G+!L6B<>(F5Z[DOF.'ISR!<0\J0\?4;
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M!L9*R^J"85XX;U,(X&<;T>&V!P81TOE-6Y'2YF7.OI<WK=<*LHNE6>[X\Q_
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M,@/$A/GNN@^A3I(%)MZ1NC0R3+=J<%/UY7ZAVVM\*-^1]+,KWR^)_$!VTSO
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MMJ'@95Z2Y<%8%?H9<K-*-XN9#7()Q'J)-;&W%B;?9O^J48_W,J+(:C<_<4-
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M@J"O:Q"O:4$ 5]Y,?)VW5Q'B\Z)X .Q H3I^K1IC(H3GKAO],&]C/40%]"P
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MP+R%$'5!<&D"K(J+1J8T7Q+!WJC]P<[353=E7(Q[PUI?\N\M:'[\V*/*=<<
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M$ 4==-!!!QW_M[!E&?4[6;U!*O AEQ2)*!\@+B&I@*89R@E5(3$PYX"H%&]
MOL="^B:H@!=\_9PD4^>/4HB@87 .E!2Y4H%8VY9+>9(]O?3=%UV/J8!S N7(
M:M07Y."51400P9OVP%G!KS]:M*2##CKHH.._!_2-*G3000<==/Q)P=J-WI#1
M>[QA^P1Z=S6BJ(,*L*-/PE.>4 ''1 IH=1N[SC7!JS_*($+]X%VP>:N!/51@
M>M\ <2\F$_/]-[=9R:/AA/!1^YL(#]T6BOH0#[L.[!/RY4^_AH0..NB@@XZ?
M#G V8D,VCV'CU@GXH0 JX)I"$89;DZ%,E#EMDNC\#J&X3Q=_6!$T_?Q0\6N+
M%-()O%;"4JI,SL>)3&_/(8G#)W<'A?(QO&#%&MO8(_8B1F((X9327#!1+,42
M4AGXGM3(@EA+L,/5S9N/<I .%A^@ K&NFE2@1(@*$"(AV&VX 3)S-Y2R29T*
M5'3V@8A-4@7(<H11!:*I>B63C;(;MI,*-!<E( ;9$20M,,Z38$?QFA&E D \
M%1BRLO4]E="KE$N+X9"!<[<%_[$ =OOSG]SM:"85 NZOUR8HKY?F.[,<2@4>
MZ5 !O!2BC!F+)G)DH4B; ZF 3UJ^T&CX76(_'P4.*7J%_$[Z'2KPA*,<L2AN
M 2-L U,!-J,'.@W'L$N%ZB02PE7B.]DM5(!1_"D5&#=I1>-V0"@".>/QD<;E
M4TZ!JP3*\LWO),=_]^8V+>I2!=Z=>/ "GCQ=\;U@]0TOWA,78.'(FC8$&1M>
MZ_+Y7G3@]R\NG:O*W3H+IM-.IYU..YUV.NUTVNFTTVFGTTY<&427S'ESH<IY
MMD^N8*F %^K86Y^ZIGMQ/?+HN?WW*T\X;9E'A5O-(#T@\QJ%\E3@&G*]YKO3
M:H)&U4M#.T0+,A:G:AEZ;PFD<3*/=Y9\4X;"N8)U)+/9,2(&?3&_UO)=PQ50
M?'*?0'"J5NMU"]%QQ>8]>A3'%636?'KUI@T_6"_QXTXPI@)G>\K A,/9Z_5_
M!UK4<U)(<W.[]+X,0K!(. >BY23.F\*8AEB_";,)S8P>?^VD0@6VZJ-)M@5$
MH>4.1#096UO S4"2G"N;(PKT[Z8"I2#4+Y44_[:)&(0J;S=J 5UX"FKZ:*/L
M!XAR)=(Q*A!G@V4E[3&D:2%_;CS^VPMXBTS?W2 ]D& ^X#6PJ%5XB IXBL(H
M,L9D=E=+=",%]]4X8,L?XB?0!KHZT,^=DE&R4?;W;^^XJ#/SG@K(KY6'/I1E
M_5ZV^H;73Z?X*F;#QA!.]^G<T[FG<T_GGLX]G7LZ]W3NZ=S3N:=S_[.YC\0L
MNQ$,,7L>XS!E6]F:QT^NOW!D9!-%*9[8GM]A35Y9B=3U'0N(OJ@YO.Q(N/SA
MG'JY.,-F!ITWA@A\?O7O<#LE@\#/"*Z]R[ 2T9OL&4:XRF<T^T9^_(.*'/C&
M1(P=O1O^5W5#.O=T[NG<T[FG<T_GGLX]G?L?<I]R$IPY4%;]:5,QEY/B4U8&
MY6\">O329"A*WLWM%[--H'.0HM?-?L97)]J'4&CS0"\-VTHX)^'4176^T]\N
M]PO?2%A'-IBP9)=$<0C2T2PR@?F3I\>KRD3B/H[_(>6 <K^]G2Q=^_211^>>
MSCV=>SKW=.Z_<3]$1L+W15P"/^W?S7=W>&W[^BMT%B(S<\N"#H )^B8[N<&K
MC]8S29.T%AB#U\IR1JB _H#*M0ZKCOR5@?XFHVV,GS3'Y\7_4$,GOJEQ+(2N
M1_H8HG-/YY[./9W[_P[N#0T=IQ=PZ>?VYY9#&#+Z!I2S%;W)DNDYV5)HPHK=
M2N \*%1SR1DNLQ+]25:UHX/W7C*\"<&\]PHSKJUT\N0BU\XD*M#MH+V!LG>6
MZ*D0<G?"1=#[>90[>;J);?_[CQI_D&V+7QK<:$M7)GT@T;FG<T_GGLX]G7M9
M*D 3_NXL Q;U1"*("AQ?EV]DLR9'$MJ!&/I"D*&U<1^29)LOB^Y,;-=?<V];
M3.=6=4E.T2)/$R^\CSK"U"\\]64>03!O\D(O:KFMO\*!7U0X5C9 %"A>9W'G
MKRH<(5;:C2%<%:G C?.KT-YU)I#,B/%(PCH3)W]AXF\?0V/"_6;N KK(^T,"
M*65VO:O\ 3E*&48T-LJ_7*;HK:SK\[M?T/2Y@+4CL\%HE#[]59_@JVFTSG)C
M6A@ALK;.^=_^8)WS55PNQ0=%XUSE-\Y3]6D:_;#,C@YU_]8I__87ZYW2C6!$
MZQ@86L<X]%NG[!1%R*]]<=T!JRT>?K3Q)^M]QTV,IC\KFOYV=__:=Z9 Z&CR
MM**7^%?8O9*-OZ!I6&D?%6B17E>QS2\J7O(=:*0L\Y:%SZ,^#6[XP0;F:2/@
M%^6PTE5#5PU=-735T%5#5PU=-735T%5#5PU=-735T%7S?U4UM'\S1WL]567
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M;BIT&+](I@BS[H D+V\OOA@&C5$/5A?G"ZZOOZ^AJ/$FS,()=OIU!9$<%L'
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MBKQ,&)[T)J IJHKFE,)1*M"\$WX7.DX%GE.!$=U.Q%2C'1G C&US[0*7ZG:
MPYPB2&[B;]%2[#JJ[A*$#S_[A>CX[P(T%U[;+QA<7HG)Y\M84XK=%,2^'*;D
M1$RV)F]S\G<<V!0=3\C%#KU-7N#G=MD?!6[-NW=)-U9J#:Y>$ 0- TN6-X+K
MPVL*(*5(:QU5$&YL\<N_HE7C?[D'(Y7QKU=BL%P<)UK'#R*3_6DS-^>B\O]X
M[RHH9*AI=SD6QMH_:7]]E6G^$$5&080BR+YIB KPNND[*-X7XV)H*'HV<(SF
M@X";[Q$B%XJ8U9$57)7OHJTEI>L]-DW'%X"OGT#L2'-T$)MIQ[#E!5M<^SSK
MDLD6C)!;%G_$"V+!&)(FVDXN5P2NS7B/0^;>,RHB--H.MF35&3&;]6PKM.+:
M1=C"J;1DZ2MT]&\.9+Y#)92F33CJ<YS/9WY6;ROOM\([C&K7RQ?:,MQ@=0YY
MIB-]<2VT1['PZ<E%V7'UC/T0?Q=("0Q$!<RM=.]DGCQ8=&"H!FNF0[X"MQ15
MH=D[+X4\&P<"AW=E4:/BW8<R7X,(8LX[0WN[W7LY]&=-8S@,^.YU7.5^K,S0
M=44?YK5$<--^8V!Y=YBMBEF(PC!>1]BM:GGI$DT7+#][,_N_$\+?ZO>\:_OE
MU/9I'FEV'>6_VX6^W[D\L:'8FY$.A=]=I_05(J^3"K"@!>"V+:H@8A[I\,\^
M=_(?.=OR?2FW8H'O]S</C:)+ U'C3:VR'!0U$**$YGPD1<^PZ\".P0=_=O/_
MK !)(TGNZDM)EK^<VKZ\?/MEL2PQEB).!8*T#:@ ZA1Z<0LL"D2$T":R5?8E
M)''A-14X+;U::K*LCKNRI/XU1@ !9IX0;Z!YRK +\*,_^X7H^.\"J/];T89,
M[ !QD@H0A:<\TU<&M4FAR%U4  .E39O:5V]"'D/45WG?T2(//A8(@6;!$OAF
M(H7BBG=3WO[LD]<9;A8H8R=8&?%IFD4B%; \;PZ.LCE;;.# ,'HH)U<YQ,_>
M-ZFR45/TX0W#K..+"8:)Y>P]+47[4*H/R?O>=8 6O$DG.<B:L-7+5&!&>G*
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M: ^]F')):2]S<,7&Q$CF<O%G_,I+[:+)U96M6KD)JO\RRWK\[YXL^^_CWW=
M_+%BY(?];Y#K111@);^4J6XV"+QC!%>D .90"J"F;!E&9B&!EOS>08A1UZ@H
M-):<%%MIEQ.!OW<<]^^-@/K@87(F?N3&YR8CWI-^^H-WTFJPJ6W])T& S_KC
MX3,/RJR6)SEG+OW2:+P-_90V@F==?#^'!$W>W#GR\Z0B"=$^W:[WL9W+5 *F
M$E(T#;:?/0$Z@[]UJ\BNRF+U9"=>H)Q^.Q;/V.(/S%3LW J(#"X2:*'O-O"G
M^D'4&O*B+5ZA7K15:)REA&MD?K*7J!)IC)$VV/.+V)T-LE!44<2R?AAN)*EW
MDSC6Q5*L:1VI;BF5?AWU<$^<2"ZYHE<H_G(:-%K-XGRU@UF71Y50IHE&Z1J6
M,5W.^:KX'\9 /!13,HF'J36.2IM9EV1HWWSM^8WWVZ$RL/\Q,5'3Q5;_@[WJ
M2/K7AYL'#XYV#]"X07LG^!5'Z:[JNOI)?PK0?1,<:B:TYKA<Q,R[K[CNKVC<
M,R[3^46-;]_&*I!^P6$VO%[5?0%]VH&O8:*W;:E7@F5)2I=).?";4'.#_X$I
M]L)8O2XXK-1 -LUX@DV#59&=E*P)-C(E\3'=MF&VB-R&D1F)(6&9+C(+$G</
M"B6DMYH\"17[ ;:#9%IL,B:H7O3CRA@>;!O&*$)+>O$F%=863KRF".D'54!B
M*$#%K74HBYF*\][<I9H.]7>IOT!8;C#^: ]=6/2N$6\]KZRSXUB'8;<?YY&Y
MG:"95V5D^]Q79+$$;L'.S20?"S.Y#1[=!^?*!XNTVO#J=^T<?7(;5)R=C_EN
MUBN=4&4PYR>Q#<(_:62ANCXK*I#^9DT!F,#S^G@9<D@T%<_0I!(E5BA 50$%
M$":R=U !P]G?H+TS[+70);B@&H+J+)E2FU![5^V1>!;,O 91'$J''/B21P'F
M;E" $-#4"#*>3$,!3E=152([##%$?<W<F@3UQ\Z961=[V.I;O-<M[R2I5O[H
M0M6=H@0VG5/N8)8-YWUPF(I@>5V(E.3'QG"1"-5DSZLW&+8D9D(\%9AJ34V7
M?_V(*OT(NI%B=D5,5$5KKV$3>2\MIQ%'_:367/_QV9L8(AT4FTOFE@X&KQA3
MOX;E13;7@S;7P)T4@'8?A ^I>4,Z>6\K]0A$KP?UH0#->5A;$C,?E$PKC=?[
MISH=[(.6D('(5LD>\,I%D >F$PN=,.NP>H@[-1Y:FG=Q5D_(N7*QN2?W3Q8O
MZK,Q[*;'H(X9CN .E3,C>_:5P>YG=C(QOS)RDV!-@<=1,?NLL2W2C*NI<=.3
M/OXZ534AK?&]W+5%PK1-](*.']$9[<_?FYW^PF40.;RML4X$QR_<(!;^\GT]
M^F M&8WM]MA>(^MV$E<P7U"/&JO+:J-:W$]&<WVI,GSFJDI40[ 2+ONL2,SZ
MZ*]!&]+KKG5@B.6JQ]>$>ASI#SY@SP\J&="'.2>>K2V8DJ5G5@A"$59= SZU
MU\>V"%VHP>:'W219]%" #R8]7PN4S[%]0H1U@DT)F@6_?21*B[8<J4*\^B;3
MA65!0M?A91EY#P0EGLI?"P@9?.(AZ##5ZB<94V@SM0F[8)*K_,TR ^0V0(AH
M@&:4+TSZH\;+U]2+N1\HYG]"#%-5-S[[/RRK[W@'2I#: >QSS)55J=TC:"I3
MD?P<\.S!T4]D;<WR2(FS>E+1DVCYK7[PM?:A;M>*ZYZHNI-31Q[[_M(ROV-C
MLA2$%'#[/P<T,3I?*<#]BJ9.:WUO,)'Q:\#;3V!Z(AL<L=@ UDFX<7 =56Z>
MU2PJ?)X"U+MBL.(+Z^O]$ZG?,-AHGZOK/(R1T\_"U?V*:56,B2_-5B!#C01>
MH]L!["G\&YC^?7"RO/\I2*1\\-1SPX6I#(()^,U@G<;PP '7G0CN.X:T $W@
M%;L<C"*X-.%/!-5?,0L2N[ID%Q#Y-XI4AQ[J(@Y3@/0W%* FGP*XK(BB\I+T
MU$[]B1L4HB$X([\+!).;/R-7.""*!'ID9]X"ZI@<274JXVK_Z6(?AJI*=K-X
M?5/U0BL*P'!X,#Z5;U+?7WG$?ZVZ7:FR?U55;$6;>P=,E!LG/4 =02C )A>R
M!8$<":< R4CRX)TM4-4XL1-U0 $H0.7^&N@K/3$NDY]<]Y/JTWZCD\A@> !5
MAWZ1@BD !VA#=P,#)D-5!G\?94%),H^LN@_[$$5K_1.TY <ZT52_MX7<<W\L
M/$FM+=.5== .0R,%**62RNPTXCKI+95OU/EHD>N^4X"<%^A!;2NR*L_L?A,%
MV..$OD6RP)VI:K;8X:<;KM)&RCV@MR5(I_^"==U8]!KKF.F_-_3*Y#A>#1Y+
M 5CW*8"^&-F0 A#40-A9Z/Y%Y"^JPRU_K(AZJF=A@.5<1!.E"-HVR WP!G1C
M.5R6A.[?E0N]38B,<CY<MRCY*SJSOY<"3+J3M:HBD>OUR.-+"J3SZ'\]E9W$
MO0O:C,9Z:U9C7Y-EAYT6RD:=K%7]!@KTW#D_:_?0&[%T>7NVNP]8K79A05/"
M"VRH;/CU:NQ<)C]DS/36 ZY?0USQYA^$/RMZ1>U_[[@7Z+0$MI3F>?K4GBR"
M'>FS8+:).?@IY+7=U:GR[HG\OMA88PDZ'OELEOTIHY)AJ<*-R>30+EGA-_!4
M-SPKZG 4X7GGCS_G[2;JX!HP+:@3CBH7JB<#.FBNJ\_N#!GLM&,B3ZN\4RY:
M0$\$SZ_#3?$EGD6.\='W=+_,(N VO";+<9D1LT97J=:/UARSV8(3WDS[^&ZN
M2-.=.YMGO,F_ZUM8$HDKI8/@N&HQ2) DWJ;V/!+[L:GTXLZ^LAE?2)]&#RW-
MK_?;S58Q;6FO=..#+0)Z4:#^XXZJH6T_MJJS+]D[$_D#6)2+]A[V;0G>[6,N
MLC?R]QVTCKA_&T)%&OZGU>!U!#>X L$K-@_?-Z;4_4(M>I66;"+#R0_*3< <
M#/A!= G\\ <4X'79_/ *C_[VR,VS9Z06N\TJ']F2:4.ASXK6[S@A_K#PQU31
MKP(3$\S%R"UQ5%&-C#@6;_0DU5!E+&$5?"! 5:S[3Q]?,B"]II[)\J'J"X:@
MKG!LVFC_SV>"A#-QXRTDY@65$-G$TA\=OK"+F0FGE3K-RMJG#:FO,5[BD-A=
M;H*,S]*I*)BVVZK8)!?Q\Z<8A*1(RW0G8B429(:#)S'J%0TN+2UIVF/YA=,:
MUE9.H9JVR9\_Y1+WM@>H).I+XL)VAV?"T%FUL?T6\??K MI2"[J$PH2 T$#;
M5<\_R:&AZ11  +DT1U2C )94R9YPW'N%D0U0^8E(7.R(L)W"=(UX;_;)!.9S
M<?0/.4@L(?$P]'$\>(=J'"<O4YGJ,04HY*0 XA2 E!/T\W@A @M[!:T0(TI)
M\ZI059>AXT!]"E)#T)@B$C>M^;V.M,:]GQZ@??]"2[8M8&I3)I>(D;^Y4IN2
M$'%<-@<EQF/HD#_$9RG '>X=U&8_!1!UU*0 GP7 QRH+C<5X'@H@ FM"'3!1
M>?+ J9.YM52YO$R<Q5/MBMB%8N2/=N2>#WJ(Z5_/,*K^U7U=T"HT\16<_X_1
MP.R=6U^;/-(ZH"IVG&XP<KUAG!PL>,+6G,!! ;X+H,C-9=1RG1G'C <&M&)V
M-,2HY2BF M&3GMM[C*?^UGS'<L2,_5A2S!D*L&KWUX<',4O+Q<@-5ZK%T%([
M6;;W5Q0].H$".",C(6=+'.?,9;W"1:-=*N3NO>K2W5HX=JNF@BNQ!H0]-!TC
M((3D"A@0$GD%(2U-HG\DAZ]\,A(E =DI_G(;582;J\?M\;!%T-F)DB4(2"7S
M8Y\,K^[1^D4*<!89HGMN:5D89*[&I,K1P7'5+;LYAP50!@K*UQEN%C$[2ABW
M&HT-7KVNWL#-!60C@,*5<Q/"FKD^2VH)<J=,SKVXIJS*O?0RH%OE)#+L&C[3
M8S3FIG[O!_'8+_43"]J9@<M+H"OR\NLHBYQ X/JW.;9K5%-+]Q)Y=E\QDW_>
M.Q+FU"TZPF?>W;X^>D[]A^7>.A[2BODJ%GH3R4E\%JK\7+Z48ZC/K,[1-U!"
M9*V3RZJ15L:*%'6 QGA**LP:#[ML2"URFD[?QVKSKG1VW6-OY81F(3E56'Q:
MYN0BD.4;*C\FG>L;K6-J;!@8%.DE#OF_T ?WW;@LBLHIOQ&J7TQ#_XH5KC6W
M/9786OOHNNJ"H%"_N2' '_9TZM',9F"7[J!10WHSJ%*CA>I+- 7D=F9\_.8_
M@X?G>^X3%,Y^.WQ6SK9<XN/?9,KS>LN3<<]9?.I1 EDM97FCX,R+9]?8!K^M
M^;$M[=^J,-S;?#@,^1)ZT+S&/W4[U<-@JE-0P"]4@._+OXXH__>H\O]?1I5]
M,>W(&%/IILP;C-+/$?<,:OLGRO'&$O*")NGT#LNT\F+*-$T=X2NH*GN$'@2"
M+8C4M6E*Z%N'?XE]>B-P-FU,OY"A3M;+H&F\2,A'X][Z0PG%EL;SPT3#]Q,.
MQ^;-T_:'\>&6[Y!A()?6EPS*#.?'HNUK.H=U>JCZ]_S?O8?#_]+Q]]W0;_TM
MDJ_07^8A5 #QF )0#7MG/M6ZCF?,'M.@^YA((!R2&.'73_*EPJ-L/N(<VE\8
M+^Z7N]//"8X-V4O]3;6KZ(_@LW^]=)5X"B=F@7?V]?3,_IE7/GX];$F:Z7LR
M_7G+H(Y;/7H&\NH?GMJ4OAM\TVK4;&A8H-WN:).9=I35D1\P@CR]);V9@S#Z
MF=OUJ67#C8TJ95Z-K;C?1>[O??A;39/37]>5#9>Z7/!ZW&1^T<8@>#Q.'MVG
M+$:^6PG=GP#O78#F0+F12ZGX%O*W0]3QA?4E&0>N0L.<PC:)QLA>$ 9[R3ZF
M?:Z,<<&QR^6*28V<LUC%P00(A&QY\L?E9E=@R#34W]9Q]I+UM.TVV+DV-Q_<
MC*-I<)O3VPFF.M<PQ<L;M]O</58N)4S:_0KO>AC%:Z+#<'[I#%2/Y9:X=E<2
M1\";!9^H15!L1%XT6B%.6_&VW*'%VD%#9NS=,:0M)DP(-.2RKT@!V-\ZE5RT
M_YCL,H<(RQ69?R$RY_X-K8@>W*9;K\1PJ BM3D9%?%7]9.)<'>7Q\TEQ(5YV
M'@]9KHI4 LN%*&E_6AE>ZK9R%SD5BSOUG#9 F!Z'EI/J>-+VT&-=)$^H8QP'
M8YE_:6KL9''B9:9XD:_)^HNQ[RZH.6M(]@H(@/LO((3&GPQ[T+I9>F2]N)%>
MS?ERF7>RCX&HYC8C-"BEI(FVG]0NZ&W;;#;[2.=J$M@_8'OKD,I?][NA(6"F
M[5)GK^8TZX@ID_??C@["%D!9L]_XBEOX#5@O&^0D)J$,I#CG>Z3<M#@C>\0N
M#^:@?284UV96-U(78OLG]ASK$#;:5Q:A52*_)W)-N-^\Y7>AI2W?;5?M:/ Z
M'M\X6J2VC+V<7];[;$16^Y!LFGW A,O4:9;$D+A$/-,B44Y8:R%3<CJRSN*^
MR=NEQ/H7:20AW*5@YX5H.L*#>BE)Z>?7>G]ER+8T 0?RVR:_Y8_?7AG6O)1%
M!4:3F1EBS3\L+KZ/R/@E>MDL_E+))Z_?]5#KBMA^%"U1'*?;JH[<4+YD5G!Z
MTS_UHOR38]AS&I46L<DZ1RH( R^P9J(S!3.3%YU_6K[:](Z%I=."[T'5?787
M;8,;&9N<W]]SLJD-O28\?'/I\6=IYZ4X'F6W[]LQ[L993*02N.0"0I^?57UL
M637%AE'@D 5-IWNG[QJD2L1J)&(AQ?+M$XO):&EW')$""*^LNE8Q6U[Z?([H
MZ!.=F::I,LNL19[QWM'HX&N/1,Z3[IH)/NQSY.^,$6)^?;D%J]RPEAD0"+?'
M:UKB#)IWU2]&WZKSF=B0PI^4>QR%K.X(7LTX0 >6GD\9\CV?)AMA]R,W-XK[
MF:LJ]_K<]<'VICI3+0\X.Q>VUT6@M9WMZ<ARL?5J;8 C;O;[C0;.9F3984R]
ME:/@=%;$P<%+UN_*Z\4T02MW8&^#U^@DJ*S5&AHLF[8@%W6K^T5-9<P](13L
MQB_>$>)0_"S]+Z'Y6$L+#,[LX#7VL'GJ2WZWP.3'+^4R)E.G3]Z)BM[RX=T
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M$J ^4[K51HVQNJ/GR2(^2I5@];O7 K))$JO04"@W'(Q#J=:<OLOAH9U::S[
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MV-[&?(03>D$1WYKX8#VE2IWWC/1'^IE]D9C )\@S8 =I9CSGDW2MJ@B$^^/
MY'?.#XQS+$>ULCYX?Y-?XHR/F"M)@Q29##7=2YM&EL3OGV-C[G8]QV"%CZC+
M[R\WJ$"79$57.0^9@L3QBW,=D62AIH-H*TW/KQ0 5>?%T0J>D3A$SAD7PJ]C
M)3J$;@QL5D2#[A$L,MWKNM(W72]M%ALV&KEJ]'QXJ0@91;*#[3",Q,?UY-:T
M&6W9XR4N,RUL"?<W93VS]R)>YVTK'0>)$O/^['1V<:M\3VWX&5XD+X1E;.R*
MV#/%/GL:M''*$B+7.A K^M!>%ULU>YR50A_XTFD(/7;-IU"797BBU%JB2,QG
MTW%E(6W8'Y5>.Q;M.S]MNOUHY )!>?]#"<N@"^N7IB9>?54B*\*0P$5%/Q4+
MT&-BY)\Y_-WM=N21A) DE6\FS1Z?06=CGJ..SM93B0 T'KE"UR#0I^.+E%F'
M#1SI,.<*R'&+GYZ4RH'LZ&MDD<<J$V?AEI55E:%:D>$>> [Y'/V^#8M'U.X;
M4XDF7(6KCFXFV Z7E/^RC*M*%4?'>CZ-WY._M7^ _N#CWL+7]WXQVN1]54W$
MJ*7C5-1SAE0E,=Y3D:?=OL^Q(R^.@)TH %M3P;G-F\KJ6P,"OENK_"#7=^!"
M[M^6N.K"P>BKHHH[)6;;>)!5NNN,YKUK)=']7Y[&%*='636@ZP8Q3:+3*&7\
MU%QJ5#V-T[AI9=Q"JV==I>5-+3+NZ28%"*)Y>BL@RH=^0>Y-H[A=PO0JIR^.
M??JGZ=-LCK;X0W/?<\)*4<']2GQ',@<I^'OT+;$<J@7VUWU-A?*K/]S;FNJZ
M_4*HXWQLJQ=:@_;=PPK(FU:-%-M.-VEZO6ZL6^_+3XU#P14'SM#[6\5IC;%:
M^;-F/J,.>%AS&B;J%HU5SNHX7_*8'%>03+G?EY7<GT-XK1:YK!LXJ<P<X\N.
M=1.O'^BJ@5H[?@":!W2-Q]CE-THR6(UO6P6#QO8'\>%2VQ] 2OU1//"7FLK
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MB"T_Q5& 1_TE &* S5<@N$^->PG\=;85B3>&,FT8+4!EG@Q=MW3/*N8*V*0
M7!W*715^^Z=.P=<)5'7[+CJ$W+C-3@ZK1N<4+4.G4&1-*:H=LNQ$[JFU ?VI
M 7Q$;7SX'$)\;;AI7.[QCVYP^K5@W9@Y7MF@[IO.,<#BK7$*T'*'2'T5:I-:
MK9-Q2%S: ?*'+EES.0R\0:U/N14ZK^#,T83;_&P4BE_*,N)XV&+4<CI)KF#
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MFKZ6P)?T]$J6X33T/Y] I&UQ!DVI!ZM*0E<'1<)#5?E>W]L]57W,MX.,1E7
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M"B_1;T:Z>2K*]E5>4*9J<7*WY-FXJN0UK4K+F/P.H^8C6FS]-1"*N[L((ZR
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MZE(X]??$Z(/KW -RSX/31P71L5A":,4F55AE\X D!4/I']9A)>-P;CQVZ=D
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M9^M .6N&'5(9+^J6CWG8LUM\35#;^/1JPO&YK8M)0JT/?+:%^9T[RK>#^)@
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MHTS^H_492)G_0KO0KQID[S!@49VPY9.L["3Z', 9^KD7.US?XRZ<=(7CDT3
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MW*$+40T/,P$=36@*D)'$6Y\9+3N/^_T_.B=/C_G;0+TE")\6^/&L9TK>;WZ
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M-B:?XX'AV\W'13O+_7N>"L_\E:&?D<7P(/@L(_Z.I9N,GX1GB,+K*NYUYRM
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M39E>OS[I-^T.6'84;5/_\>B?FH81*AB#!"7+OYDE2/NG'V:3VV_W>SW]<*>
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MVI*^LA1W$=_Q9[^PX>-P(N_J2+V<RP4E*=/E85>-LUI-Y]Q$Z6LN#E+$0*P
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MUSK ^;E'2NUT)[*U3FWO$1XH\5(FJ<Z[6<&X',?3G,\J[/JYKA3 D!P<]3P
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MJ=B0\.I83V>R<=J0B8D\C+O=T$4,-2Z6.$&]@<PGZBX[V_/QJSU1>7KPK]Y
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M9*O;]T\/>[UUF$F.B]ZIA/M)Q 1($.V6V5BUS9>Z_^JFP-_,*:")#X:#XF:
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MR,K&=(7@>?[:5O^AZ;[,$3]A<\TIBILFD,U3BZA%ZW=U/5MN'55L;'H->U?
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MHRF::8:?9'Y-F#Z3::>L?27U>(V)CL8I\MNN;KQ(4Z+  ZLL:%PSC5DSIZZ
M:NR37/0C0 /S$J1TM]$1(0S3XZ@3DG:]ONZ3,2-!-<D+1HAD$"]6[5S933D*
M%\[5U3.TCU#/_ZGY(GJ-^*.T9@0.+/QVM.O^;>-(XL^]WV^;EG[P_E ,!3^U
MG/B.F)R[+B*RY _U9=&-5;[:.I+O-[59K 3I,!I#/, _7: /G0-AOD[-FE-.
MBB7=?T[E.LM#]^B GWMD593 2I27Y;:;>7$7.4+;6$$&/.[;-$>T?0/=]-D%
M!A4FE0?G=,XQU"O NA<C;T^9#/L[S@<3*%/>Z\1O-.<A&\+:G0YB)HZ/S(<5
M(#Y0-+YP5(.>OJU)=>N[7O'LTL<K&T49?_94M*ZI#,W2X2GGP1>UF7N3%@B>
M=9'++CO=VD(H S%5?=(:\YJTVY?='EGWC')K9GK[X!@AMG/OK<;I4-3V02@W
MDI+B"\5@[?Y27U,"OF)>.$KB=NQ&^?91*C7JPQT \=NY>_*[=6K#/;(V;*2A
MKOX;]U7OQ9\<KH$3M0*')!+GB(O'C-:@&0?!7E"$46Q4G^3-'>AN^76!?C)G
MD3[@H., ?\CZ3MXA@>^I7DB/0\,:A3_KN6,).T)7UKIA:YKF&+X8$Y]FF6W0
M?<AW_ZAGPQUQ^V.#CSWS2LB1)-[#!3XG_N(<72@@)O8\R  O<(&;#ULK(?]4
M?)M3T6&R%*R_0L]*&CCWE/6W&\^2Q;XY.Q?>9RL9S-R+;,&5QB8]7*]X $KL
MP^\O*!=AYY[U%Y8MFVEL&VO<=EQ-OA4F8_7MP$[TV#NJ=AX+?@1GP/HTSEW[
MK/9E368T2=XS->=W"</<ZEMC^_[KPG_ 4_(MN$WD3>NA^00U[D1;KIJ@AQ<-
M1;;Q"Q^!V4()T]8]LI[0H%;E @.MP(?6-2Q'H@/@TGKQ3N\73$.E)]_I?"29
M(ZVQGL0HWRF(,*(I@R..2[B5_2#TB;D&<X((<IQRC@QXJMU5_[,PG*9?(;(+
M/AY<XX!XAQ@ZG1@#R>)CC^WD'7E+'Z<M=4<98'#;[3AT-AGPJH[.$4-]MUY(
MH4=%YY/.69> <0.1!K-J@2@@2!)EQMZ9]:@3FH,7C_;L*S/TD6]I.WZ;1%_Z
MS,9W4+C9-'MSD,C\9=*A6O1+\9#HTRLOK_55N-]4*.);_IRA[?U9S\GE^1A#
M9(X^/?L];0T$4))J"50.E\=FM29M3-EHRME$^;5QC;U"]00AH&O>9ILIHZ@<
MI9:D)(8I],BX .G=:=AB'_6ZI6R_F(>%T_BL8Y(\?/P2FOLLGPUA<^M0Q_NH
MD%?I+*6> ^]C5#PBHB!SJ[XD6>Q6PNQT?2=3L&&SZN-&P)Z\KF%:KM1HHW^;
M?K-^7)R7?;;95#OTTIN6K[>CGMR.;J"[8+[:@KDP053':N4L$)J7"X:1U:EL
M][H>J@"?7%9QBYVM]A;._C:2_*=-2T+/+&NONRV#=A0$Q/NO*H]NLP\>,4[#
MX\3MGQ+5?8 ;PB58JFVN)52(W%O'2<2W)._7U@RFD)8[JG4)V 8?BA@GPG'K
M+"66#(@1H42%2J4ZZU%V/I8C#L0/Y]%)H-XHO5=JWW+$;D!C;RO];/BPVAF]
M+SCVX"0!Y5+6LJ8NAK4?$&D+,GX[%K,1DT+4)Q@2E7 &$29D@&/KMY8E*!E@
MV[RLNG2VIT&/IV;N/O]-(SU'A[\YUVIZX)I3^-7CEZGIM"#C;YJ2TGQZH2P'
M"H7TAB5.5*T"(Y:QH1Y0J5' _SADN[-K9D;R[V.O-71^[(N6,,&6[/AD9T?7
M1<T'&SJF-6HTOIG&_D6L_PB9O6!VE\AO:/Z?*;\=]>.B!$P5/:NP(5O=F5Q>
M2\A@7N'/VRL^%: ,\]?S9,#<8Y4E2!9S(_Y_$V1WA9UT/);LWN.WGKM),WTM
M5HD@C9*NU>-"F@0Q)0L^R0?=E8<4=-8B:[EK>"XLG^B!/N3RFNDV&1#\+D+3
M2*/*1_')X&,1R>_4REQ8&/AIXRXDSV"U_O89"L$-R\7ME %I3:5;HJK^E-M7
MB/AJ)W3'ZQI&I*X\7V]<RGIR+5UU!BB\!BS+:2FP-Q[RZ-@I7?FT =M.[/G8
M:??R"];W3'@G=Y^+Y<@)[[JP;=G]XA=VW/^TUZ;27]_G+8%/C\WL*@_5)8J.
M;<L4HS>W5B]9!YCJ1V8A[-V36 RC#.LBG:WW"(N(<K@:CJ5E,MFYV_U'[WKO
MF]0.7;P !19=B[&S8"30SH<$WQ:ZE'2];BIV[G=LNO;9W@L$\PM2%X26NA-;
MKXT^"AHC [C0.H.EW1:,&B5#^:^NFY@^^81]1LW#JT23%]\'N-!CKY7PE?^N
MQ]+]A,W!*#G'/"\R($0AYZAX=$H9SU-P6V9"W"9X0/7!? =;R&)N,PX=@:!V
ML&Y!WB3RO^KBEODKMWA@$WD2";XC?<IS;M#55"U10ERR+9Y4.L7A5F]BW^\]
MN^2G'O!Y0FTA%5W@3KIQAB)2S#LCIDP'I"[8_IP*9M!R68VW6Q::EH_M*N*2
M'Y![FS:TQOK:5H[ICE9?\MSI](&00&9U#.=)Q-'&F$(,-=Y>E3ZFS++3PVA8
M.15YA#YI?0_9LLY$.A*M68(>6\@U03^T>-A-72>Z\9Q!-\D ;C@/-JEE*D*-
MJ)'-I:ZA9!-XENO@?_E6!L,PY_Q;7T$%:JQ/$Y!NI[ 0+OL-:=?GX?\0M2VI
M4?6X UCKV0Y*[%J7U4=]W7K*IL5J])C_]^XZFDA1DADN_ /W-_W'2(%D8=*U
MU#B-%CGMI.6IB$\9XYY[-B=#P$?CIP&0[,-]X'8>MK/,EZ:]348GJ6HH9 +M
M21=/P9F'.C9&-9[EI=2^ST*T%WP:/3*HLAP<6NW?P-C0<Z+#ZYE:OZO=W9RY
MIN^TX7VB(LIP^C*1#/A@5&6TJK*UC'L$%\/'.KJ_$]3D)OI&$_B#GB!,Z D%
M 0?3\F/G4*XC?*TQ-OBI8,?M=+9]Y9G0WP)RTJEF&I!]+B4FH\<K0!G$-!FP
MIUU*3Z!!;O.C.<^B,']*&\D 2UE@A]$D2.Z<U\R%F?K6Q81)[6YS&-_9SXKI
MBQ-%^TLFV/+[PZ2CYN?\N"_C?0O$"KXX(%\.WY0)U3RJ^G-B]J.Y"IC]MBO^
MW<,^RT\2:?<* [1VR("P.5TEYN'W?]/M5?%_FDO=4- D*,!!N.@:K_P-$I!@
MF>W9^#UUNX*Z\@,3/.\6Q0<YF@TBQWPZRP(I-$4YP/;HZD.N;\;PL7BZZ?BD
M5TC3Y2!^MBK)\19KP9'FMDC]ZHKYJ*Z_[0?O<[1(!L05G6.,\1O ,Z";1=\6
MD RXA61%COFXGEU6/Z;G)#)B(2WIIJ+:+=[B1U$'.K0V2=OZ2J'-DA<"WW%9
M1+ME.!U_(+' K!<29&-AT.>DGFA<8@[0X9/%LGO%F;6,7,;G0EO-W+35(@7;
MAU;,E](/#J8W?F2&KRN\R0P7H%AUG4P]\JW&!\;B4<V_PMY-.00:W0P(\&(E
M9/NXFF?(1\L#$"#L<1CQ*78)(NMML#P:D3L5S_GA:OZ5C>C(>\K(H) %R$^#
M;AAFP2N0"/."3E)^RA)@W9]5+%X:^FTNHUAB7B:P#W*HD1QO6N'NXN[*K=6.
MRCHK(=V^4QF9+CA-][[ S@N(X !FOS>*5'!?!(:9#LYN)NUO5/00*A,^7/2'
M/5-BY<SX8#3M3."%W[<7D3(99OSH3WI-[UJ7LE7+@_5J1% D:'[%>W;U+L#,
M@O5%N@]B.ZU.1EVBU!P%N:# H.Q=O1QTIDH4HG/N@G@MZR"LHL6SQS'7_-FK
MXN($J_FH^OW*K9[^:U_L%=+HL]<RJQ>8*6U@[S8U&&0?IL6T0D)N@ID5F'V_
M6%;$V;1\.N;Q8KT+J9[WVGC,U7C.5#U@W0VD6WCK15ZK?%/-',B3J85DM:F[
M]#>4EWZL=ZSWS^,@/\J>FO9+]=V8D,XHR)G<\"P8Y:@T?':ZX+=2_%/MQ=C/
ML8"V[JNP,EC)O"CC41X^,7-"],>8X2&S9][L5+M(P-Q[CL]D0*VF&T(&'[N(
M#*L.E-P\_7::]L.S^=K%MN2MV!\TU$L?)6 ]OG/O"/?A]VN3;>.;/@H+]MZN
MS) F/JFDRGENI+: #*R_BGVQ"8I8J -U_?&=\KOR7F5@2@0LUSX^[/W0P9OV
M7O/C??V_]!2!Z,1<<%5@+X;5M!CV0'.GS_54<JZGT+-5MXG4#U0ZDAF50 U=
MI7=-0C0=..'1Q/=5'?ZG;5>UNA9[=^YDC"[*A!NGV5JP6B40KFLB8$1W/$,>
MG&\L)^[!W1KL\""CXP_*#AUO%1[@NV"W7EEKWDI@9AE7:ZV1CH)D2_R3^;SV
MV\&&W('<F9G9TKH<"VYOF[HV7QRKK) !_D@'(!?^8IL\E[#%QW4<]E.%6_Y:
MP(#7Q1<^@A0I]M$D1?S2HFB$\2;[$-?#:-/>2>E@F=5;,OVT%]KIM!]#WCB1
M 24YS;XN)GQ5V,0X^;2*"8VIR#->6PKLSU+P!!FP,!=B'PT%4X^S63<:5AE6
M"JD\)31-$PX+D=9ZHRO]APA,$ 9<<ES'L@+/(DC"*3"XN="MVJ?YI@K<K,4?
MGW\W:)^RT4]4.GRD\MO;S:_S :$^);0H,U/@A>Z'W'N '"/-!T).'3B<<?(K
M^QY1EF=,G;:JK][SO8N6HDS^/"_ I09*.,6B)L<6BV' !N>O)II1]N:&@92N
M*<*(.' Y8OZT".B9JZ=K9/?"4;U,Z<HA"(1O7++&T2XJUQ7F29I-FS-7=*[3
MP&//0 94YQ071>##2^&-YL^B?@]L58_>@1[W6830 N=UGR(;\LY]3N <O0N"
M'[;_O/\EW:\NDNUP'AD@\D6/+NJPG6+:;Q;S?%N4YU=I\.2L=/ 57>MH:5::
M+R\O; $*U1F<JTIF?F\(>2R%Q!Q\:BG55?("/OBG'X__S5%TF2'_2U*U?RX<
MM?<<;D$&O(S G-T8.5F&/(Y#TB P7T_ 8<C=ST@LYK= 9OCI4]RO_P1YJO\C
M_SF%8@YCXQ-L8=^B0U]YA'O(MI/?@%Q3KO^,_HRQ09VP'I(!IX?:9]?JT]$Q
MOY&SMGO$F#7+ZUZ=ZW^5&JI;G0.1%-_/_^IT\;\G?T] ,R3X#AWD7_EOEX5T
M6FNGK[/F43^CSI^>[>#Q_SXGE[P(9'+D9BJ6]6[+<?QN1G_BZ"7W+.>C7!%%
MW@5\.+6SDD6*AU$3L)2%R/1LW32H+0I[1 MM9<CM_F%Y]T ^-H+U6_#2C^F
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M1N/YH7K]_[SJSER[G9X#TZP=8/D09Z["PBX3\=Z7GNUW45,/ZYKW+]WUOFP
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M8K4^N.]C6G@4CG%1:*WZJ$K$>VA2+4?Z\+=?QT>VM&Y6%5Z@P-6*6V^4J8;
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M0ZB.RWSY\T)WYN:$)5672>!']/;LI\'J!2BBQ2R,T-WB?_C&2[;<I?Y%-:?
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M;50 :S)X=MX7@J^KP,E-7JT8DY]6[?/[D)6L)MJUF=WQXGY\ZWLJ #KIL'4
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MR)H7$A(RO[<0UP#/[?D-5FB[>+$^:7630$+?&7 O=;\R_J@^8X-75&-^G#=
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M?T>SWM.K3MMT=P4>O(<D.F]-[5"C-WQHP,EQ%''C:.UAG\YCHNYOZE!+NHQ
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M35IA,H:7:JQF+9C:PQ\ASV<ZLJN6RE,%8S !E&,S5/JQ- "_6L7L\:;9NE'
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M7H1AJ2W5I%C<C%^V(+V4$:LYXB"V+\L<%:LUOK=F[_(GZ-+IB4DU#2A+1-,
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M:=C^?*6+7#%%]V=EX!6VBRPLCRTQK_Q'3,(5VA##Z0<(PO/_K6$KQ-2B'R5
MYBUVR[YD\TJ:Y=7+FX(!G2Q?T6GG5H_L@;*"KLPT%.[],KQEVO1YR&+D:6#?
M_UZ(L;>A 2?1;8A=YCH:T.0")J83(!,SK<'P& N(0%3>:+9+^,=T":/Q'<6$
M)N?/Y#77!.^*N6U6I2=.]_-5KU2M4$:#08FA%NPOZC6\8!<HBV.6%HATH_C[
MOJJD!F/N;?FX4*.0N3Y[-])$MKF3IZSM4N_U]HA$1@;M=ZL0OK-XE42E,E8!
ML]DAV3O+C!/TF]?Y=4>AX)B0P_ 8/=MKJ<!+4HYZT "<@#%5XMV5I-HQQ)R7
MZNKF.RFP,TBR:(NJ)Z_C!\(5DPUHP-4,%/E$,@V(S:5R(V+!RV<":$#X( RO
M5#*PC;C?!D/7[ LU< _#_O5)X41SJ!@-^& T0V6@GZ1MP!=D^C^/#4&M-P_1
M;2B8?4$\*(8L#>:$_?R3[QWY4\QS&Z<!SDA65WL1@3$"74^-;C<J^A*2_1F6
M^!F&S?T$%IQ_/N9S'=X1N)<I8+V[[5Q.]Y4N:,??4T^&BE';$-O)PI+4/VN_
MJ4GV8\-@G"7L>4&;"(!;:I?5GO%;?"Y/</K4DRLQZ/3C3N> A(8>)51@D\I$
M YJ54)@[T"%E!"\8XP!SHV03J#LD$(F]:YKPWAGNF46([I@!JTWT_WK@#"_1
MEB RW"86X?;;[-E'ST S2BQ['2]/,E]=O>I' USN\(FT7_N0C#=L%: !<:C9
MC[!*9,L6>V#,CZ315N/*(62V"@U(M?&;"7AFK!.D#PVS8GP@O2M)/5GBQI:Z
M[@[S].2\<4S]$T+(J^/2YX]=P*FF4]+.!'E*>.7,!&^;]OFQ/+P%64*@L=!-
M^"TOXVT>B&.D\@$7N_+UJ0D'L7F'7B&AL0+J**@"3;Y"OR\2\B@-\*3;B-+2
M=+,?@0:4A2$]4R:F%@[>[.U-MP.AV'\[QE7XK\?,9E,[9LIGR IZK<*FS72+
M2(:U6!"F']G9;" >D$3Z<,V\J15]R:K;BG7@]GBO9"RJ"D$^8T,5@,_M_E:C
M 5$)-( )G>9X'#$._DH=@\MPU/T@W0SS&?(4J3RR-5-5T*)&58?V9ZOA[-*+
M7"T(VHXO'2J5?LA57*]=Y\>:2?Y,)]?08\)3ZJ@U9+V/?L&G V]T)L@E8QJ@
M^J.&M=B'E(P0#D<15ZQWT8F+G: +-\6.?(-/WB+N$XK_="PE@@B)8YNAIOFN
M]P)%V_=%52S\1WNU2K PJ&6 ?'\PKSG_Z@V!HYWU@0A""M%TE@8PHV+]P"_M
MA>&ZEN3A;R],XGPN[<:*R@R""'?/;$"B:$#54N<^)1^JL4953.27]2V8<LZ?
MN@4$;ISG@_LK1C^RZNIN]CYR]B0)T@S&Z=2:VL09\X8:)-J=$U2P6?X>9+4(
MN286;PXN[3RT* CUIU^B$=%ASK\$\PD7\\J!",MY$BP3?#/8=7GQX)-C=E Z
M9D&%(\5?<78>5#?&!S L&T^*8H1H@##X<0FLV=^UI!"R_-7@4;%_=&U,;SHW
M^@%:H% [<FS1F7S&F5 ^2 .</$'$%RTBFBZ^"+:U;=UR.[0@^_K4^"NI'0O!
M=Y:7S54/;IT[R]8&[7-1!DT$F[U+H0$JZS@Q#7S"U'U6;,VM ]#_+_6XAOP/
MJS@6:]D?,; :(L]:*\)EF[RA5$D#*@^"IM['AQ"69E316,A%:,<,[@X=,!_#
M8P\+7M$ S(._^(:(G>0Z;!SE,-$8*+ZC0LFYC>WJ^ 7C\>E@4@YD)_.8SC;L
M?H>_:+PP85,YRNQ.>5&H?C0T27BAQJG3:4?"KO/;M5\6 Z@RV,8-7 46UN+)
M;K7*JW[B'39+O5]:R]@0Q:$C4YX3N9,S [\,.M)H^TZV<J?[$-Z>?6: '( I
MT6NEGATJV7/G-8DJV2PN3?;U_KC*1+DF%''D& <D"\(%FXW_;IY?C Z:91<Q
MR!GO64@U'"UAZXH\LV_NZ/@H]S7#!2V%SI*C6LF$&LHW*"^T7\ ]_].+?"*L
MTUZN]JVS07F*O-SDN?UL%PZ;A\O<EY,S=_F1MRGQ4 77&5 C%RI1"<1@2>09
M/=S ?(T8-#U7%ZW-VG;@LKTEEXO\Y?"[\2&1'@"/>>/&HO=ZPXSG0/'B>+MZ
M&:$GA^Z%E1'7-0PN^/M#')G"2!;+T6F?K):_NY<B"B9;'1ZZ<39[NGGRZ<\E
MZ'*;Z0'T/]\/+$H8<(T>.5VRW9ATM)L&?)0-J7J&$H;RTB/>"O'&')(!YD(#
M'& >5DH%4V0XN*N;,2"U-L!WY5O8$_Z#/V/D??!;T:$<-( E@,H)YEA19YQ$
ME6O"-PR72^JG4>[3%2%LX[]J.XU:1U'Z*$Q8J (-R'F% 9-%Z!B#]SO8HP&G
M;M. +WTT((4>H_Q-_NK_NZ*;[)-(C$THC)*AZ8*1E9VKK1NYLO=M*,OV:5)@
MEO,+5M5635?%Y9$#.@P?FZ 45Z(F,CJI9W$Q< $[R=9@\IOB5)^.5I(RX7R/
MYDC'@CFK6:+VO9?Z#%Z@<GN^ 1A&"#>:G'<PXT(ZGF?>Z#]=1SAK-][=X97Y
M>(RNC2IZ#+!HHMNL/\IG+DOZ7G*SB'PM__>ZZFJK#4]!TG9K+=3GY_>OZ'M\
M/WFTL&WT VM:$(Q$([)A(?DZ;CU8H7,QOTT@WC0M)L^ W^DU#2@/1[B2Y2E(
M;3!J0QH_ \%G/NMVR]>>TI*;O,O0Z7*Z+:0L4Y&S7_<.RVMFP&)*A(ZL$;+?
MW4RZY^B$PT N*2&U9L!W.[FG,<* +_)PW767!L!!.(,9UM"[HYK*U--X6QA[
MI=$9';@^_+81W\R5'Q5HQ3O;&2][-?AQWLP'P00 Y"B^F%L0*F?3(#(B7_7D
MBJ=R_^CUZWT*S>]_8C-Y *\UR&GJCQF<F0TD#LQE'-4HNB*@UTJZ\,&O>MA^
MHPWFROI!1]K@.9\T*AG^_LCO1LK@4W#Y;I&T+-5S8E8_ "M8_9F_T^,='KFA
M17\>=3B53ACG#+&H-;WR-P->:2<-R<K3,M>S:MK]YN.O?&&XN7FS6-D] S%!
M-3!1JK-U:V*">M+MM[@OKC\#BQ7($EFZD:*ZN24I@Y+NY*"LOI.4F=T0FO>R
M@N%T2 W6D"C$Z=FL3^Z<LH\87+XA9&[_1*C*/]TX?09N8FL120-F7_'&F"?4
M&^'5C^3G.LX-^G8HWM)BZ"+>V*IJ?'<HCXO!\$913P0RWL'!(F7 %;MN9V\5
M70X2]U<+$G/HU1 I6*9[R!'0:S#.=/S$<](SVU45\?K8DBN]_:=Q<<]/:07%
MHE)=*:$X> <ZYK=62@OH5.!,Z^1TWR[4L:HDI8 UN:?.,%-7T/]ZA'Z'[BFO
M%_:F)&MHFP@+I>3<D,=>2%T#8]OWI[HL=H_:S<;;##PO6D[%7&W[.G_:<G;;
M!PNND"=S+E'YT5A8-/4<W1E_T.E\# FT <;+4IM(*EF+4X:,A^C*QE]!=8TK
M_;^\,L/9/2BY8 ]P]$SY?ESES"EBF^OV:@#A.E5UM^[^>QGQWY=L?$H5!AK5
M*4/V$Q@01RL6='+Y<*^J:B2KNM"9>]U\O^SE4H+8U=5R*4DW0%<W4--B@;T-
MP8288J&>S C"C$*J CU;]TUL9E[TY.?'(2<YRB:6Y$%E;RW6/ARY"@",P,D3
M$2BE_U%5XJ$V_ZDJ*5=F<*Z>::R!QCV[:?*""SB,]G]+><1]: +AI ["<$9I
M,!?/Q.1 &F!-3!FU=I.MJ@_F?!+UPWS@R/=SX$D]N=\.'A/-KW%>5Q7I:H#@
M#)&)T$NX4U%S6I+M(@(_BY6*5*OXBCWVI,>=$\2O]BZ>MRF/GK00E11FOS4Q
M]F?=$"@:'B3>&1\J_46'U4A^'#OB.1\4E]!L9CU\M)./7S33!_*UNOKGA(T.
MG3.V'I,2393JX.9B!1@?,'*+'RT[D*:;L">QW!<<JRU/] NZ8*E4IS1</-!Y
M=(ZA6D=D0W">=&,*-4#G<Q:( R5!3Q+?.@W8O;_'& 6>3;O1!*Z<!_-J*N%!
M) 4FOVZ_)[MG/FXQLQ;_=O^::9MX4G]9T!F(?Y$8-D:HIZ2C,%^H7#JS2*(^
M'0%Y)PIO? ZK6P>[H5/*Y?JR'X>%]M?5^2Z&:V;\QX4KBU%$.6Q]YT]RBH..
M-:'HN1LNZ8#79SH,M0YY/+VH['\ ==C=F^[S_M/C<#V&!K"%82"GEF=P*; 6
M2<J;X/UL&,%S*G1C8'VJI@_NH;XDN7*5'XR[C3I0 $73@'U.&C"4-1(RUK9U
M(/%;A@9\I:<TL<$+,"=(! 37CSBFJ8+;(3E3.4'K,#K:M_6NHYQVZJ?2G&F
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M4!;@R.O_#7XL_B^7?U-I:QLAH)L0!V*_A6E *3U\Y=K7VXX1+^]1^ _UCM*
MKA8D$41]=Z8A)TYZ ?WK'W[]_UWE4P6=W7ZF5K$9T;T.9$)QM?\QF-H)NG^7
M6$A7=V?[#(&ICFZ,LI!LLT-!O"G5 /X*M<Y!SP-RK%&:1<L*QACCL5VP)%Z>
MLL-.Y3V(XC*!Z$.5_]';-OXI_UW%KJ %&2T0T\[.V?[PJ8@@7U=(;Q]*YO)2
MILAZ"/LR\^=,["TY'W_]U1:,FX.;'OMUS:'D<KTZ: ^5-_D6SH]0=I'+_=ZS
M\VB\GLA5\/Z0*EEZZH*I0>7/8IG*-;Z;//Y?92[K@J/TCB8U\I1X%M_W"T$,
M$5D;' .M Z]L=57MA-3L5].OXW% U-\3T/\/R*F_K-/PK)D&WVKZ7R]GVS;A
MGWJTF0_?#YOH>"%N_BT5A^Z07,E\%<0,',)DV*$L:B],A%\^9>D)9Y#7-8UC
MT[50.W2F#]H!DI1Z22N_[:N^<K?@VX?9D4("E*VD*^G*!AQV?-R.#U]?6V5"
M]AI/U<V*CX4WBJW:2W^M@*UKN<X9)CU\>?!,>3S H^6XW>"M\?FE-;OQ8,1#
MA&#V@](4"98Q,CK%X<U'/]]'B7D*Y9FG0S@@'^GLV!@YJ;MF5XYHRI8:D6AH
MC-,?,PC:OVS).5UQ>O+]D9MJO2H:WU;02^X&K-LV^F*QDVJ,NM>O@1+\^D_F
M/46G-<\MO?CRI7.Q#M%XW^)/^RS01L/C=!U4)#D,IH:RRKNTNI\LUV'Q1KDX
MJ4_9X/A,N*J92'3CW(#?AD:;/\?OE8#1R:B\<.[T4<=WIZZ*OA/S/4M56KAS
MZM0/BC1+?/ZKB"R5[75[.E H?KNHZ,[">5O?8//^_;=WS\N7M]( 30<:T*@#
M<HRA!M*I6^C_Q=Z;QT/]MHOC[U)DKRQ98BI$"64)628)227[;BHDA.QDS(2R
MAA#*-F4)68;LZ]C7(CLCVY!]F;&,8;;O]#SG.>=\GO.<YYS7[YSS^SSG^_W\
M<;U>O,RXK^V^EON^[NN*L$C)?3KC5W0^^MA];@>1!Y\_L,1I+[=!\XEZL(GG
MX.95CBS?>YA1"QQG8^PE?9&VLJ,B]WO.1MMYB:C/V!2IK,R=DK=U'VW5;U'K
MS?PB#WX*0NOH$D"S.0.>'<R8B27&P!-,92=J[N0KV/"?%1>V^=FI0N#:M\+H
MGG 4O#0J51Z@OZ+3L]J5E6Z6_32NMRUEN8<CL$T;@^!R;) =^33LE3*^R[P?
M%)J.,4[H-&*B7Q#>H:NW-<F[E_RIKJ_W"F%YSM%JF>O+:?H%P >#,H(_T U&
M88M@'*JE?BSV]W$<:KE:5XQ^2* G^:Z\^?:]2_3C_+Q)-[RX;VW.#2?3?G7J
MTK!$)W8CZ7+B>4^%9 SOAX#J)^.\MTL/'V(('D#IK1=FE%9$3'&:?@P_?.X,
M<#'P!2! +YYRPF!-:*H3*P$NU/U)L7W[BJOZ(ON0_J@X9CHBG0,KL6/\G J$
MR7X[MV#ZLHMK?>U^Z5EAET-C)Z6/]96[B03$E*1F<ODI">5LQ1,C]PT2N)Z+
M\>YP]CB]0YXQ^QAK%UX:JG],>2XWJ[8VI'URL2KA[*LKU?,//MC.Y1T,L,H+
M_!3=.[65V:V[(?73LN]5@QC!H'UT8'SI.27E\X_6=)LV>S_.K_EOI&]<.6,;
M2!@UN#?R0\\MN<ZJW4^;W$;*_?.:2UE&(;_Y_<,EF3_]QWM,^?W7#YB"]5&1
MMP>+D/9]\<X<7PGMWKG"NW,?D%>P#.L2L^SAJE<:L+VQ^-)<]!VL]L*^DKS8
MFU3GV!A2J<O4VP%70[N+;V=%>)7D2U:&C"0L+ ;+Q&W<\B 6#K04KR<O46[&
M=JN5+4$BY*/S9[2&EX.RS]6!7,]$4;:BK,/'A(*."<6NWAI];]T6(?Z*@,(E
MT13V"%3%J8 0LPZRK:[ACB4C>B;K,A6(&YD9@OOX/!@GU.I[@S3!V\JIA0(?
MFTN=J$0KUT\$"2&JUJ[=JE^IMBJR6\_;)HH3)Z-'(L3RY/^_O#KZKX R> :T
M%CB#')]KAUW&68?Z%ZS^NJ*RE;:>6O5H$_]DZV!ELX6).906^'1#]-%VA^JL
M!N>Q7R/N?FL(#7?(KO>&YZNCVRDC>!TS%H/"NIZSX<1\X-Y@T\SWH]U_M:JB
M;L0TVU-52=(U'$.PG,[$.OCNR+IY[\+<G5BA*M,)_B"9?+'.3D6#)KE(+/,,
M. 3^^%?;;6M&; YZ?M!Y(7%VPXM!J[HJ3K-'^77$YWM7<YMC$@R]OSV7^%NX
M_2=A"362,V3@\*=JA0]LR;1H[47&WZEL^#>5>IX)WW[=I<;Y8R!$^A_PI8I"
M6DIT4C5WYBOXQRH\!!(/EG^2$4&VI)SX_UO&OPL0[6=T27&N;+2T3I06T2(A
M'']5SH?S@,QTC.[8+Y]FI@)"3*@9^('A/7R$&#()_.QWQ_X?%9+[**J9!T-R
M<@A2@-9NGK_,;<CI #T=C*>K? N<2XM/-DXUP?-SA+3I.PN B<!,.5$/H03Z
MH @T,<Q",D?AN'51XJ<2IU*I=N5+PF]=/1:KD*$/TTRR]8TL%0TL(,C/8%7:
M)_F'J<#2*?]?<T<HG/!F^7PJ\%URCPH<FB:)[YR,V(679Y,0X=CI%2ZI@V-P
M CN)8WOS-TMID82>H\B'-^%86KK8C%(3RR2:0[H(H0>O="A!( H=S6J2B%3@
MI:L)%?A@M4FA0Q'TJ,"Q*205N%X[36* 8Y'?;XM11I*V8&<I'_5I'PJE(4,%
MFOXSZ(%_81<&SS5$+9VE C-@K&X?BJ"Y"S\X.D7[58D*O )AHU9H62US/15H
MI.563.0C&3'K#G!1#.@/BOZ@Z ^*_J#H#XK^H.@/BOZ@Z ^*_J#HOXLB=I:5
M]<8!Y*^&Q7]&+M_<E13 _C%KVT\$IMM!.92M"F0KYI(?KI*G":*+X=CV+XK7
M[F)!NVO_%D_-71!AUS67XA5KP(+1-YDGP6?X,,HJV9J6*#/77T,!@F !M,_]
M:Q:*_98*DR41+CAZ@*+;ND %[N?!OZO3F :?02#@?\5$\&^HX#I@U #]Z6O@
MH8N0G>-4  NB(3O]&_1B?BL66)">%KX,%8]CWV5*(A\!DQ@HC/M[O^5BYF]3
ME0]O]<B%4O,D=?*-;"J@QDZCX#]'$R?<26<??/P/DOX@Z0^2_B#I#Y+^(.G_
M>9)VE.7SX\ 8H^?P=5IDT)P*E2J@H7J.%M8<0M B*S[0;C\5J!-WT=UUWI%[
MN_U>@P2*(=%5A(8:YFN@"LI=-Y#;8'GX?Q2>C?XI<$J%_".$6O_W!8]_4/0'
M17]0] =%?U#T!T7_+D4F9=.AZ6+#8Q(YH;L7 BEG'6?AW$)TV\CZW*QM!\]0
MC*4O6P0,?[9\*6FE+Y'$191PXGM=TH?1>3M0>"WE"8^VDK^MG<EJXH')D#4]
MMB%IAGQ4=O)\OX2$S2-OI,@$W:6.?(X5>/:U<ED48<]U+V:+:\[FBI';B;VI
MM)CO!+A0DYT<>'QN4ZX@'4EAZ&[E0Q[,4P'O/*-)$[([O-8P/QG$I)*JB\OB
MU--XXO%[EW[]SY6$<07/Z1[R]<><CSF?@+DK.&I:#'W,_[;W<O</P<P$@Z9U
MBR&]$NF(N+*$?@*.:$CI.P4_5.<G45BSCSZ"NX&O5&2N^B+04]:YIOID?OX@
M0+Q5?"^T39![H,XNX\>R>5M4/?GM4F?_CQMQAQ+$J^B/V+/X=3PG+9'SP0_)
M6DT'"/QFX"7)7:N+,UV7\/=O#.HPO]?D.LESXS,P!Z1'3"4LZQ=E;_1XS&R?
MSC"TR%<WQ:]!7:+[:[Y<,68X^W8FV/HC=AN?3$C!-E^A#\:0;S#?"<8[C+L\
MXK'*9+Q8==KFPYK*4;_LGPGM""4UKR,5@Y+R6M*<#V-CW_@MWS<QN*UCL#"K
M[YDV@X:9@V"^[!0FN[",X-8&4$^(T@9E8B_P84R<DLME1E+^B">2(*;;8K$4
M;&D5$%6U#ZU-6E]WA208&K.ST_L;;A?8<J7H#H,^'\20./EGTY)+@K;7;[+,
M=5??P6T>]4-$P6<^55PM*B' 6R#.^FR/B?Y:P0BMB@WQ[8$(;L%CHFESYPN2
MK2-)?4\)4<0')#U"J-<S$=SC[!R' 3$U.[MSC1^]$QZ8"]\=[Q$,N+XFWHYT
M+?(23ZJJK4I<\6.T3[27_*K=)9Q>+4SQ.JISM*Y2O^!^Z_:MR9-REW1A095Z
M>N."*K>'Q96&XEV_1M3'XUW(J5YP-$.KC)J3Z+ALBB:CC]]+N%B9NS0TY.;C
MKCMN@XIRM)W\96]-,1^JZ00_3FAFC@+=C'[$W>WI*VEGZWN052Q=9NLJX"<D
M$ 6+)H@VHD5;^M@GGJ"YTYQSQIO#LBR:8WG-]$R^!D30*3))N_6*)Q9Z"0A5
M[_!ZZUU;-T1F^7O9@MA5!9Z F*$R;(&S]=<$9.Z&3ZEQFBD^5KRD<U)[O4L9
MN';(2H+3),5_I:_^M>')UT9Q3*0A6NJ28OGM5#N*->/V4FA+?]SG5G;"?A5R
MH(;41_M;.@O)&3M-CJ1E!\MWVSQGJ4"8K]DB,657:\FG!:,;O"9OBYB"+[5_
MI@*<D>R''5/NL6_4P$<-D;T"(/Q=PL]<AS<_S DAAI4!$R;KE2T\C]@/7_*B
MSQQ%V8&B#JSC588WPT3B1E1JOT]-G_[YXC1/R5 $THY_^MVB7P+<OF?7IQ).
M8*"E2D?&:M/AKZV%S![':?!=5[ 7I5BT01Y#X>1LDAR6?NJ;W./M<O'.KQ5X
MWP2?7"]]GP(7ABG15$]D!&HFF5<W<DJX:_[)--&-ZQFB#!GFQ<Y%&>3[HO(2
M_3517C[Q_O@Q<_>E^!\/CG1U O'M5U[/10P8#JW4KCU[B(MOMNM_1DAQPJET
M@PD7CX203Y"X*L:*OR+0]0R\<VOCN\@"U<-0OWY5%8)Y@,DM\E!%])M)"])B
MM_?UL1^=[U>TZ"KKH0$!N,&V2K3R@0&E#^\V?CN*-UR9]S)SU?%;_%CVK_X^
M!=-C+3HX5"CX246<*Y/C% B[4>[AH=+JFJ/K['JRX)3$R0<O7M _ Q0[ ,/N
M5$N+V],RF:Q12#[LR\4^7B6P]XAJ"&&3Z$:PG^7.EXRQ<297YM^XGL@N;1'P
MHKTHQ^W5VT7?):>.LDW"13IMOXK-)MC=!MT^<G[MZ]//)$J7]T=KH,X-!"5L
M3NMH@R3N<4J.D_6Y(2#<<S&H%Q/0=9+++OHNLE^(MXNXHA2Q[S2';#=K$/-E
M, Z]3E 33)EMVTHBNL^UG!>M$'27=DX3B*5[$;E92Y>;?>]RG/6R[U?-\V_G
MAVT+R_114P$E-/6)1#.T0U[RX4L_ZBZT>ZXBI%7B6%-O!R=I]$)+T0V7R='V
MW*BRRM?GV[T=DTX':(Q]AF-UE:I?H=KR7:_4)6%Q;S[=DY=Z=ZB#=(SBE4D\
ME>N*AK=]>*&%S^Y@R)FL^SQ_WR#BRL'7$H_FX<1U5./V-!J,;Q^&R5(!&XWL
MR&EV\_$N\;NL%1D_7>@N CQ'[J58%,%PI "IV5$2IP:4:Z:0_V92RUT_D:BL
MJ]^4'(5YF31S36-*TVL]AG97C>$S6>F@@;*[NHTZGY:]S7WC,$O@<8D!"2H@
MT2!3QC(GNHW,HP+V?8<)CVD.O",XIPJ[$*^\F35>VB7R^L[7NV6V<;>WM,^'
MWV9*AM9P:"9*FG:_B7+U,]^8_KB%6+?#%:I>H_2D\X\.ZE)Z&5I/4%9[M^$_
M$U:\QA#;?2I*M&!B/&5N*AY+A[>N'Y'*(%K]0&.#F%5ZTQ_Z/V'S"?O!<L2C
M<WU#O(JV;>.?X/FD&I'L:CGC%F-J9!1HHS##=)2B4J2K 7@)4\[7K5(89[%*
MVK@(1T%IW-%4\_KZTKY/+3:Y-^,;^>UJ0X\M:5Z/?7&V=N=3M95X?=&%B[BO
MAN<V50V1!V-K#7SP)NTR*L#A6S1Z=Y2D2(ZT][CTK'!T(CD@.\TP+=R%L5%X
M=SV">$%9YQ,J=&;T:*]G]6PT1A$O_S4F*-1%GF5#H+1/#FM"XHR?K0PA"7TB
MR!M]WW%B%?2/K W[Q,U=TB@L:&GK,O8AU7E.]#7"_"/.IRWY%8K$08O0L(R6
MV5-Y.0Y;T&^4O*<W&[V6:T3F<BK\>&O<DE]G9O=V^ZX0S(:SPZ"]3,MKST^U
MP@D75%]]6#D\T7)-%$^Z#7.@C(I4P(S WCH>/V()]O6&6!")L_;.B)QAY2A)
MGASSM+NCC^BA&T1_'9W8N-V9C\+JN@:G\R;-UC6(H08+O)RU].^CEM]HR,?^
M_'$/)6D@GO995U1)*SM #@,.$J3'W=0KG'ZU\S86]+R/#0&\>:8ISZD,;7];
M_]8B*O+CZ>9Z!0R7(;*P\&,?Z2DY2UD.J]M<XUV2I[THH/TSNO?T[0:G<W'3
MTNUCBT_FV>O3A[<6LJG 4; OTLI9^=2B18B2+65X(C8^FK4B0'P5%(V6>B$'
M8EO>0QT7+HZY.[#1,.Y2N>[";<;%\ZXC]?+$6]#;!ZE>R/?*6D0=WVL+)OVJ
MIZ!G0EM=&;=ZI$(>UE3&/SP;1E1.Q1Z/OG8\X(*!GM-L]:=KA<^]+N6+%46,
M/L4CQDOQE=^IP!.EVG5)<=VU^L<#A]R=H1TI4-CC9A^_6YE'.MK=?8A\;60:
MED]ODA%0![L/5U^1<T>Y&?T7 DJ[VI=%[MATP?=_IBZB;A,\9E46,AV(^@2_
MQ8&.D V$X>" U35F[W)#R-7IF$M;=  _0Y''5#TSA<G\#H*WC%[%HF6$%CO.
M: P[K=FLGUSJ4USPFF(R0-6?<IJ Q^X@UCF([@X@>N4[4)4<!\1$36'M(1\0
M6G"ZB_7DK5 )9G%;L$V[8M'T3.CZE8<X\5G![+EZ]S[*B1YF?BI0<DMYI&;E
M38)KG)QR6:.-PW+JP6-*'^C+9D@=\\P3\*Q0_R6OZ>.3#!8]4?H#XB%G=,Y_
ME6D%;4@'(S9>/Q/_"I_)Z#<C@&?NI60\>1Y0$?_0JW"BK'BL^6QX:+QBDV&C
M<GN:%C9&S4R$4>X8\OWR[2+)UR(1^2).#OS.$Y"O'3@$B;/OWB#RY7.&$'BY
M<].":V69(K_:$GY\Y19)O)K 0/1[@N*NTV,(W;TK3J3'>\9B7,M4VC%A_*X]
MAP,;/>+@H3],>E"EFZT0#NA5;!#<#BH,.5'X_:*78IV\1/^;2W&G&8V2%"1H
M>[2*P;&5,$:Y2L@K-%_!@YF\V%FF6OC:OV40W/WODCIU3KN(Q+SOZCO#?GMZ
M7(U849G6)Z@8??&"D0=JSP]NL/LYH@W[M-+ U^7;)M? _.:4\!'YZ:?VRCMM
MSB;I 756P\T18A\^_)O*6)0JRAE"N+!)NM#'M2)(1W!X:%?@&]U4EZ9EUO U
ML<)]+T167[GK5.9)[WRWD#.!V[!0H@ML''_5";-<5F]OAFU0I@)75YM>.'P#
M6>[W7P]U1;TG?+_;-VXNON6*J21Q3;>9HX*4N?QFE)1 [+[ORN>MA08W"V'#
MQRZ>(2H7*PK-.P^2<A:./G.__.T 3%0D+!H2WF.%&F'B(VC1X=TTP2G\\H>[
M8;:>+!,FQ5W+US>>2W#M\]K3=IHE(6D&&<57GQ-1N$-V;3:W6_CHXDD4UPC"
MN$=*6R!3XLO\,B2^!6^%-(I&=.).K7<1;0@CC,IFL]/L3GSL+Z-IGE*HF7ZA
M4Z.=L2J95Z;#F(5!- <X7$WDTH!Y4EI!6(,T=4Q'E"<5")WF='[J7)YVMY7/
MN/8A*%Z@=7&C1=GOK%F-^/E#"E;5BLC^1S>"M $V;5D6,>17*70IA:DM;UGP
MTI"R*-9QH/O)TT].#M"[_B#TT=87;V#?!+T3&%ZL5\G;M3-NJ_#C5\G%%-ZV
M4^%U-K.3)B;8AI_V ?!FS>[^-[L3RO?;@K1NF.Z</O%&S9(6DLX4@/A4S]"L
M> 94Z1-!MP,F@FU/DWKEO"%<UE\>&7G+VL#'-[M;<X692X._)%5,X!7LD^\C
M>T2+^9TOM=KBZ!M?-]Q-W_(*[\D1M(C>L %ST74]'*A95::_P$6V,J;EN"ED
M>4_X2D6-3GZ.IPD/6ZWM#7ZZLR$W4@.));/@?2Y/UX,M6LI\G?.P7-Z76V_:
M^X0^GPOZ^O49(* MNT+@H#"-$C4A) 6"0Q9)\;N+^:@>SKWSX'5_G,"EXR]L
M&"J3%QW DUH&>[F\[.NT#/ZH,S:GY9OUJAK!*;-C+NH&_07)$K<KD?<T!6[Z
MPQR*M>X;^8<X[K=+$<3[.G0<YH:*H'*SO+)=%H[MGCU9X25#0N1,Q9E=4=1I
MD^\([-WI,8L6/M&6 ! F-'I'*<"U%?WCT;9.Z5#&R9:'CGX1:ORLG[3IA5D\
MRF_;,'C#KV_*3MR]T:S#GV\J^31+5V+]TVME%]3D15\A=""(%]9#D_ZOTP2?
M$6?H%4S^H1E=+LLO;8XB5=M/D;;*1[1OZ4??NQRMV'DH'-,PC/Q*!=#3%$8S
M.(86<%=0SA(DV*(^.(R6E*[P&4WV3+2Y/N,/?7'QZO #V$RC?MVSZR O2M]S
M^QA/\$M!P0'*>5U[OSGQ8W<+)]=?+]C6& IK77CTV>?M1&VTA6@]G0IW!*$/
M/_7K"?<RHO3\!RAH-N :^TG?_5F..TGW--*3"Z1#'F3)5/.<NVSR\TPB[Z$&
MU6!\';F2I)/-SKUL;ETWQ>^UK5>@S,^9& .RZEZ83(L'M?)$7_M^"FSS!-D'
M'QND,+VB LR0MF3X"XK8,CY9*@R9Q8WG^Q9V9<*R]QXWK\TC:*5-XP/O1(7F
M>?O5&'0PA@V)S<'#<7V190PA*C9:@^DKPSDQ7Z_/Q-35=\@>6N$TF6=_0=/5
M(A3G&>QFF(2<,_L]'#C2U;8B5,U4@L48O[\-78@]4=G=^N[P!W'2S4H>!541
M<A7J*3)T(_TL3N53R<<E=X5QP9*9^?(O3^>8A)]P];J#?W[R6[UN24Y%7B%_
M4I68)#$2>#$H05-3]<]62]^UI,TMJV_]G)365!.*;8FWODMDA?VX!E]W^ A9
M1B>\O'8J>B?LY6@%]]<[IX['G>H+=KO$>86I6_NBF9]2?AM\)A]U@B+^Y+EL
M.A=V(]C'#]MCV&\3;S4L-&";S.^@T8_FFV<MX:B09-Q0><*ADH\_02Z1BT&O
M:N->+13.KDJQI['Y/['144R'R'\S8Q3UN?,4E!:@"PF:_G*JW34&PE36QZ&!
MM6].H@B7UR<S#"7WM&P[/A(U<N,Y?]G;5@;[? Z-LFHX0KI)",: QF^,ME'
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M/10F#UP/!OP"[JA3+]H".JYL,/M-PC-%\6AT;*$ENE$@V,4YMLHR?9'K@ I
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M[+'_FL)AIA.V6%%S*R8Q7A8A<SN8WUVF%Y [B-7@/+2?0TL*),DQ%$G8=[!
MF=0)7X9FR 1:I3)DICAQD7B[=^+IJI>7T/GQ3YH*9O?G6:"3[JRPJ"5N7:?9
MR6L#"Y>%HT<4LJ.*&X^_N+RCLJH9 9!RR335G4F@7!B .GA@J$!@%]=(RJ5I
M)PA[X0!ZTF%K8Y(2)92@_V(K\YG=#.L8?54:> :\WH:+:X+R(AU5SQ=CY_/G
M)^]B6!\^K+QR<-OH=:E4,?L.<@PMQ@R*@@O 9Q+ '%")?%\G78+S1U34TU&-
MJ/( JW)F'8UX/9E>6\,(AX0$;JDS;,=4/.*NDU]BU[,J5$&#$CE6\>I.G"[5
M#"S'#TLKK)K3Q&]87L^ABY.,\<]:&;GO>,UN3<+5P\&#)^Y"YL,08X.F(Z>-
MT&*\^P]QVQ3&*Y@85M]T" >4953]^I>4,%FGB19GO\?[G1;^Z72'OKN*-=I<
MZCA?M^$:!*\LJN;]7H14=AD9@&'4P1$9IMW1;,NP_FT6MFJE^FW(%\_[=V.^
MZ8[;4!@O3_'C!! 1#=*.W-=J)VZ)AK9<91E4$]JE7S&F\V4H<&1*EVZUTUW6
M/]?^^?-'(\W#N8UT XD1]% 5H@^\Z=HC<D:Y%JXOL*C0$RZP[YB4..JGXZQW
M_^@-R\,V;\68^(]<9F+[X8)\6]  HDQ-L0Z:-'.SSG$.SND=T62]-V5WDQ<0
MZ7MW&[CVL)W^V@.3-2_.HS'?X&,3%,97!03[#F[X<8KL-U>O/'0??D*77>N9
MY+L?&S_.U[RULPSI>:K?F,K]U$X7#2J'!^ZBPB&E23$DJ=E:J74)'\-!P:G>
MT6^WZL89>?@G$[3N905:EV@<LIFA @21OK4>G#C>@PJ\HB5<S.PM<&P,_"EM
M P2$DJ^A%WNW&D87X'FQ^+EO,9LV2E6];*I8FM\BM1!LB'RDA]@]$J?J-L;E
MXRQ[*4%0]Y3C0<8* NWMG.*0/-]*T?]JN_\RO/W'ZRUZ5E@$Z3X!G@,U(7AA
M=!D<VT9U1R^=+TF\12$]''JQ2AE(O;QWN.:Y&!WN,SM!=&\=@F5OJUS'MJ\X
MA8G2GQ^&*B);'DB>8[@H$NU@\W2OG8<N57!QQW4&])(B,D'IK&@ $>+QM:CP
MD\OHU%-!!P=*>6GSR7.=K-*U9\D3-P]--C8J-'74ZUTW)=%B]J GO^8-G0+;
M;T:C-\/J F:EU@0$%UL\QC0\R-D.'C7>->5>=XN_KDF7*';QS!7=0@YTBWU@
M?XMR<1VSN4/.+W.R@FA7!]\D!']2GT=#>MEC?=AT_#AF3@(B$55'\A[/!'<T
M3ITD(\#.\$!7<(CR60>,L_P]'^>2Y6L%)\?B[NE\LKW J^+QRM7:"9],,Q7S
M7GNDDYN8CC 8%V&P/5VZ(;X-<DIJY,>RN=CP26WYE'?091>7[&>OFT^(,?$@
M UIGV//A,^_A0)T?414JAC..FB,S$^GTZT<:1EW9)R0V?-KF-5,JU84"M\59
M.-*OF8R]O<\-EJ 9@(^($M=V2#2\S&XT0OG$S.9Z/>-.CX57#67H2^77,/YG
MXY<Z?]AZO#99^5,,C !C#>#CQ#G(.C\&P>!@?1@;O*K*U>\L4I6X2M3O'=/V
M$W>VHWVEXY'F.X6.31ZVW0-6#< /M3:-_00. ATF<<TD:)CM%%Z3K;WP6FX0
MMN7-LYOP8V]U:#2+EH# C*'ZY'!565]V_%@U(05;VY1ICAUZOG-MM[8E;]S"
M9<I8YYUR]6--H/1V&H!N.>)-',5GD%-VI-#QLW>G7\KE072KS8Y.I>6U!TYU
M_U1C(GIL7V#I[HE]<^^8@M!H[H=+,#E36#>B0FJM-&]Z#*J29% U()D:[S:;
M=N-"H0O[W86I&[P0GOW7#_!',)644S1_< TF3_F.XG FF>'0^-4[ U_#]N)6
MDE8]<JUOYI!O:O/+QV79VD6L]]Y()GMGO"CI)92V++B&/N\-SS+/2!KX]*6T
M/.98YN4OFL$*@*=@$$H%/I,,+J$";7TT'E;48J1 OCI$!JUJ[ _\"4LJX&!N
MN9%65&AE\%1&B:7@GKNFPFJ<^,Z7"  +F6# :V-I+M .>Z!R$?\PVS?^KM35
MF(*7/YPG7TSRQV#"\46S0USZBCS@9#ZIM6SB(]BWYS]_A@86EE<Y2PHOS+68
MI[J;60D&HJ\^#(Z6.7>!9P>)3J99ZGAK09KN.T,?$VJS":4=8%ZOR'J=-IN;
MM7SG0U5S*T\EF4RIDQ-$WJ$26![=>"GVU-LY6!$/(8C0LO]*'!CO@V-H94:$
M6?-2@9<P >.17J6KQ(#"ON3.K22>$!.A0TE%UW"0#YSWQ6E!H-I_.9ZX]Z=7
MW5?_G-8"R[D9$<?^;MW-7Y4?FFA;3K<B]D4;:-@7.W=0(AW1,3BAE6B6%G)O
M)<%N7V;;.T(,.=PW>_QOU%4=)JD*#KN<TWXT*"42WFXT,-DI-'3\HBY!4PYQ
M<&2:MI%D:,8R8!>K1-$^]0J\VGQMPVG^L_V7'$7U\;5U%(ENKPX48EABZF@:
M&N&4?F$BP<$3L0UZC\"^=@+O,**H0*,]%6"R33\]_#$J*UZG_N9UL_>%/P &
M_7OB.^B(/B(,LKV)HP(OO*A JWCF( \5P!ZET09*DC59-@E3/O7!M^A\C&G_
M6OEQMVW+ZP4M I?'.E?\&*J1 .$]$83^QE+9P%3EY-<!'O>)<]'$:[.?(5Z%
M9=1B]R>9D(D9/TEZ6]7(D/U$)K:BDXY?K$[^3.JRRMGR67N_E<UE;S HN>._
MOX8LG"^K"^S68>DVB@U]Q&J,S+@KYPG3$:N2YQ67Y?(>51]"?N2P<-@S.7$Z
M4/B^S 72]<]&>Z)K""H@[-)!:: %,-]7>SLP4VQ)9;</Q@ZFN#LS6Q46@Q/N
MZ6ATXQN^B;O4(D[!FZ_\:G!TG@K\N<.1-$HO?VNAN*>4(7JQSKG'I7Z3HI77
M]D.<C1=_.B%-U^%;37FU'W1JCR;N^N#MQORKYD8;F75HLSY/#OZZ=^_QBY^>
M72P/^$:4("@0+&:MLH>Z*C9-/*#[I]<43#L&G[!2 3JY11M<Y%$=M/EZK>D!
MY=3LOIN@W*S?_KGX>._Z&LE\;RH@@WFOK)BOSJ]]/NEYV(M2&8LJ@"TKU3@
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MB7#H,0S,12(K-)/_?TI!]D\0,&T"R/5O,>P$S#S:\V<KF)^8%'D@9[C1G\#
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M"W)0KS7>$)0>36:%+B&E:LCQ6T@)J@<#XT[4'H\JE@P,5(E_1'Q+0E9L96;
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MZZPQ8)2,,2 I'Z?(V7"FID0G8.#3&/ME+3^GALC9M-M5[3?/Z*]]ZUNVH0R
MP5/4,7;0?7!Q#L741<_^YNG[9,1O'M%+R\  CE _AXE7.8T$&)Z<BEEXAQM!
M%I5QR[GSANW@1TNVG^0.)'TL(JO&S:)SI'08N%G/$/EQ.G82!F(K7'(K69&%
MAJ/XT($Q]@N1'QM?WF6,Y[$'?JPXN\]^QBQM_;'BS&+C6@R_]!_JTWD17U,+
MGL0'<);]7"PY%G$7"-E+N$"*3\2/ *V)D%O<YK=$:1-D.B&)N1B#K"S/]6!
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MR<R3F ;6$4C\2 EV@;\=!JB2@I J5JQ1S=*[1*=DWOT ):8]BB:)>:Y*;(_
MA6>%D;.0 LD#VT_H#"^.YJ<&!<>>C9^,OVL7LL>"["- KR$S9Z:,($5W,\XG
ME4/'_$')UPFV.A,*/&D9]>OW^>_4%?DH%/KXOLN:HC.Q.;TZWB]R.^UF<Q<V
M#K$GHD1]$F03XRVLTD13T\;E#CW:7YXA'**M:RT;6Q@W'UB*1(K@(PZ18B5_
M?.#>D\3ORCW9,<YVNP8'VZ?.$SX$^_ ZIO-6O[NE>LF-S#YFZ4D9WT*"@7X5
M%-NMZ$AL@5^'P;9"#5WK'@81#*=]?O!RX,;3&-FYLVHN/5TM$] ^%Q\-FB5!
MT<SRC.=H9RGS-";4>5M<ZM,-;+F#)7>C"R>;0,OZH#S>4@_>JQ];IQ;%7]]+
M/_?E;FS@"^"M8VY[M%SI>'KU*Q,GJV1A^D.V( ]O]$VJDM?7<>.K][3M5"?[
MM%\O6?[4*\)OH]"5\BWG<OTLF@))'?-@-R('=/XKEZ'^<)7@7Z(.D1Z<+/DV
M)>$SU&["3IG;G0$#IX:OO[@XID++N=72_L0%!@8)SZ'=O6F?<_%W@@Y?//9Q
MPR]GB3-O9V<</"9?Q.9_H*]'B_5&.LWFHVV/#@9TG2!D5+3=0U6GAM?*8<?N
M([.O@*$WM4%NJ91J%Q1N:;?G=7I&&9]ZA=U R<Y30\N]K8Z_#2ES\:H/@;WU
MLYA+A.>OIZ1BXR4P>7]M:H%E=USDH"=N, #Q((JZ,F5(>2]X<^ DIH#T%P\[
MB-2.:#X8>&M.@8''5) V\1M#K;0HD3]>AQF4MNRK1;%7BT>?;+].PP0Z]=QL
MW174R5RR?15RG<?;>3\/<+Y>U3=5699T[] 5/[]QO)U):DI+F/'LGJY%-^]'
M?6MP=K>HLX-[WI!L=*YI6][]Y*.E;_#+3."+ZT=6M/JX#5HE):TV$!#J2-DV
M<$C_H)&?2P169%O(XN7QW\PM<U'6&;9Q$WK_I,FET6 [=SO1^/PS@XN;C$(Z
MAFS)HB,BAD2?FH-T&[_XHS,%]>FU)^H5ZPY^*AF,O"9!LNJR_(&^!;U5K@?S
MGX8C3FWM3>L\IV.JN)2CY</?$H<.INU-2=-?-D!_A8%G7ZF&G)6(U&?S>B&U
MN0X,;'C=3V*N1H0^71!1VY*D@'&2'&O+N@[.6#=8KEY/B<#0^?ZK5\;]X<(!
M1/^)HR$K)'!E?\OA..L<SKH!DB]Y^YY@G6@JOB:R9FF\T=E^76"^&27/;2C+
MI5"T<#U)T"<QN>0DZ<C7KSGMQVL_A);<M)#4-%D*C [$U*YV$WQ<=))>.=!M
M;9\P@;5I;M[ZD8)5%I7T_V(A67V*A(XMW/<BQD0E2[3]]=S6B_=D5N@;E+;<
M#W\XS7%#&;LX+C4U):A=<B];?A3B'*X=?$?79<Q6=(?3C)L[K<<(:ND3.!"C
M<"!+\0T/X8#[7G\4&&R$SZ)&B0ZV5-T/=38T)[!G\+[/:"C5LLJ7]T0Q%2A(
MK9R5-[D42[>WY]&4S-_=''!3-M5R??=2]V/W.7?#%8,PT*5<NG78OTQY5[O>
MW.8Q7:D3)55C-T.,'DY4NT[[,<[X[1W.,3J93S&$##;+E>/FA07.G]";#W""
M@:K(P%DQ^J0I_4E*=EQZ7^%TY3F]\@<*RSH:?.@HM\B(DEB_9>FM);(5QM+S
M)JW)-_<I9[T;D4FQZZ$8($I*YZ\]-O@?-^[#]G],^T\?MEM61 Q+;J.V)23W
M["+86_+42I6N<$@^?'\=#^8Y:0,R1TE4 H<GB\2B"<* 1')I0XJ!?.GQPW49
M%S>O3-WIFQS;F4=)FCYJZ ^6&=(UH">=[1RZ#PP$_=AY@QU ,7EML<N#*.BD
M&5&O')1&.W-N5H/C4C*9C>;R/YVAP58$GX+C$FE@WW.0/HWZ<;[@HO]>)#,_
MCVY6<R'_=)S:"FU"CCU"J@C\3L2[3 _M3>P 3-O^!,A3ROV2Z&#?;\[XN8^+
M*AIS2"5H](G(7.O[7W!"HX6&^E+&=8'K M<%K@M<%[@N<%W@NL!UX7=TP:09
M'!KWV.!B^>O++EFS3.AGUIW-?I,6'-1P%M'^-A:>Y2?R3[_1&51YKRC5*W4R
M>C'QQRT!#XWY5+\Y4U+G<DESZ9>\>SD"[B5_*'5_\\E9(E2C,(GK=0%8H1'A
MQ,@'A]PD_PO]S2+] %*'^I<>):X+7!>X+G!=X+K =>%_YL*O7B0@1<=Q4E6D
MTE,?3ML"8YQS&/:C3-.E$JKM3E1'Q*PTBC;[8R5/W7?]@7S*Z>CWPKZ?7-0O
M&+V*:TTD;?[YUE8<M(U2BED0:*/,EB-VR,QH:8;8" RD&FMS5IU;BI"KH RD
ML*5AX-2T+<3^45%8_<;$A MA^ ;TT0*SL$FXT^H__0Q"TB FV(=9\0(&&LYI
M6\<6F/YTG&X# VN1@R=-8("R$09HG>B$YY Z:G*S'@R<WJ3ZWH]F_]MS,#_W
M\X<K6T&N(UQ'N(YP'>$ZPG7D[^)(569]IV.)B5=R[>ZE*.)@;O87U'*)S8(=
M;WFGH9\\NOG=Q&;F4]7.=3QV2S=:4+?\/L=ORRPZD>EVXFX-;^"CLM8 XNU6
M:+I6N:4)6?9[*+V8+P9F?]D[%T0J]5C#3W^WC<0<AH%'2?H]AAP',/]J<@PU
M;K\V[9V(CIJ5X^^^U^]O-($_O+ME3^[!7"C^RY_]Y3.$]]7H=<Q7+3IJ#XCG
M_KNO\HGVHR15##E)Z15QQ1V>Q?=");89H!JN>VB2K&CVSV]2R3[V3GO/<[Y:
MUNBQ+[OHLS5%Y\QZ6LADO6N71S7C':5S)[Y>UF2/[W[Y4$(2W&A[S,WIP]=V
MH56HJ:!AUHI0NF'[MLNO[6._OVP[EBA-)I_>)GBCFQ6=-8P!5.1@ &7"GIRT
MMR?6=C$$61.%L4]^;$83TS9J2ENL/3"IG6^VM+SIU3<WRYQE"35<<+KUD7'E
MPE[B_4.*F<^.G?C\H(%P\R"XC2508#@$ ]Y\5;:D8J+<"GO')WWTK5 <U635
MU_K'O7)0;=MH8P+.M&\#;:6+T!..(8-ON9/>5#=CAI[A3W$^5,^?&IPSD2IP
M^D=?^"9I+G%E;2:11CHJUS\)]C\H4^@__793BIK(E7^)]P9_S_<%_^D:=R/"
MOVO7>/W1JG3>DFTIW_,JG_>3*0&#YZ7\C#N/C/>:9#?7GS6S]RG0BG<A7_#7
M:R3UMZ1:?#&>[CX\[,3;$-0_K_ONS:<[09%#DM9[@N/51/3%O/\>R?7/V_ZW
M1=1#Z#AF2^'K>(4@=&(E'1F<72D5X)+ &V1)4V0L8]\2Q3##82XDJ*09'-]#
M04^..VCWU[<O8*1I<ARF#QWS8S>+AQB=_KMCYK;_=4U_>HM9BXI2HH;[>W.M
M6\ZHGI>;2Y@HG2F7Y*-7FFR^YER^.AS/>X>07L3/=O"I_))W.6VD<_)+[IF"
MW4U/JG0Z?'0ISX=VN#_[MV\.H!R;LD\_6O/MP/0>6_=7VS5%$N]_*1[>1&_O
MHZQEWT(15#;<2)75C[@67V[;N/O:&M3%.=7G)$+M03_/I5\Z(-X%P566S5_?
M47/"W8(-M?/FY[&$WH<_5T8I53ZEA,)R&-AV^L<7DQ[\O1G^K39.:4MH,6!Y
M-"^DKOVW/]/77QYGWHWK)R8%(JN-V,+I_]873XA&#<K?$Q2P"H\(*^&T%EC0
MB 5N^SB:Q6PKGL\0FIXR[1:6[<V/GVD7UO9J.X/6H>^M9_,5Y&LU6[8IRMF*
M6_2IEOMO$W1XP-!SDC_C87HEIR 7/#SHNDW#7O?R)3=R,8K/(Y8Y9A[E\)+A
MV:?:37@%\3V @95'A7.GW 0(O#Z9[JK*WVZ*NY3R3+A_7):1H:4LZ)S^@RO&
MT,[&'31)7]?WW82>:^IZ)T:T[TCV]T.B,6H [D&2];RULG=M6/54=*]Z8'OW
M=L-DW J:418EM\$2I^'(FL1%\SR95QA\BZ*O6WQ'YPR<M4LTM6W8(Y6S4MR3
M5Q-@:#(3*]EK"C(NMB0T*8K;=MWI4"WPET+==V1<N5SY;4%_ X^Q3[FR?'3\
M/=#)<>O](U$)><3[#A@^RNG_'NC_8^V/M=&QJ"W,%J8?\#TQUF_M?_@.TM_S
M%P3^Z1HI&[\*H;.'.HND'<ZV19JB1P95!M(\[@-._OC>L';2%D5HO0>HC@\N
MILP=3(%X82#^W*Q5K!_#<?FO6DRTM[=;Z-*\ESXCE97MK55UM&[3)@U=(RIO
MH:5+1H6)O6?!28^TB69_=_X3RU_H5:J>3[I#3O&TM(_5?[8/ZIRMF#;11AM^
M;(@#%^P.'#\I(A   WV@8W.VW+8P4<51YX'[CN6%1[62%C$!F+OV*UT<#,G-
MM6//+?4\VW2\GZ*6NP,X5S==VTXAQZ[;JM'_Z/:4J7X)QB<$C,)EO76QUZ==
M?OM2&1WEF-1#EA(W"@@DZ 5Y==/,_7FG,FCJ@ZO#</L'SG\1=+\;" .XURM0
M80[N)I_HVLX31LHF5]T8^6#P N89:%>_=B)TE\GG\$0K[Z#UU:O+M1;EGK%?
MM.?3G<N9VOZ9WQ8W;-$AMTP1GRAF/BE&^S2P)&WG%2HH@@6:_<9M\J!:05--
MI'2]V%PW#'P:&K$O;ND%Z($DW-'V6ZU'Y=JR7VS<_32R0AD&G-IC4(D3:U5:
MU0M",QO#KGT*.S]_!4S&7$E,%Q_@K8A2&%SVUM/_@++,"WA.VA_UJ4$S8$BU
M99$W9WF5P&A^Z"4SE.*)"Y&1MU,;A[ B%.MI_@%MO[[3+4?3U.<&;F@6U-@K
MW!%_RWBUG7:-P#Z.\<:,KTB%@6$%Z$"!XQ)2@X4T8S@N73 @;:[7W[?*%KO1
M*:OI(;\">6*#^(6=\[J8,+?(_!7,]E4IERY5H+0T>'S"MK80;0NUT\&!7/9>
M&#BU 2GP=H(T)U(,OA._HG7/>=+-UH<.E]>3CU73@CQNW;%G/RJR@X%GNO0$
M&#A#AJ[*@_3I!]%'Z1:#1)\0]6BIQGL/2W;*;4_G.3?LQ#=Q(71J@V1;<BNI
M.-ZSY.KR#7G<:Z;90)^P-?I TU#+0S/U/KU/^%5M3;P $W5VRE4T ?NJ;SU:
MUA;+A],22'E7UVN\XUI'!GYB5&4N%:,B&4O1Q"D,GL1L<7&\W):YW&?IL5);
M3/74C4C4?8>UBVORK/7U5;518EXN!A'.%UM^O&19=X+DCQ)=(#V5%/<W;+T1
M/;(GQ]0E;3K[M<1S&95?#JZ,)":DN0K^A+)KJ9U&6:HGI.*45CWM&J?:AYT>
MJG^Q!A-R%P:* G%CUT3E-#43B5K>-=^OQHFUF&0L4 9D*FIEA@2>."9;W[]F
MPN_N9;]_BZES4N=6U(M@3\%QVUS2,\I-&! G"++/YS:\_T4^F[RF=?U]%?I<
M%2/I%X_SI%S;]R\80X]<Z-7\@L8E=@URPI^+Y,A4C+>BJMN$V#WYJ9U'5*X,
MN:_X=OM);_9D/6B%84CU*L  :3-T,S/TT]W1>%'E8/^)QI$^:C<D @-OUV3
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MF;TXY[)%LO=7_KLQ.0DM#*<G.%7\&ZU(>4EPJ1CD]4;$;\.;<:OQ =[.TQX
MCKZZUIXB 56E6[L^AO[,+XMRAVR]F9BEV=((.NB8KV?*(>+&S.<,!=]_#PS<
MI.HJ@"0%^!(10#I+;#A&6;5*)&5D.\=X:YQSY?IW2AL2P+L4'GX(&]KLIV%G
MBYF9RG*)EAC178!.\Q+5GY, 1RA'?+0W8ZC?O4*O?CU3J6>E*=K-?!;7GD9W
M*NL.^.SMD'6=^P?D#%-#5(J=F"9_!WB$<L:'N/:ZZMG].MP8=2NUM<O1XL6
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M%.;.KM;[Y5OFU&S&%78EY5Q;933O$GT\/QVE[4)9RZQM'TBL!0:#FT-/[WI
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M_51>G00_1C__<% 52DMG/@,TPN]AZ]"\'9 K1ZHA T4I4_?>MQ:T,HN(KGW
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M!:'KXU-DW(/;](IYNDO7I^4'RW5[XUP;(1T2TN5P;)60X;2K&]NWDN&$LWV
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M?NT\<N/NUW5;T/HW:0IT B5,MV$!#DDV6[@8:JO5H"4:'6\U;L'F#< )$RS
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M3F=Z+C7=$0OZS(LW!V9Y";Y7<RKPXC>RT+J-B6Z:>S5^S. 6 _>X&?@-[3"
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M,QO,F"<',?(,PP4E20WN8KQO"3[U5.) \N1ZA9_U#2GQK2 @30?VIH)\AVO
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MM#A!!U:0QWZJ9-(?]"]0J>1_A))^JD7K]'.5G T=#..YXT\WX+10UUN&^([
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M^VBMYW&>BNXQ6IMSRL!6CI]:^?;#5 UUQ76*OJR4*<E_WL>9]OK0IN/1$1&
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MT)'\G4\4&ST.NY6X]>$+%^'C%6CX^OF76JCV[[?D\BON_%8C)J,>^W%_O->
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MF+LJ]5=76[CZR\KKU7;BQ1>>>-Z7^FH\)9,A/]H__0%Q?>]FKZM^M_A:DK&
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MBKD?/!,@PE!/:]U3!LXM9B$K0.Y?8#Z8NS[>D+_ ?-\T9.48#(Y]S)@H7 S
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MCILUY.9,Z08_>LH1C9-(?LK!BFCEL7%I6PLX&?< %7(],'4I*[KL.)/;L?2
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MQ!1E"/)WM3D>]+8&P??:) NO?*.B7//ZP"RV.KV#+*0O\($O: _T/J_:%08
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M[*9W9*W==&M?RV,%LVXK'V=*V!SP>4<K*E)X)/0%;%C1UJ%0&7 [\IGWZ F
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M>++5F_XY:!!<(0%6G0Y(@"FM*>3J'/F3!,!].NT.OX/X#J:319+#J8$</PD
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M[K+P>#'\%C7;R^WMV4IH7DN*7\I$^KE\VQ,VE0P7<R^&AQ[V@DH26J.<:C3
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M7-*'B]T!'W3(B9Y9=ONK-$HA7A)RZBU) $I8NXDR=YQ?>L*E8.D'K(]\6TD
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M=J+ZK4$LI++:3RNB2"LOX].=7)W.;-]X=E6Z'G]<=BR&[XCMMT/OTE\J!7%
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M8C4^LLAP.Y5S^_'&L97V_D=L5_P 45<(F@C_\7>Q@;FQHT5IEW=:C1[%Y/3
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M5/DU#JC@'F1V"DM%6G! =Z<AZWL > 1";4G\'P<';-V(Q+?"ER!?GZ+IW#D
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M*%/7<W0'+1N(EKC*G9:NRE3WSZ^TNS/'>+S*#UB?&_,/%/BQ&K7  <TD(4<
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M2VZ(EQ4&H280>GS6G/]0TC,N R4[A]T3V%Q6V[G$S_BI92+!BL5-%=<!?:F
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MU200%R8UVQ8%BB04<A-NHO.;-?#2A$8Q):%27]F<@S9;]K>>GY(LH,28YL/
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M9ZCX9?>%I"*S<'_X6L /J^O[=@, _1MQT4CNDPWF@ _>6C$E'5?37PG]91.
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M^O1D?'W5R+5EM(9!DV?QGP@6;LK-N9FD])!JYU].3MGUW40 QP#*OS.Y<NZ
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MI%J.$@P8$9'\)==- W_EYVW2-2B=7S,\AL+(AT^@)PI?2WQU59YY7QH&;L/
MD*92JU1DGA$K_T<WX,^*WSDD(KJ3Z:H&#;TU:,U&\FM+3+O"O7.U+2_H,!"
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MS/=L9Q6=OE0J 5;CK$I_I19MOX]C,5#'#DKR*K5,+/[O9K+.5T4$_@?T#-O
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M1YZ!@S;G&C\/1M#V)D3ZR7"D_.C30?^LD,$7XB?W6,+ 3#U#5]6:K@X=U\!
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M3W%5FI_4VW4U/[K/_ZSX=H#6YR51Y.<%]\$ 8X@E;5(9G:6B5-PY*3^,F2F
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M%^$/ZXD#2#WFS" <XMX_'\+WX<-Y&2A:,J0F>0\<%96?)%5SY<@75EW1*_9
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MBQ:(7GE*#<S=3C=XQSX$AF0YG[UC0Y/P!*;RKV*X6'C2I\#6!>BT.)(&#<'
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M:2ML&/"1:1?;+DV4F ^MO.1B-]I#+8+X2!]4]FIDW"U[U89*P],>]D9PFL*
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MPI%;R<8E]ZR3-Y>I/"(OPC(^VNAW@,D0EX&#'.$&3AY\E@C\WM)PD19?&&2
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MX":1SASH33\.V63@ZNQLYZAF3\4W@:Q>PY+=ZZ.[UZIKPVUJ@]E%EI7?1.0
M@,\ 2'82DGQ#,I@,7##K$IK3L!+6"U->4>\X^7DTG8BO0V9-5$.,@^@_%>+Y
M#X<LQT&6$]67U97#)24$ZFS2#W:H4UX>GT ^?TH!\,M&4@#;OX"DR\4K>'S'
M/[=-=SJI92KQSA<I3?U+6=Y-1?A+^.3"@2>?^#_VD@N\:R)R8$ %I[RXH26D
M8<^W[ @LA/,?IX3^/8/D0.)?LDR:!MV&%178#Q1ZL$T40((_QH'4@-BTE#FM
MA.8N5*\3TUHCP;NCU$5V"?DS=92.*+M-5@]80$E"#L'J"+M89N0'.)W3[:2Y
M>\D*$U+PR\T(3!]S<X+1Z-?QHX&!B\&?);X&"- 02O(@&RXHT)0A2M01+CU&
M%/:_IA-D>T>F;'D$==LKA[0B3,:QG>B^PGVH,T*\VK!9'=(%?9R_\7L/)HW<
MDE=#[31^KXN?,>('2=TQ)!:%!=D07(GLF0.F?."1TL@I*]K(IZ:3I*<YJUIZ
MX+ W%R G;\C'L"SK<=&(7-8XU'C^YL\N*I?G<>4ONI'L=TWT6Y_P;^-\9;6@
MQ"7$%+S''*=30 $X_]'-"9APG92\/=##^?)EB.9A#(!++(0K+0EPX309!6T'
ML\*$QL.2/_BL!5MFW3B0S)Q?9-S K6]X=-2QO15[Y)I[+)O!U28TW#.LQE;_
MYO\XT?_OI_X@D[>W@&\I@ /(77?\V@+^JK&,G[P([/&V8W;$C]W_*,=> 8BE
M&OGC1#35TOM_O=]A0E>2M=G#*  HS2DW=4EP IU>IO:^1R5G;*^4T@HM-T[0
M\V;]S^K#:C6N 1*5FB93]&=*?TV)C99C\_0G92*#:#0;QR32!=@QR;80J/*Q
M, T&^1F\Y(9K)8=Z(Q:HX@GE<M4* Z]&N>88CA4TJ<J9SGU_@]_E<5A@:^PL
M=HQ*Y @RBX.JP7]-Q )#W84]PS(Q$:_?%$F?KA\@KZ"30X]!7%N%]C9,_'))
M?@S/=;9Z\/[($MB#K[,X%]7*47&-/=><<XRW34_L]O0@RV9+B_N#5DYBIH?
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M]T#-7ON3J$&LE$RQL<_60&*6*6X?>S+F>UE)!WK!\6+>XRV-V?U5%GF'AFZ
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M:U5!;S*+_=?X*\<V]UK -&30NC2S_"8#_CBA=WT5VW=I"178?O P'R^+U=^
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MVDRWE&ZUF.@:_W>B:9,UU7ND^J^>:O:[3.8?(>^AZ"_$F[6=R4.*#[*D?I"
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M[CS;NCCW)=O7I5,AP1!3+(UU8'F9T^IZUY\.8]I(?\J1S,L=[_^.J&]KK#S
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M_AL.("L'(HENWG/=KK:#<]$%1ZX$[$?? 4GYN6'9=B>CY\JC]U2STRO9B23
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MIY"!%<E*Q1/V!@+O7<)<1M,)G0B_S<GT7>DEMWN?*RSLU%FW[[,9%@, 93O
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MQJ+9) _LRD#Y?<>,+_M&MXE8JADU?R[ZH0X_&6Q4&@4V+:7@@I/ )9FQBR2
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M$0H7(%W!#JE6)6_H5C8,)VC&?S=4+=$07/![T-NTWO/A0%Z_%7.Z3BZ7](Z
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M/_B"]FU%[2H+_5&+-/-.[[IS, LL%B?%=M*&" 2A?.#W)I_\HUVU])<ID52
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M.<:;?KXXQA'/0V'06%<Q5*\51)(8H 2OU#G&40'OS25=1M9U#C-W"4D]OB+
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M]O@%;GI!^6T&R#)ZIS"[MQ5_"&[9_WGI"D)W6#!04JSG=SK#,S4Y/M\L])@
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MB>#KL"<UN-&?QR;S@^EOQ+;V_."3K\D+1 N.#7@98PA4%?N5!_9,1T/)I"#
MW\R8$_A%VY1[MGTP'2?UL69H<^@-7$*[J&&3);!Q\]D)?(^-J3LLI/?3^^HO
M&!B8P 5&67%F%FA<#\P*<''#1:ANK*L<IY&9B/IIG5BN9GO&Q,LUD:B5O"E^
M3*'RF@X5T+R'I5'0I#7XGXS:S=$$4]_S5 #BZ*\$V\UE$9;9-AE&/\87@!?
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MB*B34X \WRL^;[ H0Y3L<86,)/A&\3#JH_>OB]HF*\+ZK;KX+9BBL4QJL*Y
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MY4QJR!8@V +W1!>GU)9@\5[7KEA"> >KXTR9:ZLW?^AH%'[5&]67:N]YFI:
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MR3HLD% "<]"S0 &O'CS9+#-/YWU*?MA:*/4"QRR+C-LD@+DL<PS0HE(""ZV
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M1'"<2WHKKVR<7FITQ24?V7CBWSF(@2 /(2Q;5S9]ZX<L+37:(1?")PS= ;[
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M9S6P7 P9%CUO4_9AW1:4_N'R9XX6#7B5P$JHCV<!9\11+A6SES>YG;-U%6D
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M$5?.*2<B,^67G<AL$Q@*0#HHIT8!GO93 *)?#7UJ1?+IZ(4G@B:F\T,*/!3
M_^F(H/;WMTB/J7$_CSR_G]1R_=TI?XOKKI&)X=.TY^/WFJ?@S:!S,).*$Z@E
MR_S(<L4L0P3_L-@2H^_TP)QY<W)IG99A7:",=R.+1NF=>-5 1BVC-X<%M:M.
MIT=^4KYXLG7A\;V(YQQ-42' +BH87>:!D&-R8$I.Q7JF-BG0[D1@'C-_^X-!
MLZ^>=3M/$\]W*6IGP;&*W>?XO&P46V^DLIQ92(Z<12E,7]%5#71'8Y7]:H-N
MR ?KP>^%/?R?%3W/#)S$?HB=\E7:Y"_HY##D:UDD6E3#=G%BTUEA-8*M^J9]
MB8-!H_$.V1L%KW9D:<>Y$L\**GD/'%:\Q]>3E:\EAM+V_O<I>Z-72+AI,J->
M5KXIW(P"4%TKFUOGC10&=N B]F<25V#S"GVSC/=:^>U?&S&Q2"G8K/D&_R3)
MC_#5.!#Y;'F#NE$C9(@"#,&=-M!=<NNR;4-TRKL[A:[%\K10N^F%?(P2X]A4
MN+6A&U-ZW7>' J2$9\(54H#)X)#,/J%52,E*H=F5L?LL52E\2\\E^FOUYJ7D
M3LO.5>_^]=F >2F:R3 N*=AR>>KGJ!L*[DP@D"6.2;A.U9ZIN%JJ";^?%!:8
M@C:Y_8>[Y'AXW!?C@*?>6.4*U.G4D.Z3=XV+!CM<76'="A7=%,!I8F5,M*.3
M?%)3; 6;;D0!RJY^LGN6Z'7^21X4BT7OOX)L%%/].H'I5@%0GO;J7@+)"O7S
M457\_@CBZ-O542/\6:DLKEDO-_,E4.4+?<@;U"N;M*42'S^S[=QJ"L U404E
M/"+>PIW7OI%5&AS\X(&^6QC;''7"CC<'Y;WN@A2J!@+M*JMW/L'%=S*\G+--
MOWJH.KL)J'(AW<U5<WOUNK+.P?B;1',N$S4PBHQZ0690XT5X^?J.XUMKJGHY
MROMVQU.;RODCY\9*KW?(1<CHM_3JZ630(4^+!QKTX UVP$0Y$7(ZB)A/ 79"
M('^EF/2;8_2@NFDCF^+[?8X4(/(?CM3:-I1'7_FS@7M&S0J7*,#SSB;ON>H=
MIR(*8#O>[K4#%X/'5K<YC#U+M"ZD[2ZR*;CP70C"YK\+00=A$MX(Q^N82D%/
MP2TI@/W4L!J\V#>MA3 X[]Z_&/$&E0+_\>NUDUC=V&>"Z;8OYRDF1^+6IWF)
M(J!S!LOH(? @VOJ]FD@Q*:MSK$P5[+X:BMA^TR3K-E<U'B)POU'1)>VRZI>Q
M0+>)8V0>*/$2KCWXQ<J9SBNGHX?C!H4O.'*(/G9.?C<Y^?2QLW$XX["VGKEZ
MXQC8["<]6$@_K;QJE 6SQCZ,9U_W5VB4:2D>GA#.YK;A9M_9H^'TO\'"TOD>
ME6Q3Z(E95!P3\K.^7<3T,']BAJD4 V%;)A_N]1O#D$S752HXC_@8W FF*68(
MDW]QL<BF,"BZ*W&Q9 V1*0<F>'K6JT1(E9)X-7''[0 Q)?7T]6:7E.A"T%%9
M,D="AM]$\NEX"9FX8/$\U2L2H3K')Y.)Q5GECKYYF%R!^/MVV@M/FL_HR6M6
M\9*JB4??MYAUP12Y:U5O>W+J6JT<.W,>! .G%-(T0<KG\CSHZS&($T:+7V\<
M7-9ZTS'ZK$61[@"MO!I-,WO>S-)E02&>@B"<+E3'OHE#<@ &SU?-Q0??0^K6
M."-$S:^D$;+3Z$+)K4^E%^^7:)FH\J1*&SGI_4<5I_^-T9__<?@_=/Y$AR,W
M5.6H>N_!(CS6SU-_ ?[GW3Z_MQIE./GO-Z49AYC#]X3+H-O3KE078V#!3\EY
M'"WWXQ\'(.>_Q\/K2OM@-#EM(K%F$J4[ G4:0)!*DAK84A9*/F"JP"^LF_^)
MH^GLG6N%!.19<A\:I$GU2,*\LX/ (AI]\"E+^V<;Q)F]$(4HVNGW LNF-Z P
MOU$("([AQML[3,EZEILNB#F^RIX9:;F)1I]X3SC1AY7WP,RO7LY\;'[ABU9:
M-]Q:,[A^2K]Q#*06+R)1QZ(PX@FZ==S3/&LHHI<"/!M87,-\#/-7UH(*D>O
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M5X,.IFQA-X%XI2=Y-<IL8*1K+4_)QJUK3HQ=1<H1BORMGR?]03=!=KN=@Q0
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M9_;\VQ/"Z^SBC%HW#OQUCM//,%9NFMCC-A6A&N-4<M\_5CC^\\-"?=#+4Y!
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MK0SQV-Q#V83];;@BHSY+_Z^>]/](_*5DKH[M7^)A[QCBJ0+V]!]E&?Y4*'?
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MH2CW%:S]^NTCI)"R-_>AF4CIK:/7PDA7:[(; @1L7?P;JD\\Q[Q2=B-B,"#
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MZ9DL()J3D68F^&7QL:-V<T+C5GWJ9HH];]&(L3:MRK&HW=90**^HX!6'V+%
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MYOPFR^;5KO#79WE'#LA&KR"EM8O;L M+&38">:4%]@(ZU_IO'W4\WC/3DBU
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MU\AWU4D5I#C*8AA3N)_FF@ST<M<(<,CNHE">K<M<S9?18;:AV8LPM0L-["#
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M5ZB'*",I:@]PZ#U%Z%NM\?-\"?S/'P5SGN)%-2XTC5YXI2,U\;P$K9$(7SG
M)QW]R?@Z?Y)=:-/PW13+-;@K^D"8"WKT9HY!RW8P8G]+R&3#IQH>ML.W4*1M
M<"NYZ<4^]"S5@L?.ZXLD[O5>\T5X(LS;;.WD2+E9Y9!53R8ND?E%7DW\6Y&=
MJ#E0B'@#B-QAU+^9^*;RTX'A[3GS.*'YM9_4EW=-K]P2>^KMX.$;37$-SCJ4
MFFD+)EBUS"F="NE[/\R#>X>F-C$1D0;(<+AC7&Q)D'A-]>#>^P3=/XC406),
MKYLX0/SRSZN >\NO-3(II3/SH#<O7-NZ_*HT6.-K79/#&:XFZ,[Y#%<SL0##
MZ(G*Z*WFN6N*!KIKL7D&#5$Z0YO(%U<$. :D!^^L?S\CN,U^$ ;5I?5#RI,R
MBE>2^3@):5N>Y_MO^>=O".>"B1UI;.GOYJ_,.BJ I"8FNKT]>2ZT#_;RG]#L
MM_\<T0CP%<# +J:^LTHVZNH142\:?KQEMPX::\=JTOCP;)+Q/"FI)P0;KL=!
MT >8U[ !CAA'8D;K2N/;H>P0<,S%VS1ODF/3UG%06 90^@O7(_!HN'W-U05.
MZ\TG&2I?LL;5@@X/G_GQ6=D$ZA*-69,J:L,MK4MC+QK_NJ]_J.T!F92)X8K
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M[YY:JLL2$T8,^< "Q^ 9Q*3F0$>3#OA0D7SDJW]TVFQUA'U*AWT=]ZO+WX0
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M1'3@K0^PS8&.Z]S+M4MWY2V6(*:1;3?6J\UN( +]J7%5TO^95>W*Q^$R5^@
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M1)T.T+N/Y$=:KK4L6OC(PH: -^>J;,S<I4(8JQLUTQ^;=\J1*[*W=YQRREO
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MR(..AC!LFW315'/#TA!D0;><#D">H ,&GC9P(O^B\\IQR,BJ;T?Z/?++N)8
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M\(/2HC:*]%)WRLMV N]B0TD7<W+%5'E893[:46S/J?E#[Y3+8,76^'(KC'?
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M1'H/=YA*,',<6QY'D<!L$^IR_P=[[QW5U+?W"0<;B@41$$0@*E404!'I1%1
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M[!9<'J VZ*RJ3$ZO36#?]_!;A(%8O9ZH\JNH:_1U@ 5UR0@*1V5B]# E) ,
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M^YZ5:7$\W2#9*A;J]GSZND%,H=EQK7M>6!]&$B@^[IEU5.OFD&-FW< 'A$V
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M8"*5]H.Y!VI.OBNO0%E=:G_Q3&I#TOIL\$Y1V)8A(\!-(-LQPE['\M4+WCW
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M4WY8KN[)Y;*^-2OI&R\+I6V'##Z_BC&W\P6ZVR$WKX[!L4'PI2(()[82!QM
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M%@^1QNL%?U5U<H8)"6D_N,YW"/B'X1&W$#(/_9M7'$85LQ  #AW%DN,,"H>
M&]?&5(NH$MM[7.EA8@T@G?^TXLRA;U"&E-FF M3U.=-776+LLY,'Y#A:H:^;
M_*X7E*$UZ3E0#QDFX%QC*D[52?KCPR_*TH1(_&Y;W?XZ2E.B,<#A-*]*'&J
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M T^/ZK23CZ338VKN3,'/^2QH<O&8E Y_X];,POTQNS; T^YIU6(4>"!0U.[
MSVML.,PK9.AY&"_1*V-&DV)\K+3LGI-@> A5T89K^W6K<,<W5X?EXP_OAO'<
MU6<#' B\;LL*KPIX).14S#2BT<G"E#.=9+'I^'FK:IJBK10(>Z7"_8N]%5,*
M1XA2$"1'6V/GU42SBYCB_)D(RW;7KD/O_-<;X'6' Y#$XKI"J"SQ9.0TI2R^
M])WOIH3&59>O:K3G2?XOO% ]X(/+C-N56!$L]&:FO7%!1G97<4!6?SU*.5?[
M2?&)B#L?'X\K1I!1+UC+GT%EH4=O_'LF@)@ 9JBGQDQ@'%"A#UKP'-:#^>GX
M7-L_7$1N2'6?E)2BRP;BR5V&B;!&Y)G;^Z@@Y_FI!4:=Y$9=+#M#L<Y?H4#5
MY0.RQ+-+@KL*_MXR[-&-MDG>^[RG@XY204\VM0Y2(91[LQ.BSZH&"K9KM1LL
M*ZDWUTZPU=A<?&, (%B-5[:ZW^T=?'(C*CC?V ?QJ&C(\?*6(^J%YGO($-\]
M8-0)\]145#+<&;YWN0I,#[W(!/2=Y]G6_WL7?^H?BTS *R3/TE?VP-(13Y57
MC=H).RJK0A/]#[O0NIR!39:6P@%Y2W"*D? 9)B M^Q$34/\.1-.'\A#A9/=A
MAM22=U5*0NXR^>G8>$!"]!IZ!O? TDFOM4NLED5CSY)<Z.S;D!X7QJ4@L"<E
MEJKO(UK/_XQU?7Y-QKS?>?WMGD,V)I'/T=5<?^_^8L$QU2 TF')V:@(\R][B
M;X*+M9L)VZ6:/*M\N3G;-7E/M6#<8CREI=:]$5CH'_XNILG\FMY1D PZX< X
M7@.832<Z+",.0E5^P01L[3)]8/7B^6_&UU3MKKAL* D_I_MY\')S+K&HT?'C
M-"P]%=I+,4\1W_3VQ8RQ6T]6-LSR[.M $ID 0?C<%(TURY?ZK*.TO9)\GF8I
M2M=&[O$C*&W@_630IDP _=$!BWGD:#;C'(8FK@&:9D'CNW J<$UJEFK8M5DS
MT5Z^X9;D3'=8L?_WRW@:B4,RG@RSD.&%/'P[H#G B"C!>(Q_"UKC<?EM!]I#
MDC?ZKH2VP/B'.I W%NKSV;PF!(.+]OX0FP!929RMGP$'^5UVJY#C=Z;R#2C<
MZ&A"+42$DLBI,=B<](S*RK">29,/<\]??.",?KQX_/L1#='"@T&('M![Y.9K
M_E9ZA T3H!Y&OX#J[CWQ&'\68ULMEO.TQB_[/0Q;$O5Q;]+";2V0H;^O?N\W
MDA\_OJ=)WF$"/H+?PE=KL8RW0@$FD.NP2<SF,:(+W;N*"?AED?K'*N859$^$
M-9\1 SC]H.+N/I%K))Z%Z"Q>P(-D07I4+>/-A?3_=P[]O6*2Z2,)PN$9GAJ%
M<L55\>K*/>5).*?AL@R4@_J*P@_AA!HE&CQO*\1>,ODR?O+0][3+D(+[Y;23
M04:[0SP+R.+=9DU(&)++T;EFQ^E5ATS9X,N;6^*I%C!0U90S^WC4=X?^)5Z=
M1])M03I\GEM'Q<\K?Y2,033!/#@]?U,G:#4)298.;_)+[BF=JLZ17DT8:9>-
M]XP-+)K[,L)6#)JX$)'R71Z5DY.JOBB=PD[!$)UMHL<Z(7TS>O'Q6I^^E:NN
MO1)_!Z\U [W#.'$)^\ L$<]-0*=-<AOSNRX=*U1BCP!P5>I!? VY2 )3K>\8
MHB/@<T69]>164_6<NC>W+%3>N[6WIK614PVN084IA.F-B#@I(?G:N+R#(14#
MSD>W3GF,?W-=39%2M+3D#-OVHTU0)-W]IUP0^X?S:ZKG$<_Y+;M/[UFJQ[3#
M<^I%B>REL$]/I;G_0<?.XQZ05;V5ZR5_MI![RJ[%BL^[_[(>'XC$SGCHY,^H
MR?Q]W\F#IY=VCY7*!%@"'74=OGWV^2O06Y#ZGI /:/<K? :20*2S^.A[Y-"]
M_PL4T__Q 7E 8PF(3\ G3( ;9EL6E?)7A_N&);XU/GL%@9B![SZ'AV_;L%;;
M$(O\^@_;E\+<H"S(B4Z;Y:)RFL.7=E%]8[092AZ+H3]H 9)Y:U@ OF$>Q3%C
M$YY .[VCVDI'EM*E!J8V0M*0NB4A^L&-ZI=7?H#\Z/>4#=-8_$(G _[+N)4)
M.*A'<]@JUJ;XS^2;=XAU<IUP.%\6'='JYO)2_%-%CQ3O+:X+B(8?K!]\)Z'H
MQ_99%(E#E F8<=!XF79=KLL*+*1[6^<9&8)]L"W&.!,IP @:!E'.(&<A-V"C
M_)%9F3.@DS*9@W)/RJ*/W&X39*OQK$>Q-&FP_BQD_RP+1FCGP"P*,JQ=/IT,
M:=1])(S*A-CI/N%0BR_;..:J^)&7,ZP_2EAZL2O375SMEJ==A?SS7?S_TDV?
M%\I#,_#SX=KUW*+U_GT= #)FC< $7(8T, %_ECYRP#8#_[8LP%(_[!JE^OY
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M7Q6M'87YO0'(@J$QE0\OS1!K+E.@XN5]9+BS15/\H='1.&!=MM3M_4(V!B#
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M"/5B+G9G-2\"+#]^/S9E6!1J.B@(,4'*1<2$7-<0&VM=!M&N\,O1#_^ $Z^
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MZ'/HVJY#2F$1'^C- <R4S.Y(AT[7;>@OO"<#DD;+;:1TU(@V"7>>_:;GBLR
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M<] Y>/O6F0"#1\V9/Q3:(U 3-^"+7^92 HS1N7U,@!4R1%%Z5<K'6BGWV9Q
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M>H$.8#"+J)XR6T#SC!IXOOO3'MWGE"(;]6@K Y21@7F$ =.3<;/7^R&_Q,2
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M8I$!4J2@ VO*5IJ^L.J[^"'TMZA=[DS#-!QBJOZ"_@8YSQRR4AB] '8=VLT
M?4/1.B$[*PQ0<=XB*]U:F+E0 R%HX$WW D**^;D32?5A@&Y'6NVT"6BU!>B^
M/#W2?5932##ZXR-4&_8<$V^R">&1VP)"SY.*W^06 I=5,Q&2&ICRE5JD?3>+
M7\F@NDB0NEU$<7D-P!$?C0@7)@HF-C?PZ+N$[?28UV^L +99M4.H 3G,":6U
M_CY@W"*0@BDCST=) B&9EKZOS+_UR6@Y7YPS3?CQ=%N]_C,%.A_W*L$@]A>]
MRR/F:GGKD(Q^ #U%]>R.D_IN0S)[G&CME<$A< U;5_UR#1OI*,8[GWY,NY0
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M/5FSOVP7'N'9,2<X&OI..U/+'[WK0?+$7$%/342M9MEE$;H*^5_5FGQ]P\X
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M&* I U([$#HR09U$Q@1F:?KBE@?!Y#D2,FYK)=;ML\60-I$!4IB>(#U R#-
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M(V2I?-WD>^41-Q\Y9C:=. <0R@H[N+A6%WJP(SP5<DV,<,'V.S8I:0K7"G*
M14QUZ_=LAAWB>D$0?WO!$ =8&\O&?*55"2V\+/ZA/JIM-+0 QM)%5*FA?:@G
MA:+C'QU^=%G.7#'\.OC61;8"Z;8_\]I>9)>P!W85!]A<0"$QUM_F $L,'*2
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M@E='B#D%R5A$51MDOYG(L$]H/^Q54;X!VS'D.)9M:_64/?N9^GB'#BX0V?@
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M471>0+TY\L/=]?S1-YJ&1PW0_]$=DJ2!/Q)><_^<\)I&H&!9SV6V@3\T0+:
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MMH3V'G'BNP-W0CIQ0@WI>:D9+\0F,V6[:\&/=+Q%>WV'D.)-H:M@(7A^XM\
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MCGCH5IYNQ0&>HFXC>5T3SN0WI$_,5TQ.A58Y^TAP/7@Y<^&1\SQ)-K9@_9!
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MX-':NJJUY%7C)E>,5=[K]VN<R.$ /'4GCI:=D2EJ*M5KEYKVXJ\9<4M87)<
M^WOC9.9,3Y].YZA+N X]8F?HE\BRT9N2<J,A4M-6LZAV!TASDL1^=),#U-MC
MFV[0\$I6VU.3<6$X.YKXE\'.FRIXZ1C![UJ1[:R>&43XF(>)VAC3I2WMW:>.
MP.[+.\O<+9!G+F&_(S\06#6HQ7$.D)TR?$1 /["DS-NY8&%>FV@7W=]]]6',
M871T>+M-GM:"BB*32Q?V_YQZV#2[F>2<G0WMWV[$B/N<:MY_^2U^72&+1.0
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MQ=+44ND@!*"TPAAN0U%RUA[L"63*_ET8,<V]Q%##+>7M_X"._Z7!U*<FB)L
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MUM]MNY>R;[*03/0/&ECEF763?KU+PBK_>K\"=\[3"W@AU!'-W(\;W)@'_]$
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MQGYB$4+K8[UEI^Q)[P=>I@>86VRWT6];)CDE^C.+=LSE'8PPZT72&^G=RPQ
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M]">?T4,PX]=?ML_6I!/"<8B4T[APB_<E#_3>2W6$@V;KO[A27AIO'ZI;4/J
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MR^*((FJB 60+-T%QJ;,QMY$&WT;"YP.V94?KG'1H8$J4;5K-3#T=Q"=9HQ?
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M#[>:;S'\+0N,W,FR9S\SS7,Y+_CNT],_93]A_0.;NVMLB#&^Q7U1VS[ ME<
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M--HJF)FE>]9J>OF<S%'PK4E;G(+: *'$* ,O7*34RI%MYZG("CX=N&2$'7C
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MVKVXQR1.;U%YLJ9)T6TB>]GT[X*NR*Z1?<#=+QK4\N!["=(.)C\^)O#*BPO
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M#'\^'.[-7?BG\36C#O&MU@4R'?V NJ^A,^(D@G8E TI]TF'RMFA/0>%,WM:
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M*=_NZ2^%_]H%E\N<T1J*&]E?\_-J185?'!O782O_^,!<&);&I2*IH@)?<M"
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M#U._6\ 1[?&D957!--=HZM;V%)(_:+[+]*(=C,_F1F7Y]T@/>Y*;1S^!#[4
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MPK-]/9W\P"_FRGP%LO+]UTX*W9'_&:*7E1*AQ9]"?=D[/P%I;?63PEJISQ_
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MLRE9$ 7OA@O$/]I)B%-PMG-C^_I1,"WPPDG0+$_ XJI9]+$V%8LJA)/1*13
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M4M)RXN/0J,I8BVJIF584J5RR,,'PW9!GY]U#)2+L9HXB*8#-0RH1,V#=,*4
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M:3KI0V-6!OD6-QR>Y:G6Q&KD-E^6D?Y207-T5&C-4UAS5I6[I?X0SX,)@O/
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ME*&74D6Q/!W$O.^NM)6'V48W7GR^H?LE)"%N#(L(.!":GZPA)O-:70;T]$V
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MM7$@%'*C7/**H.40>Z?[U#[*$#OLEPZ]PND1/)7F=99SL]$1H$P!<!Q;[PZ
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MXR7"I/0!Z$;]A[CFKW=.'XI\;K_IS[#W_OMCHHC_;AT/&/H " ,@#( P ,(
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M9!6UI:QH=Y#T%=DYWDI-CB[C<FXV>V\6>E[=_*  Q3Q;5_\@KJ^9@]R?$/&
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M'<^&5<]AS/9,/Q[^X&D!Y&M&0D/ (G9^9221=Y\FVO#$K5L9_%R.V9#0MLW
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M0]R)Y&9O]/"CC<H]3T+#+L86Q4B)=R?@4V$J\H9YFX2JM4@H0 \+NJR%[=\
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M8G_^*%>A'&X<D8A4Z_:6):>^,3N'OH=Y2L"^@$J\8:%<[[QHS?1:N/&?/S$
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M3D:: 393 !(Z6'D#N]NB!Q=\1#@W)4S>\T ;7M<28D-L ]" HPGA3P7("D
MSK=C 63- 3X(?DH(L).="32ZU(Z*#[/DQQ)C[*G$B?LP-HI92V/"%8:<C@:0
MV-&C\2F_YQ7$T.'4SG$D)-'W<QG<]!%86J11'@#M&?,ZAW<.5(2=2@"YIR=)
M2*6G+<C!D%>G(??VK05B'IX[;Q/+2=JGA2BE+R:A'1R$?;5(+/3@):0&)=X9
M<E 4LWCY#$*)X\]K"ARSUTWQ4VFVA(C&6N<:^SV%Y^)X(?.\L&A X/$7^EN
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MF1W!V?EV]]UWG-V7'^=YNJMN/.?<$^X]=2[^;<H8@OB['!!<8(G6_T-5750
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M5.BZV#4J&OF%"_5WCFZ7P@JSD8(.I$$3S>QTL&*.$A)%ETPL!C?>P&8!^@<
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M48_+&29[ N;:O^N<-1VLI9?X6G+BCS"BME6S?09')R*N:$+G=D-\ H@9SF9
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M],CH AI[^VE-QK&G9UKRD1=R7"A!_M#X4;@P_# EP%<VK(<?@]E.<OA:O(:
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MSFE\&_Q]RWV<,Z+EO@WICIV=FP'$O3:9>N7FT<P:J8^%3'K*0P"UV;%A@OZ
MY>!^9PD!(+@VN/IK]EJE3"NM9@3NC+4$E7'<W#0QT*CEGQO7T;O;4OY=WSI$
M@5U']/;)V=PGY^%!*E6.H5%U=G5VJH%=%U5959SU1\ :0 >QB;EWZ=IUD)62
M'+P$#0+VOKX=V5%0#><_-J7/)$;DZ_];A65_V*>_W2<B)7+?_^^H"/XCU,[]
M'S)8U_H$(:5W1%\+IIJ:;5M4R0\*E[J_WA8M7_@F=]1F\+H$BZ[<%XS0&:0T
M@(6]-^Z28Q-K;<2[7IFKVLJLGQ _7KG;8-.G5IFFWY0+K*@N)#[NO6?'8*JE
M<&4AQAM7,$7)X>*#*/>E/,^J<7P?GQ?5T5* K'.<,Z0[1?:M+')G+<<5!&YK
M*K>O-DLR%!A?+B4 DG..=C;JLK"7M;L.\R>879MAGXK1N\TG:- CGE+092^$
M"HH "-FI2:/;<"A=99&2L9]E@06%%"P^O#.Y G7E^4[E'%>EO'G_LXVBYHV-
M(!IMG3=_=XSX^]62___0\/>K)7\?_4-FLGO/=T*"IB0B9.XGGPRZ<(LT0C<?
ME?B/13)NMB*?>-F>G<R?G,(PJ9\6/'&AL<3'=F4,@#_C5%!)#?F8:;W:FHGR
MG9TE]ZO,+A^*'_ NZ$O5CEJ!FV[GC\R8^9+^L(RA._&L/?!X[>Z,B<HY121A
MYI&3>0MAV@7\[I9WIUG&7_AG* $[_%K9==?GZ7Q5<^>4[Z4&SBM<F;\T=/O^
MT9 (93T<VE!7C6H-(K\_6)YEQ^#I;MK)!\U<.%>D=YY15<H^<;/J.])=#2M;
MC>.^[?:R5/9*F1"EEX4.2F/OE]OTZ[3>>[.WR$JHV\HT_0:*^2=V" "K0=7,
M@:FR4IVE73;1:^=>>+U^3!426H>\G;KX)FGSFWM]'6<  = L%0/7\C;I2T!R
MEBC?5?2F2]E7_F.VF?JZPQ$Z?)4FA;3OSHM2$H8.5B?;=TFBU^!,-]7B<F-L
MK/.Y4F<L::>\P$A-^.(YISN3= 1/EF!?K:?3+Q9O7F#98_O].M.OB-VC$J_L
MQ!UF#H1\:) JX'R11.96&\-QGALSO.+;B-D7F-57Y6_?)LI\YW=/[>L."8 M
M,,5BQL7-.<HT7>VZ::;/RC)6;HY'<BV]EX,X>I \NY&,/#GPR<)WV4W#-WP9
M$>@M]_K8EV,OS!,E.$+,-VFNX;W*FN"_#G54^NHF["U]_7[=^F"U*:H[$/$L
M?K(W0=MHCFV_M@!I7.%89%33]$ -]-QYL_0A:.!UI77\%VW3W9!]*V/4Y7C;
MPNE9 P[ZJU_I#)GOLV(4^*4["8!K:/BM37K]R9&>6*/O/_H][[()?'=ZM,1]
M@%U,_'%J^7-YO8P 8/12@US:W"H8=$H6?&FHGOWALNKMM0T#[9[1QFQ>3XL@
M/0:.]([T19LIX6IP]AL8:<VY#FWJ2N:8=K""IFH\_I0TIBL0O$>4WX[^[5]E
MXDS&^:1W68Q$H&F*@J\@'$VLAHIFDV+&.Q=.M]$45C7U9A[UF[+RZ\KUQ6(#
M'>'IW[_[*6Q*VQJ8+;Z],1XMWD]]!%<9;;E@*^%4FER7-'EM_F XA0%:OW3
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MR-J>(_C0+J])!:KRJY56VYI(/\>/=[^0#'9<EWMX4'W+;\8.[C@5J2]NX!O
M/><SUX7?0\.\1/#&8]X(3?&L'_B/U#PW9 O$YR$_X#_!SI#)<2NQM<-N:_9J
M:IUDB:W4*+47'OY?U$^!F.O=6>^65^W C?I='K+PD;NF6Z9XN:(G:PU*W:L3
M,[26S0VY1@%*VW7G=#BR+O566Y, #63:FLL+1P80+A-^0E>FQ:&S%23 4")J
MO<G/4IRX+HZ1W/ K(!R %I55&4TF0*S_:BO!$20 )9$$>+8,/27CL).J0-1?
MHL&GTH4XN99V9D)F.ZU@Q"AVGK -)I18'^/((]=[ P,GA/,3C<ZXR<WR%A %
MB?K@EWW0%742P!5Y#+Y+ D0W5^KCM8]S$%96NMV/_C75DXF7[MDULGZAO,AH
M+\*@J%X __X.=+L>NO&HHA ML8CI'B5XJ!S AYM5";G@5W!V_%,LS+]D(W%S
MUT;JGMK[I>W^H)\+F,IS$Y30J<DF1#0HD/"S\0DZ=TEZ/O)H5N1)?=5[UCSZ
MV>+\7KM>D,@%2)SM/LMQP;%47?'I;C;.U>L7S ABA1 =GT4*C4!?S$>9^-XK
MF>V*LZ$*<:3M[^E33'D&^VTR.">)]71$%YP8800B[ZPYIU2/O'(4XWS>S\OU
M>V(WR8_K[<7&0#5"\_'G[Y!=MZMFEIWQ(=WR'2&(NVY]315+,O&5\]&0"NKH
M(-5\9AS_6HK0)$^[6LMB8E,K98"[]9R<?U[1D.G8GJ>(^7@3\;"E147(4$2!
MIO',+G#?.;A[76_+T9'ZV1/(]Y*$_K88P>\\?YU_20(5MD8/#8J1V@U\\E$]
MT$8P129XG(N-@Y#*1CTQKGAS._Z8Z29;9YO69MJ5OHQ/.3M#YT5H5/<XB '/
M]AT;KO.RS$H R88;TKC.!1P*9=L?SQN'+H+0$MMSH@UA<UW*K_D0"%.B;PR/
MS_MN <!'ZD&36&(7""@]3^7'O&\PYGK[_;2I;6W5"!^GVC?W>T=BEY<'Q4N"
MKW@[7R)4CI_>X^^@S]:\E:(B4LC*$SY*UQG"\J'@"3 F4\X5K3/ELQ-R'%YH
MPO NPKRL<JJYB00HT?WM%@=CWB?>\_L3;+SNQ4SW2H1#<=+T)1)Z\K4H,,/K
M8NT-6;@!(9M(.X .[*97OMJP(8,K&"EXT6*)'V*8^?[P])*NI[6ER$E0TV J
M.Q"(-C/%JX/8,9V&IK!X,D=%N;:2]?S;F_]FU X$[\"61Q:!,3XG#%K;+TH$
MRQ,OR <-0STZ?.7+OYW0LV-B:G*=/!W2!^)S7:?%1&]K+K_VLGNNOG7)W<9!
MG2DRDTT4M3RXU_K2[EW'")R%;&B1$,GC1S&%N5L?G=.U4W.=IG=+%YY$?1WC
M4J$XHS/>1K]/][$_DG#2^ION4?4_C#;DQ(\+CQFGO"#;S[8$*;Z3]8+GWP5:
MP"X2X$#0&71,CA=]-?]<39_1?16439:1_EK$?[0__W\J :APQ(IY&0E =CT;
M:HVI3<ZM\P>B9.Q6#SWBU1>-<]Q[/?3?S5!MR# W/?6+09?S\0%E/ LX4YU0
M0B:<X&H2X/08VO56=,@(7%4,72>C/B(<.SHXH^(1D9W"K_=&ZRZO4H8>9>6_
MON>9U3B?V X=HVT%YP4CQ'_ZE\%+]<*"8MGUE.W"6M247:UE9X:5_PF#F;'#
M/QR)TL9LF8]G%OS:$BM=CDK ;23HZYGZG;;+%;TKQS G^ZTLW&$9>H LH'W(
M,6I D9C8D__M8HRPT%YV%6! ^#$0T-/J>39(66FDN^L,.OM[<36BB"@%=28+
M $D&KP0(YAN-US\]E+[#\M&*_F;6@Z@MWC<3^!\7G?YM0],/@>;JZN"D&56&
M97FK%EF\P\4 X9];U4\?LJ2N9 'HX> 2\__)*PXBR_-3-,LUT7R8YMQLA_J4
MKH0"QW+_2\4SW7>&K[F^7/YXH0? ^=R^B4=K?<+0I'N^8K[;C:X@KI) ;3%:
M*ATGKP^]:;[[.ZG])JZ8\T!9EI(^8,4+_LN!JICQ?V5NRZI\:,\CX.G/$O-A
MQ,I-:MSHA?S_/"&LR1#QG_/%.M+&"N^%Q0B67/M720!5T>#.?:R*%/\(M#QD
MLEHM>0"G\Z>I[!<)(+>B8 2'MFDOT0P\Z\')3+'*I"!"9@2YWDB.#)<[%&J*
M:GFXF)%-W5##1'6!!.!RRJ*ILR]/M+YRW:XZ[1,4:K,GDIF34BHU-<8]3[U[
MY=4+;I\$N2<)#9S9:6 #ZH/2)UU@-FDP_72OO>.-D3MY'%;Z-1K+@]54%XXH
M,-+KE88_\BP*;Y=XCDM!$D 3Y](1D2>@S!,+OX5#)52-SQB%[(1[ADD*4B!3
M(<F&8Z):4<))3B@OM:/N@6N >"A1'-K&EBWVE9!\,E NE>4VY>.]&Q=YAKJY
M5!)(I'>[8>V4I3[9/-C:6(([67RX'9J5E9*L>H7_QX/[Q6U-P!88,V+QRA"'
M+K$/Y_K*,0A9Z1_\D+6K?7/;VE_U?O(,@[NO6DU,U3Y6LU'9_Z<_Z!5.A>J@
M9G\Z@J*4*B# V-*C4>).8IGZLQ0[69[S<.V<4/^LPD5$@LQYT!6J$H?Z*/U0
MN?N]P%$;ZJ.2(M@4_<#+@>8$^=[XI#Y&"BR%-:^J[BU1PZ0M+^N[F/'"Y2<I
M@9-,/+%K(@ZUCT]/E=;JI@1_:G7<GRL^%K^&=R4!WODJEX] RT*&3AQ._!%.
MTPU9M1/N9ZBO6[Z(*?.4V3FD./++ZF3&[DS'LN+YF+D0W\>9K\8OGDW.(0NL
M5#V=)5O=&5PU>67MI"\Q]BJZ*6-) &^7BYU%CML^???66W"L!!-6?-E1"<?\
M%/WD2[>R3?K&SPM(03TPCZ>U +FGTB=)>R[8@LYS6*RXZI_LN\\;U:_9T'4I
M H@%M\L$<XIL[N\7B3O4C^U''E_>?RW@'!AU+G'$6\M;>P(W'88Z2-\0WC+7
ME+P0SE^<(8._5!_RJO%5C([0GJ'M<MFV-0\6Y^OM.KC)?+%WXOF,SN)$, LK
M]<SZIAGW96R3^#NO[2+_HY/1M=HZY[3,/1]Z,T-.? '8]P$RX+!/<-4"F&72
M-##/[@<CTI, -W1_!G_=R7+*.;-^A7?1DUL@#]0M^<=;&YU6.BH48;3W8P)O
MS,Y.;@6 N@>TVL9NCMZY-6I&15ET,WJ:L'=9 ,V4MDP"Q,RC,S8&)Z!VA _]
MM69XLEY\:2M?YE _K5^O>L-HL&I2%W3@A))#1C;+DP?F^LG>\@[8]7"9;O>P
ML:GVP1^?C!'B3?Q#\J,39R&EUA-0A4BIPKZDSQ)XDG73,H+1S'KE4-[CZ.I>
M(QO&TPB=63^E\>''A/ALC/'-P0 1S^XRZJE:<Z&JX-;[5>IUH"D&W8,*0K+G
M&M3WMV4(E."TB'?$>!IB7!HFN]DWQX&G2W$?I,*'OL8KDNE9VY!!3J).7E8:
MV6\4_]WI!QA'G\9X@Z_.!>=JUSNPU7IMQ2NRZ5(U26H3LOE,P^8WM@ZNEUL,
M5(*P5ZC/4/%#!DM9JUT>\;]/M%5.(FY+5,O)TOL$1I=3XRFO0^4.W1C\NHTP
MWBW)!G42PAEY@O>[8*K$)F?Z&$:#"<Y5T0E]5:;'7/-AS6).6?2A=U;CO+D4
M937R7."L1\;K"2^!U2)5R2<193>2N1/>#"_O5?XL.OM[O Q]+LSY3,J(+R59
M7MMF*:NP=+L^>'?X1T5Y7?SBG1<N/[1^*61I*M@(%+RP"!'&HDB *S*1^U*(
M';>*X.Q'9PBG^9IK0.UP147GWX(%?1%(L47K&NIN)._3>"2.1OXFG1O.WE),
M,D&L,2F&7===2':'[+OU!8HG\7ZXVW&7(D^XR5VX%/X;9RT9,9WQFB!IK:W*
M),1?IJ-CD59IY7K:?O[.MYJAJJG-RVY#/9NKNRJ@.07WR.6=6'X^\R<;"?/>
MM] %T9%#.'M.).,I)UF?=^KAN]2?S;QF!5[GN?/__D)!O-@$E3N(<S9OPE!E
M\^_B=]W=!8Q=W_H ?+C'U/Z*CE] M*T>>,5OV1!M-Y34IO?"\XMH_IH,7A[D
M;DE@W/5X5OWC9%IWBGDL&^0T?%O3'9DL:"> N5@>I((Y.#F@BM0LM[C83K5D
M?,@93'47B))>930\X-5U%!A-\E^I_[*:KI9JPO]E9J7L^#8<ZVQ&ULM J_+1
M1EAE</I#HO%N0U-%>$)?A>!/B4-%WBX8*V)1'(T_AYRH3RJ,&Q^&C"!8GP>\
MYLZJ6CO2?Z3Y^EER<@-9N;[<_-^=(?O_E/)_,W7_?UO^EV7JIDX@CK/#3]Q:
M%:WO:CCW?JNAA*(>KA^I0"Z$9Q"<]\2G5=F(=%,I;#0_VTS/@6+Z^!YXI(GT
M.>*:ZAV&X!420 4S)Y+L=P33R';(B3E?7FK[+]#HE6+XJQ%QEWW1^?[:FD2[
MN&YT>4;X60S!#CU>P1+5"/[N]/'&X-RT^IL('34N%> Z),D>@Q?9G9\H6!HU
M1T6LH+6/\KU%);VJ(Y#GTQXSH7NQN@O]\>^;>6/NQI=<7KI5%4],P".>[?D]
M8V.7C7ZQ=I0U5X0_QL4AI^W;&/S"%Q\'5%YF.W*NJDWF"OI^B>. '[C@O!""
M1VW[U&5/^GU0:QX^OAS1F;(C2HGAEN&]1K<[CI!0NALD-$JD\VM;UAB]4549
M.VQF!6QPO^[W@(AFI?11FBCV@W ![>_PS17.!GC+R<(O2!O+]HA[%X&M$];<
M_\ZT8L[0!@PQYMM$QJ#[HTHB?G/MRB-=]"IK,\BIR\H<&40_BCH>8^F?;>^X
MM.)[G08<#3(#$O.UK2H2J*6JCJ"[_HX+;E>K0Q=UKSE6^]1_S[C2F#1)=?SH
M0YE=2&GW^UZ^(\7M]:NKK2^;ZY1-]-UU$6Y8 1W)JVCO5>7>^PU0*[+8X0\7
MY<@>SYHR>0G2H<W2O@5?L?Q#VU]@&.&?6#&]2@D,,MF =,Q_:&;!<F1O0J?:
M7EQ;WSFIKG;@.LF)?\@'^.;"AL1<Q4 F((M#OX:DW5AGX/OBTSO&;^,3;UZ:
M!N_>I\9?;!0XR<#FA-S&:S<X /%:E3GC]Z&[EVR:=;$,(:'.AW@K\=W&@44X
MKMX90L;HU+K)X(>MX\3V/F)YVKYPD_@DM*7A+'?S!<X]2)&"J" -ZQH'$Q_H
M@&H$VN?/T.-0-#.Y"J$*80QAVH 6L8H=X$B !6[?\Y&$75 #\<HY[2)DFJ/%
M6@A#^S[![7JAH^+1-J7'3,L'5I]%#Y6D"[)<\JAJIWKOYJK\6<=3][/J&GTI
M^BYH-.N-=@QE#/[C>_OJ] <Y-IQEO[S<6XVI>5!;+*V0J"L8\&)U-)PY=K;_
M<CR&@6CV!R$2Z[-B"WPDLEKQ.XO-*<*<I6)H/G<CV%4Y RGAF1M5(_-$%&5=
ML$8"=$"I=-&'W>;(2/M7B<5BUQQ%Q!1ZD()D8/41RKZVO3,_#5O\53<L-<\V
M,0V4&R/VAVS(=<QOS3;'':P3RB9,NHS.KS^+-<7S.1U/GO^]E27K%5;\Q\O5
M)]^WAT@ 8[)7:/+LNBJ?4,(8&1OL0'?.E WMS>@F 5XVPLZ%B@['G(_$'QO
MRF9>U/*V#4,WOL.1RA"N=@2S -[M6 D9==(.#;W !L\E 6Q)@"D:X@TK?06!
M)9%&OY"3IQ:6OS69D[G?GO-FV _%!R9#9(?IAIL3.,(+XG.%I9D3]JT=SAJ9
M)4JI&IV' ^"=/O;;'2=#UA:-!EU)[;=2'&:HC*G#+N]=AB/=IFP6)(,$,,).
MYH8Z<RRC_!U\F?.OD@NC?\F]T<JJI>1,3-Z!EMOOLM<W9<)#\=I>T,JE#G.7
MF2]@AX>RT=.X96IJ[-MC3H+ $O+*9M9]]/':AR*+#T4T'9.WN'.'/IT\]Z<N
MNX@0R;5@^&C#)1>#V9XLC0,5F^2_7[I#GRG@*-I0,'DFV8-P>C6+DX'8?+-0
M@N[F>9]A(-DD0%53;04!YNWLU1M_OTHYJY:!!XZ\BA-C\6WM)0'\B9%=[L:?
M)PKP?Q?V<!3+_T8A?R$68/-;06[$8QAQ'!Y (+]I)<H/16Q-^HOA(%@R(@%Q
M'.*-H3CSIO632%XB8V0<=(=%_ #>4Z%. M#HXO7Q.2&=GTB G@3B+&PKY"64
M(=@ACWC[?!BU_0/O_6]3+E9#X!5)&W( '2$!'C%IE6YH02Q'1KV=HUJ0N+:*
MPCPV/>Q22&WV8DC*V3KN%1#;;)X&GRPA 8Y,X8/Y/,*V1.^S;9S]34B\>:@B
M^_!D9.UDPB8D!=U>36;)$40'@EM,53\*F[:"I(7G!%W!1+:=@W>:EMRHK;?4
M1$,V+$6KOKU7NPYRG?\L-I2<];W9)Z_ESQOP58(XR[N"V%@;_29VI]FALQ &
MEF?40EKIU@?NOCNG.S0DP'A^WAXUG&F'3$(0]L_0IXNW/RR+Q+D4U(^J-GOM
M5URB^Z)7QW%JNP#4^CGQT\^_+6.NW,<Z3[_="'[E3WI]3,.1PJL8P=**3X(Y
M8>X/+RR362@.)QQ$!:8/>E1/K'*R:#=__>U=HK)%;^0MI8 ?"S5PG75.LJ6&
MUZ=UN3&+?7$:<"YHC6Q&3-8]UVDGK'4!SK.ZFE%8. ;XF)#>S#PUL7$RV.GS
M\GZ]]D<]%5F05$+\-UM)[I7S]#/.]7OISA3OQO..CB#K9Z*ZI;T>&YH*(??,
M/TD?0U?/-]PA5?#NUH42?CS'XMF8=-&$S^P W<T2GA=#&AL[]Q*4D08B*B>/
ML%-S"N@A]!^XY]KVU%.;_J2G%.ZO[S+BRM%Y!*"!\Z*+A7$CRMNBZ8E>YIZ;
MZXKCJW25I#T=S2(B+<8U=P',N'E.3!%(";;A290)[MXQBO3FY2$X\;>/-F<?
M^^$#YY'X>G:5J"*H ^$%"0!TM4XE 90*-M6[$B+N0Y@;@;ZY5I1/6A2F.;Y3
MW]6A[IOQ40A3! XC)*5+V _;TSO7TGX\'$>->U1*M.&9[&3!Q&:"\S'O8DW"
MT7ST''#D>/=!N\7,MWDVL)0$$,%V^JP;87U\N+^;B=;TCI/&^^:V$[_:L%II
M,Y( Q6^O\W?_] 7/D@ ^S8$\O^W"2M'>1Q^" \!8\)>C(.4T%2YEFU]3E:6[
MXV TF'>I3^@"]0ACU7GBF7'3H__./!5P&!@J]W:4"/13>^YKHQO/>ZS[D038
MD)Y%?0[YW=>/EFEKC=>,MX'9*+P+^0S7A;>6%:HS&8FO0;^"L]&T_5?4=(MM
MSOYN7XC=_P\CK7],#@M5_N.""#UJ;3(>>OCO@4QC4!S9_/7&P=MC)$"*ZS]7
MI6NS?I^1/[8T=^"_V980NIV_HY!18UAC13CG6JK -XHZN#7:OB57RM%[B8W]
MKC^S7@T8?7_W")3YQ-'5\.5JV?*HR7B R;M*%SJFUU[]SL&U-SN>-ZL_,CV
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M9)G"38A&=?]4-1Q?"I1<)<>H^@2I_[JQ!G@XD0E"[U?(GRDS.1&J\#:>K>)
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M '%B%\EZDR!Z;"6/I1TO51;/>2XG^?GQTS5HZ9;3:,%"JK<#]6:E]R?669+
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MP;.K$?6+#'LDG@!HQ.KR!L(LY"P[0(S#;HW;$89D#1%]:EYOWEIH:PRI'+*
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MJY'8=/S//'S4TV68.0W(1S3X?J\ 4_3NBV0K53P/Y4USHH:JTHHN[D'U1M;
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MLP4B%X@?]?#1'^YI'*/V-[^\D>&G!=4Y0;(EM$N,D$3S\#P6IX[09/Q]VW5
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MNW#V:!JJG%J1RJ9?O@VSOW/M,E<-DL0)Z.;/,AN4=ND0*(2%+_!&RO([#MJ
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MJ+.;QC*,6]ZG2PTNXH74^/B"H_E&X^J2D8N#4[8':-6_/G:+]2].Y>H0&IH
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M+U& SN"[11(9I?G*S+JJ:G^/_;C_*<$$\)#JCQZJ.-V4I)9I@:L/<?=K+PO
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MA[7F<.<(L";R9*211S&[ONMS0>A=XPN\[F$*$70#"A')56>PI#2OR_"?+RG
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M5HRTI\X<K]":SN%157H\85AO^P1QTA1 5S-:;2-;?IZ1^4FO81[%8<[S)#G
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MK!X3J(>N#W8Q,L0,65]L&7Z2;?)<NS><>-]>#"%\W-UL-0=G:26MW>#67AJ
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MG=O#;"HP]%  8^R'Z%17W%*_](;$Y"T*4$6C6P?. P4-83US%K6^D&?#12E
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M'\%75VAHO*1U.<]4<Y\XN?B_V'OON":VK6]\$ 5% 460W@0!I8F =((B341
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M?^)QTH_+:DY'WWIMU;*7M]B%:Y*\X(3*9+6P$(C8W'$!MK0:]96EC4=^KJ5
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MU+*%HCB;061+28S]/),1,QTV%CQ<= RDGU^>>;,?CWS*E4^A;'Q*Z=/S?!Q
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M4U&ZNGQPTZ//B*NOV'JHY2/T8=HP!:BDP'(J>M*N+D*W<RB%1US>2<1 H 6
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M XR8D1,O>SZIUQY(M<9]S8QD>VX3IJE8T/"+:N]25 G>C]OS(@JW\F T&/8
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MN7HZU5EA\@T..+UJ_:@,I1HXXY59'/I^)UJ]_7T<,[.3:W- \N&D ;32:/:
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M"*%^8:!U(/W1JI-QXT4D)) EZA+T5C];.,VU]\.*).&M;$'[8 5SX=K3PSC
M7 ;58?>48HY6+<V*V_\XTYNY<@C:2)H:!R3%@'<G_[1SM<J-'P=(\=6NX\,_
M.MNJBO,G:!RD7:M+++C;5D>B@^1#4&$WFMPU\_!:F.".?V(*R$(1F-="Q!R2
M.V&H\"I2E3T8=K,1.@^^_W2RUF?]YH:*CQ=T?^YI9E>\H6KDD]2@OCGIP@'(
MC$H-?GA.@;9TX9&YR[QFV%O+Z_O(2'R4&;]W_7UF8:]^RC;GWV,J.*R&U8)B
MV>A:OUE4X"F)!AI0?<!MKWTSE/ 6^7>M$JI4<0 ;7SY>C^T@"X\#UNHS&\Z+
MZ:01W=/T:F79('77G0S54K&KU]-<Z:@P?P 6@#HRG$>_LIBEVX=,J6(B5^FQ
MY:58OS[5A^IC2<2H\SHQ^JBD7,D\7>/$Y!#FJ5N79)BC/=('Q?,TO,E.SIP;
M+O[Q>D7<<H4^_3 M-)MFI"$R+.:%V 3/.P)64&/#+">*9?#3<%/6^_[U_)BU
M!HEF@04:Z")8"7,9!T2XIT$&K^,5?+C&#@7"A%24'KIWX"UF_!?Z(I>*9LZ>
M\1,]TUV2M&]E )4/RSSID!=^<Z XX4VS(+<;H,#MY6IYQT>F=H5*!X&8*]+>
M-4DA[I7U0:QJ9P9D+L+O&D]ZE&R 5?//+M47!++ TSS.H",L(?4>FI_B^'A@
MK7RCT7=,E4"Q&.[Y*SLX8&B)VI!?)Q8Z5MR=)3VE!-H_FRD5F'Z(\$7797!$
M(2K7>6^VV%Z8)%AJF,-\/6^4__T23J>'U.?WSCTG[G]V5,S?'I_?.V?D^[WI
M =<'^T71SC'3";]P8&8P&"EBOMBAQ=6W1:OV&2*X3S*YG/>+I1U;AW1'>0IT
MW%9I/>\C0^./ Y82<9=*'Y?RM;#[@OBQXC(8[@8/MN%@?D8+]2R WB^2\!">
ML#_X#G,2/_U9\5==4ST\8=%6PPUINS$ ^;9':N&T.G-@@BK:/"GX0 K2RJR-
MOQ2>C)('.5$36 5[O$;B;W:+HZ!H!Q_=O)*&XPT/GKIN%*@B:C%A^(9&X?@^
M5&ZBOTX@PT?<"'MZ1AI$G+XR67;4X8W->\\''J:Y86C$M&[)M\+CINPO]71R
M9@FFTA^<,MXZ3MXY4'U^\O4G3D_+UPYAYAJ'3F;[0:C:H.N=EHC5AP8/BE-:
MNE^?PRR SY\R5]&9M>CW..Z<9&'YR))"F]?2UD_Q=1*%W QB21"V*_="TW&"
M*.6%!^MB7MI%X:BO^^2\_IL7"_1I&I38>K$2^*GY"K:]RXSU[M_L=S^-?[1;
M+_&/5H9_M OPI)R'A0X>+-\**9_]#;S/(_P'(!^&]\L^&6-1>!ND8OQCZ!+Y
MU<+>I9]278<QY;?(IS7PBUT:FY]^$;TH\W$(4ZHK]OWL_<C_CKC\IRCE;>^?
M=V_(,.(%>>.?CHB.APC>5,KB72>X-E:S_(=#C8%I5\%9$J[4"JC0SWZPWP/<
M/V[4F"GY,7H)?&:A:O<8'[2'O?K9T_6/BK_MU\CI_TO@(D-G)/9-H_ \"S?#
M:F[ZNC,C8'N4PI#]'<@L6%3KU=?Z@@6\\+L^_G44]ODGG3 !>)H=;(1]UG[E
MIH5WCWSROBUFX&W3A<I.7_#9*M!4[:F,Z#3(CFNX8*$JA_PD@B$GW,@&1:A9
M,H!YF W659[7^[QT3R7#]IA7EZ<K73OW^.--\SJV)#SIW3\V%XH/I8*9]]>9
ML2^Y\9P> -I@MX!M+W)B?<!\BQ$9-6D6//[/S*\(,I@!9U5<2T.D+SL;:R _
MY)I99.^5"HY4V60.S=+'AA'=GBZ*Z*?O,>>T^WC%]6]6;(DDNGM (LLPC,I0
M27HH_PQY=@U>)*WA!9#!=-@^J5MV[[(1#D"0!QG1]$ORY@P-+WE8?MY99S#?
M>2$_Q^85408'\B;S0I>*APNW15Z6Y$(8G*5/931Z.]^A5L<!)2&B(*/:F]P?
M,<;(30UD4AK[XW']A(LM;16AI[GYGR%2=C!E61A2Q*=UPHGB=UQ)/0:G\F,G
MKTOX?#T8+%UDIL8(YM33KM?\'_;> ZRI+6L?/X@*B! %$902E*8"8J&W8*$H
M(J(" D)04)H0:=(" 9%>(B*H* 1%1*1$I-=(%Q'I()W0.PDUD/:+]][_S!WO
MG9G[?3/SG_F>.8_/>AY%SM[[7>_>:[UKGW/VJ3ZZ_6;QY==^JH$;';.\+XVC
M-#,Z"'2 E<1RE7@[=<_Q/EV.;/SD]4\/CL@@N3LV=ZPL[D7*$)X$46!>;S\_
M40J#Q+]Q72[&&R_7XQ.F\_4C_'C;;WC06LT*!0\67)ZKGVU?EAOQ@Y&"O$8C
M:OO?].F'3O!;]DR2FV90\<ZK]DLW[7>9]S08=UJP=!XDL@2Z-=",.9QRSN/F
M#_5^1+^%)2(SS-.JL6'<)"'\2+Q\<?MMQ[;3:1-&M"7R9F#WEG?GI\)=QKUC
M2.WXBG2\[^5;X6T.66I/GSH=/#UJ-\4OR#K=I#\L$UR""5WU\3J:.5[0-GIW
M65>9AY.)_ YRV=O'^$,/Q9B0/W;PU+O7$B47(C/5BJ&?BQ=Y*8AV-[+)@5:^
MH<'WPA<NA::HERW53]>7:XZMY*0\V%NH,L3-()+!2/?KH4TF;,SLE*/92'VP
MC*J*EU-)-OF9H\4QG,WC6Y]W1\[77X&KMM]__^X[B1)_O3XI3_DXQ%TFE^*I
M>^%#64?9\Z<W^PYZ<15PZM]];1SF4'A\T,$[J$:Z8I^3: P_W^=X42'?M^&=
MX2D7C]3^9;W2N;S-I]!?7=P3<9;@]]S*)]V+]U(*B_Y!HTHI_4NOW60GLN_'
MGIOQG RC V.W.G&S"PCJSJY;%MU.5F5=J^RA9L@3_><.RA^/D])1)1ONS[O9
MG$;;0P<:U%MQL\]14XYP)1*&IF5N1JN88"S")A_H7^]*;F1S_HM'PN!+9W9$
ML%F8J%;=B=0P%HS]5TDC1X,T'JLIF<!!,;0Y(2@_YZY3)G!?LUE%NQ^FEP(-
MP,J3GA 8-:%.9[;,2I_)T96>;PVA5W-/GVNXS**X(O?)$UZK,+B[\_)F+:%Z
M_)$X^9&,^\'R=@U2*W[>=!OY>E-J_^A$N+N8Z]RP)3I;_7&"LX>FQ+ZZ-E68
M%N%B(=8\J_Q-HKJ^B>CIT(IQ])8*-"$M) L)P3_-I'2R[7AFDUBT<\ $G4SS
M-Y0<"O?C?1^6F&_[1OCNPRUCM--EL2/0VN?HO35=>W>7)SW5;RZB+2'TODVI
MX4YJ?=@_GI:U\-6J[OLB?Y!2L[X9VAPG.2+L(\P';[$A8A&D[SE%%+5*E%CF
M64[UT:["AEI "4,/VAH-<&2U3\^^I<6*W'6.-M1Y]ZCMT]<7Y;.Y@;^I@EHH
M&IV.[C@^>^.NRQM=N<J/8^VN^R>["0O5%<_DY[PHM&G!;8&-Z: VR8SZ^93I
M$B)\:.F2.V9S"K>YI=N9\'QD>R >PRZ7E(I:<PB\NW1GR1KU.*CR<[I@E-=D
M#8=1MQDQ.-7WEDRBP\GT<_)QGW:PG&::<U#$>B4TI6U%7Z(FX<8@W_>;&.51
MBT,L:9$Q@TL8:P"UR6T44MG,;UO!T^[.EZ\[]*%!ZMTGU32D?Q&-1ZX9:4+D
MQ(P@]DA//'=>>^Y\)V;Q6\/REAX^2XBSGHPGOT632"9IV\C98(=Y+IO*Q]17
M@,][/N?5CU=(^P=(I801%+>4=_;3^[JD*];O)[=?%;@/ZQ6@:K=CV#Z48RZ6
M!L_T&@6/B',^.E!Y67) 58Q8?:%#.B7$3$*_[!+S^7>FAR%8 6P+<?'\N30W
MQ?,GT%+HO7".F7G7M1NI@[XI*DC<@4*;=CZL*TF7L !G,]-#O3V2G>KR4O6]
MZUC:=>Z9BR=7>/(]B+I577>?\5\+OGABK_#7^C[ F%5=KC:=U'CQ:-.;J5VR
M42+*\5YL4??C=T#VB01@KLP]=S'C.'1J</+,#Q571H^Z%$6C!:F'OY7;CJ"U
MWSW*I9=T(6S)OT?I%G,1EO]=<&AXEI+M]UV[F__N/5O0_C.,)W=X<6/?'=0@
M;),MT[Z'X$&)+( M0JE;VWPXG-"F#"7#G/?/4+W@"V3_6@-?(/O?&_@"V3\8
M0\ 7R$#[OV-W2"HT+3/H.IIVWV%_ 9(AG$6DT>1ZAJ253:HV2^EZ^RK\X_P_
MX^UM\1_.BS=.8L24^GD<U0T^:1$\Y$8]8N)\G-&;UC]CQ_._SBY&4.U]->5_
M/D<>F&;XD?5O$E)-Q%'"]]=3O7%+69]_]8\WA=P]F$,&FCP=7O\5//SZQ'BL
M&-:4(?DBC& +&"IKAZZ5J<]S60--:[>@?_<B_4^U7XZ-[S3*LH,O[0JDS@!M
M?_%<Q!0=^.'!B;S@.AZ/4YI[C(+_[=2#]M]EYI  :;WZ4#SRU@TCUPU+O]?&
M:A;/AQW9\LJ5LL7-"WGY5/0-#5I0\,]O+GXJDOST/8;6S(*9[S_=P,SWOS,P
M\_TK,]_T_+TNE8']2VRG;%^'Q04[QX0OPTBG9!$;ZRCRYM"H(:_UK<M']<\T
MVGY_6^$!MQ8=P'C0 5S6]W/_V%)0S:5T8*B+#NROL+:9&_-RY)F!$^[;#BTO
MT('U55P=^E=-:9^ V(C\W7:4'OHH"9EI>C^A""<H4,@X*A5!3*'MTN.G^0[1
M:(6DUB^!/9^6>B4[</BMK;C) 3JP.(N*@OZZTVAKH:_:\:T6J72 53R*#J@O
MT@&4V?>S#/^B7U?A-1?5@O!5F5^/\=>]/F/)C1G/,T[_RP'"?MVOP">U%VCI
M5^6ZOQ[A#]U.G (= SH&= SH&- QH&/^18XI?8U4;EE8/.O2IW)XZVC3#>K/
MR+?Q+.POK%J$F/:HQO0JWM5H>-:,RK*D W\)KL5'_K_!1^#D 1T#.@9TS/_O
MCC$=^J@LV;P_O_3A%R;JK#?5(>4)7C^XC?>&C?"!<U <BICZ-; GM_+MWP&/
M!/T,3D#0,:!C0,?\;<<X.&B2K/#D1F,O1]';G-K<QT:9!Z/=&+\:UFI1GX54
M;,G,%KF6E7@U^^(MJZ%9DZ&_:-(-]#4X"?^C'9,N/3]>$G<S6#Y>:^KM"3WO
M2#_6UA0ELO@RK2,2E>5@>LWLVM$^6Y$ ?;BT1G/7DV.="AUC9<>'$;DEYC/"
M^W@?%\XPK2+@J??R#"X--#V^>F_'H5<QI_X)._7@VUO_2@/?WOH'#'Q[ZU_P
M]I:@/"/D"2G %O:/SK[OP(W635*KK_N*[F0XW/+?_7#CO^RAR91DU"=-U(!<
MHJDR"^6!,;5=8__F(B70>A,]>;W<??^?_OJ?[09=!SH O40'*F")[NM0XJ($
M.6W#^,#O_/"RI;.;@>9_YA=T?OUM/=>X5A*"IFK-2#8A&SLN[-:MP1#7><F8
MCBX]!\]8FOH('7#=3&CX?ASYFW_['6TP?_X;#,R?_X"!^1/,GV#^!/,GF#__
M:^T?S9_7T;7H7=.#>TB($6DSHV(S->6NID&[;UR[A$[ZL\UHV[]-$W]D&BO^
MV,SFRU7C!%3U.8H<([6\&Z)1].A C0$=X) @=-.",U!D(J/=W1;8CASX\@S<
ME0Z(U&TV02;AWFI'PY?U27:P8-R*G!D=& K#D<)A^->T_72@I9,Q+_S$Z<#(
MH<UX29JO[@)J#&KRDC*[J)W::F'W8^/:%%E,-7QS?Q8=6*P9HFA"+]>BFM-]
MFRF!L[*P1-^IE1+)IM^V3 >"8TF,&'#&$$<E/:<#H2DSU[ ;JS+%=."A[^V0
M96RYT!--K[0?VR:TH3A04_:,>8KC1A'W^.KRT 'UU'78$B2SA>:^GM(VA97]
M;=.T_?IX+)7#B ZLCR!H!]'I-W&3'163M%.K"="O%2O>YCP3F!]:_HU/5Z6,
M*9M/^NG )_7<,QO=@VC=5V7M/S;\@T/54\/I .8R&;/!TF6+4B:W3KO] ;:T
M_T26,,@5R!7(%<@5R!7(%<@5R!7(%<C5_YBK[E]_1'$<^T,#*_"=M&X8:Z:;
MI(X$,373Y=7#SXZ3H[%TX,*,V/U:,])E.O 1OK'_2DV+OFG$HG99JP5CT!PA
M! ]:2(0^97L1'1AU0U7?H @RH(RTTP&F;!AIP&95X+N7:%L8;IK:[(+2_+07
MM3_\H4NA!M^G#6I8AC%OKJ$V-J#E0HV:GMT4>6CET*:0-(RP?Y0.1+7^IB%?
M[9^F !WPQRU!LF[0@<DQOQ4?:9Y1..$;B@4UY9G' .* IBEH_]C4K\:JGA_"
M("J&W#J79QSUVZ']V%*'\W>"2.S?&0)!@B!!D"!($"0($@0)@@1!@B!!D"!(
M$"0(\O\:R/_O'(R1'T=H)+O8!QWN5WA?2IIH-3 3I2:,HBDAOS?NUI(G%,]^
M.E#D@,[>0E[K)DE(O_B4I)8K]5D#>NM[W^Y?Z,"/,,0":NG SS@"1M[3@>4E
MF+=:?#@12[H#"\2MJ)JBAN7JZ0!_"HT?,KQ(A>S%D#B<Z4#=-/6_F"P0) @2
M! F"!$&"($&0($@0) @2!/E70'9%!]"! XRQN'4_^&W]8=&*NX,+E.]^.4YL
M>G7H2D/!+V/G_6'L(^36Q3\_B.W5A27;4_84Y[BAZ^/OC 4&.#C/TH'KLQ@Z
M$%Q-4J$#9VK3:,S74<027>:?[@/_=$>5N?9_X(7VS>CO-W49PT2-04VK&472
M)^K4FJED'0[_GL9)!UJ(=HSA=4,I3N@?2Z49Q>^WTRG;OM]/=X#0 9C(>DJ/
M+7;_;P8'^TU3;T=PDQTX B_MU&HFC$)!#Z)OO2IS^*'VFOI-0^HI?T;)TO4_
M*..F0)0@2A EB!)$":($4?Z?06F?3P?0;U%#T*\E9#1I/9;:3LF8*$7T\0Z/
M7#_;-!JAP;Q%OR=;#36;Z);KUP??:BK!7-]E'2<,^=#OC>I6UF>.^ $_T7=J
M8>J/# ;S7RMD09 @2! D"!($"8($0?X+0)I#@QF_6Z>_.85ZB$VD S]*CT)9
M6)_N<%96RNL*U3RMHQ<YLNHO0#9MS@W_>1#7RG[61W"B!,6WEC:Y*A=K89)-
MZ\%M/YHM8EOF;CO#O96:,-I-*^Y"_';#1^8_0=K]=PA8$"6($D0)H@11@BA!
ME/]2E-D_?B0=+FGJ]VV(1:0TZ'G]W@##2HFY;H&==*!;>=YL;83$'T@'>+<T
M,Q [H4B=$G]^/C \6N87%%U3V%V,SK^1Q!B=SV-H6_I_0E&@SH9J(=LP0!0R
M0#SI<$;](LM$]+/PO\A17YX1**$/NA4WY9O+&*?9SW*TOE)F$WJ'#A#V_J)'
MX7_2HX6_Z-'Y%>-05/4=)!=#1:[]-+J?].@/3?VY3^'-P9_U:&&KQ0&&'LTA
MZ-)"^F"4;;_HT1];,O@3SL!9SY\%Z9"F9\AOQO:;IO[R7B6($\0)X@1Q@CA!
MG"!.$">($\0)X@1Q@CA!G"!.$.>_ ><4KBNMPSCD-T-$D'C77I',B;RU]X2$
M"),16?EZMPFX&#L!;LES.?OZXC44#:T:YJ]("8D?_GSU]:,EU-CEVDNQYZX:
M^]FNAQ]Z5=14%7[H^X'+OV]EQFLM="#6C!1%!RRK&?UF^1AZXN:?EN)N#86.
MIE%T^1A@9\V?PM83X"/P9TUAM&WZVAO0T,<&FGXC?I?^W2=H@P8::*"!]N\U
MGA7('(0.2#@,ZZ]C<2O!(Q5^V%>P84PH=*V,L.M&# W332L[*MG\!=4_BPJ&
MQZH<@R_*XFIPLGY-K9H\I)C-9 /-/<!?,^.'M*Y>\X5\LCQ%(Z<]2P)7CM&[
M%=[;*_[H'+\+X5WR([^XV0ZC/'N?(S%OXYM@15]?J[T6XYRI'T93#L-#42L'
M2!@ZL'4=^OUXS%0_ABQH"1E!4;C[440>\H"F+V:SW9CF*U..D:%AVQGI&+T
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MMUJP[/ >'9%PN1VA*4P:4T#ZGQ=D$!%2+\/DJ6]2W.:.WC.]Z9=Z1R.AU^9
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M2 VW"+"J^(1Y&L8Y_8RS=_QI21M#RR8!=&G2MTAT7='B-RQ-;_TLPSD16*I
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MYX43T*C#-C>]'5?>B;^0(%#(:KTZ+>+>W2!RD7-&]E#I5B'Q-0%_U(JDU\Y
MRDW/;)DZV^Z)TVI6IVBPO5XT7>\*%"7$$UV@H%;>_8V39Z;J5YM#OP@5?WDX
M:>:];S2W1G/M@M=:%$BMYF]O;MOONJY*)V;,N=]H\</;9).KC8K4:0OO!E<B
MPV"^BZDH'D+>,/%Q0&&)BY2M^R7C;[DY;^EG]%\#H!?Z6774<QL(W-C5D]G%
MQ)9FH<>O;=OSM#C?>K1?"P;3: BBV\JFD"TH[M+GY56-B7IC=FVEZ85! CUS
M\>67(1,.;@=E6KCN]U^Q"B&'L>>?:1S=V*@I\\1V:3@PRFJ(-\$F<6QXYL%#
M%HNN_=;ZM!3NNA^:7@[NF&O=/'"'T'[+MT+<D>BC<$2N*TPD;S.#'<'RBN'V
MU]P^1ZD\R\B97GE_[_0AZ@L50I9*OP%P7_@PHHHU';>$8.W-WS"U>#[,L_CL
M6?W9([C1'>5R,(%0WH&?@T_XR;2YAEF8ALFH@A$!;O;#<D:T!073?WPN #-H
M7GY'O-Y])\Q.,/):%,.6)I(_UO9ZO@%.V:?Z:O','\9,=*UNQ%1OH"H5MN>Q
M6TN\K>EL5N,D%3SYZ9\=VEJ02UWL6_-9TS_ZU%'7@EHP&L)DK/-24WX7Y%PL
MN[G9[WR--V*UY_M;4R6CTF)4QH#=L5.\A@06<CCY:\[L*^14,QQ=J5R*ENSK
M]_$[#MDKG6]!L1V PNK/#S8JO""GYT5:N(KW)T#2*Q+K)F-?S#4_.7NY9UW\
MM_HIX$<X9=H8. RFIUR>(CW#JB$CB[=7RVOK$O0Z.,L=! 0+>P4]WF]O_0='
MQ9/=*>2R*A((%_HBO\:TQ/)D:JPC U8J)S:AYAU\DS(L8Y("J,1YX)%8TS:F
M\/+FNN0G8Q]M-^K?FD+1KC<C&=-_B'LKM99Q@;$FBO#A*BBC4>5NUQE-<D.]
M\</LW4SS1B_/->KB$03@-\J \)6F'PV-*<,Z-0@YXY'YM23S"VLO.8_2Z\32
ME@O[-<#.ZZ> [Y"V)M#]VPCL!VW_)N]>-U_YA'LS-BJUL'SR;',5%;CU%# %
M:47Q72;RI*K6>U=Q^@[+M.A?8,V393"ER0A77 EZ-MZ!GMK2)3C@^+?:>"WH
M#C$C+(SD/#YC4=^(4D55' H4ZHOL0D_T0%^.DIY@?R[MC>T:@9V435/0%Z=\
MWM0FJM1>5]\0R^A6!7V!F2\3SQ#8/+NTJM:W:RPZ'DY<F LM\<MWHYI5WDS^
M"&H16WX/(-N4VG0C.1KEL&@#(B+2RS_@^CETTG>.H7NZMII)-@?<P^/]""Z4
M#1'R'L6S@KN=O<14%,#O*,IIWF6 7KVN:3:Y5_'U@F)KJW2@7 I@557_C)_2
M#TB56JBQM26?%-\CPJ;[<JN8P8T <S;(,[>-H2SL$8E+1J>AD:&$H'YD6"/&
MIOSS\$W$5L*3!/";=X?J:42'L%. /3K,FK?*TM_UW(8/U+CD>BZ@P5L]IZ^!
MEOC<S\T,Q0&V8PN?4QW,#Q[6JL3.Y9>3,XCW@IZSU[H,EG)W%XBJOQ-VI!D@
M_0L";[@<RZVUX K<$K[X(VCGQ;"+]<9B5& _EVV@D1]IE\"R+&2YH-O]^2!U
MDODI&N[I8@'P$&"[T8V:MX&UG-AZVD"R,RX.2*D^RH(XGN2 7@V7?76\+C+7
MVW3A>50A;8 F%]7Q(-&0,J#LTQU)4KF"S+5R"KEO&>KFOCE-:A>^63O\@K15
M1^ COEA',33S.5E?:,22R8>=J?=_JW)D9;M^FGDN#&5YWTNN;#X/U5U4&W^7
MV%9OA'\X?WGP!\@IQ>4/LR5B3,5&(#5/>3R/\FN^$M%>%@$YYZGF \'N3A]:
M)O_@F FH655K=?""?!)CO/$-2%,-\#]J+7N/1_+!^%6U[6QNIU/]2)C14CGW
MNE3677'7#/0O!"X-"&H2> #.OZZE@YT-QWNG7'9J1"KKP[V['JS9JX7['9M2
M&"5/ ?)$RA*(Z*(!ND\2)20[XSQ:\/ KE94I;7.K^J+G'[2FO7;/%W/KEZPL
M8_H'C)_W-#HA_(7QORTA565=05C(XG;R6"C(&H7XOC'XH\>TR^*ARCM!8D+F
M828+Z#VJ2CR8PD;%TU @/Y4HX34L]=C _?'!97?JV#L=#M50[ET2U[TIE7Q+
M(ZH^M1]=D^*C=]] UZZ)/%=">Y E.^#T)/;Q4X#C*8!W?A[RBE,[7U<FM7"+
MD[*GZ[WV<H74/[,'->G=9IOR8]O^A*V\,PSO/6,Y'7X?9#'^J<<Y2:9'_1J/
MT-C03%:#Q2-,WP*"YUF[4TFKUZ)EX0W5OJS+-?W*OD7!2FBI3)\>S,%CSFXO
M6@^M2X;,[X7$HD,DK_+1LH^PSS7?)AP3.28VZB^OHK"D![&OPLRK])_U-0'%
MVC!),T 5L[3ED#2:?G@G$G3]@(U]&LID7N=4Y:+]TPDMZ;!=F1870O["=F&[
MPZ8PDZU1\E\!6'\R_!FALM-P 3$%Z8!?-*/[E>(:N7L]@>.M4-+J'2I\OYP&
MZ.LI@/.,*1LM\F0DJXN-C,V9:]XP;U/MBZP8?\4ZCQ%D\SN>?GI6L".<!N:X
MATCL7K[.,6(-(T]G3Y"+9C.>K<39'DSB3])%<IK7_)3DP]0EM@[#!YMJ*L9Q
MO5PFZ96S@6]OQMTU878!,,<IMK2"M='$R["KJ=K*CMB<FU=8IR-VKNR/I)'F
M7K@_8%AW5[$1-#X';D5,[9Y5?-Y;T"ISC#AVI^$&^7?UKV"]?,5>LQ6 W0]5
MV5)_6ZS:'.J:N@Q)K8D@@'NPJQN\\]3YJDW#\*[NS^UP%@$<22.*0Z6P$YY*
M N,4<?E!C> R%_JI3^\4[H=D569*H8+$X%Q4 __'@! ',R)_4Z7!UOMNEU8#
M1P^A/US !B:2V7XJ'.P!K4KX,D/<E8B,RUA*]ADNPA?ZO\'R87(<5V+?BKJ7
M7PR62SEN7XS=%EV,9:.MQX7.9%QN EX:XQBP*,M[JU6W[A<T$:(A^'N>Q/6
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M$=<Q(XC]F1G;,@"4PQ;A\[$RG<Z?I:1EQ(9N?7E;E/_JN<Z>0LYK!E,\WTR
MY(3DRBD@ E%N'UOP:DPA@V5D9:#D=QM3D4JRTU/%RGW5Z^[3@>O%#Q"-*F3#
MW(DKG_*FS'6EAG.K]!G[W$02=!D!?3?_?%Y.\$L!M.'6.LJ827)#E/DE*^MY
M@Z#*/\7OJA+B)\_;?2;3P=:6C @2.D%V[H/K<"[4Z$O3Z=4Y*^G,%^0%ZAZ_
MD^78!Y^&20_)L1CX-9)E8L=4;,3UD@.GS"A#!SX9\.<Z.AN'GUWOGB\#:6L
M_<X#J@K$VS!9;%/6]#14P:"A+=3)2X)NNN+PBM6$^#3-\'L #LR&:+USX-S0
MDC(?LNLY_5)CO[CLZ7I,W65S4?RZT:,-]% S[?_>E[?@\NL.OR51+7!%Q2Q/
MJV-^UDNUR)]]=ZAQ?TEW^RN6V)TBC[5P](8+C.!!E?-.QE+4MS'UM]I^'-(Z
M#(3\AKEA!;J4:UMB8V]N*'R_4))!6I^J JS>%GX1BVCN.@XZZ%GO"@0;.*_N
M3D_^)'%7 !9N5P/4EW]^/@7<.]%!76\6)UTFY"\@6#L+H&-3>*'+I3Q<SM$/
M)3_MWZLPJ;:S29/TB.T*5$\\:W1^!<),.)OGMIOLU A,>H =) G$2+D NX=;
M30]P6W#VKRNY^%'WK4NU!$;#75:67QLMU.6\P3;Y5W+;&4M',@E_B(LN.;"0
MG;H?6GK+K)37E\:UYWO%X1H7U2'9%]4)F6)K10 #/UB-6%CI)[MO)%V[7"=:
M(1G')=P9 :RVIPS-\X,7#6!J"?AAFZW:'1=/PHRMY++T5:$V5K>93\ 2V >B
M"@6=$HMA*GTE? 6G1IX8Y%@@YZTWOY')!\M=JN@'T+YQ?0LL !P0=PD2GXI]
MI*1(#/)XPH6$@,=WUV+<LWAH]DN[6T"UD.!&$U^6C 8'GT6G/RV<O]K\G\^%
MCIP3/)( %G)O^H&WB=CQ.Q4&!@B:=?>N)OZ]WNNVJE1]/_EBC2!KUB]PJ7@9
M;%F4?%$1FGY*>Q%U_E+R>PD&GEIF<%!BED.F79=*B 9(V\):L\"BT\-9U>?V
ML 1T-;0]NW#EO"XMR&(?'0,6D(*?(R",1ET/IJ,?J#24?2_V[O_V>-N^%^V:
MU/R4'$>1VT2QDGQ/ 8QK'='R?BZS?19:=*W'Q:X*[.5^DC6/RXXB5&&31-$E
MMC/,Q4QZ/.Q2=0K@<D).)24-G]6RM3[6\2E3I>B/&0P+*0!2-V%X>0OQ'L3I
MA>*<LNBS<RV0OQ]WOZ4>$WE^)4:Y$!P=8.EZ5A_IL"LW=/FP>07W))X=X_#<
M^R ,]Z*0> N2KU'_JZ,W\L50\1P['>KSWFL6VM=PA\NQ4D9BXS,UJ(JCMJO2
M+[RQ2>;Q^N ITW2W4X!5 4T]SJC#9+$LC(,P*%]WR 0MSD8E](M3:W+2V5_,
M8!T50]J![RVJ,\!'^7F[T!RSCDDI=F.)OBP5=9I>E\H_:0%:W6;> #>0]P[_
M#&P_NFLE:%DXK(V:5._O*+_I,EF5X ZW5KIUG/MJ'%&IB^&GJ?SL:67@G.%Q
M*_7HI$HF@P"^!R"K9F759J@T0-="Q_3LC-<WW?GT>B[E9K*)$[:(=QWGJ77B
MZD-#N_(]"HY#+U9[/8Q(=?^=T5%.LQX@^8WP9/D40+ 0IJ_ 77-*W+@]WOGK
M_+,?#A+%IF[=]^/<,"%SS9SD;*\/9=&HJB)'9<OC7I9?%MP9Y^Y\>JW7/:$W
MQ!' 9;IN%%XE:<3LJ.P=^S+#ZE-HH_= 6=:E4+ZCEDP6?HFLP)N-ILM"G"TG
M=U/R4(733D\96E/^X(,#N+QLMJEN[8=_0)V]$\8-4PZM13*-\7CP>=K]'NE+
MB(=UK!,G!2<^I0W+:]N-ZHI0])U1B'7J_>\UH9D-(:L?X^,>M^5@[O@R!WQ<
M6*J7 5+Z(,R- H[QVHO.AD^?WSA2;F.JC3N)6\@\!006<%$MG1B1N+2,4G"F
MC[#:OW,+B4-3KR158G3O.@YXHG'>1[\#>+%]R\#0YNL;KOZ+37>?R9OM8RX+
MB =FI [@U2)ZU&*Y0Y=!DXF+M5%5=2YBV%)D3L_/NSY^VO46!GS;[<^IFJ/H
M\67O:%/FMRMQ2WK9/YSRAJX_L;T97>3KN&A)ZP"29>]Z(#!C'P@V=NY05Z",
M3!FULG%/.9J>7-[)O=698!WILJ)M7"(669MQ'(7L:LKZN2-]IY^I0%"?%E=<
M\6/]IXXFJ6@!09  DI(,!2@MYT\!&]J_ 0$5X XK3@.L-/+#K=2>*I=K2V.2
M64=&1ZH=S)RQC3/+  Y_QN.U3B36&,SB5"O-&TZZA2C)*C_G7#CV^X)' DJR
M-M]8.>/S6H_J&;^\ !^G7!PN7JEW$6^E"%8%_[K7[GZ'YP;JVBE $%TKMA84
ME48'W'1EH?1 F& J>>1/).5;3N;4^CX%_7OWR+X+H8_06#JR! VZD8D8 '6%
MC&95XGB"/!8+\@(^^ KUU$?*#?3NB4IL];!,U^B=Q/!EUX5>COSKB^F])%AT
M]:QHF$#2YZMKMX_R28*C!QC3]K;'6'P!^D+-I[Y4\X\.SVUZ'[+JZ(,E;0_*
M<E$O(?Q&2ZC@\LE9/5ODW88 -?,8_0^,. I 27/[(]7NX2J*!^4H X3Q1]J,
ME5D$/-">%TZVI4UF5KG)1\4[&X%6[+\VWFWTWIATD>!22 @*UO<#U%:$GNB_
M/9Y@*[@@I9N50MHGV&&7.^:KPCO\(U*._]1]3FTR>%K?%Q&7QB-:ITIG$MM"
MK0$<& =A352\ZKU"6MQ[7PO\23 T$XW??'Q'0WWRUC:*'OP*? X&J>?WRJET
MXI\DUL._5EM (-)!(I0TX<;G]D50+;P&P6;1F3;,A=XYV5(C8??1IQP']9_T
MVJ1S ;]]YSO1$Q\,;KL4DVXG+=\=*[DI;^'_K%)74D:T+SZ&L-+3<SFB7WW7
M G &#:<]* 8[N:< :^_Y$RG3>1 S8B45:D1IO8T\N2RYM[^$C#Z,!4'S,121
M=^TET]/=-KYUWI7ZYR?,DPEFR_%;&>F2AVR+L:1$5X93P,25OY[]7(#GR%]3
MW6_"[I),.)S?L>0;-/%Q^/WJE8MQ?_ZX[F2Q?8DM%R9?&X]J-'VQ &'<3*'D
M4:QBD#1&5Y1KE"6.Q '^\9!T"Z_:#Z> US)1ML^>^5Y;Z-EV'W"J"22/"IT$
MJE0*9N0$LOGB>/\*U:H:KGXEZ! ?!]X4]L),620HKEPK3M\?%[09IS9B1K1J
MDL !GA5;S=S-0Y?LI]<LGI5,F&RV%#OLH9>'FFQ:YK^/M[O2.E5,Q[*8;_FH
MW.[S+6ZK-1)9%G<.+AHF:) ?O,3M;A=BE[N5/>/*PC&>3+]SM'VS[]9TR4U\
M-&9'L1/> PZ,Z*'C6CC\!YZ21<P#%E.CQ" IX YRYWL:MZL]@/AT%N[BI(Q\
M?PJP04:S.;GO>CR_EQIALR2M\RNQ>H2SG2T5-/M<1Z\?CL<E_EZ&O)O:(KS1
M\O(H<DQ,O[44IV/K^]Q5(DR,3NS[GEYW029;ZBE@X>M1PI7(A51CA-?ESI%B
MM5$;FE. UJT92ML8NP6,Q3S;6*QNI%0L/G EOAJXGM4L0RC#SB^! FV&!;J-
MK=J2=32=\.EW5(H_3:,$Q%Q0OG[+X%!GDB)!#>?<!>>+?80-*#FHE_RY7N):
MI/VFH;4=%GTMHPFG ;*FS"0T(JBO<S^@38G^7ONC#[1*=]:#29S-7/RF,9<9
M5;LR!@U\+DKEL(U0O!9 ',WG2698T["8W&4!Y_6J%[(Z%LM/WO^!M:>C+OWL
MKECC3L7F+Y9U0(2G7\E">9CJOM9X6F:[%'0[ASWW7I&/;,CV_ V %PY"TD'8
M?F05+XFPB2* 0TX!L>,BV,H.^)4JPN0BBYSQF-<E'#2L?VJ)0<9J_-(?[H^D
M#O81GW.!8)-O2FLQ8WQ74NZ&71AIZ!6E>V(LJR^>*5Q]&29"=(+!&L<;]3T6
MI/G_9 X>K#(4-!K&5ANU2B FM;I4:CP&C('E) UR'8QE4>5+\8'9]<8G7L*Z
M7U[=?=H9J.I;TKM&<RW'1HQS #OV7_GH"BA4E(YZ>/97B[_>*]H]?<]@,T^]
M]"SVKRM\Z6^G(RC<HD+]4.'Q$G@O@O&P1-$"T2;-'?FD[9FYH9A[6;,/K)N\
MX$A]"F@SFE)I15Y 3U9]Z)4Z?)N;>@]E(D@0NK?PR6U\)T%C)<@Z&Y*&XC@%
MV*$$2-<)X3:\(9A#-;^Y1_ATL$EY9.,$(WM'<:/H5='5'J"HX I;(YQOEI"R
MWW+RB-#5*K_+05]CK248>:F2)G#AJ^0^,P?50H*R\;GP]R2;+"A(+_'Q^*&*
MR[561;EGS0-&63'% 8%7FM_B?#"G@$6K:TMZ,'#F*W[L'4"&+UV.T::IR#3H
M">C!X3@,1DX.[V;C6[<HVAIV2GHZ4,7[%C:4(,OX^7%Z@9%([/<T05/M,U@\
MZ;R8'.+"(=$H[?3MUSGA-3--[SW00T$N$):;.E 5HO^/7=Y]ZVN;</JZJFJP
MGZ6AMH-;SWHT/^L7RO6YX[(L"A_L.;:V<U9Z%Z90\"'L@W! 3K8MEG/83[B[
M@@]8L53>:$.4A=W&)25+YV1P#Q]\X=.+V=6K-="W4?O\&J P&"0\B@U,M"0G
MP57UN7Q8Y*>T?Q:'W:QVE1:4?!ZUO'I'L;?=/VH N,G"3?=IQB(TC==8,8%A
MV=S&;?!C5,BQ*1KQWW!( 3;_I=,*VG$*./N.QGQIU:F<1)COR*>T/+5#TP91
MM7:_1A:6R9-3P79]R.ASD/-;1W(34'NE>^=BR0$'@:16_?7LAGTT35K\8>?_
MS1YE#%3!#N,'L>*QU?156_MNBP%W'O* ,1QY#!?^"J<$:2A8D]T,R>G#Z>.J
M$AX*?F[PD &3Z9LP=)MQG_NA]U55VV4:M=\P,/$NI6N(<'OTUCQ59T"1$^92
MIWK<>;0;@TVH(SZZ/R>.OE7TXIY<K#\YT85RR4GX7(!HM\4S?!(^52?9S>N:
M_.IUS>B1FW9,0;5O@4 A0"8CB!'U&LE*>HAKB@W+&BSS+/HPL,2W8Z=S9S.W
M!C<3Z+;;&0"$I(! C=(^6!E\<,:^/L@ARDJWQ"DZI%I+'8/2]O+J/EO2)S*+
M;)P64'3;R=.&EQY.!=.Z'B#5P)^LPSO*(#<- >XU%#]%S@E!JRKM6KSI/0P1
M^/"I.FQL-M#G97''_@2=DOKR6!-C,QVYOM%5_#W\JE,&UW=I53]Y*@N)+H-G
MO\-$:0HG+M',Q&N +&$<A';>+A2+E7-2RJW^1!ONWIJH6;WBX1N "H"W0""Z
M-$!R4#*&H+6@1^&'W1Y050RZ6_/TYW4^/WG,_CT$KWUWC61%)G6SW#\?.)M.
M?OKG4#\U%3QX5.H ,EEY'S5R_>OW[S5)._JEXF\C^2.18HDMW/W093P!FQ'B
M*UT;7N6,YO@\[?3#5SN';2>GZ";IL2D:Q+RM:H5;:Z<($ZR^]GAB: R<7&])
MYO?&>OS\)=1"G*"E?8#YL298-@YG(<?"^0B/C/3>>$(PQ+8?"?N/XM,JEA4U
M[DB@[S/O1Z4 ]G?I$:T:C6I%K_1=ET L5NL\_:W:LTT##8^/O":B@,2OL=4!
M^GFOO%/&TET0+]RX_WSZY2PEU]::<%=4)$A(DQL;BW$ARCJ!F:JFP5S0!U==
M#IRN\(Q[R]X;^N!S\:.7_>7W:><UQ8&"^]UYE!9KI1]CJGRE!/O-1Y?6]W/&
M&E!A5VOM=,L];4X!-)ELW[9ZU,7/%A,5P4H5;VH1LGG2^.PV,K?@TV"34"1]
M\T(:T32/D'C7B(. ,!G*R?!_W%0+9<8/R;OK_F"O,SNOR?<;MHCMQK-CN\.#
MK:!M.T8<<R'QS@R.TJ;#BB(S!VH:VYJ9K/:[%$9QZF?*TU!&_4S@BJ_7"P'V
MG;_L^-8L29G\HY%]6:!'RBO5'\DX=_].Y/5)N^H972V)5L$5NX^LX:*UA>U8
MF<5?/'W4!-[V7&H,W4&/.8Z">ZA_U._\YQ0P-8RW'""!%B,;G18%//(U7ZW7
MGKRJ<*QIH./03;BW^)FZZ8;[S9 XMNKE>#MMS^?K[7\=.8=<F\<.^/.$KSY+
MKO2;&9PC#DZK@XSZ]CON\%_' G+K48W^BC1!$ W8?=PC*&AQ-^*0,"(_Y?5N
MG/TJWSF-_.?JTQ4:@JZ=NU,VK4C@%6>A>ZM6NA:3C4Y)C,+:Z-E]!A%C839Q
MQ14::Y#;7Y]FJ'B<YH)XPOENF]ZB=_9"D294 *(MV;D'81\;.@"#$PH+^I92
M"W>E%B(/F9;$)"^/1"W022D!DL3BT1<N].O.>H.IU06=\/'3G0L0-E6W*!KU
M5"[T>$-]$CA2GFI5&'#V#!F6^@JV#Z&E)&GW%;J$?0Y+SIB,EWN-:TG&RH)X
MT)WI&6T?5R[LO43-:^$Q9A.R]?%QFH+G=?V.YY>2MPT64+QFAN"P2W]CC,V9
M/O^ZCW86I0H4EGTP /US<RO8[\2AI2Q,EB1*<,TCP)<H5G<P<K<ZHD7EG43=
M>\^#O8 ONGP5>S/9-/]FF(AVSHG$MJESC55/9OE'>#9<+;,6NRA7[%;YB6_'
M>ZFQ=L$'HY(+<\.Q4#Z]R)IS^FX^12[,J8N_<&.N*!!(G,_UGO]G/QG<Z:P+
MIY? ;E-F(:S'D<7.MS_D:[F=OZ*GI9?SD29]S=$DYDO/"B. > I8ZL88+B#>
MC;MOC/L\W#P9L5D;KAH0RE9[%Z7W^,2VMAK:CFB]N\#[NFA!B:7V2Y#(:*#[
MEZW:WBZW:9\:_]%30 BD?.YS"LRBML,AU62DE-=WZ'EZ@J('>E?L(=_\N!-
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MR1:<3OH?LU>\UL2^1(.D9GI6[*J# X^\<7[B[WNNQ8/-0[Z\MO7=F9X+)$!
M3U ;-EL*:0E2V:^J?3^Q%.0CO5!3$U*<W>PO0V*5(0EM62:@9G+M1 85[93
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MIS'NUE$&G7GW.'^379MM\P^1U4#5QXEMG\])24'<<TJ?0K\<6RV"=(B=F&4
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MB;^6^=3_9YW^_P/K].4*X/:Q_UPX\&%98\;TA4RTP91X_(W,2U^ECX1"=1B
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M;W%QSYFX9/=YQFO,#5<=KC*ZUA5=LE/_YI53P_!]ZZ)GQ/3*ECM+5"EDT86
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M(;JV-=6G\I?GJHI6H^*WE@%IG:&/T^Z)'.?>AASAZ-N-P6VAF0RLBP&XCZB
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M'S.TCI=[3\PS47\F&[NI&U!$;_G  /(,0B*((!PJ&GG.M6H<%:_2MV9JZMI
MSMN:CW%;DWO=^0W&1C #D Y45^(.I@,<5X>-6U-P*J\>$CUM?-K>UJ\]]JF1
MQ.V<SJ;2:F:DAY.?BD@GDF_=/B6HB"!3./=22/&$Y/096.*T3'^%%NS3DH47
M>SCV>Z#:D7 UZ,6TKN>R:6[KUO!1"D[P^:?Z %/YK_DY:W*]S$@H&V)9&9=\
M7_<[H6C9Y'B<D@*^YK9#VMLA-0[2#Z0'?31G\TF3(O,N0FG2X9BK%11VE6(N
M-[G;FZ6E>7<?7$NO% 3R9-.;)=RV+/_*(TG_.X^("[+LL\R"8[,ER<XSKR2L
MF?+TGF]1JF@A-3.CBK52\&E7<L2>9>_^+O.YF50V.OZDB@6^'P_7R]K<\WC!
M )KOR-!]NP(@N)A8E#M8V'06PS_5EQ^@V)Y@>NF!AI]!\^;LU^:=0';HA680
M&9D80S(EW^%-],&2#4ZDLK.42<[>TM!&3#^D)AL^/J^9:#\;JI$3F5,5$TF7
M62:-ZQ8XJT>KNCT_VES-'^<Q__0QW]5#N!21R5S^Q[Q/X'^,S&^L21#LJ4?)
MX3XK)@4Y1O6)MJY;WXQ>",@(/H#&W?5=9]=9V>@;6^C<HEXA:^#>/-K45]B:
M>*%HL^-ZTEOLPJ['*\S,;9;%7[^Q0B@7V&&JY"$%?W/7RM/F*P>#;N8^+%Z=
M.RP9%=OWJ)=6@%0!AS, L&-3Q9G]'0HM\WI2YQ]-R@.IDU(+?QG'FQ*,9I(Q
M%"-R$WV?8IZEH*F!F(+=S=E-TZK6.B;[VV\AO3499J^G4[=+YSSE(3%86A0Z
MGSWIX)Z^_$Y=VSN#[Y/X0BT]8Q*A2ZM%@&=[7GBHUB@VR/F>!KWTN5(UU@53
M?6RD,?\G[YY$W12(=)5L]=85X\CDL0]T#%[Z-?Z@#IC*41:DSBZ0_QB)HR)H
M<>X^4_Q;<#)2UJA27WY<ILQI.B+MOE^/)^N;DNM/6GI9 ,II#GQ=N,;;U-/1
M!KQIABT9?R:&LR^S;]RT;&$ GYV[>AI9V_VF#PU[WO,0N_$TR_O;&$5^04:*
M*0KT.[4NB"R[;7 ">R3H!-@@<[:;($6@D1OH8YKJ?TVJ$A"IQI<I7TRN7,0(
M-:D'P&:FWTATQ:)?>IYFFU@B%?^VZ4LNL)1BH0_RU>(UT'THP8#G2D>0@^._
M&U7,M.\Y)WAZB<I<<CXZ5>\!L7$@HN^1GU TR*](+WYYZDH%;-VI&529,H0I
MLT49Y6C;S["W/1&W?YP?\=I91$-*D@$0C$AO!W0O!;RC& Q66$]IK'F($GI\
M3_)]DQ 0L6, EZ!1KM0 VEL?;"AV%#4N:C;\@5:\L$JY^'%ULZ%AP1_] GKN
M)QE.T27+X0YO[TY+#"XDF&<+>)V:ZAA*NVAH9>TYX)=\6SRJK_%@@>VP$ /(
M8NJ\)V!:52ZX$'F4:EI)KIT)A@I8C?VX[^4MDQHK:]^KIG$K[=*"T RVPFO-
M,M^%2)[ 32SZE\-U7E=!W*T$OO'(:ZMISGA!,OPAG^'45^MQ# !^#+ZO\1&S
MQD$ -=_+C$0\P<LE<7TGGERJ/O9@=RV3E3]?UL&=WQW_B%@M_O0,*]YKK =_
M.+,%*FFSLKN/V/]3>=3DX8EJ)XO#V6J],*]G=%^242MX?,60C,$'HWC&7-2'
M!7X(IL6MGS(T/_K4$*2ZF;*:0%AHPPC09:==)0],J"NVR=NUGA803>//4FE2
M8A?*LQ,GG<5')I'LM#=-DE2-$?PP5>M@+VWMNHK+,*IJTC3J?K28G:%XRB-@
MMDF1/CR.:ND3[<--W6H3C?H>QP\3^BX@99)WOPT(G(F^E;WL-JXM-ZL%.T;V
M,AU>%0O)?NLA\=VHQL+\<4CGXY .Q 0EB'J)/D'0?35+<=GRS;LJ52OE6_UG
M* <#\#/#[!(_=JU*$(_1^<$QU73AVDS?Z1A=,HOVJT 3>QT"CA[VISEH<$=\
M\%2%LJE<R9.3S_T=0G.?FJB>8H*Y&WZ#K$?G<#,\BZA?N\NCB)7PEM*]3VI_
M<#WDB9X(E ?C+B$[FYE20E7*"W"[L:5H2_27?R]MW"^L?'[Y"(AU*&RZ*0*=
MC)K)P8(1Q7"^@('?\BKYKL_=C0B)VODAL.<7Z3V<%-%0SC,E6'Z7N%DX>%GS
M=GK?H\RJ#9;L<<-DX]U#ZG*'V*4U<L'*Y!S*[0 0SF=KS/81N'B9^'@<^?R=
MI>&VG\Q)2KCWFIW2?T_$EYI$Z*VZ(@2"*5K$MGO6NO^IPGV%PQ_WG=FTLF/>
M2\2JKO%1N<C>A\N;FPX3EO3J+X<H"R-0#;?30K:R@,V^&'CUL7!MA\##R5^\
MO''6W;$W3DW(5]7'+CJ)2+].+ _KG_/;/Z<A?-O2D#=1N:1(*N4&7! YG%,^
M'3/# +C-\##VB3>:7)8&F,$["0:5HV?2M-,LN9N%EB)2$\5)J$\Q'5P8@0"C
MVX3L/"V86NQ-4W7O=)+SU[&<*T[XL69Q3F _JX$+!UKSS4/ B8V8Z-4*L16.
MW_$F5W;Y\\ZPUTJS9NV.4Y/(@7A;Y^8@RK(D1+ZN@;1I-=$MNNZCG%1[>>K3
M=9VO.N]9M]5G%]8L9]"1F>A"F/SX<%4,_UW7EKMM#,!6_-G'D%K/EZP::(F_
MNBN;1\Y42[*FR3U%.B=8\,X$GXUDW8L?(.M0>%U=[TN6$D6M*FUOS@4F%71H
M&8F?JJ7-Q>O7[\^$<D"#2X-0\5!':!3]=+F+95M/OHW'N<Q[[GT";W5(<WFH
MYC_[CW2U0L>EF?3K6/?/#<D1BSM*IS,1;-ZAFN4SS_!3)EV/Y0:+-REX4*L2
M/_('7;,\36R)^Q3]9X$;DXC7*U4D)CK/^W[]VKT,UH<'('MS1([AU=M>>5AX
MI*X(EY)L#65F./1  1(98=PZRD:/@,9_;L-T;@,GU4';43'^DLII%W-=+3:[
MQ4M1Y\)$KCDE^+!F;?8=E/FF-HK1VYAD>TGG!Z*%D'>9F-(EQJ..*TMY+-\
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M>-AX$G-!]Y\MQ(3VU6? POIX#-LB\D08HF9'SGC]6B E\1N7TLQ3*"= Z)O
MTXVK<AC _1KH]K6=" ; QA3QJ;(=*!)?"@,P&-Y=8SYK&6L8 _@T"=D_'=1R
M,/R* 7Q-G\50V(T8P+M%UA71OPQ:T&D8CYR43.3Q9"@+&;E4BE;$;?F:OG@%
M%C?;O<_F(Z_\UVQY%U8,^27%(8 +-[5=Y\/?-VMV]?28S#U[B_C3(#:5_+#4
M/J[ZU(CXS1K4S+O4E\],9XX8)P"K6<T/N;*-C["DKZ7NE$%);K1G&)SCTN.
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M]LV:IP$).FJ@/B<)OFEX,.K*GHL!T&33,&I-8.KU(?IQ6[?-Q1M7]]?110S
M:4Q;KO9=ZGSB^HVI3_EG(.T&0 B.Z$7Z1("U>AB:G7-55&WTO!CG7C%3(J6;
MIG'B-@,H5VY+#'L]<H, FZ7E=/9QP-!WE[:6/G4$D)!F;<47SL5.U. AEZC%
M"^@H^*<_U9_?>(3EVY$KPM0<,1Q8S6>]KTTGW4K[T7?B2035L"F;'$R8:,-R
MJ0CD!3SJ*'$7O?5X<5"[8.[<Q[N9,IM" 2*2X:&:0?_!U>=_]#W7I(CJ/D,L
MHH4IH;;U1ZQM,COZ]DY)JC"C\M0&/38(H-:1O6?1 F3U#KYE)%^:2V5%TH!:
M^)BGF*N(5VI&&'Z\T8LNJD1B2M^<-4MFD/.AB/$1)&D&D$8I9  C;_KH":K[
M.GJ0U_[PBF-=E)[ $VD,X.[M)^$/?IY,BOGYG,]H2/0G69]RBMPWFQ)[ZRXQ
MWW)?,7%SK_K6LDS"RI?L/XJIS3D;-5T:8G66B[:"++=,!DJV%90'KP^N#0QT
M#IR*9C\I<O>GH9!1/R>9\A_'4<,?6G:B_E.GZ4[**)INMGN% : 3T#3Q7S_^
M[@!8\+?QU#8C5$%6NO%T$O,M)J.VLW^'7H3.9),^%85JWWCZ^7VVF9E#(#"?
M\>!F+N70&@,($=TO;SJPC0A>>0[#*0FZS/J*)OKW^-EK"P@8OA<)2GP+&I0>
MLAP> BP7L&MXG%P(>+8C&>U>#"%UA'<KO^]T2HH7IEHZS_(@PRT7T&LC>#$4
M']6N>J#4T>J60;EUX-77L\ZG1IW'KH(=4O4@EO1>R7/I-VBOJ4K%4\(O2ROV
M'-RSK>S]$[VW$RT7,&T;QY?VX1UOE#KLSD;CS2L2S#63QJU/5J29I,U$/31'
M(@32+OU 1M-[D4*:EJM;.+/3B\HA1===7TN^]3P^3[_)/(/P"AXE W)'D8NN
M<I6 Z[-'F+']1#/I=F#:X8&5L;W@5LN:'L2! ;0UZTJB^L7:L60N+P;0M<@
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M9/MJ%=2/DB[CL'J.")U]X+3P2,-2A/:$K>4,]PF$V.Q L=8!Y@]O[!&BZ+.
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M]ZTB\_G>]N<!Y\3V;6 Z44,[OHVV3FX!D1FE80H^0B:;MT)W?"2^']L%4<V
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M@@+[SXST&MOBP^H'GNB0%1ZPG/ CEOR_HW/27:29KIBCVSHG.[F92H63\[>
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M QF[CL9^@0&LU3^-'T'N8J0%':$DC&TT#R,@A*XCO6YEQQ?R%D_JC>P52M'
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M&<G^5XXQ;YY YD Q8/R!J]JP9'1),OTU_"EN01:58#XG%60;] VY<I\I"/K
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M31X X3?R.M)QV,)3$QPHIX*V-/&8U:J0HY+V^!KV,1P<$_9I>@VVLU!E&1B
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MY>5Q8$'G!-8!EIC%NFB1*@23W/IZZ_;EGTYQ^@,K5;2T@K"VAE//)R,I9-Y
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M:[![9V_F897VD7"3< V7<$TU30LIDLP[[TJ#NGY,<#:D(8B8I[X+YT)?8X6
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M0*;.5 =+G7G@<R0^B9ZKX6^=L=7KYM>YV_YP;5Y"G>I/6E4QDCI2^W2DYPR
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M5$&,]4R\J=>1\+:6@ Q:A@\_CNN>KG*O<&=)1?&S<'OFB8JBXR5E@5)>'6:
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M%XV7S?/7U8Q^.%2%<Q77??E$:,N6(F)TT8>_7B'S($\9?)4PG54YMS;&CXU
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M>W:5]J:JO8QWJRJ^K8>R170[$J\@L?PP?!3>]0RP.D2<7$TY' MP;\N:6NB
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M^ST+BEYF8"8ET)\%%KRD:\Y&FO1X3>J12R \__MK+A\U94KO)['J08%>RF
M+U&'@;<U$S_$YJ&0^QG<0:\E<%C-U%>N/)0BX/8I5O-8D1Z/K&(H*\X+KS#Q
M_*FK!QPJ'E1[5*Y]<>Z]K_9:X\FV82"'P"B!!<HYV'+=_X8UU21KG*Y&J@9O
MHJ3NG4>X5IJ22[=36M=B=N',A/9Y ,.^,;?FY<S!ZN?ZD_1+N+HBNHS2*IB5
M.)LCE"VZ*VNFY^$;S?2>5JGD66>QLJ'"A?OT-[WP&LRROF> /Z!X8AQ-&,@B
MD;2.#Y%GR2Q(UD!M!&55.?OMT6OWKWJ\8CCZ@)Q7#./=50U)0]=N,B\*L6#<
M),VW'EM133'N]GUK5P/[<]($<L3*[<-S]EWI.SH:+%L^YDVUY4^:EWTO+1WD
MYCR\%'I'C:4SYE4.G>HU QNB/P(H:^Q-I42OZPE0\2()ATVOM:@IWK;N_92I
MJ) DH> IBX6_@HJ6GD7<2%A25)2DOB$_*GH;HR3"SN19(A8 5ND"H'EHT&$O
MNB=<B7G2/ZASW"S<:DU40J_?EOY[K>@VGYJ@5 NM[.*R+'-7T-=Z#%7'4OYF
M_Q*282U1FS1C.Z+P9=0RQ]/G\79<H;S$NZN%&Q;VB,WKZ'GJ'<7M ]RKBI[-
M"BM5GM7LOD[6^ 5I-R^K^J]X;O1\-'I9'ZV4['+G0XZUN86Y^K<?2$Z&6\8V
MPV['+4]5/<F_RF2#7B-LSH!CH3W8Y(WE,T EOJ7]]+."TQ*8""\XY@.A<4IC
MB2H.H^^_1*G4G2^?+S :R=%YZ:X"L0GB'T$4X@E7"?/C%68=MLM;<NIE!JZ$
M\1$],8T=7DL#W%=/W;E+S0,CAYE8TZ#GR3W+VHKZQY=L,)"EDNR$3D/K5^"*
MGHZL5\E:7@&?+XOKO4N::'A\FM'+DV1P*=9K0#,Y\0"9.@MK4\3_"P#3^2)Y
M]\L% *:>2OR8"EB!.".FX1TM"NCG\R#TRV1GJ:,DU:/T-^U#:N5,,O=IB1GJ
MC7E#160&_'<@3T!1$X1K:!WXDJ+J]1K70/66_JNA42*JK/2V0[%Q"?;D.659
MK=;EL XXR8+Y@H6Y)39^ETTLP^R!HR%VY7Y1D9H5V,\*2]8\1V=K:*A7E$ND
MW'HI5,GQW];L&!C+C\0GN]/#)LW/)7R/U0PF8I$0AX%W&$USU'L%NSBY^]86
MG4!?)5TW\ ;25)DZHVOS):^W+82?\+<)T1YI#9;!M[>VMY6&MPK4XU$UD:TW
M8T0CV0N($64.2W[GOYCQ_!WNG 'WF[W'5"R'4!BRUP5.?C1K[L'N?%5Q=$3M
M#2F\]!0#E)N.Q'L=ASSG=3ONZQDPD8$DO)$\D52@FVWC%>?NOQJC/]2M<DGD
M+GN7?T\[<DJ\'4R!MR9_M1^L9E[?$G6+VV0G/W*9JYOV7F<^)"[($@AYCG?!
M:BR!IRJ7#%OJ<SXL#T5.3'MG:).AZ :@'T!'T3SDT5;!RB?&*(>MQL6%:T[H
MNTN%H"C)MW5O&\2GO\\7+-+7;T1WR]E-#*8/O'FRQ"ZVK#,FF#TJ>.>Z7<V$
M:'1<3YV",3)3Z/1E"'BC5M<CSV(]A..9K(AY'U^HSP"CL@D8RRBSILPN_0;F
M<@9$*3%^<_H\@:C9]DU*3;?3YH'@*4+?8&N"XZ#UY)T[KQ>J$KJ# A3X@V"H
M7Y;EGTTLY-KLGX/Y5CE#\;N>2K:1Q-EPM\$SP$:8Q&0NH"&ULL3Y%87 I:87
M.1MO)Q_UU-Z3\X-G*S O0D!XQ6$&+?3O9-<O4S3T;X5_K.(&_LM=#HP./\_2
M'M[<XFM(/3'A4L]<7XS@_0&0SK#9)28GF!W['8Y@B0*661V;W%$;1O6CFSF[
MU=0F45:.U_GL].?2>.E&RR"-UD9#RN ,2&7MECT,'3@DP?YLV-+A7 %W?_N&
M>Y##+_1K);1/5UZ#+>DN6\3^7L@,F"KM(4YO#&X&.]YEI#]&9)Z7FF,Y&/%#
M32P,<^?0\I[YK2K%1Q8?[NRGT07$K6/>ZGW:52>*#Y!L=4*@=1$4=WT3@I:$
MGFW/!8C>YWY56^Z:GY"-K,L&B6-VNF&,(>,$OFHT_TN)-6\$2/MV+^2]YW:,
MVHX;TXN"IBNAGVID;:M =[#,R_*Z$0@V09_+]YAW7 57,_ONNI&_]Q-092+C
M].%<3.QVV7='79BD+T.%AVDS4*6WV:7(.+]OI*8^8Y\;,$VPRB=6>-HTTK50
MC@A5L%PZAM[_6>1DG*Q[^.')2'X<5X!X4I>5% ]_<CCYC5#%X18#K!K.$%O9
M@V!/;C.+RLA5R6-]\[UIPY'/%$.OWM^O:<R;C>S?&&XIAC.AU38+41  KV;-
MLG827RU55($43O92$"*S-S):O,\*R/;\7!L/5<S\+\<?[?7E6GRB.SMLDG[O
M?#U50[5PU&= KX\NCFP6MIER=/1&0=IU&4SC/'UM,ZG+J="LUTF\53E1?[3P
MMCHG&X<8:+BI%J6VF8<2CI@7Y. <JF9W7M]7/B18XM%-0>;,,B;O5A/,@,.8
M"_K6O]'\KZ%@:)WS#?DR=N8O-^\M@0W(:VO0_DZ,%=4H5+3HIY?[D^!?QQ6F
M%26Y=F\XITU-?)1I[RY+]D&93S/PTFBY#8.LN\UC;@OZZL/Z!?VLD10F<8T\
M#X.7)R2(U@TN@C?^FU7/1+,>^3\WKP9;+_9L]>0XIUN6?5P>#^8WBKOO\#B>
M^_"(S4:<E#0Q(83JZ#L;J.B.ZY/FVM3YI9NKM2F:&E>+F"TO&"\4/.7P2QC$
MY@/T1I>?F*439A[KC*K0=*J((.*OC^NP_9/W /!./P.V;-&U'8="GO.W(O2@
M[*DGT NV"QD9^=@KCH-=OTY(0HO<:4X+]YJ97UCNZ+Y=Y =!(>^-M'A?09'=
MOC_*;"#+(O'>E2RGX8L*-Y.VMM%4&*]2,M\JN_MT]_.LIUQ&:;>8B$C NL"\
MTG\V\F1?!EWZDYX6#>7YZG3277JGOJCC^HE1CK3I%]Y4GK!(DL4@HDR77^#_
M,_3-YN%ZR-]Y5\LJ_N]YS7_WO(;TJO[?1Y_!7;%M:)@J=@)5[ JRJ&^IKJIM
M-!\+5KJO05TD!VCETCQ5F1E)?[.XTQ;,L)@:'93WQ]CXR/?(#^SD.\JK]F+F
MWN+5!TSM\:-$OQ:JX=WG&IVW'KV&'O\TY/3KQY'9)S2EZR\W W/IH_,O4E]R
M]TA;@1('82Z3"D-:XH']3)U%O0X .[^J?U:"#>U(>Q1C,(F]*Q-#_\' V23\
MMQVGRG+%R&D8RCZN$LD?)W%XO_L^UZ^0.I2^%KC5N&NA:K4;2X!@^]4JT0=Q
M(T[I_OZ"B<NGIZ,5%5$V$;P.SJ163;[\Q'-/+D(GL);/5(1C?/Q>B<P77M7L
M"@I5EU'"0C0/%B(1E>YA(?06U#_!VD&E!I=S'XU:#V2H0J)#"Q=2]'0\1F*
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MSM\P5D>)]GJZLJ;[>\#4(5(+9A:.K KB%%>ZOLY_[6Y0UG'C>4\<WHF)ZP.
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M 0X+Q]P<Y!=-20A"J,"@"VO;/&,56BW2N_12MT9>Y8CK\/BM.TP2L44BU%<
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M)[QG62>P$WIAM"UL"VK![E]_ECK3L77YE*CSBWY:N1)F*";3X?J]A[PT2 B
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M_2/O[>47++8\0Z#*X7]]&;OR1 YJLO9<_(D!$^![.<L?_K0L^A_*'1W 7U$
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MFT<[:U?0R?Q:;#<2.K2^M;NG3/Q)[TVN_KE7OD,!R"Y-Y!48J171!KE$//$
M'0/92BQG#;P8TU:W6::VOC70JRDB#9HE=@O)[(+R9&XD\8+5+W(?!7B9=FP0
M/)C;=VR6GMW:%& (6I_E7,##:A%=$L=]5_.;1RT=B\R'^+EX'[E!LP-Z@&#8
M1NZ.5V,4*>$+?,T=,4I/;)N _MKP8CD6?'P2)Q=A1:U7<>^C%O2$]8S_D*Y2
MCL7O]8$ND!BE2CR0 4P7M+J-4@!7@TB\?"(C5P:^D&^OOK8J3B3H=')I\*,6
M2;0KLHTV$&:6V'64+H][?WACHWJGG-.W'^7[0";,Y+6J _7P7]E'A!(A_EB-
MP(Y^OCQM._%(3\V.=&KL[FX<!? S$6SVV&7;LK5L.]$)M>F&:[:B&E?#S]>$
M.P@U&V0%\YY0GM5R!C02*4D3:#J3(SB.KF\V2JU\Q^,"_+XIQT"UWB"P7X[_
MUWT3!-\7TF<R&$;H96&\Y17HY;@]H7=;[CG[#T>5"GE_EY/Q3#G\-9X;A/SC
MFP3H KG2\3TA(:#>Q>7!\>U'#![G+M4CC(:6]+PA_Y)=9S1W.C+6/O+:>ZIM
M:3+9\T)+I.Z6&K^)D>U]'#\^DQ"$_;IC)6AL<6S[D4WB0F0V;X[).<]'D/NJ
MM+RA*R.B@'\9Y^Y]Q-8^=AWCNQ@DW^W=AZ2U<#Y_N77E>3=9;0)!5"$,+LS'
MN/W&+C>X!KB5-FS.2UF+E]L]X*<>/:6Z2EW[EZ)L+L1P;ZECM]$U,[66D;62
M7A=?F7T9L9/I>TG]NCLPQJ.7-[3_:#&LFM0:+# S4_3"<4ZX1E-!1M>1[OZ!
M\E/Q/W[[34&#Y(G#XB1>PFGVE#?+E%FMJ],^"3F;HD$F/J>FVHX3ZIZP4F.=
MM;EEYR3[O3N6D;501S3!C5.M7WR2"I;Y_<+*%NQ8YX/8[1'7:VZJSIO"_40Z
M0_B"ZS;,E(R"0%QI [F;OM2E//G=='$D3?#V;:XW)/KR+C+);X+(OMO^:%H+
MQQ(G'GN0)LVD--;W2QB])#)9&0=O9P*"7!_:N19/3EM8WDS%IPY_OM[%T]D;
M<_T3Z %PZK.1!40<]S1QH4S8QMAFM&RO#")-;>!Q[G[_:N%HEAM(+$3V R)K
M/W&Z#5V>[OVP-M9ZK)"7 FA756G<^J&D*RS?ID]N-BUY20&<#2)M+S8DT"&V
M/>D>BTKB:VJ[!P5M>,<\!D5#D:H?J.<DD/!G\ @&G 'Z/M$;&S5>G>?ZF1\L
M=1GR)PHXOY B+13M(:RJ6NI&G84;J^MCUE'WF02&ZCW=UWG<- S4P%S!'6#.
M.#.EM!#7I<,+L_#WOU5Y6.8U(7D@:E*:ZL:6$O$'(>T)=//@6'=F=JWRT-#\
MV:6/EK>+@/&=A]]N33NIP$./)M;T<^','Q\Z!SS'Z#I%ISIDP<]6G ;WQ0"5
M)\(>%$>>S-UQL;UV(JBAI"MAS9)DNGD*<+Z-'S[1@B!'7 @H^?>Y-XG_G'HS
M!$V;F*4%ZIV0'!"V8.ES39#YS'H,G;.RO@'DR:*"R\U\E0?*U'VJTDZA/T_,
M'AJ)BL#<4BUO>:_I/V-CT=O79B20,/_Z!M5>$&<B&L;M,"<_7#!6+7AGWF2D
M6/0*?BLI:4Q[O<@'=-JT!^ PLO4ZL9%0K'CGU/?:EO+NC!#D$<VG]!5>\LX'
M9=^591%4B"I7S&'^']+F+)W_LUD[QHKVEA/MD*IOK@)1QK8&N[B8%M8JX6+
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MH]N7#(6R)KR>B%>BT1U@NGFE=Y#7KJ8>*B%Q"03ZT+<N,=5\"Q?5"ZWA3(N
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M3&KMSX>1O9RJ)\&> N .7((B@A:Q3NWC\\RMO+X!-VNC-;&6A3,"+W;K9T7
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M(XQG-&C,*)1PE&LY=!(DX#0;C<AV6)SI!#?_%L+3:=<5SF@OK!WN_!:*8FQ
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MC_5G$5+6FO.:UW7?UYK3VTTE ,74KQC^Y4.*8-:/WNN%>:1/&=(?CQ837/;
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ML%@W10/&U9</I0!GF&,[JOQ1H^C@@R/0^1BQNBA'N=6'5_T".C90,L&QN]"
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MB"PDOEFX_J ;67,^9F)/C?VWUI3%5#[I\7?P0L\Q3J-GFN+%UT+@!=C11!K
M2U5V-IG,X*%.C=QMWQ9-O=5AKA,X+-O?@/BB=<H']]'X8OM9%VY.X/%]9@#P
M.A:D[H8';7#/"6K=W2DOH%CH-3ZZ('VJ1T7^94_NY7ZMEM)]]#'\\U]*E"Q5
MI7F/UXV73N<3'2TJ/#_/=!C>3F8QF>%38^@04F][+51T)&YUG?04]JH52@3-
M7_$0-A<;&I&1LNOL/1O<U'54((=ZYL2X+$,4[R>_07$AQ\5I@*LNU,^T&?/'
MH'5%_8]!RX@Z&M^X\X\.^O]]_/?QW\?_D4>]XS]<-!LC"Y!*<7)&6@QFLY\&
M& KG@%CIZ@K6E0O%%]H'^5166C=T@<2,UB JI%<8200',;0=>=(.P@F'G*@>
MVB.]_38L<N-RM_ TEX:*A!NV3A9JC*I!@!%C$':XM\U)2U=CF,=]$:X)EXT+
M)P(_0438V=DU5Q/EHP%".G&,RL8S[^H)#H.KQA9YG7==-87(B1T3!V\*TH"#
M7O_^MH0I1NQ!</E4:-Y:"0SU&(A\OM?Q*W:FZ@Z#1N-<RLIIN.Y9*RE*'E6Z
MS'K:)?U-3MU5E-AW0*.?="V'K+_OL,BX 1DWU,DP) H=<'TYF;]6Q6.\Z'V_
MI+US@1/]%NDZP^YV9H$&1-V)(=6UGIZ^2_GM] ;<'0IJP>B0^;$6,DPP4X.?
M"K\E'/.F/M7[K8T+E!R(BY+2<9 IK3FWL3:CTY-$E%:EDLI2'+_H*%[:KJ9"
M_"6;2JI6*F.UXW:P!B^"G1*)X"=6M?@K5C%7S>O$W"^+7O5Y:C'GH3%. XS'
M,Q'<)32 G080Z<I.$W4&.?<80Z\WZ$N4MTB7 J,(?W^8;ON.02WOJ]$G(5]2
M-C+B#53B#<XDGV *,>)5#<S*(QO@4HORBBBHJ+V8&,6G+7:-"4Z"N[LOX^?V
MMC6$>/Z3]RXX[[O!CZ,!=X;=/$1&ZO5V++Z77>WV9AY\%,+0!BPD/(E8Z-^,
MP?:SK9C6FH9Z\^[W<]Y[+5I7?F&S2.[$KFI_[<;-XUW]#SM.8R88VS%<Y(#W
M,^OJLL/:OX)84O+*"5\$=JL[EJ=S['F8[$+,_]K=^7D</+6NE4H#L(II^6U*
MTJBO%](FA)0L:<"L!<N"&1AGY,$UU8U-.$N$5UM4>W"1+ZQUK7 D[5V+I0'U
M:JZK:"&B8L\\3V@%DMU%Y%QZ7-VM/N8[CE^KA;XVR1X<PRA*YN%]-XKP0?JB
M0B:YS]K-P>IW*64"+P)R&1(#.&X67V;</Q^-1T?0@(J\5I2@,ZY;L88EPJ-+
MR"VU1#C4UE:<2^!/1'H."7,=OT],(=F0(3B=C)>4=U\ZYP/-F,W<%(8:Y9H6
MI*05P_M?Z'=J.#'.2"Q!IG9OIY.P]Y+R;Q=VVW[-2P>PQ@O>T\@Y35TR6WW:
MG!&=FL5"N*B24O$9A7P;,M)W1_:49"5'1WU(I5.>N\+ YN-3<CZA4%<8J3D5
MPD$6+(!Y/@"OI(>=9GTA9^O^=<Z_ &B=OL_2"Z%?'4Z+'BSD[(I%4&W(ODQE
M=F&RSAF1E6<TH#.B*- -FO;DC]488P^-V; +[1F6-.N4E$DZO5\FE'.@PRA,
M$!GFA+X@LA#*B"\7,GBM[OJ 0% .U2DUFS9^=E;E1'*LLO*%!CD&X?LLI::M
M2-S]!"Z+61BZQ5_@>='+O,E^3VEV@\,?P9I[RA&02+0K\3W)%@9J.K)O63D*
ML[HR^J+G=$6H>YBL<D_/@<\RZ6/*N/52XW6<;AC<F'2?;)EN\<7*'"W&<S[[
MPYD#GV]["]\.-1Y!K56.:;!,HDH^)Z@GX1AO.0_G6AF^]/K:RG3A;0BJ[3(D
M#C[[?QO.NW.1X\? E,LUZ/KRP(M#&H//RWM.F/SJZ#M;%7)I)?(KM^[B\;\W
M=/_EQ3D@-,9Q]O"B$ N=_=S%4(,D?KKV__.,$^,?SR>*[ <#46NM:,!EB4&(
M#0TX%*Z$[E,\Z:36-(.NA&_3:6Y/$W)_\.!0TRJ)!*(!W<=+Z;IW'45A"U([
M:O2DU$,6([7H]-H523EF<"3WSS/ (@V8RX;N2! [J1AANIP^7XJ<>S\IT$[F
M*[RZ-'TR0Q<RXY&4MLM  [;31_^8N)%=Z 7P$3F4!FBX'*#BD2>MB<VXV0>X
MW5)MV'AU:58GIZ68SYD5=H.4E8X@>JBG8QQ 3' 7HO]17]Y75Y.C3PV+J54<
MYI:W2HJ/E2:>%U,M8/<</K^?0/3]L\%X=(I(_UW'BNB@T X?P9G.C]:0KI&U
MAY]?+U)?-+])R7@\./4[R0"5>KO_^&M]P7<6:.&$!C(8CV[ZI3(TNJV'5\^Z
M.G<NQ'F4+Y<&^"NU@HJOK3@Q=B*Q]%L&@JS(SWN0V:KH%^TLLA5#%4+^=&R;
M)7)[T( ."0SQ'<D(=A+[*793K,RC<"WZH^YGY^3"07F"J7U7K'_JC4X-?],P
M1!^43UV*;$W\XOE[3:_QG'GO"/GAD]QV5TYK$UX40Q6'8OXT;+I-X#[+*(()
MYY;0.GMB%2$X9)=M(:@N(R9>8STHVWWC&<#7K084K=&+'48>XDIA?_H?&!_*
M^>M0Z:72P=L/]Y'XWS9$T]4L^ 3)@7RRCIB$K8-RK9AL>A:O#)3JNYW_O>46
M-7WKJ%3@FV"KXHVF') G$3EO@>2%@35'-P54>4:-[UP;?\O_AA2:&-CNQ7VX
M2I*E:UQ<_C./T\3X*\7U\J*?]3Z%N:=V]_]JH0%<9[H9$U_IO-(DG9\B1!$=
M_3YEW8+PK_0 G=U27?'N+VF 9 9H&@D26'Z? ]+^T"A+>8]QDW"E7-\#1_B:
M7A$I?;<_<IKU?B'[N&:K9^PYX9>)#'VZ>8@NA!0Q;@'-]G1=2+[>HNA"9?MG
M?:G23E42S%<RQU[G6(BFZ-9RO(:Z(:5X3[\<.LG81G6I2O/Y.=.V:/NJ7#\S
MD%>6++%GV]1XL0KO$;*GYC(2JAEH?W:]JG*1*2'_!C@<!ME\CY-;GP>_WJPW
M?C_%G^6I&Y?J"DN3LYQR%)5YU?5*8XNO;L[T->('N.(^T<@=?GW>;*D6U]-E
MQ3K'_ZG4X89'&C%7/)E%>#'(,QJ@G,A?SKYI9I?N:/8ASK"NINDQHVC*N"G*
M C$ .;6M4):ONQ#(9\U[>*F&L[</\CO%AI2 7<C<N[XKOBE#LC$GEMVNQ>4%
M_S(IJ7W(32BZR$L>[V=6?K/#'7$\DH6/=UF!8?[\[2*\""$Z9*F=_3KJ3."7
M8PFUR9;;XBMG4XBF:X%P&Q([^53MZSVRUFA1[+43DU(7KYB>(KT6FO,_7?-8
M[>#:GOC&$4#&4-[0M?Q</1U7H%S(E7<2^\<P,C3 'G*H+,-, \;:4$=B!A0-
M>FS)J ;0 '%($7)\3)SZUG1-$&$%.Z#>0SZA 27%1I2K.:!AE<L?@B"*&#>C
M0V4IC[]-R@9C*TJM=*#A(/]QETQY4,Y6'.Z27)#=S:[(_6U7&O#!!*/9"*8!
M71%8#(EY"KGRZ3]VF?_QY.#!!HD&B&HUT0 "*SWC?AZ'A_X;:OX#!R\S_G3]
M)^IMN!"7J6QTW2ADQ4@#BM,PW]F O81Q)%5/*HV"I!?IE<?;(W.0;S2 G&@A
M<T2E4\:?!;/YC,N0J5:J7AB$<.[/AXL6&U%9?]. BYA8Y/H.B,)04/BO./AO
M,!@D]_^-@\L0!_1$:#/X?*-08]F7M?21QB\>?I>*VLZ9<A2Z!A5^9(Y*N-J:
MN<_<6$I<QE6"8L&G]V5 -T5-XV)BKDR_Y&YQM%$/6ORB'NN*!85@SE7T3R3,
M2^?:%#D?7.R>W9@L3IV5C'Y$+A6#2<KI;7R?\6," B7^$YZ42Z5S4-PN-51=
M[$\_$B3UFE7[' V(0S#C1[.K_'6C]E9-@?(S][[U@DD#C;R!+Q.T+)?;^B<#
MFJ"G)1V=KV<$.CYZ?%%-_LY;AR14:9WT;=OADCX5QL$@9="_8W' ;+ JORWN
MH$4%&N$U(9[::133';5EIA K=\\LB/F5D8;$8O]$SX)X.R86S"T-;]#G:>FY
M48N)=GT$*WHFR=9Z9DYQGGF$/X'_K]!HDDX01&:__U!E1HO::0[9JQY;._YO
M77D!B5UY N;G[P%U"/%-US7![13?,TB_)Y?HL2)D @Y'O!OK155Z--5AHH3X
M*_#2X>YC*EMTCILZ4&RU-)[5)E-PH8=A6MXVDPTX@$10+U7A(X+W!-T'6IOI
M -(J&&5<8U1]@V7:5!.:C2ICV32D 6ROQ7"SD?/IZZUR!G;19CJKSS,I&S+X
M"ZJ)-UA$'47!)448)]1KWW3S81%\8^RW4_#DZ<BE9?!.]S=*)P[?YW\>V'LB
ML0":Y"<,5F*&H)I$7^]7R3>OH)[>__F6K6DS3$!)N?D9"Q\@L.CONQ$Q/QOY
M2P7WZ5?)PLWVVD'^YT_LDJ<D/?NK(EY]9WYD?5F4Z]X6;)$13&6C!YRHA\X?
MTSCDR,CS$7(.!=FY6Z]/CUL/2JZ@U7]80/D',!L0$#5E>@3\9ZDEQ8,+.6Y!
M YPZ-?B059UM/101HP$XG\W-J?;\CK&T)<7F9.$I6SI]+36[)D))LD"5>FS\
MQF9!FI[HQGCW*LZ:CUU7X'F14<ZE[<HGWG,B+Z[-)H8S\1[SM?X+]!1FPDDM
M5@D)X.&<"I4OVR:]A_*[(K=D^-0[/6./@FY&K]( .\RD;JNI.M,@&3Q_VN T
MC_G0F0W"MI]P/']^V8Z;SYPLD_2@7Y/(#6$@\%9EHE1^)4>'5(C?,XY<ZSNV
M[BJV L\:;2D5" '8DU:L6A_&&4M1[S>/WV'BJ:Q</QO[<?-"='"U-<.N(R_W
M5N-%8ME</^OX]:6"^;BK@PR9#JM\LQ/&^@ZJ>_?OPAU)VG ?#"5G4\8+R;(Z
M!L%%KCAY\Y,FTFP-JZX6MA(?2OI\^1W5S2@ ^"!Q]_J)._AEBE<I]>%8&6(,
MO.-.E?UC5J<!1P^YX0<T@(D&X(O??H1%M%GQU[W[,'(]F"E53T2RU$]"7H^5
MD>U6YF[LW,$<A9MD^L0P@*0.ZU"^7U=4_R 14IO2L8$$/E+/,NRBR6?ZJ3K;
M/,BQ6,B1[-CTVT,,29C\[">5"[;\P(-3CU#KD.<BK!0=.\]C<MSW:HA/4K4=
M8VC\A,B6T7'R2YQI&Y1KQLF*?W3(9%BJJ'?X V^FL,;W&O;OC*_6#SPUP!>0
MS1KTVE"P B$P&5' UP.?DJ[3*>$)G"DE=.@P_1!*93OI>!5NB/L])":<HL<I
M<E3:>\&&R +M:Y GO*3DJ[+DPD4'O3PX7-8_N#Q19>:[F'V%UR X?BSV:U9;
MB#JT(1'6J<"PKP8W)2')RCON>Q#^R<Z=[Y R#SUP&X/37Q2=?7'*6W2Q*L^"
ME,0\Z/7S?0K7W(RS;P;YW3NV<VP;$:%=OXVL7,476(*>$;-PLU:XA?!=]\W^
MB9E.5A7R0%4E[RF20Y R#9B S/,1PW%0W62_^AE=0Y:[M=T]#K**U_9_V+,'
M9(YUH\Y>2B-$4@HA)466#0E3*09Q;Y;MRT4/^]2JWW6.EJ@SP)_7$NDUBK7B
MS;S>QX:ACX:POP3:D4*W;\?/^C6O_O0W+40TJ3.XSEBTJ2O6WEIWQTR,%I.7
M=%J_3^R?_(9LZ@4"\US=N-^6*^)T2C393BS$P=ARK!GVN*7^N#EO4J<@9V3(
MK+B^J3N#RP$6,SX^E<X+;H7?KBYI@)Z]BMFSA=XV_8&L2@M&J^KB%@S'GL\[
MTS-XR[R8D]F@]3(#:H7OH7I;=DB0<O_X$ &&6XZ"2_ZZCI<*4VE+L5155/25
M:#PQPLXW 3K57BK["N#K, +;F4],K1)6/5R93'Z*^;2S,1FGI 0IK^FC8R&V
M1I/BK=2SN(UL-KSVGK^&X>OLEJ/?E4V/#YUF$DYHV0<KL[SD8SI%L?U*O_&I
M4=8'5;_$!Z7<'CGV)A-D07Q-AS7BWP2RAQF6D.7;K49L3\D7\#IH\0BOD9'G
MA;&I!P-T7-)I+E7W!A9$<?=NJ)KVT:N.4?_AU:,#2C#]$NNV/M7MG)V4,XHS
M.0"#&ODGIEU,QM@&H6O:IVRP"<O607-AAYH.SQUS!':7H27B<>5H%K(US%L_
MF['0G 8X3,IU6"IL*VB?G1-@+(_=$W!D3 <HY]"1?Q,*$**GT$E=OC(R<NOG
MZE@LRS'MGMM&-4\75GG151+]5%6R.@T(1^'RVLZ?=1+:GY.?6"['DU?42G5F
M<\\#G90T,D)=F'SNIX=]2N!F+')BS#[>Z!T'<&;KH2VRJ6"AZR=U"%+A-_-N
M+R"&G"F07Q*$R!B!*!4CZ56T8QWU6HB1&)K#DF0_*ADR88W\6BTIXKD!KW+H
M+S2DPRX)@*N1A&**B7U+DOJP!:,R!_!.K^R@+$&J/-"6GB.#^=IL.0 S('@<
M+DZ"D>]@AN&NKG,%?K^D)(Q";F;\]?B;6%;'HZK\1Q()/M</O!%(Q,POYOH!
MQ)7F>>,SBAF%4SJ-,/#57JX-._$QIUMJKP)/ X&7<"#"<QRZM9_5.<VW]G%Q
MP;QAAG?ZTM'.A2MQ69I7>&W"C9/EF(UNJ,X%W!WYR/-3E4>V\R5CK,*K?'N/
M?-7SN.V) T(:KBJA_L*GU:/L(K>/Q/3!&>'JBH8WVLNEQ:I=[R+9>4]MLHAD
MQ@)&@0N@N%_'<5(QEFM4\:$/+5MF%[(<TN]A?!1ZA/[JN[:M 9:GSM U5?UU
M;!&H=;(RZ?WXZI/PF8V2Z;N.)V)Z^97@S2]8^V^(J._/(N@<<$>[ D0ZW4]G
MC];H+*03*L9_;/.8V&CYYM7YGB8J.%%+(,7Z7.H#P+&Y8X<GG&^283D[L(IP
M#%_Y5B;T.I+5[T?MM%+RFI5^7&7Y<9N[S26QKWD[/+M4=X- !O_%[N^!T7^U
M@9P#*D!(([LOX_,HP3+(/:VQ%LRW67): )+$,DT#+J'KU<4G>O+A"GBWHEH^
M<91>7;0"N*WW9!!$'DKG1V6.;;TWL;KM<4H6(Z-&&Y7QAJY1%Q_T<M7.*1MW
M-S,*>\8NB-.UA2ZZ#SU9UGD>W0Z)3\!:^'4-[:V7#VX4Q3R#J$6:)D5\>:43
M>-9THI&?\IX*)G:VJR CO(PX.K^L574-:IWEZ*YBBUV6?'19^>'.LOH(;GL3
M@HTSPJ9M,GYQ^<*GMRT]9OZM^JI/C:0@ACM15@2M-7V?91IZ4AT@WL3JI+BR
M9WV<FG%)^GHX6?'#X("K6CCU%&*NB^GJW"GVO/3M[?+UI_? 8CN3_-6>=3W9
MLNLHR_.[R'!4N6,(];*3SX&LZ[ET][S?H9Z??O65W#VSL#3)&[>>'5LC$#N'
M-X$'DK2(C-B1S.0UQ,7RZIK'W\>==Z3:6[-;GZ'2;LR5&-,CY2)UFBZ&#T+@
M-MBA'*=1?SDK\Z[==EN.:$5[.&,)PKAYXWB@-DF$7JGJB!!JS31R]4X%'M2)
M$8(E+"B^!\>CR[L59D^_N_?NLXA _LDT:Q!>Z88#(Y^P#_H;Y!F&W]GJ E$F
M;R4UY::+/Q]LV\9IG&E7[.W"A9+7QSU_XD.S)X"V?]"D423YS-)C"'N](:_U
M4^_[[0%!-G? /ZF/W_^SD0#Z'8(-KHG7;6*P65"6[*6CS?5W5M^W3H^;"XED
MU71V"Y^NT5\[";($$.\&K(SF9B=3L*@XR6?9D#.3SF=*?V]ZOSO^,0FUE;QL
MHTH#3G)N6_JVHZ8,FQO9!S_'M/(8$W,M[=OT 8^RV\CZ'6MW1E)!LC]7@].?
M"9$>"6<LUC!G]XK$F$T#9>X=>Y5WR2XIQ@VB?8).__>5-DIR[[Y']%-/5V89
M=!$&+8-TU,T=_$SW7D+9R&)$7S1U8);[Z;9=]M*58O6)0I?GRG&LW7PK?-\>
M/T*8/4P8JKNI]UQ*N*(J5LN#3?)E1P.W1A/CRG$ \?Q__)0>-!M2F959.5LN
M5",:^5A::M/^S[B*VR?>T8#&MQ%8Z .R"J6XD;\;MVV083+&G)3_Y$G[\9'8
M;P8[DM'O[S5]]?TB(AP?%#L?= WI4<1.UY)A1R;O.:;3$?FOH03C!>]^RGXY
MXCH64HII IV OQK:QQ>[J!1]_I1GR*E7?CBO[92IR KBY_*5.!4Z;3J=?6'
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MKD7&)8(0ZTGF.3^928%X$T9AE'WM-!B\CRC>5%8*O*&L: H902<T)^D^>6'
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MPQPM][:+\0IBU++T%T+1?A]0=1A0W6D.U-'YNTX@8)243U8%[58]Z<A.TSY
M3-T'; ,_J.90Y<@.F64/F;KW 37/#(?W@<PS-&DJVZ4!+[Q*#U6DV(?N.EE%
MEKI'D!1LO384SLL 1O0J _4LNF&+E)Q5LP^P&I,E1S\?:UW9!T;W@4>3I090
MGW4E>?HW@5;7ZF'LWO^\JP!\_U97J8F+!J9AS'MGP5^A."VEJ43[2"OZ:2R#
M=Z+"$S+G5<<K*@.=<6^C@4U,/)0%/N-#$='4H!708DO7-+#%M/2>[MY&U\GE
M8=][Y,^8T?EI_CTI*SGS;_1)\-.7IN9+BU^A6_\0%]B$JO64^/_D!<PR]NY2
MF&8@,:6+M"I;DA/W^1%O:67N";&M;I8'*W7!23'V-2>B 4J.V<%ZY*F"<1&Y
M%I^-NXGZ_"G7OE03%;Y<]HA#[M[!A^*F,2?LWC>94C#-BDO<'SLL%H=FF50E
M0\6/2X@JAIL.,D[55K\-D@\0GY[DK_,75H=';HU<K%$7O2/ ;#KY*B/%)CA%
M(BFNI.0@1F@[*]?)^.@=T8O[0%B/0V:!<A$9NE)-4/Q=:[T/:! GR_ B^4M'
M_[&:&L).J:">1,K-QL[M9IQ"<#I[/MFY<Y3]2=G.NV=$XX\F[W;.5%_]'RK/
MQ0!U6M@>J#PCZYJ7T1ZS;3EJ^A+/+"UYLMAT!5]7N5O^0WC<+XE\EF]D=V27
MS[L2IW3T4_;!YG5:YZY*,7;B'D%"P'BKT11RR-X''J,?!F;1Y&K[R(ABUW'A
MJ#+7K=;=SGFM2L\;J!X,(V[F"M+9I!]=N@^4P49]R5B-%8S#Z,:YU9:=GLEN
MSZD:DV@@IV A152B_WQQC4F_]"IL29%W://+3V^M9_2:RN$VNO+!!MXCUH@V
MCQG$L=K,QZL)=GF7YEE: [^>/1RSQ62P0\!@0:Z,W9/;!PYO16B4)#59GW<L
M^ $*AXN/8AS\9TY2'$$(XNJ\L"H]C0W=@D?NT#D&MEX6]\G-/')-488];DYE
M&KO<AGHE^>&(JL"7I6C@=^.,W(J;"S%]UCLU>C7@MO(;MT>GS5?LBX[.:3[&
M7'Q[3=A5,DQ$>N'YN)22M/1SPSR3V:%9Y6AS6T$S70$[\7*Q!%.04<\@O]%9
MM]\L^1>7G6".=O724!,H&STOTSQB;.<FS\FL]<3?TVH?J(>.PJ]09&=/8B]]
M<5+_\)'L4^JRE*!]&PQR0/)3",Q5:W>X\J:V,+1Y'PB%02D#,X,#2DTI:F(V
MIPM6*PY9^HH?CIGC<E?(#0V>. 1#@@T=XFMQFO0T7KCG=);Q6LX GT2KJE#G
M.X\6HZG _!5U*<87%#/B@!'%8'H<P;%HII+JX[.V(9/ZY?-OGPF\MS:CQ+3-
MIN8P0L=OO@D>!^,A0D*]93U*:M1W#;V]0H:F%B7\Y@_G/6-2ZYX)I4T<\S\!
M4/C)GP>V,N&$X>B'?>E>QNH=ZGD,=V9Z+V;;8#L-8'-Q/W;FZQ"18,Q\KN6A
M/+V<"#^_+<8SQ>XYW[99#O_+A\9K5H__%A_VI58A(+"H8C"J,DXC=:CDK( M
M;'@RE+X5$[K0@KN6=S!#"N1]D9VM*DMAG37(3KYJP!LM:*5??UB41;S$$*3$
M7)(XF;5W>U7W*<ABRW(SA+,37M1G 10&R<S8<@6(31511"V3#>P=:E4<GRGM
M\D[O[#783EFUJ@F]+JRI:#0;NW6#F9F(GTX-@_$M^)ZP#_]PKJ#?S]?7C+DS
M:^Y^C,;N$]0-0%"5CY#&O*+T 6DZ:Y0TZR+=K,(]XCA,FFK],&$1);SB7J\Y
M38@#NOM1)5LT7N!@1_X-WX--VM,1O!2<^=#CZ@>T)!>T]^GV4;3=[[?'YCUN
M3#V9L\UPOZ"*S4&)(,\,S+0&;R$X+.#I1S)="W]7*?_&_IB(<[=XKJPX57E5
M"O@L=X(BJ4,)GQG/A""*#&GJTP%]."9S+[L'[84K.JY@X E2,'36Q4K:.^+.
M\S"?QTW/E*2M>@165-XTHO&GB@,.CBG9[5_YDH-I%CV3;AIK=#TKD_E%[F&B
M[<.FT%;M7*S6\G*E%&,02:4.M#+(R)F8J</1]5Z9'$$7"EZ,]7X7<G_!DU'J
M=_I;1L;V%YYI_I4B:!V.W^GN!.JTBYWKZHDNE[$F;1O34S!#O]CRO2 O$>>I
MO&Q..0)_(Y9B">=40A]%/T+;H1_YP1=1>ID_5UY+4--3U4;C<KX$YD?0,O<!
M>QSE1FKE9.N>!&(<-W:S611?2,-TC)C/PVSF-6HJS4H/'!Z.)$3F(N*?>X_'
M&FL/S1-;QVP5#!W)-ST!FT2?\UOG6,5C7FC<MX'> $E/+> T[;F7<03L[("F
MCDJ4DHCIK8&)-JYHB;+P5Q&(URB?EJ$6%50DWS*>!\5+\9R=CXQ+F)56U+PZ
M/E/^;"5M<A^H$;H_O1OZXFFH52 O \FH"&S"C1K+(76SF.RGE[^#^O!5KNA<
MD^@$:>M+V0RH=VPS7<>6A'"\RV:B)VU/UC:[\8]F2\8)K,DTJBW<J?WX-DBS
M9Q979\P98$H\G1HAPOG<);>R)BR%^]/SA[Q?#GF=NU0O[#,?W4;+Q#F\(7+B
MK>*I <NYMY#F90?NS^\!I?75;U#@79-7P)!]C>J%,NT#,_Y(Y9Y+]!%Z$U5K
M%Q&8LX(#M5N-QW5R,7[[=?=3KU^?]N1I&"_LX8!SY<3S91=AT@.NDHF.U\BU
M5S-'ZMAJGHD+LG->FGM88PU*X#[0 F9*Z4+YPY@&NE1BRV3ZJ1Z3T.X1K7<F
MG,SW;V5X2]:@V=#U6J?B2+8DZ/,T9SM7EZT.JQA"_.]'<X3REH%M[%>I;,ZG
M=5,,O2BA!>Y'=)&!MP.?<^;"?LZYKH$^'9;[V^S 5/_$".$<XCD#/$I+ J__
M&MAVUCGKEC=&0/[UY.9+8D=&AOLER<.V\TW%6(HD"L/1O6K8LJ/B [Z>F7.N
M#"0C?M91V*O'%300@<$ZP$.*8D-*+3/Q0_(,5=!5\MM P="8X/F,BS&?+JAP
M 3V]#*OF^P /C)N"F)UZ42HJ,9 RW]$6LJ3X%<FZ=+-5?$(X-/B%\]?_EC6U
M@5E3.)@U691'WOS6D;WC]5A^>4_:A.) 9YT_-B%-B6R!2#!4E W('E+D5-L4
MSA#-^4?2=/T?29/-##:\4H7L$%'\O9@B$)&B;6BH 9GUU2R:H[)/ ](?05\C
M!>([R2<49"NS<*4"_A[0NR6_'$*ANNB(UT)G5BL$6U8(XK"2&00CVE:.8D+7
MB&_"$%/0CQ^7)4*^H>U_"^+C?/T*!D3D$;K_\-S"#DT]8;#CE(KWLO%1%W]4
MR,]_KXI9*0_*JA)^HE7_7560F6^3_QEZ.LLDL+@TDL!+%>=Y5L(&G]*](+^9
M\Z"BA_A%=1GQ".PQ(DA3.NNR&U]_QZSQ<:WF<E>7X@XWV5<>/:_F")0(97]A
M,C:OFHU(;=P'.(JEMN(Y%XL<AYPW+QA9WVE1J1*UJ.GR\@(M+9S>"_V:NB=G
M+&BQC">^W <>!J;5RZ!Z:!AR[+AMPH[KIBET63[&9[DKD$$'\,1#JB7W 1;)
MD(MP3EK^*GXT)6&,EMNQL3>9(U0Z1X"]5NKM^X?]Y9N%G@ -+^@P]VP&,>8J
M/ MWJ1_:Y%QNJ5\/;W@MKCJA"WP_IR\@^4&K%I1SB,Z!H5M4WM$H09^PQE]*
MV+ P?__MZ5[G!L3HQ]9P4#5SSIX2L:LT.+M>MC;=U2+A].OW:C85<>89MHGN
M%]0TS4#3'8 +I/($ELW6M,;"9Q1'YYVO?PZ,I,JI=M+=4G'=>RHN.ZU.NR&@
M1&&/T$!?9(>C6-,E!KS=* :X0GJK(QDAN0)]A-_\YMJ3]HHZTJ)A5MVG+5S6
M !()NJ&4R/E\!@-*]R.0_!KG:/GM&]4]KS)6)T:6EYQSO2SXDE\J%-:;*+#D
M@O\:U;UKM,@](8)E&W9+XV.U9*"BJU?IL^M.!IH)W.?,%CX#6UC9YP<64"CL
M&+*E_H$,H_IHQ?V*N? )!M75A&UL.6@C,:CC].:LHT2FN;MQGS8H6--G$;JU
M,:>+'\.?_:681*=>6 Q.2-L]"OZ: ]'%JE,ZB(J-:"$OI(O2NY2IC9$DY[RQ
MZ>N<_G&7V',9SZ'919W['F5#GIT'(TN]X=[7<4IWBSG#;VM+25WQR<M<</5M
MN0AX$7-H-7<@YYLO5H:SXPN63_0\6:('A8G7U%PFR^W%QVIC05(D$'SK120)
M;F%O^K"N$@/VQ2^O._@>.G*A5/G%+<*3%WZ"(LR:=\Q6-HDL 4S])7\GQ8UY
MUY+<J)*C>S6?=.5K-H>Q?,LO;QR1?%[-_X:RJ9MZE73DM=NG$8.VB!G/XGW
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MH:57H ZC$1Q5,.?Y#_+!UJN@?Q%IXIZ\),%SJHT]^F9?Q.6S F*#+V\PMZK
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MHP'#=0?XZ&/QV>P?C:#@H2[F?=_R\:G B6XGKVG6BCQ8TX #S3N;I74^7+6
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MH9Y_'#ZY\H;P&B&><TORYP'UDV#?32(<4LO (?&BE*2![Z;"(RL'UM=]#=A
M1!U(\=F40YR85C,*Z(.IEV/2YM4*: SE!"4+YD\.K;K:X,D)DOH3)Z<>DSC8
MVT*@FVW$E-_;34'J&\JV,S_+'K<"YHG%AH6=B+JAE7I6*);O,@E%LW1U=62/
M#5R4<L 7O MB##O:1WDD<+"KH!PF=QW1+4CTMB7Z1AW1@!-=!?%RY[D4$V"'
M^AQQDT?ZZ,OK'>AS^!\=Y[,/2ZB>V2J::JR,AGD]75?E-]\8'EE%]XV53QJ!
M[?Y^4V8G0RGXO$IBXBBV0DR"P+8LWTY#(I3L_C+HZU:6':Q$NE_L"^VJ@!;^
MKO<*IMY%RA6KF1[X/!R_[X._IZO?"O^L4^+N*=20]UU_#X #ZKO^+N1.ON_[
M^X =L2^V/9-G]_I8K6<4O!C'CZR-E\-"-J_QZV4<\^S4++^[*8N<_1BWB-X4
MS&)Z;O]YR+HX=:ZHA\,HBK =6KZ3V#0BCE#,5!8!S:;$)QHWVF2/$CK&B2F8
M&OU.V1-)\2A\[RW-;;&[)YT\! 9FZ==QWC$WIL$#?>G^K33M92DSE"7, <&O
MG#$GQYSSE#G)=>2TU+L\+BE3F*]I^^]W?$IS4US\6U;?7VVKNGB@Y:XGT_-I
MS[+(CC$)^9",Q'>)1>,X"$#]48'P->NH'6SY7F90?HJI(8U<@FFA'2+HAQTJ
M/$$:[?GVE:&#=OA<H#U&ZI20)"L4Z2 H]%55D"1K3C60[#)+DX:Z1HMMYT6F
M_'H%U,RR:_\X9"TU89O$,7$8V $VO(C9YD'H>:E0V&8A'FNE__!BQ18TVB/6
MK^N_:+RW]@G9O![8!HAIKA78"@R5G'&Q3;C18S(M)%]Y@@T,BQ?*HI%BU7BJ
MC-QRDDX?3[UARK+8;!I(3.1I=9X4T]A.3D QX1/J3<<DS'ARG5BLZ:0(,.V9
M,7W0: <;Z+--,4O0/U/$ J O-DR]PNML"'VJW*LI4.NZ4@)$G[E-(N_(R?0O
M%5,B;ZHZ8SJ#GO5\X).^0L.,L>N'-"+4#\P0U'3]>'G-<LN <5-B#PXFL"><
M$!-1>?I@0GE*VCHQD6'J%(GDR>*K"N$P8:=B-_*4G*!]HAM>\7%#ROJYGZCZ
MZKG_E[/&*PGV R:$@>^$V HBVS--*_5CT,P]<=#:HZ0-.-3 @TDG@'UBDJN'
M*3"IWO&#M 4.98\]&:V4MVZ!DZQ(U & 5U4#<(:<J@B)%23'^[;=9'YKAK'4
MU^4G?K5S=*.S_V/5_;4RSXYSDN#02U+L4].Q4X=$D1>#!O[*8+%2%@=ZY/#Y
M*?FUPX W4"\;')8/!)9BOY@FTLY4F%+:]X_J8'(N-D O3JZ\>\]4^X<4#G19
MQ!=5HX6E<%AWV/ 2-IV-'UZTF'RGUO;"^DV>O&9*\]0 <A)N /D!#CR?,)T5
M>"02RL0=A:!9)>U[D[9 $8.*.%AX2]9CODSK$R74PG0%F%"IWJN#Q"QJNGJ\
MXNK=5@<)&FJS.OR@JLO0:W8:$AXTO"*/64TV WW4VZQ1&N/ ]0T<!ZGIVW[J
M&S'H^D$<M.XKT'N>3]/D=3$]1]FYQ4WOWGWHWY9>B([R5/8N5 6G8$)]F?Q]
M6]6-6-<%^D3YAYUM*.HU->(]C$AUSQ,UGK*$N2S1,_KA%YY7E^5_17N4T26S
MAI^R^OD"C=RM'A[MR-/2KQW.56TWJJ. 7_@R=8XA\_>HLRO FY^\^2?SG;Z6
M2<4^R>K-MWAS]RO9?'HLZ^1=_GG[\% ^\VRYJLYOHTT761?LB@)?6;<7\\]M
M,P"*I_15Z"""33IJO-DVHYL9CEO:7>XULG:<[]I<]8EW5)'@[K02T\]8F"*3
MY&E]3P?XJO#^8QF?I+JX2(!;K;V+/"OZ?5\6K")G3[TA9<X^H(K9:+O,W"P>
M-*&8"V/Y(8Y,-\).3.+4CA-JFB[$A)J$IEDW-;!0?M8U<A], 5I-TYP3,Y24
M\0.H4CJPW.%IZPFZQHU:[!8A(A69*M.P5K5.A,@^-4C$7I(,OA;Y$Q,;=A9T
M_;P_D@?:SC8_S7L@5HC#P(BP%P:A8QLV<2-0Q]X)6+J=HSWD???X"\2A T.E
M$\P2#(BJ80$P[#E&O88I]@($JHI?3D!:-THY3_)9+%+@%=F9%X?>K*V1^+&H
MZ6&(R6@B)C$M'"4QP:;C^*Z16BFQ#=@,#$'(FF6]C\>__UM@F?Y_H!8?Z'P,
M44Z*B;X6_DAY#6J;JTK3IVR:ABC<E:=K -EQ/FT#N@#\CN(SC;<E6YDY%4WX
MD*NALV.?G?B!0PF.3=N(P\0P/%<H46H,@&[Y[T"B'4S 03_*D_GKB:64PB09
M2"3H;F**$JFKB<$%5[N9F"*G?S$Q^9RF$=JCI:]=W>O/S6TDN!T&OUCD!5Z4
MS[4B063'Q+/B %97L1[NFA5"@\B"3A@OL9N")L7WN4= 5::@Q\&^OT%+T*K-
M#5YP,]::!:X0\^]K:+CZ+0%/%]> @D3[)K; $ZGIS8:T-<OOF']:L>^]&NX+
MZ]@.CB)BXC0TO"1P^2 G\69+,\ T'P<==+0'C_;P 9UPYA@VK<!5LP&F<2<X
M(-,P=HX5@!8^"EDBUW!'YN. M<$1)'&R:<W<&NNUF!&DYJ@AC.@[<'>V;6SW
M^9YN-EU/S=/F+*Y-<438/]B[H9WX%HE,H33AX>5UWYRWC0\;B+"VLB/<F'=C
ME]$(#$=!R .YL.-42#FP \NMYKZ.D])W7B>>DKT7XI.^FIS95P-EL$R4@L3'
MH1_%.'3,,':HY86I!;L..@6A^Q:H2?]^=32C#GH!=,85T7N?);1"KWL:\G;4
MJB]N'2=&V=7.&8"5;W3&"#R_R!E]4DWJQ6B;,8?:./!2@EW+"ER;#RVW06W&
M1B%IEL)F1&<[.?+=(=FB06%9K@7T0D8) X GWEF.A:;+F%G:-*56O-!ERRRY
M<RD5*N;976_KJB8Y3[WCF<7,0W]^ER?-]8%@ZN;X"KIE4OB&9(;0:<E31R-,
M['HPT0XHS]M.LJ<LV9*-HLL3,?*DDAPGEETMF7&>M'[2HL#3:D[(L;S$9K)U
M$AG8C-S 22P:FY90:=4<(-U.W\ 9,9^ !V.5W 'Y$CF(JR0?KI1W^'VD'$*S
M#144.S3Q[-N'N_\IOG[('[.KO$K8?T-G.T^OHEDJ&^#H-GM@K+E # 7TX>/-
M.]Y L<H8$R#C7F>X,7^$JF,$3#IG>:!A;+,8K5)GZLS2JYVK8B3VSU;!-^1K
MEM]F54PV[9736_:[L^Y))#5Q% 4!CKS8L-GO#,,)H77+9U TR_"^I+<%O*OL
M;4##ZY?/>30?755".4QHI8B6JF4>)6I1/?/YJJO7-(\2-E37//XP_-S<CUM_
M5U5;]KV_S<&'YL02NN]9&634@$8=[ OVU15U7HAV"YACP?Q)J8AZF,1-$:[A
MA!2@4>IXG%IWM;-1@+C^P2CRN*94OMDA%FT.[[N<6=.-HM@/M4A.#U>34!R:
M7HQ)E%I>&-DD].(_<GK'NR[=*DSA6X"SD/B$K?B<82[N#QZ-L6J2]BK567M+
M-D[,CW[Q?="6ER<\>JBKP$ ]$@X]E\9])_5)> I8O5;6W1)4OZ\T.P5,!^?5
MJ8 I=U2\/_1<.8U)>E: B<_^D88TC:V$.+:;_%$7-=F(J?3>VB#S;0]!6/QO
M^2OR\S3Z3!#3DI*DP93:>P%ZP$IG '-%.J*_\JHB/4#2J00./0*/.-R6A%\1
M?'Y^B(K-:>F1YZ0X#!T3>SX-W,@D@4]-T2C#T<J:?9T.%FJ!B<<2CJF?CQ](
MTP23$D%R0%&"0=2E(@/'*ZT6#1@DH!\!&'X [O6_+7\EF\OJ.KTIR]_+-WER
MG>X[@/Q<YKSK1_.7ZNTF^;6J\[NK(D^JUR7[X:E,?B]A[8+40-,=2RBSHD2_
M4U(V??C>DJSLNMOPSN%'O7!VU3[,7[C,GU'OS?J>U/S5#>_Q]8'RB76/CYLL
M;EK@_$JKME<7HRYK$N_1ZVW9_N:IB6WS-<3C%HHV<3[$L?[^ :,AW\G6*6YR
MI);M4@$:12BL%LM1R[)^V$?QRA*!VKS*>7,F!N7S4WRU'X8B&J0=?EU[@#9O
M>H+TNH=U,O>9ED^\"_)5(3H:9HH) F':Y?1#0[0BI"M6&3-4R@5I1]9<+T [
M3=11<';F4<ETH(?'3?%,:;=QPW&!CT538T*3]J1I?-O^W_EN?RSJWVG-<Y7N
M\NQ?-&G2P[LBO-,(K97Z.'!<%R=>:+B1'T=!"II;L0K6FO7'+WFY!XOB?H0P
MYL*S&_G 3NR\R'%+21O#Q5$3+3QZA_1*(H%93JM\ 6)!C.]N7^5COOM8[F%C
MFHANMY%'E=<7K;[DDZ"?:8T.:%^@RP<^$U=A[M::'%:5"+8*SNMFE:VY#6<I
M:JL"ERBG_DR: 89\M5UV5 .3SU+/GFARG?<FJOQ<%M59I-@,* YC)\%N1-*0
MF'YDN4*%BI+P-9\5'"'N\%5M\[FXCQ0[*5JL$/NY/N!U@>XX9H!*9 FV3ZOU
M%9@)5- ='[LF?D?XH$\]/M[V^?BS?CX"BKSU\E.N[EL'7V%UX?)<F2P5EUAV
MO>IQ>9J/"LH7+ -W]:^*SW1#8W:N?*"$]V&#%/@,OJQ9]7;UP&@'&76@ 6W1
MQNF>]^T7DPQ3D'+4@OSX28JDO/CA%5?SX2<)ZGOPTP]*)E8=A)>O=IWV9'6@
M#[''3".;FT9N@@T_<$S+BOR$@BI?YT&N9 TU*,PWX97EFYC+JI8;"\P9#=V(
MQ6E3E=0S#W#=U!QA!IPEV(B_*3VTJ7B@M^3;H:7I6"D?-4(<623 1A+9@>E$
M7DQ!I7P3L#2+>E?BSD"C VSI@KXIGHE)NR).P,1<F@DRXY#FR%,W_V@4TMH#
MC^9('IAP-/N*FN+<U]EFRT,PYX+=)/@$*>\ADSHX,L. 6H%/(F <?1J>9N'N
MH&F<'W+*/\$HM#JNP 1]:(;(CDEK%/*.$*JIGO<4VHN6]8Z0/E?=._::VDGP
M@_+/>T@9'@[-V,).[#F&Z=@6B81ZBXL"U*P CJ:^]V-#E?01/\M",16@DC$P
M';",)\HFOVO2 ;/@OHLI[W-:0/@].37PD=9\AN9NA.:K9SX_LS=&L9N=F=$A
MQ=#6%UO,XD^9BG"#("'$LB/3 %G\<!1TA^'X4-%T4WRM$-]'5.S'@Y(]*D!C
M08+-8LI#+_.  3WP,-9N^B&W;8N<_7G+'N\>+7(M.DB>7XJTD@0"J^HI>0:=
M:JX%*RGIZ,7CRY</]8*.7MT**T3]#Q5[TSD8$+KG _YJ2(8IB:$&7PC"@J4]
MODXH5-7C:[?L2_;X.B%MIL?7Z=-PH3NT9;O\EE6B@G;\EO:@W@Z8X(D]0->\
M(,F3!(W.[?O@?>&0%*6[#J,O)1DG2ZTF#<,D]"5@Y DYL_FW)@>R/FNWW%C$
M26C@*(P2]E.21&X<AHYG_L%$+BI$;>*C]2'?4Q\*Y 3B;8B;C!_TM04-S.P\
M9HB8[2I-)$QH.C :NBL/$J#(3CQ>>U43<)"L4^MN^"%):3H>E?)QR]>\3KN
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MC/VIIM6 A\-4>>3Z.+ #"S--GAB6XP<^$9HE.PY"L_)M>@*8: <3$$X99HA
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M:6[$BQT)?Z1=?1W'HT)?6G!ROD;'")!3 2=/RGL0H$S683BF0*UGT*W]$B[
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MU<(?)NS4NA]Y2O9*[UV>W&;U!GB=MWM+LU@T,*!7>'N*IB5B&3$P:1BXNKM
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MR#NJ&A5Y'BZ"C6G!W.[T R6-5(O79@^\NHIAS4'R.RS>=:L#?3%7IBQ$][S
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M6C9 QV#9O\[&.C_V)D8J)-[1.,4>7H_&,+CUT+0-]'8X=,,8^X83F[%'8IJ
M3H2&)#2;XP78@#S$@M"5!S5"PBROU\E0V97 95DTH"9L>45@6< Y?(155P1.
MX.][4I9M@Y<OHX>P+)3UJ(M#.Z#8- /7BZTDM&*A17"6BF:KJVGRW%W;0NB+
M[,'HN(K$S'"UX#!+;&3.03+#>S',R:2JY\(HC6U[*\R).>BA,/NP;-N6[)5]
M]O6)8#WPSV__F:7_=:#=_>[EQK,^TZ!)P!9(:N#8"T,_HJ;G!J#+ Z*$-1MP
M\PV?F>FF=:!=600U*6C4&O0#L_,YU2C?KT+%5=9V19#LQAU78,H8-EL!OB_?
M\BG/:J]T/1)&\_ZUA*WIB>VRC>TNL?BY)XV$8(ZF26RRH%^CAG"SQ,&[,_6T
M(FKQ:V0%KN&->$=IU8?3T\(H;)C4([!Y5Z1Q <=:'TT\*8MS49^5<=2R5_J)
M5&38YK!M1LK6Z(38F"8[R]GM'"<6*VM<(J0[+]S 1'1H<^@8LM@/$*:L>:-4
MJ0)@;EA2>@G$C'G15J!G3 R\,9+&O'A#5(V%Y^46R:^T.J/F7U=5D8:'JK[8
MEG]E@N19Q83:U]CZS?EW/Q5E41,'!C&P8]EN'-K^CD;)'QFMQ%90,'VA+SMH
MONPC%\(?]Q=:EO^!V&N(]ZA I,,/JG)>NM'AZ%2U 5N 5VO<LQWLVXF'$R.(
M$]>W/<MR(%&+'IVO@%/^V/HVK!"'@6EC.XAV+$*,#=LQ_F 1;)A_"(UW.0%^
MZ5#- X] X:H7"T6UJA.V''(-7C1Y0=<]55YR=*J84Q?+2FM#4:@+I[]I)"RM
MGGZ@+#^0!"PFA_6.J@/9[]\>2!K_6M;8.&VY\+E 210%4VPXW9O7BQNY+3N(
M\X->RW]'#7)2RQ, QE)05?.N19.6P-M>804I+MV2D%\.:5*0QG; DC"A+W D
M@:_*8N ]%/F_:'3JDML[F'),!X=&8.+8IZ;+8A./4*&#J2D"FKU \Q6_M"2A
MB' ]7<P;M0H)81;<=C!MJ4GCWO6DA*+>R4N[!O/N86E*)0#OQB59AKOKO;<Q
MV-TXUT.HNXGG)&\?1Q%OM5(^D#<>E%QG,?M)<:#QEY2$Z;Z^;3?,Q-4['-,G
MV"<QQ:YGT-@+@L1UA$ T)6AK]BY'3M!+PTI="D4:9A#]BR^O,PVD5BM6;/^B
M25TP5W72U$-'4RT?J,/(E;K4W@KY55W-!5#>]O8M7"6#"[820\AF^+\_LZ#G
M6'O>=R<^<R=AX-MX1PW#=8*8^ $0S/IB_&WR^37)TZ43:!;_4B&BR7MI,:5R
M]H(22F3J1^58D:"_'&_CO/RH,,-T_/AC\*W^8Q%?%\4C+9[3K Z[ZE:J@AO[
MT9<UVTN'&J!Q[+2HRQOSU5+"S.6Q(!P)Z0(T3%AHT(Y[5C"I_?7XB)OMIF<%
MZNZ=YQ^4;)S.8VI^G)W6G2J'-Y)XY_3(Q4'HVBS>)=39T<3U@@02ZHX1V63'
MW*$);)H^IA:Q0'6ML#*;YPXYY65<<_*H:IP^1F+;SNDS0@Y:I\\]NP+)M.3Y
ML+N\>"1__3.M?O F4<RCLA^,(]755DH\)\!61$+LN62'?<>(<&CXKF4'D6W[
M](^,/O'"[T<@)"F0%]@!<X\CT+E1T]89_<F9XKV?:[AG\E?S@X;+4S/H*J^1
MH$M:5?MF1<H31)M[>J1I3R3=*5IJQL0<B+8)T ,'W;"+_MF=$<8UZK"-[L-]
M^C1__5P.ZE-232K!.J$L; ^W*:FD4<!,V;$D_>(A+)G!\GN<K[6K;1%C^_G\
MQ UP8(<[;!@1\>+0,J,=#(=Y@I#F*.5,%C5T14!Q89H2]#D*Y ?Z%1G1X4YB
M02Y5CF"*S+;&OB#LP*"7GE=Q!E]WW*Z= _<5M/A690J.XN=&?=\3^::?>X<U
M](U6AT+PYHF$#I=3 ?K4!S-Y2<UM<FHOHA%%A_>SI-[Q#%]$!?-'^4(CR$*H
ML#&:4<L&T^%K7M'ZI]]?]FEUOA_SC7]?9C^_[H;U<5V(B6M'D<\BA, $HJK
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M 3WRI.;K#GJ=?]]7/VB!JA\DZ]4>"\V*1"64>O4I*YQ2R-K&=5;JE3HLR])
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M,=GG(]0+:XZ(YC3"F2IJR0*\^)1>!-9:!=+"%L:AH#)GJE,2 Q89!9++K0B
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MW/>>81AB/XP<;#EV8 :^1PP7M M8I*C9.Q[I(S[+J/I!$6TIUTZR!NG,&Y;
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MHL_^_606)IL$&U&O7E^V54?34@'E2 6@%YAK+B!QJ>NN=*$K6=&SG04R4*6
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M:>XGLZM?U/1VNP:[T4!(B(*3[SBTO&(([2M>T2M(TX6P$K T" ";H9ODVB@
M8A>-NU$3^^[[3;PG;GD(Y;$#FD(;UB!6DF$</MWWDJ@/I'82DM?Y30^AX=(N
M #*?8Z[!"]ELR40;H!0,@M'4!:E8[U'JRZ=M*O+ZO^G!,E#.!2!E+_$HBH%A
M#AQRMA).B^#ZC>GCY"EL/AX^^DNW/S3JA9JF-B*?ZIG9S81&%BA721!.B\PQ
M6''N4KLR.PDI8=])X@8/%W,Q9F3K.E5*H&C8*Q'E1GMD(+.I-YG5S"5L+ D/
M14<)L@!3\7&B]&0Z64S</+C?RXO8;_4T"'T>W?#%?9MH4/2CD#+ &&*$<8I6
M/G68I2MMA5PVI@G C**0 NS,&E\']FFC'%#85<"SRC(2K]%P:MO33DW>@_4X
MVF^'V!!5% "J,V-B(X#YA;J/@?$@LO!)<QOHV&)QZR)$!A].( *41961R%54
M[JL-U&N'ZTY>,; ;A(C-+7$D]61$7GP-\+=?51-[F#QR<=\6:PCD"QX;-D+N
MI8+::KZQ1VX_8-@W0=Z-+C%(DDFR #MT&,^BLD P;H(CX"F1T).*I4[/ZFE5
M1G.N1[(J X5=@--]7L^68OAULOAV?CM?U->N>5H"[4?)2MO8I5, ;Q5SE%M<
M)7_%TY&T8BS1>%[2&$K*VD]UW>#>/W&R)2.B@8AE4K0Q2@AEM27TF$WK>>AB
MK$]ZD"2095G;UE;8BC.@8F*)99":BCFC]W9,';A?Y0T?O_:IZRAA%[%?75]/
M%M?+&]E9?.X:"X&ZF=G!2B4\T HY0&SLD60H=29USO ><O*TTGSE?2F-,@JP
M/T=(2%&@&7$ >X@$DP)6(O4E^<  8_)J1J^*JD2J* !4:_6\=B:-(*&!JB@#
MW",,C;-.\^2/-S=HR)TBF$:W.U];]11T 4 YLW;Y5%Y-+]3$?IB=JYM)V#'7
MV-HJS!-^$M(B0#UB3!G+$4N=>GR8JMS7':. *;$R"H#7%[=0DYFS[U0S"SOT
M_,R8V^O;97[^6^<G9K(=Y6(,2!:KR!FAA6'>![82P^LP5;DSW4>!5V)E% "O
M;4%MY[M (*E"P!+%(;(4(9'^H<0F%7E/<B/!9Z"P"SC"'7(BMZPKK(#6C *L
MO1:R4D[3U.>X0S3EZ66>*R@P7"W)8):CV-?%4BG?7/AW:OJ2HU25OUY.\7IE
MP/:PEK$F&*$:2"$<8 I3*3VV\@>L"28U#PL&Q3PN+31Q&'KSKYI@1R#AN)I@
M>\5=A-?4L8J1$R3P8"@PTCEK-25H;W.QWTU-L/T:[EL3;*^X"\#-X4(U1GH@
MH0S;OF:&58PJJU,#YF1K@NU7[]$UP?;*N@2T'"Q7Q1$'BG$""#%*6X2A%?^J
M";9?KT?7!-LKY+)@TE*NRC@(A,,>\(JX<$!5$J,Q;M-.JR987YCT$7(!,#F<
M8"ZY#4!7'#"!I8F9DIZ-YN1^/*HD1J8:7_V\E'X"+@ B:V'R<-C\W"PYLLM;
MF0O7+-O:;#U,(2H^A&/ 8:PYDE@PF=Q?.4Q6(0Y,3\VWWX@E44-9R%IU1SJ[
M77RKF\D_G=VRH[$YD@BL&.@,=5A4HDK]YG0/.868H^1(&B3V$A&TI[^69K&@
M Q* &<Z,X<)0,DX-U $=SL:O\C02AOH*_M2:2#S)<5[[SS?AGRTK./YEIF[M
M9+&9C#L@N'QHGE$CS$<QF2C,_&$6:')/,[<^M/<>!  Q8 D/.*J"#T929]BT
MD#)N,!D:"A1F$%!46<P\5 SM:]]ZZL'D%/H^+GZ\5\(%;&:=(U["(: H0P!;
M;K0R7&.5>@V<9/QXOX;[QH_WBKL W!P.:BADPHE5!5\.*\M\A1 BJ:O2G6S\
M>+]ZCXX?[Y5U"6@Y&-JDN +*5Q404%7(0 R]3EZ'[N3BQ_OU>G3\>*^0"X!)
M_UKE3 9!*0T!=IYK9B0T2B:&SX_1+."H[6HDA10&M9:@/ PG2,,Y(-H*S#FA
MEJ:._OPXS0+VZ_OH9@%[A5\ ?#J5)J>5 )IR 3 -6SP3BMGD#S/Z5X'/V#)@
MOW;[5('?*^H"\'*X[X%V#B@B*?"2&XRE<5Z/V>ZFA)O1Q$@9*.0"8-(A8$H$
M$%4EE[XAM$AQ:$=+XSKN9C13LX!^Y^]^ BX (E_<G9O=NO=!2KL*.KS[;J:W
M,2 >J_>%_[>7ZOM6&HFV0"G+@>3,>$@E02Z]LWPTF84<W7LB8\L6C:NF I#X
M$*2?73T4J&ZM.JGC*98@!K!2$BKDE,>IW^VT$E/(62P-JM*(O #L? EJ" 3$
M"OEOPTJ9UC=12 ]<;;WZ9Q0(52$ :1 7A\0YE#J2N)>@O)8ID=*W#%0J#10
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M VDX ]1I 154F%HS9M9'(C[R;JZO#.'L0"A@,;QU868S><[H6J]/*!!0"FO
M(1<5T[0B-/7SC_7Y\]K/_&BH$ZFF %CM21E<OQ[S#FC'.8 >^0HBRI1(_3QS
M0(;G:':N.*@E4%<!H'NO)LTRR^Y9OI_]KZII5!#TE@\=F DR44!2*2#$MO+)
M=^B]!.5]ZU8<!-,IKP D;J<-/(GM(8FTU8&)K5V@8@ AZ15D+L:)$L.R.W5Y
M'\05A]&1U%HD8"\:=Z,F]NT#/0]=9L]F=MGP_6P^=]O+4H637_C  D&]4]Q9
M3I)'<_I16EHAAC2X.0C/Y$H<FB$\EG6-[)S?-E$9N[G"L4HD1PHP9BK/.!<<
MC]!V^B!=I555>"4@#E10R;"+:7C[&%-:  $% TQ5 G,</H3T=9"W25IIY15>
M$WR#U%3.PXAM[LZ,J6^#BW2A[N.55##NX9/F-A X47HR77H_6_ZS4\%_5@X0
M:K#7V KHU.B8[$)I:2487@FBR958I$]Y'M.5@_#B\]+SX-H')[YY9/!^J^:9
M\T [!P&#'EN#&,0H]0']2!)+J[[P2N!,I[8B4;G<'IY$N6?!40F!\@(#(R G
MU')LDC>6.(*\THHLO.9N/EA=!2"Q^VW7UAJ#&"@C'$">:6B,XHBG/LQTIRZO
M52PN2#226OL#M@YK<4S OI_,5!!ZFR ]EP8#BB4.+HN)-?&JR*N@'@I=I;>@
MQU.9UY">"H!3J;D RQM8,\[9^?N@C-9:4I$A$M:CT[$_E@;*$0%<<&FPE,';
M%JEOP@\2561Z43)4;*<7)511"9A3][W+[*SS2;@"LO(8X(HS@IA%%4Y=\JLO
MK45F#XV&T-=0:#F!I^[2W60P[#E ZBI6,*\J[;%2#HY01;8C=7ECH*^,T9&4
M5H O&MF*_XL/Y>_4=+40@\0F)J ^_N)L9E]^L/;-56VF[:/EPVO[=]_-LI?]
ME[""WGGOMOTI)210RE* G>?$:DH026V$7Y?#0EY5?$R2\EXP.$Y]Z6R=65EL
MC*,$X-P[H0P54"<O;3.$X$+ZQA0 [*-45TR!^J0L8P^!EM@!2WV%,";,R]2!
ML_'1.MKU5\EHW:NZPNO8O'5STTR6!]C:O[F=!^G.YVIFP]E@,J_]Q=I,+SGJ
M5K_FF.%3U:WIS5*B>C4/%Z;+VDC3B=D3^[)* LV"PTRA<\(B#S%-G7_13LU0
M\_<HVC5YGSU(^?,+*5\&P;X)__+O6]<M/*Y69X$P6&H!PZ]$:E_U>"HSO_5(
M@YY-@S>RLI)%L=);N*^WU]>JN:_]U\G5;.(G1LT6VT+N8]PZCIS*KO5AY-5-
M&C<&:&,Q8(AJ8E0X89CD-:5',VE[)=NZ,@R#85$8## SDE"C*Y+^K5 GRD[%
M=.U%R=8+H/1**=A<G=?3 ,RZ66GMJG&K:GM][%/;4.D*!'8@-9$%^MQ<J=GD
MG\NIGNL1KG:Q]>WKLW^((*KI<ZG"UKM'RH"J( -.V8HHYJ30J1=N$L*'5P1^
MTM2=.XL/EZZ6$[R=S,VTGM\VKG4=01,;?H6]GV-?6<P0\LG;81U!7EX+]_HH
MW"XB/(XF"[:(+1=Z?1RV/5>#*1RT#H0F,H?/ZO[L7[9Z6-[XG=?SQ?RY&<3C
M?6 ; B&IPDE"5<!YC*H*46AUZHKTPR@>7$N@Z^QOUF=O74J26Z!Q+.A@PZ'+
M8:)I\F2A@23G-92OB,^MV@2OJ.J"K6:L-C]9Y6ZI62SA'+UF-^M[UMTW7#I_
MLB/)B8SHVGQG&_,]@V@G)CFHK*9 4*N M((JZPA2R5O%'T5@BJX1!R?;O4R"
M.%@4!_<84*5AA92#PB>_=CZ*PKP&<#QL[6HK,9+>"C9OVQT)>CF$VZ,D<P8/
M$)C(AJV&;@.2E#;6XN& 6*4IK:06-K5C]Y*"]$U%/M4+UP'(,-:W1 P"KE7P
M%XSSAJ6^2^E,7%[;,P 3AQM_I%!'P7:EK;1W'^O2.E8J&].-V$26IFVR'3C3
M1@><*0DDQ 9X%_UG9(@@K]5K()4U:AM__P)8LD^T!L*&!>"L<)A6R(?M]978
M+\XB)<5.U^X+0Y54L)7ZZJZBP_=AYNOFNG\X;'N49-[/ 0)3M09:3?/%W<0N
M5+.KG7@RL?9F?(\.'?#"&X<L"WM?ZNH_;;0,]H@VQCT$Z\"NQAXH;2K@*@(%
ME,8PG#H\U8&LS+6J4V!CRQ]*K(R";<SJC=^E^MXO8+3^SU-9E5:2$IF3I_'W
M'M&76K60Q7,S#*CAGF#JB*A&* '11DZ"4@.;0[<"N((Q:1PKP+'!%"*G8/+T
MAGWT9"^0E@03.ZH'I-% P2;DDUM685^Q>N-6K\[Z&)/= Z4R*QW(3!6M4<TL
M[!KQ(<=RDC8D"0&!UI( [AQV4!+C9>JS4QLM0TW+YKBMJ/8& N$5!5!@X9&V
M%4_>J[&5F,P1FA0XV+0H:01?L#GY>JOG[A^W8;1W=WUSHK;&2)>=N8^X5.>=
MC4G:< ,=!U**F!^,*N(]M95)W@:UA9;!YYV-<5MAS"L!I E_.,(JI[Q4(YQR
MVHC)?+9)@8.MLTT2P1=M/[HD4(^?$9XI,[R0#'$)(5 4ARVHPFQ9(YV2U,>)
M]!GB4?9_>^ISO>QH/KE^2O);BW,M)[Q?_=F:5(*]!MHK! @.OQ&:Q>?RA\ U
MC(1320W?"X]'D_6*VBB@/LM?YNZS?S=?3 )/VZ6Y>"7CNT<"+/>55();"%.O
MIY<49.Y0DA9*"81< $0^N=_6Y-+4L_"C6:4==UL"U@#)K0*8$($T1=96Z:N?
M'4=CYBXDX\!L5$65['OMS(U>=BKMYVGM&V_<A.Y=1!>9ULTD!!IK!#1Q#E.&
MB%2I4V+RIG5_-=^<O9V&N7>K:KT\VT-!H?NE^EK7E]<<*"5)S(<S1&(L*Y<Z
MCW$XU3]2<O=>E&Z=45]7X07L[,\<OPMVL;YW[JMK[B;&[1; V70YY/(-4JS8
M&<Z#_PPZ6-:26"JF51"(6J"EL(!RQ"O$'?$R=:[@:,SD=4F+6! YX5&RX[&5
MP3C Z6@;:[RDX1&=C?UIHHRHV"^> :QTA21%7+G4%]R)4X>?EL*R#GO+ CB\
M*<0$?$& XI4!3FG*,,(8^O%LX='DEIQ>O!<W[=9K7)65;)^V,N4&V*>VL<9+
MZQO1/G5-X%*5 HJ0"L1&PQP25^'D]\BC)?<]^[,;,ZS)^,W]PR];;V2<J(!@
M%@+#'$.:$XQY\L</_4@]C23 O1C:<P@936D%6ZR=Z3+]C=:^X4;-\!G3M>J8
MWV&M!<)K"5!%E&4"8FU2YR6/E>>S=O+8F"%6%3-G,_MV,KV-A;[;]NU5;IN"
M0 @B@*3:0J2@-F(\TW44J:>1([070WN.BZ,IK:B@R=EL,;&1I<E=.!F;VV99
M4OS=]U@RV=G8PB&ZFK>/95LZYU#%ACB""0X8$TIRJ#%*W@(N/1=YPR0C(SJ+
MJ@O>IX^H@_K6+=1DVFO[[C%+AD*O.QE\_7JOG )I@NUT1F)5"8T9++\XXC+9
M8E#EJ^5FLBD,QRQ0QGC *9.58IXP8@ZA+1$MIY(,LQ<P+Y)A7ED_&??X>;/X
MVS.'SKX+DEQV)?D^V4K;8(X 3:D%7.I*.T2PZ!;$#).L+;;PM^>%MF_^/+C*
M H ZL38*1-3;^EI-9IM<: .!0K&WL6 $$6*D1IUNB'M@:D5!'E2ET^P!J/00
M<V:P7"P%%[U)-;O_L[O6KMDD/[9!DIYS  4D,+B05A*? "4[IBX+'GVT6:<3
M;49D6#?YVT=WI:9+4=SO6B>6(R"($X#*"G.&!-=HGP,X=^:/5_7=SV'H%2C"
M#\]XV#%AG@->S@UHJ-0S V9%]>Y%(SP'FL@*4(PKK4GE$-MW"WD8+>NSY3$;
M@]55)Y!=1ITOE\HOEW<?/Y[OMF[:<B")XX )XZ6H%-QZ;=UR+%H?-9]R^RNE
M3B&AW*K]Y'Z;UZI1;R;US3?57*OS^N/"[F;$8@^$40Q@QACW"BMMJTZJWC=+
MGBT@G>J32;" ./1E^-YGOU:F>Y>]JZ0!&E$.N*TLJ23VQG9R%8^("NTD)$^"
M?4YG(9U>"@#7&OFQ\N>G>J:>/UDOA+5[[4#N@61, L9Y.,!Y&!9FZB<?1Y*8
M-RR7 !3UZVFH  "V]2)HV;9AD!RM./#2H_ QXH*FSJG;3U'FJ.^88.C8):*'
M9G([5(-VBH]MS2)Q[":-C 92*&^""V$\MYU<KS3TY&FFF7/KS:7,$NSDJI_H
M1A?1L\5Y, #WD]G5+VIZNR54B2W0C%'@K#<&*LZ=29T7TXFP4[W3Z F7'8UB
MT^HNMT&]<(V)@KL*SD[8A'ZIXT7D.U//ZNN)63ZE=_/%F_M5(':K@3AQ0 F%
M@/=,>"8AY%AVLIM'37NJ8<QAF!M9/058PB\Q#6/F[&/NS9DQM]>WRT=2;YV?
MF,D61]@+("B"@%6644R=Y57J]YB'J3K5DW(:&YA8:\?C4*YP.'-7<<[A)O#C
M)"RQN7OOW!=G7'"1[99+$^^KH"4 2>^@,!H2V\W.;8]]JKY> F,V4- %)]>U
M]+X<D$AW8,21FW:.F2 W2M=$#"L@@FL%M"%<$($<3-Z"K8C>G<\)KFVG^H=P
M@FGY]7IL8>?YS08I"BLHP)66X?!&I4A>;30]%S]@)]"]F&Y/?,Z"B^SY6K?1
M%[Z)31\^J6NW*U:+-0;:2@*TY)IKA;G3G=)M#V9J;<^=^9E;9BS4"163&5A?
MW,UM8[ZIN7O:'#=9VGW#*3$#RB$&H!>*"N6L$2H!VCH3E#,/;*C.Z[$5D#OJ
M\B>*/\SNPM%]N1AWQ^&E<$#'OC3>0ZVHQ01N=DQJ.73L&CT?'$;28)U2G+GQ
M<%Y?S53+30^50(BP7)PV#"E(':7=BH.N#9HG@O9*VN\KO (B8)TNF3U30'&"
M */0!AXHLCAU;]G^&2&CO0\LQ(M)IZH"\#;PUMER$=BS! A.!/>6!+$E+];\
MPR6)[ =%VB21O1K*O<N%;?HYQ+2;?J5$..X*#"B2D$GCN+6TJ].S.?A)9WCL
MUV2=4*P%V*7C,E1DI8 P7@/K$26:!89@ZF!?@MRA\6I>OP*R1M!,;O,36Z.[
M9AE[N[VYF=X_+9K=O!B'@% < >Z]<!PAJ3SJZ'COG2AS)>O7,DLIQ9W[A5]3
MVUNS^-P\5-/<M<MSZ8& K I'#20D-8Z0;@V.#SWQVS%W7@05XI@G44P9P(KR
M>N"@Y<6DU-&P<@B(DS L/<<JU.D,V U=VP3DBQ<-U^DV0 8*./?.]>'BX>J\
M_0FL8)(!! 6F)KAVQ'3;J38&SJ[TH7JJ$PFM['?#A@1O7H<]F$MDA25"H+U9
M4..\&TZ>HU+8_C)4$04_)2;0 ^V,!3"X<U!Y@9#85VCP!WE*O%]='9\2[Y5=
M[HWBF->2SGH@D=  *LR-L8H*ICOM&H/?F[[Z4^/]2NO[WG2O! N.JAQA/C^V
M9?TQ#($R" (M,5&4>\=IZN)E*>GOA$OV@V]IV8%1P*+XJI:EFF-KA4^W<54_
M-(^9?YC/;V/WP#4NMR+Y6 .%#0,>8>J048AO%JD;GAIW!'UY ]SY4+29^S:6
M2G-OYVN,Q:S"2=#G4KN/Z=.?USG[4U//M^1(C .:6PO"YB<QAA6DF_646S;Y
MX^?.&Q3/CL;7T%A9]O,PAUMM@RH-=/28,*8<*8P"=ZE3&8XB,&\D-3MFQU=J
M 8A]*+ Z_U0O7)3LQSJPLN(L>E*?W.+\MMGU?HY; T1PHP#GMH)24 'WUF<;
M4*#W,'%Y8S+%('4<9>;>Z-O$&Q9C?/"Y^NEY62[%NJ+R[.JJ63Z$6WH\.]\?
M0ZI!^  !*RU&@AJTU6*]]2(S(5EY3V#9 9Q9S^4@_#B^XU/[[0T' Z7"@==:
M3IF%PDO/CP3T\51TPB__O>!W9"V6 ]>7\OQ2WZMI+&S[O.6LVF5NQ6.6C[>,
M 9QHQ""U7(ENT=6CI^X$S.KW LPQ]%6 $QO76'PD^.MD\>W\=KZHKUWS<:+T
M9#I9W$<YMW@]VL:$+ H\L1;YBM.*R<0N;$?2.L%4_+ P'5.1I5K+Z*0_+[S8
M%SGZ[A=JLK7\%.= "RF!L\9KPQ'EO%OQT^/G[@1$^<,"\34T5KK!W,HJD0AH
M)QEPCB#L"4*\>E4SV2V2#W]84*;76@$0_.+NW.S6K7J-[9;@JA]9<)Y??'=;
M!EMG/:6 K+0(,".25<S+"J4NGYF0_&[P_O%OJG(AHK3%L,W.$]MG\[D+_V\O
MU?<M45,&)*<26"\HM0SS]#D'/<CL!NX?]^+KM32<V\L]7+ZJLA0(7'$@G+2<
M4(;5YFDK;9TP].->3:40>0%F;Z]#\[!B F_UU6SRSVWND-1 *2T!AQ+IRGK)
M?.IF ,=1V V6/_X]U(AZ[8W:.]?H.DE1V' *G"TF:OHV,#*M;Y8OFV?VB[N*
M=1[KYO[/DZD+/,_<A;I?BO_YS+A]3D1 0>.!T5IJ"SGCLEL@= @5W6#Z@]\V
MO9H:"Z[,^-C-W-G812YL)BL06#N)_U73#S-?-]?+#P=4:^PQ2ZH*CD,93%35
M,8:*IO7\MEGFN#X3\L4M*\.>U_/%?$FJCJ0^XJVU])U0X62/"8 5YJ)"Q%&8
M^G@[C.)T=1Q;%+AF--[</W_G@8ZSWU1C=R8"$X6!LDH A)U#$!MA9&J7(1GQ
M>1-87Q&S[>4:7U/]!?C#*\K#EW<]T*&5 8HA"I20%<7!GY<J=1CV!0&EU&E\
M51!L9E3UUD@!<.HON&>V9_9BJF;ME<@,K8 ,*QM(IUB%,1'6\=06=00^,I>_
MZ0^K35N96\<%X/Q=\$+K>^>6*;J?;Z( 6BJPJ,"(QPI0)03%R!++4C>*:24F
MLSG-CI-Z#*45@+Z#DFT3;.LA5E,'-+8"8(J]A5 (I5[=IAZDNI0"B#G=@U?6
M_2FC??G'+VX>DR%7669H*XQB+)"0"*"JRJF**Z]5\M-90OH+M^B)L9<*^D.!
M4,HBT(=YUYN\O_M^,UGE_^Y.M/25#GL=5(!4%BMB,38V=0W19,1GW@ *@/^K
M0Z  [#_Y;:M*1+O5\*E>5AQWJ\4^OZP7:KK^^Q@]^E0O_NH6S]= :X[@EFI0
M+(:/N $4:H)$933RJ=NNO ICF8O3Y5TSY4'G1UY/*_/ROFX>/HK?V]II(8ZU
M7X*(H((D>+M<:9(ZJ/BZ'&8NS_6#KK#A8"I@J?56SH-I^5/XXF+^X6'C_M5-
MKKY%*=ZY1EVYY2_?JH5[KR;-SB>(Q&B@-+4 :RF\XL8SFGJMO3*+F0L'%> "
M%@JGDTLZ>(SGU*M""ZN3HEE,[B:+>U\W8:B5F)+G(1P[\;BI"8/$4&2V M<.
M",$K )E2E3',09FZ+%3F;(6!=N#S[6*^4+-E6GL]G89--OYR:W,U08Z8$<",
M8-1;74&5.NMC'$Y^I#R&O6A.O4$D ,8/X'6M26%5P&PKR[F2L9,[!L@(0A%6
MRNCD=9-2,W&BL>.$R!QOL?2 2>]U<K/<CK\N5+,H8K6\="IW%E&K/ 82R0H(
M0QU&% IH]U7(SG\.*:""W@^X8H9"Y0?86X(:O)LL;F,YS+5XO!<,.> 9B<<L
M6@%%I +0&.PAA5XE#SV/P,:)!IK+72U#H7+\:I&KU3);5K:RE\4LFH,[K:T0
MD!@;H!1TE#,%C4K=@BR/0U9>W+C<!3,,)@,=LG<S6\1:>?<]=OF:+ZLO[A0"
M<00HZ3VPV#$/+8+:I$Y)3,Y$7E?LA$_TP^!0BL/5)^UA6P ; >\O+J:4!F/Q
M^'CT5DW#GG>]?<MD-!":8L"Y8Y(KYI@:9<6\+IMY';;<:ZI@2)6RZ@:8G5]6
MU[VSF'SD3'0FZ_C106MDB0&BL@PHK;#6!F%"2MN<NO*6U[_+O;Y* T\IBVJ
MW3DLE[[F2&H!!/,<$*.I0-@1AO=U(,NQPZ7C/F\.0>Z%680*C@)@*4LWS=%T
M0T0/PG,7S<2X>)+VNT_2F,7..% #@YB20CG&26DQ]..YS%O%._=2+!=0OY\E
MMY6]"U'0(J*@\D97UDFIZ"@/(L9G[8>Y\1T%X7D6Y%%P.YT[XM87CUTR#_<*
MB,1V1ER9<%*6TD!D.*Q&<4U?A[T?YDZYB#69"7:GL#L>$LV.V\5#\O$B%CM#
M3FM0Z2K6MW4,0"(KA R!.'DSKM?F\8>YP3Z)M3DF $]A@8[C3RAK@4;A).*8
MET1)K"A3/[#[>@KWXT4LQPQP^_%NU(_R['W,S7$>6$T<Y=!RYT1A*[$C:WE;
M6IUPE&8,Z/P >]O1<>3]TN(0**H\P-I:5F'.$"IMH0WC.&^OKA->?Z\(M!]@
M6:[Y !]FBV8RFT_,SH>@E!L@-*OB:U"O+>4TZ+ZP%=?*3-Y^8R>\F-+ HY1U
MDB;_YZ4@7EYK\N >AY]T)2I@B18<:4T4+.U>O9V;S%W0<B^5_ @YX3?UZY_&
MS7<V=P]Z6]2KJ.S#@_,'B8WXRKXO*:_U[CZ)J,I[B1_ ;;T%DA(,*!42<Z<Y
MPJES%DKI&]"I$,[9=#ED^.FSWRQULZ1TNT!H$*,7.I@N#(% #$**!+(P>1F7
M,1CY8=[A'\)R>S^!7+ HP<T*JEYNEI_]AUFPAN[C Y-OU%3-S'8E<A[SP#10
M"$J ?25M1:4P7*>&>@>Z2NE$D T^FX!.K<L"\)E&MA]W5G9:RM<!J1@%6#@D
MO%,V'(<20SDQ"Z44V"X%]3D14L ">>#,V=V,/_BJFUQAY("VX2?E/(,N>.F2
MI"Z_U(VRO$8\*W@VF\JDUV3"MHCI3Z>!N>O)8NG/J9F-R>>3<'"?F8D;<M#L
M,&JJ,^.Q#"0Z_JU->[8Y[9,WW>8A&\B 5E( JP3E4C!M:.JH\%$$#FJZN6>F
MG1L+P0(HS@V 2GGDA+/,V$.(ZC137C,V'B1>-,=,*NZ,>^>\6?SM2XP2[O*(
M726!6/;3UD(H9IVFLE.;E3#JVNH(?WM>&2\FS .5$118#Y5F"1#8T5THD U9
M<#ZE\T 'AB6%&FF2# 0Y&S\-4-:FNGM(+K/"_ZR^3ZYOKW<3;JB(17XKP W#
M3%/EI>J4H7! Y2\FS:ST/BJK4\BO@(/2Y^C$K1O '0L Z0JHRAE F-)2<:E0
ME3H6OHN./&?Z\;:$9#(O$#<[FMSQ>)WN@(!: %P)6#$",?2I8Z*[*<GK>0[7
M\ '(]!!W1M LE]1:ZW@UW=L\?K<E53$KPV('6)"5]L8Y2S8JU[:<4HZ=N2SL
M]%%U_5IRSPVJKRJPL P*/3$SW\N-<0@H;&PPV=+*6*:S0KX3B@Y.E3<$G1HV
M:25;P([U)>@C$/ M+(&U);&6&/-8Z.&ROG"-KYOK]W6SE.K\S?W.]L.1:17<
M.V8%J(3%GC-,O$KM&B4A/,\#L?%]J=?7ZFE#.;*\VS144@&).0.B0E Y7U'/
M4^>B)R$\[_:< 7#I(-]3^[EW^4CVYYE[.PF?+]Q\]_XCL (ZF@U1*8\)M6RM
M$_S>G7WG\">+LKXZKI,*O 3(7/Y6'^" "B"=@<!P*2HM%/=:=(;,UO!Y'< "
M(#-,X+DALY3%AYF=K&ZU6SA0$&BG"*B\%1(S[ SK!IF=P^=]MY\9,L,%7H O
MMC25?DUF._=WAH&J4 6X@V&?A](2D[H?U4Y"\CQ$']_M'R[U J"S7G$BB.A3
M/5//GUR&G^9AZ<6T^=TKH_)AZW4( >L1A-8PS6"GV[ACLI6.(S&OTY0 %)O)
M1R-J*/=V]ZF^JS].3,R>.KMJG&N/[%0, <4\!D9@%):I%WKS*5C+GM<^1UZD
MC*K7.KV0<V-ECRW_V);E1[0"RB@$F#?!TZ-2.X\ZH:;+;'D*X8ZWL8TCYMRX
MN:@7@9F)FFY>-6QRP:D!VI-@E<.'UA/M+#>=P-(Z19D)13WU6"<7:LD/-..+
MP6_U-&AH_NX?MY/%_9FURR[J:OIA%H\ARUF&O+L\;H9DSRD',)8H3?9AVI:D
M1Q@W-F$M0,Y9SPGSX="5^N''"PK2O6)<"O?-_?E4S7?;8419.$DR XA$1/C*
M558G[[353D[FE/[^>F]_(3A,Y 6<P+[>ZOG$3E1S'Z\['QC:=6J(34^DU!@(
M'+NA$LFU3=[<HXV84E[T#53W)HR2R+X$$#V3_TE=AQ_7#A"[0V1>5+%RL@,>
M:T0XD5)5R5]%'Z0J,ZS2J'\35&EU40"Z+IK)G5JXBZDR^TZ/F (-'0>JXI)#
MR6)8(S&B=E.2&46)]5TG%W[N(]CEV_/Z-S=;IO,<"$%X&[T CV/N,R>8:R9,
MMT/8GDDR/\P=!Q]))5N D7EZ([_<V_<8XV"#@:26 "X@4]Q++-AH10XVB2GE
MC7=B/RB)[ L T3K]+=F'V /%M ?A?](03'R%4[<'WZ8B\PZ51KUU4EF7@);Z
M^KJ>+?DXVVTTK9% .4: <\Q3:"6$+/6EZ385F9^L#M3K)DR&";D$F*P$\NOR
M?F;QN?D2:Y[N6CZ,!9M;20ZH,A56BFJ6O&9U*S&9VR^,M#.ED7VI(-J]O*"
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M'T5@-PR>4-A]//6<5/6*YW[9J[\OJVHOO_9X9$A:RJ+[=./5M>C)\MA%+I;
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MXK_K:7R*,;_\K?[X\;RE-'V40E @@(I94D&KG46=]J#6*?*IO;^ZZN2RRXV
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MK]E;I%.ONSWD#-R<GJ2YT^W#-AC(BK/P5VE=19!FY*#V=XZ<UV5)I<Z-_6:
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M@&+*  &:*&ES&D%B!3(FL28]"VE3I6V-XXA+C58!-)71*0ALMNP$,2( 01>
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MV,M$ <64 0(T4=+F-(+$"F1,8DUZ%M*F2ML:QQ&7&JT":"JC4Q#8;-D)8D0
M@BX X>8!RYQR NP*:>I=K5 B[O%6/#B!X$4\$.$I/$HJ(<L 5M+/B,O6,!PP
M1;X\,O0>TMH@NM' TS:S#9L9VJ0I/P8Y2E!]\.5UV*OX8(%[PE\> G('[?.8
MIO\&+"X01M GOD_#*Z*<G/+:[C^$DF,"")7&4DBWNC:H +EK*JUG1)2"TNNA
M&GS%I>M\;$!QC[TFWZY $S5<39T2>15]L5I)X4^QMDZL%)(;21.0H2KP&:(D
M3;6E3.UWJ_5IW?.GMH ..8_HB%58F\JT5IQH'Z?EG5AE?!P1ZH?UL@>_)4""
MR,PX'L27,_$A SHY$$#W^MN WIO-MG"]/P_N#6_<$E,I"+7<ZI(3X7.+B*<J
ME*#,C5C "H$N>2*5='.J G:9I4WF$>C!%?;'ANA:%>OSRD,SH:HV%8+;^JHE
M3;41W@%?STZ@Q&)$(<:Q!RK:/"2"M7K ,6XR62&?/T\DIP>"Y$#--U.N:L]?
M%&;(,JPHY10#9'=4ALNB8P\^#H^[BT4/7!R(7&I#29KHVCWMP3X9@R^E@>KM
M[--')98L*GF_%R&L!/KC<4<&GAWVQ(%@KV'1$-9M>-#)O2GN?,].#'X&=U*J
MURE6C@2"M;RZ0VNAK<-VNN1$739%1<V545"3<[NL&HC /%Q!>&;W$VA8=\Z4
MO ?57!D\DH^^>DY?!]$#/G(-GL61RU\\B@6\HQ73$/&M0VQ%.D19GU%(;-6F
M2^\XUJ=.&[O,W;X!51:%= [@([2>:*P.J%](],\K.4%<(XM:8FG\2U7R8O?
M'[5$]_U.J<O47RZ\_/]QZN_/V5<*ZRY<(HFHHZ,LG8]3"8B1)N\NCS4SX/>4
M2$,=YE.IKR#]G>?B1NBSD-><0,*=P@ZNXP('6EA2W9,H;>I.'()0P_(P"MG<
M8BJW=8% P57RDVERPLZ[L^>;J0_KO'.%"3DS2"01QA\\_2&"_%UU [4HI$=9
M3K6: N7(DD^:*W?3,"84E=)SP-Y9K@-'\@T@(_#^*QF_?;"O!-_@<GF*9%?U
M!.'VXC@>=L;#R+_DWM]KY\]U36^"NP=,"[U7O+(P6GP98P*J%)^/9.D=\8/&
MC:Y$.Z>+$;W:GE(BPT*GV04>_:%[]=:[W0EOOIW!_V)AN>EN^ZY3)[;[AIUV
M/QX\V=UIQT_V?4QMMWU^_G3OEVKM]=K=\_V</?4+$18#U]M6O'Q]U#M:#&AV
MT:C#/&$O]7U$M-L>=BM'\BRFZH,](B?:D%NATM4WA7#<QP7X:;Z9XY_1U%X<
M]Y%G_.?&F_N-N1Y2Z#^BO&$%X@Q2[.\I&:W>^&O,!E[X]I'YWJ/Q/:[YS0.D
M-5W%L-_P=,/^;;!TI)K(5V77N82,O5WFWE_"$6@[-J<^[>Q(:NN_KJJT]:\L
M1^'N?0I;O[=:P=KGK<YJ"$\0V[7;'O*)GV@UG^'78J?^5VI_ 5!+ P04
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M7NH  '9T=G0M,C R-C V,S N>'-D4$L! A0#%     @ ":,&7?-!7X,0#0
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;,BYH=&U02P4&      L "P#D @  ?&4/

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>vtvt-20260630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2026"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2026"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2026"
  xmlns:us-gaap="http://fasb.org/us-gaap/2026"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:vtvt="http://vtvtherapeutics.com/20260630"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="vtvt-20260630.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-08-06</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-08-06</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:VTvLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:NewsoaraBiopharmaCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-30</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-31</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:G42AgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-31</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:G42AgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:CognaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:G42AgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-31</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:G42AgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:G42AgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:G42AgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:G42AgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:G42AgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:CognaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vtvt:IPLicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:CognaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vtvt:IPLicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:CognaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vtvt:IPLicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:CognaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vtvt:IPLicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:CognaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:CommercialSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:CognaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:CommercialSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:CognaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:CommercialSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:CognaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:CommercialSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:CognaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:CommercialSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:NewsoaraBiopharmaCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-30</startDate>
            <endDate>2026-01-30</endDate>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:NewsoaraBiopharmaCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-02-28</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:NewsoaraBiopharmaCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-27</startDate>
            <endDate>2024-02-27</endDate>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis">
                    <us-gaap:QName.domain>us-gaap:ResearchAndDevelopmentExpense</us-gaap:QName.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis">
                    <us-gaap:QName.domain>us-gaap:ResearchAndDevelopmentExpense</us-gaap:QName.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis">
                    <us-gaap:QName.domain>us-gaap:ResearchAndDevelopmentExpense</us-gaap:QName.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis">
                    <us-gaap:QName.domain>us-gaap:ResearchAndDevelopmentExpense</us-gaap:QName.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis">
                    <us-gaap:QName.domain>us-gaap:GeneralAndAdministrativeExpense</us-gaap:QName.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis">
                    <us-gaap:QName.domain>us-gaap:GeneralAndAdministrativeExpense</us-gaap:QName.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis">
                    <us-gaap:QName.domain>us-gaap:GeneralAndAdministrativeExpense</us-gaap:QName.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis">
                    <us-gaap:QName.domain>us-gaap:GeneralAndAdministrativeExpense</us-gaap:QName.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vtvt:DevelopmentalAndRegulatoryMilestonePaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">vtvt:TypeOneDiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:NovoLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2007-02-28</instant>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vtvt:DevelopmentalAndRegulatoryMilestonePaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">vtvt:TypeTwoDiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:NovoLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2007-02-28</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vtvt:DevelopmentalAndRegulatoryMilestonePaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">vtvt:OtherIndicationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:NovoLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2007-02-28</instant>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vtvt:SalesBasedMilestonesPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:NovoLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2007-02-28</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-01</startDate>
            <endDate>2025-08-31</endDate>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-08-31</instant>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:PrivatePlacementPreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-08-31</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-01</startDate>
            <endDate>2025-08-31</endDate>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-08-31</instant>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:CommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-08-31</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:CommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-01</startDate>
            <endDate>2025-08-31</endDate>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-01</startDate>
            <endDate>2024-02-29</endDate>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-29</instant>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:PrivatePlacementPreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-29</instant>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-01</startDate>
            <endDate>2024-02-29</endDate>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:PrivatePlacementPreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-29</instant>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-05</instant>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtvt:StockWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtvt:StockWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtvt:StockWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:CommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtvt:TDCowenSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-28</instant>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtvt:TDCowenSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-28</instant>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-17</startDate>
            <endDate>2024-09-17</endDate>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtvt:TDCowenSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtvt:TDCowenSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtvt:TDCowenSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtvt:TDCowenSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vtvt:MacAndrewsAndForbesIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-19</instant>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">vtvt:VTvTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vtvt:MacAndrewsAndForbesIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-30</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vtvt:MacAndrewsAndForbesIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vtvt:MacAndrewsAndForbesIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">vtvt:ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vtvt:MacAndrewsAndForbesIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:MFTTPHoldingsTwoLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-27</instant>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:PrivatePlacementInvestorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-27</instant>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
        </entity>
        <period>
            <instant>2024-02-27</instant>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vtvt:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">vtvt:CadisegliatinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vtvt:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">vtvt:CadisegliatinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vtvt:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">vtvt:CadisegliatinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vtvt:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">vtvt:CadisegliatinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vtvt:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">vtvt:OtherProjectsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vtvt:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">vtvt:OtherProjectsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vtvt:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">vtvt:OtherProjectsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vtvt:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">vtvt:OtherProjectsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vtvt:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vtvt:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vtvt:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vtvt:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:MFTTPHoldingsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="rate">
        <measure>utr:Rate</measure>
    </unit>
    <unit id="boardofdirectorsnumber">
        <measure>vtvt:boardOfDirectorsNumber</measure>
    </unit>
    <unit id="partner">
        <measure>vtvt:partner</measure>
    </unit>
    <unit id="segment">
        <measure>vtvt:Segment</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-27">0001641489</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-28">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-29">2026</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-30">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag contextRef="c-1" id="f-31">false</dei:AmendmentFlag>
    <vtvt:EntityPublicFloatPercent contextRef="c-144" decimals="2" id="f-424" unitRef="number">0.33</vtvt:EntityPublicFloatPercent>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-457"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="c-178" decimals="0" id="f-515" unitRef="number">1</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <dei:DocumentType contextRef="c-1" id="f-1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c-1" id="f-2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2026-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-37524</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-6">vTv Therapeutics Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-8">47-3916571</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-9">3980 Premier Dr</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-10">Suite 110</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-11">High Point</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-12">NC</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-13">27265</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-14">336</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-15">841-0300</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-16">Class A common stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-17">VTVT</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-18">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-19">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-20">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-21">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-22">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-23">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="c-1" id="f-24">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-2" decimals="INF" id="f-25" unitRef="shares">3953928</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-26" unitRef="shares">92</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-32" unitRef="usd">86643000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-5" decimals="-3" id="f-33" unitRef="usd">88932000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseCurrent contextRef="c-4" decimals="-3" id="f-34" unitRef="usd">416000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="c-5" decimals="-3" id="f-35" unitRef="usd">743000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-36" unitRef="usd">530000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-5" decimals="-3" id="f-37" unitRef="usd">218000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-3" id="f-38" unitRef="usd">87589000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-5" decimals="-3" id="f-39" unitRef="usd">89893000</us-gaap:AssetsCurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-4" decimals="-3" id="f-40" unitRef="usd">4000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-5" decimals="-3" id="f-41" unitRef="usd">6000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-4" decimals="-3" id="f-42" unitRef="usd">87593000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-5" decimals="-3" id="f-43" unitRef="usd">89899000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-44" unitRef="usd">6992000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-45" unitRef="usd">6557000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <vtvt:WarrantLiabilityCurrent contextRef="c-6" decimals="-3" id="f-46" unitRef="usd">25000</vtvt:WarrantLiabilityCurrent>
    <vtvt:WarrantLiabilityCurrent contextRef="c-7" decimals="-3" id="f-47" unitRef="usd">84000</vtvt:WarrantLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-48" unitRef="usd">7017000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-49" unitRef="usd">6641000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-50" unitRef="usd">1830000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-5" decimals="-3" id="f-51" unitRef="usd">18669000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <vtvt:WarrantyLiability contextRef="c-8" decimals="-3" id="f-52" unitRef="usd">114000</vtvt:WarrantyLiability>
    <vtvt:WarrantyLiability contextRef="c-9" decimals="-3" id="f-53" unitRef="usd">152000</vtvt:WarrantyLiability>
    <us-gaap:Liabilities contextRef="c-4" decimals="-3" id="f-54" unitRef="usd">8961000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-5" decimals="-3" id="f-55" unitRef="usd">25462000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-4" id="f-56" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-5" id="f-57" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-10"
      decimals="INF"
      id="f-58"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-11"
      decimals="INF"
      id="f-59"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-10" decimals="INF" id="f-60" unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-11" decimals="INF" id="f-61" unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-11" decimals="INF" id="f-62" unitRef="shares">3938803</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-10" decimals="INF" id="f-63" unitRef="shares">3938654</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c-11" decimals="-3" id="f-64" unitRef="usd">39000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-10" decimals="-3" id="f-65" unitRef="usd">39000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-12"
      decimals="INF"
      id="f-66"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-13"
      decimals="INF"
      id="f-67"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-12" decimals="INF" id="f-68" unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-13" decimals="INF" id="f-69" unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-13" decimals="INF" id="f-70" unitRef="shares">92</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-12" decimals="INF" id="f-71" unitRef="shares">241</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c-13" decimals="-3" id="f-72" unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-12" decimals="-3" id="f-73" unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-4" decimals="-3" id="f-74" unitRef="usd">394205000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-5" decimals="-3" id="f-75" unitRef="usd">391090000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-3" id="f-76" unitRef="usd">-315612000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-5" decimals="-3" id="f-77" unitRef="usd">-326692000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-78" unitRef="usd">78632000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-5" decimals="-3" id="f-79" unitRef="usd">64437000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-3" id="f-80" unitRef="usd">87593000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-5" decimals="-3" id="f-81" unitRef="usd">89899000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-14" decimals="-3" id="f-82" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-15" decimals="-3" id="f-83" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-84" unitRef="usd">36839000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-16" decimals="-3" id="f-85" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-14" decimals="-3" id="f-86" unitRef="usd">8770000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-15" decimals="-3" id="f-87" unitRef="usd">4103000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-88" unitRef="usd">17748000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-16" decimals="-3" id="f-89" unitRef="usd">6933000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-14" decimals="-3" id="f-90" unitRef="usd">5160000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-15" decimals="-3" id="f-91" unitRef="usd">3618000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-92" unitRef="usd">9758000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-16" decimals="-3" id="f-93" unitRef="usd">7291000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c-14" decimals="-3" id="f-94" unitRef="usd">13930000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-15" decimals="-3" id="f-95" unitRef="usd">7721000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-3" id="f-96" unitRef="usd">27506000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-16" decimals="-3" id="f-97" unitRef="usd">14224000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-14" decimals="-3" id="f-98" unitRef="usd">-13930000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-15" decimals="-3" id="f-99" unitRef="usd">-7721000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-100" unitRef="usd">9333000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-16" decimals="-3" id="f-101" unitRef="usd">-14224000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-17" decimals="-3" id="f-102" unitRef="usd">29000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-18" decimals="-3" id="f-103" unitRef="usd">12000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-19" decimals="-3" id="f-104" unitRef="usd">38000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-20" decimals="-3" id="f-105" unitRef="usd">-5000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-21" decimals="-3" id="f-106" unitRef="usd">35000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-22" decimals="-3" id="f-107" unitRef="usd">54000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-23" decimals="-3" id="f-108" unitRef="usd">59000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-24" decimals="-3" id="f-109" unitRef="usd">26000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:InvestmentIncomeInterest contextRef="c-14" decimals="-3" id="f-110" unitRef="usd">812000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-15" decimals="-3" id="f-111" unitRef="usd">275000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-1" decimals="-3" id="f-112" unitRef="usd">1650000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-16" decimals="-3" id="f-113" unitRef="usd">606000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-14" decimals="-3" id="f-114" unitRef="usd">-13054000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-15" decimals="-3" id="f-115" unitRef="usd">-7380000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-116" unitRef="usd">11080000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-16" decimals="-3" id="f-117" unitRef="usd">-13597000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-14" decimals="-3" id="f-118" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-15" decimals="-3" id="f-119" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-120" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-16" decimals="-3" id="f-121" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss contextRef="c-14" decimals="-3" id="f-122" unitRef="usd">-13054000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-15" decimals="-3" id="f-123" unitRef="usd">-7380000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-3" id="f-124" unitRef="usd">11080000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-16" decimals="-3" id="f-125" unitRef="usd">-13597000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-14" decimals="-3" id="f-126" unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-15" decimals="-3" id="f-127" unitRef="usd">-1334000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-128" unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-16" decimals="-3" id="f-129" unitRef="usd">-2459000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c-14" decimals="-3" id="f-130" unitRef="usd">-13054000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-15" decimals="-3" id="f-131" unitRef="usd">-6046000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-132" unitRef="usd">11080000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-16" decimals="-3" id="f-133" unitRef="usd">-11138000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-14" decimals="-3" id="f-134" unitRef="usd">-13054000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-15" decimals="-3" id="f-135" unitRef="usd">-6046000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-1" decimals="-3" id="f-136" unitRef="usd">11080000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-16" decimals="-3" id="f-137" unitRef="usd">-11138000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-25"
      decimals="2"
      id="f-138"
      unitRef="usdPerShare">-1.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-26"
      decimals="2"
      id="f-139"
      unitRef="usdPerShare">-0.92</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-27"
      decimals="2"
      id="f-140"
      unitRef="usdPerShare">0.89</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-28"
      decimals="2"
      id="f-141"
      unitRef="usdPerShare">-1.69</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-25" decimals="0" id="f-142" unitRef="shares">12409316</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-26" decimals="0" id="f-143" unitRef="shares">6587070</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-27" decimals="0" id="f-144" unitRef="shares">12409297</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-28" decimals="0" id="f-145" unitRef="shares">6584969</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-25"
      decimals="2"
      id="f-146"
      unitRef="usdPerShare">-1.05</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-26"
      decimals="2"
      id="f-147"
      unitRef="usdPerShare">-0.92</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-27"
      decimals="2"
      id="f-148"
      unitRef="usdPerShare">0.76</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-28"
      decimals="2"
      id="f-149"
      unitRef="usdPerShare">-1.69</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-25" decimals="0" id="f-150" unitRef="shares">12409316</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-26" decimals="0" id="f-151" unitRef="shares">6587070</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-27" decimals="0" id="f-152" unitRef="shares">14541788</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-28" decimals="0" id="f-153" unitRef="shares">6584969</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-29"
      decimals="INF"
      id="f-154"
      unitRef="shares">3938654</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-29" decimals="-3" id="f-155" unitRef="usd">39000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-30"
      decimals="INF"
      id="f-156"
      unitRef="shares">241</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-30" decimals="-3" id="f-157" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-31" decimals="-3" id="f-158" unitRef="usd">392478000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-32" decimals="-3" id="f-159" unitRef="usd">-302558000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-33" decimals="-3" id="f-160" unitRef="usd">89959000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c-34" decimals="-3" id="f-161" unitRef="usd">-13054000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-35" decimals="-3" id="f-162" unitRef="usd">-13054000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-36" decimals="-3" id="f-163" unitRef="usd">1727000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-35" decimals="-3" id="f-164" unitRef="usd">1727000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="c-37"
      decimals="INF"
      id="f-165"
      unitRef="shares">-149</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="c-38"
      decimals="INF"
      id="f-166"
      unitRef="shares">149</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-39"
      decimals="INF"
      id="f-167"
      unitRef="shares">3938803</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-39" decimals="-3" id="f-168" unitRef="usd">39000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-40"
      decimals="INF"
      id="f-169"
      unitRef="shares">92</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-40" decimals="-3" id="f-170" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-41" decimals="-3" id="f-171" unitRef="usd">394205000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-42" decimals="-3" id="f-172" unitRef="usd">-315612000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-43" decimals="-3" id="f-173" unitRef="usd">78632000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-44"
      decimals="INF"
      id="f-174"
      unitRef="shares">2612257</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-44" decimals="-3" id="f-175" unitRef="usd">26000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-45"
      decimals="INF"
      id="f-176"
      unitRef="shares">577349</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-45" decimals="-3" id="f-177" unitRef="usd">6000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-46" decimals="-3" id="f-178" unitRef="usd">312698000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-47" decimals="-3" id="f-179" unitRef="usd">-304810000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-48" decimals="-3" id="f-180" unitRef="usd">7920000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-49" decimals="-3" id="f-181" unitRef="usd">977000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-50" decimals="-3" id="f-182" unitRef="usd">8897000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c-51" decimals="-3" id="f-183" unitRef="usd">-6046000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-52" decimals="-3" id="f-184" unitRef="usd">-6046000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-15" decimals="-3" id="f-185" unitRef="usd">-6046000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-53"
      decimals="INF"
      id="f-186"
      unitRef="shares">700</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-54" decimals="-3" id="f-187" unitRef="usd">9000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-52" decimals="-3" id="f-188" unitRef="usd">9000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-15" decimals="-3" id="f-189" unitRef="usd">9000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="c-53"
      decimals="INF"
      id="f-190"
      unitRef="shares">-4258</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-54" decimals="-3" id="f-191" unitRef="usd">51000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-52" decimals="-3" id="f-192" unitRef="usd">51000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-15" decimals="-3" id="f-193" unitRef="usd">51000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-54" decimals="-3" id="f-194" unitRef="usd">930000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-52" decimals="-3" id="f-195" unitRef="usd">930000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-15" decimals="-3" id="f-196" unitRef="usd">930000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-55" decimals="-3" id="f-197" unitRef="usd">-1334000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-15" decimals="-3" id="f-198" unitRef="usd">-1334000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-56"
      decimals="INF"
      id="f-199"
      unitRef="shares">2617215</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-56" decimals="-3" id="f-200" unitRef="usd">26000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-57"
      decimals="INF"
      id="f-201"
      unitRef="shares">577349</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-57" decimals="-3" id="f-202" unitRef="usd">6000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-58" decimals="-3" id="f-203" unitRef="usd">313586000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-59" decimals="-3" id="f-204" unitRef="usd">-310856000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-60" decimals="-3" id="f-205" unitRef="usd">2762000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-61" decimals="-3" id="f-206" unitRef="usd">-357000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-62" decimals="-3" id="f-207" unitRef="usd">2405000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-63"
      decimals="INF"
      id="f-208"
      unitRef="shares">3938654</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-63" decimals="-3" id="f-209" unitRef="usd">39000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-64"
      decimals="INF"
      id="f-210"
      unitRef="shares">241</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-64" decimals="-3" id="f-211" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-65" decimals="-3" id="f-212" unitRef="usd">391090000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-66" decimals="-3" id="f-213" unitRef="usd">-326692000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-67" decimals="-3" id="f-214" unitRef="usd">64437000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c-68" decimals="-3" id="f-215" unitRef="usd">11080000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-69" decimals="-3" id="f-216" unitRef="usd">11080000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-70" decimals="-3" id="f-217" unitRef="usd">3115000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-69" decimals="-3" id="f-218" unitRef="usd">3115000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="c-71"
      decimals="INF"
      id="f-219"
      unitRef="shares">-149</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="c-72"
      decimals="INF"
      id="f-220"
      unitRef="shares">149</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-39"
      decimals="INF"
      id="f-221"
      unitRef="shares">3938803</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-39" decimals="-3" id="f-222" unitRef="usd">39000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-40"
      decimals="INF"
      id="f-223"
      unitRef="shares">92</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-40" decimals="-3" id="f-224" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-41" decimals="-3" id="f-225" unitRef="usd">394205000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-42" decimals="-3" id="f-226" unitRef="usd">-315612000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-43" decimals="-3" id="f-227" unitRef="usd">78632000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-73"
      decimals="INF"
      id="f-228"
      unitRef="shares">2612257</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-73" decimals="-3" id="f-229" unitRef="usd">26000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-74"
      decimals="INF"
      id="f-230"
      unitRef="shares">577349</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-74" decimals="-3" id="f-231" unitRef="usd">6000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-75" decimals="-3" id="f-232" unitRef="usd">311885000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-76" decimals="-3" id="f-233" unitRef="usd">-299718000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-77" decimals="-3" id="f-234" unitRef="usd">12199000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-78" decimals="-3" id="f-235" unitRef="usd">2102000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-79" decimals="-3" id="f-236" unitRef="usd">14301000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c-80" decimals="-3" id="f-237" unitRef="usd">-11138000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-81" decimals="-3" id="f-238" unitRef="usd">-11138000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-16" decimals="-3" id="f-239" unitRef="usd">-11138000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-82"
      decimals="INF"
      id="f-240"
      unitRef="shares">700</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-83" decimals="-3" id="f-241" unitRef="usd">9000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-80" decimals="-3" id="f-242" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-81" decimals="-3" id="f-243" unitRef="usd">9000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-16" decimals="-3" id="f-244" unitRef="usd">9000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="c-82"
      decimals="INF"
      id="f-245"
      unitRef="shares">-4258</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-83" decimals="-3" id="f-246" unitRef="usd">51000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-81" decimals="-3" id="f-247" unitRef="usd">51000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-84" decimals="-3" id="f-248" unitRef="usd">0</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-16" decimals="-3" id="f-249" unitRef="usd">51000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-83" decimals="-3" id="f-250" unitRef="usd">1743000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-81" decimals="-3" id="f-251" unitRef="usd">1743000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-16" decimals="-3" id="f-252" unitRef="usd">1743000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-84" decimals="-3" id="f-253" unitRef="usd">-2459000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-16" decimals="-3" id="f-254" unitRef="usd">-2459000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-56"
      decimals="INF"
      id="f-255"
      unitRef="shares">2617215</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-56" decimals="-3" id="f-256" unitRef="usd">26000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-57"
      decimals="INF"
      id="f-257"
      unitRef="shares">577349</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-57" decimals="-3" id="f-258" unitRef="usd">6000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-58" decimals="-3" id="f-259" unitRef="usd">313586000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-59" decimals="-3" id="f-260" unitRef="usd">-310856000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-60" decimals="-3" id="f-261" unitRef="usd">2762000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-61" decimals="-3" id="f-262" unitRef="usd">-357000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-62" decimals="-3" id="f-263" unitRef="usd">2405000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-3" id="f-264" unitRef="usd">11080000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-16" decimals="-3" id="f-265" unitRef="usd">-13597000</us-gaap:ProfitLoss>
    <us-gaap:Depreciation contextRef="c-1" decimals="-3" id="f-266" unitRef="usd">2000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-16" decimals="-3" id="f-267" unitRef="usd">12000</us-gaap:Depreciation>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-268" unitRef="usd">3115000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-16" decimals="-3" id="f-269" unitRef="usd">1743000</us-gaap:ShareBasedCompensation>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-23" decimals="-3" id="f-270" unitRef="usd">-59000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-24" decimals="-3" id="f-271" unitRef="usd">-26000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-19" decimals="-3" id="f-272" unitRef="usd">-38000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-20" decimals="-3" id="f-273" unitRef="usd">5000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-274" unitRef="usd">-327000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-16" decimals="-3" id="f-275" unitRef="usd">-833000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="c-1" decimals="-3" id="f-276" unitRef="usd">312000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="c-16" decimals="-3" id="f-277" unitRef="usd">-82000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c-1" decimals="-3" id="f-278" unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c-16" decimals="-3" id="f-279" unitRef="usd">-67000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-1" decimals="-3" id="f-280" unitRef="usd">435000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-16" decimals="-3" id="f-281" unitRef="usd">189000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-1" decimals="-3" id="f-282" unitRef="usd">-16839000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-16" decimals="-3" id="f-283" unitRef="usd">0</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c-1" decimals="-3" id="f-284" unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c-16" decimals="-3" id="f-285" unitRef="usd">-90000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-286" unitRef="usd">-2289000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-16" decimals="-3" id="f-287" unitRef="usd">-10782000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-1" decimals="-3" id="f-288" unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-16" decimals="-3" id="f-289" unitRef="usd">9000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-1" decimals="-3" id="f-290" unitRef="usd">0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-16" decimals="-3" id="f-291" unitRef="usd">51000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-292" unitRef="usd">0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-16" decimals="-3" id="f-293" unitRef="usd">-42000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-294" unitRef="usd">-2289000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-16" decimals="-3" id="f-295" unitRef="usd">-10824000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-5" decimals="-3" id="f-296" unitRef="usd">88932000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-79" decimals="-3" id="f-297" unitRef="usd">36746000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-298" unitRef="usd">86643000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-62" decimals="-3" id="f-299" unitRef="usd">25922000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="c-1" id="f-300">Description of Business and Basis of Presentation &lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Description of Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;vTv Therapeutics Inc. (the &#x201c;Company,&#x201d; the &#x201c;Registrant,&#x201d; &#x201c;we&#x201d; or &#x201c;us&#x201d;) was incorporated in the state of Delaware in April 2015. The Company is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. The Company&#x2019;s clinical pipeline is led by &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;cadisegliatin&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, currently in a Phase 3 trial, a potential first-in-class oral liver-selective glucokinase activator being investigated as an adjunctive therapy to insulin for the treatment of type 1 diabetes. The Company and its development partners are investigating multiple molecules across different indications for chronic diseases. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;vTv Therapeutics Inc. is a holding company, and its principal asset is a controlling equity interest in vTv Therapeutics LLC (&#x201c;vTv LLC&#x201d;), the Company&#x2019;s principal operating subsidiary.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has determined that vTv LLC is a variable-interest entity (&#x201c;VIE&#x201d;) for accounting purposes and that vTv Therapeutics Inc. is the primary beneficiary of vTv LLC because (through its managing member interest in vTv LLC and the fact that the senior management of vTv Therapeutics Inc. is also the senior management of vTv LLC) it has the power and benefits to direct all of the activities of vTv LLC, which include those that most significantly impact vTv LLC&#x2019;s economic performance. vTv Therapeutics Inc. has therefore consolidated vTv LLC&#x2019;s results pursuant to Accounting Standards Codification Topic 810, &#x201c;Consolidation&#x201d; in its Unaudited Condensed Consolidated Financial Statements. The assets and liabilities of vTv LLC represent substantially all of the Company&#x2019;s consolidated assets and liabilities with the exception of the Warrants and $67.6 million of cash and cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Various holders own non-voting interests in vTv LLC, representing a de minimis amount of economic interest. Effectively, vTv Therapeutics Inc.&#x2019;s interest is approximately 100.0% of vTv LLC&#x2019;s economic results. vTv Therapeutics Inc. has provided financial and other support to vTv LLC in the form of its purchase of vTv Units with the net proceeds of the Company&#x2019;s various debt and equity transactions in prior years and equity purchase agreements with various parties. v&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tv Therapeutics Inc. will not be required to provide financial or other support for vTv LLC. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;However, vTv Therapeutics Inc. will control its business and other activities through its managing member interest in vTv LLC, and its management is the management of vTv LLC. Nevertheless, because vTv Therapeutics Inc. will have no material assets other than its interests in vTv LLC, any financial difficulties at vTv LLC could result in vTv Therapeutics Inc. recognizing a loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To date, the Company has not generated any product revenue and has not achieved profitable operations. The continuing development of our drug candidates will require additional financing. From its inception through June&#160;30, 2026, the Company has funded its operations primarily through a combination of private placements of common and preferred equity, research collaboration agreements, upfront and milestone payments for license agreements, debt and equity financings and the completion of its IPO in August 2015. As of June&#160;30, 2026, the Company had an accumulated deficit of $315.6&#160;million and has generated net losses in each year of its existence. As of June&#160;30, 2026, the Company&#x2019;s liquidity sources included cash and cash equivalents of $86.6 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 30, 2026, the Company entered into a Second Amendment to License Agreement with Newsoara Biopharma Co., Ltd. (&#x201c;Newsoara&#x201d;) (the &#x201c;Second Amendment&#x201d;). Under the Second Amendment, Newsoara's rights in the Company's PDE4 inhibitor, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;HPP737&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, will expand to include all countries of the world upon Newsoara's payment of the upfront fee of $20.0 million. See Note 3 for further details.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-85" decimals="-5" id="f-301" unitRef="usd">67600000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <vtvt:PercentageOfNonVotingEconomicInterestByParent contextRef="c-86" decimals="1" id="f-302" unitRef="number">1.000</vtvt:PercentageOfNonVotingEconomicInterestByParent>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-5" id="f-303" unitRef="usd">-315600000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-5" id="f-304" unitRef="usd">86600000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <vtvt:LicenseFeeReceived contextRef="c-87" decimals="-5" id="f-305" unitRef="usd">20000000.0</vtvt:LicenseFeeReceived>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-306">Summary of Significant Accounting Policies&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Unaudited Interim Financial Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;). The accompanying Condensed Consolidated Balance Sheet as of June&#160;30, 2026, Condensed Consolidated Statements of Operations for the three and six months ended June&#160;30, 2026 and 2025, Condensed Consolidated Statement of Changes in Stockholders&#x2019; Equity for the three and six months ended June&#160;30, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2026 and 2025, and Condensed Consolidated Statements of Cash Flows for the six months ended June&#160;30, 2026 and 2025 are unaudited. These unaudited financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (&#x201c;SEC&#x201d;) for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. These financial statements should be read in conjunction with the audited financial statements and the accompanying notes for the year ended December&#160;31, 2025, contained in the Company&#x2019;s Annual Report on Form 10-K. The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company&#x2019;s financial position as of June&#160;30, 2026, the results of operations for the three and six months ended June&#160;30, 2026 and 2025, and cash flows for the six months ended June&#160;30, 2026 and 2025. The December&#160;31, 2025 Condensed Consolidated Balance Sheet included herein was derived from the audited financial statements but does not include all disclosures or notes required by GAAP for complete financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The financial data and other information disclosed in these notes to the financial statements related to the three and six months ended June&#160;30, 2026 and 2025 are unaudited. Interim results are not necessarily indicative of results for an entire year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company does not have any components of other comprehensive income recorded within its Condensed Consolidated Financial Statements, and, therefore, does not separately present a statement of comprehensive income in its Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On an ongoing basis, the Company evaluates its estimates, including those related to the grant date fair value of equity awards, the fair value of warrants to purchase shares of its Class A common stock and the useful lives of property and equipment, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgments about the carrying value of assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There has been uncertainty and disruption in the global economy and financial markets due to a number of factors, including geopolitical instability, inflationary pressures, high interest rates, a recessionary environment, domestic and global monetary and fiscal policy, changes in trade policy, including tariffs or other trade restrictions or the threat of such actions, banking and other financial institution instability and other factors. Our business may also be impacted by changes or disruptions at the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) and other government agencies. The Company has taken into consideration any known impacts to its accounting estimates to date and is not aware of any additional specific events or circumstances that would require any additional updates to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of the filing date of this Quarterly Report on Form 10-Q.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no material changes to the Company&#x2019;s significant accounting policies during the three and six months ended June&#160;30, 2026, as compared to those disclosed in Note 2 Summary of Significant Accounting Policies included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2025. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Disaggregation of Income Statement Expenses:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In November 2024, the FASB issued ASU No. 2024-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201c;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures: Disaggregation of Income Statement Expenses.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d; This guidance requires disclosures about significant expense categories, including but not limited to, inventory purchases, employee compensation, depreciation, amortization, and selling expenses&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This amendment is effective for our annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. We are currently assessing the impact of this guidance on our disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <vtvt:UnauditedInterimFinancialInformationPolicyPolicyTextBlock contextRef="c-1" id="f-307">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Unaudited Interim Financial Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;). The accompanying Condensed Consolidated Balance Sheet as of June&#160;30, 2026, Condensed Consolidated Statements of Operations for the three and six months ended June&#160;30, 2026 and 2025, Condensed Consolidated Statement of Changes in Stockholders&#x2019; Equity for the three and six months ended June&#160;30, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2026 and 2025, and Condensed Consolidated Statements of Cash Flows for the six months ended June&#160;30, 2026 and 2025 are unaudited. These unaudited financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (&#x201c;SEC&#x201d;) for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. These financial statements should be read in conjunction with the audited financial statements and the accompanying notes for the year ended December&#160;31, 2025, contained in the Company&#x2019;s Annual Report on Form 10-K. The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company&#x2019;s financial position as of June&#160;30, 2026, the results of operations for the three and six months ended June&#160;30, 2026 and 2025, and cash flows for the six months ended June&#160;30, 2026 and 2025. The December&#160;31, 2025 Condensed Consolidated Balance Sheet included herein was derived from the audited financial statements but does not include all disclosures or notes required by GAAP for complete financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The financial data and other information disclosed in these notes to the financial statements related to the three and six months ended June&#160;30, 2026 and 2025 are unaudited. Interim results are not necessarily indicative of results for an entire year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company does not have any components of other comprehensive income recorded within its Condensed Consolidated Financial Statements, and, therefore, does not separately present a statement of comprehensive income in its Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;</vtvt:UnauditedInterimFinancialInformationPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-308">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On an ongoing basis, the Company evaluates its estimates, including those related to the grant date fair value of equity awards, the fair value of warrants to purchase shares of its Class A common stock and the useful lives of property and equipment, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgments about the carrying value of assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There has been uncertainty and disruption in the global economy and financial markets due to a number of factors, including geopolitical instability, inflationary pressures, high interest rates, a recessionary environment, domestic and global monetary and fiscal policy, changes in trade policy, including tariffs or other trade restrictions or the threat of such actions, banking and other financial institution instability and other factors. Our business may also be impacted by changes or disruptions at the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) and other government agencies. The Company has taken into consideration any known impacts to its accounting estimates to date and is not aware of any additional specific events or circumstances that would require any additional updates to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of the filing date of this Quarterly Report on Form 10-Q.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-309">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Disaggregation of Income Statement Expenses:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In November 2024, the FASB issued ASU No. 2024-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201c;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures: Disaggregation of Income Statement Expenses.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d; This guidance requires disclosures about significant expense categories, including but not limited to, inventory purchases, employee compensation, depreciation, amortization, and selling expenses&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This amendment is effective for our annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. We are currently assessing the impact of this guidance on our disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="c-1" id="f-310">Collaboration Agreements&lt;div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;G42 Agreements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and G42 Investments AI Holding RSC Ltd, a private limited company (&#x201c;G42 Investments&#x201d;), entered into a Common Stock Purchase Agreement (the &#x201c;G42 Purchase Agreement&#x201d;), on May 31, 2022, pursuant to which the Company sold to G42 Investments 259,657 shares of the Company&#x2019;s Class A common stock, for an aggregate purchase price of $25.0 million, which was paid (i) $12.5 million in cash at the closing and (ii) $12.5 million in the form of a promissory note of G42 Investments paid in 2023. G42 Investments agreed to certain transfer restrictions (including restrictions on short sales or similar transactions) and restrictions on further acquisitions of shares. The Company granted G42 Investments certain shelf and piggyback registration rights with respect to those shares, including the ability to conduct an underwritten offering to resell such shares under certain circumstances. The registration rights include customary cooperation, cut-back, expense reimbursement, and indemnification provisions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contemporaneously with the G42 Purchase Agreement, in 2022, the Company entered into a collaboration and license agreement (the &#x201c;Collaboration Agreement&#x201d;) with Cogna Technology Solutions LLC, an affiliate of G42 Investments, with those rights transferring to G42 Healthcare Research Technology Projects LLC ("G42"), an affiliate of G42 Investments. The Collaboration Agreement requires G42 to work with the Company in performing clinical trials for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;cadisegliatin&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;TP399)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; as well as jointly creating a global development plan to develop, market, and commercialize &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;cadisegliatin &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in certain countries in the Middle East, Africa, and Central Asia (the &#x201c;Partner Territory&#x201d;). Under the terms of the Collaboration Agreement, G42 obtained a license under certain intellectual property controlled by the Company to enable it to fulfill its obligations and exercise its rights under the Collaboration Agreement, including to develop and commercialize &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;cadisegliatin&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the Partner Territory. Specifically, the Company will share various protocols with G42 related to conducting the clinical trials and will provide the patient dosages and placebo of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;cadisegliatin &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;needed to conduct the trials. Under the Collaboration Agreement, G42 has the right to develop and commercialize &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;cadisegliatin &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in the Partner Territory at its own cost. The Company may supply at cost, or G42 may manufacture, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;cadisegliatin &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for commercial sale under terms to be agreed upon by the parties at a later date. Separately, the Company will conduct its clinical trials for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;cadisegliatin &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;outside of the Partner Territory at its own cost. The results of each party&#x2019;s clinical trials may be combined by the Company to seek FDA approval in the United States for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;cadisegliatin&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The G42 Purchase Agreement also provides for, following the receipt of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;cadisegliatin &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;FDA Approval, at the option of G42 Investments, either (a) the issuance of the Company&#x2019;s Class A common stock (the &#x201c;Milestone Shares&#x201d;) having an aggregate value equal to $30.0 million or (b) the payment by the Company of $30.0 million in cash (the &#x201c;Milestone Cash Payment&#x201d;). The issuance of the Milestone Shares or the payment of the Milestone Cash Payment, as applicable, is conditioned upon receipt of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;cadisegliatin &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;FDA Approval and subject to certain limitations and conditions set forth in the G42 Purchase Agreement. There can be no assurance that the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;cadisegliatin &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;FDA Approval will be granted or as to the timing thereof. Once commercialization takes place in the Partner Territory, the Company will receive royalties in the single digits from G42 Healthcare on the net sales of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;cadisegliatin &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for a period of at least ten years after the first commercial sale of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;cadisegliatin &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in the Partner Territory.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A premium was paid on the Class A common stock by G42 Investments of $18.7 million, net of a note receivable discount of $0.6 million, which was deferred and recorded as a contract liability. This premium was determined to be the transaction price for all remaining obligations under the agreements and accounted for under ASC 808 or ASC 606 based on determination of the unit of account. As of December 31, 2025, $18.7 million was recorded in the Consolidated Balance Sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that certain commitments under the agreements are in the scope of ASC 808 as both the Company and G42 are active participants in the clinical trials of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;cadisegliatin&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and both are exposed to significant risks and rewards based on the success of the clinical trials and subsequent FDA approval. G42 is determined to be a vendor of the Company during the clinical trial phase, working on the Company&#x2019;s behalf to complete research and development activities, and not in a customer capacity. The Company accounted for the commitments related to the clinical trials, which includes transfer of trial protocols, supply of clinical trial dosages, and collaboration on the joint development committee as an ASC 808 unit of account, applying the recognition and measurement principles of ASC 606 by analogy. The Company will recognize collaboration revenue for its development activities under ASC 808 over time based on the estimated period of performance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;By applying the principles in ASC 606 by analogy, the Company identified the performance obligation and considered the timing of satisfaction of the obligation to account for the pattern of revenue recognition. In order to recognize collaboration revenue, generally, the Company would begin satisfying its performance obligation and G42 would need to be able to use and benefit from delivery of the assets or services. The performance obligation under the agreements that fall &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;within the ASC 808 unit of account are concentrated in the clinical trials. As of June&#160;30, 2026, the clinical trials had not commenced. Accordingly, no collaboration revenue was recognized for the ASC 808 unit of account during the three and six months ended June&#160;30, 2026 and 2025. $1.3 million remains deferred and recorded in contract liabilities as of June&#160;30, 2026.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company identified certain commitments that are in the scope of ASC 606 as G42&#x2019;s relationship is that of a customer for these commitments. The significant performance obligations that are in the scope of ASC 606 are (1) the development, commercialization and manufacturing license of the intellectual property (IP) once restrictions on the use of the IP have been lifted by the Company and (2) a potential material right to a commercial supply agreement. As a result, the Company recognizes revenue associated with the development, commercialization, and manufacturing license at a point in time upon the release of the IP restrictions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2026, the Company lifted the contractual restrictions on the use of the IP. Accordingly, the Company determined that control of the license was transferred to G42 at that point in time, and the related performance obligation was satisfied. During the six months ended June&#160;30, 2026, the Company recognized $16.9&#160;million license revenue associated with the transfer of the IP. No license revenue was recognized during the three months ended June&#160;30, 2026 or the three and six months ended June&#160;30, 2025. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company will recognize revenue from the material right related to G42&#x2019;s ability to purchase the commercial supply at cost as G42 purchases the commercial supply from the Company, which will occur after the completion of the initial clinical trials (if G42 decides to purchase the clinical supply from the Company). No revenue has been recognized related to the commercial supply agreement during the three and six months ended June&#160;30, 2026 and 2025, as G42 has not exercised its option to purchase commercial supply as of those dates. $0.5 million remains deferred and recorded in contract liabilities as of June&#160;30, 2026.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Newsoara License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is party to a license agreement with Newsoara Biopharma Co., Ltd., (&#x201c;Newsoara&#x201d;) (the &#x201c;Newsoara License Agreement&#x201d;) under which Newsoara obtained an exclusive and sublicensable license to develop and commercialize the Company&#x2019;s phosphodiesterase type 4 inhibitors (&#x201c;PDE4&#x201d;) program, including the compound &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;HPP737&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, in China, Hong Kong, Macau, Taiwan and other pacific rim countries (collectively, the &#x201c;Newsoara License Territory&#x201d;). Additionally, under the Newsoara License Agreement, the Company obtained a non-exclusive, sublicensable, royalty-free license to develop and commercialize certain Newsoara patent rights and know-how related to the Company&#x2019;s PDE4 program for therapeutic uses in humans outside of the Newsoara License Territory. In accordance with ASC 606, the Company identified all of the performance obligations at the inception of the Newsoara License Agreement. The significant obligations were determined to be the license and the technology transfer services. The Company determined that the license and technology transfer services represent a single performance obligation because they were not capable of being distinct on their own. The transaction price was fully allocated to this combined performance obligation and the related revenue was recognized during the year ended December 31, 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Newsoara License Agreement was amended in 2020 to change certain future milestone payments and patent rights (the &#x201c;First Newsoara Amendment&#x201d;). On January 30, 2026, the Company entered into a new Second Amendment with Newsoara. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Although the Company had previously entered into an amendment with Newsoara to expand the Original Agreement, that amendment became null and void in June 2025. Under the new Second Amendment, Newsoara's rights in the Company's PDE4 inhibitor, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;HPP737&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, will expand to include all countries of the world upon Newsoara's payment of the upfront fee of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$20.0 million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Second Amendment also requires Newsoara to pay vTv LLC up to approximately &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$50.0 million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in development milestones, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$65.0 million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in sales-related milestones and royalties in the mid single digits depending upon sales volumes.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In February 2026, the Company received and recognized the $20.0 million upfront payment from Newsoara as stipulated in the Second Amendment and recognized the related revenue due to satisfying the performance obligation.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2026, development milestones totaling $3.0 million had been recognized in prior periods by the Company under the Second Amendment.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="c-88" decimals="0" id="f-311" unitRef="shares">259657</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <vtvt:SaleOfStockConsiderationReceivedOnTransactionGross contextRef="c-89" decimals="-5" id="f-312" unitRef="usd">25000000.0</vtvt:SaleOfStockConsiderationReceivedOnTransactionGross>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-88" decimals="-5" id="f-313" unitRef="usd">12500000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:AccountsNotesAndLoansReceivableNetCurrent contextRef="c-90" decimals="-5" id="f-314" unitRef="usd">12500000</us-gaap:AccountsNotesAndLoansReceivableNetCurrent>
    <vtvt:CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue contextRef="c-90" decimals="-5" id="f-315" unitRef="usd">30000000.0</vtvt:CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue>
    <vtvt:CollaborateArrangementContingentConsiderationTransferredCash contextRef="c-89" decimals="-5" id="f-316" unitRef="usd">30000000.0</vtvt:CollaborateArrangementContingentConsiderationTransferredCash>
    <vtvt:CollaborativeArrangementRoyaltiesReceivablePeriod contextRef="c-91" id="f-317">P10Y</vtvt:CollaborativeArrangementRoyaltiesReceivablePeriod>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-92" decimals="-5" id="f-318" unitRef="usd">18700000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <vtvt:CollaborativeArrangementNoteReceivableDiscountPaid contextRef="c-93" decimals="-5" id="f-319" unitRef="usd">600000</vtvt:CollaborativeArrangementNoteReceivableDiscountPaid>
    <us-gaap:ContractWithCustomerLiability contextRef="c-5" decimals="-3" id="f-320" unitRef="usd">18700000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-93" decimals="INF" id="f-321" unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-94" decimals="INF" id="f-322" unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-95" decimals="INF" id="f-323" unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-96" decimals="INF" id="f-324" unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:ContractWithCustomerLiability contextRef="c-92" decimals="-5" id="f-325" unitRef="usd">1300000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-97" decimals="-5" id="f-326" unitRef="usd">16900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-98" decimals="INF" id="f-327" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-99" decimals="INF" id="f-328" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-100" decimals="INF" id="f-329" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-101" decimals="INF" id="f-330" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-102" decimals="INF" id="f-331" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-103" decimals="INF" id="f-332" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-104" decimals="INF" id="f-333" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiability contextRef="c-105" decimals="-5" id="f-334" unitRef="usd">500000</us-gaap:ContractWithCustomerLiability>
    <vtvt:LicenseFeeReceived contextRef="c-87" decimals="-5" id="f-335" unitRef="usd">20000000.0</vtvt:LicenseFeeReceived>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-106" decimals="-5" id="f-336" unitRef="usd">50000000.0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <vtvt:PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable contextRef="c-87" decimals="-5" id="f-337" unitRef="usd">65000000.0</vtvt:PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable>
    <vtvt:LicenseFeeReceived contextRef="c-107" decimals="-5" id="f-338" unitRef="usd">20000000.0</vtvt:LicenseFeeReceived>
    <vtvt:PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable contextRef="c-108" decimals="-5" id="f-339" unitRef="usd">3000000.0</vtvt:PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-340">Share-Based Compensation&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has issued non-qualified stock option awards to management, other key employees, consultants, and non-employee directors and these options ratably vest over a four-year service period. In addition, we issued options in connection with the private placement on February 27, 2024, that vest ratably over a three-year period. The option awards expire after a term of ten years from the date of grant. As of June&#160;30, 2026, the Company had total unrecognized stock-based compensation expense for its outstanding stock option awards of approximately $13.5 million, which is expected to be recognized over a weighted average period of 3.0 years. The weighted average grant date fair value of options granted during the six months ended June&#160;30, 2026 and 2025 was $28.05 and $15.01 per option, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity related to the stock option awards for the six months ended June&#160;30, 2026:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.023%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.642%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.243%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.413%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.243%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.413%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.246%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Shares &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted &lt;br/&gt;Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Awards outstanding at December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,017,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;564,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41,687)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Awards outstanding at June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,540,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable at June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;border-top:3pt double #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;604,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:3pt double #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:3pt double #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:3pt double #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:3pt double #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:3pt double #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:3pt double #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:3pt double #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining contractual term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.1 Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest at June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,275,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining contractual term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.1 Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Compensation expense related to the grants of stock options is included in research and development and general and administrative expense as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:39.525%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.376%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.525%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.251%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-109" id="f-341">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-110" id="f-342">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-109" id="f-343">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c-111" decimals="-5" id="f-344" unitRef="usd">13500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-109" id="f-345">P3Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-109"
      decimals="2"
      id="f-346"
      unitRef="usdPerShare">28.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-112"
      decimals="2"
      id="f-347"
      unitRef="usdPerShare">15.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-348">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity related to the stock option awards for the six months ended June&#160;30, 2026:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.023%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.642%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.243%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.413%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.243%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.413%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.246%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Shares &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted &lt;br/&gt;Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Awards outstanding at December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,017,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;564,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41,687)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Awards outstanding at June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,540,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable at June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;border-top:3pt double #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;604,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:3pt double #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:3pt double #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:3pt double #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:3pt double #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:3pt double #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:3pt double #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:3pt double #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining contractual term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.1 Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest at June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,275,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining contractual term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.1 Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-5" decimals="INF" id="f-349" unitRef="shares">1017620</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-5"
      decimals="2"
      id="f-350"
      unitRef="usdPerShare">25.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-1" decimals="INF" id="f-351" unitRef="shares">564719</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-352"
      unitRef="usdPerShare">36.52</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="c-1" decimals="0" id="f-353" unitRef="shares">41687</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-354"
      unitRef="usdPerShare">30.60</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-4" decimals="INF" id="f-355" unitRef="shares">1540652</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-356"
      unitRef="usdPerShare">29.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-4" decimals="-3" id="f-357" unitRef="usd">17857000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c-4" decimals="INF" id="f-358" unitRef="shares">604164</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-359"
      unitRef="usdPerShare">29.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-4" decimals="-3" id="f-360" unitRef="usd">9795000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-361">P7Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="c-4" decimals="INF" id="f-362" unitRef="shares">1275464</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-363"
      unitRef="usdPerShare">28.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-364">P8Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-365">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Compensation expense related to the grants of stock options is included in research and development and general and administrative expense as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:39.525%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.376%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.525%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.251%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-113" decimals="-3" id="f-366" unitRef="usd">533000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-114" decimals="-3" id="f-367" unitRef="usd">307000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-115" decimals="-3" id="f-368" unitRef="usd">977000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-116" decimals="-3" id="f-369" unitRef="usd">534000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-117" decimals="-3" id="f-370" unitRef="usd">1194000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-118" decimals="-3" id="f-371" unitRef="usd">623000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-119" decimals="-3" id="f-372" unitRef="usd">2138000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-120" decimals="-3" id="f-373" unitRef="usd">1209000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-14" decimals="-3" id="f-374" unitRef="usd">1727000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-15" decimals="-3" id="f-375" unitRef="usd">930000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-376" unitRef="usd">3115000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-16" decimals="-3" id="f-377" unitRef="usd">1743000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-378">Commitments and Contingencies&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company is involved in various legal proceedings arising in the normal course of business. If a specific contingent liability is determined to be probable and can be reasonably estimated, the Company accrues and discloses the amount. The Company is not currently a party to any material legal proceedings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Novo Nordisk&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2007, the Company entered into an Agreement (the &#x201c;Novo License Agreement&#x201d;) Concerning Glucokinase Activator Project with Novo Nordisk A/S (the &#x201c;Novo Nordisk&#x201d;) whereby the Company obtained an exclusive, worldwide, sublicensable license under certain Novo Nordisk intellectual property rights to discover, develop, manufacture, have manufactured, use and commercialize products for the prevention, treatment, control, mitigation or palliation of human or animal diseases or conditions. As part of this license grant, the Company obtained certain worldwide rights to Novo Nordisk&#x2019;s GKA program, including rights to preclinical and clinical compounds such as&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; cadisegliatin&lt;/span&gt;. This agreement was amended in May 2019 to create milestone payments applicable to certain specific and non-specific areas of therapeutic use. Under the terms of the amended Novo License Agreement, the Company has potential developmental and regulatory milestone payment obligations totaling up to $6.0 million for approval of a product for the treatment of type 1 diabetes, $50.5 million for approval of a product for the treatment of type 2 diabetes, or $115.0 million for approval of a product in any other indication. The Company may also be obligated to pay an additional $75.0 million in potential sales-based milestones, as well as royalty payments, at mid-single digit royalty rates, based on tiered sales of commercialized licensed products. As of June&#160;30, 2026, the Company does not have any commercialized licensed products.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <vtvt:PotentialMilestonePayment contextRef="c-121" decimals="-5" id="f-379" unitRef="usd">6000000.0</vtvt:PotentialMilestonePayment>
    <vtvt:PotentialMilestonePayment contextRef="c-122" decimals="-5" id="f-380" unitRef="usd">50500000</vtvt:PotentialMilestonePayment>
    <vtvt:PotentialMilestonePayment contextRef="c-123" decimals="-5" id="f-381" unitRef="usd">115000000.0</vtvt:PotentialMilestonePayment>
    <vtvt:PotentialMilestonePayment contextRef="c-124" decimals="-5" id="f-382" unitRef="usd">75000000.0</vtvt:PotentialMilestonePayment>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-383">Stockholders&#x2019; Equity &lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock and Pre-funded Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2025, the Company entered into a securities purchase agreement with certain Private Placement Investors pursuant to which the Company issued and sold an aggregate of 682,018 shares of Class A common stock at a purchase price of $15.265 per share, Pre-funded Warrants to purchase &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,561,714&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; shares of Class A common stock at a purchase price of $15.255 per Pre-funded Warrant, and accompanying Common Warrants to purchase up to &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,243,732&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; shares of Class A common stock for aggregate gross proceeds of approximately $80.0 million,&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; before deducting offering costs payable by us&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Pre-funded Warrants were immediately exercisable at an exercise price of $0.01 per share. The Common Warrants are &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;exercisable at &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$22.71&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; per share and expire upon the earlier of the fifth anniversary of issuance or &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;90 days &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;following the announcement of positive top-line data from the Company&#x2019;s ongoing CATT1 clinical trial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2024, the Company entered into a securities purchase agreement with certain Private Placement Investors pursuant to which the Company issued and sold an aggregate of 464,377 shares of Class A common stock at a purchase price of $11.81 per share and Pre-funded Warrants to purchase 3,853,997 shares of Class A common stock at a purchase price of $11.80 per Pre-funded Warrant for aggregate gross proceeds of approximately $51.0 million, b&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;efore deducting offering costs payable by us&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Pre-funded Warrants were immediately exercisable at an exercise price of&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$0.01 per share and contain customary beneficial ownership limitations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 5, 2024, the Company entered into a letter agreement with the Private Placement Investors pursuant to which the investors exchanged an aggregate of 116,493 shares of Class A common stock for 116,590 Pre-funded Warrants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Equity-Based Stock Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the equity-based stock warrant activity for the six months ended June&#160;30, 2026:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.703%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.329%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.780%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:2.025%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.563%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,714,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.69&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired or cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at June 30, 2026*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,714,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,714,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt"&gt;Amount includes 8,470,624 Pre-Funded Warrants and 5,243,732 Common Warrants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Pre-Funded and Common Warrants were classified as a component of permanent equity in the Company&#x2019;s Condensed Consolidated Balance Sheet as they are freestanding financial instruments that are immediately exercisable, do not embody an obligation for the Company to repurchase its own shares and permit the holders to receive a fixed number of shares of common stock upon exercise. All of the shares underlying the Pre-Funded Warrants have been included in the weighted-average number of shares of common stock used to calculate net loss per share attributable to common stockholders because the shares may be issued for little or no consideration, are fully vested and are exercisable after the original issuance date of the Pre-Funded Warrants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ATM Offering&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 28, 2024, we entered into a sales agreement (the &#x201c;TD Cowen Sales Agreement&#x201d;) with Cowen and Company, LLC (&#x201c;TD Cowen&#x201d;), pursuant to which we may offer and sell, from time to time, through or to TD Cowen, as sales agent or principal, shares of our Class A common stock, having an aggregate offering price of up to $50.0 million (the &#x201c;TD Cowen ATM Offering&#x201d;). Pursuant to General Instruction I.B.6 of Form S-3, at no time will we sell securities registered on the registration statement relating to the TD Cowen ATM Offering with an aggregate amount exceeding one-third of our public float in any 12-calendar month period, so long as our public float remains below $75.0 million. Under the terms of the TD Cowen Sales Agreement, we will pay TD Cowen a commission of 3.0% of the aggregate proceeds from the sale of shares and reimburse certain legal fees or other disbursements. On September 17, 2024, the Company sold 179,400 shares of Class A common stock under the TD Cowen ATM Offering for net proceeds of $2.5 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and six months ended June&#160;30, 2026 and 2025, the Company did not sell any shares of Class A common stock under the TD Cowen ATM Offering.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-125"
      decimals="INF"
      id="f-384"
      unitRef="shares">682018</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-126"
      decimals="3"
      id="f-385"
      unitRef="usdPerShare">15.265</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-127"
      decimals="INF"
      id="f-386"
      unitRef="shares">4561714</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-127"
      decimals="3"
      id="f-387"
      unitRef="usdPerShare">15.255</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="c-127"
      decimals="INF"
      id="f-388"
      unitRef="shares">5243732</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="c-128" decimals="-5" id="f-389" unitRef="usd">80000000.0</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-129"
      decimals="2"
      id="f-390"
      unitRef="usdPerShare">0.01</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-130"
      decimals="2"
      id="f-391"
      unitRef="usdPerShare">22.71</us-gaap:SaleOfStockPricePerShare>
    <vtvt:WarrantsAndRightsImmediatelyExercisableTerm contextRef="c-131" id="f-392">P90D</vtvt:WarrantsAndRightsImmediatelyExercisableTerm>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-132"
      decimals="INF"
      id="f-393"
      unitRef="shares">464377</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-133"
      decimals="2"
      id="f-394"
      unitRef="usdPerShare">11.81</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-134"
      decimals="INF"
      id="f-395"
      unitRef="shares">3853997</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-134"
      decimals="2"
      id="f-396"
      unitRef="usdPerShare">11.80</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="c-135" decimals="-5" id="f-397" unitRef="usd">51000000.0</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-136"
      decimals="2"
      id="f-398"
      unitRef="usdPerShare">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <vtvt:CommonStockParOrStatedValueOfPrivatePlacementShares
      contextRef="c-137"
      decimals="INF"
      id="f-399"
      unitRef="shares">116493</vtvt:CommonStockParOrStatedValueOfPrivatePlacementShares>
    <vtvt:CommonStockParOrStatedValueOfPrivatePlacementPreFundedWarrantsShares
      contextRef="c-137"
      decimals="INF"
      id="f-400"
      unitRef="shares">116590</vtvt:CommonStockParOrStatedValueOfPrivatePlacementPreFundedWarrantsShares>
    <us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock contextRef="c-1" id="f-401">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the equity-based stock warrant activity for the six months ended June&#160;30, 2026:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.703%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.329%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.780%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:2.025%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.563%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,714,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.69&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired or cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at June 30, 2026*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,714,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,714,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt"&gt;Amount includes 8,470,624 Pre-Funded Warrants and 5,243,732 Common Warrants.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="c-138"
      decimals="INF"
      id="f-402"
      unitRef="shares">13714356</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <vtvt:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-138"
      decimals="INF"
      id="f-403"
      unitRef="usdPerShare">8.69</vtvt:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="c-139"
      decimals="INF"
      id="f-404"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <vtvt:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-139"
      decimals="INF"
      id="f-405"
      unitRef="usdPerShare">0</vtvt:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="c-139"
      decimals="INF"
      id="f-406"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <vtvt:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-139"
      decimals="INF"
      id="f-407"
      unitRef="usdPerShare">0</vtvt:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
      contextRef="c-139"
      decimals="INF"
      id="f-408"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="c-140"
      decimals="INF"
      id="f-409"
      unitRef="shares">13714356</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <vtvt:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-140"
      decimals="INF"
      id="f-410"
      unitRef="usdPerShare">8.69</vtvt:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <vtvt:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber
      contextRef="c-140"
      decimals="INF"
      id="f-411"
      unitRef="shares">13714356</vtvt:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber>
    <vtvt:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-140"
      decimals="INF"
      id="f-412"
      unitRef="usdPerShare">8.69</vtvt:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-141"
      decimals="INF"
      id="f-413"
      unitRef="shares">8470624</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-142"
      decimals="INF"
      id="f-414"
      unitRef="shares">5243732</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <vtvt:SaleOfStockAggregateOfferingPrice contextRef="c-143" decimals="-5" id="f-415" unitRef="usd">50000000.0</vtvt:SaleOfStockAggregateOfferingPrice>
    <vtvt:EntityPublicFloatThreshold contextRef="c-144" decimals="-5" id="f-416" unitRef="usd">75000000.0</vtvt:EntityPublicFloatThreshold>
    <vtvt:SaleOfStockMaximumSecuritiesToBeSoldPercentOfPublicFloat contextRef="c-144" decimals="3" id="f-417" unitRef="rate">0.030</vtvt:SaleOfStockMaximumSecuritiesToBeSoldPercentOfPublicFloat>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-145"
      decimals="INF"
      id="f-418"
      unitRef="shares">179400</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-145" decimals="-5" id="f-419" unitRef="usd">2500000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-146"
      decimals="INF"
      id="f-420"
      unitRef="shares">0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-147"
      decimals="INF"
      id="f-421"
      unitRef="shares">0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-148"
      decimals="INF"
      id="f-422"
      unitRef="shares">0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-149"
      decimals="INF"
      id="f-423"
      unitRef="shares">0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c-1" id="f-425">Related-Party Transactions&lt;div style="margin-top:4pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;MacAndrews &amp;amp; Forbes Incorporated&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 19, 2025, MacAndrews converted all 577,108 outstanding shares of their Class B common stock (together with an equal number of vTv LLC units) into Class A common stock. As a result, vTv Therapeutics Inc. now owns approximately 100% of vTv LLC, as of September 30, 2025. Further, as of June&#160;30, 2026, MacAndrews directly or indirectly holds 1,490,090 shares of the Company&#x2019;s Class A common stock. As a result, MacAndrews&#x2019; holdings represent approximately 37.8% of the combined voting power of the Company&#x2019;s outstanding common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into several agreements with MacAndrews or its affiliates as further detailed below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Exchange Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the terms of the Exchange Agreement, but subject to the Amended and Restated LLC Agreement of vTv Therapeutics LLC, the vTv Units (along with a corresponding number of shares of the Class B common stock) are exchangeable for (i) shares of the Company&#x2019;s Class A common stock on a one-for-one basis or (ii) cash (based on the fair market value of the Company&#x2019;s Class A common stock as determined pursuant to the Exchange Agreement), at the Company&#x2019;s option (as the managing member of vTv Therapeutics LLC), subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. Any decision to require an exchange for cash rather than shares of Class A common stock will ultimately be determined by the entire Board of Directors. On September 19, 2025, MacAndrews exchanged 577,108 shares under the provisions of the Exchange Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Tax Receivable Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and MacAndrews are party to a tax receivable agreement (the &#x201c;Tax Receivable Agreement&#x201d;), which provides for the payment by the Company to M&amp;amp;F TTP Holdings Two LLC (&#x201c;M&amp;amp;F&#x201d;), as successor in interest to vTv Therapeutics Holdings, LLC (&#x201c;vTv Therapeutics Holdings&#x201d;), and M&amp;amp;F TTP Holdings LLC (or certain of its transferees or other assignees) of 85% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that the Company actually realizes (or, in some circumstances, the Company is deemed to realize) as a result of (a) the exchange of Class B common stock, together with the corresponding number of vTv Units, for shares of the Company&#x2019;s Class A common stock (or for cash), (b) tax benefits related to imputed interest deemed to be paid by the Company as a result of the Tax Receivable Agreement and (c) certain tax benefits attributable to payments under the Tax Receivable Agreement. MacAndrews exchanged 577,108 shares pursuant to the Exchange Agreement (discussed above), and the Company has not recognized any liability, nor has it made any payments pursuant to the Tax Receivable Agreement as of June&#160;30, 2026.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investor Rights Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is party to an investor rights agreement with M&amp;amp;F, as successor in interest to vTv Therapeutics Holdings (the &#x201c;Investor Rights Agreement&#x201d;). The Investor Rights Agreement provides M&amp;amp;F with certain demand, shelf, and piggyback registration rights with respect to its shares of Class A common stock and also provides M&amp;amp;F with certain governance rights, depending on the size of its holdings of Class A common stock. Under the Investor Rights Agreement, M&amp;amp;F was initially entitled to nominate a majority of the members of the Board of Directors and designate the members of the committees of the Board of Directors. The Investor Rights Agreement was amended on February 27, 2024, to alter M&amp;amp;F governance rights that now entitles M&amp;amp;F the right to designate two members of our Board of Directors, and as part of the Private Placement, the Private Placement Investors have rights to designate three members of our Board of Directors, making it more difficult for a third party to acquire control of our Board. The agreement with the Private Placement Investors also provides that five of our directors must approve certain actions including any acquisition by a third party, which makes it more difficult for our Board of Directors to approve such a transaction.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="c-150"
      decimals="INF"
      id="f-426"
      unitRef="shares">577108</us-gaap:InvestmentOwnedBalanceShares>
    <vtvt:OwnershipPercentageOfMajorityOwner
      contextRef="c-151"
      decimals="INF"
      id="f-427"
      unitRef="number">1</vtvt:OwnershipPercentageOfMajorityOwner>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="c-152"
      decimals="INF"
      id="f-428"
      unitRef="shares">1490090</us-gaap:InvestmentOwnedBalanceShares>
    <vtvt:OwnershipPercentageOfMajorityOwner contextRef="c-153" decimals="3" id="f-429" unitRef="number">0.378</vtvt:OwnershipPercentageOfMajorityOwner>
    <vtvt:RedeemableNonControllingInterestExchangeAgreementStockConversionRatio contextRef="c-154" decimals="0" id="f-430" unitRef="number">1</vtvt:RedeemableNonControllingInterestExchangeAgreementStockConversionRatio>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-155"
      decimals="INF"
      id="f-431"
      unitRef="shares">577108</us-gaap:CommonStockSharesOutstanding>
    <vtvt:PercentageOfAmountOfCashSavings contextRef="c-153" decimals="2" id="f-432" unitRef="number">0.85</vtvt:PercentageOfAmountOfCashSavings>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-155"
      decimals="INF"
      id="f-433"
      unitRef="shares">577108</us-gaap:CommonStockSharesOutstanding>
    <vtvt:NumberOfBoardOfDirectorsRightToDesignateMembers
      contextRef="c-156"
      decimals="0"
      id="f-434"
      unitRef="boardofdirectorsnumber">2</vtvt:NumberOfBoardOfDirectorsRightToDesignateMembers>
    <vtvt:NumberOfBoardOfDirectorsRightToDesignateMembers
      contextRef="c-157"
      decimals="0"
      id="f-435"
      unitRef="boardofdirectorsnumber">3</vtvt:NumberOfBoardOfDirectorsRightToDesignateMembers>
    <vtvt:NumberOfBoardOfDirectorsToApproveCertainActions
      contextRef="c-158"
      decimals="0"
      id="f-436"
      unitRef="boardofdirectorsnumber">5</vtvt:NumberOfBoardOfDirectorsToApproveCertainActions>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c-1" id="f-437">Segment Information&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Chief Operating Decision Maker (&#x201c;CODM&#x201d;) is our President and Chief Executive Officer, Paul Sekhri. The CODM makes decisions on resource allocation, assesses performance of the business, and monitors budget versus actual results using net loss. Net (loss) income is also a measure that is considered in monitoring budget versus actual results. The measure of the segment assets is reported on the Condensed Consolidated Balance Sheet as total assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company manages its business activities on a consolidated basis and operates in a single reportable segment. Its operations primarily focus on the research and development of its lead product candidate, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;cadisegliatin,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and it has not yet generated any product revenue. All of the Company&#x2019;s principal operations, assets, and decision-making functions are based in the U.S., and as a result, all of our financial information is derived from domestic sources except for collaboration and license revenue of $36.8 million during the six months ended June&#160;30, 2026, which was derived from two foreign collaboration partners located in China and United Arab Emirates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant segment expenses are included in the table below and represent direct and indirect research and development expenses by project for the three and six months ended June&#160;30, 2026, and 2025 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:51.209%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.375%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.396%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.375%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.396%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.375%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.396%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.378%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Direct research and development expense:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cadisegliatin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other projects&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indirect research and development expense&#x2020;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:25.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.828%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:89.972%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Includes HPP737 and azeliragon&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2020;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Includes share-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Segment revenue is consistent with what is presented in the Company&#x2019;s Condensed Consolidated Statements of Operations. Other segment items consist of (i) operating expenses, which include share-based compensation, (ii) interest and other expense and (iii) income tax expense, all of which are reflected in the Company&#x2019;s Condensed Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-159" decimals="-5" id="f-438" unitRef="usd">36800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <vtvt:NumberOfForeignCollaborationPartners
      contextRef="c-1"
      decimals="INF"
      id="f-439"
      unitRef="partner">2</vtvt:NumberOfForeignCollaborationPartners>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="c-1" id="f-440">&lt;div style="margin-top:4pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant segment expenses are included in the table below and represent direct and indirect research and development expenses by project for the three and six months ended June&#160;30, 2026, and 2025 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:51.209%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.375%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.396%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.375%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.396%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.375%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.396%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.378%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Direct research and development expense:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cadisegliatin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other projects&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indirect research and development expense&#x2020;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:25.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.828%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:89.972%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Includes HPP737 and azeliragon&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2020;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Includes share-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <vtvt:DirectResearchAndDevelopmentExpense contextRef="c-160" decimals="-3" id="f-441" unitRef="usd">5488000</vtvt:DirectResearchAndDevelopmentExpense>
    <vtvt:DirectResearchAndDevelopmentExpense contextRef="c-161" decimals="-3" id="f-442" unitRef="usd">1992000</vtvt:DirectResearchAndDevelopmentExpense>
    <vtvt:DirectResearchAndDevelopmentExpense contextRef="c-162" decimals="-3" id="f-443" unitRef="usd">11995000</vtvt:DirectResearchAndDevelopmentExpense>
    <vtvt:DirectResearchAndDevelopmentExpense contextRef="c-163" decimals="-3" id="f-444" unitRef="usd">2910000</vtvt:DirectResearchAndDevelopmentExpense>
    <vtvt:DirectResearchAndDevelopmentExpense contextRef="c-164" decimals="-3" id="f-445" unitRef="usd">240000</vtvt:DirectResearchAndDevelopmentExpense>
    <vtvt:DirectResearchAndDevelopmentExpense contextRef="c-165" decimals="-3" id="f-446" unitRef="usd">136000</vtvt:DirectResearchAndDevelopmentExpense>
    <vtvt:DirectResearchAndDevelopmentExpense contextRef="c-166" decimals="-3" id="f-447" unitRef="usd">317000</vtvt:DirectResearchAndDevelopmentExpense>
    <vtvt:DirectResearchAndDevelopmentExpense contextRef="c-167" decimals="-3" id="f-448" unitRef="usd">249000</vtvt:DirectResearchAndDevelopmentExpense>
    <vtvt:IndirectResearchDevelopmentExpense contextRef="c-168" decimals="-3" id="f-449" unitRef="usd">3042000</vtvt:IndirectResearchDevelopmentExpense>
    <vtvt:IndirectResearchDevelopmentExpense contextRef="c-169" decimals="-3" id="f-450" unitRef="usd">1975000</vtvt:IndirectResearchDevelopmentExpense>
    <vtvt:IndirectResearchDevelopmentExpense contextRef="c-159" decimals="-3" id="f-451" unitRef="usd">5436000</vtvt:IndirectResearchDevelopmentExpense>
    <vtvt:IndirectResearchDevelopmentExpense contextRef="c-170" decimals="-3" id="f-452" unitRef="usd">3774000</vtvt:IndirectResearchDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-168" decimals="-3" id="f-453" unitRef="usd">8770000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-169" decimals="-3" id="f-454" unitRef="usd">4103000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-159" decimals="-3" id="f-455" unitRef="usd">17748000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-170" decimals="-3" id="f-456" unitRef="usd">6933000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-458">Income Taxes&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to U.S. federal income taxes as well as state taxes. The Company did not record an income tax provision for the three and six months ended June&#160;30, 2026 and 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management has evaluated the positive and negative evidence surrounding the realization of its deferred tax assets, including the Company&#x2019;s history of losses, and under the applicable accounting standards determined that it is more-likely-than-not that the deferred tax assets will not be realized. The difference between the effective tax rate of the Company and the U.S. statutory tax rate of 21% on June&#160;30, 2026, is due to the valuation allowance against the Company&#x2019;s expected net operating losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed in Note 7, the Company is party to a tax receivable agreement with a related party which provides for the payment by the Company to M&amp;amp;F (or certain of its transferees or other assignees) of 85% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that the Company actually realizes (or, in some circumstances, the Company is deemed to realize) as a result of certain transactions. As no transactions have occurred which would trigger a liability under this agreement, the Company has not recognized any liability related to this agreement as of June&#160;30, 2026.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <vtvt:PercentageOfAmountOfCashSavings contextRef="c-171" decimals="2" id="f-459" unitRef="number">0.85</vtvt:PercentageOfAmountOfCashSavings>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-460">Net (Loss) Income per Share&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic (loss) income per share is computed by dividing net (loss) income attributable to vTv Therapeutics Inc. by the weighted average number of shares of Class A common stock outstanding during the period. Diluted net (loss) income per share is computed by dividing net (loss) income by the weighted-average number of shares of common stock and potentially dilutive shares of common stock outstanding during the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For dilutive securities, all outstanding stock options, and Common Warrants, are considered potentially outstanding common stock. The dilutive effect, if any, of stock options, and Common Warrants is calculated using the treasury stock method. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the numerator and denominator used in the calculation of basic and diluted net (loss) income per share of Class A common stock is as follows (amounts in thousands, except number of shares and per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.321%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.392%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.144%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.411%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.074%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.329%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.144%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.329%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.077%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic net (loss) income per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (loss) income &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,054)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,380)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,597)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Net loss attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,334)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,459)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (loss) income attributable to common shareholders of vTv Therapeutics Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,054)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,046)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,138)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average vTv Therapeutics Inc. Class A common stock &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,409,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,587,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,409,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,584,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic net (loss) income per share of vTv Therapeutics Inc. Class A common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.05)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.92)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted net (loss) income per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (loss) income &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,054)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,380)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,597)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Net loss attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,334)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,459)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (loss) income attributable to common shareholders of vTv Therapeutics Inc&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,054)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,046)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,138)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average vTv Therapeutics Inc. Class A common stock &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,409,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,587,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,541,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,584,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted net (loss) income per share of vTv Therapeutics Inc. Class A common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.05)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.92)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:2.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:2.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:90.720%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;The shares underlying the pre-funded warrants to purchase shares of the Company&#x2019;s common stock have been included in the calculation of the weighted average number of shares outstanding, basic and diluted, for the three and six months ended June&#160;30, 2026 and 2025.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potentially dilutive securities not included in the calculation of dilutive net loss per share are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.372%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.865%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.396%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.867%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Class B common stock &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;577,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock options granted under the Plan &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;674,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,018,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock warrants &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;693,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,666,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;___________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:2.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:2.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:90.720%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Shares of Class B common stock do not share in the Company&#x2019;s earnings and are not participating securities. Accordingly, separate presentation of loss per share of Class B common stock under the two-class method has not been provided. Each share of Class B common stock (together with a corresponding vTv Unit) is exchangeable for one share of Class A common stock.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-461">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the numerator and denominator used in the calculation of basic and diluted net (loss) income per share of Class A common stock is as follows (amounts in thousands, except number of shares and per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.321%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.392%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.144%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.411%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.074%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.329%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.144%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.329%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.077%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic net (loss) income per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (loss) income &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,054)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,380)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,597)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Net loss attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,334)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,459)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (loss) income attributable to common shareholders of vTv Therapeutics Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,054)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,046)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,138)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average vTv Therapeutics Inc. Class A common stock &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,409,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,587,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,409,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,584,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic net (loss) income per share of vTv Therapeutics Inc. Class A common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.05)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.92)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted net (loss) income per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (loss) income &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,054)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,380)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,597)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Net loss attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,334)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,459)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (loss) income attributable to common shareholders of vTv Therapeutics Inc&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,054)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,046)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,138)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average vTv Therapeutics Inc. Class A common stock &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,409,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,587,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,541,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,584,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted net (loss) income per share of vTv Therapeutics Inc. Class A common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.05)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.92)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:2.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:2.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:90.720%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;The shares underlying the pre-funded warrants to purchase shares of the Company&#x2019;s common stock have been included in the calculation of the weighted average number of shares outstanding, basic and diluted, for the three and six months ended June&#160;30, 2026 and 2025.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:ProfitLoss contextRef="c-14" decimals="-3" id="f-462" unitRef="usd">-13054000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-15" decimals="-3" id="f-463" unitRef="usd">-7380000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-3" id="f-464" unitRef="usd">11080000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-16" decimals="-3" id="f-465" unitRef="usd">-13597000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-14" decimals="-3" id="f-466" unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-15" decimals="-3" id="f-467" unitRef="usd">-1334000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-468" unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-16" decimals="-3" id="f-469" unitRef="usd">-2459000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-14" decimals="-3" id="f-470" unitRef="usd">-13054000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-15" decimals="-3" id="f-471" unitRef="usd">-6046000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-1" decimals="-3" id="f-472" unitRef="usd">11080000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="c-1" decimals="-3" id="f-473" unitRef="usd">11080000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-16" decimals="-3" id="f-474" unitRef="usd">-11138000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="c-16" decimals="-3" id="f-475" unitRef="usd">-11138000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-25" decimals="0" id="f-476" unitRef="shares">12409316</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-26" decimals="0" id="f-477" unitRef="shares">6587070</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-27" decimals="0" id="f-478" unitRef="shares">12409297</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-28" decimals="0" id="f-479" unitRef="shares">6584969</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-28" decimals="0" id="f-480" unitRef="shares">6584969</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-25"
      decimals="2"
      id="f-481"
      unitRef="usdPerShare">-1.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-26"
      decimals="2"
      id="f-482"
      unitRef="usdPerShare">-0.92</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-27"
      decimals="2"
      id="f-483"
      unitRef="usdPerShare">0.89</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-28"
      decimals="2"
      id="f-484"
      unitRef="usdPerShare">-1.69</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-28"
      decimals="2"
      id="f-485"
      unitRef="usdPerShare">-1.69</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ProfitLoss contextRef="c-14" decimals="-3" id="f-486" unitRef="usd">-13054000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-15" decimals="-3" id="f-487" unitRef="usd">-7380000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-3" id="f-488" unitRef="usd">11080000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-16" decimals="-3" id="f-489" unitRef="usd">-13597000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-14" decimals="-3" id="f-490" unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-15" decimals="-3" id="f-491" unitRef="usd">-1334000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-492" unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-16" decimals="-3" id="f-493" unitRef="usd">-2459000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="c-14" decimals="-3" id="f-494" unitRef="usd">-13054000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="c-15" decimals="-3" id="f-495" unitRef="usd">-6046000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="c-1" decimals="-3" id="f-496" unitRef="usd">11080000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="c-16" decimals="-3" id="f-497" unitRef="usd">-11138000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-25" decimals="0" id="f-498" unitRef="shares">12409316</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-26" decimals="0" id="f-499" unitRef="shares">6587070</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-27" decimals="0" id="f-500" unitRef="shares">14541788</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-28" decimals="0" id="f-501" unitRef="shares">6584969</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-25"
      decimals="2"
      id="f-502"
      unitRef="usdPerShare">-1.05</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-26"
      decimals="2"
      id="f-503"
      unitRef="usdPerShare">-0.92</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-27"
      decimals="2"
      id="f-504"
      unitRef="usdPerShare">0.76</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-28"
      decimals="2"
      id="f-505"
      unitRef="usdPerShare">-1.69</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-506">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potentially dilutive securities not included in the calculation of dilutive net loss per share are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.372%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.865%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.396%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.867%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Class B common stock &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;577,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock options granted under the Plan &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;674,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,018,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock warrants &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;693,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,666,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;___________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:2.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:2.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:90.720%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Shares of Class B common stock do not share in the Company&#x2019;s earnings and are not participating securities. Accordingly, separate presentation of loss per share of Class B common stock under the two-class method has not been provided. Each share of Class B common stock (together with a corresponding vTv Unit) is exchangeable for one share of Class A common stock.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-172" decimals="0" id="f-507" unitRef="shares">92</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-173" decimals="0" id="f-508" unitRef="shares">577349</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-174" decimals="0" id="f-509" unitRef="shares">674538</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-175" decimals="0" id="f-510" unitRef="shares">1018250</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-176" decimals="0" id="f-511" unitRef="shares">19160</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-177" decimals="0" id="f-512" unitRef="shares">70639</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="0" id="f-513" unitRef="shares">693790</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-16" decimals="0" id="f-514" unitRef="shares">1666238</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SubsequentEventsTextBlock contextRef="c-1" id="f-516">Subsequent Events&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated subsequent events through August&#160;6, 2026, and determined that there have been no events that have occurred that would require adjustments to our disclosures or the Unaudited Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-14" id="f-517">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-14" id="f-518">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-14" id="f-519">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-14" id="f-520">false</ecd:Rule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
